<table>
<thead>
<tr>
<th>Program Number</th>
<th>Abstract Title</th>
<th>First Name</th>
<th>Last Name</th>
<th>Disclosure Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>P6-09-13</td>
<td>The association between pCR status after neoadjuvant chemotherapy and sites of first distant relapse after surgery: A sub-study of the EORTC 10994/NSC-00-00 trial</td>
<td>Kim</td>
<td>Aalders</td>
<td>Dr. Aalders has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-26</td>
<td>Validation of a Chinese nomogram with a Dutch breast cancer population: Excellent prediction of the probability of axillary lymph node metastasis</td>
<td>Merel</td>
<td>Aarniek</td>
<td>Merel Aarniek has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-16</td>
<td>Establishment of molecular profiling for individual treatment - decisions in early breast cancer - Clinical impact of PAM50 and PAM50 risk of recurrence score after more than 16 years follow up</td>
<td>Mariët</td>
<td>Aaserud</td>
<td>Mariët Aaserud has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-12-02</td>
<td>Efficacy-efficacy analysis of adding neoadjuvant chemotherapy with pertuzumab, in patients with HER2+ breast cancer in Spain</td>
<td>Joan</td>
<td>Alaravil</td>
<td>Ms. Alaravil has disclosed that she is a consultant.</td>
</tr>
<tr>
<td>OT2-02-03</td>
<td>Pilot study of zirconium-89 bevacizumab positron emission tomography for imaging angiogenesis in patients with inflammatory breast carcinoma receiving preoperative chemotherapy</td>
<td>Amanda</td>
<td>Abbott</td>
<td>Ms. Abbott has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-04-19</td>
<td>Elucidating the tumor immune microenvironment phenotype in early stage untreated BRCA-mutated breast cancer patients</td>
<td>Sara</td>
<td>Abbott</td>
<td>Dr. Abbott has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-01-21</td>
<td>Novel CD246-downstream signaling pathway involved in breast tumor suppression</td>
<td>Zakaria</td>
<td>Abd Elmageed</td>
<td>Dr. Abd Elmageed has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-15-15</td>
<td>Phase II study of nab-paclitaxel followed by oral nabavabe in patients with metastatic/recurrent triple negative breast cancer previously treated with anthracycline and taxane</td>
<td>Rees</td>
<td>Abdel-Halim</td>
<td>Dr. Abdel-Halim has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-16</td>
<td>Identification of proliferation related drivers and their roles in precision medicine for breast cancers: A retrospective multidimensional comparative, integrated genomic, transcriptomic, and protein analysis</td>
<td>Tarek</td>
<td>Abd El-Fatah</td>
<td>Dr. Abd El-Fatah has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-04-05</td>
<td>Cross-talk between RNA methyltransferase and demethylase regulates breast cancer growth and progression</td>
<td>Nourhan</td>
<td>Abdel-Fattah</td>
<td>Nourhan Abdel-Fattah has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-15-01</td>
<td>Prognostic significance of CD8b tumor-infiltrating lymphocytes (TILs) CD4+ TILs and TILs in male breast cancer</td>
<td>Symne</td>
<td>Abdel-Jouad</td>
<td>Dr. Abdel-Jouad has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-09-09</td>
<td>The effects of treatment-induced symptoms, depression and age on sexuality in premenopausal women with early breast cancer receiving adjuvant endocrine therapy</td>
<td>Khitamah</td>
<td>Abdi</td>
<td>Khitamah Abdi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-01-19</td>
<td>Sentinel: A way to avoid sentinel node biopsy (SNB) in patients with a preoperative diagnosis of ductal cancer in situ (DCIS)</td>
<td>Shahin</td>
<td>Abdul-Kaleh</td>
<td>Shahin Abdul-Kaleh has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-14-03</td>
<td>Novel visualization tools to search ongoing clinical trials and track trial results for metastatic breast cancer</td>
<td>Mubul</td>
<td>Abdulsar</td>
<td>Mubul Abdulsar has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-03-12</td>
<td>CD44/6 inhibitor resistant ER-positive cells remain dependent on estrogen signalling and retain sensitivity to endocrine therapy</td>
<td>Rula</td>
<td>Abdughani</td>
<td>Rula Abdughani has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-01-17</td>
<td>The combination of preoperative computed tomography lymphography and intraoperative fluorescence imaging navigation for sentinel lymph node biopsy of early breast cancer patients</td>
<td>Hajime</td>
<td>Abe</td>
<td>Dr. Abe has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-01-31</td>
<td>Validation of novel diagnostic kits using the semi-dry dot-blot method for detecting metastatic lymph nodes in breast cancer; distinguishing macrometastases and micrometastases</td>
<td>Sumiko</td>
<td>Abe</td>
<td>Dr. Abe has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-20-06</td>
<td>Results of an educational program delivered through e-learning, focused on nursing for primary breast cancer patients</td>
<td>Kyoko</td>
<td>Abe</td>
<td>Ms. Abe has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
200 experiences of oncoplastic surgery with the omental flap reconstruction

Norie Abe
Dr. Abe has no relevant financial relationships to disclose.

Research biopsies in oncology-patient willingness, perceptions, understanding, and experience: An integrative review
Elizabeth Abraham
Ms. Abraham has no relevant financial relationships to disclose.

MetaPHER phase IIB multicenter, open-label, single-arm safety study of subcutaneous trastuzumab in combination with pertuzumab and docetaxel in patients with HER2-positive advanced breast cancer: Final results
Jacinta Abraham
Jacinta Abraham has disclosed that she is the PI for MetaPHER study (Roche).

The True effect of aromatase inhibitor (AI) treatment on global gene expression (expr) changes in postmenopausal ER+ breast cancer (BC) patients: A POSTIC study (CRUK/07/015)
Evans Abigail
Evans Abigail has no relevant financial relationships to disclose.

Impact of institution of young women's breast cancer clinic on time to treatment and utilization of fertility, genetics and social work consultations in women under age 50 with newly diagnosed early stage breast cancer
Jame Abraham
Dr. Abraham has no relevant financial relationships to disclose.

Detecting high mutational load ER+ breast cancer patients through FoundationOne cancer gene panel mutations
Jame Abraham
Dr. Abraham has no relevant financial relationships to disclose.
A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

Diffuse optical tomography can predict pathologic complete response in patients with HER2+ or triple negative breast cancer under neoadjuvant chemotherapy

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

Factors associated with follow-up medical care among women with early stage breast cancer

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

Factors associated with multidisciplinary care in the management of early stage breast cancer

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

Diffuse optical tomography can predict pathologic complete response in patients with HER2+ or triple negative breast cancer under neoadjuvant chemotherapy

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

Factors associated with follow-up medical care among women with early stage breast cancer

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

Factors associated with multidisciplinary care in the management of early stage breast cancer

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

FAP (fibroblast activation protein) analysis in breast tumor cells and stroma after neoadjuvant treatment

Daniel Acosta
Dr. Acosta has no relevant financial relationships to disclose.

Diffuse optical tomography can predict pathologic complete response in patients with HER2+ or triple negative breast cancer under neoadjuvant chemotherapy

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

Factors associated with follow-up medical care among women with early stage breast cancer

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

Factors associated with multidisciplinary care in the management of early stage breast cancer

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

FAP (fibroblast activation protein) analysis in breast tumor cells and stroma after neoadjuvant treatment

Daniel Acosta
Dr. Acosta has no relevant financial relationships to disclose.

Diffuse optical tomography can predict pathologic complete response in patients with HER2+ or triple negative breast cancer under neoadjuvant chemotherapy

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

Factors associated with follow-up medical care among women with early stage breast cancer

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

Factors associated with multidisciplinary care in the management of early stage breast cancer

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

FAP (fibroblast activation protein) analysis in breast tumor cells and stroma after neoadjuvant treatment

Daniel Acosta
Dr. Acosta has no relevant financial relationships to disclose.

Diffuse optical tomography can predict pathologic complete response in patients with HER2+ or triple negative breast cancer under neoadjuvant chemotherapy

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

Factors associated with follow-up medical care among women with early stage breast cancer

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

Factors associated with multidisciplinary care in the management of early stage breast cancer

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

FAP (fibroblast activation protein) analysis in breast tumor cells and stroma after neoadjuvant treatment

Daniel Acosta
Dr. Acosta has no relevant financial relationships to disclose.

Diffuse optical tomography can predict pathologic complete response in patients with HER2+ or triple negative breast cancer under neoadjuvant chemotherapy

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

Factors associated with follow-up medical care among women with early stage breast cancer

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

Factors associated with multidisciplinary care in the management of early stage breast cancer

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

FAP (fibroblast activation protein) analysis in breast tumor cells and stroma after neoadjuvant treatment

Daniel Acosta
Dr. Acosta has no relevant financial relationships to disclose.

Diffuse optical tomography can predict pathologic complete response in patients with HER2+ or triple negative breast cancer under neoadjuvant chemotherapy

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

Factors associated with follow-up medical care among women with early stage breast cancer

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

Factors associated with multidisciplinary care in the management of early stage breast cancer

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

FAP (fibroblast activation protein) analysis in breast tumor cells and stroma after neoadjuvant treatment

Daniel Acosta
Dr. Acosta has no relevant financial relationships to disclose.

Diffuse optical tomography can predict pathologic complete response in patients with HER2+ or triple negative breast cancer under neoadjuvant chemotherapy

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

Factors associated with follow-up medical care among women with early stage breast cancer

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

Factors associated with multidisciplinary care in the management of early stage breast cancer

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

FAP (fibroblast activation protein) analysis in breast tumor cells and stroma after neoadjuvant treatment

Daniel Acosta
Dr. Acosta has no relevant financial relationships to disclose.

Diffuse optical tomography can predict pathologic complete response in patients with HER2+ or triple negative breast cancer under neoadjuvant chemotherapy

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

Factors associated with follow-up medical care among women with early stage breast cancer

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

Factors associated with multidisciplinary care in the management of early stage breast cancer

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

FAP (fibroblast activation protein) analysis in breast tumor cells and stroma after neoadjuvant treatment

Daniel Acosta
Dr. Acosta has no relevant financial relationships to disclose.

Diffuse optical tomography can predict pathologic complete response in patients with HER2+ or triple negative breast cancer under neoadjuvant chemotherapy

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

Factors associated with follow-up medical care among women with early stage breast cancer

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

Factors associated with multidisciplinary care in the management of early stage breast cancer

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

FAP (fibroblast activation protein) analysis in breast tumor cells and stroma after neoadjuvant treatment

Daniel Acosta
Dr. Acosta has no relevant financial relationships to disclose.

Diffuse optical tomography can predict pathologic complete response in patients with HER2+ or triple negative breast cancer under neoadjuvant chemotherapy

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

Factors associated with follow-up medical care among women with early stage breast cancer

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.

Factors associated with multidisciplinary care in the management of early stage breast cancer

Melissa Accordino
Dr. Accordino has no relevant financial relationships to disclose.
BRE12-158: A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer (TNBC)

Semidele Adesunloye
Dr. Adesunloye has no relevant financial relationships to disclose.

P2-04-14

A cell profile associated with regional lymph node progression in breast cancer

Sahane Adler
Dr. Adler has no relevant financial relationships to disclose.

P6-11-10

Preliminary efficacy of the novel PARP1 inhibitor, (P1104E) in triple negative breast cancer models.

Alex Adjei
Dr. Adjei has no relevant financial relationships to disclose.

P1-12-05

Erlotinib-associated survival advantage over standard of care drugs in a model of brain metastases of breast cancer

Chris Addis
Mr. Addis has no relevant financial relationships to disclose.

P3-13-01

Prognostic significance of CD8+ tumor-infiltrating lymphocytes (TILs), CD4+ TILs and TILs in male breast cancer

Olisa Adeoti
Dr. Adeoti has no relevant financial relationships to disclose.

OT2-01-14

Triple-negative first-line study: Neoadjuvant trial of nab-paclitaxel and atezolizumab, a PD-L1 inhibitor, in patients with triple negative breast cancer (TNBC) [NCT02530489]

Beatriz Adrada
Dr. Adrada has no relevant financial relationships to disclose.

OT2-01-20

Phase IIB study of neoadjuvant panitumumab combined with carboplatin and paclitaxel (PaCT) for anthracycline-resistant triple-negative breast cancer (TNBC)

Beatriz Adrada
Dr. Adrada has no relevant financial relationships to disclose.

P4-06-03

An annotated collection of pre- and post-therapy breast cancer patient-derived xenograft models built from fine needle aspiration samples aligned with ongoing clinical trials documenting response to treatment

Beatriz Adrada
Dr. Adrada has no relevant financial relationships to disclose.

P5-16-30

Feasibility trial for identification of patients for eliminating breast cancer surgery following neoadjuvant systemic therapy

Beatriz Adrada
Dr. Adrada has no relevant financial relationships to disclose.

P3-04-05

Identification of SARK985, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong antitumor activity in wild-type and mutant ER+ breast cancer models

Francisco Adrian
Mr. Adrian has no relevant financial relationships to disclose.

P1-10-17

Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer

Mary Aby Vago
Dr. Aby Vago has no relevant financial relationships to disclose.

P2-01-35

A one-day protocol with activities lower than 20 MBq for the detection of sentinel lymph nodes - Experience after 150 cases

Shabnam Afsah
Shabnam Afsah has no relevant financial relationships to disclose.

P6-12-02

SYD985, a novel anti-HER2 ADC, shows promising activity in patients with HER2-positive and HER2-negative metastatic breast cancer

Philippe Aftimos
Mr. Aftimos has disclosed that he is a principal investigator in the trial.

P3-14-01

International validation of the EORTC patient-reported outcome measure (PROM) in breast reconstruction (BR): The EORTC QLQ-BRECON23 evaluating the psychometric properties and clinical effectiveness

Maryam Afzal
Dr. Afzal has no relevant financial relationships to disclose.

P5-11-08

Immunogenicity of eflapegrastim in a phase 2 open-label dose-ranging study of eflapegrastim in breast cancer patients receiving docetaxel and cyclophosphamide (TC) regimen

Richy Agajanian
Dr. Agajanian has no relevant financial relationships to disclose.

OT1-01-11

Randomized phase 2 study of a novel, long-acting G-CSF (eflapagrostim) versus pegfilgrastim in the management of chemotherapy-induced neutropenia in early-stage breast cancer patients receiving docetaxel and cyclophosphamide (TC) regimen (ADVANCE study)

Richy Agajanian
Dr. Agajanian has no relevant financial relationships to disclose.

P5-11-09

Erlotinib in breast cancer patients in a phase 2, open-label, dose-ranging study of eflapegrastim in breast cancer patients receiving TC regimen

Richy Agajanian
Dr. Agajanian has no relevant financial relationships to disclose.

P6-09-16

Identification of proliferation-related derivers and their roles in precision medicine for breast cancers: A retrospective multidimensional comparative, integrated genomic, transcriptomic, and protein analysis

Devika Agarwal
Dr. Agarwal has no relevant financial relationships to disclose.

P2-04-27

CTLA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer

Pankaj Agarwal
Pankaj Agarwal has no relevant financial relationships to disclose.
Ki67-positive CTCs are associated with early disease relapse in patients with early breast cancer undergoing adjuvant chemotherapy

Sofia Agelaki
Ms. Agelaki has no relevant financial relationships to disclose.

Prevalence of insulin-like growth factor-1 receptor (IGF-1R) expression in circulating tumor cells (CTCs) of patients with early breast cancer and its association with E-cadherin expression and patient survival

Sofia Agelaki
Ms. Agelaki has no relevant financial relationships to disclose.

Voice of cancer patients: Analysis of patient concerns regarding pregnancy and fertility preservation in patients with breast cancer

Alok Aggarwal
Dr. Aggarwal has disclosed that she has ownership in Scry Analytics.

Prevalence of insulin-like growth factor-1 receptor (IGF1R) expression in circulating tumor cells (CTCs) of patients with early breast cancer and its association with E-cadherin expression and patient survival

Sofia Agelaki
Ms. Agelaki has no relevant financial relationships to disclose.

Impact of a decision-support tool on the utilization of colony-stimulating factors and incidence of febrile neutropenia among patients with breast cancer

Abiy Agiro
Dr. Agiro has no relevant financial relationships to disclose.

Prognostic relevance of caspase 8 polymorphisms for breast cancer

Bankfalvi Agnes
Dr. Agnes has no relevant financial relationships to disclose.

Genomic variants in 5 male breast cancers using whole genome sequencing

Vartika Agrawal
Dr. Agrawal has no relevant financial relationships to disclose.

Molecular evaluation of Peruvian patients with hereditary breast cancer reveals a novel germline mutation in BRCA1

Alfredo Aguilar
Mr. Aguilar has no relevant financial relationships to disclose.

BGB234, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy in mammary adenocarcinoma

Kristina Aguilera
Dr. Aguilera has disclosed that she receives salary.

Phase I multicenter clinical trial evaluating the combination of trastuzumab emtansine (T-DM1) and non-pegylated liposomal doxorubicin (NPLD) in HER2-positive metastatic breast cancer (NCT04220631 study)

Elena Aguín
Dr. Aguín has no relevant financial relationships to disclose.

Selection of presumed CD49f antagonists and their biological evaluation in breast cancer cells

Charmina Aguirre-Alvarado
Dr. Aguirre-Alvarado has no relevant financial relationships to disclose.

Stemting radiotherapy in women 2-45 years with early breast cancer and favorable histopathology after breast-conserving surgery, sentinel node biopsy and adjacent endocrine therapy is safe

Sohan Ahlgren
Dr. Ahlgren has no relevant financial relationships to disclose.

Early-utilization pattern of palbociclib 1 year post-approval in the United States

Jin Seok Ahn
Mr. Ahn has no relevant financial relationships to disclose.

Clinical utility of serial monitoring of circulating tumor DNA (ctDNA) in patients with neoadjuvant chemotherapy (NAC) for locally advanced breast cancer (LABC)

Jin Seok Ahn
Dr. Ahn has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1-05-15</td>
<td>Multi-omics and immuno-oncology profiling reveal distinct molecular signatures of young Asian breast cancers</td>
<td>Jin Seok Ahn</td>
<td>Dr. Ahn has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-50</td>
<td>Impact of young age on recurrence and mortality after surgery in breast cancer: 25 years active surveillance</td>
<td>Jin Seok Ahn</td>
<td>Dr. Ahn has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT1-01-12</td>
<td>A phase II, multicenter, randomized trial of enbulin plus gemcitabine (FG) vs paclitaxel plus gemcitabine (FG) in patients with HER2-negative metastatic breast cancer as first line chemotherapy</td>
<td>Jin-Hee Ahn</td>
<td>Dr. Ahn has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-02-14</td>
<td>Circulating cell-free DNA (ctDNA) measured by a simple fluorescent assay to predict relapse in triple negative breast cancer patients receiving neoadjuvant chemotherapy: A biomarker substudy of prospective observational study (NCT01001159, NCT01001156)</td>
<td>Jin-Hee Ahn</td>
<td>Dr. Ahn has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-13-15</td>
<td>Longitudinal patterns of postdiagnosis weight changes according to adjuvant systemic treatments in Korean breast cancer survivors</td>
<td>Sei Hyun Ahn</td>
<td>Dr. Ahn has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-38</td>
<td>Impact of young age on recurrence and mortality after surgery in breast cancer: 15 years active surveillance</td>
<td>Jin Seok Ahn</td>
<td>Dr. Ahn has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-02-14</td>
<td>Prognostic significance of a modified residual disease in breast and nodules (mRDBN) algorithm after neoadjuvant therapy for breast cancer</td>
<td>Jin-Hee Ahn</td>
<td>Dr. Ahn has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-03-04</td>
<td>Ex vivo shear wave elastography of axillary lymph nodes: predicting nodal metastasis in patients with primary breast cancer: A pilot study</td>
<td>Sung Gae Ahn</td>
<td>Dr. Ahn has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-14</td>
<td>To excise or not? Scoring system for predicting malignancy in patients diagnosed with intra ductal papilloma of ultrasound-guided core needle biopsy</td>
<td>Soo Hyung Ahn</td>
<td>Dr. Ahn has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-01-01</td>
<td>HER2 activity regulates the pro-trastuzumab immune tumor microenvironment</td>
<td>Mei-Lin Ah-See</td>
<td>Mei-Lin Ah-See has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-21-33</td>
<td>HER2+ activity regulates the pre-trastuzumab immune tumor microenvironment</td>
<td>Piera Aversa</td>
<td>Piera Aversa has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S6-01</td>
<td>Comparative analysis of the genomic landscape of breast cancers from women of African and European ancestry</td>
<td>Mustapha Ajani</td>
<td>Mustapha Ajani has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-16-28</td>
<td>A single institution clinical experience with neoadjuvant docetaxel/carboplatin/pertuzumab (TCP): A safety and efficacy analysis</td>
<td>Bushra Alazraki</td>
<td>Dr. Alazraki has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-01-09</td>
<td>Arginine hydroxymethyl glutamine green (AGu-HMRG) is promising fluorescence probe for rapid diagnosis of breast cancer: Protocol of the feasibility study of real time imaging for breast cancer examination</td>
<td>Tadahiko Akashi</td>
<td>Ms. Akashi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-16-10</td>
<td>Zoledronic acid combined with neoadjuvant chemotherapy for HER2-negative early breast cancer (ZOLE: 1 trial): Survival outcomes of a randomized multicenter phase 2 trial</td>
<td>Kouhei Akazawa</td>
<td>Dr. Akazawa has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-07-05</td>
<td>Risk of metachronous contralateral breast cancer: Systematic review and meta-analysis</td>
<td>Annalisa Alcarin</td>
<td>Dr. Alcarin has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-07-01</td>
<td>Ex vivo shear wave elastography of axillary lymph nodes: predicting nodal metastasis in patients with primary breast cancer: A pilot study</td>
<td>Sung Gae Ahn</td>
<td>Dr. Ahn has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-09-01</td>
<td>Plasma osteoprotegerin and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers</td>
<td>Mohammad Alibari</td>
<td>Dr. Alibari has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-06-04</td>
<td>Arginine hydroxymethyl glutamine green (AGu-HMRG) is promising fluorescence probe for rapid diagnosis of breast cancer: Protocol of the feasibility study of real time imaging for breast cancer examination</td>
<td>Mustapha Ajani</td>
<td>Mustapha Ajani has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-07-05</td>
<td>Arginine hydroxymethyl glutamine green (AGu-HMRG) is promising fluorescence probe for rapid diagnosis of breast cancer: Protocol of the feasibility study of real time imaging for breast cancer examination</td>
<td>Delbal Alcarin</td>
<td>Delbal Alcarin has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
Magnetic resonance imaging (MRI) surveillance for patients with dense breasts and a previous breast cancer (BC) and/or high risk lesion

Hyder Al Attar
Dr. Al Attar has no relevant financial relationships to disclose.

The importance of axo-regional tumor burden and surgery on survival in patients with de novo stage IV breast cancer; post-hoc analyses of protocol M027-05

Kalil & Akgol
Dr. Akgol has no relevant financial relationships to disclose.

A phase II study to compare fulvestrant (F) 500mg plus placebo versus (vs) 500mg plus palbociclib (P) as first line treatment for postmenopausal women with hormone-receptor (HR) positive advanced breast cancer (BC) sensitive to endocrine therapy (ET) “The FUPPER study” (SICCAN/2014-12)

Messias & Azzam
Mr. Azzam has no relevant financial relationships to disclose.

Unhealthy lifestyle patterns are prevalent in unaffected BRCA mutation carriers & are associated with increased oxidative stress and telomere length alterations

Dhafir Al-azawi
Dhafir Al-azawi has no relevant financial relationships to disclose.

First-line ribociclib plus letrozole in patients with de novo HR+, HER2- advanced breast cancer (ABC): A subgroup analysis of the MONALEESA-2 trial

Emilio Alba
Mr. Alba has disclosed that he is a consultant for Roche and Pfizer and a speaker for Roche and Celgene. He has also disclosed that he has a contract with Nanostring.

Impact of post-progression therapy on overall survival (OS) in the IMELDA randomized phase III trial evaluating the addition of capecitabine (CAP) to maintenance bevacizumab (BEV) for HER2 negative metastatic breast cancer (mBC)

Emilio & Alba
Mr. Alba has disclosed that he is a consultant for Roche and Pfizer.

Efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial

Kathy Albain
Dr. Albain has disclosed that she is a consultant for Roche/Genentech, Pfizer and Novartis. She has also disclosed that Genomic Health, Inc. supported this research activity in part by conducting sample preparation, NGS analyses and bioinformatics. No direct funding was provided to her. The NCI provided research support as listed on the abstract.

Committee Member

Dr. Albain has disclosed that she receives consulting fees from Novartis - single advisory board. This relationship does not impact her ability review presentations.

A phase II study to compare fulvestrant (F) 500mg plus placebo versus (vs) 500mg plus palbociclib (P) as first line treatment for postmenopausal women with hormone-receptor (HR) positive advanced breast cancer (BC) sensitive to endocrine therapy (ET) “The FUPPER study” (SICCAN/2014-12)

Joan Albanell
Ms. Albanell has disclosed that she is on Pfizer’s Advisory Board.

Impact of MAF gene amplification on disease recurrence and effects of adjuvant zoledronic acid in early breast cancer

Joan Albanell
Dr. Albanell has no relevant financial relationships to disclose.

Discovery of molecular predictors of late breast cancer specific events (BCSE) in ER+, node+ breast cancer - new transcriptome expression whole gene analysis of the phase III adjuvant trial SWOG S8814

Joan Albanell
Dr. Albanell has disclosed that she is a consultant.

Phase IIb study evaluating the safety and clinical activity of peritumoural combined with peritumoural and paclitaxel in HER2-low metastatic breast cancer

Joan Albanell
Dr. Albanell has disclosed that she is a consultant for Roche.
Impact of delay neoadjuvant chemotherapy on pathologic complete response in locally advanced breast cancer evidence of the real world in Mexico

Alberto Albarado

Dr. Albarado has no relevant financial relationships to disclose.

Predictive value of GZ/PE/TET after neoadjuvant endocrine treatment in breast cancer

Jean Louis Albertini

Mr. Albertini has no relevant financial relationships to disclose.

Challenges faced across borders to open European academic multicentre projects: The EFA-Net TRANSSCAN JTC 2011

Jean Louis Albertini

Mr. Albertini has no relevant financial relationships to disclose.

Results of multigene assay (MammaPrint™) and molecular subtyping (BluePrint™) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIME decision impact study

Eche-Suarez Albert

Prof. Albert has no relevant financial relationships to disclose.

Prediction of underestimation associated with flat epithelial atypia, atypical ductal hyperplasia and atypical lobular hyperplasia by needle biopsy: Experience in an Argentine breast unit

Agustina Albrecht

Dr. Albrecht has no relevant financial relationships to disclose.

A multi-OMIC analysis to explore the impact of “actionable” genomic alterations on protein pathway activation: Clinical implication for precision medicine in metastatic breast cancer

Jessica Aldrich

Ms. Aldrich has no relevant financial relationships to disclose.

Inhibition of ER-positive breast cancer progression with duavee, a new form of hormone replacement therapy

Emily Aledort

Ms. Aledort has no relevant financial relationships to disclose.

The development of personalized diagnostic tests and therapeutic strategies in breast cancer

Fares Al-Ejeh

Fares Al-Ejeh has no relevant financial relationships to disclose.

Breast cancer after Hodgkin lymphoma: influence of endogenous and exogenous gonadal hormones on the radiation dose-response relationship

Berthe Aleman

Dr. Aleman has no relevant financial relationships to disclose.

CORM vaccines in HER2 positive advanced breast cancer patients: Real world practice from a multicenter observational study

Daniele Alexis

Ms. Alexis has no relevant financial relationships to disclose.

A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)

Jose Enrique Alis-Martinez

Dr. Alis-Martinez has disclosed that he is a consultant for Cellgene. He also disclosed that he receives institutional research funding.

Cancer-associated fibroblasts release exosomal microRNAs that dictate an aggressive phenotype in breast cancer

Affinito Alessandra

Dr. Alessandra has no relevant financial relationships to disclose.

Epithelial mesenchymal transition associated with high miR-221 and integrin β6 leads to poor prognosis in hormone receptor positive HER2- negative breast cancers

Annie Alexander

Ms. Alexander has no relevant financial relationships to disclose.

Molecular native impacts chemo-resistance and invasive mechanisms, enhances doxorubicin retention and induces downregulation of CD44+/CD24- and E-Cad+/Vim+ subpopulations in MCF-7 cell resistant model

Bontempo Alexander

Dr. Alexander has no relevant financial relationships to disclose.

Prognostic impact of the inclusion of uPA/PAL-1 in ER+Her2- and early breast cancer adjunctive treatments decision making

Marie Alexandre

Ms. Alexandre has no relevant financial relationships to disclose.

Melatonin treatment: A transcriptomic networks in a xenograft model of breast cancer

Pamela Alexandre

Ms. Alexander has no relevant financial relationships to disclose.

SFX-01 targets Wnt signalling to inhibit stem-like cells in breast cancer patient-derived xenograft tumours

Denis Alferez

Dr. Alferez has no relevant financial relationships to disclose.

Stage at presentation and time to treatment for American Indian patients diagnosed with breast cancer

Ozer Algan

Dr. Algan has no relevant financial relationships to disclose.

MBG-BRAD02: A phase I/II trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) &/or surgical ablation for newly oligometastatic breast cancer

Pema Al-Hallaq

Dr. Al-Hallaq has no relevant financial relationships to disclose.

Prospective longitudinal study of epithelial thickening in breast cancer patients treated with conventional versus hypofractionated radiotherapy

Arif Al-

Dr. A has no relevant financial relationships to disclose.
**P6-07-06**
Effect of serum biomarkers (activin A, CASK, HER2, TIMP-1, and uPA) on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: CCTG MA.31

Ayesha Ali
Ayesha Ali has no relevant financial relationships to disclose.

**P3-04-18**
The impact of circulating androgens on the androgen receptor in aromatase inhibitor resistant breast cancer

Azlena Ali
Azlena Ali has no relevant financial relationships to disclose.

**P2-08-04**
Phase 2/2 study of oral selvedermel (VT-464), a dual CYP17-lyase inhibitor and androgen receptor (AR) antagonist, in patients with advanced AR positive triple negative (TNBC) or estrogen receptor (ER) positive breast cancer (BC)

Mayhem Ali
Dr. Ali has no relevant financial relationships to disclose.

**P1-05-07**
Comprehensive genomic profiling of clinically malignant phyllodes tumors of the breast reveals frequent mutation of IGF2 and other genes associated with PI3K and RAS pathway activation

Siraj Ali
Siraj Ali has disclosed that he receives salary from and has ownership in Foundation Medicine, Inc.

**P1-05-07**
Comprehensive genomic profiling of 8,614 breast carcinoma reveals therapeutically targetable molecular subtypes beyond those defined by hormone-receptor expression

Siraj Ali
Siraj Ali has disclosed that he receives salary from and has ownership in Foundation Medicine, Inc.

**P1-07-02**
Are we missing actionable targets in breast cancer? Novel insights into recurrent Net alterations

Siraj Ali
Siraj Ali has disclosed that he receives salary from and has ownership in Foundation Medicine.

**P1-02-10**
Reduced serum B-cell maturation antigen levels predict poor outcome in metastatic breast cancer patients in a phase 3 randomized 2nd-line hormone therapy trial

Suhail Ali
Suhail Ali has no relevant financial relationships to disclose.

**P6-07-06**
Effect of serum biomarkers (activin A, CASK, HER2, TIMP-1, and uPA) on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: CCTG MA.31

Suhail Ali
Suhail Ali has no relevant financial relationships to disclose.

**P4-03-10**
Prognostic and predictive marker in the tumor microenvironment of breast cancers

Zomera Ali
Dr. Ali has no relevant financial relationships to disclose.

**P5-10-01**
Adherence to healthy lifestyle behaviors in a predominantly Hispanic population of women undergoing screening mammography

Trishna Ali-Shaw
Ms. Ali-Shaw has no relevant financial relationships to disclose.

**P5-12-02**
Can a supervised exercise program compared to usual care prevent aromatase inhibitor-induced musculoskeletal pain in women with breast cancer?

Suzanne Allan
Ms. Allan has no relevant financial relationships to disclose.

**P3-13-09**
Prediction of underestimation associated with flat epithelial atypia, atypical ductal hyperplasia and atypical lobular hyperplasia by needle biopsy: Experience in an Argentine breast unit

Carola Allemand
Dr. Allemand has no relevant financial relationships to disclose.

**S2-03**
Does BRCA status affect outcome in young breast cancer patients? Results from the prospective study of outcomes in sporadic and hereditary breast cancer (POSH)

Jamie Allen
Jamie Allen has no relevant financial relationships to disclose.

**P3-01-03**
Milky Way sign: A potential predictive sign of breast cancer on digital breast tomosynthesis

Kimberly Allison
Dr. Allison has no relevant financial relationships to disclose.

**P98-01**
Race and age differences in PAM50 biomarker status in the Carolina breast cancer study

Emma Allott
Ms. Allott has no relevant financial relationships to disclose.

**QT7-02-09**
Phase II pre-surgical window trial of talapristone acetate (TPA) in early breast cancer and DCIS patients: Distribution of TPA in plasma, normal breast tissue and tumors

Subhashini Allu
Dr. Allu has no relevant financial relationships to disclose.

**P6-07-06**
Effect of serum biomarkers (activin A, CASK, HER2, TIMP-1, and uPA) on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: CCTG MA.31

Yaser Al-Marrawi
Dr. Al-Marrawi has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1-01-03</td>
<td>Dynamics of circulating tumor cells during the course of chemotherapy and prognostic relevance across molecular subtypes in high-risk early breast cancer patients - Results from the adjuvant SUCCESS A trial</td>
<td>Marianna Alunni-Fabbroni Dr. Alunni-Fabbro has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>P4-07-01</td>
<td>Profiling miRNA in high-risk post-operative early breast cancer patients to detect possible association to correlation with immune system antimembrane response</td>
<td>Marianna Alunni-Fabbro</td>
<td>Dr. Alunni-Fabbro has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-01-11</td>
<td>Effect of supplementation with eicosapentaenoic and docosahexaenoic omega-3 polyunsaturated fatty acid on the chemotoxicity in Mexican patients with locally advanced breast cancer (LABC) treated with neoadjuvant chemotherapy (Neoadx)</td>
<td>Michael Alvarado Dr. Alvarado has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>P2-11-10</td>
<td>SentimagIC: A non-inferiority trial comparing superparamagnetic iron oxide vs. Tc99 and blue dye in the detection of axillary sentinel nodes in patients with early stage breast cancer</td>
<td>Alberto Alvarado-Miranda Dr. Alvarado-Miranda has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>OT2-02-02</td>
<td>A randomized, open-label, multicenter, phase 2/3 study of eribulin mesylate in combination with FOLFIRI in patients with metastatic breast cancer</td>
<td>Ricardo Alvarez Dr. Alvarez has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>OT3-02-04</td>
<td>Profiling behavior change and weight loss in breast cancer survivors on hormonal adjuvant therapy: An energy balance research in cancer (EnBAR) prospective study</td>
<td>Ricardo Alvarez Dr. Alvarez has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>OT3-07-02</td>
<td>A randomized study of personalized music therapy for patients with early stage breast cancer receiving chemotherapy</td>
<td>Carolina Alvarez Tapias Dr. Alvarez has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>OT3-08-01</td>
<td>A randomized study of personalized music therapy for patients with early stage breast cancer receiving chemotherapy</td>
<td>Carolina Alvarez Tapias Dr. Alvarez has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>P1-01-19</td>
<td>Circulating tumor cells in triple-negative breast cancer patients express prostate related genes and show different genetic profiles in US and German patient cohorts</td>
<td>Ricardo Alvarez Dr. Alvarez has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>P2-02-07</td>
<td>Determination of breast cancer based on circulating protein biomarker profile using the DLINK proteomics multiplexed proximity extension assay</td>
<td>Ricardo Alvarez Dr. Alvarez has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>P1-12-01</td>
<td>Assessing response in locally advanced breast cancer treated with neoadjuvant chemotherapy: Predictive and prognostic potential of volume-based metabolic variables with 18F-FDG PET/CT</td>
<td>Ruth Alvarez-Cabellos Ms. Alvarez-Cabellos has disclosed that she is listed as Co-inventor for PAM50 Classifier Patent.</td>
<td></td>
</tr>
<tr>
<td>P1-03-03</td>
<td>Determining the prognostic role of early and end-of-chemotherapy HER2+ FDG PET/CT in patients with locally advanced breast cancer</td>
<td>Carolina Alvarez Tapias Dr. Alvarez Tapias has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>P09-04</td>
<td>How European and US young women cope with breast cancer and fertility concerns</td>
<td>Erez Amadoti Dr. Amadoti has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
</tbody>
</table>
S6-01 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian short-HER trial  
Laura Amaducci  
Ms. Amaducci has no relevant financial relationships to disclose.

P1-05-22 The value of RNA-Seq for the detection of clinically actionable targets in breast cancer: A small cohort analysis  
Anu Amallraja  
Ms. Amallraja has no relevant financial relationships to disclose.

P1-05-23 Utilities and challenges of RNA-Seq based expression and variant calling in a clinical setting  
Anu Amallraja  
Ms. Amallraja has no relevant financial relationships to disclose.

S3-01 IMENEO: International MItA analyses of curationg tumor cell detection in early breast cancer patients treated by NEoadjuvant chemotherapy  
Dominic Amara  
Mr. Amara has no relevant financial relationships to disclose.

S6-01 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian short-HER trial  
Massimo Ambroggi  
Massimo Ambroggi has no relevant financial relationships to disclose.

P5-09-02 Breast cancer risk prediction using a polygenic risk score in women of African ancestry: Findings from GWAS in breast cancer in the African diaspora  
Stefan Ambs  
Dr. Ambs has no relevant financial relationships to disclose.

P6-02-08 Modulation of indoleamine 2,3-dioxygenase (IDO1) expression in breast cancer cells by activated CD8+ T cells is controlled by DNA promoter methylation  
Stefan Ambs  
Dr. Ambs has no relevant financial relationships to disclose.

P4-21-09 Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2 positive early breast cancer (BIG 1-056)  
Helene Amels  
Ms. Amels has no relevant financial relationships to disclose.

P1-05-27 Evaluation of the Oncogene focus and comprehensive assay for therapeutic stratification in early hormone receptor positive breast cancers  
Kutaka Amigo  
Mr. Amigo has no relevant financial relationships to disclose.

P5-11-06 BEAUTY and the breast: Is adjuvant chemotherapy the right time for a beauty boost? Results of a randomised controlled trial  
Philippe Amiel  
Dr. Amiel has no relevant financial relationships to disclose.

P4-21-16 Phase III trial to evaluate patient's preference for subcutaneous versus intravenous trastuzumab administration in patients with HER2 positive advanced breast cancer (MBC) under IV trastuzumab (IV-I) treatment for at least 4 months; CHAIR-ER-SC study (GIRCAM/2012-07)  
Yolanda Amigó  
Ms. Amigó has no relevant financial relationships to disclose.

P1-09-02 Oncology and gene expression results from SC1/1007 Nedelkulbin phase II clinical trial in HER2-negative early breast cancer  
Sara Amílano Parraga  
Dr. Amílano Parraga has no relevant financial relationships to disclose.

Q71-01-04 VENTANA (SOLTI-1501): Oral metronomic vinorelbine combined with endocrine therapy in luminal/HER2-negative early breast cancer: A window of opportunity trial  
Sara Amílano Parraga  
Dr. Amílano Parraga has no relevant financial relationships to disclose.

P5-15-05 Randomized phase II study evaluating different schedules of nab-paclitaxel in metastatic breast cancer (MBC): Results of the SNAV study  
Sara Amílano Parraga  
Dr. Amílano Parraga has no relevant financial relationships to disclose.

P4-06-01 Patient derived DCIS mouse-intraductal (MNID) models recapitulate the full spectrum of human patient pathology and histologic features including progression to invasion in a subset of cases  
Amanda Amir  
Dr. Amir has no relevant financial relationships to disclose.

P4-06-01 Effect of race on triple negative breast cancer outcomes  
Suchi Amir  
Dr. Amir has no relevant financial relationships to disclose.

P1-05-01 Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ER positive metastatic breast cancer patients: Results of the COMETI Phase 2 trial  
Eitan Amir  
Dr. Amir has no relevant financial relationships to disclose.

P2-05-19 Impact of TP53 functional mutation type on clinical outcomes of advanced breast cancer patients  
Eitan Amir  
Dr. Amir has no relevant financial relationships to disclose.
Comparing the frequency and types of genetic aberrations between older and younger women with metastatic breast cancer at the University of North Carolina at Chapel Hill

A-phase II, open-label, multi-center study of ANG1005, a novel brain-penetrant peptide-drug conjugate, in breast cancer patients with recurrent CNS metastases

The incidence and outcomes of brain metastases in HER2-positive metastatic breast cancer with the advent of modern anti-HER2 therapies

"Breast Cancer Initiative (BCI2.5): A Framework for Systemic Improvement in Global Breast Cancer Outcomes"

Combination of targeted therapies for advanced triple negative breast cancer. A phase II trial of nab-paclitaxel and bevacizumab followed by maintenance targeted therapy with bevacizumab and erlotinib

Combined targeted therapies for advanced triple negative breast cancer: A phase II trial of nab-paclitaxel and bevacizumab followed by maintenance targeted therapy with bevacizumab and erlotinib

Clinical heterogeneity in breast cancer and its impact on clinical biomarkers

Pathologic recombination deficiency in PD-L1, PD-L2, Jak2 (PDJ) amplified triple negative breast carcinoma

Combined targeted therapies for advanced triple negative breast cancer: A phase II trial of nab-paclitaxel and bevacizumab followed by maintenance targeted therapy with bevacizumab and erlotinib

Effect of PD-1 and PD-L1 in the tumor microenvironment on overall survival of triple-negative breast cancer patients

Conditional reactivation of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) in the mouse mammary epithelium alters mammary gland development

Specific detection of anti-Her2-PEGylated PrecisionMRX® nanoparticles measured using superparamagnetic relaxometry

EMCO 07-READ: A randomized phase III trial comparing six cycles of docetaxel and cyclophosphamide (DC) to three cycles of epirubicin and cyclophosphamide followed by three cycles of docetaxel (DC-2) in patients with early breast cancer

Sentinel: A way to avoid sentinel node biopsy (SNB) in patients with a preoperative diagnosis of ductal cancer in situ (DCIS)

Breast ultrasound surveillance with image fusion technique in a short-interval follow-up for BI-RADS category 3 mass lesions

Eribulin mesylate (eribulin) showed inhibitory effects on epithelial-mesenchymal transition (EMT) in tumors of metastatic breast cancer patients. -First preliminary report of a prospective study.
Inhibition of cancer-associated fibroblast function by farnesoid X receptor activation: Experimental basis for a novel therapeutic strategy in breast cancer

Sebastiano Ando
Dr. Ando has no relevant financial relationships to disclose.

The Y537S ESR1 mutation is a dominant driver of distant ER-positive breast cancer metastasis

Diogo Andrade
Mr. Andrade has no relevant financial relationships to disclose.

Clinical examination and breast MRI as predictors of pathologic complete response post neoadjuvant therapy in HER2 overexpressed subtypes and triple negative breast cancer

Felipe Eduardo Andrade
Dr. Andrade has no relevant financial relationships to disclose.

The use of hypofractionated radiotherapy for the treatment of women with early breast cancer in the Brazilian public health system may increase access to treatment: Cost effectiveness and budget impact analyses

Verena Andrade
Ms. Andrade has no relevant financial relationships to disclose.

SOLAR-1: A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy

Fabrice Andre
Dr. Andre has disclosed that he has contracts with Novartis, AstraZeneca, Lilly, Roche and Pfizer.

ENDEAR: A randomized international phase 3 study comparing the efficacy and safety of enzalutamide in combination with paclitaxel chemotherapy or as monotherapy vs placebo with paclitaxel in patients with advanced diagnostics-positive triple negative breast cancer

Fabrice Andre
Dr. Andrade has no relevant financial relationships to disclose.

Genomic analysis to evaluate response to neoadjuvant anastrozole and fulvestrant in post-menopausal ER-positive HER2-negative breast cancer patients included in the UCBG CARMINA02 trial

Fabrice Andre
Dr. Andrade has no relevant financial relationships to disclose.

Everolimus plus trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: Overall survival results from BOLERO-1

Fabrice Andre
Dr. Andrade has no relevant financial relationships to disclose.

First-line ribociclib plus letrozole in patients with de novo HR+, HER2- advanced breast cancer (ABC): A subgroup analysis of the MONALEESA-2 trial

Fabrice Andre
Dr. André has disclosed that he has contracts with Novartis, AstraZeneca, Lilly, Roche and Pfizer.

High-throughput genome analysis and therapeutic decision for patients with HER2-negative metastatic breast cancer: First feasibility and molecular results of the randomized phase II study SAFIR2 BREAST (UCBG-0105/1304)

Fabrice Andre
Mr. Andrade has no relevant financial relationships to disclose.

ST8SIA1 regulates tumorigenesis in triple negative breast cancer

Michael Andreffi
Dr. Andreff has no relevant financial relationships to disclose.

GD2-mediated FAK signaling regulates breast cancer stem cell function in triple negative breast cancer

Michael Andreffi
Dr. Andreff has no relevant financial relationships to disclose.

Metabolics stress induces GD2 expression and cancer stem cell phenotype in triple negative breast cancer

Michael Andreffi
Dr. Andreff has no relevant financial relationships to disclose.

ST8SIA1 is over-expressed in triple negative breast cancer and associated with p53 mutations

Michael Andreffi
Dr. Andreff has no relevant financial relationships to disclose.
A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer

Eleni Andreopoulou
Dr. Andreopoulou has no relevant financial relationships to disclose.

A phase I study of low dose oral cyclophosphamide (C) plus the poly-ADP-ribose polymerase (PARP) inhibitor veliparib (V) in women with HER2/neu-negative, metastatic breast cancer (MBC). NCI P8853

Eleni Andreopoulou
Dr. Andreopoulou has no relevant financial relationships to disclose.

A novel fluorescence in situ hybridization assay to detect 9p24.1 amplification in triple negative breast cancer

Mariacarla Andreozzi
Ms. Andreozzi has no relevant financial relationships to disclose.

Concordance with National comprehensive cancer network (NCI2)/metastatic breast cancer guidelines and impact on overall survival

Forero Andres
Dr. Andres has no relevant financial relationships to disclose.

Neoadjuvant non-pegylated liposomal doxorubicin plus paclitaxel, trastuzumab and pertuzumab in patients with HER2+ breast cancer - final results of the SOLTI OPTI-HER HEART study

Raquel Andrés
Dr. Andrés has no relevant financial relationships to disclose.

The value of RNA-Seq for the detection of clinically actionable targets in breast cancer - A small cohort analysis

Amanda Andrews
Ms. Andrews has no relevant financial relationships to disclose.

Concordance with National comprehensive cancer network (NCI2)/metastatic breast cancer guidelines and impact on overall survival

Forero Andres
Dr. Andres has no relevant financial relationships to disclose.

A fit-for-purpose NGS system that reports ERBB2 (HER2) mutations and copy number variants for clinical trials research and drug development

Bernard Andruss
Dr. Andruss has disclosed that he receives salary from and has ownership in Asuragen, Inc.

A phase II clinical trial of VST-1001 (dilute fluorescein) in lymphatic mapping and sentinel lymph node localization in clinically node negative breast cancer

Robert Andtbacka
Dr. Andtbacka has disclosed that he has a patent with and has ownership in Vestan Inc.

Disruption of the estradiol-regulated NTN1-UNC5A dependence receptor signaling axis causes a hybrid basal/ luminal molecular phenotype in estrogen receptor-positive breast cancer cells

Manjushree Anjanappa
Manjushree Anjanappa has no relevant financial relationships to disclose.

Dual targeting of mammary tumors and tumor-associated functional limitations through inhibition of NF-κB

Rizo Annaliza
Ms. Rizo has disclosed that she is an employee and a stockholder of Cepheid.

Effect of PD-L1 and PD-L2 in the tumor microenvironment on overall survival of triple-negative breast cancer patients

Lakshmanan Annamalai
Dr. Annamalai has disclosed that she is an employee of Merck & Co, Inc.

Disruption of the estradiol-regulated NTN1-UNC5A dependence receptor signaling axis causes a hybrid basal/ luminal molecular phenotype in estrogen receptor-positive breast cancer cells

Manjushree Anjanappa
Manjushree Anjanappa has no relevant financial relationships to disclose.

Comparison of the Xpert breast cancer stratifier mRNA assay with central ER, PR, HER2, and Ki67 immunohistochemistry (IHC) for rapid biomarker analysis in developing countries

Rizo Annaliza
Ms. Rizo has disclosed that she is an employee and a stockholder of Cepheid.

Effect of PD-L1 and PD-L2 in the tumor microenvironment on overall survival of triple-negative breast cancer patients

Lakshmanan Annamalai
Dr. Annamalai has disclosed that she is an employee of Merck & Co, Inc.

Oncoscan-AS1, a breast cancer specific and Estrogen receptor α-dependent long noncoding RNA, is a key component of the pathway controlling cell growth and migration

Laura Annaratone
Ms. Annaratone has no relevant financial relationships to disclose.
P3-07-03
GPNNMB activates EGFR to overcome Mek-inhibition: implications for the development of rational targeted therapy combinations in triple negative breast cancer
Matthew Annis
Dr. Annis has no relevant financial relationships to disclose.

P2-09-09
The effects of treatment-induced symptoms, depression and age on sexuality in premenopausal women with early breast cancer receiving adjuvant endocrine therapy
Fatih Ansat
Mr. Ansat has no relevant financial relationships to disclose.

P5-08-08
Baseline (BL) characteristics, treatment (tx) patterns, and outcomes in patients with hormone receptor (HR)+ vs HR- HER2+ disease from the SYMHTH registry
Vince Antao
Mr. Antao has disclosed that he receives salary from Genentech and has ownership in F. Hoffmann-La Roche, Ltd.

P5-08-27
Treatment patterns and clinical outcomes in patients with hormone receptor (HR)-HER2+ metastatic breast cancer and low vs high levels of HR positivity from the SYMHTH Registry
Vince Antao
Mr. Antao has disclosed that he receives salary from Genentech and has ownership in F. Hoffmann-La Roche, Ltd.

P1-11-02
A comparison of models (johnsonian, the Van Nuys prognostic Index, the Memorial-Sloan-Kettering Cancer Center DCIS nomogram) to predict ipsilateral breast events in patients with ductal carcinoma in situ (DCIS) of the breast after breast-conserving surgery failed to replicate results of the oncotype DCIS recurrence score
Andrew Antell
Dr. Antell has no relevant financial relationships to disclose.

P5-15-12
Real-life activity of oral vinorelbine in metastatic breast cancer patients in the Unicancer ESME database
Goncalves Anthony
Dr. Anthony has no relevant financial relationships to disclose.

P1-07-09
A multi-OMIC analysis to explore the impact of "actionable" genomic alterations on protein pathway activation: Clinical implication for precision medicine in metastatic breast cancer
Stephen Anthony
Dr. Anthony has disclosed that he is a consultant for Paradigm and Genentech. He has also disclosed that he is on the Speaker's Bureau for Spectrum Pharmaceutical.

P1-12-10
Phase III trial of palbociclib (PD-0332991) in combination with endocrine therapy (exemestane or fulvestrant) versus chemotherapy (capecitabine) in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with resistance to aromatase inhibitors. "The PEARL study" (GEICAM/2013-02)
Antonio Antón
Mr. Antón has disclosed that he is on Advisory boards for Roche and Bayer.

P2-01-06
Evaluating the feasibility of a web-based preference-tolerant randomized trial of risk-based vs. annual breast cancer screening: WISDOM study pilot
Hoda Anton-Culver
Dr. Anton-Culver has no relevant financial relationships to disclose.

P1-08-01
Regulation of estrogen receptor-α by NF1
Meenakshi Anurag
Meenakshi Anurag has no relevant financial relationships to disclose.

P4-03-06
Microenvironment induced DDR2 mediates stromal-cancer interactions and metastasis growth in breast cancer
Talha Aparicio
Dr. Aparicio has no relevant financial relationships to disclose.

P5-13-17
A multi-center prospective study of radiofrequency ablation therapy for small breast carcinomas
Kenjiro Aogi
Dr. Aogi has disclosed that he is a speaker for Chugai, Eisai, Sanofi, SRL, AstraZeneca, Taiho, Novartis, Mozhella, Ono, Otsuka, Nihon Medi-Physics and Daiichi Sankyo.

P4-21-14
A randomized phase II trial of trastuzumab + capecitabine versus lapatinib + capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP
Kenjiro Aogi
Kenjiro Aogi has disclosed that he is a speaker for Chugai, Eisai, Sanofi, SRL, AstraZeneca, Taiho, Novartis, Daiichi Sankyo, Mozhella, Ono, Otsuka, Nihon Medi-Physics and Eli Lilly.
Effect of serum biomarkers (actinin A, CA9, HER2, TIMP-1, and uPA) on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: CCTG MA.31

Differential protein expression in primary breast cancer tumors spreading to liver or elsewhere

Power-remote: A randomized study evaluating the effect of a remote-based weight loss program in women with early stage breast cancer

Race associated disparities in an urban population of adolescent and young adult (AYA) women with breast cancer

High-risk breast cancer is less likely to occur in the ductal hyperplasia lesions or low-grade DCIS ~ Consideration of long-term follow-up observation after surgical biopsy

Study on over diagnosis of high-precision breast cancer screening ~ Consideration from epidemiological point of view

The non-invasive treatment for sentinel lymph node metastasis by photodynamic therapy using a verteporfin solubilized phospholipid polymer aggregate

Randomized trial of exercise intervention vs. usual care for breast cancer patients with aromatase inhibitor to prevent and improve the aromatase inhibitor induced arthralgia

The feasibility of nurse intervention to improve and maintain the BMI of breast cancer survivors over 25 to appropriate levels

Effect of supplementation with eicosapentaenoic and docosahexaenoic omega-3 polyunsaturated fatty acid on the chemotoxicity in Mexican patients with locally advanced breast cancer (LABC) treated with neoadjuvant chemotherapy (NeoCT)

Effect of supplementation with eicosapentaenoic and docosahexaenoic omega-3 polyunsaturated fatty acid on the chemotoxicity in Mexican patients with locally advanced breast cancer (LABC) treated with neoadjuvant chemotherapy (NeoCT)
Risk of metastases after ipsilateral breast tumour recurrence changes overtime according to patient and tumour characteristics: Implications for treatment

Ilaria Ardoino

Ms. Ardoino has no relevant financial relationships to disclose.

Microenvironment released IG2R mediates ovarian-cancer interactions and metastasis growth in breast cancer

Caroline Arellano-Garcia

Ms. Arellano-Garcia has no relevant financial relationships to disclose.

Stem cell-like transcriptional reprogramming in metastatic resistance

Enrique Javier Arenas

Dr. Arenas has no relevant financial relationships to disclose.

Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab based therapy

Javier Arima

Dr. Arima has no relevant financial relationships to disclose.

The importance of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive recurrent and advanced breast cancer

Javier Arima

Dr. Arima has no relevant financial relationships to disclose.

PD-L1 expression and decreased tumor infiltrating lymphocytes are associated with poor prognosis in patients with triple negative breast cancer

Nobuyuki Arima

Dr. Arima has no relevant financial relationships to disclose.

Preclinical characterization of VX-984, a selective DNA-dependent protein kinase (DNA-PK) inhibitor in combination with doxorubicin in breast and ovarian cancers

Rieko Arimoto

Rieko Arimoto has disclosed that he is an employee of own stock or stock options in Vertex Pharmaceuticals Incorporated.

A phase II of S-222611, a reversible EGFR and HER2 inhibitor, combined with trastuzumab +/- chemotherapy in patients with HER2-positive metastatic breast cancer

Akinori Arimura

Akinori Arimura has disclosed that he receives salary.

A randomized phase II neoadjuvant study comparing docetaxel and cyclophosphamide (TC) with 5-fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel (FEC-D) for hormone receptor-negative breast cancer: The Kanagawa breast oncology group (KBOG) 1101 study

Hitoshi Arioka

Dr. Arioka has no relevant financial relationships to disclose.

Saving in clinical trials: A possible challenge for improving health care for breast cancer patients

Francesca Arizio

Ms. Arizio has no relevant financial relationships to disclose.

Heavily pre-treated breast cancer patients show promising responses in the first in human study of the first-In-class fatty acid synthase (FASN) inhibitor, TVB-2640 in combination with paclitaxel

Hendrik-Tobias Arkenau

Mr. Arkenau has no relevant financial relationships to disclose.

RAD1901 demonstrates anti-tumor activity in multiple models of ER-positive breast cancer treatment resistance

Heklo Arulk

Heklo Arulk has disclosed that he receives salary from Radius Health, Inc.

POWER-remote: A randomized study evaluating the effect of a remote-based weight loss program in women with early stage breast cancer

Mary Armaras

Ms. Armas has no relevant financial relationships to disclose.

A monoclonal antibody against hypo-glycosylated bone sialoprotein II has application for diagnostic purposes in samples of breast cancer patients and for treatment of skeletal metastasis caused by MDA-MB-231 breast cancer cells in rats

Franz Armbuster

Dr. Armbuster has no relevant financial relationships to disclose.

HER2 positive breast cancer and subclinical cardiotoxicity by echocardiogram 2D Strain: Do chemotherapy sequence matter?

Alejandro Armengol-Alonso

Dr. Armengol-Alonso has no relevant financial relationships to disclose.

A phase I study of AZD0106, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC)

Anne Armstrong

Ms. Armstrong has disclosed that AstraZeneca sponsored this trial.

Promotion of immune tolerance using epigenetic modulation and immune checkpoint inhibition in mouse models of breast cancer

Todd Armstrong

Dr. Armstrong has no relevant financial relationships to disclose.
High-throughput genome analysis and therapeutic decision for patients with HER2-negative metastatic breast cancer: First feasibility and molecular results of the randomized phase II study SAFIR02 BREAST (UCBG-0105/1304)

Monica Arnedos

Ms. Arnedos has no relevant financial relationships to disclose.

Uridine diphosphate glucose dehydrogenase is required for hyaluronic acid production and breast cancer invasion

James Arnold

Mr. Arnold has no relevant financial relationships to disclose.

Beyond ONC012 in breast cancer: Search for additional moderately penetrant risk gene variants by analyzing the oligogenic disease course in ONCO mutation carriers

Norbert Arnold

Mr. Arnold has no relevant financial relationships to disclose.

Breakpoint for the prevention of chemotherapy-induced nausea and vomiting in breast cancer patients receiving multiple cycles of aromatase chemotherapy

Suja Arora

Suja Arora has disclosed that she receives salary from and has ownership in Tarsus.

Rolapitant for the prevention of chemotherapy-induced nausea and vomiting in breast cancer patients receiving multiple cycles of emetogenic chemotherapy

Sujata Arora

Sujata Arora has disclosed that she receives salary from and has ownership in Tesaro.

Beyond CHEK2 in breast cancer: Search for additional moderately penetrant risk gene variants by analyzing the oligogenic disease course in CHEK2 mutation carriers

Norbert Arnold

Mr. Arnold has no relevant financial relationships to disclose.

Treatment of ESR2 mutant and PIK3CA mutant patient-derived breast cancer xenograft models reveals differential anti-tumor responses to estrogen receptor degraders and PI3K inhibitors in vivo

Alfonso Arrazate

Mr. Arrazate has disclosed that he is an employee of Genentech, A Member of the Roche Group.

Feasibility trial for identification of patients for eliminating breast cancer surgery following neoadjuvant systemic therapy

Elsa Arrbic

Dr. Arrbic has no relevant financial relationships to disclose.

Drugomic profiling of liquid biopsy: Plasma DNA does not accurately reflect tumor DNA in metastatic breast cancer

Bradley Arrick

Dr. Arrick has no relevant financial relationships to disclose.

Consistent dosing-time dependent tolerability of everolimus (EV) in a pilot study in women with metastatic breast cancers (MBC) and in a mouse chronopharmacology investigation

Jennifer Arondeau

Dr. Arondeau has no relevant financial relationships to disclose.

Association of pre-chemotherapy peripheral blood pro-inflammatory (IL-6, CRP) and coagulation (D-dimer) markers with chemotherapy toxicity in women with breast cancer

Anait Arsenyan

Anait Arsenyan has no relevant financial relationships to disclose.

Introduction of H1047R oncogenic mutation of PI3K p110alpha subunit in HER2-overexpressing mammary epithelial cells confers a 'stem-like' phenotype and acute sensitivity to HSP90 inhibition

Carlos Arteaga

Dr. Arteaga has no relevant relationships to disclose.

Differential effect of chemotherapy on immune gene expression signatures based on molecular subtype of breast cancer

Carlos Arteaga

Dr. Arteaga has no relevant relationships to disclose.

Genomic profiling of residual ER+ breast cancers treated with prolonged neoadjuvant letrozole reveals novel alterations in clinically resistant tumors

Carlos Arteaga

Dr. Arteaga has no relevant relationships to disclose.

An acquired HER2 TKI-driven gatekeeper mutation induces resistance to neratinib in a patient with HER2 mutant-driven breast cancer

Carlos Arteaga

Dr. Arteaga has no relevant relationships to disclose.

POTHER1 mediates resistance to CDK4/6 inhibitors through dysregulation of 5-phase cyclins/cyclin dependent kinases (CDKs)

Carlos Arteaga

Dr. Arteaga has no relevant relationships to disclose.

First-line ribociclib plus letrozole in patients with de novo HR+, HER2- advanced breast cancer (ABC): A subgroup analysis of the MONALEESA-2 trial

Carlos Arteaga

Dr. Arteaga has no relevant relationships to disclose.

A phase 2 open-label study of lucitanib in patients (pts) with TGF alpha-dominant metastatic breast cancer (MBC)

Carlos Arteaga

Dr. Arteaga has no relevant relationships to disclose.
<table>
<thead>
<tr>
<th>Paper ID</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P6-12-09</td>
<td>Pan-HER, an antibody mixture with antitumor activity against drug-resistant HER2-overexpressing breast cancers with high ERBB ligand expression</td>
<td>Carlos Arteaga</td>
<td>Dr. Arteaga has no relevant relationships to disclose.</td>
</tr>
<tr>
<td>P2-05</td>
<td>Inhibition of mutant HER2 results in synthetic lethality when combined with ER antagonists in ER+/HER2 mutant human breast cancer cells</td>
<td>Carlos Arteaga</td>
<td>Dr. Arteaga has no relevant relationships to disclose.</td>
</tr>
<tr>
<td>P2-08</td>
<td>Neratinib + fulvestrant in ERBB2-mutant, HER2-non-amplified, estrogen receptor (ER) positive, metastatic breast cancer (MBC): Preliminary analysis from the phase I SUMMIT trial</td>
<td>Carlos Arteaga</td>
<td>Dr. Arteaga has disclosed that he has a contract with and is a consultant for PUMA Biotechnology.</td>
</tr>
<tr>
<td>P1-02-08</td>
<td>Prostate-002: A prospective, multi-center study to determine the effectiveness of a biomarker assay to distinguish benign from invasive breast cancer in women with BI-RADS 3, 4 and 5 imaging reports</td>
<td>Elayne Arterbery</td>
<td>Dr. Arterbery has no relevant relationships to disclose.</td>
</tr>
<tr>
<td>P1-06-04</td>
<td>Molecular characterisation, subtype concordance and prognostic group assignment between patient-matched primary breast tumours and axillary lymph node metastases</td>
<td>Laura Arthur</td>
<td>Ms. Arthur has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-08-27</td>
<td>The S22210 test significantly predicts response and survival in both pre and post-menopausal women with ER-positive breast cancers</td>
<td>Laura Arthur</td>
<td>Ms. Arthur has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-07-09</td>
<td>CPM rate among individuals with breast cancer who underwent multiple gene testing for hereditary cancer: Single institution experience</td>
<td>Norm Arun</td>
<td>Dr. Arun has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-07</td>
<td>Double blinded validation study to assess performance of IBM artificial intelligence platform, Watson for oncology in comparison with Manipal multidisciplinary tumour board - First study of 638 breast cancer cases</td>
<td>NIR Arun</td>
<td>NIR Arun has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-06-05</td>
<td>Development and validation of a new non-parametric breast cancer risk assessment model on US and European screening populations</td>
<td>Patrick Arneux</td>
<td>Dr. Arneux has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-13-17</td>
<td>A multi-center prospective study of radiofrequency ablation therapy for small breast carcinomas</td>
<td>Sota Asaga</td>
<td>Dr. Asaga has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-05</td>
<td>Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes (TILs) and residual cancer burden (RCB)</td>
<td>Yuka Asano</td>
<td>Dr. Asano has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-04-20</td>
<td>Predicting therapeutic effect by on tumor-invasion lymphocytes (TILs) in endocrine therapy for stage IV breast cancer</td>
<td>Yuka Asano</td>
<td>Dr. Asano has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-08-25</td>
<td>Circulating tumor cell clusters-associated gene signature is a novel prognostic predictor in patients with breast cancer</td>
<td>Yuka Asano</td>
<td>Yuka Asano has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-01-10</td>
<td>Development of photoacoustic vascular imaging system for breast cancer</td>
<td>Tazufumi Asoo</td>
<td>Tazufumi Asoo has disclosed that he is an employee of and stock holder of Canon Inc., Japan.</td>
</tr>
<tr>
<td>P2-01-14</td>
<td>Lymphatic microsurgical preventive healing approach (LYMPHA) for the primary prevention of lymphedema</td>
<td>Jeffrey Ascherman</td>
<td>Dr. Ascherman has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-22-17</td>
<td>Safety of the combination of everolimus plus exemestane in the Italian cohort of patients enrolled in the expanded access &quot;BALLET&quot; study</td>
<td>S Ascone</td>
<td>S Ascone has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2A-03</td>
<td>Chemotherapy-related risk factors associated with lymphedema in breast cancer patients: Should repeated ipsilateral arm infusions be avoided?</td>
<td>Marie Asdourian</td>
<td>Ms. Asdourian has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-06-09</td>
<td>Prediction of relapse in patients with locally advanced breast cancer after neoadjuvant treatment</td>
<td>Cleavie Asrey</td>
<td>Dr. Asrey has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
Effect of supplementation with eicosapentaenoic and docosahexaenoic omega-3 polyunsaturated fatty acid on the chemotoxicity in Mexican patients with locally advanced breast cancer (LABC) treated with neoadjuvant chemotherapy (NeoCT)

Horacio Astudillo-de la Vega

Dr. Astudillo-de la Vega has no relevant financial relationships to disclose.

The importance of loco-regional tumor burden and surgery on survival in patients with de novo stage IV breast cancer; post-hoc analyses of protocol MF07-01

Can Atalay

Dr. Atalay has no relevant financial relationships to disclose.

Stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer

Rachel Atkinson

Dr. Atkinson has no relevant financial relationships to disclose.

Tropomyosin-related kinase A is overexpressed in HER2-positive breast cancers

John Attia

Mr. Attia has no relevant financial relationships to disclose.

High-throughput genome analysis and therapeutic decision for patients with HER2-negative metastatic breast cancer: First feasibility and molecular results of the randomized phase II study SAFIR2 BREAST (UCBG-0105/1304)

Valery Attignon

Ms. Attignon has no relevant financial relationships to disclose.

Factors predicting treatment outcomes of angiosarcoma of breast: A 25 year single institution experience

Kristopher Atwood

Mr. Atwood has no relevant financial relationships to disclose.

Development of a recurrence risk stratification schema to inform treatment decisions in breast cancer patients undergoing mastectomy with 1-3 positive nodes

Mary Atwood

Ms. Atwood has no relevant financial relationships to disclose.

De novo and relapsed metastatic breast cancer: Presentation and survival changes over time 1990-2009

Mary Atwood

Ms. Atwood has no relevant financial relationships to disclose.

Characteristics of physician detected breast cancer

Mary Atwood

Ms. Atwood has no relevant financial relationships to disclose.

uPA/PAI-1 and adjuvant chemotherapy decision-making in early breast cancer

Yves Aubard

Dr. Aubard has no relevant financial relationships to disclose.

Tissue kallikrein-related peptidase 4, a novel biomarker in triple-negative breast cancer

Michaela Aubele

Prof. Aubele has no relevant financial relationships to disclose.

A phase 2 open-label study of lucitanib in patients (pts) with FGF aberrant metastatic breast cancer (MBC)

M Audeh

Dr. Audeh has no relevant financial relationships to disclose.

Real-life activity of oral vinorelbine in metastatic breast cancer patients in the Unicancer ESME database

Mailliez Audrey

Dr. Audrey has no relevant financial relationships to disclose.

The role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+ HR+ phase II trial evaluating 12-weeks of neoadjuvant TDM1 ± endocrine therapy (ET) versus T + ET in HER2-positive hormone-receptor-positive early breast cancer (EBC)

Doris Augustin

Dr. Augustin has no relevant financial relationships to disclose.

Mechanisms of drug sensitization by DHA on doxorubicin-resistant human breast adenocarcinoma

Allal Auhtit

Dr. Auhtit has no relevant financial relationships to disclose.

Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ER positive metastatic breast cancer patients: Results of the COMETI Phase 2 trial

Kimberly Aung

Ms. Aung has no relevant financial relationships to disclose.

Circulating tumor DNA (ctDNA): A real-time application of precision medicine to the management of metastatic breast cancer (MBC)

Laura Austin

Dr. Austin has disclosed that she is on the Speaker’s Bureau for Guardant Health.

Overview of breast cancer mortality trends in the world

Philippe Attali

Dr. Attali has no relevant financial relationships to disclose.

Genomic characterization of HR2 primary breast cancers

Nicola Axini

Ms. Axini has no relevant financial relationships to disclose.

A randomized study comparing Mitotax to topotecan for female breast cancer survivors with dyspareunia

Ricardo Avarez

Dr. Avarez has no relevant financial relationships to disclose.

African Americans have more aggressive invasive lobular carcinoma subtypes and inferior early outcomes: SEER 2010-2013

Tiffany Avery

Dr. Avery has no relevant financial relationships to disclose.
Comparative analysis of the genomic landscape of breast cancers from women of African and European ancestry

Chinedum Babalola

Chinedum Babalola has no relevant financial relationships to disclose.

A phase II clinical trial of VST-1001 (dilute fluorescein) in lymphatic mapping and sentinel lymph node localization in clinically node negative breast cancer

Giddy Babiera

Dr. Babiera has no relevant financial relationships to disclose.

Femara plus ribociclib or placebo as neo-adjuvant endocrine therapy for women with ER+, HER2-negative early breast cancer - The Feline trial

Shella Beccaray

Ms. Beccaray has no relevant financial relationships to disclose.

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (PERUSE)

Thomas Bachelot

Mr. Bachelot has disclosed that he is a consultant for and receives travel support from Novartis, Roche and AstraZeneca.

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy in patients ≥65 years with HER2-positive locally recurrent/metastatic breast cancer: Subgroup analyses of the PERUSE study

Thomas Bachelot

Mr. Bachelot has disclosed that he is a consultant for and receives travel support from Novartis, Roche and AstraZeneca.

Ribociclib + fulvestrant in postmenopausal women with HR+, HER2- advanced breast cancer (ABC)

Thomas Bachelot

Mr. Bachelot has disclosed that he is a consultant for and receives travel support from AstraZeneca, Novartis and Roche.

Comparison of mutational landscapes of primary breast cancer and first metastatic release: Results from the ESOP study

Thomas Bachelot

Dr. Bachelot has disclosed that he is a consultant for and receives travel support from Novartis, Roche and AstraZeneca.

High-throughput genome analysis and therapeutic decision for patients with HER2 negative metastatic breast cancer - First feasibility and molecular results of the randomized phase II study SAFIR22 BREAST (UCBG-0105/1304)

Thomas Bachelot

Mr. Bachelot has disclosed that he is a consultant for and receives travel support from Novartis, Roche and AstraZeneca.

BELLE-3: A phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2-, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment

Thomas Bachelot

Mr. Bachelot has disclosed that he is a consultant for and receives travel support from Novartis, Roche and AstraZeneca.

Sociodemographic and economic factors are essential determinants of weight gain between before and after cancer diagnosis: Results from the prospective population-based NutriNet-Santé cohort

Patrick Bachmann

Dr. Bachmann has no relevant financial relationships to disclose.

Omitting radiotherapy in women ≥ 65 years with early breast cancer and favorable histology after breast-conserving surgery, sentinel node biopsy and adjuvant endocrine therapy is safe

Kilian Bachmeier

Dr. Bachmeier has no relevant financial relationships to disclose.

A novel non-canonical Notch1-IKKα-mTORC2-AKT pathway maintains survival in triple negative breast cancer cells and cancer stem-like cells

Kandis Backus

Ms. Backus has no relevant financial relationships to disclose.

A targetable EGFR-driven tumor-initiating program in breast cancer

Dunarel Badescu

Dunarel Badescu has no relevant financial relationships to disclose.

BEL12-158: A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer (TNBC)

Sunil Babve

Dr. Babve has no relevant financial relationships to disclose.

Impact of heterogeneity of DDS on immune cell infiltrations

Sunil Babve

Dr. Babve has disclosed that he is co-PI of the grant.
Impact of magnetic resonance imaging on conversion from wide local excision to mastectomy in patients with ductal carcinoma in situ: First results from the ECOG-ACRIN 4112 prospective study

Sunil Badve
Sunil Badve has no relevant financial relationships to disclose.

Independent validation of E2F4/E2F6 gene signature in BIG 1-98: A randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone-receptor-positive, early breast cancer

Sunil Badve
Sunil Badve has disclosed that he has stock in SYSGenomics, LLC.

Evaluation of tumor-infiltrating lymphocytes (TILs) and their association with hormone-receptor deficiency and BRCA1/2 mutation status in triple-negative breast cancer (TNBC): A pooled analysis

Sunil Badve
Sunil Badve has no relevant financial relationships to disclose.

Building an experience engine to make cancer treatment decisions using machine learning

Rajendra Badwe
Ms. Badwe has no relevant financial relationships to disclose.

Changes of tumor-infiltrating lymphocytes and programmed death-ligand 1 positivity after neoadjuvant chemotherapy in patients with locally advanced breast cancer

Jeoung Won Bae
Jeoung Won Bae has no relevant financial relationships to disclose.

Clinical utility of serial monitoring of circulating tumor DNA (ctDNA) in patients with locally advanced breast cancer (LABC)

Soo Youn Bae
Soo Youn Bae has no relevant financial relationships to disclose.

Oncologic outcomes of immediate breast reconstruction after neoadjuvant chemotherapy in breast cancer patients: A matched case control study

Soo Youn Bae
Soo Youn Bae has no relevant financial relationships to disclose.

Conditional disease-free survival among patients with breast cancer

Soo Youn Bae
Soo Youn Bae has no relevant financial relationships to disclose.

Impact of young age on recurrence and mortality after surgery in breast cancer: 25 years active surveillance

Soo Youn Bae
Soo Youn Bae has no relevant financial relationships to disclose.

Re-excision rate in breast conservation surgery after neoadjuvant chemotherapy

Young Kyoung Bae
Young Kyoung Bae has no relevant financial relationships to disclose.

Nuclear grade has a limited role in predicting recurrence in DCIS following breast conserving surgery: A population-based study

Frederick Baehner
Dr. Baehner has disclosed that he receives salary from and stock in Genomic Health, Inc.

SEER study of breast cancer-specific mortality in patients with poor differentiation tumors treated based on recurrence score results

Frederick Baehner
Dr. Baehner has disclosed that he receives salary from and has ownership in Genomic Health, Inc.

Discovery of molecular predictors of late breast cancer specific events (BCSE) in ER+, node+ breast cancer - new transcriptome expression whole gene analysis of the phase III adjuvant trial SWOG S8814

Frederick Baehner
Dr. Baehner has disclosed that he is an employee of Genomic Health Inc and that he receives salary and owns stock.

Comprehensive comparison of prognostic signatures for breast cancer in TransATAC

Rick Baehner
Mr. Baehner has disclosed that he is an employee of Genomics Health Inc.

A phase III trial evaluating pCR in patients with HR+, HER2- positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCPH)-/- in estrogen deprivation: MIG oncology NSABP B-52

Luis Roa-Diaz
Mr. Roa-Diaz has no relevant financial relationships to disclose.

Lapatinib after pertuzumab and ado-trastuzumab emtansine in metastatic HER2-positive breast cancer

Luis Roa-Vallejo
Dr. Roa-Vallejo has no relevant financial relationships to disclose.

Can a supervised exercise program compared to usual care prevent aromatase inhibitor-induced musculoskeletal pain in women with breast cancer?

Rebecca Bagchi
Ms. Bagchi has no relevant financial relationships to disclose.

Body image in women with breast cancer using a scalp cooling system to reduce chemotherapy induced alopecia

Erika Bagman
Dr. Bagman has disclosed that she receives salary from and has ownership in Obigena.
<table>
<thead>
<tr>
<th>Paper ID</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P06-04</td>
<td>HORD study: How European and US young women cope with breast cancer and fertility concerns</td>
<td>Vincenzo Bagnardi</td>
<td>Mr. Bagnardi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-09-10</td>
<td>Pathological complete response to neoadjuvant trastuzumab is dependent on HER2/EGFR ratio in HER2-amplified early breast cancer</td>
<td>Zuzanna Bago-Horvath</td>
<td>Dr. Bago-Horvath has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-10-01</td>
<td>Efficacy and safety of the therapeutic cancer vaccine immutac (I-APT) in early breast cancer: results from a prospective, randomized, neoadjuvant phase II study (ABESIG-16)</td>
<td>Zuzanna Bago-Horvath</td>
<td>Dr. Bago-Horvath has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-04-08</td>
<td>Non-nuclear SUMO dynamics regulate mammary epithelial cell transformation</td>
<td>Shaymaa Bahnassy</td>
<td>Shaymaa Bahnassy has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-04-21</td>
<td>Androgen receptor in tamoxifen-resistant breast cancer is affected by SUMO</td>
<td>Shaymaa Bahnassy</td>
<td>Shaymaa Bahnassy has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-07-07</td>
<td>ERα1 amplification and 5'-3' exon imbalance in metastatic breast cancer</td>
<td>Amir Bahrani</td>
<td>Mr. Bahrani has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-08-06</td>
<td>ATRX (histone breast baseline) in liver cancer</td>
<td>Feng Bai</td>
<td>Feng Bai has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-03-01</td>
<td>An international multicenter study to evaluate reproducibility of automated scoring methods for assessment of Ki67 in breast cancer</td>
<td>Valai Bai</td>
<td>Valai Bai has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-07-03</td>
<td>Mesenchymal subtype negatively associated with the presence of immune infiltrate within a triple negative breast cancer classifier</td>
<td>Daniel Bailey</td>
<td>Mr. Bailey has disclosed that he receives salary from and has ownership in Insight Genetics, Inc.</td>
</tr>
<tr>
<td>P1-07-14</td>
<td>Roles of immune infiltration in patients with triple-negative breast cancers by molecular subtype and in patients with inflammatory and non-invasive breast cancers</td>
<td>Daniel Bailey</td>
<td>Mr. Bailey has disclosed that he receives salary from Insight Genetics, Inc.</td>
</tr>
<tr>
<td>OT3-01-03</td>
<td>A phase 1 trial of the safety and immunogenicity of a DNA plasmid-based vaccine (WOKVAC) encoding epitopes derived from three breast cancer antigens (IGFBP2, HER2, and IGF1R) in patients with breast cancer</td>
<td>Howard Bailey</td>
<td>Dr. Bailey has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P02-06</td>
<td>Metabolite repair deficiency reduces endocrine therapy resistance in breast cancer</td>
<td>Matthew Bainbridge</td>
<td>Dr. Bainbridge has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P01-13</td>
<td>Something from nothing? The call for quality control in liquid biopsy studies</td>
<td>Pushpinder Bains</td>
<td>Dr. Bains has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT1-04-03</td>
<td>Cambridge breast met trial 1 (CamBMIT): A proof-of-principle phase Ib / randomised phase 2 study of afludizib penetration into brain metastasis for patients undergoing neurosurgical resection, both with and without prior loss, targeted radiotherapy</td>
<td>Richard Baird</td>
<td>Dr. Baird has disclosed that he received a unrestricted educational grant for CamBMIT trial from Eisai-Ingbloheim.</td>
</tr>
<tr>
<td>P02-05</td>
<td>Phase II of POSIDON: A phase Ib / randomised phase II trial of tamsulosin plus taxol or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment</td>
<td>Richard Baird</td>
<td>Mr. Baird has disclosed that he received an unrestricted educational grant for contract research from Genentech. He has also disclosed that he received from Genentech - travel expenses to present at international conference (ECCD-0941) and honorarium for presenting at Genentech internal meeting (ECCD-0941).</td>
</tr>
<tr>
<td>OT3-12-02</td>
<td>A phase II of L-223011, a reversible EGFR and HER2 inhibitor, combined with trastuzumab +/- chemotherapy in patients with HER2-positive metastatic breast cancer</td>
<td>Richard Baird</td>
<td>Mr. Baird has disclosed that he is a consultant for and receives travel reimbursement from Shionogi. He also disclosed that he has a contract with Shionogi.</td>
</tr>
<tr>
<td>P4-21-08</td>
<td>A phase II study of AZD456, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC)</td>
<td>Richard Baird</td>
<td>Mr. Baird has disclosed that he is a consultant for and receives travel reimbursement from Shionogi. He also disclosed that he has a contract with Shionogi.</td>
</tr>
<tr>
<td>P6-12-04</td>
<td>A phase II study of AZD4956, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC)</td>
<td>Richard Baird</td>
<td>Mr. Baird has disclosed that AstraZeneca sponsored this trial.</td>
</tr>
<tr>
<td>P4-12-20</td>
<td>Predictors of social support among newly diagnosed breast cancer patients seeking care at an urban safety net academic medical center</td>
<td>Sharon Bajwa</td>
<td>Ms. Bajwa has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-10-09</td>
<td>Efficacy results of a phase 1/2 study of glanzircept to receptor (GIR) antagonist meparepitope (MFF) in combination with pertuzumab in GRA-positive triple-negative breast cancer (TNBC)</td>
<td>Gabrielle Baker</td>
<td>Ms. Baker has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Poster Number</td>
<td>Title</td>
<td>Presenter</td>
<td>Disclosures</td>
</tr>
<tr>
<td>---------------</td>
<td>----------------------------------------------------------------------</td>
<td>-----------------</td>
<td>-------------------------------------------------</td>
</tr>
<tr>
<td>P1-02-08</td>
<td>Provista-002: A prospective, multi-center study to determine the effectiveness of a biomarker assay to distinguish benign from invasive breast cancer in women with BI-RADS 3, 4 and 5 imaging reports</td>
<td>Karen Baker</td>
<td>Dr. Baker has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-22-11</td>
<td>Combined therapeutic strategies for advanced triple negative breast cancer: A phase II trial of nab-paclitaxel and bevacizumab followed by maintenance targeted therapy with bevacizumab and erlotinib</td>
<td>Kelsey Baker</td>
<td>Ms. Baker has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-09</td>
<td>Programmed death 1 (PD-1) and PD-1 ligand (PD-L1) distribution in triple negative breast cancer (TNBC)</td>
<td>Fabari Baker</td>
<td>Dr. Baker has disclosed that he receives salary from Caris Life Sciences.</td>
</tr>
<tr>
<td>P3-02-06</td>
<td>Magnetic resonance imaging (MRI) surveillance for patients with dense breasts and a previous breast cancer (BC) and/or high risk lesion</td>
<td>Sharmila Balasingham</td>
<td>Sharmila Balasingham has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-10-01</td>
<td>Utilization and outcomes of post-mastectomy radiotherapy in women with 3-3+ positive axillary nodes following neoadjuvant chemotherapy: A multiparametric, propensity-adjusted National cancer database analysis</td>
<td>Gounelappa Balasubramani</td>
<td>Dr. Balasubramani has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-07-06</td>
<td>Immune signatures define and affect prognosis in triple negative breast cancer subtypes</td>
<td>Győrfy Balazs</td>
<td>Győrfy Balazs has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-02-02</td>
<td>The predictive value of sentinel node biopsy (SNB) in early breast cancer after neo-adjuvant chemotherapy (NACT): A prospective study</td>
<td>Marcella Baldewijns</td>
<td>Dr. Baldewijns has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-11-10</td>
<td>Preclinical efficacy of the novel PIM2 kinase inhibitor, JP11646 in triple negative breast cancer models</td>
<td>Carmen Baldinno</td>
<td>Dr. Baldino has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S6-01</td>
<td>12 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: results of the phase III multicentric Italian short-HER trial</td>
<td>Sara Balduzzi</td>
<td>Ms. Balduzzi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-09-10</td>
<td>Pathological complete response to neoadjuvant trastuzumab is dependent on HER2/CPI-17 ratio in HER2-amplified early breast cancer</td>
<td>Marija Balic</td>
<td>Dr. Balic has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-15-13</td>
<td>Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Final FFS results of a phase II trial (ABCSG-40)</td>
<td>Marija Balic</td>
<td>Dr. Balic has disclosed that she is a consultant for and receives traveler grants from Mundipharma.</td>
</tr>
<tr>
<td>P6-10-01</td>
<td>Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomized, neoadjuvant phase II study (ABCSG-34)</td>
<td>Marija Balic</td>
<td>Dr. Balic has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-04-02</td>
<td>Improving immunotherapy response by epigenetic modulation</td>
<td>Justin Balko</td>
<td>Dr. Balko has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-04-02</td>
<td>Differential effect of chemotherapy on immune gene expression signatures based on molecular subtype of breast cancer</td>
<td>Justin Balko</td>
<td>Dr. Balko has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-10-02</td>
<td>MHC-II positive breast tumors are more immunogenic and may preferentially select for LAG-3-positive tumor immune infiltrates</td>
<td>Justin Balko</td>
<td>Dr. Balko has disclosed Incyte pharmaceuticals funds research in his lab.</td>
</tr>
<tr>
<td>P6-09-16</td>
<td>Identification of proliferation-related drivers and their role in precision medicine for breast cancers: A retrospective multidimensional comparative, integrated genomic, transcriptomic, and protein analysis</td>
<td>Graham Bell</td>
<td>Dr. Bell has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-11-01</td>
<td>Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study</td>
<td>Annamaria Ballari</td>
<td>Ms. Ballari has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-07-21</td>
<td>High reduction of circulating tumour cells in HER2-negative locally advanced or metastatic breast cancer (LAMBC) patients treated with eribulin as third line chemotherapy (ONSITE study)</td>
<td>Anaíse Balestier-García</td>
<td>Ms. Balestier-García has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-07-17</td>
<td>Squalene epoxidase is a potential metabolic oncogene by amplification with clinical implications in breast carcinoma: An in silico pan-cancer study with in vitro evidence</td>
<td>Alberto Balestier</td>
<td>Dr. Balestier has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
Predictors of locoregional recurrence after neoadjuvant chemotherapy and surgery for node positive breast cancer:
Results from ACOSOG Z1071 (Alliance)
Karla Ballman
Dr. Ballman has no relevant financial relationships to disclose.

Long-term outcome of HER2-normal early stage breast cancer (ECRC) patients (Pts) treated with docetaxel-cyclophosphamide (TC) chemotherapy (CTx): Maturity results of a single-institution experience
Josephine Battle
Ms. Battle has no relevant financial relationships to disclose.

Duration of fasting before taking lapatinib is associated with skin toxicity in neoadjuvant treatment of HER2 positive breast cancer:
A cohort study from (BCRC 16/Neo-LaTH)
Eva Balislev
Dr. Balislev has no relevant financial relationships to disclose.

Oncologic outcomes of immediate breast reconstruction after neoadjuvant chemotherapy in breast cancer patients:
A matched case control study
Sa Ik Bang
Sa Ik Bang has no relevant financial relationships to disclose.

The ectopic FOXA1 expression correlates to the luminal breast cancer stem cells
Hiroko Bando
Dr. Bando has no relevant financial relationships to disclose.

NRG-BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) &/or surgical ablation for newly oligometastatic breast cancer
Nanna Bandos
Dr. Bandos has no relevant financial relationships to disclose.

NRG oncology/NSABP B-51/RTOG 1304: A phase III superiority clinical trial designed to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RMTI to breast RT post breast-conserving surgery (BCS) will reduce invasive cancer events in patients (pts) with positive axillary (Ax) nodes and convert to ypT0 after neoadjuvant chemotherapy (NC)
Hanna Bandos
Dr. Bandos has no relevant financial relationships to disclose.

A randomized, double-blinded, placebo-controlled clinical trial to evaluate extended adjuvant endocrine therapy (5 years of letrozole) in postmenopausal women with hormone-receptor positive breast cancer who have completed previous adjuvant endocrine therapy: Initial results of NRG oncology/NSABP B-42
Hanna Bandos
Dr. Bandos has no relevant financial relationships to disclose.

An international multicenter study to evaluate reproducibility of automated scoring methods for assessment of ki67 in breast cancer
Nanna Bandos
Dr. Bandos has no relevant financial relationships to disclose.

A novel anti-HER2 ADC, shows promising activity in patients with HER2 positive and HER2 negative metastatic breast cancer
Udai Banerji
Udai Banerji has disclosed that he is a principal investigator in the trial.

Oncologic outcomes of immediate breast reconstruction after neoadjuvant chemotherapy in breast cancer patients:
A matched case control study
Sa Ik Bang
Sa Ik Bang has no relevant financial relationships to disclose.

Comparison of HER2, estrogen and progesterone receptor expression profiles of primary tumor, synchronous axillary lymph node metastases and circulating tumor cells in early breast cancer patients
Aghes Bankfashi
Ms. Bankfashi has no relevant financial relationships to disclose.

Community breast navigation improves breast cancer screening in Hartford, CT
Kashira Banks
Ms. Banks has no relevant financial relationships to disclose.
Targeted and selective degradation of estrogen receptor (ER) alpha by PROTACs

Marcus Bantscheff
Mr. Bantscheff has disclosed that he receives salary and has ownership.

The perception of chronic pain among breast cancer survivors

Ying Bao
Dr. Bao has no relevant financial relationships to disclose.

Arthritis-associated aging perceptions predict adherence to aromatase inhibitors among women with breast cancer

Ying Bao
Dr. Bao has no relevant financial relationships to disclose.

An randomized study comparing Mediator to topical lidocaine for female breast cancer survivors with dyspareunia

Summer Baptist
Biosource Baraitar
Biosource Baraitar has no relevant financial relationships to disclose.

Increased stromal lymphocytes in breast cancer patients with autologous dendritic cell vaccination plus neoadjuvant chemotherapy

Summer Baptist
Biosource Baraitar
Biosource Baraitar has no relevant financial relationships to disclose.

Vitamin D as a potential biomarker of aggressiveness in non-metastatic breast cancer

Summer Baptist
Biosource Baraitar
Biosource Baraitar has no relevant financial relationships to disclose.

Dr. Bao has no relevant financial relationships to disclose.

Arthralgia-associated aging perceptions predict adherence to aromatase inhibitors among women with breast cancer

Ting Bao
Dr. Bao has no relevant financial relationships to disclose.

The perception of chronic pain among breast cancer survivors

Ting Bao
Dr. Bao has no relevant financial relationships to disclose.

A randomized study comparing MoistHer to topical lidocaine for female breast cancer survivors with dyspareunia

Summer Baptist
Dr. Baptist has no relevant financial relationships to disclose.

A randomized study comparing MoistHer to topical lidocaine for female breast cancer survivors with dyspareunia

Summer Baptist
Dr. Baptist has no relevant financial relationships to disclose.

Increased stromal lymphocytes in breast cancer patients with autologous dendritic cell vaccination plus neoadjuvant chemotherapy

Summer Baptist
Dr. Baptist has no relevant financial relationships to disclose.

A randomized study comparing MoistHer to topical lidocaine for female breast cancer survivors with dyspareunia

Summer Baptist
Dr. Baptist has no relevant financial relationships to disclose.

Increased stromal lymphocytes in breast cancer patients with autologous dendritic cell vaccination plus neoadjuvant chemotherapy

Summer Baptist
Dr. Baptist has no relevant financial relationships to disclose.

Increased stromal lymphocytes in breast cancer patients with autologous dendritic cell vaccination plus neoadjuvant chemotherapy

Summer Baptist
Dr. Baptist has no relevant financial relationships to disclose.

Increased stromal lymphocytes in breast cancer patients with autologous dendritic cell vaccination plus neoadjuvant chemotherapy

Summer Baptist
Dr. Baptist has no relevant financial relationships to disclose.

Arthralgia-associated aging perceptions predict adherence to aromatase inhibitors among women with breast cancer

Ting Bao
Dr. Bao has no relevant financial relationships to disclose.
A phase 1 study of RAD1901, a novel, oral selective estrogen receptor degrader, for the treatment of ER-positive advanced breast cancer
Aditya Bardia
Aditya Bardia has disclosed that he is a consultant for Novartis, Genentech and Immunomedics.

Research biopsies in oncology-patient willingness, perceptions, understanding, and experience: An integrative review
Aditya Bardia
Dr. Bardia has disclosed that he is a consultant for Novartis, Genentech and Immunomedics.

Sacituzumab govitecan (IMMU-132), an anti-Trop-2 SN-38 antibody-drug conjugate (ADC) for the treatment of refractory/multiresistant metastatic triple-negative breast cancer (mTNBC) - Updated results
Aditya Bardia
Dr. Bardia has no relevant financial relationships to disclose.

Role of tumor microenvironment, as assessed by breast MRI background parenchymal enhancement (BPE), in modulating response to neoadjuvant chemotherapy in young women with localized breast cancer
Aditya Bardia
Dr. Bardia has no relevant financial relationships to disclose.

Effect of supplementation with eicosapentaenoic and docosahexaenoic omega-3 polyunsaturated fatty acid on the chemotoxicity in Mexican patients with locally advanced breast cancer (LABC) treated with neoadjuvant chemotherapy (NeoCT)
Juan Bargallo-Rocha
Dr. Bargallo-Rocha has no relevant financial relationships to disclose.

Li-Fraumeni syndrome in females with early onset breast cancer in a Mexican population
Enrique Bargallo-Rocha
Dr. Bargallo-Rocha has no relevant financial relationships to disclose.

Shared decision-making approach in breast reconstruction in a developing country
Enrique Bargallo-Rocha
Dr. Bargallo-Rocha has no relevant financial relationships to disclose.

Young women with breast cancer in Mexico: A report of the pilot phase of the "Mujer Joven y Fuerte" prospective cohort
Enrique Bargallo-Rocha
Dr. Bargallo-Rocha has no relevant financial relationships to disclose.

Tumor and serum DNA methylation in women receiving neoadjuvant chemotherapy (PST) with or without vorinostat in primary operable HER2-negative breast cancer in TBCRC008
Edward Barileon
Mr. Barileon has no relevant financial relationships to disclose.

21-gene recurrence score® in patients with primary metastatic ER+ HER2- breast cancer
Jone Barinoff
Dr. Barinoff has no relevant financial relationships to disclose.

Effects of local and radiation enhanced TGFβ on the invasive nature of inflammatory breast cancer cells
Sangjucta Barkataki
Sangjucta Barkataki has no relevant financial relationships to disclose.

Incidence of germline BRCA1- and BRCA2-mutated breast cancer in the US
Arie Barlev
Dr. Barlev has disclosed that he is an employee of Medivation, Inc.

Discovery of molecular predictors of late breast cancer specific events (BCSE) in ER+, node+ breast cancer - new transcriptome expression whole gene analysis of the phase III adjuvant trial SWOG S8814
Ishan Barman
Prof. Barman has no relevant financial relationships to disclose.

Early detection of development of a pre-metastatic niche in lungs in response to primary breast tumor using Raman spectroscopy
William Barlow
Dr. Barlow has no relevant financial relationships to disclose.

Decoding the genetic basis of mammary mineralization and their putative role in promotion of distant metastases
Shan Barman
Prof. Barman has no relevant financial relationships to disclose.

A phase 2 randomized, double-blind, placebo-controlled trial of sodium-233 chloride with exemestane and everolimus in patients with HER2-negative, hormone receptor-positive breast cancer and bone metastases
Agusit Barnadas
Dr. Barnadas has disclosed that he is a consultant for Pfizer and Roche. He also disclosed he has contracts with Roche, Pfizer and AstraZeneca and receives honoraria from Roche, Celgene, AstraZeneca and Pfizer and travel, accommodation and expenses from Roche.

Increased tumor perfusion following treatments with trastuzumab as measured by contrast-enhanced ultrasound
Stephanie Barnes
Dr. Barnes has no relevant financial relationships to disclose.

Quantitative in vivo imaging of intratumoral heterogeneity to assess tumor response to trastuzumab treatment in a preclinical model of HER2+ breast cancer
Stephanie Barnes
Ms. Barnes has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
<th>Disclosures</th>
</tr>
</thead>
<tbody>
<tr>
<td>PAINTER: Evaluation of eribulin tolerability and correlation between a set of polymorphisms and neuropathies in patients with metastatic breast cancer</td>
<td>Sandro Barni</td>
<td>Mr. Barni has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-09-12: Dose dense adjuvant chemotherapy in patients with early breast cancer: Differential treatment effects according to composite index of benefit</td>
<td>Sandro Barni</td>
<td>Mr. Barni has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-15-17: Platinum salts in advanced breast cancer: A systematic review and meta-analysis of randomized clinical trials</td>
<td>Sandro Barni</td>
<td>Dr. Barre has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-16-19: Evaluation of weekly paclitaxel plus carboplatin followed by anthraimidoxine chemotherapy on the neoadjuvant treatment of patients with triple-negative breast cancer</td>
<td>Sandro Barni</td>
<td>Dr. Barre has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-10-06: Genomic testing for HRD among women with a personal diagnosis of breast cancer in patients with Medicaid as compared to patients with private insurance</td>
<td>Paul Barone</td>
<td>Dr. Baran has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-03-07: Evaluation of weekly paclitaxel plus carboplatin followed by bevacizumab for breast cancer</td>
<td>Patrice Barnes</td>
<td>Dr. Barone has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-13-04: Use of an absorbable implant to mark the lumpectomy cavity: Initial report of 300 patients in a multi-center registry database</td>
<td>Julie Barone</td>
<td>Ms. Barone has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-04-05: Preoperative axillary ultrasound needle sampling in breast cancer: Comparing the sensitivity of fine needle aspiration cytology and core needle biopsy</td>
<td>Simone Barone</td>
<td>Dr. Barn has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-02-21: Preoperative axillary ultrasound needle sampling in breast cancer: Comparing the sensitivity of fine needle aspiration cytology and core needle biopsy</td>
<td>Simon Barr</td>
<td>Mr. Barr has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-14-14: Endoscopic 3D latissimus dorsi muscle harvesting for immediate breast reconstruction: Results of our 7 patients experience in Antoine Lacassagne Nice Cancer Center</td>
<td>Emmanuel Barranger</td>
<td>Dr. Barranger has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S3-08: Sentinel node detection after neoadjuvant chemotherapy in patient without previous axillary node involvement (GANEA 2 trial): Follow-up of a prospective multi-institutional cohort</td>
<td>Emmanuel Barranger</td>
<td>Dr. Barranger has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-05-02: Conditional expression of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) in the mouse mammary epithelium alters mammary gland development</td>
<td>Kate Barrett</td>
<td>Ms. Barnett has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P08-05: Comparative analysis of the genomic landscape of breast cancers from women of African and European ancestry</td>
<td>Jordi Barreto</td>
<td>Mr. Barreto has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-17-05: Claudin-4 expression is associated with disease free survival in breast carcinoma in situ: Mean follow up of 8.2 years</td>
<td>Carolina Barreto</td>
<td>Dr. Barreto has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-03-13: Claudin-4 expression is associated with disease free survival in breast carcinoma in situ: Mean follow up of 8.2 years</td>
<td>Carolina Barreto</td>
<td>Dr. Barreto has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-01-21: Claudin-4 expression is associated with disease free survival in breast carcinoma in situ: Mean follow up of 8.2 years</td>
<td>Carolina Barreto</td>
<td>Dr. Barreto has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S6-01: BRCA1 methylation status, silencing and treatment effect in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)</td>
<td>Sophie Barnett</td>
<td>Ms. Barnett has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
S6-01  BRCA1 methylation status, silencing and treatment effect in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)  Peter Barrett-Lee  Mr. Barrett-Lee has no relevant financial relationships to disclose.

P6-15-01  Analysis of neural function in MONARCH 1: A phase 2 study of abemaciclib, a CDK4 & 6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for metastatic breast cancer (MBC)  Susana Barriga  Ms. Barriga has disclosed that she has a contract with and is employed by Eli Lilly and Company.

S4-06  Biological effects of abemaciclib in a phase2 neoadjuvant study for postmenopausal patients with hormone receptor positive, HER2 negative breast cancer  Susana Barriga  Ms. Barriga has disclosed that she has a contract with and is employed by Eli Lilly and Company.

S5-04  Low-Fat dietary pattern and breast cancer overall survival in the women’s health initiative dietary modification randomized controlled trial  Wendy Barrington  Dr. Barrington has no relevant financial relationships to disclose.

P1-12-10  Safety and efficacy of trastuzumab emtansine (T-DM1) in 399 patients with central nervous system metastases: Exploratory subgroup analysis from the KAMILLA study  Carlos Barrios  Mr. Barrios has disclosed that he is a consultant for Boehringer-Ingelheim, GSK, Novartis, Pfizer, Roche/Gentech, Eisai and Biogen.  He has also disclosed that he has contracts with Boehringer Ingelheim, GSK, Roche/Gentech, Lilly, Sanofi, Takeda, Mylan, Merck, Abbvie, Astellas, Bionx, BMS, Daiichi Sankyo, AstraZeneca, AB Science, Amgen, Astra, AbbVie, MedImmune, Meda, Ely Lilly, Roche, Genentech, and Sanofi.

P3-08-10  Time-evolution of the efficacy of first line aromatase inhibitors (AI) in hormone receptor positive (HR+) advanced breast cancer (ABC): A moving target  Carlos Barrios  Dr. Barrios has no relevant financial relationships to disclose.

P6-16-04  Real World data and patterns of care of metastatic breast cancer (MBC) in Brazil: First results of LACOG 0132 retrospective study  Carlos Barrios  Dr. Barrios has no relevant financial relationships to disclose.

P4-22-21  NCI9782: A phase 1 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors  Laurel Barroilhet  Dr. Barroilhet has no relevant financial relationships to disclose.

OBI-01-09  Feasibility and safety of avoiding granulocyte colony-stimulating factor prophylaxis during the paclitaxel portion of dose dense doxorubicin-cyclophosphamide and paclitaxel regimen  Bomsoulho Barros-Sousa  Mr. Barros-Sousa has no relevant financial relationships to disclose.

P5-02-06  The impact of the introduction of breast cancer screening on a symptomatic breast cancer unit  Kevin Barry  Mr. Barry has no relevant financial relationships to disclose.

P5-10-08  Estrogen receptor quantitative measures and differences in breast cancer survival  Marc Barry  Dr. Barry has no relevant financial relationships to disclose.

S5-05  Impact of pre-operative exercise on breast cancer gene expression  William Barry  Mr. Barry has no relevant financial relationships to disclose.

OBI-01-09  Feasibility and safety of avoiding granulocyte colony-stimulating factor prophylaxis during the paclitaxel portion of dose dense doxorubicin-cyclophosphamide and paclitaxel regimen  Todd Barry  Dr. Barry has disclosed that he is a consultant for Prelude Corporation.

P1-07-05  Integrated transcriptional analysis of the triple negative 'proliferation paradox': High proliferation, chemosensitivity, and poor prognosis  William Barstis  Dr. Barstis has no relevant financial relationships to disclose.

P1-12-04  Phase I dose-escalation trial of ONT-380 in combination with trastuzumab in patients (pts) with HER2+ breast cancer brain metastases  William Barry  Dr. Barry has no relevant financial relationships to disclose.

S5-05  Impact of pre-operative exercise on breast cancer gene expression  William Barry  Mr. Barry has no relevant financial relationships to disclose.

P1-12-07  Phase IIb single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine in the treatment of patients with HER2+ positive metastatic breast cancer with progression in the CNS after trastuzumab (TRIO-US B-09)  John Barstis  Dr. Barstis has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Disclosures</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1-10-02</td>
<td>A signature predictive of early vs. late recurrence after radiation treatment (RT) for breast cancer that may inform the biology of early, aggressive recurrences</td>
<td>Harry Bartelink</td>
<td>Dr. Bartelink has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-07-03</td>
<td>Epithelial origin of rapid biopsy: Plasma DNA does not accurately reflect tumor DNA in metastatic breast cancer</td>
<td>Richard Barth</td>
<td>Dr. Barth has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT1-04-07</td>
<td>VICTORIANE: A randomized phase 3 study assessing the addition of oral everolimus to aromatase inhibitors for the treatment of patients with metastatic breast cancer</td>
<td>Philippe Berthelemy</td>
<td>Dr. Berthelemy has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-07-02</td>
<td>ST8SIA1 regulates tumourigenesis in triple negative breast cancer</td>
<td>Chandra Bartholomeusz</td>
<td>Dr. Bartholomeusz has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT2-01-06</td>
<td>Phase III study of palbociclib (PD-033991) in combination with endocrine therapy ( exemestane or fulvestrant) versus chemotherapy (cyclophosphamide) in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (mBC) patients with resistance to hormone inhibitors. “The FEAR study” (GIDEON/2013-02)</td>
<td>Cynthia Bartlett</td>
<td>Ms. Bartlett has disclosed that she is a Pfizer employee.</td>
</tr>
<tr>
<td>OT1-03-01</td>
<td>The UK CRGS trial Randomising patients with low or low intermediate grade ductal carcinoma in situ (DCIS) to surgery or active monitoring</td>
<td>John Bartlett</td>
<td>Dr. Bartlett has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-03-01</td>
<td>An international multicenter study to evaluate reproducibility of automated scoring methods for assessment of Ki67 in breast cancer</td>
<td>John Bartlett</td>
<td>Dr. Bartlett has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-05-17</td>
<td>Evaluation of the Oncoscore focus and comprehensive assays for therapeutic stratification in early hormone receptor positive breast cancer</td>
<td>John Bartlett</td>
<td>Dr. Bartlett has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-07-06</td>
<td>MicroRNAs associated with acquired taxane resistance in a breast cancer cell line model</td>
<td>John Bartlett</td>
<td>Dr. Bartlett has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-08-06</td>
<td>Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with Trastuzumab</td>
<td>John Bartlett</td>
<td>Dr. Bartlett has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-07</td>
<td>5-year follow-up and biomarker discovery for adjuvant endocrine therapy: results of the TEAM trial</td>
<td>John Bartlett</td>
<td>Dr. Bartlett has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-15-03</td>
<td>nab-paclitaxel + carboplatin vs gemcitabine/eribulin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomised phase 2 portion of the IBCSG trial</td>
<td>Delores Barton</td>
<td>Ms. Barton has disclosed that she is an employee of Celgene Corporation.</td>
</tr>
<tr>
<td>P1-08-06</td>
<td>BC 300 receptor is related to the progression of triple negative breast cancer</td>
<td>Marie Barton</td>
<td>Ms. Barton has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-14-31</td>
<td>An estimation of the population survival benefit of first-line chemotherapy and immunotherapy for breast cancer</td>
<td>Michael Barton</td>
<td>Mr. Barton has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-03-06</td>
<td>Microenvironmental control of breast cancer subtype elicited by estrogen growth factors signaling</td>
<td>Michael Bartoschek</td>
<td>Mr. Bartoschek has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-09-10</td>
<td>Pathological complete response to neoadjuvant trastuzumab is dependent on HER2/CD17 ratio in HER2-amplified early breast cancer</td>
<td>Rupert Bartsch</td>
<td>Mr. Bartsch has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-22-20</td>
<td>Efficacy and safety of everolimus plus exemestane in HR+, HER2- advanced breast cancer progressing on/or after prior endocrine therapy, in routine clinical practice: 2nd interim analysis from STEPAUT</td>
<td>Rupert Bartsch</td>
<td>Mr. Bartsch has disclosed that he is a consultant for Novartis and receives lecture honoraria, travel and research support from Novartis.</td>
</tr>
<tr>
<td>P6-10-01</td>
<td>Efficacy and safety of the therapeutic cancer vaccine bamecitabine (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ARCoS 54)</td>
<td>Rupert Bartsch</td>
<td>Dr. Bartsch has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-16-16</td>
<td>Role of tumour microenvironment, as assessed by breast MRI background parenchymal enhancement (BPE), in modulating response to neoadjuvant chemotherapy in young women with localized breast cancer</td>
<td>Regina Barislay</td>
<td>Dr. Barislay has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-04-25</td>
<td>Role of miR-130b in development of resistance to endocrine therapy in breast cancer cells</td>
<td>Pratima Basak</td>
<td>Dr. Basak has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy

Jose Baselga
Dr. Baselga has no relevant financial relationships to disclose.

Phase II study of trastuzumab, pertuzumab, and valproic acid for HER2-positive metastatic breast cancer: Results from NeoALTTO

Jose Baselga
Dr. Baselga has disclosed that he is a consultant for Novartis, Juno Therapeutics, Aura Biosciences, Verastem and Infinity Pharmaceuticals.

Plasma microRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from SOUTHERNNEIDERBULIN phase II clinical trial in HER2-negative early breast cancer

Jose Baselga
Dr. Baselga has no relevant financial relationships to disclose.

SANDPIPER: Phase II study of the P3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA-mutant tumors

Jose Baselga
Dr. Baselga has no relevant financial relationships to disclose.

Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2 positive early breast cancer (BIG 1-06)

Jose Baselga
Dr. Baselga has no relevant financial relationships to disclose.

Efficacy and gene expression results from SOLTI1007 NEOERIBULIN phase II clinical trial in HER2-negative early breast cancer

Jose Baselga
Dr. Baselga has no relevant financial relationships to disclose.

Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2 positive early breast cancer (BIG 1-06)

Jose Baselga
Dr. Baselga has no relevant financial relationships to disclose.

Phase II study of taselisib (GDC-0032) plus fulvestrant in HER2-negative, hormone receptor-positive advanced breast cancer: Analysis by PIK3CA and ESR1 mutation status from circulating tumor DNA

Jose Baselga
Dr. Baselga has no relevant financial relationships to disclose.

Neratinib + fulvestrant in ERBB2-mutant, HER2-non-amplified, estrogen receptor (ER)-positive, metastatic breast cancer (MBC): Preliminary analysis from the phase II SUMMIT trial

Jose Baselga
Dr. Baselga has no relevant financial relationships to disclose.

impact of estrogen receptor expression in breast cancer: Optimizing timing of biopsy

Mark Basik
Mr. Basik has no relevant financial relationships to disclose.

Charnian reserve and response to controlled ovarian supersalmonization (COS) in breast cancer women with and without BRCA mutation

Laurent Bassan
Ms. Bassan has no relevant financial relationships to disclose.

Trastuzumab IV versus SC: A time, motion and cost assessment in a lean operating day care oncology unit

Farzad Basik
Dr. Basik has no relevant financial relationships to disclose.

Breast cancer brain metastases show limited intrinsic subtype switching, yet exhibit acquired ERBB2 amplifications and activating mutations

Ahmed Bassan
Dr. Bassan has no relevant financial relationships to disclose.

Rates of successful engraftment in breast cancer xenograft models based on tissue type: Primary vs relapsed disease

Cherie Bates
Ms. Bates has no relevant financial relationships to disclose.

High concordance of ER, PR, HER2 and Ki67 by central IHC and FISH with mRNA measurements by GeneXpert® breast cancer stratifier assay

Michael Bates
Mr. Bates has no relevant financial relationships to disclose.

High concordance of a closed system, near point of care, RT-qPCR breast cancer assay for HER2 (ERBB2) mRNA compared to both IHC/FISH and quantitative immunofluorescence

Michael Bates
Mr. Bates has no relevant financial relationships to disclose.

Highly reproducible decentralized gene expression analysis of ESR1, PGR, ERBB2 and MKi67 on an automated, standardized molecular diagnostics platform, GeneXpert

Michael Bates
Mr. Bates has no relevant financial relationships to disclose.

Analytical validation for the RT-qPCR based multiplex mRNA measurements of ER, PgR, HER2, and Ki67 from FFPE tumor tissue using the GeneXpert breast cancer stratifier assay

Michael Bates
Mr. Bates has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>OT2-02-05</td>
<td>Pilot study of zirconium-89 bevacizumab positron emission tomography for imaging angiogenesis in patients with inflammatory breast carcinoma receiving preoperative chemotherapy</td>
<td>Jennifer Bellon</td>
<td>Dr. Bellon has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-17-07</td>
<td>Improved long-term outcomes of breast-conserving therapy for women with ductal carcinoma in situ</td>
<td>Jennifer Bellon</td>
<td>Ms. Bellon has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-12-04</td>
<td>Breast cancer subtype, age and lymph node status as predictors of local recurrence following breast-conserving therapy</td>
<td>Jennifer Bellon</td>
<td>Dr. Bellon has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-06-09</td>
<td>Relationships between breast cancer subtypes and expression of autophagy-related genes</td>
<td>Soufian Belmiloudi</td>
<td>Dr. Belmiloudi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-11-11</td>
<td>A phase I/II study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA)</td>
<td>Vrashid Berman</td>
<td>Dr. Berman has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-06-10</td>
<td>Next generation sequencing (NGS) reveals high mutation rates in all established breast cancer subtypes with subtype-specific patterns</td>
<td>Vahid Berman</td>
<td>Dr. Berman has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-15-01</td>
<td>Prognostic significance of CD3a+ tumor-infiltrating lymphocytes (TILs), CD4+ TILs and TILs in male breast cancer</td>
<td>Samuel Ben Hassoun</td>
<td>Dr. Ben Hassoun has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-21-17</td>
<td>BELS: Safety and tolerability of all home administration of trastuzumab (Herceptin®) subcutaneous for the treatment of patients with HER2-positive early breast cancer</td>
<td>Rosa Ben-Baruch</td>
<td>Ms. Ben-Baruch disclosed that she is a participant in moderation tumor board discussions for Roche.</td>
</tr>
<tr>
<td>P1-05-20</td>
<td>The incidence and outcomes of brain metastases in HER2-positive metastatic breast cancer with the advent of modern anti-HER2 therapies</td>
<td>Julia Benbow</td>
<td>Ms. Benbow has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-12-08</td>
<td>Diagnosing cognitive impairment (‘chemo brain’) in breast cancer survivors</td>
<td>Gloria Benbrook</td>
<td>Dr. Benbrook has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-43</td>
<td>BCL-2 as a long-term prognostic factor in invasive lobular carcinomas of the breast</td>
<td>Pär-Ola Bendahl</td>
<td>Dr. Bendahl has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT3-02-04</td>
<td>A randomized controlled trial comparing acupuncture versus usual care for the treatment of aromatase inhibitor-induced arthralgia (AIAX) in women with early-stage breast cancer</td>
<td>Grace Bendinger</td>
<td>Ms. Bendinger has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT3-07-05</td>
<td>Positive behavior change and weight loss in breast cancer survivors on hormonal adjuvant therapy: An energy balance research in cancer (EnBaR) prospective study</td>
<td>Grace Bendinger</td>
<td>Ms. Bendinger has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT3-07-04</td>
<td>A randomized study comparing MoistHer to topical lidocaine for female breast cancer survivors with dyspareunia</td>
<td>Grace Bendinger</td>
<td>Ms. Bendinger has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT3-08-01</td>
<td>A randomized study of personalized music therapy for patients with early stage breast cancer receiving chemotherapy</td>
<td>Grace Bendinger</td>
<td>Ms. Bendinger has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT3-09-05</td>
<td>Efficacy of screening and treatment of breast cancer patients reporting high level of distress</td>
<td>Grace Bendinger</td>
<td>Ms. Bendinger has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-15-03</td>
<td>nab-paclitaxel + carboplatin vs gemcitabine/docetaxel as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the T0cky trial</td>
<td>Carmelo Bengal</td>
<td>Mr. Bengal has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-03-05</td>
<td>A comprehensive molecular analysis of inflammatory breast carcinoma: A model of immunosuppressive triple negative breast cancer subtype</td>
<td>Vanessa Basham</td>
<td>Ms. Basham has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>PD1-06</td>
<td>Comparison of mutational landscapes of primary breast cancer and first metastatic relapse: Results from the EGIST study</td>
<td>Vanessa Basham</td>
<td>Ms. Basham has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S1-09</td>
<td>Radioactive seed localization versus wire-guided localization of nonpalpable invasive and in situ breast cancer: A Danish multicenter randomized controlled trial</td>
<td>Camil Benian</td>
<td>Dr. Benian has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC)

Mark Bennett

Dr. Bennett has disclosed that he is employed by Calithera.

Clinical value of 18F-fluorodeoxyglucose PET in HER2-positive breast cancer patients with a clinical dilemma

Frederike Bensch

Prof. Benson has no relevant financial relationships to disclose.

The impact of a change in margin width on rates of re-excision following breast conserving surgery

John Benson

Prof. Benson has no relevant financial relationships to disclose.

A liquid biopsy test for breast cancer detection provides persistent diagnostic results in patients over six months

Kasey Benson

Dr. Benson has disclosed that he is a patent holder, a salary employee of and owns stock of Provista Diagnostics.

A blood-based proteomic Videssa® breast assay performs comparably in women with dense and non-dense breasts

Kasey Benson

Dr. Benson has disclosed that he is a salary employee of, patent holder and owns stock in Provixta Diagnostics.

Comparative analysis of the genomic landscape of breast cancers from women of African and European ancestry

Odunayo Benson

Dr. Benson has no relevant financial relationships to disclose.

A novel progesterone receptor (PR)-RNA polymerase III association represses estrogen-dependent growth in breast tumor patient-derived xenografts

David Bentley

Dr. Bentley has no relevant financial relationships to disclose.

A breast magnetic resonance imaging (MRI) useful for diagnosis of additional sites of disease in patients recently diagnosed with ductal carcinoma in situ (DCIS)

Ana Benveniste

Dr. Benveniste has no relevant financial relationships to disclose.

Is breast magnetic resonance imaging (MRI) useful for diagnosis of additional sites of disease in patients recently diagnosed with ductal carcinoma in situ (DCIS)?

Ana Benveniste

Dr. Benveniste has no relevant financial relationships to disclose.

Identification of breast cancers with an indolent disease course: 70 gene indolent threshold validation in a Swedish randomized trial of tamoxifen vs. not, with 20-year outcomes

Christopher Benz

Dr. Benz has no relevant financial relationships to disclose.

Comprehensive genomic characterization of circulating tumor cells (CTCs) in metastatic breast cancer (MBC) sheds light on the biology of blood-borne metastasis

Christopher Benz

Mr. Benz has disclosed that he is the President of Genomic Research at NantOmics.

Identifying patient-specific neoepitopes for cell-based and vaccine immunotherapy across breast cancer classifications reveals rarely shared recurrent neoepitopes

Steven Benz

Mr. Benz has disclosed that he is an employee of NantOmics.

Identification of breast cancers with an indolent disease course: 20 gene incident threshold validation in a Swedish randomized trial of tamoxifen vs. not, with 20-year outcomes

Christopher Benz

Dr. Benz has no relevant financial relationships to disclose.

Comprehensive genomic characterization of circulating tumor cells (CTCs) in metastatic breast cancer (MBC) sheds light on the biology of blood-borne metastasis

Christopher Benz

Mr. Benz has disclosed that he is the President of Genomic Research at NantOmics.

HER2 status remains the primary predictor of improved survival in patients with BCBM over the past 2 decades (1996-2015)

Peterson Bercedis

Dr. Bercedis has no relevant financial relationships to disclose.
P5-11-01 Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study Paola Berchialla Dr. Berchialla has no relevant financial relationships to disclose.

P4-03-11 Fibroblasts isolated from the “normal-like” tissue adjacent to breast tumours suppress healthy epithelial progenitor cell proliferation while supporting tumour cell growth Alexx Berdnikov Mr. Berdnikov has no relevant financial relationships to disclose.

P1-02-10 Reduced serum B-cell maturation antigen levels predict poor outcome in metastatic breast cancer patients in a phase 3 randomized 2nd-line hormone therapy trial James Berenson Dr. Berenson has disclosed that he is an Officer, and Stockholder in OncoTracker, a commercial entity to develop BCM as a biomarker.

P3-01-01 Automated, low-cost palpable breast lump triage for economically-developing countries Wendie Berg Dr. Berg has no relevant financial relationships to disclose.

P2-07-11 Discovery of molecular predictors of late breast cancer specific events (BCSE) in ER+, nodal breast cancer - new transcriptional expression whole gene analysis of the phase III adjuvant trial SWOG S8814 Jona Bergamaschi Dr. Bergamaschi has disclosed that she is an employee of Genomic Health Inc. and that she receives salary and owns stock.

P4-21-32 Treatment of early HER2-positive breast cancer in francotumors: a in everyday clinical practice: An overview after 10 years of its approval Atlana Bergamaschi Mr. Bergamaschi has no relevant financial relationships to disclose.

P1-01-02 Circulating tumor cells (CTC) and endothelial cells (CEC) prognostic value in HER2 negative metastatic breast cancer patients treated with first line weekly paclitaxel and bevacizumab: First results of a prospective cohort from the French Breast Cancer InterGroup Unicancer (UCBR): COMET study Frederique Berger Mr. Berger has no relevant financial relationships to disclose.

P1-03-05 A comprehensive molecular analysis of medullary breast carcinoma: A model of immunomodulatory triple negative breast cancer subtype Frederique Berger Mr. Berger has no relevant financial relationships to disclose.

P3-02-01 A monoclonal antibody against hypo-glycosylated bone sialoprotein II has application for diagnostic purposes in samples of breast cancer patients and for treatment of skeletal metastasis caused by MDA-MB-231 breast cancer cells in rats Inna Berger Dr. Berger has no relevant financial relationships to disclose.

P4-06-01 Patient derived DCIS mouse-intraductal (MIND) models recapitulate the full spectrum of human patient pathology and histologic features including progression to invasion in a subset of cases Jona Berger Mr. Berger has no relevant financial relationships to disclose.

P4-04-23 A monoclonal antibody against hypo-glycosylated bone sialoprotein II has application for diagnostic purposes in samples of breast cancer patients and for treatment of skeletal metastasis caused by MDA-MB-231 breast cancer cells in rats Inna Berger Mr. Berger has no relevant financial relationships to disclose.

P6-10-03 EXTREME 012 - Long-lasting responses in a phase II study of pembrolizumab for metastatic triple-negative breast cancer (mTNBC) Koenen Berger Dr. Berger has disclosed receiving research funding, through Karolinska University Hospital or Karolinska Institutet, from Astrazeneca, Amgen, Bayer, Merck, Pfizer, Roche, and Sanofi-Aventis.

P1-07-07 Multi-level gene expression signatures provide significant prognostic information in metastatic breast cancer patients Jonas Berg Dr. Berg has disclosed receiving research funding, through Karolinska University Hospital or Karolinska Institutet, from Astrazeneca, Amgen, Bayer, Merck, Pfizer, Roche, and Sanofi-Aventis.

P1-03-05 Molecular differences between screen-detected and interval breast cancers are largely explained by PAM50 subtypes Jonas Berg Dr. Berg has no relevant financial relationships to disclose.

P2-09-03 Long-term comparison of anastrozole versus tamoxifen: Results from LATTE/ATAC Jonas Berg Dr. Berg has disclosed that Karolinska Institute receives the following grant support: Amgen, AstraZeneca, Bayer, Merck, Roche, Sanofi-Aventis.

P2-01-19 SentiNot: A way to avoid sentinel-node biopsy (SNB) in patients with a preoperative diagnosis of ductal cancer in situ (DCIS) Leif Bergkvist Leif Bergkvist has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Paper Number</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3-04-09</td>
<td>Genomic analysis to evaluate response to neoadjuvant aromatase and fulvestrant in post-menopausal ER-positive HER2-negative breast cancer patients included in the UCBG CARMINA02 trial</td>
<td>Virginie Bernard</td>
<td>Dr. Bernard has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-06</td>
<td>Comparison of mutational landscapes of primary breast cancer and first metastatic relapse: Results from the ESPOE study</td>
<td>Virginie Bernard</td>
<td>Dr. Bernard has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>073-05-05</td>
<td>Three-monthly dynamic evaluation of CEA and CA15-3 (followed by 18-FDG PET) vs usual practice in the follow-up of early breast cancer (BC) patients (pts): A prospective randomized trial</td>
<td>Alessandra Bernardi</td>
<td>Dr. Bernardi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-12-16</td>
<td>Delivery and anti-tumor activity of nanoparticle eribulin (HalIRI, MM-398) in metastatic xenograft models of triple negative breast cancer</td>
<td>Nicholas Bernardi</td>
<td>Dr. Bernard has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>072-01-11</td>
<td>Phase II of POSITIV: A phase II/III randomized phase II trial of exemestane plus taxotere or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment</td>
<td>Rene Bernardi</td>
<td>Dr. Bernardi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-11-06</td>
<td>Bromodomain inhibitors represent a rational therapeutic option for the treatment of invasive lobular carcinoma</td>
<td>Rene Bernardi</td>
<td>Dr. Bernardi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-09-09</td>
<td>The effects of treatment-induced symptoms, depression and age on sexuality in premenopausal women with early breast cancer receiving adjuvant endocrine therapy</td>
<td>Sigrid Bernhard</td>
<td>Sigrid Bernhard has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-14-13</td>
<td>Total mastectomy and immediate breast reconstruction for breast cancer: A ten-year Canadian single institution experience</td>
<td>Christine Berrier</td>
<td>Dr. Berrier has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-10-04</td>
<td>Accelerated partial breast irradiation versus whole breast irradiation: Health-related quality of life analysis from a phase 3 trial</td>
<td>Marco Bernini</td>
<td>Dr. Bernini has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-09-12</td>
<td>A single-blind, randomized, placebo-controlled phase II study to evaluate the impact of oral (bendroflumethiazide on bone mineral density in osteoporotic breast cancer patients receiving adjuvant aromatase inhibitors: Final results of the single-center BONADUV trial</td>
<td>Marco Bernini</td>
<td>Dr. Bernini has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-06-05</td>
<td>Development and validation of a non-parametric breast cancer risk assessment model on US and European screening populations</td>
<td>Agnieszka Berenson</td>
<td>Dr. Berenson has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-20-03</td>
<td>Collateral damage from metastatic breast cancer - Preliminary results</td>
<td>Leslie Bernstein</td>
<td>Dr. Bernstein has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-19-03</td>
<td>A meta-analysis of cognitive impairment in breast cancer survivors treated with chemotherapy</td>
<td>Lori Bernstein</td>
<td>Dr. Bernstein has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-35</td>
<td>Proposal for a new breast cancer staging classification: Incorporating clinical and biologic factors</td>
<td>Donald Berry</td>
<td>Dr. Berry has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
Efficacy of high-dose vitamin D plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial

Donald Berry

Dr. Berry has disclosed that he receives consulting fees from and being co-owner of Berry Consultants.

The evaluation of ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial

Donald Berry

Dr. Berry has disclosed that he receives consulting fees from and being co-owner of Berry Consultants.

Multivariate analysis of subtype and gene expression signatures predictive of pathologic complete response (pCR) in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance)

Donald Berry

Dr. Berry has disclosed that he receives consulting fees from and being co-owner of Berry Consultants.

Determining the optimal vaccination strategy using a combination of the folate binding protein (FBP) peptide vaccine (E39+GM-CSF) and an attenuated version (E39') to maximize the immunologic response in breast cancer patients

John Berry

Dr. Berry has no relevant financial relationships to disclose.

Nonsteroidal, tissue selective androgen receptor modulator (SARM), enobosarm, reduces growth of androgen receptor-positive breast cancer in patient-derived preclinical models

Michael Berry

Dr. Berry has no relevant financial relationships to disclose.

The effect of adjuvant chemotherapy in a large consecutive series of ER-positive HER-2 negative early breast cancers

Patrick Bertles

Mr. Bertles has no relevant financial relationships to disclose.

A targetable EGFR-driven tumor-initiating program in breast cancer

Nicholas Bertos

Mr. Bertos has no relevant financial relationships to disclose.

Mechanisms of CD8+ T cell immunosuppression in triple negative breast cancer

Nicholas Bertos

Dr. Bertos has no relevant financial relationships to disclose.

The prognostic and predictive effect of tumor infiltrating lymphocytes is not determined by B-cells or PD-L1 expression in inflammatory breast cancer

François Bertucci

Mr. Bertucci has no relevant financial relationships to disclose.

Identification of SARR39093, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong antitumor activity in wild-type and mutant ER+ breast cancer models

Laurent Berivet

Ms. Berivet has no relevant financial relationships to disclose.

Pre-clinical antitumor activity, tumor localization, and pharmacokinetics of MP0274, an apoptosis inducing, biparatopic HER2-targeting DARPin®

Ralph Bessace

Mr. Bessace has disclosed that he receives salary and has ownership.

Genomic analysis to evaluate response to neoadjuvant anastrozole and fulvestrant in post-menopausal ER-positive HER2-negative breast cancer patients included in the UCBG CARMINA02 trial

Nadia Bessofiane

Ms. Bessofiane has no relevant financial relationships to disclose.

Prognostic significance of CA125 tumor-infiltrating lymphocytes (TILs), CD4+ TILs and TILs in male breast cancer

Them Bertaieh

Dr. Bertaieh has no relevant financial relationships to disclose.

Preclinical validation of a new tumor imaging agent targeting m6A to detect breast tumor using NIR light imaging

Frederic Bouver

Mr. Bouver has no relevant financial relationships to disclose.

A patient centered intervention for adaptation of cancer risk reduction guidelines in breast cancer survivors

Therese Beyers

Dr. Beyers has no relevant financial relationships to disclose.

The y537s ESR1 mutation is a dominant driver of distant ER-positive breast cancer metastasis

Amanda Beyer

Ms. Beyer has no relevant financial relationships to disclose.
A phase II study to compare fulvestrant (F) 500mg plus placebo (P) versus (vs) F 500mg plus palbociclib (P) as first line treatment for postmenopausal women with hormone receptor (HR)-positive advanced breast cancer (BC) sensitive to endocrine therapy (ET). “The FLIPPER study” (GEICAM/2014-12)

The FLIPPER study

A phase 2 study of poziotinib in patients with HER2-positive metastatic breast cancer (MBC) who have received prior HER2 regimens for MBC

Randomized phase 3 study of a novel, long-acting G-CSF (erflapegrastim) versus pegfilgrastim in the management of chemotherapy-induced neutropenia in early-stage breast cancer patients receiving docetaxel and cyclophosphamide (TC) (ADVANCE study)

A comprehensive molecular analysis of medullary breast carcinoma: A model of immunomodulatory triple negative breast cancer subtype

Preclinical efficacy of the novel PIM2 kinase inhibitor, JP11646 in triple negative breast cancer models

Phase I trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer

Mitochondria-nuclear communication regulates epithelial-mesenchymal transition and metastasis in triple negative breast cancer

Prostate cancer brain metatases show limited intrinsic subtype switching, yet exhibit acquired ERBB2 amplifications and activating mutations

A multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer: Early results of unplanned boost participants

Two-year follow-up results of a multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer

Disruption of the estradiol-regulated NTN1-UNC5A dependence receptor signaling axis causes a hybrid basal/luminal molecular phenotype in estrogen receptor-positive breast cancer cells

Role of CRISPRi, a long non-coding RNA, in development of resistance to endocrine therapy in breast cancer cells

A multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer: Early results of unplanned boost participants

Two-year follow-up results of a multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer

Disruption of the estradiol-regulated NTNS1-UNC5A dependence receptor signaling axis causes a hybrid basal/luminal molecular phenotype in estrogen receptor-positive breast cancer cells

A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA)
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P5-13-05</td>
<td>Effect of aromatase inhibitor (AI) therapy on sleep and activity patterns in early stage breast cancer</td>
<td>Manali Bhave</td>
<td>Dr. Bhave has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-01-16</td>
<td>Introduction of H1474R somatic mutation of PI3K p110alpha subunit in HER2-overexpressing mammary-epithelial cells confers a 'stem-like' phenotype and acute sensitivity to HSP90 inhibition</td>
<td>Neil Bhola</td>
<td>Dr. Bhola has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-08-10</td>
<td>Heterogeneity of PD-L1 expression in primary tumors and central lymph node metastases of triple negative breast cancer</td>
<td>Rui Qi</td>
<td>Dr. Qi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-08-09</td>
<td>Social media's impact on patient utilization of high-risk clinics for genetic counseling and testing services</td>
<td>Yara Baghi</td>
<td>Ms. Baghi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-09-04</td>
<td>A RB-1 loss-of-function gene signature (RBsig) predicts resistance to neoadjuvant chemotherapy in HER2+/OH+ breast cancer patients</td>
<td>Chiara Bagnoli</td>
<td>Ms. Bagnoli has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-02-07</td>
<td>Metabolomic analysis by nuclear magnetic resonance spectroscopy discriminates hormone receptor positive/HER2 negative breast cancer cell lines resistant to palbociclib</td>
<td>Chiara Bagnoli</td>
<td>Ms. Bagnoli has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-09-04</td>
<td>Proliferation and p21 refine risk of relapse in residual disease after HER2-directed therapies</td>
<td>Giula Bianchi</td>
<td>Ms. Bianchi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-10-04</td>
<td>A single-blind, randomized, placebo-controlled phase II study to evaluate the impact of oral ibandronate on bone mineral density in osteoporotic breast cancer patients receiving adjuvant aromatase inhibitors: final results of the single-center BONADUV trial</td>
<td>Simonetta Bianchi</td>
<td>Prof. Bianchi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-08-12</td>
<td>Proliferation and p21 refine risk of relapse in residual disease after HER2-directed therapies</td>
<td>Giampaolo Bianchini</td>
<td>Mr. Bianchini has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-09-03</td>
<td>Native sculpting of the triple negative breast cancer genome</td>
<td>Giampaolo Bianchini</td>
<td>Mr. Bianchini has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-09-03</td>
<td>Long-term comparison of anastrozole versus tamoxifen: Results from LATTE/ATAC</td>
<td>Angelo Bianco</td>
<td>Mr. Bianco has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-28</td>
<td>Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision-making</td>
<td>Frederic Bicciato</td>
<td>Dr. Bicciato has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-09-13</td>
<td>A RB-1 loss-of-function gene signature (RBsig) predicts resistance to neoadjuvant chemotherapy in HER2+/OH+ breast cancer patients</td>
<td>Silvio Bicciato</td>
<td>Dr. Bicciato has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-06-29</td>
<td>Novel cytokine RNA aptamers that distinguish between metastasis-prone and indolent breast and prostate cancers</td>
<td>Silvio Bicciato</td>
<td>Dr. Bicciato has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Abstract ID</td>
<td>Title</td>
<td>Authors</td>
<td>Financial Relationships</td>
</tr>
<tr>
<td>------------</td>
<td>--------------------------------------------------------------------------------------------------------------</td>
<td>---------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>P1-01-02</td>
<td>Circulating tumor cells (CTC) and endothelial cells (CEC) prognostic value in HER2 negative metastatic breast cancer patients treated with first line weekly paclitaxel and bevacizumab: Results of a prospective cohort from the French Breast Cancer InterGroup Unicancer (UCBG) COMET study</td>
<td>François-Clement Bidard</td>
<td>Dr. Bidard has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S3-01</td>
<td>IMENEO: International Meta-analysis of circulating tumor cell detection in early breast cancer patients treated by Neoadjuvant chemotherapy</td>
<td>Francois-Clement Bidard</td>
<td>Mr. Bidard has disclosed that this meta-analysis has been funded by an unconditional grant from Janssen Diagnostics to the author's institution.</td>
</tr>
<tr>
<td>P2-01-06</td>
<td>Comparison of mutational landscapes of primary breast cancer and first metastatic relapse: Results from the ESPORE study</td>
<td>François-Clément Bidard</td>
<td>Dr. Bidard has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-04-05</td>
<td>Immunomodulation effects of metronomic oral Vinorelbine (mVRib) with or without capecitabine (CAPE), on Trg values in advanced breast cancer (ABC) patients (pts). Preliminary results of the VICTOR-5 study</td>
<td>Paolo Bidoli</td>
<td>Dr. Bidoli has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-03-05</td>
<td>A comprehensive molecular analysis of medullary breast cancer subtype: A model of immunomodulatory triple negative breast cancer subtype</td>
<td>Ivan Bièche</td>
<td>Dr. Bièche has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-04-09</td>
<td>Genomic analysis to evaluate response to neoadjuvant anastrozole and fulvestrant in post-menopausal ER-positive HER2-negative breast cancer patients included in the UCBG CAMMINA02 trial</td>
<td>Ivan Bièche</td>
<td>Dr. Bièche has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-01-06</td>
<td>Comparison of mutational landscapes of primary breast cancer and first metastatic relapse: Results from the ESPORE study</td>
<td>Ivan Bièche</td>
<td>Dr. Bièche has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-01-08</td>
<td>High-throughput genome analysis and therapeutic decision for patients with HER2 negative metastatic breast cancer: First feasibility and molecular results of the randomized phase II study SABRIN2 BREAST (UCBG-0105/1304)</td>
<td>Ivan Bièche</td>
<td>Dr. Bièche has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-03-05</td>
<td>High concordance of ER, PR, HER2 and MSI by central IHC and FISH with mRNA measurements by Genesign® breast cancer classifier assays</td>
<td>Wojciech Biernat</td>
<td>Dr. Biernat has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-21</td>
<td>Predictive value of quantitative HER2 and HER3 levels combined with downstream signaling markers in HER2 positive advanced breast cancer patients treated with lapatinib</td>
<td>Wojciech Biernat</td>
<td>Dr. Biernat has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-09-11</td>
<td>Risk of metastases after ipsilateral breast tumour recurrence changes overtime according to patient and tumour characteristics: Implications for treatment</td>
<td>Emilie Bifulco</td>
<td>Dr. Bifulco has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-06-07</td>
<td>Metabolite-guided long-term prediction of outcome in tumour-in treated breast cancer patients.</td>
<td>Elia Biganzoli</td>
<td>Dr. Elia Biganzoli has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-06-09</td>
<td>Metabolite-guided long-term prediction of outcome in tumour-in treated breast cancer patients.</td>
<td>Elia Biganzoli</td>
<td>Dr. Elia Biganzoli has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-14-09</td>
<td>Luminal A Breast cancer: Is it really a “good prognosis” disease? Preliminary results of the SIM-13 - AMBRA study</td>
<td>Laura Biganzoli</td>
<td>Dr. Elia Biganzoli has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-15-07</td>
<td>First and further line choices of treatment for HER2 VE metastatic breast cancer (MBC) according to adjuvant treatment and biological subtype. Preliminary results of the observational SIM-13 - AMBRA: Italian study</td>
<td>Laura Biganzoli</td>
<td>Dr. Elia Biganzoli has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT1-04-05</td>
<td>Cambridge brain mets trial 1 CamBMT1: A proof-of-principle phase 1b / randomised phase 2 study of alatimib penetration into brain metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy</td>
<td>Heather Biggs</td>
<td>Ms. Biggs has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
Safety of the combination of everolimus plus exemestane in the Italian cohort of patients enrolled in the expanded access 'BALLET' study

C. Bighin

C. Bighin has no relevant financial relationships to disclose.

RAD1901 demonstrates anti-tumor activity in multiple models of ER-positive breast cancer treatment resistance

Teeru Bihani

Teeru Bihani has disclosed that he receives salary from Radius Health, Inc.

Phase 2 trial of everolimus and/or trastuzumab in hormone refractory, hormone receptor (HR) positive, HER2 normal metastatic breast cancer (MBC)

Xiaoxian Bill Li

Dr. Bill Li has no relevant financial relationships to disclose.

The UK 2019 National Randomising patients with low or low intermediate grade ductal carcinoma in situ (DCIS) to surgery or active monitoring

Lucinda Billingham

Ms. Billingham has no relevant financial relationships to disclose.

Evaluation of lymph node ratio (LNR) as a prognostic indicator in node-positive breast cancer

Brian Bird

Mr. Bird has no relevant financial relationships to disclose.

Is 6 hour monitoring for administration related reactions after first administration of subcutaneous trastuzumab (THRI) necessary? A single institution audit

Brian Bird

Mr. Bird has no relevant financial relationships to disclose.

Dose dense adjuvant chemotherapy in patients with early breast cancer: Differential treatment effects according to composite index of benefit

Giancarlo Bisagni

Mr. Bisagni has no relevant financial relationships to disclose.

Neo-adjuvant treatment with trastuzumab and pertuzumab associated with palbociclib and fulvestrant in HER2 positive and ER-positive breast cancer: Effect on Ki67 during and after treatment. A phase II Michelangelo study

Giancarlo Bisagni

Mr. Bisagni has no relevant financial relationships to disclose.

Expression of miR-18a and miR-210 in normal breast tissue as candidate markers of breast cancer risk

Jared Bischof

Mr. Bischof has no relevant financial relationships to disclose.

Development of a novel HER2 testing strategy, using image-based cell-sorting to isolate pure cell populations from FFPE upstream of FISH

Farideh Bischoff

Dr. Bischoff has no relevant financial relationships to disclose.

Dynamic regulation of a microRNA-mRNA network during breast cancer metastasis reveals an essential tumor-promoting role for miR-200

Faridéh Bischoff

Dr. Bischoff has no relevant financial relationships to disclose.

Novel cytotoxic RNA aptamers that distinguish between metastasis-prone and indolent breast and prostate cancers

Kamette Bishopric

Dr. Bishop has no relevant financial relationships to disclose.

Opto-acoustic imaging of the breast: Deregulation and dysplasia of suspicious breast masses

Bob Bischofs

Mr. Bischos has no relevant financial relationships to disclose.
P3-03-06 Characterization of HER2-positive breast cancer (BC) cells selected for tolerance to trastuzumab-induced antibody-dependent cell-mediated cytotoxicity (ADCC)

Yamika Biswas

Dr. Biswas has no relevant financial relationships to disclose.

P1-05-19 Circulating tumor cells in triple-negative breast cancer patients express prostate-related genes and show different genetic profiles in US and German patient cohorts

Ann-Kathrin Bittner

Ms. Bittner has no relevant financial relationships to disclose.

P6-07-11 Serum levels of RANKL are increased in primary breast cancer patients in the presence of disseminated tumor cells in the bone marrow

Ann-Kathrin Bittner

Ms. Bittner has no relevant financial relationships to disclose.

P1-11-05 Influence of race and age on mastectomy rates in women with stage I, hormone-sensitive breast cancer: A SEER-based study

Mirika Blittori

Dr. Blittori has no relevant financial relationships to disclose.

P3-14-01 International validation of the EORTC patient-reported outcome measure (PRoM) in breast reconstruction (BR): The EORTC QLG-BRECON23 evaluating the psychometric properties and clinical effectiveness

Vesna Blic Radics

Dr. Blic Radics has no relevant financial relationships to disclose.

P1-10-05 Omitting radiotherapy in women ≥65 years with early breast cancer and favorable histopathology after breast conserving surgery, sentinel node biopsy and adjuvant endocrine therapy is safe

Judith Bjöhle

Dr. Bjöhle has no relevant financial relationships to disclose.

P6-11-16 PYTHIA: A phase II study of palbociclib plus fulvestrant versus placebo plus fulvestrant for pretreated patients with ER+/HER2- metastatic breast cancer

Lynette Blacher

Ms. Blacher has no relevant financial relationships to disclose.

P2-01-05 A phase II clinical trial of VST-1001 (dilute fluorescein) in lymphatic mapping and sentinel lymph node localization in clinically node negative breast cancer

Dalliah Black

Dr. Black has no relevant financial relationships to disclose.

P4-06-04 Triple negative breast cancer patient-derived xenografts: Molecular characteristics and sensitivity to emerging therapies

Dalliah Black

Dr. Black has no relevant financial relationships to disclose.

P2-04-02 Recognition of autologous neoantigens by tumor infiltrating lymphocytes derived from breast cancer metastases

Mary Black

Ms. Black has no relevant financial relationships to disclose.

P3-08-03 Safety, immunogenicity and efficacy of proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in breast cancer patients

Kimberly Blackwell

Ms. Blackwell has disclosed that she receives honorarium for consulting from Sandoz and Novartis.

P3-08-05 Aromatase inhibitors and endothelial function: Is there an association with early cardiovascular disease?

Anne Blaes

Dr. Blaes has no relevant financial relationships to disclose.

P4-22-16 First-line ribociclib plus letrozole in patients with de novo HR+, HER2- advanced breast cancer (ABC): A subgroup analysis of two randomized, double-blind, phase III trials

Kimberly Blackwell

Ms. Blackwell has disclosed that she receives honorarium for consulting from Sandoz and Novartis.

P3-14-01 A phase II randomized trial of pembrolizumab with carboplatin and gemcitabine for treatment of patients with metastatic triple negative breast cancer (mTNBC)

Amanda Blackford

Ms. Blackford has no relevant financial relationships to disclose.

P2-04-19 Elucidating the tumor immune microenvironment phenotype in early stage untreated BRCA-mutated breast cancer patients

Kimberly Blackwell

Dr. Blackwell has no relevant financial relationships to disclose.

P2-11-05 A non-inferiority trial comparing superparamagnetic iron oxide vs. Tc99 and blue dye in the detection of axillary sentinel nodes in patients with early stage breast cancer

Sarah Blair

Dr. Blair has no relevant financial relationships to disclose.

P4-22-16 Factors associated with genetic testing in a cohort of breast cancer survivors

Anne Blair

Dr. Blair has no relevant financial relationships to disclose.

P3-08-03 Chemotherapeutic response in breast cancer survivors' reported quality and coordination of care

Anne Blair

Dr. Blair has no relevant financial relationships to disclose.

S5-07 Aromatase inhibitors and endothelial function: Is there an association with early cardiovascular disease?

Anne Blair

Dr. Blair has no relevant financial relationships to disclose.

P2-01-11 Sentinel: A non-inferiority trial comparing superparamagnetic iron oxide vs. Tc99 and blue dye in the detection of axillary sentinel nodes in patients with early stage breast cancer

Sarah Blair

Dr. Blair has no relevant financial relationships to disclose.
| P72-01-13 | A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA) | Joanne Blum | Dr. Blum has disclosed that she is a consultant for Medivation, Inc. |
| P3-08-01 | TruRisk® based next-generation sequencing in BRCA1/2-negative breast and ovarian cancer families reveals high mutation prevalence in additional risk genes | Britta Blümcke | Dr. Blümcke has no relevant financial relationships to disclose. |
| P1-05-25 | Patterns of translational dysregulation in models of estrogen receptor+/- breast cancer | Scott Blume | Dr. Blume has no relevant financial relationships to disclose. |
| P6-09-45 | Long-term follow-up of early stage breast cancer patients with results of MammaPrint®, OncoType DX® and MammoStrat® risk classification assays | Lisa Blumencrancz | Ms. Blumencrancz has disclosed that she is an employee of Agendia, Inc. |
| P6-09-45 | Long-term follow-up of early stage breast cancer patients with results of MammaPrint®, OncoType DX® and MammoStrat® risk classification assays | Peter Blumencrancz | Dr. Blumencrancz has disclosed that he is on the Speaker’s Bureau for Agendia, Inc. |
| P73-06-05 | Measuring the impact of MammaPrint on treatment in breast cancer patients: A prospective registry (IMPACt) | Lisa Blumencrancz | Ms. Blumencrancz has disclosed that she is employed by Agendia. |
| P5-06-25 | Genomic and microenvironmental intra-tumor heterogeneity in breast cancer patients | Peter Blumencrancz | Mr. Blumencrancz has disclosed that he is on the Speaker’s Bureau for Agendia, Inc. |
| P3-07-08 | Molecular subtype-specific expression of long noncoding RNA regulates proliferation of basal-like breast cancer cells | Sonja Boatman | Ms. Boatman has no relevant financial relationships to disclose. |
| P6-09-07 | Mutation characteristics and tumor infiltrating lymphocytes in early and metastatic HER2+ breast cancer | Matthias Bobos | Mr. Bobos has no relevant financial relationships to disclose. |
| P4-03-06 | Microenvironmental control of breast cancer subtype elicited by paracrine growth factors signaling | Matteo Bocci | Mr. Bocci has no relevant financial relationships to disclose. |
| P1-10-11 | Prostate vs. supine positioning for optimizing radiation heart exposure during left breast radiotherapy: A simple clinical tool for prediction* | Kristine Bode | Dr. Bode has no relevant financial relationships to disclose. |
| P5-01-30 | Genomic and microenvironmental intra-tumor heterogeneity in breast cancer patients | Amy Bodi | Dr. Bodi has no relevant financial relationships to disclose. |
| P1-08-03 | Identification and characterization of a novel endocan substrate, PKD1, and its interaction with the estrogen receptor | Ann Bode | Ms. Bode has no relevant financial relationships to disclose. |
| P5-13-13 | Enhancing compliance with national nutrition recommendations in breast cancer survivors. Experience in an underprivileged community | Chloé Bodere | Ms. Bodere has no relevant financial relationships to disclose. |
| P6-05-05 | Upregulated purinergic signaling enhances cell proliferation in human and murine breast carcinomas | Ebbe Bødtkjer | Dr. Bødtkjer has no relevant financial relationships to disclose. |
| P3-14-02 | Post-mastectomy breast reconstruction in elderly women: Complications and the impact of individual surgeons | Isabel Boero | Dr. Boero has no relevant financial relationships to disclose. |
| P6-09-54 | Long-term recurrence risk and risk-based follow-up after breast cancer treatment | Liesbeth Boersma | Prof. Boersma has no relevant financial relationships to disclose. |
| P5-05-03 | Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases | Emile Bogart | Dr. Bogart has no relevant financial relationships to disclose. |
| P7-01-33 | Non-sentinel lymph node involvement in early breast cancer patients: Performance of two predictive nomograms integrating the analysis of sentinel nodes by one step nucleic acid amplification in a cohort of 290 patients | Florence Boiffard | Dr. Boiffard has no relevant financial relationships to disclose. |
Exclusive fat grafting breast reconstruction after mastectomy: Feasibility and complications on 54 patients

Florence Boiffard

Dr. Boiffard has no relevant financial relationships to disclose.

Tumor RNA disruption index as a tool to predict response to neoadjuvant chemotherapy in breast cancer: Optimizing timing of biopsy

Jean-Francois Boisson

Dr. Boisson has no relevant financial relationships to disclose.

BEAUTY and the breast: is adjuvant chemotherapy the right time for a beauty boost? Results of a randomised controlled trial

Floriane Boiron

Dr. Boiron has no relevant financial relationships to disclose.

High-affinity activated natural killer (haNK) cells augment trastuzumab efficacy in a mouse model of HER2 positive human metastatic breast cancer

Laurent Boissel

Mr. Boissel has disclosed that he receives salary from and has a patent with NantKwest. He has also disclosed that he has ownership in NantKwest.

Prognostic value of angioptin invasion and FOXA1 co-expression in non-metastatic triple-negative breast cancer

Florence Boissiere

Florence Boissiere has no relevant financial relationships to disclose.

BRCA1 promoter hypermethylation, but not BRCA1 expression, is associated with basal-like features and good prognosis in triple negative breast cancer

Florence Boissiere

Florence Boissiere has no relevant financial relationships to disclose.

BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer

Anais Boism

Anais Boism has no relevant financial relationships to disclose.

SentimagIC: A non-inferiority trial comparing super paramagnetic iron oxide vs. Tc99 and blue dye in the detection of axillary sentinel nodes in patients with early stage breast cancer

Richard Bold

Dr. Bold has no relevant financial relationships to disclose.

Detection of molecular alterations in breast cancer through next generation sequencing of both tumor tissue and circulating tumor DNA: The UC San Diego Moores Cancer Center experience

Sarah Boles

Dr. Boles has no relevant financial relationships to disclose.

Efficacy of first-line bevacizumab (BEV)-containing therapy for poor-prognosis advanced breast cancer (ABC): Subgroup analysis of the Geman ATTAIN observational study

Emil Boile

Mr. Boile has disclosed that he is employed as statistician of the executing CRO.

SOPH is a critical regulator of triple-negative breast cancer cell growth and invasion

Lukshmi Boillu

Dr. Boillu has no relevant financial relationships to disclose.

Inhibition of death-associated protein kinase 1 enhances chemotherapy action against triple-negative breast cancer

Lukshmi Boillu

Dr. Boillu has no relevant financial relationships to disclose.

Variation in the use of neoadjuvant chemotherapy for breast cancer in the Netherlands. A lack of consensus

Alessandra Bologna

Ms. Bologna has no relevant financial relationships to disclose.

Prognostic significance of a modified residual disease in breast and nodes (mRDBN) algorithm after neoadjuvant therapy for breast cancer

Marguerite Bonaventura

Dr. Bonaventura has no relevant financial relationships to disclose.

Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer

Igor Bondarenko

Igor Bondarenko has no relevant financial relationships to disclose.

Efficacy and tolerability of veliparib (V) and temozolomide (TMZ) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: A randomized, phase 2 study

Igor Bondarenko

Igor Bondarenko has no relevant financial relationships to disclose.

A RB-1 loss-of-function gene-signature (RBsig) predicts resistance to neoadjuvant chemotherapy in HER2+/ER+ breast cancer patients

Martina Boreschi

Ms. Boreschi has no relevant financial relationships to disclose.
Metabolomic analysis by nuclear magnetic resonance spectroscopy discriminates hormone receptor positive/HER2 negative breast cancer cell lines resistant to palbociclib

Martina Bonchi
Ms. Bonchi has no relevant financial relationships to disclose.

P6-02-07

The expression ofloyd osteal and fibroblastic focus is related to inflammation in breast cancer

Jin Song
Dr. Song has no relevant financial relationships to disclose.

P6-05-05

Evaluation of intra-tumor heterogeneity, test reproducibility and their impact in breast cancer samples assessed by Prosigna™ Results from a decision impact prospective study and a matched case-control study

Amandine Bonhomme
Ms. Bonhomme has no relevant financial relationships to disclose.

P2-12-04

Ribociclib + fulvestrant in postmenopausal women with HR+, HER2- advanced breast cancer (ABC)

Valentina Boni
Ms. Boni has no relevant financial relationships to disclose.

P2-13-04

BGB324, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy in mammary adenocarcinoma

Anna Boniecka
Dr. Boniecka has disclosed that she receives salary.

P2-04-06

The mammmary ducts create a favourable microenvironment for xenografting of luminal and molecular apocrine breast tumours

Herve Bonnefoi
Dr. Bonnefoi has no relevant financial relationships to disclose.

P4-22-02

12 years' median follow up (MFU) of BIG 1-98: Adjuvant letrozole, tamoxifen and their sequence for postmenopausal women with endocrine responsive early breast cancer

Hervé Bonnefoi
Dr. Bonnefoi has no relevant financial relationships to disclose.

P2-08-15

The association between pCR status after neoadjuvant chemotherapy and sites of first distant relapse after surgery: A substudy of the EORTC 10094/BIG-1-00 trial

Hervé Bonnefoi
Dr. Bonnefoi has no relevant financial relationships to disclose.

P6-09-10

Real-world treatment patterns and survival among triple negative breast cancer patients versus patients with other breast cancer subtypes in early stage breast cancer

Patrick Bonnet
Mr. Bonnet has disclosed that he receives salary from and has ownership in Abbvie.

P5-08-15

Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: A randomized phase II study SATR21 (ECOG-1505/1306)

Patrick Bonnet
Mr. Bonnet has disclosed that he has ownership in and is an employee of AbbVie.

P2-08-13

Rapid-germ-line BRCA screening for locally advanced breast cancer changes surgical procedure after neoadjuvant chemotherapy

Francoise Bonnet
Dr. Bonnet has no relevant financial relationships to disclose.

P5-16-23

Efficacy and tolerability of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) or placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer

Patrick Bonnet
Mr. Bonnet has disclosed that he is an employee of and has ownership in AbbVie.

P4-22-02

VICTORIANE: A randomized phase 3 study assessing the addition of oral vinorelbine to aromatase inhibitors for the treatment of patients with metastatic breast cancer

Francis Bonnemain
Dr. Bonnemain has no relevant financial relationships to disclose.

OT1-04-07
A phase I/II of S-222611, a reversible EGFR and HER2 inhibitor, combined with trastuzumab +/- chemotherapy in patients with HER2-positive metastatic breast cancer

Jacques Bonneterre

Dr. Bonneterre has no relevant financial relationships to disclose.

Inhibition of cancer-associated fibroblast function by far-red A1 receptor activation: Experimental basis for a novel therapeutic strategy in breast cancer

Daniele Benediglio

Dr. Benediglio has no relevant financial relationships to disclose.

Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer

Patrick Bontemps

Dr. Bontemps has no relevant financial relationships to disclose.

Maintenance of genomic integrity in dormant circulating tumor cells

Debashish Boral

Dr. Boral has no relevant financial relationships to disclose.

The evolution of breast cancer circulating tumor cells mediating brain metastasis

Debashish Boral

Dr. Boral has no relevant financial relationships to disclose.

Ovarian reserve and response to controlled ovarian hyperstimulation (COH) in breast cancer women with and without BRCA mutation

Jacques Bonneterre

Dr. Bonneterre has no relevant financial relationships to disclose.

Adjuvant and neoadjuvant chemotherapy for elderly patients (≥70 years) with early high-risk breast cancer: A retrospective analysis of 118 patients

Jacques Bonneterre

Dr. Bonneterre has no relevant financial relationships to disclose.

Differential turnover of estrogen receptor alpha in invasive ductal carcinoma

David Boone

Dr. Boone has no relevant financial relationships to disclose.

Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer

Patrick Bontemps

Dr. Bontemps has no relevant financial relationships to disclose.

Comparison of mutational landscapes of primary breast cancer and first metastatic relapse: Results from the ESOPE study

Jacques Bonneterre

Dr. Bonneterre has no relevant financial relationships to disclose.

Inhibition of cancer-associated fibroblast function by far-red A1 receptor activation: Experimental basis for a novel therapeutic strategy in breast cancer

Daniele Benediglio

Dr. Benediglio has no relevant financial relationships to disclose.

Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer

Patrick Bontemps

Dr. Bontemps has no relevant financial relationships to disclose.

Differential turnover of estrogen receptor alpha in invasive ductal carcinoma

David Boone

Dr. Boone has no relevant financial relationships to disclose.

Maintenance of genomic integrity in dormant circulating tumor cells

Debashish Boral

Dr. Boral has no relevant financial relationships to disclose.

The evolution of breast cancer circulating tumor cells mediating brain metastasis

Debashish Boral

Dr. Boral has no relevant financial relationships to disclose.

Comparison of mutational landscapes of primary breast cancer and first metastatic relapse: Results from the ESOPE study

Jacques Bonneterre

Dr. Bonneterre has no relevant financial relationships to disclose.

Inhibition of cancer-associated fibroblast function by far-red A1 receptor activation: Experimental basis for a novel therapeutic strategy in breast cancer

Daniele Benediglio

Dr. Benediglio has no relevant financial relationships to disclose.

Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer

Patrick Bontemps

Dr. Bontemps has no relevant financial relationships to disclose.

Differential turnover of estrogen receptor alpha in invasive ductal carcinoma

David Boone

Dr. Boone has no relevant financial relationships to disclose.

Maintenance of genomic integrity in dormant circulating tumor cells

Debashish Boral

Dr. Boral has no relevant financial relationships to disclose.

The evolution of breast cancer circulating tumor cells mediating brain metastasis

Debashish Boral

Dr. Boral has no relevant financial relationships to disclose.

Comparison of mutational landscapes of primary breast cancer and first metastatic relapse: Results from the ESOPE study

Jacques Bonneterre

Dr. Bonneterre has no relevant financial relationships to disclose.

Inhibition of cancer-associated fibroblast function by far-red A1 receptor activation: Experimental basis for a novel therapeutic strategy in breast cancer

Daniele Benediglio

Dr. Benediglio has no relevant financial relationships to disclose.

Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer

Patrick Bontemps

Dr. Bontemps has no relevant financial relationships to disclose.

Differential turnover of estrogen receptor alpha in invasive ductal carcinoma

David Boone

Dr. Boone has no relevant financial relationships to disclose.

Maintenance of genomic integrity in dormant circulating tumor cells

Debashish Boral

Dr. Boral has no relevant financial relationships to disclose.

The evolution of breast cancer circulating tumor cells mediating brain metastasis

Debashish Boral

Dr. Boral has no relevant financial relationships to disclose.

Comparison of mutational landscapes of primary breast cancer and first metastatic relapse: Results from the ESOPE study

Jacques Bonneterre

Dr. Bonneterre has no relevant financial relationships to disclose.

Inhibition of cancer-associated fibroblast function by far-red A1 receptor activation: Experimental basis for a novel therapeutic strategy in breast cancer

Daniele Benediglio

Dr. Benediglio has no relevant financial relationships to disclose.

Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer

Patrick Bontemps

Dr. Bontemps has no relevant financial relationships to disclose.

Differential turnover of estrogen receptor alpha in invasive ductal carcinoma

David Boone

Dr. Boone has no relevant financial relationships to disclose.

Maintenance of genomic integrity in dormant circulating tumor cells

Debashish Boral

Dr. Boral has no relevant financial relationships to disclose.

The evolution of breast cancer circulating tumor cells mediating brain metastasis

Debashish Boral

Dr. Boral has no relevant financial relationships to disclose.

Comparison of mutational landscapes of primary breast cancer and first metastatic relapse: Results from the ESOPE study

Jacques Bonneterre

Dr. Bonneterre has no relevant financial relationships to disclose.

Inhibition of cancer-associated fibroblast function by far-red A1 receptor activation: Experimental basis for a novel therapeutic strategy in breast cancer

Daniele Benediglio

Dr. Benediglio has no relevant financial relationships to disclose.

Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer

Patrick Bontemps

Dr. Bontemps has no relevant financial relationships to disclose.

Differential turnover of estrogen receptor alpha in invasive ductal carcinoma

David Boone

Dr. Boone has no relevant financial relationships to disclose.

Maintenance of genomic integrity in dormant circulating tumor cells

Debashish Boral

Dr. Boral has no relevant financial relationships to disclose.

The evolution of breast cancer circulating tumor cells mediating brain metastasis

Debashish Boral

Dr. Boral has no relevant financial relationships to disclose.

Comparison of mutational landscapes of primary breast cancer and first metastatic relapse: Results from the ESOPE study

Jacques Bonneterre

Dr. Bonneterre has no relevant financial relationships to disclose.

Inhibition of cancer-associated fibroblast function by far-red A1 receptor activation: Experimental basis for a novel therapeutic strategy in breast cancer

Daniele Benediglio

Dr. Benediglio has no relevant financial relationships to disclose.

Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer

Patrick Bontemps

Dr. Bontemps has no relevant financial relationships to disclose.

Differential turnover of estrogen receptor alpha in invasive ductal carcinoma

David Boone

Dr. Boone has no relevant financial relationships to disclose.

Maintenance of genomic integrity in dormant circulating tumor cells

Debashish Boral

Dr. Boral has no relevant financial relationships to disclose.

The evolution of breast cancer circulating tumor cells mediating brain metastasis

Debashish Boral

Dr. Boral has no relevant financial relationships to disclose.

Comparison of mutational landscapes of primary breast cancer and first metastatic relapse: Results from the ESOPE study

Jacques Bonneterre

Dr. Bonneterre has no relevant financial relationships to disclose.

Inhibition of cancer-associated fibroblast function by far-red A1 receptor activation: Experimental basis for a novel therapeutic strategy in breast cancer

Daniele Benediglio

Dr. Benediglio has no relevant financial relationships to disclose.

Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer

Patrick Bontemps

Dr. Bontemps has no relevant financial relationships to disclose.

Differential turnover of estrogen receptor alpha in invasive ductal carcinoma

David Boone

Dr. Boone has no relevant financial relationships to disclose.

Maintenance of genomic integrity in dormant circulating tumor cells

Debashish Boral

Dr. Boral has no relevant financial relationships to disclose.

The evolution of breast cancer circulating tumor cells mediating brain metastasis

Debashish Boral

Dr. Boral has no relevant financial relationships to disclose.
P2-09-11  Metabolite-guided long-term prediction of outcome in tamoxifen treated breast cancer patients
Elin Borgen Dr. Borgen has no relevant financial relationships to disclose.

P6-13-01  Proteomic response in breast cancer treated with neoadjuvant chemotherapy with and without bevacizumab: Reverse phase protein array (RPPA) results from NeoAva - A randomized phase II study
Elin Borgen Dr. Borgen has no relevant financial relationships to disclose.

P3-01  IMENEO: International Meta-analysis of circulating tumor cell detection in early breast cancer patients treated by neoadjuvant chemotherapy
Elin Borgen Dr. Borgen has no relevant financial relationships to disclose.

P1-12-03  Association between tumor genotype and development of brain metastasis in patients with hormone receptor positive breast cancer: A retrospective analysis of the AIN2 trial
Darrell Berger Mr. Berger has no relevant financial relationships to disclose.

P6-16-04  Real World data and patterns of care of metastatic breast cancer (MBC) in Brazil: First results of LACOG 0312 retrospective study
Elin Borgen Dr. Borgen has no relevant financial relationships to disclose.

OT1-02-09  A phase 2 randomised, double-blind, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ metastatic breast cancer (MBC) not responding to T
Virginia Borges Dr. Borges has no relevant financial relationships to disclose.

OT1-04-06  MBS-BR002: A phase II trial of standard of care therapy with or without stereotactic body radiation therapy (SBRT) &/or surgical ablation for newly oligometastatic breast cancer
Virginia Borges Dr. Borges has no relevant financial relationships to disclose.

P3-08-07  Drugs don't work if people don't take them: Non-initiation of endocrine therapy in young women
Virginia Borges Dr. Borges has no relevant financial relationships to disclose.

P4-12-05  Extracellular vesicles from young women's and postpartum breast cancer display unique proteomic content, alter breast cancer aggressive behavior, and influence immune cell function
Virginia Borges Dr. Borges has no relevant financial relationships to disclose.

P4-21-01  Efficacy results of a phase Ib study of ONT-380, an oral HER2-specific inhibitor, in combination with capecitabine (C) and trastuzumab (T) in HER2+ metastatic breast cancer (MBC), including patients (pts) with brain metastases (mets)
Virginia Borges Dr. Borges has no relevant financial relationships to disclose.

OT3-06-01  KARISMA, The karma intervention study...- A tamoxifen dose determination trial
Signe Borgquist Dr. Borgquist has no relevant financial relationships to disclose.

P2-07-03  Insulin and breast cancer risk: Novel insights from mammographic density analyses
Signe Borgquist Dr. Borgquist has no relevant financial relationships to disclose.

P5-04-27  Overcoming novel molecular pathways driving endocrine resistance in breast cancer
Signe Borgquist Dr. Borgquist has no relevant financial relationships to disclose.

P4-03-15  Joint influence by paracrine adipocyte signals and metabolic conditions on breast cancer
Signe Borgquist Dr. Borgquist has no relevant financial relationships to disclose.

P6-02-04  Axovastatin insensitivity is associated with increased lipid droplet accumulation and fatty acid metabolism in breast cancer cells
Signe Borgquist Dr. Borgquist has no relevant financial relationships to disclose.

P4-01-07  A liquid biopsy test for breast cancer detection provides consistent diagnostic results in patients over six months
Sherri Borman Dr. Borman has disclosed that she is a salary employee of and owns stock of Provista Dx.

P4-22-22  Cobimetinib (C) combined with paclitaxel (P) as a first-line treatment in patients (pts) with advanced triple-negative breast cancer (COLET study): Updated clinical and biomarker results
Marleen Borms Ms. Borms has disclosed that she is a consultant for and receives grants from Roche.

P2-05-05  Intratumor heterogeneity of the estrogen receptor predicts less benefit from tamoxifen therapy and poor long-term breast cancer patient survival - Retrospective analyses of the STO-3 randomized trial
Alexander Borowsky Dr. Borowsky has no relevant financial relationships to disclose.

P5-02-05  Evaluating the feasibility of a web-based preference-tolerant randomized trial of risk-based vs. annual breast cancer screening: WISDOM study pilot
Alexander Borowsky Dr. Borowsky has disclosed that he is a consultant for Roche/Genentech.
Identification of breast cancers with an indolent disease course: 10 gene indolent threshold validation in a Swedish randomized trial of tamoxifen vs. not, with 20-year outcomes

High reduction of circulating tumour cells in HER2-negative locally advanced or metastatic breast cancer (LAMBC) patients treated with eribulin as third line chemotherapy (INSITE study)

Proteomic response in breast cancer treated with neoadjuvant chemotherapy with and without bevacizumab: Reverse phase protein array (RPPA) results from NeoXus - A randomized phase II study

Randomized phase II study evaluating different schedules of nab-paclitaxel in metastatic breast cancer (MBC): Results of the SNAP study

Preference of taxotere administration route (intravenous or subcutaneous) in patients in the Czech Republic. Cross-sectional study on 429 patients

Adjuvant dose dense doxorubicin-cyclophosphamide (DAC) or docetaxel-AC (TAC) for high-risk breast cancer: First results of the randomized MATADOR (BOOG-2004-04) trial

PTEN immunohistochemistry is a predictor of mismatch repair status in breast cancer

CD103+/PD-1+ T-cells identify a subset of triple-negative breast cancer eligible for targeted checkpoint inhibition

Plasma microRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from Neo-ALTTO

Identification of SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong antitumor activity in wild-type and mutant ER+ breast cancer models

CDK4/6 inhibitor resistant ER-positive cells remain dependent on estrogen signalling and retain sensitivity to endocrine therapy

Preclinical characterization of VX-984, a selective DNA-dependent protein kinase (DNA-PK) inhibitor in combination with doxorubicin in breast and ovarian cancers

The measurement of gait speed: An easy way to select older patients with breast cancer for an adapted therapeutic decision making

Predictive value of FDG-PET/CT after neoadjuvant endocrine treatment in breast cancer

Tumor and serum DNA methylation in women receiving neoadjuvant chemotherapy (PIT) with or without vorinostat in primary operable HER2-negative breast cancer in TRICRIB

Dr. Borowsky has no relevant financial relationships to disclose.

Dr. Borrega García has no relevant financial relationships to disclose.

Dr. Borrero-Dale has no relevant financial relationships to disclose.

Dr. Bos has no relevant financial relationships to disclose.

Dr. Boss has no relevant financial relationships to disclose.

Dr. Bosh has no relevant financial relationships to disclose.

Ms. Boschi has no relevant financial relationships to disclose.

Ms. Bouchekioua-Bouzaghou has no relevant financial relationships to disclose.

Ms. Bouguessa has disclosed that she is an employee of may own stock or stock options in Vertex Pharmaceuticals Incorporated.

Dr. Boucher has disclosed that she is an employee of may own stock or stock options in Vertex Pharmaceuticals Incorporated.

Dr. Boucher has no relevant financial relationships to disclose.

Dr. Bouguessa has no relevant financial relationships to disclose.

Ms. Bougdad has no relevant financial relationships to disclose.

Dr. Boughey has no relevant financial relationships to disclose.
Delineation of internal mammary nodal target volumes in breast cancer radiotherapy

Tumor and procedural factors associated with positive margins at lumpectomy in women undergoing breast conservation surgery

Predictors of locoregional recurrence after neoadjuvant chemotherapy and surgery for node positive breast cancer: Results from ACOSOG Z1071 (Alliance)

Efficacy of HER2 inhibitor trastuzumab plus standard neoadjuvant therapy in high-risk breast cancer: Results from the S8-SPY 2 trial

The evolution of gastrectomy/mesenteric plus standard neoadjuvant therapy in high-risk breast cancer: Results from the S8-SPY 2 trial

How 11-gene recurrence score assay is being used to individualize adjuvant chemotherapy recommendations in ER+,HER2-negative breast cancer: A national cancer data base study

Comparison of mutational landscapes of primary breast cancer and first metastatic relapse: Results from the ESOPE study

Long-term follow-up of persistent breast dermopigmentation after sentinel lymph node identification using superparamagnetic iron oxide particles (SIENNA®)

How to assess surgical margin status of breast conserving operations

Technical skill of surgical residents may affect margin status of breast conserving operations

Weight gain after breast cancer diagnosis and patients' opinion on weight loss strategies

BEAUTY and the breast: Is adjuvant chemotherapy the right time for a beauty boost? Results of a randomized controlled trial

Prognostic significance of CD8+ tumor-infiltrating lymphocytes (TILs), CD4+ TILs and TILs in male breast cancer

Technical skill of surgical residents may affect margin status of breast conserving operations

Weight gain after breast cancer diagnosis and patients' opinion on weight loss strategies

BEAUTY and the breast: Is adjuvant chemotherapy the right time for a beauty boost? Results of a randomized controlled trial

Prognostic significance of CD8+ tumor-infiltrating lymphocytes (TILs), CD4+ TILs and TILs in male breast cancer

Prognostic significance of CD8+ tumor-infiltrating lymphocytes (TILs), CD4+ TILs and TILs in male breast cancer

The UK C08-03 trial Randomizing patients with low or low-intermediate grade ductal carcinoma in situ (DCIS) to surgery or active monitoring

Glucastrin receptor modulation affects ER+ breast cancer cell proliferation

IMENEO: International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEoadjuvant chemotherapy

Photodynamic therapy for the treatment of primary breast cancer: Preliminary results of a phase I/IIa clinical trial
Can the risk of radiation-induced cardiac disease in breast cancer be mitigated with cardiac-sparing techniques?
Julie Bradley
Dr. Bradley has no relevant financial relationships to disclose.

Prognostic and predictive marker in the tumor microenvironment of breast cancers
Amy Brady
Ms. Brady has no relevant financial relationships to disclose.

Phase I multicenter clinical trial evaluating the combination of trastuzumab emtansine (T-DM1) and non-pegylated liposomal doxorubicin (NPLD) in HER2-positive metastatic breast cancer (MBC) (MEDOPP038 study)
Elaine Brain
Dr. Brain has disclosed that he is a consultant for Roche.

Challenges faced across borders to open European academic multicentre projects: The ET-FES program part of the ERA-Net TRANSCAN ITC 2011
Elaine Brain
Dr. Brain has no relevant financial relationships to disclose.

Comparison of mutational landscapes of primary breast cancer and first metastatic relapse: Results from the ESOPE study
Elaine Brain
Dr. Brain has no relevant financial relationships to disclose.

"Treatment of metastatic breast cancer in older adults" Speaker, Educational Session
Etienne Brain
Dr. Brain has disclosed that he receives consulting fees from Amgen, Roche, Hospira, Teva, Astrazeneca and Janssen. He also disclosed that he does contracted research for Teva and HalloPharma (Gagne/Siperous). These relationships do not impact his ability to present an unbiased presentation.

Efficacy results of a phase 1/2 study of glucocorticoid receptor (GR) antagonist mifepristone (MIFE) in combination with eribulin in GR-positive triple-negative breast cancer (TNBC)
Fadi Braiteh
Fadi Braiteh has disclosed that he receives salary from US Oncology. He has also disclosed that he is a consultant for Amgen, Ambry Genetics, BIND Therapeutics, bioTheranostics, Caris Life Sciences, Lilly, Foundation Medicine, Incyte, Ipsen, Teva, Insys Therapeutics, Merriamck, MolecularHealth, Novartis, Novocure, Roche/Sanofi, Sanofi and Pfizer.

Therapeutic targeting of RAGE in the tumor and tumor microenvironment inhibits breast progression and metastasis
Alexander Braley
Mr. Braley has no relevant financial relationships to disclose.

PAINTER: Evaluation of olitumab tolerability and correlation between a set of polymorphisms and neuropathy in patients with metastatic breast cancer
Annalisa Bramati
Ms. Bramati has no relevant financial relationships to disclose.

A study to determine the optimal method of detection and threshold for lymphoedema intervention: A multi-centre prospective study
Maria Bramley
Ms. Bramley has no relevant financial relationships to disclose.

Inflammation and breast cancer risk: Novel insights from mammographic density analyses
Judith Brand
Dr. Brand has no relevant financial relationships to disclose.

9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian short-HRs trial
Furong Brandberg
Dr. Brandberg has no relevant financial relationships to disclose.

BRCAsearch - results of population-based screening of BRCA1 and BRCA2 germline mutations in incident breast cancer in South Sweden
Elba Brandes
Ms. Brandes has no relevant financial relationships to disclose.

21-gene recurrence score® in patients with primary metastatic ER+ HER2- breast cancer
Christiane Brandt
Dr. Brandt has no relevant financial relationships to disclose.

Bone marrow adipocytes and breast cancer in women with a history of breast cancer
Susan Brandel
Ms. Brandel has no relevant financial relationships to disclose.

RANK ligand as a target for breast cancer prevention in BRCA1 mutation carriers
Daniel Brandstetter
Mr. Brandstetter has disclosed that he is a former employee and stockholder of Amgen.

Plasma microRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from Neo-ALTTO
San Brase
Dr. Brase has disclosed that he is an employee of Novartis Pharmaceuticals.

Association between tumor genotype and development of brain metastases in patients with hormone receptor positive (Her2)<br>HER2+ metastatic breast cancer
Priscilla Brastianos
Ms. Brastianos has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1-09-05</td>
<td>The role of immune and apoptosis markers for prediction of pCR in the WSG-ASAPHT HER2+/HR+ phase II trial evaluating 12-weeks of neoadjuvant TDM1 + endocrine therapy (ET) versus T + ET in HER2-positive hormone-receptor-positive early breast cancer (EBC)</td>
<td>Michael Braun</td>
<td>Dr. Braun has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-14-09</td>
<td>Quality of life assessed by BREAST-Q in patients with delayed immediate tissue expander based breast reconstruction with and without radiotherapy</td>
<td>Michael Braun</td>
<td>Dr. Braun has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-10-08</td>
<td>Factors affecting the administration of post-mastectomy radiation therapy (PMRT) in Michigan</td>
<td>Thomas Braun</td>
<td>Dr. Braun has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-12-04</td>
<td>Breast cancer subtype, age and lymph node status as predictors of local recurrence following breast-conserving therapy</td>
<td>Lisa Braumstein</td>
<td>Dr. Braumstein has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-04-22</td>
<td>RAD101 demonstrates anti-tumor activity in multiple models of HER-positive breast cancer treatment resistance</td>
<td>Heather Brechbuhl</td>
<td>Ms. Brechbuhl has disclosed that she works for Peter Kabos, M.D. at the University of Colorado Denver. He is the PI for a research contract agreement between the University and Radius.</td>
</tr>
<tr>
<td>P3-05-03</td>
<td>A novel progesterone receptor (PR)-RNA polymerase II association represses estrogen-dependent growth in breast tumor patient-derived xenografts</td>
<td>Heather Brechbuhl</td>
<td>Dr. Brechbuhl has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-06-05</td>
<td>Development and validation of a new non-parametric breast cancer risk assessment model on US and European screening populations</td>
<td>Yizhe Brechenade</td>
<td>Dr. Brechenade has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-01</td>
<td>Platinum salts in advanced breast cancer: A systematic review and meta-analysis of randomized clinical trials</td>
<td>David Breckenridge</td>
<td>Mr. Brekenridge has disclosed that he receives salary from Gilead Sciences.</td>
</tr>
<tr>
<td>P5-15-17</td>
<td>Development and validation of a new non-parametric breast cancer risk assessment model on US and European screening populations</td>
<td>Giacomo Brechbuhl</td>
<td>Mr. Brekenridge has disclosed that he has a contract.</td>
</tr>
<tr>
<td>P2-04-08</td>
<td>DCIS, a biologic risk profile predicts risk of recurrence after breast conserving surgery in a Kaiser Permanente NW population</td>
<td>Troy Bremner</td>
<td>Dr. Bremer has disclosed that he receives salary from and has a patient with Prelude Corporation. He has also disclosed that he has an NIH Grant R44CA162744-05.</td>
</tr>
<tr>
<td>P1-10-19</td>
<td>Two-year follow-up results of a multi-center trial of intraoperative electronic brachytherapy during breast conservation surgery for early stage breast cancer</td>
<td>Amy Bremner</td>
<td>Dr. Bremner has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-10-20</td>
<td>A multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer: Early results of unplanned boost participants</td>
<td>A Bremner</td>
<td>Dr. Bremner has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-03-16</td>
<td>Molecular and immunologic characterization of EMT and invasion mechanisms, enhances doxorubicin retention and induces downregulation of CD44+/CD24− and E-Cad+/Vim− subpopulations in MCF-7 cells resistant model</td>
<td>Ugalde-Villanueva Brenda</td>
<td>Dr. Brenda has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-06-05</td>
<td>Breast cancer organoid cultures preserve intra-tumor heterogeneity and reveal intrinsically resistant phenotypes to standard chemotherapies</td>
<td>David Brenin</td>
<td>Dr. Brenin has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-12-01</td>
<td>The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer</td>
<td>Meghan Brenner</td>
<td>Ms. Brenner has disclosed that she is a consultant for BMS.</td>
</tr>
<tr>
<td>P1-09-16</td>
<td>Randomized study of COX2 inhibition on systemic inflammation in obese and non-obese subjects</td>
<td>Andrew Brenner</td>
<td>Dr. Brenner has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-12-02</td>
<td>A phase II, open-label, multi-center study of ANG1005, a novel brain-penetrant peptide drug conjugate, in breast cancer patients with recurrent CNS metastases</td>
<td>Andrew Brenner</td>
<td>Dr. Brenner has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-04-02</td>
<td>Obesity-induced ERα in luminal-A breast cancer cells</td>
<td>Andrew Brenner</td>
<td>Dr. Brenner has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-02-05</td>
<td>Modulation of TAK1 under obese conditions</td>
<td>Andrew Brenner</td>
<td>Dr. Brenner has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
Heavily pre-treated breast cancer patients show promising responses in the first in human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640 in combination with paclitaxel. Andrew Brenner

Dr. Brenner has no relevant financial relationships to disclose.

The importance of the ultimate ratio of Omega-6 to Omega-3 fatty acids in the efficacy of fish oil supplements in suppressing inflammation in obese postmenopausal women. Andrew Brenner

Dr. Brenner has no relevant financial relationships to disclose.

The association between angiotensin receptor blockers usage and breast cancer characteristics. Baruch Brenner

Prof. Brenner has no relevant financial relationships to disclose.

The association between smoking and breast cancer characteristics and outcome. Baruch Brenner

Prof. Brenner has no relevant financial relationships to disclose.

HER2-associated lipogenic phenotype as a potential therapeutic target in breast cancer patients. Maria Brentani

Prof. Brentani has no relevant financial relationships to disclose.

Metabolomic profiling of breast cancer and adjacent tissue. Maria Brentanni

Ms. Brentanni has no relevant financial relationships to disclose.

Factors affecting the administration of post-mastectomy radiation therapy (PMRT) in Michigan. Tara Breslin

Dr. Breslin has no relevant financial relationships to disclose.

Rapid germline BRCA screening for locally advanced breast cancer changes surgical procedure after neoadjuvant chemotherapy. Christel Breton-Callu

Dr. Breton-Callu has no relevant financial relationships to disclose.

The measurement of gait speed: An easy way to select older patients with breast cancer for an adapted therapeutic decision making. Alexandre Bricou

Dr. Bricou has no relevant financial relationships to disclose.

Breast implant associated anaplastic large cell lymphoma (BIA-ALCL): The UK experience and first reported case of neoadjuvant brentuximab. James Bristol

Mr. Bristol has no relevant financial relationships to disclose.

Identifying metastatic drivers in pattern derived armament models of triple negative breast cancer. Christopher Brown

Ms. Brown has no relevant financial relationships to disclose.

Development and validation of a non-parametric breast cancer risk assessment model on US and European screening populations. Zehida Brix

Dr. Brix has no relevant financial relationships to disclose.

Evaluation of women with BRCA mutations and breast cancer tested at an NCI designated comprehensive cancer center: A cost of illness estimation. Diana Briner

Ms. Briner has disclosed that AstraZeneca funding this research.

Elucidating the tumor immune microenvironment phenotype in early stage untreated BRCA-mutated breast cancer patients. Silvia Broadwater

Ms. Broadwater has no relevant financial relationships to disclose.

HER2 status remains the primary predictor of improved survival in patients with BCaM over the past 2 decades (1996-2015). Silvia Broadwater

Ms. Broadwater has no relevant financial relationships to disclose.
Clinical outcomes of estrogen-receptor negative breast carcinoma are associated with protein hormone-cognate receptor gene expression

Dr. Brock has no relevant financial relationships to disclose.

Comparison of the Xpert breast cancer stratifier mRNA assay with central ER, PR, HER2, and Ki67 immunohistochemistry (IHC) for rapid biomarker analysis in developing countries

Dr. Brock has disclosed that she receives Salary and Grant support from Cepheid.

Improved long-term outcomes of breast-conserving therapy for women with ductal carcinoma in situ

Ms. Brock has no relevant financial relationships to disclose.

Feasibility and safety of avoiding granulocyte colony-stimulating factor prophylaxis during the palbociclib portion of dose dense doxorubicin-cyclophosphamide and palbociclib regimen

Dr. Brock has disclosed that this work was sponsored by Astra-Zeneca.

A new oral SERD AZD9496 for treatment of hormone dependent postmenopausal breast cancer

Ms. Brodie has no relevant financial relationships to disclose.

The genomic landscape of breast metastatic carcinoma

Dr. Brogi has no relevant financial relationships to disclose.

Intra-tumor genetic heterogeneity and histologic heterogeneity within metastatic breast cancers: Genotypic phenotypic correlations

Dr. Brogi has no relevant financial relationships to disclose.

Breast carcinoma with 21 gene recurrence score lower than 18: Rate of distant metastases in a large series with clinical follow-up

Dr. Brogi has no relevant financial relationships to disclose.

The landscape of somatic genetic alterations in BRCA1 and BRCA2 breast cancers

Dr. Brogi has no relevant financial relationships to disclose.

The footprint of the aging stroma in older breast cancer patients

Dr. Brohee has no relevant financial relationships to disclose.

Targeting inflammatory pathways: A phase 2 trial of the JAK inhibitor ruxolitinib in combination with exemestane for aromatase inhibitor-resistant, estrogen receptor-positive breast cancer

Dr. Bromberg has disclosed that he has a contract with AstraZeneca.

Treatment patterns and resource utilization among patients with HR+/HER2- metastatic breast cancer in a privately insured US population

Ms. Bromund has disclosed that she receives salary from and has ownership in Eli Lilly and Company.

Treatment patterns and resource utilization among elderly Medicare patients with HR+/HER2- metastatic breast cancer

Ms. Bromund has disclosed that she receives salary from and has ownership in Eli Lilly and Company.

Neutralisation of BCL2/XL enhances the cytotoxicity of T-DM1 in vivo

Ms. Bron has no relevant financial relationships to disclose.

The UK LORIS trial: Randomizing patients with low or low intermediate grade ductal carcinoma in situ (DCIS) to surgery or active monitoring

Ms. Brookes has no relevant financial relationships to disclose.

Utilization and outcomes of embolization in triple negative metastatic breast cancer: Real-world findings

Ms. Broos has disclosed that she receives salary from Cardinal Health.

CDK8 inhibition improves the efficacy of ER- and HER2-targeted drugs in breast cancer

Ms. Broude has disclosed that she is a consultant for Senex Biotechnology Inc.

Evaluation of subclonality in the CTC and DTC compartment of patients with metastatic breast cancer using low pass whole genome and AmpliSeq panel sequencing

Dr. Brouwer has no relevant financial relationships to disclose.

Evaluation of HER2 expression and amplification on CTCs using DEPArray analysis and sorting followed by FISH

Dr. Brouwer has no relevant financial relationships to disclose.

A phase 1 safety study of topical cabazitaxel (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA)

Ms. Brouwer has no relevant financial relationships to disclose.

CDK1 markers in circulating tumor cell versus circulating cell-free DNA of metastatic breast cancer patients before first-line endocrine therapy and at progression

Ms. Brouwers has no relevant financial relationships to disclose.
Clinical value of $^{89}$Zr-trastuzumab PET in HER2-positive breast cancer patients with a clinical dilemma
Adrienne Brouwers
Dr. Brouwers has no relevant financial relationships to disclose.

The footprint of the aging stroma in older breast cancer patients
Barbara Brouwers
Dr. Brouwers has no relevant financial relationships to disclose.

Age-related microRNAs and their biomarker potential in chemotherapy-treated older breast cancer patients
Barbara Brouwers
Dr. Brouwers has no relevant financial relationships to disclose.

Safety and efficacy results from phase I study of BYL 719 plus nab-paclitaxel in HER2 negative metastatic breast cancer
Alexandra Brown
Ms. Brown has no relevant financial relationships to disclose.

Trastuzumab improves outcomes of New Zealand women with HER2+ stage I-III breast cancer
Charis Brown
Charis Brown has no relevant financial relationships to disclose.

Investigating the impact of pregnancy on breast cancer biology using DNA copy number profiling
David Brown
Ms. Brown has no relevant financial relationships to disclose.

Squalene epoxidase is a potential metabolic oncogene by amplification with clinical implications in breast carcinoma: An in silico pan-cancer study with in vitro evidence
David Brown
Mr. Brown has no relevant financial relationships to disclose.

Analysis of breast cancer in young women in the department of defense (DOD) database
Derek Brown
Mr. Brown has no relevant financial relationships to disclose.

Tumor infiltrating macrophages, lymphocytes and matrix metalloproteinase 9 (MMP-9) expression in breast cancer
Jason Brown
Dr. Brown has no relevant financial relationships to disclose.

PARTNER - Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients
Jessica Brown
Dr. Brown has no relevant financial relationships to disclose.

Metabolic obesity, adipose inflammation and aromatase: Potential drivers of breast cancer risk in women with normal body mass index
Kristy Brown
Ms. Brown has no relevant financial relationships to disclose.

Trends in age of breast cancer diagnosis for women with pathogenic variants in genes associated with increased breast cancer risk
Krystal Brown
Dr. Brown has disclosed that she receives salary from and has ownership in Myriad Genetic Laboratories, Inc.

Genetic testing for HBOC among women with a personal diagnosis of breast cancer in patients with Medicaid as compared to patients with private insurance
Krystal Brown
Ms. Brown has disclosed that she receives salary from and has ownership in Myriad Genetic Laboratories, Inc.

Definition of internal mammary nodal target volumes in breast cancer radiotherapy
Lindsey Brown
Dr. Brown has no relevant financial relationships to disclose.

Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ER positive metastatic breast cancer patients: Results of the COMETI Phase 2 trial
Martha Brown
Ms. Brown has no relevant financial relationships to disclose.

DNA immunosuppression reveals m6A/mRNA-protein interactions in basal-like breast cancer
Melissa Brown
Ms. Brown has no relevant financial relationships to disclose.

FOX A1 induces a pro-metastatic secretome through ER-dependent and independent transcriptional reprogramming in endocrine-resistant breast cancer
Myles Brown
Dr. Brown has no relevant financial relationships to disclose.

Impact of pre-operative exercise on breast cancer gene expression
Myles Brown
Ms. Brown has no relevant financial relationships to disclose.

Committee Member/Moderator, Basic Science Forum 3 "Novel Approaches for Targeting Transcription and the Epigenome"
Myles Brown
Dr. Brown has disclosed that he receives consulting fees from Novartis, Pfizer and SV Life Sciences. These relationships do not impact his ability to present an unbiased presentation.

VAENIT trial: Phase II trial of the meldepemut-5 peptide vaccine in women with DCIS of the breast
Powel Brown
Dr. Brown has no relevant financial relationships to disclose.

SOX9 is a critical regulator of triple-negative breast cancer cell growth and invasion
Powel Brown
Mr. Brown has no relevant financial relationships to disclose.

Inhibition of death-associated protein kinase 1 enhances chemotherapy action against triple-negative breast cancer
Powel Brown
Mr. Brown has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Committee Member/Speaker, Educational Session</th>
<th>Title</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Brown</td>
<td>&quot;Non-endocrine strategies: beyond the estrogen receptor&quot;</td>
<td>Powel Brown Dr. Brown has disclosed that he receives consulting fees from Susan G. Komen Foundation. He also disclosed that he has ownership interest in Gene Tie (&lt;1% of total stock). These relationships do not impact his ability to present an unbiased presentation.</td>
</tr>
<tr>
<td>Robert Brown</td>
<td>BRCA2 multilocation status, silencing and treatment effect in the N17 trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA/2 breast cancer (EUK/07/013)</td>
<td>Robert Brown Mr. Brown has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Alacoque Browne</td>
<td>Serum levels of RANKL are increased in primary breast cancer patients in the presence of disseminated tumor cell in the bone marrow.</td>
<td>Alacoque Browne Mr. Browne has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Lamorna Brown-Swigart</td>
<td>DNA repair deficiency biomarkers and MMRHPYR high/supersensitive high2 risk as predictors of veliparib/carboplatin response: Results from the neoadjuvant i-SPY 2 trial for high risk breast cancer.</td>
<td>Lamorna Brown-Swigart Ms. Brown-Swigart has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Sara Yvonne Brucker</td>
<td>Efficacy of first-line bevacizumab (BEV)-containing therapy for poor-progression advanced breast cancer (ABC): Subgroup analyses of the German AVANTI observational study.</td>
<td>Sara Brucker Ms. Brucker has disclosed that she is a consultant for and has a contract with Novartis.</td>
</tr>
<tr>
<td>Sara Yvonne Brucker</td>
<td>Reliability and acceptance of e-based survey instruments for measuring patient reported outcomes (PRO) in breast cancer patients: First results of the ePROCOM study</td>
<td>Sara Yvonne Brucker Prof. Brucker has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Sara Yvonne Brucker</td>
<td>IMENEO: International Meta-analysis of circulating tumor cell detection in early breast cancer patients treated with adjuvant chemotherapy</td>
<td>Sara Yvonne Brucker Ms. Brucker has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Daniel Bruetman</td>
<td>COLET: A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer (TNBC)</td>
<td>Daniel Bruetman Dr. Bruetman has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Adam Brufuly</td>
<td>Prognostic impact of genomic risk stratification with breast cancer index in patients with clinically low risk, hormone receptor-positive, node-negative, T1 breast cancer</td>
<td>Adam Brufuly Dr. Brufuly has disclosed that he is a consultant for Genentech. He also disclosed that he has a contract with Genentech.</td>
</tr>
<tr>
<td>Adam Brufuly</td>
<td>A multi-institutional, prospective study of incorporating the genomic platform breast cancer index as a tool for decision-making regarding extension of adjuvant endocrine therapy</td>
<td>Adam Brufuly Dr. Brufuly has disclosed that he is a consultant for Biotheranostics, Inc.</td>
</tr>
<tr>
<td>Adam Brufuly</td>
<td>Cobimetinib (C) combined with paclitaxel (P) as a first-line treatment in patients (pts) with advanced triple-negative breast cancer (COLET study): Updated clinical and biomarker results</td>
<td>Adam Brufuly Dr. Brufuly has disclosed that he is a consultant for and has a contract with Genentech, Inc.</td>
</tr>
<tr>
<td>Page</td>
<td>Title</td>
<td>Authors</td>
</tr>
<tr>
<td>------</td>
<td>-------------------------------------------------------------------------------------------</td>
<td>--------------------------------</td>
</tr>
<tr>
<td>P1-08-12</td>
<td>Dose dense adjuvant chemotherapy in patients with early breast cancer: Differential treatment effects according to composite index of benefit</td>
<td>Paolo Bruzzi</td>
</tr>
<tr>
<td>P2-11-05</td>
<td>Incidence and severity of diarrhea with neratinib + intensive loperamide prophylaxis in patients (pts) with HER2+ early-stage breast cancer (IBC): Interim analysis from the multicenter, open-label, phase II control trial</td>
<td>Richard Bryce</td>
</tr>
<tr>
<td>P02-08</td>
<td>Neratinib + fulvestrant in ERBB2-mutant, HER2-non-amplified, estrogen receptor (ER)-positive, metastatic breast cancer (MBC): Preliminary analysis from the phase II SUMMIT trial</td>
<td>Richard Bryce</td>
</tr>
<tr>
<td>P3-07-08</td>
<td>Incidence of breast cancer in patients with early breast cancer treated with the ASCO-recommended prognostic factors uPA/PAI-1; a multicenter cohort study (PiA)</td>
<td>Joerg Buchmann</td>
</tr>
<tr>
<td>P6-07-01</td>
<td>Development of a Prosigna® (PAM50)-based classifier for the selection of advanced triple negative breast cancer (TNBC) patients treated with enzalutamide</td>
<td>Wesley Buckingham</td>
</tr>
<tr>
<td>P6-16-23</td>
<td>Neoadjuvant chemotherapy changes surgical procedure after neoadjuvant chemotherapy</td>
<td>Virginie Builen</td>
</tr>
<tr>
<td>P5-05-11</td>
<td>Fibroblasts isolated from the “normal-like” tissue adjacent to breast tumours suppress healthy epithelial progenitor cell proliferation while supporting tumour cell growth</td>
<td>Ed Buchel</td>
</tr>
<tr>
<td>P2-12-07</td>
<td>Rapid germline BRCA1 screening for locally advanced breast cancer: Positive predictive value</td>
<td>Einar Bucher</td>
</tr>
<tr>
<td>P2-03-09</td>
<td>The ASCO-recommended prognostic factors of uPA/PAI-1 in a multicenter cohort study (PiA)</td>
<td>Joerg Buchmann</td>
</tr>
<tr>
<td>P2-12-07</td>
<td>Neuroleptics in breast cancer risk</td>
<td>Wen Bu</td>
</tr>
<tr>
<td>P5-14-12</td>
<td>Long-term outcome of HER2-normal early stage breast cancer (ETBC) patients (Pt(s)) treated with docetaxel-cyclophosphamide (TC) chemotherapy (Ch): Maturity results of a single-institution experience</td>
<td>Conor Buckley</td>
</tr>
<tr>
<td>P2-03-09</td>
<td>Prediction of 10yr distant recurrence (DR) using the Prosigna® (PAM50) assay in histological subgroups of a Danish breast cancer group (DBC) cohort of postmenopausal Danish women with hormone receptor-positive (HR)-negative breast cancer (BC): Allocated to 5yr of endocrine therapy (ET) alone</td>
<td>Wesley Buckingham</td>
</tr>
<tr>
<td>P5-14-12</td>
<td>Basal-like triple-negative breast cancer patients (Pt(s)) treated with docetaxel-cyclophosphamide (TC) chemotherapy (Ch): Maturity results of a single-institution experience</td>
<td>Conor Buckley</td>
</tr>
<tr>
<td>P2-03-09</td>
<td>The effects of treatment-induced symptoms, depression and age on sexuality in premenopausal women with early breast cancer receiving adjuvant endocrine therapy</td>
<td>Steven Buchner</td>
</tr>
</tbody>
</table>
Combined targeted therapies for advanced triple negative breast cancer: A phase II trial of nab-paclitaxel and bevacizumab followed by maintenance targeted therapy with bevacizumab and erlotinib

Barbara Buening
Ms. Buening has no relevant financial relationships to disclose.

A phase II study to compare fulvestrant (F) 500mg plus placebo versus (vs) F 500mg plus palbociclib (P) as first line treatment for postmenopausal women with hormone receptor (HR)-positive, HER-2 negative advanced breast cancer (ABC) sensitive to endocrine therapy (ET). “The FLIPPER study” (GEICAM/2014-12)

Coralia Buono
Ms. Buono has no relevant financial relationships to disclose.

P6-10-05
OT3-02-07
P6-12-03
P3-01-01
P1-09-06
P3-13-02
P6-04-02
P6-12-12
P5-13-06
P4-20-04
P4-17-03
P5-09-08
P1-09-06
P2-12-02
P3-13-02
P1-09-06
P3-13-02
P4-04-02
P6-12-12
P5-13-06

P4-22-11

Prognostic and predictive relevance of cell cycle progression (CCP) score in ductal carcinoma in situ: Results from the UK/ANZ DCIS trial

Katrina Bull
Ms. Bull has disclosed that she receives salary and has ownership in Myriad.

Cambridge brain metastasis trial 1 (CAMELOT): A proof-of-principle phase 1b / randomised phase 2 study of alatibin penetration into brain metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy

Gemma Bullen
Ms. Bullen has no relevant financial relationships to disclose.

P3-08-01
P3-09-03
P7-12-02
P3-02-12
P1-09-06
P3-13-02
P4-04-02
P6-12-12
P5-13-06

P5-13-06

A study to determine the optimal method of detection and threshold for lymphoedema intervention: A multi-centre prospective study

Nigel Bundled
Mr. Bundled has no relevant financial relationships to disclose.

Phase I study of the JAK-1/2 inhibitor ruxolitinib with weekly palbociclib for the treatment of HER2 negative metastatic breast cancer (MBC)

Craig Bunnell
Dr. Bunnell has no relevant financial relationships to disclose.

Factors associated with follow up medical care among women with early stage breast cancer

Diana Buist
Dr. Buist has no relevant financial relationships to disclose.

Comparative performance of surveillance mammography and breast MRI in women with a history of breast cancer

Sarah Bujac
Ms. Bujac has disclosed that she is an AstraZeneca employee.

Impact of primary surgery on short-term survival of older breast cancer patients in the UK

Donna Buono
Ms. Buono has no relevant financial relationships to disclose.

A phase I study of AZD9496, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC)

Alexandra Bukowski
Ms. Bukowski has no relevant financial relationships to disclose.

Molecular evaluation of Peruvian patients with hereditary breast cancer reveals a novel germline mutation in BRCA1

Jose Bukje
Mr. Bukje has no relevant financial relationships to disclose.

A phase I study of AZD4563, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC)

Sarah Bujac
Ms. Bujac has disclosed that she is an AstraZeneca employee.

Impact of surgical resection on short-term outcomes for patients with brain metastases from breast cancer: Results from the Cambridge Brain Metastasis Trial

Gemma Bullen
Ms. Bullen has no relevant financial relationships to disclose.

Low-level gonosomal mosaicism of de novo BRCA1 gene mutation - The origin of a constitutional mutation in a breast cancer family

Max Builara
Mr. Builara has no relevant financial relationships to disclose.

Prognostic and predictive relevance of cell cycle progression (CCP) score in ductal carcinoma in situ: Results from the UK/ANZ DCIS trial

John Bumberry
Dr. Bumberry has no relevant financial relationships to disclose.

TruRisk® based next-generation sequencing in BRCA1/2-negative breast and ovarian cancer families reveals high mutation prevalence in additional risk genes

Lucie Bulo
Dr. Bulo has no relevant financial relationships to disclose.

Impact of primary surgery on short-term survival of older breast cancer patients in the UK

Nigel Bundled
Mr. Bundled has no relevant financial relationships to disclose.

Cochrane review of capecitabine for hormone receptor positive versus hormone receptor negative breast cancer

Max Builara
Mr. Builara has no relevant financial relationships to disclose.

Impact of primary surgery on short-term survival of older breast cancer patients in the UK

Donna Buono
Ms. Buono has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P5-13-14</td>
<td>Factors associated with multidisciplinary care in the management of early stage breast cancer</td>
<td>Donna Buono</td>
<td>Ms. Buono has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-22-16</td>
<td>First-line ribociclib plus letrozole in patients with de novo HR+, HER2- advanced breast cancer (ABC): A subgroup analysis of the MONALEESA-2 trial</td>
<td>Olga Burdaeva</td>
<td>Ms. Burdaeva has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-03</td>
<td>The genomic landscape of breast metaplastic carcinoma</td>
<td>Kathleen Burke</td>
<td>Dr. Burke has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-04-06</td>
<td>Intratumor genetic heterogeneity and histologic heterogeneity within metaplastic breast cancers: Somatic targeting by histology</td>
<td>Kathleen Burke</td>
<td>Dr. Burke has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-02-14</td>
<td>The landscape of somatic genetic alterations in BRCA1 and BRCA2 breast cancers</td>
<td>Kathleen Burke</td>
<td>Dr. Burke has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-03-14</td>
<td>Stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer</td>
<td>Jared Burks</td>
<td>Dr. Burks has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S1-02</td>
<td>PrECOG 0102: A randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in post-menopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC) resistant to aromatase inhibitor (AI) therapy</td>
<td>Brian Burnette</td>
<td>Dr. Burnette has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-12-06</td>
<td>New method to measure functional HER2-driven signaling activity in primary tumor cells identifies HER2-negative breast cancer cell samples with abnormal HER2 signaling activity</td>
<td>David Burns</td>
<td>Dr. Burns has disclosed that he receives salary and has ownership.</td>
</tr>
<tr>
<td>P4-22-14</td>
<td>Single agent palbociclib with or without trastuzumab for the treatment of Rb+ advanced breast cancer</td>
<td>Jessica Burnell</td>
<td>Mr. Burnell has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-12</td>
<td>Overexpression of fractalkine and platelet-activating factor-α (PAF) as novel targets for HER2+ breast cancer: Overall survival results from BOLERO-3.</td>
<td>Car-Friedrich Buring</td>
<td>Dr. Buring has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-22-13</td>
<td>First-line ribociclib plus letrozole in patients with de novo HR+, HER2- advanced breast cancer (ABC): A subgroup analysis of the MONALEESA-2 trial</td>
<td>Howard Burns</td>
<td>Mr. Burns has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-04-14</td>
<td>Flare up of breast cancer patients with promising response in the first in human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640 in combination with paclitaxel</td>
<td>Howard Burns</td>
<td>Mr. Burns has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-01-02</td>
<td>The genomic landscape of breast metaplastic carcinoma</td>
<td>Kathleen Burke</td>
<td>Dr. Burke has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-01-16</td>
<td>Circulating tumor cells (CTCs) biomarker evaluation from patients with metastatic breast cancer (MBC) utilizing the TargetSelect® platform</td>
<td>Howard Burns III</td>
<td>Dr. Burns III has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-04-09</td>
<td>A phase 2 open label study of axitinib in combination with endocrine therapy in resistant hormone receptor-positive HER2-negative advanced breast cancer</td>
<td>Howard Burns III</td>
<td>Dr. Burns III has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-14</td>
<td>Everolimus plus trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: Overall survival results from BOLERO-1.</td>
<td>Howard Burns</td>
<td>Mr. Burns has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-09-09</td>
<td>Circulating tumor cells (CTCs) biomarker evaluation from patients with metastatic breast cancer (MBC) utilizing the TargetSelect® platform</td>
<td>Howard Burns</td>
<td>Mr. Burns has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-11-09</td>
<td>Phase I study of the antibody-drug conjugate (ADC) SGN-UV1A in patients with heavily pretreated metastatic breast cancer</td>
<td>Howard Burns III</td>
<td>Dr. Burns III has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-01-16</td>
<td>Circulating tumor cells (CTCs) biomarker evaluation from patients with metastatic breast cancer (MBC) utilizing the TargetSelect® platform</td>
<td>Howard Burns III</td>
<td>Dr. Burns III has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-04-09</td>
<td>A phase 2 open label study of axitinib in combination with endocrine therapy in resistant hormone receptor-positive HER2-negative advanced breast cancer</td>
<td>Howard Burns III</td>
<td>Dr. Burns III has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-12-04</td>
<td>Trends in positive predictive values following transition from screen film to digital mammography</td>
<td>Paul Burrows</td>
<td>Dr. Burrows has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>ID</td>
<td>Title</td>
<td>Authors</td>
<td>Financial Relationships</td>
</tr>
<tr>
<td>----</td>
<td>----------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>P2-09-09</td>
<td>The effects of treatment-induced symptoms, depression and age on sexuality in premenopausal women with early breast cancer receiving adjuvant endocrine therapy</td>
<td>Harold Burstein</td>
<td>Dr. Burstein has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-15-08</td>
<td>A phase II study of ributinib as early-line treatment for HER2-MBC: Evaluation of efficacy, toxicity, and patient-reported outcomes</td>
<td>Harold Burstein</td>
<td>Dr. Burstein has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-14-02</td>
<td>Triple negative breast cancer – Adjuvant chemotherapy use and survival outcomes in Stage IIA disease</td>
<td>Gary Burton</td>
<td>Dr. Burton has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-09-08</td>
<td>Predictive effect of cytotoxic tumor infiltrating lymphocytes in HER2-positive metastatic breast cancer: A correlative study with CCTG MA.31</td>
<td>Samantha Buuga</td>
<td>Ms. Buuga has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P05-08</td>
<td>Depression of LAG-3 in breast cancer, and its association with subtype and outcome</td>
<td>Samantha Buuga</td>
<td>Ms. Buuga has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-10-09</td>
<td>Prospective cross-sectional study on participation in mammography screening according to immigration background and education status</td>
<td>Christoph Busch</td>
<td>Mr. Busch has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P06-04</td>
<td>A phase II trial to define European and US young women cope with breast cancer and fertility concerns</td>
<td>Katharina Baer</td>
<td>Ms. Baer has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P03-02</td>
<td>A phase II trial to define European and US young women cope with breast cancer and fertility concerns</td>
<td>Mary Bush</td>
<td>Ms. Bush has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-04-04</td>
<td>DNA methylation landscapes of breast cancer progression to brain metastasis: A pre-clinical study</td>
<td>Mary Butow</td>
<td>Ms. Butow has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P06-03</td>
<td>Preserving fertility in young women undergoing chemotherapy for early breast cancer: the Maanricht experience</td>
<td>Elena Butalid</td>
<td>Dr. Butalid has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-10-07</td>
<td>Lung survival of patients with locally advanced breast cancer on combined neoadjuvant chemotherapy and immune adjuvantation: Modern lessons from an old study</td>
<td>Jan Buter</td>
<td>Dr. Buter has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-11-02</td>
<td>Women's experiences with a decision aid for neoadjuvant systemic therapy for operable breast cancer</td>
<td>Phyllis Butow</td>
<td>Dr. Butow has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P05-02</td>
<td>Breast implant associated anaplastic large cell lymphoma (BIA-ALCL): The UK experience and first reported case of neoadjuvant brentuximab</td>
<td>Mark Butterworth</td>
<td>Mr. Butterworth has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-12-10</td>
<td>Safety and efficacy of trastuzumab emtansine (T-DM1) in 199 patients with central nervous system metastases: Exploratory subgroup analysis from the INELZA study</td>
<td>Peter Button</td>
<td>Mr. Button has disclosed that he receives salary from F. Hoffman-La Roche.</td>
</tr>
<tr>
<td>P5-15-06</td>
<td>Impact of post-progression therapy on overall survival (OS) in the INELZA randomized phase III trial evaluating the addition of capcitabine (CAP) to maintenance bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC)</td>
<td>Peter Button</td>
<td>Mr. Button has disclosed that he receives salary from Roche.</td>
</tr>
<tr>
<td>P02-08</td>
<td>Neratinib + fulvestrant in HER2BB2-mutant, HER2-non-amplified, estrogen receptor (ER)-positive, metastatic breast cancer (MBC): Preliminary analysis from the phase II SUMMIT trial</td>
<td>Anna Butturini</td>
<td>Ms. Butturini has disclosed that she receives salary from Puma Biotechnology Inc.</td>
</tr>
<tr>
<td>P2-04-07</td>
<td>Immune profiling of post-neoadjuvant high-risk metastatic breast cancer (HRBC): Preliminary analysis from the phase II SUMMIT trial</td>
<td>Anna Butturini</td>
<td>Ms. Butturini has disclosed that she receives salary from Puma Biotechnology Inc.</td>
</tr>
<tr>
<td>P5-05-02</td>
<td>Quantitative EStrom measurements in THBC from the 1-SPY 2 TRIAL correlate with HER2-GFR co-activation and heterodimerization</td>
<td>Meredith Butow</td>
<td>Dr. Butow has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-11-18</td>
<td>Trajectory of patient (Pt) reported physical function (PF) during and after neoadjuvant chemotherapy in the 1-SPY 2 trial</td>
<td>Meredith Butow</td>
<td>Dr. Butow has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
P6-11-02  Efficacy of high-risk breast cancer patients with baseline circulating miR-19b-3p and miR-4687-5p as potential biomarkers: Results from the I-SPY 2 trial
Meredith Buxton  Dr. Buxton has no relevant financial relationships to disclose.

P5-08-05  The evaluation of ganitumab/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial
Meredith Buxton  Dr. Buxton has no relevant financial relationships to disclose.

S2-06  Prospective family cohort analysis of genetic/environment interactions in breast cancer: Body mass index
Saundra Buys  Dr. Buys has no relevant financial relationships to disclose.

P4-22-13  Everolimus plus trastuzumab and pertuzumab as first-line therapy in women with HER2+ advanced breast cancer: Overall survival results from BOLERO-3
Marc Buzaglo  Mr. Buzaglo has disclosed that he receives salary from and owns stock in IDEC Inc.

P3-10-12  Breast cancer clinical trials: Patient experiences, preferences, and insights into improving participation
Joanne Buzy  Dr. Buzy has no relevant financial relationships to disclose.

P2-08-03  The role of CDK4/6 inhibitors in the development of breast cancer: A systematic review of phase I and II clinical trials
Aman Buzdar  Mr. Buzdar has no relevant financial relationships to disclose.

P4-20-08  Evaluation of a multidisciplinary cancer team audit tool quality in a breast cancer unit (BCU) in Mexico
Stara Alejandra Cabello  Dr. Cabello has no relevant financial relationships to disclose.

P1-07-09  A multi-OMIC analysis to explore the impact of “actionable” genomic alterations on protein pathway activation: Clinical implication for precision medicine in metastatic breast cancer
Sarah Byron  Ms. Byron has no relevant financial relationships to disclose.

OT3-02-07  Evaluation of a multidisciplinary cancer team audit tool quality in a breast cancer unit (BCU) in Mexico
Stara Alejandra Cabello  Dr. Cabello has no relevant financial relationships to disclose.

P4-22-13  Everolimus plus trastuzumab and pertuzumab as first-line therapy in women with HER2+ advanced breast cancer: Overall survival results from BOLERO-3
David Cabello  Dr. Cabello has disclosed that he is an employee of Translational Research in Oncology (TRIO), a company contracted by Novartis for the conduct of some study related activities (e.g., Data Management).

P6-16-01  The importance of local-regional tumor burden and surgery on survival in patients with de novo stage IV breast cancer: post-hoc analyses of protocol MF07-01
Neslihan Caboglu  Dr. Caboglu has no relevant financial relationships to disclose.

P5-11-16  Do breast cancer patients and nurses outside clinical trial prefer subcutaneous trastuzumab over conventional intravenous infusion? Instituto Oncologico Nacional experience
Angela Cabrera  Dr. Cabrera has no relevant financial relationships to disclose.

P2-11-10  Effect of supplementation with eicosapentaenoic and docosahexaenoic omega-3 polyunsaturated fatty acid on the chemotoxicity in Mexican patients with locally advanced breast cancer (LABC) treated with neoadjuvant chemotherapy (NeoCT)
Paula Calleja  Dr. Calleja has no relevant financial relationships to disclose.
Impact of delay neoadjuvant chemotherapy on pathologic complete response in locally advanced breast cancer evidence of the real world in Mexico  
Paula Cabrera  
Dr. Cabrera has no relevant financial relationships to disclose.

Shared decision-making approach in breast reconstruction in a developing country  
Paula Cabrera-Galeana  
Dr. Cabrera-Galeana has no relevant financial relationships to disclose.

Three-monthly dynamic evaluation of CEA and CA15-3 (followed by 18-FDG PET) vs usual practice in the follow-up of early breast cancer (BC) patients (pts): A prospective randomized trial (VINCONI-patient-oriented new surveillance study, Italy)  
Nicoleta Cacciat  
Dr. Cacciat has no relevant financial relationships to disclose.

Flutamide reduced tumor progression and altered steroid hormone secretion in human and canine inflammatory breast cancer cell lines  
Sara Caseres  
Dr. Caseres has no relevant financial relationships to disclose.

Squalene epoxidase is a potential metabolic oncogene by amplification with clinical implications in breast carcinoma: An in silico pan-cancer study with in vitro evidence  
Irene Cafla  
Dr. Cafla has no relevant financial relationships to disclose.

Sparing in clinical trials: A possible challenge for improving health care for breast cancer patients  
Celeste Cagnazzo  
Dr. Cagnazzo has no relevant financial relationships to disclose.

9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: results of the phase III multicentric Italian short-HER trial  
Katia Cagossi  
Ms. Cagossi has no relevant financial relationships to disclose.

PALINA: A phase II safety study of palbociclib in combination with letrozole in African American women with hormone receptor positive HER2 negative advanced breast cancer  
Ling Cai  
Dr. Cai has no relevant financial relationships to disclose.

Race associated disparities in an urban population of adolescent and young adult (AYA) women with breast cancer  
Ling Cai  
Dr. Cai has no relevant financial relationships to disclose.

An annotated collection of pre- and post-therapy breast cancer patient-derived xenograft models built from fine needle aspiration samples aligned with ongoing clinical trials documenting response to treatment  
Shirong Cai  
Shirong Cai has no relevant financial relationships to disclose.

Comprehensive analysis of the DNA damage repair and maintenance pathways that regulate TNBC sensitivity to replication stress  
Shirong Cai  
Shirong Cai has no relevant financial relationships to disclose.

Identifying metastatic drivers in patient derived xenograft models of triple negative breast cancer  
Shirong Cai  
Shirong Cai has no relevant financial relationships to disclose.

Identification of proliferation related derivers and their roles in precision medicine for breast cancers: A retrospective multidimensional comparative, integrated genomic, transcriptomic, and protein analysis  
Carlos Caldas  
Dr. Caldas has no relevant financial relationships to disclose.

Bromodomain inhibitors represent a rational therapeutic option for the treatment of invasive lobular carcinoma  
Carlos Caldas  
Dr. Caldas has no relevant financial relationships to disclose.

Cambridge brain mets trial 1 (CamBMT1): A proof-of-principle phase Ib / randomised phase II study of afatinib penetration into brain metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy  
Burcu Cakar  
Dr. Cakar has no relevant financial relationships to disclose.

Assessing the impact of loss of NFE2 protein on endocrine therapy resistance  
Burcu Cakar  
Dr. Cakar has no relevant financial relationships to disclose.

Phase II of POSIDON: A phase Ib / randomised phase II trial of trametinib plus tamoxifen or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment  
Burcu Cakar  
Dr. Cakar has no relevant financial relationships to disclose.

Identification of proliferation related derivers and their roles in precision medicine for breast cancers: A retrospective multidimensional comparative, integrated genomic, transcriptomic, and protein analysis  
Carlos Caldas  
Dr. Caldas has no relevant financial relationships to disclose.

Granulocyte inhibitors represent a rational therapeutic option for the treatment of invasive lobular carcinoma  
Carlos Caldas  
Dr. Caldas has no relevant financial relationships to disclose.
P5-09-08  Molecular evaluation of Peruvian patients with hereditary breast cancer reveals a novel germline mutation in BRCA1
Gabriela Calderon  Ms. Calderon has no relevant financial relationships to disclose.

S4-06  Biologic effects of abemaciclib in a phase2 neoadjuvant study for premenopausal patients with hormone receptor positive, HER2 negative breast cancer
Charles Caldwell  Dr. Caldwell has disclosed that he has a contract with and is employed by Eli Lilly and Company.

P5-08-17  Breast cancer in octogenarians: A community hospital experience
Debbie Callejas  Ms. Callejas has no relevant financial relationships to disclose.

OT3-01-05  Functional MRI signatures of immune response to targeted breast cancer therapy
Kristine Callahan  Dr. Calhoun has no relevant financial relationships to disclose.

P4-21-17  Phase I trial of naxitamab in combination with trastuzumab in metastatic HER2 positive breast cancer
Andrea Califfano  Dr. Califfano has no relevant financial relationships to disclose.

P4-05-02  Conditional extinction of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) in the mouse mammary epithelium alters mammary gland development
David Callen  Dr. Callen has no relevant financial relationships to disclose.

P2-05-04  Evaluation of intra-tumor heterogeneity, test reproducibility and their impact in breast cancer samples assessed by Prosigna™: Results from a decision impact prospective study and a matched case-control study
Celine Callens  Dr. Callens has no relevant financial relationships to disclose.

P3-04-09  Neoadjuvant non-pegylated liposomal doxorubicin plus paclitaxel, trastuzumab and pertuzumab in patients with HER2+ breast cancer - Final results of the SOLTI OPTI-HER HEART study
Isabel Calvo  Dr. Calvo has no relevant financial relationships to disclose.

P4-21-16  Phase III trial to evaluate patient's preference for subcutaneous versus intravenous trastuzumab administration in patients with HER2 positive advanced breast cancer (ABC) under IV trastuzumab (IV-t) treatment for at least 4 months: ChangHER-SC study (GEICAM/2012-07)
Mari Carmen Camaré  Ms. Camara-Jurado has no relevant financial relationships to disclose.
First-line rucaparib plus cetuximab in patients with advanced HPV+, HER2- advanced breast cancer (ABC). A subgroup analysis of the MONALEESA-2 trial

David Cameron

Dr. Cameron has disclosed that Novartis provided some funds (paid to another institution) to support an academic led study with a different agent (not rucaparib/LEE011) in breast cancer.

The association between pCR status after neoadjuvant chemotherapy and sites of first distant relapse after surgery: A substudy of the EORTC, 10094/BIG-1-01 trial

David Cameron

Prof. Cameron has no relevant financial relationships to disclose.

Adjuvant treatment with trastuzumab and docetaxel in stage II/III breast cancer. The ADURe trial (BIG 02/94) 10 year follow-up

David Cameron

Dr. Cameron has no relevant financial relationships to disclose.

Association of background parenchymal enhancement with breast cancer risk factors and tumor characteristics

Cristina Campassi

Dr. Campassi has no relevant financial relationships to disclose.

Challenges faced across borders to open European academic multicentre projects: The ET-FES program part of the ERA-Net TRANSCAN. JTC 2011

Eleonora Campazzi

Dr. Campazzi has no relevant financial relationships to disclose.

Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2 positive early breast cancer (BIG 1-05)

Christine Campbell

Ms. Campbell has no relevant financial relationships to disclose.

Identifying the remaining causes of hereditary breast cancer

Ian Campbell

Dr. Cameron has no relevant financial relationships to disclose.

Identifying the remaining causes of hereditary breast cancer

Ian Campbell

Dr. Cameron has no relevant financial relationships to disclose.

Identifying the remaining causes of hereditary breast cancer

Ian Campbell

Dr. Cameron has no relevant financial relationships to disclose.

Identifying the remaining causes of hereditary breast cancer

Ian Campbell

Dr. Cameron has no relevant financial relationships to disclose.

Identifying the remaining causes of hereditary breast cancer

Ian Campbell

Dr. Cameron has no relevant financial relationships to disclose.

Identifying the remaining causes of hereditary breast cancer

Ian Campbell

Dr. Cameron has no relevant financial relationships to disclose.

Identifying the remaining causes of hereditary breast cancer

Ian Campbell

Dr. Cameron has no relevant financial relationships to disclose.

Identifying the remaining causes of hereditary breast cancer

Ian Campbell

Dr. Cameron has no relevant financial relationships to disclose.

Identifying the remaining causes of hereditary breast cancer

Ian Campbell

Dr. Cameron has no relevant financial relationships to disclose.

Identifying the remaining causes of hereditary breast cancer

Ian Campbell

Dr. Cameron has no relevant financial relationships to disclose.

Identifying the remaining causes of hereditary breast cancer

Ian Campbell

Dr. Cameron has no relevant financial relationships to disclose.

Identifying the remaining causes of hereditary breast cancer

Ian Campbell

Dr. Cameron has no relevant financial relationships to disclose.

Non-sentinel lymph node involvement in early breast cancer: patients: Performance of two predictive nomograms integrating the analysis of sentinel nodes by one step nucleic acid amplification in a cohort of 299 patients

Loic Campion

Dr. Campion has no relevant financial relationships to disclose.

Exclusive fat grafting breast reconstruction after mastectomy: Feasibility and complications on 54 patients

Loic Campion

Dr. Campion has no relevant financial relationships to disclose.

Sentinel node detection after neoadjuvant chemotherapy in patients without previous axillary node involvement (GAMMA 2 trial): Follow-up of a prospective multi-institutional cohort

Loic Campion

Dr. Campion has no relevant financial relationships to disclose.

A phase 2 randomized, double-blind, placebo-controlled trial of sodium-223 dichloride with exemestane and everolimus in patients with HER2-negative, hormone receptor-positive breast cancer and bone metastases

Mario Campone

Mr. Campone has disclosed that he is a consultant for Novartis, AstraZeneca, Pfizer, Roche and Menarini. He also disclosed he is a speaker for Novartis, AstraZeneca, Pfizer and Roche.

He disclosed he receives honoraria from Novartis, AstraZeneca, Pfizer, Sanofi, Roche and Menarini.

Mr. Campone has also disclosed that he receives travel, accommodation/expenses from Novartis, AstraZeneca, Pfizer and Roche.

A phase 1 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors

Robby Campbell

Dr. Campbell has no relevant financial relationships to disclose.

OCT1-04-05

GUCA-1: A phase II study of apalutamide and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR), human epidural growth factor receptor 2-negative (HER2-) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy

Mario Campone

Mr. Campone has disclosed that he is a consultant for Novartis, AstraZeneca, Pfizer, Roche and Menarini. He also disclosed he is a speaker for Novartis, AstraZeneca, Pfizer and Roche.

Mr. Campone has also disclosed that he receives travel, accommodation/expenses from Novartis, AstraZeneca, Pfizer and Roche.

OCT2-02-04

A phase (II) of S-22331, a reversible EGFR and HER2 inhibitor, combined with trastuzumab and chemotherapy in patients with HER2-positive metastatic breast cancer

Mario Campone

Mr. Campone has disclosed that he is a consultant for Novartis, AstraZeneca, Pfizer, Roche and Menarini. He also disclosed he is a speaker for Novartis, AstraZeneca, Pfizer and Roche.

Mr. Campone has also disclosed that he receives travel, accommodation/expenses from Novartis, AstraZeneca, Pfizer and Roche.

OCT2-05-08

Evaluation of selatparib (C) and bemotecilamide (TMZ) in a phase 2 randomised study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) in patients with (HR+)/(HER2-) or (HR-)/(HER2+) advanced breast cancer

Mario Campone

Mr. Campone has disclosed that he is a consultant for Novartis, AstraZeneca, Pfizer, Roche and Menarini. He also disclosed that he receives travel, accommodation/expenses from Novartis, AstraZeneca, Pfizer and Roche.

P4-22-02

OCT2-02-04

A phase (II) of S-22331, a reversible EGFR and HER2 inhibitor, combined with trastuzumab and chemotherapy in patients with HER2-positive metastatic breast cancer

Mario Campone

Mr. Campone has disclosed that he is a consultant for Novartis, AstraZeneca, Pfizer, Roche and Menarini. He also disclosed he is a speaker for Novartis, AstraZeneca, Pfizer and Roche.
First-line ribociclib plus letrozole in patients with de novo HR+, HER2- advanced breast cancer (ABC): A subgroup analysis of the MONALEESA-2 trial

Mario Campone

Mr. Campone has disclosed that he is a consultant and speaker for Novartis, AstraZeneca and Pfizer. He has also disclosed that he has a contract with Novartis.

Comparison of mutational landscapes of primary breast cancer and first metastatic relapse: Results from the ESOPE study

Mario Campone

Dr. Campone has no relevant financial relationships to disclose.

High-throughput genome analysis and therapeutic decision for patients with HER2-negative metastatic breast cancer: First feasibility and molecular results of the randomized phase II study S414R22 BREAST (UCB-0105/1306)

Mario Campone

Dr. Campone has no relevant financial relationships to disclose.

Efficacy and tolerability of veliparib (L-87-CBM) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)/C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: A randomized, phase 2 study

Mario Campone

Dr. Campone has disclosed that he is a speaker for Novartis, AstraZeneca, Pfizer, Sanofi, Roche and Menarini. He has also disclosed that he receives travel, accommodations/expenses from Novartis, AstraZeneca, Pfizer and Roche.

Challenges faced across borders to open European academic multicentre projects: The EIT-FIS program part of the ERA-Net TRANSCAN JTC 2011

Sara Campora

Dr. Campora has no relevant financial relationships to disclose.

Challenges faced across borders to open European academic multicentre projects: The EIT-FIS program part of the ERA-Net TRANSCAN JTC 2011

Davide Camporese

Dr. Camporese has no relevant financial relationships to disclose.

Fertility concerns in young women after diagnosis of breast cancer: Experience of a breast cancer unit in Mexico

Karen A Campos-Gomez

Dr. Campos-Gomez has no relevant financial relationships to disclose.

Fertility concerns in young women after diagnosis of breast cancer: Experience of a breast cancer unit in Mexico

Seul Campo-Sgozmez

Dr. Campo-Sgozmez has no relevant financial relationships to disclose.

Evaluation of a multidisciplinary cancer team quality in a breast cancer unit (BCU) in Mexico

Seul Campo-Sgozmez

Dr. Campo-Sgozmez has no relevant financial relationships to disclose.

Maintenance immunotherapy in estrogen receptor negative (ER-) locally advanced (LA) and/or metastatic breast cancer (MBC) - long term follow-up of a phase II study

Giampiero Candeloro

Dr. Candeloro has no relevant financial relationships to disclose.

BRE12-15: A phase II randomised controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer (TNBC)

Vikki Canfield

Dr. Canfield has no relevant financial relationships to disclose.

Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ER positive metastatic breast cancer patients: Results of the COMETI Phase 2 trial

Emily Cannell

Ms. Cannell has no relevant financial relationships to disclose.

t-DM1 in HER2+ advanced breast cancer patients: Real world practice from a multicenter observational study.

María José Cantero

Ms. Cantero has no relevant financial relationships to disclose.

Assessing response in locally advanced breast cancer treated with neoadjuvant chemotherapy: Predictive and prognostic potential of volume-based metabolic variables with 18F-FDG PET/CT

Katia Carmona

Ms. Carmona has no relevant financial relationships to disclose.

Neoadjuvant non-pegylated liposomal doxorubicin plus paclitaxel, trastuzumab and pertuzumab in patients with HER2+ breast cancer - Final results of the SOLT-OP1-HER HEART study

Blanca Cantos Sánchez de Roche

Dr. Cantos Sánchez de Roche has disclosed that he is on an Advisory Board for Roche.

Li-Fraumeni syndrome in females with early onset breast cancer in a Mexican population

David Canto-De Leon

Dr. Canto-De Leon has no relevant financial relationships to disclose.

The importance of loco-regional tumor burden and surgery on survival in patients with de novo stage IV breast cancer: post hoc analyses of protocol MMT-01

Süley Kenturk

Dr. Kenturk has no relevant financial relationships to disclose.

Regulation of estrogen receptor α by NF-κB

Jin Cao

Mr. Cao has no relevant financial relationships to disclose.
Recurrent functionally diverse in-frame ESR1 gene fusions drive endocrine resistance in breast cancer

In-situ hybridization of microRNA and support vector machines-based prognostic classifiers for breast cancer

Tumor infiltrating lymphocytes in recurrent HER2+ and triple negative breast cancer: Prognostic value according to tumor phenotype

In-situ hybridization of microRNA and support vector machines-based prognostic classifiers for breast cancer

GATA3 inhibits breast basal-like tumorigenesis

Genome-wide identification of transcripts regulated by estrogen in MCF-7 cells using BrU-seq

Tumor infiltrating lymphocytes in recurrent HER2+ and triple negative breast cancer: Prognostic value according to tumor phenotype

IMENEO: International Meta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEOadjuvant chemotherapy

Neoadjuvant weekly carboplatin and paclitaxel followed by dose dense epirubicin and cyclophosphamide in triple negative breast cancer patients: A single arm phase II study from the Belgian Society of Medical Oncology

Improved long-term outcomes of Breast-conserving therapy for women with ductal carcinoma in situ

Breast cancer subtype, age and lymph node status as predictors of local recurrence following breast-conserving therapy

FAPα (fibroblast activation protein-α) analysis in breast tumor cells and stroma after neoadjuvant treatment

Enhanced efficacy of redirected T-cell therapy of TNBC with a Trop-2/CD3 bispecific antibody in combination with a checkpoint inhibitor

Can surrogate pathological subtyping replace molecular subtyping? Outcome results from the MINDACT trial

Stomatitis in patients treated with first-line everolimus (EVE) plus letrozole (LET): Results from BOLERO-4 trial

A fit-for-purpose NGS system that reports ERBB2 (HER2) mutations and copy number variants for clinical trials research and drug development

A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB)
Comparing the frequency and types of genetic aberrations between older and younger women with metastatic breast cancer at the University of North Carolina at Chapel Hill

Lisa Carey

Dr. Carey has no relevant financial relationships to disclose.

The incidence and outcomes of brain metastases in HER2+ breast cancer in older women

Lisa Carey

Dr. Carey has no relevant financial relationships to disclose.

Comparative toxicity and effectiveness of trastuzumab combined with anthracycline versus platinum chemotherapy regimens for adjuvant therapy of HER2+ breast cancer in older women

Lisa Carey

Dr. Carey has no relevant financial relationships to disclose.

Multivariate analysis of subtype and gene expression signatures predictive of pathologic complete response (pCR) in triple-negative breast cancer (TNBC) - CALGB 40605 (Alliance)

Lisa Carey

Dr. Carey has no relevant financial relationships to disclose.

Discovery of molecular predictors of late breast cancer-specific events (BCSE) in ER+, node+ breast cancer - new transcriptional expression whole gene analysis of the phase III adjuvant trial SWOG 8814

Lisa Carey

Dr. Carey has no relevant financial relationships to disclose.

Race and age differences in PAM50 biomarker status in the Carolina breast cancer study

Lisa Carey

Dr. Carey has no relevant financial relationships to disclose.

Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer

Lisa Carey

Dr. Carey has disclosed that she has contracts with GlaxoSmithKline and Genentech/Roche.

Clinical evaluation of miR-100 as a predictor of endocrine-responsiveness in hormone receptor-positive breast cancer

Marilisa Cargnelutti

Dr. Cargnelutti has no relevant financial relationships to disclose.

A phase II, open-label, multi-center study of ANG1005, a novel brain-penetrant peptide-drug conjugate, in breast cancer patients with recurrent CNS metastases

Jose Carlito

Dr. Carillo has no relevant financial relationships to disclose.

Omitting radiotherapy in women ≥ 65 years with early breast cancer and favorable histopathology after breast-conserving surgery, sentinel node biopsy and adjuvant endocrine therapy is safe

Michael Carlson

Mr. Carlberg has no relevant financial relationships to disclose.

DBCG 07-READ: A randomized phase III trial comparing six cycles of docetaxel and cyclophosphamide (DC) to three cycles of epirubicin and cyclophosphamide followed by three cycles of docetaxel (EC-D) in patients with early breast cancer

Dorte Carlson

Dorte Carlson has no relevant financial relationships to disclose.

Diagnosing cognitive impairment (“chemo brain”) in breast cancer survivors

Barbara Carlson

Dr. Carlson has no relevant financial relationships to disclose.

A combination of dual inhibition in HER2-network by T-DM1 and GSK-2636508 provides maximal antitumor efficacy in preclinical model of HER2+ breast cancer

Ms. Carlson has no relevant financial relationships to disclose.

Dynamics of cancer stem cell surface marker, CD44 and CD44v6 in the antitumor efficacy of PARP inhibitor in combination with PI3K pathway inhibitor in TNBC xenograft model

Jennifer Carlson

Ms. Carlson has no relevant financial relationships to disclose.

Preclinical efficacy of dasatinib in combination with PARP inhibitor plus standard cytotoxic agent in triple-negative breast cancer xenograft model

Jennifer Carlson

Ms. Carlson has no relevant financial relationships to disclose.

Gain and amplification of RAC1 GTP-ase in BC: Explaining alterations in patients by experiments using TNBC model

Jennifer Carlson

Ms. Carlson has no relevant financial relationships to disclose.

Gain and amplification of RAC1 GTP-ase in BC: Explaining alterations in patients by experiments using TNBC model

Jennifer Carlson

Ms. Carlson has no relevant financial relationships to disclose.
Cancer stem cells define 3D clonogenic growth response to rational combinations of PI3K-isoform specific inhibitors in TNBC
Jennifer Carlson
Ms. Carlson has no relevant financial relationships to disclose.

Deep-IrInfrared Imaging to identify venous impairment after breast cancer surgery
Brigit Carly
Ms. Carly has no relevant financial relationships to disclose.

Early detection of secondary lymphedema after cancer treatment
Brigit Carly
Ms. Carly has no relevant financial relationships to disclose.

Molecular online intraoperative assessment of response and invasive mechanisms, enhances dose reduction and induces down-regulation of COX4/COX2 and E-Cad/Vim subpopulations in MCF-7 cells resistant model
Access Carmen
Dr. Carmen has no relevant financial relationships to disclose.

Screening, management, cancer diagnoses, and outcomes of women with germline BRCA mutations in Israel: The Nogs Clinic experience
Moshe Carmon
Dr. Carmen has no relevant financial relationships to disclose.

Phase II trial of selinexor for metastatic triple negative breast cancer
Dawn Carney
Ms. Carney has no relevant financial relationships to disclose.

Effect of serum biomarkers (activin A, CAIX, HER2, TIMP-1, and uPA) on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: CEGT MA 31
Walker Carney
Dr. Carney has no relevant financial relationships to disclose.

Tumor and serum DNA methylation in women receiving preoperative chemotherapy (PST) with or without vorinostat in primary operable HER2-negative breast cancer in TBCRC008
John Carpenter
Mr. Carpenter has no relevant financial relationships to disclose.

A solution to the APOBEC mutation paradox in breast cancer
Michael Carpenter
Mr. Carpenter has no relevant financial relationships to disclose.

A multi-OMIC analysis to explore the impact of “actionable” genomic alterations on protein pathway activation: Clinical implication for precision medicine in metastatic breast cancer
John Carpten
Dr. Carpten has no relevant financial relationships to disclose.

Phase III study of gabbexate (FD-013591) in combination with endocrine therapy (etanoxate or fulvestrant) versus chemotherapy (palbociclib) in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with resistance to gomidec inhibitors. "The PEARL study" (GECAM/2013-02)
Eva Carrasco
Ms. Carrasco has no relevant financial relationships to disclose.

Phase 2 study of investigational TORC1/2 inhibitor TAK-228 with fulvestrant in women with ER-positive/HER2-negative advanced or metastatic breast cancer that has progressed during or after aromatase inhibitor therapy
Eva Carrasco
Ms. Carrasco has disclosed that she receives salary from GEICAM (Spanish Breast Cancer Group) and that GEICAM (employer) contracted by Millennium Pharmaceuticals, Inc., to perform study presented in abstract.

Phase II study to compare fulvestrant (F) 500mg plus placebo versus (vs) 500mg plus palbociclib (P) as first line treatment for postmenopausal women with hormone receptor (HR) positive advanced breast cancer (BC) sensitive to endocrine therapy (ET). "The FULFAR study" (GECAM/2014-12)
Eva Carrasco
Ms. Carrasco has no relevant financial relationships to disclose.

Phase II trial to evaluate patient’s preference for subcutaneous versus intravenous trastuzumab administration in patients with HER2 positive advanced breast cancer (MBC) under IV trastuzumab (IV-I) treatment for at least 4 months. ChangHER-SC study (GECAM/2012-07)
Eva Carrasco
Ms. Carrasco has disclosed that she has an immediate family member that is a consultant for and has a contract with Roche.

Phase 2 study of investigational TORC1/2 inhibitor TAK-228 with fulvestrant in women with ER-positive/HER2-negative advanced or metastatic breast cancer that has progressed during or after aromatase inhibitor therapy
Eva Carrasco
Ms. Carrasco has disclosed that she receives salary from GEICAM (Spanish Breast Cancer Group) and that GEICAM (employer) contracted by Millennium Pharmaceuticals, Inc., to perform study presented in abstract.

A phase II study to compare fulvestrant (F) 500mg plus placebo versus (vs) 500mg plus palbociclib (P) as first line treatment for postmenopausal women with hormone receptor (HR) positive advanced breast cancer (BC) sensitive to endocrine therapy (ET). "The FULFAR study" (GECAM/2014-12)
Eva Carrasco
Ms. Carrasco has no relevant financial relationships to disclose.

A phase II trial to evaluate patient’s preference for subcutaneous versus intravenous trastuzumab administration in patients with HER2 positive advanced breast cancer (MBC) under IV trastuzumab (IV-I) treatment for at least 4 months. ChangHER-SC study (GECAM/2012-07)
Eva Carrasco
Ms. Carrasco has disclosed that she has an immediate family member that is a consultant for and has a contract with Roche.
Something from nothing? The case for quality control in liquid biopsy studies

Steven Carrasco

Mr. Carrasco has no relevant financial relationships to disclose.

Biological functions of ERβ in triple negative breast cancer and its utility as a novel therapeutic drug target

Jason Carroll

Dr. Carroll has no relevant financial relationships to disclose.

A single-blind, randomized, placebo-controlled phase II study to evaluate the impact of oral ibandronate on bone mineral density in osteoporotic breast cancer patients receiving adjuvant aromatase inhibitors: Final results of the single-center WOMEN-UV trial

Sáulo Carta

Dr. Carta has no relevant financial relationships to disclose.

How do real-world treatment patterns compare to guideline recommendations for first-line metastatic breast cancer patients in US community clinics?

Gillis Carrigan

Dr. Carrigan has disclosed that he receives salary from Genentech and has ownership in Roche.

A randomized trial of accelerated breast radiotherapy utilizing either 3-dimensional radiotherapy versus intensity modulated radiotherapy

Carlo Casta

Dr. Casta has no relevant financial relationships to disclose.

Long-term follow-up of early stage breast cancer patients with results of Mammaprint®, Oncotype DX® and MammoStrat® risk classification assays

Ebonie Carter

Ms. Carter has no relevant financial relationships to disclose.

Biological functions of ERβ in triple negative breast cancer and its utility as a novel therapeutic drug target

Jason Carroll

Dr. Carroll has no relevant financial relationships to disclose.

A single-blind, randomized, placebo-controlled phase II study to evaluate the impact of oral ibandronate on bone mineral density in osteoporotic breast cancer patients receiving adjuvant aromatase inhibitors: Final results of the single-center WOMEN-UV trial

Sáulo Carta

Dr. Carta has no relevant financial relationships to disclose.

Learning curve for the SAVI SCOUT breast localization and surgical guidance system

Dennis Carter

Ms. Carter has no relevant financial relationships to disclose.

A comparison of the micro-impulse radar SAVI SCOUT to the radioactive I125 seed in localization of non-palpable breast cancer for breast conserving therapy

William Carter

Dr. Carter has no relevant financial relationships to disclose.

Treatment patterns and resource utilization among elderly Medicare patients with HR+/HER2- metastatic breast cancer

Gebra Carter

Dr. Carter has disclosed that he receives salary from and has ownership in Eli Lilly and Company.

Treatment patterns and resource utilization among patients with HR+/HER2- metastatic breast cancer

Gebra Carter

Dr. Carter has disclosed that he receives salary from and has ownership in Eli Lilly and Company.

A comparison of the micro-impulse radar SAVI SCOUT to the radioactive I125 seed in localization of non-palpable breast cancer for breast conserving therapy

William Carter

Dr. Carter has no relevant financial relationships to disclose.

Phase III trial to evaluate patient's preference for subcutaneous versus intravenous trastuzumab administration in patients with HER2 positive advanced breast cancer (ABC) under IV trastuzumab (IV-t) treatment for at least 4 months. ChangHER-SC study (GEICAM/2012-07)

Ana Casas

Ms. Casas has no relevant financial relationships to disclose.

Phase III trial to evaluate patient's preference for subcutaneous versus intravenous trastuzumab administration in patients with HER2 positive advanced breast cancer (ABC) under IV trastuzumab (IV-t) treatment for at least 4 months. ChangHER-SC study (GEICAM/2012-07)

Maribel Carvajal

Ms. Carvajal has no relevant financial relationships to disclose.

Phase III trial to evaluate patient's preference for subcutaneous versus intravenous trastuzumab administration in patients with HER2 positive advanced breast cancer (ABC) under IV trastuzumab (IV-t) treatment for at least 4 months. ChangHER-SC study (GEICAM/2012-07)

Maribel Carvajal

Ms. Carvajal has no relevant financial relationships to disclose.

High concordance of a closed system, near point of care, RT-qPCR breast cancer assay for HER2 (ERBB2) mRNA compared to both IHC/FISH and quantitative immunofluorescence

Daniel Carvajal-Hausdorf

Dr. Carvajal-Hausdorf has no relevant financial relationships to disclose.

Phase III trial to evaluate patient's preference for subcutaneous versus intravenous trastuzumab administration in patients with HER2 positive advanced breast cancer (ABC) under IV trastuzumab (IV-t) treatment for at least 4 months. ChangHER-SC study (GEICAM/2012-07)

Ana Casas

Ms. Casas has no relevant financial relationships to disclose.

Phase III trial to evaluate patient’s preference for subcutaneous versus intravenous trastuzumab administration in patients with HER2 positive metastatic breast cancer (MBC) patients with resistance to aromatase inhibitors. “The PEARL study”

Gebra Carter

Dr. Carter has disclosed that he receives salary from and has ownership in Eli Lilly and Company.

Phase III trial to evaluate patient’s preference for subcutaneous versus intravenous trastuzumab administration in patients with HER2 positive metastatic breast cancer (MBC) patients with resistance to aromatase inhibitors. “The PEARL study”

Gebra Carter

Dr. Carter has disclosed that he receives salary from and has ownership in Eli Lilly and Company.

Phase III trial to evaluate patient’s preference for subcutaneous versus intravenous trastuzumab administration in patients with HER2 positive metastatic breast cancer (MBC) patients with resistance to aromatase inhibitors. “The PEARL study”

Gebra Carter

Dr. Carter has disclosed that he receives salary from and has ownership in Eli Lilly and Company.

Phase III trial to evaluate patient’s preference for subcutaneous versus intravenous trastuzumab administration in patients with HER2 positive metastatic breast cancer (MBC) patients with resistance to aromatase inhibitors. “The PEARL study”

Gebra Carter

Dr. Carter has disclosed that he receives salary from and has ownership in Eli Lilly and Company.

Phase III trial to evaluate patient’s preference for subcutaneous versus intravenous trastuzumab administration in patients with HER2 positive metastatic breast cancer (MBC) patients with resistance to aromatase inhibitors. “The PEARL study”

Gebra Carter

Dr. Carter has disclosed that he receives salary from and has ownership in Eli Lilly and Company.

Phase III trial to evaluate patient’s preference for subcutaneous versus intravenous trastuzumab administration in patients with HER2 positive metastatic breast cancer (MBC) patients with resistance to aromatase inhibitors. “The PEARL study”

Gebra Carter

Dr. Carter has disclosed that he receives salary from and has ownership in Eli Lilly and Company.
A single-blind, randomized, placebo-controlled phase II study to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: Final results of the single-center BONADIUV trial

Donato Casella
Dr. Casella has no relevant financial relationships to disclose.

Preclinical efficacy of the novel FIN2 kinase inhibitor, JP11646 in triple-negative breast cancer models

Lustie Caserta
Mr. Caserta has no relevant financial relationships to disclose.

Cyclin d1 binding to chromatin and the induction of chromosomal instability requires the fuzzy domain

Mathew Casimiro
Mr. Casimiro has no relevant financial relationships to disclose.

Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer

Corrado Castellane
Dr. Castellane has no relevant financial relationships to disclose.

Psychosocial distress monitoring in a multidisciplinary, inner city breast center

Maria Castaldi
Dr. Castaldi has no relevant financial relationships to disclose.

Molecular evaluation of Peruvian patients with hereditary breast cancer reveals a novel germline mutation in BRCA1

Carlos Castañeda
Mr. Castañeda has no relevant financial relationships to disclose.

Psychological distress monitoring in a multidisciplinary, inner city breast center

Marie Costard
Dr. Costard has no relevant financial relationships to disclose.

Molecular evaluation of Peruvian patients with hereditary breast cancer reveals a novel germline mutation in BRCA1

Dr. Costard has no relevant financial relationships to disclose.

Do patients and nurses outside clinical trial prefer subcutaneous trastuzumab over conventional intravenous infusion? Instituto Oncologico Nacional experience

Omar Castillo-Fernandez
Dr. Castillo-Fernandez has no relevant financial relationships to disclose.

PALINA: A phase II safety study of palbociclib in combination with letrozole in African American women with hormone receptor-positive HER2 negative advanced breast cancer

Julie Castle
Ms. Castle has no relevant financial relationships to disclose.

Assessing response in locally advanced breast cancer treated with neoadjuvant chemotherapy: Predictive and prognostic potential of volume-based metabolic variables with 18F-FDG PET/CT

Ana Castro
Ms. Castro has no relevant financial relationships to disclose.

Prediction of underestimation associated with flat epithelial atypia, atypical ductal hyperplasia and atypical lobular hyperplasia by needle biopsy: Experience in an Argentine breast unit

Mariana Castro Barba
Dr. Castro has no relevant financial relationships to disclose.

Young women with breast cancer in Mexico: A report of the pilot phase of the "Mujer Joven y Fuerte" prospective cohort

Andrea Castro-Sánchez
Dr. Castro-Sánchez has no relevant financial relationships to disclose.

Development and validation of a new non-parametric breast cancer risk assessment model on US and European screening populations

Nathalie Catajar
Dr. Catajar has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2-05-10</td>
<td>UCG2 2-14: A prospective multicenter non-randomized trial evaluating the effect of EndoPredict® (EPclin®) clinico-genomic test on treatment decision making among patients with intermediate clinical risk</td>
<td>Stéphanie Catala</td>
<td>Dr. Catala has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-01-04</td>
<td>Assessing response in locally advanced breast cancer treated with neoadjuvant chemotherapy: Predictive and prognostic potential of volume-based metabolic variables with 18F-FDG PET/CT</td>
<td>Emilie Català</td>
<td>Mr. Català has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-03-07</td>
<td>Inhibition of cancer-associated fibroblast function by farnesoid X receptor activation: Experimental basis for a novel therapeutic strategy in breast cancer</td>
<td>Stefania Catalano</td>
<td>Dr. Catalano has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-04-07</td>
<td>The new oral ERBI Alzheimer is efficacious in antagonizing ER and circumventing resistance to endocrine therapy</td>
<td>Maria Letizia Cataldo</td>
<td>Ms. Cataldo has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S4-01</td>
<td>A novel BRD4 inhibitor enhances endocrine therapy efficacy and overcomes endocrine resistance in estrogen receptor-positive breast cancer models</td>
<td>Maria Letizia Cataldo</td>
<td>Ms. Cataldo has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-14-01</td>
<td>International validation of the EORTC patient-reported outcome measure (PROQ) in breast reconstruction (BRR): The EORTC QLQ-BRECON23 evaluating the psychometric properties and clinical effectiveness</td>
<td>Giuseppe Catarotto</td>
<td>Dr. Catarotto has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-01-05</td>
<td>A phase II clinical trial of VST-1001 (dilute fluorescein) in lymphatic mapping and sentinel lymph node localization in clinically node negative breast cancer</td>
<td>Aliqsal Caudle</td>
<td>Dr. Caudle has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-16-30</td>
<td>Feasibility trial for identification of patients for eliminating breast cancer surgery following neoadjuvant systemic therapy</td>
<td>Aliqsal Caudle</td>
<td>Dr. Caudle has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-07-19</td>
<td>Dual inhibition of the MEK5 and PI3K pathways synergistically reduces proliferation and viability in triple negative breast cancer cells</td>
<td>Jane Cavanna</td>
<td>Dr. Cavanna has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S6-01</td>
<td>Randomized study of CD34 inhibition on systemic inflammation in obese and non-obese subjects</td>
<td>Luigi Caverna</td>
<td>Mr. Caverna has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-08-16</td>
<td>Pathway Analysis of 18F-FDG uptake in breast cancer: Results from a decision impact prospective study and a matched case-control study</td>
<td>David Cavazzini</td>
<td>Dr. Cavazzini has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-02-05</td>
<td>Early detection of PATX in obese conditions</td>
<td>David Cavazzini</td>
<td>Dr. Cavazzini has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-08-12</td>
<td>Novel adjuvant chemotherapy in patients with early breast cancer: Differential treatment effects according to composite index of benefit</td>
<td>Giolamaria Caviroff</td>
<td>Ms. Caviroff has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S6-01</td>
<td>Evaluation of in vitro heterogeneity, test reproducibility and their impact in breast cancer samples assessed by Prosigna®: Results from a decision impact prospective study and a matched case-control study</td>
<td>Maria Giovanna Cavazzini</td>
<td>Ms. Cavazzini has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-04</td>
<td>Immunomodulation effects of metronomic oral Vinorelbine (mVRL), with or without capecitabine (CAPE), on Treg levels in advanced breast cancer (ABC) patients (ipsi). Preliminary results of the VICTOR-5 study</td>
<td>Marina Cazzaniga</td>
<td>Prof. Cazzaniga has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-14-09</td>
<td>Luminal A breast cancer: Is it really a &quot;good prognosis&quot; disease? Preliminary results of the SIM-13 - AMBRA study</td>
<td>Marina Cazzaniga</td>
<td>Prof. Cazzaniga has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-15-07</td>
<td>First and further line choices of treatment for HER2-VE metastatic breast cancer (MBC) according to adjuvant treatment and biological subtype. Preliminary results of the observational &quot;SIM-13 - AMBRA&quot; Italian study</td>
<td>Marina Cazzaniga</td>
<td>Prof. Cazzaniga has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-08-11</td>
<td>Primary aminic metabolites and risk of breast cancer molecular subtypes in northern Mexican women</td>
<td>Mariano Cebrian</td>
<td>Dr. Cebrian has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
Quantitative proteomic analysis of FGFR by mass spectrometry may improve identification of FGFR amplified tumors sensitive to inhibitor therapy

Fabiola Cecchi

Fabiola Cecchi has disclosed that he is paid by NantOmics.

A single-blind, randomized, placebo-controlled phase II study to evaluate the impact of oralibandronate on bone mineral density in osteoporotic breast cancer patients receiving adjuvant aromatase inhibitors: Final results of the single-center BONADUV trial

Sara Ceschin

Dr. Ceschin has no relevant financial relationships to disclose.

A phase Ib study evaluating the safety and clinical activity of lumetuzumab combined with pertuzumab and paclitaxel in HER2-low metastatic breast cancer

Maurizio Ceppi

Dr. Ceppi has disclosed that he is an employee of the sponsor. He also disclosed that he is a Roche stock owner.

Phase Ib study evaluating the safety and clinical activity of lumetuzumab combined with pertuzumab and paclitaxel in HER2-low metastatic breast cancer

Andres Cervantes

Dr. Cervantes has disclosed that he is a consultant for Merck Serono, Amgen, Servier, Eli Lilly, Novartis and MSD. He also disclosed that he has contracts with Merck Serono, Amgen, Servier, Eli Lilly, Novartis, MSD, Roche and Genentech.

Dose dense adjuvant chemotherapy in patients with early breast cancer: Differential treatment effects according to composite index of benefit

Marco R. Ceppi

Mr. Ceppi has no relevant financial relationships to disclose.

Phase II study of taselisib (GDC-0032) plus fulvestrant in HER2-negative, hormone receptor-positive advanced breast cancer: Analysis by PIK3CA and ESR1 mutation status from circulating tumor DNA

Andres Cervantes

Mr. Cervantes has disclosed that he is a consultant for Merck Serono, Amgen, Servier, Roche, Lilly and Novartis. He also disclosed that he has contracts with Roche and Merck Serono.

Challenges faced across borders to open European academic multicentre projects: The ET-FES program part of the ERA-Net TRANSCAN JTC 2011

Alessia Cesaro

Dr. Cesaro has no relevant financial relationships to disclose.

Impact of TP53 functional mutation type on clinical outcomes of advanced breast cancer patients

David Cescon

Dr. Cescon has no relevant financial relationships to disclose.

Association between BMI and residual estradiol levels in postmenopausal women using adjuvant letrozole: Results of a prospective study

Dr. Cescon has no relevant financial relationships to disclose.

Clinical outcome of patients with advanced triple negative breast cancer with germline and somatic variants in homologous recombination gene

Dr. Cescon has no relevant financial relationships to disclose.

Capecitabine in early breast cancer: A meta-analysis of randomized controlled trials

Dr. Cha has disclosed that he receives salary from and has ownership in Genentech.

HER2 and hormonal receptor analysis in breast cancer synchronous node metastases could add therapeutic information

Reinaldo Chacon

Dr. Chacon has no relevant financial relationships to disclose.

Dr. Cha has disclosed that he receives salary from and has ownership in Genentech.

Dr. Cha has disclosed that he receives salary from and has ownership in Genentech.

Dr. Cha has disclosed that he receives salary from and has ownership in Genentech.
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P4-21-16</td>
<td>Phase III trial to evaluate patient's preference for subcutaneous versus intravenous trastuzumab administration in patients with HER2-positive advanced breast cancer (ABC) treated with neoadjuvant chemotherapy (NACT)</td>
<td>José Chacón</td>
</tr>
<tr>
<td>P6-09-13</td>
<td>CASCADE study: rapid survival decline per treatment line in metastatic breast cancer</td>
<td>José Chacón</td>
</tr>
<tr>
<td>P6-07-21</td>
<td>Determining the prognostic role of early and end-of-neoadjuvant chemotherapy 18F-FDG PET/CT in patients with locally advanced breast cancer</td>
<td>José Ignacio Chacón López-Muñiz</td>
</tr>
<tr>
<td>P3-03</td>
<td>High reduction of circulating tumour cells in HER2-negative locally advanced or metastatic breast cancer (LAMB) patients treated with eribulin as third line chemotherapy (OCTETE study)</td>
<td>José Ignacio Chacón Lopez-Muñiz</td>
</tr>
<tr>
<td>P4-02-04</td>
<td>Study of onctuit Ibk: recurrence score in bilateral synchronous primary invasive breast cancer</td>
<td>Suhasan Chaddha</td>
</tr>
<tr>
<td>P6-09-42</td>
<td>The role of serum neoptxHsqto-lymphocyte ratio (NLR) in triple-negative breast cancer</td>
<td>Byung Joo Chae</td>
</tr>
<tr>
<td>OT1-01-12</td>
<td>A phase II, multicenter, randomized trial of eribulin plus gemcitabine (EG) vs. paclitaxel plus gemcitabine (PG) in patients with HER2-negative metastatic breast cancer as first-line chemotherapy</td>
<td>Yee Soo Chae</td>
</tr>
<tr>
<td>P5-11-03</td>
<td>Impact of pre-operative exercise and mind-body interventions on patient-reported outcomes in women with newly diagnosed breast cancer</td>
<td>Anees Chagpar</td>
</tr>
<tr>
<td>P6-08-20</td>
<td>Introduction of H1047R oncogenic mutation of PIK3 p110alpha subunit in HER2-overexpressing mammary epithelial cells confers a 'stem-like' phenotype and acute sensitivity to HSP90 inhibition</td>
<td>Anindita Chakrabarty</td>
</tr>
<tr>
<td>P6-08-21</td>
<td>Introduction of H1047R oncogenic mutation of PIK3 p110alpha subunit in HER2-overexpressing mammary epithelial cells confers a 'stem-like' phenotype and acute sensitivity to HSP90 inhibition</td>
<td>Kausik Chakraborty</td>
</tr>
<tr>
<td>P6-10-20</td>
<td>A multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer: Early results of unplanned boost participants</td>
<td>Pavan Chalasani</td>
</tr>
<tr>
<td>P6-10-19</td>
<td>Introduction of H1047R oncogenic mutation of PIK3 p110alpha subunit in HER2-overexpressing mammary epithelial cells confers a 'stem-like' phenotype and acute sensitivity to HSP90 inhibition</td>
<td>Pavan Chalasani</td>
</tr>
<tr>
<td>P5-11-03</td>
<td>Impact of pre-operative exercise and mind-body interventions on patient-reported outcomes in women with newly diagnosed breast cancer</td>
<td>Anees Chagpar</td>
</tr>
<tr>
<td>P6-08-21</td>
<td>Introduction of H1047R oncogenic mutation of PIK3 p110alpha subunit in HER2-overexpressing mammary epithelial cells confers a 'stem-like' phenotype and acute sensitivity to HSP90 inhibition</td>
<td>Anindita Chakrabarty</td>
</tr>
<tr>
<td>P5-10-19</td>
<td>Two-year follow-up results of a multi-center trial of neoadjuvant chemotherapy during breast conservation surgery for early stage breast cancer</td>
<td>Anindita Chakrabarty</td>
</tr>
<tr>
<td>P5-12-01</td>
<td>A phase II, open-label, multi-center study of ANG1005, a novel brain-penetrant peptide-drug conjugate, in breast cancer patients with recurrent CNS metastases</td>
<td>Pavani Chalasani</td>
</tr>
<tr>
<td>Session</td>
<td>Title</td>
<td>Author</td>
</tr>
<tr>
<td>-----------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>OT1-04-01</td>
<td>Cambridge brain mets trial 1 (CamBMT1): A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy</td>
<td>Anthony Chalmers</td>
</tr>
<tr>
<td>P6-07-03</td>
<td>Broken promise of liquid biopsy: Plasma DNA does not accurately reflect tumor DNA in metastatic breast cancer</td>
<td>Mary Chamberlin</td>
</tr>
<tr>
<td>P5-13-16</td>
<td>Arthralgia-associated aging perceptions predict adherence to aromatase inhibitors among women with breast cancer</td>
<td>Dianne Chambless</td>
</tr>
<tr>
<td>P1-05-28</td>
<td>Mutations treatment: A transcriptomic networks in a xenograft model of breast cancer</td>
<td>Roger Chammas</td>
</tr>
<tr>
<td>P5-04-07</td>
<td>The new oral GANT619219 is efficacious in antagonising ER and circumventing resistance to endocrine therapy</td>
<td>Gary Chamness</td>
</tr>
<tr>
<td>P6-07-03</td>
<td>Predictive value of TDI-PESTC after neoadjuvant endocrine treatment in breast cancer</td>
<td>Laurence Champion</td>
</tr>
<tr>
<td>P2-11-03</td>
<td>First-in-human trial in patients with de novo HR+, HER2- advanced breast cancer (ABC): A subgroup analysis of the MONARCHESCA2 trial</td>
<td>Arlene Chan</td>
</tr>
<tr>
<td>P4-22-16</td>
<td>Phase II/III single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of patients with HER2 positive metastatic breast cancer with progression in the CNS after trastuzumab (TRO-025-B-02)</td>
<td>David Chan</td>
</tr>
<tr>
<td>P1-12-07</td>
<td>Biological effects of alamencicib in a phase2 neoadjuvant study for postmenopausal patients with hormone receptor positive, HER2 negative breast cancer</td>
<td>David Chan</td>
</tr>
<tr>
<td>P1-08-01</td>
<td>Regeneration of estrogen receptor -α by NF1</td>
<td>Doug Chan</td>
</tr>
<tr>
<td>P1-08-07</td>
<td>Assessing the impact of loss of NF1 protein on endocrine resistance therapy</td>
<td>Doug Chan</td>
</tr>
<tr>
<td>P3-08-02</td>
<td>Multi-gene panel testing for hereditary cancer predisposition in smoking high risk breast and ovarian cancer patients</td>
<td>Sallie Chan</td>
</tr>
<tr>
<td>P3-09-08</td>
<td>Exercise and triple negative breast cancer: Unravelling the anti-neoplastic molecular factors through novel culture method</td>
<td>Stefanie Chan</td>
</tr>
<tr>
<td>P4-22-21</td>
<td>Cost-effectiveness of pre-implantation genetic diagnosis for BRCA mutation carriers</td>
<td>Kelvin Chan</td>
</tr>
<tr>
<td>P6-09-16</td>
<td>Identification of proliferation related drivers and their roles in precision medicine for breast cancers: A retrospective multidimensional comparative, integrated genomic, transcriptomic, and protein analysis</td>
<td>Stephen Chan</td>
</tr>
</tbody>
</table>
S6-01
BRCA1 methylation status, silencing and treatment effect in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer

Stephen Chan
Mr. Chan has no relevant financial relationships to disclose.

OT1-04-03
Randomized phase II study of induction bevacizumab, etoposide and cisplatin followed by whole brain radiotherapy (WBRT) versus WBRT alone in breast cancer with untreated brain metastases (APLUS)

Dwan-Ying Chang
Dwan-Ying has no relevant financial relationships to disclose.

P4-06-03
A signature predictive of early vs. late recurrence after radiation treatment (RT) for breast cancer that may inform the biology of early, aggressive recurrences

Ben Chandler
Mr. Chandler has no relevant financial relationships to disclose.

P4-06-02
Mutant GATA3 actively promotes the growth of normal and malignant mammary cells

Natasha Chandiramani
Dr. Chandiramani has no relevant financial relationships to disclose.

P4-06-09
Assessing the impact of loss of NF1 protein on endocrine therapy resistance

Eric Chang
Mr. Chang has no relevant financial relationships to disclose.

P1-10-20
Enhanced efficacy of redirected T-cell therapy of TNBC with a Trop-2/CD3 bispecific antibody in combination with a checkpoint inhibitor

Ken Chang
Dr. Chang has disclosed that he receives salary.

P1-02-06
Serial monitoring of circulating tumor DNA in patients with metastatic breast cancer

Jenny Chang
Dr. Chang has no relevant financial relationships to disclose.

P6-14-02
An anti-FGF2 antibody based therapy results in dramatic reduction of TNBC PDOX tumors in humanized mice models

Jenny Chang
Dr. Chang has no relevant financial relationships to disclose.

P6-14-01
Enhanced efficacy of redirected T-cell therapy of TNBC with a Trop-2/CD3 bispecific antibody in combination with a checkpoint inhibitor

Ken Chang
Dr. Chang has disclosed that he receives consulting fees from Merz.

P1-08-07
Regulation of estrogen receptor α by NF1

Eric Chang
Mr. Chang has no relevant financial relationships to disclose.

P5-05-01
Physico-chemical regulation of EMT by microtubule associated protein 7 (MAP7)

Jenny Chang
Dr. Chang has no relevant financial relationships to disclose.

P1-10-19
Two-year follow-up results of a multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer

Helena Chang
Dr. Chang has no relevant financial relationships to disclose.

P1-10-18
A multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer: Early results of unplanned boost participants

Eric Chang
Mr. Chang has no relevant financial relationships to disclose.

P4-06-01
An annotated collection of pre- and post-therapy breast cancer patient-derived xenograft models built from fine needle aspiration samples aligned with ongoing clinical trials documenting response to treatment

Jeffrey Chang
Dr. Chang has no relevant financial relationships to disclose.

P3-03-02
Inhibition of AOS1 promotes cell stress response and augments docetaxel-mediated apoptosis in TNBC

Jenny Chang
Dr. Chang has no relevant financial relationships to disclose.

P6-14-03
“Assessment of residual disease and treatment implications post neoadjuvant therapy”

Jenny Chang
Dr. Chang has no relevant financial relationships to disclose.

P6-14-01
Committee Member/Moderator/Speaker, Educational Session “Imaging and Local Issues in Neoadjuvant Therapy”

Jenny Chang
Dr. Chang has no relevant financial relationships with commercial interests to disclose.

P1-08-08
A signature predictive of early vs. late recurrence after radiation treatment (RT) for breast cancer that may inform the biology of early, aggressive recurrences

Ben Chandler
Mr. Chandler has no relevant financial relationships to disclose.

P2-04-17
Directing NK cells to Trop-2-expressing breast and other cancers, with chimeric antigen receptors

Chien-Hsing Chang
Dr. Chang has disclosed that he receives consulting fees from Neurogenics, Astellas, Chugui, Sermonix and Agendia. He also disclosed that he does contracted research for Novartis. Dr. Chang has no relevant financial relationships to disclose.

P1-10-17
A signature predictive of early vs. late recurrence after radiation treatment (RT) for breast cancer that may inform the biology of early, aggressive recurrences

Ben Chandler
Mr. Chandler has no relevant financial relationships to disclose.

P2-04-16
Randomized phase II study of induction bevacizumab, etoposide and cisplatin followed by whole brain radiotherapy (WBRT) versus WBRT alone in breast cancer with untreated brain metastases (APLUS)

Dwan-Ying Chang
Dwan-Ying has no relevant financial relationships to disclose.

P4-06-09
Mutant GATA3 actively promotes the growth of normal and malignant mammary cells

Natasha Chandiramani
Dr. Chandiramani has no relevant financial relationships to disclose.

P4-06-08
Synergistic effect of EGFR inhibitor and paclitaxel in newly patient derived metastatic carcinoma cell line which harbored EGFR gene amplification

Dwan-Ying Chang
Dwan-Ying has no relevant financial relationships to disclose.

P4-06-01
A signature predictive of early vs. late recurrence after radiation treatment (RT) for breast cancer that may inform the biology of early, aggressive recurrences

Ben Chandler
Mr. Chandler has no relevant financial relationships to disclose.

P1-10-17
A signature predictive of early vs. late recurrence after radiation treatment (RT) for breast cancer that may inform the biology of early, aggressive recurrences

Ben Chandler
Mr. Chandler has no relevant financial relationships to disclose.

P1-10-17
A signature predictive of early vs. late recurrence after radiation treatment (RT) for breast cancer that may inform the biology of early, aggressive recurrences

Ben Chandler
Mr. Chandler has no relevant financial relationships to disclose.

P2-04-16
Randomized phase II study of induction bevacizumab, etoposide and cisplatin followed by whole brain radiotherapy (WBRT) versus WBRT alone in breast cancer with untreated brain metastases (APLUS)

Dwan-Ying Chang
Dwan-Ying has no relevant financial relationships to disclose.

P4-06-09
Mutant GATA3 actively promotes the growth of normal and malignant mammary cells

Natasha Chandiramani
Dr. Chandiramani has no relevant financial relationships to disclose.

P4-06-08
Synergistic effect of EGFR inhibitor and paclitaxel in newly patient derived metastatic carcinoma cell line which harbored EGFR gene amplification

Dwan-Ying Chang
Dwan-Ying has no relevant financial relationships to disclose.

P1-08-08
A signature predictive of early vs. late recurrence after radiation treatment (RT) for breast cancer that may inform the biology of early, aggressive recurrences

Ben Chandler
Mr. Chandler has no relevant financial relationships to disclose.

P2-04-16
Randomized phase II study of induction bevacizumab, etoposide and cisplatin followed by whole brain radiotherapy (WBRT) versus WBRT alone in breast cancer with untreated brain metastases (APLUS)

Dwan-Ying Chang
Dwan-Ying has no relevant financial relationships to disclose.
A signature predictive of early vs. late recurrence after radiation treatment (RT) for breast cancer that may inform the biology of early, aggressive recurrences
Laura Chang  Dr. Chang has no relevant financial relationships to disclose.

Circulating inflammatory markers, growth factors, and tumor associated antigens in women with early stage breast cancer receiving neoadjuvant metformin
Martin Chang  Dr. Chang has no relevant financial relationships to disclose.

An international multicenter study to evaluate reproducibility of automated scoring methods for assessment of Ki67 in breast cancer
Martin Chang  Dr. Chang has no relevant financial relationships to disclose.

Long term rates of breast preservation after breast-conserving therapy for ductal carcinoma in situ
Martin Chang  Dr. Chang has no relevant financial relationships to disclose.

Epitope receptor (CD-R) in breast carcinoma tissue: Ubiquitous expression and correlation with leptin-mediated signaling, but not with systemic markers of obesity
Martin Chang  Dr. Chang has no relevant financial relationships to disclose.

P6-09-04  Nuclear grade has a limited role in predicting recurrence in DCIS following breast conserving surgery: A population-based study
Martin Chang  Dr. Chang has no relevant financial relationships to disclose.

Src homology 2 domain containing transforming protein 1 and steroid receptor coactivator-3 as novel targets for triple-negative breast cancer
Yu-Fang Chang  Dr. Chang has no relevant financial relationships to disclose.

Randomized phase II study of induction bevacizumab, etoposide and cisplatin followed by whole brain radiotherapy (WBRT) versus WBRT alone in breast cancer with untreated brain metastases (A-PLUS)
Yuan-Ching Chang  Yuan-Ding Chang has no relevant financial relationships to disclose.

The effect of family history on screening procedures and prognosis in breast cancer patients - Results of a large population-based case-control study on breast cancer
Jenny Chang-Claude  Dr. Chang has no relevant financial relationships to disclose.

Consistent dosing time dependent tolerability of everolimus (EV) in a pilot study in women with metastatic breast cancers (MBC) and in a mouse chronopharmacology investigation
Yunhua Chang-Marchand  Dr. Chang-Marchand has no relevant financial relationships to disclose.

The impact of the 21 gene recurrence score (RS) on chemotherapy prescribing in estrogen receptor (ER) positive, lymph node positive early stage breast cancer in Ireland
Calvin Chao  Mr. Chao has no relevant financial relationships to disclose.

Association of pre-chemotherapy peripheral blood pro-inflammatory (IL-6, CRP) and coagulation (D-dimer) markers with chemotherapy toxicity in women with breast cancer
Joseph Chao  Dr. Chao has no relevant financial relationships to disclose.

Randomized phase II study of induction bevacizumab, etoposide and cisplatin followed by whole brain radiotherapy (WBRT) versus WBRT alone in breast cancer with untreated brain metastases (A-PLUS)
Yu-Chung Chao  Yu-Chung Chao has no relevant financial relationships to disclose.

Randomized phase II study of induction bevacizumab, etoposide and cisplatin followed by whole brain radiotherapy (WBRT) versus WBRT alone in breast cancer with untreated brain metastases (A-PLUS)
Tao-Yi Chao  Dr. Chao has no relevant financial relationships to disclose.

Tartrate-resistant acid phosphatase (TRACP) modulates breast cancer pre-metastatic niche
Tao-Yi Chao  Dr. Chao has no relevant financial relationships to disclose.

Young women with breast cancer in Mexico: A report of the pilot phase of the “Nuestra joven y fuerte” prospective cohort
Judy Arna Chapman  Dr. Chapman has no relevant financial relationships to disclose.

Development of a panel of serum-based protein biomarkers for the non-invasive detection of breast cancer in BI-RADS category 4 patients
Karen Chapman  Dr. Chapman has disclosed that she receives salary from and has ownership in OncoCyte Corporation.

Mutation characteristics and tumor infiltrating lymphocytes in early and metastatic HER2 positive breast cancer
Elpida Charalambous  Elpida Charalambous has no relevant financial relationships to disclose.
Preclinical characterization of VX-984, a selective DNA-dependent protein kinase (DNA-PK) inhibitor in combination with doxorubicin in breast and ovarian cancers

Paul Charifson

Mr. Charifson has disclosed that he is an employee of Vertex Pharmaceuticals Incorporated.

Beauty and the breast: Is adjuvant chemotherapy the right time for a beauty boost? Results of a randomized controlled trial

Cécile Charles

Dr. Charles has no relevant financial relationships to disclose.

Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple-negative breast cancer

Elodie Chardon

Elodie Chardon has no relevant financial relationships to disclose.

BRCA1 promoter hypermethylation, but not BRCA1 expression, is associated with basal-like features and good prognosis in triple negative breast cancer

Elodie Chardon

Elodie Chardon has no relevant financial relationships to disclose.

S100β as a predictive biomarker and monitoring tool in endocrine resistant breast cancer

Sara Charmaez

Dr. Charmaez has no relevant financial relationships to disclose.

Endocrine resistance in endocrine therapy in breast cancer cells

Sumanta Chatterjee

Dr. Chatterjee has no relevant financial relationships to disclose.

Fibroblasts isolated from the "normal-like" tissue adjacent to breast tumours suppress healthy epithelial progenitor cell proliferation while supporting tumour cell growth

Sumanta Chatterjee

Dr. Chatterjee has no relevant financial relationships to disclose.

MDM2 as a critical target for LM22A-1, a novel G1/S inhibitor in triple-negative breast cancer

Sumanta Chatterjee

Dr. Chatterjee has no relevant financial relationships to disclose.

S100β as a marker of hypoxic breast cancer cells

Sumanta Chatterjee

Dr. Chatterjee has no relevant financial relationships to disclose.

A randomized study evaluating the effect of a remote-based weight loss program in women with early stage breast cancer

Madhu Chaudhry

Madhu has no relevant financial relationships to disclose.

Long-term follow-up of persistent breast dermopigmentation after sentinel lymph node identification using superparamagnetic iron oxide particles (SIENNA+®)

Marie Pierre Chauvet

Dr. Chauvet has no relevant financial relationships to disclose.

Sentinel node detection after neoadjuvant chemotherapy in patient without previous axillary node involvement (GANEA 2 trial): Follow-up of a prospective multi-institutional cohort

Marie Pierre Chauvet

Dr. Chauvet has no relevant financial relationships to disclose.

Global Cancer Institute online tumor boards to improve global patterns of clinical practice for breast cancer

Yanin Chavarri-Guerra

Dr. Chavarri-Guerra has no relevant financial relationships to disclose.

A school-based breast health (Bi) educational program to increase breast cancer awareness in a rural Mexican community: A qualitative comparative analysis of students', relatives' and teachers' perceptions

Yanin Chavarri-Guerra

Dr. Chavarri-Guerra has no relevant financial relationships to disclose.

Feasibility trial for identification of patients for eliminating breast cancer surgery following neoadjuvant systemic therapy

Mariana Chavez-MacGregor

Dr. Chavez-MacGregor has no relevant financial relationships to disclose.

Li-Fraumeni syndrome in females with early onset breast cancer in a Mexican population

Mariana Chavez-MacGregor

Dr. Chavez-MacGregor has no relevant financial relationships to disclose.

Evaluation of a risk score based on biologic factors to enhance prognostic stratification by the American Joint Committee on Cancer (AJCC) Staging System

Mariana Chavez-MacGregor

Dr. Chavez-MacGregor has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Paper ID</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2-04-07</td>
<td>Immune profiling of post neoadjuvant high metastatic risk (ICB-III) residual disease in patients with early triple negative breast cancer</td>
<td>Maggie Cheang</td>
<td>Dr. Cheang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-09-02</td>
<td>True effect of aromatase inhibitor (AI) treatment on global gene expression (expi) changes in postmenopausal ER+ breast cancer (BC) patients: A POETIC study (CREA/07/015)</td>
<td>Maggie Cheang</td>
<td>Dr. Cheang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-10-02</td>
<td>The impact of intrinsic subtypes and molecular features on aromatase inhibitor induced reduction of proliferation marker of R+7 in primary ER+ breast cancer: A POETIC study (CREA/07/015)</td>
<td>Maggie Chen U</td>
<td>Dr. Cheang has disclosed that she is listed as Co-inventor for PAM50 Classifier Patent.</td>
</tr>
<tr>
<td>S6-01</td>
<td>BRCA2 methylation status, silencing and treatment effect in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CREA/08/012)</td>
<td>Maggie Chen U</td>
<td>Ms. Cheang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S4-05</td>
<td>Expression of the DEK oncogene promotes M2 polarization and iron recycling in tumour associated macrophages</td>
<td>Jonathan Cheek</td>
<td>Mr. Cheek has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-01-29</td>
<td>In the era of conservative surgery, can patients presenting with node positive breast cancer be spared axillary node dissection post neoadjuvant chemotherapy? A meta-analysis and review of literature</td>
<td>Rita El Hage Chehade</td>
<td>Dr. Chehade has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-14-03</td>
<td>Does fat transfer increase the risk of breast cancer recurrence? A meta-analysis involving 2382 patients</td>
<td>Rita El Hage Chehade</td>
<td>Dr. Chehade has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-17-08</td>
<td>The role of sentinel lymph node biopsy in patients with ductal carcinoma in situ: An updated meta-analysis involving 9803 patients</td>
<td>Rita El Hage Chehade</td>
<td>Dr. Chehade has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-15-04</td>
<td>Molecular mediators of mammographic density</td>
<td>Claude Chehla</td>
<td>Mr. Chehla has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-03-09</td>
<td>Genetic analysis to evaluate response to letrozole anastrozole and fulvestrant in post-menopausal ER-positive HER2-negative breast cancer patients included in the UCBG CARMEN02 trial</td>
<td>Walid Chemlali</td>
<td>Walid Chemlali has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P0-01-06</td>
<td>Comparison of mutational landscapes of primary breast cancer and first metastatic relapse: Results from the ESPORE study</td>
<td>Walid Chehla</td>
<td>Walid Chehla has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-12-08</td>
<td>Phase I study of low dose oral cyclophosphamide (1C) plus the intravenous 5-fluorouracil (5F) in women with HER2/neu negative oestrogen locally advanced/metastatic breast cancer (MBC): NO FAM53</td>
<td>Alice Chen</td>
<td>Dr. Chen has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-09-08</td>
<td>Predictive effect of cytosolic tumor infiltrating lymphocytes in HER2-positive metastatic breast cancer: A correlative study with CCTG MA.31</td>
<td>Bingshu Chen</td>
<td>Dr. Chen has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-07-06</td>
<td>Effect of serum biomarkers (CA15-3, CEA, CA125, TIMP-1, and sP4) on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with paclitaxel: CCTG MA.31</td>
<td>Bingshu Chen</td>
<td>Dr. Chen has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-03-17</td>
<td>Cytotoxic resistant and phosphatase (TRAP5) modulates breast cancer pre-metastatic niche</td>
<td>Chin-Ming Chen</td>
<td>Dr. Chin-Ming has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-10-03</td>
<td>Plasminogen inactivates TRAIL-induced apoptosis in TRAIL-resistant triple negative breast cancer cells</td>
<td>Chih-Jung Chen</td>
<td>Dr. Chen has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-01-10</td>
<td>Cumulative analysis of breast cancer sentinel lymph node identification rate by radionuclide: A 15-year experience</td>
<td>Chi-Ming Chen</td>
<td>Dr. Chi-Ming has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-04-10</td>
<td>Using the allelic specific copy number profile to predict the poor prognosis breast cancer patients of Taiwanese</td>
<td>Darren Chen</td>
<td>Dr. Darren has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-13-14</td>
<td>Clinicopathologic factors related to surgical margin involvement, reoperation, and residual breast cancer in primary operable breast cancer: An analysis of 2050 patients</td>
<td>Dar-Ren Chen</td>
<td>Dr. Dar-Ren has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
Single domain antibody (SBT-100) inhibits growth of human HER2+ and triple negative breast cancers (TNBC) in xenografts by binding STAT3 and P-STAT3

Dong Chen

Dong Chen has no relevant financial relationships to disclose.

Integration of whole-genome sequencing and functional screening to identify breast cancer lung metastatic drivers

Hai-Quan Chen

Hai-Quan Chen has no relevant financial relationships to disclose.

Reduced serum B-cell maturation antigen levels predict poor outcome in metastatic breast cancer patients in a phase 3 randomized 2nd-line hormone therapy trial

Haining Chen

Dr. Chen has disclosed that he is a Stockholder in OncodexTracker, a commercial entity to develop BCMA as a biomarker.

Military reverse mapping using fluorescence imaging in the surgical treatment for breast cancer patients

Honggang Chen

Honggang Chen has no relevant financial relationships to disclose.

Pre-operative breast MRI would not benefit breast cancer patients’ survival, even in young patients treated with breast-conservative surgery

Jiajian Chen

Dr. Chen has no relevant financial relationships to disclose.

Reduced serum B-cell maturation antigen levels predict poor outcome in metastatic breast cancer patients in a phase 3 randomized 2nd-line hormone therapy trial

Jiajian Chen

Dr. Chen has no relevant financial relationships to disclose.

A single-center report of 125 cases of occidental internal mammary lymph node biopsy in free abdominal flap breast reconstructions

Jiajian Chen

Dr. Chen has no relevant financial relationships to disclose.

ARID2 is a novel therapeutic target for checkpoint-resistance in metastatic breast cancer

Jiernai Chen

Jiernai Chen has no relevant financial relationships to disclose.

Diagnostic performance of supplemental screening with molecular breast imaging in women with dense breast tissue

John Chen

Dr. Chen has no relevant financial relationships to disclose.

Reduced expression of miR-200c-3p contributes to cell migration and invasion in paclitaxel-resistant breast cancer cell line

Junqing Chen

Dr. Chen has no relevant financial relationships to disclose.

A nomogram to predict the survival benefit of surgical axillary staging in T1 breast cancer patients

Kai Chen

Kai Chen has no relevant financial relationships to disclose.

The development of nomograms to predict axillary lymph node status in breast cancer patients

Kai Chen

Kai Chen has no relevant financial relationships to disclose.

FOXA1 induces a pro-metastatic secretome through ER-dependent and independent transcriptional reprogramming in endocrine-resistant breast cancer

Kaifu Chen

Dr. Chen has no relevant financial relationships to disclose.

Network integration of epigenomic data: Leveraging the concept of master regulators in ER negative breast cancer

Kang Chen

Dr. Chen has no relevant financial relationships to disclose.

Triple negative breast cancer patient-derived xenografts: Molecular characteristics and sensitivity to emerging therapies

Ken Chen

Dr. Chen has no relevant financial relationships to disclose.

Targeting SET to disrupt oncogenic CIP2A feedforward loop shows therapeutic potential in triple negative breast cancer cells

Kuan-Feng Chen

Dr. Chen has no relevant financial relationships to disclose.

The mutation detection and a high throughput screening of driver mutations in PI3K/akt pathway by next generation sequencing

Li Chen

Li Chen has no relevant financial relationships to disclose.

Integration of whole-genome sequencing and functional screening to identify breast cancer lung metastatic drivers

Li Chen

Li Chen has no relevant financial relationships to disclose.

Tartrate-resistant acid phosphatase (TRACP) modulates breast cancer pre-metastatic niche

Li-Chia Chen

Dr. Chen has no relevant financial relationships to disclose.

Comparative analysis of the genomic landscape of breast cancers from women of African and European ancestry

Lin Chen

Li Chen has no relevant financial relationships to disclose.

Lymphatic microsurgical preventive healing approach (LYMPHA) for the primary prevention of lymphedema

Margaret Chen

Dr. Chen has no relevant financial relationships to disclose.

A novel subgroup of estrogen-receptor positive breast cancer may benefit from super-enhancer-guided patient selection for erlotinib acid receptor agonist treatment

Mei Chen

Mei Chen has disclosed that he is an employee of and holder of shares and options for Syros Pharmaceuticals.
P2-04-18 JAK2 and FDL1 amplification enhance the dynamic expression of PD-L1 in triple negative breast cancer

Meixuan Chen
Meixuan Chen has no relevant financial relationships to disclose.

P6-07-17 CS9 inhibition improves the efficacy of ER- and HER2-targeted drugs in breast cancer

Meixuan Chen
Meixuan Chen has no relevant financial relationships to disclose.

P3-07-05 Evaluation of a risk score based on biologic factors to enhance prognostic stratification by the American Joint Committee on Cancer (AJCC) Staging System

Rebecca Chen
Ms. Chen has no relevant financial relationships to disclose.

P4-21-26 Population pharmacokinetics (PK) and exposure-response (E-R) analysis of trastuzumab emtansine (T-DM1) in patients with HER2+ metastatic breast cancer (MBC) who have received at least two prior regimens of HER2-directed therapy

Shang-Chiu Chen
Dr. Chen has disclosed that he receives salary from and has ownership in Roche.

P5-16-08 Risk factors of locoregional relapse in locally advanced breast cancer treated with neoadjuvant chemotherapy following mastectomy and radiotherapy

Sheng Chen
Dr. Chen has no relevant financial relationships to disclose.

P5-16-13 Predictive and prognostic value of Ki-67 expression in triple-negative breast cancer

Sheng Chen
Dr. Chen has no relevant financial relationships to disclose.

P6-09-17 Evaluation of a risk score based on biologic factors to enhance prognostic stratification by the American Joint Committee on Cancer (AJCC) Staging System

Rebecca Chen
Ms. Chen has no relevant financial relationships to disclose.

P6-07-18 A pilot study of the impact of a single dose of zoledronic acid on biomarkers in breast cancer

Shiaun Chen
Dr. Chen has no relevant financial relationships to disclose.

OT1-04-03 Randomized phase II study of trastuzumab, docetaxel and cisplatin followed by whole brain radiotherapy (WBRT) versus WBRT alone in breast cancer with untreated brain metastases (A-PLUS)

Shih-Chih Chen
Dr. Chen has no relevant financial relationships to disclose.

P3-13-14 Clinicopathologic factors related to surgical margin involvement, reoperation, and residual breast cancer in primary operable breast cancer - An analysis of 2050 patients

Shou-Tung Chen
Dr. Chen has no relevant financial relationships to disclose.

OT1-04-04 Randomized phase II study of trastuzumab, docetaxel and cisplatin followed by whole brain radiotherapy (WBRT) versus WBRT alone in breast cancer with untreated brain metastases (A-PLUS)

Tom Wei-Wu Chen
Tom Wei-Wu Chen has no relevant financial relationships to disclose.

OT1-04-05 Synergistic effect of EGFR1 inhibitor and paclitaxel in newly patient derived metastatic carcinoma cell line which harbored EGFR gene amplification

Tom Wei-Wu Chen
Tom Wei-Wu Chen has no relevant financial relationships to disclose.

P4-06-09 Synergistic effect of EGFR1 inhibitor and paclitaxel in newly patient derived metastatic carcinoma cell line which harbored EGFR gene amplification

Tom Wei-Wu Chen
Tom Wei-Wu Chen has no relevant financial relationships to disclose.

P3-04-11 ER is required for mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer cells and patients' tumors

Vivian Chen
Ms. Chen has no relevant financial relationships to disclose.

P2-01-16 Comparison of axillary nodal status between different defined clinically node-negative breast cancer: Is ACOSOG Z0011 criteria applicable to preoperative cytologically negative axilla?

Weiguo Chen
Weiguo Chen has no relevant financial relationships to disclose.

P6-12-12 Phase I study of the JAK 1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer (MBC)

Wendy Chen
Ms. Chen has no relevant financial relationships to disclose.

P1-08-02 Regulation of estrogen receptor-alpha by c-MET

Xi Chen
Xi Chen has no relevant financial relationships to disclose.

P02-03 Recurrent functionally diverse in-frame PIK3CA and HRAS gene fusions drive endocrine resistance in breast cancer

Xi Chen
Xi Chen has no relevant financial relationships to disclose.

Speaker, Basic Science Forum 2 "Unfolding the unfolded protein response in breast cancer"
Comparison of axillary nodal status between different defined clinically node negative breast cancer: is ACOSOG Z0011 criteria applicable to preoperative cytologically negative axilla?

Xiaosong Chen

Dr. Chen has no relevant financial relationships to disclose.

Non-anthracycline-containing docetaxel plus cyclophosphamide was inferior to docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative or HER2 positive breast cancer: long term follow-up result from NATT study

Xiaosong Chen

Dr. Chen has no relevant financial relationships to disclose.

Adrenergic-specific PCR assay for estrogen receptor (ER) mutation detection

Xiaoying Chen

Xiaoying Chen has disclosed that he receives salary from Roche RMS.

Allele-specific PCR assay for estrogen receptor (ESR1) mutation detection

Xiaoying Chen

Xiaoying Chen has disclosed that he receives salary from Roche RMS.

Preclinical validation of a new tumor imaging agent targeting αvβ3 to detect breast tumor using NIR-light imaging

Yao Chen

Yao Chen has no relevant financial relationships to disclose.

Cross-talk between RNA methyltransferase and demethylase regulates breast cancer growth and progression

Yu-Chih Chen

Yu-Chih has no relevant financial relationships to disclose.

Breast cancer brain metastases show limited intrinsic subtype switching, yet exhibit acquired ERBB2 amplifications and activating mutations

Yijian Chen

Yijian Chen has no relevant financial relationships to disclose.

The lymph node ratio as an independent prognostic factor for node-positive triple-negative breast cancer

Ying-Le Chen

Ying-Le Chen has no relevant financial relationships to disclose.

Cumulative analysis of breast cancer sentinel lymph node identification rate by radioscopy: A 13-year experience

Yin-Ren Chen

Yin-Ren Chen has no relevant financial relationships to disclose.

Targeting SET to disrupt oncogenic CIP2A feedforward loop shows therapeutic potential in triple negative breast cancer cell

Yi-Ting Chen

Yi-Ting Chen has no relevant financial relationships to disclose.

Microenvironment induced DDR2 mediates stromal-cancer interactions and metastasis growth in breast cancer

Yu-Chih Chen

Yu-Chih has no relevant financial relationships to disclose.

Improved long-term outcomes of breast-conserving therapy for women with ductal carcinoma in situ

Yu-Hui Chen

Yu-Hui Chen has no relevant financial relationships to disclose.

Reduced expression of miR-200c-3p contributes to cell migration and invasion in paclitaxel-resistant breast cancer cell

Zhanhong Chen

Zhanhong Chen has no relevant financial relationships to disclose.

Mutational landscape of breast cancers from PALB2 germline mutation carriers

Georgia Chenevix-Trench

Ms. Chenevix-Trench has no relevant financial relationships to disclose.

Factors predicting treatment outcomes of angiosarcoma of breast: A 25 year single institution experience

Richard Cheney

Mr. Cheney has no relevant financial relationships to disclose.

Quality, not quantity": 10X hot-spot (HS) analysis of lymphocyte markers (CD3, CD8, CD4, CD20) in tumor-infiltrating lymphocytes (TILs) is superior to whole tumor (WT) analysis in triple-negative breast cancer (TNBC)

Zhengming Chen

Zhengming has no relevant financial relationships to disclose.

Tissue microarray (TMA) based immunohistochemical studies of lymphocyte-specific markers yield inaccurate results in triple-negative breast cancer (TNBC)

Zhengming Chen

Zhengming has no relevant financial relationships to disclose.

Stromal density of tumor-infiltrating lymphocytes (TILs): Challenging the 50% threshold that defines lymphocyte predominant breast cancer (LPRC)

Zhengming Chen

Zhengming has no relevant financial relationships to disclose.

Molecular landscape of breast cancers from PALB2 germline mutation carriers

Georgia Chenevix-Trench

Ms. Chenevix-Trench has no relevant financial relationships to disclose.

Randomized phase II study of induction bevacizumab, etoposide and cisplatin followed by whole brain radiotherapy (WBRT) versus WBRT alone in breast cancer with untreated brain metastases (A-PLUS)

Ann-Li Cheng

Ann-Li has no relevant financial relationships to disclose.
Unique overlapping subtypes of triple-negative breast and ovarian cancers and sensitivity of "mesenchymal-like" cancers to HSP90 inhibition is revealed by integrated gene expression and drug sensitivity profiling
Chao Cheng
Dr. Cheng has no relevant financial relationships to disclose.

ER reactivation rapidly elicits cell death effects in anti-estrogen-resistant breast cancer
Chao Cheng
Dr. Cheng has no relevant financial relationships to disclose.

Broken promise of liquid biopsy: Plasma DNA does not accurately reflect tumor DNA in metastatic breast cancer
Chao Cheng
Dr. Cheng has no relevant financial relationships to disclose.

Treatment of ESR1 mutant and PIK3CA mutant patient-derived breast cancer xenograft models reveals differential anti-tumor responses to estrogen receptor degraders and PI3K inhibitors in vivo
Eric Cheng
Mr. Cheng has disclosed that he is an employee of Genentech, A Member of the Roche Group.

Identification of SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong antitumor activity in wild-type and mutant ER+ breast cancer models
Jane Cheng
Ms. Cheng has no relevant financial relationships to disclose.

Characterization of an estrogen-dependent breast cancer bone metastasis
Julia Cheng
Ms. Cheng has no relevant financial relationships to disclose.

Evaluation of the impact of oncoprobe DX test results on systemic therapy in breast cancer patients at the BC cancer agency (BCCA)
Yi-Chao Cheng
Y-Chao Cheng has no relevant financial relationships to disclose.

Overall survival of patients with non-metastatic triple negative breast cancer who received neoadjuvant vs adjuvant chemotherapy: Cohort analysis of National cancer data base NCDB 2010 - 2011
Yee Chung Cheng
Dr. Cheng has no relevant financial relationships to disclose.

Development of molecular predictors of late breast cancer specific events (BCSE) in ER+, node+ breast cancer - new transcriptome expression whole gene analysis of the phase III adjuvant trial SWOG S8814
Diana Cherbavaz
Dr. Cherbavaz has disclosed that as an employee of Genomic Health, Inc., she receives a salary and she receives and owns stock.

Predictive value of FDG-PET/CT after neoadjuvant endocrine treatment in breast cancer
Pascal Cheval
Pascal Cheval has no relevant financial relationships to disclose.

Comprehensive comparison of breast cancer molecular portraits by African and European ancestry in the cancer genome atlas
Andrew Chemnitz
Mr. Chemnitz has no relevant financial relationships to disclose.

Population pharmacokinetics (PK) and exposure-response (E-R) analysis of trastuzumab emtansine [T-DM1] in patients with HER2+ metastatic breast cancer (MBC) who have received at least two prior regimens of HER2-directed therapy
Nataliya Chernyukhin
Dr. Chernyukhin has disclosed that she receives salary from and has ownership in Roche.

ZBTB2 is a novel therapeutic target for cisplatin-resistance in metastatic breast cancer
Isabella Cheuk
Ms. Cheuk has no relevant financial relationships to disclose.

Immediate breast reconstruction is highly accepted by breast cancer patients undergoing mastectomy when routinely offered- Recent experience of an Australian tertiary oncoplastic breast unit
Deborah Cheung
Ms. Cheung has no relevant financial relationships to disclose.
DNA methylation landscapes of breast cancer progression to brain metastasis: A pre-clinical study

P1-04-04
Garrett Cheung
Mr. Cheung has no relevant financial relationships to disclose.

Circulating tumor cells (CTC) and endothelial cells (EC) prognostic value in HER2 negative metastatic breast cancer patients treated with first line weekly paclitaxel and bevacizumab: First results of a prospective cohort from the French Breast Cancer InterGroup Incurve (UCRG) COMET study

P1-01-02
Marten Chevrier
Mr. Chevrier has no relevant financial relationships to disclose.

Circulating tumor cells (CTC) and endothelial cells (CEC) prognostic value in HER2 negative metastatic breast cancer: First results of a prospective cohort from the French Breast Cancer InterGroup Incurve (UCRG) COMET study

P2-01-02
Mr. Chevrier has no relevant financial relationships to disclose.

P2-02-14
Chongwei Chi
Mr. Chi has no relevant financial relationships to disclose.

PD-1-IRDye800CW as a novel probe for fluorescence molecular imaging and image guided intraoperative surgery in breast tumor mouse model

P2-03-34
Stephen Chia
Dr. Chia has no relevant financial relationships to disclose.

Phase I trial of osimertinib in combination with trastuzumab in metastatic HER2 positive breast cancer

P2-21-27
Stephen Chia
Mr. Chia has no relevant financial relationships to disclose.

Pertuzumab and trastuzumab plus standard neoadjuvant chemotherapy regimens in patients with HER2-positive early breast cancer: Efficacy analysis of a phase II cardiotoxicity study (TRYPHENA)

P2-24-02
Stephen Chia
Mr. Chia has no relevant financial relationships to disclose.

Population-based long-term outcomes of pathological complete response after neoadjuvant chemotherapy in stage III breast cancer: The British Columbia experience

P5-18-17
Stephen Chia
Mr. Chia has no relevant financial relationships to disclose.

A randomized, double-blinded, placebo-controlled clinical trial to evaluate extended adjuvant endocrine therapy (5 years of letrozole) in postmenopausal women with hormone receptor positive breast cancer who have completed previous adjuvant endocrine therapy: Trial results of NSABP B-42

P1-04-06
Stephen Chia
Mr. Chia has no relevant financial relationships to disclose.

Efficacy of hormone inhibitor galetrone plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial

P6-11-02
Dr. Chen has no relevant financial relationships to disclose.

The evaluation of pantamycin/methotrexate plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial

P6-11-04
Dr. Chen has no relevant financial relationships to disclose.

Trajectory of patient (Pt) reported physical function (PF) during and after neoadjuvant chemotherapy in the I-SPY 2 trial

P5-11-18
Amy Chien
Dr. Chien has no relevant financial relationships to disclose.

Geographic variation in the female breast cancer mortality rates across counties in United States

P2-07-14
Dr. Chen has no relevant financial relationships to disclose.

A phase I trial of the safety and immunogenicity of a DNA plasmid-based vaccine (WOKVAC) encoding epitopes derived from three breast cancer antigens (IGFBP2, HER2, and IGF1R) in patients with breast cancer

P7-03-01
Jennifer Childs
Ms. Childs has no relevant financial relationships to disclose.

Allele-specific PCR assay for estrogen receptor (ESR1) mutation detection

P6-11-07
Mr. Cheung has disclosed that he is employed by and has a contract with Eli Lilly and Company.

Abemaciclib exposure-response relationship in patients with metastatic breast cancer in MONARCH 1

P6-11-13
Dr. Chin has disclosed that he receives salary from Roche RMS.

Bromodomain inhibitors represent a rational therapeutic option for the treatment of invasive lobular carcinoma

P6-11-06
Dr. Chin has no relevant financial relationships to disclose.
P4-22-12  Ribocebib + fulvestrant in postmenopausal women with HR+, HER2- advanced breast cancer (ABC)
Soo Chin Lee
Soo Chin Lee has no relevant financial relationships to disclose.

P2-05-15  Multi-omics and immunomonitoring profiling reveal distinct molecular signatures of young Asian breast cancer
Keath Ching
Dr. Ching has no relevant financial relationships to disclose.

P2-04-02  Recognition of autologous neoantigens by tumor infiltrating lymphocytes derived from breast cancer metastases
Manshini Chinnasamy
Dr. Chinnasamy has no relevant financial relationships to disclose.

P2-09-09  The effects of treatment-induced symptoms, depression and age on sexuality in premenopausal women with early breast cancer receiving adjuvant endocrine therapy
Jacquie Chirgwin
Ms. Chirgwin has no relevant financial relationships to disclose.

P5-15-04  A randomized phase II neoadjuvant study comparing docetaxel and cyclophosphamide (TC) with 5-fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel (FEC-D) for hormone receptor-negative breast cancer: The Kanagawa breast oncology group (KBOG) 1101 study
Takashi Chishima
Dr. Chishima has no relevant financial relationships to disclose.

P2-04-06  Network integration of epigenomic data: Leveraging the concept of master regulators in ER negative breast cancer
Dhananjay Chitale
Dr. Chitale has no relevant financial relationships to disclose.

P5-10-06  Race associated disparities in an urban population of adolescent and young adult (AYA) women with breast cancer
Ami Chitalia
Dr. Chitalia has no relevant financial relationships to disclose.

OT3-04-01  BRE12-158: A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer (TNBC)
Chris Chitambar
Dr. Chitambar has no relevant financial relationships to disclose.

P6-09-37  Ductal carcinoma in situ: Patient outcomes and association with hormone receptors
Christopher Chitambar
Dr. Chitambar has no relevant financial relationships to disclose.

OT1-04-03  Randomized phase II study of ribociclib in postmenopausal women with HR+, HER2- advanced breast cancer (ABC)
Juliann Chmielecki
Ms. Chmielecki has disclosed that she is an employee of Foundation Medicine Inc.

P2-03-11  Genomic pattern of breast carcinomas carrying mutations of non-BRCA homologous recombination genes
Chang-Fang Chu
Chang-Fang Chu has no relevant financial relationships to disclose.

P2-09-06  Breast cancer brain metastases show limited intrinsic subtype switching, yet exhibit acquired ERBB2 amplifications and activating mutations
Rowan Chlebowski
Dr. Chlebowski has disclosed that he is a consultant for Pfizer, Novartis, Amgen, Novo Nordisk, Genomic Health and Genentech and a speaker for Genentech and Novartis.

P2-03-10  Low-fat dietary pattern and breast cancer overall survival in the Women’s Health Initiative dietary modification randomized controlled trial
Rowan Chlebowski
Dr. Chlebowski has disclosed that he receives consulting fees from Pfizer, Novartis, Amgen, Novo Nordisk, Genomic Health and Genentech. He also disclosed fees for non-CME services received directly from commercial interests from Genentech and Novartis. These relationships do not impact his ability to review presentations.

P6-07-08  The complete spectrum of ESR1 mutations from 7590 breast cancer tumor samples
Juliann Chmielecki
Ms. Chmielecki has disclosed that she is an employee of Foundation Medicine Inc.

P01-05  Breast cancer brain metastases show limited intrinsic subtype switching, yet exhibit acquired ERBB2 amplifications and activating mutations
Juliann Chmielecki
Dr. Chmielecki has disclosed that he receives salary from and has ownership in Foundation Medicine Inc.

OT1-04-06  Weekly docetaxel and daily oral cyclophosphamide followed by nab-paclitaxel for adjuvant therapy of high-risk localized breast cancer
Eung Nam Cho
Dr. Cho has no relevant financial relationships to disclose.

P2-01-12  Development of prediction model for omission of sentinel lymph node biopsy in T1 breast cancer
Eung Nam Cho
Dr. Cho has no relevant financial relationships to disclose.
Impact of young age on recurrence and mortality after surgery in breast cancer: 15 years active surveillance  
Suehe Cho  
Dr. Cho has no relevant financial relationships to disclose.

A pilot study of the impact of a single dose of zolendronic acid on biomarkers in breast cancer  
Mye Cho  
Dr. Cho has no relevant financial relationships to disclose.

Multi-omics and immune-oncology profiling reveal distinct molecular signatures of young Asian breast cancers  
Soonweng Cho  
Soonweng Cho has no relevant financial relationships to disclose.

An anti-FOL antibody-based therapy results in dramatic reduction of TRBCPIX tumors in humanized mice models  
Jong Chol  
Dr. Chol has no relevant financial relationships to disclose.

Inhibition of NOS promotes ER stress response and augments docetaxel-mediated apoptosis in TRBC  
Dong Soon Chol  
Dr. Chol has no relevant financial relationships to disclose.

Physico-chemical regulation of EMT by microtubule associated protein 1 (MAP1)  
Dong Soon Chol  
Dr. Chol has no relevant financial relationships to disclose.

Association of pre-chemotherapy peripheral blood pro-inflammatory (IL-6, CRP) and coagulation (D-dimer) markers with chemotherapy toxicity in women with breast cancer  
Jennifer Chol  
Ms. Chol has no relevant financial relationships to disclose.

Modulation of indoleamine 2, 3-dioxygenase (IDO2) expression in breast cancer cells by activated CD8+ T cell is controlled by CHI3L1 promoter methylation  
Seong Hyeon Chol  
Dr. Chol has no relevant financial relationships to disclose.

The association between patient comorbidity and breast cancer survival  
Juye Chol  
Juye Chol has no relevant financial relationships to disclose.

An alteration of hormonal receptor status throughout tumor progression related to prognosis in breast cancer patients  
Juye Chol  
Juye Chol has no relevant financial relationships to disclose.

Risk factors affecting post-operative complication after immediate reconstruction with implant for operable breast cancer patients  
Jin Hyuk Chol  
Dr. Chol has no relevant financial relationships to disclose.

Re-excision rate in breast conservation surgery after neoadjuvant chemotherapy  
Jung Eun Chol  
Dr. Chol has no relevant financial relationships to disclose.

Changes of tumor-infiltrating lymphocytes and programmed death-ligand1 positivity after neoadjuvant chemotherapy in patients with locally advanced breast cancer  
Jung Yoon Chol  
Jung Yoon Chol has no relevant financial relationships to disclose.

Randomized phase 1 study of a novel, long-acting SGP [erlapagastim] versus pegylplagim in the management of chemotherapy-induced neutropenia in early-stage breast cancer patients receiving doxorubicin and cyclophosphamide (TC) chemotherapy regimens for MBC  
Mir Rim Chol  
Dr. Chol has disclosed that he receives salary from and has ownership in Spectrum Pharmaceuticals.

A phase 2 study of dacarbazine in patients with HER2-positive metastatic breast cancer (MBC) who have received prior HER2 regimens for MBC  
Mir Rim Chol  
Dr. Chol has disclosed that he receives salary from and has ownership in Spectrum Pharmaceuticals.

Sustained efficacy of erlapagastim in breast cancer patients in a phase 2, open-label, dose-ranging study  
Mir Rim Chol  
Dr. Chol has disclosed that he receives salary from and has ownership in Spectrum Pharmaceuticals.

The CXCR4 expression is positively associated with microtubule signaling molecules in triple-negative breast cancer  
Seul Ki Chol  
Seul Ki Chol has no relevant financial relationships to disclose.

Changes of tumor-infiltrating lymphocytes and programmed death-ligand1 positivity after neoadjuvant chemotherapy in patients with locally advanced breast cancer  
Yoon Ja Chol  
Yoon Ja Chol has no relevant financial relationships to disclose.

Multi-omics and immune-oncology profiling reveal distinct molecular signatures of young Asian breast cancers  
Yoon Ja Chol  
Yoon Ja Chol has no relevant financial relationships to disclose.

A randomized, open-label, multicenter, phase 1b/2 study of eribulin mesylate in combination with PEGylated recombinant human hyaluronidase in patients with human epidermal growth factor receptor 2-negative, high-hyaluronan metastatic breast cancer  
Embroinos Chondros  
Mr. Chondros has disclosed that he is a full time employee of Biopharmaceutical Company and has ownership in Halozyme.

MicroRNAs associated with acquired taxane resistance in a breast cancer cell line model  
Taryne Cheng  
Taryne Cheng has no relevant financial relationships to disclose.

Provisional validation of a new tumor-imaging agent targeting αvβ3 to detect breast tumor using NIR-light imaging  
Nicolas Choppin  
Mr. Choppin has no relevant financial relationships to disclose.

Impact of young age on recurrence and mortality after surgery in breast cancer: 15 years active surveillance  
Suehe Cho  
Dr. Cho has no relevant financial relationships to disclose.

A pilot study of the impact of a single dose of zolendronic acid on biomarkers in breast cancer  
Mye Cho  
Dr. Cho has no relevant financial relationships to disclose.

Multi-omics and immune-oncology profiling reveal distinct molecular signatures of young Asian breast cancers  
Soonweng Cho  
Soonweng Cho has no relevant financial relationships to disclose.

An anti-FOL antibody-based therapy results in dramatic reduction of TRBCPIX tumors in humanized mice models  
Jong Chol  
Dr. Chol has no relevant financial relationships to disclose.

Inhibition of NOS promotes ER stress response and augments docetaxel-mediated apoptosis in TRBC  
Dong Soon Chol  
Dr. Chol has no relevant financial relationships to disclose.

Physico-chemical regulation of EMT by microtubule associated protein 1 (MAP1)  
Dong Soon Chol  
Dr. Chol has no relevant financial relationships to disclose.

Association of pre-chemotherapy peripheral blood pro-inflammatory (IL-6, CRP) and coagulation (D-dimer) markers with chemotherapy toxicity in women with breast cancer  
Jennifer Chol  
Ms. Chol has no relevant financial relationships to disclose.

Modulation of indoleamine 2, 3-dioxygenase (IDO2) expression in breast cancer cells by activated CD8+ T cell is controlled by CHI3L1 promoter methylation  
Seong Hyeon Chol  
Dr. Chol has no relevant financial relationships to disclose.

The association between patient comorbidity and breast cancer survival  
Juye Chol  
Juye Chol has no relevant financial relationships to disclose.

An alteration of hormonal receptor status throughout tumor progression related to prognosis in breast cancer patients  
Juye Chol  
Juye Chol has no relevant financial relationships to disclose.

Risk factors affecting post-operative complication after immediate reconstruction with implant for operable breast cancer patients  
Jin Hyuk Chol  
Dr. Chol has no relevant financial relationships to disclose.

Re-excision rate in breast conservation surgery after neoadjuvant chemotherapy  
Jung Eun Chol  
Dr. Chol has no relevant financial relationships to disclose.

Changes of tumor-infiltrating lymphocytes and programmed death-ligand1 positivity after neoadjuvant chemotherapy in patients with locally advanced breast cancer  
Jung Yoon Chol  
Jung Yoon Chol has no relevant financial relationships to disclose.

Randomized phase 1 study of a novel, long-acting SGP [erlapagastim] versus pegylplagim in the management of chemotherapy-induced neutropenia in early-stage breast cancer patients receiving doxorubicin and cyclophosphamide (TC) chemotherapy regimens for MBC  
Mir Rim Chol  
Dr. Chol has disclosed that he receives salary from and has ownership in Spectrum Pharmaceuticals.

A phase 2 study of dacarbazine in patients with HER2-positive metastatic breast cancer (MBC) who have received prior HER2 regimens for MBC  
Mir Rim Chol  
Dr. Chol has disclosed that he receives salary from and has ownership in Spectrum Pharmaceuticals.

Sustained efficacy of erlapagastim in breast cancer patients in a phase 2, open-label, dose-ranging study  
Mir Rim Chol  
Dr. Chol has disclosed that he receives salary from and has ownership in Spectrum Pharmaceuticals.

The CXCR4 expression is positively associated with microtubule signaling molecules in triple-negative breast cancer  
Seul Ki Chol  
Seul Ki Chol has no relevant financial relationships to disclose.

Changes of tumor-infiltrating lymphocytes and programmed death-ligand1 positivity after neoadjuvant chemotherapy in patients with locally advanced breast cancer  
Yoon Ja Chol  
Yoon Ja Chol has no relevant financial relationships to disclose.

Multi-omics and immune-oncology profiling reveal distinct molecular signatures of young Asian breast cancers  
Yoon Ja Chol  
Yoon Ja Chol has no relevant financial relationships to disclose.

A randomized, open-label, multicenter, phase 1b/2 study of eribulin mesylate in combination with PEGylated recombinant human hyaluronidase in patients with human epidermal growth factor receptor 2-negative, high-hyaluronan metastatic breast cancer  
Embroinos Chondros  
Mr. Chondros has disclosed that he is a full time employee of Biopharmaceutical Company and has ownership in Halozyme.

MicroRNAs associated with acquired taxane resistance in a breast cancer cell line model  
Taryne Cheng  
Taryne Cheng has no relevant financial relationships to disclose.

Provisional validation of a new tumor-imaging agent targeting αvβ3 to detect breast tumor using NIR-light imaging  
Nicolas Choppin  
Mr. Choppin has no relevant financial relationships to disclose.
| P1-02-01 | Circulating tumor DNA analysis to predict relapse and overall survival in early breast cancer - Longer follow-up of a proof-of-principle study | Neha Chopra | Dr. Chopra has no relevant financial relationships to disclose. |
| P2-04-08 | ERKiX, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy in mammary adenocarcinoma | Salem Chouaib | Dr. Chouaib has disclosed that he has a contract. |
| P3-09-05 | Clinical outcome of patients with advanced triple-negative breast cancer with gemtuzumab and somatic variants in homologous recombination gene | Helen Chou | Ms. Chou has no relevant financial relationships to disclose. |
| P1-08-17 | Endometrial multigene test in the prediction of response and outcome after neoadjuvant hormonal treatment with letrozole and paclitaxel (OXTRA-NAB) | Louis Chou | Dr. Chou has no relevant financial relationships to disclose. |
| P2-01-13 | Can axillary lymph node clearance be avoided in women with node positive breast cancer receiving primary chemotheraphy? | Mahfuja Chowdhury | Mahfuja Chowdhury has no relevant financial relationships to disclose. |
| P3-17-09 | Resolution of DCS in patients with early breast cancer receiving primary chemotherapy for invasive breast cancer | Mahfuja Chowdhury | Mahfuja Chowdhury has no relevant financial relationships to disclose. |
| P3-07-18 | Exercise and triple negative breast cancer: Unravelling the anti-neoplastic molecular factors through novel culture method | Sarah Chou | Dr. Chou has no relevant financial relationships to disclose. |
| P5-17-04 | Mechanisms of drug sensitisation by DNA damage-resistant human breast adenocarcinoma | Waseem Chow | Waseem Chow has no relevant financial relationships to disclose. |
| P2-12-03 | Comprehensive genomic profiling of 14 cases of breast angiosarcoma | Edwan Choy | Dr. Choy has no relevant financial relationships to disclose. |
| P3-08-03 | Variation associated with genetic testing in a cohort of breast cancer survivors | Elizabeth Christopfel | Dr. Christopfel has no relevant financial relationships to disclose. |
| P5-08-23 | The share thoughts on breast cancer study: A Greater Plains collaborative cohort characterisation project | Elizabeth Christopfel | Dr. Christopfel has no relevant financial relationships to disclose. |
| P5-08-26 | Treatment patterns for breast cancer brain metastasis | Elizabeth Christopfel | Dr. Christopfel has no relevant financial relationships to disclose. |
| P0-05-05 | Survivorship care planning: associated with breast cancer survivors’ reported quality and coordination of care | Elizabeth Christopfel | Dr. Christopfel has no relevant financial relationships to disclose. |
| P1-03-14 | Assessment of atypical characteristics in ductal carcinoma in situ of the breast: An inter-observer variability study | Marie-Rose Christiaens | Ms. Christiaens has no relevant financial relationships to disclose. |
| P0-04-04 | Effectiveness of myofascial techniques in addition to a standard physical therapy program as postoperative intervention for upper limb pain in breast cancer patients: A randomized controlled trial | Marie-Rose Christiaens | Ms. Christiaens has no relevant financial relationships to disclose. |
| P5-15-12 | Real-life activity of oral vinorelbine in metastatic breast cancer patients in the Unicancer ESME database | Céllent Christian | Dr. Christian has disclosed that ESME Data Platform granted by Roche, Pierre Fabre and Pfizer. |
| P5-06-03 | Upregulated purinergic signaling enhances cell proliferation in human and murine breast carcinomas | Peer Christiansen | Dr. Christiansen has no relevant financial relationships to disclose. |
| P6-09-07 | Mutation characteristics and tumor infiltrating lymphocytes in early and metastatic HER2-positive breast cancer | Christian Christodoulou | Mr. Christodoulou has no relevant financial relationships to disclose. |
| P2-04-05 | Test-retest fidelity of FDG SUVmax in bone and non-boney metastatic breast cancer lesions in local area network PET/CT examiners | Rebecca Christophel | Ms. Christophel has no relevant financial relationships to disclose. |
| P1-02-04 | Real-life activity of oral vinorelbine in metastatic breast cancer patients in the Unicancer ESME database | Jazz Christo | Dr. Christo has no relevant financial relationships to disclose. |
| P5-15-12 | Real-life activity of oral vinorelbine in metastatic breast cancer patients in the Unicancer ESME database | Jazz Christo | Dr. Christo has no relevant financial relationships to disclose. |
| P5-08-08 | Baseline (B) characteristics, treatment (H) patterns, and outcomes in patients with hormone receptor (H+) vs HR- HER2+ disease from the SytHERs registry | Laura Chu | Ms. Chu has disclosed that she receives salary from Genentech and has ownership in F. Hoffmann-La Roche, Ltd. |
| P6-08-24 | How do real-world treatment patterns compare to guideline recommendations for first-line metastatic breast cancer patients in US community clinics? | Laura Chu | Ms. Chu has disclosed that she receives salary from Genentech and has ownership in F. Hoffmann-La Roche, Ltd. |
| P5-08-27 | Treatment patterns and clinical outcomes in patients with hormone receptor (H+) HER2+ metastatic breast cancer and low vs high levels of HR positivity from the SytHERs Registry | Laura Chu | Ms. Chu has disclosed that she receives salary from Genentech and has ownership in F. Hoffmann-La Roche, Ltd. |

Note: The document contains a table with research topics and affiliations, along with disclosures of financial relationships for each author.
P4-21-07 Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and docetaxel in patients ≥65 years with HER2-positive locally recurrent/metastatic breast cancer: Subgroup analyses of the PERSEUS study Eva Ciruelos Dr. Ciruelos has no relevant financial relationships to disclose.

P4-21-16 Phase III trial to evaluate patient’s preference for subcutaneous versus intravenous trastuzumab administration in patients with HER2-positive advanced breast cancer (ABC) under IV trastuzumab (IV-t) treatment for at least 4 months. ChangHER-SC study (GECAM 2012-07) Eva Ciruelos Dr. Ciruelos has no relevant financial relationships to disclose.

P4-22-02 Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) in pts with pCR (≤30% CTCs in patients pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer Dennis Citrin Mr. Citrin has no relevant financial relationships to disclose.

S2-04 Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) in pts with BRCA1 or BRCA2 mutations and metastatic breast cancer: A randomized, phase 2 study Dennis Citrin Mr. Citrin has no relevant financial relationships to disclose.

P1-11-04 Looking beyond the margins: Economic costs and complications associated with repeated breast-conserving surgeries Andrew Cittadine Mr. Cittadine has disclosed that he receives salary from and has ownership in Diagnostic Photonics, Inc. He has also disclosed that he has a patent with Diagnostic Photonics, Inc.

P4-20-03 Collateral damage from metastatic breast cancer - Preliminary results Jessica Ciglar Dr. Ciglar has no relevant financial relationships to disclose.

P5-05-02 NED29 promotes breast cancer metastasis by regulating mitochondrial functions Rebecca Clancy Ms. Clancy has no relevant financial relationships to disclose.

OT2-01-05 TRINITI-1: Ribociclib + everolimus (EVE) + exemestane (EXE) triplet combination in men or postmenopausal women with HR+, HER2- advanced breast cancer (ABC) following progression on a cyclin-dependent kinase (CDK) 4/6 inhibitor Amy Clark Dr. Clark has no relevant financial relationships to disclose.

P2-08-03 Targeting inflammatory pathways: A phase 2 trial of the JAK-Inhibitor ruxolitinib in combination with exemestane for aromatase inhibitor-resistant, estrogen receptor-positive breast cancer Amy Clark Dr. Clark has no relevant financial relationships to disclose.

P4-22-14 Single agent palbociclib with or without trastuzumab for the treatment of HER2 advanced breast cancer Amy Clark Dr. Clark has no relevant financial relationships to disclose.

P5-11-18 Trajectory of patient (Pt) reported physical function (PF) during and after neoadjuvant chemotherapy in the I-SPY 2 trial Amy Clark Dr. Clark has no relevant financial relationships to disclose.

P6-09-14 Prognostic significance of a modified residual disease in breast and nodes (mRDBN) algorithm after neoadjuvant therapy for breast cancer Beth Clark Dr. Clark has no relevant financial relationships to disclose.

P1-01-14 The complete spectrum of ESR1 mutations from 7000 breast cancer tumor samples: Early clinical results Karen Clark Ms. Clark has no relevant financial relationships to disclose.

P6-07-08 The complete spectrum of ESR1 mutations from 7000 breast cancer tumor samples: Early clinical results Travis Clark Mr. Clark has disclosed that he is an employee of Foundation Medicine Inc.
Circulating tumor cells in triple-negative breast cancer patients express prostate related genes and show different genetic profiles in US and German patient cohorts

Lorenzo Cohen

Mr. Cohen has no relevant financial relationships to disclose.

The role of HER2 mutations in resistance to endocrine therapy in ER+ breast cancer

Opher Cohen

Dr. Cohen has no relevant financial relationships to disclose.

Whole exome and transcriptome sequencing of resistant ER+ metastatic breast cancer

Opher Cohen

Dr. Cohen has no relevant financial relationships to disclose.

Descriptive and environmental factors are essential determinants of weight gain between before and after cancer diagnosis: Results from the prospective population-based French-Samll cohort

Patrice Cohen

Dr. Cohen has no relevant financial relationships to disclose.

A large-scale functional screen to identify resistance mechanisms to selective estrogen receptor degraders fulvestrant and GDC-810 in ER+ breast cancer

Ofir Cohen

Dr. Cohen has no relevant financial relationships to disclose.

Peer navigation for people affected by hereditary breast, ovarian and related cancers: Results from the first six months

Sandra Cohen

Ms. Cohen has no relevant financial relationships to disclose.

Systematic review of clinical trials for monoclonal antibody biosimilars in HER2-positive breast cancer

Jennifer Cire

Ms. Cire has disclosed that she receives salary from Pfizer Inc.

Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer

Evan Cohick

Mr. Cohick has no relevant financial relationships to disclose.

Return to work after breast cancer diagnosis: An observational prospective study of 125 patients in South America

Daniela Cohe

Ms. Cohe has no relevant financial relationships to disclose.

Should modified radical mastectomy be modified? A phase 1 study to evaluate infraradical mastectomy for invasive breast cancer

Michel Cobson

Dr. Cobson has no relevant financial relationships to disclose.

The importance of loco-regional tumor burden and surgery on survival in patients with de novo stage IV breast cancer; post-hoc analyses of protocol MMST-01

E-web Col

Dr. Col has no relevant financial relationships to disclose.

Addition of ovarian function suppression to endocrine therapy in premenopausal women with early breast cancer: A meta-analysis

Nananda Col

Dr. Col has no relevant financial relationships to disclose.

Dose dense adjuvant chemotherapy in patients with early breast cancer: Differential treatment effects according to composite index of benefit

Giuseppe Colantuoni

Mr. Colantuoni has no relevant financial relationships to disclose.

OBRG 07-READ: A randomized phase III trial comparing six cycles of docetaxel and cyclophosphamide (DC) to three cycles of paclitaxel and cyclophosphamide followed by three cycles of docetaxel (EC-D) in patients with early breast cancer

Tooren Col

Dr. Col has disclosed that he receives travel support from Roche.

MicroRNA-27a mediates deregulation of energy metabolism in breast cancer

John Cole

Dr. Cole has no relevant financial relationships to disclose.

Targeted and selective degradation of estrogen receptor (ER) alpha by PROTACs

Kevin Coleman

Mr. Coleman has disclosed that he receives salary and has ownership.

A phase 2 randomized, double-blind, placebo-controlled trial of endocrine therapy, pi-radium-223 dichloride in HER2-negative, hormone receptor-positive breast cancer patients with bone metastases

Robert Coleman

Mr. Coleman has disclosed that he has contracts with Bayer and Celgene and receives honoraria from Amgen.

A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2-negative, hormone receptor-positive breast cancer and bone metastases

Robert Coleman

Mr. Coleman has disclosed that he has contracts with Bayer and Celgene and receives honoraria from Amgen.

Maximizing recruitment and retention of patients into UK-ANZ POSNOC trial

Robert Coleman

Dr. Coleman has no relevant financial relationships to disclose.
Breast implant associated anaplastic large cell lymphoma (BIA-ALCL): The UK experience and first reported case of neoadjuvant brentuximab

Nick Collis

Mr. Collis has no relevant financial relationships to disclose.

Her2 and hormonal receptor analysis in breast cancer synchronic node metastases could add therapeutic information

Deborah Collyar

Ms. Collyar has no relevant financial relationships with commercial interests to disclose.

Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision-making

Deborah Collyar

Ms. Collyar has no relevant financial relationships with commercial interests to disclose.

Her2 and hormonal receptor analysis in breast cancer synchronic node metastases could add therapeutic information

Deborah Collyar

Ms. Collyar has no relevant financial relationships with commercial interests to disclose.

Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision-making

Deborah Collyar

Ms. Collyar has no relevant financial relationships with commercial interests to disclose.

Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision-making

Deborah Collyar

Ms. Collyar has no relevant financial relationships with commercial interests to disclose.

Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision-making

Deborah Collyar

Ms. Collyar has no relevant financial relationships with commercial interests to disclose.

Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision-making

Deborah Collyar

Ms. Collyar has no relevant financial relationships with commercial interests to disclose.

Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision-making

Deborah Collyar

Ms. Collyar has no relevant financial relationships with commercial interests to disclose.

Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision-making

Deborah Collyar

Ms. Collyar has no relevant financial relationships with commercial interests to disclose.

Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision-making

Deborah Collyar

Ms. Collyar has no relevant financial relationships with commercial interests to disclose.

Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision-making

Deborah Collyar

Ms. Collyar has no relevant financial relationships with commercial interests to disclose.

Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision-making

Deborah Collyar

Ms. Collyar has no relevant financial relationships with commercial interests to disclose.

Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision-making

Deborah Collyar

Ms. Collyar has no relevant financial relationships with commercial interests to disclose.

Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision-making

Deborah Collyar

Ms. Collyar has no relevant financial relationships with commercial interests to disclose.

Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision-making

Deborah Collyar

Ms. Collyar has no relevant financial relationships with commercial interests to disclose.

Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision-making

Deborah Collyar

Ms. Collyar has no relevant financial relationships with commercial interests to disclose.

Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision-making

Deborah Collyar

Ms. Collyar has no relevant financial relationships with commercial interests to disclose.

Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision-making

Deborah Collyar

Ms. Collyar has no relevant financial relationships with commercial interests to disclose.

Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision-making

Deborah Collyar

Ms. Collyar has no relevant financial relationships with commercial interests to disclose.

Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision-making

Deborah Collyar

Ms. Collyar has no relevant financial relationships with commercial interests to disclose.

Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision-making

Deborah Collyar

Ms. Collyar has no relevant financial relationships with commercial interests to disclose.

Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision-making

Deborah Collyar

Ms. Collyar has no relevant financial relationships with commercial interests to disclose.

Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision-making

Deborah Collyar

Ms. Collyar has no relevant financial relationships with commercial interests to disclose.

Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision-making

Deborah Collyar

Ms. Collyar has no relevant financial relationships with commercial interests to disclose.

Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision-making

Deborah Collyar

Ms. Collyar has no relevant financial relationships with commercial interests to disclose.

Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision-making

Deborah Collyar

Ms. Collyar has no relevant financial relationships with commercial interests to disclose.

Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision-making

Deborah Collyar

Ms. Collyar has no relevant financial relationships with commercial interests to disclose.

Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision-making

Deborah Collyar

Ms. Collyar has no relevant financial relationships with commercial interests to disclosure.
S4-04 Tumor microenvironment of metastasis (TMEM) score is associated with early distant recurrence in hormone receptor (HR) positive, HER2-negative early stage breast cancer (ESBC)
John Condeelis
Dr. Condeelis has disclosed that he receives royalties, owns stock and has a patent.

P4-03-12 Cancer-associated fibroblasts release exosomal microRNAs that dictate an aggressive phenotype in breast cancer
Serdana Cordorelli
Dr. Cordorelli has no relevant financial relationships to disclose.

P3-04-15 The PI3K inhibitor, capoletib, has selective activity in breast cancer cell lines and shows robust combined activity with hormonal blockade and CDK-4/6 inhibition in ER+ breast cancer cell line xenografts
Sylain Corélin
Dr. Corélin has no relevant financial relationships to disclose.

P4-21-01 Efficacy results of a phase 1b study of CMT-380, an oral HER2-specific inhibitor, in combination with capcitabine (C) and trastuzumab (T) in HER2+ metastatic breast cancer (MBC), including patients (pts) with brain metastases (mets)
Alix Corélin
Ms. Corélin has no relevant financial relationships to disclose.

P6-03-04 Comprehensive genomic profiling to assess tumor mutation burden in >8,000 breast cancer cases: Implications for immunotherapy
Caitlin Connelly
Dr. Connelly has disclosed that she receives salary from and has ownership in Foundation Medicine.

P4-03-13 Obesity and breast cancer: The adipocyte-macrophage interaction as a mediator of metastasis
Linda Condorelli
Dr. Condorelli has no relevant financial relationships to disclose.

P6-08-10 Osteoprotegerin mediates tumor-promoting effects of Interleukin-1beta in breast cancer cells
Linda Connolly
Dr. Connolly has no relevant financial relationships to disclose.

P1-05-22 The value of RNA-Seq for the detection of clinically actionable targets in breast cancer - A small cohort analysis
Cacey Conklin
Ms. Conklin has no relevant financial relationships to disclose.

P5-08-23 The share thoughts on breast cancer study: A Greater Plains collaborative cohort characterization project
Daniel Connolly
Mr. Connolly has no relevant financial relationships to disclose.

P3-09-02 The value of RNA-Seq for the detection of clinically actionable targets in breast cancer - A small cohort analysis
Elizabeth Connolly
Ms. Connolly has no relevant financial relationships to disclose.

P1-09-15 Tumor and serum DNA methylation in women receiving preoperative chemotherapy (PST) with or without vorinostat in primary operable HER2-negative breast cancer in TBCRC008
Alison Conlin
Ms. Conlin has no relevant financial relationships to disclose.

P2-04-11 Promotion of immunogenicity using epigenetic modulation and immune checkpoint inhibition in mouse models of breast cancer
Roisin Connolly
Mr. Conte has disclosed that he receives research funding for clinical trials to his institution from Genentech, Novartis, Puma Biotechnology, Clovis and Merrimack.

P6-09-09 A phase 2 open-label study of lucitanib in patients (pts) with triple-negative metastatic breast cancer (TNMBC): A pooled analysis
Roisin Connolly
Dr. Connolly has disclosed that he has contracts with Genentech, Novartis and Puma Biotechnology.

P6-11-03 A phase 2 study of olaparib as early-line treatment for HER2-MBC: Evaluation of efficacy, toxicity, and patient-reported outcomes
Roisin Connolly
Ms. Connolly has no relevant financial relationships to disclose.

P1-12-06 Factors related to the prognosis of breast cancer patients after the development of brain metastases
Pierfranco Conte
Ms. Conte has disclosed that he is a consultant for Novartis, Roche, Celgene, AstraZeneca, Eli Lilly and OBI Pharma and is a speaker for Novartis and Roche. He has also disclosed that he has contracts with Merk-Serono, Novartis and Roche.
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2-05-20</td>
<td>Tumor infiltrating lymphocytes in recurrent HER2+ and triple-negative breast cancer: Prognostic value according to tumor phenotype</td>
<td>Pierfranco Conte</td>
<td>Dr. Conte has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-22-05</td>
<td>First-line ribociclib plus letrozole in patients with de novo HR+, HER2+ advanced breast cancer (ABC): A subgroup analysis of the MONALEESA-2 trial</td>
<td>Pierfranco Conte</td>
<td>Mr. Conte has disclosed that he is a consultant for Novartis, Roche, Celgene, AstraZeneca, Eli Lilly and OBI Pharmaceutical and is a speaker for Novartis and Roche. He has also disclosed that he has contracts with Merck-Serono, Novartis and Roche.</td>
</tr>
<tr>
<td>P3-15-03</td>
<td>nkt-pulsed + carboplatin or gemcitabine vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomised phase 2 portion of the TRAcyta trial</td>
<td>Pierfranco Conte</td>
<td>Mr. Conte has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S6-01</td>
<td>Tumors on 2 year adjacent trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian short-Her trial</td>
<td>Pierfranco Conte</td>
<td>Mr. Conte has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-05-09</td>
<td>Glucocorticoid receptor modulation affects ER+ breast cancer cell proliferation</td>
<td>Suzanne Conzen</td>
<td>Dr. Conzen has disclosed that she is an inventor on patent 'Methods and compositions related to glucocorticoid receptor (GR) antagonists and breast cancer.' This patent covers GR-negative breast cancer and therefore is not directly relevant to this work.</td>
</tr>
<tr>
<td>P6-12-15</td>
<td>First-line ribociclib plus letrozole in patients with de novo HR+, HER2- advanced breast cancer (ABC): A subgroup analysis of the MONALEESA-2 trial</td>
<td>Suzanne Conzen</td>
<td>Ms. Conzen has disclosed that she is an inventor of 2 patents licensed to Concept.</td>
</tr>
<tr>
<td>P3-12-04</td>
<td>Is 6 hour monitoring for administration related reactions after first administration of subcutaneous trastuzumab necessary? A single institution audit</td>
<td>James Cook</td>
<td>Mr. Cook has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-04-06</td>
<td>Targeting of the unfolded protein response signaling arms differentially regulates macrophage proliferation, plasticity, and breast cancer cell clearance</td>
<td>Katherine Cook</td>
<td>Dr. Cook has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P08-02</td>
<td>Tumor subtype and survival differences between Hispanic and non-Hispanic white breast cancer patients in the California cancer registry</td>
<td>Linda Cook</td>
<td>Dr. Cook has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-04-03</td>
<td>Differential effect of chemotherapy on immune gene expression signatures based on molecular subtype of breast cancer</td>
<td>Rebecca Cook</td>
<td>Dr. Cook has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-10-20</td>
<td>A multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer: Early results of unplanned boost participants</td>
<td>L Coomer</td>
<td>C Coomer has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-03-05</td>
<td>Development of a panel of serum-based protein biomarkers for the non-invasive detection of breast cancer in BI-RADS category 4 patients</td>
<td>Karen Copeland</td>
<td>Ms. Copeland has disclosed that she is a consultant for Oncolyte Corporation.</td>
</tr>
<tr>
<td>P5-15-16</td>
<td>Utilization and outcomes of eribulin in triple negative metastatic breast cancer: Real-world findings</td>
<td>Brenda Copson</td>
<td>Ms. Copson has disclosed that she receives salary from Eisai, Inc.</td>
</tr>
<tr>
<td>OT2-01-15</td>
<td>PARTNER - Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients</td>
<td>Ellen Copson</td>
<td>Dr. Copson has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>PO6-02</td>
<td>Local recurrence in young women with invasive breast cancer, the prospective study of outcomes in sporadic and hereditary breast cancer (POSH)</td>
<td>Ellen Copson</td>
<td>Ms. Copson has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S2-03</td>
<td>Does BRCA status affect outcome in young breast cancer patients? Results from the prospective study of outcomes in sporadic and hereditary breast cancer (POSH)</td>
<td>Ellen Copson</td>
<td>Dr. Copson has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-08-05</td>
<td>Phase II trial of palbociclib in combination with fulvestrant for the treatment of androgen receptor (AR)+ metastatic breast cancer (MBC)</td>
<td>Adriana Corben</td>
<td>Dr. Corben has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-10-09</td>
<td>Development of trastuzumab resistance: Results from the phase III multicentric Italian short-Her trial</td>
<td>Kimberly Corbin</td>
<td>Dr. Corbin has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
DSCAM-AS1, a breast cancer specific and Estrogen receptor α-dependent long noncoding RNA, is a key component of the pathway controlling cell growth and migration.

Francesca Cordero
Dr. Cordero has no relevant financial relationships to disclose.

Increased stromal lymphocytes in breast cancer patients with axillary nodal disease: implications for early stage breast cancer surgery.

C Corn
Dr. Corn has no relevant financial relationships to disclose.

Impact of pre-operative exercise on breast cancer gene expression.

Macintosh Cornwell
Macintosh Cornwell has no relevant financial relationships to disclose.

The Y537S ESR1 mutation is a dominant driver of distant ER-positive breast cancer metastasis.

Arnoldo Corona-Rodriguez
Mr. Corona-Rodriguez has no relevant financial relationships to disclose.

Challenges faced across borders to open European academic multicentre projects: The ET-FES program part of the ERA-Net TRANSCAN JTC 2011.

Davide Corradengo
Dr. Corradengo has no relevant financial relationships to disclose.

Prediction of underestimation associated with flat epithelial atypia, atypical ductal hyperplasia and atypical lobular hyperplasia by needle biopsy: Experience in an Argentine breast unit.

Francisco Corrao
Dr. Corrao has no relevant financial relationships to disclose.

Evaluating cosmetic outcome following breast conserving surgery in trials: panel versus objective evaluation and the role of patient reported outcome measures (PROMs).

Eveline Corten
Dr. Corten has no relevant financial relationships to disclose.

PIQHASSO: Open label, non-randomized, multicenter phase 1/2b study investigating safety and efficacy of PQR309 and eribulin combination in patients (pts) with locally advanced (LA) or metastatic HER2- negative breast cancers.

Javier Cortes
Dr. Cortes has disclosed that he is a consultant for Roche and Celgene. He also disclosed that he has contracts with Eisai and Novartis.

SOPHIA: A phase 3, randomized study of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in the treatment of patients with HER2+ metastatic breast cancer.

Javier Cortes
Dr. Cortes has disclosed that he is a consultant for Celgene and Roche/Genentech. He also disclosed that he receives honoraria from Celgene, Eisai, Novartis and roche/Genentech.

Phase 3 study of etirinotecan pegol versus treatment of physician’s choice in patients with metastatic breast cancer who have stable brain metastases previously treated with an anthracycline, a taxane, and capecitabine.

Javier Cortes
Mr. Cortes has disclosed that he is a consultant for Roche, Novartis, Eisai and Celgene.

NICEAR: A randomized international phase 3 study comparing the efficacy and safety of enzalutamide in combination with paclitaxel chemotherapy or an monotherapy vs placebo with paclitaxel in patients with advanced diagnostic-positive triple-negative breast cancer.

Javier Cortes
Mr. Cortes has disclosed that he is a consultant for Roche, AstraZeneca and Celgene and a speaker for Roche, Eisai and Novartis.

Challenges faced across borders to open European academic multicentre projects: The ET-FES program part of the ERA-Net TRANSCAN JTC 2011.

Javier Cortes
Dr. Cortes has no relevant financial relationships to disclose.

A single-arm phase 2 study to assess clinical activity, efficacy and safety of enzalutamide with trastuzumab in HER2+ AR+ metastatic or locally advanced breast cancer.

Javier Cortes
Mr. Cortes has disclosed that he is a consultant for Roche, Celgene, AstraZeneca and Celgene and a speaker for Roche, Eisai and Novartis.
null-paclitaxel + carboplatin or gemcitabine vs gemcitabine/carboplatin or gemcitabine as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 3 portion of the tNACity trial

Javier Cortes

Mr. Cortes has disclosed that he is a speaker for Roche, Eisai and Novartis.

Randomized phase II study evaluating different schedules of nab-paclitaxel in metastatic breast cancer (MBC): Results of the SNAP study

Javier Cortes

Dr. Cortes has no relevant financial relationships to disclose.

Phase IIb study evaluating the safety and clinical activity of lurvetuzumab combined with pertuzumab and paclitaxel in HER2-low metastatic breast cancer

Javier Cortes

Dr. Cortes has disclosed that he receives honoraria from Roche, Eisai and Novartis and consultant fees from Roche, Celgene, AstraZeneca and Cellectis.

Phase I multicenter clinical trial evaluating the combination of lurvetuzumab emtansine (ITM) and non-pegylated liposomal doxorubicin (MPA) in HER2-positive metastatic breast cancer (MBC): MEDIOP106 study

Paulo Cortes

Mr. Cortes has no relevant financial relationships to disclose.

Randomized phase II study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA-mutant tumors

Javier Cortés

Mr. Cortés has disclosed that he is a consultant for Roche, Celgene, AstraZeneca and Cellestia. He also disclosed that he is a speaker for Roche, Eisai and Novartis.

Phase II of POSEIDON: A phase Ib / randomized phase II trial of tamoxifen plus taselisib or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment

Javier Cortés

Mr. Cortés has no relevant financial relationships to disclose.

Efficacy and gene expression results from SOLTI1007 NEOERIBULIN phase II clinical trial in HER2-negative early breast cancer

Javier Cortés

Dr. Cortés has disclosed that he is a consultant for Roche, Celgene, AstraZeneca and Cellestia and a speaker for Roche, Eisai and Novartis. He has also disclosed that he has ownership in Medica Scientia Innovation Research - MedSIR Med and has an investigational grant from Roche.

Pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: Efficacy analysis of a phase II/III cardiac safety study (TRYPHALA)

Javier Cortés

Mr. Cortés has disclosed that he is a consultant for Roche, Celgene, AstraZeneca and Novartis. He has also disclosed that he has ownership in Medica Scientia Innovation Research.

Expression of miR-18a and miR-210 in normal breast tissue as candidate markers of breast cancer risk

Fabricio Costa

Dr. Costa has no relevant financial relationships to disclose.

High-grade human cytomegalovirus IEA is associated with expression of COX-2 and 5-LO in human breast cancer samples

Helena Costa

Ms. Costa has no relevant financial relationships to disclose.

Low expression levels of hormone receptors (ER-α and PGR) in human breast cancer samples is significantly associated with high-grade human cytomegalovirus-IEA

Helena Costa

Ms. Costa has no relevant financial relationships to disclose.

Two-year follow-up results of a multi-center trial of intra-operative electron beam therapy during breast conservation surgery for early stage breast cancer

P Costa

Dr. Costa has no relevant financial relationships to disclose.
A multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer: Early results of unplanned boost participants
P Costa
P Costa has no relevant financial relationships to disclose.

Return to work after breast cancer diagnosis: An observational prospective study of 125 patients in South America
Romulo Costa
Mr. Costa has no relevant financial relationships to disclose.

Peripheral sensory neuropathy occurrence and resolution: Results from the neoadjuvant randomized GeparSepto study (GBG 69)
Serban Costa
Serban Costa has no relevant financial relationships to disclose.

Relationship between density and breast tumor pathology in a contemporary set of patients
Nicholas Costantino
Mr. Costantino has no relevant financial relationships to disclose.

HER2 and hormonal receptor analysis in breast cancer synchronous node metastases could add therapeutic information
Marie Costanzo
Dr. Costanzo has no relevant financial relationships to disclose.

Biological effects of abemaciclib in a phase2 neoadjuvant study for postmenopausal patients with hormone receptor positive, HER2 negative breast cancer
Timothy Cotigan
Dr. Cotigan has disclosed that he has a contract with and is employed by Eli Lilly and Company.

Comprehensive genomic profiling of 34 cases of breast angiosarcoma
Gregory Cote
Dr. Cote has no relevant financial relationships to disclose.

A clinically validated DNA microarray for high-resolution HER2 testing defines a new genomic subtype in high-risk breast cancer with equivocal results by IHC and FISH
Philip Cotter
Dr. Cotter has no relevant financial relationships to disclose.

Development of a novel HER2 testing strategy, using image-based cell-sorting to isolate pure cell populations from FFPE upstream of FISH
Philip Cotter
Dr. Cotter has no relevant financial relationships to disclose.

Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer
Paul Cottu
Dr. Cottu has no relevant financial relationships to disclose.

Evaluation of intra-tumor heterogeneity, test reproducibility and their impact in breast cancer samples assessed by Prosigna™: Results from a decision impact prospective study and a matched case-control study
Paul Cottu
Dr. Cottu has no relevant financial relationships to disclose.

Comparison of mutational landscapes of primary breast cancer and first metastatic relapse: Results from the FISPORE study
Paul Cottu
Dr. Cottu has no relevant financial relationships to disclose.

Optimized prediction of deleterious missense mutations in BRCA1 and BRCA2 genes
Fergus Couch
Dr. Couch has no relevant financial relationships to disclose.

Associations between breast cancer subtypes and mutations in cancer predisposition genes identified by clinical genetic testing of breast cancer patients
Fergus Couch
Dr. Couch has no relevant financial relationships to disclose.

Breast cancer risks associated with mutations in cancer predisposition genes identified by clinical genetic testing of 40,000 breast cancer patients
Fergus Couch
Dr. Couch has no relevant financial relationships to disclose.

AACR Outstanding Investigator Award for Breast Cancer Research
Fergus Couch
Prof. Couch has no relevant financial relationships with commercial interests to disclose.

POWER-remote: A randomized study evaluating the effect of a remote-based weight loss program in women with early stage breast cancer
Janelle Coughlin
Ms. Coughlin has disclosed that she receives research funding from Healthways.

From monoclyc re-programming to the expansion of tumor infiltrating lymphocytes for adoptive T cell therapies
George Coukos
Dr. Coukos has no relevant financial relationships to disclose.

CDK4 phosphorylation status and corresponding gene expression profile predict sensitivity to Palbociclib
Katie Coulombe
Dr. Coulombe has no relevant financial relationships to disclose.
Epigenome-wide association study for breast cancer risk using whole genome and target captured bisulphite sequencing: A pooled case-control study nested in the breakthrough generations study
Penny Coulson
Ms. Coulson has no relevant financial relationships to disclose.

Scalp cooling alopecia prevention trial (SCALP) for patients with early stage breast cancer
Jay Courtright
Dr. Courtright has no relevant financial relationships to disclose.

Melatonin treatment: A transcriptomic networks in a xenograft model of breast cancer
Lucio Coutinho
Dr. Coutinho has no relevant financial relationships to disclose.

Two-year follow-up results of a multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer
C Cox
Dr. Cox has no relevant financial relationships to disclose.

Learning curve for the SAVI Scout breast localization and surgical guidance system
Charles Cox
Mr. Cox has disclosed that he is a consultant and is on the speakers bureau for Cianna Medical. He has also disclosed that he is the PI of current study, funded by Cianna Medical.

MINT trial yields MammaPrint High1/High2 risk classes associated with significant differences in pCR and receptor subtype
Charles Cox
Mr. Cox has disclosed that he is a MINT investigator.

Long-term follow-up of early stage breast cancer patients with results of MammaPrint, Oncotype DX® and MammaStar® risk classification assays
Joanne Cox
Ms. Cox has disclosed that she has a contract with and is employed by Lilly and Company.

Isolated sternal metastases: The place of surgical resection
Maude Coyette
Dr. Coyette has no relevant financial relationships to disclose.

Diagnosing cognitive impairment (“chemo brain”) in breast cancer survivors
Melissa Craft
Dr. Craft has no relevant financial relationships to disclose.

Discovery of molecular predictors of late breast cancer specific events (BCSE) in ER+, node+ breast cancer - new transcriptome expression whole gene analysis of the phase III adjuvant trial SWOG S8814
Michael Crager
Dr. Crager has disclosed that he is an employee of Genomic Health Inc and that she receives salary and owns stock.

A multi-OmIC analysis to explore the impact of “actionable” genomic alterations on protein pathway activation: Clinical implication for precision medicine in metastatic breast cancer
David Craig
Mr. Craig has no relevant financial relationships to disclose.

Gene fusions and network expression in HER2+ breast cancer: Implications for personalized medicine
Justin Craig
Mr. Craig has no relevant financial relationships to disclose.

Pathological complete response is associated with excellent outcomes in BRCA mutation associated triple negative breast cancer
Gregory Crane
Dr. Crane has no relevant financial relationships to disclose.

Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple-negative breast cancer
Evelyne Crapez
Ms. Crapez has no relevant financial relationships to disclose.

Multi-gene panel testing for hereditary cancer predisposition in unsolved high risk breast and ovarian cancer patients
Beth Crawford
Ms. Crawford has no relevant financial relationships to disclose.

Nanotheranostics using plasmonic gold nanostars to target inflammatory breast cancer cells and tumor emboli
Bridget Crawford
Ms. Crawford has no relevant financial relationships to disclose.

Relationship between overall survival and surrogate measures in patients with metastatic breast cancer treated with chemotherapy
Jeffrey Crawford
Dr. Crawford has no relevant financial relationships to disclose.

Recurrent functionally diverse in-frame ERBB2 gene fusions drive endocrine resistance in breast cancer
Chad Creighton
Dr. Creighton has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Affiliation</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD2-04</td>
<td>FOXA1 induces a pro-metastatic secretome through ER-dependent and independent transcriptional reprogramming in endocrine-resistant breast cancer</td>
<td>Chad Creighton</td>
<td>Dr. Creighton has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>P4-21-42</td>
<td>MetaHR phase IIb multicenter, open-label, single-arm safety study of subcutaneous trastuzumab in combination with pertuzumab and docetaxel in patients with HER2-positive advanced breast cancer: First results</td>
<td>Aulde Crepelle-Filchais</td>
<td>Aulde Crepelle-Filchais has disclosed that he is a F. Hoffman-La Roche employee.</td>
<td></td>
</tr>
<tr>
<td>P05-07</td>
<td>From monocye re-programming to the expansion of tumor infiltrating lymphocytes for adoptive T cell therapy</td>
<td>Lucas Grasso</td>
<td>Dr. Grasso has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>P08-02</td>
<td>Tumor subtype and survival differences between Hispanic and non-Hispanic white breast cancer patients in the California cancer registry</td>
<td>Rosemary Cress</td>
<td>Dr. Cress has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>P4-21-08</td>
<td>A phase I/II of S-22031, a reversible EGFR and HER2 inhibitor, combined with trastuzumab +/- chemotherapy in patients with HER2-positive metastatic breast cancer</td>
<td>Nicola Cresti</td>
<td>Nicola Cresti has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>OT1-01-05</td>
<td>PAINTER: Evaluation of eribulin tolerability and correlation between a set of polymorphisms and neuropathy in patients with metastatic breast cancer</td>
<td>Elisabetta Cretella</td>
<td>Ms. Cretella has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>P06-04</td>
<td>HER2 study: How European and US young women cope with breast cancer and fertility concerns</td>
<td>Elisabetta Cretella</td>
<td>Ms. Cretella has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>P3-13-22</td>
<td>Should modified radical mastectomy be modified? A phase 1 study to evaluate infraradical mastectomy for invasive breast cancer</td>
<td>André Crevecoeur</td>
<td>Dr. Crevecoeur has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>S4-03</td>
<td>Targeted and selective degradation of estrogen receptor (ER) alpha by PROTACs</td>
<td>Andrew Crew</td>
<td>Mr. Crew has disclosed that he receives salary and has ownership.</td>
<td></td>
</tr>
<tr>
<td>OT1-01-10</td>
<td>Multi-center phase II trial of AYI-1215 (ficlatirosid) combined with nab-paclitaxel in unresectable or metastatic breast cancer</td>
<td>Katherine Crew</td>
<td>Dr. Crew has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>OT2-01-19</td>
<td>An randomized phase II trial of fulvestrant with or without dasiibib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer</td>
<td>Katherine Crew</td>
<td>Dr. Crew has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>OT3-01-06</td>
<td>VATIS trial: Phase II trial of the milpepin-5 peptide vaccine in women with [tCoG] of the breast</td>
<td>Katherine Crew</td>
<td>Dr. Crew has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>P2-07-01</td>
<td>Chemoprevention uptake among women with atypical hyperplasia, lobular and ductal carcinoma in situ</td>
<td>Katherine Crevecoeur</td>
<td>Dr. Crevecoeur has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>P4-21-06</td>
<td>Diffuse optical tomography can predict pathologic complete response in patients with HER2+ or triple negative breast cancer undergoing neoadjuvant chemotherapy</td>
<td>Katherine Crew</td>
<td>Dr. Crew has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>P4-21-17</td>
<td>Phase II trial of naxitumab in combination with trastuzumab in metastatic HER2 positive breast cancer</td>
<td>Katherine Crew</td>
<td>Dr. Crew has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>S4-03</td>
<td>Targeted and selective degradation of estrogen receptor (ER) alpha by PROTACs</td>
<td>Craig Crew</td>
<td>Mr. Crew has disclosed that he has ownership.</td>
<td></td>
</tr>
<tr>
<td>P4-03-12</td>
<td>Cancer-associated Hereditarian release exosomal microRNA that dictate an aggressive phenotype in breast cancer</td>
<td>Quintavalle Cristina</td>
<td>Dr. Cristina has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>OT3-01-05</td>
<td>A phase 3 study of PD-L1 and CTLA-4 inhibition and immunopharmacogenomics in metastatic breast cancer</td>
<td>Massimo Cristofanilli</td>
<td>Dr. Cristofanilli has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>P4-03-06</td>
<td>Prognostic values of circulating tumor cells (CTC) and cancer associated macrophage-like cells (CAMA) enumerations in metastatic breast cancer: The role for innate immunity in the metastatic process</td>
<td>Massimo Cristofanilli</td>
<td>Dr. Cristofanilli has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>P1-01-05</td>
<td>Estrogen receptor 3 (ESR3) mutations in circulating tumor DNA (ctDNA): A guide to the management of advanced breast cancer (ABC)</td>
<td>Massimo Cristofanilli</td>
<td>Dr. Cristofanilli has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
</tbody>
</table>
P4-22-06  Treatment postprogression in women with endocrine-resistant HR+/HER2- advanced breast cancer who received palbociclib plus fulvestrant in PALOMA-3

Maximo Cristofanilli  Dr. Cristofanilli has disclosed that he is a consultant for Dompe and a speaker for Pfizer.

P4-22-07  Long-term safety of palbociclib in combination with endocrine therapy in treatment-naive and previously treated women with HR+, HER2- advanced breast cancer: A pooled analysis from randomized phase 2 and 3 studies

Maximo Cristofanilli  Dr. Cristofanilli has disclosed that he is a consultant for Dompe and a speaker for Pfizer.

P01-02  Circulating tumor DNA (ctDNA): A real-time application of precision medicine to the management of metastatic breast cancer (MBC)

Maximo Cristofanilli  Dr. Cristofanilli has no relevant financial relationships to disclose.

P5-11-10  Evaluation of the relationship between psychological distress and risk for breast cancer

Aliged Crocker  Dr. Cristofanilli has no relevant financial relationships to disclose.

P4-06-05  Treatment of ESR1 mutant and PIK3CA mutant patient-derived breast cancer xenograft models reveals differential anti-tumor responses to estrogen receptor degraders and PI3K inhibitors in vivo

Lisa Crocker  Ms. Crocker has disclosed that she is an employee of Genentech, A Member of the Roche Group.

P6-04  The PI3K inhibitor, taselisib, has enhanced potency in PIK3CA mutant models through a unique mechanism of action

Lisa Crocker  Ms. Crocker has disclosed that she receives salary from Genentech, Inc.

P2-05  Inhibition of mutant HER2 results in synthetic lethality when combined with ER antagonists in ESR1 HER2 mutant human breast cancer cells

Sarah Crossmann  Ms. Crossmann has no relevant financial relationships to disclose.

P6-16-04  Novel targeting of mammary tumors and tumor-associated functional limitations through inhibition of NF-κB

Eduardo Crouenberger  Mr. Crouenberger has no relevant financial relationships to disclose.

P6-15-03  Two-year follow-up results of a multi-center trial of intraoperative electronic brachytherapy during breast conservation surgery for early stage breast cancer

Cynara Croomer  Dr. Croomer has no relevant financial relationships to disclose.

P5-06-09  Cyclin D1 binding to chromatin and the induction of chromosomal instability requires the fuzzy domain

Marco Crosariol  Mr. Crosariol has no relevant financial relationships to disclose.

P2-04-27  CTSA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer

Erika Crosby  Dr. Crosby has no relevant financial relationships to disclose.

P3-03-03  An acquired HER2 17q11 gatekeeper mutation induces resistance to neratinib in a patient with HER2 mutant-driven breast cancer

Karen Cross  Dr. Cross has disclosed that he receives salary from AstraZeneca.

P3-13-04  Use of an absorbable implant to mark the lumpectomy cavity: Initial report of 300 patients in a multi-center registry database

Michael Cross  Mr. Cross has no relevant financial relationships to disclose.

P2-02-03  Recurrent functionally diverse in-frame ESR1 gene fusions drive endocrine resistance in breast cancer

Robert Crowder  Mr. Crowder has no relevant financial relationships to disclose.

P4-09-01  Tumor suppressor control of the cancer stem cell angiogenic niche

David Crowe  Mr. Crowe has no relevant financial relationships to disclose.

P4-11-01  A genetic model of mammary gland fibrosis and cancer risk

David Crowe  Mr. Crowe has no relevant financial relationships to disclose.

P1-05-18  Genomic copy-number alterations (CNA) associated with pCR in HER2-positive (HER2+) early-stage breast cancer (BrCa) patients receiving neoadjuvant trastuzumab (T)

John Crown  Dr. Crown has disclosed that he receives research funding from Roche.

P4-21-27  Plasma chemokine profile of HER2+ breast cancer (BrCa) patients treated with docetaxel (D) and carboplatin (C) in combination with trastuzumab (T) and/or lapatinib (L) in the neo-adjuvant setting

John Crown  Mr. Crown has disclosed that he received research funding from Roche and GSK.

P5-14-12  Long-term outcome of HER2-normal early-stage breast cancer (ESBC) patients (Pts) treated with docetaxel-cyclophosphamide (TC) chemotherapy (CTx): Mature results of a single-institution experience

John Crown  Mr. Crown has no relevant financial relationships to disclose.
Evaluation of the Oncomine focus and comprehensive assay for therapeutic stratification in early hormone receptor positive breast cancer

Cheryl Crozier

Mr. Crozier has no relevant financial relationships to disclose.

Evaluation of the Oncomine focus and comprehensive assays for therapeutic stratification in early hormone receptor positive breast cancers

Cheryl Crozier

Mr. Crozier has no relevant financial relationships to disclose.

P1-10-11

Prone vs. supine positioning for optimizing radiation heart exposure during left breast radiotherapy: A simple clinical tool for prediction*

Adrienn Cserháti

Adrienn Cserháti has no relevant financial relationships to disclose.

ENCORE 602: A randomized, placebo-controlled, double-blind, multicenter phase 2 study both a phase 2b lead-in of axelozimab with or without entinostat in patients with advanced triple negative breast cancer (aTNBC)

Scott Cudicich

Mr. Cudicich has disclosed that he receives salary from Syndax.

P1-12-07

BEETLE-3: A Phase III study of lapatinib  + fulvestrant in postmenopausal women with HER2+ HER2- advanced breast cancer

Ribor Cuisi

Ribor Cuisi has no relevant financial relationships to disclose.

P1-05-39

Axillary reverse mapping using fluorescence imaging in the surgical treatment for breast cancer patients

Kaelong Cui

Kaelong Cui has no relevant financial relationships to disclose.

P1-10-01

Tumor-infiltrating lymphocyte (TIL) assessment distilled into two binary parameters in triple-negative breast cancer (TNBC)

Xiaoyan Cui

Dr. Cui has no relevant financial relationships to disclose.

Folate receptor alpha (FRA) expression in triple-negative breast cancer (TNBC)

Xiaoyan Cui

Dr. Cui has no relevant financial relationships to disclose.

P6-09-55

"Quality, not quantity": 10X hot-spot (HS) analysis of lymphocyte markers (CD3, CD8, CD4, CD20) in tumor-infiltrating lymphocytes (TILs) is superior to whole tumor (WT) analysis in triple-negative breast cancer (TNBC)

Xiaoyan Cui

Dr. Cui has no relevant financial relationships to disclose.

P6-09-56

Tissue microarray (TMA) based immunohistochemical studies of lymphocyte-specific markers yield inaccurate results

Xiaoyan Cui

Dr. Cui has no relevant financial relationships to disclose.

P6-09-57

Stromal density of tumor-infiltrating lymphocytes (TILs): Challenging the 50% threshold that defines lymphocyte predominant breast cancer (LPBC)

Xiaoyan Cui

Dr. Cui has no relevant financial relationships to disclose.

P5-11-10

Evaluation of the relationship between psychological distress and risk for breast cancer

Melissa Cude

Ms. Cude has no relevant financial relationships to disclose.

P2-16-01

Relationship between overall survival and surrogate measures in patients with metastatic breast cancer treated with chemotherapy

Eva Culikova

Dr. Culikova has no relevant financial relationships to disclose.

P6-12-05

Pilot study of axitinib-92 leukotriene E4-exon10 fissure screening for imaging angiogenesis in patients with inflammatory breast carcinoma receiving preoperative chemotherapy

Audun Culbane

Dr. Culbane has no relevant financial relationships to disclose.

P1-09-07

A model with polygenic risk score and mammographic density predicts interval cancers

Steven Cummings

Dr. Cummings has no relevant financial relationships to disclose.
Combined targeted therapies for advanced triple negative breast cancer: A phase II trial of nab-paclitaxel and bevacizumab followed by maintenance targeted therapy with bevacizumab and erlotinib

Arianne Cundy
Ms. Cundy has no relevant financial relationships to disclose.

Breast implant associated anaplastic large cell lymphoma (BIA-ALCL)- The UK experience and first reported case of neoadjuvant breast cancer

David Cunningham
Mr. Cunningham has no relevant financial relationships to disclose.

SOPHIA: A phase 3, randomized study of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in the treatment of patients with HER2+ metastatic breast cancer

Sukwatee Curtigiano
Dr. Curtigiano has no relevant financial relationships to disclose.

A phase 2 randomised, double-blinded, controlled study of ONT-380, a placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unselectable locally advanced or metastatic breast carcinoma (MBC) (PRECISE/MBC)

Sukwatee Curtigiano
Dr. Curtigiano has no relevant financial relationships to disclose.

Breast cancer in the Bahamas: Revisiting the adequacy of national screening guidelines

DuVaughn Curling
Dr. Curling has no relevant financial relationships to disclose.

Magnetic resonance imaging (MRI) surveillance for patients with dense breasts and a previous breast cancer (BC) and/or high risk lesion

Belinda Curpen
Dr. Curpen has no relevant financial relationships to disclose.

NRG oncology/NSABP B-51/RTOG 1304: A phase III superiority clinical trial designed to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) will reduce invasive cancer events in patients (pts) with positive axillary (Ax) nodes and convert to ypT0 after neoadjuvant chemotherapy (NC)

Walter Curran, Jr
Mr. Curran has no relevant financial relationships to disclose.

Epigenome-wide association study for breast cancer risk using whole genome and target captured bisulphite sequencing: A pooled case-control study nested in the breakthrough generations study

Edward Curry
Mr. Curry has no relevant financial relationships to disclose.

Estrogen receptor 1 (ESR1) mutations in circulating tumor DNA (ctDNA): A guide to the management of advanced breast cancer

Rebecca Curry-Edwards
Ms. Curry-Edwards has no relevant financial relationships to disclose.

Circulating tumor DNA (ctDNA): A real-time application of precision medicine to the management of metastatic breast cancer (MBC)

Rebecca Curry-Edwards
Ms. Curry-Edwards has no relevant financial relationships to disclose.

Utility of the orally bioavailable selective estrogen receptor degrader AZD9496 in ESR1 mutant preclinical models of estrogen receptor positive breast cancer

Jon Curwen
Mr. Curwen has disclosed that he receives salary and has ownership.

Patient derived DCS mouse intraductal (MDM) models recapitulate the full spectrum of human patient pathology and morphologic features including progression to invasion in a subset of cases

Therese Cusick
Dr. Cusick has no relevant financial relationships to disclose.

NEDD9 promotes breast cancer metastasis by regulating mitochondrial functions

Mary Lou Cutler
Dr. Cutler has no relevant financial relationships to disclose.

Neratinib + fulvestrant in ERBB2-mutant, HER2-non-amplified, estrogen receptor (ER) positive, metastatic breast cancer (MBC): Preliminary analysis from the phase II SUMMIT trial

Richard Cutler
Mr. Cutler has disclosed that he receives salary from Puma Biotechnology, Inc.

Identification, clinical characteristics and treatment outcomes of somatic human epidermal growth factor receptor 2 (HER2) mutations in metastatic breast cancer patients

Richard Cutler Jr.
Mr. Cutler has disclosed that he receives salary from and has ownership in Puma Biotechnology, Inc.

An acquired HER2 T798I gatekeeper mutation induces resistance to neratinib in a patient with HER2 mutant-driven breast cancer

Richard Cutler, Jr.
Mr. Cutler has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>PD2-05</th>
<th>Inhibition of mutant HER2 results in synthetic lethality when combined with ER antagonists in ER+/HER2 mutant human breast cancer cells</th>
<th>Richard Cutler, Jr.</th>
<th>Mr. Cutler has disclosed that he receives salary from and has ownership in Puma Biotechnology Inc.</th>
</tr>
</thead>
<tbody>
<tr>
<td>PD6-02</td>
<td>Local recurrence in young women with invasive breast cancer; the prospective study of outcomes in sporadic and hereditary breast cancer (POSH)</td>
<td>Ramon Cutress</td>
<td>Ramon Cutress has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S2-03</td>
<td>Does BRCA status affect outcome in young breast cancer patients? Results from the prospective study of outcomes in sporadic and hereditary breast cancer (POSH)</td>
<td>Ramon Cutress</td>
<td>Ramon Cutress has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-02-01</td>
<td>Circulating tumor DNA analysis to predict relapse and overall survival in early breast cancer - Longer follow-up of a proof-of-principle study</td>
<td>Ron Cutts</td>
<td>Ron Cutts has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-06-06</td>
<td>Pragmatic and predictive relevance of cell cycle progression (CCP) score in ductal carcinoma in situ: Results from the UK/ANZ DCIS trial</td>
<td>Caroline Cuvier</td>
<td>Dr. Cuvier has disclosed that he receives a proportion of royalties for CCP score. He has also disclosed that he is a consultant for Myriad and Cepheid and has contracts with Genomic Health Inc., Myriad and AstraZeneca.</td>
</tr>
<tr>
<td>P1-09-06</td>
<td>Long-term comparison of anastrozole versus tamoxifen: Results from LATTE/ATAC</td>
<td>Jack Cuzick</td>
<td>Dr. Cuzick has disclosed that he receives grant support from AstraZeneca.</td>
</tr>
<tr>
<td>S6-05</td>
<td>Comprehensive comparison of prognostic signatures for breast cancer in TransATAC</td>
<td>Jack Cuzick</td>
<td>Dr. Cuzick has disclosed that he receives grant support from AstraZeneca.</td>
</tr>
<tr>
<td>P2-05-21</td>
<td>Predictive value of quantitative HER2 and HER3 levels combined with downstream signaling markers in HER2-positive advanced breast cancer patients treated with lapatinib</td>
<td>Bogumila Czartoryska-Arlukowicz</td>
<td>Bogumila Czartoryska-Arlukowicz has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT3-06-01</td>
<td>KARISMA, The karima intervention study. - A tamoxifen dose determination trial</td>
<td>Kamila Czene</td>
<td>Dr. Czene has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-03-03</td>
<td>Molecular differences between screen-detected and interval breast cancers are largely explained by PAM50 subtypes</td>
<td>Kamila Czene</td>
<td>Dr. Czene has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-03</td>
<td>Intra-tumor heterogeneity of the estrogen receptor predicts less benefit from tamoxifen therapy and poor long-term breast cancer patient survival - Retrospective analyses of the STO-3 randomized trial</td>
<td>Kamila Czene</td>
<td>Dr. Czene has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-06-06</td>
<td>A clinical model for assessment of the individual breast cancer risk</td>
<td>Kamila Czene</td>
<td>Dr. Czene has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-07-03</td>
<td>Intratumor and breast cancer risk: Novel insights from mammographic density analyses</td>
<td>Kamila Czene</td>
<td>Dr. Czene has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-07-07</td>
<td>Gene expression signatures and immunohistochemical subtypes add prognostic value to each other</td>
<td>Kamila Czene</td>
<td>Dr. Czene has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-15-02</td>
<td>Phenotypically distinct HRG positive cancer cells impact standard of care therapies in metastatic breast cancer models</td>
<td>Akos Czibere</td>
<td>Akos Czibere has disclosed that he is an employee of Merrimack Pharmaceuticals and holder of stock options.</td>
</tr>
<tr>
<td>P6-09-44</td>
<td>Tumor infiltrating lymphocytes (TILs) is associated with improved overall survival in triple-negative breast cancer (TNBC) patients treated with neoadjuvant chemotherapy (NAC)</td>
<td>Alexandre André da Costa</td>
<td>Dr. da Costa has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-14-01</td>
<td>International validation of the EORTC patient-reported outcome measure (PROM) in breast reconstruction (BR): The EORTC QLG-BRECON23 evaluating the psychometric properties and clinical effectiveness</td>
<td>René da Costa Vieira</td>
<td>Dr. da Costa Vieira has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-07-08</td>
<td>Mixed ductal-lobular carcinomas of the breast: Abrogated cell adhesion in the clonal evolution from ductal to lobular morphology</td>
<td>Leonardi da Silva</td>
<td>Dr. da Silva has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
An update on trends in nipple-sparing mastectomy incision locations: A systematic review of the literature with pooled meta-analysis
David Daar
Dr. Daar has no relevant financial relationships to disclose.

Differential turnover of estrogen receptor alpha in invasive lobular carcinoma
David Daar
Dr. Daar has no relevant financial relationships to disclose.

Prognostic significance of a modified residual disease in breast and nodes (mRDBN) algorithm after neoadjuvant therapy for breast cancer
David Daar
Dr. Daar has no relevant financial relationships to disclose.

How population-based data complement trial data in the adjuvant-endocrine treatment of Erb+Her2+ breast cancers
Gwen Dackus
Ms. Dackus has disclosed that she is an employee of Optum and has ownership in UnitedHealth Group. She also disclosed that Optum received funding from Abbvie to participate in this research.

Differential turnover of estrogen receptor alpha in invasive lobular carcinoma
David Dabbs
Dr. Dabbs has no relevant financial relationships to disclose.

Prognostic significance of a modified residual disease in breast and nodes (mRDBN) algorithm after neoadjuvant therapy for breast cancer
David Dabbs
Dr. Dabbs has no relevant financial relationships to disclose.

Identification of preclinical mechanisms driving acquired resistance to selective ERa degraders (SERDs), CDK4/6 inhibitors, or to combinations of both agents
Anneleen Daemen
Ms. Daemen has disclosed that she is an employee of Genentech, A Member of the Roche Group.

Tartrate-resistant acid phosphatase (TRACP) modulates breast cancer pre-metastatic niche
Ming-Shen Dai
Ms. Dai has disclosed that she receives research funding from Healthways.

Her2 is not a cancer subtype but rather a driver found in all intrinsic subtypes and highly enriched in molecular apocrine tumors
Anneleen Daemen
Ms. Daemen has disclosed that she is an employee of Genentech, Inc. and holds shares of Roche.

Identification of practical mechanisms driving acquired resistance to selective ERa degraders (SERDs), CDK4/6 inhibitors, or to combinations of both agents
Anneleen Daemen
Ms. Daemen has disclosed that she is an employee of Genentech, A Member of the Roche Group.

The importance of loco-regional tumor burden and surgery on survival in patients with de novo stage IV breast cancer: post-hoc analyses of protocol MF07-01
Temel Dagoglu
Dr. Dagoglu has no relevant financial relationships to disclose.

The importance of loco-regional tumor burden and surgery on survival in patients with de novo stage IV breast cancer: post-hoc analyses of protocol MF07-01
Temel Dagoglu
Dr. Dagoglu has no relevant financial relationships to disclose.

Trends in positive predictive values following transition from screen film to digital mammography
Parker Dahl
Parker Dahl has no relevant financial relationships to disclose.

Phase 1/2 study of oral neratinib (VT-464), a dual CYP17 lyase inhibitor and androgen receptor (AR) antagonist, in patients with advanced AR positive triple negative (TNBC) or estrogen receptor (ER) positive breast cancer (BC)
Nasir DaCosta
Ms. DaCosta Byfield has disclosed that she is an employee of Optum and has ownership in UnitedHealth Group. She also disclosed that Optum received funding from Abbvie to participate in this research.

Identification of practical mechanisms driving acquired resistance to selective ERa degraders (SERDs), CDK4/6 inhibitors, or to combinations of both agents
Anneleen Daemen
Ms. Daemen has disclosed that she is an employee of Genentech, A Member of the Roche Group.

Trends in positive predictive values following transition from screen film to digital mammography
Parker Dahl
Parker Dahl has no relevant financial relationships to disclose.

Prognostic significance of a modified residual disease in breast and nodes (mRDBN) algorithm after neoadjuvant therapy for breast cancer
David Dabbs
Dr. Dabbs has no relevant financial relationships to disclose.

Risk of metastases after ipsilateral breast tumour recurrence changes overtime according to patient and tumour characteristics: Implications for treatment
Maria Grazia Daidone
Dr. Daidone has no relevant financial relationships to disclose.

The importance of loco-regional tumor burden and surgery on survival in patients with de novo stage IV breast cancer: post-hoc analyses of protocol MF07-01
Temel Dagoglu
Dr. Dagoglu has no relevant financial relationships to disclose.

The importance of loco-regional tumor burden and surgery on survival in patients with de novo stage IV breast cancer: post-hoc analyses of protocol MF07-01
Temel Dagoglu
Dr. Dagoglu has no relevant financial relationships to disclose.

Treatment of ER2 mutant and PIK3CA mutant patient-derived breast cancer xenograft models reveals differential anti-tumor responses to estrogen receptor degraders and PI3K inhibitors in vivo
Anneleen Daemen
Ms. Daemen has disclosed that she is an employee of Genentech, A Member of the Roche Group.

Prognostic significance of a modified residual disease in breast and nodes (mRDBN) algorithm after neoadjuvant therapy for breast cancer
David Dabbs
Dr. Dabbs has no relevant financial relationships to disclose.

Plasma microRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from Neo-ALTTO
Maria Grazia Daidone
Dr. Daidone has no relevant financial relationships to disclose.

BRE12-158: A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer (TNBC)
Karen Daily
Dr. Daily has no relevant financial relationships to disclose.

A randomized, double-blinded, placebo-controlled clinical trial to evaluate extended adjuvant endocrine therapy (5 years of letrozole) in postmenopausal women with hormone receptor-positive breast cancer who have completed previous adjuvant endocrine therapy: Initial results of NSG oncology/NSAMP B-42
Shaker Dakil
Ms. Dakil has disclosed that she receives research funding from Healthways.

Relationship between overall survival and surrogate measures in patients with metastatic breast cancer treated with chemotherapy
David Dale
Dr. Dale has no relevant financial relationships to disclose.
Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy
Chau Dang
Dr. Dang has no relevant financial relationships to disclose.

Cardiac safety of dual anti-HER2 therapy in the neoadjuvant setting for treatment of HER2-positive breast cancer
Chau Dang
Dr. Dang has disclosed that he has contracts with Genentech and GlaxoSmithKline.

Primary analysis of BERENICE: A phase II cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with locally advanced, inflammatory, or early-stage, unilateral, and invasive HER2-positive breast cancer
Chau Dang
Dr. Dang has disclosed that he has performed consulting work for Roche/Genentech but no honorarium was accepted. He has also disclosed that he receives research funding with Roche/Genentech.

Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase II trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer
Chau Dang
Dr. Dang has disclosed that he has contracts with Roche/Genentech and GlaxoSmithKline.

A phase II open-label study of everolimus in combination with endocrine therapy in resistant hormone receptor-positive HER2-negative advanced breast cancer
Brooke Daniel
Dr. Daniel has no relevant financial relationships to disclose.

A randomized trial of 15 fraction vs 25 fraction pencil beam scanning proton radiotherapy after mastectomy in patients requiring regional nodal irradiation
Visscher Daniel
Dr. Daniel has no relevant financial relationships to disclose.

Clinical outcomes of estrogen-receptor negative breast carcinoma are associated with protein hormone-cognate receptor gene expression
Michael Daniels
Ms. Daniels has no relevant financial relationships to disclose.

Cancer-associated fibroblasts release exosomal microRNAs that dictate an aggressive phenotype in breast cancer
Fiore Danilo
Dr. Danilo has no relevant financial relationships to disclose.

Metabolic obesity, adipose inflammation and aromatase: Potential drivers of breast cancer risk in women with normal body mass index
Andrew Dannenberg
Mr. Dannenberg has no relevant financial relationships to disclose.

Molecular evaluation of Peruvian patients with hereditary breast cancer reveals a novel germline mutation in BRCA1
Pierina Danos
Ms. Danos has no relevant financial relationships to disclose.

BRE12-158: A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer (TNBC)
Pierne Danes
Ms. Danes has no relevant financial relationships to disclose.

Phase 1/2 study of oral seviteronel (VT-464), a dual CYP17-lyase inhibitor and androgen receptor (AR) antagonist, in patients with advanced AR positive triple negative (TNBC) or estrogen receptor (ER) positive breast cancer (BC)
Michael Danso
Dr. Danso has no relevant financial relationships to disclose.

PD-L1 expression in triple negative breast cancer (TNBC) is associated with improved outcomes
Yahya Daoud
Dr. Daoud has no relevant financial relationships to disclose.

A clinical model for assessment of the individual breast cancer risk
Hatef Darabi
Dr. Darabi has no relevant financial relationships to disclose.

Evaluation of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarker in different subtypes of breast cancer treated with neoadjuvant therapy - A metaanalysis of 1771 patients
Silvia Darb-Esfahani
Ms. Darb-Esfahani has no relevant financial relationships to disclose.

Circulating tumor cell number and CTC-endothelium therapy index predict clinical outcomes in ER positive metastatic breast cancer patients: Results of the COMETI Phase 2 trial
Elisabeth Darga
Ms. Darga has no relevant financial relationships to disclose.

Patient derived DCS mouse-implantable (MINO) models recapitulate the full spectrum of human patient pathology and histologic features including progression to invasion in a subset of cases
Joy Darragh
Dr. Darragh has no relevant financial relationships to disclose.
Development and validation of a new non-parametric breast cancer risk assessment model on US and European screening populations
Laureen Dartois
Dr. Dartois has no relevant financial relationships to disclose.

ST8SIA1 regulates tumorigenesis in triple negative breast cancer
Abhishek Dasgupta
Abhishek Dasgupta has no relevant financial relationships to disclose.

Novel regulation of breast cancer cell aggressiveness by cancer testis antigen
Santanu Dasgupta
Dr. Dasgupta has no relevant financial relationships to disclose.

Increased glycolysis directly activates transcriptional coactivator SRC-3 to promote aggressive metastatic breast cancer
Subhamoy Dasgupta
Dr. Dash has no relevant financial relationships to disclose.

Network integration of epigenomic data: Leveraging the concept of master regulators in ER negative breast cancer
Indrani Datta
Indrani Datta has no relevant financial relationships to disclose.

Physico-biochemical regulation of EMT by microtubule associated protein 7 (MAP7)
Bhuvanesh Dave
Dr. Dave has no relevant financial relationships to disclose.

Prognostic significance of a modified residual disease in breast and nodes (mRDBN) algorithm after neoadjuvant therapy for breast cancer
Nancy Davidson
Dr. Davidson has no relevant financial relationships to disclose.

The REQUITE-AB study: Validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality of life in breast cancer patients
Susan Davidson
Ms. Davidson has no relevant financial relationships to disclose.

Photodynamic therapy for the treatment of primary breast cancer: Preliminary results of a phase IIa clinical trial
Timothy Davidson
Dr. Davidson has no relevant financial relationships to disclose.
P2-03
Recurrent functionally diverse in-frame ESR1 gene fusions drive endocrine resistance in breast cancer

Sherri Davies
Ms. Davies has no relevant financial relationships to disclose.

P3-03-02
Inhibition of NOS promotes ER stress response and augments estrogen-mediated apoptosis in TNBC

Daniel Davila-Gonzalez
Mr. Davila-Gonzalez has no relevant financial relationships to disclose.

P5-14-02
An anti-POD antibody-based Therapy results in dramatic reduction of TNBC PD2 tumors in humanized mice models

Daniel Davila-Gonzalez
Mr. Davila-Gonzalez has no relevant financial relationships to disclose.

P5-08-18
Treatment patterns and resource utilization among patients with HR+/HER2- metastatic breast cancer in a privately insured US population

Keith Davis
Mr. Davis has disclosed that RTI Health Solutions received funding from Eli Lilly and Company to conduct this research.

P5-08-19
Treatment patterns and resource utilization among elderly Medicare patients with HR+/HER2- metastatic breast cancer

Keith Davis
Mr. Davis has disclosed that RTI Health Solutions received funding from Eli Lilly and Company to conduct this research.

P1-10-20
A multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer: Early results of unplanned boost participants

M Davis
Mr. Davis has no relevant financial relationships to disclose.

P4-21-23
At retrospective evaluation of cardiovascular recovery and oncologic outcomes associated with interrupted and continuous adjuvant trastuzumab in the setting of mild left ventricular dysfunction

Margot Davis
Dr. Davis has no relevant financial relationships to disclose.

P1-10-19
Two-year follow-up results of a multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer

Marshall Davis
Dr. Davis has no relevant financial relationships to disclose.

P6-01-11
Distinct recruitment of tumor-associated immune cells correlates with increased pro-malignant chemokines in tumors expressing epithelial atypical chemokine receptor 1 (ACKR1/DARC), indicating a unique tumor microenvironment

Melissa Davis
Dr. Davis has no relevant financial relationships to disclose.

P2-03-05
High concordance of ER, PR, HER2 and Ki67 by central IHC and FISH with mRNA measurements by GeneXpert® breast cancer stratifier assay

Simon Davonport
Mr. Davonport has disclosed that he has a contract with Cepheid.

P6-06-01
High-grade human cytomegalovirus IEA is associated with expression of COX-2 and 5-LD in human breast cancer samples

Belgis Davoudi
Belghis Davoudi has no relevant financial relationships to disclose.

P6-06-02
Low expression levels of hormone receptors (ER-α and PGR) in human breast cancer samples is significantly associated with high-grade human cytomegalovirus-IEA

Belghis Davoudi
Belghis Davoudi has no relevant financial relationships to disclose.

P5-16-22
Survival after adjuvant and neoadjuvant chemotherapy in elderly patients with triple negative breast cancer: A Cleveland Clinic experience

Hamed Daw
Dr. Daw has no relevant financial relationships to disclose.

P4-21-18
Pre-clinical antitumor activity, tumor localization, and pharmacokinetics of MP0274, an apoptosis inducing, biparatopic HER2-targeting DARPin®

Keith Dawson
Dr. Dawson has disclosed that he receives salary and has ownership.

P2-03-04
Application of digital-FCR technologies to determine c-MET copy number variation in paired primary breast cancer and brain metastases

Timothy Dawson
Mr. Dawson has no relevant financial relationships to disclose.

P3-06
A phase II trial evaluating pCR in patients with HR-, HER2- positive breast cancer treated with neoadjuvant (docetaxel), carboplatin, trastuzumab, and pertuzumab (TCHP +/- -estrogen deprivation: MRI oncology/NSABP B-52

Connelly Dayani
Dr. Dayani has no relevant financial relationships to disclose.

071-01-05
PANTHER: Evaluation of estrus lability and correlation between a set of polymorphisms and reactivity in patients with metastatic breast cancer

Maria Dazzani
Ms. Dazzani has no relevant financial relationships to disclose.

P4-07-06
MicroRNAs associated with acquired tamoxifen resistance in a breast cancer cell line model

Akiter O’Costa
Mr. O’Costa has no relevant financial relationships to disclose.

P3-04-10
Utility of the orally bioavailable selective estrogen receptor degrader AZD9496 in ESR1 mutant preclinical models of estrogen receptor-positive breast cancer

Calina O’Cruz
Ms. O’Cruz has disclosed that she receives salary and has ownership.

P1-05-22
The value of BSK-5 for the detection of clinically actionable targets in breast cancer - A small cohort analysis

Pradip Dix
Dr. Dix has no relevant financial relationships to disclose.
Effectiveness of myofascial techniques in addition to a standard physical therapy program as postoperative intervention for upper limb pain in breast cancer patients: A randomized controlled trial.

Long survival of patients with locally advanced breast cancer on combined neoadjuvant chemotherapy and immune potentiation: Modern lessons from an old study.

The role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+/HR+ phase II trial evaluating 12-weeks of neoadjuvant TDM1 ± endocrine therapy (ET) versus T + ET in HER2-positive hormone-receptor-positive early breast cancer (EBC).

Biomarker analysis from the neoadjuvant KRISTINE study in HER2-positive early breast cancer (EBC).

Safety and efficacy results from phase I study of BNT 710 plus nab-paclitaxel in HER 2 negative metastatic breast cancer.

Clinical value of 18F-trastuzumab PET in HER2-positive breast cancer patients with a clinical dilemma.

Phase II in-human dose escalation study of the optical molecular imaging tracer bevacizumab-800cw for molecular fluorescence guided surgery in primary breast cancer patients.

ESR1 mutations in circulating tumor cell versus circulating cell-free DNA of metastatic breast cancer patients before first line endocrine therapy and at progression.

Residual cancer burden (RCB) as a strong prognosis factor in breast cancer (BC) patients treated with neoadjuvant chemotherapy (NACT) based on carboplatin, doxorubicin and taxanes.

Phase III study of nab-paclitaxel + carboplatin or gemcitabine vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the tnAcity trial.

Novel cytotoxic RNA aptamers that distinguish between metastasis-prone and indolent breast and prostate cancers.


Primary analysis of FERTAV: A randomised, two-arm, open-label, multicenter phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first-line patients with HER2-positive and hormone receptor-negative metastatic or locally advanced breast cancer.

Proliferation and p21 refine risk of relapse in residual disease after HER2-directed therapies.

Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer.
PS-15-09  Evaluation of growth modulation index as a marker of benefit for consecutive lines of treatment for metastatic breast cancer
  Pilar de la Morena Barrio  
  Dr. de la Morena Barrio has no relevant financial relationships to disclose.

P3-02  Plasma miRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from SOLTI-ALTTO
  Lorena de la Peña  
  Dr. de la Peña has no relevant financial relationships to disclose.

P1-09-09  Neoadjuvant non-negated liposomal doxorubicin plus paclitaxel, trastuzumab and pertuzumab in patients with HER2-negative breast cancer: Final results of the SOLTI-OPTI-HER HEART study
  Lorena de la Peña  
  Dr. de la Peña has no relevant financial relationships to disclose.

P4-21-05  Neoadjuvant non-negated liposomal doxorubicin plus paclitaxel, trastuzumab and pertuzumab in patients with HER2-negative breast cancer: Final results of the SOLTI-OPTI-HER HEART study
  Lorena de la Peña  
  Dr. de la Peña has no relevant financial relationships to disclose.

S3-02  Plasma microRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from SOLTI-ALTTO
  Lorena de la Peña  
  Dr. de la Peña has no relevant financial relationships to disclose.

PS-14-09  Efficacy and gene expression results from SOLTI-ALTTO
  Lorena de la Peña  
  Dr. de la Peña has no relevant financial relationships to disclose.

P4-21-11  Efficacy and gene expression results from SOLTI-ALTTO
  Lorena de la Peña  
  Dr. de la Peña has no relevant financial relationships to disclose.

P1-09-12  Neoadjuvant non-negated liposomal doxorubicin plus paclitaxel, trastuzumab and pertuzumab in patients with HER2-negative breast cancer: Final results of the SOLTI-OPTI-HER HEART study
  Lorena de la Peña  
  Dr. de la Peña has no relevant financial relationships to disclose.

P4-21-11  Neoadjuvant non-negated liposomal doxorubicin plus paclitaxel, trastuzumab and pertuzumab in patients with HER2-negative breast cancer: Final results of the SOLTI-OPTI-HER HEART study
  Lorena de la Peña  
  Dr. de la Peña has no relevant financial relationships to disclose.

S3-02  Neoadjuvant non-negated liposomal doxorubicin plus paclitaxel, trastuzumab and pertuzumab in patients with HER2-negative breast cancer: Final results of the SOLTI-OPTI-HER HEART study
  Lorena de la Peña  
  Dr. de la Peña has no relevant financial relationships to disclose.

P2-14-03  Neoadjuvant non-negated liposomal doxorubicin plus paclitaxel, trastuzumab and pertuzumab in patients with HER2-negative breast cancer: Final results of the SOLTI-OPTI-HER HEART study
  Lorena de la Peña  
  Dr. de la Peña has no relevant financial relationships to disclose.

P1-09-12  Dose dense adjuvant chemotherapy in patients with early breast cancer: Differential treatment effects according to composite index of benefit
  Michelle De Laurentiis  
  Ms. De Laurentiis has no relevant financial relationships to disclose.

OT2-01-05  SANDPIPER: Phase III study of the PS-13 kinase inhibitor taselisib (GDC-0383) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA-mutant tumors
  Michelle De Laurentiis  
  Mr. De Laurentiis has disclosed that he is a consultant for Roche, Novartis, Celgene, Pfizer and Eisai. He also disclosed that he has contracts with Roche, Novartis, Celgene and Pfizer.

P4-21-11  SANDPIPER: Phase III study of the PS-13 kinase inhibitor taselisib (GDC-0383) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA-mutant tumors
  Michelle De Laurentiis  
  Mr. De Laurentiis has disclosed that he is a consultant for Roche, Novartis, Celgene, Pfizer and Eisai. He also disclosed that he has contracts with Roche, Novartis, Celgene and Pfizer.

P5-14-09  SANDPIPER: Phase III study of the PS-13 kinase inhibitor taselisib (GDC-0383) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA-mutant tumors
  Michelle De Laurentiis  
  Mr. De Laurentiis has disclosed that he is a consultant for Roche, Novartis, Celgene, Pfizer and Eisai. He also disclosed that he has contracts with Roche, Novartis, Celgene and Pfizer.

P5-15-07  SANDPIPER: Phase III study of the PS-13 kinase inhibitor taselisib (GDC-0383) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA-mutant tumors
  Michelle De Laurentiis  
  Mr. De Laurentiis has disclosed that he is a consultant for Roche, Novartis, Celgene, Pfizer and Eisai. He also disclosed that he has contracts with Roche, Novartis, Celgene and Pfizer.

P6-17-02  Evaluation of the impact of Oncotype DX test results on systemic therapy in breast cancer patients at the BC Cancer Agency (BCCA)
  Mario de Lemos  
  Mr. de Lemos has no relevant financial relationships to disclose.

P6-09-44  Tumor infiltrating lymphocytes (TILs) is associated with improved overall survival in triple-negative breast cancer (TNBC) patients treated with neoadjuvant chemotherapy (NAC)
  Vladimir de Lima  
  Dr. de Lima has no relevant financial relationships to disclose.

OT1-04-02  NRG oncology/RTOG 1119: Phase II randomized study of whole brain radiotherapy with concurrent lapatinib in patients with brain met from HER2-positive breast cancer — A collaborative study of RTOG & KROG (NCT01622868)
  Jennifer De Los Santos  
  Dr. De Los Santos has no relevant financial relationships to disclose.

P1-10-04  Accelerated partial breast irradiation versus whole breast irradiation: Health-related quality of life analysis from a phase 3 trial
  Carla De Luca Cardillo  
  Dr. De Luca Cardillo has no relevant financial relationships to disclose.

P2-09-32  High-throughput pharmacogenomic platform to functionally profile breast cancer vulnerabilities in the context of the 3-dimensional tumor microenvironment
  Ricardo De Matos Simoes  
  Dr. De Matos Simoes has no relevant financial relationships to disclose.
Phase II of POSEIDON: A phase Ib randomized phase II trial of tamoxifen plus taselisib or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment

Aurelia de Vries Schultink
Ms. de Vries Schultink has no relevant financial relationships to disclose.

BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer
Alexandre de Wind
Dr. de Wind has no relevant financial relationships to disclose.

The incidence and outcomes of brain metastases in HER2-positive metastatic breast cancer with the advent of modern anti-HER2 therapies
Alixson Deal
Ms. Deal has no relevant financial relationships to disclose.

Highly pre-treated breast cancer patients show promising responses in the first in human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640 in combination with paclitaxel
Emma Dean
Ms. Dean has no relevant financial relationships to disclose.

SYD985, a novel anti-HER2 ADC, shows promising activity in patients with HER2-positive and HER2-negative metastatic breast cancer
Emma Dean
Ms. Dean has disclosed that she is a principal investigator in the trial.

An international multicenter study to evaluate reproducibility of automated scoring methods for assessment of Ki67 in breast cancer
Michelle Deen
Ms. Deen has no relevant financial relationships to disclose.

Refining the prognostic value of Ki67 biomarker by ataxia telangiectasia mutated (ATM) status in a retrospective study of early stage hormone receptor positive breast cancer
Michelle Deen
Ms. Deen has no relevant financial relationships to disclose.

Stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer
Marc Debels
Dr. Debels has no relevant financial relationships to disclose.

Time-evolution of the efficacy of first line aromatase inhibitors (AI) in hormone receptor positive (HR+) advanced breast cancer (ABC): A moving target
Marcio Debiasi
Dr. Debiasi has no relevant financial relationships to disclose.

Estrogen receptor-positive breast cancer in BRCA2 mutation carriers shows a BRCAlike profile, suggesting sensitivity to drugs targeting homologous recombination deficiency
Trashem Debipersad
Trashem Debipersad has no relevant financial relationships to disclose.

Rapid germline BRCA screening for locally advanced breast cancer changes surgical procedure after neoadjuvant chemotherapy
Marc Debled
Dr. Debled has no relevant financial relationships to disclose.

Predictive value of quantitative HER2 and HER3 levels combined with downstream signaling markers in HER2-positive advanced breast cancer patients treated with lapatinib
Syelina Debok-Serich
Syelina Debok-Serich has no relevant financial relationships to disclose.

Phase II study of neoadjuvant pertuzumab combined with chemotherapy and paclitaxel for triple-negative breast cancer (TNBC)
Tripathy Deb
Tripathy Deb has no relevant financial relationships to disclose.

A phase 2 open label study of everolimus in combination with endocrine therapy in resistant hormone receptor-positive HER2-negative advanced breast cancer
Laura DeBuick
Dr. DeBuick has no relevant financial relationships to disclose.

Ovarian reserve and response to controlled ovarian hyperstimulation (COH) in breast cancer women with and without BRCA mutation
Christine Decanter
Ms. Decanter has no relevant financial relationships to disclose.
Does BRCA status affect outcome in young breast cancer patients? Results from the prospective study of outcomes in sporadic and hereditary breast cancer (POSH)
Brennan Decker
Mr. Decker has no relevant financial relationships to disclose.

BELLE-3: A phase III study of letrozole + fulvestrant in postmenopausal women with HER2, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment
Thomas Decker
Mr. Decker has disclosed that he receives advisory board consulting fees.

Breastcancer weekly chemoprevention and palliative follow-up by docetaxel and cyclophosphamide in triple negative breast cancer patients. A single arm phase II study from the Belgian Society of Medical Oncology
Sone Decoster
Dr. Decoster has no relevant financial relationships to disclose.

KINETIC-012: Long-lasting responses in a phase II study of pembrolizumab for metastatic triple-negative breast cancer (mTNBC)
Claire Dees
Dr. Dees has disclosed that she has contracts with Merck, Pfizer, Bayer, Lilly, Cerulean and Novartis.

The incidence and outcomes of brain metastases in HER2-positive metastatic breast cancer with the advent of modern anti-HER2 therapies
S Dees
Dr. Dees has no relevant financial relationships to disclose.

Comprising the frequency and types of genetic alterations between older and younger women with metastatic breast cancer at the University of North Carolina at Chapel Hill
Elizabeth Dees
Dr. Dees has no relevant financial relationships to disclose.

Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy
Patricia Defusco
Dr. Defusco has no relevant financial relationships to disclose.

Challenges faced across borders to open European academic multicentre projects: The ET-FES program part of the ERA-Net TRANSCAN-JTC 2011
Tom Degenhardt
Dr. Degenhardt has no relevant financial relationships to disclose.

Randomized study of COX2 inhibition on systemic inflammation in obese and non-obese subjects
Linda deGraffenried
Dr. deGraffenried has no relevant financial relationships to disclose.

Modulation of FASN under obese conditions
Linda deGraffenried
Dr. deGraffenried has no relevant financial relationships to disclose.

The importance of the ultimate ratio of Omega-6 to Omega-3 fatty acids in the efficacy of fish oil supplements in suppressing inflammation in obese postmenopausal women
Linda deGraffenried
Dr. deGraffenried has no relevant financial relationships to disclose.

Endoscopic 3D latissimus dorsi muscle harvesting for immediate breast reconstruction. Results of our 7 patients experience in Antoine Lacassagne Nice Cancer Center
Magda Dejode
Magda Dejode has no relevant financial relationships to disclose.

Evaluation of women with BRCA mutations and breast cancer tested at an NCI designated comprehensive cancer center: A cost of illness estimation
Rishi Deka
Rishi Deka has no relevant financial relationships to disclose.

Use of an absorbable implant to mark the lumpectomy cavity: Initial report of 300 patients in a multi-center registry database
Nayana Dekhne
Nayana Dekhne has no relevant financial relationships to disclose.

Dose dense adjuvant chemotherapy in patients with early breast cancer: Differential treatment effects according to composite index of benefit
Lucia Del Mastro
Prof. Del Mastro has no relevant financial relationships to disclose.
Non-adjuvant treatment with trastuzumab and pertuzumab associated with palbociclib and fulvestrant in HER2-positive and ER-positive breast cancer: Effect on Ki67 during and after treatment. A phase II Michelangelo study

Lucia Del Mastro

Dr. Del Mastro has no relevant financial relationships to disclose.

Luminal A breast cancer: Is it really a “good prognosis” disease? Preliminary results of the GIM-13 - AMBRA study

Lucia Del Mastro

Prof. Del Mastro has no relevant financial relationships to disclose.

First and further line choices of treatment for HER2-VE metastatic breast cancer (MBC) according to adjuvant treatment and biological subtype. Preliminary results of the observational “GIM-13 - AMBRA” Italian study

Lucia Del Mastro

Prof. Del Mastro has no relevant financial relationships to disclose.

Implications of financial modeling in breast cancer clinical research from 1990 to 2010

Maria Del Monte-Millan

Ms. Del Monte-Millan has no relevant financial relationships to disclose.

Luminal A breast cancer: Is it really a “good prognosis” disease? Preliminary results of the GIM-13 - AMBRA study

Lucia Del Mastro

Prof. Del Mastro has no relevant financial relationships to disclose.

First and further line choices of treatment for HER2-VE metastatic breast cancer (MBC) according to adjuvant treatment and biological subtype. Preliminary results of the observational “GIM-13 - AMBRA” Italian study

Lucia Del Mastro

Prof. Del Mastro has no relevant financial relationships to disclose.

Implications of financial modeling in breast cancer clinical research from 1990 to 2010

Maria Del Monte-Millan

Ms. Del Monte-Millan has no relevant financial relationships to disclose.

Luminal A breast cancer: Is it really a “good prognosis” disease? Preliminary results of the GIM-13 - AMBRA study

Lucia Del Mastro

Prof. Del Mastro has no relevant financial relationships to disclose.

First and further line choices of treatment for HER2-VE metastatic breast cancer (MBC) according to adjuvant treatment and biological subtype. Preliminary results of the observational “GIM-13 - AMBRA” Italian study

Lucia Del Mastro

Prof. Del Mastro has no relevant financial relationships to disclose.

Implications of financial modeling in breast cancer clinical research from 1990 to 2010

Maria Del Monte-Millan

Ms. Del Monte-Millan has no relevant financial relationships to disclose.

Luminal A breast cancer: Is it really a “good prognosis” disease? Preliminary results of the GIM-13 - AMBRA study

Lucia Del Mastro

Prof. Del Mastro has no relevant financial relationships to disclose.

First and further line choices of treatment for HER2-VE metastatic breast cancer (MBC) according to adjuvant treatment and biological subtype. Preliminary results of the observational “GIM-13 - AMBRA” Italian study

Lucia Del Mastro

Prof. Del Mastro has no relevant financial relationships to disclose.

Implications of financial modeling in breast cancer clinical research from 1990 to 2010

Maria Del Monte-Millan

Ms. Del Monte-Millan has no relevant financial relationships to disclose.
P6-07-21
High reduction of circulating tumour cells in HER2-negative locally advanced or metastatic breast cancer (LAMBC) patients treated with eribulin as third line chemotherapy (ONSITE study)
Ignacio Delgado Mingorance
Mr. Delgado Mingorance has no relevant financial relationships to disclose.

P6-15-02
Phenotypically distinct HRG positive cancer cells impact standard of care therapies in metastatic breast cancer models
Sethan Demars
Ms. Demars has disclosed that he is an employee of Merrimack Pharmaceuticals and holder of stock options.

P6-07-22
Can surrogate pathological subtyping replace molecular subtyping? Outcome results from the MINDACT trial
Patrizia Dell'Orto
Ms. Dell'Orto has no relevant financial relationships to disclose.

P3-04-19
Inhibition of ER-positive breast cancer progression with duavee, a new form of hormone replacement therapy
Anna Dembío
Ms. Dembío has no relevant financial relationships to disclose.

P6-11-02
Efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial
Angela DeMichele
Dr. DeMichele has disclosed that she received fees for serving on advisory boards and travel support from Pfizer and Novartis and grant support from Pfizer, Novartis, Genentech, Incyte, Calithera, and Roche.

P4-08-03
Inhibition of ER-positive breast cancer progression with duavee, a new form of hormone replacement therapy
Anna Dembío
Ms. Dembío has no relevant financial relationships to disclose.

P3-05-19
Quantitative ERα measurements in TNBC from the I-SPY 2 trial correlate with HER2-EGFR co-activation and heterodimerization
Angela DeMichele
Dr. DeMichele has no relevant financial relationships to disclose.

P4-22-14
Single agent palbociclib with or without trastuzumab for the treatment of Rb+ advanced breast cancer
Angela DeMichele
Dr. DeMichele has disclosed that she has contracts with Novartis, Pfizer, Genentech, Incyte, Calithera and Janssen.

P3-12-06
Dying in clinical trials: A possible challenge for improving health care for breast cancer patients
Paola Demartini
Dr. Demartini has no relevant financial relationships to disclose.

P3-01-01
Comparative performance of surveillance mammography and breast MRI in women with a history of breast cancer
Wendy Demartini
Dr. Demartini has no relevant financial relationships to disclose.

P4-22-04
A randomized, double-blind, phase 2 study of ruxolitinib (RUX) or placebo (PBO) in combination with capecitabine (CAPE) in patients (pts) with advanced HER2-negative breast cancer (ABC) and elevated C-reactive protein (CRP), a marker of systemic inflammation
Angela DeMichele
Dr. DeMichele has no relevant financial relationships to disclose.

P5-11-18
Trajectory of patient (Pt) reported physical function (PF) during and after neoadjuvant chemotherapy in the I-SPY 2 trial
Angela DeMichele
Dr. DeMichele has disclosed that she receives fees for serving on advisory boards and travel support from Pfizer and Novartis. She has also disclosed that she receives grant support from Pfizer, Novartis, Genentech, Insys, Calithera, and Roche.

P1-01-01
Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ER positive metastatic breast cancer patients: Results of the COMETI Phase 2 trial
Angela DeMichele
Dr. DeMichele has disclosed that her institution received payment from Janssen to perform this research, but that she did not receive any personal remuneration.

P2-11-02
A longitudinal look at toxicity management within a platform trial: Lessons from the I-SPY 2 TRIAL
Angela DeMichele
Dr. DeMichele has no relevant financial relationships to disclose.

P3-02-05
Quantitative ERα measurements in TNBC from the I-SPY 2 trial correlate with HER2-EGFR co-activation and heterodimerization
Angela DeMichele
Dr. DeMichele has no relevant financial relationships to disclose.

P4-22-04
Targeting inflammatory pathways: A phase 2 trial of the JAK-inhibitor ruxolitinib in combination with exemestane for aromatase inhibitor-resistant, estrogen receptor-positive breast cancer
Angela DeMichele
Dr. DeMichele has disclosed that she is a consultant for Pfizer and Novartis and has contracts with Insys, Novartis, Pfizer, Genentech, Janssen and Calithera.

P4-22-04
A longitudinal look at toxicity management within a platform trial: Lessons from the I-SPY 2 TRIAL
Angela DeMichele
Dr. DeMichele has no relevant financial relationships to disclose.

P4-22-04
Targeting inflammatory pathways: A phase 2 trial of the JAK-inhibitor ruxolitinib in combination with exemestane for aromatase inhibitor-resistant, estrogen receptor-positive breast cancer
Angela DeMichele
Dr. DeMichele has disclosed that she is a consultant for Pfizer and Novartis and has contracts with Insys, Novartis, Pfizer, Genentech, Janssen and Calithera.

P4-22-04
Single agent palbociclib with or without trastuzumab for the treatment of Rb+ advanced breast cancer
Angela DeMichele
Dr. DeMichele has no relevant financial relationships to disclose.

P5-11-18
Trajectory of patient (Pt) reported physical function (PF) during and after neoadjuvant chemotherapy in the I-SPY 2 trial
Angela DeMichele
Dr. DeMichele has disclosed that she receives fees for serving on advisory boards and travel support from Pfizer and Novartis. She has also disclosed that she receives grant support from Pfizer, Novartis, Genentech, Insys, Calithera, and Roche.

P6-07-22
Efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial
Angela DeMichele
Dr. DeMichele has disclosed that she received fees for serving on advisory boards and travel support from Pfizer and Novartis and grant support from Pfizer, Novartis, Genentech, Insys, Calithera, and Roche.
Peripheral sensory neuropathy occurrence and resolution: Results from the neoadjuvant randomized GeparSepto study (GBG 69)
Carsten Denkert

Evaluation of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarker in different subtypes of breast cancer treated with neoadjuvant therapy: A metaanalysis of 1771 patients
Carsten Denkert

Committee Member/Speaker, Educational Session”Tumor-infiltrating lymphocytes (TILs) and genomic signatures of immune cells”
Carsten Denkert

Prospective evaluation of the predictive value of biomarkers with complete pathologic response using neoadjuvant chemotherapy plus trastuzumab + pertuzumab in Her2 (+) breast cancer patients with invasive tumors
Valeria Denninghoff

Efficacy of screening and treatment of breast cancer patients reporting high level of distress
Diane Denney

Prediction of relapse in patients with locally advanced breast cancer after neoadjuvant treatment
Susan Dent

Obesity, dyslipidemia, and diabetes as risk factors for trastuzumab-related cardiotoxicity in breast cancer patients
Susan Dent

Preserving fertility in young women undergoing chemotherapy for early breast cancer; the Maastroct experience
Wouter Dercksen

Preserving fertility in young women undergoing chemotherapy for early breast cancer; the Maastroct experience
Josien Derhaag

10-year follow-up and biomarker discovery for adjuvant endocrine therapy; results of the TEAM trial
Maaike Derks

Differential regulation of miRNA8 and miRNA148a influences metastatic potential: Comparison between locally invasive BT474 and metastatic MDA-MB-231 xenografts
Krisha Devai

Preserving fertility in young women undergoing chemotherapy for early breast cancer; the Maastroct experience
Wouter Dercksen

Preserving fertility in young women undergoing chemotherapy for early breast cancer; the Maastroct experience
Josien Derhaag

10-year follow-up and biomarker discovery for adjuvant endocrine therapy; results of the TEAM trial
Maaike Derks

Differential regulation of miRNA8 and miRNA148a influences metastatic potential: Comparison between locally invasive BT474 and metastatic MDA-MB-231 xenografts
Krisha Devai

Carsten Denkert has no relevant financial relationships to disclose.

Dr. Denkert disclosed receipt of intellectual property rights/patient holder patent on immune markers in breast EP14153692.0. He also disclosed that he receives consulting fees from Astrazeneca. He receives fees for non-time services, received directly from commercial interest from Celgene, Roche and Tesa. He disclosed he does contracted research for Sividon Diagnostics, Cologne. He also has ownership interest as he is the CEO and stock holder of Sividon Diagnostics, Cologne, Germany. These relationships do not impact his ability to present an unbiased presentation.

Valeria Denninghoff

Drs. Dent has disclosed that she received funds for advisory boards for Roche, AstraZeneca, Merck, Pfizer and Eisai.

Drs. Dent has disclosed that she is on Advisory boards for Pfizer, Amgen, Hoffman LaRoche and Eisai.

Drs. Dent has disclosed that she received research funds for Sividon Diagnostics, Cologne.

Dr. Derbel has no relevant financial relationships to disclose.

Dr. Dercksen has no relevant financial relationships to disclose.

Dr. Derhaag has no relevant financial relationships to disclose.

Dr. Derks has no relevant financial relationships to disclose.

Ms. Devai has no relevant financial relationships to disclose.
Identifying the remaining causes of hereditary breast cancer
Lisa Devereux
Ms. Devereux has no relevant financial relationships to disclose.

Anti-proliferative and anti-inflammatory estrogen receptor agents for treatment of endocrine-resistant breast cancer
Sarka Devi
Sarka Devi has no relevant financial relationships to disclose.

Measuring what is important to patients in clinical trials: Hearing the patient's voice
Peggy Devine
Ms. Devine has no relevant financial relationships to disclose.

Use of an absorbable implant to mark the lumpectomy cavity: Initial report of 300 patients in a multi-center registry database
Kiran Devisetty
Kiran Devisetty has no relevant financial relationships to disclose.

Effectiveness of myofascial techniques in addition to a standard physical therapy program as postoperative intervention for upper limb pain in breast cancer patients: A randomized controlled trial
Nale Devvoogdt
Nate Devvoogdt has no relevant financial relationships to disclose.

Determining the breast tumor margin through genomics of the cancer-stromal interaction
Shubhada Dhage
Dr. Dhage has no relevant financial relationships to disclose.

A combination of dual inhibition in Rb-E2F network by T-DM1 and GDC-0980 provides maximal antitumor efficacy in preclinical model of HER2+ breast cancer
Nandini Day
Dr. Day has no relevant financial relationships to disclose.

Cancer stem cells define 3D spheroid growth response to rational combinations of PI3K-isozyme specific inhibitors in TNBC model
Nandini Day
Dr. Day has no relevant financial relationships to disclose.

Histone acetyltransferase 1 interacts with estrogen receptor alpha (ERα) and affects the transcriptional activity of ERα in breast cancer cells
Ahmed Dhamad
Ahmed Dhamad has no relevant financial relationships to disclose.

BELLE-3: A phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2-, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment
Bharani Dharan
Bharani Dharan has disclosed that he is an employee of and has ownership in Novartis.

An ex vivo platform predicts anti-tumor outcome of metabolically targeted, algorithm-driven combination therapy in triple-negative breast cancer
Andrew Dhawan
Mr. Dhawan has no relevant financial relationships to disclose.

Histone acetyltransferase 1 interacts with estrogen receptor alpha (ERα) and affects the transcriptional activity of ERα in breast cancer cells
Ahmed Dhamad
Ahmed Dhamad has no relevant financial relationships to disclose.

Dynamics of cancer stem cell surface marker, CD44 and CD44v6 in the antiproliferative efficacy of PARP inhibitor in combination with PI3K pathway inhibitor in TNBC xenograft model
Nandini Day
Dr. Day has no relevant financial relationships to disclose.

Precisely efficacy of docetaxel in combination with PARP inhibitor plus standard cytotoxic agent in triple-negative breast cancer xenograft model
Nandini Day
Dr. Day has no relevant financial relationships to disclose.

Differential mutation pattern between neoadjuvant and metastatic settings in breast cancer patients
Nandini Day
Dr. Day has no relevant financial relationships to disclose.

A combination of dual inhibition in Rb-E2F network by T-DM1 and GDC-0980 provides maximal antitumor efficacy in preclinical model of HER2+ breast cancer
Nandini Day
Dr. Day has no relevant financial relationships to disclosure.

Histone acetyltransferase 1 interacts with estrogen receptor alpha (ERα) and affects the transcriptional activity of ERα in breast cancer cells
Ahmed Dhamad
Ahmed Dhamad has no relevant financial relationships to disclose.

Histone acetyltransferase 1 interacts with estrogen receptor alpha (ERα) and affects the transcriptional activity of ERα in breast cancer cells
Ahmed Dhamad
Ahmed Dhamad has no relevant financial relationships to disclose.
Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate (ADC) for the treatment of relapsed/refractory, metastatic triple-negative breast cancer (mTNBC): Updated results

Jennifer Diamond

Dr. Diamond has no relevant financial relationships to disclose.

Establishment and characterization of 5SY42C, an ESR1-mutant 8x+ breast cancer cell line and xenograft from a patient with acquired resistance to endocrine therapy

Armando Diaz

Mr. Diaz has no relevant financial relationships to disclose.

Quantitative proteomic analysis of FGFR by mass spectrometry may improve identification of FGFR amplified tumors sensitive to inhibitor therapy

Maria Díaz Delgado

Ms. Diaz Delgado has no relevant financial relationships to disclose.

Association between tumor genotype and development of brain metastases in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer

Dora Dias-Santagata

Dr. Dias-Santagata has no relevant financial relationships to disclose.

Li-Fraumeni syndrome in females with early onset breast cancer in a Mexican population

José Diaz-Chavez

Dr. Diaz-Chavez has no relevant financial relationships to disclose.

Establishment and characterization of ST941/C; an ESR1-mutant ER+ breast cancer cell line and xenograft from a patient with acquired resistance to endocrine therapy

Armando Diaz

Mr. Diaz has no relevant financial relationships to disclose.

Prospective evaluation of the predictive value of biomarkers with complete pathologic response using neoadjuvant chemotherapy plus trastuzumab + pertuzumab in Her2 (+) breast cancer patients with invasive tumors

Patrice Diaz-Cantón

Dr. Diaz-Cantón has disclosed that he is a consultant for Roche.

Quantitative proteomic analysis of FGFR by mass spectrometry may improve identification of FGFR amplified tumors sensitive to inhibitor therapy

Maria Díaz Delgado

Ms. Diaz Delgado has no relevant financial relationships to disclose.

Phase II/III single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of patients with HER2-positive metastatic breast cancer with progression in the CNS after trastuzumab (TRIO-US B-09)

Brian DiCarlo

Dr. DiCarlo has disclosed that he has contracts with Bristol Myers Squibb, Medivation/Biomarin, Pfizer, Gilead, Takeda, Genentech, Incyte, AstraZeneca, Novartis, Lilly and Clovis.

Phase II/III single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of patients with HER2-positive metastatic breast cancer with progression in the CNS after trastuzumab (TRIO-US B-09)

Robert Dicke

Dr. Dicke has no relevant financial relationships to disclose.

A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)

Maura Dickler

Dr. Dickler has disclosed that she is a consultant for Novartis, Pfizer, Roche/Genentech, Neovacs and AstraZeneca. She also disclosed that she receives institutional funding.

Breast carcinoma with 21-gene recurrence score lower than 18: Rate of distant metastases in a large series with clinical follow-up

Maura Dickler

Dr. Dickler has no relevant financial relationships to disclose.

Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy

Maura Dickler

Dr. Dickler has no relevant financial relationships to disclose.

Phase II study of taselisib (GDC-0032) plus fulvestrant in HR+/HER2- metastatic breast cancer: Analysis by PIK3CA and ESR1 mutation status from circulating tumor DNA

Maura Dickler

Dr. Dickler has disclosed that she is a consultant for Roche/Genentech, Pfizer, Novartis, AstraZeneca and Neovacs. She also disclosed that she receives consulting fees from Roche/Genentech, Pfizer, AstraZeneca, Novartis and Eli Lilly.

Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy

Maura Dickler

Dr. Dickler has no relevant financial relationships to disclose.

Phase II study of taselisib (GDC-0032) plus fulvestrant in HR+/HER2- metastatic breast cancer: Analysis by PIK3CA and ESR1 mutation status from circulating tumor DNA

Maura Dickler

Dr. Dickler has disclosed that she is a consultant for Roche/Genentech, Pfizer, Novartis, AstraZeneca and Neovacs. She also disclosed that she receives consulting fees from Roche/Genentech, Pfizer, AstraZeneca, Novartis and Eli Lilly. These relationships do not impact her ability to review presentations.

Committee Member

Maura Dickler

Dr. Dickler has disclosed that she receives consulting fees from Roche/Genentech, Pfizer, AstraZeneca, Novartis and Neovacs. She also disclosed that she does contracted research for Roche/Genentech, Pfizer, AstraZeneca, Novartis and Eli Lilly.
Feasibility of assessing radiation response with MRI/CT directed preoperative accelerated partial breast irradiation in the prone position for hormone sensitive early stage breast cancer
Dominic DiCostanzo
Dr. DiCostanzo has no relevant financial relationships to disclose.

Factors related to the prognosis of breast cancer patients after the development of brain metastases
Maria Vittoria Dieci
Dr. Dieci has no relevant financial relationships to disclose.

Prognostic significance of a modified residual disease in breast and nodes (mRDBN) algorithm after neoadjuvant therapy for breast cancer
Maria Vittoria Dieci
Dr. Dieci has no relevant financial relationships to disclose.

Prognostic significance of a modified residual disease in breast and nodes (mRDBN) algorithm after neoadjuvant therapy for breast cancer
Maria Vittoria Dieci
Dr. Dieci has no relevant financial relationships to disclose.

Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: A randomized, phase 2 study
Véronique Diéras
Ms. Diéras has disclosed that she is a consultant for Roche Genentech, Novartis, Pfizer and AbbVie.

Long-term safety of palbociclib in combination with endocrine therapy in treatment-naive and previously treated women with HR+, HER2- advanced breast cancer: A pooled analysis from randomised phase 2 and 3 studies
Véronique Diéras
Ms. Diéras has disclosed that she is a consultant for Roche, Novartis, AbbVie and Pfizer and is a speaker for Roche, Novartis and Pfizer.

Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: A randomized, phase 2 study
Véronique Diéras
Ms. Diéras has disclosed that she is a consultant for Roche Genentech, Novartis, Pfizer and AbbVie.

Clinical and pathological characteristics of a representative cohort of long-term metastatic breast cancer (MBC) survivors
Brenda Diergaarde
Dr. Diergaarde has no relevant financial relationships to disclose.

Methylation of BRCA1 and response to the PARP inhibitor veliparib
Brenda Diergaarde
Dr. Diergaarde has no relevant financial relationships to disclose.

A randomized trial evaluating biompedance spectroscopy vs. tape measurement in the prevention of lymphedema following breast cancer treatment
Mary Dietrich
Ms. Dietrich has no relevant financial relationships to disclose.

Preoperative prediction of axillary lymph node status based on artificial neural network algorithm model
Olof Dieguez
Dr. Dieguez has no relevant financial relationships to disclose.
Cobimetinib (C) combined with paclitaxel (P) as a first-line treatment in patients (pts) with advanced triple-negative breast cancer (COLET study): Updated clinical and biomarker results

Luc, Dirix
Dr. Dirix has no relevant financial relationships to disclose.

A phase I trial of the safety and immunogenicity of a DNA plasmid-based vaccine (WOKVAC) encoding epitopes derived from three breast cancer antigens (IGFBP2, HER2, and IGF1R) in patients with breast cancer

Mary, Dirix
Dr. Dirix has no relevant financial relationships to disclose.

OT3-01-05

Committee Member

A phase II trial of the safety and immunogenicity of a DNA plasmid-based vaccine (WOKVAC) encoding epitopes derived from three breast cancer antigens (IGFBP2, HER2, and IGF1R) in patients with breast cancer

Luc, Dirix
Dr. Dirix has no relevant financial relationships to disclose.

P5-08-05

Prospective family cohort analyses of gene-environment interactions in breast cancer: Body mass index

Gillian, Dite
Dr. Dite has no relevant financial relationships to disclose.

P2-05-23

EP3-receptor expression is a prognostic marker for overall survival and progression-free survival in sporadic breast cancer

Nina, Ditsch
Ms. Ditsch has no relevant financial relationships to disclose.

P5-08-06

Analytical and clinical validation of a fully automated tissue-based quantitative assay (MetaSite Breast™) to detect the likelihood of distant metastases in hormone receptor (HR) positive, HER2-negative early stage breast cancer (ESBC)

Michelle, Ditschelis
Ms. Ditschelis has disclosed that she receives salary.

P1-04-06

Prospective family cohort analyses of gene-environment interactions in breast cancer: Body mass index

Gillian, Dite
Dr. Dite has no relevant financial relationships to disclose.

P6-09-27

Network integration of epigenomic data: Leveraging the concept of master regulators in ER negative breast cancer

George, Divine
Dr. Divine has no relevant financial relationships to disclose.

P1-06-04

Molecular characterization, subtype concordance and prognostic group assignment between patient-matched primary breast tumours and axillary lymph node metastases

Michael, Dixon
Mr. Dixon has no relevant financial relationships to disclose.

P6-09-13

Intratumorthermochrometry cannot be used to detect PD-L1/IAK-2 amplification

Michael, Dixon
Mr. Dixon has no relevant financial relationships to disclose.

P3-13-18

Technical skill of surgical residents may affect margin status of breast conserving operations

Brane, Deric
Dr. Deric has no relevant financial relationships to disclose.

P6-07-26

ST8SIA1 is over-expressed in triple negative breast cancer and associated with p53 mutations

Kim-Anh, Do
Dr. Do has no relevant financial relationships to disclose.

P5-14-11

An estimation of the population survival benefit of first-line chemotherapy and immunotherapy for breast cancer

Viet, Do
Mr. Do has no relevant financial relationships to disclose.

P4-22-12

Ribociclib + fulvestrant in postmenopausal women with HR+, HER2- advanced breast cancer (ABC)

Jason, Dobson
Mr. Dobson has disclosed that he is an employee of Novartis.

P6-04-01

Engineering mesenchymal stem cells (MSCs) to secrete tumour-suppressing exosomes for breast cancer therapy

Peter, Dockery
Mr. Dockery has no relevant financial relationships to disclose.

P3-01-02

Trends in positive predictive values following transition from screen film to digital mammography

Bobbie Jo, Docktor
Dr. Docktor has no relevant financial relationships to disclose.
Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer
Susan Domchek
Dr. Domchek has disclosed that she is a consultant for EMD Serono and AbbVie and received research support (institution) from AbbVie, Clovis, AstraZeneca and Pharmamar.

Single-agent palbociclib with or without trastuzumab for the treatment of RebR advanced breast cancer
Susan Domchek
Dr. Domchek has disclosed that she is a consultant for AbbVie and received research funding through the University of Pennsylvania from AbbVie, Clovis, AstraZeneca and Pharmamar.

Spectrum of hereditary breast and ovarian cancer gene variants in an African American cohort
Susan Domchek
Dr. Domchek has no relevant financial relationships to disclose.

S2-04
Treatment of early HER2-positive breast cancer in trastuzumab era in everyday clinical practice: An overview after 10 years of its approval
Marta Domenech
Marta Domenech has no relevant financial relationships to disclose.

P1-12-08
Patterns of axillary evaluation in older patients (pts) with breast cancer and impact on adjuvant therapy
Laura Dominici
Dr. Dominici has no relevant financial relationships to disclose.

P1-14-09
Luminal A breast cancer: Is it really a "good prognosis" disease? Preliminary results of the GIM-13 - AMBRA study
Michela Donadio
Dr. Donadio has no relevant financial relationships to disclose.

P5-11-02
Impact of pre-operative exercise and mind-body interventions on patient-reported outcomes in women with newly diagnosed breast cancer
Laura Dominici
Dr. Dominici has no relevant financial relationships to disclose.

P5-15-07
First and further line choices of treatment for HER2+ metastatic breast cancer (MBC) according to adjuvant treatment and biological subtype. Preliminary results of the observational "GIM-13 - AMBRA" Italian study
Michela Donadio
Dr. Donadio has no relevant financial relationships to disclose.

P2-05-03
Exome sequencing of human breast cancer tissues resistant to taxanes
Yu Dong
Dr. Dong has no relevant financial relationships to disclose.

P1-02-30
Tumor microenvironment of metastasis (TME) score is associated with early distant recurrence in hormone receptor (HR)-positive, HER2-negative early stage breast cancer (ESBC)
Michael Donovan
Dr. Donovan has disclosed that he is a consultant for MetaStat, Inc.

P1-06-09
Estrogen Receptor (ER) immunoexpression of MAM205 antibody is a useful biomarker to predict chemotherapy response in HER2-positive breast cancer patients
Ting Dong
Ting Dong has no relevant financial relationships to disclose.

P3-05-02
Tumor microenvironment of metastasis (TME) score is associated with early distant recurrence in hormone receptor (HR)-positive, HER2-negative early stage breast cancer (ESBC)
Michael Donovan
Dr. Donovan has disclosed that he is a consultant for MetaStat, Inc.

P4-21-32
Use of an aptamer library based next generation omics platform for the development of a novel trastuzumab predictive assay
Valery Domenech
Valery Domenech has disclosed that he receives salary from and has ownership from Chris Life Sciences.

P2-03-07
Exome sequencing of human breast cancer tissues resistant to taxanes
Yu Dong
Dr. Dong has no relevant financial relationships to disclose.

P1-02-24
Evaluating lymph node ratio (LNR) as a prognostic indicator in node-positive breast cancer
Eoin Donnellan
Eoin Donnellan has no relevant financial relationships to disclose.

P2-05-06
Analytical and clinical validation of a fully automated tissue-based quantitative assay (Metasite Breast™) to detect the likelihood of distant metastasis in hormone receptor (HR)-positive, HER2-negative early stage breast cancer (ESBC)
Eoin Donnellan
Eoin Donnellan has no relevant financial relationships to disclose.

P2-05-06
Luminal A breast cancer: Is it really a "good prognosis" disease? Preliminary results of the GIM-13 - AMBRA study
Michela Donadio
Dr. Donadio has no relevant financial relationships to disclose.

P5-15-07
First and further line choices of treatment for HER2+ metastatic breast cancer (MBC) according to adjuvant treatment and biological subtype. Preliminary results of the observational "GIM-13 - AMBRA" Italian study
Michela Donadio
Dr. Donadio has no relevant financial relationships to disclose.

P4-07-05
MicroRNA-27b mediates deregulation of energy metabolism in breast cancer
Shengli Dong
Dr. Dong has no relevant financial relationships to disclose.

P3-05-02
Quantitative ERα measurements in TNBC from the I-SPY 2 TRIAL correlate with HER2-EGFR co-activation and heterodimerization
Ting Dong
Ting Dong has no relevant financial relationships to disclose.

P2-03-07
Exome sequencing of human breast cancer tissues resistant to taxanes
Yu Dong
Yu Dong has no relevant financial relationships to disclose.

P1-02-24
Evaluating lymph node ratio (LNR) as a prognostic indicator in node-positive breast cancer
Eoin Donnellan
Eoin Donnellan has no relevant financial relationships to disclose.

P2-05-06
Analytical and clinical validation of a fully automated tissue-based quantitative assay (Metasite Breast™) to detect the likelihood of distant metastasis in hormone receptor (HR)-positive, HER2-negative early stage breast cancer (ESBC)
Eoin Donnellan
Eoin Donnellan has no relevant financial relationships to disclose.

P4-22-02
Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer
Susan Domchek
Dr. Domchek has disclosed that she is a consultant for EMD Serono and AbbVie and received research support (institution) from AbbVie, Clovis, AstraZeneca and Pharmamar.
A multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer: early results of unplanned boost participants

Dr. Dooley has no relevant financial relationships to disclose.

A multiplexed immunofluorescence identifies phenotypic heterogeneity of circulating tumor cells in breast cancer

Dr. Dooley has no relevant financial relationships to disclose.

Two-year follow-up results of a multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer

Dr. Dooley has no relevant financial relationships to disclose.

Ovarian reserve and response to controlled ovarian hyperstimulation (COH) in breast cancer women with and without BRCA mutation

Dr. O’Rourke has no relevant financial relationships to disclose.

Association of background parenchymal enhancement with breast cancer risk factors and tumor characteristics

Dr. Dorgan has no relevant financial relationships to disclose.

Planning and implementation of two regional one-stop breast health centres within a large geographic health authority: Outcomes and quality improvements in health service delivery

Dr. Dorgan has no relevant financial relationships to disclose.

miR363-3p mediates maintenance and resistance of breast cancer stem cells (BCSC)

Dr. Dormoy has no relevant financial relationships to disclose.

Tissue Balkoven-related peptidase 4, a novel biomarker in triple-negative breast cancer

Dr. Dorn has no relevant financial relationships to disclose.

From monocyte re-programming to the expansion of tumor infiltrating lymphocytes for adoptive T cell therapy

Dr. Doucey has no relevant financial relationships to disclose.

Primary analysis of BERENICE: A phase II cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with locally advanced, inflammatory, or early-stage, unilateral, and invasive HER2-positive breast cancer

Ms. Douthwaite has disclosed that she is a current employee of Roche Products.
| P5-15-06 | Impact of post-progression therapy on overall survival (OS) in the IMEXIA randomized phase III trial evaluating the addition of capcitabine (CAP) to maintenance bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC) |
| Dinesh Doval | Dinesh Doval has no relevant financial relationships to disclose. |
| P6-12-05 | A phase I study of AZD9496, a novel oral, selective estrogen receptor degrader (ESRD) in women with estrogen receptor-positive, HER-2 negative advanced breast cancer (ABC) |
| Tom Dowdall | Dr. Dowdall has disclosed that he is an AstraZeneca employee. |
| P1-02-03 | Circulating inflammatory markers, growth factors, and tumor associated antigens in women with early stage breast cancer receiving neoadjuvant metformin |
| Ryan Dowling | Dr. Dowling has no relevant financial relationships to disclose. |
| P6-02-03 | Lactate receptor (GPR-1) in breast carcinoma tissue: Utilization expression and correlation with leptin-mediated signaling, but not with systemic markers of obesity |
| Ryan Dowling | Dr. Dowling has no relevant financial relationships to disclose. |
| P3-04-03 | MaXY Way Sign: A potential predictive sign of breast cancer on digital breast tomosynthesis |
| John Downey | Dr. Downey has no relevant financial relationships to disclose. |
| P6-07-06 | Effect of serum biomarkers (actin, A, CASK, HER2, TIMP-1, and uPA) on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: CTG3 MA-31 |
| Suzanne Downs | Ms. Downs has disclosed that she is a full-time employee and stockholder in R&D Systems, Inc, Minn, MN. |
| P1-02-01 | Circulating tumor DNA analysis to predict relapse and overall survival in early breast cancer - Longer follow-up of a proof-of-principle study |
| Mitch Dowsett | Dr. Dowsett has no relevant financial relationships to disclose. |
| P1-03-01 | An international multicenter study to evaluate reproducibility of automated scoring methods for assessment of ki67 in breast cancer |
| Mitch Dowsett | Dr. Dowsett has no relevant financial relationships to disclose. |
| P2-04-07 | In vivo profiling of post neoadjuvant high metastatic risk (hMR) residual disease in patients with early triple negative breast cancers |
| Mitch Dowsett | Dr. Dowsett has no relevant financial relationships to disclose. |
| P2-05-01 | Clinico-pathological relationships with ki67 in POSTIC (CRUK/07/015) - Critical lessons for assessing ki67 for prognosis and as a pharmacodynamic marker |
| Mitch Dowsett | Dr. Dowsett has disclosed that he is a consultant for Radius Health Inc. and GTh Inc. He also disclosed that he receives academic funding from Pfizer. |
| P2-08-03 | Long-term comparison of anastrozole versus tamoxifen: Results from LATTE/ATAC |
| Mitch Dowsett | Dr. Dowsett has disclosed that he is a consultant for Radius and GTh. |
| P2-10-02 | The impact of intrinsic subtypes and molecular features on aromatase inhibitor induced reduction of proliferation marker of ki67 in primary ER+ breast cancer: A POETIC study (CRUK/07/015) |
| Mitch Dowsett | Dr. Dowsett has disclosed that he is a consultant for Radius Health Inc. and GTh Inc. He also disclosed that he receives academic funding from Pfizer. |
| P3-03-09 | Resistance to palbociclib depends on multiple targetable mechanisms highlighting the potential of drug holidays and drug switching to improve therapeutic outcome |
| Mitch Dowsett | Dr. Dowsett has disclosed that he is a consultant for Radius and GTh. He also disclosed that he receives academic research funding from Pfizer. |
| S6-05 | Comprehensive comparison of prognostic signatures for breast cancer in TransATAC |
| Mitch Dowsett | Dr. Dowsett has disclosed that he receives lecture fees from Myriad. |
| P2-08-02 | True effect of aromatase inhibitor (AI) treatment on global gene expression (expr) changes in postmenopausal (ER+) breast cancer (BC) patients: A POETIC study (CRUK/07/015) |
| Mitchell Dowsett | Prof. Dowsett has disclosed that he receives academic funding from Pfizer. |
| P6-07-30 | Identifying novel glycosylation markers in HER2+ breast cancer using MALDI mass spectrometry |
| Richard Drake | Dr. Drake has no relevant financial relationships to disclose. |
| P3-01-33 | Non-sentinel lymph nodes involvement in early breast cancer patients: Performance of two predictive nomograms integrating the analysis of sentinel nodes by one step nucleic acid amplification in a cohort of 299 patients |
| Francois Driesen | Dr. Driesen has disclosed that he receives academic research funding from Pfizer. |
| P3-14-04 | Exclusive fat grafting breast reconstruction after mastectomy: Feasibility and complications on 54 patients |
| Francois Driesen | Dr. Driesen has no relevant financial relationships to disclose. |
| P3-06-02 | Therapeutic targeting of RAGE in the tumor and tumor microenvironment inhibits breast progression and metastasis |
| Katherine Drews-Elger | Dr. Drews-Elger has no relevant financial relationships to disclose. |
| P3-08-01 | TruRisk® based next-generation sequencing in BRCA2- negative breast and ovarian cancer families reveals high mutation prevalence in additional risk genes |
| Julia Driesen | Ms. Driesen has no relevant financial relationships to disclose. |
Prospective association between breast cancer risk and an individual dietary index based on the British Food Standards Agency nutrient profiling system

Pauline Ducrot

Dr. Ducrot has no relevant financial relationships to disclose.

Effect of PD-1 and PD-L1 in the tumor microenvironment on overall survival of triple-negative breast cancer patients

Amylou Duerck

Dr. Duerck has no relevant financial relationships to disclose.

The impact of the 23 gene recurrence score (RS) on chemotherapy prescribing in estrogen receptor (ER) positive, lymph node positive early stage breast cancer in Ireland

Karen Duffy

Ms. Duffy has no relevant financial relationships to disclose.

Long-term effects of weight loss on breast cancer biomarkers in postmenopausal women

Catherine Duggan

Dr. Duggan has no relevant financial relationships to disclose.

Williams Duder

Dr. Duder has no relevant financial relationships to disclose.

Technology as a change agent for improving breast cancer quality care

William Dudley

Dr. Dudley has disclosed that he is a consultant for Carevive.

Drugs Dugan

Dr. Dugan has no relevant financial relationships to disclose.

Pertuzumab and trastuzumab in combination with weekly paclitaxel delivers high pCR rates with favourable toxicity profile in neo-adjuvant treatment of Her-2 positive breast cancer

Tom Dugan

Dr. Dugan has no relevant financial relationships to disclose.

Pertuzumab and trastuzumab in combination with weekly paclitaxel delivers high pCR rates with favourable toxicity profile in neo-adjuvant treatment of Her-2 positive breast cancer

Tom Dugan

Dr. Dugan has no relevant financial relationships to disclose.

PD-1 and PD-L1 in the tumor microenvironment on overall survival of triple-negative breast cancer patients

Amylou Duerck

Dr. Duerck has no relevant financial relationships to disclose.

The impact of the 23 gene recurrence score (RS) on chemotherapy prescribing in estrogen receptor (ER) positive, lymph node positive early stage breast cancer in Ireland

Karen Duffy

Ms. Duffy has no relevant financial relationships to disclose.

Long-term effects of weight loss on breast cancer biomarkers in postmenopausal women

Catherine Duggan

Dr. Duggan has no relevant financial relationships to disclose.

Evaluation of weekly paclitaxel plus carboplatin followed by anthracycline chemotherapy on the neoadjuvant treatment of patients with triple-negative breast cancer

Francine Dutil

Dr. Dutil has no relevant financial relationships to disclose.

The importance of loco-regional tumor burden and surgery on survival in patients with de novo stage IV breast cancer; post-hoc analyses of protocol M07-01

Katherine Dumais

Dr. Dumais has no relevant financial relationships to disclose.

Rates of ipsilateral breast tumor recurrence (IBTR) following breast conserving surgery (BCS) and hypofractionated radiotherapy for ductal carcinoma in situ (DCIS)

Catherine Dumais

Dr. Dumais has no relevant financial relationships to disclose.

A multi-OMIC analysis to explore the impact of "actionable" genomic alterations on protein pathway activation: Clinical implication for precision medicine in metastatic breast cancer

Bryant Dunetz

Mr. Dunetz has no relevant financial relationships to disclose.

Cambridge brain mets trial 1 (CamBMT1): A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy

Laurence Dunn

Mr. Dunn has no relevant financial relationships to disclose.

The REQUITE-AB study: Validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality of life in breast cancer patients

Alison Dunning

Ms. Dunning has no relevant financial relationships to disclose.

Does BRCA status affect outcome in young breast cancer patients? Results from the prospective study of outcomes in sporadic and hereditary breast cancer patients (POSH)

Alison Dunning

Ms. Dunning has no relevant financial relationships to disclose.

Sentinel node detection after neoadjuvant chemotherapy in patient without previous axillary node involvement (GANE 2 trial): Follow-up of a prospective multi-institutional cohort

Pierre-Francois Dupre

Dr. Dupre has no relevant financial relationships to disclose.

Aromatase inhibitors and endothelial function: Is there an association with early cardiovascular disease?

Daniel Duprez

Dr. Duprez has no relevant financial relationships to disclose.

Evaluation of the effects of palbociclib plus letrozole on QoL interval

Chandra Durairaj

Ms. Durairaj has disclosed that she receives salary from and has ownership in Pfizer.
P4-21-04 Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (PERUSE) Valerie Easton Ms. Easton has disclosed that her salary is paid by Roche.

P4-21-07 Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy in patients ≥65 years with HER2-positive locally recurrent/metastatic breast cancer: Subgroup analyses of the PERUSE study Valerie Easton Ms. Easton has disclosed that her salary is paid by Roche.

S4-04 Cardiac safety of dual anti-HER2 therapy in the neoadjuvant setting for treatment of HER2-positive breast cancer Annie Eaton Dr. Eaton has disclosed that he is an employee of and holder of shares and options for Syros Pharmaceuticals.

P6-06 A novel subgroup of estrogen receptor positive breast cancer may benefit from super-enhancer guided patient selection for fulvestrant and palbociclib treatment Matthew Eaton Ms. Eaton has disclosed that she receives salary from F Hoffmann La-Roche.

P6-11-18 Imaging outcome of pregnancy associated breast cancer: A case-control study Seren Eaton Seren Eaton has no relevant financial relationships to disclose.

P1-05-20 Comparing the frequency and types of genetic aberrations between older and younger women with metastatic breast cancer at the University of North Carolina at Chapel Hill David Eberhard Dr. Eberhard has no relevant financial relationships to disclose.

P1-05-03 The genomic landscape of breast metaplastic carcinoma Carey Eberle Dr. Eberle has no relevant financial relationships to disclose.

P3-02-04 Is breast magnetic resonance imaging (MRI) useful for diagnosis of additional sites of disease in patients recently diagnosed with ductal carcinoma in situ (DCIS)? Eileen Ebyoma Dr. Ebyoma has no relevant financial relationships to disclose.

PD6-02 Local recurrence in young women with invasive breast cancer: the prospective study of outcomes in sporadic and hereditary breast cancer (POSH) Diana Escles Ms. Escles has no relevant financial relationships to disclose.

S2-03 Does BRCA status affect outcome in young breast cancer patients? Results from the prospective study of outcomes in sporadic and hereditary breast cancer (POSH) Diana Escles Ms. Escles has no relevant financial relationships to disclose.

P4-21-18 Cardiac safety of dual anti-HER2 therapy in the neoadjuvant setting for treatment of HER2-positive breast cancer Valerie Easton Ms. Easton has disclosed that her salary is paid by Roche.

P1-11-04 Looking beyond the margins: Economic costs and complications associated with repeated breast-conserving surgeries Saral Edelman Mr. Edelman has disclosed that he receives salary from Irving Multispecialty Clinic. He has also disclosed that he is a speaker for Insys Corp. and receives travel/accommodation/expenses from Blue Cross/Blue Shield of Illinois.

P2-01-18 Preoperative prediction of axillary lymph node status based on artificial neural network algorithm model Patrik Edén Dr. Edén has no relevant financial relationships to disclose.

S6-04 The FIKX inhibitor, sarloa, has enhanced potency in TNI/CA mutant models through a unique mechanism of action Kyle Edgar Dr. Edgar has disclosed that he receives salary from Genentech, Inc.
Immediate breast reconstruction is highly accepted by breast cancer patients undergoing mastectomy when routinely offered.

Recent experience of an Australian tertiary oncoplastic breast unit

Senarath Edirimanne

Senarath Edirimanne has no relevant financial relationships to disclose.

Use of an absorbable implant to mark the lumpectomy cavity: Initial report of 300 patients in a multi-center registry database

David Edmonson

Mr. Edmonson has no relevant financial relationships to disclose.

Omitting radiotherapy in women ≥ 65 years with early breast cancer and favorable histopathology after breast-conserving surgery, sentinel node biopsy and adjuvant endocrine therapy is safe

Per Edlund

Dr. Edlund has no relevant financial relationships to disclose.

Identifying metastatic drivers in patient derived xenograft models of triple negative breast cancer

John Edwards

Mr. Edwards has no relevant financial relationships to disclose.

Trastuzumab improves outcomes of New Zealand women with HER2+ stage III breast cancer

Melissa Edwards

Ms. Edwards has no relevant financial relationships to disclose.

Comparison of the Qpert breast cancer stratifier mRNA assay with central ER, PR, HER2, and IHC immunohistochemistry (IHC) for rapid biomarker analysis in developing countries

Lai Edwin

Mr. Lai has disclosed that he is an employee and a stockholder of Cepheid.

Mutational characteristics and tumor infiltrating lymphocytes in early and metastatic HER2 positive breast cancer

Ioannis Efstratiou

Ioannis Efstratiou has no relevant financial relationships to disclose.

Serum-triglycerides among triple negative breast cancer patients as a biomarker of poor outcome

Anne Elise Eggen

Dr. Eggen has no relevant financial relationships to disclose.

Efficacy and safety of everolimus plus exemestane in HR+, HER2- advanced breast cancer progressing on or after prior endocrine therapy, in routine clinical practice: 2nd interim analysis from STEPAUT

Daniel Egle

Dr. Egle has no relevant financial relationships to disclose.

Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomized, neoadjuvant phase-II study (ABCSG-41)

Daniel Egle

Dr. Egel has no relevant financial relationships to disclose.

BELLE-3: A phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2-, aromatase inhibitor (AI)-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment

Daniel Egle

Dr. Egle has no relevant financial relationships to disclose.

PRE-07: Phase 1 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors

Jens Eickhoff

Dr. Eickhoff has no relevant financial relationships to disclose.

The SCAN-B study: 5-year summary of a large-scale population-based prospective breast cancer translational genomics platform covering a wide geography of Sweden (NCT02306096)

Anna Ehinger

Dr. Ehinger has no relevant financial relationships to disclose.

Can polyploid tumor cells possessing stem cell features be induced in resistant breast carcinomas?

Jens Ekdots

Dr. Ekdots has no relevant financial relationships to disclose.

Pathological complete response to neoadjuvant trastuzumab is dependent on HER2/CPI17 ratio in HER2-amplified early breast cancer

Daniel Egil

Dr. Egil has no relevant financial relationships to disclose.
A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA)

Wolfgang Eiermann
Dr. Eiermann has no relevant financial relationships to disclose.

Multi-level gene expression signatures provide significant prognostic information in metastatic breast cancer patients

Zakaria Einbeigi
Dr. Einbeigi has no relevant financial relationships to disclose.

Rates of successful engraftment in breast cancer xenograft models based on tissue type: Primary vs relapsed disease

Peter Eirew
Dr. Eirew has no relevant financial relationships to disclose.

Magnetic resonance imaging (MRI) surveillance for patients with dense breasts and a previous breast cancer (BC) and/or high risk lesion

Andrea Eisen
Dr. Eisen has no relevant financial relationships to disclose.

Phase 2/3 study of oral rivaroxaban (XAMI), a dual CYP17-lyase inhibitor and androgen receptor (AR) antagonist, in patients with advanced AR positive triple negative (TNBC) or estrogen receptor (ER) positive breast cancer (BC)

Joel Eisner
Dr. Eisner has disclosed that he receives salary from and has ownership in Innocrin Pharmaceuticals, Inc.

Prediction of 10yr distant recurrence (DR) using the Prosigna® (PAM50) assay in histological subgroups of a Danish breast cancer group (DBCG) cohort of postmenopausal Danish women with hormone receptor-positive (HR+) early breast cancer (EOC) allocated to 5yr of endocrine therapy (ET) alone

Bent Ejertsen
Mr. Ejertsen has disclosed that he has contracts with Novartis and Puma and has unrestricted research grants from Roche, Novartis and Nanostring Technologies.

Rates of successful engraftment in breast cancer xenograft models based on tissue type: Primary vs relapsed disease

P1-07-10

Bent Ejertsen
Mr. Ejertsen has disclosed that he has research grants from Nanostring, Roche and Novartis and travel support from Celgene.

DBCG 07-READ: A randomized phase III trial comparing six cycles of docetaxel and cyclophosphamide (DC) to three cycles of epirubicin and cyclophosphamide followed by three cycles of docetaxel (EC-D) in patients with early breast cancer

Bent Ejertsen
Dr. Ejertsen has disclosed that he contracts with Novartis and Puma. He also disclosed that he received unrestricted research grants from Roche, Novartis and Nanostring.

In the era of conservative surgery, can patients presenting with node positive breast cancer be spared axillary node dissection post neoadjuvant chemotherapy? A meta-analysis and review of literature

Omar El Tokhy
Mr. ElTokhy has no relevant financial relationships to disclose.

The role of sentinel lymph node biopsy in patients with ductal carcinoma in situ. An updated meta-analysis involving 9803 patients

Omar El Tokhy
Mr. ElTokhy has no relevant financial relationships to disclose.

Identification of SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong antitumor activity in wild-type and mutant ER+ breast cancer models

Youssef El-Ahmed
Youssef El-Ahmed has no relevant financial relationships to disclose.

Therapeutic targeting of RAGE in the tumor and tumor microenvironment inhibits breast progression and metastasis

Dorraya El-Ashry
Dr. El-Ashry has no relevant financial relationships to disclose.

A hierarchy of cancer associated fibroblasts in situ and in circulation promote breast cancer metastasis

Dorraya El-Ashry
Dr. El-Ashry has no relevant financial relationships to disclose.

Novel cytotoxic RNA aptamers that distinguish between metastasis-prone and indolent breast and prostate cancers

Dorraya El-Ashry
Dr. El-Ashry has no relevant financial relationships to disclose.

Long-term rates of breast preservation after breast-conserving therapy for ductal carcinoma in situ

Leela Elavathil
Dr. Elavathil has no relevant financial relationships to disclose.

Nuclear grade has a limited role in predicting recurrence in DCIS following breast conserving surgery. A population-based study

Leela Elavathil
Dr. Elavathil has no relevant financial relationships to disclose.

Immune sculpting of the triple negative breast cancer genome

Ahmed El-Balat
Mr. El-Balat has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>S4-07</td>
<td>BELLE-3: A phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2-, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment</td>
<td>Mona El-Hashimy</td>
<td>Ms. El-Hashimy has disclosed that she is an employee of and has ownership in Novartis.</td>
</tr>
<tr>
<td>P5-16-02</td>
<td>Pathological complete response is associated with excellent outcomes in BRCA mutation-associated triple negative breast cancer</td>
<td>Manana Elia</td>
<td>Dr. Elia has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-08-04</td>
<td>Phase 1/2 study of oral neratinib (VT-464), a dual CYP17 lyase inhibitor and estrogen receptor (ER) antagonist, in patients with advanced AR positive triple negative (TNBC) or estrogen receptor (ER) positive breast cancer (BC)</td>
<td>Anthony Elia</td>
<td>Dr. Elia has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-11-02</td>
<td>Efficacy of NPI0390 inhibitor gemelinen plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial</td>
<td>Anthony Elia</td>
<td>Dr. Elia has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-11-04</td>
<td>The evaluation of ganitumab/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial</td>
<td>Anthony Elia</td>
<td>Dr. Elia has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-03-04</td>
<td>Concordence of local immunohistochemistry with TargetPrint microarray based assessment of ER, PR and Her2 and Blueprint molecular subtyping in the Symphony Triple A study</td>
<td>Sjoerd Elias</td>
<td>Dr. Elias has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-03</td>
<td>Impact of 10-gene signature use on adjuvant chemotherapy decisions in early breast cancer patients: Results of the prospective symmetry triple A study</td>
<td>Sjoerd Elias</td>
<td>Dr. Elias has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-15-15</td>
<td>Phase II study of navellese plus carboplatin followed by oral navellese in patients with metastatic/recurrent triple-negative breast cancer previously treated with anthracycline and taxane</td>
<td>Moustafa El-Ibrashi</td>
<td>Moustafa El-Ibrashi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT2-03-05</td>
<td>A randomised trial of 15 fraction vs 25 fraction pencil beam scanning proton radiotherapy after mastectomies in patients requiring regional nodal irradiation</td>
<td>Yan Elizabeth</td>
<td>Dr. Elizabeth has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT1-02-02</td>
<td>Prospective evaluation of the predictive value of biomarkers with complete pathologic response using neoadjuvant chemotherapy plus trastuzumab + pertuzumab in Her2 (+) breast cancer patients with invasive tumors</td>
<td>Patricia Eclavee</td>
<td>Dr. Eclavee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-08-02</td>
<td>Efficacy of the 70-gene signature use on adjuvant chemotherapy decisions in patients with HER2+ breast cancer</td>
<td>Eric Elkin</td>
<td>Mr. Elkin has disclosed that he is employed by Myriad Genetics at time of study - received salary and stock options.</td>
</tr>
<tr>
<td>P2-08-06</td>
<td>A prospective study of 15 fraction vs 25 fraction pencil beam scanning proton radiotherapy after mastectomies in patients requiring regional nodal irradiation</td>
<td>Richard Elledge</td>
<td>Mr. Elledge has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-09-19</td>
<td>Two-year follow-up results of a multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer</td>
<td>Ellenholm</td>
<td>Dr. Ellenhorn has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-03-06</td>
<td>Improvement in risk predictive value of Nottingham prognostic index by determining EPBB tumor tissue expression for estrogen receptor positive breast cancer patients</td>
<td>Robert Elliott</td>
<td>Mr. Elliott has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-07-06</td>
<td>Effect of serum biomarkers (CA125, CA15.3, HER2, TIMP-1, and uPA) on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: CCTG MA.31</td>
<td>Catherine Ells</td>
<td>Dr. Ells has disclosed that she is employed by and has ownership in GlaxoSmithKline.</td>
</tr>
<tr>
<td>P6-09-45</td>
<td>Long-term follow-up of early stage breast cancer patients with results of MammaPrint®, Oncotype DX® and MammoStrat® risk classification assay</td>
<td>Debora Ellis</td>
<td>Ms. Ellis has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
Contribution of germline mutations in cancer predisposition genes to tumor etiology in women diagnosed with invasive breast cancer before 40 years

Rachel Ellsworth
Dr. Ellsworth has no relevant financial relationships to disclose.

Relationship between obesity and breast tumor pathology in a contemporary set of patients

P6-05-04

Rachel Ellsworth
Dr. Ellsworth has no relevant financial relationships to disclose.

Psychosocial distress monitoring in a multidisciplinary, inner city breast center

P4-19-04

Tarek Elrafei
Dr. Elrafei has no relevant financial relationships to disclose.

Macromolecular capillarytome in heavily pretreated metastatic triple negative breast cancer

P5-15-14

Wael El-Sadda
Dr. El-Sadda has no relevant financial relationships to disclose.

Phase II study of navicline plus carboalgin followed by oral navicline in patients with metastatic/recurrent triple negative breast cancer previously treated with anthracycline and taxane

P5-15-15

Wael El-Sadda
Dr. El-Sadda has no relevant financial relationships to disclose.

Dorstatom plus trialzumab and palicitum as first-line therapy in women with HER2+ advanced breast cancer: Overall survival results from BOLERO-1

P4-22-13

Amr Elsaid
Dr. Elsaid has disclosed that she is a consultant for Pfizer.

Patient derived DCS mouse-intracranial (MIND) models recapitulate the full spectrum of human patient pathology and histologic features including progression to invasion in a subset of cases

P4-06-01

Hanan Elsarraj
Dr. Elsarraj has no relevant financial relationships to disclose.

CPM rate among individuals with breast cancer who underwent multiple gene testing for hereditary cancer: Single institution experience

P2-07-09

Nisreen Elsayegh
Nisreen Elsayegh has no relevant financial relationships to disclose.

Impact of TP53 functional mutation type on clinical outcomes of advanced breast cancer patients

P2-05-10

Christine Elser
Ms. Elser has disclosed that she is a consultant for Pfizer.

Association between BMI and residual estradiol levels in post-menopausal women using adjacent leucine: Results of a prospective study

P2-09-14

Christine Elser
Ms. Elser has no relevant financial relationships to disclose.

Clinical outcome of patients with advanced triple negative breast cancer with germline and somatic variants in homologous recombination gene

P3-09-05

Christine Elser
Ms. Elser has disclosed that she is a consultant for Pfizer.

BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype in TNBC cells: Implications for breast cancer early lesions

P5-07-05

Wael ElShamy
Dr. Elshamy has no relevant financial relationships to disclose.

Photodynamic therapy for the treatment of primary breast cancer: Preliminary results of a phase IIa clinical trial

P07-02-01

Soha El-Sheikh
Dr. El-Sheikh has no relevant financial relationships to disclose.

Comprehensive genomic profiling of clinically malignant phyllodes tumors of the breast reveals frequent mutation of MYB and other genes associated with PIK3 and RAS pathway activation

P1-05-07

Soma Eustis
Dr. Eustis has disclosed that she receives salary from and has ownership in Foundation Medicine, Inc.

Comprehensive genomic profiling of 8,054 breast carcinoma reveals therapeutically targetable molecular subtypes beyond those defined by hormone receptor expression

P4-05-08

Soma Eustis
Dr. Eustis has disclosed that she receives salary from and has ownership in Foundation Medicine, Inc.

Cancer-associated fibroblasts release exosomal microRNAs that dictate an aggressive phenotype in breast cancer

P4-05-12

Donnamarina Eustis
Dr. Eustis has no relevant financial relationships to disclose.

Trastuzumab improves outcomes of New Zealand women with HER2+ stage I-III breast cancer

P4-21-28

Mark Elwood
Mr. Elwood has no relevant financial relationships to disclose.

Inducing immune responses to tumor associated carbohydrate antigens by a carbohydrate mimetic peptide vaccine: Clinical experience in phase I and phase II trials

P6-10-06

Peter Emanuel
Dr. Emanuel has no relevant financial relationships to disclose.

"Breast Cancer Immunotherapy: Building on Clinical Success"

Leikha Emens
Dr. Emens has disclosed that she receives royalty from Aduro Biotech. She has also disclosed that she receives consulting fees from AstraZeneca, Roche, Syndax, Amgen, Celgene, BMS and Vaccinex. She disclosed that she does contracted research for AstraZeneca, Roche, Genentech, EMD Serono, Massy and Amplimmune. These relationships do not impact her ability to present an unbiased presentation.
Evaluation of contrast-enhanced ultrasonography for early prediction of response to neoadjuvant chemotherapy in triple negative breast cancer

P4-02-06
Akiko Emi
Ms. Emi has no relevant financial relationships to disclose.

Prognostic associations of tumor-infiltrating lymphocytes (TILs) in metastatic HER2-positive breast cancer (BC) treated with trastuzumab and pertuzumab: A secondary analysis of the CLEOPATRA study

P5-16-04
Clark Emma

Development of photoacoustic vascular imaging system for breast cancer

P2-03-07
Yumi Endo
Ms. Endo has no relevant financial relationships to disclose.

Exome sequencing of human breast cancer tissues resistant to taxanes

P3-16-04
Takaaki Endo
Takaaki Endo has disclosed that he is an employee of and stock holder of Canon Inc., Japan.

A randomized phase II neoadjuvant study comparing docetaxel-and cyclophosphamide (TC) with 5-fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel (FEC-D) for hormone receptor-negative breast cancer: The Kanagawa Breast Oncology group (KBOG) 1011 study

P5-02-10
Yuki Endo
Takashi Endo
Takashi Endo has disclosed that he is an employee of and stock holder of Canon Inc., Japan.

Prognostic associations of tumor-infiltrating lymphocytes (TIL) in metastatic HER2-positive breast cancer patients treated by HER2-directed chemotherapy

P5-13-01
Dr. Engelsen has no relevant financial relationships to disclose.

BGB324, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy in mammary adenocarcinoma

P3-04-08
Agnete Engelsen
Dr. Engelsen has no relevant financial relationships to disclose.

Dual HER2 blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: A subanalysis of data from the randomized phase II GeparSepto trial

P4-21-06
Knut Engvik
Knut Engvik has no relevant financial relationships to disclose.

Evaluation of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarker in different subtypes of breast cancer treated with neoadjuvant therapy: A metaanalysis of 3771 patients

P3-08
Knut Engvik
Knut Engvik has no relevant financial relationships to disclose.

Pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: Efficacy analysis of a phase II cardiac safety study (TRYPHAENA)

P4-21-02
Jennifer Eng-Wong
Ms. Eng-Wong has disclosed that she is an employee of Genentech/ Roche.

Primary analysis of BENENCE: A phase II cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with locally advanced, inflammatory, or early-stage, unilateral, and invasive HER2-positive breast cancer

P4-21-43
Jennifer Eng-Wong
Ms. Eng-Wong has disclosed that she receives salary from Genentech, Inc. and has ownership in Roche.

Pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: Efficacy analysis of a phase II cardiac safety study (TRYPHAENA)

P4-21-02
Alexandru Erucu
Mr. Erucu has no relevant financial relationships to disclose.

Circulating inflammatory markers, growth factors, and tumor associated antigens in women with early stage breast cancer receiving neoadjuvant metformin

P1-02-03
Marguerite Erris
Dr. Erris has no relevant financial relationships to disclose.

Association between BMI and residual estradiol levels in postmenopausal women using adjuvant letrozole: Results of a prospective study

P2-09-14
Marguerite Erris
Dr. Erris has no relevant financial relationships to disclose.
Leptin receptor (OB-R) in breast carcinoma tissue: Ubiquitous expression and correlation with leptin-mediated signaling, but not with systemic markers of obesity
Marguerite Emnis
Dr. Emnis has no relevant financial relationships to disclose.

Serial monitoring of circulating tumor DNA in patients with metastatic breast cancer
Rachel Emnis
Ms. Emnis has no relevant financial relationships to disclose.

A randomized controlled trial comparing acupuncture versus usual care for the treatment of aromatase inhibitor-induced arthralgia (AIIA) in women with early-stage breast cancer
Joe Emson Jr.
Dr. Emson Jr. has no relevant financial relationships to disclose.

Positive behavior change and weight loss in breast cancer survivors on hormonal adjuvant therapy: An energy balance research in cancer (EnBar) retrospective study
Joe Emson Jr.
Dr. Emson Jr. has no relevant financial relationships to disclose.

The impact of the introduction of breast cancer screening on a symptomatic breast cancer unit
Rachel Emnis
Ms. Emnis has no relevant financial relationships to disclose.

The impact of the introduction of breast cancer screening on a symptomatic breast cancer unit
Rachel Emnis
Ms. Emnis has no relevant financial relationships to disclose.

Analytical and clinical validation of a fully automated tissue-based quantitative assay (MetaSite Breast™) to detect the likelihood of distant metastasis in hormone receptor (HR)-positive, HER2-negative early-stage breast cancer (ESBC)
David Entenberg
Mr. Entenberg has no relevant financial relationships to disclose.

Paclitaxel induced mena- and TMEM-mediated pro-metastatic changes in the breast cancer microenvironment
David Entenberg
Mr. Entenberg has no relevant financial relationships to disclose.

Tumor microenvironment of metastasis (TMM) score is associated with early distant recurrence in hormone receptor (HR) positive, HER2-negative early stage breast cancer (ESBC)
David Entenberg
Mr. Entenberg has no relevant financial relationships to disclose.

An international multicenter study to evaluate reproducibility of automated scoring methods for assessment of Ki67 in breast cancer
Emeka Enwere
Dr. Enwere has no relevant financial relationships to disclose.

Refining the prognostic value of Ki67 biomarker by ataxia telangiectasia mutated (ATM) status in a retrospective study of early stage hormone receptor positive breast cancer
Emeka Enwere
Dr. Enwere has no relevant financial relationships to disclose.

An international multicenter study to evaluate reproducibility of automated scoring methods for assessment of Ki67 in breast cancer
Emeka Enwere
Dr. Enwere has no relevant financial relationships to disclose.

Risk Factors for high risk breast density patterns in Hispanic/Latinas living in the Northeast, US
Lianne Epstein
Ms. Epstein has no relevant financial relationships to disclose.

BRE12-158: A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer (TNBC)
John Ertan
Dr. Ertan has no relevant financial relationships to disclose.

PTEN immunohistochemistry is a predictor of mismatch repair status in breast cancer
Oguz Ertol
Ms. Ertol has no relevant financial relationships to disclose.

The importance of loco-regional tumor burden and surgery on survival in patients with de novo stage IV breast cancer; post-hoc analyses of protocol MF07-01
Fagan Erdem
Ms. Erdem has no relevant financial relationships to disclose.

Can peglated tumor cells possessing stem cell features be reduced in resistant breast carcinomas?
Eliana Erkens
Dr. Erkens has no relevant financial relationships to disclose.

Therapeutic targeting of RAGE in the tumor and tumor microenvironment inhibits breast progression and metastasis
Irye Ergenol
Dr. Ergenol has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Presentation</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1-07-10</td>
<td>Prediction of 10yr distant recurrence (DR) using the Prosigna® (PAM50) assay in histological subgroups of a Danish breast cancer group (BRCA) cohort of postmenopausal Danish women with hormone receptor-positive (HR+) early breast cancer (EM)</td>
<td>Jens Eriksen</td>
<td>Jens Eriksen has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT3-06-01</td>
<td>A randomized intervention study: A randomized dose determination trial</td>
<td>Mikkal Eriksson</td>
<td>Dr. Eriksson has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-06-06</td>
<td>A clinical model for assessment of the individual breast cancer risk</td>
<td>Mikkal Eriksson</td>
<td>Dr. Eriksson has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-01-19</td>
<td>Sentinel: A way to avoid sentinel-node biopsy (SNB) in patients with a preoperative diagnosis of ductal cancer in situ (DCIS)</td>
<td>Staffan Eriksson</td>
<td>Staffan Eriksson has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-04-09</td>
<td>Investigating the effects of low-dose mixtures of endocrine contaminants on breast cancer initiation</td>
<td>Mayla Emile</td>
<td>Ms. Emile has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-13-01</td>
<td>Determining the breast tumor margin through genomics of the cancer-stromal interaction</td>
<td>Amanda Ernlund</td>
<td>Ms. Ernlund has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-08-01</td>
<td>Trish atooked next-generation sequencing in BRCA1/2 - negative breast and ovarian cancer families reveal high mutation prevalence in additional risk genes</td>
<td>Carina Ernst</td>
<td>Ms. Ernst has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-09-04</td>
<td>Beyond CHEK2 in breast cancer: Search for additional moderately penetrant risk gene variants by analyzing the allelic disease course in CHEK2 mutation carriers</td>
<td>Carina Ernst</td>
<td>Ms. Ernst has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-07-21</td>
<td>Cytotoxic potential of the BRCA1/2-p53 binding antagonist and the GSK2830371 WIP1 inhibitor on MX-1 and MX-2 human breast cancer cells</td>
<td>Jeremy Eslander</td>
<td>Dr. Eslander has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-12-23</td>
<td>Predicting residual disease in breast conservative surgery after neoadjuvant treatments in breast cancer patients using the margin index tool</td>
<td>Antonio Eugenio-Colmenarejo</td>
<td>Dr. Eugenio-Colmenarejo has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-20-03</td>
<td>Collateral damage from metastatic breast cancer: Preliminary results</td>
<td>Leah Eshraghi</td>
<td>Ms. Eshraghi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P03-01</td>
<td>Automated, low-cost palpable breast lump triage for economically-developing countries</td>
<td>Leah Eshraghi</td>
<td>Ms. Eshraghi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-14-08</td>
<td>Immediate breast reconstruction is highly accepted by breast cancer patients undergoing mastectomy when routinely offered: Recent experience of an Australian tertiary oncoplastic breast unit</td>
<td>Guy Edick</td>
<td>Mr. Edick has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-02-05</td>
<td>Comparison of non-breed and ovarian cancer phenotypes of BRCA1/2 mutation carriers across multi-gene panel</td>
<td>Carin Espenscheid</td>
<td>Carin Espenscheid has disclosed that she receives salary from Ambry Genetics.</td>
</tr>
<tr>
<td>P2-03-07</td>
<td>Predicting germ line mutations in BRCA1/2 and beyond: A comparison of women with single and multiple breast primaries</td>
<td>Carin Espenscheid</td>
<td>Carin Espenscheid has disclosed that she is a full time employee of Ambry Genetics.</td>
</tr>
<tr>
<td>P4-06-06</td>
<td>Consistent dosing-time dependent tolerability of everolimus (EV) in a pilot study in women with metastatic breast cancer (MBC) and in a mouse chronopharmacology investigation</td>
<td>Mary Espié</td>
<td>Dr. Espié has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-06-05</td>
<td>Claudin-4 expression is associated with disease free survival in breast carcinoma in situ: Mean follow up of 8.2 years</td>
<td>Juliana Espinola</td>
<td>Dr. Espinola has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-07-32</td>
<td>Vitamin D as a potential biomarker of aggressiveness in non-metastatic breast cancer</td>
<td>Jaime Espinós</td>
<td>Dr. Espinós has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-03-03</td>
<td>Determining the prognostic role of early and end-of-neoadjuvant chemotherapy 18F-FDG PET/CT in patients with locally advanced breast cancer</td>
<td>Ruth Espinosa-Anión</td>
<td>Dr. Espinosa-Anión has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-01-04</td>
<td>Assessing response in locally advanced breast cancer treated with neoadjuvant chemotherapy: Predictive and prognostic potential of volume-based metabolic variables with 18F-FDG PET/CT</td>
<td>Ruth Espinosa-Anión</td>
<td>Dr. Espinosa-Anión has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
P2-14-01 Metastatic trial search: Advocacy groups collaborate to engage metastatic breast cancer patients in clinical trials
Michelle Esser
Dr. Esser has no relevant financial relationships to disclose.

P4-17-01 YSC's "shady pink elephant" end of life series
Michelle Esser
Dr. Esser has no relevant financial relationships to disclose.

P2-05-01 Intra-tumor heterogeneity of the estrogen receptor predicts less benefit from tamoxifen therapy and poor long-term breast cancer patient survival - Retrospective analyses of the STO-3 randomized trial
Laura Esserman
Dr. Esserman has no relevant financial relationships to disclose.

P2-11-02 A longitudinal look at toxicity management within a platform trial: Lessons from the I-SPY 2 Trial
Laura Esserman
Dr. Esserman has no relevant financial relationships to disclose.

P2-14-01 Metastatic trial search: Advocacy groups collaborate to engage metastatic breast cancer patients in clinical trials
Laura Esserman
Dr. Esserman has no relevant financial relationships to disclose.

P3-05-02 Quantitative Er measurements in TNBC from the I-SPY 2 Trial correlate with HR2/EGFR co-activation and heterodimerization
Laura Esserman
Dr. Esserman has no relevant financial relationships to disclose.

P5-03-03 Evaluating the feasibility of a web-based preference tolerant randomized trial of risk-based vs. annual breast cancer screening: WISDOM study pilot
Laura Esserman
Dr. Esserman has no relevant financial relationships to disclose.

P5-11-18 Trajectory of patient (Pt) reported physical function (PF) during and after neoadjuvant chemotherapy in the I-SPY 2 trial
Laura Esserman
Dr. Esserman has no relevant financial relationships to disclose.

P6-11-02 The evaluation of gatinib/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial
Laura Esserman
Dr. Esserman has no relevant financial relationships to disclose.

P6-11-04 Evaluating the feasibility of a web-based preference tolerant randomized trial of risk-based vs. annual breast cancer screening: WISDOM study pilot
Laura Esserman
Dr. Esserman has no relevant financial relationships to disclose.

P3-05-02 Effect of MRI imaging contrast kinetic thresholds for prediction of neoadjuvant chemotherapy response in breast cancer subtypes - Results from ACRN 6637 / I-SPY 1 trial
Laura Esserman
Dr. Esserman has no relevant financial relationships to disclose.

P07-02 Identification of breast cancers with an indolent disease course: 20 gene indelent threshold validation in a Swedish randomized trial of tamoxifen vs. not, with 20 year outcomes.
Laura Esserman
Dr. Esserman has no relevant financial relationships to disclose.

P3-17-04 Presentation of a Bayesian decision model for the treatment of ductal carcinoma in situ (DCIS) of the breast
Rafael Estevan
Mr. Estevan has no relevant financial relationships to disclose.

P4-03-16 FAPα (fibroblast activation protein-α) analysis in breast tumor cells and stroma after neoadjuvant treatment
Laura Estévez
Dr. Estévez has no relevant financial relationships to disclose.

P2-04-03 Differential effect of chemotherapy on immune gene expression signatures based on molecular subtypes of breast cancer
M Valeria Estrada
Dr. Estrada has no relevant financial relationships to disclose.

P3-05-03 PI3K/PDK1 mediates resistance to CDK4/6 inhibitors through dysregulation of 5-phase cyclin/cyclin dependent kinases (CDKs)
Monica Estrada
Dr. Estrada has no relevant financial relationships to disclose.
The importance of loco-regional tumor burden and surgery on survival in patients with de novo stage IV breast cancer: post-hoc analyses of protocol MK07-01

Turkkan Evrensel

Dr. Evrensel has no relevant financial relationships to disclose.

Primary analysis of BERENICE: A phase II cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with locally advanced, inflammatory, or early-stage, unilateral, and invasive HER2-positive breast cancer

Michael Ewer

Mr. Ewer has disclosed that he has received a book royalty, probably NA. He has also disclosed that he is a consultant for AstraZeneca and on the advisory board for Pharmacies.

BELS: Safety and tolerability of at home administration of trastuzumab (Herceptin®) subcutaneous for the treatment of patients with HER2-positive early breast cancer

Ella Exen

Ms. Exen has no relevant financial relationships to disclose.

DBIG07-READ: A randomized phase III trial comparing six cycles of docetaxel and cyclophosphamide (DC) to three cycles of doxorubicin and cyclophosphamide followed by three cycles of docetaxel (DC-D) in patients with early breast cancer

Marianne Essert

Dr. Essert has no relevant financial relationships to disclose.

Phase II trial of selinexor for metastatic triple negative breast cancer

Martine Esterman

Dr. Esterman has disclosed that she has a contract with GTx.

Pathological complete response to neoadjuvant trastuzumab is dependent on HER2/CEP17 ratio in HER2-amplified early breast cancer

Ruth Exner

Ms. Exner has no relevant financial relationships to disclose.

Systematic review of clinical trials for monoclonal antibody biosimilars in HER2-positive breast cancer

Reginald Ewesuedo

Dr. Ewesuedo has disclosed that he receives salary from and has ownership in Pfizer Inc.

Systemic review of clinical trials for monoclonal antibody biosimilars in HER2-positive breast cancer

Reginald Ewesuedo

Dr. Ewesuedo has disclosed that he receives salary from and has ownership in Pfizer Inc.

Phase I trial of sildenafil for metastatic triple negative breast cancer

Ruth Exner

Ms. Exner has no relevant financial relationships to disclose.

Prostate specific membrane antigen (PSMA) expression in breast cancer and its metastases

Eamer Ezziddin

Dr. Ezziddin has no relevant financial relationships to disclose.

 importância do tumor de localização regional e cirurgia na sobrevida em pacientes com câncer de mama estadio IV de novo: análise post-hoc de protocolo MK07-01

Turkkan Evrensel

Dr. Evrensel não tem relações financeiras relevantes a declarar.

Análise primária de BERENICE: uma eia de segurança do cardíaco do uso de pertuzumab, trastuzumab e quimioterapia de abordagem alquímica em pacientes com câncer de mama localmente avançado, inflamatório ou de estágio inicial, unilateral e invasivo HER2-pelo câncer de mama positivo

Michael Ewer

Mr. Ewer declarou que recebeu uma renda por ebooks, provavelmente NA. Também declarou que é consultor para AstraZeneca e na Junta Consultiva para Pharmacies.

Estudos randômicos de fase III comparando seis ciclos de docetaxel e ciclofosfamida (DC) com três ciclos de doxorubicina e ciclofosfamida seguidos por três ciclos de docetaxel (DC-D) em pacientes com câncer de mama precoce

Marianne Essert

Dr. Essert não tem relações financeiras relevantes a declarar.

Evaluación de eficacia terapéutica y correlación entre un conjunto de polimorfismos y neuropatía en pacientes con metástasis de cáncer de mama

Alessandra Fabi

Ms. Fabi não tem relações financeiras relevantes a declarar.

PAINTER: Avaliação da tolerabilidade de eribulin e correlação entre um conjunto de polimorfismos e neuropatia em pacientes com câncer de mama metastático

Alessandra Fabi

Ms. Fabi não tem relações financeiras relevantes a declarar.

Alterations in the gut microbiome of post-menopausal women 2 weeks after initiating a structured weight loss intervention

Carol Fabian

Dr. Fabian não tem relações financeiras relevantes a declarar.

Changes in gut microbiome of post-menopausal women 2 weeks after initiating a structured weight loss intervention

Carol Fabian

Dr. Fabian não tem relações financeiras relevantes a declarar.

Patient derived DCIS mouse intraductal (MIND) models recapitulate the full spectrum of human patient pathology and histologic features including progression to invasion in a subset of cases

Veronica Fabiano

Dr. Fabiano não tem relações financeiras relevantes a declarar.

Her2 and hormonal receptor analysis in breast cancer synchronous node metastases could add therapeutic information

Veronica Fabiano

Dr. Fabiano não tem relações financeiras relevantes a declarar.

Prospective study of acupuncture in the rehabilitation of women undergoing surgical treatment of breast cancer in relation to the strength and quality of life

Gil Facina

Dr. Facina não tem relações financeiras relevantes a declarar.

Comprehensive genome profiling to assess tumor mutation burden in >8,000 breast cancer cases: Implications for immunotherapy

David Fabrizio

Dr. Fabrizio declarou que recebe renda de vendas e possui propriedade na Foundation Medicine.

Prospective study of acupuncture in the rehabilitation of women undergoing surgical treatment of breast cancer in relation to the strength and quality of life

Gil Facina

Dr. Fabina não tem relações financeiras relevantes a declarar.

Comprehensive genome profiling to assess tumor mutation burden in >8,000 breast cancer cases: Implications for immunotherapy

David Fabrizio

Dr. Fabiana declarou que recebe renda de vendas e possui propriedade na Foundation Medicine.

Comprehensive genome profiling to assess tumor mutation burden in >8,000 breast cancer cases: Implications for immunotherapy

David Fabrizio

Dr. Fabiana declarou que recebe renda de vendas e possui propriedade na Foundation Medicine.

Comprehensive genome profiling to assess tumor mutation burden in >8,000 breast cancer cases: Implications for immunotherapy

David Fabrizio

Dr. Fabia declarou que recebe renda de vendas e possui propriedade na Foundation Medicine.

Comprehensive genome profiling to assess tumor mutation burden in >8,000 breast cancer cases: Implications for immunotherapy

David Fabrizio

Dr. Fabiana declarou que recebe renda de vendas e possui propriedade na Foundation Medicine.

Comprehensive genome profiling to assess tumor mutation burden in >8,000 breast cancer cases: Implications for immunotherapy

David Fabrizio

Dr. Fabiana declarou que recebe renda de vendas e possui propriedade na Foundation Medicine.
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Disclosures</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1-09-15</td>
<td>Tumor and serum DNA methylation in women receiving preoperative chemotherapy (PST) with or without vorinostat in primary operable HER2-negative breast cancer in TBCRC008</td>
<td>Mary Fackler</td>
<td>Ms. Fackler has disclosed that QM-MSP and cMethDNA assays are licensed by Cepheid Corporation. This is managed by Johns Hopkins University. Patent awarded for QM-MSP, patent application submitted for cMethDNA assays. This is managed by Johns Hopkins University. She also disclosed that she is a consultant for Cepheid Corporation. This is managed by Johns Hopkins University.</td>
</tr>
<tr>
<td>P2-10-05</td>
<td>PowerPIRC trial: Changes in tumor proliferation index and quality of life with 7 days of preoperative tamoxifen</td>
<td>Rachel Factor</td>
<td>Dr. Factor has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P05-07</td>
<td>From monocline re-programming to the expansion of tumor infiltrating lymphocytes for adaptive T cell therapy</td>
<td>Evelina Fann-ent Hull</td>
<td>Beekne Fann-ent Hull has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-04-16</td>
<td>Steroid receptor co-activator 1 mediation of cancer cell reprogramming in endocrine resistant breast cancer</td>
<td>Ails Fagan</td>
<td>Dr. Fagan has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-04-17</td>
<td>Global transcriptional repression by the coactivator SRC-1 mediates disease progression in treatment-resistant breast cancer</td>
<td>Ails Fagan</td>
<td>Dr. Fagan has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-05-08</td>
<td>A phase 2 study of eribulin as early-line treatment for HER2-MBC: Evaluation of efficacy, toxicity, and patient-reported outcomes</td>
<td>Meredith Fagan</td>
<td>Dr. Fagan has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT1-03-01</td>
<td>The UK LORIS trial: Randomizing patients with low or low intermediate grade ductal carcinoma in situ (DCIS) to surgery or active monitoring</td>
<td>Patricia Fairbrother</td>
<td>Ms. Fairbrother has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-01-10</td>
<td>Development of photothermal vascular imaging system for breast cancer</td>
<td>Elham Fabranshahi</td>
<td>Pham Fabranshahi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-07-07</td>
<td>Gene expression signatures and immunohistochemical subtypes add prognostic value to each other</td>
<td>Claudette Falato</td>
<td>Dr. Falato has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-11-09</td>
<td>Factors related to the prognosis of breast cancer patients after the development of brain metastases</td>
<td>Cristiana Falci</td>
<td>Dr. Falci has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-20</td>
<td>Tumor infiltrating lymphocytes in recurrent HER2+ and triple negative breast cancer: Prognostic value according to tumor phenotype</td>
<td>Cristiana Falci</td>
<td>Dr. Falci has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P05-05</td>
<td>Metabolic obesity, adipose inflammation and aromatase: Potential drivers of breast cancer risk in women with normal body mass index</td>
<td>Domenick Falcone</td>
<td>Mr. Falcone has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-16-02</td>
<td>Nanotheranostics using plasmonic gold nanostars to target inflammatory breast cancer cells and tumor emboli</td>
<td>Andrew Fales</td>
<td>Mr. Fales has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-15</td>
<td>Establishment of molecular profiling for individual treatment decisions in early breast cancer - Clinical impact of PAM50 and PAM50 risk of recurrence score after more than 16 years follow up</td>
<td>Ragnhild Falk</td>
<td>Dr. Falk has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-12-06</td>
<td>Genomic variants in 5 male breast cancers using whole exome sequencing</td>
<td>John Fallon</td>
<td>Dr. Fallon has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-04-16</td>
<td>Ongoing mutated cancers with whole exome sequencing</td>
<td>John Fallon</td>
<td>Dr. Fallon has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT1-03-01</td>
<td>Maximizing recruitment and retention of patients into UK-ANZ POSNOC trial</td>
<td>Lesley Fallowfield</td>
<td>Ms. Fallowfield has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT3-03-02</td>
<td>Maximizing recruitment and retention of patients into UK-ANZ POSNOC trial</td>
<td>Lesley Fallowfield</td>
<td>Ms. Fallowfield has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
Treatment of early HER2-positive breast cancer in trastuzumab era in everyday clinical practice: An overview after 10 years of its approval

Catalina Falo
Catalina Falo has no relevant financial relationships to disclose.

Comparative analysis of the genomic landscape of breast cancers from women of African and European ancestry

Adelyinka Falusi
Adelyinka Falusi has no relevant financial relationships to disclose.

Integrative analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer

Chen Fan
Chen Fan has no relevant financial relationships to disclose.

Multivariate analysis of subtype and gene expression signatures predictive of pathologic complete response (pCR) in triple-negative breast cancer (TNBC): CALGB 40605 (Alliance)

Cheng Fan
Cheng Fan has no relevant financial relationships to disclose.

Patient derived DCIS mouse-intraductal (MINC) models recapitulate the full spectrum of human patient pathology and histologic features including progression to invasion in a subset of cases

Fang Fan
Dr. Fan has no relevant financial relationships to disclose.

Spectral CT based radiomics signature: A potential biomarker for preoperative prediction of lymph node metastasis in breast cancer

Mengjie Fang
Mengjie Fang has no relevant financial relationships to disclose.

Proteomic response in breast cancer treated with neoadjuvant chemotherapy with and without bevacizumab: Reverse phase protein array (RPPA) results from NeoAva - A randomized phase II study

Anne Fangberget
Dr. Fangberget has no relevant financial relationships to disclose.

Race is not a contributing factor to breast cancer-free interval outcome for patients with equal access to healthcare treated at a military medical center

Jamie Fantacone_Campbell
Jamie Fantacone_Campbell has no relevant financial relationships to disclose.

Association of background parenchymal enhancement with breast cancer risk factors and tumor characteristics

Rawan Faramand
Dr. Faramand has no relevant financial relationships to disclose.

Two-year follow-up results of a multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer

M Farha
Dr. Farha has no relevant financial relationships to disclose.

A multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer: Early results of unplanned boost participants

Maen J Farha
Maen J Farha has no relevant financial relationships to disclose.

Estrogen receptor β2 and β5 increase expression of ABCG2 and drug resistance of the triple-negative breast cancer cell line SUM159

Michelle Farina
Ms. Farina has no relevant financial relationships to disclose.

PAINTER: Evaluation of eribulin tolerability and correlation between a set of polymorphisms and neuropathy in patients with metastatic breast cancer

Gabriella Farina
Ms. Farina has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Paper ID</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P6-09-14</td>
<td>Prognostic significance of a modified residual disease in breast and nodes (mRDBN) algorithm after neoadjuvant therapy for breast cancer</td>
<td>Daniel Farrugia</td>
<td>Dr. Farrugia has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-07-16</td>
<td>Quantitative proteomic analysis of FGFR by mass spectrometry may improve identification of FGFR amplified tumors sensitive to inhibitor therapy</td>
<td>Roberta Faasani</td>
<td>Dr. Faasani has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S3-03</td>
<td>PAM50 intrinsic subtype as a predictor of pathological complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2-positive breast cancer: First results of the PAMELA clinical trial</td>
<td>Roberta Faasani</td>
<td>Dr. Faasani has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT1-01-10</td>
<td>Multi-center phase III trial of AXY-1213 (Docetaxel) combined with nab-paclitaxel in unresectable or metastatic breast cancer</td>
<td>Julie Faasano</td>
<td>Dr. Faasano has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT1-02-04</td>
<td>The DETECT V-study - Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemotherapy or endocrine therapy in patients with HER2-positive and hormone-receptor positive metastatic breast cancer</td>
<td>Peter Fasching</td>
<td>Mr. Fasching has disclosed that he is a consultant for Amgen, Roche, Genentech, and Pfizer. He has also disclosed contracts with Amgen (Contract with Institution/Employer) and Novartis (Contract with Institution/Employer).</td>
</tr>
<tr>
<td>OT1-03-18</td>
<td>RIBECCA - A phase Ib, multi-center, open label study for women with estrogen receptor positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole</td>
<td>Peter Fasching</td>
<td>Dr. Fasching has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT1-04-02</td>
<td>DETECT III and IV: Individualized CTC-based therapy of metastatic breast cancer</td>
<td>Peter Fasching</td>
<td>Dr. Fasching has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-01-03</td>
<td>Dynamics of circulating tumor cells during the course of chemotherapy and prognostic relevance across molecular subtypes in high-risk early breast cancer patients - Results from the adjuvant SUCCESS A trial</td>
<td>Peter Fasching</td>
<td>Dr. Fasching has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-09-02</td>
<td>Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSinto in triple-negative early breast cancer</td>
<td>Peter Fasching</td>
<td>Dr. Fasching has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-09-11</td>
<td>Outcome after neoadjuvant chemotherapy in progesterone receptor negative breast cancer patients - A pooled analysis of individual patient data from ten prospectively randomised controlled neoadjuvant trials</td>
<td>Peter Fasching</td>
<td>Dr. Fasching has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-02</td>
<td>Archival surveillance with a combination of tumor marker CA27.29 and detection of circulating tumor cells ten years after primary diagnosis strongly predicts subsequent prognosis</td>
<td>Peter Fasching</td>
<td>Dr. Fasching has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-07-01</td>
<td>Profiling miRNA in high risk post-operative early breast cancer patients to detect possible association to correlation with immune system anti-tumor response</td>
<td>Peter Fasching</td>
<td>Mr. Fasching has disclosed that he is a consultant for Amgen, Roche, Genentech, and Pfizer. He has also disclosed contracts with Amgen (Contract with Institution/Employer) and Novartis (Contract with Institution/Employer).</td>
</tr>
<tr>
<td>P4-12-07</td>
<td>CCND1 amplification in early breast cancer patients: Correlation with subtypes and prognosis</td>
<td>Peter Fasching</td>
<td>Mr. Fasching has disclosed that he is a consultant for Amgen, Roche, Genentech, and Pfizer. He has also disclosed contracts with Amgen (Contract with Institution/Employer) and Novartis (Contract with Institution/Employer).</td>
</tr>
<tr>
<td>P5-16-18</td>
<td>The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer</td>
<td>Peter Fasching</td>
<td>Dr. Fasching has disclosed that he is a consultant for Amgen, Roche, Genentech, and Pfizer. He has also disclosed contracts with Amgen (Contract with Institution/Employer) and Novartis (Contract with Institution/Employer).</td>
</tr>
<tr>
<td>P6-06-04</td>
<td>Breast cancer after Hodgkin lymphoma: Influence of pre-existing antitumor immunity on the radiation dose-response relationship</td>
<td>Sandra Fase</td>
<td>Ms. Fase has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-22-12</td>
<td>Ribociclib + fulvestrant in postmenopausal women with HR+, HER2- advanced breast cancer (ABC)</td>
<td>Angelica Fasolo</td>
<td>Ms. Fasolo has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
P2-11-04  Efficacy and safety of darbepoetin alfa or epoetin beta in 2994 high-risk early breast cancer patients participating in the German adjuvant intergroup node-positive study (GAIN)  Tanja Fehm  Dr. Fehm has no relevant financial relationships to disclose.

P3-13-06  Development and validation of a nomogram predicting pathological axillary status (ypN0 vs. ypN+) in a subgroup of patients converting from cN+ to ycN0 through neoadjuvant therapy (NAT) - A transGENTINA substudy  Tanja Fehm  Dr. Fehm has no relevant financial relationships to disclose.

P4-07-01  Profiling miRNA in high risk post-operative early breast cancer patients to detect possible association to correlation with immune system antitumor response  Tanja Fehm  Dr. Fehm has no relevant financial relationships to disclose.

P6-16-08  Characterization of neuroendocrine breast carcinomas for biomarkers of therapeutic options  Rebecca Feldman  Dr. Feldman has disclosed that she is an employee of Caris Life Sciences.

S1-04  A randomized, double-blinded, placebo-controlled clinical trial to evaluate extended adjuvant endocrine therapy (5 years of letrozole) in postmenopausal women with hormone receptor positive breast cancer who have completed previous adjuvant endocrine therapy: initial results of NRG oncology/NSABP B-42  Louis Feilotter  Mr. Feilotter has disclosed that he has a contract with Genentech.

S3-06  A phase III trial evaluating pCR in patients with HR+, HER2- positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen deprivation: NRG oncology/NSABP B-52  Louis Feilotter  Mr. Feilotter has disclosed that he has a contract with Genentech.

S5-06  Randomized, placebo-controlled trial of duloxetine for aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS) in early stage breast cancer (SWOG 1202)  Louis Feilotter  Mr. Feilotter has disclosed that he has a contract with Genentech.

P2-08-05  Evaluation of the Oncomine focus and comprehensive assays for therapeutic stratification in early hormone receptor positive breast cancers  Kimberley Feigin  Dr. Feigin has no relevant financial relationships to disclose.

P1-05-27  Deep Infrared Imaging to identify venous impairment after breast cancer surgery  Véronique Feipel  Ms. Feipel has no relevant financial relationships to disclose.

P3-13-26  Single agent palbociclib in combination with trastuzumab for the treatment of androgen receptor (AR)+ metastatic breast cancer (MBC)  Kimberley Feigin  Dr. Feigin has no relevant financial relationships to disclose.

P3-13-28  Lipofilling of the axilla to reduce secondary lymphedema after axillary lymph node dissection  Véronique Feipel  Ms. Feipel has no relevant financial relationships to disclose.

P2-01-14  Postoperative radiotherapy for lymph node positive breast cancer  Rebecca Feldman  Dr. Feldman has disclosed that she is an employee of Caris Life Sciences.

P4-22-14  Single agent palbociclib with or without trastuzumab for the treatment of HER2 advanced breast cancer  Michael Feldman  Dr. Feldman has disclosed that he is a consultant for Philips Healthcare and Inspirata.

P2-15-01  Profiling miRNA in high risk post-operative early breast cancer patients to detect possible association to correlation with immune system antitumor response  Tanja Fehm  Dr. Fehm has no relevant financial relationships to disclose.

P3-13-06  Development and validation of a nomogram predicting pathological axillary status (ypN0 vs. ypN+) in a subgroup of patients converting from cN+ to ycN0 through neoadjuvant therapy (NAT) - A transGENTINA substudy  Tanja Fehm  Dr. Fehm has no relevant financial relationships to disclose.

P4-07-01  Profiling miRNA in high risk post-operative early breast cancer patients to detect possible association to correlation with immune system antitumor response  Tanja Fehm  Dr. Fehm has no relevant financial relationships to disclose.

P6-16-08  Characterization of neuroendocrine breast carcinomas for biomarkers of therapeutic options  Rebecca Feldman  Dr. Feldman has disclosed that she has a contract with Genentech.

OT3-02-08  Open label, phase 2 safety, efficacy, and pharmacokinetic study of pre-surgical intramuscular and intraductal fulvestrant in women with invasive breast cancer or DCIS undergoing mastectomy or lumpectomy  Sheldon Feldman  Dr. Feldman has disclosed that he has a contract with Genentech.

P2-01-14  Lymphatic microsurgical preventive healing approach (LYMPHA) for the primary prevention of lymphedema  Sheldon Feldman  Dr. Feldman has disclosed that he has a contract with Genentech.

P2-15-01  Building an experience engine to make cancer treatment decisions using machine learning  Nancy Feldman  Dr. Feldman has no relevant financial relationships to disclose.

P3-04-01  ESRR mutations, ESRR fusions and co-occurring alterations assessed in breast cancer tumors  Rebecca Feldman  Dr. Feldman has disclosed that he receives salary from Caris Life Sciences.

P6-07-27  Open label, phase 2 safety, efficacy, and pharmacokinetic study of pre-surgical intramuscular and intraductal fulvestrant in women with invasive breast cancer or DCIS undergoing mastectomy or lumpectomy  Rebecca Feldman  Dr. Feldman has disclosed that she is an employee of Caris Life Sciences.

P2-08-05  Targeting inflammatory pathways: A phase 2 trial of the JAK- inhibitor ruxolitinib in combination with exemestane for aromatase inhibitor-resistant, estrogen receptor-positive breast cancer (BMC)  Kimberley Feigin  Dr. Feigin has no relevant financial relationships to disclose.

P2-01-14  Lymphatic microsurgical preventive healing approach (LYMPHA) for the primary prevention of lymphedema  Sheldon Feldman  Dr. Feldman has disclosed that he has a contract with Genentech.

P3-13-06  Development and validation of a nomogram predicting pathological axillary status (ypN0 vs. ypN+) in a subgroup of patients converting from cN+ to ycN0 through neoadjuvant therapy (NAT) - A transGENTINA substudy  Tanja Fehm  Dr. Fehm has no relevant financial relationships to disclose.

P4-07-01  Profiling miRNA in high risk post-operative early breast cancer patients to detect possible association to correlation with immune system antitumor response  Tanja Fehm  Dr. Fehm has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P6-09-05</td>
<td>Prognostic and predictive values of high endothelial venules (HEV) and tumor infiltrating CD8+ lymphocytes (CD8) in tumors of patients included in the adjuvant PACS04 trial: HEV is predictive of outcome for HER2+ tumors exposed to trastuzumab</td>
<td>Thomas Filleron</td>
<td>Dr. Filleron has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-08-01</td>
<td>High-throughput genome analysis and therapeutic decision for patients with HER2-negative metastatic breast cancer: First feasibility and molecular results of the randomized phase II study SHIHER2 BREAST (UCBG-0105/158)</td>
<td>Thomas Filleron</td>
<td>Dr. Filleron has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-05-01</td>
<td>Diet, development and predisposition to breast cancer: The impact of sugar derived metabolites (AGIs) on pubertal mammary gland development</td>
<td>Victoria Fice</td>
<td>Ms. Fice has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-12-06</td>
<td>Hemiretinal, tissue selective androgen receptor modulator (SARM), enobosarm, reduces growth of androgen receptor-positive breast cancer in patient-derived preclinical models</td>
<td>Richard Fine</td>
<td>Dr. Fine has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-18-03</td>
<td>Measuring what is important to patients in clinical trials: Hearing the patient's voice</td>
<td>Sandra Finestone</td>
<td>Dr. Finestone has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-18-04</td>
<td>The advocates in science (AIS), a research advocacy program of Susan G. Komen</td>
<td>Sandra Finestone</td>
<td>Dr. Finestone has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT3-05-01</td>
<td>Three-monthly dynamic evaluation of CEA and CA15-3 (followed by 18-FDG PET) vs usual practice in the follow-up of early breast cancer (EC) patients (pts): A prospective randomized trial (KRONOS-patient-oriented new surveillance study, Italy)</td>
<td>Angela Feni</td>
<td>Dr. Feni has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-02-02</td>
<td>The association of higher tumor HER2 load with treatment response to neoadjuvant therapy in HER2 positive breast cancer patients</td>
<td>Manisha Finkelstein</td>
<td>Ms. Finkelstein has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-16-21</td>
<td>Dietetic value of breast MRI in detecting mammographically occult contralateral breast cancer: Can we target women more likely to have contralateral breast cancer based on primary tumor clinicopathologic factors?</td>
<td>Jessica Finlay-Schultz</td>
<td>Mr. Finn has disclosed that he is a consultant for Pfizer, Novartis and Bayer.</td>
</tr>
<tr>
<td>P6-11-07</td>
<td>Phenotypically distinct HRG positive cancer cells impact standard of care therapies in metastatic breast cancer models</td>
<td>Sangee Finn</td>
<td>Ms. Fink has disclosed that she is an employee of Merck</td>
</tr>
</tbody>
</table>
S5-06 Randomized, placebo-controlled trial of duloxetine for aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS) in early stage breast cancer (SWOG 1202) 
Michael Fisch
Mr. Fisch has no relevant financial relationships to disclose.

P3-04-10 Utility of the orally bioavailable selective estrogen receptor degrader AZD5494 in ER+1 mutant preclinical models of estrogen receptor positive breast cancer 
David Fisher
Mr. Fisher has disclosed that he receives salary and has ownership.

P1-11-05 Influence of race and age on mastectomy rates in women with stage I, hormone-sensitive breast cancer: A SEER-based study 
James Fisher
Dr. Fisher has disclosed that he is an employee of Myriad.

P6-12-15 Efficacy results of a phase 1/2 study of glucocorticoid receptor (GR) antagonist mifepristone (MF) in combination with eribulin in GR-positive triple negative breast cancer (TNBC) 
Robert Fischman
Mr. Fischman has disclosed that he is an employee of Corcept.

P1-09-10 Pathological complete response to neoadjuvant trastuzumab is dependent on HER2/CPI-17 ratio in HER2-amplified early breast cancer 
Florian Fischman
Florian Fischman has no relevant financial relationships to disclose.

P8-05-04 Comparative analysis of the genomic landscapes of breast cancers from women of African and European ancestry 
Dominic Fitzgerald
Ms. Fitzgerald has no relevant financial relationships to disclose.

P1-08-03 Sialic evolution of hormone receptor status and metastatic profile among patients with metastatic breast cancer 
Donna Fitzgerald
Ms. Fitzgerald has no relevant financial relationships to disclose.

P1-12-03 Association between tumor genotype and development of brain metastasis in patients with hormone receptor positive (HER2-) metastatic breast cancer 
Donna Fitzgerald
Ms. Fitzgerald has no relevant financial relationships to disclose.

P6-12-16 Delivery and anti-tumor activity of nanoparticle clonostatin (NCL) in metastatic auromart models of triple negative breast cancer 
Jonathan Fitzgerald
Dr. Fitzgerald has disclosed that he is an employee of and has ownership of stock options from Merrimack Pharmaceuticals.

P2-01-38 Factors that can be used to guide further axillary treatment following positive sentinel lymph node biopsy 
Sheila FitzGerald
Ms. FitzGerald has no relevant financial relationships to disclose.

P3-10-09 Predictors of social support among newly diagnosed breast cancer patients seeking care at an urban safety net academic medical center 
Sofiana Flacks
Dr. Flacks has no relevant financial relationships to disclose.

P1-09-06 Prognostic and predictive relevance of cell cycle progression (CCP) score in ductal carcinoma in situ: Results from the UK/ANZ DCIS trial 
Zael Flade I
Mr. Flade has disclosed that he receives salary and has ownership in Myriad.

P6-11-16 PYTHIA: A phase II study of palbociclib plus fulvestrant versus placebo plus fulvestrant for pretreated patients with ER+/HER2- metastatic breast cancer 
Patrick Flad I
Ms. Flad has no relevant financial relationships to disclose.

P1-04-01 Grapemine-wide association study for breast cancer risk using whole genome and target captured bisulphite sequencing: A pooled case-control study nested in the Breakthrough Generations Study 
James Flanagan
Mr. Flanagan has no relevant financial relationships to disclose.

S4-03 Targeted and selective degradation of estrogen receptor (ER) splice variants by PROTACs 
John Flanagan
Mr. Flanagan has disclosed that he receives salary and has ownership.

OT3-01-01 A phase II study of PD-L1 and CTLA-4 inhibition and immunopharmcogenomics in metastatic breast cancer 
Lisa Flamm
Dr. Flamm has no relevant financial relationships to disclose.

P1-05-06 Circulating tumor DNA (ctDNA): A real-time application of precision medicine to the management of metastatic breast cancer (MBC) 
Lisa Flamm
Dr. Flamm has no relevant financial relationships to disclose.

P01-02 Development and validation of a nomogram predicting pathological axillary status (ypN+) in a subgroup of patients converting from cN+ to ycN0 through neoadjuvant therapy (NAT) - A transSENTINA substudy 
Barbara Fliege
Ms. Fliege has no relevant financial relationships to disclose.

P3-13-06 Breast cancer education, counseling, and support for Jewish women: Preliminary results of a CDC program evaluation 
Adina Fleischmann
Ms. Fleischmann has no relevant financial relationships to disclose.
OT3-02-03
Long-term follow-up of TEXT and SOFT trials of adjuvant endocrine therapies for premenopausal women with HR+ early breast cancer
Gini Fleming
Dr. Fleming has no relevant financial relationships to disclose.

P2-09-09
The effects of treatment-induced symptoms, depression and age on sexuality in premenopausal women with early breast cancer receiving adjuvant endocrine therapy
Gini Fleming
Dr. Fleming has no relevant financial relationships to disclose.

P6-12-06
Phase 1/2 study of oral endocrine (VT-464), a dual CYP17/AR inhibitor and androgen receptor (AR) antagonist, in patients with advanced AR-positive triple negative (TNBC) or estrogen receptor (ER) positive breast cancer (BC)
Ronald Fleming
Dr. Fleming has disclosed that he receives salary from and has ownership in InIron Pharmaceuticals, Inc.

P5-08-21
The effect of family history on screening procedures and prognosis in breast cancer patients - Results of a large population-based case-control study on breast cancer
Dieter Fleisch-Jans
Dr. Fleisch-Jans has no relevant financial relationships to disclose.

P15-12
Real-life activity of oral enzalutamide in metastatic breast cancer patients in the Unicorn EMME database
Dalcro Florence
Dr. Florence has no relevant financial relationships to disclose.

P11-10
The effect of supplementation with eicosapentaenoic and docosahexaenoic omega-3 polyunsaturated fatty acids on the chemosensitivity in Mexican patients with locally advanced breast cancer (LABC) treated with neoadjuvant chemotherapy (NACT);
Diana Flores-Diaz
Dr. Flores-Diaz has no relevant financial relationships to disclose.

P6-09-33
CASCADE study: Rapid survival decline per treatment line in metastatic breast cancer
Jesús Flores
Mr. Flores has no relevant financial relationships to disclose.

P2-11-10
Phase 1/2 trial of oral enzalutamide (VT-464), a dual CYP17/AR inhibitor and androgen receptor (AR) antagonist, in patients with advanced AR-positive triple negative (TNBC) or estrogen receptor (ER) positive breast cancer (BC)
Gini Fleming
Dr. Fleming has no relevant financial relationships to disclose.

P2-08-04
Nonsteroidal, tissue selective androgen receptor modulator (SARM), enobosarm, reduces growth of androgen receptor-positive breast cancer in patient-derived preclinical models
Martin Fleming
Dr. Fleming has no relevant financial relationships to disclose.

P3-03-14
Assessment of stromal characteristics in ductal carcinoma in situ of the breast: An inter-observer variability study
Giancarlo Floris
Dr. Floris has no relevant financial relationships to disclose.

P2-03-05
Identification, clinical characteristics and treatment outcomes of cosmetic human epidermal growth factor receptor 2 (HER2) mutations in metastatic breast cancer patients
Giancarlo Floris
Dr. Floris has no relevant financial relationships to disclose.

P4-03-01
The footprint of the aging stroma in older breast cancer patients
Giancarlo Floris
Dr. Floris has no relevant financial relationships to disclose.

P5-14-06
A prospective study to evaluate the effect of adjuvant chemotherapy on the breast cancer mortality rate in elderly breast cancer patients
Giancarlo Floris
Dr. Floris has no relevant financial relationships to disclose.

P6-08-32
The association of breast cancer subtype and breast cancer survival with parity and time since last birth
Giancarlo Floris
Dr. Floris has no relevant financial relationships to disclose.

P6-09-33
The association of breast cancer subtypes and breast cancer survival with parity and time since last birth
Giancarlo Floris
Dr. Floris has no relevant financial relationships to disclose.

P2-14-01
Metastatic trial search: Advocacy groups collaborate to engage metastatic breast cancer patients in clinical trials
Lois Flowers
Dr. Flowers has no relevant financial relationships to disclose.

P2-14-03
Novel evalutaion tool to search ongoing clinical trials and track trial results for metastatic breast cancer patients
Lois Flowers
Dr. Flowers has no relevant financial relationships to disclose.

P4-03-01
The footprint of the aging stroma in older breast cancer patients
Giancarlo Floris
Dr. Floris has no relevant financial relationships to disclose.

P5-14-06
The effect of adjuvant chemotherapy in a large consecutive series of ER-pos HER-2 negative early breast cancer patients
Giancarlo Floris
Dr. Floris has no relevant financial relationships to disclose.

P6-09-32
The association of breast cancer subtype and breast cancer survival with parity and time since last birth
Giancarlo Floris
Dr. Floris has no relevant financial relationships to disclose.

P6-09-33
CASCADE study: Rapid survival decline per treatment line in metastatic breast cancer
Jesús Flores
Mr. Flores has no relevant financial relationships to disclose.

P2-14-02
Epigenome-wide association study for breast cancer risk using whole genome and target captured bisulfite sequencing: A pooled case-control study nested in the breakthrough generations study
Kimy Flower
Ms. Flower has no relevant financial relationships to disclose.

P2-14-01
Metastatic trial search: Advocacy groups collaborate to engage metastatic breast cancer patients in clinical trials
Lois Flowers
Dr. Flowers has no relevant financial relationships to disclose.

P2-14-03
Novel evaluation tool to search ongoing clinical trials and track trial results for metastatic breast cancer patients
Lois Flowers
Dr. Flowers has no relevant financial relationships to disclose.

S3-06
A phase III trial evaluating pCR in patients with HR+, HER2- positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen deprivation: NRG oncology/NSABP B-32
Patrick Flynn
Mr. Flynn has no relevant financial relationships to disclose.

S5-06
Randomized, placebo-controlled trial that of duloxetine for aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMS) in early stage breast cancer (SWOG 1202)
Patrick Flynn
Mr. Flynn has no relevant financial relationships to disclose.

P2-05-10
Landscape 2:014: A prospective multicenter non-randomized trial evaluating the effect of EndoPredict® (EndoP®) clinico-genomic test on treatment decision making among patients with intermediate clinical risk
Cyril Foà
Dr. Foà has no relevant financial relationships to disclose.
Intratumoral heterogeneity of Ki67 expression in early breast cancers exceeds variability between individual tumours

Dr. Focke has no relevant financial relationships to disclose.

An optimized workflow to analyse ESR1 mutations in both circulating cell-free and circulating tumour cell DNA by digital PCR

Mr. Foekens has no relevant financial relationships to disclose.

Delivery and anti-tumor activity of nanopaposomal雌estrol (mRNA; MK-288) in metastatic xenograft models of triple negative breast cancer

Dr. Foltz has disclosed that he is a consultant (MR expertise) for Merrimack Pharmaceuticals.

Long-term rates of breast preservation after breast-conserving therapy for ductal carcinoma in situ

Ms. Fong has no relevant financial relationships to disclose.

Young women with breast cancer in Mexico: A report of the pilot phase of the "Nuestra Joven y Fuerte" prospective cohort

Dr. Fonseca has no relevant financial relationships to disclose.

Return to work after breast cancer diagnosis: An observational prospective study of 125 patients in South America

Mr. Fonseca has no relevant financial relationships to disclose.

The use of hypofractionated radiotherapy for the treatment of women with early breast cancer in the Brazilian public health system may increase access to treatment: Cost effectiveness and budget impact analyses

Dr. Fonseca has no relevant financial relationships to disclose.

Prognostic and predictive relevance of cell cycle progression (CCP) score in ductal carcinoma in situ: Results from the UK/ANZ DCIS trial

Dr. Forbes has no relevant financial relationships to disclose.

Long-term comparison of anastrozole versus tamoxifen: Results from the LATTE/ATAC

Dr. Forbes has no relevant financial relationships to disclose.

Menopausal symptoms as predictors of long-term adherence in the International breast cancer intervention study (IBIS-1)

Dr. Forbes has no relevant financial relationships to disclose.

The yield of germline genetic testing in breast cancer patients diagnosed prior to age 50

Mr. Forbes has no relevant financial relationships to disclose.

Young women with early stage breast cancer and their supportive care needs: Results from a regional survey

Mr. Forbes has no relevant financial relationships to disclose.

Elucidating the tumor immune microenvironment phenotype in early stage untreated BRCA-mutated breast cancer patients

Dr. Force has no relevant financial relationships to disclose.

Evaluating targets in localized and advanced breast cancer by sequencing tumor DNA at diagnosis and after progression (ELSA)

Dr. Ford has disclosed that he has a contract with Myriad Genetics, Inc.

Evaluation of tumor infiltrating lymphocytes (TILs) and their association with homologous recombination deficiency and BRCA1/2 mutation status in triple-negative breast cancer (TNBC): A pooled analysis

Dr. Ford has disclosed that he has a contract with Myriad Genetics, Inc.

Multiple-gene panel testing for hereditary cancer risk reveals a racial/ethnic disparity in genetic information

Ms. Ford has no relevant financial relationships to disclose.

A physical activity and dietary counseling intervention in breast cancer survivors and changes in known and novel prognostic biomarkers

Ms. Ford has no relevant financial relationships to disclose.

PALOMA: A phase II safety study of palbociclib in combination with letrozole in African American women with hormone receptor positive HER2 negative advanced breast cancer

Dr. Forero has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>OT2-01-12</td>
<td>A randomized, placebo-controlled, double-blind, multicenter phase 2 study (both a phase 3b lead-in) of atezolizumab with or without entinostat in patients with advanced triple negative breast cancer (aTNBC)</td>
<td>Andres Forero</td>
<td>Forero has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT2-01-19</td>
<td>Effect of high inhibitor gain-inhibiting plus standard neoadjuvant therapy in high-risk breast cancer: Results from the A-SPY 2 trial</td>
<td>Andres Forero</td>
<td>Forero has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-11-02</td>
<td>The evaluation of ganetespib/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the A-SPY 2 trial</td>
<td>Andres Forero</td>
<td>Forero has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-11-04</td>
<td>The evaluation of ganetespib/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the A-SPY 2 trial</td>
<td>Andres Forero</td>
<td>Forero has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-12-12</td>
<td>The evaluation of ganetespib/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the A-SPY 2 trial</td>
<td>Andres Forero</td>
<td>Forero has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-12-04</td>
<td>The evaluation of ganetespib/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the A-SPY 2 trial</td>
<td>Andres Forero</td>
<td>Forero has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-11-01</td>
<td>The evaluation of ganetespib/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the A-SPY 2 trial</td>
<td>Andres Forero</td>
<td>Forero has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-05-04</td>
<td>The evaluation of ganetespib/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the A-SPY 2 trial</td>
<td>Andres Forero</td>
<td>Forero has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-10-03</td>
<td>The evaluation of ganetespib/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the A-SPY 2 trial</td>
<td>Andres Forero</td>
<td>Forero has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-10-01</td>
<td>The evaluation of ganetespib/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the A-SPY 2 trial</td>
<td>Andres Forero</td>
<td>Forero has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-03</td>
<td>The evaluation of ganetespib/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the A-SPY 2 trial</td>
<td>Andres Forero</td>
<td>Forero has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-14</td>
<td>The evaluation of ganetespib/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the A-SPY 2 trial</td>
<td>Andres Forero</td>
<td>Forero has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P7-02-02</td>
<td>The evaluation of ganetespib/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the A-SPY 2 trial</td>
<td>Andres Forero</td>
<td>Forero has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-21-34</td>
<td>The evaluation of ganetespib/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the A-SPY 2 trial</td>
<td>Andres Forero</td>
<td>Forero has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-43</td>
<td>The evaluation of ganetespib/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the A-SPY 2 trial</td>
<td>Andres Forero</td>
<td>Forero has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
The role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+/HR+ phase II trial evaluating 12-weeks of neoadjuvant TDM1 ± endocrine therapy (ET) versus T + ET in HER2-positive hormone-receptor-positive early breast cancer (IBC).

Helmut Forstbauer

Dr. Forstbauer has no relevant financial relationships to disclose.

HER2 activity regulates the pro-trastuzumab immune tumor microenvironment.

Luca Forte

Luca Forte has no relevant financial relationships to disclose.

Something from nothing? The case for quality control in liquid biopsy studies.

Victoria Fortin

Ms. Fortin has no relevant financial relationships to disclose.

Mutational and microenvironmental intra-tumor heterogeneity in DCIS.

Angelo Fortinato

Dr. Fortinato has no relevant financial relationships to disclose.

Gene expression signatures and immunohistochemical subtypes add prognostic value to each other.

Theodosios Foulidis

Dr. Foulidis has no relevant financial relationships to disclose.

The role of estrogen receptor-α by NF1.

Charles Foulds

Dr. Foulds has no relevant financial relationships to disclose.

Regulation of estrogen receptor-α by NF1.

Charles Foulds

Dr. Foulds has no relevant financial relationships to disclose.

Increased glycolysis directly activates transcriptional coactivator SRC-3 to promote aggressive metastatic breast cancer.

Charles Foulds

Dr. Foulds has no relevant financial relationships to disclose.

Mutational landscape of breast cancers from PALB2 germline mutation carriers.

William Foulkes

Mr. Foulkes has no relevant financial relationships to disclose.

Predictive value of TGS-PT/CT after neoadjuvant endocrine treatment in breast cancer.

Emmanuel Fourrier

Mr. Fourrier has no relevant financial relationships to disclose.

Rapid genome-wide BRCA screens for locally advanced breast cancer changes surgical procedure after neoadjuvant chemotherapy.

Marien Fourrier

Dr. Fourrier has no relevant financial relationships to disclose.

Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer.

Alain Fourquet

Dr. Fourquet has no relevant financial relationships to disclose.

Targeting inflammatory pathways: A phase II trial of the JAK-inhibitor ruxolitinib in combination with exemestane for aromatase inhibitor-resistant, estrogen receptor-positive breast cancer.

Kevin Fox

Dr. Fox has no relevant financial relationships to disclose.

Single agent palbociclib with or without trastuzumab for the treatment of Rb+ advanced breast cancer.

Kevin Fox

Dr. Fox has no relevant financial relationships to disclose.

Return to work after breast cancer diagnosis: An observational prospective study of 125 patients in South America.

Natalia Fraile

Dr. Fraile has no relevant financial relationships to disclose.

Comprehensive genomic profiling to assess tumor mutation burden in ~8,000 breast cancer cases: Implications for immunotherapy.

Garrett Frampton

Dr. Frampton has disclosed that he receives salary from and has ownership in Foundation Medicine.

NOSTRA PRELIM: A non randomised pilot study designed to assess the ability of image guided core biopsies to detect residual disease in patients with early breast cancer who have received neoadjuvant chemotherapy to inform the design of a planned trial.

Adele Francis

Dr. Francis has disclosed that she is a consultant for Roche and Genomic Health.

The UK LORIS trial randomising patients with low or low intermediate grade ductal carcinoma in situ (DCIS) to surgery or active monitoring.

Adile Francis

Dr. Francis has no relevant financial relationships to disclose.

Multicentre observational study evaluating why mastectomies are advised by UK multi-disciplinary teams.

Adile Francis

Dr. Francis has no relevant financial relationships to disclose.

LORIS trial of active monitoring for DCIS: How does the online pathology eligibility review process work?

Adile Francis

Dr. Francis has no relevant financial relationships to disclose.
Long-term follow-up of TEXT and SOFT trials of adjuvant endocrine therapies for premenopausal women with HR+ early breast cancer

Prudence Francis

Dr. Francis has disclosed that she has presented the results of SOFT and TEXT trials for Pfizer at international meeting without personal compensation.

Breaded in the Bahamas: Revisiting the adequacy of national screening guidelines

Wesley Francis

Mr. Francis has no relevant financial relationships to disclose.

DCIS biological risk profile predicts risk of recurrence after breast conserving surgery in a Kaiser Permanente NW population

Melanie Francisco

Dr. Francisco has no relevant financial relationships to disclose.

Accelerated partial breast irradiation versus whole breast irradiation: Health-related quality of life analysis from a phase II trial

Stacie Fransz

Dr. Fransz has no relevant financial relationships to disclose.

The metastatic breast cancer project: Translational genomics through direct patient engagement

Elizabeth Frank

Ms. Frank has no relevant financial relationships to disclose.

Impact of pre-operative exercise and mind-body interventions on patient-reported outcomes in women with newly diagnosed breast cancer

Elizabeth Frank

Ms. Frank has no relevant financial relationships to disclose.

Impact of pre-operative exercise on breast cancer gene expression

Elizabeth Frank

Ms. Frank has no relevant financial relationships to disclose.

A randomized controlled trial comparing acupuncture versus usual care for the treatment of aromatase inhibitor-induced arthralgia (AIIA) in women with early-stage breast cancer

Harris Frank

Harris Frank has no relevant financial relationships to disclose.

Breast cancer in the Bahamas: Revisiting the adequacy of national screening guidelines

Paul Frankel

Dr. Frankel has no relevant financial relationships to disclose.

Phase II trial of the addition of pembrolizumab to letrozole and palbociclib in patients with metastatic estrogen receptor positive breast cancer who have stable disease on letrozole and palbociclib

Paul Frankel

Dr. Frankel has no relevant financial relationships to disclose.

Phase II trial of pertuzumab, trastuzumab, and nab-paclitaxel in patients (pts) with HER2 overexpressing (HER2+) locally advanced or inflammatory breast cancer (LABC) or untreated stage IV metastatic breast cancer (MBC)

Paul Frassoldati

A Frassoldati has no relevant financial relationships to disclose.

The impact of genomic mutation on metastatic breast cancer treatment: A retrospective clinical trial

André Franken

André Franken has no relevant financial relationships to disclose.

A new workflow comprising size-based CTC enrichment followed by in situ labeling and micromanipulation with CellCollector™ enables label-free enrichment, isolation and characterization of circulating tumor cells in breast cancer

Jan Franko

Dr. Franko has no relevant financial relationships to disclose.

Influence of winter season, driving distance, and time on receipt of breast conserving therapy among Iowa urban and rural patients

Daniela Frankova

Dr. Frankova has no relevant financial relationships to disclose.

Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomized, neoadjuvant phase II study (ABCSG-34)

Sophie Frantal

Ms. Frantal has disclosed that she is an employee of the non-profit organization ABCSG which served as legal & regulatory sponsor of ABCSG34 Trial. ABCSG is not a commercial interest as defined by ACCME. ABCSG34 Trial has been commercially sponsored by the commercial interest Merck.

HOHO study: How European and US young women cope with breast cancer and fertility concerns

Alessandra Frassoldati

Ms. Frassoldati has no relevant financial relationships to disclose.

Safety of the combination of exemestane plus exemestane in the Italian cohort of patients enrolled in the expanded access "BALLET" study

A Frassoldati

Mr. Frassoldati has no relevant financial relationships to disclose.
P4-21-10 Neo-adjuvant treatment with trastuzumab and pertuzumab associated with palbociclib and fulvestrant in HER2 positive and ER-positive breast cancer: Effect on Ki67 during and after treatment. A phase II Michelangelo study  
Antonio Frassoldati  
Dr. Frassoldati has no relevant financial relationships to disclose.

P4-07-09 Differential expression of microRNAs (miRNAs) in HER2 negative breast cancer (BC)  
Juan Fresno-Vara  
Dr. Fresno-Vara has no relevant financial relationships to disclose.

P1-12-04 Phase I dose-escalation trial of ONT-380 in combination with trastuzumab in patients (pts) with HER2+ breast cancer brain metastases  
Rachel Freedman  
Dr. Freedman has no relevant financial relationships to disclose.

P5-11-02 Phase I study of the JAK 1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2 negative metastatic breast cancer (MBC)  
Rachel Freedman  
Dr. Freedman has no relevant financial relationships to disclose.

P3-17-03 ECSG and the risk of breast cancer death - A case control study  
Ilma Fredriksson  
Dr. Fredriksson has no relevant financial relationships to disclose.

P6-11-11 Abemaciclib exposure-response relationship in patients with metastatic breast cancer in MONARCH 1  
Martin Frenzel  
Mr. Frenzel has disclosed that he is employed by and has a contract with Eli Lilly and Company.

P4-21-26 Population pharmacokinetics (PK) and exposure-response (E-R) analysis of trastuzumab emtansine (T-DM1) in patients with HER2+ metastatic breast cancer (MBC) who have received at least two prior regimens of HER2-directed therapy  
Jonathan French  
Dr. French has disclosed that he is an employee of Metrum Research Group LLC and was contracted as a paid consultant to Roche/Genentech for this research.

P5-02-03 Evaluating the feasibility of a web-based preference-tolerant randomized trial of risk-based vs. annual breast cancer screening: WISDOM study pilot  
Miya Frick  
Ms. Frick has no relevant financial relationships to disclose.

P6-16-02 Beta-adrenergic receptor blockers (BB) and increased progression free survival (PFS) in patients with advanced triple negative breast cancer (TNBC): A retrospective analysis of the ROSE/TRIO012 study  
Rafael Fresno  
Dr. Fresno has no relevant financial relationships to disclose.

P2-04-12 Results of the continuing education program in oncoplasty and breast reconstruction of the Brazilian Society of Mastology at Araújo Jorge Hospital in Goiânia  
Rafael Freitas-Junior  
Dr. Freitas-Junior has no relevant financial relationships to disclose.

P2-02-05 Pathological complete response to neoadjuvant trastuzumab is dependent on HER2/CEP17 ratio in HER2-amplified early breast cancer  
Michael Fridrik  
Mr. Fridrik has no relevant financial relationships to disclose.

P4-17-04 Restoration of phosphatidylserine by monoclonal antibodies enhances the activity of immune checkpoint ligand targeting antibodies in murine breast tumors  
Bruce Freimark  
Dr. Freimark has disclosed that he is a Peregrine employee.

P6-12-12 Phase I/II trial of the neuropeptidearginine demethylase inhibitor ACT-085359 combined with weekly paclitaxel in HER2+ metastatic breast cancer  
Rachel Freedman  
Dr. Freedman has no relevant financial relationships to disclose.

P2-01-06 Patterns of adjuvant evaluation in older patients (pts) with breast cancer and impact on adjuvant therapy  
Rachel Friedman  
Dr. Friedman has disclosed that she receives institutional funding from Novo Nordisk, Sanofi, and Puma.

P5-15-02 Impact of pre-operative exercise and mind-body interventions on patient-reported outcomes in women with newly diagnosed breast cancer  
Rachel Friedman  
Dr. Friedman has no relevant financial relationships to disclose.

P3-13-10 A comparison of the micro-impulse neural SAVI SCOUT to the radioactive 125 seed in localization of non-palpable breast cancer for breast conserving therapy  
Thomas Frazier  
Dr. Frazier has no relevant financial relationships to disclose.

P4-21-39 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian short-HERA trial  
Antonio Frassoldati  
Mr. Frassoldati has no relevant financial relationships to disclose.

P4-08-10 Differential expression of microRNAs (miRNAs) in HER2 negative breast cancer (BC)  
Isac Freire  
Mr. Freire has no relevant financial relationships to disclose.

P1-19-06 Population pharmacokinetics (PK) and exposure-response (E-R) analysis of trastuzumab emtansine (T-DM1) in patients with HER2+ metastatic breast cancer (MBC) who have received at least two prior regimens of HER2-directed therapy  
Jonathan French  
Dr. French has disclosed that he is an employee of Metrum Research Group LLC and was contracted as a paid consultant to Roche/Genentech for this research.

P1-09-10 Pathological complete response to neoadjuvant trastuzumab is dependent on HER2/CEP17 ratio in HER2-amplified early breast cancer  
Michael Fridrik  
Mr. Fridrik has no relevant financial relationships to disclose.
OT1-04-04 A phase 2 randomized, double-blind, placebo-controlled trial of endocrine therapy ± radium-223 dichloride in HER2-negative, hormone receptor-positive breast cancer patients with bone metastases
Georgeta Fried
Ms. Fried has no relevant financial relationships to disclose.

P4-22-17 BELUS: Safety and tolerability of at home administration of trastuzumab (Herceptin®) subcutaneous for the treatment of patients with HER2-positive early breast cancer
Georgeta Fried
Ms. Fried has no relevant financial relationships to disclose.

OT1-03-04 The DETECT V-study - Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemotherapy in patients with HER2-positive and hormone receptor-positive metastatic breast cancer
Thomas Friedl
Dr. Friedl has no relevant financial relationships to disclose.

OT3-04-02 DETECT III and IV - Individualized CTC-based therapy of metastatic breast cancer
Thomas Friedl
Dr. Friedl has no relevant financial relationships to disclose.

P2-01-05 Dynamics of circulating tumor cells during the course of chemotherapy and prognostic relevance across molecular subtypes in high-risk early breast cancer patients - Results from the adjunct SUCCESS A trial
Thomas Friedl
Dr. Friedl has no relevant financial relationships to disclose.

P3-05-02 Active surveillance with a combination of tumor marker CA27.29 and detection of circulating tumor cells two years after primary diagnosis strongly predicts subsequent prognosis
Thomas Friedl
Dr. Friedl has no relevant financial relationships to disclose.

P4-07-01 Profiling miRNA in high risk post-operative early breast cancer patients to detect possible association to correlation with immune system antitumor response
Thomas Friedl
Dr. Friedl has no relevant financial relationships to disclose.

P4-23-02 Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomised study of the efficacy and tolerability of V-TMZ or capecitabine (C) and paclitaxel (P) vs placebo (Plc) in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer
Michael Friedlander
Mr. Friedlander has disclosed that he is a consultant for AstraZeneca, Roche and Pfizer.

P2-09-12 Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc) in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: A randomized, phase 2 study
Michael Friedlander
Mr. Friedlander has disclosed that he is a consultant for AstraZeneca, Roche and Pfizer.

P3-04-24 Identification of precise cellular mechanisms driving acquired resistance to selective ESR1 degraders (SERDs), CDK4/6 inhibitors, or to combinations of both agents
Lori Friedman
Ms. Friedman has disclosed that she is an employee of Genentech, A Member of the Roche Group.

P4-06-05 Treatment of ESR1 mutant and PIK3CA mutant patient-derived breast cancer xenograft models reveals differential anti-tumor responses to estrogen receptor degraders and PI3K inhibitors in vivo
Lori Friedman
Ms. Friedman has disclosed that she receives salary from Genentech, Inc.

P5-03-05 Development of a panel of serum-based protein biomarkers for the non-invasive detection of breast cancer in BI-RADS category 4 patients
Lyssa Friedman
Ms. Friedman has disclosed that she is a consultant for OncoCyte Corporation.
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Author(s)</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P4-18-02</td>
<td>Peer navigation for people affected by hereditary breast, ovarian and related cancers: Results from the first six months</td>
<td>Susan Friedman</td>
<td>Dr. Friedman has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-10</td>
<td>Molecular differences between screen-detected and interval breast cancers are largely explained by PAM50 subtypes</td>
<td>Kay Friedrichs</td>
<td>Dr. Friedrichs has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-03-03</td>
<td>Molecular differences between screen-detected and interval breast cancers may benefit from super-enhancer-guided patient selection for selective acid receptor agonist treatment</td>
<td>Christian Fritz</td>
<td>Dr. Fritz has disclosed that he is an employee of and holder of shares and options for Synus Pharmaceuticals.</td>
</tr>
<tr>
<td>P6-11-18</td>
<td>Characterization of HER2-positive breast cancer (BR) cells selected for tolerance to trastuzumab-induced antibody-dependent cell-mediated cytolysis (ADCC)</td>
<td>Rebecca Fratianne</td>
<td>Ms. Fratianne has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-13-08</td>
<td>Preclinical validation of a new tumor imaging agent targeting CD30 to detect breast tumor using NIR light imaging</td>
<td>Elke Frey</td>
<td>Ms. Frey has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-07-16</td>
<td>Multilevel gene expression signatures provide significant prognostic information in metastatic breast cancer patients</td>
<td>Marianne Frostick Stolt</td>
<td>Ms. Frostick Stolt has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-04-21</td>
<td>Androgen-receptor in tamoxifen-resistant breast cancer is affected by SMARCO</td>
<td>Glenn Frutiz</td>
<td>Mr. Frutiz has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-12-02</td>
<td>Sarcoma-triggers central among triple negative breast cancer patients as a biomarker of poor outcome</td>
<td>Hanne Friedenberg</td>
<td>Dr. Friedenberg has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-18-01</td>
<td>Site-specific activation of cancerlinins in the breast cancer bone microenvironment</td>
<td>Jan Frye</td>
<td>Ms. Frye has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-06-08</td>
<td>Characterization of an estrogen-dependent murine model of human estrogen receptor-positive breast cancer bone metastasis</td>
<td>Jennifer Frye</td>
<td>Ms. Frye has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-10-03</td>
<td>A randomized trial of accelerated breast radiotherapy utilizing either 3-dimensional radiotherapy versus intensity modulated radiotherapy</td>
<td>Shannon Fryman</td>
<td>Ms. Fryman has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-23</td>
<td>A comparison of models (physician, the Van Nuys prognostic index, the Memorial-Sloan-Kettering Cancer Center DCIS nomogram) to predict ipsilateral breast events in patients with ductal carcinoma in situ (DCIS) of the breast after breast-conserving surgery failed to replicate results of the oncotype DCIS recurrence score</td>
<td>Shanmugam Fu</td>
<td>Ms. Fu has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-11-02</td>
<td>Multilevel gene expression signatures provide significant prognostic information in metastatic breast cancer patients</td>
<td>Marianne Frostick Stolt</td>
<td>Ms. Frostick Stolt has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-11-12</td>
<td>Pilot study of carboplatin, nab-paclitaxel and pembrolizumab for metastatic triple-negative breast cancer (ongoing clinical trial)</td>
<td>Wenyen Fu</td>
<td>Dr. Fu has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-01-13</td>
<td>The new oral SERD AZD9496 is efficacious in antagonizing ER and circumventing resistance to endocrine therapy</td>
<td>Xiaoyong Fu</td>
<td>Dr. Fu has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-04-07</td>
<td>Activation of a pro-metastatic secretome through ER-dependent and independent transcriptional reprogramming in endocrine-resistant breast cancer</td>
<td>Xiaoyong Fu</td>
<td>Dr. Fu has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-04-01</td>
<td>A novel BRD4 inhibitor enhances endocrine therapy efficacy, and circumvents resistance in estrogen receptor-positive breast cancer models</td>
<td>Xiaoyong Fu</td>
<td>Dr. Fu has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S4-01</td>
<td>A novel BRD4 inhibitor enhances endocrine therapy efficacy, and circumvents resistance in estrogen receptor-positive breast cancer models</td>
<td>Xiaoyong Fu</td>
<td>Dr. Fu has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-11-12</td>
<td>Re-evaluating outcomes of partial-breast irradiation using multicatheter brachytherapy for Japanese patients with breast cancer by European brachytherapy phase 3 trial</td>
<td>Hiroshi Fuchikami</td>
<td>Dr. Fuchikami has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-03-05</td>
<td>A comprehensive molecular analysis of mediastinal breast carcinoma: A model of immunomodulatory triple-negative breast cancer subtype</td>
<td>Laetitia Fuhmann</td>
<td>Fuhrmann has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
Validation of novel diagnostic kits using the semi-dry dot-blot method for detecting metastatic lymph nodes in breast cancer; distinguishing micrometastases and macrometastases

Junya Fukuoka

Dr. Fukuoka has no relevant financial relationships to disclose.

A randomized phase II trial of trastuzumab + capcitabine versus lapatinib + capcitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: UK0061010/ELTOP

Junya Fukuoka

Ms. Fukuoka has no relevant financial relationships to disclose.

Using ultrasound findings to predict high tumor-infiltrating lymphocytes in triple negative breast cancer

Atsushi Fukuuchi

Mr. Fukuuchi has no relevant financial relationships to disclose.

Preoperative assessment of breast cancer survival using ultrasound diameter and shear wave elastography

Frances Fuller-Pace

Frances Fuller-Pace has no relevant financial relationships to disclose.

Which measure of the interim changes in breast tumoral volume at breast MRI in response to neoadjuvant chemotherapy best predicts final pathological response?

Frances Fuller-Pace

Frances Fuller-Pace has no relevant financial relationships to disclose.

The footprint of the aging stroma in older breast cancer patients

Debora Fumagalli

Ms. Fumagalli has no relevant financial relationships to disclose.

Using ultrasound findings to predict high tumor-infiltrating lymphocytes in triple negative breast cancer

Atsushi Fukuuchi

Mr. Fukuuchi has no relevant financial relationships to disclose.

Preoperative assessment of breast cancer survival using ultrasound diameter and shear wave elastography

Frances Fuller-Pace

Frances Fuller-Pace has no relevant financial relationships to disclose.

Which measure of the interim changes in breast tumoral volume at breast MRI in response to neoadjuvant chemotherapy best predicts final pathological response?

Frances Fuller-Pace

Frances Fuller-Pace has no relevant financial relationships to disclose.

Preoperative assessment of breast cancer survival using ultrasound diameter and shear wave elastography

Frances Fuller-Pace

Frances Fuller-Pace has no relevant financial relationships to disclose.

Which measure of the interim changes in breast tumoral volume at breast MRI in response to neoadjuvant chemotherapy best predicts final pathological response?

Frances Fuller-Pace

Frances Fuller-Pace has no relevant financial relationships to disclose.

Preoperative assessment of breast cancer survival using ultrasound diameter and shear wave elastography

Frances Fuller-Pace

Frances Fuller-Pace has no relevant financial relationships to disclose.

Which measure of the interim changes in breast tumoral volume at breast MRI in response to neoadjuvant chemotherapy best predicts final pathological response?

Frances Fuller-Pace

Frances Fuller-Pace has no relevant financial relationships to disclose.

Preoperative assessment of breast cancer survival using ultrasound diameter and shear wave elastography

Frances Fuller-Pace

Frances Fuller-Pace has no relevant financial relationships to disclose.

Which measure of the interim changes in breast tumoral volume at breast MRI in response to neoadjuvant chemotherapy best predicts final pathological response?

Frances Fuller-Pace

Frances Fuller-Pace has no relevant financial relationships to disclose.

Preoperative assessment of breast cancer survival using ultrasound diameter and shear wave elastography

Frances Fuller-Pace

Frances Fuller-Pace has no relevant financial relationships to disclosing.
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>OT2-01-16</td>
<td>Evaluating targets in localized and advanced breast cancer by sequencing tumor DNA at diagnosis and after progression (ELSA)</td>
<td>Anu Gaba</td>
<td>Dr. Gaba has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-08-04</td>
<td>Phase 2/3 study of oral olaparib (LY-404036), a dual CYP11A1 type inhibitor and androgen receptor (AR) antagonist, in patients with advanced AR positive triple negative (TNBC) or estrogen receptor (ER) positive breast cancer (BC)</td>
<td>Nisheet Gabrail</td>
<td>Dr. Gabrail has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-26-05</td>
<td>Serial evolution of hormone receptor status and mutational profile among patients with metastatic breast cancer</td>
<td>Michele Gaddi</td>
<td>Dr. Gaddi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-01-09</td>
<td>Dynamics of circulating tumor cells during the course of chemotherapy and prognostic relevance across molecular subtypes in high-risk early breast cancer patients - Results from the adjuvant SUCCESS A trial</td>
<td>Greg Gade</td>
<td>Dr. Gade has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-20-11</td>
<td>Combined targeted therapies for advanced triple negative breast cancer: A phase II trial of nab-paclitaxel and bevacizumab followed by maintenance targeted therapy with bevacizumab and everolimus</td>
<td>Vijayakrishna Gadi</td>
<td>Dr. Gadi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-14-10</td>
<td>Weekly docetaxel and daily oral cyclophosphamide followed by nab-paclitaxel for adjuvant therapy of high-risk localized breast cancer</td>
<td>Vijayakrishna Gadi</td>
<td>Dr. Gadi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-08-11</td>
<td>Functional MSI signatures of immune response to targeted breast cancer therapy</td>
<td>Yue Gaddi</td>
<td>Dr. Gaddi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-08-17</td>
<td>Breast cancer in octogenarians: A community hospital experience</td>
<td>Vijayakrishna Gaddaram</td>
<td>Dr. Gaddaram has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-15-12</td>
<td>Real-life activity of oral visreraline in metastatic breast cancer patients in the UniCancer ESME database</td>
<td>Simon Gaeta</td>
<td>Mr. Gaeta has disclosed that ESME Data Platform granted by Roche, Pierre Fabre and Pfizer.</td>
</tr>
<tr>
<td>P5-08-25</td>
<td>The association between smoking and breast cancer characteristics and outcome</td>
<td>Omar Gal</td>
<td>Dr. Gal has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-13-01</td>
<td>Socioeconomic factors are essential determinants of weight gain between before and after cancer diagnosis: Results from the prospective population-based NutriNet-Santé cohort</td>
<td>Pilar Galan</td>
<td>Dr. Galan has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-04-04</td>
<td>Detection of ESR1 mutations in matched primary and metastatic samples from endocrine-resistant lobular breast cancer patients</td>
<td>Christine Galant</td>
<td>Dr. Galant has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-14-18</td>
<td>Isolated seroma metastases: the place of surgical resection</td>
<td>Christine Galant</td>
<td>Dr. Galant has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-08-04</td>
<td>Prospective evaluation of the predictive value of biomarkers with complete pathologic response using neoadjuvant chemotherapy plus trastuzumab + pertuzumab in Her2 (+) breast cancer patients</td>
<td>Christine Galant</td>
<td>Dr. Galant has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-13-01</td>
<td>Real-time monitoring for adverse reactions after first administration of subcutaneous trastuzumab necessary? A single institution audit</td>
<td>Raimundas Galuzauskas</td>
<td>Raimundas Galuzauskas has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-11-06</td>
<td>HER2 positive breast cancer and subclinical cardiotoxicity by echocardiogram 2D Strain, Do chemotherapies sequence matter?</td>
<td>Jaime Galindo-Uribe</td>
<td>Dr. Galindo-Uribe has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-13-01</td>
<td>Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study</td>
<td>Dafna Gallova</td>
<td>Dr. Gallova has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-11-01</td>
<td>PALONA: A Phase I safety study of palbociclib in combination with letrozole in African American women with hormone receptor positive HER2 negative advanced breast cancer</td>
<td>Christopher Gallagher</td>
<td>Dr. Gallagher has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-10-02</td>
<td>Increasing participation in research - breast cancer (Inspire-BrC)</td>
<td>Christopher Gallagher</td>
<td>Dr. Gallagher has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
Unhealthy lifestyle patterns are prevalent in unaffected BRCA mutation carriers & are associated with increased oxidative stress and telomere length alterations

Single agent palbociclib with or without trastuzumab for the treatment of Rb+ advanced breast cancer

Phase II of POSEIDON: A phase Ib / randomized phase II trial of olaparib plus taxol or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment

Plasma chemokine profile of HER2+ breast cancer (BC) patients treated with docetaxel (D) and carboplatin (C) in combination with trastuzumab (T) and/or lapatinib (L) in the neo-adjuvant setting

Bremsstrahlung inhibitors represent a rational therapeutic option for the treatment of invasive tubular carcinoma

Li-Fraumeni syndrome in females with early onset breast cancer in a Mexican population

Implications of financial modeling in breast cancer clinical research from 1990 to 2010

HOHO study: How European and US young women cope with breast cancer and fertility concerns

Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study

Squalene epoxidase is a potential metabolic oncogene by amplification with clinical implications in breast carcinoma: An in silico pan-cancer study with in vitro evidence

miR363-3p mediates maintenance and resistance of breast cancer stem cells (BCSC)

Accurate and reliable automated breast density measurements with no ionizing radiation using fat-water decomposition MRI

Breast density change at 6 months is associated with change at 12 months as measured by fat-water decomposition MRI in women on tamoxifen

The importance of the ultimate ratio of Omega-6 to Omega-3 fatty acids in the efficacy of fish oil supplements in suppressing inflammation in obese postmenopausal women

PAM50 intrinsic subtype as a predictor of pathological complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2 positive breast cancer: First results of the PAMELA clinical trial

Efficacy and gene expression results from SOLTI1007 NEOERIBULIN phase II clinical trial in HER2-negative early breast cancer

Phase III study of gabozarib (PD-0332991) in combination with endocrine therapy ( exemestane or fulvestrant) versus chemotherapy ( capecitabine) in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with resistance to Progressed Inhibitors. The “PEARL study” (GEICAM/2013-02)

Comprehensive comparison of breast cancer molecular portraits by African and European ancestry in the cancer genome atlas
Expression of LAG-3 in breast cancer, and its association with subtype and outcome

Environmental influence on epigenetic markers in the development of breast cancer

Circulating tumor cells in triple-negative breast cancer patients express prostate related genes and show different genetic profiles in US and German patient cohorts

Definition of breast cancer based on circulating protein biomarker profile using the DLINX proteomics multiplexed immunoassay extension assay

The Y537S ESR1 mutation is a dominant driver of distant ER-positive breast cancer metastasis

True effect of aromatase inhibitor (AI) treatment on global gene expression (exp) changes in postmenopausal ER breast cancer (BC) patients: A POETIC study (CRUK/07/015)

The impact of intrinsic: subtypes and molecular features on aromatase inhibitor induced reduction of proliferation marker of Ki67 in primary ER breast cancer: A POETIC study (CRUK/07/015)

Resistance to palbociclib depends on multiple targetable mechanisms highlighting the potential of drug holidays and drug switching to improve therapeutic outcome

BCAP31 promotes breast cancer progression via suppressing RNF1 expression

Comparison of axillary nodal status between different defined clinically node negative breast cancer: is ACOSOG Z0011 criteria applicable to preoperative cytologically negative axilla?

Accurate and reliable automated breast density measurements with no ionizing radiation using fat-water decomposition MRI

A phase II study to compare fulvestrant (F) 500mg plus placebo versus (vs) 500mg plus palbociclib (P) as first line treatment for postmenopausal women with hormone receptor (HR)-positive advanced breast cancer (BC) sensitive to endocrine therapy (ET): "The FLIPPER study" (SGC/J/2014-12)

BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer

Sensitivity to lapatinib differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA and relies on production of PIP3

Evaluation of Further infiltrating lymphocytes (ITLs) and their association with homologous recombination deficiency and BRCA1/2 mutation status in triple-negative breast cancer (TNBC): A pooled analysis

Patent information and availability

Financial relationships information
Committee Member: Judy Garber

Dr. Garber has disclosed that her spouse receives consulting fees from Novartis and Pfizer. She also disclosed that she receives funded research from Myriad and Ambrey. These relationships do not impact her ability to review presentations.

P1-12-01 A phase II, open-label, multi-center study of ANG1005, a novel brain-penetrant peptide-drug conjugate, in breast cancer patients with recurrent CNS metastases
Agustin Garcia
Dr. Garcia has no relevant financial relationships to disclose.

P5-08-30 Utilization of oncotype DX for breast cancer in different facility-types in Louisiana
Agustin Garcia
Dr. Garcia has no relevant financial relationships to disclose.

P4-20-03 Implications of financial modeling in breast cancer clinical research from 1990 to 2010
Nelson Garcia
Dr. Garcia has no relevant financial relationships to disclose.

P5-10-20 Impact of "immunohistochemistry-based molecular subtype" on chemo-sensitivity and survival in Hispanic breast cancer patients following neoadjuvant chemotherapy (MAC)
Nelson Garcia
Mr. Garcia has no relevant financial relationships to disclose.

P6-09-33 CASCARD study: Rapid survival decline per treatment line in metastatic breast cancer
Jesus Garcia
Dr. Garcia has no relevant financial relationships to disclose.

P5-17-04 Presentation of a Bayesian decision model for the treatment of ductal carcinoma in situ (DCIS) of the breast
Juan Miguel Garcia
Mr. Garcia has no relevant financial relationships to disclose.

P6-09-33 CASCARD study: Rapid survival decline per treatment line in metastatic breast cancer
Paula Garcia
Mr. Garcia has no relevant financial relationships to disclose.

P5-15-09 Evaluation of growth modulation index as a marker of benefit for consecutive lines of treatment for metastatic breast cancer
Elisa Garcia Garre
Mr. Garcia Garre has no relevant financial relationships to disclose.

P5-15-09 Evaluation of growth modulation index as a marker of benefit for consecutive lines of treatment for metastatic breast cancer
Elena Garcia Martinez
Dr. Garcia Martinez has no relevant financial relationships to disclose.

P6-07-21 High reduction of circulating tumour cells in HER2-negative locally advanced or metastatic breast cancer (LAMBC) patients treated with eribulin as third line chemotherapy (ONSITE study)
Ismael Garcia Saben
Mr. Garcia Saben has no relevant financial relationships to disclose.

P03-03 Determining the prognostic role of early and end-of- neoadjuvant chemotherapy 18F-FDG PET/CT in patients with locally advanced breast cancer
Ana Maria Garcia Vicente
Ms. Garcia Vicente has no relevant financial relationships to disclose.

P4-04-01 Phase II of POSEIDON: A phase IIb / randomized phase II trial of bemasan plus taxol/ibu in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment
Montserrat Garcia-Closas
Montserrat Garcia-Closas has no relevant financial relationships to disclose.

OT2-01-11 Phase II of POSEIDON: A phase IIb / randomized phase II trial of bemasan plus taxol/ibu in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment
Javier Garcia-Corbacho
Mr. Garcia-Corbacho has no relevant financial relationships to disclose.

P4-04-05 Identification of SANK45987, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong antitumor activity in wild-type and mutant ER+ breast cancer models
Carles Garcia-Echevarria
Mr. Garcia-Echevarria has no relevant financial relationships to disclose.

P4-22-18 Phase II safety, efficacy, and molecular analysis of ribociclib (LEE011) plus letrozole for the treatment of ER+, HER2- advanced breast cancer
Laura Garcia-Estevez
Ms. Garcia-Estevez has no relevant financial relationships to disclose.

P4-20-08 Evaluation of a multidisciplinary cancer team quality in a breast cancer unit (BCU) in Mexico
Maritza Garcia Garces
Dr. Garcia-Garces has no relevant financial relationships to disclose.

P1-02-01 Circulating tumor DNA analysis to predict relapse and overall survival in early breast cancer - Longer follow-up of a proof-of-principle study
Jose Garcia Saenz
Dr. Garcia Saenz has no relevant financial relationships to disclose.

P4-21-05 Neoadjuvant non-pegylated liposomal doxorubicin plus paclitaxel, trastuzumab and pertuzumab in patients with HER2+ breast cancer - Final results of the SOLTI OPTI-HER HEART study
Jose Garcia-Saenz
Dr. Garcia-Saenz has no relevant financial relationships to disclose.
Proteomic response in breast cancer treated with neoadjuvant chemotherapy with and without bevacizumab: Reverse phase protein array (RPPA) results from NeoaVu - A randomized phase II study

Amy Garrett
Ms. Garrett has no relevant financial relationships to disclose.

Phase II of POSEIDON: A phase Ib / randomized phase II trial of (tamoxifen plus taxolib or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment

Laia Garriga
Ms. Garriga has no relevant financial relationships to disclose.

Combined targeted therapies for advanced triple negative breast cancer: A phase II trial of nab-paclitaxel and bevacizumab followed by maintenance targeted therapy with bevacizumab and erlotinib

Mitchell Garrison
Dr. Garrison has no relevant financial relationships to disclose.

PAINTER: Evaluation of eribulin tolerability and correlation between a set of polymorphisms and neuropathy in patients with metastatic breast cancer

Ornella Garrone
Dr. Garrone has no relevant financial relationships to disclose.

Luminal A breast cancer: Is it really a "good prognosis" disease? Preliminary results of the GIM-13 - AMBRA study

Omella Garrone
Dr. Garrone has no relevant financial relationships to disclose.

First and further lines of treatment for HER2-VE metastatic breast cancer (MBC) according to adjuvant treatment and biological subtype. Preliminary results of the observational "GIM-13 - AMBRA" Italian study

Omella Garrone
Dr. Garrone has no relevant financial relationships to disclose.


Pere Gascon
Pere Gascon has no relevant financial relationships to disclose.

CCND1 amplification in early breast cancer patients: Correlation with subtypes and prognosis

Armén Gasparyan
Mr. Gasparyan has no relevant financial relationships to disclose.

The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer

Jennifer Gass
Ms. Gass has no relevant financial relationships to disclose.

Programmed death 1 (PD-1) and PD-1 ligand (PD-L1) distribution in triple negative breast cancer (TNBC)

Oran Gatalica
Dr. Gatalica has no relevant financial relationships to disclose.

Use of an aptamer library based next generation omics platform for the development of a novel trastuzumab predictive assay

Oran Gatalica
Dr. Gatalica has disclosed that he receives salary from and has ownership from Chris Life Sciences.
Comprehensive genomic profiling of clinically malignant phyllodes tumors of the breast reveals frequent mutation of NF1 and other genes associated with PI3K and RAS pathway activation.

Laurie Gay

Dr. Gay has disclosed that she receives salary from and has ownership in Foundation Medicine, Inc.

Comprehensive genomic profiling of 8,654 breast carcinoma reveals therapeutically targetable molecular subtypes beyond those defined by hormone-receptor expression

Laurie Gay

Dr. Gay has disclosed that she receives salary from and has ownership in Foundation Medicine, Inc.

Comprehensive genomic profiling of 34 cases of breast angiosarcoma

Laurie Gay

Dr. Gay has disclosed that she is an employee of Foundation Medicine with equity interest.

Are we missing actionable targets in breast cancer? Novel insights into recurrent Ret alterations

Laurie Gay

Ms. Gay has disclosed that he receives salary from and has ownership in Foundation Medicine.

Preclinical validation of a novel tumor imaging agent targeting αvβ3 to detect breast tumor using NIR-light imaging

Pascal Gayet

Pascal Gayet has no relevant financial relationships to disclose.

Plasma chemokine profile of HER2+ breast cancer (BC) patients treated with docetaxel (D) and carboplatin (C) in combination with trastuzumab (T) and/or lapatinib (L) in the neo-adjuvant setting

Nicola Gaynor

Ms. Gaynor has no relevant financial relationships to disclose.

Immune profiling of post neoadjuvant high metastatic risk (RCB- II/III) residual disease in patients with early triple negative breast cancers

Patrycja Gazinka

Patrycja Gazinka has no relevant financial relationships to disclose.

BRCA2: methylation status, silencing and treatment effect in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA2 breast cancer (CTN/BR1312)

Patrycja Gazinka

Patrycja Gazinka has no relevant financial relationships to disclose.

Maximization induced DDR2 mediates stromal-cancer interactions and metastasis growth in breast cancer

Chunyi Ge

Chunyi Ge has no relevant financial relationships to disclose.

Results of multiplex assay (MammaPrint®) and molecular subtyping (BluePrint®) substantially impact treatment decision making in early breast cancer: final analysis of the NGS PRIME decision impact study

Gerhard Gebauer

Prof. Gebauer has no relevant financial relationships to disclose.

9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian short HER trial

Vittorio Gebbia

Mr. Gebbia has no relevant financial relationships to disclose.

Utilization and outcomes of post mastectomy radiotherapy in women with 1-3 positive axillary nodes following neoadjuvant chemotherapy: A multiply-imputed, propensity-adjusted National cancer database analysis

Brian Gebhardt

Dr. Gebhardt has no relevant financial relationships to disclose.

Standardization of nodal radiation therapy (RT) through changes to a breast cancer clinical pathway (CP) in a large, integrated comprehensive cancer center network

Brian Gebhardt

Dr. Gebhardt has no relevant financial relationships to disclose.

Osteoprotegerin mediates tumor-promoting effects of Interleukin-1β in breast cancer cells

Dirk Geerts

Dr. Geerts has no relevant financial relationships to disclose.

Beyond CHEK2 in breast cancer: Search for additional moderately penetrant risk gene variants by analyzing the oligogenic disease course in CHEK2 mutation carriers

Andrea Gehrig

Ms. Gehrig has no relevant financial relationships to disclose.

A randomized study comparing MoistHer to topical lidocaine for female breast cancer survivors with dyspareunia

John Geisler

Dr. Geisler has no relevant financial relationships to disclose.

Steroid receptors and steroidogenic enzymes in human breast cancer: Associations with breast cancer subtypes and clinical outcome

Jürgen Geisler

Mr. Geisler has no relevant financial relationships to disclose.

High-grade human cytomegalovirus IEA is associated with expression of COX-2 and 5-LO in human breast cancer samples

Jürgen Geisler

Mr. Geisler has no relevant financial relationships to disclose.

Low expression levels of hormone receptors (ERα and PGR) in human breast cancer samples is significantly associated with high-grade human cytomegalovirus IEA

Jürgen Geisler

Mr. Geisler has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Disclosures</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2-05-16</td>
<td>Establishment of molecular profiling for individual treatment decisions in early breast cancer - Clinical impact of PAM50 and PAM50 risk of recurrence score after more than 16 years follow up</td>
<td>Gry Geitvik</td>
<td>Gry Geitvik has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT3-02-05</td>
<td>Long-term follow-up of TEXT and SOFT trials of adjuvant endocrine therapies for premenopausal women with HR+ early breast cancer</td>
<td>Richard Gelber</td>
<td>Dr. Gelber has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-09-05</td>
<td>12 years median follow up (MFU) of BIG 1-98: Adjuvant letrozole, tamoxifen and their sequence for postmenopausal women with endocrine responsive early breast cancer</td>
<td>Richard Gelber</td>
<td>Dr. Gelber has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-11-16</td>
<td>ESTRA: A phase II study of palbociclib plus fulvestrant versus placebo plus fulvestrant for pre-treated patients with ER+/HER2- metastatic breast cancer</td>
<td>Richard Gelber</td>
<td>Dr. Gelber has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-09-07</td>
<td>Drugs don’t work if people don’t take them: Non-initiation of endocrine therapy in young women</td>
<td>Shari Gelber</td>
<td>Ms. Gelber has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P06-04</td>
<td>HER2 study: How European and US young women cope with breast cancer and fertility concerns</td>
<td>Shari Gelber</td>
<td>Ms. Gelber has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT3-02-09</td>
<td>A phase II randomised, double-blinded, controlled study of ONT-380 vs placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC)</td>
<td>Karen Gelman</td>
<td>Dr. Gelman has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-09-08</td>
<td>Predictive effect of cytotoxic tumor infiltrating lymphocytes in HER2-positive metastatic breast cancer: A correlative study with CCTG MA.31</td>
<td>Karen Gelman</td>
<td>Dr. Gelman has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-06-10</td>
<td>Rates of successful engraftment in breast cancer xenograft models based on tissue type: Primary vs relapsed disease</td>
<td>Karen Gelman</td>
<td>Dr. Gelman has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-22-07</td>
<td>Long-term safety of paclitaxel in combination with endocrine therapy in treatment-naive and previously treated women with HR+, HER2- advanced breast cancer: A pooled analysis from randomised phase 2 and 3 studies</td>
<td>Karen Gelman</td>
<td>Ms. Gelman has disclosed that she is on the Canadian Advisory Board and has contracts with Canadian Cancer Trials Group (PALESTRA trial), Pfizer (PAO35MA-2 trial).</td>
</tr>
<tr>
<td>P6-07-06</td>
<td>The Y537S ESR1 mutation is a dominant driver of distant ER-positive breast cancer metastasis</td>
<td>Luca Salamino</td>
<td>Luca Salamino has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S4-02</td>
<td>Oncologic outcome of pregnancy associated breast cancer: A case control study</td>
<td>Mario Germiniani</td>
<td>Ms. Germiniani has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-07-03</td>
<td>The complete spectrum of ESR1 mutations from 7590 breast cancer tumor samples</td>
<td>Steven Gendreau</td>
<td>Mr. Gendreau has disclosed that he is an employee of Genentech Inc.</td>
</tr>
<tr>
<td>OT1-01-05</td>
<td>T-DM1 in HER2 positive advanced breast cancer patients: Real world practice from a multicenter observational study</td>
<td>Daniele Giulio Generali</td>
<td>Ms. Generali has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT3-03-03</td>
<td>Challenges faced across borders to open European academic multicentre projects: The ET-PEIS program part of the ERA-Net TRANSCEAN (TY): 2011</td>
<td>Alessandra Genovese</td>
<td>Dr. Gennari has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
Randomized phase II study evaluating different schedules of nab-paclitaxel in metastatic breast cancer (MBC): Results of the SNAP study

Alessandra Gennari

Dr. Gennari has disclosed that she is a consultant and speaker for Teva, Eisai and Celgene.

Evaluation of intra-tumor heterogeneity, test reproducibility and their impact in breast cancer samples assessed by Prosigna™: Results from a decision impact prospective study and a matched case-control study

David Gentian

Mr. Gentian has no relevant financial relationships to disclose.

Global Cancer Institute online tumor boards to improve global patterns of clinical practice for breast cancer

Nedjaib Georgieva

Dr. Georgieva has no relevant financial relationships to disclose.

Prevalence of insulin-like growth factor-1 receptor (IGF1R) expression in circulating tumor cells (CTCs) of patients with early breast cancer and its association with the eastern expression and patient survival

Vasiliki Georgoulis

Vasiliki Georgoulis has no relevant financial relationships to disclose.

Evaluation of intra-tumor heterogeneity, test reproducibility and their impact in breast cancer samples assessed by Prosigna™: Results from a decision impact prospective study and a matched case-control study

David Gentian

Mr. Gentian has no relevant financial relationships to disclose.

Risk of metastases after ipsilateral breast tumour recurrence changes overtime according to patient and tumour characteristics: Implications for treatment

Massimiliano Gennaro

Dr. Gennaro has no relevant financial relationships to disclose.

Race and age differences in PAM50 biomarker status in the Carolina breast cancer study

Joseph Geradts

Dr. Geradts has no relevant financial relationships to disclose.

Can polyploid tumor cells possessing stem cell features be induced in resistant breast carcinoma?

Bozena Geraschke

Dr. Geraschke has no relevant financial relationships to disclose.

Development of a novel HER2 testing strategy, using image-based cell-sorting to isolate pure cell populations from FFPE specimens of IHC

Amanda Gerber

Ms. Gerber has no relevant financial relationships to disclose.

Comparison of axillary sentinel lymph node biopsy versus no axillary surgery in patients with early-stage invasive breast cancer and breast-conserving surgery: A randomised controlled trial

Jose Geraltz

Dr. Geraltz has no relevant financial relationships to disclose.

Peripheral sensory neuropathy occurrence and resolution: Results from the neoadjuvant randomized GeparSepto study (GBG 69)

Bernd Geraltz

Dr. Geraltz has no relevant financial relationships to disclose.

Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSimo in triple-negative early breast cancer

Bernd Geraltz

Dr. Geraltz has no relevant financial relationships to disclose.

SOLAR-1: A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy

Caroline Gerba

Ms. Gerba has disclosed that she receives salary from and has ownership in Novartis.

First-line ribociclib plus letrozole in patients with de novo HR+, HER2- advanced breast cancer (ABC): A subgroup analysis of the MONALEESA-3 trial

Caroline Gerba

Ms. Gerba has disclosed that she is a Novartis employee and has ownership in Novartis.
First-line ribociclib plus letrozole in patients with de novo HR+, HER2- advanced breast cancer (ABC): A subgroup analysis of the MONALEESA-2 trial

Caroline Germa

Ms. Germa has disclosed that she is a Novartis employee and has ownership in Novartis.

Phase II safety, efficacy, and molecular analysis of ribociclib (LEE011) plus letrozole for the treatment of ER+, HER2- advanced breast cancer

Caroline Germa

Ms. Germa has disclosed that she is a Novartis employee and has ownership in Novartis.

Genetic variation in CYP3A affects steady-state exemestane concentrations but does not explain inter-race difference

Christina Gerch

Ms. Gerch has no relevant financial relationships to disclose.

Experience in the ABC Medical Center of Mexico City 2010-2015 using scalp-cooling system (DigniCap) for prevention of alopecia induced by chemotherapy

Raquel Gersan

Dr. Gersan has no relevant financial relationships to disclose.

Landscape of somatic mutations in inflammatory breast cancer whole-genome sequences

Mark Gaertlein

Dr. Gaertlein has no relevant financial relationships to disclose.

Analytical and clinical validation of a fully automated tissue-based quantitative assay (MetaSite Breast™) to detect the likelihood of distant metastasis in hormone receptor (HR)-positive, HER2-negative early stage breast cancer (ESBC) with local recurrence in young women with invasive breast cancer; the prospective study of outcomes in sporadic and hereditary breast cancer (POSH)

Sue Gerty

Ms. Gerty has no relevant financial relationships to disclose.

Does BRCA status affect outcome in young breast cancer patients? Results from the prospective study of outcomes in sporadic and hereditary breast cancer (POSH)

Sue Gerty

Ms. Gerty has no relevant financial relationships to disclose.

A randomized, double-blind, phase 2 study of ruxolitinib (RUX) or placebo (PBO) in combination with capecitabine (CAPE) in patients (pts) with advanced HER2-negative breast cancer (ABC) and elevated C-reactive protein (CRP), a marker of systemic inflammation

Ryan Geschwindt

Mr. Geschwindt has disclosed that he is an employee and stockholder of Incyte Corporation.

KEYNOTE-012: Long-lasting responses in a phase Ib study of pembrolizumab for metastatic triple-negative breast cancer (mTNBC)

Ravit Geva

Ravit Geva has no relevant financial relationships to disclose.

The genomic landscape of breast metaplastic carcinoma

Felipe Geyer

Dr. Geyer has no relevant financial relationships to disclose.

Intra-tumor genetic heterogeneity and histologic heterogeneity within metaplastic breast cancers: Genotypic-phenotypic correlations

Felipe Geyer

Dr. Geyer has no relevant financial relationships to disclose.

Mutational landscape of breast cancers from PALB2 germline mutation carriers

Felipe Geyer

Dr. Geyer has no relevant financial relationships to disclose.

The landscape of somatic genetic alterations in BRCA1 and BRCA2 breast cancers

Felipe Geyer

Dr. Geyer has no relevant financial relationships to disclose.

A randomized, double-blind, placebo-controlled clinical trial to evaluate extended adjuvant endocrine therapy (5 years of letrozole) in postmenopausal women with hormone-receptor positive breast cancer who have completed previous adjuvant endocrine therapy: Initial results of NRG oncology/NSABP B-42

Charles Geyer, Jr

Mr. Geyer has no relevant financial relationships to disclose.

A phase III trial evaluating gilteritinib in patients with HR+, HER2- positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCP) +/- estrogen deprivation: NRG oncology/NSABP B-52

Charles Geyer, Jr

Mr. Geyer has disclosed that he receives travel to attend Advisory Board without consulting fee.

CHARACTERIZATION OF NEUROENDOCRINE BREAST CARCINOMAS FOR BIOMARKERS OF THERAPEUTIC OPTIONS

Anatole Ghazalpour

Dr. Ghazalpour has disclosed that he is an employee of Caris Life Sciences.

Factors related to the prognosis of breast cancer patients after the development of brain metastases

Cristina Ghiozzi

Dr. Ghiozzi has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Committee Member/Speaker, Educational Session</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2-03-04</td>
<td>&quot;Widening the scenario for long term treatment of metastatic HER2+ breast cancer&quot;</td>
<td>Luca Gianni</td>
<td>Dr. Gianni has disclosed that he receives consulting fees from Roche, GlaxoSmithKline, Pfizer, Boehringer Ingelheim, Celgene, Taiho Pharmaceutical, Tiziana Pharma, Synthon, AstraZeneca, Genomic Health, Merck, Sharp &amp; Dohme and Synaffix. These relationships do not impact his ability to present an unbiased presentation.</td>
</tr>
<tr>
<td>P6-09-07</td>
<td>Mutational characteristics and tumor infiltrating lymphocytes in early and metastatic HER2 positive breast cancer</td>
<td>Eleni Giamou et al.</td>
<td>Ms. Giannoulatou has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-02-11</td>
<td>Clinical examination and breast MRI as predictors of pathologic complete response post neoadjuvant therapy in HER2 overexpressed subtypes and triple negative breast cancer</td>
<td>Daniela Gianetti et al.</td>
<td>Dr. Giannoulatou has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-20</td>
<td>Long-term follow-up of persistent breast derrmopigmentation after sentinel lymph node identification using superparamagnetic iron-oxide particles (SIENNA®)</td>
<td>Syksia Giaratano</td>
<td>Dr. Giaratano has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-01-23</td>
<td>Factors related to the prognosis of breast cancer patients after the development of brain metastases</td>
<td>Tommaso Giaratano</td>
<td>Dr. Giaratano has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-12-06</td>
<td>Pertuzumab and trastuzumab in combination with weekly paclitaxel delivers high pCR rates with favourable toxicity profile in neoadjuvant treatment of Her-2 positive breast cancer</td>
<td>Erica Gibrin</td>
<td>Dr. Gibrin has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-21-23</td>
<td>A retrospective evaluation of cardiovascular recovery and oncologic outcomes associated with interrupted and continuous adjunct trastuzumab in the setting of mild left ventricular dysfunction</td>
<td>Jordan Gibson</td>
<td>Jordan Gibson has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-09-03</td>
<td>Low-level gonosomal mosaicism of a de novo BRCA1 gene mutation - The origin of a constitutional mutation in a breast cancer family</td>
<td>Jutta Giesecke</td>
<td>Dr. Giesecke has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-34</td>
<td>Clinical and pathological characteristics of a representative cohort of long-term metastatic breast cancer (MBC) survivors</td>
<td>Daniel Goedert</td>
<td>Dr. Goedert has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-03-06</td>
<td>Mechanisms of CD8+ T cell immuno-suppression in triple negative breast cancer</td>
<td>Mathieu Gogoux</td>
<td>Dr. Gogoux has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-08-02</td>
<td>Multi-gene panel testing for hereditary cancer predisposition in unselected high risk breast and ovarian cancer patients</td>
<td>Eida Göl</td>
<td>Eida Göl has disclosed that his salary is paid by and he owns stock in Color Genomics.</td>
</tr>
<tr>
<td>P5-10-04</td>
<td>Spectrum of hereditary breast and ovarian cancer gene variants in an African American cohort</td>
<td>Eida Göl</td>
<td>Eida Göl has disclosed that he receives salary and has ownership.</td>
</tr>
<tr>
<td>P6-11-10</td>
<td>Preclinical efficacy of the novel FKHD2 kinase inhibitor, IP16446 in triple negative breast cancer models</td>
<td>Malgorzata Gil</td>
<td>Dr. Gil has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-21-32</td>
<td>Treatment of early HER2-positive breast cancer in trastuzumab naive patients in everyday clinical practice: An overview after 10 years of its approval</td>
<td>Miguel Gil</td>
<td>Dr. Gil has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-17-01</td>
<td>Adjunct treatment with zoladexic acid (ZOL) in stage II/III breast cancer: The AZURE trial (BIG 01/04) 10 year follow-up</td>
<td>Miguel Gil</td>
<td>Dr. Gil has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT1-04-01</td>
<td>Cambridge brain mets trial 1 (CamBMT1): A proof-of-principle phase 1b / randomized phase 2 study of afatinib penetration into brain metastases for patients undergoing neurological resection, both with and without prior low-dose, targeted radiotherapy</td>
<td>Fiona Gilbert</td>
<td>Ms. Gilbert has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-05-02</td>
<td>ONCO201 tills breast cancer cells by inhibiting mitochondrial respiration</td>
<td>Sam Gilbert</td>
<td>Dr. Gilbert has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
Triple-negative first-line study: Neoadjuvant trial of nab-paclitaxel and atezolizumab, a PD-L1 inhibitor, in patients with triple negative breast cancer (TNBC) (NCT02530489)

Michael Gilcrease
Dr. Gilcrease has no relevant financial relationships to disclose.

Phase III study of neoadjuvant panitumumab combined with carboplatin and paclitaxel (PACT) for anthracycline-resistant triple-negative breast cancer (TNBC)

Michael Gilcrease
Dr. Gilcrease has no relevant financial relationships to disclose.

NCI-2016-00367: A phase IIB study of neoadjuvant ZT regimen (enzalutamide therapy in combination with weekly paclitaxel) for androgen receptor (AR)-positive triple-negative breast cancer (TNBC)

Michael Gilcrease
Dr. Gilcrease has no relevant financial relationships to disclose.

Feasibility trial for identification of patients for eliminating breast cancer surgery following neoadjuvant systemic therapy

Michael Gilcrease
Dr. Gilcrease has no relevant financial relationships to disclose.

Estrogen receptor 1 (ESR1) mutations in circulating tumor DNA (ctDNA): A guide to the management of advanced breast cancer (ABC)

Francis Giles
Dr. Giles has no relevant financial relationships to disclose.

Circulating tumor DNA (ctDNA): A real-time application of precision medicine to the management of metastatic breast cancer (MBC)

Francis Giles
Dr. Giles has no relevant financial relationships to disclose.

A novel progesterone receptor (PR)-RNA polymerase III association represses estrogen-dependent growth in breast tumor patient-derived xenografts

Austin Gillen
Dr. Gillen has no relevant financial relationships to disclose.

Copy number aberration-induced gene breakage analysis identifies recurrent FOXP1 fusions in breast cancer

Cheryl Gillett
Ms. Gillet has no relevant financial relationships to disclose.

BRCA2 methylation status, silencing and treatment effect in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)

Cheryl Gillett
Ms. Gillett has no relevant financial relationships to disclose.

Association of co-amplicons with immune infiltration in subtypes of HER2-Positive breast cancer

Hannah Gilmore
Dr. Gilmore has no relevant financial relationships to disclose.

Genomic profiling of residual ER+ breast cancers treated with prolonged neoadjuvant letrozole reveals novel alterations in clinically resistant tumors

Jennifer Giltnane
Ms. Giltnane has disclosed that she is an employee of Genentech, A Member of the Roche Group.

Treatment of ESR1 mutant and PIK3CA mutant patient-derived breast cancer xenograft models reveals differential anti-tumor responses to estrogen receptor degraders and PI3K inhibitors in vivo

Jennifer Giltnane
Ms. Giltnane has disclosed that she receives salary from Genentech.

MHC-II positive breast tumors are more immunogenic and may preferentially select for LAG-3-positive tumor immune infiltrates

Jennifer Giltnane
Ms. Giltnane has disclosed that she receives salary from Genentech.

Sentinel node detection after neoadjuvant chemotherapy in patient without previous axillary node involvement (GANEA 2 trial): Follow-up of a prospective multi-institutional cohort

Pierre Gimbergues
Dr. Gimbergues has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Disclosures</th>
</tr>
</thead>
<tbody>
<tr>
<td>P5-14-09</td>
<td>Luminal A breast cancer: Is it really a “good prognosis” disease? Preliminary results of the GIM-13 - AMBRA study</td>
<td>Monica Giordano</td>
<td>Dr. Giordano has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-15-07</td>
<td>First and further line choices of treatment for HER2-VE metastatic breast cancer (MBC) according to adjuvant treatment and biological subtype. Preliminary results of the observational GIM-13 - AMBRA Italian study</td>
<td>Monica Giordano</td>
<td>Dr. Giordano has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-04</td>
<td>HER2O study: How European and US young women cope with breast cancer and fertility concerns</td>
<td>Monica Giordano</td>
<td>Ms. Giordano has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-20-05</td>
<td>Patient-reported cosmetic outcomes in older breast cancer survivors: A population-based survey study</td>
<td>Sharon Giordano</td>
<td>Dr. Giordano has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-08-02</td>
<td>Improving the AJCC breast cancer staging system by incorporating tumor biomarkers</td>
<td>Sharon Giordano</td>
<td>Dr. Giordano has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-08-02</td>
<td>Improving the AJCC breast cancer staging system by incorporating tumor biomarkers</td>
<td>Sharon Giordano</td>
<td>Dr. Giordano has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P9-09-17</td>
<td>Evaluation of a risk score based on biological factors to enhance prognostic stratification by the American Joint Committee on Cancer (AJCC) Staging System</td>
<td>Sharon Giordano</td>
<td>Dr. Giordano has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-09-21</td>
<td>Clinical evaluation of m8-100 as a predictor of endocrine-responsiveness in hormone receptor-positive breast cancer</td>
<td>Silvia Giordano</td>
<td>Dr. Giordano has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-22-06</td>
<td>Treatment of postprogession in women with endocrine-resistant m8-HER2-advanced breast cancer who received palbociclib plus-lucrinat in PALOMA-3</td>
<td>Carla Giorgiatti</td>
<td>Ms. Giorgiatti has disclosed that she receives salary from and has ownership in Pfizer.</td>
</tr>
<tr>
<td>P1-12-06</td>
<td>Factors related to the prognosis of breast cancer patients after the development of brain metastases</td>
<td>Carlo Alberto Giorgi</td>
<td>Dr. Giorgi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-05-20</td>
<td>Tumor infiltrating lymphocytes in recurrent HER2+ and triple negative breast cancer: Prognostic value according to tumor phenotype</td>
<td>Carlo Alberto Giorgi</td>
<td>Dr. Giorgi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S6-01</td>
<td>9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian short-HER trial</td>
<td>Francesco Giotta</td>
<td>Mr. Giotta has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-22-02</td>
<td>Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboptatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer</td>
<td>Vincent Giranda</td>
<td>Mr. Giranda has disclosed that he is an employee of and has ownership in AbbVie.</td>
</tr>
<tr>
<td>S2-04</td>
<td>Efficacy and tolerability of veliparib (V; ABB-888) in combination with carboptatin (C) and paclitaxel (P) in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: A randomized, phase 2 study</td>
<td>Vincent Giranda</td>
<td>Mr. Giranda has disclosed that he is an employee of and has ownership in AbbVie.</td>
</tr>
<tr>
<td>P6-09-05</td>
<td>Prognostic and predictive values of high endothelial venules (HEV) and tumor infiltrating CD8+ lymphocytes (CD8) in tumors of patients included in the adjuvant PACS04 trial: HER2 is predictive of outcome for HER2+ tumors exposed to trastuzumab</td>
<td>Jean-Philippe Girard</td>
<td>Dr. Girard has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-32</td>
<td>Prognostic factors in breast cancer (BC) associated with the development of brain metastases (BM): A retrospective study of FAS pts</td>
<td>Christophe Girardet</td>
<td>Dr. Girardet has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-16-09</td>
<td>Metabolic obesity, adipose inflammation and aromatase: Potential drivers of breast cancer risk in women with normal body mass index</td>
<td>Dipak Giri</td>
<td>Dr. Giri has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-21-26</td>
<td>Prospective study of acupuncture in the rehabilitation of women undergoing surgical treatment of breast cancer in relation to the strength and quality of life</td>
<td>Sandhya Girish</td>
<td>Dr. Girish has disclosed that he receives salary from and has ownership in Rehco.</td>
</tr>
<tr>
<td>P2-12-05</td>
<td>Prognostic factors in breast cancer (BC) associated with the development of brain metastases (BM): A retrospective study of FAS pts</td>
<td>Christophe Girardet</td>
<td>Dr. Girardet has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
UCBG 2-14: A prospective multicenter non-randomized trial evaluating the effect of EndoPredict® (EPclin®) clinico-genomic test on treatment decision making among patients with intermediate clinical risk

Véronique Girre
Dr. Girre has no relevant financial relationships to disclose.

IMENEO: International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEOadjuvant chemotherapy

Rafael Giliberto Criado
Mr. Giliberto Criado has no relevant financial relationships to disclose.

SentinWave: A non-inferiority trial comparing super-paramagnetic iron oxide vs. Tc99 and blue dye in the detection of axillary sentinel nodes in patients with early stage breast cancer

Mark Gittleman
Dr. Gittleman has no relevant financial relationships to disclose.

Committee Member
David Gius
Dr. Gius has no relevant financial relationships with commercial interests to disclose.

Cancer-associated fibroblasts release exosomal microRNAs that dictate an aggressive phenotype in breast cancer

Roscigno Giuseppina
Dr. Giuseppina has no relevant financial relationships to disclose.

Pertuzumab and trastuzumab in combination with weekly paclitaxel delivers high pCR rates with favourable toxicity profile in neo-adjuvant treatment of Her-2 positive breast cancer

Laurence Gladieff
Mr. Gladieff has no relevant financial relationships to disclose.

12 years' median follow up (MFU) of BIG 1-98: Adjuvant letrozole, tamoxifen and their sequence for postmenopausal women with endocrine responsive early breast cancer

Laurence Gladieff
Mr. Gladieff has no relevant financial relationships to disclose.

DNA repair deficiency biomarkers and MammaPrint high1/(ultra)high2 risk as predictors of veliparib/carboplatin response: Results from the neoadjuvant I-SPY 2 trial for high risk breast cancer

Annuska Glas
Ms. Glas has disclosed that she is an employee of Agendia, Inc.

Tumor and procedural factors associated with positive margins at lumpectomy in women undergoing breast conservation surgery

Amy Glasgow
Ms. Glasgow has no relevant financial relationships to disclose.

A phase I study of NA2021, an oral selective estrogen receptor degrader, to determine changes in the T7-ES1 uptake and tumor responses in ER-positive, HER2-negative, advanced breast cancer patients

Andor Glaudemans
Andor Glaudemans has no relevant financial relationships to disclose.

IHOH study: How European and US young women cope with breast cancer and fertility concerns

Agnes Glisy
Ms. Glisy has no relevant financial relationships to disclose.

Comparison of survival and clinicopathological features between patients with breast cancer and HIV infection versus breast cancer without HIV infection

Olga Glisz
Dr. Glisz has no relevant financial relationships to disclose.

Time differences in breast cancer diagnosis among minorities in a large referral academic center

Olga Glisz
Dr. Glisz has no relevant financial relationships to disclose.

Phase multicenter clinical trial evaluating the combination of trastuzumab emtansine (T-DM1) and non-pegylated liposomal doxorubicin (NPLD) in HER2-positive metastatic breast cancer (NCIC CR-06 trial)

Joseph Gligorov
Dr. Gligorov has disclosed that he is a speaker for Roche Genentech.

Impact of post-progression therapy on overall survival (OS) in the INELDA randomized phase III trial evaluating the addition of capcitabine (CAF) to maintenance bevacizumab (BEV) for HER2 negative metastatic breast cancer (mBC)

Joseph Gligorov
Mr. Gligorov has disclosed that he is a consultant for Roche, Eisai, Genentech, Texas, Pfizer, Novartis and a speaker for Roche, Eisai, Genentech, Texas and Novartis. He has also disclosed that he has contracts with Roche and Eisai.

The 22-gene assay in the decision impact assessment of ER+, HER2- Breast cancer: A French real life prospective study

Denise Glocos
Ms. Glocos has no relevant financial relationships to disclose.

Value of cancer care for metastatic breast cancer patients and providers

Denise Glocos
Ms. Glocos has no relevant financial relationships to disclose.

Pertuzumab weekly carboplatin and paclitaxel followed by dose dense epirubicin and cyclophosphamide in triple negative breast cancer patients: A single arm phase II study from the Belgian Society of Medical Oncology

Philippe Glocos
Dr. Glocos has no relevant financial relationships to disclose.

PD6-04

HOHO study: How European and US young women cope with breast cancer and fertility concerns

Agnes Glisy
Ms. Glisy has no relevant financial relationships to disclose.

Comparison of survival and clinicopathological features between patients with breast cancer and HIV infection versus breast cancer without HIV infection

Olga Glisz
Dr. Glisz has no relevant financial relationships to disclose.

Time differences in breast cancer diagnosis among minorities in a large referral academic center

Olga Glisz
Dr. Glisz has no relevant financial relationships to disclose.

Phase multicenter clinical trial evaluating the combination of trastuzumab emtansine (T-DM1) and non-pegylated liposomal doxorubicin (NPLD) in HER2-positive metastatic breast cancer (NCIC CR-06 trial)

Joseph Gligorov
Dr. Gligorov has disclosed that he is a speaker for Roche Genentech.

Impact of post-progression therapy on overall survival (OS) in the INELDA randomized phase III trial evaluating the addition of capcitabine (CAF) to maintenance bevacizumab (BEV) for HER2 negative metastatic breast cancer (mBC)

Joseph Gligorov
Mr. Gligorov has disclosed that he is a consultant for Roche, Eisai, Genentech, Texas, Pfizer, Novartis and a speaker for Roche, Eisai, Genentech, Texas and Novartis. He has also disclosed that he has contracts with Roche and Eisai.

The 22-gene assay in the decision impact assessment of ER+, HER2- Breast cancer: A French real life prospective study

Denise Glocos
Ms. Glocos has no relevant financial relationships to disclose.

Value of cancer care for metastatic breast cancer patients and providers

Denise Glocos
Ms. Glocos has no relevant financial relationships to disclose.

Pertuzumab weekly carboplatin and paclitaxel followed by dose dense epirubicin and cyclophosphamide in triple negative breast cancer patients: A single arm phase II study from the Belgian Society of Medical Oncology

Philippe Glocos
Dr. Glocos has no relevant financial relationships to disclose.
Early detection of development of a pre-metastatic niche in lungs in response to primary breast tumor using Raman spectroscopy

Prof. Glunde has no relevant financial relationships to disclose.

Decoding the genetic basis of mammary neovascularization and their putative role in promotion of distant metastases

Prof. Glunde has no relevant financial relationships to disclose.

Chemotherapy (CT) decision in patients (pts) with node-positive (N+), ER+, early breast cancer (EBC) in the wake of new ASCO guidelines - A different take on the evidence for the 21-gene recurrence score (RS) assay

Dr. Gluz has disclosed that he receives honoraria from Genomic Health.

Results of multigene assay (MammaPrint®) and molecular subtyping (BluePrint®) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIME decision impact study

Dr. Gluz has no relevant financial relationships to disclose.

Pathological complete response to neoadjuvant trastuzumab is dependent on HER2/CEP17 ratio in HER2-amplified early breast cancer

Dr. Grant has disclosed that he receive consulting fees from AstraZeneca, Accelsiors, Amgen, Novartis, GlaxoSmithKline and Roche. He disclosed that he also does contracted research for Amgen, AstraZeneca, Celgene, GSK, Novartis, Pfizer and Roche. These relationships do not impact his ability to review presentations.

Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer

Aline Gobillon has no relevant financial relationships to disclose.

HER2 expression in clinical breast cancer samples: A novel detection methodology for HER2 protein quantitation using fluorescent nanoparticles

Dr. Goda has disclosed that he is an employee of Konica Minolta.
A novel non-canonical Notch1-IKKα-mTORC2-AKT pathway maintains survival in triple negative breast cancer cells and cancer stem-like cells

Todd Golde

Dr. Golde has no relevant financial relationships to disclose.

Targeting NK cells to Trop-2-expressing breast and other cancers, with chimeric antigen receptors

David Goldberg

Dr. Goldberg has disclosed that he receives salary, has a parent and has ownership.

Sialiculubam gevitecan (SMAN-132), an anti-Trop-2-SN-38 antibody-drug conjugate (ADC) for the treatment of relapsed/refractory, metastatic triple-negative breast cancer (mTNBC) - Updated results

David Goldberg

Dr. Goldberg has disclosed that he receives salary from and has ownership in Immunomedics, Inc. He also disclosed that he has a patent with Immunomedics, Inc.

Enhanced efficacy of redirected T-cell therapy of TNBC with a Trop-2/CD3 bispecific antibody in combination with a checkpoint inhibitor

David Goldberg

Dr. Goldberg has disclosed that he receives salary and has ownership.

A multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer: Early results of unplanned boost participants

S. Golder

Dr. Golder has no relevant financial relationships to disclose.

Two-year follow-up results of a multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer

Stephen Golder

Dr. Golder has no relevant financial relationships to disclose.

Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate (ADC) for the treatment of relapsed/refractory, metastatic triple-negative breast cancer (mTNBC): Updated results

David Goldberg

Dr. Goldberg has disclosed that he receives salary from and has ownership in Immunomedics, Inc. He also disclosed that he has a patent with Immunomedics, Inc.

Enhanced efficacy of redirected T-cell therapy of TNBC with a Trop-2/CD3 bispecific antibody in combination with a checkpoint inhibitor

David Goldberg

Dr. Goldberg has disclosed that he receives salary and has ownership.

Optimized prediction of deleterious missense mutations in BRCA1 and BRCA2 genes

David Goldgar

Dr. Goldgar has no relevant financial relationships to disclose.

 Associations between breast cancer subtypes and mutations in cancer predisposition genes identified by clinical genetic testing of breast cancer patients

David Goldgar

Dr. Goldgar has no relevant financial relationships to disclose.

Breast cancer risks associated with mutations in cancer predisposition genes identified by clinical genetic testing of 60,000 breast cancer patients

David Goldgar

Dr. Goldgar has no relevant financial relationships to disclose.

Long-term follow-up of TEXT and SOFT trials of adjuvant endocrine therapies for premenopausal women with HR+ early breast cancer

Aaron Goldhirsch

Dr. Goldhirsch has no relevant financial relationships to disclose.

12-years’ median follow up (MFU) of BIG 1-98: Adjuvant letrozole, tamoxifen and their sequence for postmenopausal women with endocrine responsive early breast cancer

Aaron Goldhirsch

Dr. Goldhirsch has no relevant financial relationships to disclose.

Chemotherapeutic (CT) decision in patients (pts) with node-positive (N+), ER+, early breast cancer (EBC) in the wake of new ASCO guideline - A different take on the evidence for the 21-gene recurrence score (RS) assay

Leanne Goldstein

Dr. Goldstein has no relevant financial relationships to disclose.

Genomic analysis of molecular discordance of paired primary and recurrent triple negative breast cancer

Leanne Goldstein

Dr. Goldstein has no relevant financial relationships to disclose.

Phase II randomized trial of pembrolizumab with carboplatin and gemcitabine for treatment of patients with metastatic triple-negative breast cancer (mTNBC)

Lori Goldstein

Dr. Goldstein has no relevant financial relationships to disclose.

Programmed death 1 (PD-1) and PD-L1 expression (PD-L1) distribution in triple negative breast cancer (TNBC)

Lori Goldstein

Dr. Goldstein has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Author</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>S1-02</td>
<td>PrECOG 0102: A randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in post-menopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC) resistant to aromatase inhibitor (AI) therapy</td>
<td>Lori Goldstein</td>
<td>Dr. Goldstein has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S4-04</td>
<td>Tumor microenvironment of metastasis (TMEM) score is associated with early distant recurrence in hormone receptor (HR) positive, HER2-negative early stage breast cancer (ESBC)</td>
<td>Lori Goldstein</td>
<td>Dr. Goldstein has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-08-25</td>
<td>The association between smoking and breast cancer characteristics and outcome</td>
<td>R. Goldhaber</td>
<td>Dr. Goldhaber has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-11-02</td>
<td>Impact of pre-operative exercise and menopausal interventions on patient-reported outcomes in women with newly diagnosed breast cancer</td>
<td>Mehran Golshan</td>
<td>Mehran Golshan has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-05-13</td>
<td>The metastatic breast cancer project: Translational genomics through direct patient engagement</td>
<td>Todd Golub</td>
<td>Dr. Golub has disclosed that he is a consultant for Foundation Medicine, H3 Biomedicine and Pfizer and has ownership in Foundation Medicine and H3 Biomedicine.</td>
</tr>
<tr>
<td>P3-03-01</td>
<td>A novel high throughput secreted factor screen and bioinformatics pipeline identifies microenvironment-derived FGFR2 as a mechanism of resistance to anti-estrogens, PI3K, and mTOR inhibitors in ER+ breast cancer</td>
<td>Todd Golub</td>
<td>Dr. Golub has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-09-10</td>
<td>A new oral SERD AZD9496 for treatment of hormone-dependent postmenopausal breast cancer</td>
<td>Olga Golubova</td>
<td>Olga Golubova has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>O7-02-08</td>
<td>Open label, phase 2, safety, efficacy, and pharmacokinetic study of pre-surgical intramuscular and intraductal fulvestrant in women with invasive breast cancer or DCIS undergoing mastectomy or lumpectomy</td>
<td>Ameer Gomberawalla</td>
<td>Ameer Gomberawalla has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-01-14</td>
<td>Lymphatic microsurgical preventive healing approach (LYMPHA) for the primary prevention of lymphedema</td>
<td>Ameer Gomberawalla</td>
<td>Ameer Gomberawalla has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-01-08</td>
<td>Specific detection of anti-Her2 PEGylated PrecisionMRX nanoparticles measured using superparamagnetic relaxometry</td>
<td>Andrew Gomez</td>
<td>Mr. Gomez has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-11-10</td>
<td>Effect of supplementation with eicosapentaenoic and docosahexaenoic omega-3 polyunsaturated fatty acid on the chemotoxicity in Mexican patients with locally advanced breast cancer (SABC) treated with neoadjuvant chemotherapy (NeoCT)</td>
<td>Enrique Gomez</td>
<td>Dr. Gomez has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-09-08</td>
<td>Molecular evaluation of Peruvian patients with hereditary breast cancer reveals novel germline mutations in BRCA2</td>
<td>Henry Gomez</td>
<td>Dr. Gomez has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-10-02</td>
<td>MBC-2 positive breast tumors are more immunogenic and may preferentially select for LAG-3 positive tumor immune infiltrates</td>
<td>Henry Gomez</td>
<td>Dr. Gomez has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P08-02</td>
<td>Tumor subtype and survival differences between Hispanic and non-Hispanic white breast cancer patients in the California cancer registry</td>
<td>Scarlett Gomez</td>
<td>Dr. Gomez has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>O7-01-04</td>
<td>Ventana (SOL1-202): Oral metformin monotherapy combined with endocrine therapy in luminal/HER2-negative early breast cancer: A window of opportunity trial</td>
<td>Patricia Gomez-Pardo</td>
<td>Gomez-Pardo has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-16-20</td>
<td>Impact of &quot;immune/chemosensitivity-based molecular subtype&quot; on chemosensitivity and survival in Hispanic breast cancer patients following neoadjuvant chemotherapy (NAC)</td>
<td>Rodrigo Gomez-Wolf</td>
<td>Gomez-Wolf has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>

**Notes:**
- Dr. Goldstein has no relevant financial relationships to disclose.
- Mehran Golshan has no relevant financial relationships to disclose.
- Todd Golub has disclosed that he is a consultant for Foundation Medicine, H3 Biomedicine and Pfizer and has ownership in Foundation Medicine and H3 Biomedicine.
- Ameer Gomberawalla has no relevant financial relationships to disclose.
- Andrew Gomez has no relevant financial relationships to disclose.
- Enrique Gomez has no relevant financial relationships to disclose.
- Henry Gomez has no relevant financial relationships to disclose.
- Scarlett Gomez has no relevant financial relationships to disclose.
- Patricia Gomez-Pardo has no relevant financial relationships to disclose.
- Rodrigo Gomez-Wolf has no relevant financial relationships to disclose.
A multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer: Early results of unplanned boost participants

Victor Gonzalez
Mr. Gonzalez has disclosed that he served on an advisory panel for Xoft and received associated travel and lodging expenses.

Implications of financial modeling in breast cancer clinical research from 1990 to 2010

Jesús González
Dr. González has disclosed that he receives salary and has ownership in Avelas Biosciences, Inc.

Intraoperative tumor detection using a ratiometric activatable fluorescent peptide: A first-in-human phase I study allows tumors to be visualized in the operating room

Evaristo Gonzalez Del Val
Dr. Gonzalez Del Val has no relevant financial relationships to disclose.

A phase II study to compare fulvestrant (F) 500mg plus palbociclib (P) versus (vs) F 500mg plus placebo (P) as first line treatment for postmenopausal women with hormone receptor (HR) positive advanced breast cancer (BC) sensitive to endocrine therapy (ET) - "The FLIPPER study" (SOLITI-2014-12)

Lucía González-Cortijo
Ms. González-Cortijo has no relevant financial relationships to disclose.

Phase III trial to evaluate patient's preference for subcutaneous versus intravenous trastuzumab administration in patients with HER2 positive advanced breast cancer (ABC) under IV trastuzumab (IV-t) treatment for at least 4 months. ChangHER-SC study (GEICAM/2012-07)

Lucía González-Cortijo
Ms. González-Cortijo has no relevant financial relationships to disclose.

Neoadjuvant non-pegylated eposomal doxorubicin plus paclitaxel, trastuzumab and pertuzumab in patients with HER2+ breast cancer - final results of the SOLTI OPTI-HER HEART study

Antonio González-Martín
Dr. González-Martín has no relevant financial relationships to disclose.

Neoadjuvant non-pegylated eposomal doxorubicin plus paclitaxel, trastuzumab and pertuzumab in patients with HER2+ breast cancer - final results of the SOLTI OPTI-HER HEART study

Santiago González-Santiago
Dr. González-Santiago has no relevant financial relationships to disclose.

Patient-reported cosmetic outcomes in older breast cancer survivors: A population-based survey study

Nathan Goodwin
Mr. Goodwin has no relevant financial relationships to disclose.

Impact of a decision-support tool on the utilization of colony-stimulating factors and incidence of febrile neutropenia among patients with breast cancer

Andrea Goodwin
Ms. Goodwin has no relevant financial relationships to disclose.

Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ET positive metastatic breast cancer patients: Results of the COMETI Phase 2 trial

Pamela Goodwin
Dr. Goodwin has no relevant financial relationships to disclose.

Circulating inflammatory markers, growth factors, and tumor associated antigens in women with early stage breast cancer receiving neoadjuvant tamoxifen

Pamela Goodwin
Dr. Goodwin has no relevant financial relationships to disclose.

Circulating inflammatory markers, growth factors, and tumor associated antigens in women with early stage breast cancer receiving neoadjuvant trastuzumab

Pamela Goodwin
Dr. Goodwin has no relevant financial relationships to disclose.
Association between BMI and residual estradiol levels in post-menopausal women using adjuvant letrozole: Results of a prospective study

Pamela Goodwin
Dr. Goodwin has no relevant financial relationships to disclose.

Leptin receptor (OB-R) in breast carcinoma tissue: Ubiquitous expression and correlation with leptin-mediated signaling, but not with systemic markers of obesity

Pamela Goodwin
Dr. Goodwin has no relevant financial relationships to disclose.

IMENEO: International Meta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEoadjuvant chemotherapy

Mandar Gopalkrishna Karhade
Mandar Gopalkrishna Karhade has no relevant financial relationships to disclose.

Efficacy of screening and treatment of breast cancer patients reporting high level of distress

Chip Gordon
Mr. Gordon has no relevant financial relationships to disclose.

Evaluating the feasibility of a web-based preference-tolerant randomised trial of risk-based vs. annual breast cancer screening: WISDOM study pilot

Deborah Gordon
Dr. Gordon has no relevant financial relationships to disclose.

Targeted and selective degradation of estrogen receptor (ER) alpha by PROTACs

Deborah Gordon
Ms. Gordon has disclosed that she receives salary and has ownership.

A liquid biopsy test for breast cancer detection provides consistent diagnostic results in patients over six months

Kelly Gordon
Dr. Gordon has disclosed that he is a salary employee of Provista Dx.

Evaluating the feasibility of a web-based preference-tolerant randomized trial of risk-based vs. annual breast cancer screening: WISDOM study pilot

Deborah Gordon
Ms. Gordon has disclosed that she receives salary and has ownership.

A blood-based proteomic Videssa® breast assay performs comparably in women with dense and non-dense breasts

Deborah Gordon
Dr. Gordon has disclosed that he is a salary employee of and owns stock in Provixta Diagnostics.

ATM mutations contribution to hereditary breast-pancreatic cancer

Ora Gorringe
Ms. Gorringe has disclosed that she receives salary from and has ownership in Myriad Genetic Laboratories, Inc.

Factors affecting the administration of post-mastectomy radiation therapy (PMRT) in Michigan

David Gorski
Dr. Gorski has no relevant financial relationships to disclose.

Obesity, dyslipidemia, and diabetes as risk factors for trastuzumab-related cardiotoxicity in breast cancer patients

Nina Gosh
Dr. Gosh has no relevant financial relationships to disclose.

Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes (TILs) and residual cancer burden (RCB)

Wataru Goto
Wataru Goto has no relevant financial relationships to disclose.

Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes (TILs) and residual cancer burden (RCB)

Wataru Goto
Dr. Goto has no relevant financial relationships to disclose.

Young women with breast cancer in Mexico: A report of the pilot phase of the “Mujer Joven y Fuerte” prospective cohort

Paul Goss
Dr. Goss has no relevant financial relationships to disclose.

CSMD1 SNPs selectively affect anastrozole response in postmenopausal breast cancer patients

Paul Goss
Dr. Goss has no relevant financial relationships to disclose.

Atopic dermatitis: Implications of genetic, environmental, and biologic factors

Nina Goto
Dr. Goto has no relevant financial relationships to disclose.

A comprehensive analysis of GNAS DNA copy number, levels of mRNA and protein expression in primary breast cancer

Lisa Goto-Yamaguchi
Ms. Goto-Yamaguchi has no relevant financial relationships to disclose.

Prognostic significance of CD8+ tumor-infiltrating lymphocytes (TILs), CD4+ TILs and TILs in male breast cancer

Aida Goucha
Dr. Goucha has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Committee Member</th>
<th>Title</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>P3-11-05</strong></td>
<td>Committee Member</td>
<td>William Gradishar Dr. Gradishar has no relevant financial relationships with commercial interests to disclose.</td>
</tr>
<tr>
<td><strong>P2-05-02</strong></td>
<td>Clinicopathological relationships with 68E7 in POETIC (NCIC/CTG/07/015) - Critical lessons for assessing 68E7 for prognosis and as a pharmacodynamic marker</td>
<td>Joachim Graf Joachim Graf has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td><strong>P6-13-02</strong></td>
<td>Efficacy of first-line bevacizumab (BEV)-containing therapy for poor-prognosis advanced breast cancer (ABC): Subgroup analyses of the German AVANTI observational study</td>
<td>Andrea Grafe Ms. Grafe has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td><strong>P5-16-02</strong></td>
<td>Pathological complete response is associated with excellent outcomes in BRCA mutation associated triple negative breast cancer</td>
<td>Stephanie Grall Dr. Graham has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td><strong>P3-13-04</strong></td>
<td>Use of an absorbable implant to mark the lumpectomy cavity: Initial report of 300 patients in a multi-center registry database</td>
<td>Cathy Graham Ms. Graham has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td><strong>P2-05-01</strong></td>
<td>Reliability and acceptability of e-based survey instruments for measuring patient reported outcomes (PROs) in breast cancer patients: First results of the ePROCOM study</td>
<td>Joachim Graf Joachim Graf has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td><strong>P6-13-02</strong></td>
<td>Psychological complete response is associated with excellent outcomes in BRCA mutation associated triple negative breast cancer</td>
<td>Stephanie Graff Ms. Graff has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td><strong>P5-16-02</strong></td>
<td>Pathological complete response is associated with excellent outcomes in BRCA mutation associated triple negative breast cancer</td>
<td>Stephanie Graff Ms. Graff has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td><strong>P3-13-04</strong></td>
<td>Use of an absorbable implant to mark the lumpectomy cavity: Initial report of 300 patients in a multi-center registry database</td>
<td>Cathy Graham Ms. Graham has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td><strong>OTT-01-09</strong></td>
<td>PALINA: A phase II safety study of palbociclib in combination with letrozole in African American women with hormone receptor positive HER2 negative advanced breast cancer</td>
<td>Deena Graham Dr. Graham has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td><strong>OTT-01-09</strong></td>
<td>PALINA: A phase II safety study of palbociclib in combination with letrozole in African American women with hormone receptor positive HER2 negative advanced breast cancer</td>
<td>Deena Graham Dr. Graham has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td><strong>S1-04</strong></td>
<td>Discovery of molecular predictors of late breast cancer specific events (BCSE) in ER+, node+ breast cancer - new transcriptome expression whole gene analysis of the phase III adjuvant trial SWOG S8814</td>
<td>Julie Gray Dr. Gralow has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td><strong>P2-07-07</strong></td>
<td>Discovery of molecular predictors of late breast cancer specific events (BCSE) in ER+, node+ breast cancer - new transcriptome expression whole gene analysis of the phase III adjuvant trial SWOG S8814</td>
<td>Julie Gray Dr. Gralow has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td><strong>P3-03-02</strong></td>
<td>Discovery of molecular predictors of late breast cancer specific events (BCSE) in ER+, node+ breast cancer - new transcriptome expression whole gene analysis of the phase III adjuvant trial SWOG S8814</td>
<td>Julie Gray Dr. Gralow has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td><strong>P4-22-11</strong></td>
<td>Combined targeted therapies for advanced triple negative breast cancer: A phase II trial of nab-paclitaxel and bevacizumab followed by maintenance targeted therapy with bevacizumab and erlotinib</td>
<td>James Graff Dr. Graff has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td><strong>P1-05-30</strong></td>
<td>Combined targeted therapies for advanced triple negative breast cancer: A phase II trial of nab-paclitaxel and bevacizumab followed by maintenance targeted therapy with bevacizumab and erlotinib</td>
<td>Matthew Graham Dr. Graham has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td><strong>P4-22-11</strong></td>
<td>Weekly doxorubicin and daily oral cyclophosphamide followed by nab-paclitaxel for adjuvant therapy of high-risk localized breast cancer</td>
<td>Julie Graff Dr. Graff has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td><strong>P1-05-30</strong></td>
<td>Weekly doxorubicin and daily oral cyclophosphamide followed by nab-paclitaxel for adjuvant therapy of high-risk localized breast cancer</td>
<td>Julie Graff Dr. Graff has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td><strong>P5-14-10</strong></td>
<td>Weekly doxorubicin and daily oral cyclophosphamide followed by nab-paclitaxel for adjuvant therapy of high-risk localized breast cancer</td>
<td>Julie Graff Dr. Graff has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td><strong>P3-03-02</strong></td>
<td>Inhibition of NOS promotes ER stress response and augments docetaxel-mediated apoptosis in TNBC</td>
<td>Yacov Granados Dr. Granados has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td><strong>P5-14-10</strong></td>
<td>Inhibition of NOS promotes ER stress response and augments docetaxel-mediated apoptosis in TNBC</td>
<td>Yacov Granados Dr. Granados has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td><strong>P3-03-02</strong></td>
<td>Inhibition of NOS promotes ER stress response and augments docetaxel-mediated apoptosis in TNBC</td>
<td>Yacov Granados Dr. Granados has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td><strong>P1-10-04</strong></td>
<td>Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multi-center trial</td>
<td>James Gravata Dr. Gravata has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td><strong>P3-03-04</strong></td>
<td>Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multi-center trial</td>
<td>James Gravata Dr. Gravata has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td><strong>P1-10-04</strong></td>
<td>Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multi-center trial</td>
<td>James Gravata Dr. Gravata has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td><strong>P3-03-04</strong></td>
<td>Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multi-center trial</td>
<td>James Gravata Dr. Gravata has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
A directed siRNA screen identifies INHBA as a major regulator of tumor aggressiveness in basal HER2 breast cancer

Independent validation of early/late gene signature in BIG 1-08: A randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer

Targeting of phosphatidylserine by monoclonal antibodies enhances the activity of immune checkpoint IAGt targeting antibodies in murine breast tumors

Tumor microenvironment of metastasis (TMEM) score is associated with early distant recurrence in hormone receptor (HR) negative, HER2-negative, early stage breast cancer (ESBC)

Identification of proliferation related derivers and their roles in precision medicine for breast cancers: A retrospective multidimensional comparative, integrated genomic, transcriptomic, and protein analysis

A real-world evidence study to define the prevalence of endocrine therapy-naive hormone receptor-positive locally advanced or metastatic breast cancer in the US

Identification of proliferation related derivers and their roles in precision medicine for breast cancers: A retrospective multidimensional comparative, integrated genomic, transcriptomic, and protein analysis

A real-world evidence study to define the prevalence of endocrine therapy-naive hormone receptor-positive locally advanced or metastatic breast cancer in the US

Impact of magnetic resonance imaging on conversion from wide local excision to mastectomy in patients with ductal carcinoma in situ: First results from the ECOG-ACRIN 4112 prospective study

A real-world evidence study to define the prevalence of endocrine therapy-naive hormone receptor-positive locally advanced or metastatic breast cancer in the US

Sorafenib 2 domain containing transforming protein 1 and sterol receptor coactivator-3 as novel targets for triple-negative breast cancer

Sorafenib 2 domain containing transforming protein 1 and sterol receptor coactivator-3 as novel targets for triple-negative breast cancer

Determining the optimal vaccination strategy using a combination of the folate binding protein (FBP) peptide vaccine (E39+GM-CSF) and an attenuated version (E39') to maximize the immunologic response in breast cancer patients

Determining the optimal vaccination strategy using a combination of the folate binding protein (FBP) peptide vaccine (E39+GM-CSF) and an attenuated version (E39') to maximize the immunologic response in breast cancer patients

Zoledronic acid (ZOL) in stage II/III breast cancer. The AZURE trial (BIG 01/04) 10 year follow-up

Zoledronic acid (ZOL) in stage II/III breast cancer. The AZURE trial (BIG 01/04) 10 year follow-up

DNA methylation signature predicting bevacizumab efficacy in metastatic breast cancer

DNA methylation signature predicting bevacizumab efficacy in metastatic breast cancer

Efficacy and safety of everolimus plus exemestane in HR+, HER2 advanced breast cancer progressing on/after prior endocrine therapy, in routine clinical practice: 2nd interim analysis from STEPAUT

Efficacy and safety of everolimus plus exemestane in HR+, HER2 advanced breast cancer progressing on/after prior endocrine therapy, in routine clinical practice: 2nd interim analysis from STEPAUT

Capacitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Final PP results of a phase II trial (AGMAT-MBC-6)

Capacitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Final PP results of a phase II trial (AGMAT-MBC-6)

CpG methylated signature predicting bevacoumbre efficacy in metastatic breast cancer

CpG methylated signature predicting bevacoumbre efficacy in metastatic breast cancer

Cost-effectiveness of pre-implantation genetic diagnosis for BRCA mutation carriers

Cost-effectiveness of pre-implantation genetic diagnosis for BRCA mutation carriers

Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Final PP results of a phase II trial (AGMAT-MBC-6)

Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Final PP results of a phase II trial (AGMAT-MBC-6)

Effective use of pre-implantation genetic diagnosis for BRCA mutation carriers

Effective use of pre-implantation genetic diagnosis for BRCA mutation carriers

Adjuvant treatment with zoledronic acid (ZOL) in stage II/III breast cancer. The AZURE trial (BIG 01/04) 10 year follow-up

Adjuvant treatment with zoledronic acid (ZOL) in stage II/III breast cancer. The AZURE trial (BIG 01/04) 10 year follow-up

A physical activity and dietary counseling intervention in breast cancer survivors and changes in kroean and novel prognostic biomarkers

A physical activity and dietary counseling intervention in breast cancer survivors and changes in kroean and novel prognostic biomarkers

Src homology 2 domain containing transforming protein 1 and steroid receptor coactivator-3 as novel targets for triple-negative breast cancer

Src homology 2 domain containing transforming protein 1 and steroid receptor coactivator-3 as novel targets for triple-negative breast cancer

Sorafenib 2 domain containing transforming protein 1 and sterol receptor coactivator-3 as novel targets for triple-negative breast cancer

Sorafenib 2 domain containing transforming protein 1 and sterol receptor coactivator-3 as novel targets for triple-negative breast cancer

Enhancing the activity of immune checkpoint IAGt targeting antibodies in murine breast tumors

Enhancing the activity of immune checkpoint IAGt targeting antibodies in murine breast tumors

Sorafenib 2 domain containing transforming protein 1 and sterol receptor coactivator-3 as novel targets for triple-negative breast cancer

Sorafenib 2 domain containing transforming protein 1 and sterol receptor coactivator-3 as novel targets for triple-negative breast cancer

Determining the optimal vaccination strategy using a combination of the folate binding protein (FBP) peptide vaccine (E39+GM-CSF) and an attenuated version (E39') to maximize the immunologic response in breast cancer patients

Determining the optimal vaccination strategy using a combination of the folate binding protein (FBP) peptide vaccine (E39+GM-CSF) and an attenuated version (E39') to maximize the immunologic response in breast cancer patients

Zoledronic acid (ZOL) in stage II/III breast cancer. The AZURE trial (BIG 01/04) 10 year follow-up

Zoledronic acid (ZOL) in stage II/III breast cancer. The AZURE trial (BIG 01/04) 10 year follow-up

A physical activity and dietary counseling intervention in breast cancer survivors and changes in kroean and novel prognostic biomarkers

A physical activity and dietary counseling intervention in breast cancer survivors and changes in kroean and novel prognostic biomarkers

Efficacy and safety of everolimus plus exemestane in HR+, HER2 advanced breast cancer progressing on/after prior endocrine therapy, in routine clinical practice: 2nd interim analysis from STEPAUT

Efficacy and safety of everolimus plus exemestane in HR+, HER2 advanced breast cancer progressing on/after prior endocrine therapy, in routine clinical practice: 2nd interim analysis from STEPAUT

Capacitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Final PP results of a phase II trial (AGMAT-MBC-6)

Capacitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Final PP results of a phase II trial (AGMAT-MBC-6)

DNA methylation signature predicting bevacoumbre efficacy in metastatic breast cancer

DNA methylation signature predicting bevacoumbre efficacy in metastatic breast cancer

Efficacy and safety of everolimus plus exemestane in HR+, HER2 advanced breast cancer progressing on/after prior endocrine therapy, in routine clinical practice: 2nd interim analysis from STEPAUT

Efficacy and safety of everolimus plus exemestane in HR+, HER2 advanced breast cancer progressing on/after prior endocrine therapy, in routine clinical practice: 2nd interim analysis from STEPAUT

Capacitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Final PP results of a phase II trial (AGMAT-MBC-6)

Capacitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Final PP results of a phase II trial (AGMAT-MBC-6)
Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomized, neoadjuvant phase-II study (ABCSG-34)  
Richard Greil

Dr. Greil has disclosed that he is a consultant for Merck and a speaker for Merck, Roche, Takeda, Amgen, BMS. He has also disclosed that he has a contract with Merck.

The mammary ducts create a favourable microenvironment for xenografting of luminal and molecular apocrine breast tumors  
Thomas Greally

Mr. Greally has no relevant financial relationships to disclose.

P6-02-10  
Results of multigene assay (MammaPrint®) and molecular subtyping (BluePrint®) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIME decision impact study  
Julien Grenier

Dr. Grenier has no relevant financial relationships to disclose.

UCBG 2-14: A prospective multicenter non-randomized trial evaluating the effect of EndoPredict® (EPclin®) clinico-genomic test on treatment decision making among patients with intermediate clinical risk  
Julien Grenier

Dr. Grenier has no relevant financial relationships to disclose.

Results of multigene assay (MammaPrint®) and molecular subtyping (BluePrint®) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIME decision impact study  
Frank Griesinger

Prof. Griesinger has no relevant financial relationships to disclose.

The long term outcome of female patients treated with primary endocrine therapy for non-metastatic breast cancer  
Adam Griffard

Mr. Griffard has no relevant financial relationships to disclose.

Factors affecting the administration of post-mastectomy radiation therapy (PMRT) in Michigan  
Jennifer Griggs

Dr. Griggs has no relevant financial relationships to disclose.

Copy number alteration-induced gene breakage analysis identifies recurrent FOXP1 fusions in breast cancer  
Anita Grigoriadis

Dr. Grigoriadis has no relevant financial relationships to disclose.

Comparing the frequency and types of genetic aberrations between older and younger women with metastatic breast cancer at the University of North Carolina at Chapel Hill  
Juneko Grilley-Olson

Dr. Grilley-Olson has no relevant financial relationships to disclose.

A RB-1 loss-of-function gene-signature (RBsig) predicts resistance to neoadjuvant chemotherapy in HER2+/ER+ breast cancer patients  
Andrea Grilli

Ms. Grilli has no relevant financial relationships to disclose.

Nonsteroidal, tissue selective androgen receptor modulator (SARM), enobosarm, reduces growth of androgen receptor-positive breast cancer in patient-derived preclinical models  
Brandy Grimes

Ms. Grimes has no relevant financial relationships to disclose.

The association of higher tumor HER2 load with treatment response to neoadjuvant therapy in HER2 positive breast cancer patients  
Erin Grimm

Dr. Grimm has no relevant financial relationships to disclose.

Heavily pre-treated breast cancer patients show promising responses in the first in human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640 in combination with paclitaxel  
Katherine Grimmer

Ms. Grimmer has disclosed that she is a consultant to 3-V Biosciences.
P2-08-02 Progression-free survival results in patient subgroups from a Phase 3 randomized trial of fulvestrant 500 mg vs anastrozole for hormone receptor-positive advanced breast cancer (FALCON)

Lynda Grinsted

Ms. Grinsted has disclosed that she receives salary from and has ownership in AstraZeneca.

P2-08-09 Progression-free survival results in postmenopausal Asian women: Subgroup analysis from a phase 3 randomized trial of fulvestrant 500 mg vs anastrozole for hormone receptor-positive advanced breast cancer (FALCON)

Lynda Grinsted

Ms. Grinsted has disclosed that she receives salary from and has ownership in AstraZeneca.

P1-09-05 Results of multigene assay (MammaPrint®) and molecular subtyping (BluePrint®) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIME decision impact study

Eva-Maria Grischke

Prof. Grischke has no relevant financial relationships to disclose.

P6-09-10 Impact of institution of young women's breast cancer clinic on time to treatment and utilization of fertility, genetics and social work consultations in women under age 50 with new diagnosis of early stage breast cancer

Stephen Grobmyer

Dr. Grobmyer has no relevant financial relationships to disclose.

P2-12-04 Impact of institution of young women's breast cancer clinic on time to treatment and utilization of fertility, genetics and social work consultations in women under age 50 with new diagnosis of early stage breast cancer

Stephen Grobmyer

Dr. Grobmyer has no relevant financial relationships to disclose.

P1-02-08 Selective elimination of axillary surgery after primary systemic treatment in clinically node-positive breast cancer patients by combining PET/CT and the MARI procedure (marking the axilla with radioactive iodine seeds)

Emilie Groen

Dr. Groen has no relevant financial relationships to disclose.

P2-03-05 Molecular differences between screen-detected and interval breast cancers are largely explained by PHASO subtypes

Janek Grönberg

Dr. Grönberg has no relevant financial relationships to disclose.

P1-10-21 Influence of timing of radiation therapy following breast-conserving surgery on 10-year disease-free survival

Karin Groothuis-Oudshoorn

Ms. Groothuis-Oudshoorn has no relevant financial relationships to disclose.

P6-09-54 Long-term recurrence risk and risk-based follow-up after breast cancer treatment

Karin Groothuis-Oudshoorn

Dr. Groothuis-Oudshoorn has no relevant financial relationships to disclose.

P5-07-13 Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer

Adrienne Gropper

Dr. Gropper has no relevant financial relationships to disclose.

P5-07-13 Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer

James Grothey

Dr. Grothey has no relevant financial relationships to disclose.

P3-10-03 Socioeconomic disparities in needle biopsy prior to breast cancer surgery across physician referral networks

Cary Gross

Dr. Gross has disclosed that he has contracts with 21st Century Oncology, Johnson and Johnson and Pfizer.

P3-09-04 Beyond CHEK2 in breast cancer: Search for additional moderately penetrant risk gene variants by analyzing the oligogenic disease course in CHEK2 mutation carriers

Eva Groß

Ms. Groß has no relevant financial relationships to disclose.

P0-13-01 Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer

Leahht Gross

Leeaht Gross overdeep Gondara has no relevant financial relationships to disclose.

P2-04-20 PD-L1 expression in triple negative breast cancer (TNBC) is associated with improved outcomes

Daniel Grosser

Dr. Grosser has no relevant financial relationships to disclose.

P5-07-13 Stromal kinome screening identifies a novel regulatory kinase implicated in fibroblast-mediated progression of invasion in triple negative breast cancer tumours

Ankhil Grothey

Ankhil Grothey has no relevant financial relationships to disclose.

P4-03-02 Stromal kinome screening identifies a novel regulatory kinase implicated in fibroblast-mediated progression of invasion in triple negative breast cancer tumours

Teresa Grothey

Dr. Grothey has no relevant financial relationships to disclose.

P4-03-02 Stromal kinome screening identifies a novel regulatory kinase implicated in fibroblast-mediated progression of invasion in triple negative breast cancer tumours

Teresa Grothey

Dr. Grothey has no relevant financial relationships to disclose.
Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate (ADC) for the treatment of relapsed/refractory, metastatic triple-negative breast cancer (mTNBC): Updated results

Michael Guarino
Dr. Guarino has no relevant financial relationships to disclose.

Factors related to the prognosis of breast cancer patients after the development of brain metastases

Valentina Guarneri
Dr. Guarneri has no relevant financial relationships to disclose.

Tumor infiltrating lymphocytes in recurrent HER2+ and triple negative breast cancer: Prognostic value according to tumor phenotype

Valentina Guarneri
Dr. Guarneri has no relevant financial relationships to disclose.

9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian short HER trial

Valentina Guarneri
Dr. Guarneri has no relevant financial relationships to disclose.

Phase 1/2 study of oral Abemaciclib (VT-466), a dual CYP17-lyase inhibitor and androgen receptor (AR) antagonist, in patients with advanced AR positive triple negative (TNBC) or estrogen receptor (ER) positive breast cancer (BC)

Ayca Guclalp
Dr. Guclalp has disclosed that he receives from Pfizer: salary support for a clinical trial (to the institution); Innocrin: salary support for a clinical trial (to the institution); Medivation: salary support for a clinical trial (to the institution).

Phase II trial of palbociclib in combination with bicalutamide for the treatment of androgen receptor (AR)+ metastatic breast cancer (MBC)

Ayca Guclalp
Dr. Guclalp has disclosed that he receives salary from and has ownership in Novartis.

Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy

Ayca Guclalp
Dr. Guclalp has no relevant financial relationships to disclose.

Metabolic obesity, adipose inflammation and aromatase: Potential drivers of breast cancer risk in women with normal body mass index

Ayca Guclalp
Dr. Guclalp has no relevant financial relationships to disclose.

A novel subgroup of estrogen receptor positive breast cancer may benefit from super-enhancer guided patient selection for retinoic acid receptor agonist treatment

Gernot Guderian
Gernot Guderian has disclosed that he is an employee of and holder of shares and options for Syros Pharmaceuticals.

A phase II study to compare fulvestrant (F) 500mg plus placebo versus (vs) F 500mg plus palbociclib (P) as first line treatment for postmenopausal women with hormone receptor (HR)-positive advanced breast cancer (BC) sensitive to endocrine therapy (ET). "The FLIPPER study" (GEICAM/2014-12)

Juan Guerra
Mr. Guerra has no relevant financial relationships to disclose.

Establishment and characterization of ST941/C; an ESR1-mutant ER+ breast cancer cell line and xenograft from a patient with acquired resistance to endocrine therapy

Marcus Guerra
Ms. Guerra has no relevant financial relationships to disclose.

Genomic profiling of residual ER+ breast cancers treated with prolonged neoadjuvant letrozole reveals novel alterations in clinically resistant tumors

Marcus Guerra
Ms. Guerra has no relevant financial relationships to disclose.

Ermin-HER, an antibody mixture with antim tumor activity against drug-resistant HER2-overexpressing breast cancers with high ERBB ligand expression

Angel Guerrero
Dr. Guerrero has no relevant financial relationships to disclose.

Selection of presumed CD49f antagonists and their biological evaluation in breast cancer cells

Sandra Guerrero-Rodríguez
Ms. Guerrero-Rodríguez has no relevant financial relationships to disclose.

Steroid receptors and steroidogenic enzymes in human breast cancer: Associations with breast cancer subtypes and clinical outcome

Fosita Guastri
Ms. Guastri has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Author</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2-04-22</td>
<td>Porous silicon microparticle potentiates anti-tumor immunity</td>
<td>Maria Guevara</td>
<td>Ms. Guevara has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-09-08</td>
<td>Molecular evaluation of Peruvian patients with hereditary breast cancer reveals a novel germline mutation in BRCA1</td>
<td>Maria Guevara-Fujita</td>
<td>Ms. Guevara-Fujita has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P05-07</td>
<td>From monocyte re-programming to the expansion of tumor infiltrating lymphocytes for adoptive T cell therapy</td>
<td>Nicolas Guevara</td>
<td>Dr. Guue has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-14-13</td>
<td>Total mastectomy and immediate breast reconstruction for breast cancer: A ten-year Canadian single-institution experience</td>
<td>Manon Guez</td>
<td>Dr. Guez has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-14-01</td>
<td>Metastatic breast cancer patients in clinical trials</td>
<td>Camila Guevara</td>
<td>Ms. Guevara has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-03-02</td>
<td>Breast implant associated anaplastic large cell lymphoma (BIA-ALCL): The UK experience and first reported case of neoadjuvant brentuximab</td>
<td>Sarah Guevara</td>
<td>Ms. Gue has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-14-12</td>
<td>ER is required for miR1253 inhibitor-induced feedback activation of PI3K/AKT to inhibit breast cancer cell growth</td>
<td>Jiang Guevara-Fujita</td>
<td>Ms. Guevara-Fujita has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-07-03</td>
<td>Broken promise of liquid biopsy: Plasma DNA does not accurately reflect tumor DNA in metastatic breast cancer</td>
<td>Jiang Guevar</td>
<td>Dr. Gui has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-16-15</td>
<td>Lymph-vascular invasion in the absence of stromal invasion after neoadjuvant therapy: A rare pattern of residual carcinoma that lacks an AJCC/UICC T category</td>
<td>Marie-Christine Guevbert</td>
<td>Dr. Guibert has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-10-01</td>
<td>Genomic profiling of residual ER+ breast cancers treated with prolonged neoadjuvant letrozole reveals novel alterations in clinically resistant tumors</td>
<td>Vicente Guevar</td>
<td>Dr. Guilen has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-13-08</td>
<td>Preclinical validation of a new tumor imaging agent targeting uPA to detect breast tumor using NIR-light imaging</td>
<td>Stephanie Guevermet</td>
<td>Ms. Guevermet has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-09-02</td>
<td>Unhealthy lifestyle patterns are prevalent in unaffected BRCA mutation carriers &amp; are associated with increased oxidative stress and telomere length alterations</td>
<td>Sinier Guiven</td>
<td>Dr. Guin has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-04</td>
<td>Evaluation of intra-tumor heterogeneity, test reproducibility and their impact in breast cancer samples assessed by Prosigna™: Results from a decision impact prospective study and a matched case-control study</td>
<td>Jean-Marc Guinebretiere</td>
<td>Dr. Guinebretiere has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-31</td>
<td>The REQUITE-AB study: Validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality of life in breast cancer patients</td>
<td>Sara Gutierrez-Enrique</td>
<td>Ms. Gutierrez-Enrique has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-05-06</td>
<td>Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple-negative breast cancer</td>
<td>Severine Gueli</td>
<td>Dr. Gueli has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-06-08</td>
<td>BRCA1 promoter hypermethylation, but not BRCA1 expression, is associated with basal-like features and good prognosis in triple negative breast cancer</td>
<td>Severine Gueli</td>
<td>Dr. Gueli has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-28</td>
<td>Prognostic impact of the inclusion of uPA/PLA-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision making</td>
<td>Severine Gueli</td>
<td>Dr. Gueli has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-12-09</td>
<td>Clinical characteristics of CNS metastases of different breast cancer subtypes - Results from a cohort study</td>
<td>Joachim Gullbo</td>
<td>Dr. Gulbo has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-05-18</td>
<td>Genomic copy number alterations (CNA) associated with pCR in HER2-positive (HER2+) early-stage breast cancer (BrCa) patients receiving neoadjuvant trastuzumab (T)</td>
<td>Sabine Gueli</td>
<td>Dr. Gulbo has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-14-12</td>
<td>Long-term outcome of HER2-normal early stage breast cancer (ER+) patients (Pts) treated with docetaxel-cyclophosphamide (TC) chemotherapy (CTx): MATURE results of a single-institution experience</td>
<td>Sabine Gueli</td>
<td>Dr. Gulbo has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-16-01</td>
<td>The importance of loco-regional tumor burden and surgery on survival in patients with de novo stage IV breast cancer: post hoc analyses of protocol MK07-03</td>
<td>Bahadir Guelio</td>
<td>Dr. Gulie has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
P1-09-03
Preoperative imaging of breast cancer patients seeking care at an urban safety net academic medical center
Christine Gunn
Dr. Gunn has no relevant financial relationships to disclose.

P1-03-13
Chronic inhibition of signal transducer and activator of transcription 3/5 in treatment-resistant human breast cancer cell subtypes: Convergence on the reactive oxygen species/SUMOylation pathway and its effects on xCT expression and system s activity
Patrick Gunning
Mr. Gunning has no relevant financial relationships to disclose.

P4-04-06
Diffuse optical tomography can predict pathologic complete response in patients with HER2+ or triple negative breast cancer undergoing neoadjuvant chemotherapy
Jacqueline Gunther
Ms. Gunther has no relevant financial relationships to disclose.

P1-08-03
Identification and characterization of a novel endoxifen substrate, PKCβ1, and its interaction with the estrogen receptor
Chunhua Guo
Dr. Guo has no relevant financial relationships to disclose.

OT1-01-09
Feasibility and safety of avoiding granulocyte colony-stimulating factor prophylaxis during the paclitaxel portion of dose dense doxorubicin-cyclophosphamide and paclitaxel regimen
Hao Guo
Hao Guo has no relevant financial relationships to disclose.

P1-12-04
Phase I dose-escalation trial of ONT-380 in combination with trastuzumab in patients (pts) with HER2+ breast cancer brain metastases
Hao Guo
Hao Guo has no relevant financial relationships to disclose.

P2-08-11
An orally bioavailable selective estrogen receptor downregulator
Shanchun Guo
Dr. Guo has no relevant financial relationships to disclose.

P2-04-14
T cell profile associated with regional lymph node progression in breast cancer
Yi Guo
Dr. Guo has no relevant financial relationships to disclose.

P5-04-02
MRG oncology/NSABP B-51/RTOG 1304: A phase III superiority clinical trial designed to determine if chest wall and regional nodal radiotherapy (CW/R) post mastectomy (Mx) or the addition of RNRT to breast RT post breast- conserving surgery (BCS) will reduce invasive cancer events in patients (pts) with positive axillary (Ax) nodes and convert to ypN0 after neoadjuvant chemotherapy (NC)
Nilendu Gupta
Dr. Gupta has no relevant financial relationships to disclose.

P5-16-12
Pericentric and trisomic/2 in combination with weekly paclitaxel delivers high pCR rates with favourable toxicity profile in neo-adjuvant treatment of Her-2 positive breast cancer
Niraj Gupta
Dr. Gupta has no relevant financial relationships to disclose.

P3-03-10
Pertuzumab reduces paclitaxel resistance in breast cancer by inhibiting HER2/J-catenin signaling
Niraj Gupta
Dr. Gupta has no relevant financial relationships to disclose.
P6-10-03 KEYNOTE-012: Long-lasting responses in a phase Ib study of pembrolizumab for metastatic triple-negative breast cancer (mTNBC)  Shilpa Gupta  Shilpa Gupta has no relevant financial relationships to disclose.

P2-15-01 Building an experience engine to make cancer treatment decisions using machine learning  Sudip Gupta  Dr. Gupta has no relevant financial relationships to disclose.

PD5-08 Multiple-gene panel testing for hereditary cancer risk reveals a racial/ethnic disparity in genetic information  Tanya Gupta*  Ms. Gupta* has no relevant financial relationships to disclose.

P6-18-01 The importance of loco-regional tumor burden and surgery on survival in patients with de novo stage IV breast cancer; post-hoc analyses of protocol MK07-01  Sunay Gurleyik  Dr. Gurleyik has no relevant financial relationships to disclose.

P1-08-03 Serial evolution of hormone receptor status and mutational profile among patients with metastatic breast cancer  Joseph Rorski  Mr. Rorski has no relevant financial relationships to disclose.

P5-13-18 The feasibility of nurse intervention to improve and maintain the BMI of breast cancer survivors over 25 to appropriate levels  Hiroko Gushikawa  Hiroko Gushikawa has no relevant financial relationships to disclose.

P6-01-10 Estrogen receptor β2 and β5 increase expression of ABCG2 and drug resistance of the triple-negative breast cancer cell line SUM159  Jan-åke Gustafsson  Dr. Gustafsson has no relevant financial relationships to disclose.

P3-05-06 Analytical and clinical validation of a fully automated tissue-based quantitative assay (MetaSite Breast™) to detect the likelihood of distant metastasis in hormone receptor (HR)-positive, HER2-negative early stage breast cancer (ESBC)  Mark Gustavson  Dr. Gustavson has disclosed that he receives salary and owns stock and stock options.

P3-04-23 Combination therapy of targeted anti-cancer pathways and estrogen receptor ligands and their responses in de novo endocrine resistant cell models  Lauren Gutgevall  Ms. Gutgevall has no relevant financial relationships to disclose.

P2-11-01 Influence of hormone replacement therapy following bilateral salpingo-oophorectomy on mammographic breast density in women newly diagnosed with breast cancer  Amber Guth  Dr. Guth has no relevant financial relationships to disclose.

P2-04-02 FOXA1 induces a pro-metastatic secretome through ER-dependent and independent transcriptional reprogramming in endocrine-resistant breast cancer  Dagmar Guth  Dr. Guth has no relevant financial relationships to disclose.

Committee Member
Carolina Gutierrez  Dr. Gutierrez has no relevant financial relationships to disclose.

P5-08-22 Impact of delay neoadjuvant chemotherapy on pathologic complete response in locally advanced breast cancer evidence of the real world in Mexico  Luz Guzman  Mrs. Guzman has no relevant financial relationships to disclose.

P6-20-08 Evaluation of a multidisciplinary cancer team quality in a breast cancer unit (BCU) in Mexico  Palenon Gutiérrez-Balderas  Dr. Gutiérrez-Balderas has no relevant financial relationships to disclose.

P2-07-09 CNP7 rate among individuals with breast cancer who underwent multiple gene testing for hereditary cancer: Single institution experience  Angelica Gutiérrez-Barrera  Ms. Gutiérrez-Barrera has no relevant financial relationships to disclose.

P3-14-10 Shared decision-making approach in breast reconstruction in a developing country  Luz Gutiérrez-Zacarias  Dr. Gutiérrez-Zacarias has no relevant financial relationships to disclose.

P6-01 A randomized phase III trial of carboplatin compared with doxorubicin for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)  Alexander Gutin  Dr. Gutin has disclosed that he receives salary from and has ownership of stock and stock options in Myriad Genetics. He has also disclosed that he has patient rights assigned to Myriad Genetics.

P6-08-01 Progesteron of estrogen receptor-β by NF1  David Dittmann  Dr. Dittmann has no relevant financial relationships to disclose.

P3-05-06 Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer  Marian Gutowski  Dr. Gutowski has no relevant financial relationships to disclose.

P6-09-28 Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2- and early breast cancer adjuvant treatments decision making  Marian Gutowski  Dr. Gutowski has no relevant financial relationships to disclose.
S3-08 Sentinel node detection after neoadjuvant chemotherapy in a patient without previous axillary node involvement (GANEA 2 trial): Follow-up of a prospective multi-institutional cohort
Marian Gutowski
Dr. Gutowski has no relevant financial relationships to disclose.

P4-12-07 CD74 amplification in early breast cancer patients: Correlation with subtypes and prognosis
Roberta Guzman
Ms. Guzman has no relevant financial relationships to disclose.

P6-09-16 Identification of proliferation-related drivers and their roles in precision medicine for breast cancers: A retrospective, multidimensional comparative, integrated genomic, transcriptomic, and protein analysis
Balazs Gyanchandani
Dr. Gyanchandani has no relevant financial relationships to disclose.

P6-09-49 Three-gene signature predictive of high residual risk of recurrence after adjuvant chemotherapy in ER-positive HER2-negative breast cancer
Balazs Gyanchandani
Dr. Gyanchandani has no relevant financial relationships to disclose.

S1-01 Whole exome and transcriptome sequencing of resistant ER+ metastatic breast cancer
Gavin Haan
Dr. Haan has no relevant financial relationships to disclose.

P2-01-10 Exome sequencing of circulating tumor cells in metastatic breast cancer
Josien Haan
Josien Haan has no relevant financial relationships to disclose.

P3-05-02 Active surveillance with a combination of tumor marker CA27.29 and detection of circulating tumor cells two years after primary diagnosis strongly predicts subsequent prognosis
Lothar Hieber
Lothar Hieber has no relevant financial relationships to disclose.

P1-11-08 Tumor and procedural factors associated with positive margins at lumpectomy in women undergoing breast conservation surgery
Elizabeth Habermann
Dr. Habermann has no relevant financial relationships to disclose.

P2-05-02 Active surveillance with a combination of tumor marker CA27.29 and detection of circulating tumor cells two years after primary diagnosis strongly predicts subsequent prognosis
Lothar Hieber
Lothar Hieber has no relevant financial relationships to disclose.

P4-20-07 Research biopsies in oncology-patient willingness, perceptions, understanding, and experience: An integrative review
Karleen Habin
Ms. Habin has no relevant financial relationships to disclose.

P6-07-10 Clinical validation signature predicting taxane/trastuzumab efficacy in metastatic breast cancer
Hubert Hackl
Prof. Hackl has no relevant financial relationships to disclose.

S1-10 Clinical implications of somatic mutations in post-menopausal early-stage estrogen receptor (ER)-positive HER2-negative breast cancer (BC): Results from the BIG 1-98 study
Wolfgang Hackl
Dr. Hackl has disclosed that he is a Novartis employee and owns stock in Novartis.  He also disclosed that he receives royalties from Letrozole.

P4-21-06 Dual HER2 blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: A subanalysis of data from the randomized phase III GeparSepto trial
John Hackmann
Mr. Hackmann has no relevant financial relationships to disclose.

P5-16-03 Peripheral sensory neuropathy occurrence and resolution: Results from the neoadjuvant randomized GeparSepto study (GBG 49)
Stephanie Haddad
Ms. Haddad has no relevant financial relationships to disclose.

P5-16-22 Survival after adjuvant and neoadjuvant chemotherapy in elderly patients with triple negative breast cancer: A Cleveland Clinic experience
Alido Haddad
Dr. Haddad has no relevant financial relationships to disclose.

P2-12-03 Prospective study of acupuncture in the rehabilitation of patients undergoing surgical treatment of breast cancer in relation to the strength and quality of life
Cimena Haddad
Dr. Haddad has no relevant financial relationships to disclose.

P5-16-16 Role of tumour microenvironment, as assessed by breast MRI background parenchymal enhancement (BPE), in modulating response to neoadjuvant chemotherapy in young women with localized breast cancer
Stephanie Haddad
Ms. Haddad has no relevant financial relationships to disclose.
P3-14-07  Neoadjuvant radiotherapy in mastectomy and immediate autologous free flap reconstruction. Findings from the primary radiotherapy and DIEP flap (PRADA) pilot study
Dimitri Hadjiminas
Dr. Hadjiminas has no relevant financial relationships to disclose.

P1-07-10  Prediction of 10yr distant recurrence (DR) using the Prosigna® (PAM50) assay in histological subgroups of a Danish breast cancer group (DBCG) cohort of postmenopausal Danish women with hormone receptor-positive (HR+) early breast cancer (EBC) allocated to 5yr of endocrine therapy (ET) alone
Taryn Haffner
Ms. Haffner has disclosed that she is an employee of and has stock options in NanoString Technologies.

P4-08-02  Integration of transcriptomic, proteomic and drug response data in triple negative breast cancer cell lines and PDX models.
Marc Hafner
Dr. Hafner has no relevant financial relationships to disclose.

P6-07-33  Metrics of drug sensitivity based on growth rate inhibition correct for the confounding effects of variable division rates
Marc Hafner
Dr. Hafner has no relevant financial relationships to disclose.

P3-03-13  Chronic inhibition of signal transducer and activator of transcription 3/5 in treatment-resistant human breast cancer cell subtypes: Convergence on the reactive oxygen species/SUMOylation pathway and its effects on lct expression and activity
Sina Haftchenary
Sina Haftchenary has no relevant financial relationships to disclose.

P4-12-10  Prognostic relevance of caspase 8 polymorphisms for breast cancer
Bachmann Hagen
Dr. Hagen has no relevant financial relationships to disclose.

P4-06-05  Treatment of ESR1 mutant and PIK3CA mutant patient-derived breast cancer xenograft models reveals differential anti-tumor responses to estrogen receptor degraders and PI3K inhibitors in cell
Jeff Hager
Mr. Hager has disclosed that he is a shareholder of Seragon Pharmaceuticals Inc.

PD-03  Multivariate analysis of subtype and gene expression signatures predictive of pathologic complete response (pCR) in triple-negative breast cancer (TNBC): CALGB-40603 (Alliance)
Owen Hahn
Dr. Hahn has no relevant financial relationships to disclose.

P1-09-02  Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer
Eric Hahnen
Dr. Hahnen has no relevant financial relationships to disclose.

P3-08-01  Low-level gonosomal mosaicism of a de novo BRCA1 gene mutation - The origin of a constitutional mutation in a breast cancer family
Eric Hahnen
Dr. Hahnen has no relevant financial relationships to disclose.

P3-09-03  Beyond CHEK2 in breast cancer: Search for additional moderately penetrant risk gene variants by analyzing the oligogenic disease course in CHEK2 mutation carriers
Benjamin Halbre-Kains
Dr. Halbre-Kains has no relevant financial relationships to disclose.

P4-22-09  A phase 2 open label study of everolimus in combination with endocrine therapy in resistant hormone receptor-positive HER2 negative advanced breast cancer
John Hainsworth
Dr. Hainsworth has no relevant financial relationships to disclose.

P3-17-07  Determining the optimal vaccination strategy using a combination of the folate binding protein (FBP) peptide vaccine (E39+GM-CSF) and an attenuated version (E39') to maximize the immunologic response in breast cancer patients
Elaine Hale
Dr. Hale has no relevant financial relationships to disclose.
Efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial
Barbara Haley
Dr. Haley has no relevant financial relationships to disclose.

The evaluation of ganitumab/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial
Barbara Haley
Dr. Haley has no relevant financial relationships to disclose.

P1-05-30
Carcinom and microenvironmental intra-tumor heterogeneity in DCIS
Allison Hall
Mr. Hall has no relevant financial relationships to disclose.

Evidence for tumor heterogeneity and clonal evolution during invasive progression of breast cancer
Allison Hall
Mr. Hall has no relevant financial relationships to disclose.

P1-09-01
Impact of MAPK gene amplification on disease recurrence and effects of adjuvant zedolonic acid in early breast cancer
Andrew Hall
Mr. Hall has no relevant financial relationships to disclose.

PrECOG 0102: A randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in post-menopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC) resistant to aromatase inhibitor (AI) therapy
Barbara Haley
Dr. Haley has no relevant financial relationships to disclose.

Women's experiences with a decision aid for neoadjuvant systemic therapy for operable breast cancer
Alix Hall
Alix Hall has no relevant financial relationships to disclose.

Concordance with National comprehensive cancer network (NCCN) metastatic breast cancer guidelines and impact on overall survival
Karina Halkova
Ms. Halkova has no relevant financial relationships to disclose.

Technology as a change agent for improving breast cancer quality care
Karina Halkova
Ms. Halkova has disclosed that she has a contract.

Impact of MAF gene amplification on disease recurrence and effects of adjuvant zoledronic acid in early breast cancer patients treated by NEDiagnostic chemotherapy
Carafyon Hall
Ms. Hall has no relevant financial relationships to disclose.

Extracellular vesicles from young women’s and postpartum breast cancer display unique proteomic content, alter breast cancer aggressive behavior, and influence immune cell function
Jessica Hall
Ms. Hall has no relevant financial relationships to disclose.

Molecular differences between screen-detected and interval breast cancers are largely explained by PAM50 subtypes
Per Hall
Dr. Hall has no relevant financial relationships to disclose.

A clinical model for assessment of the individual breast cancer risk
Per Hall
Dr. Hall has no relevant financial relationships to disclose.

Insulin and breast cancer risk: Novel insights from mammographic density analyses
Per Hall
Dr. Hall has no relevant financial relationships to disclose.

Use of a 3-D Bioabsorbable tissue marker in 61 patients over two years
William Hall
Dr. Hall has no relevant financial relationships to disclose.

Identification of SARA91905, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong antitumor activity in wild-type and mutant ER+ breast cancer models
Frank Halley
Mr. Halley has no relevant financial relationships to disclose.

Quality of life assessed by BREAST-Q in patients with delayed immediate tissue expander based breast reconstruction with and without radiotherapy
Moritz Hamann
Mr. Hamann has no relevant financial relationships to disclose.

Quality of life assessed by BREAST-Q in patients with delayed immediate tissue expander based breast reconstruction with and without radiotherapy
Ulrich Hamann
Mr. Hamann has no relevant financial relationships to disclose.

CARE: mutations in circulating tumor cell versus circulating cell-free DNA of metastatic breast cancer patients before first-line endocrine therapy and at progression
Paul Hamberg
Mr. Hamberg has no relevant financial relationships to disclose.
Inhibition of Pin1 or CDK-mediated Smad3 phosphorylation reduces triple negative breast cancer cell EMT, migration and invasion

Randala Hamdan
Dr. Hamdan has no relevant financial relationships to disclose.

Impact of radiotherapy on complications and patient-reported satisfaction with breast reconstruction: Findings from the prospective multicenter MROC study

Jennifer Hamill
Ms. Hamill has no relevant financial relationships to disclose.

Analytical and clinical validation of a fully automated tissue-based quantitative assay (MetaSite™) to detect the likelihood of distant metastasis in hormone receptor (HR)-positive, HER2-negative early stage breast cancer (ESBC)

Douglas Hamilton
Mr. Hamilton has disclosed that he receives salary and owns stock and stock options.

Tumor microenvironment of metastasis (TMM) score is associated with early distant recurrence in hormone receptor (HR) positive, HER2-negative early stage breast cancer (ESBC)

Douglas Hamilton
Mr. Hamilton has disclosed that he receives salary from MetaStat.

Phase 2 study of abemaciclib plus tamoxifen or abemaciclib alone in women with previously treated hormone receptor-positive (HR+), HER2- metastatic breast cancer

Erika Hamilton
Ms. Hamilton has disclosed that she receives institutional research funding.

Circulating tumor cells (CTCs) biomarker evaluation from patients with metastatic breast cancer (MBC) utilizing the TargetSelector™ platform

Erika Hamilton
Dr. Hamilton has no relevant financial relationships to disclose.

Phase III safety, efficacy, and molecular analysis of ribociclib (LEE011) plus letrozole for the treatment of ER+, HER2- advanced breast cancer

Joanna Hamilton
Dr. Hamilton has no relevant financial relationships to disclose.

A phase I study of AZD9496, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER2- metastatic breast cancer (MBC), including patients (pts) with brain metastases (mets)

Patricia Hamilton
Ms. Hamilton has disclosed that she is an employee of Genentech, A Member of the Roche Group.

ESR1 amplification and 5'-3' exon imbalance in metastatic breast cancer

Ron Hamilton
Dr. Hamilton has no relevant financial relationships to disclose.

Breast cancer brain metastases show limited intrinsic subtype switching, yet exhibit acquired ERBB2 amplifications and activating mutations

Karen Hampsch
Ms. Hampsch has disclosed that she is employed by CarisVive.

Long-term outcome of HER2-normal early stage breast cancer (ESBC) patients (Pts) treated with docetaxel-cyclophosphamide (TC) chemotherapy (CT): Mature results of a single-institution experience

Lisa Hammond
Ms. Hammond has no relevant financial relationships to disclose.

Clinically dormant ER+ breast tumors exhibit AKT activation

Riley Hampsch
Riley Hampsch has no relevant financial relationships to disclose.
CCND1 amplification in early breast cancer patients: Correlation with subtypes and prognosis

Volkert Hanf

Dr. Hanf has disclosed that he is a consultant for Novartis.

Unhealthy lifestyle patterns are prevalent in unaffected BRCA mutation carriers & are associated with increased oxidative stress and telomere length alterations

Yvonne Hanhauser

Ms. Hanhauser has no relevant financial relationships to disclose.

Ductal carcinoma in situ: Patient-outcomes and association with hormone receptors

Ahmed Hanif

Dr. Hanif has no relevant financial relationships to disclose.

An acquired HER2 T798I gatekeeper mutation induces resistance to neratinib in a patient with HER2 mutant-driven breast cancer

Ariella Haniker

Dr. Haniker has no relevant financial relationships to disclose.

Long-term rates of breast preservation after breast-conserving therapy for ductal carcinoma in situ

Wedad Hanna

Dr. Hanna has no relevant financial relationships to disclose.

Nuclear grade has a limited role in predicting recurrence in DCIS following breast conserving surgery: A population-based study

Wedad Hanna

Dr. Hanna has no relevant financial relationships to disclose.

A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA)

Alison Hannah

Ms. Hannah has disclosed that she is an employee of Medivation, Inc.

Long-term follow-up of persistent breast demography after sentinel lymph node identification using superparamagnetic iron oxide particles (SIENNA+®)

Karina Hannelique

Dr. Hannelique has no relevant financial relationships to disclose.

Value-based approach to treatment of HER2 positive breast cancer: Examining the evidence

Malek Hannouf

Mr. Hannouf has no relevant financial relationships to disclose.

Extracellular vesicles from young women’s and postpartum breast cancer display unique proteomic content, alter breast cancer aggressive behavior, and influence immune cell function

Kirk Hansen

Dr. Hansen has no relevant financial relationships to disclose.

Incidence and severity of diarrhea with neratinib + intensive loperamide prophylaxis in patients (pts) with HER2+ early-stage breast cancer (EC): Interim analysis from the multicenter, open-label, phase II control trial

Vincent Hansen

Mr. Hansen has no relevant financial relationships to disclose.

Pertuzumab and trastuzumab in combination with weekly paclitaxel delivers high pCR rates with favourable toxicity profile in neo-adjuvant treatment of Her-2 positive breast cancer

Den Hanson

Ms. Hanson has no relevant financial relationships to disclose.

Utility of the orally bioavailable selective estrogen receptor degrader AZD9496 in ESR1 mutant preclinical models of estrogen receptor positive breast cancer

Lyndsey Hanson

Ms. Hanson has disclosed that she receives salary and has ownership.

Outcome after neoadjuvant chemotherapy in prostate receptor negative breast cancer patients - A pooled analysis of individual patient data from ten prospectively randomised controlled neoadjuvant trials

Claus Hanusch

Mr. Hanusch has no relevant financial relationships to disclose.

Long-term comparison of anastrozole versus tamoxifen: Results from LATTE/ATAC

Claus Hanusch

Mr. Hanusch has no relevant financial relationships to disclose.

Dual HER2 blockade with pertuzumab and trastuzumab in HER2 positive early breast cancer: A subanalysis of data from the randomized phase III GeparSepto trial

Claus Hanusch

Mr. Hanusch has disclosed that he is a speaker for Celgene and Roche.

Peripheral sensory neuropathy occurrence and resolution: Results from the neoadjuvant randomized GeparSepto study (GBG 69)

Claus Hanusch

Mr. Hanusch has disclosed that he is a consultant for Celgene.

Evaluation of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarker in different subtypes of breast cancer treated with neoadjuvant therapy - A metaanalysis of 3771 patients

Claus Hanusch

Mr. Hanusch has no relevant financial relationships to disclose.

Adipocyte fatty acid binding protein levels predict risk of obesity associated breast cancer

Jiaqing Hao

Mr. Hao has no relevant financial relationships to disclose.

Outcome after neoadjuvant chemotherapy in prostate receptor negative breast cancer patients - A pooled analysis of individual patient data from ten prospectively randomised controlled neoadjuvant trials

Claus Hanusch

Mr. Hanusch has no relevant financial relationships to disclose.

Long-term comparison of anastrozole versus tamoxifen: Results from LATTE/ATAC

Claus Hanusch

Mr. Hanusch has no relevant financial relationships to disclose.
Disruption of the estradiol-regulated NTN1-UNC5A dependence receptor signaling axis causes a hybrid basal/luminal molecular phenotype in estrogen receptor-positive breast cancer cells

Yingyang Hao

Yingyang Hao has no relevant financial relationships to disclose.

Yukiyo Hara

Dr. Hara has disclosed that he receives salary from and has ownership in Novartis Pharmaceuticals Corporation.

A randomized phase II study of trastuzumab response-guided neo-adjuvant chemotherapy for HER2-positive breast cancer

Fumikata Hara

Dr. Hara has no relevant financial relationships to disclose.

The escape PTEN expression correlates to the luminal breast cancer stem cell

Riikka Hara

Dr. Hara has no relevant financial relationships to disclose.

Treatment patterns for breast cancer brain metastasis

Bjarni Haraldsson

Bjarni Haraldsson has no relevant financial relationships to disclose.

Rates of immune infiltration in patients with triple-negative breast cancers by molecular subtype and in patients with inflammatory and non-inflammatory breast cancers

Kenichi Harano

Dr. Harano has no relevant financial relationships to disclose.

A phase 1 study of RAD1901, a novel, oral selective estrogen receptor degrader, for the treatment of ER positive advanced breast cancer

Wael Harb

Wael Harb has disclosed that he is a consultant for Onyx Pharmaceuticals and has a contract with Horizon Oncology Research, Inc.

The ectopic FOXA1 expression correlates to the luminal breast cancer stem cells

Hisato Hara

Dr. Hara has no relevant financial relationships to disclose.

Challenges faced across borders to open European academic multicentre projects: The ET-TEIS program part of the ERA-NET TRANSCAN JTC 2011

Nadia Harbeck

Ms. Harbeck has disclosed that she is a consultant and speaker for Roche, Novartis and Pfizer. She also disclosed that the center for clinical trials is sponsored by Roche, Novartis and Pfizer.

Chemotherapy (CT) decision in patients (pts) with node-positive (N+), ER+, early breast cancer (EBC) in the wake of new ASCO guideline - A different take on the evidence for the 21-gene recurrence score (RS) assay

Nadia Harbeck

Dr. Harbeck has disclosed that she receives honoraria from Genomic Health.

The role of immune and apoptosis markers for prediction of pCR in the NSG-ADAPT HER2+ early breast cancer phase II trial evaluating 12-weeks of nesafuridine DM1 + endocrine therapy (IT) versus T + IT in HER2-positive hormone-receptor-positive early breast cancer (EBC)

Nadia Harbeck

Dr. Harbeck has disclosed that he receives research support and is a consultant and speaker.

Efficacy and gene expression results from SOLTI1007 NEUROTHINK phase II clinical trial in HER2-negative early breast cancer

Nadia Harbeck

Dr. Harbeck has disclosed that he receives honoraria for lectures from Nanostring.

Efficacy and safety of darbepezol alla or epoetin beta in 2994 high risk early breast cancer patients participating in the German adjuvant intergroup node-positive study (GAI2)

Nadia Harbeck

Ms. Harbeck has disclosed that she is a speaker for Roche and Amgen.

Cardiac biomarkers for early detection and prediction of toxicities and/or late effects in breast and breast cancer patients

Nadia Harbeck

Dr. Harbeck has no relevant financial relationships to disclose.

Palbociclib in combination with endocrine therapy in treatment-naive and previously treated elderly women with HR+, HER2- advanced breast cancer: A pooled analysis from randomized phase 2 and 3 studies

Nadia Harbeck

Ms. Harbeck has disclosed that she is a consultant for Eli Lilly, Novartis and Pfizer and a speaker for Novartis and Pfizer. She has also disclosed Study conduct (Institution).

Treatment postprogression in women with endocrine-resistant HER2-HR advanced breast cancer who received palbociclib plus fulvestrant in PALOMA-3

Nadia Harbeck

Ms. Harbeck has disclosed that she is a speaker for Novartis and Pfizer.

nab-paclitaxel + carboplatin or gemcitabine vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the TRANform trial

Nadia Harbeck

Ms. Harbeck has disclosed that she is a consultant and speaker for Celgene Corporation. She also disclosed that she has a contract to Breast Center of the University of Munich from Celgene Corporation.

Ovarian cancer - Cancer care in Europe: What is the clinical pathway for a patient with ovarian cancer? A survey of 150 European Gynaecological Oncology centres

Nadia Harbeck

Ms. Harbeck has disclosed that she is a consultant for Celgene Corporation.
P6-09-10 Results of multigene assay (MammaPrint®) and molecular subtyping (BluePrint®) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIME decision impact study

Nadia Harbeck

Prof. Harbeck has disclosed that she is on an advisory board.

P6-11-05 Phase 3 trial of CE-BV3, a small molecule inhibitor of glutaminase (GLS), in combination with paclitaxel (Pacl) in patients (pts) with triple negative breast cancer (TNBC)

James Harding

Dr. Harding has no relevant financial relationships to disclose.

P1-08-01 Regulation of estrogen receptor-α by NF1

Swati Haricharan

Dr. Haricharan has no relevant financial relationships to disclose.

P1-07-01 Assessing the impact of loss of NF1 protein on endocrine therapy resistance

Swati Haricharan

Dr. Haricharan has no relevant financial relationships to disclose.

P02-03 Recurrent functionally diverse in-frame ESR1 gene fusions drive endocrine resistance in breast cancer

Swati Haricharan

Dr. Haricharan has no relevant financial relationships to disclose.

P02-06 Mismatch repair deficiency induces endocrine therapy resistance in breast cancer

Swati Haricharan

Dr. Haricharan has no relevant financial relationships to disclose.

P3-05-09 Glucocorticoid receptor modulation affects ER+ breast cancer proliferation

Ryan Hargrove

Mr. Hargrove has no relevant financial relationships to disclose.

S4-03 The importance of the ultimate ratio of Omega-6 to Omega-3 fatty acids in the efficacy of fish oil supplements in suppressing inflammation in obese postmenopausal women

Brittany Harlow

Ms. Harlow has no relevant financial relationships to disclose.

P2-01-11 Prosigna®: A non-inferiority trial comparing super paramagnetic iron oxide vs. Tc-99 and blue dye in the detection of axillary sentinel nodes in patients with early stage breast cancer

Quantin Harmer

Dr. Harmer has disclosed that he is an employee of Endomagnetics.

P5-08-12 HER2 status remains the primary predictor of improved survival in patients with BCMI over the past 2 decades (1996-2015)

Kathleen Harman

Dr. Harman has no relevant financial relationships to disclose.

P03-02 Paclitaxel-induced men- and TNE-mediated pro-metastatic changes in the breast cancer microenvironment

Robin Harnney

Dr. Harnney has no relevant financial relationships to disclose.

P03-02 Intraoperative tumor detection using a ratiometric activatable fluorescent peptide: A first-in-human phase I study allows tumors to be visualized in the operating room

Alex Haroutunian

Dr. Haroutunian has disclosed that he receives salary and has ownership in Avelas Biosciences, Inc.

S6-01 BRCA1 methylation status, silencing and treatment effect in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)

Catherine Harper-Wynne

Ms. Harper-Wynne has disclosed that she is a consultant for Pfizer, Eisai and Roche.

P1-07-16 Multi-level gene expression signatures provide significant prognostic information in metastatic breast cancer patients

Darrell Harris

Dr. Harrell has no relevant financial relationships to disclose.

P3-06-08 HDAC6 deacetylates HMGN2 to regulate Stat5a activity and breast cancer growth

Karl Harris

Dr. Harris has no relevant financial relationships to disclose.

P1-06-28 HDACi-induced changes in cancer cells synergize with conventional therapy and enhance tumor cell killing

Mark Harries

Ms. Harries has no relevant financial relationships to disclose.

S6-01 BRCA2 methylation status, silencing and treatment effect in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)

Karin Harries

Dr. Harries has no relevant financial relationships to disclose.

P2-01-28 Intraoperative assessment of the sentinel node (SN) in breast cancer by one step nucleic acid assay (OSNA): Experience of over 800 patients

Simon Hargrove

Mr. Hargrove has no relevant financial relationships to disclose.

P1-06-02 Impact of heterogeneity of DCIS on immune cell infiltrations

Adrian Harris

Dr. Harris has no relevant financial relationships to disclose.

S6-01 Development of a Prosigna® (PAM50)-based classifier for the selection of advanced triple negative breast cancer (TNBC) patients for treatment with enzalutamide

Edith Harris

Ms. Harris has disclosed that she is an employee of and has ownership in Nanobridging Technologies, Inc.
Improved long-term outcomes of breast-conserving therapy for women with ductal carcinoma in situ

Breast cancer subtypes, age and lymph node status as predictors of local recurrence following breast-conserving therapy

Association of co-amplification with immune infiltration in subtypes of HER2-positive breast cancer

Integrated analysis of multi-dimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase II trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer

A solution to the APOBEC mutation paradox in breast cancer

Cambridge brain mets trial 1 (CamBMT1): A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiosurgery

A RB-1 loss-of-function gene signature (RBsig) predicts resistance to neoadjuvant chemotherapy in HER2+ breast cancer patients

Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ER-positive metastatic breast cancer patients: Results of the COMETI Phase 2 trial

First-line ribociclib plus letrozole in patients with de novo HR+, HER2- advanced breast cancer (ABC): A subgroup analysis of the MONALEESA-2 trial

Optimized prediction of deleterious missense mutations in BRCA1 and BRCA2 genes

Breast cancer risks associated with mutations in cancer predisposition genes identified by clinical genetic testing of 60,000 breast cancer patients

The DETECT V-study - Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemotherapy or endocrine therapy in patients with HER2-positive and hormone-receptor positive metastatic breast cancer

The DETECT III and IV - Individualized CTC-based therapy of metastatic breast cancer

IMENEO: International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEoadjuvant chemotherapy

The RELIABILITY and acceptance of e-based survey instruments for measuring patient reported outcomes (PRO) in breast cancer patients: First results of the ePROCOM study

Breast cancer brain metastases show limited intrinsic subtype switching, yet exhibit acquired RBRE5 amplifications and activating mutations

Hemoglobin repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer

Molecular differences between screen-detected and interval breast cancers are largely explained by PAM50 subtypes
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1-05-01</td>
<td>Landscape of somatic mutations in inflammatory breast cancer whole-genome sequences</td>
<td>Christos Hatzis</td>
<td>Dr. Hatzis has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-09-15</td>
<td>A multi-institutional, prospective study of incorporating the genomic platform breast cancer index as a tool for decision-making regarding extension of adjuvant endocrine therapy</td>
<td>Christos Hatzis</td>
<td>Dr. Hatzis has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-23</td>
<td>SETERRA - A robust 18-gene predictor of sensitivity to endocrine therapy in metastatic breast cancer</td>
<td>Christos Hatzis</td>
<td>Dr. Hatzis has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-49</td>
<td>Three-gene signature predictive of high residual risk of recurrence after adjuvant chemotherapy in ER-positive HER2-negative breast cancer</td>
<td>Christos Hatzis</td>
<td>Dr. Hatzis has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S1-06</td>
<td>Immune sculpting of the triple negative breast cancer genome</td>
<td>Christos Hatzis</td>
<td>Mr. Hatzis has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-06-04</td>
<td>Breast cancer after Hodgkin lymphoma: Influence of endogenous and exogenous gonadal hormones on the radiation dose-response relationship</td>
<td>Michael Hauptmann</td>
<td>Dr. Hauptmann has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-07-05</td>
<td>Risk of metachronous contralateral breast cancer: Systematic review and meta-analysis</td>
<td>Michael Hauptmann</td>
<td>Dr. Hauptmann has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-09-16</td>
<td>How population-based data complement trial data in the adjuvant endocrine treatment of ER+/HER2+ breast cancers</td>
<td>Michael Hauptmann</td>
<td>Dr. Hauptmann has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-01-04</td>
<td>Comprehensive genomic characterization of circulating tumor cells (CTCs) in metastatic breast cancer (MBC) shed light on the biology of blood-borne metastasis</td>
<td>Louai Hauranieh</td>
<td>Louai Hauranieh has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-02-12</td>
<td>Determination of a serum progranulin (GP88/PGRN) level associated with overall survival in metastatic breast cancer patients</td>
<td>Douglas Hawkins</td>
<td>Dr. Hawkins has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-03-06</td>
<td>Improvement in risk predictive value of Nottingham prognostic index by determining GP88 tumor tissue expression for estrogen receptor positive breast cancer patients</td>
<td>Douglas Hawkins</td>
<td>Dr. Hawkins has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-08-03</td>
<td>Identification and characterization of a novel-endosomal substrate, PHE21, and its interaction with the estrogen receptor</td>
<td>John Hawes</td>
<td>Dr. Hawes has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-07-20</td>
<td>Biological functions of ERβ in triple negative breast cancer and its utility as a novel therapeutic drug target</td>
<td>John Hawse</td>
<td>Dr. Hawse has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-04-04</td>
<td>Activation of ERβ in triple negative breast cancer results in cell cycle arrest</td>
<td>John Hawse</td>
<td>Dr. Hawse has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-16-10</td>
<td>Olaparib, and combined with neoadjuvant chemotherapy for HER2-negative early breast cancer (JONE 1 trial): Survival outcomes of a randomized multicenter phase 2 trial</td>
<td>Fukushima Hayashi</td>
<td>Dr. Hayashi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-04-13</td>
<td>Difference of immune microenvironment between primary and recurrent tumours in breast cancer patients</td>
<td>Naoki Hayashi</td>
<td>Ms. Hayashi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Page</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| P2-05-16 | Clinicopathological predictors for low risk recurrence distinguished by 21-gene recurrence score in estrogen receptor-positive invasive breast cancer patients  
Naoki Hayashi  
Naoki Hayashi has disclosed that he receives honoraria from Genomic Health, Inc.  |
| P5-15-20 | Squadin (SQUAD1) showed inhibitory effects on epithelial-mesenchymal transition (EMT) in tumors of metastatic breast cancer patients. -First preliminary report of a prospective study-  
Takemori Hayashi  
Takemori Hayashi has no relevant financial relationships to disclose.  |
| P5-09-04 | Assessment of breast cancer risk among atomic-bomb survivors based on ATM polymorphisms, radiation dose, and age at exposure  
Tomomori Hayashi  
Dr. Hayashi has no relevant financial relationships to disclose.  |
| P1-01-37 | Technical feasibility and validity of sentinel lymph node biopsy in patients with unilateral breast tumor recurrence  
Tetsu Hayashi  
Mr. Hayashi has no relevant financial relationships to disclose.  |
| P4-09-03 | Obesity-induced EMT in breast cancer cells  
Mitsuo Hayashi  
Ms. Hayashi has no relevant financial relationships to disclose.  |
| P2-05-20 | Comparing the frequency and types of genetic alterations between older and younger women with metastatic breast cancer at the University of North Carolina at Chapel Hill  
Dr. Haynes has no relevant financial relationships to disclose.  |
| P1-01-01 | Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ER positive metastatic breast cancer patients: Results of the COMETI Phase 2 trial  
Daniel Hayes  
Dr. Hayes has disclosed that his institution has been awarded a patent naming him as the principle inventor on the CTC-ETI and licensed it to Janssen, the manufacturer of CellSearch and he receives royalties annually. He also disclosed that he has contracts with Janssen, Pfizer, AstraZeneca, Puma and Eli Lilly. He disclosed that he has stock options (not relevant to this presentation) from Inbiomotion and Oneimmune.  |
| P1-03-01 | An international multicenter study to evaluate reproducibility of automated scoring methods for assessment of Ki67 in breast cancer  
Daniel Hayes  
Dr. Hayes has no relevant financial relationships to disclose.  |
| P6-09-11 | Genetic variation in CYP3A affects steady-state exemestane concentrations but does not explain inter-race difference  
Daniel Hayes  
Dr. Hayes has disclosed that he receives research funding from Pfizer and that the trial was sponsored by Pfizer and Novartis.  |
| P07-07 | Discovery of molecular predictors of late breast cancer specific events (BCSE) in ER+, node+ breast cancer - new transcriptome expression whole gene analysis of the phase II trial SWOG S8814  
Dr. Hayes has no relevant financial relationships to disclose.  |
| Committee Member | A fit-for-purpose NGS system that reports ERBB2 (HER2) mutations and copy number variants for clinical trials research and drug development  
Brian Hayes  
Dr. Hayes has disclosed that he receives salary from and has ownership in Asuragen, Inc.  |
| P1-02-08 | Provista-002: A prospective, multi-center study to determine the effectiveness of a biomarker assay to distinguish benign from invasive breast cancer in women with BI-RADS 3, 4 and 5 imaging reports  
Ali Haythem  
Dr. Haythem has no relevant financial relationships to disclose.  |
| P1-05-20 | Comparing the frequency and types of genetic alterations between older and younger women with metastatic breast cancer at the University of North Carolina at Chapel Hill  
Michelle Haywood  
Ms. Haywood has no relevant financial relationships to disclose.  |
| P4-15-04 | Molecular mediators of mammographic density  
Linda Haywood  
Dr. Haywood has no relevant financial relationships to disclose.  |
| P3-15-01 | Prognostic significance of CD8+ tumor-infiltrating lymphocytes (TILs), CD4+ TILs and TILs in male breast cancer  
Manel Hedden  
Mr. Hedden has no relevant financial relationships to disclose.  |
| P1-04-07 | Environmental influence on epigenetic markers in the development of breast cancer  
Chunyan He  
Dr. He has no relevant financial relationships to disclose.  |
| P2-03-10 | A fit-for-purpose NGS system that reports ERBB2 (HER2) mutations and copy number variants for clinical trials research and drug development  
Brian Hayes  
Dr. Hayes has disclosed that he receives salary from and has ownership in Asuragen, Inc.  |
| P1-02-08 | Provista-002: A prospective, multi-center study to determine the effectiveness of a biomarker assay to distinguish benign from invasive breast cancer in women with BI-RADS 3, 4 and 5 imaging reports  
Ali Haythem  
Dr. Haythem has no relevant financial relationships to disclose.  |
| P1-05-20 | Comparing the frequency and types of genetic alterations between older and younger women with metastatic breast cancer at the University of North Carolina at Chapel Hill  
Michelle Haywood  
Ms. Haywood has no relevant financial relationships to disclose.  |
| P4-15-04 | Molecular mediators of mammographic density  
Linda Haywood  
Dr. Haywood has no relevant financial relationships to disclose.  |
| P3-15-01 | Prognostic significance of CD8+ tumor-infiltrating lymphocytes (TILs), CD4+ TILs and TILs in male breast cancer  
Manel Hedden  
Mr. Hedden has no relevant financial relationships to disclose.  |
| P1-04-07 | Environmental influence on epigenetic markers in the development of breast cancer  
Chunyan He  
Dr. He has no relevant financial relationships to disclose.  |
Comparison of axillary nodal status between different defined clinically node negative breast cancer: Is ACOSOG Z0011 criteria applicable to preoperative cytologically negative axilla?

Jianrong He

Jianrong He has no relevant financial relationships to disclose.

The lymph node ratio as an independent prognostic factor for node-positive triple-negative breast cancer

Min He

Min He has no relevant financial relationships to disclose.

Use of natural language processing on mammography and pathology findings to supplement BI-RADS to improve clinical decision making in breast cancer care

Yian Cheng

Dr. He has no relevant financial relationships to disclose.

Recurrent functionally diverse in-frame ESR1 gene fusions drive endocrine resistance in breast cancer

Yaping He

Yaping He has no relevant financial relationships to disclose.

In the era of conservative surgery, can patients presenting with node positive breast cancer be spared axillary node dissection post neoadjuvant chemotherapy? A meta-analysis and review of literature

Hannah Headon

Ms. Headon has no relevant financial relationships to disclose.

Does fat transfer increase the risk of breast cancer recurrence? A meta-analysis involving 2382 patients

Hannah Headon

Ms. Headon has no relevant financial relationships to disclose.

The role of sentinel lymph node biopsy in patients with ductal carcinoma in situ. An updated meta-analysis involving 5803 patients

Hannah Headon

Ms. Headon has no relevant financial relationships to disclose.

Aromatase inhibitors and endothelial function: Is there an association with early cardiovascular disease?

Robert Hebbel

Dr. Hebbel has no relevant financial relationships to disclose.

Identification of SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong antitumor activity in wild-type and mutant ER+ breast cancer models

Andrew Hebert

Mr. Hebert has no relevant financial relationships to disclose.

A targetable EGFR-driven tumor-initiating program in breast cancer

Steven Hébert

Mr. Hébert has no relevant financial relationships to disclose.

A phase I trial of the safety and immunogenicity of a DNA plasmid-based vaccine (WOKVAC) encoding epitopes derived from three breast cancer antigens (IGFBP2, HER2, and IGF1R) in patients with breast cancer

Brandy Heckman-Stoddard

Dr. Heckman-Stoddard has no relevant financial relationships to disclose.

A randomized trial of 15 fraction vs 25 fraction pencil beam scanning proton radiotherapy after mastectomy in patients requiring regional nodal irradiation

Villaret Hector

Dr. Hector has no relevant financial relationships to disclose.

Patient derived DCLS mouse-intracranial (mICR) models recapitulate the full spectrum of human patient pathology and histologic features including progression to invasion in a subset of cases

Ellie Heddons

Ms. Heddons has no relevant financial relationships to disclose.

Risk of primary and contralateral breast cancer in BRCA1/2 mutation carriers previously affected with ovarian cancer

Bernadette Hoemskerck-Gerritsen

Dr. Hoemskerck-Gerritsen has no relevant financial relationships to disclose.

Identifying metastatic drivers in patient derived xenograft models of triple negative breast cancer

Timothy Heffernan

Mr. Heffernan has no relevant financial relationships to disclose.

The SCAN-B study: 5-year summary of a large-scale population-based prospective breast cancer translational genomics platform covering a wide geography of Sweden (NCT02356096)

Cecilia Hagardt

Dr. Hagardt has no relevant financial relationships to disclose.
Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer

John Hegde
Dr. Hegde has no relevant financial relationships to disclose.

A novel nomogram model can predict oncopotype DX results thus reducing healthcare expenditures

Robert Heidel
Dr. Heidel has no relevant financial relationships to disclose.

Prognostic significance of nuclear factor kappa B in node-negative breast cancer is most pronounced in luminal B breast cancer

Anne-Sophie Heimes
Dr. Heimes has no relevant financial relationships to disclose.

The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer

Alexander Hein
Dr. Hein has no relevant financial relationships to disclose.

Neuroleptics in breast cancer risk

Sarah Hein
Dr. Hein has no relevant financial relationships to disclose.

A novel nomogram model can predict oncotype DX results thus reducing healthcare expenditures

Robert Heidel
Dr. Heidel has no relevant financial relationships to disclose.

Prognostic significance of nuclear factor kappa B in node-negative breast cancer is most pronounced in luminal B breast cancer

Anne-Sophie Heimes
Dr. Heimes has no relevant financial relationships to disclose.

The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer

Alexander Hein
Dr. Hein has no relevant financial relationships to disclose.

Neuroleptics in breast cancer risk

Sarah Hein
Dr. Hein has no relevant financial relationships to disclose.

A novel nomogram model can predict oncotype DX results thus reducing healthcare expenditures

Robert Heidel
Dr. Heidel has no relevant financial relationships to disclose.

Prognostic significance of nuclear factor kappa B in node-negative breast cancer is most pronounced in luminal B breast cancer

Anne-Sophie Heimes
Dr. Heimes has no relevant financial relationships to disclose.

The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer

Alexander Hein
Dr. Hein has no relevant financial relationships to disclose.

Neuroleptics in breast cancer risk

Sarah Hein
Dr. Hein has no relevant financial relationships to disclose.

A novel nomogram model can predict oncotype DX results thus reducing healthcare expenditures

Robert Heidel
Dr. Heidel has no relevant financial relationships to disclose.

Prognostic significance of nuclear factor kappa B in node-negative breast cancer is most pronounced in luminal B breast cancer

Anne-Sophie Heimes
Dr. Heimes has no relevant financial relationships to disclose.

The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer

Alexander Hein
Dr. Hein has no relevant financial relationships to disclose.

Neuroleptics in breast cancer risk

Sarah Hein
Dr. Hein has no relevant financial relationships to disclose.

A novel nomogram model can predict oncotype DX results thus reducing healthcare expenditures

Robert Heidel
Dr. Heidel has no relevant financial relationships to disclose.

Prognostic significance of nuclear factor kappa B in node-negative breast cancer is most pronounced in luminal B breast cancer

Anne-Sophie Heimes
Dr. Heimes has no relevant financial relationships to disclose.

The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer

Alexander Hein
Dr. Hein has no relevant financial relationships to disclose.

Neuroleptics in breast cancer risk

Sarah Hein
Dr. Hein has no relevant financial relationships to disclose.

A novel nomogram model can predict oncotype DX results thus reducing healthcare expenditures

Robert Heidel
Dr. Heidel has no relevant financial relationships to disclose.

Prognostic significance of nuclear factor kappa B in node-negative breast cancer is most pronounced in luminal B breast cancer

Anne-Sophie Heimes
Dr. Heimes has no relevant financial relationships to disclose.

The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer

Alexander Hein
Dr. Hein has no relevant financial relationships to disclose.

Neuroleptics in breast cancer risk

Sarah Hein
Dr. Hein has no relevant financial relationships to disclose.

A novel nomogram model can predict oncotype DX results thus reducing healthcare expenditures

Robert Heidel
Dr. Heidel has no relevant financial relationships to disclose.

Prognostic significance of nuclear factor kappa B in node-negative breast cancer is most pronounced in luminal B breast cancer

Anne-Sophie Heimes
Dr. Heimes has no relevant financial relationships to disclose.

The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer

Alexander Hein
Dr. Hein has no relevant financial relationships to disclose.

Neuroleptics in breast cancer risk

Sarah Hein
Dr. Hein has no relevant financial relationships to disclose.

A novel nomogram model can predict oncotype DX results thus reducing healthcare expenditures

Robert Heidel
Dr. Heidel has no relevant financial relationships to disclose.

Prognostic significance of nuclear factor kappa B in node-negative breast cancer is most pronounced in luminal B breast cancer

Anne-Sophie Heimes
Dr. Heimes has no relevant financial relationships to disclose.

The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer

Alexander Hein
Dr. Hein has no relevant financial relationships to disclose.

Neuroleptics in breast cancer risk

Sarah Hein
Dr. Hein has no relevant financial relationships to disclose.
Development and validation of a nomogram predicting pathological axillary status (ypN0 vs. ypN+) in a subgroup of patients converting from cN+ to cN0 through neoadjuvant therapy (NAT) - A transSENTINA substudy

Gisela Helms
Ms. Helms has no relevant financial relationships to disclose.

Detection of molecular aberrations in breast cancer through next generation sequencing of both tumor tissue and circulating tumor DNA: The UC San Diego Moores Cancer Center experience

Teresa Helsten
Dr. Helsten has no relevant financial relationships to disclose.

Whole exome and transcriptome sequencing of resistant ER+ metastatic breast cancer

Karia Helvie
Ms. Helvie has no relevant financial relationships to disclose.

Quantitative proteomic analysis of FGFR by mass spectrometry may improve identification of FGFR amplified tumors sensitive to inhibitor therapy

Todd Hembrough
Mr. Hembrough has disclosed that he is paid by NantOmics.

A phase 2 open label study of everolimus in combination with endocrine therapy in resistant hormone receptor-positive HER2 negative advanced breast cancer

Brian Hemphill
Dr. Hemphill has no relevant financial relationships to disclose.

Association between tumor genotype and development of brain metastasis in patients with hormone receptor positive (HR+/HR-) HER2- metastatic breast cancer

Laura Henderson
Ms. Henderson has no relevant financial relationships to disclose.

Comparative performance of surveillance mammography and breast MRI in women with a history of breast cancer

Louise Henderson
Ms. Henderson has no relevant financial relationships to disclose.

The association between angiotensin receptor blockers usage and breast cancer characteristics

Daniel Hendler
Dr. Hendler has no relevant financial relationships to disclose.

The efficacy and safety of the addition of ibandronate to adjuvant hormonal therapy in postmenopausal women with hormone-receptor positive early breast cancer. First results of the TEAM IIB trial (BOOG 2006-04)

M Hendriks
Dr. Hendriks has no relevant financial relationships to disclose.

Prognostic significance of nuclear factor kappa B in node-negative breast cancer is most pronounced in luminal B breast cancer

Jan Hengstler
Dr. Hengstler has no relevant financial relationships to disclose.

The 21 gene recurrence score (RS) on chemotherapy prescribing in estrogen receptor (ER) positive, lymph node positive early stage breast cancer in Ireland

Bryan Hennessy
Mr. Hennessy has no relevant financial relationships to disclose.

Randomized phase II study evaluating different schedules of nab-paclitaxel in metastatic breast cancer (MBC): Results of the SNAP study

Bryan Hennessy
Mr. Hennessy has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>A randomized, double-blind, placebo-controlled clinical trial to evaluate extended adjuvant endocrine therapy (5 years of letrozole) in postmenopausal women with hormone-receptor positive breast cancer who have completed previous adjuvant endocrine therapy: Initial results of NRG oncology/NSABP B-42</td>
<td>Bryan Hennessy</td>
<td>Dr. Hennessy has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Unregulated purinergic signaling enhances cell proliferation in human and murine breast carcinomas</td>
<td>Mikkel Henriksen</td>
<td>Dr. Henriksen has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Breast cancer risk prediction using a polygenic risk score in women of African ancestry: Findings from GWAS in breast cancer in the African diaspora</td>
<td>Aminel Henmis</td>
<td>Aminel Henmis has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>BRCA-to-BCR2 - results of population-based screening of BRCA1 and BRCA2 germline mutations in incident breast cancer in South Sweden</td>
<td>Karen Henriksson</td>
<td>Mr. Henriksson has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Factors affecting the administration of post-mastectomy radiation therapy (PMRT) in Michigan</td>
<td>N. Henry</td>
<td>Dr. Henry has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Effect of aromatase inhibitor (AI) therapy on sleep and activity patterns in early-stage breast cancer</td>
<td>N. Lynn</td>
<td>Dr. Lynn has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Upregulated purinergic signaling enhances cell proliferation in human and murine breast carcinomas</td>
<td>N. Lynn</td>
<td>Dr. Lynn has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Randomized, placebo-controlled trial of duloxetine for aromatase inhibitor (AI) associated musculoskeletal symptoms (AARMSS) in early-stage breast cancer (SWOG 022)</td>
<td>N. Lynn</td>
<td>Dr. Lynn has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2 positive breast cancer</td>
<td>Norah Henry</td>
<td>Dr. Henry has disclosed that she has contracts with sanofi-aventis, Boehringer, Celldex. She also disclosed that she receives Travel, Accommodations, and Expenses from Celldex.</td>
</tr>
<tr>
<td>Sexual functioning among breast cancer survivors and their partners: A pilot study</td>
<td>Ronda Henry-Tillman</td>
<td>Dr. Henry-Tillman has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>The E3C expression is positively associated with interferon signaling molecules in triple-negative breast cancer</td>
<td>Sun-Hee Heo</td>
<td>Dr. Heo has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Evaluation of intra-tumor heterogeneity, test reproducibility and their impact in breast cancer samples assessed by Prosigna™: Results from a decision impact prospective study and a matched case-control study</td>
<td>Delphine Hequet</td>
<td>Dr. Hequet has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Increasing participation in research - breast cancer (Inspire-BrC)</td>
<td>Ms. Herbolsheimer</td>
<td>Ms. Herbolsheimer has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Pre-clinical antitumor activity, tissue localization, and pharmacokinetics of MP0274, an apoptosis inducing, bivalent HER2-targeting DARPin®</td>
<td>Jörg Herbst</td>
<td>Dr. Herbst has disclosed that he receives salary and has ownership.</td>
</tr>
<tr>
<td>Prospective association between breast cancer risk and an individual dietary index based on the British Food Standards Agency nutrient profiling system</td>
<td>Serge Hercberg</td>
<td>Dr. Hercberg has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Sociodemographic and economic factors are essential determinants of weight gain between before and after cancer diagnosis: Results from the prospective population-based MultiNet-Sante cohort</td>
<td>Serge Hercberg</td>
<td>Dr. Hercberg has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Three-gene signature predictive of high residual risk of recurrence after adjuvant chemotherapy in ER-positive HER2-negative breast cancer</td>
<td>Peter Herman</td>
<td>Mr. Herman has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Radiation seed localization versus wire-guided localization of nonpalpable invasive and in situ breast cancer: A Danish multicenter randomized controlled trial</td>
<td>Jonas Hermansen</td>
<td>Mr. Hermansen has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Local recurrence in young women with invasive breast cancer: the prospective study of outcomes in sporadic and hereditary breast cancer (POSH)</td>
<td>Aurora Hernandez</td>
<td>Ms. Hernandez has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Glucocorticoid receptor modulation affects ER+ breast cancer cell proliferation</td>
<td>Kyle Hernandez</td>
<td>Dr. Hernandez has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
P3-13-26  Deep Infrared Imaging to identify venous impairment after breast cancer surgery  Dina Hertens  Ms. Hertens has no relevant financial relationships to disclose.

P3-13-27  Lipolifting of the axilla to reduce secondary lymphedema after axillary lymph node dissection  Dina Hertens  Ms. Hertens has no relevant financial relationships to disclose.

P3-13-28  Genetic variation in CYP3A affects steady-state exemestane concentrations but does not explain inter-race difference  Daniel Hertz  Dr. Hertz has no relevant financial relationships to disclose.

P6-09-09  Relationships between breast cancer subtypes and expression of autophagy-related genes  Eric Hervouet  Dr. Hervouet has no relevant financial relationships to disclose.

OT2-01-22  NCT02458587: A phase II trial of epirubicin docetaxel, bevacizumab and everolimus (EDE) in patients (pts) with localized triple-negative breast cancer (TNBC) with tumors predicted insensitive to standard neoadjuvant chemotherapy (NACT)  Ken Hess  Dr. Hess has no relevant financial relationships to disclose.

OT2-01-20  Phase IB study of nab-paclitaxel combined with lapatinib and pertuzumab (Pact) for anthracycline-resistant triple-negative breast cancer (TNBC)  Kenneth Hess  Dr. Hess has no relevant financial relationships to disclose.

OT2-01-14  NCI-2016-00367: A phase IB study of neoadjuvant 21 regimens (omalizumab therapy in combination with weekly paclitaxel) for androgen receptor (AR) positive triple-negative breast cancer (TNBC)  Kenneth Hess  Dr. Hess has no relevant financial relationships to disclose.

OT3-03-05  NC1-2016-00367: A phase IIIB study of neoadjuvant ZT regimen (enzalutamide therapy in combination with weekly paclitaxel) for androgen receptor (AR)-positive triple-negative breast cancer (TNBC)  Kenneth Hess  Dr. Hess has no relevant financial relationships to disclose.

P4-21-20  Lapatinib after pertuzumab and ado-trastuzumab emtansine in metastatic HER2-positive breast cancer  Kenneth Hess  Dr. Hess has no relevant financial relationships to disclose.

P5-03-05  Development of a panel of serum-based protein biomarkers for the non-invasive detection of breast cancer in BI-RADS category 4 patients  Lyndal Hesterberg  Mr. Hesterberg has disclosed that he is a consultant for OncoCyte Corporation.

P4-22-12  Ribociclib + fulvestrant in postmenopausal women with HR+, HER2- advanced breast cancer (ABC)  Becker Hewes  Mr. Hewes has disclosed that he is an employee of Novartis.

P2-08-03  Targeting inflammatory pathways: A phase 2 trial of the JAK-inhibitor ruxolitinib in combination with exemestane for aromatase inhibitor-resistant, estrogen receptor-positive breast cancer (TRN1)  Elizabeth Honour  Dr. Honour has no relevant financial relationships to disclose.

P4-01-06  Diffuse optical tomography can predict pathologies complete response in patients with HER2+ or triple negative breast cancer undergoing neoadjuvant chemotherapy  Hanna Hishoosh  Ms. Hishoosh has no relevant financial relationships to disclose.

P4-21-02  Pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: efficacy analysis of a phase II cardiac safety study (TYPHONIA)  Faram Hishoosh  Tamas Hikish has no relevant financial relationships to disclose.

P1-02-12  Determination of a serum progranulin (GP88/PGRN) level associated with overall survival in metastatic breast cancer patients  David Hicks  Mr. Hicks has no relevant financial relationships to disclose.

P1-03-06  Improvement in risk predictive value of Nottingham prognostic index by determining FISH tumor tissue expression for estrogen receptor positive breast cancer patients  David Hicks  Mr. Hicks has disclosed that he receives salary.

P1-03-10  HER2 expression in clinical breast cancer samples: A novel detection methodology for HER2 protein quantitation using fluorescent nanoparticles  David Hicks  Dr. Hicks has disclosed that he is a Speakers Bureau Member for Genentech.

P2-04-03  Differential effect of chemotherapy on immune gene expression signatures based on molecular subtype of breast cancer  Melissa Hicks  Dr. Hicks has no relevant financial relationships to disclose.
Predictive factors of pathologic complete response to neoadjuvant chemotherapy in patients with Luminal HER2(-) local advanced breast cancer using the IOMM microarray

Alfredo Hidalgo-Miranda

Dr. Hidalgo-Miranda has no relevant financial relationships to disclose.

A randomized trial of 15 fraction vs 25 fraction pencil beam scanning proton radiotherapy after mastectomy in patients requiring regional nodal irradiation

Tina Hieken

Dr. Hieken has no relevant financial relationships to disclose.

Diffuse optical tomography can predict pathologic complete response in patients with HER2+ or triple negative breast cancer undergoing neoadjuvant chemotherapy

Andreas Hielscher

Andreas Hielscher has no relevant financial relationships to disclose.

Quantitative proteomic analysis of FGFR by mass spectrometry may improve identification of FGFR amplified tumors sensitive to inhibitor therapy

Cinta Hierro

Ms. Hierro has no relevant financial relationships to disclose.

A phase I trial of the safety and immunogenicity of a DNA plasmid-based vaccine (WOKVAC) encoding epitopes derived from three breast cancer antigens (IGFBP2, HER2, and IGF1R) in patients with breast cancer

Stefan Higgins

Mr. Higgins has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy

Tomoko Higuchi

Tomoko Higuchi has no relevant financial relationships to disclose.

Eribulin mesylate (eribulin) showed inhibitory effects on epithelial-mesenchymal transition (EMT) in tumors of metastatic breast cancer patients. -First preliminary report of a prospective study-

Masahiro Hikichi

Mr. Hikichi has no relevant financial relationships to disclose.

Transmembrane protein 33 (TMEM33) induces apoptosis via ERK signaling and autophagy in breast cancer cells

Leena Hilakivi-Clarke

Dr. Hilakivi-Clarke has no relevant financial relationships to disclose.

Comparison of axillary sentinel lymph node biopsy versus no axillary surgery in patients with early-stage invasive breast cancer and breast-conserving surgery: A randomized prospective surgical trial. The Intergroup-Sentinel-Mamma (INSEMA)-trial

Guido Hildebrandt

Dr. Hildebrandt has no relevant financial relationships to disclose.

S100β as a predictive biomarker and monitoring tool in endocrine resistant breast cancer

Arnold Hill

Mr. Hill has no relevant financial relationships to disclose.

Steroid receptor co-activator 1 mediation of cancer cell reprogramming in endocrine resistant breast cancer

Arnold Hill

Mr. Hill has no relevant financial relationships to disclose.

Global transcriptional repression by the coactivator SRC-1 mediates disease progression in treatment-resistant breast cancer

Arnold Hill

Mr. Hill has no relevant financial relationships to disclose.

The impact of circulating androgens on the androgen receptor in aromatase inhibitor resistant breast cancer

Arnold Hill

Mr. Hill has no relevant financial relationships to disclose.

Estrogen receptor quantitative measures and differences in breast cancer survival

Arnold Hill

Mr. Hill has no relevant financial relationships to disclose.

SOX9 is a critical regulator of triple-negative breast cancer cell growth and invasion

Jamal Hill

Mr. Hill has no relevant financial relationships to disclose.

Inhibition of death-associated protein kinase 1 enhances chemotherapy action against triple-negative breast cancer

Jamal Hill

Mr. Hill has no relevant financial relationships to disclose.

Use of a 3-D bioabsorbable tissue marker in 61 patients over two years

Laurie Hill

Ms. Hill has no relevant financial relationships to disclose.

Staff Member

Sharon Hill

Ms. Hill has no relevant financial relationships with commercial interests to disclose.

Prospective cross-sectional-study on participation in mammography screening according to immigration background and education status

Peter Hillemans

Prof. Hillemans has no relevant financial relationships to disclose.

Preclinical characterization of VX-984, a selective DNA-dependent protein kinase (DNA-PK) inhibitor in combination with docetaxel in breast and ovarian cancers

Shawn Hiltz

Mr. Hiltz has disclosed that he is an employee of may own stock or stock options in Vertex Pharmaceuticals Incorporated.

Molecular differences between screen-detected and interval breast cancers are largely explained by PAM50 subtypes

Camille Hildes

Dr. Hildes has no relevant financial relationships to disclose.
Clinico-pathological relationships with Ki67 in POETIC (CRUK/07/015) - Critical lessons for assessing Ki67 for prognosis and as a pharmacodynamic marker

Margaret Hills
Ms. Hills has no relevant financial relationships to disclose.

The impact of intrinsic subtypes and molecular features on aromatase inhibitor induced reduction of proliferation marker of Ki67 in primary ER+ breast cancer: A POETIC study (CRUK/07/015)

Margaret Hills
Ms. Hills has no relevant financial relationships to disclose.

Predictors of aggressive end-of-life care in women metastatic breast cancer

Grace Hillyer
Dr. Hillyer has no relevant financial relationships to disclose.

Factors associated with follow up medical care among women with early stage breast cancer

Grace Hillyer
Dr. Hillyer has no relevant financial relationships to disclose.

Factors associated with multidisciplinary care in the management of early stage breast cancer

Grace Hillyer
Dr. Hillyer has no relevant financial relationships to disclose.

Factors associated with multidisciplinary care in the management of early stage breast cancer

Grace Hillyer
Dr. Hillyer has no relevant financial relationships to disclose.

Scalp cooling alopecia prevention trial (SCALP) for patients with early stage breast cancer

Susan Hilsenbeck
Dr. Hilsenbeck has no relevant financial relationships to disclose.

A novel high-throughput secreted factor screen and bioinformatics pipeline identifies microenvironment-derived FGF2 as a mechanism of resistance to anti-estrogens, PI3K, and mTOR inhibitors in ER+ breast cancer

Sharon Hinton
Ms. Hinton has no relevant financial relationships to disclose.

Comparative toxicity and effectiveness of trastuzumab combined with anthracycline versus platinum chemotherapy regimens for adjuvant therapy of HER2+ breast cancer in older women

Sharon Hinton
Ms. Hinton has no relevant financial relationships to disclose.

Functional MRI signatures of immune response to targeted breast cancer therapy

Susan Hippe
Ms. Hippe has no relevant financial relationships to disclose.

Validation of novel diagnostic kits using the semi-dry dot-blot method for detecting metastatic lymph nodes in breast cancer: distinguishing macrometastases and micrometastases

Hiroshi Hirakawa
Dr. Hirakawa has no relevant financial relationships to disclose.

Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes (TILs) and residual cancer burden (RCB)

Kosei Hirakawa
Dr. Hirakawa has no relevant financial relationships to disclose.

Comparative toxicity and effectiveness of trastuzumab combined with anthracycline versus platinum chemotherapy regimens for adjuvant therapy of HER2+ breast cancer in older women

Kosei Hirakawa
Dr. Hirakawa has no relevant financial relationships to disclose.

A novel high-throughput secreted factor screen and bioinformatics pipeline identifies microenvironment-derived FGF2 as a mechanism of resistance to anti-estrogens, PI3K, and mTOR inhibitors in ER+ breast cancer

John Hinds
Dr. Hinds has no relevant financial relationships to disclose.

A novel high-throughput secreted factor screen and bioinformatics pipeline identifies microenvironment-derived FGF2 as a mechanism of resistance to anti-estrogens, PI3K, and mTOR inhibitors in ER+ breast cancer

John Hinds
Dr. Hinds has no relevant financial relationships to disclose.

A phase II study of palbociclib plus fulvestrant versus placebo plus fulvestrant for pre-treated patients with ER+/HER2- metastatic breast cancer

Alessia Hiltbrunner
Ms. Hiltbrunner has no relevant financial relationships to disclose.

Factors associated with multidisciplinary care in the management of early stage breast cancer

Alessia Hiltbrunner
Ms. Hiltbrunner has no relevant financial relationships to disclose.

Predicting therapeutic effect by on tumor invasion lymphocytes (TILs) in endocrine therapy for stage IV breast cancer

Kosei Hirakawa
Kosei Hirakawa has no relevant financial relationships to disclose.

A novel high-throughput secreted factor screen and bioinformatics pipeline identifies microenvironment-derived FGF2 as a mechanism of resistance to anti-estrogens, PI3K, and mTOR inhibitors in ER+ breast cancer

Hiroshi Hirakawa
Dr. Hirakawa has no relevant financial relationships to disclose.

A novel high-throughput secreted factor screen and bioinformatics pipeline identifies microenvironment-derived FGF2 as a mechanism of resistance to anti-estrogens, PI3K, and mTOR inhibitors in ER+ breast cancer

Hiroshi Hirakawa
Dr. Hirakawa has no relevant financial relationships to disclose.

A novel high-throughput secreted factor screen and bioinformatics pipeline identifies microenvironment-derived FGF2 as a mechanism of resistance to anti-estrogens, PI3K, and mTOR inhibitors in ER+ breast cancer

Kosei Hirakawa
Kosei Hirakawa has no relevant financial relationships to disclose.

Factors associated with multidisciplinary care in the management of early stage breast cancer

Kosei Hirakawa
Dr. Hirakawa has no relevant financial relationships to disclose.

A phase I trial of novel antibody-drug conjugate/augmented polyphosphamide followed by epirubicin/cyclophosphamide for triple-negative breast cancer

Akira Hirano
Ms. Hirano has no relevant financial relationships to disclose.

A phase I trial of novel antibody-drug conjugate/augmented polyphosphamide followed by weekly nanoparticle albumin-bound paclitaxel with trastuzumab for HER2 positive breast cancer

Akira Hirano
Ms. Hirano has no relevant financial relationships to disclose.

Breast conserving surgery plus hormone therapy without irradiation in elderly women with early breast cancer

Akira Hirano
Ms. Hirano has no relevant financial relationships to disclose.

A phase II trial of novel antibody-drug conjugate/augmented polyphosphamide followed by epirubicin/cyclophosphamide for triple-negative breast cancer

Akira Hirano
Ms. Hirano has no relevant financial relationships to disclose.

A phase I trial of novel antibody-drug conjugate/augmented polyphosphamide followed by weekly nanoparticle albumin-bound paclitaxel with trastuzumab for HER2 positive breast cancer

Akira Hirano
Ms. Hirano has no relevant financial relationships to disclose.

Breast conserving surgery plus hormone therapy without irradiation in elderly women with early breast cancer

Akira Hirano
Ms. Hirano has no relevant financial relationships to disclose.

Validation of novel diagnostic kits using the semi-dry dot-blot method for detecting metastatic lymph nodes in breast cancer: distinguishing macrometastases and micrometastases

Hiroshi Hirakawa
Dr. Hirakawa has no relevant financial relationships to disclose.

Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes (TILs) and residual cancer burden (RCB)

Kosei Hirakawa
Dr. Hirakawa has no relevant financial relationships to disclose.

Comparative toxicity and effectiveness of trastuzumab combined with anthracycline versus platinum chemotherapy regimens for adjuvant therapy of HER2+ breast cancer in older women

Sharon Hinton
Ms. Hinton has no relevant financial relationships to disclose.

Validation of novel diagnostic kits using the semi-dry dot-blot method for detecting metastatic lymph nodes in breast cancer: distinguishing macrometastases and micrometastases

Hiroshi Hirakawa
Dr. Hirakawa has no relevant financial relationships to disclose.
First-line ribociclib plus letrozole in patients with de novo HR+, HER2- advanced breast cancer (ABC): A subgroup analysis of the MONALEESA-2 trial
Samit Hirawat
Samit Hirawat has disclosed that he is a Novartis employee and has ownership in Novartis.

First-line ribociclib plus letrozole in patients with de novo HR+, HER2- advanced breast cancer (ABC): A subgroup analysis of the MONALEESA-2 trial
Samit Hirawat
Samit Hirawat has disclosed that he is a Novartis employee and has ownership in Novartis.

Phase II safety, efficacy, and molecular analysis of ribociclib (LEE011) plus letrozole for the treatment of ER+, HER2- advanced breast cancer
Samit Hirawat
Samit Hirawat has disclosed that he is a Novartis employee and has ownership in Novartis.

Distinct recruitment of tumor-associated immune cells correlates with increased pro-malignant chemokines in tumors expressing epithelial tyrosine kinase receptor 1 (EKR1L/AMG), indicating a unique tumor microenvironment
Bupali Hire
Dr. Hire has no relevant financial relationships to disclose.

β-glutamyl hydroxyethyl thiodamid green [βGlu-HMRG] is a promising fluorescence probe for rapid diagnosis of breast cancer: - The feasibility study of real time imaging for breast tumor examination
Pake Hirata
Ms. Hirata has no relevant financial relationships to disclose.

Sociodemographic predictors for delay of treatment among a racially diverse, urban breast cancer population
Ariel Hirsh
Dr. Hirsch has no relevant financial relationships to disclose.

Comprehensive genomic profiling of clinically malignant phyllodes tumors of the breast reveals frequent mutation of MYC and other genes associated with PI3K and RAS pathway activation
Kim Hirshfield
Dr. Hirshfield has no relevant financial relationships to disclose.

Are we missing actionable targets in breast cancer? Novel insights into recurrent Ret alterations
Kim Hirshfield
Dr. Hirshfield has no relevant financial relationships to disclose.

A phase II study of eribulin followed by doxorubicin and cyclophosphamide as preoperative therapy for HER2-negative inflammatory breast cancer
Sudi Hirshfield-Bartek
Ms. Hirshfield-Bartek has no relevant financial relationships to disclose.

Pilot study of strontium-89 bevucizumab position emission tomography for imaging angio genesis in patients with inflammatory breast carcinoma receiving preoperative chemotherapy
Judith Hirshfield-Bartek
Ms. Hirshfield-Bartek has no relevant financial relationships to disclose.

Quantitative ETS measurements in TNBC from the I-SPY 2 TRIAL correlate with HER2 EGFR co-activation and heterodimerization
Gillian Hirst
Ms. Hirst has no relevant financial relationships to disclose.

DNA repair deficiency biomarkers and MammaPrint high/(ultra)high risk as predictors of veliparib/carboplatin response: Results from the neoadjuvant I-SPY 2 trial for high risk breast cancer
Gillian Hirst
Ms. Hirst has no relevant financial relationships to disclose.

Exome sequencing of human breast cancer tissues resistant to taxanes
Tomoka Hisada
Tomoka Hisada has no relevant financial relationships to disclose.

The prognostic impact of inositol polyphosphate 5-phosphatase (INPP5J) expression in breast cancer tissue
Tomoka Hisada
Tomoka Hisada has no relevant financial relationships to disclose.

Comprehensive genomic characterization of circulating tumor cells (CTCs) in metastatic breast cancer (MBC) sheds light on the biology of blood-borne metastasis
Bao Ho
Bao Ho has no relevant financial relationships to disclose.

Comprehensive genomic profiling of clinically malignant phyllodes tumors of the breast reveals frequent mutation of MYC and other genes associated with PI3K and RAS pathway activation
Kim Hirshfield
Dr. Hirshfield has no relevant financial relationships to disclose.

A phase II study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)
Ching-Liang Ho
Dr. Ho has disclosed that he receives institutional funding.

Effect of serum biomarkers (actin-A, CASK, HER2, TIMP-1, and pNA) on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: CCTG MA.31
Diep Ho
Dr. Ho has no relevant financial relationships to disclose.

A novel therapeutic target for osaxplatin-resistance in metastatic breast cancer
John Ho
Mr. Ho has no relevant financial relationships to disclose.

Quantitative ERα measurements in TNBC from the I-SPY 2 TRIAL correlate with HER2 EGFR co-activation and heterodimerization
Gillian Hirst
Ms. Hirst has no relevant financial relationships to disclose.

A phase II study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)
Ching-Liang Ho
Dr. Ho has disclosed that he receives institutional funding.

Effect of serum biomarkers (actin-A, CASK, HER2, TIMP-1, and pNA) on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: CCTG MA.31
Diep Ho
Dr. Ho has no relevant financial relationships to disclose.

A novel therapeutic target for osaxplatin-resistance in metastatic breast cancer
John Ho
Mr. Ho has no relevant financial relationships to disclose.

Quantitative ERα measurements in TNBC from the I-SPY 2 TRIAL correlate with HER2 EGFR co-activation and heterodimerization
Gillian Hirst
Ms. Hirst has no relevant financial relationships to disclose.
High concordance of ER, PR, HER2 and Ki67 by central IHC and FISH with mRNA measurements by GeneXpert breast cancer stratifier assay

High concordance of a closed system, near point of care, RT-qPCR breast cancer assay for HER2 (ERBB2) mRNA compared to both IHC/FISH and quantitative immunofluorescence

Analytical validation for the RT-qPCR based multplex mRNA measurements of ER, PgR, HER2, and Ki67 from FFPE tumor tissue using the GeneXpert breast cancer stratifier assay

Highly reproducible decentralized gene expression analysis of ESR1, PGR, ERBB2 and MKi67 on an automated, standardized molecular diagnostics platform, GeneXpert

Analytical validation for the RT-qPCR based multiplex mRNA measurements of ER, PgR, HER2, and Ki67 from FFPE tumor tissue using the GeneXpert breast cancer stratifier assay

Multivariate analysis of subtype and gene expression signatures predictive of pathologic complete response (pCR) in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance)

Identification of breast cancers with an indolent disease course: gene expression signature validation in a 24-week randomised trial of tamoxifen vs. 20-year outcomes

Identification of breast cancers with an indolent disease course: gene expression signature validation in a 24-week randomised trial of tamoxifen vs. 20-year outcomes

Recurrent functionally diverse in-frame ESR1 gene fusions drive endocrine resistance in breast cancer

Identifcation of breast cancer subtypes at time of diagnosis of hormone receptor positive breast cancer: CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer

Identification of breast cancers with an indolent disease course: gene expression signature validation in a 24-week randomised trial of tamoxifen vs. 20-year outcomes

Race and age differences in PAM50 biomarker status in the Carolina breast cancer study

Integrated analysis of multidimensional genomic data on CALGB 40603 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer

Breast cancer: multistep status, silencing and treatment effect in the TTN trial: A randomized phase III trial of capecitabine compared with docetaxel for patients with metastatic or recurrent locally advanced triple-negative or BRCA1/2 breast cancer (EORTC 80912)

Sociodemographic and economic factors are essential determinants of weight gain between before and after cancer diagnosis: Results from the prospective population-based NutriNet-Sante cohort

Feasibility trial for identification of patients for eliminating breast cancer surgery following neoadjuvant systemic therapy

Feasibility study for estimating the potential of eliminating breast cancer surgery following neoadjuvant systemic therapy

Feasibility study for estimating the potential of eliminating breast cancer surgery following neoadjuvant systemic therapy

Feasibility trial for identification of patients for eliminating breast cancer surgery following neoadjuvant systemic therapy

Feasibility study for estimating the potential of eliminating breast cancer surgery following neoadjuvant systemic therapy

A phase I study of AZD9496, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC)

National trends in neoadjuvant therapy for breast cancer

Breast cancer: multistep status, silencing and treatment effect in the TTN trial: A randomized phase III trial of capecitabine compared with docetaxel for patients with metastatic or recurrent locally advanced triple-negative or BRCA1/2 breast cancer (EORTC 80912)

A study to determine the optimal method of detection and threshold for lymphoedema intervention: A multi-centre prospective study

A phase I study of AZD9496, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC)

Breast cancer: multistep status, silencing and treatment effect in the TTN trial: A randomized phase III trial of capecitabine compared with docetaxel for patients with metastatic or recurrent locally advanced triple-negative or BRCA1/2 breast cancer (EORTC 80912)

A study to determine the optimal method of detection and threshold for lymphoedema intervention: A multi-centre prospective study

A phase I study of AZD9496, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC)

Breast cancer: multistep status, silencing and treatment effect in the TTN trial: A randomized phase III trial of capecitabine compared with docetaxel for patients with metastatic or recurrent locally advanced triple-negative or BRCA1/2 breast cancer (EORTC 80912)

A study to determine the optimal method of detection and threshold for lymphoedema intervention: A multi-centre prospective study
Duration of fasting before taking lapatinib is associated with skin toxicity in neoadjuvant treatment of HER2 positive breast cancer: A cohort study from JBCRG-16/Neo-LaTH

Masato Homma

Mr. Homma has no relevant financial relationships to disclose.

Tropomyosin-related kinase A is overexpressed in HER2 positive breast cancer

Hubert Hondermarck

Mr. Hondermarck has no relevant financial relationships to disclose.

Inhibition of Erk1 or Erk2-mediated Smad3 phosphorylation reduces triple negative breast cancer cell EMT, migration and invasion

Angela Hong

Ms. Hong has no relevant financial relationships to disclose.

Maintenance of genomic integrity in dormant circulating tumor cells

David Hong

Dr. Hong has no relevant financial relationships to disclose.

The evolution of breast cancer circulating tumor cells mediating brain metastasis

David Hong

Dr. Hong has no relevant financial relationships to disclose.

The PI3K inhibitor, taselisib, has enhanced potency in PIK3CA mutant models through a unique mechanism of action

Rebecca Hong

Dr. Hong has disclosed that she receives salary from Genentech, Inc.

Use of an absorbable implant to mark the lumpectomy cavity: Initial report of 300 patients in a multi-center registry database

Robert Hong

Mr. Hong has no relevant financial relationships to disclose.

COSMIA: A phase 3, randomized study of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in the treatment of patients with HER2+ metastatic breast cancer

Shengyan Hong

Dr. Hong has disclosed that he receives salary from and has ownership in MacroGenics.

Patient derived DCR mouse intraductal (MIN) models recapitulate the full spectrum of human patient pathology and biologic features including progression to invasion in a subset of cases

Yan Hong

Yan Hong has no relevant financial relationships to disclose.

First results from the multicenter phase III DATA study comparing 3 versus 6 years of anastrozole after 2-3 years of tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer

Aafke Honkoop

Aafke Honkoop has no relevant financial relationships to disclose.

Serum thymidine kinase 1 activity as a pharmacodynamics marker of cyclin-dependent kinase 4/6 inhibition in patients with early stage breast cancer receiving neoadjuvant palbociclib

Jeremy Hoog

Mr. Hoog has no relevant financial relationships to disclose.

Recurrent functionally diverse in-frame ESR1 gene fusions drive endocrine resistance in breast cancer

Jeremy Hoog

Mr. Hoog has no relevant financial relationships to disclose.

Comprehensive characterization of matched pre-treatment biopsies and residual disease of doxorubicin treated breast cancer

Marlous Hoogstraat

Dr. Hoogstraat has no relevant financial relationships to disclose.

Role is not a contributing factor to breast cancer-free interval outcome for patients with equal access to healthcare treated at a military medical center

Jeffrey Hooge

Dr. Hooge has no relevant financial relationships to disclose.

Risk factors for high risk breast density patterns in Hispanic/Latinas living in the Northeast, US

Regina Hoosky

Dr. Hoosky has no relevant financial relationships to disclose.

DNA methylation landscapes of breast cancer progression to brain metastasis: A pre-clinical study

Siao Hoon

Siao Hoon has no relevant financial relationships to disclose.

Castrate resistant likely candidate for hormone receptor positive versus hormone receptor negative breast cancer

Siao Hoon

Siao Hoon has no relevant financial relationships to disclose.

Risk of primary and contralateral breast cancer in BRCA1/2 mutation carriers previously affected with ovarian cancer

Maartje Hoosin

Dr. Hoosin has no relevant financial relationships to disclose.

Risk of metastases contralateral breast cancer: Systematic review and meta-analysis

Maartje Hoosin

Maartje Hoosin has no relevant financial relationships to disclose.

Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multi-center trial

Judith Hopkins

Dr. Hopkins has no relevant financial relationships to disclose.

Prospective family cohort analyses of gene-environment interactions in breast cancer: Body mass index

John Hopper

Dr. Hopper has no relevant financial relationships to disclose.
Pan-HER, an antibody mixture with antitumor activity against drug-resistant HER2-overexpressing breast cancers with high ERBB ligand expression

Ivan Horak

Mr. Horak has disclosed that he receives salary, has a patent, has a contract and is a Symphogen employee.

Chemosensitization combined with neo-adjuvant chemotherapy for HER2-negative early breast cancer (JONE 1 trial): Survival outcomes of a randomized multicenter phase 2 trial

Zsolt Horvath

Dr. Horvath has no relevant financial relationships to disclose.

ANNEO: International Meta-analysis of circulating tumor cell detection in early breast cancer patients treated by neo-adjuvant chemotherapy

Zsolt Horvath

Dr. Horvath has no relevant financial relationships to disclose.

Simultaneous analyses of HER2 gene and protein status can more precisely predict pathological complete response (pCR) to neo-adjuvant trastuzumab with chemotherapy in primary HER2-positive breast cancer

Kieran Horgan

Dr. Horgan has no relevant financial relationships to disclose.

Clinico-pathological relationships with Ki67 in POETIC (CRUK/07/015) - Critical lessons for assessing Ki67 for prognosis and as a pharmacodynamic marker

Zach Horn

Dr. Horne has no relevant financial relationships to disclose.

Zoledronic acid combined with neoadjuvant chemotherapy for HER2-negative early breast cancer (JONIE 1 trial): Survival outcomes of a randomized multicenter phase 2 trial

Jun Horiguchi

Dr. Horiguchi has no relevant financial relationships to disclose.

First-line: combination of trastuzumab and pertuzumab in human epidermal growth factor receptor 2-positive advanced breast cancer

Dr. Horii has no relevant financial relationships to disclose.

Simultaneous analyses of HER2 gene and protein status can more precisely predict pathological complete response (pCR) to neo-adjuvant trastuzumab with chemotherapy in primary HER2-positive breast cancer

Dr. Horiguchi has no relevant financial relationships to disclose.

Standardization of nodal radiation therapy (RT) through changes to a breast cancer clinical pathway (CP) in a large, integrated comprehensive cancer center network

Zachary Horn

Dr. Horne has no relevant financial relationships to disclose.

Zoledronic acid combined with neoadjuvant chemotherapy for HER2-negative early breast cancer (JONIE 1 trial): Survival outcomes of a randomized multicenter phase 2 trial

Jun Horiguchi

Dr. Horiguchi has no relevant financial relationships to disclose.

Simultaneous analyses of HER2 gene and protein status can more precisely predict pathological complete response (pCR) to neo-adjuvant trastuzumab with chemotherapy in primary HER2-positive breast cancer

Dr. Horiguchi has no relevant financial relationships to disclose.

Pharmacokinetics of eflapegrastim in a phase 2 open-label dose-ranging study in breast cancer patients receiving TC regimen

Gabriel Hortobagyi

Dr. Hortobagyi has no relevant financial relationships to disclose.

Discovery of molecular predictors of late breast cancer specific events (BCSE) in pT1, pN+ breast cancer - new transcriptome expression whole gene analysis of the phase II-adjuvant trial SWOG S0814

Gabriel Hortobagyi

Dr. Hortobagyi has no relevant financial relationships to disclose.

Pharmacokinetics of eflapegrastim: a phase 2 open-label dose-ranging study in breast cancer patients receiving TC regimen

Gabriel Hortobagyi

Dr. Hortobagyi has no relevant financial relationships to disclose.

Discovery of molecular predictors of late breast cancer specific events (BCSE) in pT1, pN+ breast cancer - new transcriptome expression whole gene analysis of the phase II-adjuvant trial SWOG S0814

Gabriel Hortobagyi

Dr. Hortobagyi has no relevant financial relationships to disclose.

Intravenous imaging with the 201Hg tracer: a promising new tool to detect breast cancer recurrence

Sarah Houston

Dr. Houston has no relevant financial relationships to disclose.

Immunohistochemistry: a useful tool for the management of patients with breast cancer

Dr. Horii has no relevant financial relationships to disclose.

Discovery of molecular predictors of late breast cancer specific events (BCSE) in pT1, pN+ breast cancer - new transcriptome expression whole gene analysis of the phase II-adjuvant trial SWOG S0814

Gabriel Hortobagyi

Dr. Hortobagyi has no relevant financial relationships to disclose.

How to broadly develop and personalize HER2-directed therapy in metastatic breast cancer

Gabriel Hortobagyi

Dr. Hortobagyi has no relevant financial relationships to disclose.

Discovery of molecular predictors of late breast cancer specific events (BCSE) in pT1, pN+ breast cancer - new transcriptome expression whole gene analysis of the phase II-adjuvant trial SWOG S0814

Gabriel Hortobagyi

Dr. Hortobagyi has no relevant financial relationships to disclose.

Optimizing the use of trastuzumab in patients with HER2+ advanced breast cancer

Sarah Houston

Ms. Houston has no relevant financial relationships to disclose.

Discovery of molecular predictors of late breast cancer specific events (BCSE) in pT1, pN+ breast cancer - new transcriptome expression whole gene analysis of the phase II-adjuvant trial SWOG S0814

Gabriel Hortobagyi

Dr. Hortobagyi has no relevant financial relationships to disclose.

How to broadly develop and personalize HER2-directed therapy in metastatic breast cancer

Gabriel Hortobagyi

Dr. Hortobagyi has no relevant financial relationships to disclose.

Discovery of molecular predictors of late breast cancer specific events (BCSE) in pT1, pN+ breast cancer - new transcriptome expression whole gene analysis of the phase II-adjuvant trial SWOG S0814

Gabriel Hortobagyi

Dr. Hortobagyi has no relevant financial relationships to disclose.

Optimizing the use of trastuzumab in patients with HER2+ advanced breast cancer

Sarah Houston

Ms. Houston has no relevant financial relationships to disclose.

Discovery of molecular predictors of late breast cancer specific events (BCSE) in pT1, pN+ breast cancer - new transcriptome expression whole gene analysis of the phase II-adjuvant trial SWOG S0814

Gabriel Hortobagyi

Dr. Hortobagyi has no relevant financial relationships to disclose.

How to broadly develop and personalize HER2-directed therapy in metastatic breast cancer

Gabriel Hortobagyi

Dr. Hortobagyi has no relevant financial relationships to disclose.

Discovery of molecular predictors of late breast cancer specific events (BCSE) in pT1, pN+ breast cancer - new transcriptome expression whole gene analysis of the phase II-adjuvant trial SWOG S0814

Gabriel Hortobagyi

Dr. Hortobagyi has no relevant financial relationships to disclose.

Optimizing the use of trastuzumab in patients with HER2+ advanced breast cancer

Sarah Houston

Ms. Houston has no relevant financial relationships to disclose.
Difference between 1st and 2nd generation serotonin receptor antagonists in triplet antiemetic therapy for highly emetogenic chemotherapy in breast cancer patients - according to recent multi-institutional double-blind randomized clinical research on the AC regimen

Keiko Hosoya
Dr. Hosoya has no relevant financial relationships to disclose.

A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)

Amr Hossam
Ameer Hossam has disclosed that he is an employee of El Lilly and Company.

A novel non-canonical Notch1-IKKα-mTORC2-AKT pathway maintains survival in triple negative breast cancer cells and cancer stem-like cells

Yaelhul Hossam
Dr. Hossam has no relevant financial relationships to disclose.

One-day dietary pattern and breast cancer overall survival in the women's health initiative dietary modification randomized controlled trial

Dajiang Hau
Dr. Hau has no relevant financial relationships to disclose.

Value of cancer care for metastatic breast cancer patients and providers

Ningg Hau
Dr. Hau has no relevant financial relationships to disclose.

A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)

Jean Louis Houpeau
Dr. Houpeau has no relevant financial relationships to disclose.

P5-10-02
African Americans have more aggressive invasive lobular carcinoma subtypes and inferior early outcomes: SEER 2010-2013

Marina Howard-McNatt
Dr. Howard-McNatt has no relevant financial relationships to disclose.

SFX-01 targets Wnt signalling to inhibit stem-like cells in breast cancer patient-derived xenograft tumours

Sacha Howell
Dr. Howell has disclosed that she receives research funding from Evgen Pharma Ltd.

Rates of immune infiltration in patients with triple-negative breast cancers by molecular subtype and in patients with inflammatory and non-inflammatory breast cancers

David Hout
Dr. Hout has disclosed that he receives salary from and has ownership in Insight Genetics, Inc.

Rates of immune infiltration in patients with triple-negative breast cancers by molecular subtype and in patients with inflammatory and non-inflammatory breast cancers

David Hout
Dr. Hout has disclosed that he receives salary from and has ownership in Insight Genetics, Inc.

Long-term follow-up of persistent breast dermopigmentation after sentinel lymph node identification using superparamagnetic iron oxide particles (Sienna+®)

Jean Louis Houpeau
Dr. Houpeau has no relevant financial relationships to disclose.

Menopausal symptoms as predictors of long-term adherence in the International breast cancer intervention study (IBIS-1)

Anthony Howell
Mr. Howell has no relevant financial relationships to disclose.

Menopausal symptoms as predictors of long-term adherence in the International breast cancer intervention study (IBIS-1)

Anthony Howell
Mr. Howell has no relevant financial relationships to disclose.

SFX-01 targets Wnt signalling to inhibit stem-like cells in breast cancer patient-derived xenograft tumours

Sacha Howell
Dr. Howell has disclosed that she receives research funding from Evgen Pharma Ltd.

Metabolic obesity, adipose inflammation and aromatase: Potential drivers of breast cancer risk in women with normal body mass index

Louise Howlader
Ms. Howlader has no relevant financial relationships to disclose.

SEER study of breast cancer-specific mortality in patients with poorly differentiated tumors treated based on recurrence score results

Nadia Howlader
Ms. Howlader has no relevant financial relationships to disclose.

Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer

Anne Hoyt
Dr. Hoyt has no relevant financial relationships to disclose.

A randomized trial of accelerated breast radiotherapy utilizing either 3-dimensional radiotherapy versus intensity modulated radiotherapy

Kathryn Howell
Dr. Howell has no relevant financial relationships to disclose.

A comparison of models (physician, the Van Nuys prognostic index, the Memorial-Sloan-Kettering Cancer Center DCIS nomogram) to predict ipsilateral breast events in patients with ductal carcinoma in situ (DCIS) of the breast after breast-conserving surgery failed to replicate results of the oncotype DCIS recurrence score

Kathryn Howell
Dr. Howell has no relevant financial relationships to disclose.

SFX-01 targets Wnt signalling to inhibit stem-like cells in breast cancer patient-derived xenograft tumours

Kathryn Howell
Dr. Howell has no relevant financial relationships to disclose.

SEER study of breast cancer-specific mortality in patients with poorly differentiated tumors treated based on recurrence score results

Kathryn Howell
Dr. Howell has no relevant financial relationships to disclose.

Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer

Anne Hoyt
Dr. Hoyt has no relevant financial relationships to disclose.
Circulating tumor DNA analysis to predict relapse and overall survival in early breast cancer - Longer follow-up of a proof-of-principle study

Sarah Hrebien
Ms. Hrebien has no relevant financial relationships to disclose.

Perioperative use of NSAID analgesic ketorolac may suppress early relapses in breast cancer: Perhaps transient systemic inflammation plays a role

William Hrushesky
Dr. Hrushesky has no relevant financial relationships to disclose.

Technical skill of surgical residents may affect margin status of breast conserving operations

Chiu-Hsieh Hsu
Dr. Hsu has no relevant financial relationships to disclose.

Weight gain after breast cancer diagnosis and patients' opinion on weight loss strategies

Chiu-Hsieh Hsu
Dr. Hsu has no relevant financial relationships to disclose.

SANDPIPER: Phase II study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA-mutant tumors

Jerry Hsu
Mr. Hsu has disclosed that he is an employee of Roche-Genentech.

Identification of SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong antitumor activity in wild-type and mutant ER+ breast cancer models

Karl Hsu
Mr. Hsu has no relevant financial relationships to disclose.

Impact of enrollment in clinical trials on survival of metastatic breast cancer patients

Limin Hsu
Limin Hsu has no relevant financial relationships to disclose.

Proposal for a new breast cancer staging classification: Incorporating clinical and biological factors

Limin Hsu
Limin Hsu has no relevant financial relationships to disclose.

Surgical targeting of breast cancer cells based on the novel 3D printed serpentine microfluidic chips

Sandy Hsu
Ms. Hsu has no relevant financial relationships to disclose.

Associations between breast cancer subtypes and mutations in cancer predisposition genes identified by clinical genetic testing of breast cancer patients

Chunling Hu
Dr. Hu has no relevant financial relationships to disclose.

Breast cancer risk associated with mutations in cancer predisposition genes identified by clinical genetic testing of 60,000 breast cancer patients

Chunling Hu
Dr. Hu has no relevant financial relationships to disclose.

A model with polygenic risk score and mammographic density predicts interval cancers

Donglei Hu
Dr. Hu has no relevant financial relationships to disclose.

Phase III trial single-arm that evaluating the combination of everolimus, lapatinib and capcitabine for the treatment of patients with HER2-positive metastatic breast cancer with progression in the CNS after trastuzumab (TRIO-US-B-09)

Kellie Hsu
Dr. Hsu has no relevant financial relationships to disclose.

Diagnostic value of breast specific gamma imaging for breast cancer

Guangfu Hu
Guangfu Hu has no relevant financial relationships to disclose.

Comprehensive comparison of breast cancer molecular portraits by African and European ancestry in the cancer genome atlas

Hai Hu
Dr. Hu has no relevant financial relationships to disclose.

Race is not a contributing factor to breast cancer-free interval outcome for patients with equal access to healthcare treated at a military medical center

Hai Hu
Dr. Hu has no relevant financial relationships to disclose.

Analysis of breast cancer in young women in the department of defense (DOD) database

Hai Hu
Dr. Hu has no relevant financial relationships to disclose.

Diagnostic value of breast specific gamma imaging for breast cancer

Hongwei Hu
Dr. Hu has no relevant financial relationships to disclose.

Both upregulated and unbiased XRIP regulates breast cancer cell fate response to androgen via NFκB signaling

Rong Hu
Dr. Hu has no relevant financial relationships to disclose.

Transmembrane protein 33 (TMEM33) induces apoptosis via JNK signaling and autophagy in breast cancer cells

Rong Hu
Dr. Hu has no relevant financial relationships to disclose.

The mutation detection and a high throughput screening of driver mutations in PI3K/AKT pathway based on next generation sequencing

Elin Hu
Dr. Hu has no relevant financial relationships to disclose.
In-situ hybridization of microRNA and support vector machines-based prognostic classifiers for breast cancer

P2-05-37

Xin Hu

Dr. Hu has no relevant financial relationships to disclose.

The 3'UTR signature defines a highly-metastatic subgroup of triple-negative breast cancer

P2-06-03

Xin Hu

Dr. Hu has no relevant financial relationships to disclose.

Integration of whole-genome sequencing and functional screening to identify breast cancer lung-metastatic drivers

P5-01-02

Xin Hu

Dr. Hu has no relevant financial relationships to disclose.

The phosphorepinephrine-specific association of STAN1 with GPR39 promotes breast cancer metastasis

P6-01-16

Xin Hu

Dr. Hu has no relevant financial relationships to disclose.

Clinico-pathological characteristics and survival outcomes in invasive papillary carcinoma of the breast: A population-based study

P6-09-29

Xin Hu

Dr. Hu has no relevant financial relationships to disclose.

Race and age differences in PAM50 biomarker status in the Carolina breast cancer study

P8-01

Zhuyuan Hu

Zhuyuan Hu has no relevant financial relationships to disclose.

Molecular evaluation of Peruvian patients with hereditary breast cancer reveals a novel germline mutation in BRCA1

P5-09-08

Francia Huaman

Ms. Huaman has no relevant financial relationships to disclose.

Risk stratification with EndoPredict signature for luminal subtype breast cancers: Re-analyzing microarray experiments with Han Chinese origin

P2-05-34

Chi-Cheng Huang

Dr. Huang has no relevant financial relationships to disclose.

Risk stratification with EndoPredict signature for luminal subtype breast cancers: Re-analyzing microarray experiments with Han Chinese origin

P2-05-34

Ching-Shui Huang

Dr. Huang has no relevant financial relationships to disclose.

POWER-remote: A Randomized study evaluating the Effect of a remote-based weight loss program in women with early stage breast cancer

P4-14-01

Chiung-Yu Huang

Dr. Huang has no relevant financial relationships to disclose.

Randomized phase II study of induction bevacizumab, etoposide and cisplatin followed by whole brain radiotherapy (WBRT) versus WBRT alone in breast cancer with untreated brain metastases (A-PLUS)

OT1-04-03

Chiun-Sheng Huang

Dr. Huang has no relevant financial relationships to disclose.

Genomic pattern of breast carcinomas carrying mutations of non-BRCA homologous recombination genes

P2-03-11

Chuan Huang

Dr. Huang has no relevant financial relationships to disclose.

Accurate and reliable automated breast density measurements with no ionizing radiation using fat-water decomposition MRI

P3-02-03

Chuan Huang

Dr. Huang has no relevant financial relationships to disclose.

Breast density change at 6 months is associated with change at 12 months as measured by fat-water decomposition MRI in women on tamoxifen

P6-09-19

Dr. Huang has no relevant financial relationships to disclose.

Targeting SET to disrupt oncogenic CIP2A feedforward loop shows therapeutic potential in triple negative breast cancer cells

P3-07-12

Chun-Teng Huang

Dr. Huang has no relevant financial relationships to disclose.

Effect of serum biomarkers (actin A, CASK, HER2, TRAP-1, and uPA) on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: CCTG MA.31

P6-07-06

Jessica Huang

Dr. Huang has no relevant financial relationships to disclose.

Adjustment of breast specific gamma imaging or ultrasound in symptomatic women with mammographic dense breasts: A single center retrospective and comparative analysis

P4-02-10

Yan Huang

Dr. Huang has no relevant financial relationships to disclose.

Reduced expression of miR-200c-3p contributes to cell migration and invasion in paclitaxel-resistant breast cancer cell line with lapatinib or trastuzumab combined with taxane: CCGT MA.31

P4-07-07

Yang Huang

Dr. Huang has no relevant financial relationships to disclose.

Risk factors of locoregional relapse in locally advanced breast cancer treated with neoadjuvant chemotherapy following mastectomy and radiotherapy

P5-16-08

Yang Huang

Dr. Huang has no relevant financial relationships to disclose.

RAIM1 species as a target for breast cancer prevention in BRCA2 mutation carriers

P5-02-04

Li-Ya Huang

Dr. Huang has disclosed that he is a former employee and stockholder of Amgen.

Pre-operative breast MRI would not benefit breast cancer patients' survival, even in young patients treated with breast-conservative surgery

P3-02-03

Naisi Huang

Naisi Huang has no relevant financial relationships to disclose.
Identification and characterization of a novel endoxifen substrate, PKCβ1, and its interaction with the estrogen receptor

Zunnan Huang

Ms. Huang has no relevant financial relationships to disclose.

Treatment postprogression in women with endocrine-resistant HR+/HER2- advanced breast cancer who received palbociclib plus fulvestrant in PALOMA-3

Cynthia Huang-Bartlett

Ms. Huang-Bartlett has disclosed that she receives salary from and has ownership in Pfizer.

Palbociclib in combination with endocrine therapy in treatment-naïve and previously treated elderly women with HR+, HER2- advanced breast cancer: A pooled analysis from randomized phase 2 and 3 studies

Cynthia Huang-Bartlett

Ms. Huang-Bartlett has disclosed that she receives salary from and has ownership in Pfizer.

Long-term safety of palbociclib in combination with endocrine therapy in treatment-naïve and previously treated women with HR+, HER2- advanced breast cancer: A pooled analysis from randomized phase 2 and 3 studies

Cynthia Huang-Bartlett

Ms. Huang-Bartlett has disclosed that she receives salary from and has ownership in Pfizer.

Treatment postprogression in women with endocrine-resistant HR+/HER2- advanced breast cancer who received palbociclib plus fulvestrant in PALOMA-3

Cynthia Huang-Bartlett

Ms. Huang-Bartlett has disclosed that she receives salary from and has ownership in Pfizer.

Palbociclib in combination with endocrine therapy in treatment-naïve and previously treated women with HR+, HER2- advanced breast cancer: A pooled analysis from randomized phase 2 and 3 studies

Cynthia Huang-Bartlett

Ms. Huang-Bartlett has disclosed that she receives salary from and has ownership in Pfizer.

Palbociclib in combination with endocrine therapy in treatment-naïve and previously treated women with HR+, HER2- advanced breast cancer: A pooled analysis from randomized phase 2 and 3 studies

Cynthia Huang-Bartlett

Ms. Huang-Bartlett has disclosed that she receives salary from and has ownership in Pfizer.

Efficacy and safety of the therapeutic cancer vaccine bevacizumab (LOV255) in early breast cancer: Results from a prospective, randomized, neoadjuvant phase II trial (ABCSG-34)

Michael Hubalek

Dr. Hubalek has no relevant financial relationships to disclose.

Bread carcinomas with 21-gene recurrence score less than 10: a role of distant metastases in a large series with clinical follow-up

Dale Huber

Mr. Huber has no relevant financial relationships to disclose.

Phase I/II trial of palbociclib in combination with bicalutamide for the treatment of androgen receptor (AR)+ metastatic breast cancer (MBC)

Clifford Hudis

Dr. Hudis has no relevant financial relationships to disclose.

Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy

Clifford Hudis

Dr. Hudis has no relevant financial relationships to disclose.

Phase II trial of palbociclib in combination with bicalutamide for the treatment of androgen receptor (AR)+ metastatic breast cancer (MBC)

Clifford Hudis

Dr. Hudis has no relevant financial relationships to disclose.

Cardiac safety of dual anti-HR2 therapy in the neoadjuvant setting for treatment of HER2 positive breast cancer

Clifford Hudis

Dr. Hudis has disclosed that he is a consultant for Pfizer, Genentech, Merck and Novartis. He has also disclosed that he receives other financial support from Breast Cancer Research Foundation.

Metabolic obesity, adipose inflammation and aromatase: Potential drivers of breast cancer risk in women with normal body mass index

Clifford Hudis

Dr. Hudis has no relevant financial relationships to disclose.

Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase II trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer

Clifford Hudis

Dr. Hudis has disclosed that he is a consultant for Roche/Genentech and Novartis.

Therapeutic targeting of RAGE in the tumor and tumor microenvironment inhibits breast progression and metastasis

Barry Hudson

Dr. Huson has no relevant financial relationships to disclose.

S100β as a predictive biomarker and monitoring tool in endocrine resistant breast cancer

Éamon Hughes

Dr. Hughes has no relevant financial relationships to disclose.

Therapeutic targeting of RAGE in the tumor and tumor microenvironment inhibits breast progression and metastasis

Barry Hudson

Dr. Huson has no relevant financial relationships to disclose.

Breast cancer risks associated with mutations in cancer predisposition genes identified by clinical genetic testing of 60,000 breast cancer patients

Robert Hunter

Dr. Hunter has disclosed that he is an employee of Ambry Genetics.

Therapeutic targeting of RAGE in the tumor and tumor microenvironment inhibits breast progression and metastasis

Barry Hudson

Dr. Huson has no relevant financial relationships to disclose.

An international multicenter study to evaluate reproducibility of automated scoring methods for assessment of Ki67 in breast cancer

Judith Hugh

Ms. Hugh has no relevant financial relationships to disclose.

DNA methylation signature predicting bevacizumab efficacy in metastatic breast cancer

Clemens Hufnagl

Dr. Hufnagl has disclosed that he has a contract with Roche.

Dr. Hufnagl has disclosed that he has a contract with Roche.

Dr. Hufnagl has disclosed that he has a contract with Roche.

S100β as a predictive biomarker and monitoring tool in endocrine resistant breast cancer

Éamon Hughes

Dr. Hughes has no relevant financial relationships to disclose.

The incidence and outcomes of brain metastases in HER2- positive metastatic breast cancer with the advent of modern anti-HR2 therapies

Melissa Hughes

Ms. Hughes has no relevant financial relationships to disclose.
Is 6-hour monitoring for administration related reactions after first administration of subcutaneous trastuzumab necessary? A single institution audit

Niamh Hughes

Niamh Hughes has no relevant financial relationships to disclose.

PARTNER - Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients

Luke Hughes-Davies

Dr. Hughes-Davies has no relevant financial relationships to disclose.

First posts: A content analysis of an online breast cancer community user's initial postings

Jina Huh

Dr. Huh has no relevant financial relationships to disclose.

The predictive value of sentinel node biopsy (SNB) in early breast cancer after neo-adjuvant chemotherapy (NACT): A prospective study

Manon Huizing

Dr. Huizing has no relevant financial relationships to disclose.

Trastuzumab IV versus SC: A time, motion and cost assessment in a lean operating day case oncology unit

Manon Huizing

Dr. Huizing has no relevant financial relationships to disclose.

Automated, low cost palpable breast lump triage for economically-developing countries

William Hubert

Mr. Hubert has no relevant financial relationships to disclose.

Molecular differences between screen-detected and interval breast cancers are largely explained by PAM50 subtypes

Keith Humphreys

Dr. Humphreys has no relevant financial relationships to disclose.

MMIA-206 suppresses triple negative breast cancer metastases by targeting ARHGAP18 and causing sustained Rho A activation

Brock Humphries

Dr. Humphries has no relevant financial relationships to disclose.

Incidence and severity of diarrhea with neratinib + intensive loperamide prophylaxis in patients (pts) with HER2+ early-stage breast cancer (BC): Interim analysis from the multicenter, open-label, phase II control trial

Daniel Hunt

Dr. Hunt has disclosed that he receives salary from and has ownership in Puma Biotechnology, Inc.

Delineation of internal mammary nodal target volumes in breast cancer radiotherapy

Katie Hurt

Dr. Hunt has no relevant financial relationships to disclose.

SentimagIC: A non-inferiority trial comparing superparamagnetic iron oxide vs. Tc99 and blue dye in the detection of axillary sentinel nodes in patients with early stage breast cancer

Kelly Hurt

Dr. Hunt has no relevant financial relationships to disclose.

Patient-reported cosmetic outcomes in older breast cancer survivors: A population-based survey study

Kelly Hurt

Dr. Hunt has no relevant financial relationships to disclose.

Improving the AIO breast cancer staging system by incorporating tumor biomarkers

Kelly Hurt

Dr. Hunt has no relevant financial relationships to disclose.

Feasibility trial for identification of patients for eliminating breast cancer surgery following neoadjuvant systemic therapy

Kelly Hurt

Dr. Hunt has no relevant financial relationships to disclose.

Predictors of locoregional recurrence after neoadjuvant chemotherapy and surgery for node positive breast cancer: Results from ACOSOG Z1071 (Alliance)

Kelly Hurt

Dr. Hunt has no relevant financial relationships to disclose.

Evaluation of a risk score based on biological factors to enhance prognostic stratification by the American Joint Committee on Cancer (AJCC) Staging System

Kelly Hurt

Dr. Hunt has no relevant financial relationships to disclose.

Recurrent functionally diverse in-frame ESR1 gene fusions drive endocrine resistance in breast cancer

Kelly Hurt

Dr. Hunt has no relevant financial relationships to disclose.

Mismatch repair deficiency induces endocrine therapy resistance in breast cancer

Kelly Hurt

Ms. Hunt has no relevant financial relationships to disclose.

A model with polygenic risk score and mammographic density predicts interval cancers

Scott Huntsman

Dr. Huntsman has no relevant financial relationships to disclose.

Comprehensive comparison of breast cancer molecular portraits by African and European ancestry in the cancer genome atlas

Dezheng Huo

Dezheng Huo has no relevant financial relationships to disclose.
P1-01-15  Outcome after neoadjuvant chemotherapy in postmenopausal receptor-negative breast cancer patients - A pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials  
Jens Huober  
Jens Huober has no relevant financial relationships to disclose.

P1-09-11  Efficacy and safety of darbepoetin alfa or epoetin beta in 2994 high risk early breast cancer patients participating in the German adjuvant intergroup node-positive study (GAPS)  
Jens Huober  
Mr. Huober has disclosed that he is a consultant for Roche and Amgen.

P1-01-03  Breast implant associated anaplastic large cell lymphoma (BIA-ALCL): The UK experience and first reported case of neoadjuvant brentuximab  
Jeremy Hurren  
Mr. Hurren has no relevant financial relationships to disclose.

P2-14-03  Novel visualization tools to search ongoing clinical trials and track trial results for metastatic breast cancer  
Marc Hurlbert  
Dr. Hurlbert has no relevant financial relationships to disclose.

P5-02-03  Breast cancer risk prediction using a polygenic risk score in women of African ancestry: Findings from GWAS in breast cancer in the African diaspora  
Dezheng Huo  
Dezheng Huo has no relevant financial relationships to disclose.

P2-05-05  Comparative analysis of the genomic landscape of breast cancers from women of African and European ancestry  
Dezheng Huo  
Dezheng Huo has no relevant financial relationships to disclose.

P2-03-06  Genomic characterization of 992 primary breast cancers  
Riikka Huovinen  
Riikka Huovinen has no relevant financial relationships to disclose.

P3-05-04  Impact of estrogen receptor expression in fluoxymesterone-treated, estrogen receptor-positive metastatic breast cancer exposed to contemporary hormonal therapy  
Lei Huo  
Dr. Huo has no relevant financial relationships to disclose.

P1-01-14  Triple-negative first-line study: Neoadjuvant trial of nab-paclitaxel and atezolizumab, a PD-L1 inhibitor, in patients with triple negative breast cancer (TNBC) (NCT02530489)  
Lei Huo  
Dr. Huo has no relevant financial relationships to disclose.

P2-01-20  Phase III study of neoadjuvant pentoxifylline combined with carboplatin and paclitaxel (PaCT) for anthracycline-resistant triple-negative breast cancer (TNBC)  
Lei Huo  
Dr. Huo has no relevant financial relationships to disclose.

P1-01-15  DETECT V - Detection of the expression of estrogen receptor and human epidermal growth factor receptor 2 on circulating tumor cells from metastatic breast cancer patients  
Jens Huober  
Jens Huober has no relevant financial relationships to disclose.

P1-01-15  Outcome after neoadjuvant chemotherapy in postmenopausal receptor-negative breast cancer patients - A pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials  
Jens Huober  
Jens Huober has no relevant financial relationships to disclose.

P3-01-04  Triple-negative first-line study: Neoadjuvant trial of nab-paclitaxel and atezolizumab, a PD-L1 inhibitor, in patients with triple negative breast cancer (TNBC) (NCT02530489)  
Lei Huo  
Dr. Huo has no relevant financial relationships to disclose.

P2-01-20  Phase III study of neoadjuvant pentoxifylline combined with carboplatin and paclitaxel (PaCT) for anthracycline-resistant triple-negative breast cancer (TNBC)  
Lei Huo  
Dr. Huo has no relevant financial relationships to disclose.

P4-21-09  Evaluation of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarker in different subtypes of breast cancer treated with neoadjuvant therapy - A metaanalysis of 3771 patients  
Jens Huober  
Jens Huober has no relevant financial relationships to disclose.

P4-21-09  Evaluation of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarker in different subtypes of breast cancer treated with neoadjuvant therapy - A metaanalysis of 3771 patients  
Jens Huober  
Jens Huober has no relevant financial relationships to disclose.

P2-03-06  Genomic characterization of 992 primary breast cancers  
Udaya Harewood  
Rita Tsvetkova has no relevant financial relationships to disclose.

S6-07-06  Effect of serum biomarkers (actinin-A, CAX, HER2, TIMP-1, and pH4) on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with chemotherapy: CTG MA.31  
Meghan Hupp  
Dr. Hupp has no relevant financial relationships to disclose.

OT1-02-05  Phase II Trial of the addition of pembrolizumab to letrozole and palbociclib in patients with metastatic estrogen receptor positive breast cancer who have stable disease on letrozole and palbociclib  
Arti Hurria  
Dr. Hurria has disclosed receiving other financial support from Celgene PI Research/Protocol; Novartis PI Research/Protocol; G5s, Inc. Consultant; Boehringer Ingelheim Pharmaceuticals Consultant; Carevive (formerly OnQ Health) Consultant and Sanofi Consultant.

P1-01-03  Breast implant associated anaplastic large cell lymphoma (BIA-ALCL): The UK experience and first reported case of neoadjuvant brentuximab  
Jeremy Hurren  
Mr. Hurren has no relevant financial relationships to disclose.

P3-01-04  Triple-negative first-line study: Neoadjuvant trial of nab-paclitaxel and atezolizumab, a PD-L1 inhibitor, in patients with triple negative breast cancer (TNBC) (NCT02530489)  
Lei Huo  
Dr. Huo has no relevant financial relationships to disclose.

P2-01-20  Phase III study of neoadjuvant pentoxifylline combined with carboplatin and paclitaxel (PaCT) for anthracycline-resistant triple-negative breast cancer (TNBC)  
Lei Huo  
Dr. Huo has no relevant financial relationships to disclose.

P2-05-05  Comparative analysis of the genomic landscape of breast cancers from women of African and European ancestry  
Dezheng Huo  
Dezheng Huo has no relevant financial relationships to disclose.

P1-01-15  Outcome after neoadjuvant chemotherapy in postmenopausal receptor-negative breast cancer patients - A pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials  
Jens Huober  
Jens Huober has no relevant financial relationships to disclose.

P3-01-04  Triple-negative first-line study: Neoadjuvant trial of nab-paclitaxel and atezolizumab, a PD-L1 inhibitor, in patients with triple negative breast cancer (TNBC) (NCT02530489)  
Lei Huo  
Dr. Huo has no relevant financial relationships to disclose.

P1-01-15  Outcome after neoadjuvant chemotherapy in postmenopausal receptor-negative breast cancer patients - A pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials  
Jens Huober  
Jens Huober has no relevant financial relationships to disclose.

OT2-01-05  Breast implant associated anaplastic large cell lymphoma (BIA-ALCL)- The UK experience and first reported case of neoadjuvant brentuximab  
Jeremy Hurren  
Mr. Hurren has no relevant financial relationships to disclose.

OT1-02-05  Phase II Trial of the addition of pembrolizumab to letrozole and palbociclib in patients with metastatic estrogen receptor positive breast cancer who have stable disease on letrozole and palbociclib  
Arti Hurria  
Dr. Hurria has no relevant financial relationships to disclose.
A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capcitabine (C) and trastuzumab (T) in patients with pre-treated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2LUMB)

"Assessing the older adult with breast cancer for treatment: whom, why, when and how?" 

P6-07-13 Association of pre-chemotherapy peripheral blood pro-inflammatory (IL-6, CRP) and coagulation (D-dimer) markers with chemotherapy toxicity in women with breast cancer

Dr. Hurria has disclosed receiving other financial support from Celgene P1 Research/Protocol; Novartis P1 Research/Protocol; GTx, Inc. Consultant; Boehringer Ingelheim Pharmaceuticals Consultant; Carevive (formerly OnQ Health) Consultant and Sanofi Consultant.

Moderator/Speaker: Educational Session "Assessment and Treatment of Older Adults with Breast Cancer"

Dr. Hurria has disclosed receiving other financial support from Celgene P1 Research/Protocol; Novartis P1 Research/Protocol; Carevive (formerly OnQ Health) Consultant and Sanofi Consultant.

P5-01-05 HER2: A Reddie B - everolimus (E) + neoadjuvant KRISTINE study in women with HER2+ early breast cancer (ABC) following progression on a cyclin-dependent kinase (CDK) 4/6 inhibitor

Sara Hurvitz

Ms. Hurvitz has disclosed that she has contracts with Amgen, Bayer, Biogen, Boehringer Ingelheim, Genentech/Roche, GSX, Lilly, Medivation, Merrimack, Novartis, OBI Pharma, Pfizer, PUMA, and Dignitana.

P5-01-13 A phase 2, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA)

Sara Hurvitz

Ms. Hurvitz has disclosed that she has contracts with Amgen, Bayer, Biogen, Boehringer Ingelheim, Genentech/Roche, GSX, Lilly, Medivation, Merrimack, Novartis, OBI Pharma, Pfizer, PUMA, and Dignitana.

P5-12-07 Phase II/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of patients with HER2+ positive metastatic breast cancer with progression in the CNS after trastuzumab (TRIO-US B-08)

Sara Hurvitz

Dr. Hurvitz has disclosed that she has contracts with Amgen, Bayer, Biogen, Boehringer Ingelheim, Genentech/Roche, GSX, Lilly, Medivation, Merrimack, Novartis, OBI Pharma, Pfizer, PUMA, and Dignitana.

P5-11-03 Incidence and severity of diarrhea with neratinib + intensive liposomal prophylaxis in patients (pts) with HER2+ early-stage breast cancer (BC): Interim analysis from the multicenter, open-label, phase IIa control trial

Sara Hurvitz

Dr. Hurvitz has no relevant financial relationships to disclose.

P5-03-02 The PI3K-inhibitor, copanlisib, has selective activity in luminal breast cancer cell lines and shows robust combined activity with hormonal blockade and CDK-4/6 inhibition in hormone receptor (HR)+ breast cancer cell line xenografts

Sara Hurvitz

Dr. Hurvitz has no relevant financial relationships to disclose.

P5-04-15 Everolimus plus trastuzumab and pacitaxel as first-line therapy in women with HER2+ advanced breast cancer: Overall survival results from BOLERO-1

Sara Hurvitz

Ms. Hurvitz has disclosed that she has contracts with Amgen, Bayer, Biogen, Boehringer Ingelheim, GSX, Lilly, Novartis, Pfizer, Biomin, Merrimack, OBI Pharma, PUMA, Diptigena, Roche and Medivation. She also disclosed that her travel is paid by OBI Pharma and Lilly.

P4-22-13 Baseline (BL) characteristics, treatment (tx) patterns, and outcomes in patients with hormone receptor (HR)+ vs HR- HER2+ disease from the SyStHERs registry

Sara Hurvitz

Ms. Hurvitz has disclosed that she has contracts with Amgen, Bayer, Biogen, Boehringer Ingelheim, GSX, Lilly, Medivation, Merrimack, Novartis, OBI Pharma, Pfizer, PUMA, Diptigena and Genentech/Roche paid to her institution.

P5-08-08 Treatment patterns and clinical outcomes in patients with hormone receptor positive (HR+) HER2+ metastatic breast cancer and low vs high levels of HR positivity from the SyStHERs Registry

Sara Hurvitz

Dr. Hurvitz has disclosed that she has contracts with Amgen, Bayer, Biogen, Boehringer Ingelheim, GSX, Lilly, Medivation, Merrimack, Novartis, OBI Pharma, Pfizer, PUMA, Diptigena and Genentech/Roche (paid to his institution).

P5-09-17 Body image in women with breast cancer using a scalp cooling system to reduce chemotherapy induced alopecia

Sara Hurvitz

Dr. Hurvitz has disclosed that she has contracts with Amgen, Bayer, Biogen, Boehringer Ingelheim, GSX, Lilly, Medivation, Merrimack, Novartis, OBI Pharma, Pfizer, PUMA, and Dignitana.

P6-07-09 Biomarker analysis from the neoadjuvant KRISTINE study in HER2-positive early breast cancer (EBC)

Sara Hurvitz

Ms. Hurvitz has disclosed that she has contracts with Amgen, Bayer, Biogen, Boehringer Ingelheim, GSX, Lilly, Medivation, Merrimack, Novartis, OBI Pharma, Pfizer, PUMA, Diptigena, and Genentech/Roche.
Biological effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with hormone receptor positive, HER2 negative breast cancer

Sara Hurvitz

Ms. Hurvitz has disclosed that he is received grants from; Amgen, Bayer, Boehringer Ingelheim, Gentech, GlaxoSmithKline, Eli Lilly and Company, Novartis, Pfizer, Roche, Biomar, Merck, OBI pharma, PUMA, Bignana and Medivation. She also disclosed that she has a contract with Eli Lilly and Company and received paid travel from Eli Lilly and Company and OBI Pharma.

Unhealthy lifestyle patterns are prevalent in unaffected BRCA mutation carriers & are associated with increased oxidative stress and telomere length alterations

Juliette Hussey

Dr. Hurvitz has no relevant financial relationships to disclose.

Metabolite-guided long-term prediction of outcome in tamoxifen treated breast cancer patients and predisposition to family cancers: Single center experience

Joana Huszno

Dr. Huszno has no relevant financial relationships to disclose.

Targeting of phosphatidylserine by monoclonal antibodies enhances the activity of immune checkpoint ligand targeting antibodies in murine breast tumors

Jeff Hutchins

Dr. Hutchins has disclosed that he is a Peregrine employee.

Genomic profiling of residual ER+ breast cancers treated with prolonged neoadjuvant letrozole reveals novel alterations in clinically resistant tumors

Katherine Hutchinson

Dr. Hutchinson has no relevant financial relationships to disclose.

Genomic and microenvironmental intra-tumor heterogeneity in DCIS

Shelley Hwang

Dr. Hwang has no relevant financial relationships to disclose.
Elucidating the tumor immune microenvironment phenotype in early stage untreated BRCA mutated breast cancer patients
Shelley Hwang
Dr. Hwang has no relevant financial relationships to disclose.

Looking beyond the margins: Economic costs and complications associated with repeated breast-conserving surgeries
Kathryn Hyer
Ms. Hyer has disclosed that she receives salary from and has ownership in Diagnostic Photonics, Inc.

The evaluation of pazopanib/melphalan plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial
Nola Hylton
Dr. Hylton has no relevant financial relationships to disclose.

Effect of MRI imaging contrast kinetic thresholds for prediction of neoadjuvant chemotherapy response in breast cancer subtypes - Results from ACRIN 6657 / I-SPY 1 trial
Nola Hylton
Dr. Hylton has no relevant financial relationships to disclose.

Multivariate analysis of subtype and gene expression signatures predictive of pathologic complete response (pCR) in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance)
Terry Hyslop
Dr. Hyslop has no relevant financial relationships to disclose.

Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer
Terry Hyslop
Dr. Hyslop has no relevant financial relationships to disclose.

Challenges faced across borders to open European academic multicentre projects: The ET-FES program part of the ERA-Net TRANSCAN JTC 2011
Massimiliano Iacozzi
Dr. Iacozzi has no relevant financial relationships to disclose.

A targetable EGFR-driven tumor-initiating program in breast cancer
Ernesto Iacucci
Mr. Iacucci has no relevant financial relationships to disclose.

Chronic lymphocytic leukemia (CLL) - A disease of the microenvironment?
Irene Iacucci
Mr. Iacucci has no relevant financial relationships to disclose.

From monocyte re-programming to the expansion of tumor infiltrating lymphocytes for adoptive T cell therapy
Mark Ibberson
Dr. Ibberson has no relevant financial relationships to disclose.
Exome sequencing of circulating tumor cells in metastatic breast cancer

Dr. Ignatiadis has disclosed that he is the principal investigator of the TREAT CTC trial supported by an educational grant from Roche and Janssen Diagnostics.

CDK4 phosphorylation status and corresponding gene expression profile predict sensitivity to Palbociclib

Dr. Ignatiadis has no relevant financial relationships to disclose.

IMENEO: International META-analysis of circulating tumor cell detection in early breast cancer patients treated by NEDD9 promotes breast cancer metastasis by regulating mitochondrial functions

Dr. Iida has no relevant financial relationships to disclose.

Novel regulation of breast cancer cell aggressiveness by cancer leukaemia antigen

Dr. Ikeda has disclosed that she receives royalties from Elsevier, 'Breast Imaging: The Requisites (book)'. She also disclosed that she receives financial support from Siemens, Inc. Tomosynthesis Reader Study; Hologic, Inc. Tomosynthesis Reader Study.

Milky Way sign: A potential predictive sign of breast cancer on digital breast tomosynthesis

Dr. Ikeda has disclosed that she receives royalties from Elsevier, 'Breast Imaging: The Requisites (book)'. She also disclosed that she receives financial support from Siemens, Inc. Tomosynthesis Reader Study; Hologic, Inc. Tomosynthesis Reader Study.

Technical feasibility and validity of sentinel lymph node biopsy in patients with triple negative breast cancer (TNBC)

Dr. Ikeda has no relevant financial relationships to disclose.

Modification and reversal of the aggressive behavior of triple negative breast cancer by caffeic acid phenethyl ester (CAPE)

Dr. Illa Bochaca has no relevant financial relationships to disclose.

Flutamide reduced tumor progression and altered steroid hormone secretion in human and canine inflammatory breast cancer cell lines

Dr. Ilarra has no relevant financial relationships to disclose.

Flutamide reduced tumor progression and altered steroid hormone secretion in human and canine inflammatory breast cancer cell lines

Dr. Ilarra has no relevant financial relationships to disclose.

Phase II, open-label, multicenter, translational study for biomarkers of eribulin mesylate: Evaluation of the utility of monitoring epithelial-to-mesenchymal transition (EMT) markers on tumor cells in the malignant plural effusion of patients with metastatic breast cancer (EXPECT-study)

Dr. Ikeda has no relevant financial relationships to disclose.

Influence of exercise or educational programs on long-term physical activity by patients after surgery for primary breast cancer: A randomized trial

Dr. Ikeda has no relevant financial relationships to disclose.

Does MRI influence surgical planning more than clinical outcome? A cohort study of breast cancer patients receiving neoadjuvant therapy

Ms. Illmann has no relevant financial relationships to disclose.

Prediction of underestimation associated with flat epithelial atypia, atypical ductal hyperplasia and atypical lobular hyperplasia by needle biopsy: Experience in an Argentine breast unit

Dr. Ezrabel has no relevant financial relationships to disclose.

Milky Way sign: A potential predictive sign of breast cancer on digital breast tomosynthesis

Dr. Ikeda has disclosed that she receives royalties from Elsevier, 'Breast Imaging: The Requisites (book)'. She also disclosed that she receives financial support from Siemens, Inc. Tomosynthesis Reader Study; Hologic, Inc. Tomosynthesis Reader Study.

Modification and reversal of the aggressive behavior of triple negative breast cancer by caffeic acid phenethyl ester (CAPE)

Dr. Illa Bochaca has no relevant financial relationships to disclose.

Flutamide reduced tumor progression and altered steroid hormone secretion in human and canine inflammatory breast cancer cell lines

Dr. Ilarra has no relevant financial relationships to disclose.

Does MRI influence surgical planning more than clinical outcome? A cohort study of breast cancer patients receiving neoadjuvant therapy

Ms. Illmann has no relevant financial relationships to disclose.

Prediction of underestimation associated with flat epithelial atypia, atypical ductal hyperplasia and atypical lobular hyperplasia by needle biopsy: Experience in an Argentine breast unit

Dr. Ezrabel has no relevant financial relationships to disclose.
A phase II, multicenter, randomized trial of eribulin plus gemcitabine (EG) vs. paclitaxel plus gemcitabine (PG) in patients with HER2-negative metastatic breast cancer as first-line chemotherapy

Seock-Ah Im

Seock-Ah Im has no relevant financial relationships to disclose.

Phase Ib safety, efficacy, and molecular analysis of ribociclib (LEE011) plus letrozole for the treatment of ER+, HER2-negative advanced breast cancer

Seock-Ah Im

Seock-Ah Im has disclosed that he has a research grant from AstraZeneca.

The PROCEED trial ELSG BR11-01 phase III multicenter randomized open-label study of irinotecan plus capecitabine versus capecitabine in patients previously treated with anthracycline and taxane for HER2 negative metastatic breast cancer

Seock-Ah Im

Seock-Ah Im has no relevant financial relationships to disclose.

A phase I study of AZD9496, a novel oral, selective estrogen receptor degrader (SERD) in patients with HER2-negative metastatic breast cancer

Seock-Ah Im

Seock-Ah Im has disclosed that AstraZeneca sponsored this trial.

Clinical utility of serial monitoring of circulating tumor DNA (ctDNA) in patients with neoadjuvant chemotherapy (NAC) for locally advanced breast cancer (LABC)

Young-Hyuck Im

Dr. Im has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy

Michiko Imamura

Michiko Imamura has no relevant financial relationships to disclose.

DYRK2 contributes to the generation of breast cancer stem cells through KLF4

Yoshimi Imawari

Yoshimi Imawari has no relevant financial relationships to disclose.

Adjuvant dose dense doxorubicin-cyclophosphamide (DDAC) or docetaxel-AC (TAC) for high-risk breast cancer: First results of the randomized MATADOR trial (BOOG-2004-04)

Alex Imholz

Dr. Imholz has no relevant financial relationships to disclose.
S1-03 First results from the multicenter phase III DATA study comparing 3 versus 6 years of anastrozole after 2-3 years of tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer
Alex Imholz
Dr. Imholz has no relevant financial relationships to disclose.

P4-02-04 Using ultrasound findings to predict high tumor-infiltrating lymphocytes in triple negative breast cancer
Mami Inagaki
Ms. Inagaki has no relevant financial relationships to disclose.

P2-01-31 Development of mathematical prediction models to identify disease-free survival events for HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy and trastuzumab
Takashi Iinamuro
Dr. Iinamuro has no relevant financial relationships to disclose.

S4-22-24 Efficacy of compression therapy using surgical gloves for nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: A phase II multicenter study by the Kamigata breast cancer study group
Takashi Iinamuro
Dr. Iinamuro has no relevant financial relationships to disclose.

S5-02 Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC2 and HDAC7, in breast and ovarian cancer
Tae Ince
Ms. Ince has disclosed that she is an employee of Genentech, A Member of the Roche Group.

P5-07-13 Patient derived DCT mouse-intraductal (MINO) models recapitulate the full spectrum of human patient pathology and histologic features including progression to invasion in a subset of cases
Marc Inciardi
Dr. Inciardi has no relevant financial relationships to disclose.

P6-11-05 Phase II study of CB-839, a small molecule inhibitor of glutaminase (GLS), in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC)
Jeffrey Infante
Dr. Infante has no relevant financial relationships to disclose.

P6-11-09 Previously treated breast cancer patients show promising responses in the first in human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640 in combination with paclitaxel
Jeffrey Infante
Dr. Infante has no relevant financial relationships to disclose.

P4-08-05 Development of mathematical prediction models to identify disease-free survival events for HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy and trastuzumab
Elen Ingalla
Ms. Ingalla has disclosed that she is an employee of Genentech, A Member of the Roche Group.

P3-07-20 Biological functions of ERβ in triple negative breast cancer and its utility as a novel therapeutic drug target
James Ingle
Dr. Ingle has no relevant financial relationships to disclose.

P01-04 Discovery of molecular predictors of late breast cancer specific events (BCSE) in ER+, node+ breast cancer - new transcriptome expression whole gene analysis of the phase III adjuvant trial SWOG S8814
James Ingle
Dr. Ingle has no relevant financial relationships to disclose.

Committee Member
James Ingle
Dr. Ingle has no relevant financial relationships with commercial interests to disclose.

S1-08 Evaluation of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarker in different subtypes of breast cancer treated with neoadjuvant therapy: A metaanalysis of 3711 patients
Barbara Ingold Heppner
Ms. Ingold-Heppner has no relevant financial relationships to disclose.

P6-04-01 Engineering mesenchymal stem cells (MSCs) to secrete tumour suppressing miRNAs for breast cancer therapy
Helen Ingoldsby
Ms. Ingoldsby has no relevant financial relationships to disclose.

P6-09-43 BCL2 as a long-term prognostic factor in invasive lobular carcinoma of the breast
Christian Ingvar
Dr. Ingvar has no relevant financial relationships to disclose.

P2-04-01 Increased tumoral lymphocytes in breast cancer patients with anthracycline dendritic cell vaccination plus neoadjuvant chemotherapy
Susana Inoges
Ms. Inoges has no relevant financial relationships to disclose.
A phase II trial of neoadjuvant docetaxel/cyclophosphamide followed by estramustine/cyclophosphamide for triple-negative breast cancer
Hiroaki Inoue

A phase II trial of neoadjuvant epirubicin/cyclophosphamide followed by weekly nanoparticle albumin-bound paclitaxel with trastuzumab for HER2-positive breast cancer
Hiroaki Inoue

Breast-conserving surgery plus hormone therapy without irradiation in elderly women with early breast cancer
Hiroaki Inoue

A phase II trial of neoadjuvant epirubicin/cyclophosphamide followed by weekly nanoparticle albumin-bound paclitaxel with trastuzumab for HER2-positive breast cancer
Hiroaki Inoue

The clinical importance of nuclear wild-type p53-induced phosphatase 1 (Wip1) expression in the invasion and the metastasis of breast cancer
Yuka Inoue

Improvement in risk predictive value of Nottingham prognostic index by determining GPBB tumor tissue expression for estrogen receptor positive breast cancer patients
Olga Ioffe

Preoperative assessment of the sentinel node (SN) in breast cancer by one step nucleic acid assay (DONA): Experience of over 800 patients
Charlotte Ion

Safety of the combination of oxaliplatin plus oxetane in the Italian cohort of patients enrolled in the expanded access "BALLETT" study
Matilde Iorio

Dynamic regulation of a microRNA-mRNA network during breast cancer metastasis reveals an essential tumor-promoting role for miR-205
Elizabeth Iorns

Platelet tyrosine kinase 6 (PTK6) promotes survival of endocrine therapy-resistant ER+ breast cancer cells
Hanna Irie

Molecular mediators of mammographic density
Alastair Ironside

Immune profiling of post neoadjuvant high metastatic risk (RCB-II/III) residual disease in patients with early triple negative breast cancers
Sheeba Irshad

Tumor-infiltrating lymphocyte (TIL) assessment distilled into two binary parameters in triple-negative breast cancer (TNBC)
Lina Irshaid

Folate receptor alpha (FRα) expression in triple-negative breast cancer (TNBC)
Lina Irshaid

Triple-negative breast cancers (TNBCs) rich in infiltrating stromal plasma cells have improved disease-free survival and overall survival
Lina Irshaid

Quality, not quantity: IHC hot-spot (HS) analysis of lymphocyte markers (CD3, CD8, CD4, CD20) in tumor-infiltrating lymphocytes (TILs) is superior to whole tumor (WT) analysis in triple-negative breast cancer (TNBC)
Lina Irshaid

Tissue microarray (TMA) based immunohistochemical studies of lymphocyte-specific markers yield inaccurate results
Lina Irshaid

Internal density of tumor-infiltrating lymphocytes (TILs): Challenging the 50% threshold that defines lymphocyte predominant breast cancer (LPBC)
Lina Irshaid
Impact of pre-operative exercise and mind-body interventions on patient-reported outcomes in women with newly diagnosed breast cancer

Impact of pre-operative exercise on breast cancer gene expression

Prognostic and predictive marker in the tumor microenvironment of breast cancers

A phase II safety study of gelitinib in combination with letrozole in African American women with hormone receptor positive HER2 negative advanced breast cancer

Estrogen receptor mutations, estrogen fusions and co-occurring alterations assessed in breast cancer tumors

Race associated disparities in an urban population of adolescent and young adult (AYA) women with breast cancer

Efficacy of Neq50 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial

The evaluation of ganitumab/mertemolin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial

Race differences in the molecular landscape of breast cancer

A phase 2 open-label study of lucitanib in patients (pts) with HER2 aberrant metastatic breast cancer (MBC)

Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA2 mutations and metastatic breast cancer

Efficacy and tolerability of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized, phase 2 study of the efficacy and tolerability of V+TMZ or Plc+TMZ in patients (pts) with HR+/HER2- metastatic breast cancer

Evaluation of tumor infiltrating lymphocytes (TILs) and their association with homologous recombination deficiency and metastatic breast cancer (mTNBC): Updated results

Evaluation of tumor infiltrating lymphocytes (TILs) and their association with homologous recombination deficiency and BRCA1/2 mutation status in triple-negative breast cancer (mTNBC): Updated results

Efficacy and tolerability of veliparib (V) or placebo (Plc) in combination with paclitaxel (P) in patients (pts) with BRCA1/2 mutations and metastatic breast cancer

Efficacy and tolerability of veliparib (V) or placebo (Plc) in combination with carboplatin (C) and paclitaxel (P) in patients (pts) with BRCA2 or BRCA2 mutations and metastatic breast cancer

Efficacy and tolerability of veliparib (V) or placebo (Plc) in combination with carboplatin (C) and paclitaxel (P) in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer

Evaluation of tumor infiltrating lymphocytes (TILs) and their association with homologous recombination deficiency and BRCA1/2 mutation status in triple-negative breast cancer (mTNBC): A pooled analysis

Association between tumor genotype and development of brain metastases in patients with hormone receptor positive (HR+)/HER2+ metastatic breast cancer

Evaluation of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer

Efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial

The evalulation of gansitumab/mertemolin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial

A phase 2 open-label study of lucitanib in patients (pts) with HER2 aberrant metastatic breast cancer (MBC)

Efficacy and tolerability of veliparib (V) in combination with temozolomide (TMZ) in patients (pts) with brain metastases in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer

Efficacy and tolerability of veliparib (V) or placebo (Plc) and temozolomide (TMZ) in patients (pts) with brain metastases in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer

Evaluation of tumor infiltrating lymphocytes (TILs) and their association with homologous recombination deficiency and BRCA1/2 mutation status in triple-negative breast cancer (mTNBC): A pooled analysis

Efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial

Efficacy and tolerability of veliparib (V) or placebo (Plc) in combination with carboplatin (C) and paclitaxel (P) in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer

Efficacy and tolerability of veliparib (V) or placebo (Plc) in combination with paclitaxel (P) in patients (pts) with BRCA2 or BRCA2 mutations and metastatic breast cancer

Efficacy and tolerability of veliparib (V) or placebo (Plc) and temozolomide (TMZ) in patients (pts) with brain metastases in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer

Efficacy and tolerability of veliparib (V) or placebo (Plc) in combination with carboplatin (C) and paclitaxel (P) in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer

Efficacy and tolerability of veliparib (V) or placebo (Plc) in combination with paclitaxel (P) in patients (pts) with BRCA2 or BRCA2 mutations and metastatic breast cancer

Efficacy and tolerability of veliparib (V) or placebo (Plc) and temozolomide (TMZ) in patients (pts) with brain metastases in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer

Efficacy and tolerability of veliparib (V) or placebo (Plc) and temozolomide (TMZ) in patients (pts) with brain metastases in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer

Efficacy and tolerability of veliparib (V) or placebo (Plc) in combination with paclitaxel (P) in patients (pts) with BRCA2 or BRCA2 mutations and metastatic breast cancer

Efficacy and tolerability of veliparib (V) or placebo (Plc) in combination with carboplatin (C) and paclitaxel (P) in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer

Efficacy and tolerability of veliparib (V) or placebo (Plc) and temozolomide (TMZ) in patients (pts) with brain metastases in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer

Efficacy and tolerability of veliparib (V) or placebo (Plc) in combination with paclitaxel (P) in patients (pts) with BRCA2 or BRCA2 mutations and metastatic breast cancer

Efficacy and tolerability of veliparib (V) or placebo (Plc) and temozolomide (TMZ) in patients (pts) with brain metastases in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer

Efficacy and tolerability of veliparib (V) or placebo (Plc) and temozolomide (TMZ) in patients (pts) with brain metastases in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer

Efficacy and tolerability of veliparib (V) or placebo (Plc) and temozolomide (TMZ) in patients (pts) with brain metastases in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer

Efficacy and tolerability of veliparib (V) or placebo (Plc) and temozolomide (TMZ) in patients (pts) with brain metastases in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer
Results of an educational program delivered through e-learning, focused on nursing for primary breast cancer patients

Chihiro Iseki
Ms. Iseki has no relevant financial relationships to disclose.

Incidence of germline BRCA1- and BRCA2-mutated breast cancer in the US

Akiko Ishihara
Dr. Ishihara has no relevant financial relationships to disclose.

Duration of fasting before taking lapatinib is associated with skin toxicity in neoadjuvant treatment of HER2 positive breast cancer: A cohort study from IBCG-16 Neo-LATH

Hiroshi Ishiguro
Hiroshi Ishiguro has disclosed that he has a contract with Chugai Pharmaceutical Co and Novartis.

Development of mathematical prediction models to identify disease-free survival events for HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy and trastuzumab

Hiroshi Ishiguro
Hiroshi Ishiguro has disclosed that he has a contract with Chugai.

The non-invasive treatment for sentinel lymph node metastasis by photodynamic therapy using a verteporfin solubilized phospholipid polymer aggregate

Kazuhiko Ishihara
Ms. Ishihara has no relevant financial relationships to disclose.

A randomized phase II neoadjuvant study comparing docetaxel and cyclophosphamide (TC) with 5-fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel (FEC-D) for hormone receptor-negative breast cancer: The Kanagawa breast oncology group (KBOG) 1101 study

Takashi Ishikawa
Prof. Ishikawa has no relevant financial relationships to disclose.

Zoledronic acid combined with neoadjuvant chemotherapy for HER2-negative early breast cancer (JONGE 1 trial): Survival outcomes of a randomized multicenter phase 2 trial

Takahide Ishikawa
Dr. Ishikawa has no relevant financial relationships to disclose.

A retrospective study about re-biopsy at disease progression on T-DM1

Makoto Ishitobi
Dr. Ishitobi has no relevant financial relationships to disclose.

ONC201 kills breast cancer cells by inhibiting mitochondrial respiration

Celia Islam
Ms. Islam has no relevant financial relationships to disclose.

Real World data and patterns of care of metastatic breast cancer (MBC) in Brazil: First results of LACOG 0312 retrospective study

Gustavo Ismael
Mr. Ismael has no relevant financial relationships to disclose.

Phase II safety, efficacy, and molecular analysis of ribociclib (LEX0101) plus letrozole for the treatment of ER+, HER2- advanced breast cancer

Nabi Islam-Khan
Nabi Islam-Khan has disclosed that he is the PI of an Investigator Initiated Protocol sponsored by Novartis.

Phase II trial of selinexor for metastatic triple negative breast cancer

Roohi Ismail-Khan
Dr. Ismail-Khan has disclosed that he has contracts with Novartis and BCI Therapeutics.

Squalene epoxidase is a potential metabolic oncogene by amplification with clinical implications in breast carcinoma: An in silico pan-cancer study with in vitro evidence

Edoardo Isnaldi
Dr. Isnaldi has no relevant financial relationships to disclose.

DNA repair deficiency biomarkers and MammaPrint high1/(ultra)high2 risk as predictors of veliparib/carboplatin response: Results from the neoadjuvant I-SPY 2 trial for high risk breast cancer

Shawnt Issakhanian
Shawnt Issakhanian has no relevant financial relationships to disclose.

The PI3K-inhibitor, copanlisib, has selective activity in luminal breast cancer cell lines and shows robust combined activity with hormonal blockade and CDK-4/6 inhibition in ER+ breast cancer cell line xenografts

Nabi Issakhanian
Nabi Issakhanian has disclosed that he is the PI of an Investigator Initiated Protocol sponsored by Novartis.

DNA repair deficiency biomarkers and MammaPrint high1/(ultra)high2 risk as predictors of veliparib/carboplatin response: Results from the neoadjuvant I-SPY 2 trial for high risk breast cancer

Shawnt Issakhanian
Shawnt Issakhanian has no relevant financial relationships to disclose.
The non-invasive treatment for sentinel lymph node metastasis by photodynamic therapy using a verteporfin solubilized phospholipid polymer aggregate
Arisa Ito
Arisa Ito has no relevant financial relationships to disclose.

Impact of germinalcenter-associated nuclear protein polymorphisms on breast cancer risk and prognosis in a Japanese population
Hidemi Ito
Hidemi Ito has no relevant financial relationships to disclose.

Prognostic factors after neoadjuvant chemotherapy in breast cancer: Surgery type as a new prognostic factor
Mitsuya Ito
Mitsuya Ito has no relevant financial relationships to disclose.

Potential clinical application of mammography conducted immediately after contrast enhanced CT as contrast enhanced subtraction mammography
Mitsuya Ito
Mitsuya Ito has no relevant financial relationships to disclose.

Sentinel lymph node biopsy to obtain enhanced ultrasonography with sonazoid in patients with breast cancer - Prospective multicenter study
Toshikazu Ito
Dr. Ito has no relevant financial relationships to disclose.

Simultaneous analyses of HER2 gene and protein status can more precisely predict pathological complete response (pCR) to neoadjuvant trastuzumab with chemotherapy in primary HER2-positive breast cancer
Yoshinori Ito
Dr. Ito has disclosed that he has contracts with Chugai, Novartis, Eisai, Parexel and MSD.

Eribulin should be a candidate strategy in combination with pertuzumab plus trastuzumab for taxane pretreated HER2 positive advance breast cancer
Yoshinori Ito
Dr. Ito has no relevant financial relationships to disclose.

Prognostic factors and survival according to tumor subtype in women presenting with breast cancer brain metastases at initial diagnosis
Julian Iturbe
Dr. Iturbe has no relevant financial relationships to disclose.

Phase II pre-surgical window trial of telapristone acetate (TPA) in early breast cancer and DCIS patients. Distribution of TPA in plasma, normal breast tissue and tumors
David Ivancic
Mr. Ivancic has no relevant financial relationships to disclose.

Expression of miR-18a and miR-210 in normal breast tissue as candidate markers of breast cancer risk
David Ivancic
Mr. Ivancic has no relevant financial relationships to disclose.

A multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer: Early results of unplanned boost participants
Oxana Ivanov
Oxana Ivanov has no relevant financial relationships to disclose.

Two-year follow-up results of a multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer
Olga Ivanov
Dr. Ivanov has no relevant financial relationships to disclose.

Comparing the frequency and types of genetic aberrations between older and younger women with metastatic breast cancer at the University of North Carolina at Chapel Hill
Anastasia Ivanova
Dr. Ivanova has no relevant financial relationships to disclose.

Molecular differences between screen-detected and interval breast cancers are largely explained by PAM50 subtypes
Emma Iverson
Dr. Iverson has no relevant financial relationships to disclose.

Evaluation of growth modulation index as a marker of benefit for consecutive lines of treatment for metastatic breast cancer
Alejandra Ivars Rubio
Dr. Ivars Rubio has no relevant financial relationships to disclose.

Optimized prediction of deleterious missense mutations in BRCA1 and BRCA2 genes
Edwin Iversen
Dr. Iversen has no relevant financial relationships to disclose.

A novel progesterone receptor (PR)-RNA polymerase III association represses estrogen-dependent growth in breast tumor patient-derived xenografts
Joshua Iwamoto
Mr. Iwamoto has no relevant financial relationships to disclose.

Phase II neoadjuvant trial of nanoparticle albumin-bound paclitaxel and trastuzumab in patients with node-negative, HER2 positive breast cancer (JCOM-B304)
Mitsuhiko Iwamoto
Dr. Iwamoto has no relevant financial relationships to disclose.
Influence of exercise or educational programs on long-term physical activity by patients after surgery for primary breast cancer: A randomized trial

Differential of immune microenvironment between primary and recurrent tumours in breast cancer patients

Clinical significance of sequential measurements of ESRI mutations in plasma cell-free DNA in estrogen receptor-positive recurrent metastatic breast cancer patients

Differential expression of exosomal miRNAs between breast cancer patients with recurrence and no recurrence

A comprehensive analysis of GNAS DNA copy number, levels of miRNA and protein expression in primary breast cancer

Development of a predictive model by gene expression profiles for pathological CR after neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer

Simultaneous analyses of HER2 gene and protein status can more precisely predict pathological complete response (pCR) to neoadjuvant trastuzumab with chemotherapy in primary HER2-positive breast cancer

Development of mathematical prediction models to identify disease-free survival events for HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy and trastuzumab

Treatment progression in women with endocrine-resistant HR+/HER2- advanced breast cancer who received palbociclib plus fulvestrant in PALOMA-3

Impact of germinal center-associated nuclear protein polymorphisms on breast cancer risk and prognosis in a Japanese population

Phase II study of pertuzumab, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy

Metabolic obesity, adipose inflammation and aromatase: Potential drivers of breast cancer risk in women with normal body mass index

Association of background parenchymal enhancement with breast cancer risk factors and tumor characteristics

Committee Member

High reduction of circulating tumour cells in HER2-negative locally advanced or metastatic breast cancer (LAMBC) patients treated with nab-paclitaxel as third line chemotherapy (CNCT 3R-AH3)

Prediction of underestimation associated with flat epithelial atypia, atypical ductal hyperplasia and atypical lobular hyperplasia by needle biopsy: Experience in an Argentine breast unit

Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2 positive early breast cancer (BIG 1-06)
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>OT1-01-07</td>
<td>A phase 2 study of eribulin followed by docetaxel and paclitaxel in women with HER2-negative inflammatory breast cancer</td>
<td>Heather Jacene</td>
<td>Dr. Jacene has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT2-02-05</td>
<td>Pilot study of ixazomib-x trial as preoperative therapy for HER2-negative inflammatory breast carcinoma</td>
<td>Heather Jacene</td>
<td>Dr. Jacene has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-21-34</td>
<td>Phase I study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy</td>
<td>Kellie Jack</td>
<td>Kellie Jack has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-09-02</td>
<td>Hemolysate repair deficiency (HRD) as a measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial</td>
<td>Christian Jackisch</td>
<td>Mr. Jackisch has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-09-11</td>
<td>Outcome after neoadjuvant chemotherapy in prostate cancer patients - A pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials</td>
<td>Christian Jackisch</td>
<td>Mr. Jackisch has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-11-04</td>
<td>Efficacy and safety of darbepoetin alfa in 2994 high-risk early breast cancer patients</td>
<td>Christian Jackisch</td>
<td>Mr. Jackisch has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-16-03</td>
<td>Sub-HR2-Blockade with pertuzumab and trastuzumab in HR2-positive early breast cancer: A subanalysis of data from the randomized phase III GeparSepto trial</td>
<td>Christian Jackisch</td>
<td>Mr. Jackisch has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-21-06</td>
<td>Breast implant associated anaplastic large cell lymphoma (BIA-ALCL): The UK experience and first reported case of nonrandomized breast carcinoma</td>
<td>Rosamond Jacklin</td>
<td>Ms. Jacklin has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-07-02</td>
<td>Concomitance with National comprehensive cancer network (NCICN) metastatic breast cancer guidelines and impact on overall survival</td>
<td>Bradford Jackson</td>
<td>Dr. Jackson has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-06-08</td>
<td>Screening, management, cancer diagnoses, and outcomes of women with germline BRCA mutations in Israel: The Naps Clinic experience</td>
<td>Matthew Jackson</td>
<td>Dr. Jackson has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-03-05</td>
<td>Comparison of non-breast and ovarian cancer phenotypes of BRCA2 mutation carriers across multi-gene panels</td>
<td>Michelle Jackson</td>
<td>Ms. Jackson has disclosed that she receives salary from Ambry Genetics.</td>
</tr>
<tr>
<td>P2-05-13</td>
<td>Negative prostate-specific antigen is associated with early breast cancer relapse, even among aggressive tumors</td>
<td>Rubie Sue Jackson</td>
<td>Dr. Jackson has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P07-03</td>
<td>A model using grade and hormone receptor staining defines groups at low vs. high risk for distant metastasis: Comparison to the 21-gene recurrence score</td>
<td>Rubie Sue Jackson</td>
<td>Dr. Jackson has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-11-13</td>
<td>Phase II study evaluating the safety and clinical activity of lumetuzumab combined with pertuzumab and paclitaxel in HER2-low metastatic breast cancer</td>
<td>Wolfgang Jacob</td>
<td>Dr. Jacob has disclosed that he is an employee of the sponsor. He also disclosed that he is a stock holder.</td>
</tr>
<tr>
<td>P4-03-13</td>
<td>Obesity and breast cancer: The adipocyte-macrophage interaction as a mediator of metastasis</td>
<td>Aaron Jacobs</td>
<td>Mr. Jacobs has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-21-19</td>
<td>Systematic review of clinical trials for monoclonal antibody biomarkers in HER2-positive breast cancer</td>
<td>Dr. Jacobs</td>
<td>Dr. Jacobs has disclosed that he receives salary from and has ownership in Pfizer Inc.</td>
</tr>
<tr>
<td>P5-13-12</td>
<td>Symptom burden, unmet need for assistance, and psychosocial adaptation among longer term breast cancer survivors</td>
<td>Linda Jacobs</td>
<td>Dr. Jacobs has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
The development of nomograms to predict axillary lymph node status in breast cancer patients

Lisa Jacobs
Ms. Jacobs has no relevant financial relationships to disclose.

An exploratory correlative biomarker analysis of N0AARF 1B-7, a phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel (P) plus neratinib (N) or trastuzumab (T) or neratinib and trastuzumab (N+T) followed by docetaxel and cyclophosphamide (AC) with postoperative T in women with locally advanced HER2-positive breast cancer

Samuel Jacobs
Dr. Jacobs has no relevant financial relationships to disclose.

SANDPIPER: Phase II study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA-mutant tumors

William Jacot
Dr. Jacot has no relevant financial relationships to disclose.

Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple-negative breast cancer

William Jacot
Dr. Jacot has no relevant financial relationships to disclose.

BRCA1 promoter hypermethylation, but not BRCA1 expression, is associated with breast-like features and good prognosis in triple-negative breast cancer

William Jacot
Dr. Jacot has disclosed that he received a research grant from AstraZeneca.

Vitamin D level impacts odds of pathologic complete response following neoadjuvant therapy in operable breast cancer

William Jacot
Dr. Jacot has no relevant financial relationships to disclose.

Prognostic impact of the inclusion of uPA/PAL-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision making

William Jacot
Dr. Jacot has no relevant financial relationships to disclose.

VICTORIANE: A randomized phase 3 study assessing the addition of oral vinorelbine to aromatase inhibitors for the treatment of patients with metastatic breast cancer

Jean-Philippe Jacquin
Dr. Jacquin has no relevant financial relationships to disclose.

UCBG 2-14: A prospective multicenter non-randomized trial evaluating the effect of EndoPredict® (EPclin®) clino-genomic test on treatment decision making among patients with intermediate clinical risk

Jean-Philippe Jacquin
Dr. Jacquin has no relevant financial relationships to disclose.

Promotion of immunogenicity using epigenetic modulation and immune checkpoint inhibition in mouse models of breast cancer

Anagha Jadhav
Anagha Jadhav has disclosed that he receives salary from Optra Technologies, Neo-Pro SEZ.

Selective use of MRI and impact on management in breast cancer

Sadaf Jafferbhoy
Sadaf Jafferbhoy has no relevant financial relationships to disclose.

Delivery and anti-tumor activity of nanopolosomal irinotecan (Nal-IRI, MM-398) in metastatic xenograft models of triple negative breast cancer

David Jaffray
Dr. Jaffray has disclosed that he is conducting research under Sponsored Research Agreement with Merrimack Pharmaceuticals.

Non-sentinel lymph nodes involvement in early breast cancer patients: Performance of two predictive nomograms integrating the analysis of sentinel nodes by one step nucleic acid amplification in a cohort of 299 patients

Isabelle Jaffre
Dr. Jaffre has no relevant financial relationships to disclose.

NOSTRA PRELIM: A non randomised pilot study designed to assess the ability of image guided core biopsies to detect residual disease in patients with early breast cancer who have received neoadjuvant chemotherapy to inform the design of a planned trial

Mariam Jafri
Dr. Jafri has no relevant financial relationships to disclose.

Etirinotecan pegol: Survival advantage over standard of care drugs in a model of brain metastases of breast cancer

Rajaganapathi Jagannathan
Rajaganapathi Jagannathan has no relevant financial relationships to disclose.

ESR1 mutations in circulating tumor cell versus circulating cell-free DNA of metastatic breast cancer patients before first-line endocrine therapy and at progression

Agnes Jager
Dr. Jager has no relevant financial relationships to disclose.

Estrone-6-sulfate levels in circulating tumor cell versus circulating cell-free DNA of metastatic breast cancer patients before first-line endocrine therapy and at progression

Agnes Jager
Dr. Jager has no relevant financial relationships to disclose.
P2-07-04 Risch of primary and contralateral breast cancer in BRCA1/2 mutation carriers previously affected with ovarian cancer
Agniesz Jager
Dr. Jager has no relevant financial relationships to disclose.

P2-08-06 Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomised study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer
Agniesz Jager
Ms. Jager has disclosed collaborations (institution level) with Abbvie, AstraZeneca, Lilly, MedImmune and TESARO.

P4-22-02 Efficacy and tolerability of veliparib (V), ABT-888 and combination with carboplatin (C) and paclitaxel (P) in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: A randomized, phase 2 study
Agniesz Jager
Ms. Jager has disclosed that she has collaboration (institution level) with Abbvie, AstraZeneca, Lilly, MedImmune and TESARO.

P3-05-02 Active surveillance with a combination of tumor marker CA27.29 and detection of circulating tumor cells two year after primary diagnosis strongly predicts subsequent progression
Bernadette Jäger
Ms. Jäger has no relevant financial relationships to disclose.

P5-16-07 Analysing the factors affecting survival of breast cancer patients with leptomeningeal metastasis
Agnaiska Jagiello-Gruszfeld
Dr. Jagiello-Gruszfeld has no relevant financial relationships to disclose.

P2-02-06 Genetic counseling, germline genetic testing, and impact of results in patients with newly diagnosed breast cancer
Reshma Jagsi
Dr. Jagsi has no relevant financial relationships to disclose.

P4-20-05 Impact of radiotherapy on complications and patient-reported satisfaction with breast reconstruction: Findings from the prospective multicenter MROC study
Reshma Jagsi
Dr. Jagsi has no relevant financial relationships with commercial interests to disclose.

P4-21-10 Characterization of neoadjuvant diarrhea in patients with early-stage HER2+ breast cancer: Findings from the phase III trial of FYMOX
Mohammad Jahanzeb
Mr. Jahanzeb has disclosed that he is a consultant for Roche.

P5-08-08 Characterization of metastasis-related diarrhea in patients with HER2+ disease from the SystHERs Registry
Mohammad Jahanzeb
Mr. Jahanzeb has disclosed that he is a consultant for Roche.

P5-08-27 Treatment patterns and clinical outcomes in patients with hormone receptor (HR)+ HER2+ metastatic breast cancer and low vs high levels of HR positivity from the SystHERs Registry
Mohammad Jahanzeb
Mr. Jahanzeb has disclosed that he is a consultant for Roche.

OT2-01-19 A randomised phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer
Tanika Jain
Dr. Jain has no relevant financial relationships to disclose.

OT3-01-01 A phase II study of PD-L1 and CTLA-4 inhibition and immunopharmacogenomics in metastatic breast cancer
Tanika Jain
Dr. Jain has no relevant financial relationships to disclose.

P1-05-06 Circulating tumor DNA (ctDNA): A real-time application of precision medicine to the management of metastatic breast cancer (MBC)
Tanika Jain
Dr. Jain has no relevant financial relationships to disclose.
OT1-02-04 The DETECT V-study - Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo- or endocrine therapy in patients with HER2-positive and hormone receptor positive metastatic breast cancer

Wolfgang Janni

Dr. Janni has disclosed that he is a speaker for and has contracts with Janssen Diagnostics, Novartis, Roche and Eisai.

OT2-01-18 RIBECCA - A phase Ib, multi-center, open label study for women with estrogen receptor positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole

Wolfgang Janni

Mr. Janni has disclosed that he is a consultant for and has a contract with Novartis.

OT3-04-02 DETECT III and IV: Individualized CTC-based therapy of metastatic breast cancer

Wolfgang Janni

Dr. Janni has disclosed that he is a consultant for and has contracts with Janssen Diagnostics, Novartis, Roche and Eisai.

P1-05-05 Dynamics of circulating tumor cells during the course of chemotherapy and prognostic relevance across molecular subtypes in high-risk early breast cancer patients - Results from the adjacent SUCCESS A trial

Wolfgang Janni

Dr. Janni has no relevant financial relationships to disclose.

P1-05-15 DETECT V - Detection of the expression of estrogen receptor and human epidermal growth factor receptor 2 on circulating tumor cells from metastatic breast cancer patients

Wolfgang Janni

Dr. Janni has no relevant financial relationships to disclose.

P2-05-02 Active surveillance with a combination of tumor marker CA27.29 and detection of circulating tumor cells two years after primary diagnosis strongly predicts subsequent progression

Wolfgang Janni

Dr. Janni has disclosed that he has a contract with Verridex.

P4-07-01 Profiling miRNA in high risk post-operative early breast cancer patients to detect possible association to correlation with immune system antitumor response

Wolfgang Janni

Dr. Janni has no relevant financial relationships to disclose.

P4-22-16 First-line ribociclib plus letrozole in patients with de novo HR+, HER2- advanced breast cancer (ABC): A subgroup analysis of the MONALEESA-2 trial

Wolfgang Janni

Mr. Janni has disclosed that he is a consultant for and has a contract with Novartis.

S4-07 BELLE-3: A phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2- advanced breast cancer (ABC): A subgroup analysis of the MONALEESA-2 trial

Wolfgang Janni

Dr. Janni has disclosed that he receives consulting fees from Novartis for advisory boards and has a research grant for Detect IV study.

P4-01-01 Phase II in-human dose escalation study of the optical molecular imaging tracer bevacizumab-800cw for molecular fluorescence guided surgery in primary breast cancer patients

Liesbeth Jansen

Dr. Jansen has no relevant financial relationships to disclose.

P1-02-02 Endocrine resistance in circulating tumor cell versus circulating cell-free DNA of metastatic breast cancer patients before first-line endocrine therapy and at progression

Maurice Jansen

Mr. Jansen has no relevant financial relationships to disclose.

P1-09-20 An optimized workflow to analyze ESR1 mutations in both circulating cell-free and circulating tumor cell DNA by digital PCR

Maurice Jansen

Mr. Jansen has no relevant financial relationships to disclose.

P3-03-05 FSR/PEDE1 mediates resistance to CDK4/6 inhibitors through downregulation of 3-phospho-cyclin/cyclin dependent kinases (CDKs)

Valerie Jansen

Dr. Jansen has no relevant financial relationships to disclose.

P06-03 Preserving fertility in young women undergoing chemotherapy for early breast cancer: the Maastricht experience

Sandra Jansen-Engelen

Ms. Jansen-Engelen has no relevant financial relationships to disclose.

P2-08-31 Metabolite-guided long-term prediction of outcome in tamoxifen treated breast cancer patients

Emiel Jansen

Dr. Jansen has no relevant financial relationships to disclose.

P2-06-04 Breast cancer after Hodgkin lymphoma: Influence of endogenous and exogenous gonadal hormones on the radiation dose-response relationship

Cécile Janus

Dr. Jans has no relevant financial relationships to disclose.
P3-10-10 Planning and implementation of two regional one-stop breast health centres within a large geographic health authority: Outcomes and quality improvements in health service delivery

Rhonda Janzen

Dr. Janzen has no relevant financial relationships to disclose.

P1-05-28 Mutations treatment II: A transcriptional networks in a xenograft model of breast cancer

Bruno Jardim-Perassi

Dr. Jardim-Perassi has no relevant financial relationships to disclose.

OT1-03-10 Multi-center phase IIb trial of ACY-1215 (Ricolinostat) combined with nab-paclitaxel in unresectable or metastatic breast cancer

Matthew Jarpe

Dr. Jarpe has disclosed that as an employee he receives salary from Acetylon.

OT1-04-06 MBC-RIB01: A phase III trial of standard of care therapy with or without sterostatic body radiotherapy (SBRT) &/or surgical ablation for newly oligometastatic breast cancer

Nora Jaskowiak

Dr. Jaskowiak has no relevant financial relationships to disclose.

P2-03-05 High concordance of ER, PR, HER2 and ERBB by central IHC and FISH with mRNA measurements by GeneXpert® breast cancer stratifier assay

Jacek Jassem

Dr. Jassem has no relevant financial relationships to disclose.

P2-05-21 Predictive value of quantitative HER2 and HER2 levels combined with downstream signaling markers in HER2-positive advanced breast cancer patients treated with lapatinib

Jacek Jassem

Dr. Jassem has no relevant financial relationships to disclose.

P2-07-14 Geographic variation in the female breast cancer mortality rates across counties in United States

Ismail Jatoi

Dr. Jatoi has no relevant financial relationships to disclose.

P3-08-03 Factors associated with genetic testing in a cohort of breast cancer survivors

Ismail Jatoi

Dr. Jatoi has no relevant financial relationships to disclose.

Committee Member

Ismail Jatoi

Dr. Jatoi has no relevant financial relationships with commercial interests to disclose.

P6-09-37 Ductal carcinoma in situ: Patient outcomes and association with hormone receptors

Gita Jayachandran

Gita Jayachandran has no relevant financial relationships to disclose.

P4-21-36 Splenic enlargement and bone marrow hyperplasia in patients receiving trastuzumab- emtansine for metastatic breast cancer

Janani Jayanthan

Janani Jayanthan has no relevant financial relationships to disclose.

P1-02-07 Delination of breast cancer based on circulating protein biomarker profile using the CLINQ proteomics multiplexed assay

Janani Jayanthan

Janani Jayanthan has no relevant financial relationships to disclose.

P5-15-12 Real-life activity of oral vinorelbine in metastatic breast cancer patients in the Unicancer ESME database

Joel Jean-Mairet

Dr. Jean-Mairet has disclosed that he is a patent inventor on an Inbiomotion SL application but have no rights. He also disclosed that he is a member of the Board of Directors of Inbiomotion and indirectly owns <0.2% of Inbiomotion stocks.

P3-13-27 Early detection of secondary lymphedema after cancer treatments

Sarah Jefferies

Ms. Jefferies has no relevant financial relationships to disclose.

P2-09-01 Impact of MAF gene amplification on disease recurrence and effects of adjuvant zoledronic acid in early breast cancer patients

Sarah Jefferies

Ms. Jefferies has disclosed that she is a Novartis employee.

P5-15-12 Real-life activity of oral vinorelbine in metastatic breast cancer patients in the Unicancer ESME database

Peppercorn Jeffrey

Dr. Jeffrey has no relevant financial relationships to disclose.

S1-10 Clinical implications of somatic mutations in post-menopausal early-stage estrogen receptor (ER)-positive HER2-negative breast cancer (BC). Results from the BIG 1-98 study

Leifény Jelley

Ms. Jelley has disclosed that she is a Novartis employee.

OT1-04-01 Cambridge brain meets 2CamBMT®: A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy

Sarah Jeffries

Ms. Jeffries has no relevant financial relationships to disclose.

P3-13-09 Development and implementation of a patient-centered, nurse practitioner-led survivorship intervention for breast cancer

Peppercorn Jeffrey

Dr. Jeffrey has no relevant financial relationships to disclose.
Patterns of axillary evaluation in older patients (pts) with breast cancer and impact on adjuvant therapy
Ahmedin Jemal
Dr. Jemal has no relevant financial relationships to disclose.

Distinct recruitment of tumor-associated immune cells correlates with increased pro-malignant chemokines in tumors expressing epithelial atypical chemokine receptor 1 (ACKR1/DARC), indicating a unique tumor microenvironment
Brittany Jenkims
Ms. Jenkins has no relevant financial relationships to disclose.

The long-term outcomes of Metasin RTqPCR intra-operative sentinel node analysis in early breast cancer
Kate Jenkims
Ms. Jenkins has no relevant financial relationships to disclose.

Cambridge brain mets trial 1 (CamBMT1): A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy
Rajesh Jena
Rajesh Jena has no relevant financial relationships to disclose.

The UK CORIS trial randomizing patients with low or intermediate grade ductal carcinoma in situ (DCIS) to surgery or active monitoring
Valerie Jenkims
Dr. Jenkins has no relevant financial relationships to disclose.

Maximising recruitment and retention of patients into UK-ANZ POSNOC trial
Valerie Jenkims
Dr. Jenkins has no relevant financial relationships to disclose.

Application of digital-PCR technology to determine c-MET copy number variation in paired primary breast cancer and brain metastases
Michael Jenkinson
Dr. Jenkinson has no relevant financial relationships to disclose.

Prognostic associations of tumor-infiltrating lymphocytes (TIL) in metastatic HER2-positive breast cancer (BC) treated with trastuzumab and pertuzumab: A secondary analysis of the CLEOPATRA study
Eng-Wong Jennifer
Ms. Eng-Wong has disclosed that she is an employee of Genentech and has stock ownership.

Triple negative breast cancer patient-derived xenografts: Molecular characteristics and sensitivity to emerging therapies
Litton Jennifer
Dr. Jennifer has no relevant financial relationships to disclose.

Evaluating targets in localized and advanced breast cancer by sequencing tumor DNA at diagnosis and after progression (ELSA)
Weiss Jennifer
Ms. Jennifer has no relevant financial relationships to disclose.

Prediction of 10yr distant recurrence (DR) using the Prosigna® (PAM50) assay in histological subgroups of a Danish breast cancer group (DBCG) cohort of postmenopausal Danish women with hormone receptor-positive (HR+) early breast cancer (EBC) allocated to 5yr of endocrine therapy (ET) alone
Maj-Britt Jensen
Maj-Britt Jensen has no relevant financial relationships to disclose.

12 years' median follow up (MFU) of BIG 1-98: Adjuvant letrozole, tamoxifen and their sequence for postmenopausal women with endocrine responsive early breast cancer
Maj-Britt Jensen
Maj-Britt Jensen has no relevant financial relationships to disclose.

Radioactive seed localization versus wire guided localization of nonpalpable invasive and in situ breast cancer: A Danish multicenter randomized controlled trial
Maj-Britt Jensen
Maj-Britt Jensen has no relevant financial relationships to disclose.

Prediction of 50yrs distant recurrence (DR) in patients with early breast cancer (DBCG) cohort of postmenopausal Danish women with hormone receptor-positive (HR+) early breast cancer (EBC) allocated to 5yr of endocrine therapy (ET) alone
Maj-Britt Jensen
Maj-Britt Jensen has no relevant financial relationships to disclose.

Maj-Britt Jensen has no relevant financial relationships to disclose.
High-throughput genome analysis and therapeutic decision for patients with HER2-negative metastatic breast cancer: First feasibility and molecular results of the randomized phase II study SAFIR02 BREAST (UCBG-0105/1304)

Marta Jimenez

Ms. Jimenez has no relevant financial relationships to disclose.

Mitochondria-nuclear communication regulates epithelial-mesenchymal transition and metastasis in triple negative breast cancer

Feng Jin

Dr. Jin has no relevant financial relationships to disclose.

Determining the prognostic role of early and end-of-neoadjuvant chemotherapy 18F-FDG PET/CT in patients with locally advanced breast cancer

Javier Jiménez

Mr. Jiménez has no relevant financial relationships to disclose.

Metabolic stress induces IG2 expression and cancer stem cell phenotypes in triple negative breast cancer

Feng Jin

Dr. Jin has no relevant financial relationships to disclose.

SANDPIPER: Phase II study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA-mutant tumors

Huaren Jin

Huaren Jin has disclosed that he is an employee of Genentech and owns Roche stock.

Phase II study of taselisib (GDC-0032) plus fulvestrant in HER2-negative, hormone receptor-positive advanced breast cancer: Analysis by PIK3CA and ESR1 mutation status from circulating tumor DNA

Huaren Jin

Huaren Jin has disclosed that he is an employee of Roche-Gentech and owns Roche stock.

Role of HIF2α, a long non-coding RNA, in development of resistance to endocrine therapy in breast cancer cells

Hye Ryang Jin

Dr. Jin has disclosed that he receives salary from and has ownership in Roche.

Risk factors of locoregional recurrence, locoregional failure pattern and role of postmastectomy radiotherapy for T1-2 breast cancer with 1-3 positive axillary lymph nodes

Jing Jin

Dr. Jin has no relevant financial relationships to disclose.

Spontaneous effect of chemotherapeutic treatment with maraviroc and ticlopidine on TNBC tumor growth and metastasis in mouse xenograft model

Kódály József

Dr. Jin has no relevant financial relationships to disclose.

Both spliced and unspliced XBP1 regulates breast cancer cell fate response to antiestrogen via NFkappaB signaling

Jiun Jin

Jiun Jin has disclosed that he is an employee of Genentech and owns Roche stock.

LIPF1 promotes breast cancer progression via suppressing RAS-MAPK expression

Jiun Jin

Jiun Jin has no relevant financial relationships to disclose.

Predictive and prognostic value of 5p-6p expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin

Jiun Jin

Jiun Jin has no relevant financial relationships to disclose.

Both spliced and unspliced XBP1 regulates breast cancer cell fate response to antiestrogen via NFkappaB signaling

Jiun Jin

Jiun Jin has no relevant financial relationships to disclose.

IsomiRs and tRNA fragments are race-dependent regulators in breast cancer

Yi Jing

Dr. Jing has no relevant financial relationships to disclose.

The non-invasive treatment for sentinel lymph node metastasis by photodynamic therapy using a verteporfin solubilized phospholipid polymer aggregate

Hiromitsu Jinno

Hiromitsu Jinno has no relevant financial relationships to disclose.

Technical feasibility and validity of sentinel lymph node biopsy in patients with unilateral breast tumor recurrence

Hiromitsu Jinno

Hiromitsu Jinno has no relevant financial relationships to disclose.

The impact of a change in margin width on rates of re-excision following breast conserving surgery

Natasha Jobe

Ms. Jobe has no relevant financial relationships to disclose.

Influence of timing of radiation therapy following breast-conserving surgery on 10-year disease-free survival

Jan Jobes

Jan Jobes has no relevant financial relationships to disclose.

Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy

Mélina Jochelson

Dr. Jochelson has no relevant financial relationships to disclose.
Comparison of the Xpert breast cancer stratifier mRNA assay with central ER, PR, HER2, and Ki67 immunohistochemistry (IHC) for rapid biomarker analysis in developing countries

Weidler Jodi

Ms. Weidler has disclosed that she is an employee and a stockholder of Cepheid.

Next generation sequencing (NGS) reveals high mutation rates in all established breast cancer subtypes with subtype-specific patterns

Touma Joel

Touma Joel has no relevant financial relationships to disclose.

Genomic characterization of 992 primary breast cancers

Heikki Joensuu

Dr. Joensuu has no relevant financial relationships to disclose.

Prognostic value of molecular tumor infiltrating lymphocyte (mTIL) signatures in HER2-positive breast cancer patients in N9831 and FinHer/FinXX trials

Touma Joel

Touma Joel has no relevant financial relationships to disclose.

Whole exome and transcriptome sequencing of resistant ER+ metastatic breast cancer

Touma Joel

Touma Joel has no relevant financial relationships to disclose.

Upregulated purinergic signaling enhances cell proliferation in human and murine breast carcinomas

Touma Joel

Touma Joel has no relevant financial relationships to disclose.

Prospective family cohort analyses of gene-environment interactions in breast cancer: Body mass index

Esther John

Dr. John has no relevant financial relationships to disclose.

Prospective cross-sectional study on participation in mammography screening according to immigration background and education status

Esther John

Dr. John has no relevant financial relationships to disclose.

HER2 status remains the primary predictor of improved survival in patients with BCBM over the past 2 decades (1996-2015)

Kirkpatrick John

Dr. John has no relevant financial relationships to disclose.

Breast cancer education, counseling, and support for Jewish women: Preliminary results of a CDC program evaluation

Andrea Johnson

Ms. Johnson has no relevant financial relationships to disclose.

A randomized controlled trial comparing acupuncture versus usual care for the treatment of aromatase inhibitor-induced arthralgia (AIIA) in women with early-stage breast cancer

Anita Johnson

Dr. Johnson has no relevant financial relationships to disclose.

Positive behavior change and weight loss in breast cancer survivors on hormonal adjuvant therapy: An energy balance research in cancer (EnBaR) prospective study

Anita Johnson

Dr. Johnson has no relevant financial relationships to disclose.

A randomized study comparing MoistHer to topical lidocaine for female breast cancer survivors with dyspareunia

Anita Johnson

Dr. Johnson has no relevant financial relationships to disclose.

A randomized study of personalized music therapy for patients with early-stage breast cancer receiving chemotherapy

Anita Johnson

Dr. Johnson has no relevant financial relationships to disclose.

Efficacy of screening and treatment of breast cancer patients reporting high level of distress

Anita Johnson

Dr. Johnson has no relevant financial relationships to disclose.

Obesity, dyslipidemia, and diabetes as risk factors for trastuzumab-related cardiotoxicity in breast cancer patients

Christopher Johnson

Dr. Johnson has no relevant financial relationships to disclose.

Comparative performance of surveillance mammography and breast MRI in women with a history of breast cancer

Siimane Johnson

Ms. Johnson has no relevant financial relationships to disclose.

MIRC-6 positive breast tumors are more immunogenic and may preferentially select for LAG-3-positive tumor immune infiltrates

Douglas Johnson

Dr. Johnson has no relevant financial relationships to disclose.

The REQUITE-AB study: Validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality of life in breast cancer patients

Kerstie Johnson

Ms. Johnson has no relevant financial relationships to disclose.
OT1-04-01 Cambridge brain mets trial 1 (CamBMT1): A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy
Alex Jonson
Alex Jonson has no relevant financial relationships to disclose.

P2-01-15 Clinical application of multi-modality fluorescent-radiolabeled system in advanced breast cancer patients with metastatic breast cancer: interim analysis for 65 patients
Jungnam Jo
Jungnam Jo has no relevant financial relationships to disclose.

P5-11-15 Radiopharmaceutical for the prevention of chemotherapy-induced nausea and vomiting in breast cancer patients receiving multiple cycles of neoadjuvant chemotherapy
Karin Jordan
Ms. Jordan has disclosed that she is a consultant for Merck, MSD, Helmsys Healthcare and Tesaro.

P4-12-05 Extracellular vesicles from young women’s and postpartum breast cancer display unique proteomic content, after breast cancer aggressive behavior, and influence immune cell function
Kimberly Jordan
Dr. Jordan has no relevant financial relationships to disclose.

P4-02-07 Preoperative assessment of breast cancer survival using ultrasonic diameter and shear wave elastography
Lee Jordan
Lee Jordan has no relevant financial relationships to disclose.

P4-01-01 Phase II in-humor dose escalation study of the optical-molecular imaging tracer bevacizumab-800cw for molecular fluorescence-guided surgery in primary breast cancer patients
Annelies Jorritsma-Smit
Ms. Jorritsma-Smit has no relevant financial relationships to disclose.

P2-08-07 Anti-proliferative and anti-inflammatory estrogen receptor agents for treatment of endocrine-resistant breast cancer
Jatinder Josan
Dr. Josan has no relevant financial relationships to disclose.

S1-07 Prognostic associations of tumor-infiltrating lymphocytes (TIL) in metastatic HER2-positive breast cancer (BC): a secondary analysis of the CLEOPATRA study
Baselga Jose
Baselga Jose has no relevant financial relationships to disclose.

P4-22-09 A phase 2 open label study of axitinib in combination with endocrine therapy in resistant hormone receptor-positive HER2-negative advanced breast cancer
Matthew Joseph
Dr. Joseph has no relevant financial relationships to disclose.

P5-01-01 Should modified radical mastectomy be modified? A phase I study to evaluate infraradical mastectomy for invasive breast cancer
Priya Joshi
Ms. Joshi has no relevant financial relationships to disclose.

P3-13-22 Inducing immune responses to tumor associated carbohydrate antigens by a carbohydrate mimetic peptide vaccine: Clinical experience in phase I and phase II trials
Doireann Joyce
Doireann Joyce has no relevant financial relationships to disclose.

P2-05-10 PBCG 2-14: A prospective multicenter non-randomized trial evaluating the effect of EndoPredict® (EPclin®) clinico-genomic test on treatment decision making among patients with intermediate clinical risk
Christelle Jouannaud
Christelle Jouannaud has no relevant financial relationships to disclose.

P4-22-10 Evaluation of the effects of palbociclib plus letrozole on QTc interval
Anil Joy
Anil Joy has disclosed that he is a consultant for Pfizer.

P6-04-01 Engineering mesenchymal stem cells (MSCs) to secrete tumor-suppressing exosomes for breast cancer therapy
Doireann Joyce
Doireann Joyce no has relevant financial relationships to disclose.
How population-based data complement trial data in the adjuvant endocrine treatment of ER+/HER2+ breast cancers

Katarzyna Jozwiak

Dr. Jozwiak has no relevant financial relationships to disclose.

Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases

Ingolf Juhaz

Dr. Juhaz has no relevant financial relationships to disclose.

High concordance of DX, PR, HER2 and MMR by central IHC and FISH with mRNA measurements by Genemxpert® breast cancer stratifier assay

Hartmut Juhl

Dr. Juhl has disclosed that he receives salary from and has ownership in Genemxpert.

Prospective association between breast cancer risk and an individual dietary index based on the British Food Standards Agency nutrient profiling system

Chantal Julian

Dr. Julian has no relevant financial relationships to disclose.

MRI oncology/NAAB B-51/RTDG 1304: A phase III superiority clinical trial designed to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) in the addition of NRTT to breast RT post breast-conserving surgery (BCS) will reduce invasive cancer events in patients (pts) with positive axillary (Ax) nodes and convert to ypT0 after neoadjuvant chemotherapy (NAC)

Thomas Julian

Mr. Julian has no relevant financial relationships to disclose.

Clinical utility of serial monitoring of circulating tumor DNA (ctDNA) in patients with neoadjuvant chemotherapy (NAC) for locally advanced breast cancer (LABC)

Hyun Ae Jung

Hyun Ae Jung has disclosed that he receives salary from and has ownership in the company that manufactures the DNA test.

Breast cancer patients after surgery and/or radiation therapy: A report from Asan medical center

Ei Jung

Ei Jung has no relevant financial relationships to disclose.

Ex vivo shear-wave elastography of axillary lymph nodes predicting nodal metastasis in patients with primary breast cancer: A pilot study

Joon Jung

Dr. Jung has no relevant financial relationships to disclose.

Mitochroma-nuclear communication regulates epithelial-mesenchymal transition and metastasis in triple negative breast cancer

Kwang Hea Jung

Dr. Jung has no relevant financial relationships to disclose.

A phase II, multicenter, randomized trial of enbuzon plus gemcitabine (EG) vs. paclitaxel plus gemcitabine (PG) in patients with HER2-negative metastatic breast cancer as first-line chemotherapy

Kwang Hea Jung

Dr. Jung has no relevant financial relationships to disclose.

Circulating cell-free DNA (ccDNA) measured by a simple fluorescent assay to predict relapse in triple negative breast cancer patients receiving neoadjuvant chemotherapy: A biomarker substudy of prospective observational study NCT02001519, NCT02001506

Kwang Hea Jung

Dr. Jung has no relevant financial relationships to disclose.

The PROCEED trial KCSG BR11-01 phase III multicenter randomized open-label study of irinotecan plus capecitabine versus capecitabine in patients previously treated with anthracycline and taxane for HER2 negative metastatic breast cancer

Kwang Hea Jung

Dr. Jung has no relevant financial relationships to disclose.

Changes of tumor-infiltrating lymphocytes and programmed death-ligand2 positivity after neoadjuvant chemotherapy in patients with locally advanced breast cancer

Seung Pil Jung

Seung Pil Jung has no relevant financial relationships to disclose.

Association of background parenchymal enhancement with breast cancer risk factors and tumor characteristics

Seung-Youn Jung

Dr. Jung has no relevant financial relationships to disclose.

Clinical applications of near infra-red imaging system for localization of non-palpable breast lesions in breast conserving surgery

So-Youn Jung

So-Youn Jung has no relevant financial relationships to disclose.

Development of prediction model for omission of sentinel lymph node biopsy in T1 breast cancer

So-Youn Jung

Dr. Jung has no relevant financial relationships to disclose.
Clinical application of multimodal fluorescent-radioactive system in advanced breast cancer patients with neoadjuvant therapy; interim analysis for 65 patients

Risk factors affecting post-operative complication after immediate reconstruction with implant for operable breast cancer patients

Risk factors affecting post-operative complication through ER-dependent and independent transcriptional reprogramming in estrogen-resistant breast cancer

Efficacy of first-line breastabrazib (BEV)-containing therapy for poor-prognosis advanced breast cancer (BC): Subgroup analyses of the German AVANTI observational study

21-gene recurrence score® in patients with primary metastatic (ER+ HER2-) breast cancer

Next generation sequencing (NGS) reveals high mutation rates in all established breast cancer subtypes with subtype-specific patterns

Sacituzumab govitecan (IMMU-132), an anti-Trop-2 SN-38 antibody-drug conjugate (ADC) for the treatment of relapsed/refractory, metastatic triple-negative breast cancer (mTNBC): Updated results

Phase Ib safety, efficacy, and molecular analysis of ribociclib (LEE011) plus letrozole for the treatment of ER+, HER2- advanced breast cancer

Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: A subanalysis of data from the Randomised phase II GeparSepto trial

Peripheral sensory neuropathy occurrence and resolution: Results from the neoadjuvant randomized GeparSepto study (GBG 69)

Intraoperative assessment of the sentinel node (SN) in breast cancer by one step nucleic acid assay (DNAx): Experience of over 800 patients

A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (mBC)
P3-05-03 A novel progesterone receptor (PR)-RNA polymerase III association represses estrogen-dependent growth in breast tumor patient-derived xenografts
Peter Kabos
Dr. Kabos has no relevant financial relationships to disclose.

P4-02-06 Evaluation of contrast-enhanced ultrasonography for early prediction of response to neoadjuvant chemotherapy in triple negative breast cancer
Takayuki Kadoya
Takayuki Kadoya has no relevant financial relationships to disclose.

P4-06-03 An annotated collection of pre- and post-therapy breast cancer patient-derived xenograft models built from fine needle aspiration samples aligned with ongoing clinical trials documenting response to treatment
Sepideh Kaffibasabadi
Sepideh Kaffibasabadi has no relevant financial relationships to disclose.

P2-03-09 Comparison of the mutational landscape of breast cancer during pregnancy and non-pregnant controls
Laura Kahmann
Ms. Kahmann has no relevant financial relationships to disclose.

P1-10-09 Delineation of internal mammary nodal target volumes in breast cancer radiotherapy
Mohamed Kahila
Mr. Kahila has no relevant financial relationships to disclose.

P1-10-11 Prone vs. supine positioning for optimizing radiation heart exposure during left breast radiotherapy: A simple clinical tool for prediction
Zsuzsanna Kahán
Dr. Kahán has no relevant financial relationships to disclose.

P1-10-07 Prospective longitudinal study of epidermal thickening in breast cancer patients treated with conventional versus hypofractionated radiotherapy
Sharron Kahn
Dr. Kahn has no relevant financial relationships to disclose.

P1-08-09 Aurora kinase-A protein stability is negatively regulated by eEF1α2 and PTEN in breast cancer: Prognostic and therapeutic implications
Kazuharu Kai
Dr. Kai has no relevant financial relationships to disclose.

P6-07-05 PD-L1 expression and decreased tumor-infiltrating lymphocytes are associated with poor prognosis in patients with triple negative breast cancer
Masaya Kai
Masaya Kai has no relevant financial relationships to disclose.

P6-01-07 Mitochondria-nuclear communication regulates epithelial-mesenchymal transition and metastasis in triple negative breast cancer
Benny Kaipparettu
Dr. Kaipparettu has no relevant financial relationships to disclose.

P4-07-03 Dynamic regulation of a microRNA-mRNA network during breast cancer metastasis reveals an essential tumor-promoting role for miR-203
Dana Kajan
Dana Kajan has no relevant financial relationships to disclose.

P1-09-16 Randomized study of COX2 inhibition on systemic inflammation in obese and non-obese subjects
Virginia Kaklamani
Dr. Kaklamani has no relevant financial relationships to disclose.

P2-08-06 A phase 1 study of RO6110, a novel, oral selective estrogen receptor degrader, for the treatment of ER-positive advanced breast cancer
Virginia Kaklamani
Dr. Kaklamani has disclosed that she is a consultant for AstraZeneca.

P6-09-09 Evaluation of tumor infiltrating lymphocytes (TILs) and their association with homologous recombination deficiency and BRCA1/2 mutation status in triple-negative breast cancer (TNBC): A pooled analysis
Virginia Kaklamani
Dr. Kaklamani has disclosed that she is a consultant for Myriad Genetics, Inc. and Eisai.

P6-16-03 Phase 2 trial of everolimus and/or trastuzumab in hormone refractory, hormone receptor (HR) positive, HER2-normal metastatic breast cancer (MBC)
Virginia Kaklamani
Dr. Kaklamani has no relevant financial relationships to disclose.
Inhibition of HDAC6 as targeted therapy for breast cancers

Kevin Kalinsky

Dimitar Kalev

Dr. Kalinsky has disclosed that he is a consultant for Pfizer, Amgen, and Biotheranostics.

Kevin Kalinsky

Mr. Kalinsky has disclosed that his spouse works for Novartis on an unrelated project.  He has also disclosed that he is a consultant for Pfizer, Amgen, and Biotheranostics.

Kevin Kalinsky

Mr. Kalinsky has disclosed that his spouse works for Novartis on something unrelated.  He has also disclosed that he is a consultant for Pfizer, Amgen, and Biotheranostics.

Kevin Kalinsky

Dr. Kaklamani has disclosed that she receives consulting fees from Eisai, Celgene, and Genentech.  These relationships do not impact her ability to present an unbiased presentation.

Kevin Kalinsky

Dr. Kaklamani has disclosed that she receives consulting fees from Eisai, Celgene, and Genentech.  These relationships do not impact her ability to present an unbiased presentation.

Kevin Kalinsky

Rohini Kaklamani has no relevant financial relationships to disclose.

Kevin Kalinsky

Dr. Kaklamani has disclosed that she receives consulting fees from Eisai, Celgene, and Genentech.  These relationships do not impact her ability to present an unbiased presentation.
<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>Survivorship care planning is associated with breast cancer survivors’ reported quality and coordination of care</td>
<td>Sailaja Kamaraju</td>
<td>Dr. Kamaraju has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population study</td>
<td>Sailaja Kamaraju</td>
<td>Dr. Kamaraju has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Abemaciclib exposure-response relationship in patients with metastatic breast cancer in MONARCH 1: Early clinical results</td>
<td>Suvarna Kamboj</td>
<td>Dr. Kamboj has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Impact of TP53 functional mutation type on clinical outcomes of advanced breast cancer patients</td>
<td>Suzanne Kamel-Reid</td>
<td>Ms. Kamel-Reid has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Clinical outcome of patients with advanced triple negative breast cancer with germline and somatic variants in homologous recombination gene</td>
<td>Suzanne Kamel-Reid</td>
<td>Ms. Kamel-Reid has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Oncologic outcome of pregnancy associated breast cancer: A case-control study</td>
<td>Sabrina Kamer</td>
<td>Ms. Kamer has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>The combination of preoperative computed tomography lymphography and intraoperative fluorescence imaging navigation for sentinel lymph node biopsy of early breast cancer patients</td>
<td>Masumi Kameyama</td>
<td>Dr. Kameyama has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>A phase II trial of neoadjuvant docetaxel/cyclophosphamide followed by estramustine/cyclophosphamide for triple-negative breast cancer</td>
<td>Mari Kamimura</td>
<td>Dr. Kamimura has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>A phase II trial of neoadjuvant epirubicin/cyclophosphamide followed by weekly nanoparticle albumin-bound paclitaxel with trastuzumab for HER2-positive breast cancer</td>
<td>Mari Kamimura</td>
<td>Dr. Kamimura has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Breast-conserving surgery plus hormone therapy without radiation in elderly women with early breast cancer</td>
<td>Mari Kamimura</td>
<td>Mari. Kamimura has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Defining novel molecular pathways driving endocrine resistance in breast cancer</td>
<td>Kamila Kaminska</td>
<td>Dr. Kaminska has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OBRK2 contributes to the generation of breast cancer stem cells through KLF4</td>
<td>Makiko Kamio</td>
<td>Ms. Kamio has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Independent validation of FAK1Y gene signature in BIG 1-98: A randomized, double-blind, phase III trial comparing letrozole and tamofoxen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer</td>
<td>Roswitha Kammler</td>
<td>Roswitha Kammler has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Clinical implications of somatic mutations in post-menopausal early-stage estrogen receptor (ER)-positive HER2-negative breast cancer (BC): Results from the BIG 1-98 study</td>
<td>Roswitha Kammler</td>
<td>Roswitha Kammler has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>PALAHA: A phase II safety study of abemaciclib in combination with letrozole in African American women with hormone receptor positive HER2 negative advanced breast cancer</td>
<td>Lois Kamugisha</td>
<td>Dr. Kamugisha has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Multicentric and immune-phenotyping reveal distinct molecular signatures of young Asian breast cancers</td>
<td>Zhengyan Kan</td>
<td>Dr. Kan has disclosed that he receives salary from and has ownership in Pfizer Inc.</td>
</tr>
<tr>
<td>Development of photacoustic vascular imaging system for breast cancer</td>
<td>Shotaro Kanai</td>
<td>Shotaro Kanai has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Results of an educational program delivered through e-learning, focused on nursing for primary breast cancer patients</td>
<td>Maiko Kanazawa</td>
<td>Ms. Kanazawa has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Factors predicting treatment outcomes of angiosarcoma of breast: A 25 year single institution experience</td>
<td>Mr. Kane</td>
<td>Mr. Kane has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Effect of serum biomarkers [actin A, CA9, HER2, TIMP-1, and uPA] on outcome in HER2+ metastatic breast cancer patients treated in first-line with lapatinib or trastuzumab combined with capecitabine: CETOG MA.31</td>
<td>Ashley Kang</td>
<td>Dr. Kang has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
The role of serum neutrophil-to-lymphocyte ratio (NLR) in triple-negative breast cancer

Bong Joo Kang

Dr. Kang has no relevant financial relationships to disclose.

Development of prediction model for omission of sentinel lymph node biopsy in T1 breast cancer

Han-Sung Kang

Dr. Kang has no relevant financial relationships to disclose.

Clinical application of multimodal fluorescent-radioactive system in advanced breast cancer patients with neoadjuvant therapy: interim analysis for 85 patients

Han-Sung Kang

Dr. Kang has no relevant financial relationships to disclose.

Impact of young age on recurrence and mortality after surgery in breast cancer: 25 years active surveillance

Danbee Kang

Danbee Kang has no relevant financial relationships to disclose.

Clinical application of multimodal fluorescent-radioactive system in advanced breast cancer patients with neoadjuvant therapy: interim efficacy for 65 patients

Han-Kun Kang

Se Hun Kang has no relevant financial relationships to disclose.

The association of higher tumor HER2 load with treatment response to neoadjuvant therapy in HER2 positive breast cancer patients

Kang-Hae Kang

Dr. Kang has no relevant financial relationships to disclose.

The association between patient comorbidity and breast cancer survival

Young Joon Kang

Young Joon Kang has no relevant financial relationships to disclose.

Novel regulation of breast cancer cell aggressiveness by cancer testis antigen

Anbarasu Kannan

Dr. Kannan has no relevant financial relationships to disclose.

Efficacy of compression therapy using surgical gloves for nanoparticle albumin-bound-paclitaxel-induced peripheral neuropathy: A phase II multicenter study by the Kamigata breast cancer study group

Yookija Kanng

Dr. Kanng has no relevant financial relationships to disclose.

The ASCO-recommended prognostic factors uPA/PAI-1 in a multicenter cohort study (PA)

Eva Kantelhardt

Dr. Kantelhardt has no relevant financial relationships to disclose.

Evaluating the feasibility of a web-based preference-tolerant randomized trial of risk-based vs. annual breast cancer screening: WISDOM study pilot

Celia Kaplan

Dr. Kaplan has no relevant financial relationships to disclose.

Characteristics of physician detected breast cancer

Henry Kaplan

Dr. Kaplan has no relevant financial relationships to disclose.

Trajectory of patient (Pt) reported physical function (PF) during and after neoadjuvant chemotherapy in the I-SPY 2 trial

Henry Kaplan

Dr. Kaplan has no relevant financial relationships to disclose.

Efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial

Henry Kaplan

Dr. Kaplan has no relevant financial relationships to disclose.

The evaluation of ganitumab/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial

Henry Kaplan

Dr. Kaplan has no relevant financial relationships to disclose.

Is breast magnetic resonance imaging (MRI) useful for diagnosis of additional sites of disease in patients recently diagnosed with ductal carcinoma in situ (DCIS)?

Megha Kapoor

Dr. Kapoor has no relevant financial relationships to disclose.
OT1-04-01 Cambridge brain mets trial 1 (CamBMT1): A proof-of-principle phase Ib / randomised phase 2 study of afatinib penetration into brain metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy
Konstantina Karabatsou
Ms. Karabatsou has no relevant financial relationships to disclose.

PD-02 Paficilase induced mena- and TMEM-mediated pro-metastatic changes in the breast cancer microenvironment
George Karagiannis
Dr. Karagiannis has no relevant financial relationships to disclose.

P2-01-19 Sentinel: A way to avoid sentinel node biopsy (SNB) in patients with a preoperative diagnosis of ductal cancer in situ (DCIS)
Andreas Karakatsanis
Andreas Karakatsanis has no relevant financial relationships to disclose.

P1-04-08 Non-metastar SUROX dynamics negate mammary epithelial cell transformation
Samaneh Karami
Samaneh Karami has no relevant financial relationships to disclose.

P3-04-21 Androgen receptor in tamoxifen-resistant breast cancer is affected by SUROX
Samaneh Karami
Samaneh Karami has no relevant financial relationships to disclose.

P6-16-01 The importance of loco-regional tumor burden and surgery on survival in patients with de novo stage IV breast cancer: post-hoc analyses of protocol MPG-01
Hassan Karakas
Dr. Karakas has no relevant financial relationships to disclose.

P5-15-02 Phase 1/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
Yassilki Karantza
Yassilki Karantza has disclosed that he is an employee and has ownership in Merck MSD.

P6-10-03 KEYNOTE-012: Long-lasting responses in a phase Ib study of pembrolizumab for metastatic triple-negative breast cancer (mTNBC)
Yassilki Karantza
Yassilki Karantza has disclosed that he receives salary from Merck.

P2-01-13 Can axillary lymph node clearance be avoided in women with node positive breast cancer receiving primary chemotherapy?
Eleni Karapanagiotou
Eleni Karapanagiotou has no relevant financial relationships to disclose.

P3-17-09 Resolution of DCIS in patients with early breast cancer receiving primary chemotherapy for invasive breast cancer
Eleni Karapanagiotou
Eleni Karapanagiotou has no relevant financial relationships to disclose.

P4-01-08 Specific detection of anti-Her2 PEGylated PrecisionMRX® nanoparticles measured using superparamagnetic relaxometry
Todor Karaulanov
Todor Karaulanov has no relevant financial relationships to disclose.

P6-10-06 Relative radioresistance in triple negative tumors in the breast: In IORT randomized clinical trial
Behzad Karbassi
Dr. Karbassi has no relevant financial relationships to disclose.

P1-09-03 In 6 hour monitoring for administration related reactions after first administration of subcutaneous trastuzumab necessary? A single institution audit
Soheilali Karmali
Soheilali Karmali has no relevant financial relationships to disclose.

P3-12-04 Outcome after neoadjuvant chemotherapy in preoperative receptor negative breast cancer patients - A pooled analysis of individual patient data from ten prospectively randomised controlled neoadjuvant trials
Thomas Karm
Mr. Karm has no relevant financial relationships to disclose.

P3-11-02 Immune sculpting of the triple negative breast cancer genome
Thomas Karm
Mr. Karm has no relevant financial relationships to disclose.

P2-11-01 Non-interventional study with neopterin/ palmitoic acid (NPA) as CMIV prophylaxis in highly or moderately emetogenic chemotherapy
Melinda Karthaus
Prof. Karthaus has no relevant financial relationships to disclose.

P3-07-21 Cyclin-dependent kinase 12 (CDK12) and the pi3k-beta PI3K inhibitor and the GSK2830191 PI3K inhibitor on MX-1 and MCF-7 human breast cancer cells
Eric Karuturi
Dr. Karuturi has no relevant financial relationships to disclose.

P3-05-04 Impact of androgen receptor expression in flusymesterone-treated, estrogen receptor-positive metastatic breast cancer exposed to contemporary hormonal therapy
Meghan Karuturi
Dr. Karuturi has no relevant financial relationships to disclose.

P2-01-29 In the era of conservative surgery, can patients presenting with node positive breast cancer be spared axillary node dissection post neoadjuvant chemotherapy? A meta-analysis and review of literature
Abdul Kaseem
Dr. Kaseem has no relevant financial relationships to disclose.

P1-09-11 Outcome after neoadjuvant chemotherapy in progesterone receptor negative breast cancer patients - A pooled analysis of individual patient data from ten prospectively randomised controlled neoadjuvant trials
Thomas Karm
Mr. Karm has no relevant financial relationships to disclose.
Does fat transfer increase the risk of breast cancer recurrence? A meta-analysis involving 2382 patients

The role of sentinel lymph node biopsy in patients with ductal carcinoma in situ. An updated meta-analysis involving 9803 patients

Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes (TILs) and residual cancer burden (RCB)

Predicting therapeutic effect by on tumor invasion lymphocytes (TILs) in endocrine therapy for stage IV breast cancer

Circulating tumor cell/battery-associated gene pathology is a novel prognostic predictor in patients with breast cancer

Transmembrane protein 33 (TMEM33) induces apoptosis via UPR signaling and autophagy in breast cancer cells

The role of sentinel lymph node biopsy in patients with ductal carcinoma in situ. An updated meta-analysis involving 9803 patients

Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes (TILs) and residual cancer burden (RCB)

Circulating tumor cell/battery-associated gene pathology is a novel prognostic predictor in patients with breast cancer

Transmembrane protein 33 (TMEM33) induces apoptosis via UPR signaling and autophagy in breast cancer cells

Comparison of HER2, estrogen and progesterone receptor expression profiles of primary tumor, synchronous axillary lymph node metastases and circulating tumor cells in early breast cancer patients

Circulating tumor cells in triple-negative breast cancer patients express prostate related genes and show different genetic profiles in US and German patient cohorts

Development of a novel HER2 testing strategy, using image-based cell-sorting to isolate pure cell populations from FFPE upstream of FISH

Serum levels of RANKL are increased in primary breast cancer patients in the presence of disseminated tumor cells in the bone marrow

Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases

Feasibility and safety of avoiding granulocyte colony-stimulating factor prophylaxis during the paclitaxel portion of dose dense doxorubicin-cyclophosphamide and paclitaxel regimen

Ki67-positive CTCs are associated with early disease relapse in patients with early breast cancer undergoing adjuvant chemotherapy

Aurora kinase-A protein stability is negatively regulated by eEF1α2 and PTEN in breast cancer: Prognostic and therapeutic implications

Efficacy of compression therapy using surgical gloves for nanoparticle albumin-bound-paclitaxel-induced peripheral neuropathy: A phase II multicenter study by the Kamigata breast cancer study group

Development of photoacoustic vascular imaging system for breast cancer

Evaluation of contrast-enhanced ultrasoundography for early prediction of response to neoadjuvant chemotherapy in triple negative breast cancer

Aurora kinase A protein stability is negatively regulated by eEF1α2 and PTEN in breast cancer: Prognostic and therapeutic implications
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Presenting Author</th>
<th>Financial Disclosures</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1-09-05</td>
<td>The role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+/HR+ phase II trial evaluating 12-weeks of neoadjuvant TDM1± endocrine therapy (ET) versus T+ ET in HER2-positive hormone-receptor-positive early breast cancer (IBC)</td>
<td>Ronald Kates</td>
<td>Prof. Kates has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-10</td>
<td>Results of multigene assay (MammaPrint®) and molecular subtyping (BluePrint®) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIME decision impact study</td>
<td>Ronald Kates</td>
<td>Prof. Kates has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT1-02-05</td>
<td>Phase II clinical trial of neratinib in patients 60 and older with HER2 over-expressed or mutated breast cancer: Trial design considerations for older adults</td>
<td>Vani Katheria</td>
<td>Vani Katheria has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-07-13</td>
<td>Association of pre-chemotherapy peripheral blood pro-inflammatory (IL-6, CRP) and coagulation (D-dimer) markers with chemotherapy toxicity in women with breast cancer</td>
<td>Vani Katheria</td>
<td>Vani Katheria has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-07</td>
<td>Comparison of the Expert breast cancer strainer mRNA assay with central ER, PR, HER2, and 657 immunohistochemistry [IHC] for rapid biomarker analysis in developing countries</td>
<td>Greiner-Ferris Kathryn</td>
<td>Ms. Greiner-Ferris has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT2-03-01</td>
<td>Results of multigene assay (MammaPrint®) and molecular subtyping (BluePrint®) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIME decision impact study</td>
<td>Ronald Kates</td>
<td>Prof. Kates has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-06-10</td>
<td>Next generation sequencing (NGS) reveals high mutation rates in all established breast cancer subtypes with subtype-specific patterns</td>
<td>Vani Katheria</td>
<td>Vani Katheria has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S5-02</td>
<td>Efficacy of compression therapy using surgical gloves for nanoparticle albumin-bound-paclitaxel-induced peripheral neuropathy: A phase II multicenter study by the Kamigata breast cancer study group</td>
<td>Hironori Kato</td>
<td>Dr. Kato has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-07-07</td>
<td>CHER2 contributes to the generation of breast cancer stem cells through AKT</td>
<td>Kumi Kato</td>
<td>Ms. Kato has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-11-12</td>
<td>Be evaluating outcomes of partial-bread irradiation using multicatheter brachytherapy for Japanese patients with breast cancer by European brachytherapy phase 3 trial</td>
<td>Masahiro Kato</td>
<td>Dr. Kato has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT3-01-01</td>
<td>A phase II study of PD-11 and CTLA-4 inhibition and immunopharmacogenomics in metastatic breast cancer</td>
<td>Tago Kato</td>
<td>Taigo Kata has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-07-11</td>
<td>The impact of FOXA1 expression correlates to the luminal breast cancer stem cells</td>
<td>Toshiki Kato</td>
<td>Toshiki Kato has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-11-03</td>
<td>Difference between 1st and 2nd generation serotonine receptor antagonists in triplet antiemetic therapy for highly emetogenic chemotherapy in breast cancer patients - according to recent multi-institutional double-blind randomized clinical research on the AC regimen</td>
<td>Noriyuki Katsumata</td>
<td>Dr. Katsumata has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-06-07</td>
<td>Combination of doxorubicin with S1P signaling modulator FY2720 significantly suppressed obesity-associated breast cancer</td>
<td>Eriko Katsuta</td>
<td>Dr. Katsuta has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-06-12</td>
<td>Marine radition model for preclinical study of curative systemic therapies</td>
<td>Eriko Katsuta</td>
<td>Dr. Katsuta has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-04-13</td>
<td>Prostate tyrosine kinase 1 (PTK1) promotes survival of endocrine therapy-resistant ER breast cancer cells</td>
<td>Igor Katsyv</td>
<td>Igor Katsyv has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-12-11</td>
<td>Comprehensive genome profiling of 34 cases of breast angiocarcinoma</td>
<td>Daniella Katz</td>
<td>Dr. Katz has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-02-06</td>
<td>Genetic counseling, germline genetic testing, and impact of results in patients with newly diagnosed breast cancer</td>
<td>Steven Katz</td>
<td>Dr. Katz has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-11-07</td>
<td>Methylation of BRCA1 and response to the PARP inhibitor veliparib</td>
<td>Tiffany Katz</td>
<td>Dr. Katz has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-08-07</td>
<td>Anti-proliferative and anti-inflammatory estrogen receptor agents for treatment of endocrine-resistant breast cancer</td>
<td>John Katzenellenbogen</td>
<td>Dr. Katz has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
P2-04-19  Elucidating the tumor immune microenvironment phenotype in early stage untreated BRCA mutated breast cancer patients  Noah Kauff  Dr. Katz has no relevant financial relationships to disclose.

OT2-01-06  Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or capecitabine (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer  Bella Kaufman  Ms. Kaufman has no relevant financial relationships to disclose.

P4-22-02  Efficacy and tolerability of veliparib (V; ABT-888) in combination with capecitabine (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: A randomized, phase 2 study  Bella Kaufman  Ms. Kaufman has no relevant financial relationships to disclose.

P4-06-01  Patient der and DCS mouse-intraductal (MINID) models recapitulate the full spectrum of human patient pathology and histologic features including progression to invasion in a subset of cases  Carolyn Kaufman  Ms. Kaufman has no relevant financial relationships to disclose.

P3-05-06  Patient der and DCS mouse-intraductal (MINID) models recapitulate the full spectrum of human patient pathology and histologic features including progression to invasion in a subset of cases  Cary Kaufman  Dr. Kaufman has no relevant financial relationships to disclose.

P3-13-04  Use of an absorbable implant to mark the lumpectomy cavity: Initial report of 100 patients in a multi-center registry database  Cary Kaufman  Dr. Kaufman has no relevant financial relationships to disclose.

P3-13-20  Use of a 3-D bioabsorbable tissue marker in 51 patients over two years  Cary Kaufman  Dr. Kaufman has no relevant financial relationships to disclose.

P5-08-08  Breakthrough of liquid biopsy: Plasma DNA does not accurately reflect tumor DNA in metastatic breast cancer: A randomized, phase 2 study  Peter Kaufman  Mr. Kaufman has disclosed that he is a consultant for Genentech and has a contract with Genentech/Roche (paid to institution).

P5-08-27  Treatment patterns and clinical outcomes in patients with hormone receptor (HR)+ HER2+ metastatic breast cancer and low vs high levels of HR positivity from the SystHERs Registry  Peter Kaufman  Mr. Kaufman has disclosed that he is a consultant for Genentech and has a contract with Genentech/Roche (paid to his institution).

P4-07-10  Epithelial mesenchymal transition associated with high miR-221 and integrin β6 leads to poor prognosis in hormone receptor positive HER2 negative breast cancers  Roma Kaul  Ms. Kaul has no relevant financial relationships to disclose.

P1-08-01  Regulation of estrogen receptor-α by NF1  Megha Shyam Kavuri  Megha Shyam Kavuri has no relevant financial relationships to disclose.

P4-21-14  A randomized phase II trial of trastuzumab + bevacizumab versus lapatinib + bevacizumab in patients with HER2 positive metastatic breast cancer previously treated with trastuzumab and taxanes: WCOG1019/85.10TOP  Yohka Kawai  Dr. Kawada has no relevant financial relationships to disclose.

QT3-07-02  Influence of exercise or educational programs on long term physical activity by patients after surgery for primary breast cancer: A randomized trial  Kenichi Kawada  Mr. Kawada has no relevant financial relationships to disclose.

OT1-02-05  Phase II neoadjuvant trial of nanoparticle albumin-bound paclitaxel and trastuzumab in patients with node-negative, Her2 positive breast cancer (OMC-8034)  Kanako Kawaiuchi  Dr. Kawaguchi has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P4-01-10</td>
<td>Development of photoacoustic vascular imaging system for breast cancer</td>
<td>Nobuko Kawaguchi-Sakita</td>
<td>Ms. Kawaguchi-Sakita has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-11-05</td>
<td>Difference between 1st and 2nd generation serotonin receptor antagonists in triplet antiepileptic therapy for highly emetogenic chemotherapy in breast cancer patients</td>
<td>Yuko Kai</td>
<td>Dr. Kawai has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-01-17</td>
<td>The combination of preoperative computed tomography lymphography and intraoperative fluorescence imaging navigation for sentinel lymph node biopsy of early breast cancer patients</td>
<td>Masayasu Kawasaki</td>
<td>Dr. Kawasaki has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-01-10</td>
<td>Development of photoacoustic vascular imaging system for breast cancer</td>
<td>Kenjiro Kawashima</td>
<td>Mr. Kawashima has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-07-04</td>
<td>Detecting early breast cancer by the combination of five serum microRNAs and its possibility of prediction of pathological complete response in neoadjuvant chemotherapy</td>
<td>Kenjiro Kawashima</td>
<td>Dr. Kawashima has disclosed that he is an employee of Toray Industries, Inc., the provider of the 3D-Gene® system.</td>
</tr>
<tr>
<td>OT3-03-01</td>
<td>MADELINE: A prospective observational study of mobile app-based patient reported outcomes in advanced breast cancer</td>
<td>James Kaye</td>
<td>Dr. Kaye has disclosed that he is an employee of RTI Health Solutions which has received funding from Pfizer for this study.</td>
</tr>
<tr>
<td>P5-08-18</td>
<td>Treatment patterns and resource utilization among patients with HR+/HER2- metastatic breast cancer in a privately insured US population</td>
<td>James Kaye</td>
<td>Dr. Kaye has disclosed that RTI Health Solutions received funding from Eli Lilly and Company to conduct this research.</td>
</tr>
<tr>
<td>P5-08-19</td>
<td>Treatment patterns and resource utilization among elderly Medicare patients with HR+/HER2- metastatic breast cancer</td>
<td>James Kaye</td>
<td>Dr. Kaye has disclosed that RTI Health Solutions received funding from Eli Lilly and Company to conduct this research.</td>
</tr>
<tr>
<td>P3-11-05</td>
<td>The combination of preoperative computed tomography lymphography and intraoperative fluorescence imaging navigation for sentinel lymph node biopsy of early breast cancer patients</td>
<td>Masayasu Kawasaki</td>
<td>Dr. Kawasaki has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S2-04</td>
<td>RANK ligand as a target for breast cancer prevention in BRCA1 mutation carriers</td>
<td>KConFab Consortium</td>
<td>KConFab Consortium has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-21-13</td>
<td>The impact of the 21 gene recurrence score (RS) on chemotherapy prescribing in estrogen receptor (ER) positive, lymph node positive early stage breast cancer in Ireland</td>
<td>Meng Kai</td>
<td>Dr. Ke has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT3-04-03</td>
<td>Adjuvant treatment with ribonucleic acid (RNA) in stage II/III breast cancer: The AURIN trial (BIG 02/06): 10 year follow-up</td>
<td>Macson Keane</td>
<td>Dr. Keane has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-17-01</td>
<td>The impact of the 21 gene recurrence score (RS) on chemotherapy prescribing in estrogen receptor (ER) positive, lymph node positive early stage breast cancer in Ireland</td>
<td>Macson Keane</td>
<td>Dr. Keane has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT3-04-03</td>
<td>Adjuvant treatment with ribonucleic acid (RNA) in stage II/III breast cancer: The AURIN trial (BIG 02/06): 10 year follow-up</td>
<td>Macson Keane</td>
<td>Dr. Keane has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-09-10</td>
<td>The role of SERTA AZTMMk for treatment of hormone dependent metastatic breast cancer</td>
<td>Amina Kazi</td>
<td>Dr. Kazi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-11-08</td>
<td>Tumor and procedural factors associated with positive margins at lumpectomy in women undergoing breast conserving surgery</td>
<td>Gary Keeney</td>
<td>Dr. Keeney has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-11-08</td>
<td>Tumor and procedural factors associated with positive margins at lumpectomy in women undergoing breast conserving surgery</td>
<td>Michael Keeney</td>
<td>Dr. Keeney has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-11-05</td>
<td>Reliability and acceptance of e-based survey instruments for measuring patient reported outcomes (PROMs) in breast cancer patients: First results of the EPICOM study</td>
<td>Lucia Kellermann</td>
<td>Ms. Kellermann has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-01-01</td>
<td>Phase II in-human dose escalation study of the optical molecular imaging tracer bevacizumab-800cw for molecular fluorescence guided surgery in primary breast cancer patients</td>
<td>Wendy Kelder</td>
<td>Dr. Kelder has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
Ovarian reserve and response to controlled ovarian hyperstimulation (COH) in breast cancer women with and without BRCA mutation

Laura Keller

Dr. Keller has no relevant financial relationships to disclose.

Evaluating lymph node ratio (LR) as a prognostic indicator in node-positive breast cancer

Amy Kelkher

Ms. Kelkher has no relevant financial relationships to disclose.

The impact of the 21 gene recurrence score (RS) on chemotherapy prescribing in estrogen receptor (ER) positive, lymph node positive early stage breast cancer in Ireland

Catherine Kelly

Ms. Kelly has no relevant financial relationships to disclose.

DNA methylation landscapes of breast cancer progression to brain metastasis: A pre-clinical study

Daniel Kelly

Mr. Kelly has no relevant financial relationships to disclose.

High concordance of ER, PR, HER2 and Ki67 by central IHC and FISH with mRNA measurements by GeneXpert® breast cancer stratifier assay

Devin Kelly

Devin Kelly has no relevant financial relationships to disclose.

Heavily pre-treated breast cancer patients show promising responses in the first in human study of the first-In-class fatty acid synthase (FASN) inhibitor, TVB-2640 in combination with paclitaxel

George Kemble

Mr. Kemble has disclosed that he is an employee of 3-V Biosciences.

Efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial

Kathleen Kemmer

Dr. Kemmer has no relevant financial relationships to disclose.

The evaluation of ganitumab/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial

DiSean Kendall

DiSean Kendall has no relevant financial relationships to disclose.

Stomatitis in patients treated with first-line everolimus (EVE) plus letrozole (LET): Results from BOLERO-4 trial

Stephan Kendall

Stephan Kendall has no relevant financial relationships to disclose.

Efficacy of screening and treatment of breast cancer patients reporting high level of distress

Daneille Kendrick

Ms. Kendrick has no relevant financial relationships to disclose.

DBCG 07-READ: A randomized phase III trial comparing six cycles of docetaxel and cyclophosphamide (DC) to three cycles of epirubicin and cyclophosphamide followed by three cycles of docetaxel (DC-D) in patients with early breast cancer

Julia Kenholm

Dr. Kenholm has disclosed that she receives travel support from Celgene.

Age-related microRNAs and their biomarker potential in chemotherapy-treated older breast cancer patients

Cindy Kenis

Ms. Kenis has no relevant financial relationships to disclose.

A randomized, double-blind, phase 2 study of navitoclax (RUX) or placebo (PBO) in combination with capecitabine (CAPE) in patients (pts) with advanced HER2-negative breast cancer (ABC) and elevated C-reactive protein (CRP), a marker of systemic inflammation

Gerard Kennealey

Mr. Kennealey has disclosed that he is an employee and stockholder of Incyte Corporation.

The effects of treatment-induced symptoms, depression and age on sexuality in premenopausal women with early breast cancer receiving adjuvant endocrine therapy

Magen Kennedy

Magen Kennedy has no relevant financial relationships to disclose.

Randomized phase II study evaluating different schedules of nab-paclitaxel in metastatic breast cancer (MBC): Results of the SNAP study

John Kennedy

Mr. Kennedy has no relevant financial relationships to disclose.

The impact of the 21 gene recurrence score (RS) on chemotherapy prescribing in estrogen receptor (ER) positive, lymph node positive early stage breast cancer in Ireland

M Kennedy

M John Kennedy has no relevant financial relationships to disclose.

The impact of the 21 gene recurrence score (RS) on chemotherapy prescribing in estrogen receptor (ER) positive, lymph node positive early stage breast cancer in Ireland

M Kennedy

M John Kennedy has no relevant financial relationships to disclose.
| P3-09-02 | Unhealthy lifestyle patterns are prevalent in unaffected BRCA mutation carriers & are associated with increased oxidative stress and telomere length alterations | John Kennedy | John Kennedy has no relevant financial relationships to disclose. |
| P6-07-08 | The complete spectrum of 33% mutations from 790 breast cancer tumor samples. | Mark Kennedy | Kennedy has no relevant financial relationships to disclose. |
| P1-08-02 | Mutant GATA3 actively promotes the growth of normal and malignant mammary cells | Parak, Kerrey | Kennedy has no relevant financial relationships to disclose. |
| P1-10-03 | A randomized trial of accelerated breast radiotherapy utilizing either 3-dimensional radiotherapy or intensity modulated radiotherapy | Kercher | Kercher has no relevant financial relationships to disclose. |
| P5-02-06 | The impact of the introduction of breast cancer screening on a symptomatic breast cancer unit | Kerin | Kerin has no relevant financial relationships to disclose. |
| P6-04-01 | Engineering mesenchymal stem cells (MSCs) to secrete tumor-suppressing exosomes for breast cancer therapy | Kerin | Kerin has no relevant financial relationships to disclose. |
| P2-06-05 | Development and validation of a novel non-parametric breast cancer risk assessment model on US and European screening populations | Kerin, Kerloopskie | Kerin has no relevant financial relationships to disclose. |
| P3-01-01 | Comparative performance of surveillance mammography and breast MRI in women with a history of breast cancer | Kerin, Kerloopskie | Kerin has no relevant financial relationships to disclose. |
| P6-03-05 | Engineering mesenchymal stem cells (MSCs) to secrete tumor-suppressing exosomes for breast cancer therapy | Kerin | Kerin has no relevant financial relationships to disclose. |
| P1-05-29 | Development and validation of a novel non-parametric breast cancer risk assessment model on US and European screening populations | Kerin, Kerin | Kerin has no relevant financial relationships to disclose. |
| P5-09-01 | Development and validation of a non-parametric breast cancer risk score and mammographic density predicts interval cancers | Kerin, Kerin | Kerin has no relevant financial relationships to disclose. |
| P2-13-10 | BRCA2: identification of BRCA2 mutations in a group of patients with breast cancer | Kerkman | Kerkman has no relevant financial relationships to disclose. |
| P1-12-01 | Breast cancer after Hodgkin lymphoma: Influence of endogenous and exogenous gonadal hormones on the radiation dose-response relationship | Kesminiene | Kesminiene has no relevant financial relationships to disclose. |
| P3-12-05 | Prospective association between breast cancer risk and an individual dietary index based on the British Food Standards Agency nutrient profiling system | Kesminiene | Kesminiene has no relevant financial relationships to disclose. |
| P3-04-06 | ER reactivation rapidly elicits cell death effects in anti-estrogen-resistant breast cancer | Kesminiene | Kesminiene has no relevant financial relationships to disclose. |
| S4-07 | BELLE-3: A phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2-, aromatase inhibitor-treated, locally advanced or recurrent breast cancer (CRUK/17/012) | Lee, Keun | Lee, Keun has no relevant financial relationships to disclose. |
| P3-08-01 | TruRisk® based next-generation sequencing in BRCA1/2-negative breast and ovarian cancer families reveal high mutation prevalence in additional risk genes | Keupp | Keupp has no relevant financial relationships to disclose. |
| P3-09-03 | Low-level germline mosaicism of a de novo BRCA1/2 gene mutations: The origin of a constitutional mutation in a breast cancer family | Keupp | Keupp has no relevant financial relationships to disclose. |
| P1-05-29 | Genomic variants in 5 male breast cancers using whole exome sequencing | Keupp, Keupp | Keupp has no relevant financial relationships to disclose. |
NRG oncology/NSABP B-51/RTOG 1304: A phase III superiority clinical trial designed to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) will reduce invasive cancer events in patients (pts) with positive axillary (Ax) nodes and convert to ypN0 after neoadjuvant chemotherapy (NC).

Atif Khan
Atif Khan has no relevant financial relationships to disclose.

Comparison of survival and clinicopathological features between patients with breast cancer and HIV infection versus breast cancer without HIV infection.

Hina Khan
Dr. Khan has no relevant financial relationships to disclose.

Comparison of survival and clinicopathological features between patients with breast cancer and HIV infection versus breast cancer without HIV infection.

Hina Khan
Dr. Khan has no relevant financial relationships to disclose.

Time differences in breast cancer diagnosis among minorities in a large referral academic center.

Hina Khan
Dr. Khan has no relevant financial relationships to disclose.

Femara plus ribociclib or placebo as neo-adjuvant endocrine therapy for women with ER+, HER2-negative early breast cancer - The Feline trial

Qamar Khan
Dr. Khan has disclosed that he is a consultant for Genentech and a speaker for Pfizer. He has also disclosed that he has investigator initiated trials funded by Novartis.

Pathological complete response is associated with excellent outcomes in BRCA mutation associated triple negative breast cancer.

Qamar Khan
Dr. Khan has no relevant financial relationships to disclose.

Safety and efficacy results from phase I study of BRI 719 plus nab-paclitaxel in HER2 negative metastatic breast cancer

Qamar Khan
Dr. Khan has disclosed that he is a consultant for Genentech and a speaker for Pfizer. He has also disclosed that he has a contract with Novartis.

Phase II pre-surgical window trial of talapostine acetate (TPA) in early breast cancer and DCIS patients: Distribution of TPA in plasma, normal breast tissue and tumors

Seema Khan
Dr. Khan has no relevant financial relationships to disclose.

Impact of magnetic resonance imaging on conversion from wide local excision to mastectomy in patients with ductal carcinoma in situ: First results from the ECOG-AACR 4112 prospective study

Seema Khan
Dr. Khan has no relevant financial relationships to disclose.

Expression of miR-32a and miR-253 in normal breast tissue at candidate markers of breast cancer risk

Seema Khan
Dr. Khan has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Title</th>
<th>Author</th>
<th>Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prediction of 10yr distant recurrence (DR) using the Prosigna® (PAM50) assay in histological subgroups of a Danish breast cancer group (BRG) cohort of postmenopausal Danish women with hormone receptor-positive (HR+) early breast cancer (EBC) allocated to 5yr of endocrine therapy (ET) alone</td>
<td>Torben Kilbøl</td>
<td>Torben Kilbøl has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Development of a panel of serum-based protein biomarkers for the non-invasive detection of breast cancer in BI-RADS category 4 patients</td>
<td>Jennifer Kild</td>
<td>Ms. Kild has disclosed that she receives salary from and has ownership in OncusCyte Corporation.</td>
</tr>
<tr>
<td>A randomized phase II neoadjuvant study comparing docetaxel and cyclophosphamide (TC) with 5-fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel (FEC-D) for hormone receptor-negative breast cancer: The Kanagawa breast oncology group (KBOG) 1101 study</td>
<td>Kimiko Kida</td>
<td>Dr. Kida has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Trends in age of breast cancer diagnosis for women with pathogenic variants in genes associated with increased breast cancer risk</td>
<td>Jennifer Kidd</td>
<td>Ms. Kidd has disclosed that she receives salary from and has ownership in OncoCyte Corporation.</td>
</tr>
<tr>
<td>Genetic testing for HBOC among women with a personal diagnosis of breast cancer in patients with Medicaid as compared to patients with private insurance</td>
<td>John Kild</td>
<td>Mr. Kild has disclosed that he receives salary and has ownership.</td>
</tr>
<tr>
<td>Effect of aromatase inhibitor (AI) therapy on sleep and activity patterns in early stage breast cancer</td>
<td>Kelley Kidwell</td>
<td>Dr. Kidwell has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Inducing immune responses to tumour-associated carbohydrate antigens by a carbohydrate mimetic peptide vaccine: Clinical experience in phase I and phase II trials</td>
<td>Thomas Kider-Emmons</td>
<td>Dr. Kider-Emmons has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Tissue kallikrein-related peptidase 4, a novel biomarker in triple-negative breast cancer</td>
<td>Marion Kiechle</td>
<td>Prof. Kiechle has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Pre-clinical antitumor activity, tumor localization, and pharmacokinetics of MPP27, an apoptosis inducing, biotargeting HER2-targeting DARPin®</td>
<td>Joel Chem</td>
<td>Dr. Chem has disclosed that he receives salary and has ownership.</td>
</tr>
<tr>
<td>Development of a recurrence risk stratification schema to inform treatment decisions in breast cancer patients undergoing mastectomy with 1-3 positive nodes</td>
<td>Douglas Kieper</td>
<td>Mr. Kieper has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Genetic variation in CYP3A affects steady-state exemestane concentrations but does not explain inter-race difference</td>
<td>Kelley Kidwell</td>
<td>Dr. Kidwell has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Inducing immune responses to tumour-associated carbohydrate antigens by a carbohydrate mimetic peptide vaccine: Clinical experience in phase I and phase II trials</td>
<td>Thomas Kider-Emmons</td>
<td>Dr. Kider-Emmons has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Radiology therapy in 1-3 node positive mastectomy patients: Who benefits?</td>
<td>Douglas Kepner</td>
<td>Mr. Kepner has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Efficacy of compression therapy using surgical gloves for nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: A phase II multicenter study by the Kamigata breast cancer study group</td>
<td>Yachihiro Kikawai</td>
<td>Dr. Kikawai has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Circulating tumour DNA analysis to predict relapse and overall survival in early breast cancer: Longer follow-up of a proof-of-principle study</td>
<td>Lucy Kilburn</td>
<td>Dr. Kilburn has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Circulating tumour DNA analysis to predict relapse and overall survival in early breast cancer: Longer follow-up of a proof-of-principle study</td>
<td>Lucy Kilburn</td>
<td>Dr. Kilburn has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Omitting radiotherapy in women ≥ 65 years with early breast cancer and favorable histopathology after breast-conserving surgery, sentinel node biopsy and adjuvant endocrine therapy is safe</td>
<td>Fredrika Killander</td>
<td>Dr. Killander has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Socioeconomic disparities in needle biopsy prior to breast cancer surgery across physician referral networks</td>
<td>Brigid Kilkease</td>
<td>Dr. Kilkease has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
Selinexor, a selective inhibitor of nuclear export, demonstrates efficacy in preclinical models of triple negative breast cancer. Dr. Kim has no relevant financial relationships to disclose.

The metastatic breast cancer project: Translational genomics through direct patient engagement. Dr. Kim has no relevant financial relationships to disclose.

Whole exome and transcriptome sequencing of resistant ER+ metastatic breast cancer. Dr. Kim has no relevant financial relationships to disclose.

Up-regulation of SPARC is associated with breast tumor progression and epithelial SPARC expression is correlated with poor survival and MMP-2 expression in patients with breast carcinoma. Ga-Eon Kim has no relevant financial relationships to disclose.

The metastatic breast cancer project: Translational genomics through direct patient engagement. Dr. Kim has no relevant financial relationships to disclose.

Breast cancer patients after kidney and liver transplantation: A report from Asan medical center. Dr. Kim has no relevant financial relationships to disclose.

Conditional disease-free survival among patients with breast cancer: A matched case control study. Dr. Kim has no relevant financial relationships to disclose.

Impact of radical mastectomy on complications and patient-reported satisfaction with breast reconstruction: Findings from the prospective multicenter MROC study. Dr. Kim has no relevant financial relationships to disclose.

Examining time to degeneration as a side effect of treatment in premenopausal breast cancer patients. Dr. Kim has no relevant financial relationships to disclose.

Interaction between body mass index and hormone receptor status as a prognostic factor in node-positive breast cancer. Dr. Kim has no relevant financial relationships to disclose.

Diffuse optical tomography can predict pathologic complete response in patients with HER2+ or triple negative breast cancer undergoing neoadjuvant chemotherapy. Dr. Kim has no relevant financial relationships to disclose.

Impact of radiation therapy on complications and patient-reported satisfaction with breast reconstruction: Findings from the prospective multicenter MROC study. Dr. Kim has no relevant financial relationships to disclose.

Impact of young age on recurrence and mortality after surgery in breast cancer: 15 years active surveillance. Dr. Kim has no relevant financial relationships to disclose.

The PROCEED trial KCSG BR11-01 phase III multicenter randomized open-label study of irinotecan plus capecitabine versus capecitabine in patients previously treated with anthracycline and taxane for HER2 negative metastatic breast cancer. Dr. Kim has no relevant financial relationships to disclose.

Oncologic outcomes of immediate breast reconstruction after neoadjuvant chemotherapy in breast cancer patients: A matched case control study. Dr. Kim has no relevant financial relationships to disclose.

The PROCEED trial KCSG BR11-01 phase III multicenter randomized open-label study of irinotecan plus capecitabine versus capecitabine in patients previously treated with anthracycline and taxane for HER2 negative metastatic breast cancer. Dr. Kim has no relevant financial relationships to disclose.

A phase II, multicenter, randomized trial of entinostat plus gemcitabine (EG) vs. paclitaxel plus gemcitabine (PG) in patients with HER2-negative metastatic breast cancer as first-line chemotherapy. Gun Min Kim has no relevant financial relationships to disclose.

Breast cancer patients after kidney and liver transplantation: A report from Asan medical center. Dr. Kim has no relevant financial relationships to disclose.

NRG oncology/RTOG 1119: Phase II randomized study of whole brain radiotherapy with concurrent lapatinib in patients with brain met from HER2-positive breast cancer — A collaborative study of RTOG & KROG (NCT01622868). Dr. Kim has no relevant financial relationships to disclose.

Study on the usefulness of the skin wound therapeutic agent 'Neo dermal activator' in breast cancer surgery. Dr. Kim has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Author</th>
<th>Affiliation</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1-02-14</td>
<td>Circulating cell-free DNA (cfDNA) measured by a simple fluorescent assay to predict relapse in triple negative breast cancer patients receiving neoadjuvant chemotherapy: A biomarker substudy of prospective observational study (NCT013001519, NCT01201506)</td>
<td>Jeong Eun Kim</td>
<td></td>
<td>Dr. Kim has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-06-08</td>
<td>The role and regulation mechanism of HOXB5 in human breast cancer cells</td>
<td>Jie Min Kim</td>
<td></td>
<td>Dr. Kim has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-05-15</td>
<td>Multi-omics and immune-omics profiling reveal distinct molecular signatures of young Asian breast cancer patients</td>
<td>Jinho Kim</td>
<td></td>
<td>Dr. Kim has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-02-11</td>
<td>Clinical utility of serial monitoring of circulating tumor DNA (ctDNA) in patients with neoadjuvant chemotherapy (NAC) for locally advanced breast cancer (LABC)</td>
<td>Ji-Yeon Kim</td>
<td></td>
<td>Dr. Kim has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-05-15</td>
<td>Multi-omics and immune-omics profiling reveal distinct molecular signatures of young Asian breast cancer patients</td>
<td>Ji-Yeon Kim</td>
<td></td>
<td>Dr. Kim has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-50</td>
<td>Impact of young age on recurrence and mortality after surgery in breast cancer: 15 years active surveillance</td>
<td>Ji-Yeon Kim</td>
<td></td>
<td>Dr. Kim has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-07-19</td>
<td>An alteration of hormonal receptor status throughout tumor progression related to prognosis in breast cancer patients</td>
<td>Jie Min Kim</td>
<td></td>
<td>Dr. Kim has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT2-04-01</td>
<td>Study on the usefulness of the skin wound therapeutic agent Neo dermal activator in breast cancer surgery</td>
<td>Joo Heung Kim</td>
<td></td>
<td>Dr. Kim has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-02-05</td>
<td>Prognostic role of PIK3CA mutational status in circulating tumor DNA (ctDNA) from HER2-positive metastatic breast cancer patients</td>
<td>Jung-Eun Kim</td>
<td></td>
<td>Dr. Kim has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-05-31</td>
<td>Studying the interactome of breast cancer: The cancer cell map initiative</td>
<td>Kyumin Kim</td>
<td></td>
<td>Dr. Kim has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-08-28</td>
<td>Incidence of germline BRCA1- and BRCA2-mutated breast cancer in the US</td>
<td>Raymond Wee Kim</td>
<td></td>
<td>Dr. Kim has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-07-12</td>
<td>An exploratory correlative biomarker analysis of NSABP BR-7, a phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel (P) plus neratinib (N) or trastuzumab (T) or neratinib and trastuzumab (N+T) followed by doxorubicin and cyclophosphamide (AC) with postoperative T in women with locally advanced HER2-positive breast cancer</td>
<td>Phillip Wee Kim</td>
<td></td>
<td>Dr. Kim has disclosed that he is a full-time employee of DiaTech Oncology.</td>
</tr>
<tr>
<td>P3-09-05</td>
<td>Clinical outcome of patients with advanced triple negative breast cancer with germline and somatic variants in homologous recombination gene</td>
<td>Bush Wee Kim</td>
<td></td>
<td>Dr. Kim has disclosed that he is an employee of Medivation, Inc.</td>
</tr>
<tr>
<td>P2-07-07</td>
<td>Comparison of survival and clinicopathological features between patients with breast cancer and HIV infection versus breast cancer without HIV infection</td>
<td>Ryung Wee Kim</td>
<td></td>
<td>Dr. Kim has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT1-01-12</td>
<td>A phase II, multicenter, randomized trial of eribulin plus gemcitabine (EG) vs. paclitaxel plus gemcitabine (PG) in patients with HER2-negative metastatic breast cancer as first-line chemotherapy</td>
<td>Se Hyun Wee Kim</td>
<td></td>
<td>Dr. Kim has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-11-10</td>
<td>Clinical applications of near infra-red imaging system for localization of non-palpable breast lesions in breast conserving surgery</td>
<td>Seok Ki Kim</td>
<td></td>
<td>Dr. Kim has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
Cobimetinib (C) combined with paclitaxel (P) as a first-line treatment in patients (pts) with advanced triple-negative breast cancer (COLET study): updated clinical and biomarker results

Sung-Bae Kim
Dr. Kim has no relevant financial relationships to disclose.

The PROCEED trial KCSG BR11-01 phase III multicenter randomized open-label study of irinotecan plus capecitabine versus capecitabine in patients previously treated with anthracycline and taxane for HER2-negative metastatic breast cancer

Tae-Yong Kim
Dr. Kim has no relevant financial relationships to disclose.

Prognostic role of PIK3CA mutational status in circulating tumor DNA (ctDNA) from HER2-positive metastatic breast cancer patients

Tae-Yong Kim
Dr. Kim has no relevant financial relationships to disclose.

Prognostic role of PIK3CA mutational status in circulating tumor DNA (ctDNA) from HER2-positive metastatic breast cancer patients

Tae-Yong Kim
Dr. Kim has no relevant financial relationships to disclose.

The prognostic impact of inositol polyphosphate 5-phosphatase PI5P (INPP5J) expression in breast cancer tissue

Tae-Sun Kim
Dr. Kim has no relevant financial relationships to disclose.

A phase II, multicenter, randomized trial of eribulin plus gemcitabine (EG) vs. paclitaxel plus gemcitabine (PG) in patients with HER2-negative metastatic breast cancer as first-line chemotherapy

Tae-Yong Kim
Dr. Kim has no relevant financial relationships to disclose.

The prognostic impact of inositol polyphosphate 5-phosphatase PI5P (INPP5J) expression in breast cancer tissue

Tae-Sun Kim
Dr. Kim has no relevant financial relationships to disclose.

Prognostic role of PIK3CA mutational status in circulating tumor DNA (ctDNA) from HER2-positive metastatic breast cancer patients

Tae-Yong Kim
Dr. Kim has no relevant financial relationships to disclose.

Prognostic role of PIK3CA mutational status in circulating tumor DNA (ctDNA) from HER2-positive metastatic breast cancer patients

Tae-Yong Kim
Dr. Kim has no relevant financial relationships to disclose.

An alteration of hormonal receptor status throughout tumor progression related to prognosis in breast cancer patients

Yumi Kim
Dr. Kim has no relevant financial relationships to disclose.

Development of prediction model for omission of sentinel lymph node biopsy in T1 breast cancer

Yun Ju
Dr. Kim has no relevant financial relationships to disclose.

HER2 status remains the primary predictor of improved survival in patients with BCBM over the past 2 decades (1996-2015)

Blackwell Kimberly
Dr. Kimberly has no relevant financial relationships to disclose.

A randomized trial of 15 fraction vs 25 fraction pencil beam scanning proton radiotherapy after mastectomy in patients requiring regional nodal irradiation

Carlen Kimberly
Dr. Kimberly has no relevant financial relationships to disclose.

Joint influence by paracrine adipocyte signals and metabolic conditions on breast cancer

Siker Kimburg
Dr. Kimburg has no relevant financial relationships to disclose.

Atorvastatin insensitivity is associated with increased lipid droplets accumulation and fatty acid metabolism in breast cancer cells

Siker Kimburg
Dr. Kimburg has no relevant financial relationships to disclose.

Changes in the gut microbiome of post-menopausal women 2 weeks after initiating a structured weight loss intervention

Bruce Kimler
Dr. Kimler has no relevant financial relationships to disclose.

Pathological complete response is associated with excellent outcomes in BRCA mutation associated triple negative breast cancer

Bruce Kimler
Dr. Kimler has no relevant financial relationships to disclose.

Elucidating the tumor immune microenvironment phenotype in early stage untreated BRCA-mutated breast cancer patients

Gretchen Kimmick
Dr. Kimmick has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Author</th>
<th>Financial Relationship Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1-01-09</td>
<td>Comparison of HER2, estrogen and progesterone receptor expression profiles of primary tumor, synchronous axillary lymph node metastases and circulating tumor cells in early breast cancer patients</td>
<td>Rainer Kimmig</td>
<td>Mr. Kimmig has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-02-19</td>
<td>Circulating tumor cells in triple-negative breast cancer patients express prostate related genes and show different genetic profiles in US and German patient cohorts</td>
<td>Rainer Kimmig</td>
<td>Mr. Kimmig has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-07-11</td>
<td>Serum levels of RANKL are increased in primary breast cancer patients in the presence of disseminated tumor cells in the bone marrow</td>
<td>Rainer Kimmig</td>
<td>Mr. Kimmig has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-21-14</td>
<td>A randomized phase II trial of trastuzumab + capecitabine versus lapatinib + capecitabine in patients with HER2 positive metastatic breast cancer previously treated with trastuzumab and letrozole: WJOG6110B/ELTOP</td>
<td>Hideharu Kimura</td>
<td>Dr. Kimura has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>QT1-02-05</td>
<td>Phase II neoadjuvant trial of nanoparticles albumin-bound paclitaxel and trastuzumab in patients with node-negative, HER2+ positive breast cancer (OMC-BC04)</td>
<td>Kosei Kimura</td>
<td>Dr. Kimura has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-01-04</td>
<td>Potential clinical application of mammography conducted immediately after contrast enhanced CT as contrast enhanced subtraction mammography</td>
<td>Paul Kinahan</td>
<td>Mr. Kinahan has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-16-24</td>
<td>Prognostic factors after neoadjuvant chemotherapy in breast cancer: Surgery type as a new prognostic factor</td>
<td>Tari King</td>
<td>Dr. King has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-02-05</td>
<td>Test-retest fidelity of FDG SUVmax in bone and non-bony metastatic breast cancer lesions in local area network PET/CT scanners</td>
<td>Andrew Kincaid</td>
<td>Mr. Kincaid has disclosed that he receives salary from and has ownership in Avagen, Inc.</td>
</tr>
<tr>
<td>P2-03-10</td>
<td>A fit-for-purpose NGS system that reports ERBB2 (HER2) mutations and copy number variants for clinical trials research and drug development</td>
<td>Jeff King</td>
<td>Mr. King has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-45</td>
<td>Long-term follow-up of early stage breast cancer patients with results of MammaPrint™, Oncotype DX™ and MammoPrint™ risk classification assay</td>
<td>Lorraine King</td>
<td>Dr. King has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-05-30</td>
<td>Genomic and microenvironmental intra-tumor heterogeneity in DCIS</td>
<td>Paul King</td>
<td>Dr. King has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-06-06</td>
<td>Evidence for tumor heterogeneity and clonal evolution during invasive progression of breast cancer</td>
<td>Madeleine King</td>
<td>Dr. King has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-14-01</td>
<td>International validation of the EORTC patient-reported outcome measure (PROM) in breast reconstruction (BR) The EORTC QLC-C30/BR23 evaluating the psychometric properties and clinical effectiveness</td>
<td>Madeleine King</td>
<td>Dr. King has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-01-06</td>
<td>Patterns of axillary evaluation in older patients (pts) with breast cancer and impact on adjuvant therapy</td>
<td>Madeleine King</td>
<td>Dr. King has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-09-23</td>
<td>SETLLOW - A robust 18-gene predictor of sensitivity to endocrine therapy in metastatic breast cancer</td>
<td>Tari King</td>
<td>Dr. King has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-56</td>
<td>Multiple-gene panel testing for hereditary cancer risk reveals a racial/ethnic disparity in genetic information</td>
<td>Kerry Kingham</td>
<td>Kerry Kingham has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-07-15</td>
<td>Treatment with a Lumos demethylase inhibitor JIB-04 sensitizes resistant breast cancer cells to chemotherapeutic drugs in an in vitro model of intrinsic resistance</td>
<td>Naoe Kinoshita</td>
<td>Ms. Kinoshita has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-01-11</td>
<td>Validation of novel diagnostic kits using the semi-dry dot-blot method for detecting metastatic lymph nodes in breast cancer; distinguishing macrometastases and micrometastases</td>
<td>Takayuki Kinoshita</td>
<td>Dr. Kinoshita has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-13-17</td>
<td>A multi-center prospective study of radiofrequency ablation therapy for small breast carcinomas</td>
<td>Takanori Kin</td>
<td>Dr. Kin has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>

*ERBB2 (HER2)*

*SETL* - A robust 18-gene predictor of sensitivity to endocrine therapy in metastatic breast cancer

*SETLLOW* - A robust 18-gene predictor of sensitivity to endocrine therapy in metastatic breast cancer

*Surgical Considerations in Patients Receiving Neoadjuvant Therapy*
Detecting early breast cancer by the combination of five serum microRNAs and its possibility of prediction of pathological complete response in neoadjuvant chemotherapy

Takayuki Kinoshita
Dr. Kinoshita has no relevant financial relationships to disclose.

Selective use of MRI and impact on management in breast cancer

Robert Kirby
Mr. Kirby has no relevant financial relationships to disclose.

Race and age differences in PAM50 biomarker status in the Carolina breast cancer study

Erin Kirk
Erin Kirk has no relevant financial relationships to disclose.

Pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: Efficacy analysis of a phase II cardiac safety study (TRYPHENA)

Sarah Kirk
Ms. Kirk has disclosed that she receives salary from Roche Products Ltd and owns Roche stock.

The PI3K inhibitor, taselisib, has enhanced potency in PIK3CA mutant models through a unique mechanism of action

Donald Kirkpatrick
Mr. Kirkpatrick has disclosed that he receives salary from Genentech, Inc.

Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer

Kenneth Kist
Dr. Kist has no relevant financial relationships to disclose.

Novel visualization tools to search ongoing clinical trials and track trial results for metastatic breast cancer

Keshan Kissoon
Keshan Kissoon has no relevant financial relationships to disclose.

Difference between 1st and 2nd generation serotonin receptor antagonists in triplet antiemetic therapy for highly emetogenic chemotherapy in breast cancer patients - according to recent multi-institutional double-blind randomized clinical research on the AC regimen

Toshiaki Kitabatake
Dr. Kitabatake has no relevant financial relationships to disclose.

The clinical importance of nuclear wild-type p53-induced phosphatase 1(Wip1) expression in breast cancer patients

Hiroyuki Kitao
Shigehisa Kitano has no relevant financial relationships to disclose.

The non-invasive treatment for sentinel lymph node metastasis by photodynamic therapy using a verteporfin solubilized phospholipid polymer aggregate

Toshiki Kita
Dr. Kita has no relevant financial relationships to disclose.

PD-L1 expression and decreased tumor-infiltrating lymphocytes are associated with poor prognosis in patients with triple negative breast cancer

Junji Kishimoto
Junji Kishimoto has no relevant financial relationships to disclose.

Difference of immune microenvironment between primary and recurrent tumours in breast cancer patients

Shigeo Kitano
Shigeo Kitano has no relevant financial relationships to disclose.

PD-L1 expression and decreased tumor-infiltrating lymphocytes are associated with poor prognosis in patients with triple negative breast cancer

Jonathan Kish
Mr. Kish has disclosed that he receives salary from Cardinal Health.

Early utilisation pattern of palbociclib 1 year post-approval in the United States

Jonathan Kish
Mr. Kish has disclosed that he receives salary from Cardinal Health.

Difference between 1st and 2nd generation serotonin receptor antagonists in triplet antiemetic therapy for highly emetogenic chemotherapy in breast cancer patients - according to recent multi-institutional double-blind randomized clinical research on the AC regimen

Toshiaki Kitabatake
Dr. Kitabatake has no relevant financial relationships to disclose.

The non-invasive treatment for sentinel lymph node metastasis by photodynamic therapy using a verteporfin solubilized phospholipid polymer aggregate

Toshiki Kita
Dr. Kita has no relevant financial relationships to disclose.

The clinical importance of nuclear wild-type p53-induced phosphatase 1(Wip1) expression in breast cancer patients

Hiroyuki Kitao
Shigehisa Kitano has no relevant financial relationships to disclose.

Difference of immune microenvironment between primary and recurrent tumours in breast cancer patients

Shigeo Kitano
Shigeo Kitano has no relevant financial relationships to disclose.

PD-L1 expression and decreased tumor-infiltrating lymphocytes are associated with poor prognosis in patients with triple negative breast cancer

Junji Kishimoto
Junji Kishimoto has no relevant financial relationships to disclose.

Difference of immune microenvironment between primary and recurrent tumours in breast cancer patients

Shigeo Kitano
Shigeo Kitano has no relevant financial relationships to disclose.

PD-L1 expression and decreased tumor-infiltrating lymphocytes are associated with poor prognosis in patients with triple negative breast cancer

Junji Kishimoto
Junji Kishimoto has no relevant financial relationships to disclose.

Difference of immune microenvironment between primary and recurrent tumours in breast cancer patients

Shigeo Kitano
Shigeo Kitano has no relevant financial relationships to disclose.

PD-L1 expression and decreased tumor-infiltrating lymphocytes are associated with poor prognosis in patients with triple negative breast cancer

Junji Kishimoto
Junji Kishimoto has no relevant financial relationships to disclose.

Difference of immune microenvironment between primary and recurrent tumours in breast cancer patients

Shigeo Kitano
Shigeo Kitano has no relevant financial relationships to disclose.

PD-L1 expression and decreased tumor-infiltrating lymphocytes are associated with poor prognosis in patients with triple negative breast cancer

Junji Kishimoto
Junji Kishimoto has no relevant financial relationships to disclose.

PD-L1 expression and decreased tumor-infiltrating lymphocytes are associated with poor prognosis in patients with triple negative breast cancer

Junji Kishimoto
Junji Kishimoto has no relevant financial relationships to disclose.

Difference of immune microenvironment between primary and recurrent tumours in breast cancer patients

Shigeo Kitano
Shigeo Kitano has no relevant financial relationships to disclose.

PD-L1 expression and decreased tumor-infiltrating lymphocytes are associated with poor prognosis in patients with triple negative breast cancer

Junji Kishimoto
Junji Kishimoto has no relevant financial relationships to disclose.

Difference of immune microenvironment between primary and recurrent tumours in breast cancer patients

Shigeo Kitano
Shigeo Kitano has no relevant financial relationships to disclose.

PD-L1 expression and decreased tumor-infiltrating lymphocytes are associated with poor prognosis in patients with triple negative breast cancer

Junji Kishimoto
Junji Kishimoto has no relevant financial relationships to disclose.

Difference of immune microenvironment between primary and recurrent tumours in breast cancer patients

Shigeo Kitano
Shigeo Kitano has no relevant financial relationships to disclose.
P2-01-11 SentimagIC: A non-inferiority trial comparing superparamagnetic iron oxide vs. Tc99 and blue dye in the detection of axillary sentinel nodes in patients with early stage breast cancer
Kaisa Kivilaid
Kaisa Kivilaid has disclosed that she is a consultant for trial operations.

OT3-07-02 Long-term recurrence risk and risk-based follow-up after breast cancer treatment: A randomized trial
Sachiko Kyotani
Ms. Kyotani has no relevant financial relationships to disclose.

P6-09-54 Influence of exercise or educational programs on long-term physical activity by patients after surgery for primary breast cancer: A randomized trial
Joost Klaase
Dr. Klaase has no relevant financial relationships to disclose.

P1-09-02 Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GePaSixto in triple-negative early breast cancer
Peter Klare
Dr. Klare has no relevant financial relationships to disclose.

P2-11-01 Non-interventional study with netupitant/ palonosetron (NEPA) as CINV prophylaxis in highly or moderately emetogenic chemotherapy
Peter Klare
Dr. Klare has no relevant financial relationships to disclose.

P6-13-02 Radiosurgery seed localization versus wire guided localization of nonpalpable invasive and in situ breast cancer: A Danish multicenter randomized controlled trial
Thomas Klausen
Dr. Klausen has no relevant financial relationships to disclose.

P4-03-03 Microenvironmnet induced DDR2 mediates stromal-cancer interactions and metastasis growth in breast cancer
Sonia Klein
Dr. Klein has no relevant financial relationships to disclose.

P2-03-02 Highly reproducible decentralized gene expression analysis of DDR1, DDR2, ERBB2 and MKI67 by central IHC and FISH with mRNA measurements by Genescope ICN breast cancer stratifier assay
Jonathan Klein
Dr. Klein has no relevant financial relationships to disclose.

S1-09-17 Study of oncotype DX® recurrence score in bilateral synchronous primary invasive breast cancer
Paula Klein
Dr. Klein has disclosed that she has contracts with Eli-Lilly, Roche Laboratories, PrECOG, LLC and Genentech.

P6-09-31 Change in the gut microbiome of post-menopausal women 2 weeks after initiating a structured weight loss intervention
Jennifer Klemp
Dr. Klemp has no relevant financial relationships to disclose.
Jennifer Klemp  
Dr. Knauer has no relevant financial relationships to disclose.

P2.03-03  Molecular differences between screen-detected and interval breast cancers are largely explained by PAM50 subtypes  
Daniel Klevening  
Dr. Klevening has no relevant financial relationships to disclose.

P5.11-19  Sexual functioning among breast cancer survivors and their partners: A pilot study  
Suzanne Kimberg  
Dr. Kimberg has no relevant financial relationships to disclose.

P5.13-10  A patient centered intervention for adaptation of cancer risk reduction guidelines in breast cancer survivors  
Amanda Klimischek  
Ms. Klimischek has no relevant financial relationships to disclose.

P5.08-20  Clinical utility of TGF with various cutoffs using 1 commercial assays relative to 15yr survival  
Alexander Klimeszcz  
Dr. Klimeszcz has no relevant financial relationships to disclose.

P2.04-10  High-affinity activated natural killer (haNK) cells augment trastuzumab efficacy in a mouse model of HER2 positive human metastatic breast cancer  
Hans Klingemann  
Mr. Klingemann has disclosed that he receives salary from, and has ownership in NextKest.

P5.13-08  Preclinical validation of a new tumor imaging agent targeting αvβ3 to detect breast tumor using high-light imaging  
Sophie Klinger  
Ms. Klinger has no relevant financial relationships to disclose.

P2.04-20  A phase I study of AZD9496, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC)  
Teresa Klinowska  
Ms. Klinowska has disclosed that she receives salary and has ownership.

P5.16-02  Pathological complete response is associated with excellent outcomes in BRCA mutation associated triple negative breast cancer  
Jennifer Kemp  
Dr. Kemp has no relevant financial relationships to disclose.

P5.04-05  Survivorship care planning is associated with breast cancer survivors’ reported quality and coordination of care  
Jennifer Kemp  
Dr. Kemp has no relevant financial relationships to disclose.

P5.03-03  Molecular differences between screen-detected and interval breast cancers are largely explained by PAM50 subtypes  
Daniel Klevening  
Dr. Klevening has no relevant financial relationships to disclose.

P5.11-19  Sexual functioning among breast cancer survivors and their partners: A pilot study  
Suzanne Kimberg  
Dr. Kimberg has no relevant financial relationships to disclose.

P5.13-10  A patient centered intervention for adaptation of cancer risk reduction guidelines in breast cancer survivors  
Amanda Klimischek  
Ms. Klimischek has no relevant financial relationships to disclose.

P5.08-20  Clinical utility of TGF with various cutoffs using 1 commercial assays relative to 15yr survival  
Alexander Klimeszcz  
Dr. Klimeszcz has no relevant financial relationships to disclose.

P2.04-10  High-affinity activated natural killer (haNK) cells augment trastuzumab efficacy in a mouse model of HER2 positive human metastatic breast cancer  
Hans Klingemann  
Mr. Klingemann has disclosed that he receives salary from, and has ownership in NextKest.

P5.13-08  Preclinical validation of a new tumor imaging agent targeting αvβ3 to detect breast tumor using high-light imaging  
Sophie Klinger  
Ms. Klinger has no relevant financial relationships to disclose.

P2.04-20  A phase I study of AZD9496, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC)  
Teresa Klinowska  
Ms. Klinowska has disclosed that she receives salary and has ownership.

P2.24-01  A prospective trial: A QtGui group collaborative to engage metastatic breast cancer patients in clinical trials  
Szymon Knackmuhs  
Ms. Knackmuhs has no relevant financial relationships to disclose.

P2.05-09  Results of mutigene assay (MammaPrint®) and molecular subtyping (BluePrint®) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIME decision impact study  
Michael Knauer  
Dr. Knauer has no relevant financial relationships to disclose.

OT2.05-01  Phase 2 study of investigational TORC1/2 inhibitor TAK-228 with fulvestrant in women with ER/PR-negative advanced or metastatic breast cancer that has progressed during or after endocrine therapy  
Michelle Kroes  
Ms. Kroes has disclosed that she receives salary from and has ownership in Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited.

P2.03-08  Influence of mutagen exposure on molecular profile in breast cancer  
Todd Kroeppe  
Dr. Kroeppe has no relevant financial relationships to disclose.

P6.07-12  A physical activity and dietary counseling intervention in breast cancer survivors and changes in breast and novel prognostic biomarkers  
Kendra Knight  
Ms. Knight has no relevant financial relationships to disclose.

P5.12-07  Prediction of 5yr distant recurrence (DR) using the Prosgene® (PAM50) assay in histological subgroups of a Danish breast cancer group (DBCG) cohort of postmenopausal Danish women with hormone receptor-positive (HR+) early breast cancer (EBC) allocated to 5yr of endocrine therapy (ET) alone  
Ann Knopp  
Ms. Knopp has disclosed that she is a consultant and speaker for Novartis. He also disclosed that he has a contract with Novartis and received travel support from Roche.

P6.05-04  DBCG-07-READ: A randomized phase III trial comparing six cycles of doxorubicin and cyclophosphamide followed by three cycles of docetaxel (DC-D) in patients with early breast cancer  
Ann Knopp  
Dr. Knopp has disclosed that she receives salary from and has a contract with Novartis. She also disclosed that she is a speaker for Novartis and receives travel support from Roche.

OT2.03-02  Feasibility of assessing radiation response with MRI/CT directed preoperative accelerated partial breast irradiation in the prone position for hormone sensitive early stage breast cancer  
Michael Knopp  
Dr. Knopp has no relevant financial relationships to disclose.

P5.08-13  Phyllodes tumours of the breast: The British Columbia cancer agency experience  
Margaret Browning  
Ms. Browning has no relevant financial relationships to disclose.

P6.11-05  A phase I open-label study of budesonide in patients [pts] with TGF αvβ3 aberrant metastatic breast cancer (MBC)  
Allison Knox  
Dr. Knox has disclosed that she receives salary from Clovis Oncology.
The importance of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive recurrent and advanced breast cancer

Toshihiro Koga
Dr. Koga has no relevant financial relationships to disclose.

An ex-vivo platform predicts anti-tumor outcome of metabolically-targeted, algorithm-driven combination therapy in triple-negative breast cancer

Mohammad Kohandel
Mr. Kohandel has no relevant financial relationships to disclose.

Zolendronic acid combined with neoadjuvant chemotherapy for HER2-negative early breast cancer (OCE1 3 trial): Survival outcomes of a randomized multicenter phase 2 trial

Noria Kohro
Dr. Kohro has no relevant financial relationships to disclose.

Ki67-positive CTCs are associated with early disease relapse in patients with early breast cancer undergoing adjuvant chemotherapy

Filippos Konsis
Filippos Konsis has no relevant financial relationships to disclose.

Adjuvant dose dense doxorubicin-cyclophosphamide (DDAC) or docetaxel-AC (TAC) for high-risk breast cancer: First results of the randomized MATADOR trial (BOOG-2004-04)

Marleen Kok
Dr. Kok has no relevant financial relationships to disclose.

International validation of the EORTC patient-reported outcome measure (PRoM) in breast reconstruction (BRR): The EORTC QLQ-BR23 evaluating the psychometric properties and clinical effectiveness

Jelal Kokan
Dr. Kokan has no relevant financial relationships to disclose.

Prevalence of insulin-like growth factor-1 receptor (IGF1R) expression in circulating tumor cells (CTCs) of patients with early breast cancer and its association with E-cadherin expression and patient survival

Maria Kokotsaki
Ms. Kokotsaki has no relevant financial relationships to disclose.

Adjuvant dose dense doxorubicin-cyclophosphamide (DDAC) or docetaxel-AC (TAC) for high-risk breast cancer: First results of the randomized MATADOR trial (BOOG-2004-04)

Hans-Christian Kolberg
Dr. Kolberg has no relevant financial relationships to disclose.

Development and validation of a nomogram predicting pathological axillary status (pN0M0 vs. pN+) in a subgroup of patients converting from cN+ to ycN0 through neoadjuvant therapy (NAT) - A transSENTINA substudy

Hans-Christian Kolberg
Dr. Kolberg has no relevant financial relationships to disclose.

Results of an educational program delivered through e-learning, focused on nursing for primary breast cancer patients

Hiroko Kokufu
Dr. Kokufu has no relevant financial relationships to disclose.

A one-day protocol with activities lower than 20 MBq for the detection of sentinel lymph nodes - Experience after 150 cases.

Hans-Christian Kolberg
Dr. Kolberg has no relevant financial relationships to disclose.

Pharmacokinetics of eflapegrastim in a phase 2 open-label dose-ranging study in breast cancer patients receiving TC regimen

Prasad Koli
Dr. Koli has disclosed that he receives salary from and has ownership in Spectrum Pharmaceuticals.

Immunogenicity of eflapegrastim in a phase 2 open-label dose-ranging study of eflapegrastim in breast cancer patients receiving TC regimen

Prasad Koli
Dr. Koli has disclosed that he receives salary from and has ownership in Spectrum Pharmaceuticals.

A novel prognostic marker and therapeutic target for breast cancer

Maartje Kolke
Ms. Kolke has no relevant financial relationships to disclose.

Pharmacokinetics of eflapegrastim in a phase 2 open-label dose-ranging study in breast cancer patients receiving TC regimen

Keinbra Kolhe
Dr. Kolhe has no relevant financial relationships to disclose.

Expression of Ki67 expression in primary breast cancer patients receiving neoadjuvant therapy

Bjoern Koll
Dr. Koll has disclosed that he receives salary from and has ownership in Spectrum Pharmaceuticals.

Intracerebral hematomas in breast cancer patients receiving RT-Neoadjuvant therapy

Koll
Dr. Koll has disclosed that he receives salary from and has ownership in Spectrum Pharmaceuticals.

Technical skill of surgical residents may affect margin status of breast conserving operations

Ian Komnakes
Dr. Komnakes has no relevant financial relationships to disclose.

Weight gain after breast cancer diagnosis and patients' opinion on weight loss strategies

Ian Komnakes
Dr. Komnakes has no relevant financial relationships to disclose.
The evaluation of ganitumab/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial

Dr. Korde has no relevant financial relationships to disclose.

Sensitivity to lapatinib differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA and relies on production of PIP3

James Korkola
Dr. Korkola has no relevant financial relationships to disclose.

A directed siRNA screen identifies INHBA as a major regulator of tumor aggressiveness in basal HER2 breast cancer

James Korkola
Dr. Korkola has no relevant financial relationships to disclose.

Development of a panel of serum-based protein biomarkers for the non-invasive detection of breast cancer in BI-RADS category 4 patients

Ronald Korn
Mr. Korn has no relevant financial relationships to disclose.

An international multicenter study to evaluate reproducibility of automated scoring methods for assessment of Ki67 in breast cancer

Elizabeth Kornaga
Ms. Kornaga has no relevant financial relationships to disclose.

Clinical utility of Ki67 with various cutoffs using 3 commercial assays relative to 15yr survival

Elizabeth Kornaga
Ms. Kornaga has no relevant financial relationships to disclose.

Effect of MRI imaging contrast kinetic thresholds for prediction of neoadjuvant chemotherapy response in breast cancer subtypes - Results from ACRN 6657/I-SPY 1 trial

John Kornak
Dr. Kornak has no relevant financial relationships to disclose.

Refining the prognostic value of Ki67 biomarker by ataxia telangiectasia mutated (ATM) status in a retrospective study of early stage hormone receptor positive breast cancer

Elizabeth Kornaga
Ms. Kornaga has no relevant financial relationships to disclose.

Establishment and characterization of ST941/C; an ESR1-mutant ER+ breast cancer cell line and xenograft from a patient with acquired resistance to endocrine therapy

Manav Korpal
Manav Korpal has no relevant financial relationships to disclose.

Predictive effect of cytotoxic tumor infiltrating lymphocytes in HER2-positive metastatic breast cancer: A correlative study with CCTG MA.31

Zuzana Kos
Zuzana Kos has no relevant financial relationships to disclose.

A randomized phase II neoadjuvant study comparing docetaxel and cyclophosphamide (TC) with 5-fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel (FEC-D) for hormone receptor-negative breast cancer: The Kanagawa breast oncology group (KBOG) 1101 study

Yoshimasa Kosaka
Dr. Kosaka has no relevant financial relationships to disclose.

Effect of PD-1 and PD-L1 in the tumor microenvironment on overall survival of triple-negative breast cancer patients

Rezvi Kosioruk
Ms. Kosioruk has no relevant financial relationships to disclose.

Metastatic characteristics and tumor infiltrating lymphocytes in early and metastatic HER2-positive breast cancer

Paris Kosmidis
Paris Kosmidis has no relevant financial relationships to disclose.
Splenic enlargement and bone marrow hyperplasia in patients receiving trastuzumab-emtansine for metastatic breast cancer

Michael Kosmin
Mr. Kosmin has no relevant financial relationships to disclose.

Phase 1 study of the antibody-drug conjugate (ADC) SGN-LIV1 in patients with heavily pretreated metastatic breast cancer

Ana Kostic
Dr. Kostic has disclosed that she has a contract with Seattle Genetics, Inc and is an employee and has stock.

Impact of germline/tumor-associated nuclear protein polymorphisms on breast cancer risk and prognosis in a Japanese population

Harumi Kotani
Dr. Kotani has no relevant financial relationships to disclose.

Precise efficacy of the novel PI3K kinase inhibitor, PJ11486 in triple negative breast cancer models

Sayaka Kotha Guvanswamy Saini
Dr. Kotha Guvanswamy Saini has no relevant financial relationships to disclose.

Mutation characteristics and tumor infiltrating lymphocytes in early and metastatic HER2-positive breast cancer

Kawski Kotoulas
Kawski Kotoulas has no relevant financial relationships to disclose.

Phase 2 osteoprotegerin and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

Joanne Koutsopoulos
Mr. Koustenis has disclosed that he is employed by and has a contract with Eli Lilly and Company.

Plasma osteoprotegerin and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

Joanne Koutsopoulos
Mr. Koustenis has disclosed that he is employed by and has a contract with Eli Lilly and Company.

Preclinical efficacy of the novel PIM2 kinase inhibitor, JP11646 in triple negative breast cancer models

Divya Kothai Guruswamy San
Dr. Kothai Guruswamy San has no relevant financial relationships to disclose.

Mutation characteristics and tumor infiltrating lymphocytes in early and metastatic HER2-positive breast cancer

Vassiliki Kotoula
Vassiliki Kotoula has no relevant financial relationships to disclose.

Impact of germinalcenter-associated nuclear protein polymorphisms on breast cancer risk and prognosis in a Japanese population

Harumi Kotani
Dr. Kotani has no relevant financial relationships to disclose.

Identification of SARAMS90, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong antitumor activity in wild-type and mutant ER+ breast cancer models

Joanne Kotsopoulos
Dr. Kotsopoulos has no relevant financial relationships to disclose.

Subgroup Analysis by prior treatment and disease burden in MONARCH 1: A phase 2 study of monotherapy abemaciclib, a CDK4 & 6 inhibitor, in patients with HR-/HER2 metastatic breast cancer (MBC) following chemotherapy

Andrew Koushan
Mr. Koushan has disclosed that he is employed by and has a contract with Eli Lilly and Company.

Abemaciclib exposure-response relationship in patients with metastatic breast cancer in MONARCH 1

Andrew Koushan
Mr. Koushan has disclosed that he is employed by and has a contract with Eli Lilly and Company.

Subgroup Analysis by prior treatment and disease burden in MONARCH 1: A phase 2 study of monotherapy abemaciclib, a CDK4 & 6 inhibitor, in patients with HR-/HER2 metastatic breast cancer (MBC) following chemotherapy

Andrew Koushan
Mr. Koushan has disclosed that he is employed by and has a contract with Eli Lilly and Company.

Relative radioresistance in triple negative tumors in the SweBCG91-RT randomized clinical trial

Ando Kovacs
Mr. Kovacs has no relevant financial relationships to disclose.

Race is not a contributing factor to breast cancer-free interval outcome for patients with equal access to healthcare treated at a military medical center

Albert Kovatich
Mr. Kovatich has no relevant financial relationships to disclose.

Predictive value of quantitative HER2 and HER3 levels combined with downstream signaling markers in HER2-positive advanced breast cancer patients treated with lapatinib

Anna Kowalczyk
Ms. Kowalczyk has no relevant financial relationships to disclose.

The importance of loco-regional tumor burden and surgery on survival in patients with de novo stage IV breast cancer: post-hoc analyses of protocol MF07-01

Ayhan Koyuncu
Dr. Koyuncu has no relevant financial relationships to disclose.

The importance of loco-regional tumor burden and surgery on survival in patients with de novo stage IV breast cancer: post-hoc analyses of protocol MF07-01

Ayhan Koyuncu
Dr. Koyuncu has no relevant financial relationships to disclose.

Cobimetinib (C) combined with paclitaxel (P) as a first-line treatment in patients (pts) with advanced triple-negative breast cancer (COTEST study): Updated clinical and biomarker results

Mark Kozloff
Mr. Kozloff has disclosed that he is a consultant and has a contract with Genentech/Roche. He has also disclosed that he is a speaker for Genentech.

ESR1 mutations in circulating tumor cell versus circulating cell-free DNA of metastatic breast cancer patients before first-line endocrine therapy and at progression

Jaco Kraan
Jaco Kraan has no relevant financial relationships to disclose.

Identification of SARAF90, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong antitumor activity in wild-type and mutant ER+ breast cancer models

Malvika Koumidis
Malvika Koumidis has no relevant financial relationships to disclose.

Breast ultrasound surveillance with image fusion technique in a short-interval follow-up for BI-RADS category 3 mass lesions

Sunko Kosaka
Dr. Kosaka has no relevant financial relationships to disclose.

Identification of SARAMS90, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong antitumor activity in wild-type and mutant ER+ breast cancer models

Malvika Koumidis
Malvika Koumidis has no relevant financial relationships to disclose.

Mutation characteristics and tumor infiltrating lymphocytes in early and metastatic HER2-positive breast cancer

Vassiliki Kotoula
Vassiliki Kotoula has no relevant financial relationships to disclose.

Mutation characteristics and tumor infiltrating lymphocytes in early and metastatic HER2-positive breast cancer

George Kouvatses
Mr. Kouvatses has no relevant financial relationships to disclose.

Impact of germinalcenter-associated nuclear protein polymorphisms on breast cancer risk and prognosis in a Japanese population

Harumi Kotani
Dr. Kotani has no relevant financial relationships to disclose.

Impact of germinalcenter-associated nuclear protein polymorphisms on breast cancer risk and prognosis in a Japanese population

Harumi Kotani
Dr. Kotani has no relevant financial relationships to disclose.

Race is not a contributing factor to breast cancer-free interval outcome for patients with equal access to healthcare treated at a military medical center

Albert Kovatich
Mr. Kovatich has no relevant financial relationships to disclose.

Predictive value of quantitative HER2 and HER3 levels combined with downstream signaling markers in HER2-positive advanced breast cancer patients treated with lapatinib

Anna Kowalczyk
Ms. Kowalczyk has no relevant financial relationships to disclose.

The importance of loco-regional tumor burden and surgery on survival in patients with de novo stage IV breast cancer: post-hoc analyses of protocol MF07-01

Ayhan Koyuncu
Dr. Koyuncu has no relevant financial relationships to disclose.

Cobimetinib (C) combined with paclitaxel (P) as a first-line treatment in patients (pts) with advanced triple-negative breast cancer (COTEST study): Updated clinical and biomarker results

Mark Kozloff
Mr. Kozloff has disclosed that he is a consultant and has a contract with Genentech/Roche. He has also disclosed that he is a speaker for Genentech.

ESR1 mutations in circulating tumor cell versus circulating cell-free DNA of metastatic breast cancer patients before first-line endocrine therapy and at progression

Jaco Kraan
Jaco Kraan has no relevant financial relationships to disclose.

Identification of SARAMS90, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong antitumor activity in wild-type and mutant ER+ breast cancer models

Malvika Koumidis
Malvika Koumidis has no relevant financial relationships to disclose.

Breast ultrasound surveillance with image fusion technique in a short-interval follow-up for BI-RADS category 3 mass lesions

Sunko Kosaka
Dr. Kosaka has no relevant financial relationships to disclose.

Identification of SARAMS90, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong antitumor activity in wild-type and mutant ER+ breast cancer models

Malvika Koumidis
Malvika Koumidis has no relevant financial relationships to disclose.
The role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+/HR+ phase II trial evaluating 12-weeks of neoadjuvant TDM1 ± endocrine therapy (ET) versus T+ ET in HER2-positive hormone-receptor-positive early breast cancer (EBC)

Stefan Kraemer

Dr. Kraemer has no relevant financial relationships to disclose.

Pan-HER, an antibody mixture with antitumor activity against drug-resistant HER2-overexpressing breast cancers with high ERBB ligand expression

Michael Kragh

Mr. Kragh has disclosed that he receives salary, has a patent, has a contract and is a Symphogen employee.

Phase 2 trial of everolimus and/or trastuzumab in hormone refractory, hormone receptor (HR) positive, HER2-normal metastatic breast cancer (MBC)

Joan Kramer

Dr. Kramer has no relevant financial relationships to disclose.

Further suppressor control of the cancer stem cell angiogenic niche

Kaitrin Kramer

Ms. Kramer has no relevant financial relationships to disclose.

Breast cancer education, counseling, and support for Jewish women: Preliminary results of a CDC program evaluation

Shira Kravitz

Shira Kravitz has no relevant financial relationships to disclose.

Results of multigene assay (MammaPrint®) and molecular subtyping (BluePrint®) substantially impact treatment decision making in early breast cancer: final analysis of the WSG PRIME decision impact study

Juergen Krauter

Prof. Krauter has no relevant financial relationships to disclose.

Diet, development and predisposition to breast cancer: The impact of sugar derived metabolites (AGEs) on pubertal mammary gland development

Bradley Krisanits

Mr. Krisanits has no relevant financial relationships to disclose.

Dynamics of cancer stem cell surface marker, CD44 and CD44v6 in the antitumor efficacy of PARP inhibitor in combination with PARP pathway inhibitor in TNBC xenograft model

Amy Krie

Dr. Krie has no relevant financial relationships to disclose.

Risk of primary and contralateral breast cancer in BRCAT1/2 mutation carriers previously affected with ovarian cancer

Naseem Kriley

Dr. Kriley has no relevant financial relationships to disclose.

Recognition of autologous neoantigens by tumor infiltrating lymphocytes derived from breast cancer metastases

Bradley Krimsits

Mr. Krimsits has no relevant financial relationships to disclose.

NCC-2015-03367: A phase IIB study of neoadjuvant ZT regimen (enzalutamide therapy in combination with weekly paclitaxel) for androgen receptor (AR)-positive triple-negative breast cancer (TNBC)

Sri Krishna

Dr. Krishna has no relevant financial relationships to disclose.

Landscape of somatic mutations in inflammatory breast cancer whole-genome sequences

Sudhri Krishnamurthy

Dr. Krishnamurthy has no relevant financial relationships to disclose.

Dynamics of cancer stem cell surface marker, CD44 and CD44v6 in the antitumor efficacy of PARP inhibitor in combination with PARP pathway inhibitor in TNBC xenograft model

Amy Krie

Dr. Krie has no relevant financial relationships to disclose.

Risk of primary and contralateral breast cancer in BRCAT1/2 mutation carriers previously affected with ovarian cancer

Naseem Kriley

Dr. Kriley has no relevant financial relationships to disclose.

Recognition of autologous neoantigens by tumor infiltrating lymphocytes derived from breast cancer metastases

Bradley Krimsits

Mr. Krimsits has no relevant financial relationships to disclose.
A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unsectatable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB)

Ian Krop
Dr. Krop has disclosed research paid to his institution from Genentech.

Circulating tumor cell number and ETC-endocrine therapy index predict clinical outcomes in ER-positive metastatic breast cancer patients: Results of the COMETI Phase 2 trial

Ian Krop
Dr. Krop has no relevant financial relationships to disclose.

Phase I dose-escalation trial of ONT-380 in combination with trastuzumab in patients (pts) with HER2+ breast cancer brain metastases

Ian Krop
Dr. Krop has no relevant financial relationships to disclose.

A single-arm phase 2 study to assess clinical activity, efficacy and safety of venetoclax with trastuzumab in HER2+ A+ metastatic or locally advanced breast cancer

Ian Krop
Dr. Krop has no relevant financial relationships to disclose.

Phase 1 study of the antibody-drug conjugate (ADC) SGN-UV1A in patients with heavily pretreated metastatic breast cancer

Ian Krop
Dr. Krop has disclosed that he has a contract with Seattle Genetics, Inc.

Whole exome and transcriptome sequencing of resistant (ER+ metastatic breast cancer

Ian Krop
Dr. Krop has disclosed that he receives salary from Vertex and is a consultant for Amgen. He has also disclosed that he has a contract with Genentech.

Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2 positive breast cancer

Ian Krop
Dr. Krop has disclosed that he is a consultant for and has ownership in Vertex Pharmaceuticals (I) and Amgen Pharmaceuticals (I). He also disclosed that he has a contract with Genentech and receives travel, accommodations and expenses from Bayer.

Predictive value of breast MRI in detecting mammographically occult contralateral breast cancer: Can we target women more likely to have contralateral breast cancer based on primary tumor clinicopathologic factors?

Jane Kruger
Ms. Kruger has no relevant financial relationships to disclose.

The association of higher tumor HER2 load with treatment response in trastuzumab therapy in HER2 positive breast cancer patients

Jane Kruger
Ms. Kruger has no relevant financial relationships to disclose.

Breast cancer after Hodgkin lymphoma: Influence of endogenous and exogenous gonadal hormones on the radiation dose-response relationship

Inge Krul
Ms. Krul has no relevant financial relationships to disclose.

Phase II trial of pertuzumab, trastuzumab, and nab-paclitaxel in patients (pts) with HER2 overexpressing (HER2+) locally advanced or inflammatory breast cancer (LABC) or untreated stage IV metastatic breast cancer (MBC)

Laura Kruper
Dr. Kruper has no relevant financial relationships to disclose.

A pilot study of the impact of a single dose of zoledronic acid on biomarkers in breast cancer

Laura Kruper
Dr. Kruper has no relevant financial relationships to disclose.

Impact of institution of young women’s breast cancer clinic on time to treatment and utilization of fertility, genetics and social work consultations in women under age 50 with new diagnosis of early stage breast cancer

Megan Kruse
Dr. Kruse has no relevant financial relationships to disclose.
P3-03-02 Inhibition of NOS promotes ER stress response and augments docetaxel-mediated apoptosis in TNBC
John Kuhn
Dr. Kuhn has no relevant financial relationships to disclose.

P1-03-04 Concordance of local immunohistochemistry with TargetPrint microarray based assessment of ER, PR and HER2 and BluePrint molecular subtyping in the Symphony Triple-A study
Anne Kuijer
Dr. Kuijer has no relevant financial relationships to disclose.

P6-08-03 Impact of 10-gene signature use on adjuvant chemotherapy decisions in early breast cancer patients: Results of the prospective symphony triple-A study
Anne Kuijer
Dr. Kuijer has no relevant financial relationships to disclose.

P4-02-01 Eribulin induces vascular remodeling and reoxygenation in advanced breast cancer patients: A comparative study with bevacizumab
Richi Kuki
Dr. Kuki has no relevant financial relationships to disclose.

P2-07-01 Chemoprevention uptake among women with atypical hyperplasia, lobular and ductal carcinoma in-situ
Rita Kukafka
Dr. Kukafka has no relevant financial relationships to disclose.

P5-10-01 Difference of immune microenvironment between primary and recurrent tumours in breast cancer patients
Rita Kukafka
Dr. Kukafka has no relevant financial relationships to disclose.

P2-04-13 Novel visualization tools to search ongoing clinical trials and track trial results for metastatic breast cancer
Maneesh Kumar
Dr. Kumar has no relevant financial relationships to disclose.

P2-14-05 Phase II of POSITRON: A phase IIb randomised phase II trial of sunitinib plus letrozole or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment
Sanjeev Kumar
Sanjeev Kumar has no relevant financial relationships to disclose.

P4-21-08 A phase II of DIS-22031, a reversible EGFR and HER2 inhibitor, combined with trastuzumab +/- chemotherapy in patients with HER2-positive metastatic breast cancer
Sanjeev Kumar
Sanjeev Kumar has no relevant financial relationships to disclose.

P1-04-08 Non-nuclear SUMO dynamics regulate mammary epithelial cell transformation
Santosh Kumar
Dr. Kumar has no relevant financial relationships to disclose.

P3-04-21 Androgen receptor in tamoxifen-resistant breast cancer is affected by SUMO
Santosh Kumar
Dr. Kumar has no relevant financial relationships to disclose.

P1-05-01 Landscape of somatic mutations in inflammatory breast cancer whole-genome sequences
Sushant Kumar
Dr. Kumar has no relevant financial relationships to disclose.

P4-21-42 MetaPHER phase IIIb multicenter, open-label, single-arm safety study of subcutaneous trastuzumab in combination with pertuzumab and docetaxel in patients with HER2-positive advanced breast cancer: First results
Sherko Kümmel
Sherko Kümmel has no relevant financial relationships to disclose.

P1-09-05 The role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+TNbc phase II trial evaluating 12-weeks of neoadjuvant TDM1 +/- endocrine therapy (ET) versus ET in HER2-positive hormone-receptor-positive early breast cancer (ERBC)
Sherko Kümmel
Dr. Kümmel has disclosed that he is a consultant for Roche, TEVA, Novartis, Amgen, Celgene, Genomic Health and Astra Zeneca and has a contract with Roche.

P1-09-11 Outcome after neoadjuvant chemotherapy in preoperative trastuzumab receptor negative breast cancer patients - A pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials
Sherko Kümmel
Sherko Kümmel has no relevant financial relationships to disclose.

P4-21-42 MetaPHER phase IIIb multicenter, open-label, single-arm safety study of subcutaneous trastuzumab in combination with pertuzumab and docetaxel in patients with HER2-positive advanced breast cancer: First results
Sherko Kümmel
Sherko Kümmel has disclosed that he is a consultant for Roche, TEVA, Novartis, Amgen, Celgene, Genomic Health and Astra Zeneca and has a contract with Roche.
Evaluation of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarker in different subtypes of breast cancer treated with neoadjuvant therapy - A metaanalysis of 3771 patients

Sherko Kümmel

Sherko Kümmel has disclosed that he is a consultant for Celgene, Teva, Amgen, Roche, Novartis, Genomic Health and Somatex. He also disclosed that he has a contract with Roche.

A phase II, open-label, multi-center study of ANG1005, a novel brain-penetrant peptide-drug conjugate, in breast cancer patients with recurrent CNS metastases

Priya Kumthekar

Dr. Kumthekar has no relevant financial relationships to disclose.

Characterization of an estrogen-dependent murine model of human estrogen receptor-positive breast cancer bone metastasis

Andrew Kunihiro

Mr. Kunihiro has no relevant financial relationships to disclose.

Site-specific activation of carcinomoids in the breast cancer bone metastases microenvironment

Andrew Kunihiro

Mr. Kunihiro has no relevant financial relationships to disclose.

Analysing the factors affecting survival of breast cancer patients with leptomeningeal metastasis

Michal Kunkiel

Dr. Kunkiel has no relevant financial relationships to disclose.

Genomic pattern of breast carcinomas carrying mutations of non-BRCA homologous recombination genes

Wen-Hung Kuo

Wen-Hung Kuo has no relevant financial relationships to disclose.

Trastuzumab improves outcomes of New Zealand women with HER2+ stage III breast cancer

Monir Kuper-Hommel

Ms. Kuper-Hommel has no relevant financial relationships to disclose.

Committee Member

Charlotte Kuperwasser

Dr. Kuperwasser has no relevant financial relationships with commercial interests to disclose.

10-year follow-up and biomarker discovery for adjuvant endocrine therapy: results of the TEAM trial

Peter Kuppen

Dr. Kuppen has no relevant financial relationships to disclose.

A randomized phase II neoadjuvant study comparing docetaxel and cyclophosphamide (TC) with 5-fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel (FEC-D) for hormone receptor-negative breast cancer: The Kanagawa breast oncology group (KBOG) 1101 study

Masaaki Kuroi

Dr. Kuroi has no relevant financial relationships to disclose.

The importance of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HR+ positive recurrent and advanced breast cancer

Kazunori Kurashita

Dr. Kurashita has no relevant financial relationships to disclose.

Difference between 1st and 2nd generation serotonin receptor antagonists in triplet antiemetic therapy for highly emetogenic chemotherapy in breast cancer patients - according to recent multi-institutional double-blind randomized clinical research on the AC regimen

Kazue Kurokawa

Dr. Kurokawa has no relevant financial relationships to disclose.

Genetic counseling, germline genetic testing, and impact of results in patients with newly diagnosed breast cancer

Allison Kurian

Dr. Kurian has disclosed that she has a contract with Myriad Genetics.

Value of cancer care for metastatic breast cancer patients and providers

Allison Kurian

Ms. Kurian has no relevant financial relationships to disclose.

Multiple-gene panel testing for hereditary cancer risk reveals a racial/ethnic disparity in genetic information

Allison Kurian

Ms. Kurian has no relevant financial relationships to disclose.

Combined targeted therapies for advanced triple negative breast cancer: A phase II trial of nab-paclitaxel and bevacizumab followed by maintenance targeted therapy with bevacizumab and endoRIB

Brenda Kurland

Dr. Kurland has no relevant financial relationships to disclose.

Combined targeted therapies for advanced triple negative breast cancer: A phase II trial of nab-paclitaxel and bevacizumab followed by maintenance targeted therapy with bevacizumab and endoRIB

Brenda Kurland

Dr. Kurland has no relevant financial relationships to disclose.

Phase 2/2 study of oral vercelotide (VT-464), a dual CYFIRTA-type inhibitor androgen receptor (AR) antagonist, in patients with advanced AR positive triple negative (TNBC) or estrogen receptor (ER) positive breast cancer (BC)

Michael Kurman

Dr. Kurman has disclosed that he is a consultant for and has ownership in inspiraxPharmaceuticals, Inc.

Duration of fasting before taking lapatinib is associated with skin toxicity in neoadjuvant treatment of HER2 positive breast cancer: A cohort study from (BCRIC)-16/Neo-LATH

Katsumasa Kurita

Katsumasa Kurita has no relevant financial relationships to disclose.
Development of mathematical prediction models to identify disease-free survival events for HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy and trastuzumab
Katsumasa Kurio
Katsumasa Kurio has no relevant financial relationships to disclose.

Prognostic relevance of caspase 8 polymorphisms for breast cancer
Schmid Kurt
Dr. Kurt has no relevant financial relationships to disclose.

Detection of molecular alterations in breast cancer through next generation sequencing of both tumor tissue and circulating tumor DNA: The UC San Diego Moores Cancer Center experience
Raulillo Kurrock
Dr. Kurrock has disclosed that she receives consultant/advisory board fees from Sequenom, Actuate Therapeutics and Biostech. Dr. Kurrock also disclosed that she receives research funding from Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine and Guardant and has membership interest in Novena, Inc. and Carematch, Inc.

Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer
Amy Kraske
Dr. Kraske has no relevant financial relationships to disclose.

Assessment of breast cancer risk among atomic-bomb survivors based on ATM polymorphisms, radiation dose, and age at exposure
Takashiro Kusumaki
Dr. Kusumaki has no relevant financial relationships to disclose.

Mixed ductal-lobular carcinomas of the breast: Abrogated cell adhesion in the clonal evolution from ductal to lobular morphology
Jamie Kutasovic
Dr. Kutasovic has no relevant financial relationships to disclose.

The development of personalized diagnostic tests and therapeutic strategies in breast cancer
Jamie Kutasovic
Dr. Kutasovic has no relevant financial relationships to disclose.

Impact of germinal center-associated nuclear protein polymorphisms on breast cancer risk and prognosis in a Japanese population
Kazuhiro Kuwashara
Kazuhiro Kuwashara has no relevant financial relationships to disclose.

Impact of germinal center-associated nuclear protein polymorphisms on breast cancer risk and prognosis in a Japanese population
Kiyotaka Kuzushima
Mr. Kuzushima has no relevant financial relationships to disclose.

Race is not a contributing factor to breast cancer-free interval outcome for patients with equal access to healthcare treated at a military medical center
Leonid Kvecher
Leonid Kvecher has no relevant financial relationships to disclose.

BRCA2 - results of population-based screening of BRCA1 and BRCA2 germline mutations in incident breast cancer in South Sweden
Anders Kristel
Dr. Kristel has no relevant financial relationships to disclose.

Therapeutic targeting of RAGE in the tumor and tumor microenvironment inhibits breast progression and metastasis
Taekyoung Kwak
Taekyoung Kwak has no relevant financial relationships to disclose.

SET ER/PR - A robust 18-gene predictor of sensitivity to endocrine therapy in metastatic breast cancer
Raulillo Kwiatkowski
Raulillo Kwiatkowski has no relevant financial relationships to disclose.

Development of prediction model for omission of sentinel lymph node biopsy in T1 breast cancer
Youngmee Kwon
Dr. Kwon has no relevant financial relationships to disclose.
Clinical application of multimodal fluorescent-radioactive system in advanced breast cancer patients with neoadjuvant therapy; interim analysis for 65 patients
Youngmee Kwon
Dr. Kwon has no relevant financial relationships to disclose.

Assessment of breast cancer risk among atomic-bomb survivors based on ATM polymorphisms, radiation dose, and age at exposure
Seishi Kyoizumi
Dr. Kyoizumi has no relevant financial relationships to disclose.

Clinical application of multimodal fluorescent-radioactive system in advanced breast cancer patients with neoadjuvant therapy; interim analysis for 65 patients
Youngmee Kwon
Dr. Kwon has no relevant financial relationships to disclose.

ZBTB2 is a novel therapeutic target for cisplatin-resistance in metastatic breast cancer
Ava Kwong
Ms. Kwong has no relevant financial relationships to disclose.

Assessment of breast cancer risk among atomic-bomb survivors based on ATM polymorphisms, radiation dose, and age at exposure
Seishi Kyoizumi
Dr. Kyoizumi has no relevant financial relationships to disclose.

Establishment of molecular profiling for individual treatment decisions in early breast cancer - Clinical impact of PAM50 and PAM50 risk of recurrence score after more than 16 years follow up
Jon Kyle
Mr. Kyle has no relevant financial relationships to disclose.

PAINTER: Evaluation of eribulin tolerability and correlation between a set of polymorphisms and neuropathy in patients with metastatic breast cancer
Nicla La Verde
Dr. La Verde has no relevant financial relationships to disclose.

T-DM1 in HER2 positive advanced breast cancer patients: Real world practice from a multicenter observational study
Nicla La Verde
Dr. La Verde has no relevant financial relationships to disclose.

A phase 1/ii study of the whole-cell vaccine BraVax™ in metastatic or locally recurrent breast cancer patients (NCT010095862)
Benjamin Lucas
Mr. Lucas has no relevant financial relationships to disclose.

The complete spectrum of ESR1 mutations from 7590 breast cancer tumor samples
Mark Lacouture
Mr. Lacouture has disclosed that he receives a salary and stock options from InCell Therapeutics Corp.

A phase 1/ii study of the whole-cell vaccine BraVax™ in metastatic or locally recurrent breast cancer patients (NCT010095862)
Benjamin Lucas
Mr. Lucas has disclosed that he receives a salary and stock options from InCell Therapeutics Corp.

The complete spectrum of ESR1 mutations from 7590 breast cancer tumor samples
Mark Lacouture
Mr. Lacouture has disclosed that he receives a salary and stock options from InCell Therapeutics Corp.

A phase 1 safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA)
Mario Lacouture
Dr. Lacouture has no relevant financial relationships to disclose.

Evaluating the feasibility of a web-based preference-tolerant randomized trial of risk-based vs. annual breast cancer screening: WISDOM study pilot
Andrea LaCroix
Dr. LaCroix has disclosed that she is a consultant for Amgen and advisor for Sermonix and Pfizer.

Evaluating the feasibility of a web-based preference-tolerant randomized trial of risk-based vs. annual breast cancer screening: WISDOM study pilot
Andrea LaCroix
Dr. LaCroix has disclosed that she is a consultant for Amgen and advisor for Sermonix and Pfizer.

High-throughput genome analysis and therapeutic decision for patients with HER2-negative metastatic breast cancer: First feasibility and molecular results of the randomized phase II study SAFIR2 BREAST (UCBG-0105/1306)
Sudhakar Lacroix
Dr. Lacroix has no relevant financial relationships to disclose.

Prognostic and predictive values of high endothelial venules (HEV) and tumor infiltrating CD8+ lymphocytes (CD8) in tumors of patients included in the adjuvant PACS04 trial: HEV is predictive of outcome for HER2+ tumors exposed to trastuzumab
Magdi Lacroix-Triki
Dr. Lacroix-Triki has no relevant financial relationships to disclose.

Utility of the orally bioavailable selective estrogen receptor degrader AZD9496 in ESR1 mutant preclinical models of estrogen receptor positive breast cancer
Brendon Ladd
Mr. Ladd has disclosed that he receives salary and has ownership.

Dynamic regulation of a microRNA-mRNA network during breast cancer metastasis reveals an essential tumor-promoting role for miR-203
Bahar Laderian
Dr. Laderian has no relevant financial relationships to disclose.
Reliability and acceptance of e-based survey instruments for measuring patient reported outcomes (PRO) in breast cancer patients: First results of the ePROCOM study

Corinna Ladra

Ms. Ladra has no relevant financial relationships to disclose.

Associations between breast cancer subtypes and mutations in cancer predisposition genes identified by clinical genetic testing of breast cancer patients

Holly LaDuca

Ms. LaDuca has disclosed that she is an employee of Ambry Genetics.

Identification, clinical characteristics and treatment outcomes of somatic human epidermal growth factor receptor 2 (HER2) mutations in metastatic breast cancer patients

Aneouschka Laenen

Aneouschka Laenen has no relevant financial relationships to disclose.

Age-related microRNAs and their biomarker potential in chemotherapy-treated older breast cancer patients

Aneouschka Laenen

Aneouschka Laenen has no relevant financial relationships to disclose.

A consecutive series of early breast cancers with a low estrogen receptor expression

Aneouschka Laenen

Aneouschka Laenen has no relevant financial relationships to disclose.

The association of breast cancer subtype and breast cancer survival with parity and time since last birth

Aneouschka Laenen

Aneouschka Laenen has no relevant financial relationships to disclose.

Prognostic and predictive values of high endothelial venules (HEV) and tumor infiltrating CD8+ lymphocytes (CD8) in tumors of patients included in the adjuvant PACS04 trial: HEV is predictive of outcome for HER2+ tumors exposed to trastuzumab

Anne-Vibeke Laenkholm

Ms. Laenkholm has disclosed that she is a consultant for Roche, NordiQC, Dako and Visiopharm and a speaker for Roche. She has also disclosed that she has a contract with NanoString Technologies and received unrestricted research grants from Roche and NanoString Technologies and received travel support from Roche.

The 21-gene assay in the decision impact assessment of ER+, HER2- Breast cancer: A French real life prospective study

Antoine Lafuma

Dr. Lafuma has disclosed that Cemka Eval received an unconditional grant from Genomic Health France for data collection and statistical analysis. The funders had no role in study design, analysis and decision to publish.

Rapid germline BRCA screening for locally advanced breast cancer changes surgical procedure after neoadjuvant chemotherapy

Delfine Lafon

Ms. Lafon has no relevant financial relationships to disclose.

Prognostic and predictive values of high endothelial venules (HEV) and tumor infiltrating CD8+ lymphocytes (CD8) in tumors of patients included in the adjuvant PACS04 trial: HEV is predictive of outcome for HER2+ tumors exposed to trastuzumab

Rémy Lafouresse

Dr. Lafouresse has no relevant financial relationships to disclose.

The 22 gene assay in the decision impact assessment of ER+, HER2- Breast cancer: A French real life prospective study

Antoine Lafuma

Dr. Lafuma has disclosed that Gemka Eval received an unconditional grant from Genomic Health France for data collection and statistical analysis. The funders had no role in study design, analysis and decision to publish.

Evaluating cosmetic outcome following breast conserving surgery in trials: panel versus objective evaluation and the role of patient reported outcome measures (PROMs)

Mihelle Lagerstål

Dr. Lagerstål has no relevant financial relationships to disclose.

Identification of SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong antitumor activity in wild-type and mutant ER+ breast cancer models

Joanne Lager

Ms. Lager has no relevant financial relationships to disclose.

Bone seeking matrix metalloproteinase-2 inhibitors prevent bone metastatic breast cancer growth

Antonio Lapezaza

Dr. Lapezaza has no relevant financial relationships to disclose.

How do real-world treatment patterns compare to guideline recommendations for first-line metastatic breast cancer patients in US community clinics?

Catherine Lai

Dr. Lai has disclosed that she receives salary from Genentech and has ownership in Roche.
High concordance of a closed system, near point of care, RT-qPCR breast cancer assay for HER2 (ERBB2) mRNA compared to both IHC/FISH and quantitative immunofluorescence

Dr. Lai has disclosed that he receives salary from Cepheid.

Clinicopathologic factors related to surgical margin involvement, reoperation, and residual breast cancer in primary operable breast cancer - An analysis of 2050 patients

Dr. Lai has no relevant financial relationships to disclose.

Predictive value of ultra-high ERBB2 mRNA expression in early breast cancer

Dr. Laible has disclosed that he receives salary from BioNTech Diagnostic GmbH.

Quantification of HER2-driven signaling (HER2S) inhibition of four different anti-HER2 drugs tested ex vivo in live primary HER2-negative breast cancer cell samples with abnormal HER2 signaling activity

Dr. Laing has disclosed that he receives salary and has ownership.

New method to measure functional HER2-driven signaling activity in primary tumor cells identifies HER2-negative breast cancers with abnormal HER2 signaling activity: New group of patients may benefit from anti-HER2 therapy

Dr. Laing has disclosed that he receives salary and has ownership.

Phase II study of pertuzumab and fulvestrant for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy

Dr. Lake has no relevant financial relationships to disclose.

A phase 2, open-label, multi-center study of ANG1005, a novel brain-penetrant peptide-drug conjugate, in breast cancer patients with recurrent CNS metastases

Dr. Lakhani has no relevant financial relationships to disclose.

RNA immunoprecipitation reveals lncRNA-protein interactions in basal-like breast cancer

Mr. Lakhani has no relevant financial relationships to disclose.

An integrated molecular analysis of invasive lobular carcinoma

Mr. Lakhani has no relevant financial relationships to disclose.

Mixed ductal-lobular carcinomas of the breast: Abrogated cell adhesion in the clonal evolution from ductal to lobular morphology

Mr. Lakhani has no relevant financial relationships to disclose.

The development of personalized diagnostic tests and therapeutic strategies in breast cancer

Mr. Lakhani has no relevant financial relationships to disclose.

Single agent palbociclib with or without trastuzumab for the treatment of HER2+ advanced breast cancer

Dr. Lal has no relevant financial relationships to disclose.

An integrated molecular analysis of invasive lobular carcinoma

Mr. Lal has no relevant financial relationships to disclose.

Identification, clinical characteristics and treatment outcomes of somatic human epidermal growth factor receptor 2 (HER2) mutations in metastatic breast cancer patients

Alshad Lalani has disclosed that he receives salary from and has ownership in Puma Biotechnology Inc.

An acquired HER2 T798I gatekeeper mutation induces resistance to neratinib in a patient with HER2-mutant-driven breast cancer

Alshad Lalani has disclosed that he receives salary from and has ownership in Puma Biotechnology Inc.

Inhibition of mutant HER2 results in synthetic lethality when combined with ER antagonists in ER+/HER2 mutant human breast cancer cells

Alshad Lalani has disclosed that he receives salary from and has ownership in Puma Biotechnology Inc.

Neratinib + fulvestrant in HER2+ -mutant, HER2-non-amplified, estrogen receptor (ER)-positive, metastatic breast cancer (NBC): Preliminary analysis from the phase II SUMMIT trial

Alshad Lalani has disclosed that he receives salary from and has ownership in Puma Biotechnology Inc.
Highly reproducible decentralized gene expression analysis of ESR1, PGR, ERBB2 and MKi67 on an automated, standardized molecular diagnostics platform, GeneXpert

Engineering mesenchymal stem cells (MSCs) to secrete tumor-suppressing exosomes for breast cancer therapy

Analysis of novel function in MONARCH 1: A phase 2 study of olaparib, a CDK4 & 6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for metastatic breast cancer (MBC)

Identification of highly concordant DDR2 mediated stromal-cancer interactions and metastasis growth in breast cancer

Molecular mediators of mammographic density

Sentinel node detection after neoadjuvant chemotherapy in patient without previous axillary node involvement (GANEA 2 trial): Follow-up of a prospective multi-institutional cohort

Assessment of stratal characteristics in ductal carcinoma in situ of the breast: An inter-observer variability study

The REQUITE-AB study: Validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality of life in breast cancer patients

Exome sequencing of circulating tumor cells in metastatic breast cancer

Identification, clinical characteristics and treatment outcomes of somatic human epidermal growth factor receptor 2 (HER2) mutations in metastatic breast cancer patients

A randomized controlled trial comparing acupuncture versus usual care for the treatment of aromatase inhibitor-induced arthralgia (AIIA) in women with early-stage breast cancer

A randomized study comparing Ministration to topical lidocaine for female breast cancer survivors with dyspareunia

A randomized study of personalized music therapy for patients with early-stage breast cancer receiving chemotherapy

Efficacy of screening and treatment of breast cancer patients reporting high level of distress

A new workflow comprising size based CTC enrichment followed by in situ labeling and micromanipulation with CellCelector™ enables label-free enrichment, isolation and characterization of circulating tumor cells in breast cancer

Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple-negative breast cancer

BRCA1 promoter hypermethylation, but not BRCA1 expression, is associated with basal-like features and good prognosis in triple negative breast cancer

Vitamin D level impacts odds of pathologic complete response following neoadjuvant therapy in operable breast cancer

Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision-making
P3-10-06 Genetic testing for HBOC among women with a personal diagnosis of breast cancer in patients with Medicaid as compared to patients with private insurance

Johnathan Lancaster

Dr. Lancaster has disclosed that she receives salary from and has ownership in Myriad Genetic Laboratories, Inc.

P3-14-02 Prognostic and predictive relevance of cell cycle progression (CCCP) score in ductal carcinoma in situ: Results from the UK/ANZ DCIS trial

Samuel Lance

Mr. Lance has no relevant financial relationships to disclose.

P1-09-06 BRCA2 methylation status, silencing and treatment effect in the TNT trial: A randomized phase II trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CALGB/ECOG 2012)

Jerry Lanchbury

Mr. Lanchbury has disclosed that he receives salary from and has ownership in Myriad Genetics. He has also disclosed that he has patent rights assigned to Myriad Genetics.

P4-19-06 Return to work after breast cancer diagnosis: An observational prospective study of 125 patients in South America

Luciana Landerio

Ms. Landerio has no relevant financial relationships to disclose.

P3-05-13 The metastatic breast cancer project: Translational genomics through direct patient engagement

Eric Lander

Dr. Lander has disclosed that he has ownership in Codiak Biosciences; Foundation Medicine; Infinity Pharmaceuticals and Neo Therapeutics.

P6-08-14 Prognostic significance of a modified residual disease in breast and nodes (mRDBN) algorithm after neoadjuvant therapy for breast cancer

Alessandra Landmann

Dr. Landmann has no relevant financial relationships to disclose.

P1-05-13 Post mastectomy breast reconstruction in elderly women: Complications and the impact of individual surgeons

Samantha Lance

Dr. Lance has no relevant financial relationships to disclose.

P6-16-05 Early identification of patients with metastatic breast cancer: A randomized controlled trial of a liquid biopsy panel in the United States

Sylva Laney

Sylva Laney has disclosed that she is an employee of Cardinal Health.

P4-22-20 Efficacy and safety of everolimus plus exemestane in HR+, HER2 advanced breast cancer progressing on/or after prior endocrine therapy, in routine clinical practice: 2nd interim analysis from STEPAN

Alois Lang

Mr. Lang has disclosed that he is a consultant for Novartis and has the contract ENEST, ABCSG 40, STEPAUT Novartis.

P2-05-21 Predictive value of quantitative HER2 and HER3 levels combined with downstream signaling markers in HER2 positive advanced breast cancer patients treated with lapatinib

Sylva Lang

Sylva Lang has no relevant financial relationships to disclose.

P3-07-10 The role of CBD/ehodM1 in triple negative breast cancer

Julie Lang

Dr. Lang has disclosed that she is a speaker for Genomic Health and has a contract with ANGLE Parsortix.

P6-11-02 Efficacy of lapatinib in patients with metastatic breast cancer: Results from the I-SPY 2 trial

Julie Lang

Dr. Lang has no relevant financial relationships to disclose.

P6-11-04 The evaluation of ganitumab plus metformin in high-risk breast cancer: Results from the I-SPY 2 trial

Julie Lang

Dr. Lang has no relevant financial relationships to disclose.

P2-09-05 The role of CBP/FOXM1 in triple negative breast cancer

Julie Lang

Dr. Lang has no relevant financial relationships to disclose.

P6-14-02 12 years' median follow up (MFU) of BIG 1-98: Adjuvant letrozole, tamoxifen and their sequences for postmenopausal women with endocrine responsive early breast cancer

István Láng

Mr. Láng has disclosed that he receives investigator fees from Novartis.

OT3-04-01 21-gene recurrence score® in patients with primary metastatic ER+, HER2- breast cancer

Matthias Langerfeld

Mr. Langerfeld has no relevant financial relationships to disclose.

OT3-04-06 BRCA1/2-15A: An phase II randomized controlled trial of genetically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer (TNBC)

Robert Langdon

Dr. Langdon has no relevant financial relationships to disclose.
Radioactive seed localization versus wire guided localization of nonpalpable invasive and in situ breast cancer: A Danish multicenter randomized controlled trial

An exploratory correlational biomarker analysis of NSABP FB-7, a phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel (P) plus neratinib (N) or trastuzumab (T) or neratinib and trastuzumab (N+T) followed by doxorubicin and cyclophosphamide (AC) with postoperative T in women with locally advanced HER2-positive breast cancer

Positive behavior change and weight loss in breast cancer survivors on hormonal adjuvant therapy: An energy balance research in cancer (EnBaR) prospective study

Efficacy of screening and treatment of breast cancer patients reporting high level of distress

An acquired HER2 T798I gatekeeper mutation induces resistance to neratinib in a patient with HER2 mutant-driven breast cancer

Factors that can be used to guide further axillary treatment following positive sentinel lymph node biopsy

The long-term outcomes of female patients treated with primary endocrine therapy for non-metastatic breast cancer

Breast cancer organoid cultures preserve intra-tumor heterogeneity and reveal intrinsically resistant phenotypes to standard chemotherapies

Pan-HER, an antibody mixture with antitumor activity against drug-resistant HER2-overexpressing breast cancers with high ERBB ligand expression

The ASCO-recommended prognostic factors uPA/PAI-1 in a multicenter cohort study (PiA)

Trastuzumab improves outcomes of New Zealand women with HER2+ stage I-III breast cancer

The 22-gene assay in the decision impact assessment of ER+, HER2- Breast cancer: A French real life prospective study

The 22-gene assay in the decision impact assessment of ER+, HER2- Breast cancer: A French real life prospective study

The metastatic breast cancer project: Translational genomics through direct patient engagement

Mechanisms of CD8+ T cell immunosuppression in triple negative breast cancer

Impact of delay neoadjuvant chemotherapy on pathologic complete response in locally advanced breast cancer evidence of the real world in Mexico

Effect of supplementation with eicosapentaenoic and docosahexaenoic omega-3 polyunsaturated fatty acid on the chemotoxicity in Mexican patients with locally advanced breast cancer (LABC) treated with neoadjuvant chemotherapy (NeoCT)

The impact of the introduction of breast cancer screening on a symptomatic breast cancer unit

The metastatic breast cancer project: Translational genomics through direct patient engagement

Pan-HER, an antibody mixture with antitumor activity against drug-resistant HER2-overexpressing breast cancers with high ERBB ligand expression

The ASCO-recommended prognostic factors uPA/PAI-1 in a multicenter cohort study (PiA)

Trastuzumab improves outcomes of New Zealand women with HER2+ stage I-III breast cancer

The 22-gene assay in the decision impact assessment of ER+, HER2- Breast cancer: A French real life prospective study

Mechanisms of CD8+ T cell immunosuppression in triple negative breast cancer

Impact of delay neoadjuvant chemotherapy on pathologic complete response in locally advanced breast cancer evidence of the real world in Mexico

Effect of supplementation with eicosapentaenoic and docosahexaenoic omega-3 polyunsaturated fatty acid on the chemotoxicity in Mexican patients with locally advanced breast cancer (LABC) treated with neoadjuvant chemotherapy (NeoCT)

The impact of the introduction of breast cancer screening on a symptomatic breast cancer unit

The metastatic breast cancer project: Translational genomics through direct patient engagement
P2-04-04
BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer
Denis Larsimont
Dr. Larsimont has no relevant financial relationships to disclose.

P3-04-04
Detection of ESR1 mutations in matched primary and metastatic samples from endocrine-resistant lobular breast cancer patients
Denis Larsimont
Dr. Larsimont has no relevant financial relationships to disclose.

P6-07-02
CDK4 phosphorylation status and corresponding gene expression profile predict sensitivity to Fulbocibib
Denis Larsimont
Dr. Larsimont has no relevant financial relationships to disclose.

P2-03-10
A fit-for-purpose NGS system that reports ERBB2 (HER2) mutations and copy number variants for clinical trials research and drug development
Jessica Larson
Dr. Larson has disclosed that she receives salary from and has ownership in Asuragen, Inc.

P4-03-14
Stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer
Richard Larson
Mr. Larson has no relevant financial relationships to disclose.

P2-03-17
The SCAN-B study: 5-year summary of a large-scale population-based prospective breast cancer translational genomics platform covering a wide geography of Sweden (NCT02306096)
Christian Larson
Dr. Larson has no relevant financial relationships to disclose.

P2-09-11
Sentinel node detection after neoadjuvant chemotherapy in patient without previous axillary node involvement (GABA 2 trial): Follow-up of a prospective multi-institutional cohort
Georgi Loary
Dr. Loary has no relevant financial relationships to disclose.

P6-11-13
Phase II study evaluating the safety and clinical activity of lumetuximab combined with pertuzumab and paclitaxel in HER2-low metastatic breast cancer
Ulrik Lassen
Dr. Lassen has no relevant financial relationships to disclose.

P2-03-10
A fit-for-purpose NGS system that reports ERBB2 (HER2) mutations and copy number variants for clinical trials research and drug development
Gary Latham
Dr. Latham has disclosed that he receives salary from and has ownership in Asuragen, Inc.

OT1-02-10
A phase 2 study of poziotinib in patients with HER2-positive metastatic breast cancer (MBC) who have received prior HER2 regimens for MBC
Kate Lathrop
Dr. Lathrop has disclosed that she is a consultant for Spectrum Pharmaceuticals and receives other financial support from Austin Pharmaceuticals.

P1-09-16
Randomised study of COX2 inhibition on systemic inflammation in obese and non-obese subjects
Kate Lathrup
Dr. Lathrup has no relevant financial relationships to disclose.

P5-14-09
Luminal A breast cancer: Is it really a "good prognosis" disease? Preliminary results of the GIM-13 - AMBRA study
Luciano Latini
Dr. Latini has no relevant financial relationships to disclose.

P5-15-07
First and further line choices of treatment for HER2-VE metastatic breast cancer (MBC) according to adjuvant treatment and biological subtype. Preliminary results of the observational "GIM - AMBRA" Italian study
Luciano Latini
Dr. Latini has no relevant financial relationships to disclose.

P4-13-01
Prospective association between breast cancer risk and an individual dietary index based on the British Food Standards Agency nutrient profiling system
Paule Latino-Martel
Dr. Latino-Martel has no relevant financial relationships to disclose.

P5-13-01
Sociodemographic and economic factors are essential determinants of weight gain between before and after cancer diagnosis: Results from the prospective population-based Nutrition-Sante cohort
Paule Latino-Martel
Dr. Latino-Martel has no relevant financial relationships to disclose.

P2-12-02
If the treatment of breast cancer was different? An analysis of chemotherapy and hormonal therapy regimens administered in the adjuvant setting before 1990
Peter Lau
Mr. Lau has no relevant financial relationships to disclose.

P4-06-05
An annotated collection of pre- and post-therapy breast cancer patient-derived xenograft models built from fine needle aspiration samples aligned with ongoing clinical trials documenting response to treatment
Rosanna Lau
Dr. Lau has no relevant financial relationships to disclose.
| P6-09-23 | SET/6 - A robust 18-gene predictor of sensitivity to endocrine therapy in metastatic breast cancer | Rosanna Lau | Dr. Lau has no relevant financial relationships to disclose. |
| P04-07 | Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population study | Purushottam Lau | Dr. Lead has no relevant financial relationships to disclose. |
| OT3-02-06 | Femara plus ribociclib or placebo as neo-adjuvant endocrine therapy for women with ER+, HER2-negative early breast cancer - The Feline trial | Spring Laura | Dr. Laura has no relevant financial relationships to disclose. |
| P1-03-01 | An international multicenter study to evaluate reproducibility of automated scoring methods for assessment of Ki67 in breast cancer | Arvydas Laurinavicius | Arvydas Laurinavicius has no relevant financial relationships to disclose. |
| P1-03-06 | Genomic characterization of 992 primary breast cancers | Susanna Lauttia | Dr. Lauttia has no relevant financial relationships to disclose. |
| PD5-06 | Prognostic value of molecular tumor infiltrating lymphocyte (mTIL) signatures in HER2-positive breast cancer patients in N9831 and FinHer/FinXX trials | Susanna Lauttia | Dr. Lauttia has no relevant financial relationships to disclose. |
| P3-13-02 | Impact of primary surgery on short-term survival of older breast cancer patients in the US | Karina LaValle | Ms. LaValle has no relevant financial relationships to disclose. |
| P2-08-01 | Regulation of estrogen receptor-α by NF1 | Philip Lavin | Mr. Lavin has no relevant financial relationships to disclose. |
| P4-02-03 | Breast biopsy histology relationships with opto-acoustic imaging of breast masses | Philip Lavin | Dr. Lavin has disclosed contracted research through Boston Biostatistics Research Foundation. He also disclosed that he has ownership in Seno Medical. |
| P1-07-06 | Obesity, dyslipidemia, and diabetes as risk factors for trastuzumab-related cardiotoxicity in breast cancer patients | Angelina Law | Dr. Law has no relevant financial relationships to disclose. |
| P1-12-04 | Phase I dose-escalation trial of OSH-380 in combination with trastuzumab in patients [x] with HER2+ breast cancer brain metastases | Elizabeth Lawler | Ms. Lawler has no relevant financial relationships to disclose. |
| P4-06-11 | Differential regulation of microRNAs and microRNA influences metastatic potential: Comparison between locally invasive BT-474 and metastatic MDA-MB-231 xenografts | Patrick Lawrence | Mr. Lawrence has no relevant financial relationships to disclose. |
| PT3-02-08 | Open label, phase 2 safety, efficacy, and pharmacokinetic study of pre-surgical intramuscular and intraductal fulvestrant in women with invasive breast cancer or DCIS undergoing mastectomy or lumpectomy | Semmel Lawrence | Dr. Lawrence has no relevant financial relationships to disclose. |
| P4-21-28 | Trastuzumab improves outcomes of New Zealand women with HER2+ stage I-II breast cancer | Ross Lawrence | Mr. Lawrence has no relevant financial relationships to disclose. |
| P3-14-10 | Utility of the orally bioavailable selective estrogen receptor degrader AZD9496 in ESR1 mutant preclinical models of estrogen receptor positive breast cancer | Mandi Lawson | Ms. Lawson has disclosed that she receives salary and has ownership. |
| P6-06-07 | Experience in the ABC Medical Center of Mexico City 2010-2015 using scalp-cooling system (DigniCap) for prevention of alopecia induced by chemotherapy | Mandy Lazar | Ms. Lazar has no relevant financial relationships to disclose. |
| P5-11-13 | Impact of enrollment in clinical trials on survival of metastatic breast cancer patients | Miguel Le Du | Dr. Le Du has no relevant financial relationships to disclose. |
| P3-07-03 | A model using grade and hormone receptor scoring defines groups at low vs. high risk for distant metastasis: Comparison to the 21-gene recurrence score | Fanny Le Du | Dr. Le Du has no relevant financial relationships to disclose. |
| P6-09-05 | Prognostic and predictive values of high endothelial venules (HEV) and tumor infiltrating CD8+ lymphocytes (CD8) in tumors of patients included in the adjuvant PACS04 trial: HEV is predictive of outcome for HER2+ tumors exposed to trastuzumab | Sophie Le Guélec | Dr. Le Guélec has no relevant financial relationships to disclose. |
UCBG 2-14: A prospective multicenter non-randomized trial evaluating the effect of EndoPredict® (EPclin®) clinico-genomic test on treatment decision making among patients with intermediate clinical risk

Annick LeRol

Dr. Le Rol has no relevant financial relationships to disclose.

PrECOG 0102: A randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in post-menopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC) resistant to aromatase inhibitor (AI) therapy

Joseph Leach

Dr. Leach has no relevant financial relationships to disclose.

Pertuzumab and trastuzumab in combination with weekly paclitaxel delivers high pCR rates with favourable toxicity profile in neo-adjuvant treatment of Her-2 positive breast cancer

Christopher Leagre

Dr. Leagre has no relevant financial relationships to disclose.

NCI9782: A phase 1 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors

Ticiana Leal

Dr. Leal has no relevant financial relationships to disclose.

Comparative analysis of the genomic landscape of breast cancers from women of African and European ancestry

Rebecca Leary

Ms. Leary has no relevant financial relationships to disclose.

MCRT872: A phase 3 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors

Josephine Lebeau

Ms. Lebeau has no relevant financial relationships to disclose.

Pertuzumab and trastuzumab in combination with weekly paclitaxel delivers high pCR rates with favorable toxicity profile in neo-adjuvant treatment of Her-2 positive breast cancer

Antje Lebrecht

Dr. Lebrecht has no relevant financial relationships to disclose.

SOPHIA: A phase 3, randomized study of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in the treatment of patients with HER2+ metastatic breast cancer

Robert Lechleider

Dr. Dr. Lechleider has disclosed that he receives salary from and has ownership in MacroGenics.

Isolated sternal metastases: The place of surgical resection

Frederic Lecouvet

Dr. Lecouvet has no relevant financial relationships to disclose.

Evaluation of weekly paclitaxel plus carboplatin followed by aromatase chemotherapy on the neo-adjuvant treatment of patients with triple-negative breast cancer

Nicholas LeCroy

Dr. LeCroy has no relevant financial relationships to disclose.

Sentinel node detection after neoadjuvant chemotherapy in patients without previous axillary node involvement (GAMES 2 trial): Follow-up of a prospective multi-institutional cohort

Fabrice LeCuyer

Dr. LeCuyer has no relevant financial relationships to disclose.

Sociodemographic and economic factors are essential determinants of weight gain between before and after cancer diagnosis: Results from the prospective population-based Nucentrix-Sante cohort

Lucie Leduc

Dr. Leduc has no relevant financial relationships to disclose.

Prospective association between breast cancer risk and an individual dietary index based on the British Food Standards Agency nutrient profiling system

Lucie Leduc

Dr. Leduc has no relevant financial relationships to disclose.

Evaluation of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarker in different subtypes of breast cancer treated with neoadjuvant therapy - A meta-analysis of 3771 patients

Bianca Leduc

Ms. Leduc has no relevant financial relationships to disclose.

Attitudes towards tissue donation for rapid autopsy among community and academic oncologists

Adrian Lee

Dr. Lee has no relevant financial relationships to disclose.

Differential turnover of estrogen receptor alpha in invasive lobular carcinoma

Adrian Lee

Dr. Lee has no relevant financial relationships to disclose.

ESR1 amplification and 5'-3' exon imbalance in metastatic breast cancer

Adrian Lee

Dr. Lee has no relevant financial relationships to disclose.
Breast cancer brain metastases show limited intrinsic subtype switching, yet exhibit acquired ERBB2 amplifications and activating mutations

Adrian Lee
Dr. Lee has no relevant financial relationships to disclose.

The role of serum neutrophil-to-lymphocyte ratio (NLR) in triple-negative breast cancer

Ahwon Lee
Dr. Lee has no relevant financial relationships to disclose.

Clinical implications of somatic mutations in post-menopausal early-stage estrogen receptor (ER)-positive HER2-negative breast cancer (BC): Results from the BIG 1-98 study

Chae Lee
Dr. Lee has no relevant financial relationships to disclose.

Cumulative analysis of breast cancer sentinel lymph node identification rate by radiologist: A 13-year experience

Chi-Chun Lee
Dr. Chi-Chun Lee has no relevant financial relationships to disclose.

Identification of a cancer stem cell-specific function for the histone deacetylase, HDAC1 and HDAC7, in breast and ovarian cancer

Chung-Wei Lee
Dr. Lee has no relevant financial relationships to disclose.

T cell profile associated with regional lymph node progression in breast cancer

Daphne Lee
Dr. Lee has no relevant financial relationships to disclose.

A novel subgroup of estrogen receptor positive breast cancer may benefit from super-enhancer guided patient selection for retinoic acid receptor agonist treatment

Emily Lee
Ms. Lee has disclosed that she is an employee of and holder of shares and options for Synos Pharmaceuticals.

Development of prediction model for omission of sentinel lymph node biopsy in T1 breast cancer

Eun Sook Lee
Dr. Lee has no relevant financial relationships to disclosure.

Clinical application of multimodal fluorescent-radioactive system in advanced breast cancer patients with neoadjuvant therapy, interim analysis for 85 patients

Eun Sook Lee
Dr. Lee has no relevant financial relationships to disclose.

Risk factors affecting post-operative complication after immediate reconstruction with implant for operable breast cancer patients

Eun Sook Lee
Dr. Lee has no relevant financial relationships to disclose.

Modulation of indoleamine 2, 3-dioxygenase (IDO) expression in breast cancer cells by activated CD8+ T cells is controlled by DNA promoter methylation

Eun-Joon Lee
Dr. Lee has no relevant financial relationships to disclose.

The association between patient comorbidity and breast cancer survival

Eun-Shin Lee
Eun-Shin Lee has no relevant financial relationships to disclose.

An alteration of hormonal receptor status throughout tumor progression related to prognosis in breast cancer patients

Eun-Shin Lee
Eun-Shin Lee has no relevant financial relationships to disclose.

Modulation of FASN under obese conditions

Gabby Lee
Dr. Lee has no relevant financial relationships to disclose.

A phase II single arm trial to assess the efficacy of ASLAN001 plus capecitabine in previously irradiated, progressing central nervous system (CNS) metastases for HER2+ breast cancer patients

Guek Eng Lee
Dr. Lee has no relevant financial relationships to disclose.

Ex vivo shear wave elastography of axillary lymph nodes predicting nodal metastasis in patients with primary breast cancer: A pilot study

Hak Woo Lee
Dr. Lee has no relevant financial relationships to disclose.

The association between patient comorbidity and breast cancer survival

Han-Byoel Lee
Han-Byoel Lee has no relevant financial relationships to disclose.

An alteration of hormonal receptor status throughout tumor progression related to prognosis in breast cancer patients

Han-Byoel Lee
Han-Byoel Lee has no relevant financial relationships to disclose.

The expression of EWSR1 is positively associated with interferon signaling molecules in triple-negative breast cancer

Hee Jin Lee
Dr. Lee has no relevant financial relationships to disclose.

Delivery and anti-tumor activity of nanoliposomal irinotecan (Nal-IRI, MM-398) in metastatic xenograft models of triple-negative breast cancer

Helen Lee
Ms. Lee has disclosed that she is an employee of and holder of stock options from Merrimack Pharmaceuticals.

Phase II trial of selinexor for metastatic triple-negative breast cancer

Jae Lee
Jae Lee has no relevant financial relationships to disclose.
Clinical utility of serial monitoring of circulating tumor DNA (ctDNA) in patients with neoadjuvant chemotherapy (NAC) for locally advanced breast cancer (LABC)

Jeong Eon Lee
Dr. Lee has no relevant financial relationships to disclose.

Multi-omics and immune-oncology profiling reveal distinct molecular signatures of young Asian breast cancers

Jeong Eon Lee
Dr. Lee has no relevant financial relationships to disclose.

Cholecystographic outcomes of immediate breast reconstruction after neoadjuvant chemotherapy in breast cancer patients: A matched case control study

Jeong Eon Lee
Dr. Lee has no relevant financial relationships to disclose.

Tamoxifen resistance: ERβR expression in hormone receptor-positive and HER2 negative breast cancer

Jeong Eon Lee
Jeong Eon Lee has no relevant financial relationships to disclose.

Impact of young age on recurrence and mortality after surgery in breast cancer: 15 years active surveillance

Jeong Eon Lee
Dr. Lee has no relevant financial relationships to disclose.

Changes of tumor-infiltrating lymphocytes and programmed death-1 positivity after neoadjuvant chemotherapy in patients with locally advanced breast cancer

Jeong Hyeon Lee
Jeong Hyeon Lee has no relevant financial relationships to disclose.

Up-regulation of SPARC is associated with breast tumor progression and epithelial SPARC expression is correlated with poor survival and MMP-2 expression in patients with breast carcinoma

Ji Shin Lee
Ji Shin Lee has no relevant financial relationships to disclose.

Up-regulation of SPARC is associated with breast tumor progression and epithelial SPARC expression is correlated with poor survival and MMP-2 expression in patients with breast carcinoma

Ji Shin Lee
Ji Shin Lee has no relevant financial relationships to disclose.

The role of serum neutrophil-to-lymphocyte ratio (NLR) in triple negative breast cancer

Jeon
Dr. Jeon has no relevant financial relationships to disclose.

Comprehensive genomic characterization of circulating tumor cells (CTCs) in metastatic breast cancer (MBC) sheds light on the biology of blood-borne metastasis

Sin Sun
Jeon Sun Lee has no relevant financial relationships to disclose.

The role and regulation mechanism of HOXB5 in human breast cancer cells

Ji-Peon
Dr. Ji-Peon Lee has no relevant financial relationships to disclose.

Longitudinal patterns of postdiagnosis weight changes according to adjuvant systemic treatments in Korean breast cancer survivors

Jong Won Lee
Dr. Lee has no relevant financial relationships to disclose.

Interaction between body mass index and hormone receptor status as a prognostic factor in node-positive breast cancer

Jong Won Lee
Dr. Lee has no relevant financial relationships to disclose.

Serum 25-hydroxyvitamin D levels and oncologic outcomes of breast cancer patients receiving neoadjuvant chemotherapy

Jun Sang Lee
Dr. Jun Sang Lee has no relevant financial relationships to disclose.

Predictive efficacy of the novel FAM22 kinase inhibitor, JP154B in triple negative breast cancer models

Jun Sang
Jun Sang Lee has no relevant financial relationships to disclose.

A phase II, multicenter, randomized trial of eribulin plus gemcitabine (EG) vs. paclitaxel plus gemcitabine (PG) in patients with HER2-negative metastatic breast cancer as first-line chemotherapy

Kaeun Seok
Kaeun Seok Lee has no relevant financial relationships to disclose.

Development of prediction model for omission of sentinel lymph node biopsy in T1 breast cancer

Kaeun Seok
Dr. Kaeun Seok Lee has no relevant financial relationships to disclose.

Clinical application of multimodal fluorescent-radioactive system in advanced breast cancer patients with neoadjuvant therapy; interim analysis for 65 patients

Kaeun Seok
Kaeun Seok Lee has no relevant financial relationships to disclose.

The PROCEED trial KCSG BR11-01 phase III multicenter randomized open-label study of irinotecan plus capecitabine versus capecitabine in patients previously treated with anthracycline and taxane for HER2 negative metastatic breast cancer

Keun Seok
Kaeun Seok Lee has no relevant financial relationships to disclose.

A phase II, multicenter, randomized trial of eribulin plus gemcitabine (EG) vs. paclitaxel plus gemcitabine (PG) in patients with HER2-negative metastatic breast cancer as first-line chemotherapy

Ki Hyun
Ki Hyun Lee has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Author</th>
<th>Relationship Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>OT1-01-12</td>
<td>A phase II, multicenter, randomized trial of eribulin plus gemcitabine (EG) vs. paclitaxel plus gemcitabine (PG) in patients with HER2-negative metastatic breast cancer as first-line chemotherapy</td>
<td>Kyung-Hun Lee</td>
<td>Dr. Lee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT2-01-13</td>
<td>A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA)</td>
<td>Kyung-Hun Lee</td>
<td>Dr. Lee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-02-05</td>
<td>Prognostic role of PTENCA mutational status in circulating tumor DNA (ctDNA) from HER2 positive metastatic breast cancer patients</td>
<td>Kyung-Hun Lee</td>
<td>Dr. Lee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-15-04</td>
<td>The PROCEED trial KCSG BR11-01 phase III multicenter randomized open-label study of irinotecan plus capecitabine versus capecitabine in patients previously treated with anthracyline and taxane for HER2 negative metastatic breast cancer</td>
<td>Kyung-Hun Lee</td>
<td>Dr. Lee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-01-12</td>
<td>Development of prediction model for omission of sentinel lymph node biopsy in T1 breast cancer</td>
<td>Moo Hyun Lee</td>
<td>Dr. Lee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-01-15</td>
<td>Clinical application of multimodal fluorescent-radioactive system in advanced breast cancer patients with neoadjuvant therapy; interim analysis for 85 patients</td>
<td>Moo Hyun Lee</td>
<td>Dr. Lee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-14-11</td>
<td>Risk factors affecting post-operative complication after immediate reconstruction with implant for operable breast cancer patients</td>
<td>Moo Hyun Lee</td>
<td>Dr. Lee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-39</td>
<td>The role of quantitative estrogen receptor status in predicting breast tumor response to neoadjuvant chemotherapy</td>
<td>Nam Lee</td>
<td>Nam Lee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT3-02-09</td>
<td>Phase II pre-surgical window trial of talazoparib acetate (TPA) in early breast cancer and DCIS patients: Distribution of TPA in plasma, normal breast tissue and tumors</td>
<td>Seokheung Lee</td>
<td>Dr. Lee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT2-01-05</td>
<td>Phase II trial of the addition of pembrolizumab to letrozole and palbociclib in patients with metastatic estrogen receptor positive breast cancer who have stable disease on letrozole and palbociclib</td>
<td>Peter Lee</td>
<td>Dr. Lee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Speaker, Educational Session</td>
<td>Ex vivo and in vivo approaches to studying the immune tumor microenvironment</td>
<td>Peter Lee</td>
<td>Dr. Lee has no relevant financial relationships with commercial interests to disclose.</td>
</tr>
<tr>
<td>P6-09-38</td>
<td>Interaction between body mass index and hormone receptor status as a prognostic factor in node-positive breast cancer</td>
<td>Kae Boul</td>
<td>Lee-Yul Lee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-02-11</td>
<td>Clinical utility of serial monitoring of circulating tumor DNA (ctDNA) in patients with neoadjuvant chemotherapy (NAC) for locally advanced breast cancer (LABC)</td>
<td>Se Kyung</td>
<td>Dr. Lee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-15</td>
<td>Multi-omics and immune-oncology profiling reveal distinct molecular signatures of young Asian breast cancer</td>
<td>Se Kyung</td>
<td>Dr. Lee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-14-12</td>
<td>Oncologic outcomes of immediate breast reconstruction after neoadjuvant chemotherapy in breast cancer patients: A matched case control study</td>
<td>Se Kyung</td>
<td>Dr. Lee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-13-07</td>
<td>Conditional disease-free survival among patients with breast cancer</td>
<td>Se Kyung</td>
<td>Dr. Lee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-38</td>
<td>Tumoural resistance: DDR expression in hormone receptor-positive and HER2 negative breast cancer</td>
<td>Se Kyung</td>
<td>Dr. Lee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-39</td>
<td>Impact of young age on recurrence and mortality after surgery for breast cancer: 15 years active surveillance</td>
<td>Se Kyung</td>
<td>Dr. Lee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-01-12</td>
<td>Development of prediction model for omission of sentinel lymph node biopsy in T1 breast cancer</td>
<td>Seeyoun Lee</td>
<td>Seeyoun Lee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-01-12</td>
<td>Development of prediction model for omission of sentinel lymph node biopsy in T1 breast cancer</td>
<td>Seeyoun Lee</td>
<td>Dr. Lee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>ID</td>
<td>Title</td>
<td>Authors</td>
<td>Financial Relationships</td>
</tr>
<tr>
<td>--------</td>
<td>----------------------------------------------------------------------------------------------------------------------</td>
<td>--------------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>P2-01-15</td>
<td>Clinical application of multicolored fluorescent-radioactive system in advanced breast cancer patients with neoadjuvant therapy: interim analysis for 65 patients</td>
<td>Seeyoun Lee</td>
<td>Dr. Lee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-01-06</td>
<td>Diffuse optical tomography can predict pathological complete response in patients with HER2+ or triple negative breast cancer undergoing neoadjuvant chemotherapy</td>
<td>Shing Lee</td>
<td>Dr. Lee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-21-17</td>
<td>Phase I trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer</td>
<td>Shing Lee</td>
<td>Dr. Lee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT1-01-12</td>
<td>A phase II, multicenter, randomized trial of eribulin plus gemcitabine (EG) vs. paclitaxel plus gemcitabine (PG) in patients with HER2-negative metastatic breast cancer as first-line chemotherapy</td>
<td>Soo Jung Lee</td>
<td>Dr. Lee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-11-13</td>
<td>Re excision rate in breast conservation surgery after neoadjuvant chemotherapy</td>
<td>Soo Jung Lee</td>
<td>Dr. Lee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-01-12</td>
<td>Second sentinel lymph node biopsy for patients with local recurrence after breast cancer surgery</td>
<td>Soo Jung Lee</td>
<td>Dr. Lee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-05-15</td>
<td>Multi-omics and immuno-oncology profiling reveal distinct molecular signatures of young Asian breast cancers</td>
<td>Soo-Hyeon Lee</td>
<td>Dr. Lee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-50</td>
<td>Impact of young age on recurrence and mortality after surgery in breast cancer: 15 years active surveillance</td>
<td>Soo-Hyeon Lee</td>
<td>Dr. Lee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-15-04</td>
<td>The PROCEED trial NCIG BR11-01 phase III multicenter randomized open-label study of irinotecan plus capecitabine versus capecitabine in patients previously treated with anthracycline and taxane for HER2 negative metastatic breast cancer</td>
<td>Suane Lee</td>
<td>Suane Lee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT3-04-01</td>
<td>BRE12-158: A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer (TNBC)</td>
<td>Theresa Lee</td>
<td>Dr. Lee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-07-13</td>
<td>Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer</td>
<td>Tung Lee</td>
<td>Dr. Lee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-38</td>
<td>Interaction between body mass index and hormone receptor status as a prognostic factor in node-positive breast cancer</td>
<td>Yura Lee</td>
<td>Ms. Lee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S5-01</td>
<td>DCIS biological risk profile predicts risk of recurrence after breast conserving surgery in a Kaiser Permanente NW population</td>
<td>Glen Leesman</td>
<td>Dr. Leesman has disclosed that he is a consultant for Prelude Corporation.</td>
</tr>
<tr>
<td>P2-05-13</td>
<td>Refining the prognostic value of KIT biomarker by ataxia telangiectasia mutated (ATM) status in a retrospective study of early stage hormone receptor positive breast cancer</td>
<td>Susan Lees-Miller</td>
<td>Dr. Lees-Miller has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-03-11</td>
<td>High-throughput genome analysis and therapeutic decision for patients with HER2-negative metastatic breast cancer: first feasibility and molecular results of the randomized phase II study SAFIR22 BREAST (BCG-0105/1304)</td>
<td>Victoria Lee-Wing</td>
<td>Ms. Lee-Wing has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>PD1-08</td>
<td>High-throughput genome analysis and therapeutic decision for patients with HER2-negative metastatic breast cancer: first feasibility and molecular results of the randomized phase II study SAFIR22 BREAST (BCG-0105/1304)</td>
<td>Claude Lefouere-Plesse</td>
<td>Ms. Lefouere-Plesse has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-14-07</td>
<td>Sentinel node detection after neoadjuvant chemotherapy in patient without previous axillary node involvement (GANE 2 trial): Follow-up of a prospective multi-institutional cohort</td>
<td>Celine Lefouere-Lacoulle</td>
<td>Dr. Lefouere-Lacoulle has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-08-09</td>
<td>Sentinel lymph node involvement in mastectomy and immediate autologous free flap reconstruction. Findings from the primary radiotherapy and DDP flap (RADIST) pilot study</td>
<td>Celine Lebreque-Lacoulle</td>
<td>Dr. Lebreque-Lacoulle has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-01-33</td>
<td>Non-sentinel lymph node involvement in early breast cancer patients: Performance of two predictive nomograms integrating the analysis of sentinel nodes by one step nucleic acid amplification in a cohort of 290 patients</td>
<td>Armelle Lefrancois</td>
<td>Dr. Lefrancois has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
P3-04-09
Genomic analysis to evaluate response to neoadjuvant anastrozole and fulvestrant in post-menopausal ER-positive HER2-negative breast cancer patients included in the UCBG CARMINA02 trial
Florence Lerebours
Dr. Lerebours has no relevant financial relationships to disclose.

P4-01-03
Predictive value of FDG-PET/CT after neoadjuvant endocrine treatment in breast cancer
Florence Lerebours
Ms. Lerebours has no relevant financial relationships to disclose.

P4-22-13
Differential expression of protein tyrosine phosphatase in patients with HER2-advanced breast cancer: Overall survival results from BOLERO-1
Guillermo Larran
Mr. Larran has no relevant financial relationships to disclose.

P5-16-15
Lymph-vascular invasion in the absence of stomal invasion after neoadjuvant therapy: A rare pattern of residual carcinoma that lacks an AJCC/UICC T category
Susan Lester
Dr. Lester has no relevant financial relationships to disclose.

P2-02-06
Promise002: A prospective, multicenter study to determine the effectiveness of a biomarker assay to distinguish benign from invasive breast cancer in women with BI-RADS 5, 4, and 5 imaging reports
Elias Lettiero
Elias Lettiero has disclosed that he is a salary employee of and owns stock in Provista Dx.

P4-01-07
A radiology biopsy test for breast cancer detection provides consistent diagnostic results in patients over six months
Elias Lettiero
Elias Lettiero has disclosed that he is a salary employee of and owns stock in Provista Dx.

P5-05-03
Joint influence of paracrine adipocyte signals and metabolic conditions on breast cancer
Barbara Lettiero
Dr. Lettiero has no relevant financial relationships to disclose.

P6-02-04
A liquid biopsy test for breast cancer detection provides consistent diagnostic results in patients over six months
Barbara Lettiero
Mr. Letsios has disclosed that he is a salary employee of and owns stock in Provista Diagnostics.

P5-09-05
A model with polygenic risk score and mammographic density predicts interval cancers
Jessica Leung
Dr. Leung has no relevant financial relationships to disclose.

P2-03-01
An international multicenter study to evaluate reproducibility of automated scoring methods for assessment of Ki67 in breast cancer
Samuel Leung
Mr. Leung has no relevant financial relationships to disclose.

P3-04-02
Predictive effect of cytotoxic tumor infiltrating lymphocytes in HER2-positive metastatic breast cancer: A correlative study with CCTG MA.31
Samuel Leung
Dr. Leung has no relevant financial relationships to disclose.

P1-03-01
An international multicenter study to evaluate reproducibility of automated scoring methods for assessment of Ki67 in breast cancer
Richard Leverson
Dr. Leverson has no relevant financial relationships to disclose.

P6-12-07
Neutralization of BCL2/XL enhances the cytotoxicity of T-DM1 in vivo
Pauline Levey
Ms. Levey has no relevant financial relationships to disclose.

P1-09-06
Prognostic and predictive relevance of cell cycle progression (CCP) score in ductal carcinoma in situ: Results from the UK/ANZ DCIS trial
Pauline Levey
Ms. Levey has no relevant financial relationships to disclose.

P2-06-06
Association of pre-chemotherapy peripheral blood pro-inflammatory (IL-6, CRP) and coagulation (D-dimer) markers with chemotherapy toxicity in women with breast cancer
Abrahm Levi
Mr. Levi has no relevant financial relationships to disclose.

P4-06-06
Consistent dosing-time dependent tolerability of everolimus (EV) in a pilot study in women with metastatic breast cancer (MBC) and in a mouse chronopharmacology investigation
Francis Levi
Dr. Levi has no relevant financial relationships to disclose.

P3-04-05
PD-L1 expression in triple negative breast cancer (TNBC) is associated with improved outcomes
Mark Levin
Mr. Levin has no relevant financial relationships to disclose.

P4-19-02
Young women with early stage breast cancer and their supportive care needs: Results from a regional survey
Mark Levin
Dr. Levin has no relevant financial relationships to disclose.

P4-12-09
The immune response in triple negative breast cancer
Mark Levin
Dr. Levin has no relevant financial relationships to disclose.

P4-03-15
Identification of SARR190, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong antitumor activity in wild-type and mutant ER+ breast cancer models
Mikhail Levit
Mikhail Levit has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1-01-02</td>
<td>Multiple-gene panel testing for hereditary cancer risk reveals a racial/ethnic disparity in genetic information</td>
<td>Peter Levonian</td>
<td>Mr. Levonian has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-10-17</td>
<td>Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer</td>
<td>Christelle Levy</td>
<td>Dr. Levy has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-04-10</td>
<td>Circulating tumor cells (CTC) and endothelial cells (EC) prognostic value in HER2 negative metastatic breast cancer patients treated with first line weekly paclitaxel and bevacizumab: First results of a prospective cohort from the French Breast-Cancer InterGroup Incurcancer (UCBG); COMET study</td>
<td>Christelle Levy</td>
<td>Dr. Levy has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-08-06</td>
<td>Screening, management, cancer diagnoses, and outcomes of women with germline BRCA mutations in Israel: The Nogs Clinic experience</td>
<td>Ephrat Levy-Lahad</td>
<td>Dr. Levy-Lahad has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-12-01</td>
<td>The value of RNA-Seq for the detection of clinically actionable targets in breast cancer: A small cohort analysis</td>
<td>Brian Leyland-Jones</td>
<td>Dr. Leyland-Jones has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-08-20</td>
<td>Mitochondria-nuclear communication regulates epithelial-mesenchymal transition and metastasis in triple negative breast cancer</td>
<td>Michael Lewis</td>
<td>Dr. Lewis has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-11-08</td>
<td>Safety and efficacy results from phase I study of BNI 719 plus olaparib/paclitaxel in HR-2 negative metastatic breast cancer</td>
<td>Sharon Lewis</td>
<td>Dr. Lewis has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-07-09</td>
<td>Biomarker analysis from the neoadjuvant KRISTINE study in HER2-positive early breast cancer (EBC)</td>
<td>Saul Lewis Phillips</td>
<td>Ms. Lewis Phillips has disclosed that she receives salary from Genentech, Inc. and has ownership interest, limited partner, StemMed Ltd., StemMed Holdings LLC. These relationships do not impact his ability to review presentations.</td>
</tr>
<tr>
<td>P1-05-22</td>
<td>The clinical utility of RNA-Seq in breast cancer: A small cohort analysis in a clinical setting</td>
<td>Brian Leyland-Jones</td>
<td>Dr. Leyland-Jones has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-05-23</td>
<td>The clinical utility of RNA-Seq in breast cancer: A small cohort analysis in a clinical setting</td>
<td>Brian Leyland-Jones</td>
<td>Dr. Leyland-Jones has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-03-02</td>
<td>The clinical utility of RNA-Seq in breast cancer: A small cohort analysis in a clinical setting</td>
<td>Brian Leyland-Jones</td>
<td>Dr. Leyland-Jones has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-07-02</td>
<td>The clinical utility of RNA-Seq in breast cancer: A small cohort analysis in a clinical setting</td>
<td>Brian Leyland-Jones</td>
<td>Dr. Leyland-Jones has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-12-01</td>
<td>The clinical utility of RNA-Seq in breast cancer: A small cohort analysis in a clinical setting</td>
<td>Brian Leyland-Jones</td>
<td>Dr. Leyland-Jones has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-03-01</td>
<td>A combination of dual inhibition in HER2-negative breast cancer patients: First results of a prospective cohort from the French Breast-Cancer InterGroup Incurcancer (UCBG); COMET study</td>
<td>Brian Leyland-Jones</td>
<td>Dr. Leyland-Jones has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-08-03</td>
<td>Dynamics of cancer stem cell surface marker, CD44 and CD44v6 in the antitumor efficacy of PARP inhibitor in combination with FISH pathway inhibitor in TNBC xenograft model</td>
<td>Brian Leyland-Jones</td>
<td>Dr. Leyland-Jones has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
P4-06-06 Consistent dosing-time dependent tolerability of everolimus (EV) in a pilot study in women with metastatic breast cancer (MBC) and in a mouse chronopharmacology investigation

Hai Mei  Li  Dr. Li has no relevant financial relationships to disclose.

P1-05-01 Landscape of somatic mutations in inflammatory breast cancer whole-genome sequences

Xiaoyong  Li  Xiaoyong Li has no relevant financial relationships to disclose.

P5-16-07 Non-anthraclycine-containing docetaxel plus cyclophosphamide was inferior to docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative or HER2 positive breast cancer: Long term follow-up result from NATT study

Xinheng  Li  Dr. Li has no relevant financial relationships to disclose.

P2-02-16 Comparison of axillary nodal status between different defined clinically node negative breast cancer: is ACOSOG Z0011 criteria applicable to preoperative cytologically negative axilla?

Yafen  Li  Yafen Li has no relevant financial relationships to disclose.

P3-16-07 Race and age differences in PARP1 expression status in the Carolina breast cancer study

Yan  Li  Yan Li has no relevant financial relationships to disclose.

P1-10-10 Risk factors of locoregional recurrence, locoregional failure pattern and role of postmastectomy radiotherapy for T1-2 breast cancers with 1-3 positive axillary lymph nodes

Yuexiong  Li  Yuexiong Li has no relevant financial relationships to disclose.

P5-05-04 Transition from a pre-malignant lesion to cancer does not require stemness of the cancer-originating cells in the lesion

Yi  Li  Dr. Li has no relevant financial relationships to disclose.

Committee Member/Moderator, Basic Science Forum 1

"Tumor exosome and metastasis"

Yi  Li  Dr. Li has no relevant financial relationships with commercial interests to disclose.

P5-10-10 Predictors of breast density among Black and Hispanic women presenting for mammographic screening

Yinan  Li  Yinan Li has no relevant financial relationships to disclose.

P6-01-09 Proposal for a new breast cancer staging classification: Incorporating clinical and biologic factors

Yisheng  Li  Yisheng Li has no relevant financial relationships to disclose.

P6-01-08 Porous silicon microparticle potentiates anti-tumor immunity

Yunfei  Li  Yunfei Li has no relevant financial relationships to disclose.

P3-07-05 CDK8 inhibition improves the efficacy of ER- and HER2-targeted drugs in breast cancer

Zhilin  Liang  Zhilin Liang has no relevant financial relationships to disclose.

P1-01-17 Establishment and preliminary clinical application of breast cancer CTC detection kit based on immune magnetic lipid microsphere/human breast mammaglobin

Xiaofei  Liang  Dr. Liang has no relevant financial relationships to disclose.

P1-03-14 Assessment of stromal characteristics in ductal carcinoma in situ of the breast: An inter-observer variability study

Louis  Libbrecht  Mr. Libbrecht has no relevant financial relationships to disclose.
A directed siRNA screen identifies INHBA as a major regulator of tumor aggressiveness in basal HER2 breast cancer

Tiera Liby

Tiera Liby has no relevant financial relationships to disclose.

Microenvironment microarrays show that microenvironment-mediated mechanisms to lapatinib differ between basal and luminal HER2+ cells.

Tiera Liby

Tiera Liby has no relevant financial relationships to disclose.

Improving the AUC breast cancer staging system by incorporating tumor biomarkers

Daphne Lichensztajn

Dr. Lichensztajn has no relevant financial relationships to disclose.

Comprehensive comparison of breast cancer molecular portraits by African and European ancestry in the cancer genome atlas

Tara Lichtenberg

Ms. Lichtenberg has no relevant financial relationships to disclose.

Improving the AJCC breast cancer staging system by incorporating tumor biomarkers

Daphne Lichensztajn

Dr. Lichensztajn has no relevant financial relationships to disclose.

Comprehensive comparison of breast cancer molecular portraits by African and European ancestry in the cancer genome atlas

Tara Lichtenberg

Ms. Lichtenberg has no relevant financial relationships to disclose.

Improving the AJCC breast cancer staging system by incorporating tumor biomarkers

Daphne Lichensztajn

Dr. Lichensztajn has no relevant financial relationships to disclose.

Improving the AJCC breast cancer staging system by incorporating tumor biomarkers

Daphne Lichensztajn

Dr. Lichensztajn has no relevant financial relationships to disclose.

From monocyte re-programming to the expansion of tumor infiltrating lymphocytes for adoptive T cell therapy

Robin Liechti

Dr. Liechti has no relevant financial relationships to disclose.

Real World data and patterns of care of metastatic breast cancer (MBC) in Brazil: First results of LACOG 0312 retrospective study

Pedro Liedke

Mr. Liedke has no relevant financial relationships to disclose.

Pertuzumab and trastuzumab in combination with weekly paclitaxel delivers high pCR rates with favourable toxicity profile in neo-adjuvant treatment of Her-2 positive breast cancer

Robert Liebross

Dr. Liebross has no relevant financial relationships to disclose.

The role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+/HR+ phase II trial evaluating 12-weeks of neoadjuvant TDM1 ± endocrine therapy (ET) versus T + ET in HER2-positive hormone-receptor-positive early breast cancer (EBC)

Cornelia Liedtke

Dr. Liedtke has disclosed that she is a consultant.

A directed siRNA screen identifies INHBA as a major regulator of tumor aggressiveness in basal HER2 breast cancer

Tiera Liby

Tiera Liby has no relevant financial relationships to disclose.

Microenvironment microarrays show that microenvironment-mediated mechanisms to lapatinib differ between basal and luminal HER2+ cells.

Tiera Liby

Tiera Liby has no relevant financial relationships to disclose.

Improving the AUC breast cancer staging system by incorporating tumor biomarkers

Daphne Lichensztajn

Dr. Lichensztajn has no relevant financial relationships to disclose.

Comprehensive comparison of breast cancer molecular portraits by African and European ancestry in the cancer genome atlas

Tara Lichtenberg

Ms. Lichtenberg has no relevant financial relationships to disclose.

Improving the AJCC breast cancer staging system by incorporating tumor biomarkers

Daphne Lichensztajn

Dr. Lichensztajn has no relevant financial relationships to disclose.

Comprehensive comparison of breast cancer molecular portraits by African and European ancestry in the cancer genome atlas

Tara Lichtenberg

Ms. Lichtenberg has no relevant financial relationships to disclose.

Improving the AJCC breast cancer staging system by incorporating tumor biomarkers

Daphne Lichensztajn

Dr. Lichensztajn has no relevant financial relationships to disclose.

Improving the AJCC breast cancer staging system by incorporating tumor biomarkers

Daphne Lichensztajn

Dr. Lichensztajn has no relevant financial relationships to disclose.

From monocyte re-programming to the expansion of tumor infiltrating lymphocytes for adoptive T cell therapy

Robin Liechti

Dr. Liechti has no relevant financial relationships to disclose.

Real World data and patterns of care of metastatic breast cancer (MBC) in Brazil: First results of LACOG 0312 retrospective study

Pedro Liedke

Mr. Liedke has no relevant financial relationships to disclose.

Pertuzumab and trastuzumab in combination with weekly paclitaxel delivers high pCR rates with favourable toxicity profile in neo-adjuvant treatment of Her-2 positive breast cancer

Robert Liebross

Dr. Liebross has no relevant financial relationships to disclose.

The role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+/HR+ phase II trial evaluating 12-weeks of neoadjuvant TDM1 ± endocrine therapy (ET) versus T + ET in HER2-positive hormone-receptor-positive early breast cancer (EBC)

Cornelia Liedtke

Dr. Liedtke has disclosed that she is a consultant.

A one-day protocol with activities lower than 20 MBq for the detection of sentinel lymph nodes - Experience after 150 cases

Cornelia Liedtke

Dr. Liedtke has no relevant financial relationships to disclose.

Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006-05)

Gerri-Jan Liefers

Dr. Liefers has no relevant financial relationships to disclose.

Safety assessment of extended adjuvant endocrine therapy with letrozole, results of the randomised phase III IDEAL trial (BOOG 2006-05)

Gerri-Jan Liefers

Dr. Liefers has no relevant financial relationships to disclose.

Development and validation of a nomogram predicting pathological axillary status (ypN0 vs. ypN+) in a subgroup of patients converting from cN+ to ycN0 through neoadjuvant therapy (NAT): A transSENTINA substudy

Cornelia Liedtke

Dr. Liedtke has no relevant financial relationships to disclose.

A one-day protocol with activities lower than 20 MBq for the detection of sentinel lymph nodes - Experience after 150 cases

Cornelia Liedtke

Dr. Liedtke has no relevant financial relationships to disclose.

Development and validation of a nomogram predicting pathological axillary status (ypN0 vs. ypN+) in a subgroup of patients converting from cN+ to ycN0 through neoadjuvant therapy (NAT): A transSENTINA substudy

Cornelia Liedtke

Dr. Liedtke has no relevant financial relationships to disclose.

Safety assessment of extended adjuvant endocrine therapy with letrozole, results of the randomised phase III IDEAL trial (BOOG 2006-05)

Gerri-Jan Liefers

Dr. Liefers has no relevant financial relationships to disclose.

Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006-05)

Gerri-Jan Liefers

Dr. Liefers has no relevant financial relationships to disclose.
Diffuse optical tomography can predict pathologic complete response in patients with HER2+ or triple negative breast cancer undergoing neoadjuvant chemotherapy

Emerson Lim

Emerson Lim has no relevant financial relationships to disclose.

Prognostic role of PIK3CA mutational status in circulating tumor DNA (ctDNA) from HER2-positive metastatic breast cancer patients

Jin Lim

Jin Lim has no relevant financial relationships to disclose.

SYD985, a novel anti-HER2 ADC, shows promising activity in patients with HER2-positive and HER2-negative metastatic breast cancer: A pilot study

Jong Won Lim

Jong Won Lim has no relevant financial relationships to disclose.

Ex vivo shear-wave elastography of axillary lymph nodes predicting nodal metastasis in patients with primary breast cancer: A pilot study

Seock-Ah Lim

Seock-Ah Lim has no relevant financial relationships to disclose.

Serum 25-hydroxyvitamin D levels and oncologic outcomes of breast cancer patients receiving neoadjuvant chemotherapy

Sung Mook Lim

Sung Mook Lim has no relevant financial relationships to disclose.

Tomosynthesis as an alternative to magnetic resonance imaging (MRI) in assessing invasive lobular carcinoma (ILC) multifocality

Yit Yoong Lim

Yit Yoong Lim has no relevant financial relationships to disclose.

Real World data and patterns of care of metastatic breast cancer (MBC) in Brazil: First results of LACOG 0312 retrospective study

Dr. Lim has no relevant financial relationships to disclose.

An international multicenter study to evaluate reproductibility of automated scoring methods for assessment of Ki67 in breast cancer

Joline Lim

Ms. Lim has disclosed that she is an investigator in the trial.

Do patients and nurses outside clinical trial prefer subcutaneous trastuzumab over conventional intravenous infusion? Instituto Oncologico Nacional experience

Maria Lim

Maria Lim has no relevant financial relationships to disclose.

Study on the usefulness of the skin wound therapeutic agent 'Neo dermal activator' in breast cancer surgery

Dr. Lim has no relevant financial relationships to disclose.

Circulating tumor DNA (ctDNA): A real-time application of precision medicine to the management of metastatic breast cancer (MBC)

Dr. Lim has no relevant financial relationships to disclose.

Patient derived DCS mouse-intratubal (MMNC) models recapitulate the full spectrum of human patient pathology and histologic features including progression to invasion in a subset of cases

Dr. Lim has no relevant financial relationships to disclose.

Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multi-center trial

Dr. Lim has no relevant financial relationships to disclose.

Patterns of axillary evaluation in older patients (pts) with breast cancer and impact on adjuvant therapy

Dr. Lim has no relevant financial relationships to disclose.

Genomic pattern of breast carcinomas carrying mutations of non-BRCA homologous recombination genes

Ching-Hung Lin

Ching-Hung Lin has no relevant financial relationships to disclose.

Synergistic effect of EGFR1 inhibitor and paclitaxel in newly patient-derived metastatic carcinoma cell line which harbored EGFR gene amplification

Ching-Hung Lin

Ching-Hung Lin has no relevant financial relationships to disclose.
Molecular differences between screen-detected and interval breast cancers are largely explained by PAM50 subtypes

Nicolas Lindberg

Mr. Lindberg has disclosed that he receives salary from and has ownership in F. Hoffmann-La Roche Ltd.

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer: Subgroup analyses of the PERUSE study

Nicolas Lindberg

Mr. Lindberg has disclosed that he receives salary from and has ownership in F. Hoffmann-La Roche Ltd.

Weekly doxorubicin and daily oral cyclophosphamide followed by nab-paclitaxel for adjuvant therapy of high-risk localized breast cancer

Henrik Lindman

Dr. Lindman has no relevant financial relationships to disclose.

Weekly differentiation of FDG SUVmax in bone and non-boney metastatic breast cancer lesions in local area network PET/CT scanners

Hannah Linden

Dr. Linden has no relevant financial relationships to disclose.

Phase II trial of nab-paclitaxel and bevacizumab followed by maintenance targeted therapy with bevacizumab and erlotinib

Hannah Linden

Dr. Linden has no relevant financial relationships to disclose.

Weekly differentiation of FDG SUVmax in bone and non-boney metastatic breast cancer lesions in local area network PET/CT scanners

Hannah Linden

Dr. Linden has no relevant financial relationships to disclose.

Weekly differentiation of FDG SUVmax in bone and non-boney metastatic breast cancer lesions in local area network PET/CT scanners

Hannah Linden

Dr. Linden has no relevant financial relationships to disclose.

Optimized test-retest fidelity of FDG SUVmax in bone and non-boney metastatic breast cancer lesions in local area network PET/CT scanners

Hannah Linden

Dr. Linden has no relevant financial relationships to disclose.

Combined targeted therapies for advanced triple negative breast cancer: A phase II trial of nab-paclitaxel and bevacizumab followed by maintenance targeted therapy with bevacizumab and erlotinib

Hannah Linden

Dr. Linden has no relevant financial relationships to disclose.

Preliminary safety and efficacy of trastuzumab emtansine (T-DM1) in 399 patients with central nervous system metastases: Exploratory subgroup analysis from the KAMILLA study

Nicolas Lindberg

Mr. Lindberg has disclosed that he receives salary from and has ownership in F. Hoffmann-La Roche Ltd.

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (PERUSE)

Nicolas Lindberg

Mr. Lindberg has disclosed that he receives salary from and has ownership in F. Hoffmann-La Roche Ltd.

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer: Subgroup analyses of the PERUSE study

Nicolas Lindberg

Mr. Lindberg has disclosed that he receives salary from F. Hoffmann-La Roche Ltd.

RANK ligand as a target for breast cancer prevention in BRCA1 mutation carriers

Geoffrey Lindeman

Mr. Lindeman has disclosed that he is on an Amgen Advisory Board and has presented at Amgen speaker's bureaus.
Intra-tumor heterogeneity of the estrogen receptor predicts less benefit from tamoxifen therapy and poor long-term breast cancer patient survival - Retrospective analyses of the STO-3 randomized trial

Linda Lindström

Dr. Lindström has no relevant financial relationships to disclose.

Steroid receptors and steroidogenic enzymes in human breast cancer: Associations with breast cancer subtypes and clinical outcome

Jonas Lindström

Dr. Lindström has no relevant financial relationships to disclose.

Chronic inhibition of signal transducer and activator of transcription 3/5 in treatment-resistant human breast cancer cell subtypes: Convergence on the reactive oxygen species/SUMOylation pathway and its effects on xCT expression and system x, activity

Katja Linher-Melville

Dr. Linher-Melville has no relevant financial relationships to disclose.

Identification of breast cancers with an indolent disease course: 70 gene indolent threshold validation in a Swedish randomized trial of tamoxifen vs. not, with 20-year outcomes

Linda Lindström

Dr. Lindström has no relevant financial relationships to disclose.

Steroid receptors and steroidogenic enzymes in human breast cancer: Associations with breast cancer subtypes and clinical outcome

Jonas Lindström

Dr. Lindström has no relevant financial relationships to disclose.

Chronic inhibition of signal transducer and activator of transcription 3/5 in treatment-resistant human breast cancer cell subtypes: Convergence on the reactive oxygen species/SUMOylation pathway and its effects on xCT expression and system x, activity

Katja Linher-Melville

Dr. Linher-Melville has no relevant financial relationships to disclose.

DCIS biological risk profile predicts risk of recurrence after breast conserving surgery in a Kaiser Permanente NW population

Steven Link

Prof. Link has disclosed that he receives salary from and has a patent with Prelude Corporation. He has also disclosed that he has an NIH Grant 8R01CA127443-03.

The efficacy and safety of the addition of fulvestrant to adjuvant hormonal therapy in postmenopausal women with hormone-receptor positive early breast cancer. First results of the TEAM-IB trial (BOOQ 2006-04)

S. Linn

Dr. Linn has disclosed that he has patent WO/2015/080585 and PCT/EP2014/080813 (Means and methods for molecular classification of BRCA-like breast and/or ovarian cancer. (Filed November 28, 2014)). He also disclosed he is an advisory board for Novartis, Roche, AstraZeneca (paid to institution) and Philips (unpaid). He disclosed received unrestricted research grant and study drug (olaparib) for REVIVAL study (NCT02141284) from Astra Zeneca, unrestricted research grant for POSEIDON study (NCT02208179) from Genentech, unrestricted research grant Triple B study (NCT01898117) from Roche (paid to institution).

Intensified alkylating chemotherapy in patients with oligo-metastatic breast cancer harboring homologous recombination deficiency: The DOLL study

Sabine Linn

Dr. Linn has disclosed that he has patent WO/2015/080585 and PCT/EP2014/080813 (Means and methods for molecular classification of BRCA-like breast and/or ovarian cancer. (Filed November 28, 2014)). He also disclosed he is an advisory board for Novartis, Roche, AstraZeneca (paid to institution) and Philips (unpaid). He disclosed received unrestricted research grant and study drug (olaparib) for REVIVAL study (NCT02141284) from Astra Zeneca, unrestricted research grant for POSEIDON study (NCT02208179) from Genentech, unrestricted research grant Triple B study (NCT01898117) from Roche (paid to institution).

Phase II of POSEIDON: A phase Ib / randomised phase II trial of olaparib / randomised phase II trial of olaparib plus taselisib or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment

Sabine Linn

Sabine Linn has disclosed that she is on advisory boards for bevacizumab (paid to the institution). She has also disclosed she received the drug (taselisib) for the POSEIDON study from Genentech (paid to the institution) and she received an unrestricted grant for Triple B study (NCT01898117) and off-label study drug.

Concordance of local immunohistochemistry with TargetPrint microarray based assessment of ER, PR and Her2 in breast cancer: The first blow is half the battle

Sabine Linn

Dr. Linn has no relevant financial relationships to disclose.

How population-based data complement trial data in the adjuvant endocrine treatment of ER+/HER2+ breast cancers

Sabine Linn

Dr. Linn has no relevant financial relationships to disclose.

Long-term survival in HER2-positive metastatic breast cancer: The first blow is half the battle

Sabine Linn

Dr. Linn has disclosed that he has patent WO/2015/080585 and PCT/EP2014/080813 (BRCA-like classifier). He also disclosed non-financial support from AstraZeneca, grants and other from Roche, grants from Genentech, other from Novartis, other from Cergentis, other from Philips Health BV, outside the submitted work.
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Author</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2-07-12</td>
<td>An exploratory correlative biomarker analysis of NSABP FB-7: a phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel (P) plus neratinib (N) or trastuzumab (T) or neratinib and trastuzumab (N+T) followed by doxorubicin and cyclophosphamide (AC) with postoperative T in women with locally advanced HER2-positive breast cancer</td>
<td>Corey Lipchick</td>
<td>Dr. Lipchick has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-04-08</td>
<td>BGB324, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy in mammary adenocarcinoma</td>
<td>Katarzyna Lipinska</td>
<td>Dr. Lipinska has disclosed that she receives salary and has ownership.</td>
</tr>
<tr>
<td>P3-08-02</td>
<td>GEMC201 flips breast cancer cells by inhibiting mitochondrial respiration</td>
<td>Stanley Lipkowitz</td>
<td>Dr. Lipkowitz has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P06-01</td>
<td>Analysis of breast cancer in young women in the department of defense (DDD) database</td>
<td>Stanley Lipkowitz</td>
<td>Dr. Lipkowitz has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>O3T-04-05</td>
<td>BREC12-158: A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer (TNBC)</td>
<td>Marc Lippman</td>
<td>Dr. Lippman has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-06-02</td>
<td>BREC12-158: A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer (TNBC)</td>
<td>Marc Lippman</td>
<td>Dr. Lippman has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-05-03</td>
<td>BREC12-158: A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer (TNBC)</td>
<td>Marc Lippman</td>
<td>Dr. Lippman has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-06-05</td>
<td>Novel cytotoxic RNA aptamers that distinguish between metastasis-prone and indolent breast and prostate cancers</td>
<td>Marc Lippman</td>
<td>Dr. Lippman has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-05-02</td>
<td>Chronic GSK3β exposure induces a metastatic phenotype in ER+ positive breast cancer cells through transcriptional reprogramming</td>
<td>Marc Lippman</td>
<td>Dr. Lippman has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-08-05</td>
<td>Genomic-wide identification of transcripts regulated by estrogen in MCF-7 cells using BrU-seq</td>
<td>Doron Lipson</td>
<td>Mr. Lipson has disclosed that he is an employee of Foundation Medicine Inc.</td>
</tr>
<tr>
<td>P3-01-03</td>
<td>Milky Way sign: A potential predictive sign of breast cancer on digital breast tomosynthesis</td>
<td>Allan Lipton</td>
<td>Dr. Lipton has disclosed that he received a research grant from Hologic, Inc.</td>
</tr>
<tr>
<td>P2-02-10</td>
<td>Reduced serum B-cell maturation antigen levels predict poor outcome in metastatic breast cancer patients in a phase 3 randomised 2x1 single-arm therapy trial</td>
<td>Allan Lipton</td>
<td>Dr. Lipton has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-07-06</td>
<td>Reduced serum B-cell maturation antigen levels predict poor outcome in metastatic breast cancer patients in a phase 3 randomised 2x1 single-arm therapy trial</td>
<td>Allan Lipton</td>
<td>Dr. Lipton has disclosed that he has contracts with Amgen, Novartis, Theranostics Health. He has also disclosed that he receives compensation from Novartis, is on the Speaker's Bureau for Novartis and has given expert testimony for Novartis.</td>
</tr>
<tr>
<td>P4-15-01</td>
<td>Cost-effectiveness of pre-implantation genetic diagnosis for BRCA mutation carriers</td>
<td>Joseph Lipton</td>
<td>Dr. Lipton has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-04-05</td>
<td>Interim analysis of the phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel (PTX) plus neratinib (NER) or trastuzumab (TR) or neratinib and trastuzumab (N+T) followed by doxorubicin and cyclophosphamide (AC) with postoperative T in women with locally advanced HER2-positive breast cancer</td>
<td>Jason Litton</td>
<td>Dr. Litton has disclosed that he receives salary from Cloud Oncology.</td>
</tr>
<tr>
<td>P6-11-03</td>
<td>A phase 2 open-label study of lucitanib in patients (pts) with HER2 aberrant metastatic breast cancer (MBC)</td>
<td>Jason Litton</td>
<td>Dr. Litton has disclosed that he receives salary from Clovis Oncology.</td>
</tr>
<tr>
<td>P3-01-03</td>
<td>Milky Way sign: A potential predictive sign of breast cancer on digital breast tomosynthesis</td>
<td>Allan Lipton</td>
<td>Dr. Lipton has disclosed that he received a research grant from Hologic, Inc.</td>
</tr>
<tr>
<td>P2-02-10</td>
<td>Reduced serum B-cell maturation antigen levels predict poor outcome in metastatic breast cancer patients in a phase 3 randomised 2x1 single-arm therapy trial</td>
<td>Allan Lipton</td>
<td>Dr. Lipton has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-07-06</td>
<td>Reduced serum B-cell maturation antigen levels predict poor outcome in metastatic breast cancer patients in a phase 3 randomised 2x1 single-arm therapy trial</td>
<td>Allan Lipton</td>
<td>Dr. Lipton has disclosed that he has contracts with Amgen, Novartis, Theranostics Health. He has also disclosed that he receives compensation from Novartis, is on the Speaker's Bureau for Novartis and has given expert testimony for Novartis.</td>
</tr>
<tr>
<td>P4-15-01</td>
<td>Cost-effectiveness of pre-implantation genetic diagnosis for BRCA mutation carriers</td>
<td>Joseph Lipton</td>
<td>Dr. Lipton has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-04-05</td>
<td>Interim analysis of the phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel (PTX) plus neratinib (NER) or trastuzumab (TR) or neratinib and trastuzumab (N+T) followed by doxorubicin and cyclophosphamide (AC) with postoperative T in women with locally advanced HER2-positive breast cancer</td>
<td>Jason Litton</td>
<td>Dr. Litton has disclosed that he receives salary from Cloud Oncology.</td>
</tr>
<tr>
<td>P6-11-03</td>
<td>A phase 2 open-label study of lucitanib in patients (pts) with HER2 aberrant metastatic breast cancer (MBC)</td>
<td>Jason Litton</td>
<td>Dr. Litton has disclosed that he receives salary from Clovis Oncology.</td>
</tr>
</tbody>
</table>
Cardiac safety of dual anti-HER2 therapy in the neoadjuvant setting for treatment of HER2-positive breast cancer

Jennifer Liu
Ms. Liu has no relevant financial relationships to disclose.

MicroRNA-367a promotes tumor growth and stemness potential by targeting FBXW7 in breast cancer

Jian Liu
Jian Liu has no relevant financial relationships to disclose.

Race is not a contributing factor to breast cancer-free interval outcome for patients with equal access to healthcare treated at a military medical center

Jianfang Liu
Jianfang Liu has no relevant financial relationships to disclose.

Axillary reverse mapping using fluorescence imaging in the surgical treatment for breast cancer patients

Jian Liu
Jian Liu has no relevant financial relationships to disclose.

MicroRNA-367a promotes tumor growth and stemness potential by targeting FBXW7 in breast cancer

Jian Liu
Jian Liu has no relevant financial relationships to disclose.

Race is not a contributing factor to breast cancer-free interval outcome for patients with equal access to healthcare treated at a military medical center

Jianfang Liu
Jianfang Liu has no relevant financial relationships to disclose.

Axillary reverse mapping using fluorescence imaging in the surgical treatment for breast cancer patients

Jian Liu
Jian Liu has no relevant financial relationships to disclose.

MicroRNA-367a promotes tumor growth and stemness potential by targeting FBXW7 in breast cancer

Jian Liu
Jian Liu has no relevant financial relationships to disclose.

Race is not a contributing factor to breast cancer-free interval outcome for patients with equal access to healthcare treated at a military medical center

Jianfang Liu
Jianfang Liu has no relevant financial relationships to disclose.

Axillary reverse mapping using fluorescence imaging in the surgical treatment for breast cancer patients

Jian Liu
Jian Liu has no relevant financial relationships to disclose.

MicroRNA-367a promotes tumor growth and stemness potential by targeting FBXW7 in breast cancer

Jian Liu
Jian Liu has no relevant financial relationships to disclose.

Axillary reverse mapping using fluorescence imaging in the surgical treatment for breast cancer patients

Jian Liu
Jian Liu has no relevant financial relationships to disclose.

MicroRNA-367a promotes tumor growth and stemness potential by targeting FBXW7 in breast cancer

Jian Liu
Jian Liu has no relevant financial relationships to disclosure.

Race is not a contributing factor to breast cancer-free interval outcome for patients with equal access to healthcare treated at a military medical center

Jianfang Liu
Jianfang Liu has no relevant financial relationships to disclose.

Axillary reverse mapping using fluorescence imaging in the surgical treatment for breast cancer patients

Jian Liu
Jian Liu has no relevant financial relationships to disclose.

MicroRNA-367a promotes tumor growth and stemness potential by targeting FBXW7 in breast cancer

Jian Liu
Jian Liu has no relevant financial relationships to disclose.

Axillary reverse mapping using fluorescence imaging in the surgical treatment for breast cancer patients

Jian Liu
Jian Liu has no relevant financial relationships to disclose.

MicroRNA-367a promotes tumor growth and stemness potential by targeting FBXW7 in breast cancer

Jian Liu
Jian Liu has no relevant financial relationships to disclose.

Axillary reverse mapping using fluorescence imaging in the surgical treatment for breast cancer patients

Jian Liu
Jian Liu has no relevant financial relationships to disclose.
Predictive effect of cytotoxic tumor infiltrating lymphocytes in HER2-positive metastatic breast cancer: A correlative study with CCTG MA.31
Shuzhen Liu
Shuzhen Liu has no relevant financial relationships to disclose.

Prospective longitudinal study of epidermal thickening in breast cancer patients treated with conventional versus hypofractionated radiotherapy
Yan Liu
Dr. Liu has no relevant financial relationships to disclose.

Novel preclinical approaches to resistance pathways: The CRISPR technology
Niele Liu
Dr. Liu has no relevant financial relationships with commercial interests to disclose.

Risk factors of locoregional recurrence, locoregional failure patterns and role of postmastectomy radiotherapy for T1-2 breast cancers with 1-3 positive axillary lymph nodes
Xinfang Liu
Xinfang Liu has no relevant financial relationships to disclose.

Visualization of the AIM interactor 1 signaling in metastatic breast cancer cells
Xili Liu
Xili Liu has no relevant financial relationships to disclose.

Clinical and molecular relevance of intra-tumor genetic heterogeneity in breast cancer: Integrative analysis of data from The Cancer Genome Atlas
Xin-Yu Liu
Xi-Yu Liu has no relevant financial relationships to disclose.

Clinical and molecular relevance of intra-tumor genetic heterogeneity in breast cancer: Integrative analysis of data from The Cancer Genome Atlas
Yi-Rong Liu
Yi-Rong Liu has no relevant financial relationships to disclose.

ERα propelled drug-resistance-facilitating global DNA hypermethylation by promoting the DNMT1 gene expression
Yue Liu
Yue Liu has no relevant financial relationships to disclose.

Risk factors of locoregional recurrence, locoregional failure patterns and role of postmastectomy radiotherapy for T1-2 breast cancers with 1-3 positive axillary lymph nodes
Yueping Liu
Yueping Liu has no relevant financial relationships to disclose.

Milky Way sign: A potential predictive sign of breast cancer on digital breast tomosynthesis
Yujie Liu
Yujie Liu has no relevant financial relationships to disclose.

Environmental influence on epigenetic markers in the development of breast cancer
Yunlong Liu
Yunlong Liu has no relevant financial relationships to disclose.

Disruption of the estradiol-regulated NTN1-UNC5A dependence receptor signaling axis causes a hybrid basal/luminal molecular phenotype in estrogen receptor-positive breast cancer cells
Yunlong Liu
Yunlong Liu has no relevant financial relationships to disclose.

Genomic analysis of molecular discordance of paired primary and recurrent triple negative breast cancer
Zheng Liu
Zheng Liu has no relevant financial relationships to disclose.

The impact of genome mutation on metastatic breast cancer treatment: A retrospective clinical trial
Zheng Liu
Zheng Liu has no relevant financial relationships to disclose.

Accelerated partial breast irradiation versus whole breast irradiation: Health-related quality of life analysis from a phase 3 trial
Lorenzo Livi
Prof. Livi has no relevant financial relationships to disclose.

Disruption of the extracellular regulated TNKS1-UNC5A dependence receptor signaling axis causes a hybrid basal/luminal molecular phenotype in estrogen receptor-positive breast cancer cells
Lorenzo Livi
Prof. Livi has no relevant financial relationships to disclose.

Luminal A breast cancer: Is it really a “good prognosis” disease? Preliminary results of the GIM-13 - AMBRA study
Lorenzo Livi
Prof. Livi has no relevant financial relationships to disclose.

First and further line choices of treatment for HER2-VE metastatic breast cancer (MBC) according to adjuvant treatment and biological subtype. Preliminary results of the observational "GIM-13 - AMBRA" Italian study
Lorenzo Livi
Prof. Livi has no relevant financial relationships to disclose.

A single-blind, randomised, placebo-controlled phase II study to evaluate the impact of oral ibandronate on bone mineral density in osteoporotic breast cancer patients receiving adjuvant aromatase inhibitors: Final results of the single-center RONADIV trial
Lorenzo Livi
Prof. Livi has no relevant financial relationships to disclose.

Luminal A Breast cancer: Is it really a “good prognosis” disease? Preliminary results of the SIM 13 - AMBRA study
Lorenzo Livi
Prof. Livi has no relevant financial relationships to disclose.

First and further line choices of treatment for HER2-VE metastatic breast cancer (MBC) according to adjuvant treatment and biological subtype. Preliminary results of the observational "GIM-13 - AMBRA" Italian study
Lorenzo Livi
Prof. Livi has no relevant financial relationships to disclose.

Discovery of molecular predictors of late breast cancer specific events (BCSE) in ER+, node+ breast cancer - new transcriptome expression whole gene analysis of the phase III adjunct trial SWOG SB0114
Robert Livingston
Dr. Livingston has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P6-12-16</td>
<td>Delivery and anti-tumor activity of nanoliposomal irinotecan (Nal-IRI, MM-398) in metastatic xenograft models of triple negative breast cancer</td>
<td>Paul Lockman</td>
<td>Dr. Lockman has disclosed that the research was conducted under a Material Transfer and Research Agreement with Merrimack Pharmaceuticals. Additional contracted research includes: NKTR Therapeutics, Synthex Precision Medicine, &amp; Lilly and Company, BioOasis.</td>
</tr>
<tr>
<td>P1-08-02</td>
<td>Mutant GATA3 actively promotes the growth of normal and malignant mammary cells</td>
<td>Kristopher Lofgren</td>
<td>Dr. Lofgren has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-12-02</td>
<td>Serum-lipid profile among triple negative breast cancer patients as a biomarker of poor outcome</td>
<td>Yingge Laffare</td>
<td>Dr. Laffare has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-22-23</td>
<td>Phase II trial of naxotrate for metastatic triple negative breast cancer</td>
<td>Loretta Lofts</td>
<td>Dr. Lofts has disclosed that she has ownership in Lilly, Angen, Merck, Silkred, and Johnson &amp; Johnson.</td>
</tr>
<tr>
<td>P4-21-29</td>
<td>HER2-associated lipogenic phenotype as a potential therapeutical target in breast cancer patients</td>
<td>Angèle Logullo</td>
<td>Prof. Logullo has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-08-01</td>
<td>IsomiRs and tRNA fragments are race-dependent regulators in breast cancer</td>
<td>Philippe Loher</td>
<td>Mr. Loher has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-16-17</td>
<td>Population based long term outcomes of pathologic complete response after neoadjuvant chemotherapy in stage I-III breast cancer: The British Columbia experience</td>
<td>Caroline Lohrach</td>
<td>Ms. Lohrach has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-03-06</td>
<td>Genomic characterization of 392 primary breast cancers</td>
<td>Serhene Loi</td>
<td>Dr. Loi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-04-15</td>
<td>O2S20x-PD-1+ T-cells identify a subset of triple-negative breast cancer eligible for targeted checkpoint inhibition</td>
<td>Serhene Loi</td>
<td>Dr. Loi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-22-06</td>
<td>Treatment postprogression in women with endocrine-resistant HR+/HER2- advanced breast cancer who received palbociclib plus fulvestrant in PALOMA-3</td>
<td>Serhene Loi</td>
<td>Dr. Loi has disclosed that her institute has received research funding from Merck, Roche-Gentech, Pfizer and Novartis.</td>
</tr>
<tr>
<td>P4-22-07</td>
<td>Long-term safety of palbociclib in combination with endocrine therapy in treatment-naive and previously treated women With HR+, HER2- advanced breast cancer: A pooled analysis from randomized phase 2 and 3 studies</td>
<td>Serhene Loi</td>
<td>Dr. Loi has disclosed that she receives contracts from Pfizer (Institution), Roche (Institution), Genentech (Institution), Merck (Institution), Novartis (Institution).</td>
</tr>
<tr>
<td>P5-10-02</td>
<td>MHC-II-positive breast tumors are more immunogenic and may preferentially select for LAG-3-positive tumor immune infiltrates</td>
<td>Serhene Loi</td>
<td>Dr. Loi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P02-08</td>
<td>Neotaxib + fulvestrant in RB82-mutant, HER2-non-amplified, estrogen receptor (ER)-positive, metastatic breast cancer (MBC): Preliminary analysis from the phase II SUMMIT trial</td>
<td>Serhene Loi</td>
<td>Dr. Loi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S1-10</td>
<td>Clinical implications of somatic mutations in post-menopausal early-stage estrogen receptor (ER)-positive HER2-negative breast cancer (BC): Results from the BIG 1-98 study</td>
<td>Serhene Loi</td>
<td>Dr. Loi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Committee Member/Speaker, Year</td>
<td>In Review</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OT1-02-09</td>
<td>&quot;Best of the year 2016: translational research&quot;</td>
<td>Serhene Loi</td>
<td>Dr. Loi has disclosed that she does contracted research for Merck, Novartis, and Roche-Gentech. These relationships do not impact her ability to present an unbiased presentation.</td>
</tr>
<tr>
<td>OT2-04-02</td>
<td>Comparison of axillary sentinel lymph node biopsy versus no axillary surgery in patients with early-stage invasive breast cancer and breast-conserving surgery: A randomized prospective surgical trial. The Intergroup-Sentinel-Mamma (INSMMA) trial</td>
<td>Silvia Lobbil</td>
<td>Dr. Lobbil has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-09-02</td>
<td>Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSecto in triple-negative early breast cancer</td>
<td>Silvia Lobbil</td>
<td>Dr. Lobbil has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT2-04-02</td>
<td>Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSecto in triple-negative early breast cancer</td>
<td>Silvia Lobbil</td>
<td>Dr. Lobbil has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
Cochrane review of capecitabine for hormone receptor positive versus hormone receptor negative breast cancer
Anne Long
Ms. Long has no relevant financial relationships to disclose.

A p53-based strategy for protecting normal breast tissue from chemotherapy-induced damage in breast conserving therapy
Meijun Long
Dr. Long has no relevant financial relationships to disclose.

Skin-metastatic and metastatic breast cancer patients’ priorities when considering a treatment decision
Margaret Longacre
Dr. Longacre has no relevant financial relationships to disclose.

H-ferritin allows nanotrimetric treatment of breast cancer with dissolution preventing drug resistance and circumventing cardiotoxicity
Erika Longhi
Dr. Longhi has no relevant financial relationships to disclose.

SOLAR-1: A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy
Anne-Sophie Longin
Ms. Longin has disclosed that she receives salary from Novartis.

Non-metastatic and metastatic breast cancer patients' priorities when considering a treatment decision
Margaret Longacre
Dr. Longacre has no relevant financial relationships to disclose.

H-ferritin allows nanotrimetric treatment of breast cancer with dissolution preventing drug resistance and circumventing cardiotoxicity
Erika Longhi
Dr. Longhi has no relevant financial relationships to disclose.

Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study
Virginia Longo
Ms. Longo has no relevant financial relationships to disclose.

Pertuzumab and trastuzumab in combination with weekly paclitaxel delivers high pCR rates with favourable toxicity profile in neo-adjuvant treatment of Her-2 positive breast cancer
Sarah Longshore
Ms. Longshore has no relevant financial relationships to disclose.

Efficacy and gene expression results from SOLTI1007 NEOERIBULIN phase II clinical trial in HER2-negative early breast cancer
Rafael Lopez
Dr. Lopez has no relevant financial relationships to disclose.

Do patients and nurses outside clinical trial prefer subcutaneous trastuzumab over conventional intravenous infusion? Instituto Oncologico Nacional experience
Roberto Lopez
Dr. Lopez has no relevant financial relationships to disclose.
OT3-01-02
CNI-001-006 trial: Reversion of T-cell exhaustion caused by chronic treatment with hypoxia-inducing antiangiogenic treatment by durvalumab in HER2-negative breast cancer: A pilot proof-of-concept trial
José Lopez-Acosta
Dr. Lopez has no relevant financial relationships to disclose.

PS-08-11
Primary anorectal malignancies and risk of breast cancer molecular subtypes in northern Mexican women
Cubeth López-Carrillo
Dr. López-Carrillo has no relevant financial relationships to disclose.

PS-06-08
BRCA1 promoter hypermethylation, but not BRCA1 expression, is associated with basal-like features and good prognosis in triple negative breast cancer
Evelyn Lopez-Craper
Dr. Lopez has no relevant financial relationships to disclose.

P1-04-01
Increased stromal lymphocytes in breast cancer patients with autologous dendritic cell vaccination plus neoadjuvant chemotheraph
Asencion Lopez-Diaz
Asencion Lopez-Diaz has no relevant financial relationships to disclose.

OT1-01-04
VENTANA (SOLTI-1501): Oral metronomic vinorelbine combined with endocrine therapy in luminal/HER2-negative early breast cancer: A window of opportunity trial
Ana Lopez-Gonzalez
Dr. Lopez-Gonzalez has no relevant financial relationships to disclose.

OT1-02-03
Phase I multicenter clinical trial evaluating the combination of trastuzumab emtansine (T-DM1) and non-pegylated liposomal doxorubicin (NPLD) in HER2-positive metastatic breast cancer (MBC) (MEDOPP038 study)
Elena Lopez-Miranda
Dr. Lopez-Miranda has no relevant financial relationships to disclose.

P6-11-13
Phase II study evaluating the safety and clinical activity of lumetuzumab combined with pertuzumab and paclitaxel in HER2-negative metastatic breast cancer
Jose Lopez-Martin
Dr. Lopez-Martin has no relevant financial relationships to disclose.

OT1-01-06
PIQHASSO: Open label, non-randomized, multicenter phase 1/2b study investigating safety and efficacy of PQR309 and eribulin combination in patients (pts) with locally advanced (LA) or metastatic HER2 (-) and triple-negative breast cancer (TNBC) (study PQR309-007)
Elena Lopez-Miranda
Dr. Lopez-Miranda has no relevant financial relationships to disclose.

OT1-02-05
Phase I multicenter clinical trial evaluating the combination of trastuzumab emtansine (T-DM1) and non-pegylated liposomal doxorubicin (NPLD) in HER2-positive metastatic breast cancer (MBC) (MEDOPP038 study)
Elena Lopez-Miranda
Dr. Lopez-Miranda has no relevant financial relationships to disclose.

P1-10-20
A multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer: Early results of unplanned boost participants
C Lopez-Penalver
C Lopez-Penalver has no relevant financial relationships to disclose.

P1-10-19
Two-year follow-up results of a multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer
Cristina Lopez-Penalver
Dr. Lopez-Penalver has no relevant financial relationships to disclose.

P4-05-16
FAPS (fibroblast activation protein-α) analysis in breast tumor cells and stroma after neoadjuvant treatment
Fernando Lopez-Rios
Dr. Lopez-Rios has no relevant financial relationships to disclose.

P4-20-01
Implications of financial modeling in breast cancer clinical research from 1990 to 2010
Sara Lopez-Tarabilla
Dr. Lopez-Tarabilla has no relevant financial relationships to disclose.

Committee Member
Charles Loprinzi
Dr. Loprinzi has disclosed that he receives consulting fees from MedPharma and Lpath. He also disclosed that he does contracted research for Pfizer and Janssen Pharmaceuticals. These relationships do not impact his ability to review presentations.

OT2-01-16
Evaluating targets in localized and advanced breast cancer by sequencing tumor DNA at diagnosis and after progression (SISIA)
Black Lora
Black Lora has no relevant financial relationships to disclose.

OT1-01-06
PIQHASSO: Open label, non-randomized, multicenter phase 1/2b study investigating safety and efficacy of PQR309 and eribulin combination in patients (pts) with locally advanced (LA) or metastatic HER2 (-) and triple-negative breast cancer (TNBC) (study PQR309-007)
Simon Lord
Dr. Lord has no relevant financial relationships to disclose.
BGB324, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy in mammary adenocarcinoma

Active surveillance with a combination of tumor marker CAL7.39 and detection of circulating tumor cells two year after primary diagnosis strongly predicts subsequent prognosis

Circulating tumor cells (CTC) and endothelial cells (CEC) prognostic value in HER2 negative metastatic breast cancer patients treated with first line weekly paclitaxel and bevacizumab: First results of a prospective cohort from the French Breast Cancer InterGroup UniCancer (UCBG): COMET study

UCBG 2-14: A prospective multicenter non-randomized trial evaluating the effect of EndoPredict® (EPclin®) clinic-genomic test on treatment decision making among patients with intermediate clinical risk

Prediction of underestimation associated with flat epithelial atypia, atypical ductal hyperplasia and atypical lobular hyperplasia by needle biopsy: Experience in an Argentine breast unit

Long-term outcome of HER2-normal early stage breast cancer (ESBC) patients (Pts) treated with docetaxel-cyclophosphamide (TC) chemotherapy (CTx): Mature results of a single-institution experience

Long survival of patients with locally advanced breast cancer on combined neoadjuvant chemotherapy and immune potentiation: Modern lessons from an old study

Development of a panel of serum-based protein biomarkers for the non-invasive detection of breast cancer in BI-RADS category 4 patients

Sentinel node detection after neoadjuvant chemotherapy in patient without previous axillary node involvement (GANEA 2 trial): Follow-up of a prospective multi-institutional cohort

Collateral damage from metastatic breast cancer - Preliminary results

Automated, low-cost palpable breast lump triage for economically-developing countries

Relationship between obesity and breast tumor pathology in a contemporary set of patients

An acquired HER2 T798 gatekeeper mutation induces resistance to neratinib in a patient with HER2 mutant-driven breast cancer

Long-term outcome of HER2-normal early stage breast cancer (ESBC) patients (Pts) treated with docetaxel-cyclophosphamide (TC) chemotherapy (CTx): Mature results of a single-institution experience

Her2 and hormonal receptor analysis in breast cancer synchronic node metastases could add therapeutic information
Long-term safety of palbociclib in combination with endocrine therapy in treatment-naive and previously treated women with HR+, HER2- advanced breast cancer: A pooled analysis from randomized phase 2 and 3 studies

Dongrui Lu

Dongrui Lu has disclosed that he receives salary from and has ownership in Pfizer.

Recognition of autologous neoantigens by tumor-infiltrating lymphocytes derived from breast cancer metastases

Jiely Lu

Dr. Lu has no relevant financial relationships to disclose.

Acupuncture for chemotherapy-induced peripheral neuropathy in breast cancer, preliminary results of a pilot randomized controlled trial

Wading Wu

Dr. Lu has no relevant financial relationships to disclose.

Randomized phase II study of docetaxel plus docetaxel vs. endocrine therapy in breast cancer with untreated brain metastases (A-PLEX)

Yen-Shen Lu

Dr. Lu has no relevant financial relationships to disclose.

SOLAR-3: A phase III study of alpelisib and fulvestrant in postmenopausal women with hormone receptor-negative, human epidermal growth factor receptor-2-negative (HER2-), advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy

Yen-Shen Lu

Dr. Lu has no relevant financial relationships to disclose.

Genomic pattern of breast carcinomas carrying mutations of non-BRCA homologous recombination genes

Yen-Shen Lu

Dr. Lu has no relevant financial relationships to disclose.

Acupuncture for chemotherapy-induced peripheral neuropathy in breast cancer, preliminary results of a pilot randomized controlled trial

Wading Wu

Dr. Lu has no relevant financial relationships to disclose.

Recognition of autologous neoantigens by tumor-infiltrating lymphocytes derived from breast cancer metastases

Jiely Lu

Dr. Lu has no relevant financial relationships to disclose.

Acupuncture for chemotherapy-induced peripheral neuropathy in breast cancer, preliminary results of a pilot randomized controlled trial

Wading Wu

Dr. Lu has no relevant financial relationships to disclose.

Randomized phase II study of docetaxel plus docetaxel vs. endocrine therapy in breast cancer with untreated brain metastases (A-PLEX)

Yen-Shen Lu

Dr. Lu has no relevant financial relationships to disclose.

SOLAR-3: A phase III study of alpelisib and fulvestrant in postmenopausal women with hormone receptor-negative, human epidermal growth factor receptor-2-negative (HER2-), advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy

Yen-Shen Lu

Dr. Lu has no relevant financial relationships to disclose.

A pan-cancer perspective of functional proteomics provides novel information content for uncommon breast cancer subtypes

Yiling Lu

Dr. Lu has no relevant financial relationships to disclose.

Proteinomic response in breast cancer treated with neoadjuvant chemotherapy with and without bevacizumab: Reverse phase protein array (RPPA) results from Neoa - A randomized phase II study

Yiling Lu

Dr. Lu has no relevant financial relationships to disclose.

Clinical value of 11C-trastuzumab PET in HER2-positive breast cancer patients with a clinical dilemma

Martijn Lub-de Hooge

Dr. Lu-b-de Hooge has no relevant financial relationships to disclose.

POWDER-remote: A randomized study evaluating the effect of a remote-based weight loss program in women with early stage breast cancer

Branden Luber

Mr. Luber has no relevant financial relationships to disclose.

A phase II study of pazopanib in patients with HER2-positive metastatic breast cancer (MBC) who have received prior HER2 regimen for MBC

Jennifer Lucas

Dr. Lucas has no relevant financial relationships to disclose.

ESR1 amplification and 5'-3' exon imbalance in metastatic breast cancer

Peter Lucas

Dr. Lucas has no relevant financial relationships to disclose.

Breast cancer brain metastases show limited intrinsic subtype switching, yet exhibit acquired ERBB2 amplifications and activating mutations

Peter Lucas

Dr. Lucas has no relevant financial relationships to disclose.

Does BRCA status affect outcome in young breast cancer patients? Results from the prospective study of outcomes in sporadic and hereditary breast cancer (PROSH)

Craig Luccarini

Mr. Luccarini has no relevant financial relationships to disclose.

Treatment with a Jumonji demethylase inhibitor JIB-04 sensitizes resistant breast cancer cells to chemotherapeutic drugs in an in vitro model of intrinsic resistance

Anthony Lucchi

Dr. Lucchi has no relevant financial relationships to disclose.

Feasibility trial for identification of patients for eliminating breast cancer surgery following neoadjuvant systemic therapy

Anthony Lucchi

Dr. Lucchi has no relevant financial relationships to disclose.
S3-01
IMENEO: International Meta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEOadjuvant chemotherapy
Anthony Lucci, Dr. Lucci has no relevant financial relationships to disclose.

P2-05-13
Can axillary lymph node clearance be avoided in women with node-positive breast cancer receiving primary chemotherapy?
Alice Lucey, Ms. Lucey has no relevant financial relationships to disclose.

P3-17-09
Resolution of DCIS in patients with early breast cancer receiving primary chemotherapy for invasive breast cancer
Alice Lucey, Ms. Lucey has no relevant financial relationships to disclose.

P6-02-07
Metabolomic analysis by nuclear magnetic resonance spectroscopy discriminates hormone receptor positive/HER2 negative breast cancer cell lines resistant to palbociclib
Claudia Luchinat, Mr. Luchinat has no relevant financial relationships to disclose.

P2-11-04
Breast cancer organoid cultures preserve intra-tumor heterogeneity and reveal intrinsically resistant phenotypes to standard chemotherapies
Katarzyna Ludwik, Ms. Ludwik has no relevant financial relationships to disclose.

P5-10-09
Prognostic associations of tumor-infiltrating lymphocytes (TILs) in metastatic HER2-positive breast cancer (BC) treated with trastuzumab and pertuzumab: A secondary analysis of the CLEOPATRA study
Stephan Luen, Dr. Luen has no relevant financial relationships to disclose.

S1-07
Prognostic associations of somatic mutations in post-menopausal early-stage estrogen receptor (ER)-positive HER2-negative breast cancer (BC): Results from the BIG 1-98 study
Stephen Luen, Dr. Luen has no relevant financial relationships to disclose.

P5-15-09
Evaluation of growth modulation index as a marker of benefit for consecutive lines of treatment for metastatic breast cancer
Gravis Luongo Giò, Dr. Luongo Giò has no relevant financial relationships to disclose.

S5-07
Clinical implications of somatic mutations in post-menopausal early-stage estrogen receptor (ER)-positive HER2-negative breast cancer (BC): Results from the BIG 1-98 study
Stephan Luen, Dr. Luen has no relevant financial relationships to disclose.

P6-18-01
Site-specific activation of c-Jun-NH2-kinase (JNK) in breast cancer bone metastasis microenvironment
Paula Luís, Dr. Luís has no relevant financial relationships to disclose.

PO6-03
Prostate cancer patients' preferences for urinary incontinence after prostatectomy: A qualitative study
Luisa Luque, Ms. Luque has no relevant financial relationships to disclose.

P4-17-03
Evaluation of a multidisciplinary cancer team quality in a breast cancer unit (BCU) in Mexico
Zamarría Luna Mendoza, Dr. Luna Mendoza has no relevant financial relationships to disclose.

P2-07-07
Multi-level gene expression signatures and immunohistochemical subtypes add prognostic value to each other
Brian Lundberg, Brian Lundberg has no relevant financial relationships to disclose.

P2-07-16
Multi-level gene expression signatures provide significant prognostic information in metastatic breast cancer patients
Brian Lundberg, Brian Lundberg has no relevant financial relationships to disclose.
Efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial
Julia Lyandres
Ms. Lyandres has no relevant financial relationships to disclose.

The evaluation of ganitumab/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial
Julia Lyandres
Ms. Lyandres has no relevant financial relationships to disclose.

Breast cancer after Hodgkin lymphoma: Influence of endogenous and exogenous gonadal hormones on the radiation dose-response relationship
Marina Lybeert
Dr. Lybeert has no relevant financial relationships to disclose.

Effect of aromatase inhibitor (AI) therapy on sleep and activity patterns in early stage breast cancer
Angela Lyden
Ms. Lyden has no relevant financial relationships to disclose.

Highly reproducible decentralized gene expression analysis of ER, PR, HER2 and MKI67 on an automated, standardized molecular diagnostics platform, GeneXpert
Mr. Lykke has disclosed that he receives salary from and has ownership in Cepheid.

Relationship between overall survival and surrogate measures in patients with metastatic breast cancer treated with chemotherapy
Gary Lyman
Dr. Lyman has no relevant financial relationships to disclose.

Bone seeking matrix metalloproteinase-2 inhibitors prevent bone metastatic breast cancer growth
Conor Lynch
Dr. Lynch has no relevant financial relationships to disclose.

Impact of androgen receptor expression in fluoxymesterone-treated, estrogen receptor-positive metastatic breast cancer exposed to contemporary hormonal therapy
Genevieve Lyons
Ms. Lyons has no relevant financial relationships to disclose.

Tumor genomic profiling of triple negative breast cancer during neoadjuvant chemotherapy: Results from a prospective trial of carboplatin and docetaxel
Cynthia Ma
Dr. Ma has disclosed that she receives research funding from Novartis and Pfizer.

Tumor genomic profiling of triple negative breast cancer: Results from the Feline trial
Cynthia Ma
Dr. Ma has disclosed that she receives research funding from Novartis and Pfizer.

Breast cancer after Hodgkin lymphoma: Influence of endogenous and exogenous gonadal hormones on the radiation dose-response relationship
Marina Lybeert
Dr. Lybeert has no relevant financial relationships to disclose.

Effect of aromatase inhibitor (AI) therapy on sleep and activity patterns in early stage breast cancer
Angela Lyden
Ms. Lyden has no relevant financial relationships to disclose.
A randomized, double-blind, phase 2 study of ruxolitinib (RUX) or placebo (PBO) in combination with capecitabine (CAPE) in patients (pts) with advanced HER2-negative breast cancer (ABC) and elevated C-reactive protein (CRP), a marker of systemic inflammation

Serum thymidine kinase 1 activity as a pharmacodynamics marker of cyclin-dependent kinase 4/6 inhibition in patients with early stage breast cancer receiving neoadjuvant palbociclib

Clinical and molecular relevance of intra-tumor genetic heterogeneity in breast cancer: Integrative analysis of data from The Cancer Genome Atlas

Serum thymidine kinase 1 activity as a pharmacodynamics marker of cyclin-dependent kinase 4/6 inhibition in patients with early stage breast cancer receiving neoadjuvant palbociclib

Recurrent functionally diverse in-frame ESR1 gene fusions drive endocrine resistance in breast cancer

Inhibition of death-associated protein kinase 1 enhances chemotherapy action against triple-negative breast cancer

DBCG 07-READ: A randomized phase III trial comparing six cycles of docetaxel and cyclophosphamide (DC) to three cycles of epirubicin and cyclophosphamide followed by three cycles of docetaxel (EC-D) in patients with early breast cancer

Total mastectomy and immediate breast reconstruction for breast cancer: A ten-year Canadian single institution experience

Safety assessment of extended adjuvant endocrine therapy with letrozole: results of the randomized phase III IDEAL trial (BOOG 2006-05)

Breast cancer organoid cultures preserve intra-tumor heterogeneity and reveal intrinsically resistant phenotypes to standard chemotherapies

Preoperative assessment of breast cancer survival using ultrasound diameter and shear wave elastography

Breast cancer subtype, age and lymph node status as predictors of local recurrence following breast-conserving therapy

Intra-tumor genetic heterogeneity and histologic heterogeneity within metaplastic breast cancers: Genotypic-phenotypic correlations

The landscape of somatic genetic alterations in BRCA1 and BRCA2 breast cancers

Value of cancer care for metastatic breast cancer patients and providers

A comprehensive molecular analysis of mediastinal breast carcinoma: A model of immunomodulatory triple-negative breast cancer subtype

The mammary ducts create a favourable microenvironment for xenografting of luminal and molecular apocrine breast tumours
<table>
<thead>
<tr>
<th>Page</th>
<th>Presentation Title</th>
<th>Author</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P5-16-23</td>
<td>Rapid germline BRCA screening for locally advanced breast cancer: changes surgical procedure after neoadjuvant chemotherapy</td>
<td>Gaëtan Macgrogan</td>
<td>Dr. Macgrogan has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-20-08</td>
<td>Evaluation of a multidisciplinary breast cancer team &amp; quality in breast cancer unit (BCU) in Mexico</td>
<td>Miguel Machado-Reyes</td>
<td>Dr. Machado-Reyes has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-21</td>
<td>Prognostic impact of metastatic pattern in stage IV breast cancer at initial diagnosis</td>
<td>Mario Machiavelli</td>
<td>Dr. Machiavelli has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-06-06</td>
<td>Consistent dosing-time dependent tolerability of everolimus (EV) in a pilot study in women with metastatic breast cancers (MBC) and in a mouse chronopharmacology investigation</td>
<td>Jean Machowski</td>
<td>Ms. Machowski has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-14-20</td>
<td>Shared decision-making approach in breast reconstruction in a developing country</td>
<td>Alejandro Maciel-Miranda</td>
<td>Dr. Maciel-Miranda has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-11-19</td>
<td>Sensual functioning among breast cancer survivors and their partners: A pilot study</td>
<td>Karen Mark</td>
<td>Ms. Mark has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-16-02</td>
<td>Beta-adrenergic receptor blockers (BB) and increased progression-free survival (PFS) in patients with advanced triple negative breast cancer (TNBC): A retrospective analysis of the ROSE/TO tO study</td>
<td>John Mackey</td>
<td>Dr. Mackey has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-12-06</td>
<td>Quantification of HER2-driven signaling (HER2s) inhibition of four different anti-HER2 drugs tested ex vivo in live primary HER2-negative breast cancer cell samples with abnormal HER2 signaling activity</td>
<td>Ian MacNeil</td>
<td>Dr. MacNeil has disclosed that he receives salary and has ownership.</td>
</tr>
<tr>
<td>P6-07-14</td>
<td>New method to measure functional HER2-driven signaling activity in primary tumor cells identifies HER2-negative breast cancers with abnormal HER2 signaling activity: New group of patients may benefit from anti-HER2 therapy</td>
<td>Ian MacNeil</td>
<td>Dr. MacNeil has disclosed that he receives salary and has ownership.</td>
</tr>
<tr>
<td>P3-14-07</td>
<td>Neoadjuvant radiotherapy in mastectomy and immediate autologous free flap reconstruction: Findings from the primary radiotherapy and DISP flap pilot study (PRADA) pilot study</td>
<td>Fiona MacNeill</td>
<td>Dr. MacNeill has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-03-02</td>
<td>Breast implant associated anaplastic large cell lymphoma (BIA-ALCL): The UK experience and first reported case of neoadjuvant brentuximab</td>
<td>Fiona MacNeill</td>
<td>Dr. MacNeill has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-21-08</td>
<td>A Phase II of 5-522311, a reversible EGFR and HER2 inhibitor, combined with trastuzumab +/- chemotherapy in patients with HER2-positive metastatic breast cancer</td>
<td>John Macpherson</td>
<td>Dr. Macpherson has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-01-06</td>
<td>Glutamine metabolism drives breast cancer invasion by providing a source of extracellular glutamate to activate the GHRM3 metabotropic glutamate receptor</td>
<td>John Macpherson</td>
<td>Dr. Macpherson has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-12-02</td>
<td>SYD985, a novel anti-HER2 ADC, shows promising activity in patients with HER2-positive and HER2-negative metastatic breast cancer</td>
<td>John Macpherson</td>
<td>Mr. Macpherson has disclosed that he is a principal investigator in the trial.</td>
</tr>
<tr>
<td>OT3-03-03</td>
<td>Challenges faced across borders to open European academic multi-centre projects: The ET-FES program part of the ERA-Net TRANSCAN-2 FCT 2011</td>
<td>Olivier Madar</td>
<td>Dr. Madar has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-21-27</td>
<td>Plasma chemokine profile of HER2+ breast cancer (BC) patients treated with docetaxel (D) and carboplatin (C) in combination with trastuzumab (T) and/or lapatinib (L) in the neo-adjuvant setting</td>
<td>Stephen Maddison</td>
<td>Mr. Maddison has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-16-02</td>
<td>Pathological complete response is associated with excellent outcomes in BRCA mutation associated triple negative breast cancer</td>
<td>Bhushadi Madhusudana</td>
<td>Dr. Madhusudana has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-12-01</td>
<td>Comprehensive genomic profiling of 34 cases of breast cancer</td>
<td>Russell Madison</td>
<td>Mr. Madison has disclosed that he is an employee of Foundation Medicine.</td>
</tr>
<tr>
<td>P3-08-05</td>
<td>The yield of germline genetic testing in breast cancer patients diagnosed prior to age 50</td>
<td>Lisa Madlensky</td>
<td>Dr. Madlensky has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
PARTNER - Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients

Saba Mahmud

Saba Mahmud has no relevant financial relationships to disclose.

Dynamics of circulating tumor cells during the course of chemotherapy and prognostic relevance across molecular subtypes in high-risk early breast cancer patients - Results from the adjacent SUCCESS A trial

Sven Mahner

Dr. Mahner has no relevant financial relationships to disclose.

EP1-01-23

P1-07-01

Molecular and clinical features of breast cancer patients to detect possible association to correlation with immune system antitumor response

Sven Mahner

Dr. Mahner has no relevant financial relationships to disclose.

P3-06-06

Development of NRG2-plex for metastatic breast cancer treatment

Junhua Mai

Dr. Mai has no relevant financial relationships to disclose.

P5-15-05

Randomized phase II study evaluating different schedules of nab-paclitaxel in metastatic breast cancer (NBR): Results of the SNAP study

Rudolf Malbach

Mr. Malbach has no relevant financial relationships to disclose.

P6-11-18

PTThA. A phase II study of palbociclib plus fulvestrant versus placebo plus fulvestrant for pretreated patients with EFR+/HER2- metastatic breast cancer

Rudolf Malbach

Mr. Malbach has no relevant financial relationships to disclose.

P5-09-06

Ovarian reserve and response to controlled ovarian hyperstimulation (COH) in breast cancer women with and without BRCA mutation

Audrey Maillez

Dr. Maillez has no relevant financial relationships to disclose.

P9-09-40

Her2 and hormonal receptor analysis in breast cancer synchronous node metastases could add therapeutic information

Mercedes Maino

Dr. Maino has no relevant financial relationships to disclose.

P1-01-09

Comparison of HER2, estrogen and progesterone receptor expression profiles of primary tumor, synchronous axillary lymph node metastasis and circulating tumor cells in early breast cancer patients

Fabian Mairinger

Mr. Mairinger has no relevant financial relationships to disclose.

P06-02

Local recurrence in young women with invasive breast cancer: the prospective study of outcomes in sporadic and hereditary breast cancer (POS)

Tom Mainsham

Mr. Mainsham has no relevant financial relationships to disclose.

P52-03

Does BRCA status affect outcome in young breast cancer patients? Results from the prospective study of outcomes in sporadic and hereditary breast cancer (POS)

Tom Mainsham

Mr. Mainsham has no relevant financial relationships to disclose.

P6-09-05

Prognostic and predictive values of high endothelial venules (HEV) and tumor infiltrating CD8+ lymphocytes (CD8) in tumors of patients included in the adjuvant PACS04 trial: HEV is predictive of outcome for HER2+ tumors exposed to trastuzumab

Veronique Maisongrosse

Dr. Maisongrosse has no relevant financial relationships to disclose.

P1-05-17

Interrogating the impact of pregnancy on breast cancer biology using DNA copy number profiling

Samira Majaj

Samira Majaj has no relevant financial relationships to disclose.

P1-03-18

An ex vivo platform predicts anti-tumor outcome of metabolically-targeted, algorithm-driven combination therapy in triple-negative breast cancer

Biswa Nath Majumder

Biswa Nath Majumder has no relevant financial relationships to disclose.

P3-03-18

An ex vivo platform predicts anti-tumor outcome of metabolically-targeted, algorithm-driven combination therapy in triple-negative breast cancer

Pradipt Majumder

Pradipt Majumder has no relevant financial relationships to disclose.

P1-04-01

Predictors of breast density among Black and Hispanic women presenting for mammographic screening

Reedha Makambi

Dr. Makambi has no relevant financial relationships to disclose.

P5-10-10


High concordance of ER, PR, HER2 and Ki67 by central IHC and FISH with mRNA measurements by GeneXpert® breast cancer stratifier assay

Rosemary Makar

Dr. Makar has no relevant financial relationships to disclose.

Pharmacokinetics of eflapegrastim in a phase 2 open-label dose-ranging study in breast cancer patients receiving TC regimen

Rostom Makharadze

Dr. Makharadze has no relevant financial relationships to disclose.

Immunogenicity of eflapegrastim in a phase 2 open-label dose-ranging study of eflapegrastim in breast cancer patients receiving TC regimen

Rostom Makharadze

Dr. Makharadze has no relevant financial relationships to disclose.

Sustained efficacy of eflapegrastim in breast cancer patients in a phase 2, open-label, dose-ranging study

Rostom Makharadze

Dr. Makharadze has no relevant financial relationships to disclose.

Prognostic significance of CD8+ tumor-infiltrating lymphocytes (TILs), CD4+ TILs and TILs in male breast cancer

Ridha Makhlouf

Ridha Makhlouf has no relevant financial relationships to disclose.

Sexual functioning among breast cancer survivors and their partners: A pilot study

Issam Makhoul

Dr. Makhoul has no relevant financial relationships to disclose.

Inducing immune responses to tumor associated carbohydrate antigens by a carbohydrate mimetic peptide vaccine: Clinical experience in phase 1 and phase II trials

Issam Makhoul

Dr. Makhoul has no relevant financial relationships to disclose.

Erlotinum plus trastuzumab and palbociclib as first-line dual-targeted therapy for women with HER2-negative metastatic breast cancer: Overview of phase II results from HER2CLIN-1

Anastas Makhoul

Anastas Makhoul has no relevant financial relationships to disclose.

Phase I trial of sunitinib in combination with trastuzumab in metastatic HER2-positive breast cancer

Della Makower

Dr. Makower has no relevant financial relationships to disclose.

Phase I trial of sunitinib in combination with trastuzumab in metastatic HER2-positive breast cancer

Della Makower

Dr. Makower has no relevant financial relationships to disclose.

Sunitinib: Enlargement and bone marrow hyperplasia in patients receiving trastuzumab-emtansine for metastatic breast cancer

Andreas Makris

Andreas Makris has no relevant financial relationships to disclose.

Adding metronomic oral Vinorelbine (mVRL), with or without capecitabine (CAPE), on Treg levels in advanced breast cancer (ABC) patients (pts). Preliminary results of the VICTOR-5 study

Sergio Malandrin

Dr. Malandrin has no relevant financial relationships to disclose.

Clonal heterogeneity in breast cancer and its impact on clinical biomarkers

Smiti Malhotra

Smiti Malhotra has no relevant financial relationships to disclose.

Analytical validation for the RT-qPCR based multiplex mRNA measurements of ER, PR, HER2, and Ki67 from FFPE tumor tissue using the GeneXpert breast cancer stratifier assay

Monisha Malik

Dr. Malik has disclosed that she receives salary from, has ownership in and contracts with Cepheid.

Genomic and microenvironmental intra-tumor heterogeneity in DCIS

Carlo Maley

Dr. Maley has no relevant financial relationships to disclose.

Evidence for tumor heterogeneity and clonal evolution during invasive progression of breast cancer

Carlo Maley

Dr. Maley has no relevant financial relationships to disclose.

Photodynamic therapy for the treatment of primary breast cancer: Preliminary results of a phase I/IIa clinical trial

Ameen Malhotra

Dr. Malhotra has no relevant financial relationships to disclose.
Patient derived DCIS mouse intraductal (MIND) models recapitulate the full spectrum of human patient pathology and histologic features including progression to invasion in a subset of cases.

Joshua Mammen

Dr. Mammen has no relevant financial relationships to disclose.

OT2-03-05

MRI oncology/NABP B-52/ORTOG 1304: A phase II superiority clinical trial designed to determine if chest wall and regional nodal radiotherapy (C(W/N)) post mastectomy (Mx) or the addition of NRT1 to breast RT post breast-conserving surgery (BCS) will reduce invasive cancer events in patients (pts) with positive Ax nodes and convert to ypN0 after neoadjuvant chemotherapy (NACT).

Eleftherios Mamounas

Eleftherios Mamounas has no financial relationships to disclose.

P1-07-02

Chemotherapy (CT) decision in patients (pts) with node-positive (N+) EBC in the wake of new ASCO guideline - A different take on the evidence for the 21-gene recurrence score (RS) assay.

Eleftherios Mamounas

Dr. Mamounas has disclosed that he is a consultant for Genomic Health, Celgene, Pfizer, Novartis, Genentech, Biotheranostics and Bayer and a speaker for Genentech and Genentech.

P1-09-05

Clinical outcome of patients with advanced triple negative breast cancer with germline and somatic variants in homologous recombination gene.

Victoria Mandilaras

Ms. Mandilaras has no financial relationships to disclose.

OT2-01-11

Phase II of POSEIDON: A phase Ib / randomized phase II trial of tamoxifen plus taselisib or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment.

Ingrid Mandjes

Ms. Mandjes has no financial relationships to disclose.

P6-09-40

Her2 and hormonal receptor analysis in breast cancer synchronic node metastases could add therapeutic information.

Pablo Mandi

Dr. Mandi has no financial relationships to disclose.

P4-03-08

Mechanisms of CD8+ T cell immunosuppression in triple negative breast cancer.

Yenkuta Manem

Yenkuta Manem has no financial relationships to disclose.
| OT3-01-02 | CNIO-BR-008 trial: Reversion of T-cell exhaustion caused by chronic treatment with hypoxia-inducing antiangiogenic treatment by durvalumab in HER2-negative breast cancer: A pilot proof-of-concept trial | Santos | Mahas | Dr. Manes has no relevant financial relationships to disclose. |
| P2-04-05 | Immunomodulation effects of metronomic oral Vinorelbine (mVRL) with or without capcitabine (CAPE), on Treg levels in advanced breast cancer (ABC) patients (pts). Preliminary results of the VICTOR-5 study | Kako | Manfrida | Dr. Manfrida has no relevant financial relationships to disclose. |
| P1-12-07 | Phase II/II single-arm trial evaluating the combination of everolimus, lapatinib and capcitabine for the treatment of patients with HER2-positive metastatic breast cancer with progression in the CNS after trastuzumab (TRO-LS B-08) | Aruna | Mani | Dr. Mani has disclosed that she has contracts with Genentech and GSK. |
| P3-14-01 | International validation of the EORTC patient-reported outcome measure (PROM) in breast reconstruction (BRR): The EORTC QLQ-BR-23 evaluating the psychometric properties and clinical effectiveness | Marie | Mani | Dr. Mani has no relevant financial relationships to disclose. |
| P6-02-02 | Uridine diphosphate glucose dehydrogenase is required for hyaluronic acid production and breast cancer invasion | Sendurai | Mani | Sendurai Mani has no relevant financial relationships to disclose. |
| P1-03-05 | A comprehensive molecular analysis of mediulary breast carcinoma: A model of immunomodulatory triple-negative breast cancer subtype | Elodie | Mané | Dr. Mané has no relevant financial relationships to disclose. |
| P1-07-17 | The SCAN-B study: 5-year summary of a large-scale population-based prospective breast cancer translational genomics platform covering a wide geography of Sweden (NCT01306076) | Natas | Manjer | Dr. Manjer has no relevant financial relationships to disclose. |
| P4-07-10 | Epithelial mesenchymal transition associated with high miR-221 and integrin-66 leads to poor prognosis in hormone receptor positive HER2 negative breast cancers | Suraj | Manjunath | Song Manjunath has no relevant financial relationships to disclose. |
| P4-02-05 | Test-retest fidelity of FDG SUVmax in bone and non-boney metastatic breast cancer lesions in local area network PET/CT scanners | David | Mankoff | Dr. Mankoff has no relevant financial relationships to disclose. |

**Committee Member**

| P3-08-04 | Trends in age of breast cancer diagnosis for women with pathogenic variants in genes associated with increased breast cancer risk | Susan | Manley | Ms. Manley has disclosed that she receives salary from and has ownership in Myriad Genetic Laboratories, Inc. |
| P2-11-08 | Stomatitis in patients treated with first-line everolimus (EVE) plus letrozole (LET): Results from BOLERO-4 trial | Jarome | Mania | Ms. Mania has disclosed that she is a Novartis employee. |
| OT3-03-02 | Maximising recruitment and retention of patients into UK-ANZ POSNOC trial | Bruce | Mann | Mr. Mann has no relevant financial relationships to disclose. |
| S2-04 | RANK ligand as a target for breast cancer prevention in BRCA1 mutation carriers | Gregory | Mann | Mr. Mann has no relevant financial relationships to disclose. |
| P5-06-09 | Cycle d1 binding to chromatin and the induction of chromosomal instability requires the fuzzy domain | Monica | Mann | Mr. Mann has no relevant financial relationships to disclose. |
| P4-02-08 | Opto-acoustic imaging of the breast: Downclassification and upclassification of suspicious breast masses | Blake | Mann | Mr. Mann has no relevant financial relationships to disclose. |
| P2-03-01 | Mutational landscape of breast cancers from PALE2 germ line mutation carriers | Arto | Mannermaa | Arto Mannermaa has no relevant financial relationships to disclose. |
| P4-21-21 | Her2 is not a cancer subtype but rather a driver found in all intrinsic subtypes and highly enriched in molecular apocrine tumors | Gerard | Manning | Mr. Manning has disclosed that he is an employee of Genentech, Inc. and holds shares of Roche. |
| P3-02-11 | Clinical examination and breast MRI as predictors of pathologic complete response post neoadjuvant therapy in HER2 overexpressed subtypes and triple negative breast cancer | Max | Mano | Dr. Mano has no relevant financial relationships to disclose. |
A large-scale functional screen to identify resistance mechanisms to selective estrogen receptor degraders fulvestrant and GDC-810 in ER+ breast cancer

Pingping Mao

Pingping Mao has no relevant financial relationships to disclose.

Efficacy results of a phase 1/2 study of glucocorticoid receptor (GR) antagonist mifepristone (MIFE) in combination with eribulin in GR-positive triple-negative breast cancer (TNBC)

Annette Marcantonio

Ms. Marcantonio has disclosed that he is an employee of Concept.

Maintenance of genomic integrity in dormant circulating tumor cells

Dario Marchetti

Dr. Marchetti has no relevant financial relationships to disclose.

The evolution of breast cancer circulating tumor cells mediating brain metastasis

Dario Marchetti

Dr. Marchetti has no relevant financial relationships to disclose.

Luminal A breast cancer: Is it really a "good prognosis" disease? Preliminary results of the GIM-13 - AMBRA study

Colin Mar

Dr. Mar has no relevant financial relationships to disclose.

First and further line choices of treatment for HER2-VE metastatic breast cancer (MBC) according to adjuvant treatment and biological subtype. Preliminary results of the observational "GIM-13 - AMBRA" Italian study

Colin Mar

Dr. Mar has no relevant financial relationships to disclose.

Efficacy results of a phase 1/2 trial of eribulin in combination with endocrine therapy in ER positive metastatic breast cancer patients: Results of the COMETI Phase 2 trial

Paolo Marchetti

Dr. Marcetti has no relevant financial relationships to disclose.

Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C)+paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer

Paolo Marchetti

Dr. Marcetti has no relevant financial relationships to disclose.

Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: A randomized, phase 2 study

P Marcom

P Marcom has disclosed that he receives research funding (institutions) from AbbVie, Veridex, Novartis and Genentech.

Elucidating the tumor immune microenvironment phenotype in early stage untreated BRCA mutated breast cancer patients

P Kelly Marcom

Dr. Marcom has no relevant financial relationships to disclose.

BRCA gene mutations do not shape the extent and organisation of tumor infiltrating lymphocytes in triple negative breast cancer

Diane Marcoux

Ms. Marcoux has no relevant financial relationships to disclose.

Tumor genomic profiling of triple negative breast cancer during neoadjuvant chemotherapy: Results from a prospective trial of carboplatin and docetaxel

Elaine Mardis

Dr. Mardis has no relevant financial relationships to disclose.

Tumor genomic profiling of triple negative breast cancer during neoadjuvant chemotherapy: Results from a prospective trial of carboplatin and docetaxel

Elaine Mardis

Dr. Mardis has no relevant financial relationships to disclose.

Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2 positive breast cancer

Elaine Mardis

Dr. Mardis has no relevant financial relationships to disclose.

PD-L1 expression in triple negative breast cancer (TNBC) is associated with improved outcomes

Mabel Mardones

Dr. Mardones has no relevant financial relationships to disclose.

Phase III study of galbocib (PD-0332991) in combination with endocrine therapy ( exemestane or fulvestrant) versus chemotherapy (paclitaxel) in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with resistance to or intolerance to aromatase inhibitors. "The PEARL study" (GEICAM/2013-02)

Mireia Margelí

Mireia Margelí has no relevant financial relationships to disclose.
Predictive value of ultra-high ESR1 mRNA expression in early breast cancer

Comparison of the mutational landscape of breast cancer during pregnancy and non-pregnant controls

Phase II study evaluating the safety and clinical activity of lumetuzumab combined with pertuzumab and paclitaxel in HER2-low metastatic breast cancer

First posts: A content analysis of an online breast cancer community user’s initial postings

Comparison of the mutational landscape of breast cancer during pregnancy and non-pregnant controls

Phase Ib study evaluating the safety and clinical activity of lumetuzumab combined with pertuzumab and paclitaxel in HER2-low metastatic breast cancer

ER is required for mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer cells and patients' tumors

Implications of financial modeling in breast cancer clinical research from 1990 to 2010
<table>
<thead>
<tr>
<th>Paper Number</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P4-03-12</td>
<td>Cancer-associated fibroblasts release exosomal microRNAs that dictate an aggressive phenotype in breast cancer</td>
<td>Nappa Martina</td>
<td>Dr. Martina has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-09-21</td>
<td>Clinical evaluation of miR-100 as a predictor of endocrine-responsiveness in hormone-receptor positive breast cancer</td>
<td>Laura Martinez</td>
<td>Dr. Martinez has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-09-22</td>
<td>Clinical evaluation of miR-100 as a predictor of endocrine-responsiveness in hormone-receptor positive breast cancer</td>
<td>Rossella Martinaella</td>
<td>Dr. Martinaella has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-11-01</td>
<td>Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study</td>
<td>Rossella Martinaella</td>
<td>Dr. Martinaella has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-12-07</td>
<td>Phase II/III single-arm trial evaluating the combination of everolimus, lapatinib and cabozantinib for the treatment of patients with HER2-positive metastatic breast cancer with progression in the CNS after trastuzumab (TEGUS-US 00)</td>
<td>Diego Martinez</td>
<td>Dr. Martinez has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-09-09</td>
<td>Efficacy and gene expression results from SOLEX1007 MEBEERBIN phase II clinical trial in HER2-negative early breast cancer</td>
<td>Jeronimo Martinez</td>
<td>Dr. Martinez has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2B-02</td>
<td>Tumor subtype and survival differences between Hispanic and non-Hispanic white breast cancer patients in the California cancer registry</td>
<td>Maria Martinez</td>
<td>Dr. Martinez has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-13-18</td>
<td>Technical skill of surgical residents may affect margin status of breast conserving operations</td>
<td>Maria Elena Martinez</td>
<td>Dr. Martinez has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-13-02</td>
<td>Weight gain after breast cancer diagnosis and patients’ opinion on weight loss strategies</td>
<td>Maria Elena Martinez</td>
<td>Dr. Martinez has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-33</td>
<td>Clinical evaluation of miR-100 as a predictor of pathological complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2-positive breast cancer: First results of the PARACLINIC trial</td>
<td>Eduardo Martinez</td>
<td>Mr. Martinez has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-17-07</td>
<td>The E2A/Enl transgenic mouse as a model for breast cancer</td>
<td>Noelia Martínez Jáñez</td>
<td>Ms. Martínez Jáñez has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-20-17</td>
<td>Young women with breast cancer in Mexico: A report of the pilot phase of the &quot;Mujer Joven y Fuerte&quot; prospective cohort trial</td>
<td>Bertha Martinez-Cannon</td>
<td>Dr. Martinez-Cannon has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-15-13</td>
<td>cascade study: rapid survival decline per treatment line in metastatic breast cancer</td>
<td>Maria Martinez</td>
<td>Dr. Martinez has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-16-04</td>
<td>Real World data and patterns of care of metastatic breast cancer (MBC) in Brazil: First results of LACOG 0312 retrospective study</td>
<td>Jeovany Martinez-Mesa</td>
<td>Jeovany Martinez-Mesa has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-17-02</td>
<td>The EA2clin test significantly predicts response and survival in both pre and post-menopausal women with HR-positive breast cancers</td>
<td>Carlos Martinez-Perez</td>
<td>Mr. Martinez-Perez has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
Distinct recruitment of tumor-associated immune cells correlates with increased pro-malignant chemokines in tumors expressing epithelial atypical chemokine receptor 1 (ACKR1/DARC), indicating a unique tumor microenvironment

Rachel Martini
Ms. Martini has no relevant financial relationships to disclose.

Increased stromal lymphocytes in breast cancer patients with autologous dendritic cell vaccination plus neoadjuvant chemotherapy

Patricia Martin-Romano
Ms. Martin-Romano has no relevant financial relationships to disclose.

True effect of aromatase inhibition (AI) treatment on global gene expression (exp) changes in postmenopausal ER+ breast cancer (BC) patients: A PDTTC study [EPIRA/2015]

Noriko Masumoto
Noriko Masumoto has no relevant financial relationships to disclose.

Prognostic value of molecular tumor infiltrating lymphocyte (mTIL) signatures in HER2-positive breast cancer patients in N9831 and FinHer/FinXX trials

Ms. Masumoto has disclosed that she receives honoraria from Chugai, Kyowa-Kirin and AstraZeneca.

Development of mathematical prediction models to identify disease-free survival events for HER2+ positive primary breast cancer patients treated by neoadjuvant chemotherapy and trastuzumab

Norie Masumoto
Norie Masumoto has no relevant financial relationships to disclose.

Evaluation of contrast-enhanced ultrasound for early prediction of response to neoadjuvant chemotherapy in triple negative breast cancer

Norie Masumoto
Norie Masumoto has no relevant financial relationships to disclose.
Residual cancer burden (RCB) as a strong prognosis factor in breast cancer (BC) patients treated with neoadjuvant chemotherapy (NACT) based on carboplatin, doxorubicin and taxanes.

Elena Mata Velasco

Dr. Mata Velasco has no relevant financial relationships to disclose.

Stem cell-like transcriptional reprogramming in metastatic resistance

Francesca Mattew

Dr. Matas has no relevant financial relationships to disclose.

Race and age differences in PAM50 biomarker status in the Carolina breast cancer study

Michelle Mathew

Ms. Mathews has no relevant financial relationships to disclose.

Phenotypically distinct HRG positive cancer cells impact standard of care therapies in metastatic breast cancer models

Sara Mathew

Ms. Mathews has disclosed that he is an employee of Merrimack Pharmaceuticals and holder of stock options.

Influence of tumour growth factor-β (TGF-β) expression in circulating tumor cells (CTCs) of patients with early breast cancer and its association with E-cadherin expression and patient survival

Alexios Matikas

Dr. Matikas has no relevant financial relationships to disclose.

Targeting inflammatory pathways: A phase 2 trial of the JAK-inhibitor ruxolitinib in combination with exemestane for aromatase inhibitor-resistant, estrogen receptor-positive breast cancer

Jennifer Matro

Dr. Matros has no relevant financial relationships to disclose.

A phase II trial of VST-1001 (dilute fluorescein) in lymphatic mapping and sentinel lymph node localization in clinically node-negative breast cancer

Cindy Matsumoto

Dr. Matsumo has no relevant financial relationships to disclose.

A proof-of-concept trial: Changes in tumor proliferation rates and quality of life with 7 days of preoperative tamoxifen

Cindy Matsumoto

Dr. Matsumo has no relevant financial relationships to disclose.

The non-invasive treatment for sentinel lymph node metastasis by photodynamic therapy using a verteporfin solubilized phospholipid polymer aggregate

Sachiko Matsuda

Ms. Matsuda has no relevant financial relationships to disclose.

Validation of novel diagnostic kits using the semi-dry dot-blot method for detecting metastatic lymph nodes in breast cancer; distinguishing macrometastases and micrometastases

Megumi Matsumoto

Dr. Matsumoto has no relevant financial relationships to disclose.

Development of photacoustic vascular imaging system for breast cancer

Yoshiaki Matsumoto

Yoshiaki Matsumoto has no relevant financial relationships to disclose.

Post mastectomy breast reconstruction in elderly women: Complications and the impact of individual surgeons

Rayna Matsuno

Dr. Matsuno has no relevant financial relationships to disclose.

Recurrent functionally diverse in-frame ESR1 gene fusions drive endocrine resistance in breast cancer

Ryoichi Matsunuma

Mr. Matsunuma has no relevant financial relationships to disclose.

Impact of germ cell/normal tissue-associated nuclear protein polymorphisms on breast cancer risk and prognosis in a Japanese population

Kaitaro Matsuzawa

Mr. Matsuzawa has no relevant financial relationships to disclose.

Breast-conserving surgery plus hormone therapy without irradiation in elderly women with early breast cancer

Ryo Matsuoka

Mr. Matsuoka has no relevant financial relationships to disclose.

A phase II trial of neoadjuvant docetaxel/cyclophosphamide followed by epirubicin/cyclophosphamide for triple-negative breast cancer

Ryo Matsuoka

Mr. Matsuoka has no relevant financial relationships to disclose.

A phase II trial of neoadjuvant epirubicin/cyclophosphamide followed by weekly nanoparticle albumin-bound paclitaxel with trastuzumab for HER2-positive breast cancer

Ryo Matsuoka

Mr. Matsuoka has no relevant financial relationships to disclose.
P5-11-03 Difference between 1st and 2nd generation serotonin receptor antagonists in triplet antiemetic therapy for highly emetogenic chemotherapy in breast cancer patients - according to recent multi-institutional double-blind randomised clinical research on the AC regimen

Joe Matsuoka
Mr. Matsuoka has no relevant financial relationships to disclose.

OT3-07-02 Influence of exercise or educational programs on long-term physical activity by patients after surgery for primary breast cancer: A randomized trial

Junji Matsuoka
Junji Matsuoka has no relevant financial relationships to disclose.

P2-05-30 OncotypeDX® for breast cancer: A multigene assay that makes a difference?

Claire Matte
Dr. Matte has no relevant financial relationships to disclose.

OT3-03-03 Challenges faced across borders to open European academic multicentre projects: The ET-FIS program part of the ERA-Net TRANSCAN FC 2011

Federvica Matteucci
Dr. Matteucci has no relevant financial relationships to disclose.

OT1-03-01 The UK LORIS trial: Randomising patients with low or low intermediate grade ductal carcinoma in situ (DCIS) to surgery or active monitoring

Lucy Matthews
Ms. Matthews has no relevant financial relationships to disclose.

P6-11-13 Phase II study evaluating the safety and clinical activity of lumretuzumab combined with pertuzumab and paclitaxel in HER2-low metastatic breast cancer

Marcus May
Dr. May has no relevant financial relationships to disclose.

P5-11-03 Difference between 1st and 2nd generation serotonin receptor antagonists in triplet antiemetic therapy for highly emetogenic chemotherapy in breast cancer patients - according to recent multi-institutional double-blind randomised clinical research on the AC regimen

Joe Matsuoka
Mr. Matsuoka has no relevant financial relationships to disclose.

OT3-07-02 Influence of exercise or educational programs on long-term physical activity by patients after surgery for primary breast cancer: A randomized trial

Junji Matsuoka
Junji Matsuoka has no relevant financial relationships to disclose.

P2-05-30 OncotypeDX® for breast cancer: A multigene assay that makes a difference?

Claire Matte
Dr. Matte has no relevant financial relationships to disclose.

OT3-03-03 Challenges faced across borders to open European academic multicentre projects: The ET-FIS program part of the ERA-Net TRANSCAN FC 2011

Federvica Matteucci
Dr. Matteucci has no relevant financial relationships to disclose.

OT1-03-01 The UK LORIS trial: Randomising patients with low or low intermediate grade ductal carcinoma in situ (DCIS) to surgery or active monitoring

Lucy Matthews
Ms. Matthews has no relevant financial relationships to disclose.

P1-09-05 Learning curve for the SWI SEDUCT breast localization and surgical guidance system

Christgen Matthias
Dr. Matthias has no relevant financial relationships to disclose.

P2-11-10 The role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+/HR+ phase II trial evaluating 12-weeks of neoadjuvant TOMT1 endocrine therapy (IT) versus T + IT in HER2-positive hormone-receptor-positive early breast cancer (IBC)

Chritsge Matthias
Dr. Matthias has no relevant financial relationships to disclose.

P6-05-03 Investigating the effects of low-dose mixtures of environmental contaminants on breast cancer initiation

Phoebe Maud
Ms. Maud has no relevant financial relationships to disclose.

P4-22-12 Risk factors in postmenopausal women with HR+, HER2 advanced breast cancer (ABC) treated with neoadjuvant chemotherapy (NeoCT)

Michela Maur
Ms. Maur has disclosed that she is a consultant for Novartis.

OT1-01-10 Multi-center phase II trial of ACY-1215 (Ficolinostat) combined with nab-paclitaxel in unresectable or metastatic breast cancer

Matthew Maurer
Dr. Maurer has disclosed that he works for BMS.

P1-03-06 Prevalence of insulin-like growth factor-1 receptor (IGF1R) expression in circulating tumor cells (CTCs) of patients with early breast cancer and its association with E-cadherin expression and patient survival

Dimetros Maroulis
Mr. Maroulis has no relevant financial relationships to disclose.

P2-03-12 Preoperative ultrasound guided needle sampling in breast cancer: Comparing the sensitivity of fine needle aspiration cytology and core needle biopsy

Anthony Maxwell
Mr. Maxwell has no relevant financial relationships to disclose.

P4-06-02 Patient derived DCS mouse intraductal (MIN2) models recapitulate the full spectrum of human patient pathology and histologic features including progression to invasion in a subset of cases

Lisa May
Dr. May has no relevant financial relationships to disclose.

P6-11-13 Phase III study evaluating the safety and clinical activity of lumretuzumab combined with pertuzumab and paclitaxel in HER2-low metastatic breast cancer

Marcus May
Dr. May has no relevant financial relationships to disclose.
P4-20-02  Value of cancer care for metastatic breast cancer patients and providers  
Suepattra May  
Dr. May has no relevant financial relationships to disclose.

P5-15-08  A phase 2 study of ibrutinib as early-line treatment for HER2-MBC: Evaluation of efficacy, toxicity, and patient-reported outcomes  
Erica Mayer  
Dr. Mayer has disclosed that she receives research support from Eisai.

P6-12-12  Phase I study of the JAK 1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer (MBC)  
Ingrid Mayer  
Dr. Mayer has no relevant financial relationships to disclose.

OT2-01-04  SOLAR-1: A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy  
Ingrid Mayer  
Dr. Mayer has disclosed that she is a consultant for and receives research funding from Novartis.

OT2-01-19  A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibitor plus cyclin-dependent kinase 4/6 inhibition in patients with unresponderable or metastatic hormone receptor positive, HER2 negative breast cancer  
Ingrid Mayer  
Dr. Mayer has no relevant financial relationships to disclose.

P4-22-15  Icluzumab galamic (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate (ADC) for the treatment of relapsed/refractory, metastatic triple-negative breast cancer (mTNBC): Updated results  
Ingrid Mayer  
Dr. Mayer has no relevant financial relationships to disclose.

P5-08-08  Baseline (BL) characteristics, treatment (tx) patterns, and outcomes in patients with hormone receptor (HR)+ vs HR-HER2+ disease from the SystHERs registry  
Musa Mayer  
Ms. Mayer has no relevant financial relationships to disclose.

P5-08-27  Treatment patterns and clinical outcomes in patients with hormone receptor (HR)+ vs HR-HER2+ disease from the SystHERs Registry  
Musa Mayer  
Ms. Mayer has no relevant financial relationships to disclose.

P5-16-11  Residual cancer burden (RCB) as a strong prognostic factor in breast cáncer (BC) patients treated with neoadjuvant chemotherapy (NACT) based on carboplatin, doxorubicin and taxanes  
Marta Mayorga Fernández  
Dr. Mayorga Fernández has no relevant financial relationships to disclose.

P2-05-23  EP3-receptor expression is a prognostic marker for overall survival and progression-free survival in sporadic breast cancer  
Doris Mayr  
Ms. Mayr has no relevant financial relationships to disclose.

P3-07-07  Inhibition of death-associated protein kinase 1 enhances chemotherapeutics action against triple-negative breast cancer  
Abhijit Mazumdar  
Dr. Mazumdar has no relevant financial relationships to disclose.

P5-08-04  SDH is a critical regulator of triple-negative breast cancer cell growth and invasion  
Abhijit Mazumdar  
Dr. Mazumdar has no relevant financial relationships to disclose.

P6-12-17  p53 mediates p53-dependent treatment of breast cancer with doxorubicin preventing drug resistance and circumventing radioresistance  
Semme Mazzucchelli  
Dr. Mazzucchelli has no relevant financial relationships to disclose.
PARTNER - Randomised, phase I/II trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germine BRCA mutated breast cancer patients
Karen McAdam
Dr. McAdam has no relevant financial relationships to disclose.

P5-15-16
Utilization and outcomes of enbrel in triple negative metastatic breast cancer: Real-world findings
Lindsay McAllister
Ms. McAllister has disclosed that she receives salary from Cardinal Health.

P6-09-14
Prognostic significance of a modified residual disease in breast and nodes (mRDBN) algorithm after neoadjuvant therapy for breast cancer
Priscilla McAuliffe
Dr. McAuliffe has no relevant financial relationships to disclose.

P1-10-15
Predictors of locoregional recurrence after neoadjuvant chemotherapy and surgery for node positive breast cancer: Results from ACOGOC 21071 (Alliance)
LindaMcCell
Ms. McCell has no relevant financial relationships to disclose.

P6-09-01
A solution to the APB116 mutation paradox in breast cancer
JenniferMcCarr
Ms. McCarr has no relevant financial relationships to disclose.

Committee Member
Patty McCarroll
Ms. McCarroll has no relevant financial relationships with commercial interests to disclose.

P1-05-16
An integrated molecular analysis of invasive lobular carcinoma
AmyMcCart Reed
Dr. McCart Reed has no relevant financial relationships to disclose.

P1-07-08
Mixed ductal-lobular carcinomas of the breast: Altered cell adhesion in the clonal evolution from ductal to lobular morphology
DamianMcCartan
Dr. McCartan has no relevant financial relationships to disclose.

P5-02-06
The impact of the introduction of breast cancer screening on a symptomatic breast cancer unit
PeterMcCarthy
Dr. McCarthy has no relevant financial relationships to disclose.

OT2-03-01
NRG oncology/NSABP B-51/RTOG 1304: A phase III superiority clinical trial designed to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) will reduce invasive cancer events in patients (pts) with positive axillary (Ax) nodes and convert to ypN0 after neoadjuvant chemotherapy (NAC)
SusanMcCloskey
Dr. McCloskey has no relevant financial relationships to disclose.

P1-05-27
Evaluation of the Oncomine focus and comprehensive assays for therapeutic stratification in early hormone receptor positive breast cancers
StephanieMccormack
Ms. McCormack has no relevant financial relationships to disclose.

OT3-04-05
BRE12-158: A phase II randomized controlled trial of genemically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer (TNBC)
MichaelMcCormick
Dr. McCormick has no relevant financial relationships to disclose.
An annotated collection of pre- and post-therapy breast cancer patient-derived xenograft models built from fine needle aspiration samples aligned with ongoing clinical trials documenting response to treatment

P4-16-03
Aaron McCoy
Mr. McCoy has no relevant financial relationships to disclose.

A meta-analysis of cognitive impairment in breast cancer survivors treated with chemotherapy

P4-19-03
Graham McCreath
Mr. McCreath has no relevant financial relationships to disclose.

Clinical outcome of patients with advanced triple negative breast cancer with germine and somatic variants in homlogous recombination gene

P3-08-05
Seaona McCuaig
Ms. McCuaig has no relevant financial relationships to disclose.

Heavily pre-treated breast cancer patients show promising responses in the first in human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2648 in combination with paclitaxel

P6-11-09
William McCulloch
Mr. McCulloch has disclosed that he is an employee.

A meta-analysis of cognitive impairment in breast cancer survivors treated with chemotherapy

Graham McCreath
Mr. McCreath has no relevant financial relationships to disclose.

Clinical outcome of patients with advanced triple negative breast cancer with germine and somatic variants in homlogous recombination gene

Seaona McCuaig
Ms. McCuaig has no relevant financial relationships to disclose.

Heavily pre-treated breast cancer patients show promising responses in the first in human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2648 in combination with paclitaxel

William McCulloch
Mr. McCulloch has disclosed that he is an employee.

Immunohistochemistry cannot be used to detect PD-L1/AK-2 amplification

Ann McCulloch
Dr. McCulloch has no relevant financial relationships to disclose.

Clonal heterogeneity in breast cancer and its impact on clinical biomarkers

Ann McCulloch
Dr. McCulloch has no relevant financial relationships to disclose.

Homologous recombination deficiency in PD-L1, PD-L2, JAK2 (PDJ) amplified triple negative breast carcinoma

Ann McCulloch
Dr. McCulloch has no relevant financial relationships to disclose.

Homozygous recombination deficiency in PD-L1, PD-L2, JAK2 (PDJ) amplified triple negative breast cancer

Ann McCulloch
Dr. McCulloch has no relevant financial relationships to disclose.

Effect of PD-L1 and PD-L1 in the tumor microenvironment on overall survival of triple-negative breast cancer patients

Ann McCulloch
Dr. McCulloch has no relevant financial relationships to disclose.

A novel fluorescence in situ hybridization assay to detect 9p24.1 amplification in triple negative breast cancer

Ann McCulloch
Dr. McCulloch has no relevant financial relationships to disclose.

Targeting ERR-α regulated lactate metabolism eliminates drug-resistant breast cancer cells

Donald McDonnell
Mr. McDonnell has no relevant financial relationships to disclose.

The share thoughts on breast cancer study: A Greater Plains collaborative cohort characterization project

Bradley McDowell
Mr. McDonnell has no relevant financial relationships to disclose.

Treatment patterns for breast cancer brain metastasis

Bradley McDowell
Mr. McDonnell has no relevant financial relationships to disclose.

Survivorship care planning is associated with breast cancer survivors’ reported quality and coordination of care

Bradley McDowell
Mr. McDonnell has no relevant financial relationships to disclose.

Disruption of the estradiol-regulated NTN1-UNC5A dependence receptor signaling axis causes a hybrid basal/luminal molecular phenotype in estrogen receptor-positive breast cancer cells

Kyle McElyea
Mr. McElyea has no relevant financial relationships to disclose.

Multicentre observational study evaluating why mastectomies are advised by UK multi-disciplinary teams

Katherine McEvoy
Dr. McEvoy has no relevant financial relationships to disclose.

Predicting germline mutations in BRCA2 and beyond: A comparison of women with single and multiple breast primaries

Rachel McFarland
Ms. McFarland has disclosed that she is a full time employee of Ambry Genetics.

ATM mutations contribution to hereditary breast-pancreatic cancer

Rachel McFarland
Ms. McFarland has disclosed that she is a full time employee.

Immunohistochemistry cannot be used to detect PD-L1/AK-2 amplification

Troy McEachron
Dr. McEachron has no relevant financial relationships to disclose.

Feasibility of assessing radiation response with MRI/CT directed preoperative accelerated partial breast irradiation in the prone position for hormone sensitive early stage breast cancer

Sohyun McElroy
Dr. McElroy has no relevant financial relationships to disclose.

Disruption of the estradiol-regulated NTN1-UNC5A dependence receptor signaling axis causes a hybrid basal/luminal molecular phenotype in estrogen receptor-positive breast cancer cells

Kyle McElyea
Mr. McElyea has no relevant financial relationships to disclose.

Multicentre observational study evaluating why mastectomies are advised by UK multi-disciplinary teams

Katherine McEvoy
Dr. McEvoy has no relevant financial relationships to disclose.

Predicting germline mutations in BRCA2 and beyond: A comparison of women with single and multiple breast primaries

Rachel McFarland
Ms. McFarland has disclosed that she is a full time employee of Ambry Genetics.

ATM mutations contribution to hereditary breast-pancreatic cancer

Rachel McFarland
Ms. McFarland has disclosed that she is a full time employee.
Associations between breast cancer subtypes and mutations in cancer predisposition genes identified by clinical genetic testing of breast cancer patients
Rachel McFarland
Ms. McFarland has disclosed that she is an employee of Ambry Genetics.

Unhealthy lifestyle patterns are prevalent in unaffected BRCA mutation carriers & are associated with increased oxidative stress and telomere length alterations
Sarah McGarrigle
Dr. McGarrigle has no relevant financial relationships to disclose.

Randomized phase 3 study of a novel, long-acting G-CSF (eflapegrastim) versus pegfilgrastim in the management of chemotherapy-induced neutropenia in early-stage breast cancer patients receiving docetaxel and cyclophosphamide (TC) regimen
Kimberly McGregor
Dr. McGregor has no relevant financial relationships to disclose.

Randomized study comparing MoistHer to topical lidocaine for female breast cancer survivors with dyspareunia
Eva McGuire
Ms. McGuire has no relevant financial relationships to disclose.

Tumor-infiltrating lymphocyte (TIL) assessment distilled into two binary parameters in triple-negative breast cancer (TNBC)
Patrick McIntire
Dr. McIntire has no relevant financial relationships to disclose.

Triple-negative breast cancers (TNBCs) rich in infiltrating stromal plasma cells have improved disease-free survival and overall survival
Patrick McIntire
Dr. McIntire has no relevant financial relationships to disclose.

"Quality, not quantity": 10X hot-spot (HS) analysis of lymphocyte markers (CD3, CD8, CD4, CD20) in tumor-infiltrating lymphocytes (TILs) is superior to whole tumor (WT) analysis in triple-negative breast cancer (TNBC)
Patrick McIntire
Dr. McIntire has no relevant financial relationships to disclose.

Tissue macroarray (TMA) based immunohistochemical studies of lymphocyte-specific markers yield inaccurate results
Patrick McIntire
Dr. McIntire has no relevant financial relationships to disclose.

Challenging the 50% threshold that defines lymphocyte predominant breast cancer (LPBC)
Patrick McIntire
Dr. McIntire has no relevant financial relationships to disclose.
Increased tumor perfusion following treatment with trastuzumab as measured by contrast-enhanced ultrasound: Dr. McIntyre has no relevant financial relationships to disclose.

Quantitative in vivo imaging of intratumoral heterogeneity to assess tumor response to trastuzumab treatment in a preclinical model of HER2+ breast cancer: Dr. McIntyre has no relevant financial relationships to disclose.

Evaluation of miracle mouthwash (MMW) plus hydrocortisone or prednisolone mouth rinses as prophylaxis for everolimus-associated stomatitis: Results of a randomized phase II study: Dr. McIntyre has no relevant financial relationships to disclose.

Factors that can be used to guide further auxiliary treatment following positive sentinel lymph node biopsy: Dr. McIntyre has no relevant financial relationships to disclose.

Factors associated with genetic testing in a cohort of breast cancer survivors: Dr. McIntyre has no relevant financial relationships to disclose.

Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC): Dr. McKay has disclosed that he is an employee of and holder of shares and options for Syros Pharmaceuticals.

Prognostic value of molecular tumor infiltrating lymphocyte (mTIL) signatures in HER2-positive breast cancer patients in N9831 and FinHer/FinXX trials: Dr. McLaughlin has no relevant financial relationships to disclose.

Evaluation in BRCA mutation associated triple negative breast cancer: Dr. McKittrick has no relevant financial relationships to disclose.

Efficacy of screening and treatment of breast cancer patients reporting high level of distress: Dr. McKnight has no relevant financial relationships to disclose.

Breast implant associated anaplastic large cell lymphoma (BIA-ALCL)- The UK experience and first reported case of neoadjuvant brentuximab: Mr. McLean has no relevant financial relationships to disclose.

Influence of mutagen exposure on molecular profile in breast cancer: Dr. McLeod has no relevant financial relationships to disclose.

The impact of the introduction of breast cancer screening on a symptomatic breast cancer unit: Mr. McLoughlin has no relevant financial relationships to disclose.

Identification of SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong antitumor activity in wild-type and mutant ER+ breast cancer models: Ms. McManus has no relevant financial relationships to disclose.

Differential mutation pattern between neoadjuvant and metastatic settings in breast cancer patients: Ms. McMillan has no relevant financial relationships to disclose.

COLET: A multistage, phase 2 study evaluating the safety and efficacy of a doublet regimen of cobimetinib (C) in combination with paclitaxel (P) or triplet regimens of C in combination with axolotinib (ateno) plus either P or nab-paclitaxel (nab-P) in metastatic triple-negative breast cancer (TNBC): Ms. McNally has disclosed that she receives salary from and has ownership in Genentech.

Cobimetinib (C) combined with paclitaxel (P) as a first-line treatment in patients (pts) with advanced triple-negative breast cancer (COLET study): Updated clinical and biomarker results: Ms. McNally has disclosed that she receives salary from and has ownership in Roche-Gentech.

Nucllease-activated oligonucleotide probes for detection of breast cancer circulating tumor cells (CTCs): Early clinical results: Dr. McNamara has no relevant financial relationships to disclose.

Steroid receptors and steroidogenic enzymes in human breast cancer: Associations with breast cancer subtypes and clinical outcome: Dr. McNamara has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Paper ID</th>
<th>Title</th>
<th>Authors</th>
<th>Relationship Disclosures</th>
</tr>
</thead>
<tbody>
<tr>
<td>OT3-02-06</td>
<td>Positive behavior change and weight loss in breast cancer survivors on hormonal adjuvant therapy: An energy balance research in cancer (EnBal) prospective study</td>
<td>John McNight</td>
<td>Dr. McNight has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT3-07-03</td>
<td>A randomized controlled trial comparing acupuncture versus usual care for the treatment of aromatase inhibitor-induced arthralgia in women with early-stage breast cancer</td>
<td>John McNight</td>
<td>Dr. McNight has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT3-08-01</td>
<td>A randomized study comparing MoistHer to topical lidocaine for female breast cancer survivors with dyspareunia</td>
<td>John McNight</td>
<td>Dr. McNight has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT3-07-05</td>
<td>Positive behavior change and weight loss in breast cancer survivors on hormonal adjuvant therapy: An energy balance research in cancer (EnBal) prospective study</td>
<td>Nancy McNulty</td>
<td>Dr. McNulty has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-01-03</td>
<td>Impact of pre-operative exercise and mind-body interventions on patient-reported outcomes in women with newly diagnosed breast cancer</td>
<td>Lisa McShane</td>
<td>Ms. McShane has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-13-02</td>
<td>Long-term effects of weight loss on breast cancer biomarkers in postmenopausal women</td>
<td>Anne McTiernan</td>
<td>Dr. McTiernan has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-11-02</td>
<td>Impact of pre-operative exercise on breast cancer gene expression</td>
<td>Anne McTiernan</td>
<td>Dr. McTiernan has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-05-03</td>
<td>Unregulated purinergic signaling enhances cell proliferation in human and murine breast carcinomas</td>
<td>Kaitlyn McWhan</td>
<td>Dr. McWhan has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-10-04</td>
<td>Accelerated partial breast irradiation versus whole breast irradiation: Health-related quality of life analysis from a phase 3 trial</td>
<td>Fiammetta Meacci</td>
<td>Dr. Meacci has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-03-03</td>
<td>Microenvironment induced DDR2 mediates stromal-cancer interactions and metastasis-growth in breast cancer</td>
<td>Natasha Mehlrosa</td>
<td>Ms. Mehlrosa has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Q3-01-02</td>
<td>Evaluation of a multidisciplinary cancer team quality in a breast cancer unit (BCU) in Mexico</td>
<td>Juan Manuel Medina-Castro</td>
<td>Dr. Medina-Castro has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-03-18</td>
<td>A hierarchy of cancer associated fibroblasts in situ and in circulation promote breast cancer metastasis</td>
<td>Kelsie Medina-Saenz</td>
<td>Kelsie Medina-Saenz has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-06-08</td>
<td>HOACs downregulate HbA1c2 to regulate Stat3 activity and breast cancer growth</td>
<td>Terry Medler</td>
<td>Dr. Medler has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-08-03</td>
<td>Targeting inflammatory pathways: A phase 2 trial of the JAK-inhibitor ruxolitinib in combination with exemestane for aromatase inhibitor-resistant, estrogen receptor-positive breast cancer</td>
<td>Christopher Medrano</td>
<td>Mr. Medrano has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S6-02</td>
<td>The efficacy and safety of the addition of abiraterone to adjuvant hormonal therapy in postmenopausal women with hormone-receptor positive early breast cancer: First results of the TEAM III trial (BOOG 2006-04)</td>
<td>Meershoek-Klein Kranenbarg</td>
<td>Ms. Meershoek-Klein Kranenbarg has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-09-08</td>
<td>Safety assessment of extended adjuvant endocrine therapy with letrozole: results of the randomized phase III IDEA trial (BOOG 2006-05)</td>
<td>Meershoek-Klein Kranenbarg</td>
<td>Ms. Meershoek-Klein Kranenbarg has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2O-07</td>
<td>5-year follow-up and biomarker discovery for adjuvant endocrine therapy: results of the TEAM trial</td>
<td>Meershoek-Klein Kranenbarg</td>
<td>Ms. Meershoek-Klein Kranenbarg has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S1-04</td>
<td>Opto-acoustic imaging of the breast: Downclassification and upclassification of suspicious breast masses</td>
<td>Meeuwis Carla</td>
<td>Ms. Meeuwis has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-02-08</td>
<td>Evaluating targets in localized and advanced breast cancer by sequencing tumor DNA at diagnosis and after progression (ELSA)</td>
<td>Meershoek-Klein Kranenbarg</td>
<td>Ms. Meershoek-Klein Kranenbarg has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT2-01-16</td>
<td>The role of inducible nitric oxide synthase in the stemness of triple negative breast cancer</td>
<td>Meershoek-Klein Kranenbarg</td>
<td>Ms. Meershoek-Klein Kranenbarg has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-11-06</td>
<td>Learning curve for the SAVI SCOUT breast localization and surgical guidance system</td>
<td>Mehndru Ankur</td>
<td>Dr. Mehndru has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-05-45</td>
<td>Long-term follow-up of early stage breast cancer patients with results of Mammaprint*, OncoType DX® and MammoStrat® risk classification assays</td>
<td>Mehndru Ankur</td>
<td>Dr. Mehndru has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-22-21</td>
<td>NCI9782: A phase 1 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors</td>
<td>Mehnert Janice</td>
<td>Dr. Mehnert has disclosed that she received from Merck 9/2013-7/2014 salary support for outcomes research project. She has also disclosed that she was on Amgen 9/2015 advisory board and received the following: Sanofi 2/2012-2/2015 research funding, study PI; Novartis 11/2014 research funding, study PI; Merck 5/2013 research funding, study PI; Polyoma 10/2013 research funding, study PI and Merck 5/2014 research funding, study PI.</td>
</tr>
<tr>
<td>OT1-04-02</td>
<td>NRG oncology/RTOG 1119: Phase II randomized study of whole brain radiotherapy with concurrent lapatinib in patients with brain metastases of HER2-positive breast cancer — A collaborative study of RTOG &amp; NRG (NCT01622868)</td>
<td>Mehta Minesh</td>
<td>Dr. Mehta has disclosed that he is a consultant for Varian. He also disclosed that he has a contract with Novocure: Institutional support for IST. He disclosed that he has YC; stock options (Divested) and receives other financial support from MONTERIS DSMB.</td>
</tr>
<tr>
<td>P6-12-13</td>
<td>Single domain antibody (SBT-106) inhibits growth of human HER2+ and triple negative breast cancers (TNBC) in xenografts by binding STAT3 and P-STAT3</td>
<td>Mehta Rutika</td>
<td>Dr. Mehta has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-11-10</td>
<td>Preclinical efficacy of the novel PAR2 kinase inhibitor, IFD1564 in triple negative breast cancer models</td>
<td>Mehta Rutika</td>
<td>Dr. Mehta has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-05-17</td>
<td>Establishment and preliminary clinical application of breast cancer CTC detection kit based on immune magnetic lipid microsphere/human breast mammmaglobin</td>
<td>Mehta Shenglan</td>
<td>Dr. Mehta has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-08-01</td>
<td>Patient derived DCS mouse-intratralucal (MINIS) models recapitulate the full spectrum of human patient pathology and histologic features including progression to invasion in a subset of cases</td>
<td>Mehto Mairajotto</td>
<td>Dr. Mehto has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT3-02-04</td>
<td>The DETECT V-study - Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemotherapy or endocrine therapy in patients with HER2-positive and hormone-receptor positive metastatic breast cancer</td>
<td>Meierotto Ruby</td>
<td>Dr. Meierotto has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT3-04-02</td>
<td>DETECT III and IV: Individualized CTC-based therapy of metastatic breast cancer</td>
<td>Meierotto Ruby</td>
<td>Dr. Meierotto has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
P1-01-15  DETECT V - Detection of the expression of estrogen receptor and human epidermal growth factor receptor 2 on circulating tumor cells from metastatic breast cancer patients
Franziska Meier-Stiegen  Dr. Meier-Stiegen has no relevant financial relationships to disclose.

P3-03-03  An acquired HER2 T798I gatekeeper mutation induces resistance to neratinib in a patient with HER2 mutant-driven breast cancer
Jens Merkel  Dr. Merkel has no relevant financial relationships to disclose.

P6-16-03  Phase 2 trial of everolimus and/or trastuzumab in hormone refractory, hormone receptor (HR) positive, HER2-normal metastatic breast cancer (MBC)
Jane Merkel  Dr. Merkel has no relevant financial relationships to disclose.

P1-05-22  The value of RNA-Seq for the detection of clinically actionable targets in breast cancer: A small cohort analysis
Tobias Mecksher  Mr. Mecksher has no relevant financial relationships to disclose.

P1-05-23  Utilities and challenges of RNA-Seq based expression and variant calling in a clinical setting
Tobias Mecksher  Dr. Mecksher has no relevant financial relationships to disclose.

P3-03-06  Characterization of HER2-positive breast cancer (BC) cells selected for tolerance to trastuzumab-induced antibody-dependent cell-mediated cytotoxicity (ADCC)
Tobias Mecksher  Mr. Mecksher has no relevant financial relationships to disclose.

P3-10-25  A randomized trial of 15 fraction vs. 25 fraction pencil beam scanning proton radiotherapy after mastectomy in patients requiring regional nodal irradiation
Penny Mei Yin  Dr. Mei Yin has no relevant financial relationships to disclose.

P4-13-01  Prospective association between breast cancer risk and an individual dietary index based on the British Food Standards Agency nutrient profiling system
Caroline Meijer  Dr. Meijer has no relevant financial relationships to disclose.

P4-17-02  Global Cancer Institute online tumor boards to improve global patterns of clinical practice for breast cancer
Gerson Mejia  Mr. Mejia has no relevant financial relationships to disclose.

P2-04-01  Increased stromal lymphocytes in breast cancer patients with autologous dendritic cell vaccination plus neoadjuvant chemotherapy
Luiz Mejias  Dr. Mejias has no relevant financial relationships to disclose.

P5-15-13  Capecitabine in combination with bendelidivine in pretreated women with HER2-negative metastatic breast cancer: Final PFS results of a phase II trial (AGATM-MBC-6)
Thomas Meierhardt  Dr. Meierhardt has no relevant financial relationships to disclose.

P5-05-09  Upregulated purinergic signaling enhances cell proliferation in human and murine breast carcinomas
Marco Mele  Dr. Mele has no relevant financial relationships to disclose.

P4-21-12  Preference of trastuzumab administration route (intravenous or subcutaneous) in patients in the Czech Republic. Cross-sectional study on 429 patients
Joshua Melesar  Dr. Melesar has no relevant financial relationships to disclose.

P5-10-02  African Americans have more aggressive invasive lobular carcinoma subtypes and inferior early outcomes: SEER 2010-2013
Susan Melisko  Dr. Melisko has no relevant financial relationships to disclose.

P5-11-17  Body image in women with breast cancer using a scalp cooling system to reduce chemotherapy induced alopecia
Susan Melisko  Dr. Melisko has disclosed that she has contracts with NewLink Genetics and Novartis.

P5-11-17  Body image in women with breast cancer using a scalp cooling system to reduce chemotherapy induced alopecia
Michelle Melisko  Dr. Melisko has disclosed that he is a consultant for Newlink Genetics and Novartis.

P1-05-22  Trajectory of patient (Pt) reported physical function (PF) during and after neoadjuvant chemotherapy in the I-SPY 2 trial
Michelle Melisko  Dr. Melisko has disclosed a patent 'Immunoliposomes that optimize internalization into target cells' with royalties paid to Merrimack (Immediate Family Member). She has also disclosed personal fees and non-financial support from Amgen; personal fees from Genentech (Immediate Family Member); Grant support from Genentech (Michelle E Melisko); Grants and non-financial support from NIH, during the conduct of the study (Immediate Family Member).
<table>
<thead>
<tr>
<th>Committee Member/Speaker, Educational Session</th>
<th>&quot;Rbi Based Follow up Care: Emerging Evidence and Oicking Guidelines&quot;</th>
<th>Michelle Melisko</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2-08-11</td>
<td>Metabolite-guided long-term prediction of outcome in tamoxifen treated breast cancer patients.</td>
<td>Gunnar Mellgren</td>
</tr>
<tr>
<td>P4-02-04</td>
<td>Opto-acoustic imaging of the breast: Gomification and classification of suspicious breast masses.</td>
<td>Elisabeth Menezes</td>
</tr>
<tr>
<td>P6-02-07</td>
<td>Metabolomic analysis by nuclear magnetic resonance spectroscopy discriminates hormone receptor positive/HER2 negative breast cancer cell lines resistant to palbociclib.</td>
<td>Gaia Meroni</td>
</tr>
<tr>
<td>P2-05-13</td>
<td>Can axillary lymph node clearance be avoided in women with node positive breast cancer receiving primary chemotherapy?</td>
<td>Ana Mera</td>
</tr>
<tr>
<td>P3-17-09</td>
<td>Resolution of DCIS in patients with early breast cancer receiving primary chemotherapy for invasive breast cancer.</td>
<td>Ana Mera</td>
</tr>
<tr>
<td>P2-05-03</td>
<td>Novel visualization tools to search ongoing clinical trials and track trial results for metastatic breast cancer.</td>
<td>Scott Meric</td>
</tr>
<tr>
<td>P2-05-21</td>
<td>Predictive value of quantitative HER2 and HER3 levels combined with downstream signaling markers in HER2-positive advanced breast cancer patients treated with lapatinib.</td>
<td>Merida Merdalska</td>
</tr>
<tr>
<td>P2-05-05</td>
<td>A phase II clinical trial of VST-1001 (dilute fluorescein) in lymphatic mapping and sentinel lymph node localization in clinically node negative breast cancer.</td>
<td>Funda Meric-Bernstam</td>
</tr>
</tbody>
</table>

Dr. Melisko has disclosed that she receives consulting fees from Biotheranostics. She also disclosed that she does contracted research for Genentech, Galena and Lilly - all funding to UC Regents. She disclosed that her spouse has ownership interest in Merrimack. She also disclosed that she receives honoraria from Pfizer and Genentech. These relationships do not impact her ability to present an unbiased presentation.

Dr. Mellgren has no relevant financial relationships to disclose.

Dr. Melnyk Jr. has no relevant financial relationships to disclose.

Dr. Menere has no relevant financial relationships to disclose.

Dr. Menere-Garcia has no relevant financial relationships to disclose.

Dr. Menes has no relevant financial relationships to disclose.

Ms. Mera has no relevant financial relationships to disclose.

Ms. Mera has no relevant financial relationships to disclose.

Dr. Meric-Bernstam has no relevant financial relationships to disclose.
P4-06-04  Triple negative breast cancer patient-derived xenografts: Molecular characteristics and sensitivity to emerging therapies

Funda Meric-Bernstam  Funda Meric-Bernstam has disclosed that she is a consultant for Genentech, Novartis, Roche, Celgene and Inflection. She has also disclosed that she has contracts with Novartis, AstraZeneca, Taiho, Genentech, Calithera, Delphiopharma, Bayer, Aileron, Jounce, Cytope and Effective Pharma.

P02-08  Neratinib + fukastatin in ERBB2-mutant, HER2-non-amplified, estrogen receptor (ER)-positive, metastatic breast cancer (mBC): Preliminary analysis from the phase II SUMMIT trial

Funda Meric-Bernstam  Funda Meric-Bernstam has disclosed that she is a consultant for Genentech, Novartis, Roche, Celgene and Inflection. She has also disclosed that she has contracts with Novartis, AstraZeneca, Taiho, Genentech, Calithera, Delphiopharma, Bayer, Aileron, Jounce, Cytope and Effective Pharma.

P06-11-05  Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC)

Funda Meric-Bernstam  Dr. Meric-Bernstam has disclosed that she is a consultant for Genentech, Novartis, Roche, Celgene and Inflection. She has also disclosed that she has contracts with Novartis, AstraZeneca, Taiho, Genentech, Calithera, Delphiopharma, Bayer, Aileron, Jounce, Cytope and Effective Pharma.

OT3-03-05  Challenges faced across borders to open European academic multicentric projects: The E-I-NET TRANSCAN ICT 2011

Domenico Franco Merlo  Dr. Merlo has no relevant financial relationships to disclose.

P2-05-11  miR363-3p mediates maintenance and resistance of breast cancer stem cells (BCSC)

Nicolas Mermod  Mr. Mermod has no relevant financial relationships to disclose.

P4-21-15  miR363-3p mediates maintenance and resistance of breast cancer stem cells (BCSC)

Tim Mortens  Mr. Mortens has no relevant financial relationships to disclose.

P2-14-01  Metastatic trial search: Advocacy groups collaborate to engage metastatic breast cancer patients in clinical trials

Shirley Mertz  Ms. Mertz has no relevant financial relationships to disclose.

P4-22-15  miR363-3p mediates maintenance and resistance of breast cancer stem cells (BCSC)

Wells Messersmith  Dr. Messersmith has no relevant financial relationships to disclose.

P1-11-04  Increasing participation in research - breast cancer (Inspire-BrC)

Leanne Metcalf  Ms. Metcalf has disclosed that she receives salary from Health Care Services Corporation, Premise Health.

P3-10-02  EP3-receptor expression is a prognostic marker for overall survival and progression-free survival in sporadic breast cancer

Alexandra Meuter  Ms. Meuter has no relevant financial relationships to disclose.

P1-06-11  A targetable EGFR-driven tumor-initiating program in breast cancer

Sarkis Meterissian  Sarkis Meterissian has no relevant financial relationships to disclose.

P4-21-18  A targetable EGFR-driven tumor-initiating program in breast cancer

Clara Metz  Ms. Metz has disclosed that she receives salary and has ownership.

P1-12-04  Pre-clinical antitumor activity, tumor localization, and pharmacokinetics of MP0274, an apoptosis inducing, biparatopic HER2-targeting DARPin®

Otto Metzger  Dr. Metzger has no relevant financial relationships to disclose.

P5-15-08  Pre-clinical antitumor activity, tumor localization, and pharmacokinetics of MP0274, an apoptosis inducing, biparatopic HER2-targeting DARPin®

Otto Metzger  Dr. Metzger has no relevant financial relationships to disclose.

P2-05-23  Comparative toxicity and effectiveness of trastuzumab combined with anthracycline versus platinum chemotherapy regiments for adjuvant therapy of HER2+ breast cancer in older women

Anne Marie Meyer  Dr. Meyer has no relevant financial relationships to disclose.

P2-05-11  A phase 2 study of eribulin as early-line treatment for HER2- MBC. Evaluation of efficacy, toxicity, and patient-reported outcomes

Otto Metzger  Dr. Metzger has no relevant financial relationships to disclose.

P1-07-12  An exploratory correlative biomarker analysis of NGSP FB-7, a phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel (P) plus neratinib (N) or trastuzumab (T) or neratinib and trastuzumab (N+T) followed by docetaxel and cyclophosphamide (AC) with postoperative T in women with locally advanced HER2-positive breast cancer

Gary Meyer  Mr. Meyer has disclosed that he is a full-time employee of OXtech Oncology.
Drugs don't work if people don't take them: Non-initiation of endocrine therapy in young women

ENCORE 602: A randomized, placebo-controlled, double-blind, multicenter phase 2 study (with a phase 3b lead-in) of abemaciclib with or without entinostat in patients with advanced triple negative breast cancer (TNBC)

Dr. Meyers has no relevant financial relationships to disclose.

OT2-01-12

ENCORE 602: A randomized, placebo-controlled, double-blind, multicenter phase 2 study (with a phase 1b lead-in) of atezolizumab with or without entinostat in patients with advanced triple negative breast cancer (TNBC)

Dr. Meyers has disclosed that he receives salary from and has ownership in Syndax.

P6-07-13

Young women with breast cancer in Mexico: A report of the pilot phase of the "Mujer Joven y Fuerte" prospective cohort

Dr. Miano has no relevant financial relationships to disclose.

P4-20-04

OCTAM-A33, a breast cancer specific and estrogen receptor dependent long noncoding RNA, is a key component of the pathway controlling cell growth and migration

Dr. Miano has no relevant financial relationships to disclose.

P6-08-12

Association of pre-chemotherapy peripheral blood pro-inflammatory (IL-6, CRP) and coagulation (D-dimer) markers with chemotherapy toxicity in women with breast cancer

Dr. Mi has no relevant financial relationships to disclose.

P3-10-04

Comparison of the 6agent breast cancer stratter mRNA assay with central EK, PK, HER2, and KI67 immunohistochemistry (IHC) for rapid biomarker analysis in developing countries

Dr. Miccinesi has no relevant financial relationships to disclose.

P2-05-07

Can axillary lymph node clearance be avoided in women with node positive breast cancer receiving primary chemotherapy?

Dr. Michelotti has no relevant financial relationships to disclose.
Tumor genomic profiling of triple negative breast cancer during neoadjuvant chemotherapy: Results from a prospective trial of carboplatin and docetaxel  
Christopher Miller  
Dr. Miller has no relevant financial relationships to disclose.

Triple negative breast cancer and factors associated with its treatment in the US - A population study using central cancer registry data  
Jacqueline Miller  
Dr. Miller has no relevant financial relationships to disclose.

Building an experience engine to make cancer treatment decisions using machine learning  
Jeffrey Miller  
Dr. Miller has no relevant financial relationships to disclose.

A Phase II randomized trial of pembrolizumab with carboplatin and gemcitabine for treatment of patients with metastatic triple negative breast cancer (mTNBC)  
Kathy Miller  
Dr. Miller has no relevant financial relationships to disclose.

SEER study of breast cancer-specific mortality in patients with poorly differentiated tumors treated based on recurrence score results  
Dave Miller  
Mr. Miller has disclosed that he receives salary from and ownership in Genomic Health, Inc.

A Phase II randomized trial of pertuzumab with carboplatin and gemcitabine for treatment of patients with metastatic triple negative breast cancer (mTNBC)  
Kathy Miller  
Dr. Miller has no relevant financial relationships to disclose.

Impact of magnetic resonance imaging on conversion from wide local excision to mastectomy in patients with ductal carcinoma in situ: First results from the ECOG-ACRIN 4112 prospective study  
Kathy Miller  
Dr. Miller has no relevant financial relationships to disclose.

A single-arm phase 2 study to assess clinical activity, efficacy and safety of enzalutamide with trastuzumab in HER2+ AR- metastatic or locally advanced breast cancer  
Kathy Miller  
Ms. Miller has disclosed no disclosures other than the support of this trial.

A phase 2 open-label study of lucitanib in patients (pts) with FGF aberrant metastatic breast cancer (MBC)  
Kathy Miller  
Dr. Miller has no relevant financial relationships to disclose.

Non-metastatic and metastatic breast cancer patients' priorities when considering a treatment decision  
Melissa Miller  
Dr. Miller has no relevant financial relationships to disclose.

First-line ribociclib plus letrozole in patients with de novo HR+, HER2- advanced breast cancer (ABC): A subgroup analysis of the MONALEESA-2 trial  
Michelle Miller  
Ms. Miller has disclosed that she is a Novartis employee and has ownership in Novartis.

Unique overlapping subtypes of triple-negative breast and ovarian cancers and sensitivity of “mesenchymal-like” cancers to HSP90 inhibition is revealed by integrated gene expression and drug sensitivity profiling  
Todd Miller  
Dr. Miller has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Title</th>
<th>Abstract</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>Triple negative breast cancer patient-derived xenografts: Molecular characteristics and sensitivity to emerging therapies</td>
<td>Gordon Mills</td>
<td>Dr. Mills has disclosed that he is a consultant for Adventist Health, AstraZeneca, Allosteric, Catena Pharmaceuticals, Critical Outcome Technologies, ISIS Pharmaceuticals, ImmunoMet, Takeda/Millennium Pharmaceuticals, MedImmune, Precision Medicine, Provista Diagnostics, Signulem Lifesciences, Symphogen, Li and receives honoraria from Symphogen, MedImmune, AstraZeneca, ISIS Pharmaceuticals, Lilly, Novartis, ImmunoMet and Allosteric. He has also disclosed that he has contracts with Adelson Medical Research Foundation, AstraZeneca, Critical Outcome Technologies, Komen Research Foundation, Nanosting, Breast Cancer Research Foundation, Kusan, Immunex, Takeda/Millennium Pharmaceuticals and has ownership in Catena Pharmaceuticals, PTV Ventures, Spendidoot Ventures, Myriad Genetics and ImmunoMet.</td>
<td></td>
</tr>
<tr>
<td>Proteomic response in breast cancer treated with neoadjuvant chemotherapy with and without bevacizumab: Reverse phase protein array (RPPA) results from NeoAva - A randomized phase II study</td>
<td>Gordon Mills</td>
<td>Dr. Mills has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>Comparison of the Aptent breast cancer stratifier mRNA assay with central ER, PR, HER2, and Ki67 immunohistochemistry (IHC) for rapid biomarker analysis in developing countries</td>
<td>Danny Milner</td>
<td>Dr. Milner has disclosed that she receives Salary and Grant support from Cepheid.</td>
<td></td>
</tr>
<tr>
<td>Longitudinal patterns of postdiagnosis weight changes according to adjuvant systemic treatments in Korean breast cancer patients</td>
<td>Eunum Min</td>
<td>Dr. Min has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA)</td>
<td>Lidia Mina</td>
<td>Dr. Mina has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>Three-monthly dynamic evaluation of CEA and CA15-3 (followed by 18-FDG PET) vs usual practice in the follow-up of early breast cancer (BC) patients (pts): A prospective randomized trial (KRONOS-patient-oriented new surveillance study, Italy)</td>
<td>Santino Minichillo</td>
<td>Dr. Minichillo has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>Specific detection of anti-Her2 PEGylated PrecisionMRX® nanoparticles measured using superparamagnetic relaxometry</td>
<td>Kyla Minser</td>
<td>Ms. Minser has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>Efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial</td>
<td>Susan Minton</td>
<td>Dr. Minton has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>The evaluation of pamidronate/dexamethasone plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial</td>
<td>Susan Minton</td>
<td>Dr. Minton has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>Factors related to the prognosis of breast cancer patients after the development of brain metastases</td>
<td>Eleonora Morarzsa</td>
<td>Dr. Morarzsa has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>Tumor infiltrating lymphocytes in recurrent HER2+ and triple negative breast cancer: Prognostic value according to tumor phenotypes</td>
<td>Eleonora Morarzsa</td>
<td>Dr. Morarzsa has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
</tbody>
</table>
OT2-01-13  Phase II of POSEIDON: A phase I / IIB randomized phase II trial of lamotrigine plus bevacizumab or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment  Josep Maria Miquel  Dr. Miquel has no relevant financial relationships to disclose.

P6-09-47  The development of personalized diagnostic tests and therapeutic strategies in breast cancer  Marinka Miranda  Ms. Miranda has no relevant financial relationships to disclose.

P1-10-05  Successful implementation of a novel breast cancer navigation program in Nuevo Leon, Mexico  Teresa Minoves-Aguilar  Dr. Minoves-Aguilar has no relevant financial relationships to disclose.

P1-05-14  Copy number aberration-induced gene breakage analysis identifies recurrent FOXP1 fusions in breast cancer  Hasan Mirza  Hasan Mirza has no relevant financial relationships to disclose.

P1-07-09  Mesenchymal subtype negatively associates with the presence of immune infiltrates within a triple negative breast cancer classifier  Hasan Mirza  Hasan Mirza has no relevant financial relationships to disclose.

P4-21-22  Oncogenic potential of HR38 mutations in human mammary epithelial cells  Rosalin Mishra  Dr. Mishra has no relevant financial relationships to disclose.

P6-01-03  Stabilizes SKT suppresses breast cancer metastasis by inhibiting cancer associated macrophages  Saijay Mishra  Dr. Mishra has no relevant financial relationships to disclose.

P1-10-17  Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer  Fremand Misrizho  Dr. Misrizho has no relevant financial relationships to disclose.

P1-10-07  Prospective longitudinal study of epithelial blistering in breast cancer patients treated with conventional versus hypofractionated radiotherapy  Donna Miter  Ms. Miter has no relevant financial relationships to disclose.

P3-08-05  Clinical outcome of patients with advanced triple negative breast cancer with germ line and somatic variants in homologous recombination gene  Maxim Misyura  Mr. Misyura has no relevant financial relationships to disclose.

P6-12-04  Phase 1 study of the antibody-drug conjugate (ADC) SGN-LIV1A in patients with heavily pretreated metastatic breast cancer  Monica Mita  Dr. Mita has disclosed that she has a contract with Seattle Genetics, Inc.

P3-04-07  The new oral SERD AZD9496 is efficacious in antagonizing ER and circumventing resistance to endocrine therapy  Tamika Mitchell  Ms. Mitchell has no relevant financial relationships to disclose.

P3-03-07  High-throughput pharmacogenomic platform to functionally probe breast cancer vulnerabilities in the context of the 3-dimensional tumor microenvironment  Constantine Mitsiades  Dr. Mitsiades has no relevant financial relationships to disclose.

P4-21-25  The importance of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive recurrent and advanced breast cancer  Shoshu Mitsuyama  Dr. Mitsuyama has no relevant financial relationships to disclose.

OT2-01-14  Neoadjuvant trial of nab-paclitaxel and atezolizumab, a PD-L1 inhibitor, in patients with triple negative breast cancer (TNBC) [NCT02303480]  Elizabeth Mittendorf  Dr. Mittendorf has no relevant financial relationships to disclose.

OT2-01-20  Phase III study of neoadjuvant pertuzumab combined with carboplatin and paclitaxel (PaxCT) for anthracycline-resistant triple negative breast cancer (TNBC)  Elizabeth Mittendorf  Dr. Mittendorf has no relevant financial relationships to disclose.

OT2-01-22  A phase II trial of lapatinib and everolimus (NCT01645897): A phase II trial of lapatinib, bevacizumab and everolimus (NCT01645897) in patients (pts) with localized triple negative breast cancer (TNBC) with tumors predicted insensitive to standard neoadjuvant chemotherapy (NACT)  Elizabeth Mittendorf  Dr. Mittendorf has disclosed that she has contracts with Celgene Biopharma, Arquigen Express, Genetech, Merck and Amgen.

OT3-01-04  VADIS trial: Phase II trial of the nelipepimut-S peptide vaccine in women with DCIS of the breast  Elizabeth Mittendorf  Dr. Mittendorf has no relevant financial relationships to disclose.

P2-01-05  A phase II clinical trial of VST-1001 (silicate fluorescent) in lymphatic mapping and sentinel lymph node localization in clinically node negative breast cancer  Elizabeth Mittendorf  Dr. Mittendorf has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2-01-11</td>
<td>SentinelIC: A non-inferiority trial comparing super-paramagnetic iron oxide vs. Tc99 and blue dye in the detection of axillary sentinel nodes in patients with early stage breast cancer</td>
<td>Elizabeth Mittendorf</td>
<td>Dr. Mittendorf has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-10-01</td>
<td>Immune characterization of inflammatory breast cancer and correlation to pathological complete response</td>
<td>Elizabeth Mittendorf</td>
<td>Dr. Mittendorf has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-01-03</td>
<td>Milky Way sign: A potential predictive sign of breast cancer on digital breast tomosynthesis</td>
<td>Kanae Miyake</td>
<td>Dr. Miyake has disclosed that he receives royalties from Elsevier, 'Breast Imaging: The Requisites (book)'. He also disclosed that he received Society of Nuclear Medicine and Molecular Imaging Wagner-Torizuka fellowship supported by Nihon Medi-Physics co.</td>
</tr>
<tr>
<td>P5-09-01</td>
<td>Predictors of locoregional recurrence after neoadjuvant chemotherapy and surgery for node positive breast cancer: Results from ACOSOG Z1071 (Alliance)</td>
<td>Elizabeth Mittendorf</td>
<td>Dr. Mittendorf has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-09-17</td>
<td>Evaluation of a risk score based on biological factors to enhance prognostic stratification by the American Joint Committee on Cancer (AJCC) Staging System</td>
<td>Elizabeth Mittendorf</td>
<td>Dr. Mittendorf has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-16-01</td>
<td>Immune characterization of inflammatory breast cancer and correlation to pathological complete response</td>
<td>Elizabeth Mittendorf</td>
<td>Dr. Mittendorf has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-01-03</td>
<td>Milky Way sign: A potential predictive sign of breast cancer on digital breast tomosynthesis</td>
<td>Kanae Miyake</td>
<td>Dr. Miyake has disclosed that he receives royalties from Elsevier, 'Breast Imaging: The Requisites (book)'. He also disclosed that he received Society of Nuclear Medicine and Molecular Imaging Wagner-Torizuka fellowship supported by Nihon Medi-Physics co.</td>
</tr>
<tr>
<td>P5-16-10</td>
<td>Zoledronic acid combined with neoadjuvant chemotherapy for HER2-negative early breast cancer (GORE 1 trial): Survival outcomes of a randomized multicenter phase 2 trial</td>
<td>Daishu Miura</td>
<td>Dr. Miura has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-11-03</td>
<td>Difference between 1st and 2nd generation serotonin receptor antagonists in triplet antiemetic therapy for highly emetogenic chemotherapy in breast cancer patients - according to recent multi-institutional double-blind randomized clinical research on the AC regimen</td>
<td>Kayo Miyake</td>
<td>Dr. Miura has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-27</td>
<td>Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy</td>
<td>Yoshimasa Miyagawa</td>
<td>Yoshimasa Miyagawa has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-01-03</td>
<td>Milky Way sign: A potential predictive sign of breast cancer on digital breast tomosynthesis</td>
<td>Kanae Miyake</td>
<td>Dr. Miyake has disclosed that he receives royalties from Elsevier, 'Breast Imaging: The Requisites (book)'. He also disclosed that he received Society of Nuclear Medicine and Molecular Imaging Wagner-Torizuka fellowship supported by Nihon Medi-Physics co.</td>
</tr>
<tr>
<td>P2-01-27</td>
<td>Sentinel lymph node biopsy by contrast-enhanced ultrasonography with sonazoid in patients with breast cancer - Prospective multicenter study</td>
<td>Tomohiro Miyake</td>
<td>Dr. Miyake has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-16-10</td>
<td>Zoledronic acid combined with neoadjuvant chemotherapy for HER2-negative early breast cancer (GORE 1 trial): Survival outcomes of a randomized multicenter phase 2 trial</td>
<td>Minoru Miyashita</td>
<td>Dr. Miyashita has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-12-01</td>
<td>Randomized trial of exercise intervention vs. usual care for breast cancer patients with aromatase inhibitor induced arthralgia</td>
<td>Mineko Miyashita</td>
<td>Dr. Miyashita has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-27</td>
<td>Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy</td>
<td>Yasuo Miyoshi</td>
<td>Yasuo Miyoshi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>QT3-07-02</td>
<td>Influence of exercise or educational programs on long-term physical activity by patients after surgery for primary breast cancer: A randomized trial</td>
<td>Yoshito Mizuno</td>
<td>Dr. Mizuno has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>QT3-07-02</td>
<td>Influence of exercise or educational programs on long-term physical activity by patients after surgery for primary breast cancer: A randomized trial</td>
<td>Yuko Mizuno</td>
<td>Dr. Mizuno has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-11-12</td>
<td>Re-evaluating outcomes of partial breast irradiation using multichannel brachytherapy for Japanese patients with breast cancer by European brachytherapy phase 3 trial</td>
<td>Yoshio Mizuno</td>
<td>Dr. Mizuno has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
P5-15-13  Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Final PFS results of a phase II trial (AGMT MBC-6)  Brigitte Mlineritsch  Dr. Mlineritsch has disclosed that she is a consultant and speaker for Mundipharma.

P6-07-10  DNA methylation signature predicting bevacizumab efficacy in metastatic breast cancer  Brigitte Mlineritsch  Dr. Mlineritsch has disclosed that she has a contract with Roche.

P2-11-05  Safety, immunogenicity and efficacy of proposed biosimilar pegfilgrastim (EA-PF0006) compared with reference pegfilgrastim in breast cancer: A randomized, double-blind, phase III trial  Min Ma  Dr. Ma has disclosed that he is an employee of Sandoz Inc.

P3-11-04  Efficacy and safety of darbepoetin alfa or epoetin beta in 2994 high risk early breast cancer patients participating in the German adjuvant intergroup node-positive study (GAIN)  Volker Miltz  Dr. Miltz has no relevant financial relationships to disclose.

P4-21-34  Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy  Shantu Moddi  Dr. Moddi has no relevant financial relationships to disclose.

P5-12-04  Phase 3 study of the antibody-drug conjugate (ADC) SGN-LIV1A in patients with heavily pretreated metastatic breast cancer  Shantu Moddi  Dr. Moddi has disclosed that he has a contract with Seattle Genetics, Inc.

P5-16-04  Efficacy results of a phase 1/2 study of glucocorticoid receptor (GR) antagonist mifepristone (MIFE) in combination with oribulin in GR-positive triple-negative breast cancer (TNBC)  Manuel Medrano  Dr. Medrano has no relevant financial relationships to disclose.

P4-22-22  Colorectal (C) combined with paclitaxel (P) as a first-line treatment in patients (pts) with advanced triple-negative breast cancer (COSY study): Updated clinical and biomarker results  Mehdi Moezi  Prof. Moezi has disclosed that he is a consultant for Millennium and BMS and a speaker for Novartis, Millennium, BMS and Pfizer. He has also disclosed that he has contracts with Genentech and BMS and is on the Board of Directors for CSNF.

P1-12-05  Phentolamine: Survival advantage over standard of care drugs in a model of brain metastases of breast cancer  Afroz Mohammad  Dr. Mohammad has no relevant financial relationships to disclose.

P2-12-16  Delivery and anti-tumor activity of nanoliposomal irinotecan (Nal-IRI, MM-398) in metastatic xenograft models of triple negative breast cancer  Zatinahhayu Mohd-Isa  Zatinahhayu Mohd-Isa has no relevant financial relationships to disclose.

P1-05-14  Detection of recurrent FGF16 fusions in breast cancer  Zainahhayu Mohd-Ika  Zainahhayu Mohd-Ika has no relevant financial relationships to disclose.
P3-10-02 Increasing participation in research - breast cancer (Inspire-BrC)  
Mahsa Mohebtash  
Mahsa Mohebtash has no relevant financial relationships to disclose.

P5-11-06 BEAUTY and the breast: Is adjuvant chemotherapy the right time for a beauty boost? Results of a randomised controlled trial  
Meriem Mokdad-Adi  
Dr. Mokdad-Adi has no relevant financial relationships to disclose.

P5-12-14 Treatment of early HER2-positive breast cancer in trastuzumab era: an everyday clinical practice: An overview after 10 years of its approval  
Dr. Mokhtech  
Meriem Mokhtech has no relevant financial relationships to disclose.

P5-13-07 The impact of the introduction of breast cancer screening on a symptomatic breast cancer unit  
Brian Molyneux  
Mr. Molyneux has no relevant financial relationships to disclose.

P5-16-14 NOSTRA PRELIM: A non randomised pilot study designed to assess the ability of image guided core biopsies to detect residual disease in patients with early breast cancer who have received neoadjuvant chemotherapy to inform the design of a planned trial  
Rachel Molynieux  
Ms. Molynieux has no relevant financial relationships to disclose.
SYD985, a novel anti-HER2 ADC, shows promising activity in patients with HER2-positive and HER2-negative metastatic breast cancer

Ellen Mommers
Ms. Mommers has disclosed that she is an employee of Synthon.

The impact of the presence of ductal carcinoma in situ in patients with invasive ductal carcinoma

Varun Monga
Varun Monga has no relevant financial relationships to disclose.

Activation of ERβ in triple negative breast cancer results in cell cycle arrest

David Monroe
Dr. Monroe has no relevant financial relationships to disclose.

Flutamide reduced tumor progression and altered steroid hormone secretion in human and canine inflammatory breast cancer cell lines

Beatriz Monalve
Dr. Monalve has no relevant financial relationships to disclose.

Mechanisms of CD8+ T cell immunosuppression in triple negative breast cancer

Anne Monette
Dr. Monette has no relevant financial relationships to disclose.

Phase III trial to evaluate patient’s preference for subcutaneous versus intravenous trastuzumab administration in patients with HER2 positive advanced breast cancer (MBC) under IV trastuzumab (IV-t) treatment for at least 4 months - ChangHEIC-SC study (GICAM/2012-07)

Álvaro Montaño
Mr. Montaño has disclosed that he is on the Speaker’s Bureau for Roche SpA and Novartis Spa.

Distinct recruitment of tumor-associated immune cells correlates with increased pro-malignant chemokines in tumors expressing epithelial atypical chemokine receptor 1 (ACKR1/DARC), indicating a unique tumor microenvironment

Michelle Monteil
Dr. Monteil has no relevant financial relationships to disclose.

Optimized prediction of deleterious missense mutations in BRCA1 and BRCA2 genes

Alvaro Monteiro
Dr. Monteiro has no relevant financial relationships to disclose.

Safety and efficacy of trastuzumab emtansine (T-DM1) in 399 patients with central nervous system metastases: Exploratory subgroup analysis from the KAMILLA study

Filippo Montemurro
Mr. Montemurro has disclosed that he is on the Speaker’s Bureau for F.Hoffmann La Roche and Novartis SPA.

Luminal A breast cancer: Is it really a “good prognosis” disease? Preliminary results of the GIM-13 - AMBRA Italian study

Filippo Montemurro
Dr. Montemurro has no relevant financial relationships to disclose.

First and further line choices of treatment for HER2-VE metastatic breast cancer (MBC) according to adjuvant treatment and biological subtype. Preliminary results of the observational “GIM-13 - AMBRA” Italian study

Filippo Montemurro
Mr. Montemurro has no relevant financial relationships to disclose.

Pilot study of carboplatin, nab-paclitaxel and pembrolizumab for metastatic triple-negative breast cancer (ongoing clinical trial)

Alberto Montero
Dr. Montero has no relevant financial relationships to disclose.

Impact of institution of young women’s breast cancer clinic on time to treatment and utilization of fertility, genetics and social work consultations in women under age 50 with new diagnosis of early stage breast cancer

Alberto Montero
Dr. Montero has no relevant financial relationships to disclose.

Challenges faced across borders to open European academic multicentre projects: The EIT-FDS program part of the ERA-Net TRANSCAN II project

Manuela Monti
Dr. Monti has no relevant financial relationships to disclose.
PAM50 intrinsic subtype as a predictor of pathological complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2-positive breast cancer: First results of the PAMILA clinical trial

Serafin Morales

Dr. Morales-Murrillo has no relevant financial relationships to disclose.

Phase III study of galbocitbib (PD-0332951) in combination with gonadotropin therapy (premenstrual or fulvestrant) versus chemotherapy (luprolide) in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with gequstes to gestase inhibitors. “The PEARL study” (EUSOMA/2018-02)

Serafin Morales

Dr. Morales-Murrillo has no relevant financial relationships to disclose.

Randomized phase II study evaluating different schedules of nab-paclitaxel in metastatic breast cancer (MBC): Results of the SNAP study

Serafin Morales

Dr. Morales-Murrillo has no relevant financial relationships to disclose.

Predictive factors of pathologic complete response to neoadjuvant chemotherapy in patients with luminal HER2-positive localized advanced breast cancer using the OMEGA microarray

Nalla Morales-Vasquez

Dr. Morales-Vasquez has no relevant financial relationships to disclose.

Incidence and severity of diarrhea with metilopride + intensive leoponidine prophylaxis in patients (pts) with HER2+ early-stage breast cancer (IBC): Interim analysis from the multicenter, open-label, phase II control trial

Saraon Moran

Ms. Moran has disclosed that she receives salary from Puma Biotechnology Inc.

Clinico-pathological relationships with 867 in POETIC (CRUK/07/015) - Critical lessons for assessing 867 for progress and as a pharmacodynamic marker

James Morden

Mr. Morden has no relevant financial relationships to disclose.

The impact of intrinsic subtypes and molecular features on aromatase inhibitor induced reduction of proliferation marker of 867 in primary ER+ breast cancer: A POETIC study (CRUK/07/015)

James Morden

Mr. Morden has no relevant financial relationships to disclose.

Evaluation of intra-tumor heterogeneity, test reproducibility and their impact in breast cancer samples assessed by Prosigna™: Results from a decision impact prospective study and a matched case-control study

Pascale Morel

Mr. Morel has disclosed that he receives salary from Nanostring.

Enhancing compliance with national nutrition recommendations in breast cancer survivors: Experience in an underprivileged community

Sandra Morello

Ms. Morello has no relevant financial relationships to disclose.

Evaluation of a multidisciplinary cancer team quality in a breast cancer unit (BCU) in México

Gladys Morelos-Gomez

Dr. Morelos-Gómez has no relevant financial relationships to disclose.

A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA)

Fernando Moreno

Dr. Moreno has no relevant financial relationships to disclose.

A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA)

Fernando Moreno

Dr. Moreno has no relevant financial relationships to disclose.

Global Cancer Institute online tumor boards to improve global patterns of clinical practice for breast cancer

Felipe Moreno-Aspitia

Dr. Moreno-Aspitia has no relevant financial relationships to disclose.
OT1-01-05
Painter: Evaluation of eribulin tolerability and correlation between a set of polymorphisms and neuropathy in patients with metastatic breast cancer
Anna Moretti
Ms. Moretti has no relevant financial relationships to disclose.

OT1-02-01
A phase II study of AZD9494, a novel oral, selective estrogen receptor degrader (ERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC)
Shefali Morgan
Shefali Morgan has disclosed that he is an AstraZeneca employee.

P6-11-03
A phase 2 open-label study of lurbinectedin in patients (pts) with FGI aberrant metabolic breast cancer (MBC)
Daniel Morganstein
Dr. Morganstein has no relevant financial relationships to disclose.

P08-05
Comparative analysis of the genomic landscape of breast cancers from women of African and European ancestry
Oludare Morhason-Bello
Oludare Morhason-Bello has no relevant financial relationships to disclose.

P6-07-05
PD-L1 expression and decreased tumor-infiltrating lymphocytes are associated with poor prognosis in patients with triple negative breast cancer
Hitomi Mori
Ms. Mori has no relevant financial relationships to disclose.

P4-02-04
Using ultrasound findings to predict high tumor-infiltrating lymphocytes in triple negative breast cancer
Masaya Mori
Masaya Mori has no relevant financial relationships to disclose.

P3-04-26
Establishment and characterization of STHK1, an ESRI-mutant triple breast cancer cell line and xenograft from a patient with acquired resistance to endocrine therapy
Alessa Moriarty
Ms. Moriarty has no relevant financial relationships to disclose.

P4-21-32
A phase II study of AZD5171, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC)
Shethah Morgan
Shethah Morgan has disclosed that he is an AstraZeneca employee.

P6-11-03
PD-L1 expression and decreased tumor-infiltrating lymphocytes are associated with poor prognosis in patients with triple negative breast cancer
Hitomi Mori
Ms. Mori has no relevant financial relationships to disclose.

P2-04-13
Difference of immune microenvironment between primary and recurrent tumours in breast cancer patients
Toru Morioka
Dr. Morioka has no relevant financial relationships to disclose.

P3-11-11
Utility of LigaSure™ vessel-sealing device in axillary dissection for breast cancer surgery: A randomized single center study
Toru Morioka
Dr. Morioka has no relevant financial relationships to disclose.

P2-05-05
Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes (TILs) and residual cancer burden (RCB)
Tamami Morisaki
Dr. Morisaki has no relevant financial relationships to disclose.

P3-04-20
Predicting therapeutic effect by on tumor invasion lymphocytes (TILs) in endocrine therapy for stage IV breast cancer
Tamami Morisaki
Dr. Morisaki has no relevant financial relationships to disclose.

P6-08-25
Circulating tumor cell-inhibitor-associated gene polycistronus is a novel prognostic predictor in patients with breast cancer
Tamami Morisaki
Tamami Morisaki has no relevant financial relationships to disclose.

P2-11-07
Duration of fasting before taking lapatinib is associated with skin toxicity in neoadjuvant treatment of HER2 positive breast cancer: A cohort study from the JBCRG-16/Neo-LaTH
Satoshi Morita
Satoshi Morita has disclosed that he receives honoraria from Chugai Pharmaceutical Co.

P5-16-04
A randomized phase II neoadjuvant study comparing docetaxel and cyclophosphamide (TC) with 5-fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel (FEC-D) for hormone receptor-negative breast cancer: The Kanagawa breast oncology group (KBOG) 1101 study
Satoshi Morita
Prof. Morita has no relevant financial relationships to disclose.

P4-22-15
Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate (ADC) for the treatment of relapsed/refractory, metastatic triple-negative breast cancer (mTNBC): Updated results
Rebecca Moroose
Dr. Moroose has no relevant financial relationships to disclose.

P5-16-28
A single-institution clinical experience with neoadjuvant docetaxel/Carboplatin/Trastuzumab/pertuzumab (TCPT): A safety and efficacy analysis
Rebecca Moroose
Dr. Moroose has disclosed that she is on the Speakers Bureau for Genentech ~$40,000 in 2015; Speaker’s Bureau for Pfizer ~ $20,000 2015; Ad Board for Pfizer and Ad Board Barharanometrics.
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1-10-12</td>
<td>Radiation therapy in 1-3 node positive mastectomy patients: Who benefits?</td>
<td>Astrid Morris</td>
<td>Dr. Morris has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-17</td>
<td>Development of a recurrence risk stratification scheme to inform treatment decisions in breast cancer patients undergoing mastectomy with 1-3 positive nodes</td>
<td>Astrid Morris</td>
<td>Dr. Morris has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-10-13</td>
<td>Can the risk of radiation-induced cardiac disease in breast cancer be mitigated with cardiac-sparing techniques?</td>
<td>Christopher Morris</td>
<td>Mr. Morris has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-33</td>
<td>Refining the prognostic value of Ki67 biomarker by ataxia telangiectasia mutated (ATM) status in a retrospective study of early stage hormone receptor positive breast cancer</td>
<td>Ion Morris</td>
<td>Dr. Morris has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-08-20</td>
<td>Clinical utility of IGA with various cutpoints using 3 commercial assays relative to 15yr survival</td>
<td>Ion Morris</td>
<td>Dr. Morris has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-05-02</td>
<td>Conditional activation of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) in the mouse mammary epithelium alters mammary gland development</td>
<td>Howard Morris</td>
<td>Dr. Morris has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-02-08</td>
<td>Promima-002: A prospective, multi-center study to determine the effectiveness of a biomarker assay to distinguish benign from invasive breast cancer in women with BI-RADS 5, 4 and 5 imaging reports</td>
<td>Michael Morris</td>
<td>Dr. Morris has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT3-02-02</td>
<td>COS 5: A randomized international phase 5 study comparing the efficacy and safety of enzolamide in combination with paclitaxel chemotherapy vs placebo with paclitaxel in patients with advanced-stage triple-negative breast cancer</td>
<td>Patrick Morris</td>
<td>Mr. Morris has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT3-04-02</td>
<td>The impact of the 21 gene recurrence score (RS) on chemotherapy prescribing in estrogen receptor (ER) positive, lymph node positive early stage breast cancer in Ireland</td>
<td>Patrick Morris</td>
<td>Mr. Morris has disclosed that he receives honoraria from Genomic Health.</td>
</tr>
<tr>
<td>P2-07-14</td>
<td>Atrial of immune infiltration in patients with triple negative breast cancer by molecular subtype and in patients with inflammatory and non-inflammatory breast cancers</td>
<td>Stephen Morris</td>
<td>Dr. Morris has disclosed that he receives salary from Insight Genetics, Inc.</td>
</tr>
<tr>
<td>P08-05</td>
<td>Chemotherapy sensitivity of HER2-positive breast cancer with a PI3K/AKT/mTOR inhibitor in vitro</td>
<td>Michael Morrisay</td>
<td>Mr. Morrisay has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-04-10</td>
<td>The long term outcomes of female patients treated with primary endocrine therapy for non-metastatic breast cancer</td>
<td>Christopher Morrow</td>
<td>Ms. Morrow has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-08-14</td>
<td>Breast cancer with 21-gene recurrence score lower than 18: Rate of distant metastases in a large series with clinical follow-up</td>
<td>Monica Morrow</td>
<td>Dr. Morrow has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-02-06</td>
<td>Genetic counseling, germline genetic testing, and impact of results in patients with newly diagnosed breast cancer</td>
<td>Monica Morrow</td>
<td>Dr. Morrow has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-13-07</td>
<td>Are there patients with T1-T2, node-negative breast cancer who are high-risk for locoregional recurrence?</td>
<td>Monica Morrow</td>
<td>Dr. Morrow has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P05-05</td>
<td>Metabolic obesity, adipose inflammation and aromatase: Potential drivers of breast cancer risk in women with normal body mass index</td>
<td>Monica Morrow</td>
<td>Dr. Morrow has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Susan G. Komen® Brinker Award for Changing Paradigms in the Local Therapy of Breast Cancer: Making Less More</td>
<td>Monica Morrow</td>
<td>Dr. Morrow has no relevant financial relationships with commercial interests to disclose.</td>
<td></td>
</tr>
<tr>
<td>P2-04-27</td>
<td>CTX-A and RAP-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer</td>
<td>Michael Morse</td>
<td>Dr. Morse has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-13-25</td>
<td>Oncoplastic breast surgery is oncologically safe in locally advanced breast cancer after neoadjuvant chemotherapy, an Egyptian experience</td>
<td>Ahmed Morisi</td>
<td>Mr. Morisi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-12-02</td>
<td>Serum triglycerides among triple negative breast cancer patients as a biomarker of poor outcome</td>
<td>Elin Mortensen</td>
<td>Dr. Mortensen has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
Phase II clinical trial of neratinib in patients 60 and older with HER2 over-expressed or mutated breast cancer: Trial design considerations for older adults

Joanne Mortimer

Dr. Mortimer has disclosed that she serves as a member for the DSMB for Puma Biotechnology Inc.

Phase II Trial of the addition of pembrolizumab to letrozole and palbociclib in patients with metastatic estrogen receptor positive breast cancer who have stable disease on letrozole and palbociclib

Joanne Mortimer

Ms. Mortimer has disclosed that she is a consultant for PUMA.

Synergistic suppression of triple negative breast cancer with the combination of PI3K inhibitor (alpelisib, BYL719) and CDK inhibitor (ribociclib, LEE011)

Joanne Mortimer

Dr. Mortimer has disclosed that he is a consultant for Puma.

Characterization of neratinib-induced diarrhea in patients with early-stage HER2+ breast cancer: Analysis from the phase III ExteNET trial

Joanne Mortimer

Ms. Mortimer has disclosed that she is a consultant for Puma (IRMC).

Phase II trial of pertuzumab, trastuzumab, and nab-paclitaxel in patients (pts) with HER2 overexpressing (HER2+) locally advanced or inflammatory breast cancer (LABC) or untreated stage IV metastatic breast cancer (MBC)

Joanne Mortimer

Dr. Mortimer has disclosed that she is a consultant for Puma.

Association of pre-chemotherapy peripheral blood pro-inflammatory (IL-6, CRP) and coagulation (D-dimer) markers with chemotherapy toxicity in women with breast cancer

Joanne Mortimer

Dr. Mortimer has no relevant financial relationships to disclose.

The impact of genomic mutation on metastatic breast cancer treatment: A retrospective clinical trial

Joanne Mortimer

Dr. Mortimer has no relevant financial relationships to disclose.

Identifiers of social support among newly diagnosed breast cancer patients seeking care at an urban safety net academic medical center

Samantha Morton

Dr. Morton has no relevant financial relationships to disclose.

Phase I/II trial of pertuzumab, trastuzumab, and nab-paclitaxel in patients (pts) with HER2 overexpressing (HER2+) locally advanced or inflammatory breast cancer (LABC) or untreated stage IV metastatic breast cancer (MBC)

Joanne Mortimer

Dr. Mortimer has disclosed that she is a consultant for Puma.

Randomized, placebo-controlled trial of subcutaneous for aromatase inhibitor (AI)-associated musculoskeletal symptoms (AMS53) in early stage breast cancer (SWOG 2002)

Anna Moseley

Ms. Moseley has no relevant financial relationships to disclose.

Identification of proliferation related drivers and their role in precision medicine for breast cancers: A retrospective multidimensional comparative, integrated genomic, transcriptomic, and protein analysis

Paul Moseley

Mr. Moseley has no relevant financial relationships to disclose.

Feasibility trial for identification of patients for eliminating breast cancer surgery following neoadjuvant systemic therapy

Tanya Moseley

Dr. Moseley has no relevant financial relationships to disclose.

Prospective cross-sectional study on participation in mammography screening according to immigration background and education status

Terry Moziy

Dr. Moziy has no relevant financial relationships to disclose.

Effect of race on triple negative breast cancer outcomes

Catherine Monfreque

Ms. Monfreque has no relevant financial relationships to disclose.

Photodynamic therapy for the treatment of primary breast cancer: Preliminary results of a phase IIIa clinical trial

Alexander Mosse

Dr. Mosse has no relevant financial relationships to disclose.

Enhanced efficacy of redirected T cell therapy of TAC with a Trop-2/CD3 bispecific antibody in combination with a checkpoint inhibitor

Ali Mostafa

Dr. Mostafa has disclosed that she receives salary and has ownership.

Trends in positive predictive values following transition from screen film to digital mammography

David Motok

Dr. Motok has no relevant financial relationships to disclose.

Influence of exercise or educational programs on long-term physical activity by patients after surgery for primary breast cancer: A randomized trial

Takayuki Motoki

Mr. Motoki has no relevant financial relationships to disclose.

Sentinel lymph node biopsy by contrast-enhanced ultrasonography with sonazoid in patients with breast cancer - Prospective multicenter study

Kazutoshi Motomura

Dr. Motomura has no relevant financial relationships to disclose.

Sentinel lymph node biopsy by contrast-enhanced ultrasonography with sonazoid in patients with breast cancer - Prospective multicenter study

Kazutoshi Motomura

Dr. Motomura has no relevant financial relationships to disclose.
Vitamin D level impacts odds of pathologic complete response following neoadjuvant therapy in operable breast cancer

Sarah Mott
Ms. Mott has no relevant financial relationships to disclose.

Ribociclib + fulvestrant in postmenopausal women with HR+, HER2-advanced breast cancer (ABC)

Marjaneh Motta
Ms. Motta has disclosed that she is an employee of and owns stocks in Novartis.

Utilization and outcomes of eribulin in triple negative metastatic breast cancer: Real-world findings

Sarah Mougalian
Ms. Mougalian has disclosed that she is a consultant for Eisai, Inc.

NRG oncology/RTOG 1119: Phase II randomized study of whole brain radiotherapy with concurrent lapatinib in patients with brain metast from HER2 positive breast cancer — A collaborative study of RTDG & RTOG (NCT01622886)

Jennifer Mu Shan
Ms. Mu Shan has no relevant financial relationships to disclose.

Triple-negative first-line study: Neoadjuvant trial of nab-paclitaxel and atezolizumab, a PD-L1 inhibitor, in patients with triple negative breast cancer (TNBC) (NCT01553048)

Stacy Moulder
Ms. Moulder has disclosed that she receives clinical research support from Novartis, Oncothyreon, Pfizer, Genentech, Roche and Takeda. She has also disclosed that she received honoraria of <$10,000 from Novartis.

An annotated collection of pre- and post-therapy breast cancer patient-derived xenograft models built from fine needle aspiration samples aligned with ongoing clinical trials documenting response to treatment

Stacy Moulder
Dr. Moulder has no relevant financial relationships to disclose.

Efficacy results of a phase Ib study of ONT-380, an oral HER2-specific inhibitor, in combination with capecitabine (C) and trastuzumab (T) in HER2+ metastatic breast cancer (MBC), including patients (pts) with brain metastases (mets)

Stacy Moulder
Dr. Moulder has no relevant financial relationships to disclose.

Palbociclib in combination with endocrine therapy in treatment-naive and previously treated elderly women with HR+, HER2-advanced breast cancer: A pooled analysis from randomized phase 2 and 3 studies

Stacy Moulder
Dr. Moulder has disclosed that she has contracts with Genentech (Institution), Oncothyreon (Institution), Pfizer (Institution).

Evaluation of the effects of palbociclib plus trastuzumab or trastuzumab emtansine in metastatic HR2-positive breast cancer

Stacy Moulder
Dr. Moulder has no relevant financial relationships to disclose.

Efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial

Stacy Moulder
Dr. Moulder has no relevant financial relationships to disclose.

The evaluation of ganitumab/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial

Stacy Moulder
Dr. Moulder has no relevant financial relationships to disclose.

“Metastatic TNBC: New targets/new strategies”

Louise Mosmey
Ms. Mosmey has no relevant financial relationships to disclose.
BELLE-3: A phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2-, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment

Marie-Ange Mouret Reynier
Dr. Mouret Reynier has no relevant financial relationships to disclose.

P1-01-02
Circulating tumor cells (CTC) and endothelial cells (CEC) prognostic value in HER2 negative metastatic breast cancer patients treated with first line weekly paclitaxel and bevacizumab: First results of a prospective cohort from the French Breast Cancer InterGroup Unicancer (UCBG) COMET study

Marie-Ange Mouret Reynier
Dr. Mouret Reynier has no relevant financial relationships to disclose.

P2-05-04
Evaluation of intra-tumor heterogeneity, test reproducibility and their impact in breast cancer samples assessed by Prosigna™: Results from a decision impact prospective study and a matched case-control study

Marie-Ange Mouret Reynier
Dr. Mouret Reynier has no relevant financial relationships to disclose.

P3-04-09
Genomic analysis to evaluate response to neoadjuvant aromatase and fulvestrant in post-menopausal ER-positive HER2-negative breast cancer patients included in the UCBG CARMEN02 trial

Marie-Ange Mouret Reynier
Dr. Mouret Reynier has no relevant financial relationships to disclose.

P4-02-13
Breast ultrasound surveillance with image fusion technique in a short-interval follow-up for BI-RADS category 3 mass lesions

Yukako Mouri
Dr. Mouret Reynier has no relevant financial relationships to disclose.

S6-03
DBCG 07-READ: A randomized phase III trial comparing six cycles of docetaxel and cyclophosphamide (DC) to three cycles of epirubicin and cyclophosphamide followed by three cycles of docetaxel (DC-D) in patients with early breast cancer

Henning Mouridsen
Dr. Mouridsen has no relevant financial relationships to disclose.

OT3-01-02
CNIO-BR-008 trial: Reversion of T-cell exhaustion caused by chronic treatment with hypoxia-inducing antiangiogenic treatment by durvalumab in HER2-negative breast cancer: A pilot proof-of-concept trial

Silvana Mouron
Dr. Mouron has no relevant financial relationships to disclose.

P6-07-28
The 23-gene assay in the decision impact assessment of ER+, HER2- breast cancer: A French real life prospective study

Jean Loup Moyedet
Dr. Moyedet has disclosed that he is a speaker for Genomic Health.

P3-13-15
An update on trends in nipple-sparing mastectomy incision locations: A systematic review of the literature with pooled analysis

Donald Mowlds
Dr. Mowlds has no relevant financial relationships to disclose.

P1-05-05
Comparison of genotyping results from tissue and circulating DNA (ctDNA) in patients with metastatic breast cancer

Beverly Moy
Dr. Moy has no relevant financial relationships to disclose.

P1-06-03
Serial evolution of hormone receptor status and mutational profile among patients with metastatic breast cancer

Beverly Moy
Dr. Moy has no relevant financial relationships to disclose.

P1-12-03
Association between tumor genotype and development of brain metastases in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer

Beverly Moy
Dr. Moy has no relevant financial relationships to disclose.

P5-13-09
Development and implementation of a patient-centered, nurse practitioner-led survivorship intervention for breast cancer

Beverly Moy
Dr. Moy has no relevant financial relationships to disclose.

P5-16-16
Role of tumor microenvironment, as assessed by breast MRI background parenchymal enhancement (BPE), in modulating response to neoadjuvant chemotherapy in young women with localized breast cancer

Beverly Moy
Dr. Moy has no relevant financial relationships to disclose.

P4-22-20
Efficacy and safety of everolimus plus exemestane in HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy, in routine clinical practice: 2nd interim analysis from STEPAUT

Bernhard Mráz
Mr. Mráz has disclosed that he receives salary from Novartis Pharma GmbH.

P1-01-05
Prognostic values of circulating tumor cells (CTC) and cancer associated macrophage-like cells (CAMLs) enumerations in metastatic breast cancer: The role for innate immunity in the metastatic process

Zhaomei Mu
Dr. Mu has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Author(s)</th>
<th>Disclosures</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1-01-03</td>
<td>Dynamics of circulating tumor cells during the course of chemotherapy and prognostic relevance across molecular subtypes in high-risk early breast cancer patients - Results from the adjourned SUCCESS A trial</td>
<td>Volkmar Mueller</td>
<td>Dr. Mueller has disclosed that he receives speaker honoraria from Amgen, AstraZeneca, Celgene, Eisai, GlaxoSmithKline, Pfizer, Pierre-Fabre, Novartis, Roche, Texas and Iaman-Cla.- He also disclosed that he is a consultant for Genomic Health, Roche, Pierre Fabre, Amgen and Eisai.</td>
</tr>
<tr>
<td>P6-13-02</td>
<td>Efficacy of first-line bevacizumab (BEV)-containing therapy for poor-prognosis advanced breast cancer (ABC): Subgroup analyses of the German AVANT! observational study</td>
<td>Volkmar Mueller</td>
<td>Mr. Mueller has disclosed that he receives speaker honoraria from Amgen, AstraZeneca, Celgene, Eisai, GlaxoSmithKline, Pfizer, Pierre-Fabre, Novartis, Roche, Texas and Iaman-Cla.- He also disclosed that he is a consultant for Genomic Health, Roche, Pierre Fabre, Amgen and Eisai.</td>
</tr>
<tr>
<td>S3-01</td>
<td>AINSEO: International meta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEoadjuvant chemotherapy</td>
<td>Volkmar Mueller</td>
<td>Mr. Mueller has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S5-16-11</td>
<td>Residual cancer burden (RCB) as a strong prognostic factor in breast cancer (BC) patients treated with neoadjuvant chemotherapy (NACT) based on carboplatin, doxorubicin and taxanes</td>
<td>Malene Míguez Esteban</td>
<td>Malene Míguez Esteban has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S3-01</td>
<td>AINSEO: International meta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEoadjuvant chemotherapy</td>
<td>Laura Muñoz</td>
<td>Mr. Muñoz has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-21-03</td>
<td>At randomised phase II study of 6X-07 response-guided preoperative chemotherapy for HER2-positive breast cancer</td>
<td>Hirofumi Muki</td>
<td>Dr. Muki has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-02-06</td>
<td>Serial monitoring of circulating tumor cells in patients with metastatic breast cancer</td>
<td>Akash Mukherjee</td>
<td>Dr. Mukherjee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-24-05</td>
<td>First-line ribociclib plus trastuzumab in patients with de-novo HR+, HER2- advanced breast cancer (ABC): A subgroup analysis of the MONALEESA-2 trial</td>
<td>Pakbak Mukhopadhyay</td>
<td>Pakbak Mukhopadhyay has disclosed that he is a Novartis employee and has ownership in Novartis.</td>
</tr>
<tr>
<td>P1-15-01</td>
<td>Analysis of renal function in MONARCH 1: A phase 2 study of abemaciclib, a CDK4 &amp; 6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for metastatic breast cancer (MBC)</td>
<td>Srikanth Mukandar</td>
<td>Srikanth Mukandar has disclosed that he has a contract with and is employed by Eli Lilly and Company.</td>
</tr>
<tr>
<td>P4-12-03</td>
<td>Estradiol receptor-positive breast cancer in BRCA2 mutation carriers shows a BRCAWS profile, suggesting sensitivity to drugs targeting homologous recombination deficiency</td>
<td>Lennart Muller</td>
<td>Mr. Muller has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P0-01-07</td>
<td>Comprehensive characterization of matched pre-treatment biopsies and residual disease of doxorubicin treated breast cancer</td>
<td>Lennart Muller</td>
<td>Mr. Muller has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT1-02-04</td>
<td>The DETECT V study - Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemotherapy or endocrine therapy in patients with HER2-positive and hormone-receptor positive metastatic breast cancer</td>
<td>Volkmar Müller</td>
<td>Dr. Müller has disclosed that he receives speaker honoraria from Amgen, AstraZeneca, Celgene, Eisai, Glaxo Smith Kline, Pfizer, Pierre-Fabre, Novartis, Roche, Texas and Iaman-Cla.- He also disclosed that he is a consultant for Genomic Health, Roche, Pierre Fabre, Amgen and Eisai.</td>
</tr>
<tr>
<td>OT1-02-09</td>
<td>A phase 2 randomised, double-blind, controlled study of OM-8890, placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unetectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB)</td>
<td>Volkmar Müller</td>
<td>Dr. Müller has disclosed that he receives speaker honoraria from Amgen, AstraZeneca, Celgene, Eisai, Glaxo Smith Kline, Pfizer, Pierre-Fabre, Novartis, Roche, Texas and Iaman-Cla.- He also disclosed that he is a consultant for Genomic Health, Roche, Pierre Fabre, Amgen and Eisai.</td>
</tr>
<tr>
<td>OT3-04-02</td>
<td>DETECT III and IV - Individualized CTC-based therapy of metastatic breast cancer</td>
<td>Volkmar Müller</td>
<td>Dr. Müller has disclosed that he receives speaker honoraria from Amgen, AstraZeneca, Celgene, Eisai, Glaxo Smith Kline, Pfizer, Pierre-Fabre, Novartis, Roche, Texas and Iaman-Cla.- He also disclosed that he is a consultant for Genomic Health, Roche, Pierre Fabre, Amgen and Eisai.</td>
</tr>
<tr>
<td>P1-01-15</td>
<td>DETECT V - Detection of the expression of estrogen receptor and human epidermal growth factor receptor 2 in circulating tumor cells from metastatic breast cancer patients</td>
<td>Volkmar Müller</td>
<td>Dr. Müller has disclosed that he receives speaker honoraria from Amgen, AstraZeneca, Celgene, Eisai, Glaxo Smith Kline, Pfizer, Pierre-Fabre, Novartis, Roche, Texas and Iaman-Cla.- He also disclosed that he is a consultant for Genomic Health, Roche, Pierre Fabre, Amgen and Eisai.</td>
</tr>
</tbody>
</table>
Phase II of POSEIDON: A phase Ib / randomized phase II trial of tamoxifen plus taselisib or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment

Susana Muñoz
Ms. Muñoz has no relevant financial relationships to disclose.

Impact of delay neoadjuvant chemotherapy on pathologic complete response in locally advanced breast cancer evidence of the real world in Mexico

Wendy Muñoz
Dr. Muñoz has no relevant financial relationships to disclose.

Residual cancer burden (RCB) as a strong prognosis factor in breast cancer (BC) patients treated with neoadjuvant chemotherapy (NACT) based on carboplatin, doxorubicin and paclitaxel

Pedro Muñoz-Cacho
Dr. Muñoz-Cacho has no relevant financial relationships to disclose.

Estimating costs of relapsing HER2+ breast cancer in Spain

Belén Muñoz-Molina
Dr. Muñoz-Molina has disclosed that he receives salary and has ownership.

Cost-effectiveness analysis of adding neoadjuvant chemotherapy with pertuzumab, in patients with HER2+ breast cancer in Spain

Belén Muñoz-Molina
Mr. Muñoz-Molina has disclosed that he receives salary and has ownership.

A targetable EGFR-driven tumor-initiating program in breast cancer

Valentina Munoz-Ramos
Ms. Munoz-Ramos has no relevant financial relationships to disclose.

Assessing response in locally advanced breast cancer treated with neoadjuvant chemotherapy: Predictive and prognostic potential of volume-based metabolic variables with 18F-FDG PET/CT

María del Mar Muñoz-Sánchez
Dr. Munoz-Sánchez has no relevant financial relationships to disclose.

Residual cancer burden as a strong prognosis factor in breast cancer patients treated with neoadjuvant chemotherapy (NACT) based on carboplatin, doxorubicin and paclitaxel

Paloma Munoz-Sánchez
Dr. Munoz-Sánchez has no relevant financial relationships to disclose.

Phase Ib safety, efficacy, and molecular analysis of ribociclib (LEE011) plus letrozole for the treatment of ER+, HER2- advanced breast cancer

Pamela Munzer
Ms. Munzer has disclosed that she receives grant research from Novartis (Dr. Munster and family member).

Determining the prognostic role of early and end-of-neoadjuvant chemotherapy 18F-FDG PET/CT in patients with locally advanced breast cancer

Pamela Munzer
Mr. Munzer has disclosed that he receives grant research from Novartis.

Accelerated partial breast irradiation versus whole breast irradiation: Health-related quality of life analysis from a phase 3 trial

Cristina Muntoni
Dr. Muntoni has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy

Keiko Murase
Dr. Murase has no relevant financial relationships to disclose.

The concept of breast contour preserving surgery as parameter in breast cancer surgery

Marc Muranu
Dr. Munere has no relevant financial relationships to disclose.

Single domain antibody (SBT-100) inhibits growth of human HER2+ and triple negative breast cancers (TNBC) in xenografts by binding STAT3 and P-STAT3

Genoveva Murillo
Ms. Murillo has no relevant financial relationships to disclose.

VENTANA (SOLTI-1501): Oral metronomic vinorelbine combined with endocrine therapy in luminal/HER2-negative early breast cancer: A window of opportunity trial

Laura Murillo
Dr. Murillo has no relevant financial relationships to disclose.

The impact of the 21 gene recurrence score (RS) on chemotherapy prescribing in estrogen receptor (ER) positive, lymph node positive early stage breast cancer in Ireland

Conleth Murphy
Dr. Murphy has no relevant financial relationships to disclose.

Oncologic outcome of pregnancy associated breast cancer: A case-control study

Conleth Murphy
Dr. Murphy has no relevant financial relationships to disclose.

Oncologic outcome of pregnancy associated breast cancer: A case-control study

Conleth Murphy
Conleth Murphy has no relevant financial relationships to disclose.

Evaluating lymph node ratio (LNR) as a prognostic indicator in node-positive breast cancer

Conleth Murphy
Conleth Murphy has no relevant financial relationships to disclose.

Is 6 hour monitoring for administration related reactions after first administration of subcutaneous trastuzumab necessary? A single institution study

Conleth Murphy
Conleth Murphy has no relevant financial relationships to disclose.

Determining the prognostic role of early and end-of-neoadjuvant chemotherapy 18F-FDG PET/CT in patients with locally advanced breast cancer

Conleth Murphy
Conleth Murphy has no relevant financial relationships to disclose.

Oncologic outcome of pregnancy associated breast cancer: A case-control study

Conleth Murphy
Conleth Murphy has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2-01-18</td>
<td>Factors that can be used to guide further axillary treatment following positive sentinel lymph node biopsy</td>
<td>Dermot Murphy</td>
<td>Dr. Murphy has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-14-02</td>
<td>Post-mastectomy breast reconstruction in elderly women: Complications and the impact of individual surgeons</td>
<td>James Murphy</td>
<td>Dr. Murphy has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-12-04</td>
<td>3.5 monitoring for administration related reactions after 1st administration of subcutaneous trastuzumab necessary? A single institution audit</td>
<td>Kate Murphy</td>
<td>Ms. Murphy has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-04-25</td>
<td>Role of H2A, a long non-coding RNA, in development of resistance to endocrine therapy in breast cancer cells</td>
<td>Leigh Murphy</td>
<td>Dr. Murphy has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-13-03</td>
<td>Breast cancer education, counseling, and support for Jewish women: Preliminary results of a CICC program evaluation</td>
<td>Sarah Murphy</td>
<td>Ms. Murphy has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT3-04-02</td>
<td>The impact of the 3G gene recurrence score (GR) on chemotherapy prescribing in estrogen receptor (ER) positive, lymph node positive early stage breast cancer in Ireland</td>
<td>Verena Murphy</td>
<td>Ms. Murphy has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-01-18</td>
<td>Factors that can be used to guide further axillary treatment following positive sentinel lymph node biopsy</td>
<td>Juliette Murray</td>
<td>Dr. Murray has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-10-06</td>
<td>The long-term outcomes of female patients treated with primary endocrine therapy for non-metastatic breast cancer</td>
<td>Juliette Murray</td>
<td>Dr. Murray has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT3-02-09</td>
<td>A phase 2 randomized, double-blinded, controlled study of ONT- HER2 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresetable locally advanced or metastatic breast carcinoma (MBC) HER2CLIMB</td>
<td>Rashmi Murthy</td>
<td>Dr. Rashmi Murphy has disclosed that he receives contracted research support paid to his institution by Cascadian Therapeutics, Inc. and Merrimack. He has also disclosed that he is a consultant for Daiichi Sankyo and Genentech.</td>
</tr>
<tr>
<td>P4-21-20</td>
<td>Laparotomy after pectorusatum and sub-trastuzumab emozinum in metastatic HER2-positive breast cancer</td>
<td>Rashmi Mustacchi</td>
<td>Dr. Mustacchi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-15</td>
<td>Proposal for a new breast cancer staging classification: incorporating clinical and biologic factors</td>
<td>Rashmi Mustacchi</td>
<td>Dr. Mustacchi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-23</td>
<td>2EXCITE- A robust 18-gene predictor of sensitivity to endocrine therapy in metastatic breast cancer</td>
<td>Rael Murthy</td>
<td>Rael Murthy has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-07-24</td>
<td>mET-196-1p and mET-466-7p as novel circulating mRNA as potential prognostic biomarkers in breast cancer</td>
<td>Mahmut Muslumanoglu</td>
<td>Dr. Muslumanoglu has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-16-01</td>
<td>The importance of socio-regional tumor burden and surgery on survival in patients with de novo stage IV breast cancer; post hoc analyses of protocol M01-03</td>
<td>Mahmut Muslumanoglu</td>
<td>Dr. Muslumanoglu has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S6-01</td>
<td>9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian short HER trial</td>
<td>Antonio Musolino</td>
<td>Dr. Musolino has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-20</td>
<td>Comparing the frequency and types of genetic alterations between older and younger women with metastatic breast cancer at the University of North Carolina at Chapel Hill</td>
<td>Hyman Muss</td>
<td>Dr. Muss has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-14-09</td>
<td>Luminal breast cancer: Is it really a “good prognosis” disease? Preliminary results of the GIM-13 - AMBRA study</td>
<td>Giorgio Mustacchi</td>
<td>Prof. Mustacchi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-15-06</td>
<td>Impact of post-progression therapy on overall survival (OS) in the IMELDA randomized phase III trial evaluating the addition of capcitabine (CA) to maintenance bevacizumab (BEV) for HER2 negative metastatic breast cancer (NBC)</td>
<td>Giorgio Mustacchi</td>
<td>Dr. Mustacchi has disclosed that he is a speaker for Celgene and a consultant for Roche and Celgene.</td>
</tr>
<tr>
<td>P5-15-07</td>
<td>First and further line choices of treatment for HER2+ metastatic breast cancer (MBC) according to adjuvant treatment and biological subtypes. Preliminary results of the observational “GIM-13 - AMBRA” Italian study</td>
<td>Giorgio Mustacchi</td>
<td>Prof. Mustacchi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-13-22</td>
<td>Should modified radical mastectomy be modified? A phase 1 study to evaluate inframammary flap reconstruction in patients receiving neoadjuvant chemotherapy</td>
<td>Eugene Mutijima</td>
<td>Dr. Mutijima has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT2-03-01</td>
<td>A randomized trial of 15 fraction vs 25 fraction pencil beam scanning proton radiotherapy after mastectomy in patients requiring regional nodal irradiation</td>
<td>Robert Mutter</td>
<td>Dr. Mutter has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
P1-10-09 Delineation of internal mammary nodal target volumes in breast cancer radiotherapy
Robert Mutter
Dr. Mutter has no relevant financial relationships to disclose.

P1-13-21 Primary surgery in inflammatory breast cancer
Mahvash Muzaffar
Dr. Muzaffar has no relevant financial relationships to disclose.

P4-02-05 Neck resectability of FDG SUVmax in bone and non-bony metastatic breast cancer lesions in local area network PET/CT scanners
Mark Muzi
Mr. Muzi has no relevant financial relationships to disclose.

P7-03-02 Patterns of translational dysregulation in models of estrogen receptor(+) and (-) breast cancer
Richard Myers
Dr. Myers has no relevant financial relationships to disclose.

P1-05-25 Patterns of translational dysregulation in models of estrogen receptor(+) and (-) breast cancer
Richard Myers
Dr. Myers has no relevant financial relationships to disclose.

P3-13-21 Primary surgery in inflammatory breast cancer
Mahvash Muzaffar
Dr. Muzaffar has no relevant financial relationships to disclose.

P4-12-06 Quantification of HER2-driven signaling (HER2S) inhibition of four different anti-HER2 drugs tested ex vivo in five primary HER2-negative breast cancer cell samples with abnormal HER2 signaling activity
Samantha Myhre
Ms. Myhre has disclosed that she receives salary and has ownership.

P9-07-14 Negative progesterone receptor in associate early breast cancer relapse, even among good prognosis tumors
Charles Mylander
Dr. Mylander has no relevant financial relationships to disclose.

P3-13-21 Primary surgery in inflammatory breast cancer
Mahvash Muzaffar
Dr. Muzaffar has no relevant financial relationships to disclose.

P1-10-09 Delineation of internal mammary nodal target volumes in breast cancer radiotherapy
Robert Mutter
Dr. Mutter has no relevant financial relationships to disclose.

P3-13-21 Primary surgery in inflammatory breast cancer
Mahvash Muzaffar
Dr. Muzaffar has no relevant financial relationships to disclose.

P4-02-05 Neck resectability of FDG SUVmax in bone and non-bony metastatic breast cancer lesions in local area network PET/CT scanners
Mark Muzi
Mr. Muzi has no relevant financial relationships to disclose.

P7-03-02 Patterns of translational dysregulation in models of estrogen receptor(+) and (-) breast cancer
Richard Myers
Dr. Myers has no relevant financial relationships to disclose.

P1-05-25 Patterns of translational dysregulation in models of estrogen receptor(+) and (-) breast cancer
Richard Myers
Dr. Myers has no relevant financial relationships to disclose.

P3-13-21 Primary surgery in inflammatory breast cancer
Mahvash Muzaffar
Dr. Muzaffar has no relevant financial relationships to disclose.

P4-12-06 Quantification of HER2-driven signaling (HER2S) inhibition of four different anti-HER2 drugs tested ex vivo in five primary HER2-negative breast cancer cell samples with abnormal HER2 signaling activity
Samantha Myhre
Ms. Myhre has disclosed that she receives salary and has ownership.

P9-07-14 Negative progesterone receptor in associate early breast cancer relapse, even among good prognosis tumors
Charles Mylander
Dr. Mylander has no relevant financial relationships to disclose.

P3-13-21 Primary surgery in inflammatory breast cancer
Mahvash Muzaffar
Dr. Muzaffar has no relevant financial relationships to disclose.

P4-02-05 Neck resectability of FDG SUVmax in bone and non-bony metastatic breast cancer lesions in local area network PET/CT scanners
Mark Muzi
Mr. Muzi has no relevant financial relationships to disclose.

P7-03-02 Patterns of translational dysregulation in models of estrogen receptor(+) and (-) breast cancer
Richard Myers
Dr. Myers has no relevant financial relationships to disclose.

P1-10-09 Delineation of internal mammary nodal target volumes in breast cancer radiotherapy
Robert Mutter
Dr. Mutter has no relevant financial relationships to disclose.

P1-10-09 Delineation of internal mammary nodal target volumes in breast cancer radiotherapy
Robert Mutter
Dr. Mutter has no relevant financial relationships to disclose.

P3-13-21 Primary surgery in inflammatory breast cancer
Mahvash Muzaffar
Dr. Muzaffar has no relevant financial relationships to disclose.

P4-02-05 Neck resectability of FDG SUVmax in bone and non-bony metastatic breast cancer lesions in local area network PET/CT scanners
Mark Muzi
Mr. Muzi has no relevant financial relationships to disclose.

P7-03-02 Patterns of translational dysregulation in models of estrogen receptor(+) and (-) breast cancer
Richard Myers
Dr. Myers has no relevant financial relationships to disclose.

P1-05-25 Patterns of translational dysregulation in models of estrogen receptor(+) and (-) breast cancer
Richard Myers
Dr. Myers has no relevant financial relationships to disclose.

P3-13-21 Primary surgery in inflammatory breast cancer
Mahvash Muzaffar
Dr. Muzaffar has no relevant financial relationships to disclose.

P4-02-05 Neck resectability of FDG SUVmax in bone and non-bony metastatic breast cancer lesions in local area network PET/CT scanners
Mark Muzi
Mr. Muzi has no relevant financial relationships to disclose.

P7-03-02 Patterns of translational dysregulation in models of estrogen receptor(+) and (-) breast cancer
Richard Myers
Dr. Myers has no relevant financial relationships to disclose.

P1-10-09 Delineation of internal mammary nodal target volumes in breast cancer radiotherapy
Robert Mutter
Dr. Mutter has no relevant financial relationships to disclose.

P1-10-09 Delineation of internal mammary nodal target volumes in breast cancer radiotherapy
Robert Mutter
Dr. Mutter has no relevant financial relationships to disclose.

P3-13-21 Primary surgery in inflammatory breast cancer
Mahvash Muzaffar
Dr. Muzaffar has no relevant financial relationships to disclose.

P4-02-05 Neck resectability of FDG SUVmax in bone and non-bony metastatic breast cancer lesions in local area network PET/CT scanners
Mark Muzi
Mr. Muzi has no relevant financial relationships to disclose.

P7-03-02 Patterns of translational dysregulation in models of estrogen receptor(+) and (-) breast cancer
Richard Myers
Dr. Myers has no relevant financial relationships to disclose.
Randomized trial of exercise intervention vs. usual care for breast cancer patients with aromatase inhibitor to prevent and improve the aromatase inhibitor induced arthralgia
Sayaka Nagamine
Sayaka Nagamine has no relevant financial relationships to disclose.

Treatment patterns and resource utilization among elderly Medicare patients with HR+/HER2-metastatic breast cancer
Saurabh Nagar
Saurabh Nagar has disclosed that RTI Health Solutions received funding from Eli Lilly and Company to conduct this research.

IMENEO: International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEOadjuvant chemotherapy
Rin Nagaoka
Ms. Nagaoka has no relevant financial relationships to disclose.

S1-02
Validation of novel diagnostic kits using the semi-dry dot-blot method for detecting metastatic lymph nodes in breast cancer; distinguishing macrometastases and micrometastases
Takashi Nagayasu
Dr. Nagayasu has no relevant financial relationships to disclose.

Impact of germinalcenter-associated nuclear protein polymorphisms on breast cancer risk and prognosis in a Japanese population
Masato Nagino
Masato Nagino has no relevant financial relationships to disclose.

Metabolic stress induces G2O expression and cancer stem cell phenotype in triple negative breast cancer
Kalnisha Naidoo
Dr. Naidoo has no relevant financial relationships to disclose.

Selinexor, a selective inhibitor of nuclear export, demonstrates efficacy in preclinical models of triple negative breast cancer
Aung Naing
Dr. Naing has no relevant financial relationships to disclose.

Epithelial mesenchymal transition associated with high miR-221 and integrin β6 leads to poor prognosis in hormone receptor positive HER2 negative breast cancers
Madhumathy Nair
Madhumathy Nair has no relevant financial relationships to disclose.

Building an experience engine to make cancer treatment decisions using machine learning
Nita Nair
Dr. Nair has no relevant financial relationships to disclose.
P3-07-02 Are we missing actionable targets in breast cancer? Novel insights into recurrent Ret alterations
Praveen Nair
Praveen Nair has no relevant financial relationships to disclose.

P2-04-19 Elucidating the tumor microenvironment phenotype in early stage untreated BRCA mutated breast cancer patients
Smita Nair
Dr. Nair has no relevant financial relationships to disclose.

P4-21-05 A randomized phase II study of 4-kb7 response-guided neoadjuvant chemotherapy for HER2-positive breast cancer
Yasushi Nakajima
Mr. Nakajima has no relevant financial relationships to disclose.

P2-01-02 The predictive value of sentinel node biopsy (SNB) in early breast cancer after neo-adjuvant chemotherapy (NACT): A prospective study
Omar Najim
Dr. Najim has no relevant financial relationships to disclose.

P5-09-04 Assessment of breast cancer risk among atomic-bomb survivors based on ATM polymorphisms, radiation dose, and age at exposure
Kei Nakachi
Dr. Nakachi has no relevant financial relationships to disclose.

P4-21-14 Elucidating the tumor immune microenvironment phenotype in early stage untreated BRCA mutated breast cancer patients
Takashige Nakaoka
Mr. Nakaoka has no relevant financial relationships to disclose.

P6-07-05 PD-L1 expression and decreased tumor-infiltrating lymphocytes are associated with poor prognosis in patients with triple negative breast cancer
Masafumi Nakamura
Mr. Nakamura has no relevant financial relationships to disclose.

P4-02-13 γ-glutamyl hydroxymethyl rhodamine green (gGlu-HMRG) is promising fluorescence probe for rapid diagnosis of breast cancer; - The feasibility study of real time imaging for breast cancer examination -
Seigo Nakamura
Seigo Nakamura has no relevant financial relationships to disclose.

OT3-01-01 A phase II study of PD-L1 and CTLA-4 inhibition and immunopharmcogenomics in metastatic breast cancer
Yusuke Nakamura
Mr. Nakamura has no relevant financial relationships to disclose.

P4-02-13 Breast ultrasound surveillance with image fusion technique in a short-interval follow-up for BI-RADS category 3 mass lesions
Shogo Nakano
Dr. Nakano has no relevant financial relationships to disclose.

P5-15-10 HER2 expression in clinical breast cancer samples: A novel detection methodology for HER2 protein quantitation using fluorescent nanoparticles
Shogo Nakano
Dr. Nakano has no relevant financial relationships to disclose.

P1-03-10 Safety, immunogenicity and efficacy of proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in breast cancer: Pooled analysis of two randomized, double-blind, phase III trials
Roumen Nakov
Roumen Nakov has disclosed that he is an employee of Sandoz Inc/Hexal AG.

P6-08-02 Disruption of the estradiol-regulated NTN1-UNC5A dependence receptor signaling axis causes a hybrid basal/luminal molecular phenotype in estrogen receptor-positive breast cancer cells
Harikrishna Nakshatri
Harikrishna Nakshatri has no relevant financial relationships to disclose.

P6-15-03 Dual targeting of mammary tumors and tumor-associated functional limitations through inhibition of NF-κB
Harikrishna Nakshatri
Harikrishna Nakshatri has no relevant financial relationships to disclose.
P6-15-03  Dual targeting of mammary tumors and tumor-associated functional limitations through inhibition of NF-κB
Poornima Nakshatri  Poornima Nakshatri has no relevant financial relationships to disclose.

P4-12-02  Development of prediction model for omission of sentinel lymph node biopsy in T1 breast cancer
Naana Balanga  Naana Balanga has no relevant financial relationships to disclose.

P3-15-04  The PROCEED trial ECOG BR12-01 phase III multicenter randomized open-label study of irinotecan plus capecitabine versus capecitabine in patients previously treated with anthracycline and taxane for HER2 negative metastatic breast cancer
Byung-Ho Nam  Dr. Nam has no relevant financial relationships to disclose.

P1-02-11  Clinical utility of serial monitoring of circulating tumor DNA (ctDNA) in patients with neoadjuvant chemotherapy (NAC) for locally advanced breast cancer (LABC)
Seok Jin Nam  Dr. Nam has no relevant financial relationships to disclose.

P1-05-15  Multiomics and immunology profiling reveal distinct molecular signatures of young Asian breast cancers
Seok Jin Nam  Dr. Nam has no relevant financial relationships to disclose.

P1-13-07  Conditional disease-free survival among patients with breast cancer
Seok Jin Nam  Dr. Nam has no relevant financial relationships to disclose.

P6-10-03  KEYNOTE-012: Long-lasting responses in a phase Ib study of pembrolizumab for metastatic triple-negative breast cancer (mTNBC)
Rita Nanda  Ms. Nanda has disclosed that she is a consultant for Genentech, Merck and Novartis. She also disclosed that she has contracts with Celgene, Corcept and Merck.

P6-11-02  Efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial
Rita Nanda  Dr. Nanda has no relevant financial relationships to disclose.

P6-11-03  A phase 2 open-label study of lucitanib in patients (pts) with FGF aberrant metastatic breast cancer (MBC)
Rita Nanda  Dr. Nanda has no relevant financial relationships to disclose.

P6-11-04  The evaluation of ganitumab/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial
Rita Nanda  Dr. Nanda has no relevant financial relationships to disclose.

P6-12-15  Efficacy results of a phase 1/2 study of glucocorticoid receptor (GR) antagonist mifepristone (MF) in combination with eribulin in GR-positive triple-negative breast cancer (TNBC)
Shivani Nanda  Shivani Nanda has disclosed that he is employed by and has a contract with Eli Lilly and Company.

P6-11-11  Abemaciclib exposure-response relationship in patients with metastatic breast cancer in MONARCH 3
Shivani Nanda  Shivani Nanda has disclosed that he is employed by and has a contract with Eli Lilly and Company.

P6-11-12  Subgroup Analysis by prior treatment and disease burden in MONARCH 1: A phase 2 study of monotherapy abemaciclib, a CDK4 & 6 inhibitor, in patients with HR+/HER2 metastatic breast cancer (MBC) following chemotherapy
Shivani Nanda  Shivani Nanda has disclosed that he is employed by and has a contract with Eli Lilly and Company.

P6-15-01  Scalp cooling alopecia prevention trial (SCALP) for patients with early stage breast cancer
Julie Nangia  Dr. Nangia has no relevant financial relationships to disclose.

Committee Member/Speaker, Educational Session
"Breast cancer risk assessments: Who is high risk?"  Julie Nangia  Dr. Nangia has no relevant financial relationships to disclose.
Treatment of ESR1 mutant and PIK3CA mutant patient-derived breast cancer xenograft models reveals differential anti-tumor responses to estrogen receptor degraders and PI3K inhibitors in vivo. 

Michelle Nannini

Ms. Nannini has disclosed that she is an employee of Genentech, A Member of the Roche Group.

The PI3K inhibitor, taselisib, has enhanced potency in PIK3CA mutant models through a unique mechanism of action.

Michelle Nannini

Dr. Nannini has disclosed that she receives salary from Genentech, Inc.

A phase I safety study of topical selatrectin (DPM5235) for the prevention of chemotherapy-induced alopecia (CIA) in vivo.

Nileen Narain

Nileen Narain has disclosed that he receives salary from Bero Pharma.

Nonsteroidal, tissue selective androgen receptor modulator (SAM), enobosarm, reduces growth of androgen receptor-positive breast cancer in patient-derived preclinical models.

Ramesh Narayanan

Dr. Narayanan has disclosed that he is a consultant for GTx, Inc. Memphis, TN.

Selective use of MRI and impact on management in breast cancer.

Sankaran Narayanan

Sankaran Narayanan has no relevant financial relationships to disclose.

A phase II trial of neoadjuvant epirubicin/cyclophosphamide followed by weekly nanoparticle albumin-bound paclitaxel with trastuzumab for HER2-positive breast cancer.

Yoshiko Nartaka

Dr. Nartaka has no relevant financial relationships to disclose.

Breast-conserving surgery plus hormone therapy without irradiation in elderly women with early breast cancer.

Yoshiko Nartaka

Yoshiko Nartaka has no relevant financial relationships to disclose.

A randomized phase II neoadjuvant study comparing docetaxel and cyclophosphamide (TC) with 5-fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel (FEC-D) for hormone receptor-negative breast cancer: The Kanagawa breast oncology group (KBOG) 1101 study.

Kazutaka Narui

Dr. Narui has no relevant financial relationships to disclose.

A phase I study of AZD9496, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC).

Tony Nash

Mr. Nash has disclosed that he is an AstraZeneca employee.

Chronic inhibition of signal transducer and activator of transcription 3/5 in treatment-resistant human breast cancer cell subtypes: Convergence on the reactive oxygen species/SUMOylation pathway and its effects on xCT expression and system xc-activity.

Mina Nashed

Ms. Nashed has disclosed that he is an employee and a stockholder of Cepheid.

An oncologist/immunologist who contributed to the development of novel HER-2 targeted agents.

Aziza Nassar

Dr. Nassar has no relevant financial relationships to disclose.

Prognostic value of molecular tumor infiltrating lymphocyte (mTIL) signatures in HER2-positive breast cancer patients in N9831 and FinHer/FinXX trials.

Tony Nash

Mr. Nash has disclosed that he is an AstraZeneca employee.

A phase I trial of AZD9496, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC).

Tony Nash

Mr. Nash has disclosed that he is an AstraZeneca employee.

A randomized phase II neoadjuvant study comparing docetaxel and cyclophosphamide (TC) with 5-fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel (FEC-D) for hormone receptor-negative breast cancer:

Kazutaka Narui

Dr. Narui has no relevant financial relationships to disclose.

A phase II study of AZD9496, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC).

Tony Nash

Mr. Nash has disclosed that he is an AstraZeneca employee.

A phase I study of AZD9496, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC).

Tony Nash

Mr. Nash has disclosed that he is an AstraZeneca employee.

A phase I trial of AZD9496, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC).

Tony Nash

Mr. Nash has disclosed that he is an AstraZeneca employee.

A phase I trial of AZD9496, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC).

Tony Nash

Mr. Nash has disclosed that he is an AstraZeneca employee.

A phase I trial of AZD9496, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC).

Tony Nash

Mr. Nash has disclosed that he is an AstraZeneca employee.

A phase I trial of AZD9496, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC).

Tony Nash

Mr. Nash has disclosed that he is an AstraZeneca employee.

A phase I trial of AZD9496, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC).

Tony Nash

Mr. Nash has disclosed that he is an AstraZeneca employee.

A phase I trial of AZD9496, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC).

Tony Nash

Mr. Nash has disclosed that he is an AstraZeneca employee.

A phase I trial of AZD9496, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC).

Tony Nash

Mr. Nash has disclosed that he is an AstraZeneca employee.

A phase I trial of AZD9496, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC).

Tony Nash

Mr. Nash has disclosed that he is an AstraZeneca employee.

A phase I trial of AZD9496, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC).

Tony Nash

Mr. Nash has disclosed that he is an AstraZeneca employee.

A phase I trial of AZD9496, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC).

Tony Nash

Mr. Nash has disclosed that he is an AstraZeneca employee.

A phase I trial of AZD9496, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC).

Tony Nash

Mr. Nash has disclosed that he is an AstraZeneca employee.

A phase I trial of AZD9496, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC).

Tony Nash

Mr. Nash has disclosed that he is an AstraZeneca employee.

A phase I trial of AZD9496, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC).

Tony Nash

Mr. Nash has disclosed that he is an AstraZeneca employee.

A phase I trial of AZD9496, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC).

Tony Nash

Mr. Nash has disclosed that he is an AstraZeneca employee.

A phase I trial of AZD9496, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC).

Tony Nash

Mr. Nash has disclosed that he is an AstraZeneca employee.

A phase I trial of AZD9496, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC).

Tony Nash

Mr. Nash has disclosed that he is an AstraZeneca employee.

A phase I trial of AZD9496, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC).

Tony Nash

Mr. Nash has disclosed that he is an AstraZeneca employee.

A phase I trial of AZD9496, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC).

Tony Nash

Mr. Nash has disclosed that he is an AstraZenaca employee.
A head-to-head comparison of paraffin-embedded MammaPrint versus oncoprint DX: A McGill University Health Center experience

Katherine Nathanson
Dr. Nathanson has no relevant financial relationships to disclose.

First and further line choices of treatment for HER2-VE metastatic breast cancer (MBC) according to adjuvant treatment and biological subtype. Preliminary results of the observational "GIM-13 - AMBRA" Italian study

Rachael Natrajan
Dr. Natrajan has no relevant financial relationships to disclose.

Establishment of molecular profiling for individual treatment decisions in early breast cancer - Clinical impact of PAM50 and PAM50 risk of recurrence score after more than 16 years follow-up

Bjørn Naume
Dr. Naume has no relevant financial relationships to disclose.

Proteomic response in breast cancer treated with neoadjuvant chemotherapy with and without bevacizumab: Reverse phase protein array (RPPA) results from NeoAva - A randomized phase II study

Bjørn Naume
Dr. Naume has no relevant financial relationships to disclose.

Treatment of early HER2-positive breast cancer in trastuzumab era in everyday clinical practice: An overview after 10 years of its approval

Valenti Navarro
Valenti Navarro has no relevant financial relationships to disclose.

Protein tyrosine kinase 6 (PTK6) promotes survival of endocrine therapy-resistant ER+ breast cancer cells

Anupma Nayak
Dr. Nayak has no relevant financial relationships to disclose.

The role of HER2 mutations in resistance to endocrine therapy-resistant ER+ breast cancer cells

Utthara Nayar
Dr. Nayar has no relevant financial relationships to disclose.

Breast cancer increased risk on women using combined oral contraceptive

Afonso Nazario
Dr. Nazário has no relevant financial relationships to disclose.
The use of hypofractionated radiotherapy for the treatment of women with early breast cancer in the Brazilian public health system may increase access to treatment: Cost effectiveness and budget impact analyses

Prospective study of acupuncture in the rehabilitation of women undergoing surgical treatment of breast cancer in relation to the strength and quality of life

Hypersensitive nanotargeted treatment of breast cancer with dorocibucin preventing drug resistance and circumventing antidrug activity

Maximierung: Interleukin-10 expression is a marker of disease progression in breast cancer with HER2 positivity.

Estrogen receptor-positive breast cancer in BRCA1 mutation carriers shows a BRCAdeficiency profile, suggesting sensitivity to drugs targeting homologous recombination deficiency

H-ferritin allows nanometronomic treatment of breast cancer with doxorubicin preventing drug resistance and circumventing cardiotoxicity

Microenvironment microarrays show that microenvironment mediated resistance mechanisms to lapatinib differ between basal and luminal HER2+ cells

Estrogen receptor-positive breast cancer in BRCA1 mutation carriers shows a BRCAdeficiency profile, suggesting sensitivity to drugs targeting homologous recombination deficiency

Comprehensive characterization of matched pre-treatment biopsies and residual disease of doxorubicin treated breast cancer

Prognostic factors in breast cancer (BC) associated with the development of brain metastases (BM): A retrospective study of 726 pts

Comparative performance of surveillance mammography and breast MRI in women with a history of breast cancer

Comparison of axillary sentinel lymph node biopsy versus no axillary surgery in patients with early-stage invasive breast cancer and breast conserving surgery: A randomised prospective surgical trial. The Intergroup-Sentinel-Mamma (INSEMA)-trial

Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer

Outcome after neoadjuvant chemotherapy in progesterone receptor negative breast cancer patients. - A pooled analysis of individual patient data from ten prospectively randomised controlled neoadjuvant trials

Efficacy and safety of darbepoetin alfa or epoetin beta in 2994 high risk early breast cancer patients participating in the German adjuvant intergroup node-positive study (GAIN)

Peripheral sensory neuropathy occurrence and resolution: Results from the neoadjuvant randomized GeparSepto study (GBG 69)

Biological functions of ERβ in triple negative breast cancer and its utility as a novel therapeutic drug target
A patient centered intervention for adaptation of cancer risk reduction guidelines in breast cancer survivors

Bonnie Nelson
Mr. Nelson has no relevant financial relationships to disclose.

Predictions of social support among newly diagnosed breast cancer patients seeking care at an urban safety net academic medical center

Kerrie Nelson
Dr. Nelson has no relevant financial relationships to disclose.

DxA methylation landscapes of breast cancer progression to brain metastasis: A pre-clinical study

Nelile Nelson
Ms. Nelson has no relevant financial relationships to disclose.

Breast cancer risk prediction using a polygenic risk score in women of African ancestry: Findings from GWAS in breast cancer in the African diaspora

Barbara Nemesure
Ms. Nemesure has no relevant financial relationships to disclose.

Squalene epoxidase is a potential metabolic oncogene by amplification with clinical implications in breast carcinoma: An in vitro pan-cancer study with in vitro evidence

Alessio Nencioni
Dr. Nencioni has no relevant financial relationships to disclose.

DNA methylation landscapes of breast cancer progression to brain metastasis: A pre-clinical study

Nelile Nelson
Ms. Nelson has no relevant financial relationships to disclose.

Predictors of social support among newly diagnosed breast cancer patients seeking care at an urban safety net academic medical center

Kerrie Nelson
Dr. Nelson has no relevant financial relationships to disclose.

DxA methylation landscapes of breast cancer progression to brain metastasis: A pre-clinical study

Nelile Nelson
Ms. Nelson has no relevant financial relationships to disclose.

Predictors of aggressive end-of-life care in women metastatic breast cancer

Alfred Neugut
Dr. Neugut has no relevant financial relationships to disclose.

Factors associated with follow up medical care among women with early stage breast cancer

Alfred Neugut
Dr. Neugut has no relevant financial relationships to disclose.

Factors associated with multidisciplinary care in the management of early stage breast cancer

Alfred Neugut
Dr. Neugut has no relevant financial relationships to disclose.

Functional IGf1R variant predicts pre-eclampsia protection from invasive breast cancer: novel california teachers study findings

Susan Neuhausen
Ms. Neuhausen has no relevant financial relationships to disclose.

A new workflow comprising size based CTC enrichment followed by in situ labeling and micromanipulation with CellCelector® enables label-free enrichment, isolation and characterization of circulating tumor cells in breast cancer

Hans Neubauer
Mr. Neubauer has no relevant financial relationships to disclose.

A randomized controlled trial comparing acupuncture versus usual care for the treatment of aromatase inhibitor-induced arthralgia (AIA) in women with early-stage breast cancer

Nathan Neufeld
Dr. Neufeld has no relevant financial relationships to disclose.

Predictors of aggressive end-of-life care in women metastatic breast cancer

Alfred Neugut
Dr. Neugut has no relevant financial relationships to disclose.

Factors associated with multidisciplinary care in the management of early stage breast cancer

Alfred Neugut
Dr. Neugut has no relevant financial relationships to disclose.

Factors associated with follow up medical care among women with early stage breast cancer

Alfred Neugut
Dr. Neugut has no relevant financial relationships to disclose.

Factors associated with multidisciplinary care in the management of early stage breast cancer

Alfred Neugut
Dr. Neugut has no relevant financial relationships to disclose.

Functional IGf1R variant predicts pre-eclampsia protection from invasive breast cancer: novel california teachers study findings

Susan Neuhausen
Ms. Neuhausen has no relevant financial relationships to disclose.

A new workflow comprising size based CTC enrichment followed by in situ labeling and micromanipulation with CellCelector® enables label-free enrichment, isolation and characterization of circulating tumor cells in breast cancer

Hans Neubauer
Mr. Neubauer has no relevant financial relationships to disclose.

Functional IGf1R variant predicts pre-eclampsia protection from invasive breast cancer: novel california teachers study findings

Susan Neuhausen
Ms. Neuhausen has no relevant financial relationships to disclose.

A new workflow comprising size based CTC enrichment followed by in situ labeling and micromanipulation with CellCelector® enables label-free enrichment, isolation and characterization of circulating tumor cells in breast cancer

Hans Neubauer
Mr. Neubauer has no relevant financial relationships to disclose.

Factors associated with multidisciplinary care in the management of early stage breast cancer

Alfred Neugut
Dr. Neugut has no relevant financial relationships to disclose.

Factors associated with multidisciplinary care in the management of early stage breast cancer

Alfred Neugut
Dr. Neugut has no relevant financial relationships to disclose.

Functional IGf1R variant predicts pre-eclampsia protection from invasive breast cancer: novel california teachers study findings

Susan Neuhausen
Ms. Neuhausen has no relevant financial relationships to disclose.

A new workflow comprising size based CTC enrichment followed by in situ labeling and micromanipulation with CellCelector® enables label-free enrichment, isolation and characterization of circulating tumor cells in breast cancer

Hans Neubauer
Mr. Neubauer has no relevant financial relationships to disclose.

Factors associated with multidisciplinary care in the management of early stage breast cancer

Alfred Neugut
Dr. Neugut has no relevant financial relationships to disclose.

Factors associated with multidisciplinary care in the management of early stage breast cancer

Alfred Neugut
Dr. Neugut has no relevant financial relationships to disclose.

Factors associated with multidisciplinary care in the management of early stage breast cancer

Alfred Neugut
Dr. Neugut has no relevant financial relationships to disclose.

Functional IGf1R variant predicts pre-eclampsia protection from invasive breast cancer: novel california teachers study findings

Susan Neuhausen
Ms. Neuhausen has no relevant financial relationships to disclose.

A new workflow comprising size based CTC enrichment followed by in situ labeling and micromanipulation with CellCelector® enables label-free enrichment, isolation and characterization of circulating tumor cells in breast cancer

Hans Neubauer
Mr. Neubauer has no relevant financial relationships to disclose.

Factors associated with multidisciplinary care in the management of early stage breast cancer

Alfred Neugut
Dr. Neugut has no relevant financial relationships to disclose.

Factors associated with multidisciplinary care in the management of early stage breast cancer

Alfred Neugut
Dr. Neugut has no relevant financial relationships to disclose.

Functional IGf1R variant predicts pre-eclampsia protection from invasive breast cancer: novel california teachers study findings

Susan Neuhausen
Ms. Neuhausen has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>High concordance of a closed system, near point of care, RT-qPCR</td>
<td>Veronique Neumenister</td>
<td>Dr. Neumenister has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Serum thymidine kinase 1 activity as a pharmacodynamics marker</td>
<td>Magnus Neumüller</td>
<td>Magnus Neumüller has disclosed that he receives salary from Boivis AB.</td>
</tr>
<tr>
<td>Two-year follow-up results of a multi-center trial of intra-</td>
<td>G Neuner</td>
<td>Dr. Neuner has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>A multi-center trial of intra-operative electronic brachytherapy</td>
<td>Geoffrey A. Neuner</td>
<td>Mr. Neuner has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Are aromatase inhibitors associated with higher myocardial</td>
<td>Joan Neuner</td>
<td>Dr. Neuner has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Assessment of stromal characteristics in ductal carcinoma in situ</td>
<td>Ines Nevelsteen</td>
<td>Ms. Nevelsteen has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Comparison of the mutational landscape of breast cancer during</td>
<td>Tanja Neunhöffer</td>
<td>Ms. Neunhöffer has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Identification, clinical characteristics and treatment outcomes of</td>
<td>Erin Neuschler</td>
<td>Dr. Neuschler has disclosed that she has a contracted research grant for Seno Medical Instrument, Inc. This relationship does not impact her ability to review presentations.</td>
</tr>
<tr>
<td>Findings of aromatase versus tamoxifen: Results from LATTE/ATAC</td>
<td>Patrick Neven</td>
<td>Dr. Neven has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>12 years median follow up (MFU) of BIG 1-98 Adjuvant letrozole,</td>
<td>Patrick Neven</td>
<td>Dr. Neven has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>The effect of adjuvant chemotherapy in a large consecutive series of</td>
<td>Patrick Neven</td>
<td>Dr. Nevan has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>The association of breast cancer subtype and breast cancer survival</td>
<td>Patrick Neven</td>
<td>Dr. Nevan has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Assessment of stromal characteristics in ductal carcinoma in situ</td>
<td>Patrick Neven</td>
<td>Dr. Nevan has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Long-term comparison of aromatase versus tamoxifen: Results from</td>
<td>Patrick Neven</td>
<td>Ms. Nevelsteen has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>The effect of adjuvant chemotherapy in a large consecutive series of</td>
<td>Patrick Neven</td>
<td>Dr. Nevan has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>The association of breast cancer subtype and breast cancer survival</td>
<td>Patrick Neven</td>
<td>Dr. Nevan has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>The effect of adjuvant chemotherapy in a large consecutive series of</td>
<td>Patrick Neven</td>
<td>Dr. Nevan has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>A consecutive series of early breast cancers with a low estrogen</td>
<td>Patrick Neven</td>
<td>Dr. Nevan has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>The association of breast cancer subtype and breast cancer survival</td>
<td>Patrick Neven</td>
<td>Dr. Nevan has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Effectiveness of myofascial techniques in addition to a standard</td>
<td>Patrick Neven</td>
<td>Dr. Nevan has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Effectiveness of myofascial techniques in addition to a standard</td>
<td>Patrick Neven</td>
<td>Dr. Nevan has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
Effect of MR imaging contrast kinetic thresholds for prediction of neoadjuvant chemotherapy response in breast cancer subtypes - Results from ACRIN 6637 / J-SPY 3 trial
David Hewitt
Dr. Hewitt has no relevant financial relationships to disclose.

Increasing participation in research - breast cancer (Inspire-BRC)
Antoinette Newman
Ms. Newman has no relevant financial relationships to disclose.

Precise characterization of VK-S8, a selective DNA-dependent protein kinase (DNA-PK) inhibitor in combination with docetaxel in breast and ovarian cancers
David Hewitt
Dr. Hewitt has no relevant financial relationships to disclose.

Multilaminar landscape of breast cancers from PALB2 germline mutation carriers
Carlotte Ng
Dr. Ng has no relevant financial relationships to disclose.

The genomic landscape of breast metaplastic carcinoma
Charlotte Ng
Dr. Ng has no relevant financial relationships to disclose.

The landscape of somatic genetic alterations in BRCA1 and BRCA2 breast cancers
Charlotte Ng
Dr. Ng has no relevant financial relationships to disclose.

Multilaminar landscape of breast cancers from PALB2 germline mutation carriers
Pei-Sze Ng
Pei-Sze Ng has no relevant financial relationships to disclose.

An estimation of the population survival benefit of first-line chemotherapy and immunotherapy for breast cancer
Cheng Ng
Dr. Ng has no relevant financial relationships to disclose.

Genomic analysis to evaluate response to neoadjuvant anastrozole and fulvestrant in post-menopausal ER-positive HER2-negative breast cancer patients included in the UCIBG CAMMAN02 trial
Carrie Ngo
Carrie Ngo has no relevant financial relationships to disclose.

Identifying patient-specific neoepitopes for cell-based and vaccine immunotherapy across breast cancer classifications reveals rarely shared recurrent neoepitopes
Andrew Nguyen
Dr. Nguyen has disclosed that he is an employee of NantOmix.

Interrogating the impact of pregnancy on breast cancer biology using DNA copy number profiling
Bastien Nguyen
Mr. Nguyen has no relevant financial relationships to disclose.

The role of CRPB/FOXM1 in triple negative breast cancer
Eui Nguyen
Eui Nguyen has no relevant financial relationships to disclose.

ST8SIA1 regulates tumorigenesis in triple negative breast cancer
Khoa Nguyen
Dr. Nguyen has disclosed that he is an employee of NantOmix.

Bioluminescence imaging during neoadjuvant chemotherapy and immunotherapy for breast cancer
Khoa Nguyen
Khoa Nguyen has no relevant financial relationships to disclose.

High-affinity activated natural killer (haNK) cells augment trastuzumab efficacy in a mouse model of HER2-positive human metastatic breast cancer
Kayan Niazi
Kayan Niazi has disclosed that he receives salary from and has a patent ownership in NantKwest.

Preclinical characterization of VX-984, a selective DNA-PK inhibitor in combination with docetaxel in breast and ovarian cancers
David Hewitt
Dr. Hewitt has no relevant financial relationships to disclose.

Bioluminol-enhanced natural killer (BiNK) cells augment trastuzumab efficacy in a mouse model of HER2-positive human metastatic breast cancer
Kayan Niazi
Kayan Niazi has disclosed that he receives salary from and has a patent ownership in NantKwest.

Identifying patient-specific neoepitopes for cell-based and vaccine immunotherapy across breast cancer classifications reveals rarely shared recurrent neoepitopes
Kayan Niazi
Kayan Niazi has disclosed that he is an employee of NantOmix.

Multi-omics and immuno-oncology profiling reveal distinct molecular signatures of young Asian breast cancers
Tan Nicholas
Dr. Nichols has no relevant financial relationships to disclose.

The impact of genomic mutation on metastatic breast cancer treatment: A retrospective clinical trial
Solomon Nicola
Dr. Nicola has no relevant financial relationships to disclose.

Bromodomain inhibitors represent a rational therapeutic option for postmenopausal patients with hormone receptor positive, HER2 negative breast cancer
Tuan Nguyen
Tuan Nguyen has disclosed that he has a contract with and is employed by Eli Lilly and Company.

Bioluminol-enhanced natural killer (BiNK) cells augment trastuzumab efficacy in a mouse model of HER2-positive human metastatic breast cancer
Kayan Niazi
Kayan Niazi has disclosed that he receives salary from and has a patent ownership in NantKwest.

Preclinical characterization of VX-984, a selective DNA-PK inhibitor in combination with docetaxel in breast and ovarian cancers
David Hewitt
Dr. Hewitt has no relevant financial relationships to disclose.

Detecting the impact of pregnancy on breast cancer biology using DNA copy number profiling
Bastien Nguyen
Mr. Nguyen has no relevant financial relationships to disclose.

The role of CRPB/FOXM1 in triple negative breast cancer
Eui Nguyen
Eui Nguyen has no relevant financial relationships to disclose.

ST8SIA1 regulates tumorigenesis in triple negative breast cancer
Khoa Nguyen
Dr. Nguyen has disclosed that he is an employee of NantOmix.

Bioluminescence imaging during neoadjuvant chemotherapy and immunotherapy for breast cancer
Khoa Nguyen
Khoa Nguyen has no relevant financial relationships to disclose.

High-affinity activated natural killer (haNK) cells augment trastuzumab efficacy in a mouse model of HER2-positive human metastatic breast cancer
Kayan Niazi
Kayan Niazi has disclosed that he receives salary from and has a patent ownership in NantKwest.

Preclinical characterization of VX-984, a selective DNA-PK inhibitor in combination with docetaxel in breast and ovarian cancers
David Hewitt
Dr. Hewitt has no relevant financial relationships to disclose.

Bioluminol-enhanced natural killer (BiNK) cells augment trastuzumab efficacy in a mouse model of HER2-positive human metastatic breast cancer
Kayan Niazi
Kayan Niazi has disclosed that he receives salary from and has a patent ownership in NantKwest.

Preclinical characterization of VX-984, a selective DNA-PK inhibitor in combination with docetaxel in breast and ovarian cancers
David Hewitt
Dr. Hewitt has no relevant financial relationships to disclose.

Bioluminol-enhanced natural killer (BiNK) cells augment trastuzumab efficacy in a mouse model of HER2-positive human metastatic breast cancer
Kayan Niazi
Kayan Niazi has disclosed that he receives salary from and has a patent ownership in NantKwest.

Preclinical characterization of VX-984, a selective DNA-PK inhibitor in combination with docetaxel in breast and ovarian cancers
David Hewitt
Dr. Hewitt has no relevant financial relationships to disclose.

Bioluminol-enhanced natural killer (BiNK) cells augment trastuzumab efficacy in a mouse model of HER2-positive human metastatic breast cancer
Kayan Niazi
Kayan Niazi has disclosed that he receives salary from and has a patent ownership in NantKwest.
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1-01-15</td>
<td>DETECT V - Detection of the expression of estrogen receptor and human epidermal growth factor receptor 2 on circulating tumor cells from metastatic breast cancer patients</td>
<td>Dieter Niederacher</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-09-04</td>
<td>Beyond CHEK2 in breast cancer: Search for additional moderately penetrant risk gene variants by analyzing the oligogenic disease course in CHEK2 mutation carriers</td>
<td>Dieter Niederacher</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S6-03</td>
<td>OBG 07-READ: A randomized phase III trial comparing six cycles of docetaxel and cyclophosphamide (DC) to three cycles of doxorubicin (DC) in patients with early breast cancer</td>
<td>Birte Nielsen</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S6-03</td>
<td>OBG 07-READ: A randomized phase III trial comparing six cycles of docetaxel and cyclophosphamide (DC) to three cycles of doxorubicin (DC) in patients with early breast cancer</td>
<td>Hanne Nielsen</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-03-01</td>
<td>An international multicenter study to evaluate reproducibility of automated scoring methods for assessment of Ki67 in breast cancer</td>
<td>Torsten Nielsen</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-09-08</td>
<td>Predictive effect of cytotoxic tumor infiltrating lymphocytes in HER2-positive metastatic breast cancer: A correlative study with COG MA.31</td>
<td>Torsten Nielsen</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P05-08</td>
<td>Expression of LAG-3 in breast cancer, and its association with subtype and outcome</td>
<td>Torsten Nielsen</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Committee Member</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P4-12-04</td>
<td>Breast cancer subtype, age and lymph node status as predictors of local recurrence following breast-conserving therapy</td>
<td>Andrzej Wiermeko</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-07-33</td>
<td>Metrics of drug sensitivity based on growth rate inhibition correct for the confounding effects of variable division rates</td>
<td>Mario Nepali</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-07-04</td>
<td>Detecting early breast cancer by the combination of five serum microRNA and its possibility of prediction of pathological complete response in neoadjuvant chemotherapy</td>
<td>Thumpei Noda</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-04-13</td>
<td>Difference of immune microenvironment between primary and recurrent tumours in breast cancer patients</td>
<td>Naoëi Nikura</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-13-11</td>
<td>Utility of Liposure™ vessel-sealing device in axillary dissection for breast cancer surgery: A randomized single center study</td>
<td>Naoki Nikura</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-03-09</td>
<td>Resistance to palbociclib depends on multiple targetable mechanisms highlighting the potential of drug holidays and drug switching to improve therapeutic outcome</td>
<td>Joanna Nikitornosz-Bunke</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-05-01</td>
<td>Increased glycolysis directly activates transcriptional coactivator SRC-3 to promote aggressive metastatic breast cancer</td>
<td>Bryan Nikolai</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-12-09</td>
<td>Clinical characteristics of CNS metastases of different breast cancer subtypes - Results from a cohort study</td>
<td>Anna Nilsson</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-09-01</td>
<td>BRCAsearch - results of population-based screening of BRCA1 and BRCA2 germline mutations in incident breast cancer in South Sweden</td>
<td>Martin Nilsson</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
Relative radioresistance in triple negative tumors in the SweBCG91-RT randomized clinical trial
Emma Niméus
Ms. Niméus has no relevant financial relationships to disclose.

Circulating inflammatory markers, growth factors, and tumor associated antigens in women with early stage breast cancer receiving neoadjuvant methotrexate
Sarij Niraula
Dr. Niraula has no relevant financial relationships to disclose.

Mechanism of drug resistance in relation to sites of metastases: Meta-analyses of randomized controlled trials in advanced breast cancer
Sarij Niraula
Dr. Niraula has no relevant financial relationships to disclose.

Scalp cooling alopecia prevention trial (SCALP) for patients with early stage breast cancer
Polly Niravath
Dr. Niravath has disclosed that she receives consulting fees from Novartis. This relationship does not impact her ability to review presentations.

Clinical examination and breast MRI as predictors of pathologic complete response post neoadjuvant therapy in HER2 overexpressed subtypes and triple negative breast cancer
Cristiane Nimir
Dr. Nimir has no relevant financial relationships to disclose.

Circulating inflammatory markers, growth factors, and tumor associated antigens in women with early stage breast cancer receiving neoadjuvant methotrexate
Sarij Niraula
Dr. Niraula has no relevant financial relationships to disclose.

The prognostic impact of inositol polyphosphate 5-phosphatase PIPP (INPP5J) expression in breast cancer tissue
Sayaka Nishikawa
Ms. Nishikawa has no relevant financial relationships to disclose.

The prognostic impact of inositol polyphosphate 5-phosphatase PIPP (INPP5J) expression in breast cancer tissue
Mayumi Nishimoto
Ms. Nishimoto has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Arisa Nishimukai
Dr. Nishimukai has no relevant financial relationships to disclose.

The importance of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive recurrent and advanced breast cancer
Reiki Nishimura
Dr. Nishimura has no relevant financial relationships to disclose.

PD-L1 expression and decreased tumor-infiltrating lymphocytes are associated with poor prognosis in patients with triple negative breast cancer
Reiki Nishimura
Dr. Nishimura has no relevant financial relationships to disclose.

A randomized phase II trial of trastuzumab + capecitabine versus lapatinib + capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP
Kazuto Nishio
Dr. Nishio has no relevant financial relationships to disclose.

A randomized phase II study of 6X-677 response-guided neoadjuvant chemotherapy for HER2-positive breast cancer
Yasuyuki Nishiyama
Dr. Nishiyama has no relevant financial relationships to disclose.

Simultaneous analyses of HER2 gene and protein status can more precisely predict pathological complete response (pCR) to neoadjuvant trastuzumab with chemotherapy in primary HER2-positive breast cancer
Hiroaki Nitta
Dr. Nitta has no relevant financial relationships to disclose.

Difference between 1st and 2nd generation serotonin receptor antagonists in triplet antiemetic therapy for highly emetogenic chemotherapy in breast cancer patients - according to recent multi-institutional double-blind randomized clinical research on the AC regimen
Yukari Nitta
Ms. Nitta has no relevant financial relationships to disclose.

Chemotherapy (CT) decision in patients (pts) with node-positive (N+), ER+, early breast cancer (EBC) in the wake of new ASCO guideline - A different take on the evidence for the 21-gene recurrence score (RS) assay
Ulrike Nitz
Dr. Nitz has disclosed that he receives honoraria from Genomic Health.
The role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+/HR+ phase II trial evaluating 12-weeks of neoadjuvant TDM1 ± endocrine therapy (ET) versus T + ET in HER2-positive hormone-receptor-positive early breast cancer (EBC)

Ulrike Nitz

Dr. Nitz has disclosed that he receives research support and is a consultant and speaker.

Results of multigene assay (MammaPrint®) and molecular subtyping (BluePrint®) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIME decision impact study

Ulrike Nitz

Prof. Nitz has disclosed that he is on an Advisory Board.

Single agent palbociclib with or without trastuzumab for the treatment of HER2+ advanced breast cancer

Isoris Nivar

Isoris Nivar has no relevant financial relationships to disclose.

Analysing the factors affecting survival of breast cancer patients with leptomenengial metastasis

Anna Niewinska

Prof. Niewinska has no relevant financial relationships to disclose.

Use of a 3-D bioabsorbable tissue marker in 63 patients over two years

Sid Nix

Mr. Nix has no relevant financial relationships to disclose.


Allen Nixon

Dr. Nixon has no relevant financial relationships to disclose.

Phase I study of low dose oral cyclophosphamide (C) plus the poly-ADP-ribose polymerase (PARP) inhibitor veliparib (V) in women with HER2/neu-negative inoperable locally advanced/metastatic breast cancer (MBC): NCI P8853

Kornblum Noah

Dr. Noah has no relevant financial relationships to disclose.

Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes (TILs) and residual cancer burden (RCB)

Satoru Noda

Satoru Noda has no relevant financial relationships to disclose.

Predicting therapeutic effect by on tumor invasion lymphocytes (TILs) in endocrine therapy for stage IV breast cancer

Satoru Noda

Satoru Noda has no relevant financial relationships to disclose.

Circulating tumor cell clusters-associated gene plakoglobin is a novel prognostic predictor in patients with breast cancer

Satoru Noda

Satoru Noda has no relevant financial relationships to disclose.

Technical skill of surgical residents may affect margin status of breast conserving operations

Jesse Nodora

Dr. Nodora has no relevant financial relationships to disclose.

Prospective cross-sectional study on participation in mammography screening according to immigration background and education status

Stefanie Noeding

Dr. Noeding has no relevant financial relationships to disclose.

Everolimus plus trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: Overall survival results from BOLERO-3

Flavioia Noel-Baron

Ms. Noel-Baron has disclosed that she is a Novartis employee.

Prospective cross-sectional study on participation in mammography screening according to immigration background and education status

Thomas Noesselt

Dr. Noesselt has no relevant financial relationships to disclose.
Three-gene signature predictive of high residual risk of recurrence after adjuvant chemotherapy in ER-positive HER2-negative breast cancer

Alberto Ocana

Dr. Ocana has no relevant financial relationships to disclose.

Implications of financial modeling in breast cancer clinical research from 1990 to 2010

Alberto Ocaña

Dr. Ocaña has no relevant financial relationships to disclose.

Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate (ADC) for the treatment of relapsed/refractory, metastatic triple-negative breast cancer (mTNBC): Updated results

Allyson Ocean

Dr. Ocean has no relevant financial relationships to disclose.

Detecting early breast cancer by the combination of five serum microRNAs and its possibility of prediction of pathological complete response in neoadjuvant chemotherapy

Takayuki Ochiya

Dr. Ochiya has disclosed that this study was supported by the "Development of Diagnostic Technology for Detection of miRNA in Body Fluids" grant from the Japan Agency for Medical Research and Development and New Energy and Industrial Technology Development Organization.

Sexual functioning among breast cancer survivors and their partners: A pilot study

Daniela Ochoa

Dr. Ochoa has no relevant financial relationships to disclose.

Bromodomain inhibitors represent a rational therapeutic option for the treatment of invasive lobular carcinoma

Darran O'Connor

Dr. O'Connor has no relevant financial relationships to disclose.

Acupuncture for chemotherapy-induced peripheral neuropathy in breast cancer, preliminary results of a pilot randomized controlled trial

Keelin O'Connor

Keelin O'Connor has no relevant financial relationships to disclose.

A phase II study to compare fulvestrant (F) 500mg plus placebo versus (vs) F 500mg plus palbociclib (P) as first line treatment for postmenopausal women with hormone receptor (HR) positive, advanced breast cancer (BC) sensitive to endocrine therapy (ET). "The FLIPPER study" (GEICAM/2014-12)

Miriam O'Connor

Ms. O'Connor has no relevant financial relationships to disclose.

The impact of the 21 gene recurrence score (RS) on chemotherapy prescribing in estrogen receptor (ER) positive, lymph node positive early stage breast cancer in Ireland

Toshinou Oda

Dr. Oda has no relevant financial relationships to disclose.

Bromodomain inhibitors represent a rational therapeutic option for the treatment of invasive lobular carcinoma

Darran O'Connor

Dr. O'Connor has no relevant financial relationships to disclose.

Acupuncture for chemotherapy-induced peripheral neuropathy in breast cancer, preliminary results of a pilot randomized controlled trial

Keelin O'Connor

Keelin O'Connor has no relevant financial relationships to disclose.

Femara plus ribociclib or placebo as neo-adjuvant endocrine therapy for women with ER+, HER2-negative early breast cancer - The Feline trial

Anne O'Dea

Dr. O'Dea has disclosed that she is a speaker for Pfizer.

Pathological complete response is associated with excellent outcomes in BRCA mutation associated triple negative breast cancer

Anne O'Dea

Dr. O'Dea has no relevant financial relationships to disclose.

Safety and efficacy results from phase I study of BTN, 710 plus bevacizumab in HER2 negative metastatic breast cancer

Anne O'Dea

Dr. O'Dea has no relevant financial relationships to disclose.

Plasma osteoprotegerin and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

Lovisa Oden

Ms. Oden has no relevant financial relationships to disclose.

Comparative analysis of the genomic landscape of breast cancers from women of African and European ancestry

Abayomi Odetunde

Abayomi Odetunde has no relevant financial relationships to disclose.

Genomic copy number alterations (CNA) associated with pCR in HER2-positive (HER2+) early-stage breast cancer (BrCa) patients receiving neoadjuvant trastuzumab (T)

Jose O'Donoghue

Mr. O'Donoghue has no relevant financial relationships to disclose.

Plasma chemokine profile of HER2+ breast cancer (BC) patients treated with docetaxel (D) and carboplatin (C) in combination with trastuzumab (T) and/or lapatinib (L) in the neo-adjuvant setting

Jose O'Donoghue

Ms. O'Donovan has no relevant financial relationships to disclose.

Plasma chemokine profile of HER2+ breast cancer (BC) patients treated with docetaxel (D) and carboplatin (C) in combination with trastuzumab (T) and/or lapatinib (L) in the neo-adjuvant setting

Jose O'Donoghue

Ms. O'Donovan has no relevant financial relationships to disclose.

Single agent palbociclib with or without trastuzumab for the treatment of HER2 advanced breast cancer

Peter O'Dwyer

Dr. O'Dwyer has disclosed that he receives research funding from JNJ.

Plasma osteoprotegerin and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

Lovisa Oden

Ms. Oden has no relevant financial relationships to disclose.

Breast implant associated anaplastic large cell lymphoma (BIA-ALCL)- The UK experience and first reported case of neoadjuvant brentuximab

Joe O'Donoghue

Mr. O'Donoghue has no relevant financial relationships to disclose.

The impact of the 21 gene recurrence score (RS) on chemotherapy prescribing in estrogen receptor (ER) positive, lymph node positive early stage breast cancer in Ireland

Toshinou Oda

Dr. Oda has no relevant financial relationships to disclose.

Breast implant associated anaplastic large cell lymphoma (BIA-ALCL)- The UK experience and first reported case of neoadjuvant brentuximab

Joe O'Donoghue

Mr. O'Donoghue has no relevant financial relationships to disclose.

Genomic copy number alterations (CNA) associated with pCR in HER2-positive (HER2+) early-stage breast cancer (BrCa) patients receiving neoadjuvant trastuzumab (T)

Jose O'Donoghue

Mr. O'Donoghue has no relevant financial relationships to disclose.

Genomic copy number alterations (CNA) associated with pCR in HER2-positive (HER2+) early-stage breast cancer (BrCa) patients receiving neoadjuvant trastuzumab (T)

Jose O'Donoghue

Mr. O'Donoghue has no relevant financial relationships to disclose.

Breast implant associated anaplastic large cell lymphoma (BIA-ALCL)- The UK experience and first reported case of neoadjuvant brentuximab

Joe O'Donoghue

Mr. O'Donoghue has no relevant financial relationships to disclose.

Comparative analysis of the genomic landscape of breast cancers from women of African and European ancestry

Abayomi Odetunde

Abayomi Odetunde has no relevant financial relationships to disclose.
Cardiac safety of dual anti-HER2 therapy in the neoadjuvant setting for treatment of HER2-positive breast cancer

Treatment of ERβ2 mutant and PIK3CA mutant patient-derived breast cancer xenograft models reveals differential anti-tumor responses to estrogen receptor degraders and PI3K inhibitors in vivo

Dyslexia, a novel anti-HER2 ADC, shows promising activity in patients with HER2-positive and HER2-negative metastatic breast cancer

Differential turnover of estrogen receptor alpha in invasive lobular carcinoma

WNT4 mediates estrogen response and resistance in invasive lobular carcinoma cells

Breast cancer brain metastases show limited intrinsic subtype switching, yet exhibit acquired ERBB2 amplifications and activating mutations

ESR1 amplification and 5'-3' exon imbalance in metastatic breast cancer

Methylation of BRCA1 and response to the PARP inhibitor olaparib

Committee Member

Prospective cross-sectional study on participation in mammography screening according to immigration background and education status

Influence of exercise or educational programs on long-term physical activity by patients after surgery for primary breast cancer: A randomized trial

A randomized phase II neoadjuvant study comparing docetaxel and cyclophosphamide (TC) with 5-fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel (FEC-D) for hormone receptor-negative breast cancer: The Kanagawa breast oncology group (KBOG) 1101 study

Difference between 1st and 2nd generation serotonin receptor antagonists in triplet antiemetic therapy for highly emetogenic chemotherapy in breast cancer patients: According to recent multi-institutional double-blind randomized clinical research on the AC regimen

The combination of preoperative computed tomography lymphography and intraoperative fluorescence imaging navigation for sentinel lymph node biopsy of early breast cancer patients

Evaluation of the relationship between psychological distress and risk for breast cancer

Differential of immune microenvironment between primary and recurrent tumours in breast cancer patients

Utility of Liquid Biopsy™ vessel-sequencing device in auxiliary dissection for breast cancer surgery: A randomized single center study

Human breast cancer biopsy samples induce eosinophil recruitment and enhance adjacent cancer cell proliferation

Breast cancer risk prediction using a polygenic risk score in women of African ancestry: Findings from GWAS in breast cancer in the African diaspora

Comparative analysis of the genomic landscape of breast cancers from women of African and European ancestry
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Disclosures</th>
</tr>
</thead>
<tbody>
<tr>
<td>P5-03-08</td>
<td>Use of natural language processing on mammography and pathology findings to supplement BI-RADS to improve clinical decision making in breast cancer care</td>
<td>Richard Ogunti</td>
<td>Dr. Ogunti has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-11-12</td>
<td>MOCHA: An institution-based care coordination app for post-hospitalization breast cancer patients</td>
<td>Richard Ogunti</td>
<td>Dr. Ogunti has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT1-01-02</td>
<td>A phase II trial of neoadjuvant docetaxel/cyclophosphamide followed by epirubicin/cyclophosphamide for triple-negative breast cancer</td>
<td>Kaoru Ogura</td>
<td>Dr. Ogura has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT1-01-03</td>
<td>A phase II trial of neoadjuvant epirubicin/cyclophosphamide followed by weekly nanoparticle albumin-bound paclitaxel with trastuzumab for HER2-positive breast cancer</td>
<td>Kaoru Ogura</td>
<td>Dr. Ogura has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-13-13</td>
<td>Breast-conserving surgery plus hormone therapy without irradiation in elderly women with early breast cancer</td>
<td>Kaoru Ogura</td>
<td>Kaoru Ogura has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-04-08</td>
<td>The role of HER2 mutations in resistance to endocrine therapy in ER+ breast cancer</td>
<td>Coyin Oh</td>
<td>Coyin Oh has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S1-02</td>
<td>Whole exome and transcriptome sequencing of resistant ER+ metastatic breast cancer</td>
<td>Coyin Oh</td>
<td>Coyin Oh has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-02-05</td>
<td>Prognostic role of PIK3CA mutational status in circulating tumor DNA (ctDNA) from HER2-positive metastatic breast cancer patients</td>
<td>Do-Youn Oh</td>
<td>Dr. Oh has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-09-04</td>
<td>Proliferation and p16 refine risk of relapse in residual disease after HER2-directed therapies</td>
<td>Do-Youn Oh</td>
<td>Dr. Oh has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-05-05</td>
<td>The expression of tumor stromal and fibrotic focus is related to inflammation in breast cancer</td>
<td>Hiison Oh</td>
<td>Dr. Oh has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-12-03</td>
<td>Association between tumor genotype and development of brain metastases in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer</td>
<td>Kevin Oh</td>
<td>Mr. Oh has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-12-08</td>
<td>Phase I study of low dose oral cyclophosphamide (C) plus the poly-ADP-ribose polymerase (PARP) inhibitor veliparib (V) in women with HR+/HER2- triple-negative, inoperable, locally advanced/metastatic breast cancer (MBC): NCI P8853</td>
<td>Sun-young Oh</td>
<td>Dr. Oh has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-22-19</td>
<td>Time on treatment of everolimus versus endocrine monotherapy or chemotherapy for early-line treatment of HR+/HER2- metastatic breast cancer: A retrospective chart review study in the US</td>
<td>Erika Ohashi</td>
<td>Ms. Ohashi has disclosed that she is a consultant for Novartis Pharmaceuticals Corporation.</td>
</tr>
<tr>
<td>P2-07-16</td>
<td>Alcohol consumption increases mammographic density in women aged 155 years</td>
<td>Hitoshi Ohashi</td>
<td>Hitoshi Ohashi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-11-07</td>
<td>Duration of fasting before taking lapatinib is associated with skin toxicity in neoadjuvant treatment of HER2 positive breast cancer: A cohort study from JBCRG-16/Neo-LaTH</td>
<td>Masahiro Ohgami</td>
<td>Mr. Ohgami has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-24-25</td>
<td>The importance of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive recurrent and advanced breast cancer</td>
<td>Takako Ohishi</td>
<td>Dr. Ohishi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-10-14</td>
<td>Breast cancer provider delay after the 2011 triple disaster in Fukushima, Japan</td>
<td>Hiromichi Ohira</td>
<td>Dr. Ohira has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-05</td>
<td>Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor infiltrating lymphocytes (TILs) and residual cancer burden (RCB)</td>
<td>Masaichi Ohi</td>
<td>Dr. Ohi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-04-20</td>
<td>Predicting therapeutic effect by on tumor invasion lymphocytes (TILs) in endocrine therapy for stage IV breast cancer</td>
<td>Masaichi Ohi</td>
<td>Dr. Ohi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-25</td>
<td>Circulating tumor cell clusters-associated gene plakoglobin is a novel prognostic predictor in patients with breast cancer</td>
<td>Masaichi Ohi</td>
<td>Masaichi Ohi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-09-04</td>
<td>Assessment of breast cancer risk among atomic-bomb survivors based on ATM polymorphisms, radiation dose, and age at exposure</td>
<td>Hiwa Oishi</td>
<td>Dr. Oishi has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
Efficacy and safety of everolimus plus exemestane in HR+, HER2-advanced breast cancer progressing on/after prior endocrine therapy, in routine clinical practice: 2nd interim analysis from STEPAUT

Leopold Öhler
Mr. Öhler has no relevant financial relationships to disclose.

The ectopic FOXA1 expression correlates to the luminal breast cancer stem cells

Osamu Ohneda
Dr. Ohneda has no relevant financial relationships to disclose.

Simultaneous analyses of HER2 gene and protein status can more precisely predict pathological complete response (pCR) to neoadjuvant trastuzumab with chemotherapy in primary HER2-positive breast cancer

Shinji Ohno
Dr. Ohno has disclosed that he is a speaker for Chugai.

Development of mathematical prediction models to identify disease-free survival events for HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy and trastuzumab

Shinji Ohno
Mr. Ohno has disclosed that he is a speaker for Chugai.

Results of an educational program delivered through e-learning, focused on nursing for primary breast cancer patients

Tomoka Ohno
Ms. Ohno has no relevant financial relationships to disclose.

Establishment of molecular profiling for individual treatment decisions in early breast cancer - Clinical impact of PAM50 and PAM50 risk of recurrence score after more than 15 years follow up

Hege Ohnstad
Hege Ohnstad has no relevant financial relationships to disclose.

Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor infiltrating lymphocytes (TILs) and residual cancer burden (RCB)

Masahiko Ohsawa
Dr. Ohsawa has no relevant financial relationships to disclose.

Circulating tumor cell clusters-associated gene plectin is a novel prognostic predictor in patients with breast cancer

Masahiko Ohsawa
Masahiko Ohsawa has no relevant financial relationships to disclose.

High concordance of ER, PR, HER2 and Ki67 by central IHC and FISH with mRNA measurements by GeneXpert® breast cancer stratifier assay

Shoichiro Ohta
Dr. Ohta has no relevant financial relationships to disclose.

A phase II, open label, multicenter, translational study for biomarkers of eribulin mesylate: Evaluation of the utility of monitoring epithelial-to-mesenchymal transition (EMT) markers on tumor cells in the malignant plural effusion of patients with metastatic breast cancer (EXPECT-study)

Masahiko Ohsawa
Dr. Ohsawa has no relevant financial relationships to disclose.

Potential clinical application of mammography conducted immediately after contrast enhanced CT as contrast enhanced subtraction mammography

Shoichiro Ohtani
Dr. Ohtani has disclosed that he is a speaker for CHUGAI pharmaceutical Company and Eisai pharmaceutical Company.

A multi-center prospective study of radiofrequency ablation therapy for small breast carcinomas

Shoichiro Ohtani
Dr. Ohtani has no relevant financial relationships to disclose.

Prognostic factors after neoadjuvant chemotherapy in breast cancer: Surgery type as a new prognostic factor

Shoichiro Ohtani
Dr. Ohtani has no relevant financial relationships to disclose.

Randomized trial of exercise intervention vs. usual care for breast cancer patients with aromatase inhibitor induced arthralgia

Noriaki Ohuchi
Dr. Ohuchi has no relevant financial relationships to disclose.

Validation of novel diagnostic kits using the semi-dry dot-blot method for detecting metastatic lymph nodes in breast cancer; distinguishing macrometastases and micrometastases

Masahiro Oikawa
Dr. Oikawa has no relevant financial relationships to disclose.

Breast cancer risk prediction using a polygenic risk score in women of African ancestry: Findings from GWAS in breast cancer in the African diaspora

Oladosu Ojengbede
Oladosu Ojengbede has no relevant financial relationships to disclose.

Comparative analysis of the genomic landscape of breast cancers from women of African and European ancestry

Oladosu Ojengbede
Oladosu Ojengbede has no relevant financial relationships to disclose.
OT3-07-02 Influence of exercise or educational programs on long-term physical activity by patients after surgery for primary breast cancer: A randomized trial
Koichiro Oka
Koichiro Oka has no relevant financial relationships to disclose.

P1-03-10 HER2 expression in African breast cancer samples: A novel detection methodology for HER2 protein quantitation using fluorescent nanoparticles
Mitsukake Okada
Dr. Okada has disclosed that he is an employee of Konic Mirella.

P4-02-06 Evaluation of contrast-enhanced ultrasound for early prediction of response to neoadjuvant chemotherapy in triple negative breast cancer
Morihito Okada
Morihito Okada has no relevant financial relationships to disclose.

P3-01-04 Potential clinical application of mammography conducted immediately after contrast enhanced CT as contrast enhanced subtraction mammography
Nobuko Okada
Ms. Okada has no relevant financial relationships to disclose.

P2-04-13 Differences of immune microenvironment between primary and recurrent tumours in breast cancer patients
Takuhito Okamura
Dr. Okamura has no relevant financial relationships to disclose.

P1-13-11 Utility of Ligasure™ vessel-sealing device in axillary dissection for breast cancer surgery: A randomized single center study
Takuhito Okamura
Dr. Okamura has no relevant financial relationships to disclose.

P88-05 Comparative analysis of the genomic landscape of breast cancers from women of African and European ancestry
Babajide Okedere
Babajide Okedere has no relevant financial relationships to disclose.

P1-08-13 The clinical importance of nuclear wild-type p53-induced phosphatase 1 (Wip1) expression in breast cancer patients
Eiji Oki
Dr. Oki has no relevant financial relationships to disclose.

P6-01-17 Clinical and clinical validation of a fully automated tissue-based quantitative assay (MetaSite ™) to detect the likelihood of distant metastasis in hormone receptor (HR)-positive, HER2-negative early stage breast cancer (ESBC)
Maja Oktay
Dr. Oktay has no relevant financial relationships to disclose.

P6-07-05 PD-L1 expression and decreased tumor-infiltrating lymphocytes are associated with poor prognosis in patients with triple negative breast cancer
Maja Oktay
Dr. Oktay has no relevant financial relationships to disclose.

P2-05-06 Pacilitaxel induced mena- and TMEM-mediated pro-metastatic changes in the breast cancer microenvironment
Maja Oktay
Dr. Oktay has no relevant financial relationships to disclose.

P05-02 Tumor microenvironment of metastasis (TMEM) score is associated with early distant recurrence in hormone receptor (HR)-positive, HER2-negative early stage breast cancer (ESBC)
Maja Oktay
Dr. Oktay has disclosed that he owns stock.

S4-04 The importance of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive recurrent and advanced breast cancer
Yasuhiro Okumura
Yasuhiro Okumura has no relevant financial relationships to disclose.

S5-02 Consistent dosing-time dependent tolerability of everolimus (EV) in a pilot study in women with metastatic breast cancers (MBC) and in a mouse chronopharmacology investigation
Oliver Omphred
Dr. Omphred has no relevant financial relationships to disclose.

P3-13-11 Determining the prognostic role of early and end-of-neoadjuvant chemotherapy 18F-FDG PET/CT in patients with locally advanced breast cancer
Amaya Olaverrí-Hernández
Dr. Olaverrí-Hernández has no relevant financial relationships to disclose.

P6-08-06 Consistent dose-response effect of cetuximab (CET) in a pilot study in women with metastatic breast cancers (MBC) and in a mouse chronopharmacology investigation
Oliver Omphred
Dr. Omphred has no relevant financial relationships to disclose.

S2-06 DNA repair deficiency biomarkers and MammaPrint high1/(ultra)high2 risk as predictors of veliparib/carboplatin response: Results from the neoadjuvant I-SPY 2 trial for high risk breast cancer
Olufunmilayo Olapade
Olufunmilayo Olapade has no relevant financial relationships to disclose.

PD3-03 PD-L1 expression and decreased tumor-infiltrating lymphocytes are associated with poor prognosis in patients with triple negative breast cancer
Yasuhiro Okumura
Yasuhiro Okumura has no relevant financial relationships to disclose.

P6-07-05 O6-06-06 Determining the prognostic role of early and end-of-neoadjuvant chemotherapy 18F-FDG PET/CT in patients with locally advanced breast cancer
Amaya Olaverrí-Hernández
Dr. Olaverrí-Hernández has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P4-01-04</td>
<td>Assessing response in locally advanced breast cancer treated with neoadjuvant chemotherapy: Predictive and prognostic potential of volume-based metabolic variables with 18F-FDG PET/CT</td>
<td>Amaya Olaverri-Hérnández</td>
<td>Dr. Olaverri-Hérnández has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-10-04</td>
<td>Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multi-center trial</td>
<td>Dwight Oldham</td>
<td>Dr. Oldham has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-03-05</td>
<td>EGFR-activating and therapeutic resistance in HER2-positive breast cancer: Interim analysis of the multicenter, open label, phase II clinical trial</td>
<td>Christopher Oldmeadow</td>
<td>Ms. Oldmeadow has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-11-03</td>
<td>Incidence and severity of diarrhea with neratinib + intensive loperamide prophylaxis in patients (pts) with HER2+ early-stage breast cancer (EBC): Interim analysis from the multicenter, open label, phase II clinical trial</td>
<td>Elizabeth O'Leary</td>
<td>Ms. O'Leary has disclosed that she receives salary from Puma Biotechnology Inc.</td>
</tr>
<tr>
<td>P6-07-21</td>
<td>High-reduction of circulating tumour cells in HER2-negative locally advanced or metastatic breast cancer (LAMBC) patients treated with veliparib as third-line chemotherapy (OCELOT study)</td>
<td>Clara Olier Garate</td>
<td>Ms. Olier Garate has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-11-13</td>
<td>Experience in the ABC Medical Center of Mexico City 2010-2015 using scalp-cooling system (DigniCap) for prevention of alopecia induced by chemotherapy</td>
<td>Guillermo Oliveira</td>
<td>Dr. Oliveira has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT1-01-06</td>
<td>PIQHASSO: Open label, non-randomized, multicenter phase 1/2b study investigating safety and efficacy of PQR309 and eribulin combination in patients (pts) with locally advanced (LA) or metastatic HER2 (+) and triple-negative breast cancer (TNBC) (study PQR309-007)</td>
<td>Mafalda Oliveira</td>
<td>Dr. Oliveira has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT2-01-11</td>
<td>Phase II of POSEIDON: A phase IIb / randomized phase II trial of tamoxifen plus taselisib or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment</td>
<td>Mafalda Oliveira</td>
<td>Dr. Oliveira has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-09-09</td>
<td>Efficacy and gene expression results from SOLTI1007: REHERBILGIN phase II clinical trial in HER2-negative early breast cancer</td>
<td>Mafalda Oliveira</td>
<td>Dr. Oliveira has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-21-05</td>
<td>Neoadjuvant non-pegylated liposomal doxorubicin plus paclitaxel, trastuzumab and pertuzumab in patients with HER2+ breast cancer: Final results of the SOLTI OPTI-HER HEART study</td>
<td>Mafalda Oliveira</td>
<td>Dr. Oliveira has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-12-01</td>
<td>Phase II study of taselisib (GDC-0032) plus fulvestrant in HER2-negative, hormone receptor-positive advanced breast cancer: Analysis by PIK3CA and ESR1 mutation status from circulating tumor DNA</td>
<td>Mafalda Oliveira</td>
<td>Dr. Oliveira has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S3-03</td>
<td>PAM50 intrinsic subtype as a predictor of pathological complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2 positive breast cancer: First results of the PAMELA clinical trial</td>
<td>Mafalda Oliveira</td>
<td>Dr. Oliveira has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-03</td>
<td>Whole exome and transcriptome sequencing of resistant ER+ metastatic breast cancer</td>
<td>Nelly Oliver</td>
<td>Nelly Oliver has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-13-22</td>
<td>Should modified radical mastectomy be modified? A phase 1 study to evaluate infraradical mastectomy for invasive breast cancer</td>
<td>Fabrice Olié</td>
<td>Fabrice Olié has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-10-06</td>
<td>Hypofractionated nodal radiotherapy (RT) did not increase arm morbidity compared to conventional fractionated nodal RT</td>
<td>Ivo Olivotto</td>
<td>Mr. Olivotto has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-01-19</td>
<td>Sentinel: A way to avoid sentinel-node biopsy (SNB) in patients with a preoperative diagnosis of ductal cancer in situ (DCIS)</td>
<td>Helena Olsson</td>
<td>Ms. Olsson has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-01-19</td>
<td>Sentinel: A way to avoid sentinel-node biopsy (SNB) in patients with a preoperative diagnosis of ductal cancer in situ (DCIS)</td>
<td>Roger Olofsson-Bagge</td>
<td>Mr. Olofsson-Bagge has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
Comprehensive comparison of breast cancer molecular portraits by African and European ancestry in the cancer genome atlas

Molecular subtype-specific expression of long non-coding RNA regulates proliferation of basal-like breast cancer cells

Breast cancer risk prediction using a polygenic risk score in women of African ancestry: Findings from GWA5 in breast cancer in the African diaspora

Comparative analysis of the genomic landscape of breast cancers from women of African and European ancestry

A signature predictive of early vs. late recurrence after radiation treatment (RT) for breast cancer that may inform the biology of early, aggressive recurrences

Molecular subtype-specific expression of long noncoding RNA regulates proliferation of basal-like breast cancer cells

Race and age differences in PAM50 biomarker status in the Carolina breast cancer study

Mismatch repair deficiency induces endocrine therapy resistance in breast cancer

Comparative analysis of the genomic landscape of breast cancers from women of African and European ancestry

Increased glycolysis directly activates transcriptional coactivator SRECB-3 to promote aggressive metastatic breast cancer

Clinicopathological predictors for low risk recurrence distinguished by 21-gene recurrence score in estrogen receptor-positive invasive breast cancer patients

Modification and reversal of the aggressive behavior of triple negative breast cancer by caffeic acid phenethyl ester (CAPE)

Comparative analysis of the genomic landscape of breast cancers from women of African and European ancestry

Increased participation in research - breast cancer (Inspire-BrC)

Clinico-pathological relationships with Ki67 in POETIC (CRUK/07/015) - Critical lessons for assessing Ki67 for prognosis and as a pharmacodynamic marker

The impact of intrinsic subtypes and molecular features on aromatase inhibitor induced reduction of proliferation marker of Ki67 in primary ER+ breast cancer: A POETIC study

BRCA1/2 methylation status, silencing and treatment effect in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer

Evaluation of miracle mouthwash (MMW) plus hydrocortisone or prednisolone mouth rinses as prophylaxis for everolimus-associated stomatitis: Results of a randomized phase II study

Comparative performance of surveillance mammography and breast MRI in women with a history of breast cancer

On Behalf of the POETIC TRAULISTS has no relevant financial relationships to disclose.

On Behalf of the POETIC Trial Management Group and Investigators has no relevant financial relationships to disclose.

On Behalf of the POETIC TRAULISTS has no relevant financial relationships to disclose.

Dr. Olsha has no relevant financial relationships to disclose.

On Behalf of the TNT Trial Management Group and Investigators has no relevant financial relationships to disclose.

Dr. Ondreyco has no relevant financial relationships to disclose.

Dr. Ondreyco has no relevant financial relationships to disclose.

Dr. O' Malley has no relevant financial relationships to disclose.
A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer (TNBC)

Bert O'Neil

Dr. O'Neil has no relevant financial relationships to disclose.

A phase I study of RAD1901, an oral selective estrogen receptor degrader, for the treatment of ER-positive advanced breast cancer

Alison O'Neill

Ms. O'Neill has disclosed that she receives salary from and has ownership in Radius Health.

A phase I study of RAD1901, an oral selective estrogen receptor degrader, to determine changes in the 4F-PES uptake and tumor responses in ER-positive, HER2-negative, advanced breast cancer patients

Alison O'Neill

Ms. O'Neill has disclosed that she receives salary from and has ownership in Radius Health.

Identification of preclinical mechanisms driving acquired resistance to selective ERa degraders (SERDs), CDK4/6 inhibitors, or to combinations of both agents

Dr. Ong has no relevant financial relationships to disclose.

Multi-center phase III trial of ACL-1215 (bicalutamide) combined with nab-paclitaxel in unresectable or metastatic breast cancer

Makia Osaki

Dr. Osaki has no relevant financial relationships to disclose.

Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes (TILs) and residual cancer burden (RCB)

Naoyoshi Onda

Dr. Onda has no relevant financial relationships to disclose.

A phase I study of RAD1901, an oral selective estrogen receptor degrader, to determine changes in the 4F-PES uptake and tumor responses in ER-positive, HER2-negative, advanced breast cancer patients

Naoyoshi Onda

Naoyoshi Onda has no relevant financial relationships to disclose.

Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes (TILs) and residual cancer burden (RCB)

Naoyoshi Onda

Naoyoshi Onda has no relevant financial relationships to disclose.

Circulating tumor cell clusters-associated gene expression is a novel prognostic predictor in patients with breast cancer

Naoyoshi Onda

Naoyoshi Onda has no relevant financial relationships to disclose.

Predicting therapeutic effect by on tumor invasion lymphocytes (TILs) in endocrine therapy for stage IV breast cancer

Naoyoshi Onda

Naoyoshi Onda has no relevant financial relationships to disclose.

A phase 2 study of eribulin as early-line treatment for HER2-MBC: Evaluation of efficacy, toxicity, and patient-reported outcomes

Thomas Openshaw

Dr. Openshaw has no relevant financial relationships to disclose.

Predictors of breast density among Black and Hispanic women presenting for mammographic screening

Bridget Oppong

Dr. Oppong has no relevant financial relationships to disclose.

Factors predicting treatment outcomes of angiosarcoma of breast: A 25 year single institution experience

Mateusz Opprchal

Mateusz Opprchal has no relevant financial relationships to disclose.
Preclinical efficacy of the novel PIM2 kinase inhibitor, JP11646 in triple negative breast cancer models

Mateusz Opyrchal
Dr. Opyrchal has no relevant financial relationships to disclose.

Comprehensive genomic characterization of circulating tumor cells (CTCs) in metastatic breast cancer (MBC) shed light on the biology of blood-borne metastasis

Andrea Ordonez
Dr. Ordonez has no relevant financial relationships to disclose.

A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer

Ruth O'Regan
Dr. O'Regan has no relevant financial relationships to disclose.

Phase 2 trial of everolimus and/or trastuzumab in hormone refractory, hormone receptor (HR) positive, HER2-normal metastatic breast cancer (MBC)

Ruth O'Regan
Dr. O'Regan has disclosed she is a consultant for Novartis, BIND Biosciences, Johnson & Johnson, AstraZeneca, Pfizer, Celgene and Genentech. She also disclosed she has ownership in Roche, Genomic Health, BIND, Biosciences, Novartis, Celgene, and Genentech and receives other financial support from Novartis, Roche and Genomic Health.

Phase 3 study of lapalsetib + fulvestrant in postmenopausal women with HR+, HER2+, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment

Ruth O'Regan
Dr. O'Regan has disclosed that she has a contract with Novartis.

The impact of the 21 gene recurrence score (RS) on chemotherapy prescribing in estrogen receptor (ER) positive, lymph-node positive early stage breast cancer in Ireland

Seamus O'Reilly
Mr. O'Reilly has no relevant financial relationships to disclose.

Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC)

Keith Oxford
Dr. Oxford has disclosed that he is employed by Calithera.

Challenges faced across borders to open European academic multicentre projects: The ET-FES program part of the ERA-Net TRANSCAN JTC 2011

Simone Oriana
Dr. Oriana has no relevant financial relationships to disclose.

A novel subgroup of estrogen receptor positive breast cancer may benefit from super-enhancer guided patient selection for retinoic acid receptor α agonist treatment

David Orlando
Dr. Orlando has disclosed that he is an employee of and holder of shares and options for Syros Pharmaceuticals.

DNA methylation landscapes of breast cancer progression to brain metastasis: A pre-clinical study

Natalie Orr
Dr. Orr has no relevant financial relationships to disclose.

Implications of financial modeling in breast cancer clinical research from 1990 to 2010

Laura Ortega
Dr. Ortega has no relevant financial relationships to disclose.

Dr. O’Reilly has no relevant financial relationships to disclose.

Mr. O’Reilly has disclosed that he has a professional relationship with the study sponsor Eisai Pharmaceuticals.

Mr. Orcajo has disclosed that he has a professional relationship with the study sponsor Eisai Pharmaceuticals.

Mr. O’Reilly has no relevant financial relationships to disclose.

Mr. Orcajo has disclosed that he has a professional relationship with the study sponsor Eisai Pharmaceuticals.

Dr. O'Regan has disclosed that she receives consulting fees from Genentech, Pfizer, and AstraZeneca. She also disclosed that she does contracted research for Genentech and Novartis. These relationships do not impact her ability to review presentations.

Mr. Orr has no relevant financial relationships to disclose.

Mr. O’Reilly has no relevant financial relationships to disclose.

Mr. O’Reilly has no relevant financial relationships to disclose.

Mr. O’Reilly has no relevant financial relationships to disclose.

Mr. Orcajo has disclosed that he has a professional relationship with the study sponsor Eisai Pharmaceuticals.

Mr. Orcajo has disclosed that he has a professional relationship with the study sponsor Eisai Pharmaceuticals.

Mr. Orcajo has disclosed that he has a professional relationship with the study sponsor Eisai Pharmaceuticals.

Mr. O’Reilly has no relevant financial relationships to disclose.

Ms. Ortega has no relevant financial relationships to disclose.

Ms. Ortega has no relevant financial relationships to disclose.

Mr. Orcajo has disclosed that he has a professional relationship with the study sponsor Eisai Pharmaceuticals.
Efficacy and gene expression results from SOLTI1007 NEOERIBULIN phase II clinical trial in HER2-negative early breast cancer
Vanesa Ortega
Dr. Ortega has no relevant financial relationships to disclose.

Assessing response in locally advanced breast cancer treated with neoadjuvant chemotherapy: Predictive and prognostic potential of volume-based metabolic variables with 18F-FDG PET/CT
Carolina Ortega-Ruipérez
Dr. Ortega-Ruipérez has no relevant financial relationships to disclose.

Prediction of underestimation associated with flat epithelial atypia, atypical ductal hyperplasia and atypical lobular hyperplasia by needle biopsies: Experience in an Argentine breast unit
Roberto Orti
Dr. Orti has no relevant financial relationships to disclose.

Non interventional study with netupitant/ palonosetron (NEPA) as CINV prophylaxis in highly or moderately emetogenic chemotherapy
Petra Ortner
Dr. Ortner has no relevant financial relationships to disclose.

A novel nomogram model can predict oncotype DX results thus reducing healthcare expenditures
Amila Orucevic
Dr. Orucevic has no relevant financial relationships to disclose.

Factors related to the prognosis of breast cancer patients after the development of brain metastases
Carolina Ortega Ruipérez
Dr. Ortega Ruipérez has no relevant financial relationships to disclose.

Tumor infiltrating lymphocytes in recurrent HER2+ and triple negative breast cancer: Prognostic value according to tumor phenotype
Carolina Ortega-Ruipérez
Dr. Ortega-Ruipérez has no relevant financial relationships to disclose.

Accelerated partial breast irradiation versus whole breast irradiation: Health-related quality of life analysis from a phase 3 trial
Lorenzo Orzalesi
Dr. Orzalesi has no relevant financial relationships to disclose.

A single-blind, randomized, placebo-controlled phase II study to evaluate the impact of oral (bandorone on bone mineral density in osteoporotic breast cancer patients receiving adjuvant aromatase inhibitors: Final results of the single-center BONADIUV trial
Lorenzo Orzalesi
Dr. Orzalesi has no relevant financial relationships to disclose.

FOXA1 induces vascular remodeling and reoxygenation in advanced breast cancer patients: A comparative study with bevacizumab
Akihiko Osaki
Dr. Osaki has no relevant financial relationships to disclose.

A novel non-canonical Notch1-IKKα-mTORC2-AKT pathway maintains survival in triple negative breast cancer cells and cancer stem-like cells
Tomofumi Osako
Tomofumi Osako has no relevant financial relationships to disclose.

A novel BRD4 inhibitor enhances endocrine therapy efficacy and circumvents endocrine-resistance in estrogen receptor-positive breast cancer models
C. Osborne
Dr. Osborne has disclosed that he is a consultant for AstraZeneca, Roche and Perkin Elmer.

A novel BRD4 inhibitor enhances endocrine therapy efficacy and circumvents endocrine-resistance in estrogen receptor-positive breast cancer models
C. Osborne
Dr. Osborne has disclosed that he is a consultant for AstraZeneca, Roche and Perkin Elmer.
Discovery of molecular predictors of late breast cancer specific events (BCSE) in ER+, node+ breast cancer - new transcriptome expression whole gene analysis of the phase III adjuvant trial SWOG S8814

C. Kent Osborne

Dr. Osborne has disclosed that he is a consultant for AZ, Roche and Perkin Elmer. He has also disclosed that he receives grant support from Gilead Sciences and AZ.

Scalp cooling alopecia prevention trial (SCALP) for patients with early stage breast cancer

C. Kent Osborne

Dr. Osborne has disclosed that he receives royalties from Lippincott. He also disclosed receiving consulting fees from AstraZeneca and Genentech. These relationships do not impact his ability to present an unbiased presentation.

PD-L1 expression in triple negative breast cancer (TNBC) is associated with improved outcomes

Cynthia Osborne

Dr. Osborne has no relevant financial relationships to disclose.

Chemotherapy (CT) decision in patients (pts) with node-positive (N+), ER+, early breast cancer (IBCS) in the wake of new ASCO guideline - A different take on the evidence for the 21-gene recurrence score (RS) assay

Joyce O'Shaugnessy

Dr. O'Shaugnessy has no relevant financial relationships to disclose.

Evaluation of miracle mouthwash (MMW) plus hydrocortisone or prednisolone mouth rinses as prophylaxis for exemestan-associated stomatitis: Results of a randomised phase II study

Joyce O'Shaugnessy

Dr. O'Shaugnessy has disclosed that she is a consultant for Genentech.

First-line ribociclib plus letrozole in patients with de novo HR+, HER2- advanced breast cancer (ABC): A subgroup analysis of the MONALEESA-2 trial

Joyce O'Shaugnessy

Dr. O'Shaugnessy has disclosed that she is a consultant for Genentech.

Baseline (BL) characteristics, treatment (tx) patterns, and outcomes in patients with hormone receptor (HR)+ vs HR- HER2+ disease from the SystHERs registry

Joyce O'Shaugnessy

Dr. O'Shaugnessy has disclosed that she is a consultant for Genentech.

Treatment patterns and clinical outcomes in patients with hormone receptor (HR)+ HER2+ metastatic breast cancer and low vs high levels of HR positivity from the SystHERs Registry

Joyce O'Shaugnessy

Dr. O'Shaugnessy has disclosed that she is a consultant for Genentech.

Abemaciclib exposure-response relationship in patients with metastatic breast cancer in MONARCH 1

Joyce O'Shaugnessy

Dr. O'Shaugnessy has disclosed that she is employed by and has a contract with Eli Lilly and Company.

Efficacy results of a phase 1/2 study of glucocorticoid receptor (GR) antagonist mifepristone (MIFE) in combination with eribulin in GR-positive triple-negative breast cancer (TNBC)

Joyce O'Shaugnessy

Dr. O'Shaugnessy has disclosed that he is a consultant for AZ, Roche and Perkin Elmer. He has also disclosed receiving consulting fees from AstraZeneca and Genentech. These relationships do not impact his ability to present an unbiased presentation.

Nab-paclitaxel + carboplatin or gemcitabine vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomised phase 2 portion of the tnAcity trial

Joyce O'Shaugnessy

Dr. O'Shaugnessy has disclosed that he is a consultant for AZ, Roche and Perkin Elmer. He has also disclosed receiving consulting fees from AstraZeneca and Genentech. These relationships do not impact his ability to present an unbiased presentation.
P2-04-13 Difference of immune microenvironment between primary and recurrent tumours in breast cancer patients
Risa Oshitanai
Dr. Oshitanai has no relevant financial relationships to disclose.

P3-13-11 Utility of Ligasure™ vessel-sealing device in axillary dissection for breast cancer surgery: A randomized single center study
Risa Oshitanai
Dr. Oshitanai has no relevant financial relationships to disclose.

P1-02-01 Circulating tumor DNA analysis to predict relapse and overall survival in early breast cancer - Longer follow-up of a proof-of-principle study
Peter Osin
Dr. Osin has no relevant financial relationships to disclose.

P5-16-20 Impact of "immunohistochemistry-based molecular subtype" on chemo-sensitivity and survival in Hispanic breast cancer patients following neoadjuvant chemotherapy (NAC)
Carlos Osia
Dr. Osia has no relevant financial relationships to disclose.

P2-10-05 Impact of PI3KCA mutations on tumor proliferation rates and quality of life with 3 days of preoperative tamsulosin
Emily Ostrander
Ms. Ostrander has no relevant financial relationships to disclose.

P3-08-02 Utility of LigaSure™ vessel-sealing device in axillary dissection for breast cancer surgery: A randomized single center study
Risa Oshitanai
Dr. Oshitanai has no relevant financial relationships to disclose.

P6-12-06 Nonsteroidal, tissue selective androgen receptor modulator (SARM), enobosarm, reduces growth of androgen receptor-positive breast cancer in patient-derived preclinical model
Roy Oswaks
Dr. Oswaks has no relevant financial relationships to disclose.

P4-02-04 Does fat transfer increase the risk of breast cancer recurrence? A meta-analysis involving 2382 patients
Medhat Oteifa
Medhat Oteifa has no relevant financial relationships to disclose.

P6-09-10 Results of multigene assay (MammaPrint®) and molecular subtyping (BluePrint®) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIME decision impact study
Florian Otto
Prof. Otto has no relevant financial relationships to disclose.

P3-10-02 Increasing participation in research - breast cancer (Inspire-BrC)
Yvonne Ottaviano
Ms. Ottaviano has no relevant financial relationships to disclose.

P4-20-03 Survivorship care planning is associated with breast cancer survivors’ reported quality and coordination of care
Julie Otte
Ms. Otte has no relevant financial relationships to disclose.

P5-16-04 Increasing participation in research - breast cancer (Inspire-BrC)
Yvonne Ottaviano
Ms. Ottaviano has no relevant financial relationships to disclose.

P6-09-10 Results of multigene assay (MammaPrint®) and molecular subtyping (BluePrint®) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIME decision impact study
Burkhard Otrema
Dr. Otrema has no relevant financial relationships to disclose.

P2-01-31 Validation of novel diagnostic kits using the semi-dry dot-blot method for detecting metastatic lymph nodes in breast cancer; distinguishing micrometastases and macrometastases
Ryota Otsubo
Dr. Otsubo has no relevant financial relationships to disclose.

P3-10-02 Increasing participation in research - breast cancer (Inspire-BrC)
Fusioe Ottaviano
Ms. Ottaviano has no relevant financial relationships to disclose.

P5-16-04 Increasing participation in research - breast cancer (Inspire-BrC)
Fusioe Ottaviano
Ms. Ottaviano has no relevant financial relationships to disclose.

P4-20-03 Survivorship care planning is associated with breast cancer survivors’ reported quality and coordination of care
Allison Ottenbacher
Dr. Ottenbacher has no relevant financial relationships to disclose.

P6-09-10 Results of multigene assay (MammaPrint®) and molecular subtyping (BluePrint®) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIME decision impact study
Kristen Otte
Ms. Otte has no relevant financial relationships to disclose.

P6-09-10 Results of multigene assay (MammaPrint®) and molecular subtyping (BluePrint®) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIME decision impact study
Penelope Ottewell
Ms. Ottewell has no relevant financial relationships to disclose.

P6-06-07 The complete spectrum of ESR1 mutations from 7590 breast cancer tumor samples
Geoff Otto
Mr. Otto has disclosed that he is an employee of Foundation Medicine Inc.

P3-07-14 Targeting ERR-α regulated lactate metabolism eliminates drug-resistant breast cancer cells
Allal Ouhtit
Dr. Ouhtit has no relevant financial relationships to disclose.

P4-05-04 Survivorship care planning is associated with breast cancer survivors’ reported quality and coordination of care
Natalia Ottaviano
Ms. Ottaviano has no relevant financial relationships to disclose.

P6-09-10 Results of multigene assay (MammaPrint®) and molecular subtyping (BluePrint®) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIME decision impact study
Florian Otto
Prof. Otto has no relevant financial relationships to disclose.

P5-07-06 The complete spectrum of ESR1 mutations from 7590 breast cancer tumor samples
Geoff Otto
Mr. Otto has disclosed that he is an employee of Foundation Medicine Inc.

P6-07-06 Radioactive seed localization versus wire guided localization of nonpalpable invasive and in situ breast cancer: A breast multicenter randomized controlled trial
Peter Ouellet
Dr. Ouellet has no relevant financial relationships to disclose.

P6-01-21 Novel CD246-downstream signaling pathway involved in breast tumor suppression
Allal Ouhtit
Dr. Ouhtit has no relevant financial relationships to disclose.
P4-19-07  Fertility concerns in young women after diagnosis of breast cancer: Experience of a breast cancer unit in México

Andrea Ovando-Trujillo

Dr. Ovando-Trujillo has no relevant financial relationships to disclose.

OT1-01-07  Pilot study of circumzen-89 bevacizumab-positive emission tomography for imaging angiogenesis in patients with inflammatory breast carcinoma receiving neoadjuvant chemotherapy

Beth Overmoyer

Dr. Overmoyer has no relevant financial relationships to disclose.

OT2-02-02  Phase I study of the AAC 1/2 inhibitor rucozolim with weekly paclitaxel for the treatment of HER2 negative metastatic breast cancer (MBC)

Beth Overmoyer

Dr. Overmoyer has no relevant financial relationships to disclose.

P6-12-12  BRC/A2: mutational status, silencing and treatment effect in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRC/A2 breast cancer (C4JUE13012)

Julie Owen

Ms. Owen has no relevant financial relationships to disclose.

P6-11-05  Phase 2 study of CB-839, a small molecule inhibitor of glutaminase (GLS), in combination with paclitaxel (Pac) in patients (its) with triple negative breast cancer (TNBC)

Taofeek Owonikoko

Dr. Owonikoko has no relevant financial relationships to disclose.

P3-09-05  Clinical outcome of patients with advanced triple negative breast cancer with germline and somatic variants in homologous recombination gene

Amit Oza

Amit Oza has disclosed that he is a consultant for Amgen, Verastem, Clovis Oncology and Immunovaccine. He has also disclosed that he is a speaker for WebRx and has contracts with Roche, Merck and AstraZeneca.

P3-10-14  Breast cancer provider delay after the 2011 triple disaster in Fukushima, Japan

Akitoko Ozaki

Dr. Ozaki has no relevant financial relationships to disclose.

P6-16-01  The importance of loco-regional tumor burden and surgery on survival in patients with de novo stage IV breast cancer: post hoc analyses of protocol MF07-01

Cihangir Ozaslan

Dr. Ozaslan has no relevant financial relationships to disclose.

P6-16-01  The importance of loco-regional tumor burden and surgery on survival in patients with de novo stage IV breast cancer: post hoc analyses of protocol MF07-01

Serdar Ozbas

Dr. Ozbas has no relevant financial relationships to disclose.

P2-11-08  Prognostic factors in breast cancer (BC) associated with the development of brain metastases (BM): A retrospective study of 726 pts

Mustafa Ogurcoglu

Mustafa Ogurcoglu has no relevant financial relationships to disclose.

P6-07-24  miR-19b-3p and miR-4687-5p as novel circulating miRNAs as potential prognostic biomarkers in breast cancer

Derya Ozturk

Derya Ozturk has no relevant financial relationships to disclose.

P6-09-52  Prognostic factors in breast cancer (BC) associated with the development of brain metastases (BM): A retrospective study of 726 pts

Mahmut Ozturk

Dr. Ozturk has no relevant financial relationships to disclose.

P6-09-52  Prognostic factors in breast cancer (BC) associated with the development of brain metastases (BM): A retrospective study of 726 pts

Olman Ozsoy

Dr. Ozsoy has no relevant financial relationships to disclose.

P6-07-24  miR-19b-3p and miR-4687-5p as novel circulating miRNAs as potential prognostic biomarkers in breast cancer

Nerim Ozturk

Dr. Ozturk has no relevant financial relationships to disclose.

P6-09-52  Prognostic factors in breast cancer (BC) associated with the development of brain metastases (BM): A retrospective study of 726 pts

Senan Ozturk

Dr. Ozturk has no relevant financial relationships to disclose.

P6-16-01  The importance of loco-regional tumor burden and surgery on survival in patients with de novo stage IV breast cancer: post hoc analyses of protocol MF07-01

Vahit Ozmen

Dr. Ozmen has no relevant financial relationships to disclose.

P6-09-52  Prognostic factors in breast cancer (BC) associated with the development of brain metastases (BM): A retrospective study of 726 pts

Mahmut Ozturk

Dr. Ozturk has no relevant financial relationships to disclose.

P6-09-52  Prognostic factors in breast cancer (BC) associated with the development of brain metastases (BM): A retrospective study of 726 pts

Olman Ozsoy

Dr. Ozsoy has no relevant financial relationships to disclose.

P6-07-24  miR-19b-3p and miR-4687-5p as novel circulating miRNAs as potential prognostic biomarkers in breast cancer

Nerim Ozturk

Dr. Ozturk has no relevant financial relationships to disclose.

P4-06-06  Consistent dosing time dependent tolerability of everolimus (EVE) in a pilot study in women with metastatic breast cancer (MBC) and in a mouse chronopharmacology investigation

Osen Orhan

Dr. Orhan has no relevant financial relationships to disclose.

OT3-08-01  An randomized study of personalized music therapy for patients with early-stage breast cancer receiving chemotherapy

Harita Pabbathi

Dr. Pabbathi has no relevant financial relationships to disclose.

OT3-02-04  A randomized controlled trial comparing acupuncture versus usual care for the treatment of aromatase inhibitor-induced arthralgia (AIA) in women with early-stage breast cancer

Sittha Pabbathi

Dr. Pabbathi has no relevant financial relationships to disclose.
Three-monthly dynamic evaluation of CEA and CA15-3 (followed by 18-FDG PET) vs usual practice in the follow-up of early breast cancer (BC) patients (pts): A prospective randomized trial (KRONOS-patient-oriented new surveillance study, Italy)

Maria Pagliaro
Ms. Pagliaro has no relevant financial relationships to disclose.

Early detection of development of a pre-metastatic niche in lungs in response to primary breast tumor using Raman spectroscopy

Santosh Paidi
Dr. Paidi has no relevant financial relationships to disclose.

Deciding the genetic basis of mammary mineralization and their putative role in promotion of distant metastases

Santosh Paidi
Dr. Paidi has no relevant financial relationships to disclose.

Oncologic outcomes of immediate breast reconstruction after neoadjuvant chemotherapy in breast cancer patients: A matched case control study

Pyan-June Paik
Dr. Paik has no relevant financial relationships to disclose.

Conditional disease-free survival among patients with breast cancer

Pyan-June Paik
Dr. Paik has no relevant financial relationships to disclose.

NRG Oncology/NSABP B-51/RTOG 1304: A phase III superiority clinical trial designed to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNR to breast RT post-breast conserving surgery (BCS) will reduce invasive cancer events in patients (pts) with positive axillary (Ax) nodes and convert to ypT0 after neoadjuvant chemotherapy (NC)

Soonmyung Paik
Soonmyung Paik has no relevant financial relationships to disclose.

A randomized, double-blinded, placebo-controlled clinical trial to evaluate extended adjuvant endocrine therapy (5 years of letrozole) in postmenopausal women with hormone receptor-positive breast cancer who have completed previous adjuvant endocrine therapy: Initial results of NRG oncology/NSABP B-42

Soonmyung Paik
Soonmyung Paik has no relevant financial relationships to disclose.

A phase III trial evaluating pCR in patients with HR-, HER2positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- aromatase deprivation: NRG oncology/NSABP B-52

Soonmyung Paik
Soonmyung Paik has no relevant financial relationships to disclose.

Sentinel node detection after neoadjuvant chemotherapy in patient without previous axillary node involvement (GARNEA 2 trial): Follow-up of a prospective multi-institutional cohort

Nicolas Paillercher
Dr. Paillercher has no relevant financial relationships to disclose.

The metastatic breast cancer project: Translational genomics through direct patient engagement

Carrie Painter
Dr. Painter has no relevant financial relationships to disclose.

Claudin-4 expression is associated with disease-free survival in breast carcinoma in situ: Mean follow-up of 8.2 years

Geiselmere Faixa
Dr. Faixa has no relevant financial relationships to disclose.

Phase 2 trial of everolimus and/or trastuzumab in hormone refractory, hormone receptor (HR)-positive, HER2-normal metastatic breast cancer (MBC)

Suchita Pakkala
Dr. Pakkala has no relevant financial relationships to disclose.

Discovering drug targets for aggressive breast cancer with TP53 missense mutations by a genome-wide screen

Anasuya Pal
Ms Pal has no relevant financial relationships to disclose.

RANK ligand as a target for breast cancer prevention in BRCA1 mutation carriers

Bhupinder Pal
Bhupinder Pal has no relevant financial relationships to disclosed.

Fertility concerns in young women after diagnosis of breast cancer: Experience of a breast cancer unit in México

Fabiola Palacios-Gutierrez
Ms. Palacios-Gutierrez has no relevant financial relationships to disclose.

Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA2 or BRCA2 mutations and metastatic breast cancer: A randomized, phase 2 study

Markéta Palácová
Ms. Palácová has no relevant financial relationships to disclose.

Fertility concerns in young women after diagnosis of breast cancer: Experience of a breast cancer unit in México

Fabiola Palacios-Gutierrez
Ms. Palacios-Gutierrez has no relevant financial relationships to disclose.
P3-14-01
International validation of the EORTC patient-reported outcome measure (PROM) in breast reconstruction (BRR): The EORTC QLQ-BRECON23 evaluating the psychometric properties and clinical effectiveness
Marie Panouilleres
Dr. Panouilleres has no relevant financial relationships to disclose.

P2-03-01
An international multicenter study to evaluate reproducibility of automated scoring methods for assessment of Ki67 in breast cancer
Linon Pantanowitz
Linon Pantanowitz has no relevant financial relationships to disclose.

OT1-03-04
The DETECT V-study - Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo- or endocrine therapy in patients with HER2-positive and hormone-receptor positive metastatic breast cancer
Klaus Pantel
Dr. Pantel has no relevant financial relationships to disclose.

OT3-04-02
DETECT III and IV - Individualized CTC-based therapy of metastatic breast cancer
Klaus Pantel
Dr. Pantel has no relevant financial relationships to disclose.

P2-01-03
Dynamics of circulating tumor cells during the course of chemotherapy and prognostic relevance across molecular subtypes in high-risk early breast cancer patients - Results from the adjacent SUCCESS A trial
Klaus Pantel
Dr. Pantel has no relevant financial relationships to disclose.

P3-05-02
Active surveillance with a combination of tumor marker CA27.29 and detection of circulating tumor cells two year after primary diagnosis strongly predicts subsequent progression
Klaus Pantel
Dr. Pantel has no relevant financial relationships to disclose.

S3-01
IMENEO: International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEOadjuvant chemotherapy
Klaus Pantel
Dr. Pantel has no relevant financial relationships with commercial interests to disclose.

P1-01-03
Dynamics of circulating tumor cells during the course of chemotherapy and prognostic relevance across molecular subtypes in high-risk early breast cancer patients - Results from the adjacent SUCCESS A trial
Contanza Paoletti
Dr. Paoletti has no relevant financial relationships to disclose.

P2-11-02
A longitudinal look at toxicity management within a platform trial: Lessons from the I-SPY 2 TRIAL
Melissa Paoloni
Dr. Paoloni has no relevant financial relationships to disclose.

P3-05-02
Quantitative ERα measurements in TNBC from the I-SPY 2 TRIAL correlate with HER2-EGFR co-activation and heterodimerization
Melissa Paoloni
Dr. Paoloni has no relevant financial relationships to disclose.

S2-06
DNA repair deficiency biomarkers and MammaPrint high1/(ultra)high2 risk as predictors of veliparib/carboplatin response: Results from the neoadjuvant I-SPY 2 trial for high risk breast cancer
Melissa Paoloni
Dr. Paoloni has no relevant financial relationships to disclose.

P2-01-02
The predictive value of sentinel node biopsy (SNB) in early breast cancer after neo-adjuvant chemotherapy (NACT): A prospective study
Konstantinos Papadimitriou
Dr. Papadimitriou has no relevant financial relationships to disclose.

P4-21-15
Trastuzumab IV versus SC: A time, motion and cost assessment in a lean operating day care oncology unit
Konstantinos Papadimitriou
Dr. Papadimitriou has no relevant financial relationships to disclose.

P3-04-26
Establishment and characterization of ST1442C: an ESR1-mutant ER+ breast cancer cell line and xenograft from a patient with acquired resistance to endocrine therapy
Kyriakos Papadopoulos
Kyriakos Papadopoulos has no relevant financial relationships to disclose.
Comprehensive genomic characterization of circulating tumor cells (CTCs) in metastatic breast cancer (MBC) sheds light on the biology of blood-borne metastasis

Quantitative ETA measurements in TNBC from the I-SPY 2 TRIAL correlate with HER2-ESPR co-activation and heterodimerization

MISCNEC: International MISCNEC analysis of circulating tumor cell detection in early breast cancer patients treated by NED/adjacent chemotherapy

Circulating cell-free DNA (CFD) measured by a simple fluorescent assay to predict relapse in triple negative breast cancer patients receiving neoadjuvant chemotherapy: A biomarker substudy of prospective observational study (NCT02001519, NCT02001506)

Changes of tumor-infiltrating lymphocytes and programmed death-1 positivity after neoadjuvant chemotherapy in patients with locally advanced breast cancer

The PROCEED trial NSCLG BR11-01 phase III multicenter randomized open-label study of gemcitabine plus capcitabine versus capcitabine in patients previously treated with anthracycline and taxane for HER2 negative metastatic breast cancer

Up-regulation of SPARC is associated with breast tumor progression and epithelial SPARC expression is correlated with poor survival and MMP-2 expression in patients with breast carcinoma

Impact of resection in clinical trials on survival of metastatic breast cancer patients

A targetable EGFR-driven tumor-initiating program in breast cancer

Mechanisms of EDB-T cell immunosuppression in triple negative breast cancer

A randomized trial of 15 fraction vs 25 fraction pencil beam scanning proton radiotherapy after mastectomy in patients requiring regional nodal irradiation

Delineation of internal mammary nodal target volumes in breast cancer radiotherapy

Serum 25-hydroxyvitamin D levels and oncologic outcomes of breast cancer patients receiving neoadjuvant chemotherapy

Clinical application of multimodal fluorescent-radiolabeled system in advanced breast cancer patients with neoadjuvant therapy; interim analysis for 65 patients

Risk factors affecting post-operative complication after immediate reconstruction with implant for operable breast cancer patients

The EGR1 expression is positively associated with interferon signaling molecules in triple negative breast cancer

Protein tyrosine kinase 6 (PTK6) promotes survival of endocrine therapy-resistant ER+ breast cancer cells
Phase Ib study evaluating the safety and clinical activity of lumretuzumab combined with pertuzumab and paclitaxel in HER2-low metastatic breast cancer

Tjoung-Won Park-Simon
Dr. Park-Simon has no relevant financial relationships to disclose.

Self-evaluation of duration of adjacent chemotherapy side effects in breast cancer patients: A prospective study

Silvia Parola
Ms. Parola has no relevant financial relationships to disclose.

Integrated transcriptional analysis of the triple negative 'proliferation paradox': High proliferation, chemosensitivity, and poor prognosis

Ann Partridge
Dr. Partridge has no relevant financial relationships to disclose.

Young women with breast cancer in Mexico: A report of the pilot phase of the "Mujer Joven y Fuerte" prospective cohort

Ann Partridge
Dr. Partridge has no relevant financial relationships to disclose.

Phase I study of the JAK 1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2 negative metastatic breast cancer (MBC)

Ann Partridge
Dr. Partridge has no relevant financial relationships to disclose.

Acupuncture for chemotherapy-induced peripheral neuropathy in breast cancer, preliminary results of a pilot randomized controlled trial

Ann Partridge
Dr. Partridge has no relevant financial relationships to disclose.
KEYNOTE-012: Long-lasting responses in a phase Ib study of pembrolizumab for metastatic triple-negative breast cancer (mTNBC)

Kumudu Pathiraja

Kumudu Pathiraja has disclosed that he receives salary from Merck.

P4-07-10

Epithelial mesenchymal transition associated with high mIR-221 and integrin β6 leads to poor prognosis in hormone receptor positive HER2 negative breast cancers

Shekhar Patil

Shekhar Patil has no relevant financial relationships to disclose.

P1-08-14

Breast carcinoma with 25-gene recurrence score lower than 18: Rate of distant metastases in a large series with clinical follow-up

Sujata Patil

Dr. Patil has no relevant financial relationships to disclose.

P2-08-05

Phase II trial of palbociclib in combination with fulvestrant for the treatment of estrogen receptor (ER)-positive, metastatic breast cancer (MBC)

Sujata Patil

Dr. Patil has no relevant financial relationships to disclose.

P3-13-07

Are there patients with T1-T2, node-negative breast cancer who are high-risk for locoregional recurrence?

Sujata Patil

Dr. Patil has no relevant financial relationships to disclose.

P2-08-08

A phase 1 study of RAD001, an oral selective estrogen receptor degrader, to determine changes in the 18F-FES uptake and tumor responses in ER-positive, HER2-negative, advanced breast cancer patients

Abhay Patki

Abhay Patki has disclosed that he receives salary from and has ownership in Radius Health.

P3-04-36

Establishment and characterization of ST941/C, an ESR1-mutant ER+ breast cancer cell line and xenograft from a patient with acquired resistance to endocrine therapy

Ambra Patnaik

Ms. Patnaik has no relevant financial relationships to disclose.

P3-14-13

Total mastectomy and immediate breast reconstruction for breast cancer: A ten-year Canadian single institution experience

Erica Patoszakai

Dr. Patoszakai has no relevant financial relationships to disclose.

P4-04-25

Obesity-induced EMT in luminal A breast cancer cells

Riddhi Patodia

Riddhi Patodia has no relevant financial relationships to disclose.

P3-16-02

ENDEAR: A randomized international phase 3 study comparing the efficacy and safety of enzalutamide in combination with paclitaxel chemotherapy or as monotherapy vs placebo in patients with advanced triple negative breast cancer

Virginia Patton

Ms. Patton has disclosed that she is a Medivation employee.

P4-22-08

A single-arm phase 2 study to assess clinical activity, efficacy and safety of enzalutamide with trastuzumab in HER2+ AR+ metastatic or locally advanced breast cancer

Virginia Patton

Ms. Patton has disclosed that she is a Medivation employee.

P5-16-02

Bone-degradation receptor blockers (BD) and increased progression free survival (PFS) in patients with advanced triple negative breast cancer (TNBC): A retrospective analysis of the ROSE/THOR312 study

Ian Patterson

Dr. Patterson has no relevant financial relationships to disclose.

P3-13-04

Use of an absorbable implant to mark the lumpectomy cavity: Initial report of 300 patients in a multi-center registry database

Brandon Patton

Mr. Patton has no relevant financial relationships to disclose.

P3-10-08

Socio-demographic predictors for delay of treatment among a racially diverse, urban breast cancer population

Gregory Patts

Mr. Patts has no relevant financial relationships to disclose.

P2-02-05

Comparison of non-breast and ovarian cancer phenotypes of BRCA1/2 mutation carriers across multi-gene panels

Tripti Paulyal

Tripti Paulyal has disclosed that he receives salary from Ambry Genetics.

P5-07-05

BRCA1/BRCA2 overexpression promotes and maintains the tumor initiating phenotype in TNBC cells: Implications for breast cancer early lesions

Abhin Paul

Dr. Paul has no relevant financial relationships to disclose.

P4-16-01

Evaluation of miracle mouthwash (MMW) plus hydrocortisone or prednisolone mouth rinses as prophylaxis for everolimus-associated stomatitis: Results of a randomized phase II study

Dheendh Paul

Dr. Paul has no relevant financial relationships to disclose.

P6-01-14

Dissection of the ABL interactor 1 signaling in metastatic breast cancer cells

Lockman Paul

Mr. Paul has no relevant financial relationships to disclose.
P5-16-12  Pertuzumab and trastuzumab in combination with weekly paclitaxel delivers high pCR rates with favourable toxicity profile in neo-adjuvant treatment of Her-2 positive breast cancer  Rob Paul  Dr. Paul has no relevant financial relationships to disclose.

P5-15-12  Real-life activity of oral vinorelbine in metastatic breast cancer patients in the Unicancer ESME database  Augereau Paule  Dr. Paule has no relevant financial relationships to disclose.

P4-17-04  Results of the continuing education program in oncoplasty and breast reconstruction of the Brazilian Society of Mastology at Braço do Norte Hospital in Goiânia  Yudi Pawitan  Dr. Pawitan has no relevant financial relationships to disclose.

P4-17-03  Global Cancer Institute online tumor boards to improve global patterns of clinical practice for breast cancer  Eduardo Paulino  Dr. Paulino has no relevant financial relationships to disclose.

P2-08-06  Molecular model for assessment of the individual breast cancer risk  Richard Paes  Mr. Paes has no relevant financial relationships to disclose.

S5-02  Scalp cooling alopecia prevention trial (SCALP) for patients with early stage breast cancer  Richard Paxman  Mr. Paxman has no relevant financial relationships to disclose.

P4-21-35  Phase II trial of pertuzumab, trastuzumab, and nab-paclitaxel in patients (pts) with HER2 overexpressing (HER2+) locally advanced or inflammatory breast cancer (LABC) or untreated stage IV metastatic breast cancer (MBC)  Benjamin Paz  Dr. Paz has no relevant financial relationships to disclose.

P6-07-21  High reduction of circulating tumour cells in HER2-negative locally advanced or metastatic breast cancer (LABC) patients treated with eribulin as third line chemotherapy (ONsite study)  Luis Paz-Ares Rodriguez  Dr. Paz-Ares Rodriguez has no relevant financial relationships to disclose.

P6-10-04  Determining the optimal vaccination strategy using a combination of the folate binding protein (FBP) peptide vaccine (E39+GM-CSF) and an attenuated version (E39) to maximize the immunologic response in breast cancer patients  Dominic Pearce  Dr. Pearce has no relevant financial relationships to disclose.

P6-09-27  The SAI2cN test significantly predicts response and survival in both pre and post-menopausal women with ER-positive breast cancers  Dominic Pearce  Mr. Pearce has no relevant financial relationships to disclose.

S4-05  Expression of the DDR2 oncogene promotes M2 polarization and iron recycling in tumor-associated macrophages  Nicholas Peace  Mr. Peace has no relevant financial relationships to disclose.

P6-08-10  Expression of the DDR2 oncogene promotes M2 polarization and iron recycling in tumor-associated macrophages  Nicholas Peace  Mr. Peace has no relevant financial relationships to disclose.

P6-12-09  Pan-HER, an antibody mixture with antitumor activity against drug-resistant HER2-overexpressing breast cancers with high ERBB ligand expression  Mikkel Pedersen  Mikkel Pedersen has disclosed that he receives salary, has a patent, has a contract and is a Symphogen employee.

P5-14-02  Triple negative breast cancer – Adjuvant chemotherapy use and survival outcomes in Stage IIB disease  Prakash Peddi  Dr. Peddi has no relevant financial relationships to disclose.

P5-13-09  Upregulated purinergic signaling enhances cell proliferation in human and murine breast carcinomas  Helene Pedersen  Dr. Pedersen has no relevant financial relationships to disclose.

P5-11-07  Proliferation and p21 refine risk of relapse in residual disease after HER2-directed therapies  Jose Pedrini  Mr. Pedrini has no relevant financial relationships to disclose.
First results from the multicenter phase III DATA study comparing 3 versus 6 years of anastrozole after 2-3 years of tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer

S1-03

Petronella Peer

Ms. Peer has no relevant financial relationships to disclose.

Evaluation of subcutaneity in the CTC and DTC compartment of patients with metastatic breast cancer using low pass whole genome and AmpliSeq panel sequencing

P1-06-01

Marc Peeters

Dr. Peeters has no relevant financial relationships to disclose.

Evaluation of HER2 expression and amplification on CTCs using DEP仪ry analysis and sorting followed by FISH

P1-06-10

Marc Peeters

Dr. Peeters has no relevant financial relationships to disclose.

Trastuzumab IV versus SC: A time, motion and cost assessment in a lean operating day care oncology unit

P1-10-10

Marc Peeters

Prof. Peeters has no relevant financial relationships to disclose.

Exome sequencing of circulating tumor cells in metastatic breast cancer

P1-01-10

Dieter Peeters

Dr. Peeters has no relevant financial relationships to disclose.

Evaluation of subcutaneity in the CTC and DTC compartment of patients with metastatic breast cancer using low pass whole genome and AmpliSeq panel sequencing

P2-07-05

Pream Peethambaram

Dr. Peethambaram has no relevant financial relationships to disclose.

Oncology & RTOG 1119: Phase II randomized study of whole brain radiotherapy with concurrent lapatinib in patients with brain met from HER2-positive breast cancer — A collaborative study of RTOG & KROG (NCT01622868)

OT1-04-02

David Peereboom

Dr. Perreboom has no relevant financial relationships to disclose.

Invasive breast cancer: A phase 1, randomized study of margariteximab plus chemotherapy vs trastuzumab plus chemotherapy in the treatment of patients with HER2+ metastatic breast cancer: A national cancer data base study

OT1-02-07

Mark Pegram

Dr. Pegram has disclosed that he receives salary from DAVAOncology and receives other financial support from Genentech, Pfizer, Novartis and AstraZeneca. He has also disclosed that he is a consultant for Genentech, Pfizer, Novartis and AstraZeneca.

NRG oncology/RTOG 1119: Phase II randomized study of whole brain radiotherapy with concurrent lapatinib in patients with brain met from HER2-positive breast cancer — A collaborative study of RTOG & KROG (NCT01622868)

OT1-04-02

Dr. Perreboom has no relevant financial relationships to disclose.

A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB)

OT1-02-09

Mark Pegram

Dr. Pegram has no relevant financial relationships to disclose.

Characterization of HER2-positive breast cancer (BC) cells selected for tolerance to trastuzumab-induced antibody-dependent cell-mediated cytotoxicity (ADCC)

P3-03-06

Mark Pegram

Dr. Pegram has no relevant financial relationships to disclose.

Randomized phase 3 study of a novel, long-acting G-CSF (eflapegrastim) versus pegfilgrastim in the management of chemotherapy-induced neutropenia in early-stage breast cancer patients receiving doxorubicin and cyclophosphamide (TC) (ADVANCE study)

OT1-01-13

Julio Peixoto

Dr. Peixoto has no relevant financial relationships to disclose.

Modulation of indoleamine 2, 3-dioxygenase (IDO1) expression in breast cancer cells by activated CD8+ T cells is controlled by DNA promoter methylation

P6-02-08

Lirong Pei

Lirong Pei has no relevant financial relationships to disclose.

Characterization of HER2-pos breast cancer (BC) cells selected for tolerance to trastuzumab-induced antibody-dependent cell-mediated cytotoxicity (ADCC)

P3-03-06

Mark Pegram

Dr. Pegram has no relevant financial relationships to disclose.

PAM50 intrinsic subtype as a predictor of pathological complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2-positive breast cancer: First results of the PAMELA clinical trial

S3-03

Alexandra Peláez

Dr. Peláez has no relevant financial relationships to disclose.

The Y537S ESR1 mutation is a dominant driver of distant ER-positive breast cancer metastasis

S3-03

Sasha Pejerrey

Sasha Pejerrey has no relevant financial relationships to disclose.

The Y537S ESR1 mutation is a dominant driver of distant ER-positive breast cancer metastasis

S3-03

Sasha Pejerrey

Sasha Pejerrey has no relevant financial relationships to disclose.

PAM50 intrinsic subtype as a predictor of pathological complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2-positive breast cancer: First results of the PAMELA clinical trial

S3-03

Alexandra Peláez

Dr. Peláez has no relevant financial relationships to disclose.

Tumor infiltrating macrophages, lymphocytes and matrix metalloproteinase 9 (MMP-9) expression in breast cancer

P4-04-03

Tatjana Pelekanou

Dr. Pelekanou has no relevant financial relationships to disclose.

Immunomodulation effects of metronomic oral Vinorelbine (mVRL) with or without capecitabine (CAPE), on Treg levels in advanced breast cancer (ABC) patients (pts). Preliminary results of the VICTOR-5 study

P2-04-05

Davide Pelizzoni

Dr. Pelizzoni has no relevant financial relationships to disclose.
Phase I study of low dose oral cyclophosphamide (C) plus the poly-ADP-ribose polymerase (PARP) inhibitor veliparib (V) in women with HER2/neu-negative inoperable locally advanced/metastatic breast cancer (MBC): NCI P8853

Christine Pellegrino
Dr. Pellegrino has no relevant financial relationships to disclose.

DCIS biological risk profile predicts risk of recurrence after breast conserving surgery in a Kaiser Permanente NW population

Jamie Pelican
Dr. Pelican has no relevant financial relationships to disclose.

Determining the prognostic role of early and end-of-neoadjuvant chemotherapy 18F-FDG PET/CT in patients with locally advanced breast cancer

Laura Pena
Dr. Pena has no relevant financial relationships to disclose.

Chemotherapy (CT) decision in patients (pts) with node-positive (N+), ER+, early breast cancer (IBC) in the wake of new ASCO guideline - A different take on the evidence for the 21-gene recurrence score (RS) assay

Francesco José Pena Pardo
Dr. Peanut-Llorca has disclosed that he has contracts with Genomic Health, Nanostring and Myriad.

Evaluation of intra-tumor heterogeneity, test reproducibility and their impact in breast cancer samples assessed by Prosigna™ - Results from a decision impact prospective study and a matched case-control study

Frederique Penault-Llorca
Dr. Penault-Llorca has disclosed that he is a consultant for and has contacts with Nanostring, Genomic Health and Myriad.

Prognostic and predictive values of high endothelial venules (HEV) and tumor infiltrating CD8+ lymphocytes (CD8) in tumors of patients included in the adjuvant PACS04 trial: HEV is predictive of outcome for HER2+ tumors exposed to trastuzumab

Frederique Penault-Llorca
Dr. Penault-Llorca has no relevant financial relationships to disclose.

Committee Member
Frederique Penault-Llorca
Dr. Penault-Llorca has disclosed that he receives consulting fees from Roche, MSD, Pfizer and AstraZeneca. These relationships do not impact his ability to review presentations.

A prospective multicenter non-randomized trial evaluating the effect of EndoPredict® (EPclin®) clinico-genomic test on treatment decision making among patients with intermediate clinical risk

Frederique Penault-Llorca
Dr. Penault-Llorca has disclosed that she is a consultant for and has contacts with Myriad Genetics, Nanostring and Genomic Health.

A novel non-canonical Notch1-IKKα-mTORC2-AKT pathway maintains survival in triple negative breast cancer cells and cancer stem-like cells

Yin Peng
Dr. Peng has no relevant financial relationships to disclose.

Preclinical characterization of VX-984, a selective DNA-dependent protein kinase (DNA-PK) inhibitor in combination with doxorubicin in breast and ovarian cancers

Marina Penney
Ms. Penney has disclosed that she is an employee of may own stock or stock options in Vertex Pharmaceuticals Incorporated.

Sexual functioning among breast cancer survivors and their partners: A pilot study

Angela Pennisi
Dr. Pennisi has no relevant financial relationships to disclose.

Inducing immune responses to tumor associated carbohydrate antigens by a carbohydrate mimetic peptide vaccine: Clinical experience in phase I and phase II trials

Angela Pennisi
Dr. Pennisi has no relevant financial relationships to disclose.
Dual targeting of mammary tumors and tumor-associated functional limitations through inhibition of NF-kB

Narsimha Penthala
Narsimha Penthala has no relevant financial relationships to disclose.

Determining the optimal vaccination strategy using a combination of the folate binding protein (FBP) peptide vaccine (E39+GM-CSF) and an attenuated version (E39) to maximize the immunologic response in breast cancer patients

George Peoples
Dr. Peoples has disclosed that he is a consultant to Galena.

Identifying metastatic drivers in patient derived xenograft models of triple negative breast cancer

Michael Peoples
Mr. Peoples has no relevant financial relationships to disclose.

Abnormal antigen presentation with neoadjuvant chemotherapy: A new strategy to improve cancer vaccine efficacy

Jose Perez
Dr. Perez has no relevant financial relationships to disclose.
P4-07-09  Differential expression of microRNAs (miRNAs) in HER2 negative breast cancer (BC)  Ana Pérez-Campos  Dr. Pérez-Campos has no relevant financial relationships to disclose.

OT1-01-04  VENTANA (SOLT-1001): Oral metronomic vinorelbine combined with endocrine therapy in luminal/HER2-negative early breast cancer: A window of opportunity trial  Jose Alejandro Pérez-Fidalgo  Dr. Pérez-Fidalgo has no relevant financial relationships to disclose.

P4-21-05  Neoadjuvant non-pegylated liposomal doxorubicin plus paclitaxel, trastuzumab and pertuzumab in patients with HER2+ breast cancer - Final results of the SOLTI-OPTI-HER HEART study  Jose Perez-Garcia  Dr. Perez-Garcia has no relevant financial relationships to disclose.

OT1-02-03  Phase 1 multicenter clinical trial evaluating the combination of trastuzumab emtansine (T-DM1) and non-pegylated liposomal doxorubicin (NPLD) in HR2-positive metastatic breast cancer (MBC) (SOLTI-MEDICP0831 study)  Jose Manuel Perez-Garcia  Dr. Perez-Garcia has no relevant financial relationships to disclose.

P2-11-06  HER2 positive breast cancer and clinical cardiac toxicity by echocardiogram 2D Strain. Do chemotherapy sequences matter?  Vinidiana Perez-Montessoro  Dr. Perez-Montessoro has no relevant financial relationships to disclose.

P3-10-05  Successful implementation of a novel breast cancer navigation program in Nuevo León, Mexico  Patricia Perez-Reyes  Dr. Perez-Reyes has no relevant financial relationships to disclose.

P4-21-32  Treatment of early HER2-positive breast cancer in trastuzumab era in everyday clinical practice: An overview after 10 years of its approval  Sonia Pernas  Ms. Pernas has no relevant financial relationships to disclose.

S3-05  Comprehensive comparison of breast cancer molecular portraits by African and European ancestry in the cancer genome atlas  Charles Perou  Dr. Perou has disclosed that he is an equity stock holder, and Board of Director Member, of BioClassifier LLC and University Genomics, and has filed a patent on the PAM50 molecular assay.

P1-05-11  Multi-level gene expression signatures provide significant prognostic information in metastatic breast cancer patients  Charles Perou  Dr. Perou has disclosed that he is listed as an inventor on a patent application on the PAM50 molecular assay. He also disclosed that he is an equity stock holder, and Board of Director Member, of BioClassifier LLC and University Genomics.
| PD1-03 | Multivariate analysis of subtype and gene expression signatures predictive of pathologic complete response (pCR) in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance) | Charles Perou | Dr. Perou has disclosed that he is an inventor on a patent application on the PAM50 and VEGF signature molecular assays. He has also disclosed that he is a Board of Director Member of BioClassifier LLC and GeneCentric Diagnostics and an equity stock holder of BioClassifier LLC and GeneCentric Diagnostics. |
| PD2-03 | Recurrent functionally diverse in-frame ESR1 gene fusions drive endocrine resistance in breast cancer | Charles Perou | Dr. Perou has no relevant financial relationships to disclose. |
| P08-01 | Race and age differences in PAM50 biomarker status in the Carolina breast cancer study | Charles Perou | Dr. Perou has disclosed that he is a patient holder on PAM50/Prosigna and has ownership interest in ProSigna. |
| S3-05 | Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase II trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer | Charles Perou | Dr. Perou has disclosed that he receives royalties from PAM50 breast cancer gene patent application and from lung gene signature. He has also disclosed that he is consultant for BioClassifier and GeneCentric Diagnostics and has ownership in Bioclassifier, GeneCentric Diagnostics. |
| S6-01 | BRCA2: mutation status, fencing and treatment effect in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA2 breast cancer | Charles Perou | Dr. Perou has no relevant financial relationships to disclose. |
| Committee Member/Speaker, Educational Session | "Triple negative breast cancer: Biology and heterogeneity" | Charles Perou | Dr. Perou has disclosed that he receives royalty and consulting fees from Bioclassifier, LLC and GeneCentric Diagnostics. He also disclosed that he does contracted research and has ownership interest in Bioclassifier, LLC and GeneCentric Diagnostics. These relationships do not impact his ability to present an unbiased presentation. |
| P2-15-01 | Building an experience engine to make cancer treatment decisions using machine learning | Paul Perry | Mr. Perry has disclosed that he has stock in Navys Network. |
| P6-09-10 | Results of multigene assay (MammaPrint®) and molecular subtyping (BluePrint®) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIME decision impact study | Marien Persoon | Ms. Persoon has disclosed that she receives salary. |
| P2-05-12 | The ASCO-recommended prognostic factors uPA/PAI-1 in a multicenter cohort study (PAI) | Susanne Peschel | Dr. Peschel has no relevant financial relationships to disclose. |
| PS-06-09 | Cyclin d1 binding to chromatin and the induction of chromosomal instability requires the fuzzy domain | Richard Pestell | Dr. Pestell has no relevant financial relationships to disclose. |
| PS-08-12 | HER2 status remains the primary predictor of improved survival in patients with BCM over the past 2 decades (1996-2015) | Fecci Peter | Dr. Peter has no relevant financial relationships to disclose. |
| S1-07 | Prognostic associations of human-infiltrating lymphocytes (HIL) in metastatic HER2-positive breast cancer (BC) treated with trastuzumab and pertuzumab: A secondary analysis of the CLEOPATRA study | Savas Peter | Mr. Savas has no relevant financial relationships to disclose. |
| P2-03-01 | Multinational landscape of breast cancers from PALB2 germline mutation carriers | Park Peterlongo | Mr. Peterlongo has no relevant financial relationships to disclose. |
| OT2-01-13 | A phase I, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMMARA) | Amy Peterson | Dr. Peterson has disclosed that she is an employee of Medivation, Inc. |
| OT3-02-02 | ENDear: A randomized international phase III study comparing the efficacy and safety of olaparib in combination with paclitaxel chemotherapy or as monotherapy vs placebo with paclitaxel in patients with advanced diagnostic-positive triple-negative breast cancer | Amy Peterson | Ms. Peterson has disclosed that she is a Medivation employee. |
| P4-22-08 | A single-arm phase 2 study to assess clinical activity, efficacy and safety of olaparib in combination with trastuzumab in HER2+ AR- metastatic or locally advanced breast cancer | Amy Peterson | Ms. Peterson has disclosed that she is a Medivation employee. |
| PS-05-01 | Talazoparib antitumor effects in BRCA-deficient breast cancer models | Amy Peterson | Dr. Peterson has disclosed that he is an employee of Medivation, Inc. |
Incidence of germline BRCA1- and BRCA2-mutated breast cancer in the US

Amy Peterson

Dr. Peterson has disclosed that he is an employee of Medivation, Inc.

Test-retest fidelity of FDG SUVmax in bone and non-boney metastatic breast cancer lesions in local area network PET/CT scanners

Lanell Peterson

Lanell Peterson has no relevant financial relationships to disclose.

A physical activity and dietary counseling intervention in breast cancer survivors and changes in breast and novel prognostic biomarkers

Lindsay Peterson

Ms. Peterson has no relevant financial relationships to disclose.

Adverse events rates in a privately insured US population on tamoxifen compared to controls from the MarketScan database

Lindsay Peterson

Dr. Peterson has no relevant financial relationships to disclose.

Analytical and clinical validation of a fully automated tissue-based quantitative assay (MetaSite Breast™) to detect the likelihood of distant metastasis in hormone receptor (HR)-positive, HER2-negative early stage breast cancer (ESBC)

Michael Peterson

Ms. Peterson has no relevant financial relationships to disclose.

Tumor microenvironment of metastasis (TME/M) score is associated with early distant recurrence in hormone receptor (HR) positive, HER2-negative early stage breast cancer (ESBC)

Michael Peterson

Dr. Peterson has disclosed that he receives salary from and has ownership in MetaStat, Inc.

Patients reported cosmetic outcomes in older breast cancer survivors: A population-based survey study

Susan Peterson

Dr. Peterson has no relevant financial relationships to disclose.

Rapid germline BRCA screening for locally advanced breast cancer changes surgical procedure after neoadjuvant chemotherapy

Adeline Petit

Dr. Petit has no relevant financial relationships to disclose.

SEER study of breast cancer-specific mortality in patients with poorly differentiated tumors treated based on recurrence score results

Valentina Petkov

Dr. Petkov has no relevant financial relationships to disclose.

Preference of trastuzumab administration route (intravenous or subcutaneous) in patients in the Czech Republic. Cross-sectional study on 473 patients

Katerina Petrkova

Dr. Petkov has no relevant financial relationships to disclose.

First-line pertuzumab plus trastuzumab in patients with de novo HR+, HER2- advanced breast cancer (ABC): A subgroup analysis of the MONALEESA-2 trial

Katerina Petrkova

Ms. Petkovskova has no relevant financial relationships to disclose.

Clinical evaluation of mT-101 as a predictor of endocrine responsiveness in hormone receptor positive breast cancer

Annalisa Petrelli

Dr. Petrelli has no relevant financial relationships to disclose.

Rapid germline BRCA screening for locally advanced breast cancer changes surgical procedure after neoadjuvant chemotherapy

Adeline Petit

Dr. Petit has no relevant financial relationships to disclose.

Platinum salts in advanced breast cancer: A systematic review and meta-analysis of randomized clinical trials

Fausto Petrelli

Dr. Petrelli has no relevant financial relationships to disclose.

Phase 2 randomized, double-blind, placebo-controlled trial of endocrine therapy + radium-223 dichloride in HER2-negative, hormone receptor-positive breast cancer patients with bone metastases

Dana Petrenciuc

Dana Petrenciuc has disclosed that he receives salary, travel, accommodations and expenses from Bayer HealthCare.

Phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2-negative, hormone receptor-positive breast cancer and bone metastases

Dana Petrenciuc

Dana Petrenciuc has disclosed that he receives salary, travel, accommodations and expenses from Bayer HealthCare.

Shh repair deficiency biomarkers and MammaPrint high1/ultra2 risk as predictors of veliparib/carboplatin response: Results from the neoadjuvant I-SPY 2 trial for high risk breast cancer

Chip Petricoin

Dr. Petricoin has no relevant financial relationships to disclose.

A multi-OMIC analysis to explore the impact of “actionable” genomic alterations on protein pathway activation: Clinical implication for precision medicine in metastatic breast cancer

Emanuel Petricoin

Mr. Petricoin has no relevant financial relationships to disclose.

A multi-OMIC analysis to explore the impact of “actionable” genomic alterations on protein pathway activation: Clinical implication for precision medicine in metastatic breast cancer

Emanuel Petricoin

Mr. Petricoin has disclosed that he is a co-inventor on the RPPA technology and receives royalty fee distributions under US Law. He has also disclosed that he is Perthera, Inc. Chief Science Officer and SAB and co-founder and equity interest holder in Perthera, Inc. and co-founder and equity interest holder in Theranostics Health, Inc.

Quantitative EffA measurements in TNBC from the I-SPY 2 Trial correlate with HER2-EGR co-activation and heterodimerization

Emanuel Petricoin

Mr. Petricoin has disclosed that he is the co-founder and equity shareholder in Perthera, Inc., co-founder and equity shareholder in Ceres Nanosciences, Inc. and co-founder and equity shareholder in Theranostics Health, Inc.
Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer

Fabio Petrocca

Dr. Petrocca has no relevant financial relationships to disclose.

Predictive value of quantitative HER2 and HER3 levels combined with downstream signaling markers in HER2-positive advanced breast cancer patients treated with lapatinib

Christos Petropoulos

Mr. Petropoulos has disclosed that he receives salary from and has ownership in LabCorp.

Multiple-gene panel testing for hereditary cancer risk reveals a racial/ethnic disparity in genetic information

Sue Petrick

Dr. Petrick has disclosed that she receives salary from and has ownership in FIDUR Therapeutics AG.

Predictive value of quantitative HER2 and HER3 levels combined with downstream signaling markers in HER2-positive advanced breast cancer patients treated with lapatinib

Christos Petropoulos

Mr. Petropoulos has disclosed that he receives salary from and has ownership in LabCorp.

Multiple-gene panel testing for hereditary cancer risk reveals a racial/ethnic disparity in genetic information

Sue Petrick

Dr. Petrick has disclosed that she receives salary from and has ownership in FIDUR Therapeutics AG.

Efficacy and safety of everolimus plus exemestane in HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy, in routine clinical practice: 2nd interim analysis from STEPAUT

Edgar Petru

Mr. Petru has disclosed that he receives lecture fees from Novartis. He also disclosed he is the Principal Investigator of an institution-sponsored (Novartis) non-interventional study, 1 study (MONALEESA) ongoing (principal investigator).

Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Final PFS results of a phase II trial (AGMT MBC-6)

Edgar Petru

Dr. Petru has disclosed that he is a speaker for Mundipharma.

Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomized, neoadjuvant phase II study (ABCSG-34)

Andreas Petzer

Dr. Petzer has disclosed that he is a speaker for and receives traveler grants from Mundipharma.

Comparation of the mutational landscape of breast cancer during pregnancy and non-pregnant controls

Nicole Pfarr

Ms. Pfarr has no relevant financial relationships to disclose.

Nonsteroidal, tissue selective androgen receptor modulator (SARM), enobosarm, reduces growth of androgen receptor-positive breast cancer in patient-derived preclinical models

Lawrence Pfeffer

Dr. Pfeffer has no relevant financial relationships to disclose.

Efficacy and safety of everolimus plus exemestane in HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy, in routine clinical practice: 2nd interim analysis from STEPAUT

Georg Pfeiler

Mr. Pfeiler has no relevant financial relationships to disclose.

Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomized, neoadjuvant phase II study (ABCSG-34)

Georg Pfeiler

Dr. Pfeiler has no relevant financial relationships to disclose.

Evaluation of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarker in different subtypes of breast cancer treated with neoadjuvant therapy: A metaanalysis of 3771 patients

Berit Pfitzner

Berit Pfitzner has no relevant financial relationships to disclose.

Modulation of FACTS under stress conditions

Tommy Pham

Mr. Pham has no relevant financial relationships to disclose.

Takozobiric antitumor effects in BRCA-deficient breast cancer models

Vernon Phan

Dr. Phan has disclosed that he is an employee of Medivation, Inc.
Improvement in risk predictive value of Nottingham prognostic index by determining GP88 tumor tissue expression for estrogen receptor positive breast cancer patients

Jeffrey Phillips

Mr. Phillips has no relevant financial relationships to disclose.

Prospective family cohort analyses of gene-environment interactions in breast cancer: Body mass index

Kelly-Anne Phillips

Dr. Phillips has no relevant financial relationships to disclose.

Risk factors for high risk breast density patterns in Hispanics/Latinos living in the Northeast, US

Samaa Philpotts

Dr. Philpotts has no relevant financial relationships to disclose.

Recurrent functionally diverse in-frame ESR1 gene fusions drive endocrine resistance in breast cancer

Changheng Phommaly

Changheng Phommaly has no relevant financial relationships to disclose.

The FIK8 inhibitor, latazol, has enhanced potency in FK566 mutant models through a unique mechanism of action

Silvan Phu

Ms. Phu has disclosed that she receives salary from Genentech, Inc.

Prostate-specific antigen and total testosterone levels in early breast cancer patients and their correlation to disease recurrence in the breast or lymph nodes: Results of the phase II multicenter trial

Robsert Phillips

Rogsbert Phillips has no relevant financial relationships to disclose.

Risk Factors for high risk breast density patterns in Hispanic/Latinas living in the Northeast, US

Liane Philpotts

Dr. Philpotts has no relevant financial relationships to disclose.

Recurrent functionally diverse in-frame ESR1 gene fusions drive endocrine resistance in breast cancer

Changheng Phommaly

Changheng Phommaly has no relevant financial relationships to disclose.

The PI3K inhibitor, taselisib, has enhanced potency in PIK3CA mutant models through a unique mechanism of action

Lilian Phu

Ms. Phu has disclosed that she receives salary from Genentech, Inc.

Can surrogate pathological subtyping replace molecular subtyping? Outcome results from the MINDACT trial

Martine Piccart-Gebhart

Dr. Piccart-Gebhart has no relevant financial relationships to disclose.

Detection of molecular alterations in breast cancer through next generation sequencing of both tumor tissue and circulating tumor DNA: The UC San Diego Moores Cancer Center experience

David Piccioni

Dr. Piccioni has no relevant financial relationships to disclose.

Exome sequencing of circulating tumor cells in metastatic breast cancer

Martine Piccart

Dr. Piccart has no relevant financial relationships to disclose.

The PI3K inhibitor, taselisib, has enhanced potency in PIK3CA mutant models through a unique mechanism of action

Chanpheng Phommaly

Chanpheng Phommaly has no relevant financial relationships to disclose.

Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib induced cardiotoxicity in patients with HER2 positive early breast cancer (BIG 1-06)

Martine Piccart

Dr. Piccart has disclosed that she is a consultant for Roche.

Evaluation of the recurrence dynamics of breast cancer (BC) according to the body mass index (BMI)

Martine Piccart

Dr. Piccart has no relevant financial relationships to disclose.

Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib induced cardiotoxicity in patients with HER2 positive early breast cancer (BIG 1-06)

Martine Piccart

Dr. Piccart has disclosed that she is a consultant for Roche.

Committee Member

Martine Piccart

Dr. Piccart has disclosed that she receives consulting fees from AstraZeneca, Invivis, Lilly, MSD, Novartis, Pfizer, Roche, Genentech, Sanofi, Symphogen, Synthon and Debiopharm. She also disclosed that she does contracted research grants to the Institut Jules Bordet from most of the companies cited under consulting fees (AstraZeneca, Invivis, Lilly, MSD, Novartis, Pfizer, Roche, Genentech, Symphogen and Debiopharm). She also disclosed other interests, she is a board member of Radius. These relationships do not impact her ability to review presentations.

Reviewing author: AstraZeneca/Genentech; Invivis; Lilly; MSD; Novartis; Pfizer; Roche; Symphogen; Synthon; Debiopharm. She also disclosed that she receives consulting fees from AstraZeneca, Invivis, Lilly, MSD, Novartis, Pfizer; Genentech; Symphogen; Debiopharm. She also disclosed other interests, she is a board member of Radius. These relationships do not impact her ability to review presentations.

Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib induced cardiotoxicity in patients with HER2 positive early breast cancer (BIG 1-06)

Martine Piccart

Dr. Piccart has disclosed that she is a consultant for Amgen, AstraZeneca, Bayer Schering Pharma, PharmaMar, Roche, Genentech, Sanofi, Symphogen, Synthon and Verastem.

Investigation of the recurrence dynamics of breast cancer (BC) according to the body mass index (BMI)

Martine Piccart

Dr. Piccart has no relevant financial relationships to disclose.

Plasma microRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from Neo-ALTTO

Martine Piccart

Dr. Piccart has disclosed that she is a consultant for Amgen, AstraZeneca, Bayer, Eli Lilly, Invivis, Merck Sharp Dome, Novartis, Pfizer, Roche, Genentech, Sanofi, Synthogen, Syntrom and Verastem.

Investigation of the recurrence dynamics of breast cancer (BC) according to the body mass index (BMI)

Martine Piccart

Dr. Piccart has no relevant financial relationships to disclose.

Plasma microRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from Neo-ALTTO

Martine Piccart

Dr. Piccart has disclosed that she is a consultant for Amgen, AstraZeneca, Bayer, Eli Lilly, Invivis, Merck Sharp Dome, Novartis, Pfizer, Roche, Genentech, Sanofi, Synthogen, Syntrom and Verastem.

Investigation of the recurrence dynamics of breast cancer (BC) according to the body mass index (BMI)

Martine Piccart

Dr. Piccart has no relevant financial relationships to disclose.

Plasma microRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from Neo-ALTTO

Martine Piccart

Dr. Piccart has disclosed that she is a consultant for Amgen, AstraZeneca, Bayer, Eli Lilly, Invivis, Merck Sharp Dome, Novartis, Pfizer, Roche, Genentech, Sanofi, Synthogen, Syntrom and Verastem.

Plasma microRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from Neo-ALTTO

Martine Piccart

Dr. Piccart has disclosed that she is a consultant for Amgen, AstraZeneca, Bayer, Eli Lilly, Invivis, Merck Sharp Dome, Novartis, Pfizer, Roche, Genentech, Sanofi, Synthogen, Syntrom and Verastem.

Plasma microRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from Neo-ALTTO

Martine Piccart

Dr. Piccart has disclosed that she is a consultant for Amgen, AstraZeneca, Bayer, Eli Lilly, Invivis, Merck Sharp Dome, Novartis, Pfizer, Roche, Genentech, Sanofi, Synthogen, Syntrom and Verastem.

Plasma microRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from Neo-ALTTO

Martine Piccart

Dr. Piccart has disclosed that she is a consultant for Amgen, AstraZeneca, Bayer, Eli Lilly, Invivis, Merck Sharp Dome, Novartis, Pfizer, Roche, Genentech, Sanofi, Synthogen, Syntrom and Verastem.
A phase II, open-label, multi-center study of ANG1005, a novel brain-penetrant peptide-drug conjugate, in breast cancer patients with recurrent CNS metastases  
David Piccioni  
Dr. Piccioni has no relevant financial relationships to disclose.

A large-scale functional screen to identify resistance mechanisms to selective estrogen receptor degraders fulvestrant and GDC-810 in ER+ breast cancer: Results from a prospective, randomized, neoadjuvant phase II study (ABCSG- 74)  
Federica Piccioni  
Federica Piccioni has no relevant financial relationships to disclose.

Prognostic and predictive values of high endothelial venules (HEV) and tumor infiltrating CD8+ lymphocytes (CD8) in tumors of patients included in the adjuvant PACS04 trial: HEV is predictive of outcome for HER2+ tumors exposed to trastuzumab  
Melanie Pichery  
Ms. Pichery has no relevant financial relationships to disclose.

Proliferation and p21 refine risk of relapse in residual disease after HER2-directed therapies  
Tadeusz Pienkowski  
Tadeusz Pienkowski has no relevant financial relationships to disclose.

A signature predictive of early vs. late recurrence after radiation treatment (RT) for breast cancer that may inform the biology of early, aggressive recurrences  
Lori Pierce  
Dr. Pierce has disclosed that she is a co-founder of PFS genomics.

Circulating tumor cells (CTC) and endothelial cells (CEC) prognostic value in HER2 negative metastatic breast cancer patients treated with first line weekly paclitaxel and bevacizumab: First results of a prospective cohort from the French Breast Cancer InterGroup Unicancer (UCBG): COMET study  
Jean-Yves Pierga  
Mr. Pierga has disclosed that he is a consultant and speaker for Roche. He has also disclosed that he has a contract with Roche.

IMENEO: International Meta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEOadjuvant chemotherapy  
Jean-Yves Pierga  
Mr. Pierga has no relevant financial relationships to disclose.

A multi-OmIC analysis to explore the impact of “actionable” genomic alterations on protein pathway activation: Clinical implication for precision medicine in metastatic breast cancer  
Mariakristen Pierobon  
Dr. Pierobon has disclosed that she is a co-inventor on technologies licensed in from Theranostics and is a shareholder at Theranostics Health.

Real-life activity of oral vinorelbine in metastatic breast cancer patients in the Unicancer ESME database  
Hassan Pierre  
Dr. Pierre has disclosed that ESME Data Platform granted by Roche, Pierre Fabre and Pfizer.

High-throughput genome analysis and therapeutic decision for patients with HER2-negative metastatic breast cancer: First feasibility and clinical results of the randomized phase II study SAFIR02 BREAST (UCB(0-015/330))  
Saelee Perron  
Saelee Perron has no relevant financial relationships to disclose.

Microenvironmental control of breast cancer subtype elicited by paracrine growth factors signaling  
Kristian Petras  
Prof. Petras has disclosed that he is named as an inventor on a patent application describing the use of a PDGF-CC antibody in breast cancer.

Isolated sternal metastases: The place of surgical resection  
Philippe Petti  
Dr. Petti has no relevant financial relationships to disclose.

Opto-acoustic imaging of the breast: Downclassification and upclassification of suspicious breast masses  
Ruud Pijnappel  
Ruud Pijnappel has no relevant financial relationships to disclose.

Impact of primary surgery on short-term survival of older breast cancer patients in the UK  
Mark Pirings  
MR. Pirings has no relevant financial relationships to disclose.

GATA3 inhibits breast basal-like tumorigenesis  
Emelya Pimentel  
Ms. Pimentel has no relevant financial relationships to disclose.

PD-L1 is highly expressed in tumor infiltrating lymphocytes in pregnancy-associated breast cancer  
Jennifer Pinkus  
Dr. Pinkus has no relevant financial relationships to disclose.

Neratinib + fulvestrant in ERBB2-mutant, HER2-non-amplified, estrogen receptor (ER)-positive, metastatic breast cancer (MBC): Preliminary analysis from the phase II SMART trial  
Sarina Piha-Paul  
Sarina Piha-Paul has no relevant financial relationships to disclose.

Opto-acoustic imaging of the breast: Downclassification and upclassification of suspicious breast masses  
Ruud Pirings  
Ruud Pirings has no relevant financial relationships to disclose.

Impact of primary surgery on short-term survival of older breast cancer patients in the UK  
Mark Pirings  
MR. Pirings has no relevant financial relationships to disclose.

GATA3 inhibits breast basal-like tumorigenesis  
Emelya Pimentel  
Ms. Pimentel has no relevant financial relationships to disclose.

PD-L1 is highly expressed in tumor infiltrating lymphocytes in pregnancy-associated breast cancer  
Jennifer Pinkus  
Dr. Pinkus has no relevant financial relationships to disclose.
The UK LORIS trial: Randomizing patients with low or low-intermediate grade ductal carcinoma in situ (DCIS) to surgery or active monitoring

Sarah Pinder
Ms. Pinder has no relevant financial relationships to disclose.

LORIS trial of active monitoring for DCIS: How does the online pathology eligibility review process work?

Sarah Pinder
Ms. Pinder has no relevant financial relationships to disclose.

Sarah Pinder
Ms. Pinder has no relevant financial relationships to disclose.

Long survival of patients with locally advanced breast cancer on combined neoadjuvant chemotherapy and immune potentiation: Modern lessons from an old study

Herbert Pinedo
Dr. Pinedo has no relevant financial relationships to disclose.

Detection of ESR1 mutations in matched primary and metastatic samples from endocrine-resistant lobular breast cancer patients

Julien Pignot
Julien Pignot has no relevant financial relationships to disclose.

Prospective study of acupuncture in the rehabilitation of women undergoing surgical treatment of breast cancer in relation to the strength and quality of life

Thais Polheiro
Dr. Polheiro has no relevant financial relationships to disclose.

Claudin-4 expression is associated with disease-free survival in breast carcinoma in situ. Mean follow up of 8.2 years

Silvia Pinto
Dr. Pinto has no relevant financial relationships to disclose.

Molecular evaluation of Peruvian patients with hereditary breast cancer reveals a novel germline mutation in BRCA1

Joseph Pinto
Mr. Pinto has no relevant financial relationships to disclose.

Claudin-4 expression is associated with disease-free survival in breast carcinoma in situ. Mean follow up of 8.2 years

Tamara Pinto
Dr. Pinto has no relevant financial relationships to disclose.

Safety of the combination of everolimus plus exemestane in the Italian cohort of patients enrolled in the expanded access "BALLET" study

P Piovano
P Piovano has no relevant financial relationships to disclose.

An international multicenter study to evaluate reproducibility of automated scoring methods for assessment of Ki67 in breast cancer

Tammy Piper
Ms. Piper has no relevant financial relationships to disclose.

In silico pan-cancer study with in vitro evidence

Daniela Piras
Ms. Piras has no relevant financial relationships to disclose.

Challenges faced across borders to open European academic multicentre projects: The ET-EIFS program part of the ERA-Net TRANSCAN-2 JTC 2011

Alejandro Piris
Dr. Piris has no relevant financial relationships to disclose.

The UK LORIS trial: Randomizing patients with low or low-intermediate grade ductal carcinoma in situ (DCIS) to surgery or active monitoring

Sarah Pirrie
Ms. Pirrie has no relevant financial relationships to disclose.

LORIS trial of active monitoring for DCIS: How does the online pathology eligibility review process work?

Sarah Pirrie
Ms. Pirrie has no relevant financial relationships to disclose.

The genomic landscape of breast metaplastic carcinoma

Salvatore Piscuoglio
Mr. Piscuoglio has no relevant financial relationships to disclose.

The landscape of somatic genetic alterations in BRCA1 and BRCA2 breast cancers

Salvatore Piscuoglio
Mr. Piscuoglio has no relevant financial relationships to disclose.

9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian short-HER trial

Marco Pita
Mr. Pita has no relevant financial relationships to disclose.

Concordance with National comprehensive cancer network (NCCN) metastatic breast cancer guidelines and impact on overall survival

Marie Piu
Dr. Piu has no relevant financial relationships to disclose.

CDK4 phosphorylation status and corresponding gene expression profile predict sensitivity to Palbociclib

Jaime Pitta
Dr. Pitta has no relevant financial relationships to disclose.
Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer

Brandelyn Pitcher

Ms. Pitcher has no relevant financial relationships to disclose.

Comprehensive comparison of breast cancer molecular portraits by African and European ancestry in the cancer genome atlas

Jason Pitt

Mr. Pitt has no relevant financial relationships to disclose.

Comparative analysis of the genomic landscape of breast cancers from women of African and European ancestry

Jason Pitt

Mr. Pitt has no relevant financial relationships to disclose.

Beta-adrenergic receptor blockers (BB) and increased progression free survival (PFS) in patients with advanced triple negative breast cancer (TNBC): A retrospective analysis of the ROSE/TRODOS2 study

Edith Pitsakis

Dr. Pitsakis has no relevant financial relationships to disclose.

Influence of hormone replacement therapy following bilateral salpingo-oophorectomy on mammographic breast density in women newly diagnosed with breast cancer

Sarah Poo

Ms. Poo has no relevant financial relationships to disclose.

A phase 2, randomized, double-blind, controlled study of ONT-380, in combination with carboplatin/paclitaxel (C/Tx) for anthracycline-resistant metastatic breast cancer patients

Kavesh Poust

Kavesh Poust has no relevant financial relationships to disclose.

A phase 2 randomized phase 3 study assessing the addition of oral vinorelbine to aromatase inhibitors for the treatment of patients with metastatic breast cancer

Kavesh Poust

Dr. Poust has disclosed that he is a consultant.

Identifying metastatic drivers in patient derived xenograft models of triple negative breast cancer

David Pivnick-Worms

Mr. Pivnick-Worms has no relevant financial relationships to disclose.

Phase IIIB study of neoadjuvant panitumumab combined with carboplatin and paclitaxel (PaCt) for anthracycline-resistant triple-negative breast cancer (TNBC)

David Pivnick-Worms

Dr. Pivnick-Worms has no relevant financial relationships to disclose.

RCT2042S5E37: A phase II trial ofgp100 vaccination, bevacizumab and everolimus (EME) in patients (pts) with localized triple-negative breast cancer (TNBC) with tumors predicted insensitive to standard neoadjuvant chemotherapy (NACT)

Helen Pivnick-Worms

Dr. Pivnick-Worms has no relevant financial relationships to disclose.

An annotated collection of pre- and post-therapy breast cancer patient-derived xenograft models built from fine needle aspiration samples aligned with ongoing clinical trials documenting response to treatment

Helen Pivnick-Worms

Dr. Pivnick-Worms has no relevant financial relationships to disclose.

Comprehensive analysis of the DNA damage repair and maintenance pathways that regulate TNBC sensitivity to replication stress

Helen Pivnick-Worms

Dr. Pivnick-Worms has no relevant financial relationships to disclose.

Identifying metastatic drivers in patient derived xenograft models of triple negative breast cancer

Helen Pivnick-Worms

Dr. Pivnick-Worms has no relevant financial relationships to disclose.

Metabolic stress induces G0 S-phase arrest and cancer stem cell phenotype in triple negative breast cancer

Badrajee Piyaranthna

Dr. Piyaranthna has no relevant financial relationships to disclose.

Mitochondria-nuclear communication regulates epithelial-mesenchymal transition and metastasis in triple negative breast cancer

Santharshige Waduge Piyaranthna

Santharshige Waduge Badrajee Piyaranthna has no relevant financial relationships to disclose.

Overview of breast cancer mortality trends in the world

Nicole Politi

Mr. Politi has no relevant financial relationships to disclose.

Plasma microRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from Neo-ALTTO

Sara Pizzamiglio

Dr. Pizzamiglio has no relevant financial relationships to disclose.

Three-monthly dynamic evaluation of CEA and CA15-3 (followed by 18-FDG PET) vs usual practice in the follow-up of early breast cancer (EC) patients (pts): A prospective random trial (KRONOS-patient-oriented new surveillance study, Italy)

Sara Pizzamiglio

Dr. Pizzamiglio has no relevant financial relationships to disclose.

Three-monthly dynamic evaluation of CEA and CA15-3 (followed by 18-FDG PET) vs usual practice in the follow-up of early breast cancer (EC) patients (pts): A prospective random trial (KRONOS-patient-oriented new surveillance study, Italy)

Nicola Pozzi

Dr. Pozzi has no relevant financial relationships to disclose.

Three-monthly dynamic evaluation of CEA and CA15-3 (followed by 18-FDG PET) vs usual practice in the follow-up of early breast cancer (EC) patients (pts): A prospective random trial (KRONOS-patient-oriented new surveillance study, Italy)

Nicola Pozzi

Dr. Pozzi has no relevant financial relationships to disclose.
Circulating tumor cells in triple-negative breast cancer patients express prostate related genes and show different genetic profiles in US and German patient cohorts

Linda Flappert  
Ms. Flappert has disclosed that she is an employee of Qiagen Hannover GmbH.

CASCADe study: Rapid survival decline per treatment line in metastatic breast cancer

Yesica Plata  
Yesica Plata has no relevant financial relationships to disclose.

Circulating tumor DNA (ctDNA): A real-time application of precision medicine to the management of metastatic breast cancer (MBC)

Alessandro Platina  
Alessandro Platina has no relevant financial relationships to disclose.

Efficacy results of a phase 1/2 study of glucocorticoid receptor (GR) antagonist mifepristone (MIFE) in combination with eribulin in GR-positive triple-negative breast cancer (TNBC)

Timothy Pluard  
Mr. Pluard has no relevant financial relationships to disclose.

HER2 positive breast cancer and subclinical cardiotoxicity by echocardiogram 2D Strains. Do chemotherapies sequence matter?

Noel Poblano-Aguilar  
Dr. Poblano-Aguilar has no relevant financial relationships to disclose.

Immunohistochemistry cannot be used to detect PD-L1/LD1:2 amplification

Barbara Pockaj  
Ms. Pockaj has no relevant financial relationships to disclose.

JAK2 and PD-L1 amplification enhance the dynamic expression of PD-L1 in triple negative breast cancer

Barbara Pockaj  
Ms. Pockaj has no relevant financial relationships to disclose.

Clonal heterogeneity in breast cancer and its impact on clinical biomarkers

Barbara Pockaj  
Dr. Pockaj has no relevant financial relationships to disclose.

Homologous recombination deficiency in PD-L1, PD-L2, JAK2 (PDJ) amplified triple negative breast carcinoma

Barbara Pockaj  
Ms. Pockaj has no relevant financial relationships to disclose.

Identification of proliferation related drivers and their roles in precision medicine for breast cancers: A retrospective multidimensional comparative, integrated genomic, transcriptomic, and protein analysis

Alan Pockley  
Dr. Pockley has no relevant financial relationships to disclose.

An exploratory correlative biomarker analysis of NSABP FR-7, a phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel (P) plus neratinib (N) or trastuzumab (T) or neratinib and trastuzumab (N+T) followed by doxorubicin and cyclophosphamide (AC) with postoperative T in women with locally advanced HER2-positive breast cancer

Kay Pogue-Geile  
Ms. Pogue-Geile has no relevant financial relationships to disclose.
P3-09-03 Low-level gonosomal mosaicism of a de novo BRCA1 gene mutation - The origin of a constitutional mutation in a breast cancer family

Esther Pohl

Dr. Pohl has no relevant financial relationships to disclose.

P3-09-04 Beyond CHEK2 in breast cancer: Search for additional moderately penetrant risk gene variants by analyzing the oligogenic disease course in CHEK2 mutation carriers

Esther Pohl

Ms. Pohl has no relevant financial relationships to disclose.

P3-04-01 CHEK2 mutations, BRCA1 features and co-occurring alterations assessed in breast cancer tumors

Paula Pohlmann

Dr. Pohlmann has no relevant financial relationships to disclose.

P3-10-02 Increasing participation in research - breast cancer (Inspire-BrC)

Paula Pohlmann

Ms. Pohlmann has no relevant financial relationships to disclose.

P6-10-07 Long survival of patients with locally advanced breast cancer on combined neoadjuvant chemotherapy and immune potentiation: Modern lessons from an old study

Paula Pohlmann

Dr. Pohlmann has no relevant financial relationships to disclose.

P08-04 Racial differences in the molecular landscape of breast cancer

Paula Pohlmann

Dr. Pohlmann has no relevant financial relationships to disclose.

P2-08-06 Proliferation and p21 define risk of relapse in residual disease after HER2-directed therapies

Sagnine Poitier

Ms. Poitier has no relevant financial relationships to disclose.

P4-15-04 Molecular mediators of mammographic density

Marc Poiriot

Mr. Poiriot has no relevant financial relationships to disclose.

P2-08-07 Anti-proliferative and anti-inflammatory estrogen receptor agents for treatment of endocrine-resistant breast cancer

Kristjana Pohlakova

Ms. Pohlakova has no relevant financial relationships to disclose.

P1-09-04 75% of breast cancer patients have a mutation in the ESR1 gene - ESR1 mutations, ESR1 fusions and co-occurring alterations assessed in breast cancer tumors

Chad Pohmann

Dr. Pohmann has no relevant financial relationships to disclose.

P6-10-07 Long survival of patients with locally advanced breast cancer on combined neoadjuvant chemotherapy and immune potentiation: Modern lessons from an old study

Paula Pohlmann

Dr. Pohlmann has no relevant financial relationships to disclose.

P08-04 Racial differences in the molecular landscape of breast cancer

Paula Pohlmann

Dr. Pohlmann has no relevant financial relationships to disclose.

P2-08-06 Proliferation and p21 define risk of relapse in residual disease after HER2-directed therapies

Sagnine Poitier

Ms. Poitier has no relevant financial relationships to disclose.

P4-15-04 Molecular mediators of mammographic density

Marc Poiriot

Mr. Poiriot has no relevant financial relationships to disclose.

P2-08-07 Anti-proliferative and anti-inflammatory estrogen receptor agents for treatment of endocrine-resistant breast cancer

Kristjana Pohlakova

Ms. Pohlakova has no relevant financial relationships to disclose.

OT1-02-04 The DETECT V-study - Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo- or endocrine therapy in patients with HER2-positive and hormone-receptor positive metastatic breast cancer

Arkadius Polasik

Dr. Polasik has no relevant financial relationships to disclose.

OT3-04-02 DETECT III and IV - Individualized CTC-based therapy of metastatic breast cancer

Arkadius Polasik

Dr. Polasik has no relevant financial relationships to disclose.

P1-01-03 Dynamics of circulating tumor cells during the course of chemotherapy and prognostic relevance across molecular subtypes in high-risk early breast cancer patients - Results from the adjunct SUCCESS A trial

Arkadius Polasik

Dr. Polasik has no relevant financial relationships to disclose.

P1-01-15 DETECT V - Detection of the expression of estrogen receptor and human epidermal growth factor receptor 2 on circulating tumor cells from metastatic breast cancer patients

Arkadius Polasik

Arkadius Polasik has no relevant financial relationships to disclose.

P4-07-01 Profiling miRNA in high risk post-operative early breast cancer patients to detect possible association to correlation with immune system antitumor response

Arkadius Polasik

Arkadius Polasik has no relevant financial relationships to disclose.

P1-01-06 Ki67-positive CTCs are associated with early disease relapse in patients with early breast cancer undergoing adjuvant chemotherapy

Eleni Politaki

Eleni Politaki has no relevant financial relationships to disclose.

P4-21-26 Population pharmacokinetics (PK) and exposure-response (E-R) analysis of trastuzumab emtansine (T-DM1) in patients with HER2+ metastatic breast cancer who have received at least two prior regimens of HER2-directed therapy

Daniel Polhamus

Dr. Polhamus has disclosed that he is an employee of Metrum Research Group LLC and was contracted as a paid consultant to Roche/Genentech for this research.

P6-07-06 KIT-positive CTCs are associated with early disease relapse in patients with early breast cancer undergoing adjuvant chemotherapy

Eloni Politiaki

Eloni Politiaki has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Author</th>
<th>Disclosures</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3-04-15</td>
<td>The PI3K-inhibitor, copanlisib, has selective activity in luminal breast cancer cell lines and shows robust combined activity with hormonal blockade and CDK-4/6 inhibition in ER+ breast cancer cell-line xenografts</td>
<td>Oliver Politz</td>
<td>Dr. Politz has disclosed that he is an employee of Bayer.</td>
</tr>
<tr>
<td>P3-14-13</td>
<td>Total mastectomy and immediate breast reconstruction for breast cancer: A ten-year Canadian single institution experience</td>
<td>Mate Poljicak</td>
<td>Dr. Poljicak has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-10-05</td>
<td>Socioeconomic disparities in needle biopsy prior to breast cancer surgery across physician referral networks</td>
<td>Craig Pollack</td>
<td>Dr. Pollack has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2S-05</td>
<td>Metabolic obesity, adipose inflammation and aromatase: Potential drivers of breast cancer risk in women with normal body mass index</td>
<td>Michael Poljak</td>
<td>Mr. Poljak has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-04-05</td>
<td>Identification of SARR439893, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong antitumor activity in wild-type and mutant ER+ breast cancer models</td>
<td>Jack Poland</td>
<td>Mr. Poland has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-09-03</td>
<td>Associations between breast cancer subtypes and mutations in cancer predisposition genes identified by clinical genetic testing of breast cancer patients</td>
<td>Eric Polley</td>
<td>Mr. Polley has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>52-01</td>
<td>Breast cancer risks associated with mutations in cancer predisposition genes identified by clinical genetic testing of 60,000 breast cancer patients</td>
<td>Carolina Poljak</td>
<td>Dr. Poljak has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-17-03</td>
<td>Global Cancer Institute online tumor boards to improve global patterns of clinical practice for breast cancer</td>
<td>Senta Poljak</td>
<td>Dr. Poljak has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Committee Member/Speaker, Basic Science Forum 3, Educational Session</td>
<td>&quot;Epigenetic targets in breast cancer&quot; &quot;Non-cell-autonomous drivers of tumor growth and progression&quot;</td>
<td>Kornelia Poljak</td>
<td>Dr. Poljak has disclosed that she receives consulting fees from Novartis. She also disclosed that she has a sponsored research agreement with Novartis. These relationships do not impact her ability to present an unbiased presentation.</td>
</tr>
<tr>
<td>P6-09-40</td>
<td>Her2 and hormonal receptor analysis in breast cancer synchronous node metastases could add therapeutic information</td>
<td>Maria Pombo</td>
<td>Dr. Pombo has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-40</td>
<td>Her2 and hormonal receptor analysis in breast cancer synchronous node metastases could add therapeutic information</td>
<td>Carolina Ponce</td>
<td>Dr. Ponce has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-09-08</td>
<td>Malignant evaluation of Peruvian patients with hereditary breast cancer reveals a novel germline mutation in BRCA1 patients</td>
<td>Jaimie Ponce</td>
<td>Jaimie Ponce has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-12-09</td>
<td>The immune response in triple negative breast cancer</td>
<td>Gregory Pond</td>
<td>Dr. Pond has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-30</td>
<td>Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with Trastuzumab</td>
<td>Gregory Pond</td>
<td>Dr. Pond has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-16</td>
<td>Identification of proliferation-related drivers and their roles in precision medicine for breast cancer: A retrospective multidimensional comparative, integrated genomic, transcriptomic, and protein analysis</td>
<td>Lorrie Ponger</td>
<td>Dr. Ponger has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-16</td>
<td>Relationship between overall survival and surrogate measures in patients with metastatic breast cancer treated with chemotherapy</td>
<td>Marek Poniewierski</td>
<td>Dr. Poniewierski has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-12-06</td>
<td>Hormonally targeted androgen receptor modulator (SARM), enobosarm, reduces growth of androgen receptor-positive breast cancer in patient-derived preclinical models</td>
<td>Suniti Ponnusamy</td>
<td>Dr. Ponnusamy has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-09-21</td>
<td>Clinical evaluation of mifepristone as a predictor of endocrine responsiveness in hormone receptor-positive breast cancer</td>
<td>Nicola Ponzone</td>
<td>Dr. Ponzone has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-10-21</td>
<td>Influence of timing of radiation therapy following breast conserving surgery on 10-year disease-free survival</td>
<td>Philip Poortmans</td>
<td>Dr. Poortmans has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-54</td>
<td>Long-term recurrence risk and risk-based follow-up after breast cancer treatment</td>
<td>Philip Poortmans</td>
<td>Prof. Poortmans has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-07-09</td>
<td>Synergistic effect of combinatorial treatment with maraviroc and tocilizumab in TNBC tumor growth and metastasis in mouse xenograft model</td>
<td>Aleksander Popel</td>
<td>Dr. Popel has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-09-21</td>
<td>Influence of timing of radiation therapy following breast conserving surgery on 10-year disease-free survival</td>
<td>Philip Poortmans</td>
<td>Dr. Poortmans has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-54</td>
<td>Long-term recurrence risk and risk-based follow-up after breast cancer treatment</td>
<td>Philip Poortmans</td>
<td>Prof. Poortmans has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Poster Discussion 8 Co-Discussant</td>
<td>Peggy Porter</td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------------------</td>
<td>-------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mr. Porter has no relevant financial relationships with commercial interests to disclose.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster 5-14-03</th>
<th>Adjunctive dose demethylciclophosphamide (ddAC) or docetaxel-AC (TAC) for high-risk breast cancer: First results of the randomized MATADOR trial (BOOG-2004-04)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Portielje has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster 5-11-14</th>
<th>Physicians perceptions of estrogen agonist/antagonists in menopausal health: An opportunity to address a trend of concerns in menopause and breast cancer survivorship</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Portielje has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster 52-03</th>
<th>Does BRCA status affect outcome in young breast cancer patients? Results from the prospective study of outcomes in sporadic and hereditary breast cancer (POSH)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Portielje has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster 54-21-08</th>
<th>A phase I/II trial of S-222611, a reversible EGFR and HER2 inhibitor, combined with trastuzumab +/- chemotherapy in patients with HER2-positive metastatic breast cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Posner has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Poster 57-03-02</th>
<th>Maximising recruitment and retention of patients into UK-ANZ POSNOC trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>The POSNOC Trial Management Group has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Staff Member 2-20-07</th>
<th>Research biopsies in oncology patient willingness, perceptions, understanding, and experience: An integrative review</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mr. Post has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Staff Member 5-13-09</th>
<th>Development and implementation of a patient-centered, nurse practitioner-led survivorship intervention for breast cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ms. Post has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Staff Member 5-09-05</th>
<th>The role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+ trial: phase II trial evaluating 12-weeks of neoadjuvant TDM1 ± endocrine therapy (ET) versus T + ET in HER2-positive hormone receptor-positive early breast cancer (EBC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Potenberg has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Staff Member 56-13-02</th>
<th>Efficacy of first-line bevacizumab (BEV)-containing therapy for poor-prognosis advanced breast cancer (ABC): Subgroup analyses of the German AVANT! observational study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mr. Pott has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Staff Member 55-07</th>
<th>Aromatase inhibitors and endothelial function: Is there an association with early cardiovascular disease?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Potter has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
</tbody>
</table>
The latest breakthroughs on the translational aspects of DNA repair pathways

Dr. Powell has disclosed that he has a contract with Merck.

OncotypeDX® for breast cancer: A multigene assay that makes a difference?

Dr. Pradotto has disclosed that he is a consultant for NanoString Technologies.

S9-03
PAM50 intrinsic subtype as a predictor of pathological complete response following neoadjuvant therapy in operable breast cancer

Stephanie Pudil

Dr. Pudil has no relevant financial relationships to disclose.

P6-03-24
Vitamin D level impacts odds of pathologic complete response following neoadjuvant therapy in operable breast cancer

Stéphane Pouderoux

Dr. Pouderoux has no relevant financial relationships to disclose.

P6-01-08
Identifying metastatic drivers in patient derived xenograft models of triple negative breast cancer

Emily Powell

Dr. Powell has no relevant financial relationships to disclose.

P1-05-15
Multi-omics and immunooxology profiling reveal distinct molecular signatures of young Asian breast cancers

Eric Powell

Dr. Powell has no relevant financial relationships to disclose.

P5-09-09
Functional IGF1R variant predicts preeclampsia protection from invasive breast cancer: Novel California teachers study findings

Mark Powell

Dr. Powell has disclosed that he receives consulting fees from Varian. This relationship does not impact his ability to present an unbiased presentation.

Speaker, Mini-Symposia 2

"The latest breakthroughs on the translational aspects of DNA repair pathways"

Simon Powell

Dr. Powell has disclosed that he receives consulting fees from Varian. This relationship does not impact his ability to present an unbiased presentation.

OT2-01-16
Evaluating targets in localized and advanced breast cancer by sequencing tumor DNA at diagnosis and after progression (ELSA)

Steven Powelson

Dr. Powelson has no relevant financial relationships to disclose.

P5-11-15
Changes in the gut microbiome of post-menopausal women 2 weeks after initiating a structured weight loss intervention

Kandy Powers

Ms. Powers has no relevant financial relationships to disclose.

P2-05-13
OncotypeDX® for breast cancer: A multigene assay that makes a difference?

Catherine Prat

Dr. Prat has disclosed that he receives consulting fees from NanoString Technologies. This relationship does not impact his ability to present an unbiased presentation.

Dr. Prat has disclosed that he is a consultant for NanoString Technologies.

S3-03
PAM50 intrinsic subtype as a predictor of pathological complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2 positive breast cancer: First results of the PAMELA clinical trial

Aleix Prat Aparicio

Dr. Prat Aparicio has disclosed that he is a consultant for Nanostring.

P6-07-07
ESR1 amplification and 5'-3' exon imbalance in metastatic breast cancer

Molly Preideigkeit

Mr. Preideigkeit has no relevant financial relationships to disclose.

S5-04
Low-fat dietary pattern and breast cancer overall survival in the women's health initiative dietary modification randomized controlled trial

Ross Prentice

Dr. Prentice has no relevant financial relationships to disclose.

P5-09-09
Functional IGF1R variant predicts preeclampsia protection from invasive breast cancer: Novel California teachers study findings

Michael Press

Dr. Press has disclosed that he is a consultant for Becton, Hologic, Fuma Biotechnology, Cepheid and Ventana. He also disclosed that he has contracts with Merck, MacroGenics, Roche, Eli Lilly, Cepheid and Translational Research in Oncology (TRIO).
Highly reproducible decentralized gene expression analysis of ESR1, PGR, ERBB2 and MKI67 on an automated, standardized molecular diagnostics platform, GeneXpert

Dr. Press has disclosed that he is a consultant for Biocartis, Halozyme, Puma Biotechnology, Cepheid and Ventana. He also disclosed that he has contracts with Merrimack, Macrogenics, Roche, Eli-Lilly, Cepheid and Translational Research in Oncology (TRIO).

CCND1 amplification in early breast cancer patients: Correlation with subtypes and prognosis

Mr. Press has disclosed that he is a consultant for Biocartis, Halozyme, Puma Biotechnology, Cepheid, and Ventana. He also disclosed that he has contracts with Merrimack, Macrogenics, Roche, Eli-Lilly and Company, Cepheid, and Translational Research in Oncology (TRIO).

Biomarker analysis from the neoadjuvant KRISTINE study in HER2-positive early breast cancer (EBC)

Dr. Press has disclosed that he is a consultant for Biocartis, Halozyme, Puma Biotechnology, Cepheid and Ventana. He also disclosed that he has contracts with Merrimack, Macrogenics, Roche, Eli-Lilly, Cepheid and Translational Research in Oncology (TRIO).

Biological effects of abemaciclib in a phase2 neoadjuvant study for postmenopausal patients with hormone receptor positive, HER2 negative breast cancer

Mr. Press has disclosed that he is a consultant for Biocartis, Halozyme, Puma Biotechnology, Cepheid, and Ventana. He also disclosed that he has contracts with Merrimack, Macrogenics, Roche, Eli-Lilly and Company, Cepheid, and Translational Research in Oncology (TRIO).

Treatment patterns and resource utilization among patients with HR+/HER2- metastatic breast cancer in a pravastatin insured US population

Mr. Price has disclosed that he receives salary from and has ownership in Eli Lilly and Company.

Long-term follow-up of TEXT and SOFT trials of adjuvant endocrine therapies for premenopausal women with HR- early breast cancer

Ms. Price has no relevant financial relationships to disclose.

12 years median follow up (MFU) of BIG 1-98: Adjuvant letrozole, tamoxifen, and their sequence for postmenopausal women with estrogen responsive early breast cancer

Ms. Price has no relevant financial relationships to disclose.

Cambridge brain mets trial 1 (CamBMT1): A proof-of-principle phase 1b / randomized phase 2 study of afatinib penetration into brain metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy

Mr. Price has no relevant financial relationships to disclose.

Recognition of autologous neoantigens by tumor infiltrating lymphocytes derived from breast cancer metastases

Dr. Prickett has no relevant financial relationships to disclose.

Breast cancer brain metastases show limited intrinsic subtype switching, yet exhibit acquired ERBB2 amplifications and activating mutations

Mr. Prieto has no relevant financial relationships to disclose.

Nonsteroidal, tissue selective androgen receptor modulator (SARM), enobosarm, reduces growth of androgen receptor-positive breast cancer in patient-derived preclinical models

Dr. Pritchard has no relevant financial relationships to disclose.

Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with Trastuzumab

Dr. Pritchard has no relevant financial relationships to disclose.

Discovery of molecular predictors of late breast cancer specific events (BCSE) in ER+, node- breast cancer - new transcriptome expression whole gene analysis of the phase III adjuvant trial SWOG S8814

Dr. Pritchard has no relevant financial relationships to disclose.

Association between BMI and residual estradiol levels in postmenopausal women using adjuvant letrozole: Results of a prospective study

Ms. Pritchard has no relevant financial relationships to disclose.

Preoperative axillary ultrasound guided needle sampling in breast cancer: Comparing the sensitivity of fine needle aspiration cytology and core needle biopsy

Ms. Pritchard has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Author(s)</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1-09-19</td>
<td>Tumor RNA disruption index as a tool to predict response to neoadjuvant chemotherapy in breast cancer: Optimizing timing of biopsy</td>
<td>Laura Pritzker, Ms. Pritzker has disclosed that she is an author on patents filed by RNA Diagnostics, Inc. and an author on patents filed by RNA Diagnostics, Inc. She has also disclosed RNA Diagnostics, Inc. Father (Kenneth Pritzker)</td>
<td>Rna Diagnostics, Inc. Father (Kenneth Pritzker): Salary Rna Diagnostics, Inc. and stock options. Father (Kenneth Pritzker): Owner of Rna Diagnostics, Inc. and stock options.</td>
</tr>
<tr>
<td>S4-05</td>
<td>Expression of the EZH2 oncogene promotes M2 polarization and iron recycling in tumor associated macrophages</td>
<td>Lisa Privette Vinnedge, Dr. Privette Vinnedge has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>OT3-02-06</td>
<td>Femara plus ribociclib or placebo as neo-adjuvant endocrine therapy for women with ER+, HER2-negative early breast cancer: The Feline trial</td>
<td>Lindsey Prochaska, Dr. Prochaska has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>P5-18-02</td>
<td>The pathological complete response is associated with excellent outcomes in BRCA mutation associated triple negative breast cancer</td>
<td>Lindsey Prochaska, Dr. Prochaska has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>P2-03-01</td>
<td>Molecular differences between screen-detected and interval breast cancers are largely explained by PAM50 subtypes</td>
<td>Gabriella Prochaska, Dr. Prochaska has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>P2-02-05</td>
<td>Comparison of non-breed and ovarian cancer phenotypes of BRCA2/2 mutation carriers across multi-gene panels</td>
<td>Jessica Profato-Partlow, Ms. Profato-Partlow has disclosed that she receives salary from Ambry Genetics.</td>
<td></td>
</tr>
<tr>
<td>P5-14-09</td>
<td>Luminal A breast cancer: Is it really a “good prognosis” disease? Preliminary results of the GIM-13 - AMBRA study</td>
<td>Paolo Pronzato, Prof. Pronzato has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>P5-15-07</td>
<td>First and further line choices of treatment for HER2-VE metastatic breast cancer (MBC) according to adjuvant treatment and biological subtype. Preliminary results of the observational GIM-13 - AMBRA Italian study</td>
<td>Paolo Pronzato, Prof. Pronzato has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>S6-01</td>
<td>Phase I and II/II/II trial of antiangiogenic treatment of breast cancer with dorodirubin preventing drug resistance and circumventing resistance</td>
<td>Davide Proserpi, Dr. Proserpi has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>P6-10-17</td>
<td>Elated sentinel nanometric treatment of breast cancer with doxorubicin preventing drug resistance and circumventing resistance</td>
<td>Davide Proserpi, Dr. Proserpi has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>P5-08-01</td>
<td>Circulating tumor cells (CTC) and endothelial cells (EC) prognostic value in HER2 negative metastatic breast cancer patients treated with first line weekly paclitaxel and bevacizumab: First results of a prospective cohort from the French Breast Cancer InterGroup Uwins Cancer (UCBG): COMET Study</td>
<td>Andrew Protter, Dr. Protter has disclosed that he is an employee of Medivation, Inc.</td>
<td></td>
</tr>
<tr>
<td>P5-01-02</td>
<td>Circulating tumor cells (CTC) and endothelial cells (EC) prognostic value in HER2 negative metastatic breast cancer patients treated with first line weekly paclitaxel and bevacizumab: First results of a prospective cohort from the French Breast Cancer InterGroup Uwins Cancer (UCBG): COMET Study</td>
<td>Charlotte Proudhon, Ms. Prouzhon has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>S3-01</td>
<td>IMENEO: International Meta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEOadjuvant chemotherapy</td>
<td>Charlotte Proudhon, Ms. Prouzhon has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>P1-10-20</td>
<td>A multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer: Early results of unplanned boost participants</td>
<td>G Proulx, G Proulx has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>P1-10-19</td>
<td>Two-year follow-up results of a multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer: Early results of unplanned boost participants</td>
<td>G Proulx, G Proulx has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>P1-10-19</td>
<td>Evaluation of subclonality in the CTC and DTC compartment of patients with metastatic breast cancer using low pass whole genome and AmpliSeq panel sequencing</td>
<td>Annemie Prové, Dr. Prové has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>P5-03-10</td>
<td>Evaluation of HER2 expression and amplification on CTCs using DEPArray analysis and sorting followed by FISH</td>
<td>Annemie Prové, Dr. Prové has no relevant financial relationships to disclose.</td>
<td></td>
</tr>
<tr>
<td>P4-22-08</td>
<td>A single-arm phase 2 study to assess clinical activity, efficacy and safety of vorinostat with trilostamine (19RS, 25S) in metastatic or locally advanced breast cancer</td>
<td>Louise Provencher, Ms. Provencher has disclosed that she is a consultant for Cies Roche, Ainger, Genomic Health, Novartis and Pfizer in the 2 last years.</td>
<td></td>
</tr>
</tbody>
</table>

Note: The financial disclosures include information on salaries, stock options, and ownership of companies. The disclosures are managed by the Primary Investigator and the corresponding author. The financial relationships are relevant to the context of the research presented and are disclosed to ensure transparency. The disclosures are presented in a manner that respects the confidentiality of the individuals involved.
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1-11-01</td>
<td>Impact of a change in margin width on rates of re-excision following breast conserving surgery in patients with ductal carcinoma in situ (DCIS)</td>
<td>Elena Provenzano</td>
<td>Dr. Provenzano has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-11-09</td>
<td>Rates of ipsilateral breast tumor recurrence (IBTR) following breast conserving surgery (BCS) and hypofractionated radiotherapy for ductal carcinoma in situ (DCIS)</td>
<td>Zebra Prose</td>
<td>Ms. Prose has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-05-17</td>
<td>Interrogating the impact of pregnancy on breast cancer biology using DNA copy number profiling</td>
<td>Giancarlo Pruneri</td>
<td>Giancarlo Pruneri has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-09-12</td>
<td>Dose dense adjuvant chemotherapy in patients with early breast cancer: Differential treatment effects according to composite index of benefit</td>
<td>Fabio Puglisi</td>
<td>Mr. Puglisi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-24-01</td>
<td>Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (PERUSE)</td>
<td>Shannon Puhalla</td>
<td>Ms. Puhalla has disclosed that she is a consultant for AbbVie, Celldex and Pfizer and receives research funding (institution) from AbbVie, Covance-Bayer, Lilly, Inly, Novartis, Pfizer, Genentech, AstraZeneca, BioMarin and Puma.</td>
</tr>
<tr>
<td>P6-09-08</td>
<td>Methylation of BRCA1 and response to the PARP inhibitor veliparib</td>
<td>Shannon Puhalla</td>
<td>Dr. Puhalla has disclosed that she is a consultant for and has a contract with Abbvie.</td>
</tr>
<tr>
<td>P6-09-34</td>
<td>Clinical and pathological characteristics of a representative cohort of long-term metastatic breast cancer (MBC) survivors</td>
<td>Shannon Puhalla</td>
<td>Dr. Puhalla has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-11-07</td>
<td>Efficacy and tolerability of veliparib (ABC-AT1446) in combination with carboplatin (C) and paclitaxel (P) vs placebo (P) in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer</td>
<td>Shannon Puhalla</td>
<td>Dr. Puhalla has disclosed that she is a consultant for and has a contract with Abvide.</td>
</tr>
<tr>
<td>S5-06</td>
<td>Randomised, placebo-controlled trial of duloxetine for aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS) in early stage breast cancer (SWOG 1202)</td>
<td>Debra Prow</td>
<td>Ms. Prow has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-04-04</td>
<td>Detection of ESR1 mutations in matched primary and metastatic samples from endocrine-resistant lobular breast cancer patients</td>
<td>Giancarlo Pruneri</td>
<td>Giancarlo Pruneri has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-15-02</td>
<td>Attitudes towards tissue donation for rapid autopsy among community and academic oncologists</td>
<td>Shannon Puhalla</td>
<td>Dr. Puhalla has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P13-12</td>
<td>Prognostic significance of a modified residual disease in breast and nodes (mRDBN) algorithm after neoadjuvant therapy for breast cancer</td>
<td>Shannon Puhalla</td>
<td>Dr. Puhalla has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-14</td>
<td>Prognostic significance of a modified residual disease in breast and nodes (mRDBN) algorithm after neoadjuvant therapy for breast cancer</td>
<td>Shannon Puhalla</td>
<td>Dr. Puhalla has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>

**Table notes:**
- **P1-11-01:** The impact of a change in margin width on rates of re-excision following breast conserving surgery in patients with ductal carcinoma in situ (DCIS).
- **P1-11-09:** Rates of ipsilateral breast tumor recurrence (IBTR) following breast conserving surgery (BCS) and hypofractionated radiotherapy for ductal carcinoma in situ (DCIS).
- **P1-05-17:** Interrogating the impact of pregnancy on breast cancer biology using DNA copy number profiling.
- **P1-09-12:** Dose dense adjuvant chemotherapy in patients with early breast cancer: Differential treatment effects according to composite index of benefit.
- **P4-24-01:** Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (PERUSE).
- **P6-09-08:** Methylation of BRCA1 and response to the PARP inhibitor veliparib.
- **P6-09-34:** Clinical and pathological characteristics of a representative cohort of long-term metastatic breast cancer (MBC) survivors.
- **P6-11-07:** Efficacy and tolerability of veliparib (ABC-AT1446) in combination with carboplatin (C) and paclitaxel (P) vs placebo (P) in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer.
- **S5-06:** Randomised, placebo-controlled trial of duloxetine for aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS) in early stage breast cancer (SWOG 1202).
- **P3-04-04:** Detection of ESR1 mutations in matched primary and metastatic samples from endocrine-resistant lobular breast cancer patients.
- **P2-15-02:** Attitudes towards tissue donation for rapid autopsy among community and academic oncologists.
- **P13-12:** Prognostic significance of a modified residual disease in breast and nodes (mRDBN) algorithm after neoadjuvant therapy for breast cancer.
<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stain cell-like transcriptional reprogramming in metastatic resistance</td>
<td>Miguel Angel Pujana</td>
</tr>
<tr>
<td>DNA methylation signature predicting bevacizumab efficacy in metastatic breast cancer</td>
<td>Walter Pulverer</td>
</tr>
<tr>
<td>Impact of pre-operative exercise on breast cancer gene expression</td>
<td>Matthew Pun</td>
</tr>
<tr>
<td>Improved long-term outcomes of breast-conserving therapy for women with ductal carcinoma in situ</td>
<td>Rinaa Punglia</td>
</tr>
<tr>
<td>Breast cancer subtype, age and lymph node status as predictors of local recurrence following breast-conserving therapy</td>
<td>Rinaa Punglia</td>
</tr>
<tr>
<td>The effect of adjuvant chemotherapy in a large prospective series of ER-positive HER2-negative early breast cancers</td>
<td>Kevin Punie</td>
</tr>
<tr>
<td>The association of breast cancer subtype and breast cancer survival with parity and time since last birth</td>
<td>Kevin Punie</td>
</tr>
<tr>
<td>Something from nothing? The case for quality control in liquid biopsy studies</td>
<td>Pavan Purj</td>
</tr>
<tr>
<td>Cyclin D1 binding to chromatin and the induction of chromosomal instability requires the fuzzy domain</td>
<td>Claudia Pupo</td>
</tr>
<tr>
<td>Use of natural language processing on mammography and pathology findings to supplement BI-RADS to improve clinical decision making in breast cancer care</td>
<td>Mamta Puppala</td>
</tr>
<tr>
<td>A phase 2 study of M33001, a novel, and selective estrogen receptor degrader, for the treatment of ER-positive advanced breast cancer</td>
<td>Dinesh Purandare</td>
</tr>
<tr>
<td>A multi-institutional, prospective study of incorporating the genomic platform breast cancer index as a tool for decision-making regarding extension of adjuvant endocrine therapy</td>
<td>Dinesh Purandare</td>
</tr>
<tr>
<td>Preoperative assessment of breast cancer survival using ultrasonographic diameter and shear wave elastography</td>
<td>Colin Purdie</td>
</tr>
<tr>
<td>Which measure of the interim changes in breast tumoral volume at breast MRI in response to neoadjuvant chemotherapy best predicts final pathological response?</td>
<td>Colin Purdie</td>
</tr>
<tr>
<td>A study to determine the optimal method of detection and threshold for lymphoedema intervention: A multi-centre prospective study</td>
<td>Arne Parashotham</td>
</tr>
<tr>
<td>A saline-diphosphate glucose dehydrogenase is required for hyaluronic acid production and breast cancer invasion</td>
<td>Preeti Purwaha</td>
</tr>
<tr>
<td>Impact of radiotherapy on complications and patient-reported satisfaction with breast reconstruction: Findings from the prospective multicenter ARRIC study</td>
<td>Andrea Pusic</td>
</tr>
<tr>
<td>Landscape of somatic mutations in inflammatory breast cancer whole-genome sequences</td>
<td>Lajos Pusztai</td>
</tr>
<tr>
<td>Immune signatures differ and affect prognosis in triple-negative breast cancer subtypes</td>
<td>Lajos Pusztai</td>
</tr>
<tr>
<td>A multi-institutional, prospective study of incorporating the genomic platform breast cancer index as a tool for decision-making regarding extension of adjuvant endocrine therapy</td>
<td>Lajos Pusztai</td>
</tr>
<tr>
<td>Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2 positive early breast cancer (BIG 1-05)</td>
<td>Lajos Pusztai</td>
</tr>
<tr>
<td>Time-gene signature predictive of high residual risk of recurrence after adjuvant chemotherapy in ER-positive HER2-negative breast cancer</td>
<td>Lajos Pusztai</td>
</tr>
</tbody>
</table>
KEYNOTE-012: Long-lasting responses in a phase Ib study of pembrolizumab for metastatic triple-negative breast cancer (mTNBC)

Lajos Pusztai

Dr. Pusztai has disclosed that he is a consultant for Merck.

A phase 3 open-label study of lucitanib in patients (pts) with FGF aberrant metastatic breast cancer (MBC)

Lajos Pusztai

Dr. Pusztai has no relevant financial relationships to disclose.

Phase 1 study of the antibody-drug conjugate (ADC) SGX-UVIA in patients with heavily pretreated metastatic breast cancer

Lajos Pusztai

Dr. Pusztai has disclosed that he has a contract with Seattle Genetics, Inc.

Immune sculpting of the triple negative breast cancer genome

Lajos Pusztai

Dr. Pusztai has disclosed that he receives consulting fees Merck, Celgene, Genentech and AstraZeneca. He also disclosed that he does contracted research for Merck, Genentech, Seattle Genetics, Novartis and AstraZeneca. These relationships do not impact his ability to review presentations.

Increased glycolysis directly activates transcriptional coactivator SRC-3 to promote aggressive metastatic breast cancer

Nagireddy Putluri

Dr. Putluri has no relevant financial relationships to disclose.

Mitochondria-nuclear communication regulates epithelial-mesenchymal transition and metastasis in triple negative breast cancer

Nagireddy Putluri

Dr. Putluri has no relevant financial relationships to disclose.

Uridine diphosphate glucose dehydrogenase is required for hyaluronic acid production and breast cancer invasion

Nagireddy Putluri

Dr. Putluri has no relevant financial relationships to disclose.

Mitochondria-nuclear communication regulates epithelial-mesenchymal transition and metastasis in triple negative breast cancer

Vasanta Putluri

Vasanta Putluri has no relevant financial relationships to disclose.

The efficacy and safety of the addition of Bibandronate to adjuvant hormonal therapy in postmenopausal women with hormone-receptor positive early breast cancer. First results of the TEAM IIB trial (BOOG 2006-05)

H Putter

Prof Putter has no relevant financial relationships to disclose.

Safety assessment of extended adjuvant endocrine therapy with letrozole; results of the randomized phase III IDEAL trial (BOOG 2006-05)

Hein Putter

Dr. Putter has no relevant financial relationships to disclose.

10-year follow-up and biomarker discovery for adjuvant endocrine therapy; results of the TEAM trial

Hein Putter

Dr. Putter has no relevant financial relationships to disclose.

Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006-05)

Hein Putter

Dr. Putter has no relevant financial relationships to disclose.

Establishment and characterization of ST941/C; an ESR1-mutant ER+ breast cancer cell line and xenograft from a patient with acquired resistance to endocrine therapy

Xiaoling Puyang

Xiaoling Puyang has no relevant financial relationships to disclose.

Oncologic outcomes of immediate breast reconstruction after neoadjuvant chemotherapy in breast cancer patients: A matched case control study

Jai-Kyoung Pyon

Jai-Kyoung Pyon has no relevant financial relationships to disclose.

Impact of radiotherapy on complications and patient-reported satisfaction with breast reconstruction: Findings from the prospective multicenter MROC study

Qi Qi

Qi Qi has no relevant financial relationships to disclose.

Low-fat dietary pattern and breast cancer overall survival in the women's health initiative dietary modification randomized controlled trial

Xicheng Qi

Xicheng Qi has no relevant financial relationships to disclose.

Predicting germline mutations in BRCA1/2 and beyond: A comparison of women with single and multiple breast primaries

Rajun Qian

Dr. Qian has disclosed that he is a full time employee of Ambry Genetics.

Breast cancer risk prediction using a polygenic risk score in women of African ancestry: Findings from GWAS in breast cancer in the African diaspora

Frank Qian

Dr. Qian has no relevant financial relationships to disclose.
Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer

Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: A randomized, phase 2 study

Cambridge brain mets trial 1 (CamBMT1): A proof-of-principle phase 2b / randomized phase 2 study of afatinib penetration into brain metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy

Determining the optimal vaccination strategy using a combination of the folate binding protein (FBP) peptide vaccine (E39+GM-CSF) and an attenuated version (E39) to maximize the immunologic response in breast cancer patients

A phase 2 study of eribulin followed by doxorubicin and cyclophosphamide as preoperative therapy for HER2-negative inflammatory breast cancer

MicroRNA-367a promotes tumor growth and stemness potential by targeting FBXW7 in breast cancer

Adjunct diagnosing with breast specific gamma imaging or ultrasound in symptomatic women with mammographic dense breasts: A single center retrospective and comparative analysis

Development of a panel of serum-based protein biomarkers for the non-invasive detection of breast cancer in BI-RADS category 4 patients

Phase II in-human dose escalation study of the optical molecular imaging tracer bevacizumab-800cw for molecular fluorescence guided surgery in primary breast cancer patients

Validation of a Chinese nomogram with a Dutch breast cancer population: Excellent prediction of the probability of axillary lymph node metastasis

Randomized study of COX2 inhibition on systemic inflammation in obese and non-obese subjects

Diversity-induced EMT in luminal A breast cancer cells
OT3-01-02
CNIO-BR-008 trial: Reversion of T-cell exhaustion caused by chronic treatment with hypoxia-inducing antiangiogenic treatment by durvalumab in HER2-negative breast cancer: A pilot proof-of-concept trial
Miguel Quintela-Fandino
Dr. Quintela-Fandino has no relevant financial relationships to disclose.

P4-21-16
Copy number alteration-induced gene breakage analysis identifies recurrent FOXF1 fusions in breast cancer
Fanasza Quinenga
Ns. Quinenga has no relevant financial relationships to disclose.

P1-05-14
Menarcheal subtype negatively associates with the presence of immune infiltrates within a triple negative breast cancer classifier
Jelmar Quitil
Jelmar Quitil has no relevant financial relationships to disclose.

P1-07-03
Factors associated with follow up medical care among women with early stage breast cancer
Farah Quijano
Dr. Quijano has no relevant financial relationships to disclose.

P5-13-16
Factors associated with multidisciplinary care in the management of early stage breast cancer
Farah Quijano
Dr. Quijano has no relevant financial relationships to disclose.

P6-08-04
Preclinical efficacy of dasatinib in combination with PARP inhibitor plus standard cytotoxic agent in triple-negative breast cancer xenograft model
R & D NCI
R&D NCI has no relevant financial relationships to disclose.

P5-15-05
Randomized phase II study evaluating different schedules of nab-paclitaxel in metastatic breast cancer (MBC): Results of the SNAP study
Manuela Rabaglio
Ms. Rabaglio has no relevant financial relationships to disclose.

P6-01-06
Screening, management, cancer diagnoses, and outcomes of women with germline BRCA mutations in Israel: The Noga Clinic experience
Nick Rabas
Mr. Rabas has no relevant financial relationships to disclose.

P3-08-06
Screening, management, cancer diagnoses, and outcomes of women with germline BRCA mutations in Israel: The Noga Clinic experience
Rachel Rabinsvitch
Dr. Rabinsvitch has no relevant financial relationships to disclose.

P6-06-05
Screening, management, cancer diagnoses, and outcomes of women with germline BRCA mutations in Israel: The Noga Clinic experience
Ron Rabinsvitch
Dr. Rabinsvitch has no relevant financial relationships to disclose.

P2-04-10
High-affinity activated natural killer (haNK) cells augment trastuzumab efficacy in a mouse model of HER2-positive human metastatic breast cancer
Shahrooz Rabizadeh
Shahrooz Rabizadeh has disclosed that he receives salary from and has a patent with NantBioscience, NantCell. He has also disclosed that he has ownership in NantKwest.

P2-04-26
Identifying patient-specific neoepitopes for cell-based and vaccine immunotherapy across breast cancer classifications reveals rarely shared recurrent neoepitopes
Shahrooz Rabizadeh
Dr. Rabizadeh has disclosed that he is an employee of NantOmics.

P6-07-11
Serum levels of RANKL are increased in primary breast cancer patients in the presence of disseminated tumor cells in the bone marrow
Tilmann Rachner
Tilmann Rachner has no relevant financial relationships to disclose.

OT1-02-04
The DETECT V-study - Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemotherapy or endocrine therapy in patients with HER2-positive and hormone receptor positive metastatic breast cancer
Brigitte Rack
Dr. Rack has disclosed that she is a consultant for Novartis and Roche. She also disclosed that she has a contract with Johnson&Johnson.

OT3-04-02
DETECT III and IV: Individualised CTC-based therapy of metastatic breast cancer
Brigitte Rack
Dr. Rack has disclosed that she is an advisor for Novartis and Roche and has a research contract with Johnson&Johnson.
P1-01-03 Dynamics of circulating tumor cells during the course of chemotherapy and prognostic relevance across molecular subtypes in high-risk early breast cancer patients - Results from the adjuvant SUCCESS A trial

Brigitte Rack
Dr. Rack has no relevant financial relationships to disclose.

P1-01-15 DETECT V - Detection of the expression of estrogen receptor and human epidermal growth factor receptor 2 on circulating tumor cells from metastatic breast cancer patients

Brigitte Rack
Ms. Rack has no relevant financial relationships to disclose.

P1-05-02 Active surveillance with a combination of tumor marker CA27.29 and detection of circulating tumor cells two year after primary diagnosis strongly predicts subsequent prognosis

Brigitte Rack
Ms. Rack has disclosed that he has a contract with Veridex.

P4-07-01 Profiling miRNA in high risk post-operative early breast cancer patients to detect possible association to correlation with immune system antitumor response

Brigitte Rack
Dr. Rack has no relevant financial relationships to disclose.

P1-03-03 High concordance of ER, PR, HER2 and Ki67 by central IHC and FISH with mRNA measurements by GeneXpert® breast cancer stratifier assay

Barbara Radecka
Dr. Radecka has no relevant financial relationships to disclose.

P2-05-02 Active surveillance with a combination of tumor marker CA27.29 and detection of circulating tumor cells two year after primary diagnosis strongly predicts subsequent prognosis

Brigitte Rack
Ms. Rack has no relevant financial relationships to disclose.

P5-05-22 Predictive value of quantitative HER2 and HER3 levels combined with downstream signaling markers in HER2-positive advanced breast cancer patients treated with lapatinib

Barbara Radecka
Ms. Radecka has no relevant financial relationships to disclose.

OT3-01-05 A phase II study of PD-L1 and PD-L1 inhibition and immunopharmacokinetics in metastatic breast cancer

Alfred Rademaker
Ms. Rademaker has no relevant financial relationships to disclose.

P1-05-06 Circulating tumor DNA (ctDNA): A real-time application of precision medicine to the management of metastatic breast cancer (MBC)

Alfred Rademaker
Dr. Rademaker has disclosed that he receives research funding from JAMA-Journal of the American Medical Association and Siemens.

P2-01-03 Estrogen receptor 1 (ESR1) mutations in circulating tumor DNA (ctDNA): A guide to the management of advanced breast cancer (ABC)

Alfred Rademaker
Dr. Rademaker has disclosed that he receives research funding from JAMA-Journal of the American Medical Association and Siemens.

OT3-04-01 BRE12-158: A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer (TNBC)

Neetu Radhakrishnan
Dr. Radhakrishnan has no relevant financial relationships to disclose.

OT3-02-04 A randomized controlled trial comparing acupuncture versus usual care for the treatment of aromatase inhibitor-induced arthralgia (AIA) in women with early-stage breast cancer survivors on hormonal adjuvant therapy: An energy balance research in cancer (EnBaR) prospective study

Karen Rados
Ms. Rados has no relevant financial relationships to disclose.

OT3-07-04 A randomized study comparing MoistHer to topical lidocaine for female breast cancer survivors with dyspareunia

Karen Rados
Ms. Rados has no relevant financial relationships to disclose.

OT3-04-01 BRE12-158: A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer (TNBC)

Neetu Radhakrishnan
Dr. Radhakrishnan has no relevant financial relationships to disclose.

OT3-02-04 A randomized controlled trial comparing acupuncture versus usual care for the treatment of aromatase inhibitor-induced arthralgia (AIA) in women with early-stage breast cancer survivors on hormonal adjuvant therapy: An energy balance research in cancer (EnBaR) prospective study

Karen Rados
Ms. Rados has no relevant financial relationships to disclose.

OT3-07-04 A randomized study comparing MoistHer to topical lidocaine for female breast cancer survivors with dyspareunia

Karen Rados
Ms. Rados has no relevant financial relationships to disclose.

OT3-08-01 A randomized study of personalized music therapy for patients with early stage breast cancer receiving chemotherapy

Karen Rados
Ms. Rados has no relevant financial relationships to disclose.

OT3-04-01 BRE12-158: A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer (TNBC)

Milan Radovich
Dr. Radovich has no relevant financial relationships to disclose.

P6-09-21 Genetic variation in CYP3A affects steady-state exemestane concentrations but does not explain inter-race difference

James Rae
Dr. Rae has no relevant financial relationships to disclose.

P02-07 Discovery of molecular predictors of late breast cancer specific events (BCSE) in ER+, node+ breast cancer - new transcriptome expression whole gene analysis of the phase III adjuvant trial SWOG S8814

James Rae
Dr. Rae has no relevant financial relationships to disclose.

P4-21-08 A phase I/II of S-222611, a reversible EGFR and HER2 inhibitor, combined with trastuzumab +/- chemotherapy in patients with HER2-positive metastatic breast cancer

Saeed Rafii
Dr. Rafii has no relevant financial relationships to disclose.
Committee Member

Susan Rafte

Ms. Rafte has no relevant financial relationships with commercial interests to disclose.

P2-05-01

Clinico-pathological relationships with Ki67 in POSTIC
CRAU/05/0125 - Critical lessons for assessing Ki67 for prognosis and as a pharmacodynamic marker

Vidya Raghavan

Vidya Raghavan has no relevant financial relationships to disclose.

P1-06-11

Development and validation of a new non-parametric breast cancer risk assessment model on US and European screening populations

Akshara Raghavendra

Dr. Raghavendra has no relevant financial relationships to disclose.

P1-06-05

Propensity score model using grade and hormone receptor staining defines high risk for distant metastasis: Comparison to the 21-gene recurrence score

Akshara Raghavendra

Dr. Raghavendra has no relevant financial relationships to disclose.

P2-05-01

A model using grade and hormone receptor staining defines high risk for distant metastasis: Comparison to the 21-gene recurrence score

Akshara Raghavendra

Akshara Raghavendra has no relevant financial relationships to disclose.

P1-06-05

Proposal for a new breast cancer staging classification: Incorporating clinical and biological factors

Akshara Raghavendra

Akshara Raghavendra has no relevant financial relationships to disclose.

P1-06-05

A model using grade and hormone receptor staining defines high risk for distant metastasis: Comparison to the 21-gene recurrence score

Akshara Raghavendra

Akshara Raghavendra has no relevant financial relationships to disclose.

P3-15-01

High-grade human cytomegalovirus IEA is associated with expression of COX-2 and S-LO in human breast cancer samples

Ahmer Rahbar

Ahmer Rahbar has no relevant financial relationships to disclose.

P6-06-01

Low expression levels of hormone receptors (ER-a and PR) in breast cancer samples is significantly associated with high-grade human cytomegalovirus IEA

Ahmer Rahbar

Ahmer Rahbar has no relevant financial relationships to disclose.

P6-06-01

Low expression levels of hormone receptors (ER-a and PR) in breast cancer samples is significantly associated with high-grade human cytomegalovirus IEA

Ahmer Rahbar

Ahmer Rahbar has no relevant financial relationships to disclose.

P3-12-12

Impact of magnetic resonance imaging on conversion from wide local excision to mastectomy in patients with ductal carcinoma in situ: First results from the ECOG-ACRIN 4112 prospective study

Nabil Rahbar

Dr. Rahbar has no relevant financial relationships to disclose.

P17-04

Mechanisms of drug sensitization by GPR4 on dextran/insulin-resistant human breast adenocarcinoma

Md Rahman

Dr. Rahman has no relevant financial relationships to disclose.

P6-01-21

Novel CD146-downstream signaling pathway involved in breast tumor suppression

Mizanur Rahman

Dr. Rahman has no relevant financial relationships to disclose.

P6-01-06

Glutamine metabolism drives breast cancer invasion by providing a source of extracellular glutamate to activate the GRM3 metabotropic glutamate receptor

Elena Rainero

Ms. Rainero has no relevant financial relationships to disclose.

P2-15-02

Attitudes towards tissue donation for rapid autopsy among community and academic oncologists

Padma Rajagopal

Dr. Rajagopal has no relevant financial relationships to disclose.

P1-04-03

Cross-talk between RNA methyltransferase and demethylase regulates breast cancer growth and progression

Subaipriya Rajamanickam

Dr. Rajamanickam has no relevant financial relationships to disclose.

P1-10-20

A multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer: Early results of unplanned boost participants

S Rahman

S Rahman has no relevant financial relationships to disclose.

P1-10-19

Two-year follow-up results of a multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer

Sophia Rahman

Sophia Rahman has no relevant financial relationships to disclose.

P2-05-22

Prognostic relevance of caspase 8 polymorphisms for breast cancer

Callies Rainier

Dr. Rainier has no relevant financial relationships to disclose.

P4-12-10

Prognostic relevance of caspase 8 polymorphisms for breast cancer

Kimmig Rainier

Dr. Rainier has no relevant financial relationships to disclose.

P6-05-06

Glutamine metabolism drives breast cancer invasion by providing a source of extracellular glutamate to activate the GRM5 metabotropic glutamate receptor

Elena Rainero

Ms. Rainero has no relevant financial relationships to disclose.

P2-15-02

A multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer: Early results of unplanned boost participants

S Rahman

S Rahman has no relevant financial relationships to disclose.

P1-10-20

Two-year follow-up results of a multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer

Sophia Rahman

Sophia Rahman has no relevant financial relationships to disclose.

P1-10-20

Prognostic relevance of caspase 8 polymorphisms for breast cancer

Callies Rainier

Dr. Rainier has no relevant financial relationships to disclose.

P4-12-10

Prognostic relevance of caspase 8 polymorphisms for breast cancer

Kimmig Rainier

Dr. Rainier has no relevant financial relationships to disclose.

P6-05-06

Glutamine metabolism drives breast cancer invasion by providing a source of extracellular glutamate to activate the GRM5 metabotropic glutamate receptor

Elena Rainero

Ms. Rainero has no relevant financial relationships to disclose.

P2-15-02

A multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer: Early results of unplanned boost participants

S Rahman

S Rahman has no relevant financial relationships to disclose.

P1-10-20

Two-year follow-up results of a multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer

Sophia Rahman

Sophia Rahman has no relevant financial relationships to disclose.

P1-10-20

Prognostic relevance of caspase 8 polymorphisms for breast cancer

Callies Rainier

Dr. Rainier has no relevant financial relationships to disclose.

P4-12-10

Prognostic relevance of caspase 8 polymorphisms for breast cancer

Kimmig Rainier

Dr. Rainier has no relevant financial relationships to disclose.

P6-05-06

Glutamine metabolism drives breast cancer invasion by providing a source of extracellular glutamate to activate the GRM5 metabotropic glutamate receptor

Elena Rainero

Ms. Rainero has no relevant financial relationships to disclose.

P2-15-02

A multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer: Early results of unplanned boost participants

S Rahman

S Rahman has no relevant financial relationships to disclose.

P1-10-20

Two-year follow-up results of a multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer

Sophia Rahman

Sophia Rahman has no relevant financial relationships to disclose.

P1-10-20

Prognostic relevance of caspase 8 polymorphisms for breast cancer

Callies Rainier

Dr. Rainier has no relevant financial relationships to disclose.

P4-12-10

Prognostic relevance of caspase 8 polymorphisms for breast cancer

Kimmig Rainier

Dr. Rainier has no relevant financial relationships to disclose.

P6-05-06

Glutamine metabolism drives breast cancer invasion by providing a source of extracellular glutamate to activate the GRM5 metabotropic glutamate receptor

Elena Rainero

Ms. Rainero has no relevant financial relationships to disclose.
P5-07 Double blinded validation study to assess performance of IBM artificial intelligence platform, Watson for oncology in comparison with Manipal multidisciplinary tumour board - First study of 538 breast cancer cases

P4-19-02 Young women with early stage breast cancer and their supportive care needs: Results from a regional survey

P6-09-51 The REQUIET-AB study: Validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality of life in breast cancer patients

P3-09-05 Clinical outcome of patients with advanced triple negative breast cancer with germline and somatic variants in homologous recombination gene

OT3-02-04 A randomized controlled trial comparing acupuncture versus usual care for the treatment of aromatase inhibitor-induced arthralgia (AIA) in women with early stage breast cancer

PT-07-14 Rates of immune infiltration in patients with triple-negative breast cancers by molecular subtype and in patients with inflammatory and non-inflammatory breast cancers

P2-02-02 Intravenous diphosphate glucose dehydrogenase is required for hyaluronic acid production and breast cancer invasion

P2-07-14 Association between BMI and residual estradiol levels in post-menopausal women using adjuvant letrozole: Results of a prospective study

P2-09-14 Cross-talk between RNA methyltransferase and demethylase regulates breast cancer growth and progression

P2-08-03 Chemotherapy related risk factors associated with lymphoedema in breast cancer patients - Should repeated prophylactic arm infusions be avoided?

P3-04-25 Role of H2FZ, a long non-coding RNA, in development of inflammatory and non-inflammatory breast cancers

P3-04-31 Fibroblasts isolated from the "normal-like" tissue adjacent to breast tumours suppress healthy epithelial progenitor cell proliferation while supporting tumour cell growth

P6-09-39 The role of quantitative estrogen receptor status in predicting breast tumor response to neoadjuvant chemotherapy

P6-11-03 A phase 2 open label study of lutidin in patients [plt] with p53 aberrant metastatic breast cancer (MBC)

PS-15-15 Prone vs. supine positioning for optimizing radiation heart exposure during left breast radiotherapy: A simple clinical tool for prediction*

PS-16-23 Rapid germline BRCA screening for locally advanced breast cancer changes surgical procedure after neoadjuvant chemotherapy

YE Ramya
Arundhati Rao
Dr. Rantalainen has no relevant financial relationships to disclose.

Lakshmi Rao
Kimberly Randolph
Ms. Randall Armel has no relevant financial relationships to disclose.

Arvind Rao
Kimberly Randolph
Rarouk-Simonet
Mr. Rárosi has no relevant financial relationships to disclose.

Emmanuelle
Ms. Randolph has no relevant financial relationships to disclose.

Dr. Rarouk-Simonet has no relevant financial relationships to disclose.

Tiziana Rancati has no relevant financial relationships to disclose.

Arundhati Rao has no relevant financial relationships to disclose.

Jacques Raphael
Dr. Raphael has no relevant financial relationships to disclose.

Mitch Raponi
Manjeet Rao
Mr. Rapoport has disclosed that he receives salary from Clovis Oncology.

Smita Rao
Afshin Raouf
Dr. Raouf has no relevant financial relationships to disclose.

Sowmya Rao
Dr. Raouf has no relevant financial relationships to disclose.

Smita Rao
Afshin Raouf
Sowmya Rao
Dr. Raouf has no relevant financial relationships to disclose.

Ms. Randolph-Jackson has no relevant financial relationships to disclose.

Dr. Raphael has no relevant financial relationships to disclose.

Bernardo Rapoport
Pamela
Mr. Rapoport has disclosed that he is a consultant and speaker for Tesaro and Merck. He also disclosed that he receives travel and accommodations expenses and honoraria from Tesaro and Merck.

Randolph-Jackson
Susan Randall Armel
Dr. Raponi has disclosed that he receives salary from Clovis Oncology.

Punam Kona
Dr. Kona has no relevant financial relationships to disclose.

Punam
Rao
Dr. Rao has no relevant financial relationships to disclose.
P6-02-02
Uridine diphosphate glucose dehydrogenase is required for hyaluronic acid production and breast cancer invasion
Uttam Rasaily
Uttam Rasaily has no relevant financial relationships to disclose.

P3-04-26
Establishment and characterisation of ST4H3+C; an ESRI-mutant 5KR breast cancer cell line and xenograft from a patient with acquired resistance to endocrine therapy
Drew Rasco
Mr. Rasco has no relevant financial relationships to disclose.

P9-07-22
Association of Hedgehog signaling pathway with luminal B subtype of breast cancer affected patients of Pakistan
Rakhshanda Rashid
Dr. Rashid has no relevant financial relationships to disclose.

P2-12-04
Impact of institution of young women’s breast cancer clinic on time to treatment and utilization of fertility, genetics and social work consultations in women under age 50 with new diagnosis of early stage breast cancer
Paola Raska
Dr. Raska has no relevant financial relationships to disclose.

P6-09-22
Detecting high mutational load ER+ breast cancer patients through FoundationOne cancer gene panel mutations
Paola Raska
Dr. Raska has no relevant financial relationships to disclose.

P1-07-10
Prediction of 5yr distant recurrence (DR) using the Prosigna® (PAM50) assay in histological subgroups of a Danish breast cancer group (BRCC) cohort of postmenopausal Danish women with hormone receptor-positive (HR+) early breast cancer (ERC) allocated to 5yr of endocrine therapy (ET) alone
Brigitte Rasmussen
Ms. Rasmussen has no relevant financial relationships to disclose.

P6-07-02
CDK4 phosphorylation status and corresponding gene expression profile predict sensitivity to Palbociclib
Eric Raspe
Dr. Raspe has no relevant financial relationships to disclose.

S3-06
A phase III trial evaluating pCR in patients with HR+, HER2-negative breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen deprivation: NSC oncology/NSABP B-32
Priya Rastogi
Priya Rastogi has no relevant financial relationships to disclose.

P4-23-02
Efficacy and tolerability of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer
Christine Ratajczak
Ms. Ratajczak has disclosed that she is an employee of and has ownership in AbbVie.

S2-08
Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: A randomized, phase 2 study
Christine Ratajczak
Ms. Ratajczak has disclosed that she has ownership in and is an employee of AbbVie.

P4-19-02
Young women with early stage breast cancer and their supportive care needs: Results from a regional survey
Emma Ratcliffe
Ms. Ratcliffe has no relevant financial relationships to disclose.

P6-09-51
The REQUITE-AB study: Validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality of life in breast cancer patients
Tim Ratliff
Mr. Ratliff has no relevant financial relationships to disclose.

OT1-04-03
Randomised phase I study of radiation bevacizumab, topotecan and cisplatin followed by whole brain radiotherapy (WBRT) versus WBRT alone in breast cancer with untreated brain metastases (A-PLUS)
Kun-Ming Rau
Kun-Ming Rau has no relevant financial relationships to disclose.

PD6-04
HOHO study: How European and US young women cope with breast cancer and fertility concerns
Daniel Rauch
Mr. Rauch has no relevant financial relationships to disclose.

OT2-01-14
Triple-negative first-line study: Neadjuvant trial of nab-paclitaxel and atezolizumab, a PD-L1 inhibitor, in patients with triple negative breast cancer (TNBC) (NCT02530489)
Gaiane Rauch
Dr. Rauch has no relevant financial relationships to disclose.

OT2-01-20
Phase IIb study of neoadjuvant panitumumab combined with carboplatin and paclitaxel (PaCT) for anthracycline-resistant triple-negative breast cancer (TNBC)
Gaiane Rauch
Gaiane Rauch has no relevant financial relationships to disclose.

P4-06-03
An annotated collection of pre- and post-therapy breast cancer patient-derived xenograft models built from fine needle aspiration samples aligned with ongoing clinical trials documenting response to treatment
Gaiane Rauch
Dr. Rauch has no relevant financial relationships to disclose.
Feasibility trial for identification of patients for eliminating breast cancer surgery following neoadjuvant systemic therapy

Gaine Rauch
Dr. Rauch has no relevant financial relationships to disclose.

NCT02456857: A phase II trial of liposomal doxorubicin, bevacizumab and everolimus (DAE) in patients (pts) with localized triple-negative breast cancer (TNBC) with tumors predicted insensitive to standard neoadjuvant chemotherapy (NACT)

Martina Rauner
Ms. Rauner has no relevant financial relationships to disclose.

Serum levels of RANKL are increased in primary breast cancer patients in the presence of disseminated tumor cells in the bone marrow

Martina Rauner
Ms. Rauner has no relevant financial relationships to disclose.

Double blinded validation study to assess performance of IBM artificial intelligence platform, Watson for oncology in comparison with Manipal multidisciplinary tumour board - First study of 638 breast cancer cases

Amit Raithan
Ms. Raithan has no relevant financial relationships to disclose.

HER2-associated trangenic phenotype as a potential therapeutic target in breast cancer patients

Graziela Ravacci
Dr. Ravacci has no relevant financial relationships to disclose.

Metabolomic profiling of breast cancer and adjacent tissue

Graziela Ravacci
Ms. Ravacci has no relevant financial relationships to disclose.

Discovery of molecular predictors of late breast cancer specific events (BCSE) in ER+, nabx breast cancer - new transcriptome expression whole gene analysis of the phase III adjuvant trial SWOG S8814

Peter Rayan
Dr. Rayan has no relevant financial relationships to disclose.

Comprehensive genomic profiling of 54 cases of breast angiogenesis

Vinoth Ravi
Dr. Ravi has no relevant financial relationships to disclose.

A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA)

Shobha Ravipaty
Shobha Ravipaty has no relevant financial relationships to disclose.

KEYNOTE-012: Long lasting responses in a phase Ib study of pembrolizumab for metastatic triple-negative breast cancer (mTNBC)

Archana Ray
Dr. Ray has disclosed ownership interest in Adjuvant Inc. This relationship does not impact his ability to review presentations.

Dual inhibition of the MEK5 and PI3K pathways synergistically reduces proliferation and viability in triple negative breast cancer cells

Christopher Raybuck
Mr. Raybuck has no relevant financial relationships to disclose.

Oncologic outcomes of immediate breast reconstruction after neoadjuvant chemotherapy in breast cancer patients: A matched case control study

Musaed Rayzah
Dr. Rayzah has no relevant financial relationships to disclose.

Multicentre observational study evaluating why mastectomies are advised by UK multi-disciplinary teams

Wajeeha Razaq
Dr. Razaq has no relevant financial relationships to disclose.

Diagnosing cognitive impairment (“chemo brain”) in breast cancer survivors

Wajeeha Razaq
Dr. Razaq has no relevant financial relationships to disclose.

The UK CORIS trial: Randomising patients with low or low intermediate grade ductal carcinoma in situ (DCIS) to surgery or active monitoring

Daniel Rea
Mr. Rea has no relevant financial relationships to disclose.

Multicentre observational study evaluating why mastectomies are advised by UK multi-disciplinary teams

Daniel Rea
Dr. Rea has no relevant financial relationships to disclose.

CORIS trial of active monitoring for DCIS: How does the online pathology eligibility review process work?

Daniel Rea
Mr. Rea has no relevant financial relationships to disclose.

NOSTRA PRELIM: A non randomised pilot study designed to assess the ability of image guided core biopsies to detect residual disease in patients with early breast cancer who have received neoadjuvant chemotherapy to inform the design of a planned trial

Daniel Rea
Dr. Rea has disclosed that he is a consultant for Genomic Health, Roche and Novartis.

10 year follow-up and biomarker discovery for adjuvant endocrine therapy results of the TEAM trial

Daniel Rea
Dr. Rea has no relevant financial relationships to disclose.
Open label, phase 2 safety, efficacy, and pharmacokinetic study of pre-surgical intramuscular and intraductal fulvestrant in women with invasive breast cancer or DCIS undergoing mastectomy or lumpectomy

Janet Rea
Ms. Rea has no relevant financial relationships to disclose.

Maintenance immunotherapy in estrogen receptor negative (ER-) locally advanced (LA) and/or metastatic breast cancer (MBC). Long-term follow-up of a phase II study

Silvia Rea
Dr. Rea has no relevant financial relationships to disclose.

Predictive factors of pathology complete response to neoadjuvant chemotherapy in patients with Luminal HER2+ local advanced breast cancer using the OMNET microarray

Rosa Rebollar-Vega
Dr. Rebollar-Vega has no relevant financial relationships to disclose.

Maintenance immunotherapy in estrogen receptor negative (ER-) locally advanced (LA) and/or metastatic breast cancer (MBC). Long-term follow-up of a phase II study

Francisco Recchia
Dr. Recchia has no relevant financial relationships to disclose.

The Y537S ESR1 mutation is a dominant driver of distant ER-positive breast cancer metastasis

Yassine Rechoum
Dr. Rechoum has no relevant financial relationships to disclose.

PROSPECTIVE evaluation of the predictive value of biomarkers with complete pathologic response using neoadjuvant chemotherapy plus trastuzumab + pertuzumab in HER2+ breast cancer patients with invasive tumors

Siomando Recinoso
Dr. Recinoso has disclosed that he is a consultant for Roche.

Maintenance immunotherapy in estrogen receptor negative (ER-) locally advanced (LA) and/or metastatic breast cancer (MBC). Long-term follow-up of a phase II study

Monica Red Brewer
Dr. Red Brewer has no relevant financial relationships to disclose.

Pan-HER, an antibody mixture with antitumor activity against drug-resistant HER2-overexpressing breast cancers with high ERBB ligand expression

Monica Red-Brewer
Ms. Red-Brewer has no relevant financial relationships to disclose.

Patient derived DCIS mouse-intraductal (MIND) models recapitulate the full spectrum of human patient pathology and histologic features including progression to invasion of a subset of cases

Mark Reddick
Dr. Reddick has no relevant financial relationships to disclose.

Pharmacokinetics of enzalutamide in a phase 2 open-label dose-ranging study in breast cancer patients receiving TC regimen

Sury Reddy
Dr. Reddy has disclosed that he receives salary from and has ownership in Spectrum Pharmaceuticals.

Immunogenicity of enzalutamide in a phase 2 open-label dose-ranging study of enzalutamide in breast cancer patients receiving TC regimen

Sury Reddy
Dr. Reddy has disclosed that he receives salary from and has ownership in Spectrum Pharmaceuticals.

Strom cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer

Jay Reddy
Dr. Reddy has no relevant financial relationships to disclose.

BRE212-SIB: A phase II randomized controlled trial of genomically directed therapy after neoadjuvant chemotherapy in patients with triple negative breast cancer (TNBC)

Nabraj Reddy
Dr. Reddy has no relevant financial relationships to disclose.

Landscape of somatic mutations in inflammatory breast cancer whole-genome sequences

Sangthetha Reddy
Dr. Reddy has no relevant financial relationships to disclose.

Immunoe-characterization of inflammatory breast cancer and correlation to pathological complete response

Sangthetha Reddy
Dr. Reddy has no relevant financial relationships to disclose.

Diagnostic performance of supplemental screening with molecular breast imaging in women with dense breast tissue

Roberta Redfern
Dr. Redfern has disclosed that he receives sponsorship from Roche Products, Pty. Limited and Amgen.

Efficacy and safety of verodermus plus exemestane in HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy, in routine clinical practice: 2nd interim analysis from STEPMAST

Andrew Redfern
Mr. Redfern has disclosed that he receives SABCS sponsorship attendance from Roche Pharmaceuticals.

Updated safety results from the first multicenter, open-label, phase IIb study investigating the combination of pertuzumab with subcutaneous trastuzumab and a taxane in patients with HER2-positive metastatic breast cancer (SAPPHIRE)

Andrew Redfern
Mr. Redfern has disclosed that he receives SABCS sponsorship attendance from Roche Pharmaceuticals.

Diagnostic performance of supplemental screening with molecular breast imaging in women with dense breast tissue

Andreas Redl
Dr. Redl has disclosed that he is an independent statistician.
Combined targeted therapies for advanced triple negative breast cancer: A phase II trial of nab-paclitaxel and bevacizumab followed by maintenance targeted therapy with bevacizumab and erlotinib
Mary Redman
Dr. Redman has no relevant financial relationships to disclose.

An annotated collection of pre- and post-therapy breast cancer patient-derived xenograft models built from fine needle aspiration samples aligned with ongoing clinical trials documenting response to treatment
Alena Redwood
Dr. Redwood has no relevant financial relationships to disclose.

Comprehensive analysis of the DNA damage repair and maintenance pathways that regulate TNBC sensitivity to replication stress
Alena Redwood
Alena Redwood has no relevant financial relationships to disclose.

Safety and efficacy results from phase I study of BTY 719 plus nab-paclitaxel in HER2-negative metastatic breast cancer
Gregory Reed
Dr. Reed has no relevant financial relationships to disclose.

The UK CRIS trial: Randomizing patients with low or low-intermediate grade ductal carcinoma in situ (DCIS) to surgery or active monitoring
Malcolm Reed
Mr. Reed has no relevant financial relationships to disclose.

Maximising recruitment and retention of patients into UK-ANZ POSNOC trial
Malcolm Reed
Mr. Reed has no relevant financial relationships to disclose.

A multi-OmIC analysis to explore the impact of "actionable" genomic alterations on protein pathway activation: Clinical implication for precision medicine in metastatic breast cancer
Alex Reeded
Alex Reeded has no relevant financial relationships to disclose.

Comparing the frequency and types of genetic alterations between older and younger women with metastatic breast cancer at the University of North Carolina at Chapel Hill
Katherine Reeder-Hayes
Dr. Reeder-Hayes has no relevant financial relationships to disclose.

Identification of proliferation-related drivers and their role in precision medicine for breast cancers: A retrospective multidimensional comparative, integrated genomic, transcriptomic, and protein analysis
Robert Rees
Dr. Rees has no relevant financial relationships to disclose.

A liquid biopsy test for breast cancer detection provides consistent diagnostic results in patients over six months
David Reese
Dr. Reese has disclosed that he is a salary employee of, patent holder and owns stock in Provista Dx.

A blood-based proteomic Videssa® breast assay performs comparably in women with dense and non-dense breasts
David Reese
Dr. Reese has disclosed that he is a salary employee of, patent holder and owns stock in Provista Diagnostics.

Biological functions of ERβ in triple negative breast cancer and its utility as a novel therapeutic drug target
Jordan Reese
Mr. Reese has no relevant financial relationships to disclose.

Activation of ERβ in triple negative breast cancer results in cell cycle arrest
Jordan Reese
Jordan Reese has no relevant financial relationships to disclose.

Pertuzumab and trastuzumab in combination with weekly paclitaxel delivers high pCR rates with favourable toxicity profile in neo-adjuvant treatment of Her-2 positive breast cancer
Dave Reeves
Dr. Reeves has no relevant financial relationships to disclose.

A-phase 2 study of eribulin followed by dosasrubib and carboplatin as neoadjuvant therapy for HER2-negative inflammatory breast cancer
Meredith Regan
Dr. Regan has no relevant financial relationships to disclose.

Long-term follow-up of TEXT and SOFT trials of adjuvant endocrine therapies for premenopausal women with HR+ early breast cancer
Meredith Regan
Ms. Regan has no relevant financial relationships to disclose.
Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ER positive metastatic breast cancer patients: Results of the COMETI Phase 2 trial  
Meredith Regan  
Ms. Regan has no relevant financial relationships to disclose.

12 years’ median follow up (MFU) of BIG 1-98: Adjuvant letrozole, tamoxifen and their sequence for postmenopausal women with endocrine responsive early breast cancer  
Meredith Regan  
Ms. Regan has no relevant financial relationships to disclose.

The effects of treatment-induced symptoms, depression and age on sexuality in premenopausal women with early breast cancer receiving adjuvant endocrine therapy  
Meredith Regan  
Ms. Regan has no relevant financial relationships to disclose.

Independent validation of faralix gene signature in BIG 1-98: A randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer  
Meredith Regan  
Ms. Regan has no relevant financial relationships to disclose.

Randomized phase II study evaluating different schedules of doc-paclitaxel in metastatic breast cancer (MBC): Results of the SNAPP study  
Meredith Regan  
Ms. Regan has no relevant financial relationships to disclose.

Clinical implications of somatic mutations in post-menopausal early-stage estrogen receptor-positive breast cancer (EMBC): Results from the BIG 1-98 study  
Meredith Regan  
Ms. Regan has no relevant financial relationships to disclose.

First posts: A content analysis of an online breast cancer community user’s initial postings  
Meera Reghunathan  
Meera Reghunathan has no relevant financial relationships to disclose.

HER2 activity regulates the pro-trastuzumab immune tumor microenvironment  
Viola Regondi  
Viola Regondi has no relevant financial relationships to disclose.

Low-level gonosomal mosaicism of a de novo BRCA1 gene mutation - The origin of a constitutional mutation in a breast cancer family  
Simone Reichstein-Gnielinski  
Dr. Reichstein-Gnielinski has no relevant financial relationships to disclose.

Post mastectomy breast reconstruction in elderly women: Complications and the impact of individual surgeons  
Christopher Reid  
Dr. Reid has no relevant financial relationships to disclose.

Identification and characterization of a novel endoxifen substrate, PKCβ1, and its interaction with the estrogen receptor  
Joel Reid  
Mr. Reid has no relevant financial relationships to disclose.

Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer  
Julia Reid  
Ms. Reid has disclosed that she is an employee of Myriad Genetics - receives salary and stock options.

Mixed ductal-lobular carcinomas of the breast: Abrogated cell adhesion in the clonal evolution from ductal to lobular morphology  
Lynne Reid  
Ms. Reid has no relevant financial relationships to disclose.

Comparison of axillary sentinel lymph node biopsy versus no axillary surgery in patients with early-stage invasive breast cancer and breast-conserving surgery: A randomised prospective surgical trial. The Intergroup-Sentinel-Mamma (INSEMA)-trial  
Toralf Reimer  
Dr. Reimer has no relevant financial relationships to disclose.

Results of multigene assay (MammaPrint®) and molecular subtyping (BluePrint®) substantially impact treatment decision making in early breast cancer: Final analysis of the VOG PRIME decision impact study  
Toralf Reimer  
Prof. Reimer has no relevant financial relationships to disclose.

Pathological complete response to neoadjuvant trastuzumab is dependent on HER2/CEP17 ratio in HER2-amplified early breast cancer  
Angelika Reiner  
Ms. Reiner has no relevant financial relationships to disclose.
RIBECCA - A phase III, multi-center, open label study for women with estrogen receptor positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole

Ralf Reiners

Mr. Reiners has disclosed that he receives salary from Novartis.

Time-evolution of the efficacy of first line aromatase inhibitors (AI) in hormone receptor positive (HR+) advanced breast cancer (ANC): A moving target

Tommas Reinet

Dr. Reinet has no relevant financial relationships to disclose.

Metastasis treatment: A transcriptional networks in a xenograft model of breast cancer

Osvaldo Reis Júnior

Osvaldo Reis Júnior has no relevant financial relationships to disclose.

Intra-tumor genetic heterogeneity and histological heterogeneity within metastatic breast cancers: Genotypic-phenotypic correlations

Osvaldo Reis Júnior

Osvaldo Reis Júnior has no relevant financial relationships to disclose.

Immune signatures define and affect prognosis in triple-negative breast cancer subtypes

Osvaldo Reis Júnior

Osvaldo Reis Júnior has no relevant financial relationships to disclose.

Committee Member

Jorge Reis-Filho

Dr. Reis-Filho has no relevant financial relationships with commercial interests to disclose.

Serum-triglycerides among triple negative breast cancer patients as a biomarker of poor outcome

Jon Reitan

Dr. Reitan has no relevant financial relationships to disclose.

The association of breast cancer subtype and breast cancer survival with parity and time since last birth

Chantal Remmerie

Ms. Remmerie has no relevant financial relationships to disclose.

MicroRNA-367a promotes tumor growth and stemness potential by targeting Fbxw7 in breast cancer

Hong Ren

Dr. Ren has no relevant financial relationships to disclose.

MiR-146a functions as suppressive non-coding gene via indirect upregulation of Let-7 to promote asymmetric division and inhibit the self-renewal ability of breast cancer stem-like cells

Hong Ren

Dr. Ren has no relevant financial relationships to disclose.

Non-nuclear SUMO dynamics regulate mammary epithelial cell transformation

Jing Ren

Jing Ren has no relevant financial relationships to disclose.

Androgen receptor in tamoxifen-resistant breast cancer is affected by SUMO

Jing Ren

Jing Ren has no relevant financial relationships to disclose.

Mastectomy weekly carboplatin and paclitaxel followed by dose dense epirubicin and cyclophosphamide in triple negative breast cancer patients: A single arm phase II study from the Belgian Society of Medical Oncology

Vincent Renard

Dr. Renard has no relevant financial relationships to disclose.

Cancer-associated fibroblasts release exosomal microRNAs that dictate an aggressive phenotype in breast cancer

Thomas Renato

Dr. Renato has no relevant financial relationships to disclose.

Osteoprotegerin mediates tumor-promoting effects of Interleukin-1beta in breast cancer cells

Ashleigh Renaud

Ms. Renaud has no relevant financial relationships to disclose.

miR363-3p mediates maintenance and resistance of breast cancer stem cells (BCSC)

Stéphanie Renaud

Ms. Renaud has no relevant financial relationships to disclose.

The EA2clin test significantly predicts response and survival in both pre and post-menopausal women with ER-positive breast cancers

Lorna Renshaw

Ms. Renshaw has no relevant financial relationships to disclose.

Molecular characterisation, subtype concordance and prognostic group assignment between patient-matched primary breast tumours and axillary lymph node metastases

Lorna Renshaw

Ms. Renshaw has no relevant financial relationships to disclose.
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (PERUSE)  
Eleonora Restuccia  
Ms. Restuccia has disclosed that she receives salary from F. Hoffmann-La Roche Ltd.

Primary analysis of PERTAIN: A randomized, two-arm, open-label, multicenter phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first-line patients with HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer  
Eleonora Restuccia  
Ms. Restuccia has disclosed that she receives salary from F. Hoffmann-La Roche Ltd.

Immunohistochemical analysis of inflammatory breast cancer and correlation to pathological complete response  
Aleksandre Reuben  
Dr. Reuben has no relevant financial relationships to disclose.

Perioperative use of NSAID analgesic ketorolac may suppress early relapses in breast cancer: Perhaps transient systemic inflammation plays a role  
Michael Retsky  
Dr. Retsky has disclosed that he has a patent pending and is a member of Board of Directors - Colon Cancer Alliance.

Immune characterization of inflammatory breast cancer and correlation to pathological complete response  
Alexandre Reuben  
Dr. Reuben has no relevant financial relationships to disclose.

NCI-2016-00367: A phase IIB study of neoadjuvant ZT regimen (enzalutamide therapy in combination with weekly paclitaxel) for androgen receptor (AR)-positive triple-negative breast cancer (TNBC)  
James Reuben  
Dr. Reuben has no relevant financial relationships to disclose.

Immune characterization of inflammatory breast cancer and correlation to pathological complete response  
James Reuben  
Dr. Reuben has no relevant financial relationships to disclose.

Flutamide reduced tumor progression and altered steroid hormone secretion in human and canine inflammatory breast cancer cell lines  
James Reuben  
Dr. Reuben has no relevant financial relationships to disclose.

Stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer  
James Reuben  
Dr. Reuben has no relevant financial relationships to disclose.

A targetable EGFR-driven tumor-initiating program in breast cancer  
Timothée Revil  
Mr. Revil has no relevant financial relationships to disclose.

IMENEO: International Meta-analysis of circulating tumor cell detection in early breast cancer patients treated by neoadjuvant chemotherapy  
Fabien Reyal  
Mr. Reyal has no relevant financial relationships to disclose.

How do real-world treatment patterns compare to guideline recommendations for first-line metastatic breast cancer patients in US community clinics?  
Carolina Reyes  
Dr. Reyes has disclosed that she receives salary from Genentech and has ownership in F Hoffmann La-Roche.

Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer  
Agne Reynaud-Bougnoux  
Dr. Reynaud-Bougnoux has no relevant financial relationships to disclose.

Functional IGf1R variant predicts preeclampsia protection from invasive breast cancer: Novel California teachers study findings  
Peggy Reynolds  
Dr. Reynolds has no relevant financial relationships to disclose.

Dynamics of circulating tumor cells during the course of chemotherapy and prognostic relevance across molecular subtypes in high-risk early breast cancer patients - Results from the adjuvant SUCCESS A trial  
Mehdi Rezaei  
Dr. Rezaei has no relevant financial relationships to disclose.
P1-09-02  Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer  
Mahdi Rezai  
Mahdi Rezai has no relevant financial relationships to disclose.

P4-18-02  Peer navigation for people affected by hereditary breast, ovarian and related cancers: Results from the first six-months  
Lisa Recorde  
Dr. Recorde has no relevant financial relationships to disclose.

P5-11-02  Comprehensive comparison of breast cancer molecular portraits by African and European ancestry in the cancer genome atlas  
Esther Rhe  
Dr. Rhe has no relevant financial relationships to disclose.

P1-05-31  Comprehensive comparison of breast cancer molecular portraits by African and European ancestry in the cancer genome atlas  
Suhn Rhe  
Suhn Rhe has no relevant financial relationships to disclose.

P1-08-01  Truffleshark®-based next-generation sequencing in BRCA1/2-negative breast and ovarian cancer families reveal high mutation prevalence in additional risk genes  
Kerstin Rheem  
Kerstin Rheem has no relevant financial relationships to disclose.

P3-09-03  Low-level gonosomal mosaicism of a de novo BRCA2 gene mutation - The origin of a constitutional mutation in a breast cancer family  
Kerstin Rheem  
Dr. Rheem has no relevant financial relationships to disclose.

P2-07-12  An association between patient comorbidity and breast cancer survival  
Jiyoung Rhu  
Jiyoung Rhu has no relevant financial relationships to disclose.

P6-07-19  An association between patient comorbidity and breast cancer survival  
Jiyoung Rhu  
Jiyoung Rhu has no relevant financial relationships to disclose.

P5-15-10  The association between patient comorbidity and breast cancer survival  
Jiyoung Rhu  
Jiyoung Rhu has no relevant financial relationships to disclose.

P2-05-33  Refining the prognostic value of Ki67 biomarker by ataxia telangiectasia mutated (ATM) status in a retrospective study of early stage hormone receptor positive breast cancer  
Karl Ribbnow  
Dr. Ribbnow has no relevant financial relationships to disclose.

P6-07-22  Refining the prognostic value of Ki67 biomarker by ataxia telangiectasia mutated (ATM) status in a retrospective study of early stage hormone receptor positive breast cancer  
Karl Ribbnow  
Dr. Ribbnow has no relevant financial relationships to disclose.

P3-09-03  Embryonic mesenchyme (embryonic) showed inhibitory effects on epithelial-mesenchymal transition (EMT) in tumors of metastatic breast cancer patients. - First preliminary report of a prospective study.  
Koki Rhi  
Dr. Rhi has no relevant financial relationships to disclose.

P3-02-11  Clinical examination and breast MRI as predictors of pathologic complete response post neoadjuvant therapy in HER2 overexpressed subtypes and triple negative breast cancer  
Karina De Cassia Ribeiro  
Dr. Ribeiro has no relevant financial relationships to disclose.

P4-17-04  Results of the continuing education program in oncoplasty and breast reconstruction of the Brazilian Society of Mastology at Araujo Jorge Hospital in Goiania  
Luiz Fernando Ribeiro  
Dr. Ribeiro has no relevant financial relationships to disclose.

P2-09-09  The effects of treatment-induced symptoms, depression and age on sexuality in premenopausal women with early breast cancer receiving adjuvant endocrine therapy  
Karin Ribi  
Dr. Ribi has no relevant financial relationships to disclose.

P5-15-07  Is luminal A breast cancer a "good prognosis" disease? Preliminary results of the GIM-13 - AMBRA study  
Ferdinando Riccardi  
Prof. Riccardi has no relevant financial relationships to disclose.

P5-14-09  Luminal A breast cancer: Is it really a "good prognosis" disease? Preliminary results of the GIM-13 - AMBRA study  
Ferdinando Riccardi  
Prof. Riccardi has no relevant financial relationships to disclose.

P4-06-21  Patient derived DCS mouse intraductal (MIND) models recapitulate the full spectrum of human patient pathology and histoologic features including progression to invasion in a subset of cases  
Laurence Ricci  
Dr. Ricci has no relevant financial relationships to disclose.

P4-22-21  A phase 2 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors  
Lauren Rice  
Dr. Rice has no relevant financial relationships to disclose.
Quantification of HER2-driven signaling (HER2S) inhibition of four different anti-HER2 drugs tested ex vivo in live primary HER2-negative breast cancer cell samples with abnormal HER2 signaling activity

Benn Rich
Dr. Rich has disclosed that he receives salary and has ownership.

New method to measure functional HER2-driven signaling activity in primary tumor cells identifies HER2-negative breast cancers with abnormal HER2 signaling activity: New group of patients may benefit from anti-HER2 therapy

Benn Rich
Dr. Rich has disclosed that he receives salary and has ownership.

Meta-analysis of cognitive impairment in breast cancer survivors treated with chemotherapy

Giil Rich
Dr. Rich has no relevant financial relationships to disclose.

The mammary ducts create a favourable microenvironment for xenografting of luminal and molecular apocrine breast tumours

 оборудования

Dr. Richard has no relevant financial relationships to disclose.

Phase II study of taselisib (GDC-0032) plus fulvestrant in HER2-negative, hormone receptor-positive advanced breast cancer: Analysis by PIK3CA and ESR1 mutation status from circulating tumor DNA

Donald Richards
Mr. Richards has no relevant financial relationships to disclose.

Efficacy results of a phase 1/2 study of glucocorticoid receptor (GHR) antagonist mifepristone (MIFE) in combination with eribulin in GR-positive triple-negative breast cancer (TNBC)

Donald Richards
Mr. Richards has no relevant financial relationships to disclose.

A randomized, double-blind, phase 2 study of nossilirib (RUN) or placebo (PBO) in combination with capecitabine (CAPE) in patients (pts) with advanced HER2-negative breast cancer (ABC) and elevated c-reactive protein (CRP), a marker of systemic inflammation

Paul Richards
Mr. Richards has no relevant financial relationships to disclose.

Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer

Andrea Richardson
Dr. Richardson has no relevant financial relationships to disclose.

Evaluation of tumor-infiltrating lymphocytes (TILs) and their association with homologous recombination deficiency and BRCA2/2 mutation status in triple-negative breast cancer (TNBC): A pooled analysis

Andrea Richardson
Dr. Richardson has disclosed that she has a patent with Myriad Genetics, Inc. Inventor on HRD assay. This relationship does not impact her ability to review presentations.

Effect of serum biomarkers (activin A, CA9, HER2, TIMP-1, and uPA) on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with capecitabine: CCTG MA.31

Angelique Richardson
Dr. Richardson has no relevant financial relationships to disclose.

A study to determine the optimal method of detection and threshold for lymphoedema intervention: A multi-centre prospective study

Katie Riches
Ms. Riches has no relevant financial relationships to disclose.

Epilplex® based next-generation sequencing in BRCA1/2 - negative breast and ovarian cancer families reveals high mutation prevalence in additional risk genes

Lisa Richters
Ms. Richters has no relevant financial relationships to disclose.

Low-level gonosomal mosaicism of a de novo BRCA1 gene mutation - The origin of a constitutional mutation in a breast cancer family

Lisa Richters
Ms. Richters has no relevant financial relationships to disclose.

Beyond CHEK2 in breast cancer: Search for additional moderately penetrant risk gene variants by analyzing the oligogenic disease course in CHEK2-mutation carriers

Lisa Richters
Ms. Richters has no relevant financial relationships to disclose.

Real-world treatment patterns and survival among triple negative breast cancer patients versus patients with other breast cancer subtypes in early stage breast cancer

Justin Ricker
Mr. Ricker has disclosed that he receives salary from and has ownership in Abbvie.

A randomized trial evaluating biomarkers to improve lymphedema screening vs. tape measurement in the prevention of lymphedema following breast cancer treatment

Sheila Ridner
Ms. Ridner has disclosed that she has a present Impedimed study.
High concordance of a closed system, near point of care, RT-qPCR assay for HER2 (ERBB2) mRNA compared to both IHC/FISH and quantitative immunofluorescence

Dr. Rimm has disclosed that he is a consultant for AstraZeneca, Agendia, Bethyl Labs, Biocartis, BMS, ClearSight, FivePrime, Genoptix/Novartis, Metamark Genetics, OptraScan, and Perkin Elmer. He has also disclosed that Genoptix, Gilead Sciences, Kolltan, Pierre Fabre, Perkin Elmer and Nantomics fund research in his lab.

Tumor infiltrating macrophages, lymphocytes and matrix metalloproteinase 9 (MMP-9) expression in breast cancer

Dr. Rimm has disclosed that he is a consultant for Astra Zeneca, Agendia, Bethyl Labs, Biocartis, BMS, ClearSight, FivePrime, Genoptix/Novartis, Metamark Genetics, OptraScan, and Perkin Elmer. He has also disclosed that Genoptix, Gilead Sciences, Kolltan, Pierre Fabre, Perkin Elmer and Nantomics fund research in his lab.

Exclusion of cancer-associated fibroblast function by farred-x receptor activation: Experimental basis for a novel therapeutic strategy in breast cancer

Mr. Rinaldi has no relevant financial relationships to disclose.

Dr. Rinnerthaler has disclosed that he is a consultant for and has a contract with Roche.

Dr. Rinnerthaler has disclosed that he is a consultant for and has a contract with Roche.

Ms. Risi has no relevant financial relationships to disclose.

Dr. Ring has disclosed that he is a consultant for Insight Genetics, Inc.

Dr. Ring has disclosed that he receives salary from Insight Genetics, Inc.

Dr. Rizel has disclosed that he receives salary from Insight Genetics, Inc.

Dr. Rizel has disclosed that he receives salary from Insight Genetics, Inc.

Dr. Rizel has disclosed that he receives salary from Insight Genetics, Inc.

Dr. Rincon has disclosed that he receives salary from Insight Genetics, Inc.

Dr. Risinger has disclosed that he receives salary from Insight Genetics, Inc.

Dr. Rivetti has disclosed that he receives salary from Insight Genetics, Inc.

Dr. Rivetti has disclosed that he receives salary from Insight Genetics, Inc.

Dr. Rivetti has disclosed that he receives salary from Insight Genetics, Inc.

Dr. Rivetti has disclosed that he receives salary from Insight Genetics, Inc.

Dr. Rivetti has disclosed that he receives salary from Insight Genetics, Inc.

Dr. Rivetti has disclosed that he receives salary from Insight Genetics, Inc.

Dr. Rizel has disclosed that he receives salary from Insight Genetics, Inc.

Dr. Rivetti has disclosed that he receives salary from Insight Genetics, Inc.

Dr. Rivetti has disclosed that he receives salary from Insight Genetics, Inc.

Dr. Rivetti has disclosed that he receives salary from Insight Genetics, Inc.

Dr. Rivetti has disclosed that he receives salary from Insight Genetics, Inc.
High concordance of ER, PR, HER2 and Ki67 by central IHC and FISH with mRNA measurements by GeneXpert® breast cancer stratifier assay

Ms. Rizo has disclosed that she receives salary from and has ownership in Cepheid.

Analytical validation for the RT-qPCR based multiplex mRNA measurements of ER, PgR, HER2, and Ki67 from FFPE tumor tissue using the GeneXpert® breast cancer stratifier assay

Ms. Rizo has disclosed that she receives salary from and has ownership in Cepheid.

Phenotypical validation of a new tumor imaging agent targeting αvβ3 to detect breast tumor using NIR-light imaging

Mr. Rizo has no relevant financial relationships to disclose.

Effect of serum biomarkers (activin A, CAS, HER2, TIMP-1, and uPA) on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane. CCG 5A31

Dr. Rizvi has no relevant financial relationships to disclose.

Analytical validation for the RT-qPCR based multiplex mRNA measurements of ER, PgR, HER2, and Ki67 from FFPE tumor tissue using the GeneXpert breast cancer stratifier assay

Ms. Rizo has disclosed that she receives salary from and has ownership in Cepheid.

Preclinical validation of a new tumor imaging agent targeting αvβ3 to detect breast tumor using NIR-light imaging

Mr. Rizo has no relevant financial relationships to disclose.

Clinical and pathological relationships with Ki67 in POETIC (CRUK/07/015) - Critical lessons for assessing Ki67 for prognosis and as a pharmacodynamic marker

Mr. Robertson has no relevant financial relationships to disclose.

Updated safety results from the first multicenter, open-label, phase IIb study investigating the combination of pertuzumab with subcutaneous trastuzumab and a taxane in patients with HER2-positive metastatic breast cancer (SAPPHIRE)

Mr. Roberts has disclosed that he receives salary from Roche Product Pty. Limited.

Propective study of acupuncture in the rehabilitation of women undergoing surgical treatment of breast cancer in relation to the strength and quality of life

Dr. Rizvi has no relevant financial relationships to disclose.

Supporting the development of a breast cancer imaging agent

Ms. Rizzo has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2-08-02</td>
<td>Progression-free survival results in patient subgroups from a Phase 3 randomized trial of fulvestrant 500 mg vs anastrozole for hormone receptor-positive advanced breast cancer (FALCON)</td>
<td>John Robertson</td>
<td>Mr. Robertson has disclosed that he is a consultant and speaker for AstraZeneca and Bayer AG. He also disclosed that he has contracts with AstraZeneca, Bayer AG and Novartis. He disclosed he has ownership in Discimmune and gives expert testimony for AstraZeneca.</td>
</tr>
<tr>
<td>P2-08-09</td>
<td>Progression-free survival results in postmenopausal Asian women: Subgroup analysis from a phase 3 randomized trial of fulvestrant 500 mg vs anastrozole for hormone receptor-positive advanced breast cancer (FALCON)</td>
<td>John Robertson</td>
<td>Mr. Robertson has disclosed that he is a consultant and speaker for AstraZeneca and Bayer AG. He also disclosed that he has contracts with AstraZeneca, Bayer AG and Novartis. He disclosed he has ownership in Discimmune and gives expert testimony for AstraZeneca.</td>
</tr>
<tr>
<td>P2-09-02</td>
<td>True effect of aromatase inhibitor (AI) treatment on global gene expression (expr) changes in postmenopausal ER+ breast cancer (BC) patients: A POETIC study (CRUK/07/015)</td>
<td>John Robertson</td>
<td>Prof. Robertson has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-10-02</td>
<td>The impact of intrinsic subtypes and molecular features on aromatase inhibitor induced reduction of proliferation marker of Ki67 in primary ER+ breast cancer: A POETIC study (CRUK/06/015)</td>
<td>John Robertson</td>
<td>Mr. Robertson has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-10-04</td>
<td>Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multi-center trial</td>
<td>Andre Robidoux</td>
<td>Dr. Robidoux has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-14-13</td>
<td>Total mastectomy and immediate breast reconstruction for breast cancer: A ten-year Canadian single institution experience</td>
<td>Andre Robidoux</td>
<td>Dr. Robidoux has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>O7S-04-01</td>
<td>BRE12-158: A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple-negative breast cancer (TNBC)</td>
<td>Kenan Robins</td>
<td>Dr. Robins has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-10-02</td>
<td>Increasing participation in research - breast cancer (Inspire-BrC)</td>
<td>Brandi Robinson</td>
<td>Ms. Robinson has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-01-01</td>
<td>Phase II in-human dose escalation study of the optical molecular imaging tracer bevacizumab-800cw for molecular fluorescence guided-surgery in primary breast cancer patients.</td>
<td>Dominic Robinson</td>
<td>Dr. Robinson has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P9S-01</td>
<td>Brain and age differences in PAM50 biomarker status in the Carolina breast cancer study</td>
<td>Whitney Robinson</td>
<td>Ms. Robinson has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-22-02</td>
<td>Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc) in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer</td>
<td>Mark Robson</td>
<td>Dr. Robson has disclosed that he is a consultant for AstraZeneca and his institution received research support from AbbVie, BioMarin, Medivation, AstraZeneca and Myriad.</td>
</tr>
<tr>
<td>P4-22-03</td>
<td>CSS: SNPs selectively affect anastrozole response in postmenopausal breast cancer patients.</td>
<td>Mark Robson</td>
<td>Dr. Robson has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-01-04</td>
<td>The landscape of somatic genetic alterations in BRCA1 and BRCA2 breast cancers</td>
<td>Mark Robson</td>
<td>Dr. Robson has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S2-02</td>
<td>The landscape of somatic genetic alterations in BRCA1 and BRCA2 breast cancers</td>
<td>Mark Robson</td>
<td>Dr. Robson has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S2-04</td>
<td>Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: A randomized, phase 2 study</td>
<td>Mark Robson</td>
<td>Dr. Robson has disclosed that he is a consultant for AstraZeneca and his institution received research support from AbbVie, BioMarin, Medivation, AstraZeneca and Myriad.</td>
</tr>
<tr>
<td>P6-07-06</td>
<td>Effect of serum biomarkers (actin,A, CAX, HER2, TIMP-1, and gHSA) on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with paclitaxel (CTG 1 MA 31)</td>
<td>Crescenzo Rocco</td>
<td>Dr. Rocco has disclosed that he is employed by and has ownership in GSK, Novartis and Pfizer.</td>
</tr>
<tr>
<td>OT1-02-15</td>
<td>A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer [EMBRACA]</td>
<td>Henri Hocse</td>
<td>Dr. Rocco has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
Chemotherapy (CT) decision in patients (pts) with node-positive (N+), ER+, early breast cancer (EBC) in the wake of new ASCO guideline - A different take on the evidence for the 21-gene recurrence score (RS) assay

Henri Roche
Dr. Roche has disclosed that he has a contract with Genomic Health.

Feasibility and safety of avoiding granulocyte colony-stimulating factor prophylaxis during the paclitaxel portion of dose dense doxorubicin-cyclophosphamide and paclitaxel regimen

Kathleen Roche
Ms. Roche has no relevant financial relationships to disclose.

Prognostic and predictive values of high endothelial venules (HEV) and tumor infiltrating CD8+ lymphocytes (CD8) in tumors of patients included in the adjuvant PAS04 trial: HEV is predictive of outcome for HER2+ tumors exposed to trastuzumab

Henri Roché
Dr. Roché has no relevant financial relationships to disclose.

Survivorship care planning is associated with breast cancer survivors' perceived quality of and coordination of care

Kathy Rock
Ms. Rock has no relevant financial relationships to disclose.

Concordance with National comprehensive cancer network (NCCN) metastatic breast cancer guidelines and impact on overall survival

Gabrielle Rocque
Dr. Rocque has disclosed that she has a contract.

Technology as a change agent for improving breast cancer quality care

Gabrielle Rocque
Dr. Rocque has disclosed that he has a contract.

Cardiac biomarkers for early detection and prediction of trastuzumab-related cardiotoxicity in patients with HER2 positive early breast cancer (BIG 1-06)

Richard Rodeheffer
Mr. Rodeheffer has no relevant financial relationships to disclose.

Long-term survival in HER2+ metastatic breast cancer: The first blow is half the battle

Sjoerd Rodenhuis
Prof. Rodenhuis has no relevant financial relationships to disclose.

Adjuvant dose dense doxorubicin-cyclophosphamide (ddAC) or docetaxel-AC (TAC) for high-risk breast cancer: First results of the randomized MADOAR trial (BR06-09-04)

Sjoerd Rodenhuis
Prof. Rodenhuis has no relevant financial relationships to disclose.

Comprehensive characterization of matched pre-treatment biopsies and residual disease of doxorubicin treated breast cancer

Sjoerd Rodenhuis
Dr. Rodenhuis has no relevant financial relationships to disclose.

Combined targeted therapies for advanced triple negative breast cancer: A phase II trial of nab-paclitaxel and bevacizumab followed by maintenance targeted therapy with bevacizumab and erlotinib

Eve Rodríguez
Dr. Rodríguez has no relevant financial relationships to disclose.

Quantitative proteomic analysis of FGFR by mass spectrometry may improve identification of FGFR amplified tumors sensitive to inhibitor therapy

Jordi Rodon
Prof. Rodon has no relevant financial relationships to disclose.

Evidence for tumor heterogeneity and clonal evolution during massive progression of breast cancer

Allen Rodríguez
Dr. Rodríguez has no relevant financial relationships to disclose.

Phylode tumours of the breast: The British Columbia cancer agency experience

Myra Rodriguez
Ms. Rodriguez has no relevant financial relationships to disclose.

Serial monitoring of circulating tumor DNA in patients with metastatic breast cancer

Angel Rodriguez
Dr. Rodriguez has no relevant financial relationships to disclose.

Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multi-center trial

Angel Rodriguez
Dr. Rodriguez has no relevant financial relationships to disclose.

Tumor subtypes and survival differences between Hispanic and non-Hispanic white breast cancer patients in the California cancer registry

Diana Rodriguez
Ms. Rodriguez has no relevant financial relationships to disclose.

Phase III trial to evaluate patient’s preference for subcutaneous versus intravenous trastuzumab administration in patients with HER2 positive advanced breast cancer (MBC) under IV trastuzumab (IV-t) treatment for at least 4 months. ChangHER-SC study (GECAM/2012-07)

César Rodríguez
Mr. Rodríguez has no relevant financial relationships to disclose.
A phase II study to compare fulvestrant (F) 500mg plus placebo versus (vs) F 500mg plus palbociclib (P) as first line treatment for postmenopausal women with hormone receptor (HR)-positive advanced breast cancer (BC) sensitive to endocrine therapy (ET).

“FLIPPER study” (Geriatric Cancer 2014-12)

Federico Rojo
Mr. Rojo has no relevant financial relationships to disclose.

A school-based breast health (BH) educational program to increase breast cancer awareness in a rural Mexican community: A qualitative comparative analysis of students’, relatives’ and teachers’ perceptions.

Maria Patricia Rojo-Castillo
Dr. Rojo-Castillo has no relevant financial relationships to disclose.

Impact of MAF gene amplification on disease recurrence and effects of adjuvant zoledronic acid in early breast cancer

Frederico Rojo
Dr. Rojo has no relevant financial relationships to disclose.

Challenges faced across borders to open European academic multicentre projects: The ET-CEP program part of the ERA-Net TRANSCAN JTC 2011

Gian Andrea Rollandi
Dr. Rollandi has no relevant financial relationships to disclose.

A comprehensive molecular analysis of medullary breast carcinoma: A model of immunomodulatory triple negative breast cancer subtype

Pierre Romero
Dr. Romero has no relevant financial relationships to disclose.

Prognostic impact of metastatic pattern in stage IV breast cancer at initial diagnosis

Alberto Romero
Dr. Romero has no relevant financial relationships to disclose.

Successful implementation of a novel breast cancer navigation program in Nuevo León, Mexico

Cristina Romero
Ms. Romero has no relevant financial relationships to disclose.

Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple-negative breast cancer

Gilles Romieu
Dr. Romieu has no relevant financial relationships to disclose.

Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision-making

Gilles Romieu
Dr. Romieu has no relevant financial relationships to disclose.

Safety of the combination of everolimus plus exemestane in the Italian cohort of patients enrolled in the expanded access “BALLET” study

S Romito
Dr. Romito has no relevant financial relationships to disclose.

CD103+/PD-1+ T-cells identify a subset of triple-negative breast cancer eligible for targeted checkpoint inhibition

Massimo Roncalli
Mr. Roncalli has no relevant financial relationships to disclose.

CDK8 inhibition improves the efficacy of ER- and HER2-targeted drugs in breast cancer

Igor Roninson
Igor Roninson has disclosed that he is a consultant for Senex Biotechnology Inc.

Deep Infrared Imaging to identify venous impairment after breast cancer surgery

Marcel Rooze
Marcel Rooze has no relevant financial relationships to disclose.

Lipofilling of the axilla to reduce secondary lymphedema after axillary lymph node dissection

Marcel Rooze
Marcel Rooze has no relevant financial relationships to disclose.

Real World data and patterns of care of metastatic breast cancer (MBC) in Brazil: First results of LACOG 0312 retrospective study

Daniela Rosa
Ms. Rosa has no relevant financial relationships to disclose.

Inhibition of AKT promotes CK stress response and augments docetaxel-mediated apoptosis in TNBC

Roberto Rosato
Dr. Rosato has no relevant financial relationships to disclose.
P5-05-01 Physico-biochemical regulation of EMT by microtubule associated protein 7 (MAP7)
Roberto Rosato
Dr. Rosato has no relevant financial relationships to disclose.

P6-14-02 An anti-PD1 antibody-based therapy results in dramatic reduction of TNBC PDX tumors in humanized mice models
Roberto Rosato
Dr. Rosato has no relevant financial relationships to disclose.

P3-07-05 GPR163 regulates EGR1 to overcome Mek-inhibition: implications for the development of rational targeted therapy combinations in triple-negative breast cancer
April Rose
Dr. Rose has no relevant financial relationships to disclose.

P4-18-02 Peer navigation for people affected by hereditary breast, ovarian and related cancers: Results from the first six months
Ziana Rose
Ms. Rose has no relevant financial relationships to disclose.

OT3-02-07 A phase I study to compare fulvestrant (F) 500mg plus palbociclib (P) versus F 500mg plus placebo (PL) as first line treatment for premenopausal women with hormone receptor (HR) positive advanced breast cancer (BC) sensitive to endocrine therapy (ET).
"The FLIPPER study" (GECAM/2014-12)
Libertad Rosell
Libertad Rosell has no relevant financial relationships to disclose.

P6-03-03 Tropomyosin-related kinase A is overexpressed in HR+ positive breast cancers
Severine Roselli
Severine Roselli has no relevant financial relationships to disclose.

P6-08-10 Osteoprotegerin mediates tumor-promoting effects of Interleukin-1β in breast cancer cells
Kim Roseman
Ms. Roseman has no relevant financial relationships to disclose.

Committee Member/Moderator, Basic Science Forum 2 "Endoplasmic Reticulum (ER) Stress"/Moderator/Speaker, Educational Session "The Tumor Ecosystem" "Paracrine Signaling and Intratumoral Heterogeneity"
Jeffrey Rosen
Dr. Rosen has no relevant financial relationships with commercial interests to disclose.

P4-22-14 Single agent palbociclib (P) or with or without trastuzumab (H) for the treatment of HR-advanced breast cancer
Mark Rosen
Dr. Rosen has no relevant financial relationships to disclose.

P2-09-07 Drugs don’t work if people don’t take them: Non-initiation of endocrine therapy in young women
Oshchina Rosenblatt
Oshchina Rosenblatt has no relevant financial relationships to disclose.

P5-02-03 Evaluation of the feasibility of a web-based preference tolerant randomized trial of risk-based vs. annual breast cancer screening: WISDOM study pilot
Sarah Rosenblatt
Sarah Rosenblatt-Wohl has no relevant financial relationships to disclose.

P3-02-08 Association of background parenchymal enhancement with breast cancer risk factors and tumor characteristics
Paula Rosenblatt
Dr. Rosenblatt has no relevant financial relationships to disclose.

P2-07-05 Inhibition of background parenchymal enhancement with breast cancer risk factors and tumor characteristics
Paula Rosenblatt
Ms. Rosenblatt has no relevant financial relationships to disclose.

Committee Member/Moderator, Basic Science Forum 2 "Endoplasmic Reticulum (ER) Stress"/Moderator/Speaker, Educational Session "The Tumor Ecosystem" "Paracrine Signaling and Intratumoral Heterogeneity"
Jeffrey Rosen
Dr. Rosen has no relevant financial relationships with commercial interests to disclose.

P3-04-11 ER is required for mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer cells and patients' tumors
Kari Rosenkrans
Dr. Rosenkrans has no relevant financial relationships to disclose.

P6-09-51 The REQUITE-AB study: Validating predictive models and biomarkers of radiotherapy toxicity to reduce side effects and improve quality of life in breast cancer patients
Barry Rosenthal
Dr. Rosenthal has no relevant financial relationships to disclose.

P04-01 Acupuncture for chemotherapy-induced peripheral neuropathy in breast cancer: preliminary results of a pilot randomized controlled trial
David Rosenthal
Dr. Rosenthal has no relevant financial relationships to disclose.

P3-07-11 Inhibition of Fos-Jun-mediated Smad phosphorylation reduces triple-negative breast cancer cell EMT, migration and invasion
Elana Rosenthal
Ms. Rosenthal has no relevant financial relationships to disclose.

P3-08-04 Trends in age of breast cancer diagnosis for women with pathogenic variants in genes associated with increased breast cancer risk
Eric Rosenthal
Dr. Rosenthal has disclosed that she receives salary from and has ownership in Myriad Genetic Laboratories, Inc.
Clinical and pathological characteristics of a representative cohort of long-term metastatic breast cancer (MBC) survivors
Margaret Rosenzweig
Dr. Rosenzweig has no relevant financial relationships to disclose.

Determining the breast tumor margin through genomics of the cancer-stromal interaction
Daniel Rosset
Dr. Rosset has no relevant financial relationships to disclose.

Phase II of POSEIDON: A phase II/ randomized phase II trial of lumascadix plus talazoparib or placebo in hormone receptor negative, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment
Milde Rosyng
Ms. Rosyng has no relevant financial relationships to disclose.

Negative progesterone receptor in associate early breast cancer relapse, even among good prognosis tumors
Martin Rosman
Dr. Rosman has no relevant financial relationships to disclose.

Comprehensive genomic profiling of clinically malignant phyllodes tumors of the breast reveals frequent mutation of NF1 and other genes associated with PI3K and RAS pathway activation
Jeffrey Ross
Dr. Ross has disclosed that he receives salary from and has ownership in Foundation Medicine, Inc.

Are we missing actionable targets in breast cancer? Novel insights into recurrent Ret alterations
Jeffrey Ross
Mr. Ross has disclosed that he receives salary from and has ownership in Foundation Medicine.

A phase II clinical trial of VST-1001 (dilute fluorescein) in lymphatic mapping and sentinel lymph node localization in clinically node negative breast cancer
Merrick Ross
Dr. Ross has no relevant financial relationships to disclose.

T-DM1 in HER2 positive advanced breast cancer patients: Real world practice from a multicenter observational study
Rosalba Rossello
Rosalba Rossello has no relevant financial relationships to disclose.

Prognostic values of circulating tumor cells (CTC) and cancer associated macrophage-like cells (CAML) enumerations in metastatic breast cancer: The role for innate immunity in the metastatic process
Giovanna Rossi
Giovanna Rossi has no relevant financial relationships to disclose.

Estrogen receptor 1 (ESR1) mutations in circulating tumor DNA (ctDNA): A guide to the management of advanced breast cancer (ABC)
Giovanna Rossi
Dr. Rossi has no relevant financial relationships to disclose.

Whole exome and transcriptome sequencing of resistant ER+ metastatic breast cancer
Asaf Rotem
Asaf Rotem has no relevant financial relationships to disclose.
<p>| | | | | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>P1-01-04</td>
<td>Comprehensive genomic characterization of circulating tumor cells (CTCs) in metastatic breast cancer (MBC) sheds light on the biology of blood-borne metastasis</td>
<td>Ritu Roy</td>
<td>Ritu Roy has no relevant financial relationships to disclose.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P2-11-08</td>
<td>Stomatitis in patients treated with first-line everolimus (EVE) plus letrozole (LET): Results from BOLERO-4 trial</td>
<td>Melanie Royce</td>
<td>Dr. Royce has disclosed that she has contracts with Novartis and Bayer (Research for conduct of clinical trials paid directly to her institution; no requested salary support for PI).</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P5-10-08</td>
<td>Oxygen receptor quantitative measures and differences in breast cancer survival</td>
<td>Melanie Royce</td>
<td>Dr. Royce has no relevant financial relationships to disclose.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OT2-01-15</td>
<td>PARTNER: Randomized, phase I/II trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA-mutated breast cancer patients</td>
<td>Rebecca Roylance</td>
<td>Dr. Roylance has no relevant financial relationships to disclose.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S6-01</td>
<td>BRCA1 methylation status, silencing and treatment effect in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer</td>
<td>Rebecca Roylance</td>
<td>Ms. Roylance has no relevant financial relationships to disclose.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P6-09-47</td>
<td>The development of personalized diagnostic tests and therapeutic strategies in breast cancer</td>
<td>Eudy Rozali</td>
<td>Esdy Rozali has no relevant financial relationships to disclose.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P1-05-11</td>
<td>Comprehensive comparison of breast cancer molecular portraits by African and European ancestry in the cancer genome atlas</td>
<td>Yaudin Ry</td>
<td>Yaudin Ry has no relevant financial relationships to disclose.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P1-03-01</td>
<td>An international multicenter study to evaluate reproducibility of automated scoring methods for assessment of Ki67 in breast cancer</td>
<td>Jason Ruan</td>
<td>Dr. Ruan has no relevant financial relationships to disclose.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P04-05</td>
<td>Survivorship care planning is associated with breast cancer survivors' reported quality and coordination of care</td>
<td>Linda Rubenstein</td>
<td>Ms. Rubenstein has no relevant financial relationships to disclose.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P2-10-04</td>
<td>Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multi-center trial</td>
<td>Peter Rubin</td>
<td>Dr. Rubin has no relevant financial relationships to disclose.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OT3-05-01</td>
<td>Three-monthly dynamic evaluation of CEA and CA15-3 (followed by 18-FDG PET) in usual practice in the follow-up of early breast cancer (EC): patients: A prospective randomized trial</td>
<td>Daniela Rubino</td>
<td>Dr. Rubino has no relevant financial relationships to disclose.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P5-14-10</td>
<td>Weekly docetaxel and daily oral cyclophosphamide followed by nab-paclitaxel for adjuvant therapy of high-risk localized breast cancer</td>
<td>Lena Rudas</td>
<td>Ms. Rudas has no relevant financial relationships to disclose.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P1-09-09</td>
<td>Efficacy and gene expression results from SGI11007 MEDI6026 phase II clinical trial in HER2-negative early breast cancer</td>
<td>Isabel Rubio</td>
<td>Dr. Rubio has no relevant financial relationships to disclose.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P3-13-23</td>
<td>Predicting residual disease in breast conservative surgery after neoadjuvant treatments in breast cancer patients using the margin index tool</td>
<td>Isabel Rubio</td>
<td>Dr. Rubio has no relevant financial relationships to disclose.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P2-13-24</td>
<td>Predicting residual disease in breast conservative surgery after neoadjuvant treatments in breast cancer patients using the margin index tool</td>
<td>Isabel Rubio</td>
<td>Dr. Rubio has no relevant financial relationships to disclose.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OT2-01-04</td>
<td>SORAR-1: A phase III study of alpelisib and fulvestrant in men and premenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy</td>
<td>Sabor Rubo</td>
<td>Mr. Rubovszky has no relevant financial relationships to disclose.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P1-09-10</td>
<td>Predicting type of endocrine therapy after neoadjuvant treatment is dependent on HER2/CEP17 ratio in HER2-amplified early breast cancer patients: Results from the PARTNER study</td>
<td>Margareta Rudas</td>
<td>Ms. Rudas has no relevant financial relationships to disclose.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P1-09-10</td>
<td>Predicting type of endocrine therapy after neoadjuvant treatment is dependent on HER2/CEP17 ratio in HER2-amplified early breast cancer patients: Results from the PARTNER study</td>
<td>Margareta Rudas</td>
<td>Ms. Rudas has no relevant financial relationships to disclose.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P2-09-07</td>
<td>Drugs don't work if people don't take them: Non-initiation of endocrine therapy in young women</td>
<td>Kathryn Ruddy</td>
<td>Ms. Ruddy has no relevant financial relationships to disclose.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P2-09-07</td>
<td>Drugs don't work if people don't take them: Non-initiation of endocrine therapy in young women</td>
<td>Kathryn Ruddy</td>
<td>Ms. Ruddy has no relevant financial relationships to disclose.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Notes:**
- **P1-01-04**
- **P2-11-08**
- **P5-10-08**
- **OT2-01-15**
- **S6-01**
- **P6-09-47**
- **P1-05-11**
- **P1-03-01**
- **P04-05**
- **P2-10-04**
- **OT3-05-01**
- **P5-14-10**
- **P1-09-09**
- **P3-13-23**
- **OT2-01-04**
- **P1-09-10**
- **P2-09-07**
S2-06
OT2-01-04
SDARC-1: A phase II study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy
Hope Rugo
Dr. Rugo has disclosed that she received research funding to her institution from Genentech, Medivation, Pfizer, Lilly, Novartis, OBI Pharma, MacroGenics and GTx.

OT2-01-07
A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2- negative (HER2-) metastatic breast cancer (MBC)
Hope Rugo
Dr. Rugo has disclosed that she received research funding to her institution from Genentech, Medivation, Pfizer, Lilly, Novartis, OBI Pharma, MacroGenics and GTx.

OT2-01-13
A phase 3, phase 2, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA)
Hope Rugo
Dr. Rugo has disclosed that she received research funding to her institution from Genentech, Pfizer, Novartis, Lilly, OBI Pharma, Merck and Medivation.

P1-01-04
Comprehensive genomic characterization of circulating tumor cells (CTCs) in metastatic breast cancer (MBC) sheds light on the biology of blood-borne metastasis
Hope Rugo
Dr. Rugo has no relevant financial relationships to disclose.

P4-22-03
Palbociclib in combination with endocrine therapy in treatment-naïve and previously treated elderly women with HR+, HER2- advanced breast cancer: A pooled analysis from randomized phase 2 and 3 studies
Hope Rugo
Dr. Rugo has disclosed that she has contracts with Pfizer (Institution), Novartis (Institution), Eli Lilly and Co (Institution), Genentech (Institution), MacroGenics (Institution), OBI Pharma (Institution), Merck (Institution), GTx (Institution). She also disclosed that she receives honoraria from Genomic Health.

P4-24-03
At-randomized, double-blind, phase 2 study of ruxolitinib (RUX) or placebo (PBO) in combination with cabazitaxel (CAB) in patients (pts) with advanced HER2-negative breast cancer (ABC) and elevated C-reactive protein (CRP), a marker of systemic inflammation
Hope Rugo
Dr. Rugo has disclosed that she received honorarium from Genomic Health and research support to her institution from Genentech, Pfizer, Novartis, Lilly, OBI pharma and MacroGenics.

P4-24-07
Long-term safety of palbociclib in combination with endocrine therapy in treatment-naïve and previously treated women With HR+, HER2- advanced breast cancer: A pooled analysis from randomized phase 2 and 3 studies
Hope Rugo
Dr. Rugo has disclosed that she has contracts with Pfizer (PALOMA-2), Novartis (Institution), Eli Lilly and Co (Institution), Genentech (Institution), MacroGenics (Institution), OBI Pharma (Institution), Merck (Institution), GTx (Institution). She also disclosed that she receives honoraria from Genomic Health.

P4-22-10
Evaluation of the effects of palbociclib plus letrozole on QTc interval
Hope Rugo
Dr. Rugo has disclosed that she has contracts with Pfizer, Novartis, Lilly, Genentech, MacroGenics, OBI pharma, Merck and GTx. She has also disclosed that she receives honoraria from Genomic Health.

P5-08-08
Baseline (BL) characteristics, treatment (tx) patterns, and outcomes in patients with hormone receptor (HR) vs HR+ HER2+ disease from the SystHErs registry
Hope Rugo
Dr. Rugo has disclosed that she is a speaker for Genomic Health and has contracts with Genentech, Pfizer, Novartis, Lilly, OBI Pharma, GTx, MacroGenics and Merck paid to his institution.

P5-08-27
Treatment patterns and clinical outcomes in patients with hormone receptor (HR)+ HER2+ metastatic breast cancer and low vs high levels of HR positivity from the SystHErs Registry
Hope Rugo
Dr. Rugo has disclosed that she is a speaker for Genomic Health, and has contracts with Genentech, Pfizer, Novartis, Lilly, OBI Pharma, MacroGenics and Merck.

P5-11-17
Study image in women with breast cancer using a scalp cooling system to reduce chemotherapy induced alopecia
Hope Rugo
Dr. Rugo has disclosed that she received research support from Genentech, Pfizer, Novartis, Lilly, OBI Pharma, MacroGenics and Merck paid to his institution. She has also disclosed that she receives honoraria from Genomic Health.

P6-11-05
A phase 2 open-label study of taselisib in patients (pt) with TSG-6 aberrant metastatic breast cancer (MBC)
Hope Rugo
Dr. Rugo has no relevant financial relationships to disclose.

P6-11-12
Subgroup Analysis by prior treatment and disease burden in MONARCH-1: A phase 2 study of monotherapy abemaciclib, a CDK4 & 6 inhibitor, in patients with HR+/HER2- metastatic breast cancer (MBC) following chemotherapy
Hope Rugo
Dr. Rugo has disclosed that she received research funding to her institution from Genentech, Medivation, Pfizer, Lilly, Novartis and OBI.

S2-06
Dr. Rugo has no relevant financial relationships to disclose.
Committee Member/Moderator, International Session "Overcoming Obstacles to Breast Cancer Management in Low and Middle Income Countries (LMICs)"/Moderator, Educational Session "Triple Negative Breast Cancer"

P2-10-01
Genomic profiling of residual ER+ breast cancers treated with prolonged neoadjuvant letrozole reveals novel alterations in clinically resistant tumors

Dr. Rugo has disclosed fees for non-CME services received directly from commercial interests from Genomic Health. She also disclosed that she does contracted research for GSK, Novartis, AstraZeneca, Genentech/Roche, Pfizer, Eisai, OBI and Macrogenics. These relationships do not impact her ability to present an unbiased presentation.

P4-22-10
Evaluation of the effects of palbociclib plus trastuzumab on QoL interval

Ana Ruiz
Mr. Ruiz has disclosed that he receives salary from and has ownership in Pfizer.

P4-21-05
Neoadjuvant non-pegylated liposomal doxorubicin plus paclitaxel, trastuzumab and pertuzumab in patients with HER2+ breast cancer - Final results of the SOL2013-05 HEART study

Isabel Ruiz
Dr. Ruiz has no relevant financial relationships to disclose.

P2-11-03
Incidence and severity of diarrhea with ramucirumab + intense laparoscopic prophylaxis in patients (pts) with HER2+ early-stage breast cancer (EBCTCG Interm cohort analysis from the multicenter, open-label, phase II control trial

Rolando Ruiz
Mr. Ruiz has disclosed that he receives salary from Puma Biotechnology Inc.

P4-17-03
Evaluation of the effects of palbociclib plus letrozole on QTc interval

Ana Ruiz
Ms. Ruiz has disclosed that she receives salary from and has ownership in Pfizer.

P3-06-09
Selection of presumed CD49f antagonists and their biological evaluation in breast cancer cells

Angel Ruiz-Moreno
Angel Ruiz-Moreno has no relevant financial relationships to disclose.

P3-14-01
International validation of the EORTC patient-reported outcome measure (PROM) in breast reconstruction (BRB): The EORTC QLG-BRECON23 evaluating the psychometric properties and clinical effectiveness

Seth Rummel
Mr. Rummel has no relevant financial relationships to disclose.

P3-06-07
PTEN immunohistochemistry is a predictor of mismatch repair status in breast cancer

Seth Rummel
Mr. Rummel has no relevant financial relationships to disclose.

P5-06-04
Breast cancer after Hodgkin lymphoma: Influence of endogenous and exogenous gonadal hormones on the radiation dose-response relationship

Nicole Russell
Mr. Russell has no relevant financial relationships to disclose.

P1-11-06
Learning curve for the SAVI SCOUT breast localization and surgical guidance system

Scott Russell
Mr. Russell has no relevant financial relationships to disclose.

P6-09-45
Long-term follow-up of early stage breast cancer patients with results of MammaPrint®, Oncotype DX® and MammoStrat® risk classification assays

Scott Russell
Mr. Russell has no relevant financial relationships to disclose.
Fibroblasts isolated from the "normal-like" tissue adjacent to breast tumours suppress healthy epithelial progenitor cell proliferation while supporting tumour cell growth

Dr. Safneck has no relevant financial relationships to disclose.

A phase II of S-220011, a reversible EGFR and HER2 inhibitor, combined with trastuzumab +/- chemotherapy in patients with HER2-positive metastatic breast cancer

Ms. Segawa has no relevant financial relationships to disclose.

BEAUTY and the breast: Is adjuvant chemotherapy the right time for a beauty boost? Results of a randomised controlled trial

Dr. Saghatchian has no relevant financial relationships to disclose.

A phase I/II of S-222611, a reversible EGFR and HER2 inhibitor, combined with trastuzumab +/- chemotherapy in patients with HER2-positive metastatic breast cancer

Ms. Segawa has no relevant financial relationships to disclose.

Numerous experiences of oncoplastic surgery with the omental flap reconstruction

Dr. Sagawa has no relevant financial relationships to disclose.

Aurora kinase A protein stability is negatively regulated by Jnk/Fas and PTEN in breast cancer: Prognostic and therapeutic implications

Dr. Saito has no relevant financial relationships to disclose.

A single-blind, randomized, placebo-controlled phase II study to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: Final results of the single-center BONADIUV trial

Dr. Saieva has no relevant financial relationships to disclose.

Aurora kinase A protein stability is negatively regulated by Jnk/Fas and PTEN in breast cancer: Prognostic and therapeutic implications

Ms. Sakaguchi has no relevant financial relationships to disclose.

A randomized phase II neoadjuvant study comparing docetaxel and cyclophosphamide (TC) with 5-fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel (FEC-D) for hormone receptor-negative breast cancer: The Kanagawa breast oncology group (KBOG) 1101 study

Dr. Saito has no relevant financial relationships to disclose.
The effects of treatment-induced symptoms, depression and age on sexuality in premenopausal women with early breast cancer receiving adjuvant endocrine therapy

Muhammed Salim

Mr. Salim has no relevant financial relationships to disclose.

The importance of loco-regional tumor burden and surgery on survival in patients with de novo stage IV breast cancer: post-hoc analyses of protocol MR07-01

Semra Sal moglu

Dr. Sal moglu has no relevant financial relationships to disclose.

Pharmacopeiogenetics and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

Leonardo Selman

Dr. Selmana has no relevant financial relationships to disclose.

Can polyplid tumor cells possessing stem cell features be induced in resistant breast carcinoma?

Kristine Salmina

Dr. Salmina has no relevant financial relationships to disclose.

Evaluation of intra-tumor heterogeneity, test reproducibility and their impact in breast cancer samples assessed by Prosigna®: Results from a decision impact prospective study and a matched case-control study

Bone Salomon

Dr. Salomon has no relevant financial relationships to disclose.

Cancer-associated fibroblasts release exosomal miRNAs that dictate an aggressive phenotype in breast cancer

Picuoglio Salavatine

Dr. Salavatine has no relevant financial relationships to disclose.

Investigating the use estrogen receptor β agonists in the prevention of breast cancer using a transgenic mouse model

Cathy Samayoa

Ms. Samayoa has no relevant financial relationships to disclose.

The clinical investigation of estrogen receptor β agonists for the treatment of breast cancer

Cathy Samayoa

Ms. Samayoa has no relevant financial relationships to disclose.

Tumor RNA disruption index as a tool to predict response to neoadjuvant chemotherapy in breast cancer: Optimizing timing of biopsy

Ali Samkari

Dr. Samkari has no relevant financial relationships to disclose.

Tumor-infiltrating lymphocytes (TILs) is associated with improved overall survival in triple-negative breast cancer (TNBC) patients treated with neoadjuvant chemotherapy (NAC)

Ali Samkari

Dr. Samkari has no relevant financial relationships to disclose.

Treatment of ESR1 mutant and PIK3CA mutant patient-derived breast cancer xenograft models reveals differential anti-tumor responses to estrogen receptor degraders and PI3K inhibitors in vivo

Deepak Sampath

Mr. Sampath has disclosed that he is an employee of Genentech, A Member of the Roche Group.

Neutralization of BCL2/XL enhances the cytotoxicity of I-DM1 in vivo

Deepak Sampath

Dr. Sampath has no relevant financial relationships to disclose.

The PI3K inhibitor, taselisib, has enhanced potency in PIK3CA mutant models through a unique mechanism of action

Rebecca San Martin

Ms. San Martin has no relevant financial relationships to disclose.

Uridine diphosphate glucose dehydrogenase is required for hyaluronic acid production and breast cancer invasion

Souzan Sanati

Dr. Sanati has no relevant financial relationships to disclose.

Tumor genomic profiling of triple negative breast cancer during neoadjuvant chemotherapy: Results from a prospective trial of carboplatin and doxetaxel

Souzan Sanati

Dr. Sanati has no relevant financial relationships to disclose.

Reduced serum B-cell maturation antigen levels predict poor outcome in metastatic breast cancer patients in a phase 3 randomised 2nd-line hormone therapy trial

Luk Sanchez

Dr. Sanchez has disclosed that he is a Stockholder in OncoTracker, a commercial entity to develop BCMA as a biomarker.

Accelerated partial breast irradiation versus whole breast irradiation: Health-related quality of life analysis from a phase 3 trial

Luk Sanchez

Dr. Sanchez has no relevant financial relationships to disclose.
A single-blind, randomized, placebo-controlled phase II study to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: Final results of the single-center BONADIUV trial

Luis Sanchez

Dr. Sanchez has no relevant financial relationships to disclose.

PI3K/PDK1 mediates resistance to CDK4/6 inhibitors through dysregulation of S-phase cyclins/cyclin dependent kinases (CDKs)

Violeta Sanchez

Ms. Sanchez has no relevant financial relationships to disclose.

MHC-II positive breast tumors are more immunogenic and may preferentially select for LAG-3-positive tumor immune infiltrates

Violeta Sanchez

Ms. Sanchez has no relevant financial relationships to disclose.

Improving immunotherapy response by epigenetic modulation

Melinda Sanders

Ms. Sanders has no relevant financial relationships to disclose.

Differential effect of chemotherapy on immune gene expression signatures based on molecular subtype of breast cancer

Melinda Sanders

Ms. Sanders has no relevant financial relationships to disclose.

Pan-HER, an antibody mixture with antitumor activity against drug-resistant HER2-overexpressing breast cancers with high ERBB ligand expression

Melinda Sanders

Ms. Sanders has no relevant financial relationships to disclose.

Adherence to healthy lifestyle behaviors in a predominantly Hispanic population of women undergoing screening mammography

Rossy Sandoval

Rossy Sandoval has no relevant financial relationships to disclose.

Can axillary lymph node clearance be avoided in women with node positive breast cancer receiving primary chemotherapy?

Ines Sandri

Ms. Sandri has no relevant financial relationships to disclose.

Resolution of DCIS in patients with early breast cancer receiving primary chemotherapy for invasive breast cancer

Ines Sandri

Ms. Sandri has no relevant financial relationships to disclose.

Disruption of the estradiol-regulated NTN1-UNC5A dependence receptor signaling axis causes a hybrid basal/luminal molecular phenotype in estrogen receptor-positive breast cancer cells

George Sandusky

Mr. Sandusky has no relevant financial relationships to disclose.

A multi-institutional, prospective study of incorporating the genomic platform breast cancer index as a tool for decision-making regarding extension of adjuvant endocrine therapy

Tara Sanft

Ms. Sanft has disclosed that research funding is provided by Biotheranostics.

Immune sculpting of the triple negative breast cancer genome

Nicole Singer

Ms. Singer has no relevant financial relationships to disclose.

Efficacy of FPI00 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial

Ashish Saril

Dr. Saril has disclosed that he receives personal fees from Berry Consultants.

The evaluation of ganitumab/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial

Ashish Saril

Dr. Saril has disclosed that Berry Consultants is a statistical consulting company that provides consulting services for a number of companies in the biopharmaceutical industry for device and drug development.
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>01-11</td>
<td>Increased stromal lymphocytes in breast cancer patients with metastatic breast cancer</td>
<td>Dr. Santa Cruz</td>
<td>Dr. Santa Cruz has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>02-06</td>
<td>DNA repair deficiency biomarkers and MammaPrint high1/(ultra)high2 risk as predictors of velipar/carboplatin response: Results from the neoadjuvant I-SPY 2 trial for high risk breast cancer</td>
<td>Ashish Sard.</td>
<td>Ashish Sard has disclosed that Berry Consultants receives compensation &amp; consulting with a number of the pharmaceutical companies involved.</td>
</tr>
<tr>
<td>05-12-02</td>
<td>Prognostic factors in breast cancer (BC) associated with the development of brain metastases (BM): A retrospective study of FPA-09</td>
<td>Jasotha Sanmugarajah</td>
<td>Jasotha Sanmugarajah has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>08-05</td>
<td>Comparative analysis of the genomic landscape of breast cancers from women of African and European ancestry</td>
<td>Ayodele Sani.</td>
<td>Ayodele Sani has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>09-09-32</td>
<td>A phase I study: Rapid survival decline per treatment line in metastatic breast cancer</td>
<td>Ana Santaballa</td>
<td>Ana Santaballa has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>07-01-01</td>
<td>OX40L inhibition plus chemotherapy in combination with autologous dendritic cell vaccination in HER2-positive advanced breast cancer</td>
<td>Cesar Santa Maria</td>
<td>Cesar Santa Maria has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>01-05-06</td>
<td>OX40L inhibition plus chemotherapy in metastatic breast cancer</td>
<td>Cesar Santa Maria</td>
<td>Cesar Santa Maria has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>04-14-01</td>
<td>Impact of heterogeneity of DES on immune cell infiltrations</td>
<td>Silberite Santamaria-Pang</td>
<td>Silberite Santamaria-Pang has disclosed that he is a GE employee.</td>
</tr>
<tr>
<td>02-07-06</td>
<td>Common tumor DNA (ctDNA) biomarkers with neoadjuvant chemotherapy: Predictive and prognostic potential of volume-based metastatic variables with 18F-FDG PET/CT</td>
<td>Libero Santarpia</td>
<td>Libero Santarpia has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>02-14-01</td>
<td>Common tumor DNA (ctDNA): A real-time application of precision medicine to the management of metastatic breast cancer (MBC)</td>
<td>Cesar Santa Maria</td>
<td>Cesar Santa Maria has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>06-16-03</td>
<td>Phase 2 trial of everolimus and/or trastuzumab in hormone refractory, hormone receptor (HR) positive, HER2-negative metastatic breast cancer</td>
<td>Cesar Santa Maria</td>
<td>Cesar Santa Maria has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>01-02-02</td>
<td>Phase 2 trial of olaparib and eribulin in patients with locally advanced breast cancer</td>
<td>Cesar Santa Maria</td>
<td>Cesar Santa Maria has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>02-06-02</td>
<td>Impact of heterogeneity of DES on immune cell infiltrations</td>
<td>Silberite Santamaria-Pang</td>
<td>Silberite Santamaria-Pang has disclosed that he is a GE employee.</td>
</tr>
<tr>
<td>01-07-06</td>
<td>Common tumor DNA (ctDNA) biomarkers with neoadjuvant chemotherapy: Predictive and prognostic potential of volume-based metastatic variables with 18F-FDG PET/CT</td>
<td>Libero Santarpia</td>
<td>Libero Santarpia has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>01-04-01</td>
<td>Assessing response in locally advanced breast cancer treated with neoadjuvant chemotherapy: Predictive and prognostic potential of volume-based metabolomic variables with 18F-FDG PET/CT</td>
<td>Josel Antonio Santiago Crespo</td>
<td>Josel Antonio Santiago Crespo has disclosed that he receives research funding from MedImmune and Pfizer.</td>
</tr>
<tr>
<td>03-03</td>
<td>Determining the prognostic role of early and end-of-neoadjuvant chemotherapy 18F-FDG PET/CT in patients with locally advanced breast cancer</td>
<td>Josel Antonio Santiago Crespo</td>
<td>Josel Antonio Santiago Crespo has disclosed that he receives research funding from MedImmune and Pfizer.</td>
</tr>
<tr>
<td>02-02-02</td>
<td>18F-FDG targets Wnt signaling to inhibit stem-like cells in breast cancer patient-derived xenograft tumours</td>
<td>Angelica Santiago-Gomez</td>
<td>Angelica Santiago-Gomez has disclosed that he receives research funding from MedImmune and Pfizer.</td>
</tr>
<tr>
<td>07-01-05</td>
<td>XE991: Evaluation of tolerability and correlation between a set of polymorphisms and neuropathy in patients with metastatic breast cancer</td>
<td>Daniela Santin.</td>
<td>Daniela Santin has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>04-21-11</td>
<td>Increased stromal lymphocytes in breast cancer patients with autologous dendritic cell vaccination plus neoadjuvant chemotherapy</td>
<td>Marta Santisteban</td>
<td>Marta Santisteban has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
Re-evaluating outcomes of partial-breast irradiation using multicatheter brachytherapy for Japanese patients with breast cancer by European brachytherapy phase 3 trial
Kazuhiko Sato
Dr. Sato has no relevant financial relationships to disclose.

A randomized phase II trial of intratumoral bevacizumab + capecitabine versus lapatinib + capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WGO61108/3/3TOP
Kazuhiko Sato
Kazuhiko Sato has no relevant financial relationships to disclose.

A randomized phase II study of Kir-6.2 response-guided preoperative chemotherapy for HER2-positive breast cancer
Misako Sato
Dr. Sato has no relevant financial relationships to disclose.

Phase II neoadjuvant trial of nanoparticle albumin-bound paclitaxel and trastuzumab in patients with node-negative, Her-2-positive breast cancer (OMIC-803A)
Naoaki Sato
Dr. Sato has no relevant financial relationships to disclose.

Next generation sequencing (NGS) reveals high mutation rates in all established breast cancer subtypes with subtype-specific patterns
Torill Sauer
Dr. Sauer has no relevant financial relationships to disclose.

Steroid receptors and steroidogenic enzymes in human breast cancer: Associations with breast cancer subtypes and clinical outcome
Torill Sauer
Torill Sauer has no relevant financial relationships to disclose.

Mixed ductal-lobular carcinomas of the breast: Abrogated cell adhesion in the clonal evolution from ductal to lobular morphology
Jodi Saunus
Dr. Saunus has no relevant financial relationships to disclose.

Phase II study of taselisib (GDC-0032) plus fulvestrant in HER2-negative, hormone receptor-positive advanced breast cancer: Analysis by PIK3CA and ESR1 mutation status from circulating tumor DNA
Heidi Savage
Ms. Savage has disclosed that she is an employee of Genentech.

Adipocyte fatty acid binding protein levels predict risk of obesity-associated breast cancer
Edward Sauter
Mr. Sauter has no relevant financial relationships to disclose.

Neratinib + fulvestrant in ERBB2-mutant, HER2 non-amplified, estrogen receptor (ER)-positive, metastatic breast cancer (MBC): Preliminary analysis from the phase II SUMMIT trial
Cristina Saura
Ms. Saura has disclosed that she is a consultant for Puma Biotechnology and Pfizer.

Inhibition of death-associated protein kinase 1 enhances chemotherapy action against triple-negative breast cancer
Michelle Savage
Ms. Savage has no relevant financial relationships to disclose.

A targetable EGFR-driven tumor-initiating program in breast cancer
Paul Savage
Mr. Savage has no relevant financial relationships to disclose.

Clinical implications of somatic mutations in post-menopause
ey early-stage estrogen receptor (ER)-positive HER2-negative breast cancer (BC): Results from the BIG 1-98 study
Peter Savas
Dr. Savas has no relevant financial relationships to disclose.

Clinical implications of somatic mutations in post-menopause
ey early-stage estrogen receptor (ER)-positive HER2-negative breast cancer (BC): Results from the BIG 1-98 study
Peter Savas
Dr. Savas has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Author(s)</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P4-22-17</td>
<td>Safety of the combination of everolimus plus exemestane in the Italian cohort of patients enrolled in the expanded access &quot;BALLET&quot; study</td>
<td>C. Savastano</td>
<td>C. Savastano has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT2-02-02</td>
<td>A randomized, open-label, multicenter, phase 1b/2 study of eribulin mesylate in combination with pegylated recombinant human hyaluronidase in patients with human epidermal growth factor receptor 2 (HER2)-negative, high-hyaluronan metastatic breast cancer</td>
<td>Claudio Savulsky</td>
<td>Mr. Savulsky has disclosed that he is an employee of and has ownership in Eisai.</td>
</tr>
<tr>
<td>PS-15-02</td>
<td>Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer</td>
<td>Claudio Savulsky</td>
<td>Mr. Savulsky has disclosed that he is an employee of and has ownership in Eisai.</td>
</tr>
<tr>
<td>P4-01-09</td>
<td>Evaluation of hydromethylflavilime green (gGlu-HMRG) as a promising fluorescence probe for rapid diagnosis of breast cancer; Feasibility study of real-time imaging for breast cancer examination</td>
<td>Terumasa Sawada</td>
<td>Terumasa Sawada has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-10-14</td>
<td>Breast cancer provider delay after the 2011 triple disaster in Fukushima, Japan</td>
<td>Toppuki Sawano</td>
<td>Dr. Sawano has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT1-04-06</td>
<td>A randomized, double-blind, placebo-controlled trial of endocrine therapy plus r-adam-223 dichloride in HER2-negative, hormone receptor-positive breast cancer patients with bone metastases</td>
<td>Amita Sawhrey</td>
<td>Mr. Sawhrey has disclosed that he receives salary from and has ownership in Bayer.</td>
</tr>
<tr>
<td>PS-02-03</td>
<td>Breast cancer Clinical Trials: Patient experiences, preferences, and insights into increasing participation</td>
<td>Sarah Sawyer</td>
<td>Dr. Sawyer has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-10-12</td>
<td>Maintenance of genomic integrity in dormant circulating tumor cells</td>
<td>Antonio Scamardo</td>
<td>Mr. Scamardo has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT1-01-05</td>
<td>PAINTER: Evaluation of eribulin tolerability and correlation between a set of polymorphisms and neuropathy in patients with metastatic breast cancer</td>
<td>Giuseppina Scandurra</td>
<td>Ms. Scandurra has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-21-11</td>
<td>T-DM1 in HER2-positive advanced breast cancer patients: Real-world practice from a multicenter observational study</td>
<td>Giuseppina Scudurra</td>
<td>Giuseppina Scudurra has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-02-03</td>
<td>Radiation therapy in patients with positive breast cancer stem cells (BCSC)</td>
<td>Valentina Scudurra</td>
<td>Valentina Scudurra has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-11</td>
<td>miR363-3p mediates maintenance and resistance of breast cancer stem cells (BCSC)</td>
<td>Antonio Scardino</td>
<td>Mr. Scardino has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-01-07</td>
<td>The evolution of breast cancer circulating tumor cells cells mediating breast metastasis</td>
<td>Antonio Scardino</td>
<td>Dr. Scardino has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-05-08</td>
<td>FACTOR: Evaluation of eribulin tolerability and correlation between a set of polymorphisms and neuropathy in patients with metastatic breast cancer</td>
<td>Giuseppina Scardurra</td>
<td>Giuseppina Scardurra has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT1-01-05</td>
<td>FACTOR: Evaluation of eribulin tolerability and correlation between a set of polymorphisms and neuropathy in patients with metastatic breast cancer</td>
<td>Giuseppina Scardurra</td>
<td>Giuseppina Scardurra has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-21-11</td>
<td>T-DM1 in HER2-positive advanced breast cancer patients: Real-world practice from a multicenter observational study</td>
<td>Giuseppina Scudurra</td>
<td>Giuseppina Scudurra has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-10-12</td>
<td>Radiation therapy in patients with positive breast cancer stem cells (BCSC)</td>
<td>Antonio Scardino</td>
<td>Mr. Scardino has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-11</td>
<td>Maintenance of genomic integrity in dormant circulating tumor cells</td>
<td>Antonio Scardino</td>
<td>Dr. Scardino has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-01-07</td>
<td>The evolution of breast cancer circulating tumor cells cells mediating breast metastasis</td>
<td>Antonio Scardino</td>
<td>Dr. Scardino has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-05-08</td>
<td>FACTOR: Evaluation of eribulin tolerability and correlation between a set of polymorphisms and neuropathy in patients with metastatic breast cancer</td>
<td>Giuseppina Scardurra</td>
<td>Giuseppina Scardurra has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-06-04</td>
<td>Proteasome inhibitors prevent bi-directional HER2/nuclear receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2/ER- positive breast cancer</td>
<td>Arno Scheid</td>
<td>Dr. Scheid has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-12-14</td>
<td>Evaluation of the impact of enzalutamide/SO2 test results on systemic therapy in breast cancer patients at the BC cancer agency (BCCA)</td>
<td>Kimberly Schaffer</td>
<td>Ms. Schaffer has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-17-03</td>
<td>Prediction of 10yr distant recurrence (DR) using the Prosigna® (PAM50) assay in histological subgroups of a Danish breast cancer group (DBC) cohort of postmenopausal Danish women with hormone receptor-positive (HR+) early breast cancer (DBC) allocated to 5yr of endocrine therapy (ET) alone</td>
<td>Carl Schaper</td>
<td>Mr. Schaper has disclosed that he is a consultant for Nanodring Technologies.</td>
</tr>
</tbody>
</table>
Drugs don’t work if people don’t take them: Non-initiation of endocrine therapy in young women

Dr. Schapira has no relevant financial relationships to disclose.

YSC’s ‘shady pink elephant” end of life series

Dr. Schapmire has no relevant financial relationships to disclose.

The prognostic and predictive effect of tumor infiltrating lymphocytes is not determined by B-cells or PD-L1 expression in inflammatory breast cancer

Ms. Schats has no relevant financial relationships to disclose.

A new oral SERD AZD9496 for treatment of hormone dependent postmenopausal breast cancer

Dr. Schech has no relevant financial relationships to disclose.

Extracellular vesicles from young women’s and postpartum breast cancer display unique proteomic content, after breast cancer aggressive behavior, and influence immune cell function

Dr. Schedin has no relevant financial relationships to disclose.

Extracellular vesicles from young women’s and postpartum breast cancer display unique proteomic content, after breast cancer aggressive behavior, and influence immune cell function

Mr. Schedin has no relevant financial relationships to disclose.

Estrogen receptor-positive breast cancer in BRCA2 mutation carriers shows a BRCAness profile, suggesting sensitivity to drugs targeting homologous recombination deficiency

Ms. Scherman has no relevant financial relationships to disclose.

Predictive value of ultra-high ESR1 mRNA expression in early breast cancer

Mr. Schefflen has no relevant financial relationships to disclose.

Quality of life assessed by BREAST-Q in patients with delayed immediate tissue expander based breast reconstruction with and without radiotherapy

Ms. Scheithauer has no relevant financial relationships to disclose.

Outcome after neoadjuvant chemotherapy in progestrone receptor negative breast cancer patients - A pooled analysis of individual patient data from ten prospectively randomised controlled neoadjuvant trials

Ms. Scheerman has no relevant financial relationships to disclose.

Dual HER2 blockade with pertuzumab and trastuzumab in HER2 positive early breast cancer: A subanalysis of data from the randomised phase III GeparSepto trial

Mr. Schem has no relevant financial relationships to disclose.

Results of multigene assay (MammaPrint®) and molecular subtyping (BluePrint®) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIME decision impact study

Mr. Scheper has no relevant financial relationships to disclose.

Preserving fertility in young women undergoing chemotherapy for early breast cancer; the Maastricht experience

Dr. Schepers-van der Sterren has no relevant financial relationships to disclose.

Circulating tumor DNA analysis to predict relapse and overall survival in early breast cancer - Longer follow-up of a proof-of-principle study

Ms. Scher has no relevant financial relationships to disclose.

Metabolomic analysis by nuclear magnetic resonance spectroscopy discriminates hormone receptor positive/HER2 negative breast cancer cell lines resistant to palbociclib

Dr. Schiff has no relevant financial relationships to disclose.
PD2-04 FOXA1 induces a pro-metastatic secretome through ER-dependent and independent transcriptional reprogramming in endocrine-resistant breast cancer
Rachel Schiff
Dr. Schiff has disclosed that she has contracts with AstraZeneca and Gilead.

SA-03 A novel BOK4 inhibitor enhances endocrine therapy efficacy and cir- cumscribes endocrine resistance in estrogen receptor-positive breast cancer models
Rachel Schiff
Dr. Schiff has disclosed that she has research grants with AstraZeneca and Gilead Sciences.

Poster Discussion 2 Co-Discussant/Committee Member/Moderator/Speaker, Educational Session "Drug Resistance - Novel Discovery Approaches and Clinical Results"
"Mechanisms of resistance to HER2-positive disease"
Rachel Schiff
Dr. Schiff has disclosed that she does contracted research for AstraZeneca. This relationship does not impact her ability to present an unbiased presentation.

PS-08-18 Treatment patterns and resource utilization among patients with HR+/HER2- metastatic breast cancer in a privately insured US population
Jeanne Schilder
Dr. Schilder has disclosed that she receives salary from and has ownership in Eli Lilly and Company.

PS-08-19 Treatment patterns and resource utilization among elderly Medicare patients with HR+/HER2- metastatic breast cancer
Jeanne Schilder
Dr. Schilder has disclosed that she receives salary from and has ownership in Eli Lilly and Company.

P2-11-01 Non-interventional study with netupitant/palonosetron (NEPA) as CINV prophylaxis in highly or moderately emetogenic chemotherapy
Eworg Schilling
Dr. Schilling has no relevant financial relationships to disclose.

P5-08-01 SANDPIPER: Phase III study of the PI3-kinase inhibitor tasekib in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA-mutant tumors
Frauke Schimmoller
Frauke Schimmoller has disclosed that he receives salary from Genentech (member of Roche Group). He also disclosed that he has patent applications as a former employee of Exelixis Inc (for an unrelated kinase inhibitor, cabozantinib, related to melanoma and prostate cancer). He disclosed that he owns Roche stock (unrelated: Exelixis Inc stock).

P2-01-03 Dynamics of circulating tumor cells during the course of chemotherapy and prognostic relevance across molecular subtypes in high-risk early breast cancer patients - Results from the adjacent SUCCESS A trial
Christian Schindlbeck
Dr. Schindlbeck has no relevant financial relationships to disclose.

P6-09-10 Results of multigene assay (MammaPrint®) and molecular subtyping (BluePrint®) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIME decision impact study
Christian Schindlbeck
Dr. Schindlbeck has no relevant financial relationships to disclose.

P6-11-13 Phase Ib study evaluating the safety and clinical activity of lumestuzumab combined with pertuzumab and paclitaxel in HER2-low metastatic breast cancer
Christoph Schindler
Dr. Schindler has no relevant financial relationships to disclose.

S4-07 The complete spectrum of ESRI mutations from 7590 breast cancer tumor samples
Erica Schleifman
Ms. Schleifman has disclosed that she is an employee of Genentech Inc.

P6-07-06 Establishing molecular profiling for individual treatment decisions in early breast cancer - Clinical impact of PAM50 and PAM50 risk of recurrence score after more than 16 years follow-up
Ellen Schlichting
Ms. Schlichting has disclosed that she is an employee of Genentech Inc.

P2-05-16 Proteomic response in breast cancer treated with neoadjuvant chemotherapy and without bevacizumab: Reverse phase protein array (RPPA) results from NeoAva - A randomized phase II study
Ellen Schlichting
Dr. Schlichting has no relevant financial relationships to disclose.

P6-03-13 A phase 2 study of eribulin followed by doxorubicin and cyclophosphamide as preoperative therapy for HER2-negative inflammatory breast cancer
Emily Schlosnagel
Ms. Schlosnagel has no relevant financial relationships to disclose.

OT1-01-07 A phase 2 study of eribulin followed by doxorubicin and cyclophosphamide as preoperative therapy for HER2-negative inflammatory breast cancer
Emily Schlosnagel
Ms. Schlosnagel has no relevant financial relationships to disclose.

OT2-01-01 SANDPIPER: Phase II study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA-mutant tumors
Frauke Schimmoller
Frauke Schimmoller has disclosed that she receives salary from Genentech (member of Roche Group). He also disclosed that he has patent applications as a former employee of Exelixis Inc (for an unrelated kinase inhibitor, cabozantinib, related to melanoma and prostate cancer). He disclosed that he owns Roche stock (unrelated: Exelixis Inc stock).

S4-07 BELLE-3: A phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2-, aromatase inhibitor-treated, locally advanced or metastatic breast cancer who progressed on or after mTOR inhibitor-based treatment
Alessio Schirone
Alessio Schirone has no relevant financial relationships to disclose.

P2-01-03 Results of multigene assay (MammaPrint®) and molecular subtyping (BluePrint®) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIME decision impact study
Christian Schindlbeck
Dr. Schindlbeck has no relevant financial relationships to disclose.

P6-11-13 Phase Ib study evaluating the safety and clinical activity of lumestuzumab combined with pertuzumab and paclitaxel in HER2-low metastatic breast cancer
Christoph Schindler
Dr. Schindler has no relevant financial relationships to disclose.

S4-07 The complete spectrum of ESRI mutations from 7590 breast cancer tumor samples
Erica Schleifman
Ms. Schleifman has disclosed that she is an employee of Genentech Inc.

P6-07-06 Establishing molecular profiling for individual treatment decisions in early breast cancer - Clinical impact of PAM50 and PAM50 risk of recurrence score after more than 16 years follow-up
Ellen Schlichting
Ms. Schlichting has disclosed that she is an employee of Genentech Inc.

P2-05-16 Proteomic response in breast cancer treated with neoadjuvant chemotherapy and without bevacizumab: Reverse phase protein array (RPPA) results from NeoAva - A randomized phase II study
Ellen Schlichting
Dr. Schlichting has no relevant financial relationships to disclose.

OT1-01-07 A phase 2 study of eribulin followed by doxorubicin and cyclophosphamide as preoperative therapy for HER2-negative inflammatory breast cancer
Emily Schlosnagel
Ms. Schlosnagel has no relevant financial relationships to disclose.
OT2-02-03 Pilot study of zirconium-89 bevacizumab positron emission tomography for imaging angiogenesis in patients with inflammatory breast carcinoma receiving neoadjuvant chemotherapy
Emily Schlosnagle
Ms. Schlosnagle has no relevant financial relationships to disclose.

P5-12-12 Phase I study of the JAK 1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer (MRBC)
Emily Schlosnagle
Ms. Schlosnagle has no relevant financial relationships to disclose.

P5-08-21 The effect of family history on screening procedures and prognosis in breast cancer patients - Results of a large population-based case-control study on breast cancer
Barbara Schmalfeldt
Dr. Schmalfeldt has no relevant financial relationships to disclose.

P2-11-04 Efficacy and safety of darbepoetin alfa or epoetin beta in 2994 high-risk early breast cancer patients participating in the German adjuvant intergroup node-positive study (GAIN)
Sabine Schmatloch
Sabine Schmatloch has no relevant financial relationships to disclose.

P3-13-06 Development and validation of a nomogram predicting pathological axillary status (pN0 vs. pN+) in a subgroup of patients converting from cN+ to cN0 through neoadjuvant therapy (NAT) - A transGENTINA substudy
Sabine Schmatloch
Sabine Schmatloch has no relevant financial relationships to disclose.

P4-22-05 Dual HER2- blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: A subanalysis of data from the randomized phase III GeparSepto trial
Sabine Schmatloch
Sabine Schmatloch has no relevant financial relationships to disclose.

P4-01-09 Characterization of neratinib-induced diarrhea in patients with early-stage HER2+ breast cancer: Analyses from the phase III ExteNET trial
Kamila Schmid
Ms. Schmid has disclosed that he is a consultant for Puma (IDMC).

P1-01-09 Comparison of HER2, estrogen and progesterone receptor expression profiles of primary tumor, synchronous axillary lymph node metastases and circulating tumor cells in early breast cancer patients
Kurt Schmid
Mr. Schmid has no relevant financial relationships to disclose.

OT1-01-06 PIQHASSO: Open label, non-randomized, multicenter phase I/IIb study investigating safety and efficacy of PQR309 and eribulin combination in patients (pts) with locally advanced (LA) or metastatic HER2 (-) and triple-negative breast cancer (TNBC) (study PQR309-007)
Peter Schmid
Peter Schmid
Mr. Schmid has no relevant financial relationships to disclose.

OT2-02-02 PIQHASSO: A randomized international phase 3 study comparing the efficacy and safety of eribulin in combination with paclitaxel chemotherapy or as monotherapy vs placebo in patients with advanced diagnostic-positive triple-negative breast cancer
Peter Schmid
Mr. Schmid has no relevant financial relationships to disclose.

P3-03-12 CDK4/6 inhibitor resistant ER-positive cells remain dependent on estrogen signaling and retain sensitivity to endocrine therapy
Peter Schmid
Mr. Schmid has disclosed that he received research support from AstraZeneca, and Genentech.

P6-11-09 Heavily pre-treated breast cancer patients show promising responses in the first in human-study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2540 in combination with paclitaxel
Peter Schmid
Mr. Schmid has no relevant financial relationships to disclose.

P02-03 Recurrent functionally diverse in-frame ESR1 gene fusions drive endocrine resistance in breast cancer
Cheryl Schmidt
Ms. Schmidt has no relevant financial relationships to disclose.

P02-06 Mutism: MuTHER: Blocky binomial model-endocrine therapy resistance in breast cancer
Cheryl Schmidt
Ms. Schmidt has no relevant financial relationships to disclose.

P3-09-04 Beyond CHEK2 in breast cancer: Search for additional moderately penetrant risk gene variants by analyzing the oligogenic disease course in CHEK2 mutation carriers
Summer Schmidt
Summer Schmidt
Mr. Schmidt has no relevant financial relationships to disclose.

P5-16-12 Pertuzumab and trastuzumab in combination with weekly paclitaxel delivers high pCR rates with favourable toxicity profile in neo-adjuvant treatment of HER-2 positive breast cancer
Kristen Schmidt
Ms. Schmidt has no relevant financial relationships to disclose.
Prognostic significance of nuclear factor kappa B in node-negative breast cancer is most pronounced in luminal B breast cancer

Marcus Schmidt

Dr. Schmidt has no relevant financial relationships to disclose.

Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2/ER+ breast cancer cells

Marcus Schmidt

Dr. Schmidt has no relevant financial relationships to disclose.

Risk of metastasis in contralateral breast cancer: Systematic review and meta-analysis

Marjanja Schmidt

Marjanja Schmidt has no relevant financial relationships to disclose.

The PI3K inhibitor, taselisib, has enhanced potency in PIK3CA mutant models through a unique mechanism of action

Stephen Schmidt

Mr. Schmidt has disclosed that he receives salary from Genentech, Inc.

Pertuzumab and trastuzumab in combination with weekly paclitaxel delivers high pCR rates with favorable toxicity profile in neo-adjuvant treatment of HER-2 positive breast cancer

Thomas Schmidt

Dr. Schmidt has no relevant financial relationships to disclose.

RIBECCA - A phase IIb, multi-center, open label study for women with estrogen receptor negative locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole

Sabine Schmidt-Wetzel

Sabine Schmidt-Wetzel has disclosed that she receives salary from Novartis.

Tissue kallikrein-related peptidase 4, a novel biomarker in triple-negative breast cancer

Manfred Schmitt

Prof. Schmitt has no relevant financial relationships to disclose.

Evaluation of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarker in different subtypes of breast cancer treated with neoadjuvant therapy: A metaanalysis of 3771 patients

Wolfgang Schmitt

Mr. Schmitt has no relevant financial relationships to disclose.

EP3-receptor expression is a prognostic marker for overall survival and progression-free survival in sporadic breast cancer

Elisa Schmoeckel

Ms. Schmoeckel has no relevant financial relationships to disclose.

Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer

Bita Schmutzler

Ms. Schmutzler has no relevant financial relationships to disclose.

Low-level gonosomal mosaicism of a de novo BRCA1 gene mutation - The origin of a constitutional mutation in a breast cancer family

Bita Schmutzler

Ms. Schmutzler has no relevant financial relationships to disclose.

Impact of treatment history on prognostic ability of breast cancer index (BCI): Subset analysis from a validation study of patients with hormone receptor-positive (HR+) breast cancer with 1-3 positive nodes

Catherine Schnabel

Dr. Schnabel has disclosed that she receives salary from, has a patent with and has ownership in Biotheranostics, Inc.

An optimized 92-gene assay for the molecular diagnosis of triple negative breast cancer

Catherine Schnabel

Dr. Schnabel has disclosed that she receives salary from, has ownership in and has a patent with Biotheranostics, Inc.

Comprehensive comparison of prognostic signatures for breast cancer in TransATAC

Catherine Schnabel

Ms. Schnabel has disclosed that she is an employee of bioTheranostics.

A multi-institutional, prospective study of incorporating the genomic platform breast cancer index as a tool for decision-making regarding extension of adjuvant endocrine therapy

Cathy Schnabel

Ms. Schnabel has disclosed that she is an employee of bioTheranostics.
P3-01-05  Influence of hormone replacement therapy following bilateral salpingo-oophorectomy on mammographic breast density in women newly diagnosed with breast cancer  Freya Schnabel  Dr. Schnabel has no relevant financial relationships to disclose.

P5-16-26  National trends in neoadjuvant therapy for breast cancer  Freya Schnabel  Dr. Schnabel has no relevant financial relationships to disclose.

OT1-02-04  The DETECT V-study - Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemotherapy or endocrine therapy in patients with HER2-positive and hormone-receptor positive metastatic breast cancer  Andreas Schneeweiss  Dr. Schneeweiss has no relevant financial relationships to disclose.

OT2-01-18  RIBECCA - A phase Ib, multi-center, open label study for women with estrogen receptor positive locally advanced or metastatic breast cancer treated with ribociclib (L0011) in combination with letrozole  Andreas Schneeweiss  Dr. Schneeweiss has no relevant financial relationships to disclose.

OT3-04-02  DETECT III and IV - Individualized CTC-based therapy of metastatic breast cancer  Andreas Schneeweiss  Dr. Schneeweiss has no relevant financial relationships to disclose.

P1-01-03  Dynamics of circulating tumor cells during the course of chemotherapy and prognostic relevance across molecular subtypes in high-risk early breast cancer patients - Results from the adjuvant SUCCESS A trial  Andreas Schneeweiss  Dr. Schneeweiss has no relevant financial relationships to disclose.

P1-09-02  Outcome after neoadjuvant chemotherapy in preoperative receptor-negative breast cancer patients - A pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials  Andreas Schneeweiss  Andreas Schneeweiss has no relevant financial relationships to disclose.

P2-05-02  Active surveillance with a combination of tumor marker CA27.29 and detection of circulating tumor cells two years after primary diagnosis strongly predicts subsequent prognosis  Andreas Schneeweiss  Andreas Schneeweiss has no relevant financial relationships to disclose.

P2-05-25  Predictive value of ultra-high ESR1 mRNA expression in early breast cancer  Andreas Schneeweiss  Dr. Schneeweiss has no relevant financial relationships to disclose.

P2-11-04  Efficacy and safety of darbepoetin alfa or epoetin beta in 2994 high risk early breast cancer patients participating in the German adjuvant intergroup node-positive study (GAIN)  Andreas Schneeweiss  Andreas Schneeweiss has no relevant financial relationships to disclose.

P3-11-05  Outcome after neoadjuvant chemotherapy in progesterone receptor negative breast cancer patients - A pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials  Andreas Schneeweiss  Andreas Schneeweiss has no relevant financial relationships to disclose.

P4-07-01  Profiling miRNA in high risk post-operative early breast cancer patients to detect possible association to correlation with immune system antitumor response  Andreas Schneeweiss  Dr. Schneeweiss has no relevant financial relationships to disclose.

P4-21-02  Pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: Efficacy analysis of a phase II cardiac safety study (TRYPHENA)  Andreas Schneeweiss  Andreas Schneeweiss has no relevant financial relationships to disclose.

P4-21-04  Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (PERUSE)  Andreas Schneeweiss  Andreas Schneeweiss has no relevant financial relationships to disclose.

P4-21-06  Dual HER2 Blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: A subanalysis of data from the randomized phase III GeparSepto trial  Andreas Schneeweiss  Andreas Schneeweiss has no relevant financial relationships to disclose.

P4-21-07  Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy in patients ≥65 years with HER2-positive locally recurrent/metastatic breast cancer: Subgroup analysis of the PERUSE study  Andreas Schneeweiss  Andreas Schneeweiss has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenters</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P5-15-03</td>
<td>nab-paclitaxel + carboplatin vs gemcitabine/paclitaxel as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the tNACity trial</td>
<td>Andreas Schneeweiss</td>
<td>Andere Schneeweiss has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-16-05</td>
<td>Peripheral sensory neuropathy occurrence and resolution: Results from the neoadjuvant randomized GeparSepto study (GBG 49)</td>
<td>Andreas Schneeweiss</td>
<td>Andere Schneeweiss has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-11-13</td>
<td>Phase II study evaluating the safety and clinical activity of lumetuzumab combined with pertuzumab and paclitaxel in HER2-low metastatic breast cancer</td>
<td>Andreas Schneeweiss</td>
<td>Dr. Schneeweiss has disclosed that he is a consultant for Roche and Glaxosmithkline.</td>
</tr>
<tr>
<td>P6-13-02</td>
<td>Efficacy of first-line brentuximab PEV-containing therapy for poor-prognosis advanced breast cancer (ABC): Subgroup analyses of the German AVANTI observational study</td>
<td>Andreas Schneeweiss</td>
<td>Andere Schneeweiss has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S1-08</td>
<td>Evaluation of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarker in different subtypes of breast cancer treated with neoadjuvant therapy - A metaanalysis of 3771 patients</td>
<td>Andreas Schneeweiss</td>
<td>Andere Schneeweiss has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT3-04-01</td>
<td>BRE12-158: A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple-negative breast cancer (TNBC)</td>
<td>Bryan Schneider</td>
<td>Dr. Schneider has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-04-07</td>
<td>A phase 2 study of eribulin as early-line treatment for HER2- MBC: Evaluation of efficacy, toxicity, and patient-reported outcomes</td>
<td>Bryan Schneider</td>
<td>Mr. Schneider has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-15-08</td>
<td>Site-specific activation of curcuminoids in the breast cancer bone metastases microenvironment</td>
<td>Claus Schnell</td>
<td>Ms. Schnell has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-02-02</td>
<td>Predictive value of breast MRI in detecting mammographically occult contralateral breast cancer: Can we target women more likely to have contralateral breast cancer based on primary tumor clinicopathologic factors?</td>
<td>Lisa Schneider</td>
<td>Dr. Schneider has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-13-01</td>
<td>Determining the breast tumor margin through genomics of the cancer-stromal interaction</td>
<td>Robert Schneider</td>
<td>Dr. Schneider has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT2-04-02</td>
<td>Comparison of axillary sentinel lymph node biopsy versus no axillary surgery in patients with early-stage invasive breast cancer and breast-conserving surgery: A randomized prospective surgical trial. The Intergroup-Sentinel-Mamma (INSEMA)-trial</td>
<td>Cornelia Schneider-Schranz</td>
<td>Dr. Schneider-Schranz has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-13-20</td>
<td>Use of a 3-D bioabsorbable tissue marker in 61 patients over two years</td>
<td>Nancy Schnell</td>
<td>Ms. Schnell has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-22-03</td>
<td>Palbociclib in combination with endocrine therapy in treatment-naive and previously treated elderly women with HR+, HER2- advanced breast cancer: A pooled analysis from randomized phase 2 and 3 studies</td>
<td>Patrick Schnell</td>
<td>Mr. Schnell has disclosed that he receives salary from and has ownership in Pfizer.</td>
</tr>
<tr>
<td>P4-22-07</td>
<td>Long-term safety of palbociclib in combination with endocrine therapy in treatment-naive and previously treated women With HR+, HER2- advanced breast cancer: A pooled analysis from randomized phase 2 and 3 studies</td>
<td>Patrick Schnell</td>
<td>Mr. Schnell has disclosed that he receives salary from and has ownership in Pfizer.</td>
</tr>
<tr>
<td>P3-12-01</td>
<td>Comprehensive genomic profiling of 34 cases of breast carcinomas</td>
<td>Stuart Schnett</td>
<td>Dr. Schnett has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S2-02</td>
<td>The landscape of somatic genetic alterations in BRCA1 and BRCA2 breast cancers</td>
<td>Stuart Schnett</td>
<td>Dr. Schnett has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Committee Member</td>
<td>The landscape of somatic genetic alterations in BRCA1 and BRCA2 breast cancers</td>
<td>Stuart Schnett</td>
<td>Dr. Schnett has no relevant financial relationships with commercial interests to disclose.</td>
</tr>
<tr>
<td>P3-14-02</td>
<td>Post-mastectomy breast reconstruction in elderly women: Complications and the impact of individual surgeons</td>
<td>Anna Schoenbrunner</td>
<td>Ms. Schoenbrunner has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
P3-07-02 Are we missing actionable targets in breast cancer? Novel insights into recurrent Ret alterations
Alexa Schrock
Alexa Schrock has disclosed that he receives salary from and has ownership in Foundation Medicine.

P5-03-06 Clinical value of 166Ga-trastuzumab PET in HER2-positive breast cancer patients with a clinical dilemma
Carolina Schroeder
Dr. Schroeder has no relevant financial relationships to disclose.

P2-05-08 Impact of treatment history on prognostic ability of breast cancer index (BCI): Subset analysis from a validation study of patients with hormone receptor-positive (HR+) breast cancer with 1-3 positive nodes
Brock Schroeder
Dr. Schroeder has disclosed that he receives salary from and has ownership in Biotheranostics, Inc.

P2-05-14 Prognostic impact of genomic risk stratification with breast cancer index in patients with clinically low risk, hormone receptor-positive, node-negative, TT breast cancer
Brock Schroeder
Dr. Schroeder has disclosed that he receives salary from and has ownership in Biotheranostics, Inc.

P2-05-18 Correlation of breast cancer index (BCI) risk classification with tumor grade and Ki-67 in a large series of patients with early-stage, ER+ breast cancer
Brock Schroeder
Dr. Schroeder has disclosed that he receives salary from and has ownership in Biotheranostics, Inc.

P2-08-15 Disparities in human epidermal growth factor receptor 2 testing completion: A population-based retrospective cohort study, 2010-2013
Mary Schroeder
Dr. Schroeder has no relevant financial relationships to disclose.

P3-10-04 African Americans have more aggressive invasive lobular carcinoma subtypes and inferior early outcomes: SEER 2010-2013
Mary Schroeder
Dr. Schroeder has no relevant financial relationships to disclose.

P5-10-02 Vitamin D level impacts odds of pathologic complete response following neoadjuvant therapy in operable breast cancer
Mary Schroeder
Dr. Schroeder has no relevant financial relationships to disclose.

P6-09-24 Vitamin D level impacts odds of pathologic complete response following neoadjuvant therapy in operable breast cancer
Mary Schroeder
Dr. Schroeder has no relevant financial relationships to disclose.

OT2-01-18 RIBECCA - A phase IIb, multi-center, open label study for women with estrogen receptor positive locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in combination with letrozole
Jorg Schubert
Mr. Schubert has disclosed that he receives salary from Novartis.

S3-04 The landscape of somatic genetic alterations in BRCA1 and BRCA2 breast cancers
Anne Schultheis
Dr. Schultheis has no relevant financial relationships to disclose.

P1-09-05 The role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+/HR+ phase II trial evaluating 12-weeks of neoadjuvant TDM1 ± endocrine therapy (ET) versus T + ET in HER2-positive hormone-receptor-positive early breast cancer (ERBC)
Johannes Schumacher
Dr. Schumacher has no relevant financial relationships to disclose.

P2-05-25 Predictive value of ultra-high ESR1 mRNA expression in early breast cancer
Johannes Schumacher
Dr. Schumacher has no relevant financial relationships to disclose.

P1-09-05 The role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+/HR+ phase II trial evaluating 12-weeks of neoadjuvant TDM1 ± endocrine therapy (ET) versus T + ET in HER2-positive hormone-receptor-positive early breast cancer (ERBC)
Johannes Schumacher
Dr. Schumacher has no relevant financial relationships to disclose.
Detection of molecular alterations in breast cancer through next generation sequencing of both tumor tissue and circulating tumor DNA: The UC San Diego Moores Cancer Center experience
Richard Schwab
Dr. Schwab has no relevant financial relationships to disclose.

Tumor subtype and survival differences between Hispanic and non-Hispanic white breast cancer patients in the California cancer registry
Richard Schwab
Dr. Schwab has no relevant financial relationships to disclose.

ER is required for mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer cells and patients' tumors
Gary Schwartz
Dr. Schwartz has no relevant financial relationships to disclose.

Quantitative proteomic analysis of FGFR by mass spectrometry may improve identification of FGFR amplified tumors sensitive to inhibitor therapy
Sarit Schwartz
Sarit Schwartz has disclosed that he is paid by NantOmics.

Influence of hormone replacement therapy following bilateral salpingo-oophorectomy on mammographic breast density in women newly diagnosed with breast cancer
Shira Schwartz
Shira Schwartz has no relevant financial relationships to disclose.

A multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer: Early results of unplanned boost participants
Barbara Schwartzberg
B Schwartzberg has disclosed that he received approximately $3200 in honorariums from Xoft in the last year.

Two-year follow-up results of a multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer
Barbara Schwartzberg
Dr. Schwartzberg has no relevant financial relationships to disclose.

Randomized phase 3 study of a novel, long-acting G-CSF (eflapegrastim) versus pegfilgrastim in the management of chemotherapy-induced neutropenia in early-stage breast cancer patients receiving docetaxel and cyclophosphamide (TC) (ADVANCE study)
Lee Schwartzberg
Dr. Schwartzberg has disclosed that he is a consultant for Spectrum Pharmaceuticals and Amgen.

Use of an aptamer library based next generation omics platform for the development of a novel trastuzumab predictive assay
Lee Schwartzberg
Dr. Schwartzberg has disclosed that he receives salary from and has ownership from Caris Life Sciences.

Pharmacokinetics of eflapegrastim in a phase 2 open-label dose-ranging study in breast cancer patients receiving TC regimen
Lee Schwartzberg
Dr. Schwartzberg has disclosed that he is a consultant for Spectrum Pharmaceuticals and Amgen.

Immunogenicity of eflapegrastim in a phase 2 open-label dose-ranging study of eflapegrastim in breast cancer patients receiving TC regimen
Lee Schwartzberg
Dr. Schwartzberg has disclosed that he is a consultant for Spectrum Pharmaceuticals and Amgen.

Sustained efficacy of eflapegrastim in breast cancer patients in a phase 2, open-label, dose-ranging study
Lee Schwartzberg
Dr. Schwartzberg has disclosed that he is a consultant for Spectrum Pharmaceuticals and Amgen.

Rolapitant for the prevention of chemotherapy-induced nausea and vomiting in breast cancer patients receiving multiple cycles of emetogenic chemotherapy
Lee Schwartzberg
Lee Schwartzberg has disclosed that he is a consultant for Eisai, Teva, Janssen, Genentech and Bristol-Myers Squibb and a speaker for Genentech, Novartis and Bristol-Myers Squibb. He has also disclosed that he has a contract with Eisai.

Nonsteroidal, tissue selective androgen receptor modulator (SARM), enobosarm, reduces growth of androgen receptor-positive breast cancer in patient-derived preclinical models
Lee Schwartzberg
Dr. Schwartzberg has no relevant financial relationships to disclose.

Genomic profiling of residual ER+ breast cancers treated with prolonged neoadjuvant letrozole reveals novel alterations in clinocrally resistant tumors
Sooi Schwartz
Dr. Schwartz has no relevant financial relationships to disclose.

Pan-HER, an antibody mixture with antitumor activity against drug-resistant HER2-overexpressing breast cancers with high ERBB ligand expression
Sooi Schwartz
Sooi Schwartz has no relevant financial relationships to disclose.
A real-world evidence study to define the prevalence of endocrine therapy-naïve hormone receptor-positive locally advanced or metastatic breast cancer in the US

John Seeger

Mr. Seeger has disclosed that he is an employee of Optum Epidemiology, which conducted this research under a contract with AstraZeneca. He has also disclosed that he is a stock owner in United Health Group.

Survival after adjuvant and neoadjuvant chemotherapy in elderly patients with triple negative breast cancer: A Cleveland Clinic experience

Synthomai Segupa

Dr. Segupa has no relevant financial relationships to disclose.

P5-09-31

The effect of family history on screening procedures and prognosis in breast cancer patients - Results of a large population-based case control study on breast cancer

Katharina Seluzicki

Ms. Seluzicki has no relevant financial relationships to disclose.

P4-01-02

Diagnostic value of breast specific gamma imaging for breast cancer

Fabjola Sejdinaj

Fabjola Sejdinaj has no relevant financial relationships to disclose.

P4-01-02

The perception of chronic pain among breast cancer survivors

Christina Seluzicki

Shrinker Seluppan has disclosed that he is paid by NaavoRx.

P5-13-08

Pathological complete response to neoadjuvant trastuzumab is dependent on HER2/CEP17 ratio in HER2-amplified early breast cancer

Michael Seifert

Mr. Seifert has no relevant financial relationships to disclose.

P3-09-22

The perception of chronic pain among breast cancer survivors

Chikako Sekine

Dr. Sekine has no relevant financial relationships to disclose.

P5-11-07

Quantitative proteomic analysis of FGFR by mass spectrometry may improve identification of FGFR amplified tumors sensitive to inhibitor therapy

Shankar Sellappan

Shankar Sellappan has disclosed that he is paid by NaavoRx.

P5-11-06

Quantitative proteomic analysis of FGFR by mass spectrometry may improve identification of FGFR amplified tumors sensitive to inhibitor therapy

Vladimir Semiglazov

Mr. Semiglazov has no relevant financial relationships to disclose.

P1-09-04

Proliferation and p21 refine risk of relapse in neoadjuvant disease after HER2-directed therapy

Semiglazov

Mr. Semiglazov has no relevant financial relationships to disclose.

P2-01-37
EP3-receptor expression is a prognostic marker for overall survival and progression-free survival in sporadic breast cancer
Anna Semmlinger
Ms. Semmlinger has no relevant financial relationships to disclose.

Aurora kinase-A protein stability is negatively regulated by eEF1α2 and PTEN in breast cancer: Prognostic and therapeutic implications
Sabata Sen
Dr. Sen has no relevant financial relationships to disclose.

A randomized phase II dose-escalation study comparing docetaxel and cyclophosphamide (TC) with 5-fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel (FEC-D) for hormone receptor-negative breast cancer: The Kanagawa breast oncology group (KBOG) 1101 study
Noriko Senda
Dr. Senda has no relevant financial relationships to disclose.

Breast health behaviors of women under 40 accessing the Avon breast health outreach program
Lindsay Senter
Ms. Senter has no relevant financial relationships to disclose.

Difference between 1st and 2nd generation serotonin receptor antagonists in triplet antineoplastic therapy for highly emetogenic chemotherapy in breast cancer patients: a randomised double-blind phase II study on the AC regimen
Rui Sennema
Dr. Sennema has no relevant financial relationships to disclose.

Breast magnetic resonance imaging (MRI) useful for diagnosis of additional sites of disease in patients recently diagnosed with ductal carcinoma in situ (DCIS)?
Karla Sepulveda
Dr. Ortiz-Perez has no relevant financial relationships to disclose.

Novel cytotoxic RNA aptamers that distinguish between metastasis-prone and indolent breast and prostate cancers
Paolo Serafini
Dr. Serafini has no relevant financial relationships to disclose.

PowerPCRC trial: Changes in tumor proliferation index and quality of life with 3 days of preoperative tamoxifen
Victoria Serrico
Ms. Serrico has no relevant financial relationships to disclose.

Experience in the ABC Medical Center of Mexico City 2010-2015 using scalp-cooling system (DigniCap) for prevention of alopecia induced by chemotherapy
Alberto Serrano
Dr. Serrano has no relevant financial relationships to disclose.

Evaluation of a multidisciplinary cancer team quality in a breast cancer unit (BCU) in Mexico
Rodrigo Serrano-Ortiz
Dr. Serrano-Ortiz has no relevant financial relationships to disclose.

Detrimental effect of a serum progranulin (GP88/PGRN) level associated with overall survival in metastatic breast cancer patients
Eleotia Serra
Dr. Serra has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Abstract ID</th>
<th>Title</th>
<th>Authors</th>
<th>Relationship Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1-03-06</td>
<td>Improvement in risk predictive value of Nottingham prognostic index by determining GP88 tumor tissue expression for estrogen receptor positive breast cancer patients.</td>
<td>Ginette Serrero</td>
<td>Dr. Serrero has disclosed that she receives salary and has ownership.</td>
</tr>
<tr>
<td>P1-14-08</td>
<td>Adjuvant and neoadjuvant chemotherapy for elderly patients (≥70 years) with early high-risk breast cancer: A retrospective analysis of 119 patients</td>
<td>Véronique Servent</td>
<td>Dr. Servent has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-33</td>
<td>CASA/CARR study: Rapid survival decline per treatment line in metastatic breast cancer</td>
<td>Sonia Serra</td>
<td>Ms. Serra has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P02-06</td>
<td>Comparison of mutational landscapes of primary breast cancer and first metastatic relapse: Results from the ESPORE study</td>
<td>Vincent Serra</td>
<td>Dr. Serra has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-44</td>
<td>Tumor-infiltrating lymphocytes (TILs) is associated with improved overall survival in triple-negative breast cancer (TNBC) patients treated with neoadjuvant chemotherapy (NAC)</td>
<td>Virginia Sessa</td>
<td>Dr. Sessa has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-09-05</td>
<td>Long-term comparison of anastrozole versus tamoxifen: Results from LATTE/ATAC</td>
<td>Ivana Sestak</td>
<td>Ms. Sestak has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S5-03</td>
<td>Menopausal symptoms as predictors of long-term adherence to the international breast cancer intervention study (IBIS-1)</td>
<td>Ivana Sestak</td>
<td>Ms. Sestak has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S6-05</td>
<td>Comprehensive comparison of prognostic signatures for breast cancer in TransATAC</td>
<td>Ivana Sestak</td>
<td>Ms. Sestak has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-05-27</td>
<td>Evaluation of the Oncotype test and comprehensive assays for therapeutic stratification in early hormone receptor positive breast cancers</td>
<td>Arun Seth</td>
<td>Dr. Seth has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Committee Member</td>
<td></td>
<td>Robert Setlik</td>
<td>Dr. Setlik has no relevant financial relationships with commercial interests to disclose.</td>
</tr>
<tr>
<td>P6-10-01</td>
<td>Efficacy and safety of the therapeutic cancer vaccine bevacizumab (L-DP725) in early breast cancer: Results from a prospective, randomized, neoadjuvant phase II study (ABC50-94)</td>
<td>Paul Sevelda</td>
<td>Prof. Sevelda has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-16-23</td>
<td>Rapid germline BRCA1 screening for locally advanced breast cancer changes surgical procedure after neoadjuvant chemotherapy</td>
<td>Nicolas Sevenda</td>
<td>Dr. Sevenda has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-03-04</td>
<td>18F breast magnetic resonance imaging (MRI) useful for diagnosis of additional sites of disease in patients recently diagnosed with ductal carcinoma in situ (DCIS)?</td>
<td>Frederick Severs</td>
<td>Dr. Severs has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-10-01</td>
<td>Estrogen induced apoptosis can be mimicked by targeting unfolded protein response</td>
<td>Catherine Seykens</td>
<td>Ms. Seykens has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-08-03</td>
<td>Impact of heterogeneous CD8+ on immune cell infiltrations</td>
<td>Christopher Seynay</td>
<td>Ms. Seynay has disclosed that he is a GE employee.</td>
</tr>
<tr>
<td>P2-04-03</td>
<td>Chemotherapy-related risk factors associated with lymphedema in breast cancer patients: Should repeated ipsilateral arm infusions be avoided?</td>
<td>Cara Seward</td>
<td>Ms. Seward has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-03-02</td>
<td>Feasibility of assessing radiation response with MRI/CT directed preoperative accelerated partial breast irradiation in the prone position for hormone sensitive early stage breast cancer</td>
<td>Aubrey Skyll</td>
<td>Dr. Skye has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-03-03</td>
<td>ERBB2 mutations in circulating tumor and circulating cell-free DNA of metastatic breast cancer patients before first-line endocrine therapy and at progression</td>
<td>Caroline Seynay</td>
<td>Ms. Seynay has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-01</td>
<td>Risk of primary and contralateral breast cancer in BRCA1/2 mutation carriers previously affected with ovarian cancer</td>
<td>Caroline Seynay</td>
<td>Dr. Seynay has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-07-04</td>
<td>Risk of metastatic contralateral breast cancer: Systematic review and meta-analysis</td>
<td>Caroline Seynay</td>
<td>Ms. Seynay has no relevant financial relationships to disclosure.</td>
</tr>
</tbody>
</table>
First results from the multicenter phase III DATA study comparing 3 versus 6 years of anastrozole after 2-3 years of tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer

Caroline Seynaeve

Ms. Seynaeve has no relevant financial relationships to disclose.

The importance of loco-regional tumor burden and surgery on survival in patients with de novo stage IV breast cancer; post-hoc analyses of protocol MF07-01

Atakan Seker

Dr. Seker has no relevant financial relationships to disclose.

Salim evolution of hormone receptor status and mutational profile among patients with metastatic breast cancer

Dennis Sgroi

Dr. Sgroi has no relevant financial relationships to disclose.

Impact of treatment history on prognostic ability of breast cancer index (BCI): Subset analysis from a validation study of patients with hormone receptor-positive (HR+) breast cancer with 1-3 positive nodes

Dennis Sgroi

Dr. Sgroi has disclosed that he has a patent with Biotheranostics, Inc.

Prognostic impact of genomic risk stratification with breast cancer index in patients with clinically low risk, hormone receptor-positive, node-negative, T3 breast cancer

Dennis Sgroi

Dr. Sgroi has disclosed that he has a patent with Biotheranostics, Inc.

Committee Member

Dennis Sgroi

Mr. Sgroi has disclosed that he receives a licensing fee from bioTheranostics Inc. for a biomarker patent. This relationship does not impact his ability to present review presentations.

TRAILA PRELIM: A non randomised pilot study designed to assess the ability of image guided core biopsies to detect residual disease in patients with early breast cancer who have received neoadjuvant chemotherapy to inform the design of a planned trial

Abeer Shaaban

Dr. Shaaban has no relevant financial relationships to disclose.

A randomized trial evaluating bioimpedance spectroscopy vs. tape measurement in the prevention of lymphedema following breast cancer treatment

Chirag Shah

Chirag Shah has disclosed that he is a consultant for Impedimed.

Regulation of estrogen receptor-α by NF1

Khushboo Shah

Khushboo Shah has no relevant financial relationships to disclose.

Trajectory of patient (Pt) reported physical function (PF) during and after neoadjuvant chemotherapy in the I-SPY 2 trial

Mamta Shah

Mamta Shah has no relevant financial relationships to disclose.

Etirinotecan pegol: Survival advantage over standard of care drugs in a model of brain metasteses of breast cancer

Neal Shah

Mr. Shah has no relevant financial relationships to disclose.

Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate (ADC) for the treatment of relapsed/refractory, metastatic triple-negative breast cancer (mTNBC): Updated results

Nikita Shah

Dr. Shah has no relevant financial relationships to disclose.

A single institution clinical experience with neoadjuvant docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP): A safety and efficacy analysis

Nikita Shah

Dr. Shah has disclosed that he is on the Pfizer and Biotheranostics Ad Board and the Speaker's Bureau for Pfizer and Eisai.

Spectrum of hereditary breast and ovarian cancer gene variants in an African American cohort

Payal Shah

Dr. Shah has no relevant financial relationships to disclose.

Association of Hedgehog signaling pathway with luminal B subtype of breast cancer affected patients of Pakistan

Syed Tahir Shah

Dr. Shah has no relevant financial relationships to disclose.

NRG oncology/NSABP B-51/RTOG 1304: A phase III superiority clinical trial designed to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNR to breast RT post-breast-conserving surgery (BCS) will reduce invasive cancer events in patients (pts) with positive axillary (Ax) nodes and convert to ypN0 after neoadjuvant chemotherapy (NC)

Simona Shaitelman

Ms. Shaitelman has disclosed that she is a consultant for MD Anderson Physician's Network. She has also disclosed that she has a grant from Baxa for work not related to this abstract.

Patient-reported cosmetic outcomes in older breast cancer survivors: A population-based survey study

Simona Shaitelman

Dr. Shaitelman has no relevant financial relationships to disclose.
**OT3-02-06**
Femara plus ribociclib or placebo as neo-adjuvant endocrine therapy for women with ER+, HER2-negative early breast cancer - The Feline trial
Priyanka Sharma
Dr. Sharma has disclosed that she receives research funding from Novartis.

**P5-18-02**
Pathological complete response is associated with excellent outcomes in BRCA mutation associated triple negative breast cancer
Priyanka Sharma
Dr. Sharma has no relevant financial relationships to disclose.

**P6-11-08**
Safety and efficacy results from phase I study of BYL 719 plus nab-paclitaxel in HER 2 negative metastatic breast cancer
Priyanka Sharma
Dr. Sharma has disclosed that she has a contract with Novartis.

**P5-13-04**
Voice of cancer patients: Analysis of patient concerns regarding pregnancy and fertility preservation in patients with breast cancer
Rahul Sharma
Rahul Sharma has no relevant financial relationships to disclose.

**P5-13-04**
Voice of cancer patients: Analysis of patient concerns regarding pregnancy and fertility preservation in patients with breast cancer
Rahul Sharma
Rahul Sharma has no relevant financial relationships to disclose.

**P6-19-18**
A new oral SERD AZD9496 is efficacious in antagonizing ER and circumventing resistance to endocrine therapy
Martin Shea
Dr. Shea has no relevant financial relationships to disclose.

**P1-01-16**
Detection of moles in breast cancer through next generation sequencing of both tumor tissue and circulating tumor DNA: The UC San Diego Moores Cancer Center experience
Rebecca Shatsky
Dr. Shatsky has no relevant financial relationships to disclose.

**P1-07-04**
Unique overlapping subtypes of triple-negative breast and ovarian cancers and sensitivity of "mesenchymal-like" cancers to HSP90 inhibition is revealed by integrated gene expression and drug sensitivity profiling
Kevin Sheehan
Mr. Sheehan has no relevant financial relationships to disclose.

**P3-03-01**
A novel high throughput secreted factor screen and bioinformatics pipeline identifies macromolecular-derived FGF2 as a mechanism of resistance to anti-estrogens, PI3K, and mTOR inhibitors in ER-sensitive breast cancer
Kevin Sheehan
Mr. Sheehan has no relevant financial relationships to disclose.

**P6-07-03**
Broken promise of liquid biopsy: Plasma DNA does not accurately reflect tumor DNA in metastatic breast cancer
Kevin Sheehan
Mr. Sheehan has no relevant financial relationships to disclose.

**P3-03-03**
Unique overlapping subtypes of triple-negative breast and ovarian cancers and sensitivity of "mesenchymal-like" cancers to HSP90 inhibition is revealed by integrated gene expression and drug sensitivity profiling
Kevin Sheehan
Mr. Sheehan has no relevant financial relationships to disclose.

**P4-04-07**
Unique overlapping subtypes of triple-negative breast and ovarian cancers and sensitivity of "mesenchymal-like" cancers to HSP90 inhibition is revealed by integrated gene expression and drug sensitivity profiling
Kevin Sheehan
Mr. Sheehan has no relevant financial relationships to disclose.

**P2-02-04**
Unique overlapping subtypes of triple-negative breast and ovarian cancers and sensitivity of "mesenchymal-like" cancers to HSP90 inhibition is revealed by integrated gene expression and drug sensitivity profiling
Kevin Sheehan
Mr. Sheehan has no relevant financial relationships to disclose.

**P6-01-03**
N-terminus Slit2 suppresses breast cancer metastasis by inhibiting tumor associated macrophages
Raham Shehab
Dr. Shehab has no relevant financial relationships to disclose.

**P6-01-03**
N-terminus Slit2 suppresses breast cancer metastasis by inhibiting tumor associated macrophages
Raham Shehab
Dr. Shehab has no relevant financial relationships to disclose.

**P5-16-02**
Unique overlapping subtypes of triple-negative breast and ovarian cancers and sensitivity of "mesenchymal-like" cancers to HSP90 inhibition is revealed by integrated gene expression and drug sensitivity profiling
Raham Shehab
Dr. Shehab has no relevant financial relationships to disclose.

**P6-05-03**
Unique overlapping subtypes of triple-negative breast and ovarian cancers and sensitivity of "mesenchymal-like" cancers to HSP90 inhibition is revealed by integrated gene expression and drug sensitivity profiling
Raham Shehab
Dr. Shehab has no relevant financial relationships to disclose.
Development of a panel of serum-based protein biomarkers for the non-invasive detection of breast cancer in BI-RADS category 4 patients

Nadia Sheibani

Ms. Sheibani has disclosed that she receives salary from and has ownership in OncoCyte Corporation.

Relationship between obesity and breast tumor pathology in a contemporary set of patients

Craig Shelley

Mr. Shelley has no relevant financial relationships to disclose.

Comprehensive comparison of breast cancer molecular portraits by African and European ancestry in the cancer genome atlas

Carl Shelley

Mr. Shelley has no relevant financial relationships to disclose.

Porous silicon microparticle potentiates anti-tumor immunity

Nadia Shen

Dr. Shen has no relevant financial relationships to disclose.

Development of INFNG-pixels for metastatic breast cancer treatment

Nadia Shen

Dr. Shen has no relevant financial relationships to disclose.

Spectral CT-based radiomics signature: A potential biomarker for preoperative prediction of lymph node metastasis in breast cancer

Jun Shen

Jun Shen has no relevant financial relationships to disclose.

Comparison of axillary nodal status between different defined clinically node negative breast cancer: Is ACSOSG 2011 criteria applicable to preoperative cytologically negative axilla?

Kunwei Shen

Kunwei Shen has no relevant financial relationships to disclose.

Non-anthracycline-containing docetaxel plus cyclophosphomide was inferior to docetaxel, anthracycline and cyclophosphomide in neoadjuvant treatment of triple negative or HER2 positive breast cancer: Long-term follow-up result from NATT study

Kunwei Shen

Dr. Shen has no relevant financial relationships to disclose.

Spectral CT-based radiomics signature: A potential biomarker for preoperative prediction of lymph node metastasis in breast cancer

Jun Shen

Jun Shen has no relevant financial relationships to disclose.

Diagnostic value of breast specific gamma imaging for breast cancer

Lei Shen

Lei Shen has no relevant financial relationships to disclose.

Biology and long-term prognosis of screening detected non-palpable breast cancer by ultrasound in hospital-based Chinese population (2001-2014)

Songjie Shen

Dr. Shen has no relevant financial relationships to disclose.

Patient-reported cosmetic outcomes in older breast cancer survivors: A population-based survey study

Yu Shen

Dr. Shen has no relevant financial relationships to disclose.

Zoledronic acid sensitized breast cancer cells to fulvestrant via ERK/FOXO3a/HIF-1 α inhibition through nuclear FOXO3a translocation

Zhenzhou Shen

Zhenzhou Shen has no relevant financial relationships to disclose.

Conditional inactivation of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) in the mouse mammary epithelium alters mammary gland development

Lei Sheng

Lei Sheng has no relevant financial relationships to disclose.

SOX9 is a critical regulator of triple-negative breast cancer cell growth and invasion

Jonathan Shepherd

Dr. Shepherd has no relevant financial relationships to disclose.

Inhibition of death-associated protein kinase 1 enhances chemotherapy action against triple-negative breast cancer

Jonathan Shepherd

Mr. Shepherd has no relevant financial relationships to disclose.

Predictive effect of cytotoxic tumor infiltrating lymphocytes in HER2-positive metastatic breast cancer: A correlation study with CTCG MA-31

Lois Shepherd

Ms. Shepherd has no relevant financial relationships to disclose.

Effect of serum biomarkers [actinin-A, CAS, HER2, TIMP-1, and uPA] on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab plus docetaxel: CTCG MA-31

Lois Shepherd

Dr. Shepherd has no relevant financial relationships to disclose.

Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P)+carboplatin (C)+TMZ (CP) in patients with BRCA1 or BRCA2 mutations and metastatic breast cancer

Stacie Shepherd

Ms. Shepherd has disclosed that she is an employee of and has ownership in AbbVie.
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Author</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P5-08-15</td>
<td>Real-world treatment patterns and survival among triple negative breast cancer patients versus patients with other breast cancer subtypes in early stage breast cancer</td>
<td>Stacie Shepherd</td>
<td>Ms. Shepherd has disclosed that she receives salary from and has ownership in AbbVie.</td>
</tr>
<tr>
<td>S2-04</td>
<td>The association between angiotensin receptor blockers usage and breast cancer characteristics</td>
<td>Daniel Shepshelovich</td>
<td>Dr. Shepshelovich has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-07-11</td>
<td>Efficacy and tolerability of veliparib (V; ABT-888) in combination with carboplatin (C) and paclitaxel (P) in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: A randomized, phase 2 study</td>
<td>Stacie Shepherd</td>
<td>Ms. Shepherd has disclosed that she has ownership in and is an employee of AbbVie.</td>
</tr>
<tr>
<td>S1-07</td>
<td>Prognostic associations of tumor-infiltrating lymphocytes (TIL) in metastatic HER2 positive breast cancer (BC) treated with trastuzumab and pertuzumab: A secondary analysis of the CLEOPATRA study</td>
<td>Lizi Sharrere</td>
<td>Dr. Lai has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-11-19</td>
<td>Sexual functioning among breast cancer survivors and their partners: A pilot study</td>
<td>Allen Sherman</td>
<td>Dr. Sherman has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-01-11</td>
<td>Diagnostic performance of supplemental screening with molecular breast imaging in women with dense breast tissue</td>
<td>Robin Sherman</td>
<td>Dr. Sherman has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-07-15</td>
<td>Economic impact of breast cancer in Mexico</td>
<td>Santiago Sherman-Caldero</td>
<td>Dr. Sherman-Caldero has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-03-09</td>
<td>Highly reproducible decentralized gene expression analysis of ERX, PGR, ERBB2 and MK67 on an automated, standardized molecular diagnostics platform, GemsetP</td>
<td>Thomas Sherwood</td>
<td>Dr. Sherwood has disclosed that he receives salary from Cepheid.</td>
</tr>
<tr>
<td>P4-03-10</td>
<td>Prognostic and predictor marker in the tumor microenvironment of breast cancers</td>
<td>Aarti Sherade</td>
<td>Dr. Sherade has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-07-31</td>
<td>Molecular mechanism of alcohol-associated breast cancer</td>
<td>Shanggang Shi</td>
<td>Dr. Shi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-01-02</td>
<td>Diagnostic value of breast specific gamma imaging for breast cancer</td>
<td>Hongcheng Shi</td>
<td>Hongcheng Shi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-03-08</td>
<td>Distalization of 11β-hydroxysteroid dehydrogenase (11βHSD) expression in breast cancer cells by activated CD8+ T cells is controlled by DNA promoter methylation</td>
<td>Xiaodong Shi</td>
<td>Dr. Shi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-02-05</td>
<td>Biology and long-term prognosis of screening detected non-palpable breast cancer by ultrasound in hospital-based Chinese population (2001-2014)</td>
<td>Xie Shi</td>
<td>Dr. Shi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-03-15</td>
<td>BRAF V600E/BMPR2 polymorphism in CYP17A1 gene is related to the prognosis of early breast cancer</td>
<td>Lei Shi</td>
<td>Lei Shi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-14-02</td>
<td>Triple negative breast cancer - Adjuvant chemotherapy use and survival outcomes in Stage IIA disease</td>
<td>Runchuan Shi</td>
<td>Dr. Shi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-07</td>
<td>The aromatase inhibitor associated with higher myocardial infarction risk in breast cancer patients? A Medicare population study</td>
<td>Youwu Shi</td>
<td>Youwu Shi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-09-05</td>
<td>A model with polygenic risk score and mammographic density predicts interval cancers</td>
<td>Yongyi Shi</td>
<td>Dr. Shi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-03-12</td>
<td>Using the allele specific copy number profile to predict the poor prognosis breast cancer patients of Taiwanese</td>
<td>Niki Shia</td>
<td>Ms. Shia has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-04-10</td>
<td>Using the allele specific copy number profile to predict the poor prognosis breast cancer patients of Taiwanese</td>
<td>Weichung Shia</td>
<td>Dr. Shia has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-07-12</td>
<td>Targeting STK11 to disrupt oncogenic ERK1/2 feedback loop shows therapeutic potential in triple negative breast cancer cells</td>
<td>Junhong Wu</td>
<td>Dr. Wu has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-07-02</td>
<td>Expression of miR-132 and miR-250 in normal breast tissue as candidate markers of breast cancer risk</td>
<td>Ali Shafar</td>
<td>Dr. Shafar has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-09-05</td>
<td>A model with polygenic risk score and mammographic density predicts interval cancers</td>
<td>Yongyi Shi</td>
<td>Dr. Shi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-07-13</td>
<td>Identification of a cancer stem cell-specific function for the histone demethylases, HDAC1 and HDAC7, in breast and ovarian cancer</td>
<td>Keesh Shakhattar</td>
<td>Dr. Shakhattar has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-02-05</td>
<td>Identification of a cancer stem cell-specific function for the histone demethylases, HDAC1 and HDAC7, in breast and ovarian cancer</td>
<td>Andrew Shelds</td>
<td>Dr. Shelds has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
Eribulin induces vascular remodeling and reoxygenation in advanced breast cancer patients: A comparative study with bevacizumab

Takashi Shigekawa
Dr. Shigekawa has no relevant financial relationships to disclose.

Zoledronic acid combined with neoadjuvant chemotherapy for HER2-negative early breast cancer (JONIE 1 trial): Survival outcomes of a randomized multicenter phase 2 trial

Yasushi Shigeoka
Dr. Shigeoka has no relevant financial relationships to disclose.

Association between tumor genotypes and development of liver metastases in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer

Helen Shih
Ms. Shih has no relevant financial relationships to disclose.

Targeting inflammatory pathways: A phase 2 trial of the JAK-inhibitor ruxolitinib in combination with exemestane for aromatase inhibitor-resistant, estrogen receptor-positive breast cancer

Natalie Shih
Ms. Shih has no relevant financial relationships to disclose.

Development of photoacoustic vascular imaging system for breast cancer

Tsuyoshi Shiina
Tsuyoshi Shiina has no relevant financial relationships to disclose.

Detecting early breast cancer by the combination of five serum microRNAs and its possibility of prediction of pathological complete response in neoadjuvant chemotherapy

Sho Shino
Dr. Shino has no relevant financial relationships to disclose.

In-homogeneous SK2 suppressed breast cancer metastasis by inhibiting tumor associated macrophages

Konstantin Shilo
Dr. Shilo has no relevant financial relationships to disclose.

The importance of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive recurrent and advanced breast cancer

Kazuo Shimada
Dr. Shimada has no relevant financial relationships to disclose.

The non-invasive treatment for sentinel lymph node metastasis by photodynamic therapy using a verteporfin solubilized phospholipid polymer aggregate

Kyosuke Shimada
Mr. Shimada has no relevant financial relationships to disclose.

Sentinel lymph node biopsy by contrast-enhanced ultrasonography with sonazoid in patients with breast cancer: Prospective multicenter study

Kenzo Shimazu
Dr. Shimazu has disclosed that he received 1,000,000 yen for contracted research.

Optimized prediction of deleterious missense mutations in BRCA1 and BRCA2 genes

Hermela Shimelis
Dr. Hermela has no relevant financial relationships to disclose.

Associations between breast cancer subtypes and mutations in cancer predisposition genes identified by clinical genetic testing of breast cancer patients

Hermela Shimelis
Hermela Shimelis has no relevant financial relationships to disclose.

Breast cancer risks associated with mutations in cancer predisposition genes identified by clinical genetic testing of 60,000 breast cancer patients

Hermela Shimelis
Dr. Shimelis has no relevant financial relationships to disclose.

Detecting early breast cancer by the combination of five serum microRNAs and its possibility of prediction of pathological complete response in neoadjuvant chemotherapy

Chikako Shimizu
Dr. Shimizu has no relevant financial relationships to disclose.

A randomized phase II neoadjuvant study comparing docetaxel and cyclophosphamide (TC) with 5-fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel (FEC-D) for hormone receptor-negative breast cancer: The Kanagawa breast oncology group (KBOG) 1101 study

Daisuke Shimizu
Dr. Shimizu has no relevant financial relationships to disclose.

Duration of fasting before taking lapatinib is associated with skin toxicity in neoadjuvant treatment of HER2 positive breast cancer: A cohort study from JBCRG-16/Neo-LaTH

Satoru Shimizu
Satoru Shimizu has no relevant financial relationships to disclose.

A phase II trial of neoadjuvant docetaxel/cyclophosphamide followed by epirubicin/cyclophosphamide for HER2-positive breast cancer

Tadao Shimizu
Dr. Shimizu has no relevant financial relationships to disclose.

A phase II trial of neoadjuvant docetaxel/cyclophosphamide followed by weekly nanoparticle albumin-bound paclitaxel with trastuzumab for HER2-positive breast cancer

Tadao Shimizu
Dr. Shimizu has no relevant financial relationships to disclose.
Breast-conserving surgery plus hormone therapy without irradiation in elderly women with early breast cancer

Detecting early breast cancer by the combination of five serum microRNAs and its possibility of prediction of pathological complete response in neoadjuvant chemotherapy

Chiniopticopathologic and immunophenotypic characterization of angiomatosis of the breast: A rare vascular entity mistaken for low-grade angiosarcoma

Triple-negative breast cancers (TNBCs) rich in infiltrating stromal plasma cells have improved disease-free survival and overall survival

"Quality, not quantity": 10X hot-spot (HS) analysis of lymphocyte markers (CD1, CD8, CD4, CD20) in tumor-infiltrating lymphocytes (TILs) is superior to whole tumor (WT) analysis in triple-negative breast cancer (TNBC)

Tissue microarray (TMA) based immunohistochemical studies of lymphocyte-specific markers yield inaccurate results

Stromal density of tumor-infiltrating lymphocytes (TILs): Challenging the 50% threshold that defines lymphocyte predominant breast cancer (LPBC)

ZBTB2 is a novel therapeutic target for cisplatin-resistance in metastatic breast cancer

The ectopic FOXA1 expression correlates to the luminal breast cancer stem cells

ERBB3 gene yields MammaPrint High1/High2 risk classes associated with significant differences in pCR and receptor subtype

Learning curve for the SAVI SCOUT breast localization and surgical guidance system

Long-term follow-up of early-stage breast cancer patients with results of MammaPrint®, Oncotype DX® and MammoStrat® risk classification assays

The association between angiotensin receptor blockers usage and breast cancer characteristics

The association between smoking and breast cancer characteristics and outcome

Impact of pre-operative exercise and mind-body interventions on patient-reported outcomes in women with newly diagnosed breast cancer

Acupuncture for chemotherapy-induced peripheral neuropathy in breast cancer, preliminary results of a pilot randomized controlled trial

Identification of SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong antitumor activity in wild-type and mutant ER+ breast cancer models
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1-05-11</td>
<td>Comprehensive comparison of breast cancer molecular portraits by African and European ancestry in the cancer genome atlas</td>
<td>Craig Shriver</td>
<td>Mr. Shriver has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-06-08</td>
<td>Race is not a contributing factor to breast cancer-free interval outcome for patients with equal access to healthcare treated at a military medical center</td>
<td>Craig Shriver</td>
<td>Dr. Shriver has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-08-11</td>
<td>Contribution of germline mutations in cancer predisposition genes to tumor etiology in women diagnosed with invasive breast cancer before 40 years</td>
<td>Craig Shriver</td>
<td>Dr. Shriver has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-05-02</td>
<td>NEDD9 promotes breast cancer metastasis by regulating mitochondrial functions</td>
<td>Craig Shriver</td>
<td>Dr. Shriver has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P06-01</td>
<td>Analysis of breast cancer in young women in the department of defense (DOD) database</td>
<td>Craig Shriver</td>
<td>Dr. Shriver has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-15-03</td>
<td>HDAC8 promotes breast cancer metastasis</td>
<td>Mikhail Shitseband</td>
<td>Mikhail Shitseband has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-06</td>
<td>Analytical and clinical validation of a fully automated tissue-based quantitative assay (MetaSite™) to detect the likelihood of distant metastasis in hormone receptor (HR)-positive, HER2-negative early stage breast cancer (ESBC)</td>
<td>Anthony Shuber</td>
<td>Dr. Shuber has disclosed that he is a consultant.</td>
</tr>
<tr>
<td>S4-04</td>
<td>Tumor microenvironment of metastasis (TMEM) score is associated with early distant recurrence in hormone receptor (HR)-positive, HER2-negative early stage breast cancer (ESBC)</td>
<td>Anthony Shuber</td>
<td>Mr. Shuber has disclosed that he receives salary from MetaStat.</td>
</tr>
<tr>
<td>P1-11-06</td>
<td>Learning curve for the SAVI SCOUT breast localization and surgical guidance system</td>
<td>Savya Shukla</td>
<td>Dr. Shukla has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-03-08</td>
<td>Induction of miR-21-3p and miR-200c (miR200c) expression in breast cancer cells by activated CD8 T cells is controlled by DNA promoter methylation</td>
<td>Austin Shull</td>
<td>Austin Shull has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-03-14</td>
<td>Inhibition of indoleamine 2, 3-dioxygenase (IDO1) expression in breast cancer cells by activated CD8+ T cells is controlled by DNA promoter methylation</td>
<td>Austin Shull</td>
<td>Austin Shull has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-11-05</td>
<td>Reliability and acceptance of e-based survey instruments for measuring patient reported outcomes (PRO) in breast cancer patients: First results of the ePROCOM study</td>
<td>Nina Sickenberger</td>
<td>Ms. Sickenberger has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-09-02</td>
<td>True effect of aromatase inhibitor (AI) treatment on global gene expression (expr) changes in postmenopausal ER+ breast cancer (BC) patients: A POETIC study (CRUK/07/015)</td>
<td>Kally Sidhu</td>
<td>Kally Sidhu has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-10-06</td>
<td>Distinct immune responses to tumor associated carbohydrate antigens by a carbohydrate mimetic peptide vaccine: Clinical experience in phase 1 and phase 2 trials</td>
<td>Eric Siegel</td>
<td>Mr. Siegel has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-07-05</td>
<td>GPRM8B activates ERβ to overcome Mek-inhibition: Implications for the development of rational targeted therapy combinations in triple negative breast cancer</td>
<td>Peter Siegel</td>
<td>Dr. Siegel has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-04-14</td>
<td>17d profile associated with regional lymph node progression in breast cancer</td>
<td>Peter Sieling</td>
<td>Dr. Sieling has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>D3-07-02</td>
<td>Influence of exercise or educational programs on long term physical activity by patients after surgery for primary breast cancer: A randomized trial</td>
<td>Tadahiko Sien</td>
<td>Tadahiko Sien has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-03-04</td>
<td>Concordance of local immunohistochemistry with TargetPrint microarray based assessment of ER, PR and Her2 and BluePrint molecular subtyping in the Symphony Triple A study</td>
<td>Sabine Seiling</td>
<td>Dr. Seiling has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-10-21</td>
<td>Influence of timing of radiation therapy following breast conserving surgery on 10-year disease-free survival</td>
<td>Sabine Seiling</td>
<td>Ms. Seiling has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-01-26</td>
<td>Validation of a Chinese nomogram with a Dutch breast cancer population: Excellent prediction of the probability of axillary lymph node metastasis</td>
<td>Sabine Seiling</td>
<td>Sabine Seiling has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Page</td>
<td>Title</td>
<td>Author</td>
<td>Financial Relationships</td>
</tr>
<tr>
<td>------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>P4-21-23</td>
<td>A retrospective evaluation of cardiovascular recovery and oncologic outcomes associated with interrupted and continuous adjuvant trastuzumab in the setting of mild left ventricular dysfunction</td>
<td>Christine Simmons</td>
<td>Dr. Simmons has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-07-08</td>
<td>The role of inducible nitric oxide synthase in the stemness of triple negative breast cancer</td>
<td>Bruno Simoes</td>
<td>Dr. Simoes has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-02</td>
<td>Of H3K27 targets H3K27 methylation to inhibit stem-like cells in breast cancer patient-derived xenograft tumours</td>
<td>Bruno Simoes</td>
<td>Dr. Simoes has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-05-02</td>
<td>Breast cancer increased risk on women using combined oral contraceptive</td>
<td>Claudio Simoes</td>
<td>Dr. Simoes has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-11-05</td>
<td>Reliability and acceptance of e-based survey instruments for measuring patient reported outcomes (PRO) in breast cancer patients: First results of the ePROCOM study</td>
<td>Elisabeth Simoes</td>
<td>Prof. Simoes has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-08-06</td>
<td>Screening, management, cancer diagnoses, and outcomes of women with germline BRCA mutations in Israel: The Noga Clinic experience</td>
<td>Edna Simon</td>
<td>Ms. Simon has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-10-04</td>
<td>Spectrum of hereditary breast and ovarian cancer gene variants in an African American cohort</td>
<td>Michael Simon</td>
<td>Dr. Simon has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-04</td>
<td>Low-fat dietary pattern and breast cancer overall survival in the women's health initiative dietary modification randomized controlled trial</td>
<td>Michael Simon</td>
<td>Dr. Simon has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-30</td>
<td>OnchipPCRD® for breast cancer: A multiplex assay that makes a difference?</td>
<td>Nenke Simon</td>
<td>Dr. Simon has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-22-17</td>
<td>Safety of the combination of everolimus plus exemestane in the Italian cohort of patients enrolled in the expanded access &quot;BALLET&quot; study</td>
<td>E Simoncini</td>
<td>E Simoncini has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-04</td>
<td>RORHD study: How European and US young women cope with breast cancer and fertility concerns</td>
<td>Edda Simonz</td>
<td>Ms. Simonz has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-10-04</td>
<td>Accelerated partial breast irradiation versus whole breast irradiation: Health-related quality of life analysis from a phase 3 trial</td>
<td>Sabriale Simontacchi</td>
<td>Dr. Simontacchi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-06-05</td>
<td>Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple-negative breast cancer</td>
<td>Soile Simony-Lafontaine</td>
<td>Dr. Simony-Lafontaine has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-08-08</td>
<td>BRCA1 promoter hypermethylation, but not BRCA1 expression, is associated with basal-like features and good prognosis in triple negative breast cancer</td>
<td>Soile Simony-Lafontaine</td>
<td>Dr. Simony-Lafontaine has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-09-13</td>
<td>Adverse events rates in a privately insured US population on tamoxifen compared to controls from the MarketScan® database</td>
<td>Kit Simpson</td>
<td>Dr. Simpson has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-05-16</td>
<td>An integrated molecular analysis of invasive lobular carcinoma</td>
<td>Peter Simpson</td>
<td>Mr. Simpson has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-07-08</td>
<td>Mixed ductal-lobular carcinomas of the breast: Ablated cell adhesion in the clonal evolution from ductal to lobular morphology</td>
<td>Peter Simpson</td>
<td>Dr. Simpson has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-06-04</td>
<td>Molecular characterisation, subtype concordance and prognostic group assignment between patient-matched primary breast tumours and axillary lymph node metastases</td>
<td>Andrew Sims</td>
<td>Mr. Sims has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-08-27</td>
<td>The E2A2On test significantly predicts response and survival in both pre- and post-menopausal women with BR-positive breast cancers</td>
<td>Andrew Sims</td>
<td>Mr. Sims has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-09-18</td>
<td>Using CDH11, a newly discovered breast cancer gene, to identify and classify breast cancer subtypes</td>
<td>Cynthia Sims</td>
<td>Dr. Sims has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-01-06</td>
<td>Patterns of axillary evaluation in older patients (pts) with breast cancer and impact on adjuvant therapy</td>
<td>Helene Shaw</td>
<td>Dr. Shaw has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-10-04</td>
<td>Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multi-center trial</td>
<td>Amy Sing</td>
<td>Dr. Sing has disclosed that she receives a salary from and has ownership in Genomic Health Inc.</td>
</tr>
</tbody>
</table>
Chemotherapy-related risk factors associated with lymphedema in breast cancer patients: Should repeated ipsilateral arm infusions be avoided?

Melissa Skolny
Ms. Skolny has no relevant financial relationships to disclose.

The association between PCR status after neoadjuvant chemotherapy and sites of first distant relapse after surgery: A substudy of the EORTC 10094/BIG-1-01 trial

Leen Sleijfer
Mr. Sleijfer has no relevant financial relationships to disclose.

Can surrogate pathological subtyping replace molecular subtyping? Outcome results from the MINDACT trial

Leen Sleijfer
Mr. Sleijfer has no relevant financial relationships to disclose.

A phase 2 randomized, double-blinded, controlled study of ONT-380 in plasma in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unmetastatic locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB)

Dennis Slamon
Dr. Slamon has no relevant financial relationships to disclose.

Enhanced tumor cell-free and circulating tumor cell DNA by digital PCR: An optimized workflow to analyze ESR1 endocrine therapy and at progression

Dennis Slamon
Dr. Slamon has disclosed that he has a contract with Eli Lilly and Company.

Phase II/III single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of patients with HER2+ triple negative breast cancer (PHERGE)

Dennis Slamon
Dr. Slamon has disclosed that he has a contract with Syndax.

Biological effects of abemaciclib in a phase2 neoadjuvant study for postmenopausal patients with hormone receptor positive, HER2-negative early breast cancer (EBC)

Dennis Slamon
Dr. Slamon has disclosed that he has a contract with Pfizer, Novartis and Syndax and has ownership in Pfizer, Novartis and BioMarin.

Phase III trial in HER2-negative breast cancer cell line xenografts

Dennis Slamon
Dr. Slamon has disclosed that he has a contract with Pfizer, Novartis and Syndax and has ownership in Pfizer, Novartis and BioMarin.

Pallitaxel in combination with endocrine therapy in treatment-naive and previously treated elderly women with HR+, HER2- advanced breast cancer: A pooled analysis from randomized phase 2 and 3 studies

Dennis Slamon
Dr. Slamon has disclosed that he is a consultant for Bayer, Eli Lilly, Novartis and BioMarin and is a speaker for Novartis. He also disclosed that he has contracts with Pfizer, Novartis and Syndax and has ownership in Pfizer, Novartis and BioMarin.

Treatment postprogression in women with endocrine-resistant HR+/HER2- advanced breast cancer who received palbociclib plus fulvestrant in PALOMA-3

Dennis Slamon
Dr. Slamon has disclosed that he is a consultant for Bayer, Eli Lilly, Novartis and BioMarin and is a speaker for Novartis. He also disclosed that he has contracts with Pfizer, Novartis and Syndax and has ownership in Pfizer, Novartis and BioMarin.

Everolimus plus trastuzumab and pertuzumab as first-line therapy in women with HER2+ advanced breast cancer: Overall survival results from BOLERO-1

Dennis Slamon
Dr. Slamon has disclosed that he is a consultant for Novartis and Pfizer, Amgen and Biomarin.

Biomarker analysis from the neoadjuvant KRISTINE study in HER2-positive early breast cancer (EBC)

Dennis Slamon
Dr. Slamon has disclosed that he has contracts with Pfizer, Novartis and Sydax and has ownership in Pfizer, Novartis and BioMarin.

Biological effects of abemaciclib in a phase2 neoadjuvant study for postmenopausal patients with hormone receptor positive, HER2-negative breast cancer

Dennis Slamon
Dr. Slamon has disclosed that he has a contract with Eli Lilly and Company.

NEG59 promotes breast cancer metastasis by regulating mitochondrial functions

Julianne Slaets
Ms. Slaets has no relevant financial relationships to disclose.

Prof kinase inhibitors prevent bi-directional HER2/ERBB4-IGFR1 signaling and reverse resistance to HER2+2 receptor-targeted therapies

George Sledge
Dr. Sledge has disclosed that he receives consulting fees from Symphogen, Radius, Ixteler and Synmalle. He also disclosed that he does contracted research for Eli Lilly. He reported other relationships with Syndax Pharma, Board of Directors. These relationships do not impact his ability to review presentations.

ESR2 mutations in circulating tumor cell versus circulating cell-free DNA of metastatic breast cancer patients before first-line endocrine therapy and at progression

Jonathan Sleeman
Dr. Sleeman has no relevant financial relationships to disclose.

An optimized workflow to analyze ESR2 mutations in both circulating cell-free and circulating tumor cell DNA by digital PCR

Stefan Sleigher
Mr. Sleigher has no relevant financial relationships to disclose.

The association between PCR status after neoadjuvant chemotherapy and sites of first distant relapse after surgery: A substudy of the EORTC 10094/BIG-1-01 trial

Leen Sleijfer
Dr. Sleijfer has no relevant financial relationships to disclose.

Can surrogate pathological subtyping replace molecular subtyping? Outcome results from the MINDACT trial

Leen Sleijfer
Leen Sleijfer has no relevant financial relationships to disclose.

A phase 2 randomized, double-blinded, controlled study of ONT-380 in plasma in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unmetastatic locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB)

Dennis Slamon
Dr. Slamon has disclosed that he has a contract with Syndax.

Phase II/III single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of patients with HER2+ triple negative breast cancer (PHERGE)

Dennis Slamon
Dr. Slamon has disclosed that he has a contract with Syndax.

Biological effects of abemaciclib in a phase2 neoadjuvant study for postmenopausal patients with hormone receptor positive, HER2-negative early breast cancer (EBC)

Dennis Slamon
Dr. Slamon has disclosed that he has contracts with Pfizer, Novartis and Syndax and has ownership in Pfizer, Novartis and BioMarin.

Phase III trial in HER2-negative breast cancer cell line xenografts

Dennis Slamon
Dr. Slamon has disclosed that he has a contract with Pfizer, Novartis and Syndax and has ownership in Pfizer, Novartis and BioMarin.

Pallitaxel in combination with endocrine therapy in treatment-naive and previously treated elderly women with HR+, HER2- advanced breast cancer: A pooled analysis from randomized phase 2 and 3 studies

Dennis Slamon
Dr. Slamon has disclosed that he is a consultant for Bayer, Eli Lilly, Novartis and BioMarin and is a speaker for Novartis. He also disclosed that he has contracts with Pfizer, Novartis and Syndax and has ownership in Pfizer, Novartis and BioMarin.

Treatment postprogression in women with endocrine-resistant HR+/HER2- advanced breast cancer who received palbociclib plus fulvestrant in PALOMA-3

Dennis Slamon
Dr. Slamon has disclosed that he is a consultant for Bayer, Eli Lilly, Novartis and BioMarin and is a speaker for Novartis. He also disclosed that he has contracts with Pfizer, Novartis and Syndax and has ownership in Pfizer, Novartis and BioMarin.

Everolimus plus trastuzumab and pertuzumab as first-line therapy in women with HER2+ advanced breast cancer: Overall survival results from BOLERO-1

Dennis Slamon
Dr. Slamon has disclosed that he is a consultant for Novartis and Pfizer, Amgen and Biomarin.

Biomarker analysis from the neoadjuvant KRISTINE study in HER2-positive early breast cancer (EBC)

Dennis Slamon
Dr. Slamon has disclosed that he is a consultant for Novartis and Pfizer. He also disclosed that he has contracts with Pfizer, Novartis and Sydax and has ownership in Pfizer, Novartis and BioMarin.

Biological effects of abemaciclib in a phase2 neoadjuvant study for postmenopausal patients with hormone receptor positive, HER2-negative breast cancer

Dennis Slamon
Dr. Slamon has disclosed that he has a contract with Eli Lilly and Company.

NEG59 promotes breast cancer metastasis by regulating mitochondrial functions

Julianne Slaets
Ms. Slaets has no relevant financial relationships to disclose.

Prof kinase inhibitors prevent bi-directional HER2/ERBB4-IGFR1 signaling and reverse resistance to HER2+2 receptor-targeted therapies

George Sledge
Dr. Sledge has disclosed that he receives consulting fees from Symphogen, Radius, Ixteler and Synmalle. He also disclosed that he does contracted research for Eli Lilly. He reported other relationships with Syndax Pharma, Board of Directors. These relationships do not impact his ability to review presentations.

ESR2 mutations in circulating tumor cell versus circulating cell-free DNA of metastatic breast cancer patients before first-line endocrine therapy and at progression

Jonathan Sleeman
Dr. Sleeman has no relevant financial relationships to disclose.

An optimized workflow to analyze ESR2 mutations in both circulating cell-free and circulating tumor cell DNA by digital PCR

Stefan Sleigher
Mr. Sleigher has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Conference</th>
<th>Title</th>
<th>Primary Author</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>P5-03-06</td>
<td>Clinical value of 89Zr-trastuzumab PET in HER2-positive breast cancer patients with a clinical dilemma</td>
<td>Stefan Sleijfer</td>
<td>Dr. Sleijfer has disclosed he has a patent for a test on circulating tumor cells in prostate cancer. He also disclosed that he is on the Speakers Bureau for GlassClimine and receives travel, accommodations and expenses from Amgen and research funding from AB Science and Sanofi.</td>
</tr>
<tr>
<td>S3-01</td>
<td>IMENEO: International META-analysis of circulating tumor cell detection in early breast cancer patients treated by NEoadjuvant chemotherapy</td>
<td>Stefan Sleijfer</td>
<td>Mr. Sleijfer has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-06-01</td>
<td>Therapeutic targeting of RAGE in the tumor and tumor microenvironment inhibits breast progression and metastatic potential</td>
<td>Joyce Slingerland</td>
<td>Dr. Slingerland has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-03-02</td>
<td>Chronic CRKL2 exposure induces a metastatic phenotype in ER-positive breast cancer cells through transcriptional reprogramming</td>
<td>Joyce Slingerland</td>
<td>Dr. Slingerland has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-08-08</td>
<td>DATAS inhibits breast basal-like tumorigenesis</td>
<td>Joyce Slingerland</td>
<td>Ms. Slingerland has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-04</td>
<td>Nuclear grade has a limited role in predicting recurrence in DCIS following breast conserving surgery: A population-based study</td>
<td>Elzbieta Boldowska</td>
<td>Mr. Boldowska has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-12-07</td>
<td>Phase II/II single-arm trial evaluating the combination of everolimus, lapatinib and capicitabine for the treatment of patients with HER2-positive metastatic breast cancer with progression in the CNS after trastuzumab (TRO-US B-09)</td>
<td>Pa Smallberg</td>
<td>Dr. Smallberg has disclosed that he has contracts with Bint Therapeutics, Sytho Corporation, Heat Biologics, Telmis, Gilead, Teva, Roche, Merck, Gannamed, Chibero, Boston, Meyers Squibb, Abbott, Astra, Celgene, Pfizer, Novartis, Millennium and Ariad Pharmaceuticals.</td>
</tr>
<tr>
<td>O72-01-05</td>
<td>TRINITI-1: Ribociclib + everolimus (EVE) + exemestane (EXE) triplet combination in pre- or postmenopausal women with HR+, HER2- advanced breast cancer (ABC) following progression on a cyclin-dependent kinase (CDK) 4/6 inhibitor</td>
<td>Yania Small</td>
<td>Ms. Small has disclosed that she is an employee of Novartis.</td>
</tr>
<tr>
<td>Committee Member</td>
<td>Committee Member</td>
<td>William Small</td>
<td>Dr. Small has disclosed fees for non-CME services received directly from commercial interests from Zeus Speaker’s Bureau. He also disclosed that he does contracted research, Co-Pi of an investigator initiated trial funded by Zeus. These relationships do not impact his ability to review presentations.</td>
</tr>
<tr>
<td>P1-03-14</td>
<td>Assessment of stromal characteristics in ductal carcinoma in situ of the breast: An inter-observer variability study</td>
<td>Ann Smeets</td>
<td>Ms. Smeets has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-03-01</td>
<td>The footprint of the aging stroma in older breast cancer patients</td>
<td>Ann Smeets</td>
<td>Ms. Smeets has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-07-08</td>
<td>Age-related microarrays and their biomarker potential in chemotherapy-treated older breast cancer patients</td>
<td>Ann Smeets</td>
<td>Ms. Smeets has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-14-06</td>
<td>The effect of adjuvant chemotherapy in a large consecutive series of ER+ HER2- negative early breast cancers</td>
<td>Ann Smeets</td>
<td>Ms. Smeets has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-12</td>
<td>A consecutive series of early breast cancers with a low estrogen receptor expression</td>
<td>Ann Smeets</td>
<td>Ms. Smeets has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-32</td>
<td>The association of breast cancer subtype and breast cancer survival with parity and time since last birth</td>
<td>Ann Smeets</td>
<td>Ms. Smeets has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-01-10</td>
<td>Exome sequencing of circulating tumor cells in metastatic breast cancer</td>
<td>Dominiek Smeets</td>
<td>Dominiek Smeets has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S3-01</td>
<td>IMENEO: International META-analysis of circulating tumor cell detection in early breast cancer patients treated by NEoadjuvant chemotherapy</td>
<td>Jeffrey Smerage</td>
<td>Mr. Smerage has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-07-02</td>
<td>Concordance with National comprehensive cancer network (NC-CN) metastatic breast cancer guidelines and impact on overall survival</td>
<td>Nithya Smita</td>
<td>Dr. Smita has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-02-28</td>
<td>Intraoperative assessment of the sentinel node (SN) in breast cancer by one step nucleic acid assay (OSNA). Experience of over 800 patients</td>
<td>Adrian Smith</td>
<td>Adrian Smith has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-13-04</td>
<td>Use of an absorbable implant to mark the lumpectomy cavity: Initial report of 300 patients in a multi-center registry database</td>
<td>Arnold Smith</td>
<td>Mr. Smith has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Publication ID</td>
<td>Title</td>
<td>Author(s)</td>
<td>Disclosures</td>
</tr>
<tr>
<td>---------------</td>
<td>------------------------------------------------------------------------------------------------------------</td>
<td>------------------</td>
<td>-------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>P3-13-04</td>
<td>Use of an absorbable implant to mark the lumpectomy cavity: initial report of 300 patients in a multicenter registry database</td>
<td>Linda Smith</td>
<td>Ms. Smith has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-04-26</td>
<td>Establishment and characterization of SPYRAL, an ER-positive, ESR1-mutant breast cancer cell line and xenograft from a patient with acquired resistance to endocrine therapy</td>
<td>Peter Smith</td>
<td>Ms. Patnaik has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-08-03</td>
<td>A directed siRNA screen identifies HRH3A as a major regulator of tumor aggressiveness in basal HER2 breast cancer</td>
<td>Rebecca Smith</td>
<td>Ms. Smith has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P05-01</td>
<td>Microenvironment microarrays show that microenvironment mediated resistance mechanisms to lapatinib differ between basal and luminal HER2+ cells</td>
<td>Rebecca Smith</td>
<td>Ms. Smith has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-09-03</td>
<td>Long-term comparison of anastrozole versus tamoxifen: Results from LATTE/ATAC</td>
<td>Robert Smith</td>
<td>Mr. Smith has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S5-03</td>
<td>Menopausal symptoms as predictors of long-term adherence in the international breast cancer intervention study G12-1</td>
<td>Samuel Smith</td>
<td>Dr. Smith has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-05-02</td>
<td>Breast implant associated anaplastic large cell lymphoma (BIA-ALCL): The UK experience and first reported case of neoadjuvant brentuximab</td>
<td>Simon Smith</td>
<td>Mr. Smith has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-10-13</td>
<td>Can the risk of radiation induced cardiac disease in breast cancer be mitigated with cardiac sparing techniques?</td>
<td>Sandra Smith</td>
<td>Dr. Smith has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-06-01</td>
<td>Patient derived DCS mouse intraductal (MDI) models recapitulate the full spectrum of human patient pathology and histologic features including progression to invasion in a subset of cases</td>
<td>William Smith</td>
<td>Dr. Smith has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-01-01</td>
<td>Circulating tumor cell number and CTC-endocrine therapy index predict clinical outcomes in ER positive metastatic breast cancer patients: Results of the COMETI Phase 2 trial</td>
<td>John Smith II</td>
<td>Dr. Smith has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-21-26</td>
<td>Population pharmacokinetics (PK) and exposure-response (E-R) analysis of trastuzumab emtansine (T-DM1) in patients with HER2+ metastatic breast cancer: Who have received at least two prior regimens of HER2-directed therapy</td>
<td>Melanie Smitt</td>
<td>Dr. Smitt has disclosed that she receives salary from and has ownership in Roche.</td>
</tr>
<tr>
<td>P3-13-12</td>
<td>The concept of breast contour preserving surgery as parameter in breast cancer surgery</td>
<td>Carolien Smorenburg</td>
<td>Dr. Smorenburg has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-21-30</td>
<td>Long-term survival in HER2-positive metastatic breast cancer: The first blow is half the battle</td>
<td>Carolien Smorenburg</td>
<td>Dr. Smorenburg has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-10-27</td>
<td>Variation in the use of neoadjuvant chemotherapy for breast cancer in the Netherlands: A lack of consensus</td>
<td>Carolien Smorenburg</td>
<td>Ms. Smorenburg has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S1-03</td>
<td>First results from the multicenter phase III DATA study comparing 3 versus 6 years of anastrozole after 2-3 years of tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer</td>
<td>Carolien Smorenburg</td>
<td>Ms. Smorenburg has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-03-04</td>
<td>Concordance of local immunohistochemistry with TargetPrint microarray based assessment of ER, PR and Her2 and BluePrint molecular subtyping in the Symphysis Triple A study</td>
<td>Caroline Smorenburg</td>
<td>Dr. Smorenburg has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-03</td>
<td>Impact of 30 gene signature use on adjuvant chemotherapy decisions in early breast cancer patients: Results of the prospective symphony triple A study</td>
<td>Caroline Smorenburg</td>
<td>Dr. Smorenburg has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-08-18</td>
<td>Treatment patterns and resource utilization among patients with HR+/HER2- metastatic breast cancer in a privately insured US population</td>
<td>Emily Smyth</td>
<td>Dr. Smyth has disclosed that she receives salary from and has ownership in Lilly and Company.</td>
</tr>
<tr>
<td>P5-08-19</td>
<td>Treatment patterns and resource utilization among elderly Medicare patients with HR+/HER2- metastatic breast cancer</td>
<td>Emily Smyth</td>
<td>Dr. Smyth has disclosed that she receives salary from and has ownership in Lilly and Company.</td>
</tr>
<tr>
<td>S2-04</td>
<td>RANKL as a target for breast cancer prevention in BRCA1 mutation carriers</td>
<td>Gordon Smyth</td>
<td>Mr. Smyth has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Conference</td>
<td>Title</td>
<td>Author</td>
<td>Financial Relationships</td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------------------------------------------</td>
<td>------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>P4-21-14</td>
<td>Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy</td>
<td>Lillian Smyth</td>
<td>Dr. Smyth has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-14-01</td>
<td>Lipid dietary pattern and breast cancer overall survival in the women's health initiative dietary modification randomized controlled trial</td>
<td>Linda Sniehlar</td>
<td>Dr. Sniehlar has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-19-04</td>
<td>Psychosocial distress monitoring in a multidisciplinary, inner city breast center</td>
<td>Carmen Saliman</td>
<td>Carmen Saliman has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-09-11</td>
<td>Metabolite-guided long-term prediction of outcome in tamoxifen treated breast cancer patients</td>
<td>Hatem Soliman</td>
<td>Dr. Soliman has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-03-01</td>
<td>An optimized 50-gene assay for the molecular diagnosis of triple-negative breast cancer</td>
<td>Harris Saifer</td>
<td>Dr. Saifer has disclosed that he receives salary from and has ownership in Biotheranostics, Inc.</td>
</tr>
<tr>
<td>OT3-04-05</td>
<td>Measuring the impact of MammaPrint on treatment in breast cancer patients: A prospective registry (IMPACT)</td>
<td>Hatem Saliman</td>
<td>Dr. Saliman has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-22-13</td>
<td>Osimertinib plus trastuzumab and pacitaxel as first-line therapy in women with HER2+/triple-negative advanced breast cancer: Overall survival results from BOLERO-3</td>
<td>Joohyuk Sohn</td>
<td>Joohyuk Sohn has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-15-04</td>
<td>Osimertinib plus pemetrexed and docetaxel as second-line therapy in patients with first-line HER2-targeted and platinum-based chemotherapy-treated HER2+ advanced metastatic breast cancer: Updated results from the TROG 18.01 trial</td>
<td>Joohyuk Sohn</td>
<td>Joohyuk Sohn has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-22-22</td>
<td>Cobimetinib (C) combined with paclitaxel (P) as a first-line treatment in patients (pts) with advanced triple-negative breast cancer (CT012) study: Updated clinical and biomarker results</td>
<td>Joohyuk Sohn</td>
<td>Joohyuk Sohn has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-19-04</td>
<td>Everolimus plus trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: Overall survival results from BOLERO-1</td>
<td>Joohyuk Sohn</td>
<td>Joohyuk Sohn has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT3-01-12</td>
<td>A phase II, multicenter, randomized trial of eribulin plus gemcitabine (EG) versus paclitaxel plus gemcitabine (PG) in patients with HER2-negative metastatic breast cancer as first-line chemotherapy</td>
<td>Joo Hyuk Sohn</td>
<td>Joo Hyuk Sohn has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-06-02</td>
<td>Low-phase I, multivariate, randomized trial of eribulin plus gemcitabine (EG) versus paclitaxel plus gemcitabine (PG) in patients with HER2-negative metastatic breast cancer as first-line chemotherapy</td>
<td>Cecilia Söderberg Naucler</td>
<td>Ms. Söderberg Naucler has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-06-01</td>
<td>High-phase I, multivariate, randomized trial of eribulin plus gemcitabine (EG) versus paclitaxel plus gemcitabine (PG) in patients with HER2-negative metastatic breast cancer as first-line chemotherapy</td>
<td>Cecilia Söderberg Naucler</td>
<td>Ms. Söderberg Naucler has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-05-01</td>
<td>High-phase I, multivariate, randomized trial of eribulin plus gemcitabine (EG) versus paclitaxel plus gemcitabine (PG) in patients with HER2-negative metastatic breast cancer as first-line chemotherapy</td>
<td>Cecilia Söderberg Naucler</td>
<td>Ms. Söderberg Naucler has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-15-04</td>
<td>The PROCEED trial KCSG BR11-01 phase III multicenter randomized open-label study of irinotecan plus capecitabine versus capecitabine in patients previously treated with anthracycline and taxane for HER2-negative metastatic breast cancer</td>
<td>Joo Hyuk Sohn</td>
<td>Joo Hyuk Sohn has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-24-13</td>
<td>Osimertinib plus trastuzumab and paclitaxel as first-line therapy in women with HER2+/triple-negative advanced breast cancer: Overall survival results from BOLERO-3</td>
<td>Joohyuk Sohn</td>
<td>Joohyuk Sohn has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-24-12</td>
<td>Osimertinib plus trastuzumab and paclitaxel as first-line therapy in women with HER2+/triple-negative advanced breast cancer: Overall survival results from BOLERO-3</td>
<td>Joohyuk Sohn</td>
<td>Joohyuk Sohn has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-15-04</td>
<td>Osimertinib plus trastuzumab and paclitaxel as first-line therapy in women with HER2+/triple-negative advanced breast cancer: Overall survival results from BOLERO-3</td>
<td>Joohyuk Sohn</td>
<td>Joohyuk Sohn has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-03-01</td>
<td>An optimized 50-gene assay for the molecular diagnosis of triple-negative breast cancer</td>
<td>Harris Saifer</td>
<td>Dr. Saifer has disclosed that he receives salary from and has ownership in Biotheranostics, Inc.</td>
</tr>
<tr>
<td>P4-22-13</td>
<td>Osimertinib plus trastuzumab and paclitaxel as first-line therapy in women with HER2+/triple-negative advanced breast cancer: Overall survival results from BOLERO-3</td>
<td>Joohyuk Sohn</td>
<td>Joohyuk Sohn has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-03-01</td>
<td>An optimized 50-gene assay for the molecular diagnosis of triple-negative breast cancer</td>
<td>Harris Saifer</td>
<td>Dr. Saifer has disclosed that he receives salary from and has ownership in Biotheranostics, Inc.</td>
</tr>
<tr>
<td>P4-22-13</td>
<td>Osimertinib plus trastuzumab and paclitaxel as first-line therapy in women with HER2+/triple-negative advanced breast cancer: Overall survival results from BOLERO-3</td>
<td>Joohyuk Sohn</td>
<td>Joohyuk Sohn has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-03-01</td>
<td>An optimized 50-gene assay for the molecular diagnosis of triple-negative breast cancer</td>
<td>Harris Saifer</td>
<td>Dr. Saifer has disclosed that he receives salary from and has ownership in Biotheranostics, Inc.</td>
</tr>
<tr>
<td>P4-22-13</td>
<td>Osimertinib plus trastuzumab and paclitaxel as first-line therapy in women with HER2+/triple-negative advanced breast cancer: Overall survival results from BOLERO-3</td>
<td>Joohyuk Sohn</td>
<td>Joohyuk Sohn has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-03-01</td>
<td>An optimized 50-gene assay for the molecular diagnosis of triple-negative breast cancer</td>
<td>Harris Saifer</td>
<td>Dr. Saifer has disclosed that he receives salary from and has ownership in Biotheranostics, Inc.</td>
</tr>
<tr>
<td>P4-22-13</td>
<td>Osimertinib plus trastuzumab and paclitaxel as first-line therapy in women with HER2+/triple-negative advanced breast cancer: Overall survival results from BOLERO-3</td>
<td>Joohyuk Sohn</td>
<td>Joohyuk Sohn has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-03-01</td>
<td>An optimized 50-gene assay for the molecular diagnosis of triple-negative breast cancer</td>
<td>Harris Saifer</td>
<td>Dr. Saifer has disclosed that he receives salary from and has ownership in Biotheranostics, Inc.</td>
</tr>
<tr>
<td>P4-22-13</td>
<td>Osimertinib plus trastuzumab and paclitaxel as first-line therapy in women with HER2+/triple-negative advanced breast cancer: Overall survival results from BOLERO-3</td>
<td>Joohyuk Sohn</td>
<td>Joohyuk Sohn has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-03-01</td>
<td>An optimized 50-gene assay for the molecular diagnosis of triple-negative breast cancer</td>
<td>Harris Saifer</td>
<td>Dr. Saifer has disclosed that he receives salary from and has ownership in Biotheranostics, Inc.</td>
</tr>
</tbody>
</table>
Correlation of breast cancer index (BCI) risk classification with tumor grade and Ki-67 in a large series of patients with early-stage, ER+ breast cancer

Dr. Soliman has disclosed that he is a consultant for Biotheranostics, Inc. and Celgene.

Phase II trial of selinexor for metastatic triple negative breast cancer

Dr. Soliman has disclosed that he is a consultant for Celgene, Eli Lilly and BCI Theranostics.

Impact of magnetic resonance imaging on conversion from wide local excision to mastectomy in patients with ductal carcinoma in situ: First results from the ECOG-ACRIN 4112 prospective study

Lawrence Solin

Dr. Solin has no relevant financial relationships to disclose.

BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer

Cinzia Solinas

Dr. Solinas has no relevant financial relationships to disclose.

Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study

Gianfranca Solinas

Gianfranca Solinas has no relevant financial relationships to disclose.

Neratinib + fulvestrant in ERBB2-mutant, HER2-non-amplified, estrogen receptor (ER) positive, metastatic breast cancer (MBC): Preliminary analysis from the phase II SUMMIT trial

David Soltani

Sajjad Soltani has disclosed that he receives salary and has ownership.

Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases

Enrich-Franz Solomayer

Dr. Solomayer has no relevant financial relationships to disclose.

Oncogenic potential of ERBB1 mutations in human mammary epithelial cells

Thomas Solomon

Mr. Solomon has no relevant financial relationships to disclose.

Quantification of HER2-driven signaling (HER2$S$) inhibition of four different anti-HER2 drugs tested ex vivo in five primary HER2-negative breast cancer cell samples with abnormal HER2 signaling activity: New group of patients may benefit from anti-HER2 therapy

Sajjad Soltani

Sajjad Soltani has disclosed that he receives salary and has ownership.

New method to measure functional HER2-driven signaling activity in primary tumor cells identifies HER2-negative breast cancer patients with abnormal HER2 signaling activity: New group of patients may benefit from anti-HER2 therapy

Sajjad Soltani

Sajjad Soltani has disclosed that he receives salary and has ownership.

Analysis of breast cancer in young women in the department of defense (DOD) database

Sanaz Soltani

Dr. Soltani has no relevant financial relationships to disclose.

Non-invasive and low-cost technique for early detection of clinically relevant breast lesions using a handheld point-of-care medical device (iBreastExam): Prospective three-arm triple-blinded comparative study for breast cancer screening in low-resource setting countries

SP Somashekhar

SP Somashekhar has no relevant financial relationships to disclose.

Double blinded validation study to assess performance of IBM artificial intelligence platform, Watson for oncology in comparison with Manipal multidisciplinary tumour board - Find study of 638 breast cancer cases

SP Somashekhar

SP Somashekhar has no relevant financial relationships to disclose.

Recognition of autologous neoantigens by tumor infiltrating lymphocytes derived from breast cancer metastases

Robert Somerville

Dr. Somerville has no relevant financial relationships to disclose.

Phase II clinical trial of neratinib in patients 60 and older with HER2 over-expressed or mutated breast cancer: Trial design considerations for older adults

George Somlo

Dr. Somlo has no relevant financial relationships to disclose.

Association of co-amplicons with immune infiltration in subtypes of HER2-Positive breast cancer

George Somlo

Mr. Somlo has disclosed that she is a consultant for Celgene, Genentech, Pfizer, Abbvie, AstraZeneca and Puma and a speaker for Takeda. He has also disclosed that he receives research support to his institution from Agenda, Celgene and Genentech.

Phase II trial of pertuzumab, trastuzumab, and nab-paclitaxel in patients (pts) with HER2 over-expressed or mutated breast cancer: Trial design considerations for older adults

George Somlo

Dr. Somlo has no relevant financial relationships to disclose.

Phase II trial of pertuzumab, trastuzumab, and nab-paclitaxel in patients (pts) with HER2 over-expressing (HER2+) locally advanced or inflammatory breast cancer (LABC) or untreated stage IV metastatic breast cancer (MBC)

George Somlo

Mr. Somlo has disclosed that she is a consultant for Celgene, Genentech, Pfizer, Abbvie, AstraZeneca and Puma and a speaker for Takeda. He has also disclosed that he receives research support to his institution from Agenda, Celgene and Genentech.
PD1-07 Comprehensive characterization of matched pre-treatment biopsies and residual disease of doxorubicin treated breast cancer Gabe Sonke Dr. Sonke has no relevant financial relationships to disclose.

P2-03-01 Mutational landscape of breast cancers from PALB2 germline mutation carriers Teo Soo Hwang Teo Soo Hwang has no relevant financial relationships to disclose.

P2-04-10 High-affinity activated natural killer (haNK) cells augment trastuzumab efficacy in a mouse model of HER2-positive human metastatic breast cancer Patrick Soon-Shiong Patrick Soon-Shiong has disclosed that he receives salary from and has a patent with NantBioscience, NantCell. He has also disclosed that he has ownership in NantKwest.

P2-04-26 Identifying patient-specific neoepitopes for cell-based and vaccine immunotherapy across breast cancer classifications reveals rarely shared recurrent neoepitopes. Patrick Soon-Shiong Dr. Soon-Shiong has disclosed that he is an employee of NantOmics.

P2-02-02 Clinical significance of TP53 mosaic mutations uncovered in constitutional genetic testing Jon Sorenson Dr. Sorenson has disclosed that he receives an annual salary for being director of engineering. He has also disclosed that stock options met and more contingent on continued employment.

P4-08-02 Integration of transcriptomic, proteomic and drug response data in triple negative breast cancer cell lines and PDX models Peter Sorger Dr. Sorger has no relevant financial relationships to disclose.

P4-07-33 Metrics of drug sensitivity based on growth rate inhibition correct for the confounding effects of variable division rates Peter Sorger Dr. Sorger has no relevant financial relationships to disclose.

P4-01-04 Assessing response in locally advanced breast cancer treated with neoadjuvant chemotherapy: Predictive and prognostic potential of volume-based metabolic variables with 18F-FDG PET/CT María del Carmen Soriano Rodriguez Mrs. Soriano Rodriguez has no relevant financial relationships to disclose.

S2-04 RANK ligand as a target for breast cancer prevention in BRCA1 mutation carriers Rosalia Soriano Ms. Soriano has disclosed that she is a former employee of Amgen.

P4-01-04 Assessing response in locally advanced breast cancer treated with neoadjuvant chemotherapy: Predictive and prognostic potential of volume-based metabolic variables with 18F-FDG PET/CT Angel Soriano-Castronuevo Angel Soriano-Castronuevo has no relevant financial relationships to disclose.
Establishment of molecular profiling for individual treatment decisions in early breast cancer - Clinical impact of PAM50 and PAM50 risk of recurrence score after more than 16 years follow up

Therese Sørbye
Ms. Sørbye has no relevant financial relationships to disclose.

H-ferritin allows nanometronomic treatment of breast cancer with doxorubicin preventing drug resistance and circumventing cardiotoxicity

Luca Sorrentino
Dr. Sorrentino has no relevant financial relationships to disclose.

Comprehensive genomic characterization of circulating tumor cells (CTCs) in metastatic breast cancer (MBC) sheds light on the biology of blood-borne metastasis

Eduardo Sosa
Mr. Sosa has no relevant financial relationships to disclose.

Interrogating the impact of pregnancy on breast cancer biology using DNA copy number profiling

Christos Sotiriou
Dr. Sotiriou has no relevant financial relationships to disclose.

Detection of EZR mutations in matched primary and metastatic samples from endocrine-resistant lobular breast cancer patients

Christos Sotiriou
Dr. Sotiriou has no relevant financial relationships to disclose.

The footprint of the aging stroma in older breast cancer patients

Christos Sotiriou
Dr. Sotiriou has no relevant financial relationships to disclose.

CDK4 phosphorylation status and corresponding gene expression profile predict sensitivity to Palbociclib

Christos Sotiriou
Dr. Sotiriou has no relevant financial relationships to disclose.

Preliminary analysis of the recurrence dynamics of breast cancer (BC) according to body mass index (BMI)

Christos Sotiriou
Dr. Sotiriou has disclosed that he receives consulting fees from Astellas, Cepheid and Vertex. He also receives travel accommodation from Roche. These relationships do not impact his ability to review presentations.

9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian short HER trial

Hector Soto Parra
Mr. Soto Parra has no relevant financial relationships to disclose.

Targeting of the unfolded protein response signaling arms differentially regulates macrophage proliferation, plasticity, and breast cancer cell clearance

David Soto-Pantoja
Dr. Soto-Pantoja has no relevant financial relationships to disclose.

A school-based breast health (BH) educational program to increase breast cancer awareness in a rural Mexican community: A qualitative comparative analysis of students’, relatives’ and teachers’ perceptions

Enrique Soto-Perez-de-Celis
Dr. Soto-Perez-de-Celis has no relevant financial relationships to disclose.

First-line ribociclib plus letrozole in patients with de novo HR+, HER2- advanced breast cancer (ABC): A subgroup analysis of the MONALEESA-2 trial

Farida Souami
Farida Souami has disclosed that she is a Novartis employee and has ownership in Novartis.

High-throughput genome analysis and therapeutic decision for patients with HER2-negative metastatic breast cancer: First feasibility and molecular results of the randomized phase II study SAFIR2 BREAST (UCBG-0105/1304)

Isabelle Soubeyran
Ms. Soubeyran has no relevant financial relationships to disclose.

Studying the interactome of breast cancer: The cancer cell map initiative

Margaret Soucheary
Ms. Soucheary has no relevant financial relationships to disclose.

Socioeconomic disparities in needle biopsy prior to breast cancer surgery across physician referral networks

Pamela Soulin
Ms. Soulin has disclosed that she has a contract with 21st Century Oncology.

Selective use of MRI and impact on management in breast cancer

Soni Souman
Soni Souman has no relevant financial relationships to disclose.

Breast cancer organoid cultures preserve intra-tumor heterogeneity and reveal intrinsically resistant phenotypes to standard chemotherapies

Miranda Sowder
Ms. Sowder has no relevant financial relationships to disclose.
P3-13-02 Impact of primary surgery on short-term survival of older breast cancer patients in the UK
Anne Marie Sowerbutts
Ms. Sowerbutts has no relevant financial relationships to disclose.

P6-16-01 The importance of loco-regional tumor burden and surgery on survival in patients with de novo stage IV breast cancer: post-hoc analyses of protocol MIST-01
Aykut Soyder
Dr. Soyder has no relevant financial relationships to disclose.

P2-06-05 Development and validation of a new non-parametric breast cancer risk assessment model on US and European screening populations
Philippe Soyer
Dr. Soyer has no relevant financial relationships to disclose.

P4-13-03 Changes in the gut microbiome of post-menopausal women 2 weeks after initiating a structured weight loss intervention
Kendra Spaeth
Ms. Spaeth has no relevant financial relationships to disclose.

P1-01-06 Ki67-positive CTCs are associated with early disease relapse in patients with early breast cancer undergoing adjacent chemotherapy
Anna Sparski
Ms. Sparski has no relevant financial relationships to disclose.

OT2-01-17 A Phase II randomized trial of pembrolizumab with carboplatin and gemcitabine for treatment of patients with metastatic triple negative breast cancer (mTNBC)
Joseph Sparano
Dr. Sparano has no relevant financial relationships to disclose.

OT2-01-19 A randomized phase II trial of fulvestrant with or without docetaxel after progression on aromatase inhibitor plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer
Joseph Sparano
Dr. Sparano has no relevant financial relationships to disclose.

P2-05-06 Comparisons of survival and clinicopathological features between patients with breast cancer and HIV infection versus breast cancer without HIV infection
Joseph Sparano
Dr. Sparano has no relevant financial relationships to disclose.

P2-07-07 Comparison of survival and clinicopathological features between patients with breast cancer and HIV infection versus breast cancer without HIV infection
Joseph Sparano
Dr. Sparano has no relevant financial relationships to disclose.

P3-02-12 Cobimetinib (C) combined with paclitaxel (P) as a first-line treatment in patients (pts) with advanced triple-negative breast cancer (CDEST study): Updated clinical and biomarker results
Joseph Sparano
Dr. Sparano has disclosed that he receives consulting fees.

P4-22-22 Phase I study of low dose oral cyclophosphamide (C) plus the poly-ADP-ribose- polymerase (PARP) inhibitor veliparib (V) in women with HER2/neu-negative inoperable locally advanced/metastatic breast cancer (MBC): NCI P8853
Joseph Sparano
Dr. Sparano has no relevant financial relationships to disclose.

P5-10-05 Time differences in breast cancer diagnosis among minorities in a large referral academic center
Joseph Sparano
Dr. Sparano has no relevant financial relationships to disclose.

P6-13-08 Paclitaxel-induced mena- and TMEM-mediated pro-metastatic changes in the breast cancer microenvironment
Joseph Sparano
Dr. Sparano has disclosed that he owns stock.

P05-02 Paclitaxel-induced mena- and TMEM-mediated pro-metastatic changes in the breast cancer microenvironment
Joseph Sparano
Dr. Sparano has disclosed that he owns stock.

S1-02 Tumor microenvironment of metastasis (TMEM) score is associated with early distant recurrence in hormone receptor (HR) positive, HER2 negative early stage breast cancer (ESBC)
Joseph Sparano
Dr. Sparano has disclosed that he receives institutional research funding from Novartis.

S4-04 PrECOG 0102: A randomized, double-blind, phase III trial of fulvestrant plus everolimus or placebo in post-menopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC): NO-FIRM 3
Joseph Sparano
Dr. Sparano has disclosed that he receives institutional research funding from Novartis.

S5-02 Phase I study of low dose oral cyclophosphamide (C) plus the poly-ADP-ribose- polymerase (PARP) inhibitor veliparib (V) in women with HER2/neu-negative inoperable locally advanced/metastatic breast cancer (MBC): NCI P8853
Joseph Sparano
Dr. Sparano has disclosed that he receives institutional research funding from Novartis.

P4-04 Tumor microenvironment of metastasis (TMEM) score is associated with early distant recurrence in hormone receptor (HR) positive, HER2 negative early stage breast cancer (ESBC)
Joseph Sparano
Dr. Sparano has disclosed that he owns stock.
Dr. Sparano has disclosed that he receives consulting fees from Genentech, Eli Lilly, Pfizer, Celldex, Juno and Merck. He also disclosed that he does contracted research for Merck, Genentech and Merck. He has ownership interest in Metallad, Inc. These relationships do not impact his ability to review presentations.

Mr. Spazzapan has no relevant financial relationships to disclose.

Ms. Spears has no relevant financial relationships to disclose.

Ms. Specht has disclosed that she is a consultant for Advaxis and AbbVie. She has also disclosed that she has contracts with Juno, Pfizer, Genentech, Janssen, Celgene, Abbvie, Nektar, Seattle Genetics, Celldex, Merck, and Merix Pharmaceuticals.

Mr. Spence has no relevant financial relationships to disclose.

Ms. Speransky has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3-13-06</td>
<td>Development and validation of a nomogram predicting pathological axillary status (ypN0 vs. ypN+) in a subgroup of patients converting from cN+ to cN0 through neoadjuvant therapy (NAT) - A transSENTINA substudy</td>
<td>Annette Staebler</td>
<td>Ms. Staebler has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-13-03</td>
<td>Breast cancer education, counseling, and support for Jewish women: Preliminary results of a CDC program evaluation</td>
<td>Sharon Stahl</td>
<td>Ms. Stahl has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-14</td>
<td>Prognostic impact of genomic risk stratification with breast cancer index in patients with clinically low risk, hormone receptor-positive, node-negative, T1 breast cancer</td>
<td>Elle Stål</td>
<td>Dr. Stål has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-03</td>
<td>Intra-tumor heterogeneity of the estrogen receptor predicts less benefit from tamoxifen therapy and poor long-term breast cancer patient survival - Retrospective analyses of the STO-3 randomized trial</td>
<td>Elle Stål</td>
<td>Dr. Stål has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-07-02</td>
<td>Identification of breast cancers with an indolent disease course: 10 gene indolent threshold validation in a Swedish randomized trial of tamoxifen vs. no, with 20-year outcomes</td>
<td>Elle Stål</td>
<td>Dr. Stål has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P9-10-07</td>
<td>Long survival of patients with locally advanced breast cancer on combined neoadjuvant chemotherapy and immune orientation: Modern lessons from an old study</td>
<td>Anita Sten</td>
<td>Ms. Sten has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-02-03</td>
<td>Circulating inflammatory markers, growth factors, and tumor associated antigens in women with early stage breast cancer assessing neoadjuvant metformin</td>
<td>Yuk Stambolic</td>
<td>Dr. Stambolic has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-08-14</td>
<td>Association between BMI and residual estradiol levels in postmenopausal women using adjuvant letrozole: Results of a prospective study</td>
<td>Yuk Stambolic</td>
<td>Dr. Stambolic has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-02-05</td>
<td>Estrogen receptor (ER-R) in breast carcinoma tissue: Ubiquitous expression and correlation with leptin-mediated signaling, but not with systemic markers of obesity</td>
<td>Yuk Stambolic</td>
<td>Dr. Stambolic has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P7-02-05</td>
<td>Leptin receptor (OB-R) in breast carcinoma tissue: Ubiquitous expression and correlation with leptin-mediated signaling, but not with systemic markers of obesity</td>
<td>Yuk Stambolic</td>
<td>Dr. Stambolic has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Committee Member</td>
<td></td>
<td>Sandi Stanford</td>
<td>Ms. Stanford has no relevant financial relationships with commercial interests to disclose.</td>
</tr>
<tr>
<td>P4-21-11</td>
<td>T-DM1 in HER2 positive advanced breast cancer patients: Real world practice from a multicenter observational study</td>
<td>Simonetta Stani</td>
<td>Simonetta Stani has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S2-03</td>
<td>Does BRCA status affect outcome in young breast cancer patients? Results from the prospective study of outcomes in sporadic and hereditary breast cancer (POSH)</td>
<td>Louise Stanton</td>
<td>Ms. Stanton has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT3-01-03</td>
<td>A phase I trial of the safety and immunogenicity of a DNA plasmid based vaccine (WOKVAC) encoding epitopes derived from three breast cancer antigens (IGFBP2, HER2, and IGF1R) in patients with breast cancer</td>
<td>Sasha Stanton</td>
<td>Dr. Stanton has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT3-01-05</td>
<td>Functional MRI signatures of immune response to targeted breast cancer therapy</td>
<td>Sasha Stanton</td>
<td>Dr. Stanton has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-12-08</td>
<td>Use of an aptamer library based next generation omics platform for the development of a novel trastuzumab predictive assay</td>
<td>Adam Stark</td>
<td>Mr. Stark has disclosed that he receives salary from and has ownership from Chris Life Sciences.</td>
</tr>
<tr>
<td>P3-08-09</td>
<td>Social media's impact on patient utilization of high-risk clinics for genetic counseling and testing services</td>
<td>Elizabeth Stark</td>
<td>Ms. Stark has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-03-02</td>
<td>Breast implant associated anaplastic large cell lymphoma (BA-ALCL)- The UK experience and first reported case of neoadjuvant brentuximab</td>
<td>Helen Stark</td>
<td>Ms. Stark has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-22-15</td>
<td>A solution to the APOBEC mutation paradox in breast cancer</td>
<td>Alexander Storodub</td>
<td>Dr. Storodub has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-05-03</td>
<td>Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate (ADC) for the treatment of relapsed/refractory, metastatic triple-negative breast cancer (mTNBC): Updated results</td>
<td>Alexander Storodub</td>
<td>Dr. Storodub has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-04-19</td>
<td>A solution to the APOBEC mutation paradox in breast cancer</td>
<td>Gabriel Starrett</td>
<td>Ms. Starrett has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-13-06</td>
<td>Elucidating the tumor immune microenvironment phenotype in early stage untreated BRCA-mutated breast cancer patients</td>
<td>Fiona Stashko</td>
<td>Ms. Stashko has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
P4-22-08 A single-arm phase 2 study to assess clinical activity, efficacy and safety of enzalutamide with trastuzumab in HER2+ Ahemorastatic or locally advanced breast cancer
Joyce Steinberg
Ms. Steinberg has disclosed that she is an Astellas employee.

P4-21-38 Cardiac safety of dual anti-HER2 therapy in the neoadjuvant setting for treatment of HER2-positive breast cancer
Richard Steingart
Mr. Steingart has no relevant financial relationships to disclose.

P4-22-04 A randomized, double-blind, phase II study of ruxolitinib (RUX) or placebo (PBO) in combination with capecitabine (CAPE) in patients (pts) with advanced HER2-negative breast cancer (ABC) and elevated C-reactive protein (CRP), a marker of systemic inflammation
Ronald Steis
Ms. Steis has no relevant financial relationships to disclose.

P3-13-07 Are there patients with T1-T2, node-negative breast cancer who are high-risk for locoregional recurrence?
Michelle Stempel
Ms. Stempel has no relevant financial relationships to disclose.

P3-12-03 Evaluation of women with BRCA mutations and breast cancer tested at an NCI designated comprehensive cancer center: A cost of illness estimation
David Stenehjem
Dr. Stenehjem has disclosed that AstraZeneca funding this research.

P2-12-01 Comprehensive genomic profiling of 34 cases of breast angiosarcoma
Phil Stephens
Dr. Stephens has disclosed that he is an employee of Foundation Medicine with equity interest.

P3-11-05 Comprehensive genomic profiling of 8,654 breast carcinoma reveals therapeutically targetable molecular subtypes beyond those defined by hormone-receptor expression
Philip Stephens
Dr. Stephens has disclosed that he receives salary from and has ownership in Foundation Medicine, Inc.

P5-11-11 Comprehensive genomic profiling to assess tumor mutation burden in >8,000 breast cancer cases: Implications for immunotherapy
Philip Stephens
Dr. Stephens has disclosed that he receives salary from and has ownership in Foundation Medicine.

P2-03-09 Comparison of the mutational landscape of breast cancer during pregnancy and non-pregnant controls
Albrecht Steenstraegte
Albrecht Steenstraegte has no relevant financial relationships to disclose.

P2-01-15 A one-day protocol with activities lower than 20 MAb for the detection of sentinel lymph nodes - Experience after 150 cases
Mikładas Stephenou
Dr. Stephenou has no relevant financial relationships to disclose.

P1-04-06 Network integration of epigenetic data: Leveraging the concept of master regulators in ER-negative breast cancer
Josma Stephen
Dr. Stephen has no relevant financial relationships to disclose.

P1-05-07 Comprehensive genomic profiling of 8,014 breast carcinoma reveals therapeutically targetable molecular subtypes beyond those defined by hormone-receptor expression
Philip Stephens
Dr. Stephens has disclosed that he receives salary from and has ownership in Foundation Medicine, Inc.

P1-05-08 Comprehensive genomic profiling of 4,014 breast carcinoma reveals frequent mutation of NF1 and other genes associated with PI3K and RAS pathway activation
Philip Stephens
Dr. Stephens has disclosed that he receives salary from and has ownership in Foundation Medicine, Inc.

P5-07-04 A comprehensive molecular analysis of medullary breast carcinoma: A model of immunomodulatory triple negative breast cancer subtype
Marc-Henry Stern
Dr. Stern has no relevant financial relationships to disclose.

P5-03-05 Reliability and acceptance of e-based survey instruments for measuring patient reported outcomes (PROM) in breast cancer patients: First results of the PROMO study
Stefan Stevanovic
Mr. Stevanovic has no relevant financial relationships to disclose.

P5-11-11 A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-refractory alopecia (CRA)
Serrec Stevens
Ms. Stevens has no relevant financial relationships to disclose.
P3-10-13 Community breast navigation improves breast cancer screening in Hartford, CT
Christina Stevenson Dr. Stevenson has no relevant financial relationships to disclose.

P2-07-05 Risk of metachronous contralateral breast cancer: Systematic review and meta-analysis
Hanoch Steyerberg Dr. Steyerberg has no relevant financial relationships to disclose.

P2-09-11 Outcome after neoadjuvant chemotherapy in progesterone receptor negative breast cancer patients - A pooled analysis of individual patient data from two prospectively randomized controlled neoadjuvant trials
Elmar Stockeler Mr. Stockeler has no relevant financial relationships to disclose.

O7-05-05 Three-monthly dynamic evaluation of CEA and CA15-3 (followed by 18-FDG PET) vs usual practice in the follow-up of early breast cancer (BC) patients (pts): A prospective randomized trial (BORDIS-patient-oriented new surveillance study, Italy)
Petrha Stieber Dr. Stieber has no relevant financial relationships to disclose.

P3-04-01 Epigenome-wide association study for breast cancer risk using whole genome and targeted captured bisulfite sequencing: A pooled case-control study nested in the breakthrough generations study
Jan Stirling Jan Stirling has no relevant financial relationships to disclose.

P2-05-19 Impact of TP53 functional mutation type on clinical outcomes of advanced breast cancer patients
Neda Stjepanovic Neda Stjepanovic has no relevant financial relationships to disclose.

P3-09-05 Clinical outcome of patients with advanced triple negative breast cancer with germline and somatic variants in homologous recombination gene
Neda Stjepanovic Neda Stjepanovic has no relevant financial relationships to disclose.

P1-03-01 Epigenome-wide association study for breast cancer risk using whole genome and targeted captured bisulfite sequencing: A pooled case-control study nested in the breakthrough generations study
Nikolaus Stoecklein Mr. Stoecklein has no relevant financial relationships to disclose.

P2-07-19 Impact of TP53 functional mutation type on clinical outcomes of advanced breast cancer patients
Tracy Stockley Tracy Stockley has no relevant financial relationships to disclose.

P3-09-05 Clinical outcome of patients with advanced triple negative breast cancer with germline and somatic variants in homologous recombination gene
Tracy Stockley Tracy Stockley has no relevant financial relationships to disclose.

P1-03-03 Clinical outcome of patients with advanced triple negative breast cancer with germline and somatic variants in homologous recombination gene
Tracy Stockley Tracy Stockley has no relevant financial relationships to disclose.

P3-02-03 A new workflow comprising size based CTC enrichment followed by on-situ labeling and micromanipulation with CellCelector™ enables label-free enrichment, isolation and characterization of circulating tumor cells in breast cancer
Alison Stopeck Dr. Stopeck has no relevant financial relationships to disclose.

P3-09-05 Breast density change at 6 months is associated with change at 12 months as measured by fat-water decomposition MRI in women on tamoxifen
Alison Stopeck Dr. Stopeck has no relevant financial relationships to disclose.

P1-03-05 A comprehensive molecular analysis of medullary breast carcinoma: A model of immunomodulatory triple negative breast cancer subtype
Dominique Stoppa-Lyonnet Dr. Stoppa-Lyonnet has no relevant financial relationships to disclose.

P3-03-05 Prospective evaluation of the predictive value of biomarkers with complete pathologic response using neoadjuvant chemotherapy plus trastuzumab + pertuzumab in Her2 (+) breast cancer patients with invasive tumors
Claudie Storino Dr. Storino has no relevant financial relationships to disclose.

P1-03-01 Selective elimination of axillary surgery after primary systemic treatment in clinically node-positive breast cancer patients by combining PET/CT and the MARI procedure (marking the axilla with radioactive iodine seeds)
Marcel Stokkel Dr. Stokkel has no relevant financial relationships to disclose.

P6-10-01 High concordance of ER, PR, HER2 and Ki67 by central IHC and FISH with mRNA measurements by GeneXpert® breast cancer stratifier assay
Mark Stonecypher Mark Stonecypher has no relevant financial relationships to disclose.

P1-03-09 Highly reproducible decentralized gene expression analysis of PIK3CA, KRAS, ERBB2 and MKI67 on an automated, standardized molecular diagnostics platform, GeneXpert
Mark Stonecypher Mark Stonecypher has no relevant financial relationships to disclose.

P3-02-03 Accurate and reliable automated breast density measurements with no ionizing radiation using fat-water decomposition MRI
Aikoum Stoepck Dr. Stoepck has no relevant financial relationships to disclose.

P6-09-19 Breast density change at 6 months is associated with change at 12 months as measured by fat-water decomposition MRI in women on tamoxifen
Aikoum Stoepck Dr. Stoepck has no relevant financial relationships to disclose.

P1-06-05 Prospective evaluation of the predictive value of biomarkers with complete pathologic response using neoadjuvant chemotherapy plus trastuzumab + pertuzumab in Her2 (+) breast cancer patients with invasive tumors
Claudie Storino Dr. Storino has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Surname</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>P07-01</td>
<td>Can surrogate pathological subtyping replace molecular subtyping? Outcome results from the MINDACT trial</td>
<td>Lisette Stork-Sloots</td>
<td>Ms. Stork-Sloots has disclosed that she is a former employee and current consultant for Agendia.</td>
</tr>
<tr>
<td>P1-09-15</td>
<td>Tumor and serum DNA methylation in women receiving preoperative chemotherapy (PST) with or without vorinostat in primary operable HER2-negative breast cancer in TBCRC008</td>
<td>Anna Storresio</td>
<td>Ms. Storresio has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-11</td>
<td>Genetic variation in CYP3A4 affects steady-state exemestane concentrations but does not explain inter-race difference</td>
<td>Anna Maria Storresio</td>
<td>Dr. Storresio has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-12-01</td>
<td>Phase II study of taselisib (GDC-0032) plus fulvestrant in HER2-negative, hormone receptor-positive advanced breast cancer: Analysis by PIK3CA and ESR1 mutation status from circulating tumor DNA</td>
<td>Thomas Stout</td>
<td>Mr. Stout has disclosed that he is an employee of Genentech/Roche, the sponsor.</td>
</tr>
<tr>
<td>P4-21-10</td>
<td>Long-term survival in HER2-positive metastatic breast cancer: The first blow is half the battle</td>
<td>Jacqueline Stouhard</td>
<td>Dr. Stouhard has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S1-01</td>
<td>Whole exome and transcriptome sequencing of resistant ER-metastatic breast cancer</td>
<td>Dan Stover</td>
<td>Dr. Stover has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-07-05</td>
<td>Integrated transcriptional analysis of the triple negative proliferation paradox: High proliferation, chemosensitivity, and poor prognosis</td>
<td>Daniel Stover</td>
<td>Dr. Stover has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-02-03</td>
<td>Evaluating the feasibility of a web-based preference-tolerant randomised trial of risk-based vs. annual breast cancer screening: WISDOM study pilot</td>
<td>Silkon Stover</td>
<td>Ms. Stover Fiscalini has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-21-32</td>
<td>Treatment of early HER2-positive breast cancer in trastuzumab-era in everyday clinical practice: An overview after 10 years of its approval</td>
<td>Agnésina Stradella</td>
<td>Agnésina Stradella has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-11-18</td>
<td>Trajectory of patient (Pt) reported physical function (PF) during and after neoadjuvant chemotherapies in the I-SPY 2 trial</td>
<td>Ian Strathey</td>
<td>Mr. Strathey has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-13-09</td>
<td>Development and implementation of a patient-centered, nurse practitioner-led survivorship intervention for breast cancer</td>
<td>Elizabeth Strand</td>
<td>Ms. Strand has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-08-06</td>
<td>Screening, management, cancer diagnoses, and outcomes of women with germline BRCA mutations in Israel: The Noga Clinic experience</td>
<td>Shalom Strano</td>
<td>Dr. Strano has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-21-26</td>
<td>Population pharmacokinetics (PK) and exposure-response (E-R) analysis of trastuzumab emtansine (T-DM1) in patients with HER2-metastatic breast cancer (MBC) who have received at least two prior regimens of HER2-directed therapy</td>
<td>Alexander Strauss</td>
<td>Dr. Strauss has disclosed that he receives salary from and has ownership in Roche.</td>
</tr>
<tr>
<td>P5-07-08</td>
<td>The role of inducible nitric oxide synthase in the stemness of triple negative breast cancer</td>
<td>Ian Stratford</td>
<td>Dr. Stratford has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-04-08</td>
<td>BSG324, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy in mammary adenocarcinoma</td>
<td>Oddbjørn Straume</td>
<td>Dr. Straume has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-03-01</td>
<td>A novel high-throughput secreted factor screen and bioinformatics pipeline identifies microenvironment-derived FGFR2 as a mechanism of resistance to anti-estrogens, PI3k, and mTOR inhibitors in ER-breast cancer</td>
<td>Kaitlin Straussman</td>
<td>Dr. Straussman has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-01-04</td>
<td>Concordance of local immunohistochemistry with TargetPrint microarray based assessment of ER, PR and Her2 and BluePrint molecular subtyping in the Symphony Triple A study</td>
<td>Marielle Straver</td>
<td>Dr. Straver has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-01-07</td>
<td>Selective elimination of auxiliary surgery after primary systemic treatment in clinically node-positive breast cancer patients by combining PET/CT and the MARI procedure (marking the axilla with radioactive iodine seeds)</td>
<td>Marielle Straver</td>
<td>Dr. Straver has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
Impact of 70-gene signature use on adjuvant chemotherapy decisions in early breast cancer patients: Results of the prospective symphony triple A study

Marieke Straver

Dr. Straver has no relevant financial relationships to disclose.

miR363-3p mediates maintenance and resistance of breast cancer stem cells (BCSC)

Athina Stravodimou

Athina Stravodimou has no relevant financial relationships to disclose.

Technology as a change agent for improving breast cancer quality care

Carrie Stricker

Mr. Stricker has no relevant financial relationships to disclose.

Breast cancer organoid cultures preserve intra-tumor heterogeneity and reveal intrinsically resistant phenotypes to standard chemotherapies

Thomas Stricker

Mr. Stricker has no relevant financial relationships to disclose.

Genomic profiling of residual ER+ breast cancers treated with prolonged neoadjuvant letrozole reveals novel alterations in clinically resistant tumors

Thomas Stricker

Dr. Stricker has no relevant financial relationships to disclose.

Influence of timing of radiation therapy following breast-conserving surgery on 10-year disease-free survival

Luc Strobbe

Mr. Strobbe has no relevant financial relationships to disclose.

Estrogen receptor β2 and β5 increase expression of ABCG2 and drug resistance of the triple-negative breast cancer cell line SUM159

Anders Strom

Dr. Strom has no relevant financial relationships to disclose.

Development of a novel HER2 testing strategy, using image-based cell-sorting to isolate pure cell populations from FFPE specimens of FISH

Lindsey Strotman

Dr. Strotman has no relevant financial relationships to disclose.

ENCORE 602: A Randomized, placebo-controlled, double-blind, multicenter phase 2 study (with a phase 1b lead-in) of abemaciclib with or without endocrine therapy in patients with advanced triple-negative breast cancer (ATOMIC)

Boeril Struyakovsky

Dr. Struyakovsky has no relevant financial relationships to disclose.

Influence of timing of radiation therapy following breast-conserving surgery on 10-year disease-free survival

Henk Struikmans

Mr. Struikmans has no relevant financial relationships to disclose.

The incidence and outcomes of brain metastases in HER2-positive metastatic breast cancer with the advent of modern anti-HER2 therapies

Ulrik Strulov Shachar

Dr. Strulov Shachar has no relevant financial relationships to disclose.

COMP140 kills breast cancer cells by inhibiting mitochondrial respiration

Christina Stuelten

Dr. Stuelten has no relevant financial relationships to disclose.

Comprehensive comparison of breast cancer molecular portraits by African and European ancestry in the cancer genome atlas

Lori Sturtz

Ms. Sturtz has no relevant financial relationships to disclose.

Race is not a contributing factor to breast cancer-free interval outcome for patients with equal access to healthcare treated at a military medical center

Lori Sturtz

Dr. Sturtz has no relevant financial relationships to disclose.

Role of INCR2, a long non-coding RNA, in development of resistance to endocrine therapy in breast cancer cells

Alex Su

Alex Su has no relevant financial relationships to disclose.

Phase I safety, efficacy, and molecular analysis of ribociclib (LEE011) plus letrozole for the treatment of ER+, HER2- advanced breast cancer

Faye Su

Ms. Su has disclosed that she is a Novartis employee and has ownership in Novartis.

A nomogram to predict the survival benefit of surgical axillary staging in T1 breast cancer patients

Fengxi Su

Ms. Su has disclosed that she is a Novartis employee and has ownership in Novartis.

The development of nomograms to predict axillary lymph node status in breast cancer patients

Fengxi Su

Ms. Su has disclosed that she is a Novartis employee and has ownership in Novartis.

A phase 3 study: safety, efficacy, and molecular analysis of ribociclib (LEE011) plus letrozole for the treatment of ER+, HER2- advanced breast cancer

Faye Su

Ms. Su has disclosed that she is a Novartis employee and has ownership in Novartis.

A phase 1b safety, efficacy, and molecular analysis of ribociclib (LEE011) plus letrozole for the treatment of ER+, HER2- advanced breast cancer

Faye Su

Ms. Su has disclosed that she is a Novartis employee and has ownership in Novartis.

A phase 3 study: safety, efficacy, and molecular analysis of ribociclib (LEE011) plus letrozole for the treatment of ER+, HER2- advanced breast cancer

Faye Su

Ms. Su has disclosed that she is a Novartis employee and has ownership in Novartis.

A phase 1b safety, efficacy, and molecular analysis of ribociclib (LEE011) plus letrozole for the treatment of ER+, HER2- advanced breast cancer

Faye Su

Ms. Su has disclosed that she is a Novartis employee and has ownership in Novartis.

A phase 1b safety, efficacy, and molecular analysis of ribociclib (LEE011) plus letrozole for the treatment of ER+, HER2- advanced breast cancer

Faye Su

Ms. Su has disclosed that she is a Novartis employee and has ownership in Novartis.
P4-03-16 | FAPα (fibroblast activation protein-α) analysis in breast tumor cells and stroma after neoadjuvant treatment
Ana Suárez-Gauthier
Dr. Suárez-Gauthier has no relevant financial relationships to disclose.

P5-04-03 | Cross-talk between RNA methyltransferase and demethylase regulates breast cancer growth and progression
Parwinder Subbarayalu
Dr. Subbarayalu has no relevant financial relationships to disclose.

P1-08-03 | Identification and characterization of a novel endoxifen substrate, PKE31, and its interaction with the estrogen receptor
Malayannan Subramaniam
Malayannan Subramaniam has no relevant financial relationships to disclose.

P1-07-15 | Detection of molar car alterations in breast cancer through next generation sequencing of both tumor tissue and circulating tumor DNA: The UC San Diego Moores Cancer Center experience
Rupa Subramanian
Dr. Subramanian has no relevant financial relationships to disclose.

PD5-01 | Microenvironment microarrays show that microenvironment mediated resistance mechanisms to lapatinib differ between basal and luminal HER2+ cells
Damir Sudar
Damir Sudar has no relevant financial relationships to disclose.

P3-12-02 | Development of mathematical prediction models to identify disease-free survival events for HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy and trastuzumab
Masahiro Sugimoto
Masahiro Sugimoto has no relevant financial relationships to disclose.

P4-24-24 | A retrospective study about re-biopsy at disease progression on T-DM1
Naotoshi Sugimoto
Dr. Sugimoto has no relevant financial relationships to disclose.

P1-06-02 | Impact of heterogeneity of DCIS on immune cell infiltrations
Yunxia Sui
Yunxia Sui has disclosed that he is a GE employee.
Tumor and serum DNA methylation in women receiving preoperative chemotherapy (PST) with or without vorinostat in primary operable HER2-negative breast cancer in TBCRC008

Saraswati Sukumar

Saraswati Sukumar has disclosed that QM-MSP and cMethDNA assays are licensed by Cepheid Corporation. This is managed by Johns Hopkins University; Patent awarded for QM-MSP, patent application submitted for cMethDNA assays. This is managed by Johns Hopkins University. She also disclosed that she is a consultant for Cepheid Corporation. This is managed by Johns Hopkins University. Scientific advisory board member of Avon Foundation for research and a participant in a research contract supported by Cepheid Corporation. This is managed by Johns Hopkins University.

The association between angiotensin receptor blockers usage and breast cancer characteristics

Aaron Sulkes

Prof. Sulkes has no relevant financial relationships to disclose.

Quantification of HER2-driven signaling (HER2 NL) in blood of four different anti-HER2 drugs tested ex vivo in live primary HER2-negative breast cancer cell samples with abnormal HER2 signaling activity

Brian Sullivan

Mr. Sullivan has disclosed that he receives salary and has ownership.

New method to measure functional HER2-driven signaling activity in primary cancer cells identifies HER2-negative breast cancers with abnormal HER2 signaling activity: New group of patients may benefit from anti-HER2 therapy

Brian Sullivan

Mr. Sullivan has disclosed that he receives salary and has ownership.

Phase II trial of sotrastuzumab emtansine for metastatic triple negative breast cancer

Daniel Sullivan

Dr. Sullivan has no relevant financial relationships to disclose.

Expression of miR-18a and miR-210 in normal breast tissue as candidate markers of breast cancer risk

Megan Sullivan

Dr. Sullivan has no relevant financial relationships to disclose.

New method to measure functional HER2-driven signaling activity in primary tumor cells identifies HER2-negative breast cancers with abnormal HER2 signaling activity: New group of patients may benefit from anti-HER2 therapy

Megan Sullivan

Dr. Sullivan has no relevant financial relationships to disclose.

An optimized 41-gene assay for the molecular diagnosis of triple negative breast cancer

Peggy Sullivan

Dr. Sullivan has no relevant financial relationships to disclose.

Identification and characterization of a novel endoxifen substrate, PKCβ1, and its interaction with the estrogen receptor

Vera Suman

Ms. Suman has no relevant financial relationships to disclose.

Optimized prediction of deleterious missense mutations in BRCA1 and BRCA2 genes

Vera Suman

Dr. Suman has no relevant financial relationships to disclose.

Biological functions of ERβ in triple negative breast cancer and its utility as a novel therapeutic drug target

Vera Suman

Dr. Suman has no relevant financial relationships to disclose.

Recurrent functionally diverse in-frame ESR1 gene fusions drive endocrine resistance in breast cancer

Vera Suman

Dr. Suman has no relevant financial relationships to disclose.

Mismatch repair deficiency induces endocrine therapy resistance in breast cancer

Vera Suman

Ms. Suman has no relevant financial relationships to disclose.

Association of pre-menopausal breast cancer with obesity and inflammatory markers with chemotherapy toxicity in women with breast cancer

Carlan Sun

Dr. Sun has no relevant financial relationships to disclose.

Identification of SARM1/BDS1 as a druggable selective estrogen receptor degrader (SERD) that has strong antitumor activity in wild type and mutant ER+ breast cancer models

Fangxian Sun

Fangxian Sun has no relevant financial relationships to disclose.

BCAP31 promotes EMT and metastasis upon nutrient deprivation through autophagy in breast cancer

Hefen Sun

Hefen Sun has no relevant financial relationships to disclose.

UHRF1 promotes breast cancer progression via suppressing KLF17 expression

He-Fen Sun

He-Fen Sun has no relevant financial relationships to disclose.

ST8SIA1 regulates tumor genesis in triple negative breast cancer

Jeffrey Sun

Mr. Sun has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P5-07-03</td>
<td>GD2-mediated FAK signaling regulates breast cancer stem cell function in triple negative breast cancer</td>
<td>Jeffrey Sun</td>
<td>Mr. Sun has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-02-01</td>
<td>Metabolic stress induces GD2 expression and breast cancer stem cell phenotype in triple negative breast cancer</td>
<td>Jeffrey Sun</td>
<td>Mr. Sun has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-15-17</td>
<td>Population based long term outcomes of pathologic complete response after neoadjuvant chemotherapy in stage I-III breast cancer: The British Columbia experience</td>
<td>Julia Sun</td>
<td>Ms. Sun has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-03-02</td>
<td>Chronic CDKL2 exposure induces a metastatic phenotype in ER+ positive breast cancer cells through transcriptional reprogramming</td>
<td>Sun Sun</td>
<td>Dr. Sun has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-08-05</td>
<td>Genome-wide identification of transcripts regulated by estrogen in MCF-7 cells using BrU-seq</td>
<td>Sun Sun</td>
<td>Dr. Sun has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-03-14</td>
<td>Identification of tumor-promoting and tumor-inhibiting genes with age dependent expression in breast cancer patients</td>
<td>LiHe Sun</td>
<td>Dr. Sun has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-09-01</td>
<td>Plasma osteoprotegerin and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers</td>
<td>Ming Sun</td>
<td>Dr. Sun has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-05-02</td>
<td>Chronic CXCL12 exposure induces a metastatic phenotype in ER-positive breast cancer cells through transcriptional reprogramming</td>
<td>Jun Sun</td>
<td>Dr. Sun has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-08-03</td>
<td>Dynamics of cancer stem cell surface marker, CD44 and CD44v6 in the antitumor efficacy of PARP inhibitor in combination with PI3K pathway inhibitor in TNBC xenograft model</td>
<td>Yuliang Sun</td>
<td>Dr. Sun has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-15-10</td>
<td>Randomized phase II study evaluating different schedules of nab-paclitaxel in metastatic breast cancer (MBC): Results of the NaPaP study</td>
<td>Zuhin Sun</td>
<td>Dr. Sun has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-19-06</td>
<td>Return to work after breast cancer diagnosis: An observational prospective study of 125 patients in South America</td>
<td>Rodrigo Sunahara</td>
<td>Ms. Sunahara has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
Establishment of molecular profiling for individual treatment decisions in early breast cancer - Clinical impact of PAM50 and PAM50 risk of recurrence score after more than 16 years follow up

My Sveli

My Sveli has no relevant financial relationships to disclose.

Increasing participation in research - breast cancer (Inspire-BrC)

Sandra Swain

Dr. Swain has no relevant financial relationships to disclose.

Primary analysis of BERENICE: A phase II cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with locally advanced, inflammatory, or early-stage, unilateral, and invasive HER2-positive breast cancer

Sandra Swain

Dr. Swain has disclosed that she is a consultant for Genentech/Roche and a non-promotional speaker for Genentech/Roche. She has also disclosed that she has a contract with Genentech/Roche.

ESR1 mutations, ESR1 fusions and co-occurring alterations assessed in breast cancer tumors

Sandra Swain

Dr. Swain has disclosed that she is a consultant with Genentech/Roche, Pfizer, Lilly and AstraZeneca and is a speaker for Genentech/Roche. She has also disclosed that she contracts with Genentech/Roche, Pfizer, Merrimack and Lilly paid to her institution.

Treatment patterns and clinical outcomes in patients with hormone receptor (HR) vs HR-HER2+ disease from the SySyHERs registry

Sandra Swain

Dr. Swain has disclosed that she is a consultant for Genentech/Roche, Pfizer, Lilly and AstraZeneca and a speaker for Genentech/Roche. She has also disclosed that she has contracts paid to institution from Genentech/Roche, Pfizer, Merrimack and Lilly.

Racial differences in the molecular landscape of breast cancer

Sandra Swain

Dr. Swain has no relevant financial relationships to disclose.

A randomized, double-blinded, placebo-controlled clinical trial to evaluate extended adjuvant endocrine therapy (5 years of letrozole) in postmenopausal women with hormone-receptor positive breast cancer who have completed previous adjuvant endocrine therapy: Initial results of NRG oncology/NSABP B-42

Sandra Swain

Dr. Swain has no relevant financial relationships to disclose.

A phase III trial evaluating GC in patients with HR+, HER2+ breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCPH) +/- estrogen deprivation: NRG oncology/NSABP B-52

Sandra Swain

Dr. Swain has disclosed that he has a contract with, is a consultant for and non-promotional speaker for Genentech/Roche.

Studying the interaction of breast cancer: The current cell map initiative

Cameron Swainick

Dr. Swainick has no relevant financial relationships to disclose.

Predictive value of breast MRI in detecting mammographically occult contralateral breast cancer: Can we target women more likely to have contralateral breast cancer based on primary tumor clinicopathologic factors?

Karen Swenson

Dr. Swenson has no relevant financial relationships to disclose.

The impact of the introduction of breast cancer screening on a symptomatic breast cancer unit

Karl Sweeney

Mr. Sweeney has no relevant financial relationships to disclose.

Predictive value of breast MRI in detecting mammographically occult contralateral breast cancer: Can we target women more likely to have contralateral breast cancer based on primary tumor clinicopathologic factors?

Karen Swenson

Dr. Swenson has no relevant financial relationships to disclose.

The association of higher tumor HER2 load with treatment response to neoadjuvant therapy in HER2 positive breast cancer patients

Karen Swenson

Dr. Swenson has no relevant financial relationships to disclose.

Epigenome-wide association study for breast cancer risk using whole genome and target captured bisulphite sequencing: A pooled case-control study nested in the breakthrough generations study

Anthony Swerdlow

Mr. Swerdlow has no relevant financial relationships to disclose.
First results from the multicenter phase III DATA study comparing 3 versus 6 years of anastrozole after 2-3 years of tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer

Astrid Swinkels
Ms. Swinkels has no relevant financial relationships to disclose.

A multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer: Early results of unplanned boost participants

AM Nisar Syed
AM Nisar Syed has no relevant financial relationships to disclose.

Two-year follow-up results of a multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer

AM Nisar Syed
AM Nisar Syed has no relevant financial relationships to disclose.

A multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer

AM Nisar Syed
AM Nisar Syed has no relevant financial relationships to disclose.

Application of digital-PCR technology to determine c-MET copy number variation in paired primary breast cancer and brain metastases

Khaja Syed
Khaja Syed has no relevant financial relationships to disclose.

Abnormal expression-response relationship in patients with metastatic breast cancer in MONARCH 3

Amanda Sykes
Mr. Sykes has disclosed that he is employed by and has a contract with Lilly and Company.

Phase II study of neoadjuvant pertuzumab combined with carboplatin and paclitaxel (PaCT) for anthracycline-resistant triple-negative breast cancer (TNBC)

Fraser Symmans
Dr. Symmans has no relevant financial relationships to disclose.

Quantitative in vivo imaging of intratumoral heterogeneity to assess tumor response to trastuzumab treatment in a preclinical model of HER2 breast cancer

Fraser Symmans
Mr. Symmans has no relevant financial relationships to disclose.

Committee Member
Fraser (William) Symmans
Dr. Symmans has disclosed that he receives consulting fees from the Breast Cancer Steering Committee (NCI). He also disclosed that he has ownership interest in Nuxera Biosciences and Ion Pharmaceuticals. These relationships do not impact his ability to review presentations.

Efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial

Fraser Symmans
Dr. Symmans has no relevant financial relationships to disclose.

The evaluation of ganitumab/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial

Fraser Symmans
Dr. Symmans has no relevant financial relationships to disclose.

The trajectory of patient (Pt) reported physical function (PF) during and after neoadjuvant chemotherapy in the I-SPY 2 trial

Fraser Symmans
Dr. Symmans has no relevant financial relationships to disclose.

TRCT20436857: A phase II trial of bexorotene, bevacizumab and everolimus (BEV) in patients (pts) with localized triple-negative breast cancer (TNBC) with tumors predicted insensitive to standard neoadjuvant chemotherapy (NACT)

Fraser Symmans
Dr. Symmans has no relevant financial relationships to disclose.

Triple-negative first-line study: Neoadjuvant trial of nab-paclitaxel and atezolizumab, a PD-L1 inhibitor, in patients with triple negative breast cancer (TNBC) [TRCT20334049]

William Symmans
Dr. Symmans has no relevant financial relationships to disclose.

Triple-negative first-line study: Neoadjuvant trial of nab-paclitaxel and atezolizumab, a PD-L1 inhibitor, in patients with triple negative breast cancer (TNBC) [TRCT20334049]

William Symmans
Dr. Symmans has no relevant financial relationships to disclose.

An annotated collection of pre- and post-therapy breast cancer patient-derived xenograft models built from fine needle aspiration samples aligned with ongoing clinical trials documenting response to treatment

William Symmans
Dr. Symmans has no relevant financial relationships to disclose.
P6-09-23 SET/ER/PR - A robust 18-gene predictor of sensitivity to endocrine therapy in metastatic breast cancer
William Symmans
Dr. Symmans has no relevant financial relationships to disclose.

P6-09-51 Phase II Trial of the addition of pembrolizumab to letrozole and palbociclib in patients with metastatic estrogen receptor positive breast cancer who have stable disease on letrozole and palbociclib
Timothy Systol
Dr. Systol has no relevant financial relationships to disclose.

P6-07-13 Association of pre-chemotherapy peripheral blood pro-inflammatory (IL-6, CRP) and coagulation (D-dimer) markers with chemotherapy toxicity in women with breast cancer
Timothy Systol
Dr. Systol has no relevant financial relationships to disclose.

P6-09-37 Ductal carcinoma in situ: Patient outcomes and association with hormone receptors
Aniko Szabo
Dr. Szabo has no relevant financial relationships to disclose.

P4-03-09 Ductal carcinoma in situ: Patient outcomes and association with hormone receptors
Aniko Szabo
Dr. Szabo has no relevant financial relationships to disclose.

P1-12-06 ERBB2-amplified breast cancer incorporates immune cell infiltration: Implications for prognosis and treatment
Hiroshi Takeda
Dr. Takeda has no relevant financial relationships to disclose.

P2-05-13 Immunohistochemical expression of BCL-2 and BCL-XL in breast cancer: A potential therapeutic target
Lorraine Tafra
Ms. Tafra has no relevant financial relationships to disclose.

P3-13-04 Leuprolide elicits a more rapid and robust immune response in breast cancer patients
Lorraine Tafra
Dr. Tafra has no relevant financial relationships to disclose.

P1-07-06 Phase II of POSEIDON: A phase II randomized phase II trial of luteal phase plus anastrozole or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment
Josep Tabernero
Mr. Tabernero has no relevant financial relationships to disclose.

P2-01-14 Lymphatic microsurgical preventive healing approach (LYMPHA) for the primary prevention of lymphedema
Bret Taback
Dr. Taback has no relevant financial relationships to disclose.

P3-13-19 Lymphatic microsurgical preventive healing approach (LYMPHA) for the primary prevention of lymphedema
Bret Taback
Dr. Taback has no relevant financial relationships to disclose.

P4-12-04 Breast cancer subtype, age and lymph node status as predictors of local recurrence following breast-conserving therapy
Alphonse Taghian
Dr. Taghian has no relevant financial relationships to disclose.

P5-13-09 Breast cancer subtype, age and lymph node status as predictors of local recurrence following breast-conserving therapy
Alphonse Taghian
Dr. Taghian has no relevant financial relationships to disclose.

PD7-03 Chemotherapy-related risk factors associated with lymphedema in breast cancer patients: Should repeated ipsilateral arm infusions be avoided?
Elda Tagliabue
Elda Tagliabue has no relevant financial relationships to disclose.

P4-21-33 HER2 activity regulates the pro-trastuzumab immune tumor microenvironment
Elda Tagliabue
Elda Tagliabue has no relevant financial relationships to disclose.

P1-12-07 Phase II trial of the addition of pembrolizumab to letrozole and palbociclib in patients with metastatic estrogen receptor positive breast cancer who have stable disease on letrozole and palbociclib
Julie Taguchi
Dr. Taguchi has disclosed that she has contracts with Biomarin, Medivation, Puma, Lilly, Esi, Nounis, Amgen and Genentech.

P5-16-10 Influence of exercise or educational programs on long-term physical activity by patients after surgery for primary breast cancer: A randomized trial
Naruto Taira
Naruto Taira has no relevant financial relationships to disclose.

OT3-07-02 Influence of exercise or educational programs on long-term physical activity by patients after surgery for primary breast cancer: A randomized trial
Naruto Taira
Naruto Taira has no relevant financial relationships to disclose.

OT2-01-11 Phase II of POSEIDON: A phase II randomized phase II trial of luteal phase plus anastrozole or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment
Josep Tabernero
Mr. Tabernero has no relevant financial relationships to disclose.

P3-13-04 Leuprolide elicits a more rapid and robust immune response in breast cancer patients
Lorraine Tafra
Ms. Tafra has no relevant financial relationships to disclose.

P2-05-13 Negative prostate-specific antigen in patients with early breast cancer with bone metastases after hormone therapy: Implications for disease progression
Lorraine Tafra
Ms. Tafra has no relevant financial relationships to disclose.

P4-12-04 Breast cancer subtype, age and lymph node status as predictors of local recurrence following breast-conserving therapy
Alphonse Taghian
Dr. Taghian has no relevant financial relationships to disclose.

P5-13-09 Breast cancer subtype, age and lymph node status as predictors of local recurrence following breast-conserving therapy
Alphonse Taghian
Dr. Taghian has no relevant financial relationships to disclose.

PDA-29-01 Chemotherapy-related risk factors associated with lymphedema in breast cancer patients: Should repeated ipsilateral arm infusions be avoided?
Elda Tagliabue
Elda Tagliabue has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Abstract</th>
<th>Author(s)</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>Determination of a serum progranulin (GP88/PGRN) level associated with overall survival in metastatic breast cancer patients</td>
<td>Nancy Tait</td>
<td>Ms. Tait has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Randomized trial of exercise intervention vs. usual care for breast cancer patients with aromatase inhibitor to prevent and improve the aromatase inhibitor induced arthralgia</td>
<td>Mutsuyo Tajasu</td>
<td>Mutsuyo Tajasu has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Influence of exercise or educational programs on long term physical activity by patients after surgery for primary breast cancer: A randomized trial</td>
<td>Taisuke Takakatake</td>
<td>Taisuke Takakatake has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Combination of docetaxel with S1P signaling modulator FYF720 significantly suppressed obesity-associated breast cancer</td>
<td>Kazuaki Takabe</td>
<td>Dr. Takabe has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Murine radical mastectomy model for preclinical study of adjunct systemic therapies</td>
<td>Mutsuyo Tajasu</td>
<td>Mutsuyo Tajasu has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes (TILs) and residual cancer burden (RCB)</td>
<td>Koji Takada</td>
<td>Dr. Takada has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Predicting therapeutic effect by on tumor invasion lymphocytes (TILs) in endocrine therapy for stage IV breast cancer</td>
<td>Koji Takada</td>
<td>Dr. Takada has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Circulating tumor cell clusters-associated gene pioglitazion is a novel prognostic predictor in patients with breast cancer</td>
<td>Koji Takada</td>
<td>Koji Takada has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Development of photothermal vascular imaging system for breast cancer</td>
<td>Masahiro Takada</td>
<td>Masahiro Takada has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Development of mathematical precision models to identify disease-free survival events for HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy and trastuzumab</td>
<td>Masahiro Takada</td>
<td>Dr. Takada has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Technical feasibility and validity of sentinel lymph node biopsy in patients with implantable breast cancer recurrence</td>
<td>Makiko Takahashi</td>
<td>Ms. Takahashi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>A phase II, open-label, multicenter, translational study for biomarkers of eribulin-mesylate: Evaluation of the utility of monitoring epithelial-to-mesenchymal transition (EMT) markers on tumor cells in the malignant plural effusion of patients with metastatic breast cancer (EXPECT-study)</td>
<td>Masato Takahashi</td>
<td>Dr. Takahashi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>A multicenter prospective study of radiofrequency ablation therapy for small breast carcinomas</td>
<td>Masato Takahashi</td>
<td>Dr. Takahashi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>A randomized phase II trial of taxotrexumab + capcitabine versus lapatinib + capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxane: W30042108/ELTOP</td>
<td>Masato Takahashi</td>
<td>Dr. Takahashi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>A randomized phase II trial of taxotrexumab + capcitabine versus lapatinib + capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxane</td>
<td>Masato Takahashi</td>
<td>Masato Takahashi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Osteosarcoma should be a candidate strategy in combination with pertuzumab plus trastuzumab for taxane pretreated HER2 positive advance breast cancer</td>
<td>Yoko Takahashi</td>
<td>Dr. Takahashi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Technical feasibility and validity of sentinel lymph node biopsy in patients with implantable breast cancer recurrence</td>
<td>Yoko Takahashi</td>
<td>Ms. Takahashi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Influence of exercise or educational programs on long term physical activity by patients after surgery for primary breast cancer: A randomized trial</td>
<td>Yoko Takahashi</td>
<td>Yoko Takahashi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>3,5-Diamino-4-(dimethylaminomethyl)imidazole green (Di-AMAC) is promising fluorescence probe for rapid diagnosis of breast cancer: - The feasibility study of real time imaging for breast cancer examination -</td>
<td>Tomoko Takamatsu</td>
<td>Tomoko Takamatsu has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
Duration of fasting before taking lapatinib is associated with skin toxicity in neoadjuvant treatment of HER2 positive breast cancer: A cohort study from BCRG-16/Neo-La'TH
Toshimi Takano
Toshimi Takano has no relevant financial relationships to disclose.

Zoledronic acid combined with neoadjuvant chemotherapy for HER2-negative early breast cancer (CORIE 1 trial): Survival outcomes of a randomized multicenter phase 2 trial
Shintaro Takao
Dr. Takao has no relevant financial relationships to disclose.

Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor infiltrating lymphocytes (TILs) and residual cancer burden (RCB)
Yutsumu Takahashi
Dr. Takahashi has no relevant financial relationships to disclose.

A randomized phase II trial of trastuzumab + capecitabine versus lapatinib + capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110L/SlTOP
Toshimi Takano
Toshimi Takano has disclosed that he has contracts with Chugai and Novartis.

Zoledronic acid combined with neoadjuvant chemotherapy for HER2-negative early breast cancer (CORIE 1 trial): Survival outcomes of a randomized multicenter phase 2 trial
Shintaro Takao
Dr. Takao has no relevant financial relationships to disclose.

Zoledronic acid combined with neoadjuvant chemotherapy for HER2-negative early breast cancer (CORIE 1 trial): Survival outcomes of a randomized multicenter phase 2 trial
Shintaro Takao
Dr. Takao has no relevant financial relationships to disclose.

Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor infiltrating lymphocytes (TILs) and residual cancer burden (RCB)
Yutsumu Takahashi
Dr. Takahashi has no relevant financial relationships to disclose.

Circulating tumor cell clusters-associated gene plakoglobin is a novel prognostic predictor in patients with breast cancer
Tsutomu Takashima
Tsutomu Takashima has no relevant financial relationships to disclose.

Zoledronic acid combined with neoadjuvant chemotherapy for HER2-negative early breast cancer (CORIE 1 trial): Survival outcomes of a randomized multicenter phase 2 trial
Shintaro Takao
Dr. Takao has no relevant financial relationships to disclose.

Zoledronic acid combined with neoadjuvant chemotherapy for HER2-negative early breast cancer (CORIE 1 trial): Survival outcomes of a randomized multicenter phase 2 trial
Shintaro Takao
Dr. Takao has no relevant financial relationships to disclose.

Zoledronic acid combined with neoadjuvant chemotherapy for HER2-negative early breast cancer (CORIE 1 trial): Survival outcomes of a randomized multicenter phase 2 trial
Shintaro Takao
Dr. Takao has no relevant financial relationships to disclose.

High-risk breast cancer is less likely to occur in the ductal hyperplasia lesions or low-grade DCIS ~ Consideration of long-term follow-up observation after surgical biopsy
Koji Takebe
Dr. Takebe has no relevant financial relationships to disclose.

Study on over-diagnosis of high-precision breast cancer screening ~ Consideration from epidemiological point of view
Koji Takebe
Dr. Takebe has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Yuichi Takatsuka
Yuichi Takatsuka has disclosed that he receives salary.

Circulating tumor cell (CTC) enumeration in early breast cancer patients treated by NEoadjuvant chemotherapy
Daisuke Takata
Daisuke Takata has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Yuichi Takatsuka
Yuichi Takatsuka has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Yuichi Takatsuka
Yuichi Takatsuka has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Yuichi Takatsuka
Yuichi Takatsuka has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Yuichi Takatsuka
Yuichi Takatsuka has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Yuichi Takatsuka
Yuichi Takatsuka has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Yuichi Takatsuka
Yuichi Takatsuka has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Yuichi Takatsuka
Yuichi Takatsuka has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Yuichi Takatsuka
Yuichi Takatsuka has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Yuichi Takatsuka
Yuichi Takatsuka has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Yuichi Takatsuka
Yuichi Takatsuka has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Yuichi Takatsuka
Yuichi Takatsuka has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Yuichi Takatsuka
Yuichi Takatsuka has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Yuichi Takatsuka
Yuichi Takatsuka has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Yuichi Takatsuka
Yuichi Takatsuka has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Yuichi Takatsuka
Yuichi Takatsuka has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Yuichi Takatsuka
Yuichi Takatsuka has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Yuichi Takatsuka
Yuichi Takatsuka has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Yuichi Takatsuka
Yuichi Takatsuka has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Yuichi Takatsuka
Yuichi Takatsuka has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Yuichi Takatsuka
Yuichi Takatsuka has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Yuichi Takatsuka
Yuichi Takatsuka has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Yuichi Takatsuka
Yuichi Takatsuka has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Yuichi Takatsuka
Yuichi Takatsuka has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Yuichi Takatsuka
Yuichi Takatsuka has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Yuichi Takatsuka
Yuichi Takatsuka has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Yuichi Takatsuka
Yuichi Takatsuka has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Yuichi Takatsuka
Yuichi Takatsuka has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Yuichi Takatsuka
Yuichi Takatsuka has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Yuichi Takatsuka
Yuichi Takatsuka has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Yuichi Takatsuka
Yuichi Takatsuka has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Yuichi Takatsuka
Yuichi Takatsuka has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Yuichi Takatsuka
Yuichi Takatsuka has no relevant financial relationships to disclose.

Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy
Yuichi Takatsuka
Yuichi Takatsuka has no relevant financial relationships to disclose.
Eribulin induces vascular remodeling and reoxygenation in advanced breast cancer patients: A comparative study with bevacizumab

P4-02-01

Hideki Takeuchi

Dr. Takeuchi has no relevant financial relationships to disclose.

Alcohol consumption increases mammographic density in women aged 45-55 years

P5-07-07

Hiroshi Takeyama

Hiroshi Takeyama has no relevant financial relationships to disclose.

Detecting early breast cancer by the combination of five serum microRNAs and its possibility of prediction of pathological complete response in neoadjuvant chemotherapy

P4-07-04

Takizawa

Dr. Takizawa has disclosed that he is an employee of Toray Industries, Inc., the provider of the 3D-Gene® system.

PIII-05-06

Farrar

Dr. Takai has no relevant financial relationships to disclose.

Estrogen receptor 1 (ESR1) mutations in circulating tumor DNA (ctDNA): A guide to the management of advanced breast cancer (ABC)

P1-05-06

Amri Ali

Dr. Tali has disclosed that he is an employee at Guardant Health.

PTHrP affects breast cancer initiation and progression through Stat5 signaling pathway

P1-09-01

Christopher Talbot

Mr. Talbot has no relevant financial relationships to disclose.

Development of a panel of serum-based protein biomarkers for the non-invasive detection of breast cancer in BI-RADS category 4 patients

P5-03-05

Olena Tam

Ms. Tam has disclosed that she receives salary from and has ownership in OncoCyte Corporation.

Randomized trial of exercise intervention vs. usual care for breast cancer patients with aromatase inhibitor to prevent and improve the aromatase inhibitor induced arthralgia

P5-12-01

Kentaro Tamaki

Dr. Tamaki has no relevant financial relationships to disclose.

Randomized trial of exercise intervention vs. usual care for breast cancer patients with aromatase inhibitor to prevent and improve the aromatase inhibitor induced arthralgia

P5-13-18

Kento Tamaki

Kento Tamaki has no relevant financial relationships to disclose.

The feasibility of nurse intervention to improve and maintain the BMI of breast cancer survivors over 25 to appropriate levels

P5-12-01

Kentaro Tamaki

Kentaro Tamaki has no relevant financial relationships to disclose.

A retrospective study about re-biopsy at disease progression on T-DM1

P4-22-24

Yasuhiro Tamaki

Dr. Tamaki has no relevant financial relationships to disclose.

The importance of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive recurrent and advanced breast cancer

P4-21-25

Kazuo Tamura

Dr. Tamura has no relevant financial relationships to disclose.

Detecting early breast cancer by the combination of five serum microRNAs and its possibility of prediction of pathological complete response in neoadjuvant chemotherapy

P4-07-04

Kenji Tamura

Dr. Tamura has no relevant financial relationships to disclose.

The REQUITE-AB study: Validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality of life in breast cancer patients

P6-09-31

Christopher Talbot

Mr. Talbot has no relevant financial relationships to disclose.

Radioactive seed localization versus wire-guided localization of non-palpable invasive and in situ breast cancer: A Danish multicenter randomized controlled trial

P1-09-01

May-Li Talman

Dr. Talman has no relevant financial relationships to disclose.

Successful implementation of a novel breast cancer navigation program in Nuevo León, México

P3-10-05

Jaime Tamez-Salazar

Dr. Tamez-Salazar has no relevant financial relationships to disclose.

The feasibility of nurse intervention to improve and maintain the BMI of breast cancer survivors over 25 to appropriate levels

P5-12-01

Kentaro Tamaki

Kentaro Tamaki has no relevant financial relationships to disclose.

Whole exome and transcriptome sequencing of resistant ER+ metastatic breast cancer

P5-12-01

Pablo Tamez

Mr. Tamez has no relevant financial relationships to disclose.

The importance of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive recurrent and advanced breast cancer

P4-21-25

Kazuo Tamura

Dr. Tamura has no relevant financial relationships to disclose.

The feasibility of nurse intervention to improve and maintain the BMI of breast cancer survivors over 25 to appropriate levels

P5-12-01

Kentaro Tamaki

Kentaro Tamaki has no relevant financial relationships to disclose.

A retrospective study about re-biopsy at disease progression on T-DM1

P4-22-24

Yasuhiro Tamaki

Dr. Tamaki has no relevant financial relationships to disclose.

The importance of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive recurrent and advanced breast cancer

P4-21-25

Kazuo Tamura

Dr. Tamura has no relevant financial relationships to disclose.

Detecting early breast cancer by the combination of five serum microRNAs and its possibility of prediction of pathological complete response in neoadjuvant chemotherapy

P4-07-04

Kenji Tamura

Dr. Tamura has no relevant financial relationships to disclose.
A randomized phase II trial of trastuzumab + capecitabine versus lapatinib + capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and/ or taxanes: WJOG6110B/ELTOP

Kenji Tamura

Kenji Tamura has no relevant financial relationships to disclose.

ESR1 mutations, ESR1 fusions and co-occurring alterations assessed in breast cancer tumors

Antoinette Tan

Priscilla Tan

Dr. Tam has disclosed that she is a consultant for Abbvie. She has also disclosed that she has contracts with Merck, Pfizer and Genentech and receives travel from Caris Life Sciences.

Impact of heterogeneity of DCIS on immune cell infiltrations

Phoebe Hoos Tan

Priscilla Tan

Dr. Hoos has no relevant financial relationships to disclose.

Pathological complete response to neoadjuvant trastuzumab is dependent on HER2/CEP17 ratio in HER2-amplified early breast cancer

Yen Tan

Yen Tan has no relevant financial relationships to disclose.

Impact of germinecenter-associated nuclear protein 1 polymorphisms on breast cancer risk and prognosis in a Japanese population

Mikiho Tanaka

Mikiho Tanaka has no relevant financial relationships to disclose.

Impact of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive recurrent and advanced breast cancer

Maki Tanaka

Maki Tanaka has no relevant financial relationships to disclose.

A phase II trial of neoadjuvant docetaxel/cyclophosphamide (TC) with S-Raimondini, epirubicin, and cyclophosphamide followed by docetaxel (FEC-D) for hormone receptor-negative breast cancer: The Kanagawa breast oncology group (KBOG) 1101 study

Kazumi Tanaka

Dr. Tanaka has no relevant financial relationships to disclose.

Impact of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive recurrent and advanced breast cancer

Toshihiro Tanaka

Toshihiro Tanaka has no relevant financial relationships to disclose.

A multiplexed immunofluorescence identifies phenotypic heterogeneity of circulating tumor cells in breast cancer

Takemi Tanaka

Takemi Tanaka has no relevant financial relationships to disclose.

Phase II neoadjuvant study comparing docetaxel and cyclophosphamide (TC) with S-Raimondini, epirubicin, and cyclophosphamide followed by docetaxel (FEC-D) for hormone receptor-negative breast cancer: The Kanagawa breast oncology group (KBOG) 1101 study

Mikiho Tanaka

Hideo Tanaka

Hideo Tanaka has no relevant financial relationships to disclose.

Pathological complete response to neoadjuvant trastuzumab is dependent on HER2/CEP17 ratio in HER2-amplified early breast cancer

Yen Tan

Yen Tan has no relevant financial relationships to disclose.

A randomized phase II trial comparing docetaxel and cyclophosphamide (TC) with S-Raimondini, epirubicin, and cyclophosphamide followed by docetaxel (FEC-D) for hormone receptor-negative breast cancer: The Kanagawa breast oncology group (KBOG) 1101 study

Maki Tanaka

Maki Tanaka has no relevant financial relationships to disclose.

Impact of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive recurrent and advanced breast cancer

Maki Tanaka

Maki Tanaka has no relevant financial relationships to disclose.

Phase II trial of neoadjuvant docetaxel/cyclophosphamide (TC) with S-Raimondini, epirubicin, and cyclophosphamide followed by docetaxel (FEC-D) for hormone receptor-negative breast cancer

Natsuko Tanaka

Natsuko Tanaka has no relevant financial relationships to disclose.

A phase II trial of neoadjuvant docetaxel/cyclophosphamide followed by epirubicin/cyclophosphamide for triple-negative breast cancer

Kimihito Tanaka

Kimihito Tanaka has no relevant financial relationships to disclose.

Impact of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive recurrent and advanced breast cancer

Maki Tanaka

Maki Tanaka has no relevant financial relationships to disclose.

Impact of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive recurrent and advanced breast cancer

Maki Tanaka

Maki Tanaka has no relevant financial relationships to disclose.

Impact of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive recurrent and advanced breast cancer

Maki Tanaka

Maki Tanaka has no relevant financial relationships to disclose.

Impact of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive recurrent and advanced breast cancer

Maki Tanaka

Maki Tanaka has no relevant financial relationships to disclose.

Impact of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive recurrent and advanced breast cancer

Maki Tanaka

Maki Tanaka has no relevant financial relationships to disclose.

Impact of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive recurrent and advanced breast cancer

Maki Tanaka

Maki Tanaka has no relevant financial relationships to disclose.

Impact of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive recurrent and advanced breast cancer

Maki Tanaka

Maki Tanaka has no relevant financial relationships to disclose.

Impact of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive recurrent and advanced breast cancer

Maki Tanaka

Maki Tanaka has no relevant financial relationships to disclose.

Impact of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive recurrent and advanced breast cancer

Maki Tanaka

Maki Tanaka has no relevant financial relationships to disclose.

Impact of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive recurrent and advanced breast cancer

Maki Tanaka

Maki Tanaka has no relevant financial relationships to disclose.

Impact of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive recurrent and advanced breast cancer

Maki Tanaka

Maki Tanaka has no relevant financial relationships to disclose.

Impact of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive recurrent and advanced breast cancer

Maki Tanaka

Maki Tanaka has no relevant financial relationships to disclose.

Impact of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive recurrent and advanced breast cancer

Maki Tanaka

Maki Tanaka has no relevant financial relationships to disclose.

Impact of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive recurrent and advanced breast cancer

Maki Tanaka

Maki Tanaka has no relevant financial relationships to disclose.

Impact of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive recurrent and advanced breast cancer

Maki Tanaka

Maki Tanaka has no relevant financial relationships to disclose.

Impact of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive recurrent and advanced breast cancer

Maki Tanaka

Maki Tanaka has no relevant financial relationships to disclo
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3-02-10</td>
<td>Selective use of MRI and impact on management in breast cancer</td>
<td>Megha Tandon</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-22-19</td>
<td>Time on treatment of everolimus versus endocrine monotherapy or chemotherapy for early-line treatment of HR+/HER2-metastatic breast cancer: A retrospective chart review study in the US</td>
<td>Dr. Tang</td>
<td>Has disclosed that he receives salary from and has ownership in Novartis Pharmaceuticals Corporation.</td>
</tr>
<tr>
<td>P6-01-14</td>
<td>Dissection of the AID interactor 1 signaling in metastatic breast cancer cells</td>
<td>Hongping Tang</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-03-07</td>
<td>High-throughput pharmacogenomic platform to functionally profile breast cancer vulnerabilities in the context of the 3-dimensional tumor microenvironment</td>
<td>Dr. Tang</td>
<td>Has disclosed that he has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-15</td>
<td>The lymph node ratio as an independent prognostic factor for node-positive triple-negative breast cancer</td>
<td>Li-Chen Tang</td>
<td>Has disclosed that he has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-03-10</td>
<td>HER2 expression in clinical breast cancer samples: A novel detection methodology for HER2 protein quantitation using fluorescent nanoparticles</td>
<td>Dr. Tang</td>
<td>Has disclosed that he has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-07-10</td>
<td>MiR-146a functions as suppressive non-coding gene via indirect upregulation of Let-7 to promote asymmetric division and inhibit the self-renewal ability of breast cancer stem-like cells</td>
<td>Dr. Tang</td>
<td>Has disclosed that he has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Committee Member</td>
<td>A phase II, open-label, multi-center study of ANG1005, a novel brain-penetrant peptide-drug conjugate, in breast cancer patients with recurrent CNS metastases</td>
<td>Shou-Chang Tang</td>
<td>Has disclosed that he has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-16-10</td>
<td>Estradiol acid combined with niosomad chemotherapy for HER2-negative early breast cancer (G0RNE 1 trial): Survival outcomes of a randomized multicenter phase 2 trial</td>
<td>Dr. Tanino</td>
<td>Has disclosed that he has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S3-05</td>
<td>Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer</td>
<td>Maki Tanaka</td>
<td>Has disclosed that he has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S6-02</td>
<td>The efficacy and safety of the addition of Bazedoxifene to adjuvant hormonal therapy in postmenopausal women with hormone-receptor positive early breast cancer. First results of the TEAM IB trial (DOCC 2006-04)</td>
<td>Dr. Tanis</td>
<td>Has disclosed that he has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-01-03</td>
<td>Dynamics of circulating tumor cells during the course of chemotherapy and prognostic relevance across molecular subtypes in high-risk early breast cancer patients - Results from the adjuvant SUCCESS A trial</td>
<td>Dr. Tanja</td>
<td>Has disclosed that he has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-10-09</td>
<td>Hypofractionated nodal radiotherapy (RT): did not increase arm morbidity compared to conventional fractionated nodal RT</td>
<td>Mr. Tarhul</td>
<td>Has disclosed that he has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-11-03</td>
<td>A phase 2 open-label study of tucatinib in patients (pts) with TFG aberrant metastatic breast cancer (MBC)</td>
<td>Dr. Tankersley</td>
<td>Has disclosed that he has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-10-03</td>
<td>Oncoskeletal dissemination in weekly bisomy prior to breast cancer surgery across physician referral networks</td>
<td>Ms. Tannenbaum</td>
<td>Has disclosed that he has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-06-05</td>
<td>Preclinical characterization of VX-984, a selective DNA-dependent protein kinase (DNA-PK) inhibitor in combination with doxorubicin in breast and ovarian cancers</td>
<td>Dr. Tanner</td>
<td>Has disclosed that he has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-06-09</td>
<td>Cyclin D1 binding to chromatin and the induction of chromosomal instability requires the fuzzy domain</td>
<td>Dr. Tantos</td>
<td>Has disclosed that he has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-04-22</td>
<td>RAD0012 demonstrates anti-tumor activity in multiple models of ER-positive breast cancer treatment resistance</td>
<td>Dr. Tao</td>
<td>Has disclosed that he has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P08-03</td>
<td>Differences in the mutational landscape in African Americans and Caucasians with triple negative breast cancer</td>
<td>Dr. Tao</td>
<td>Has disclosed that he has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
P4-06-04 Triple negative breast cancer patient-derived xenografts: Molecular characteristics and sensitivity to emerging therapies
Coya Tapia
Coya Tapia has no relevant financial relationships to disclose.

P2-03 Does BRCA status affect outcome in young breast cancer patients? Results from the prospective study of outcomes in geriatric and hereditary breast cancer (POSH)
Will Tapper
Mr. Tapper has no relevant financial relationships to disclose.

P4-13-02 Long-term effects of weight loss on breast cancer biomarkers in postmenopausal women
Jean de Oue Tapoza
Dr. Tapoza has no relevant financial relationships to disclose.

P4-03-07 Inhibition of cancer-associated fibroblast function by farnesoid X receptor activation: Experimental basis for a novel therapeutic strategy in breast cancer
Robertia Tarallo
Ms. Tarallo has no relevant financial relationships to disclose.

OT1-02-04 The DETECT V-study - Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemotherapy or endocrine therapy in patients with HER2-positive and hormone-receptor positive metastatic breast cancer
Florin-Andrei Taran
Dr. Taran has no relevant financial relationships to disclose.

OT3-04-02 DETECT III and IV - Individualized CTC-based therapy of metastatic breast cancer
Florin-Andrei Taran
Dr. Taran has no relevant financial relationships to disclose.

P1-01-15 A single-institution clinical experience with neoadjuvant docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP): A safety and efficacy analysis
Rizwan Tariq
Dr. Tariq has no relevant financial relationships to disclose.

P6-11-06 Bromodomain inhibitors represent a rational therapeutic option for the treatment of invasive lobular carcinoma
Finbarr Tarrant
Dr. Tarrant has no relevant financial relationships to disclose.

P4-05-02 Conditional inactivation of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) in the mouse mammary epithelium alters mammary gland development
Gerard Tarulli
Dr. Tarulli has no relevant financial relationships to disclose.

P2-12-06 Tumor infiltrating lymphocytes in recurrent HER2+ and triple negative breast cancer: Prognostic value according to tumor phenotype
Skulka Tasca
Dr. Tasca has no relevant financial relationships to disclose.

P2-05-20 Dissection of the Akt interactor 1 signaling in metastatic breast cancer cells
Smalligan Tate
Smalligan Tate has no relevant financial relationships to disclose.

P6-12-10 Bone seeking matrix metalloproteinase-2 inhibitors prevent bone metastatic breast cancer growth
Mairhina Tauro
Dr. Tauro has no relevant financial relationships to disclose.

P6-09-44 Tumor-infiltrating lymphocytes (TILs) is associated with improved overall survival in triple-negative breast cancer (TNBC) patients treated with neoadjuvant chemotherapy (NAC)
Monique Taveiras
Dr. Taveiras has no relevant financial relationships to disclose.

P3-12-06 Saving in clinical trials: A possible challenge for improving health care for breast cancer patients
Cristiana Taventiti
Dr. Taventiti has no relevant financial relationships to disclose.

S6-01 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian short-HR trial
Cristiana Taventiti
Ms. Taventiti has no relevant financial relationships to disclose.
Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC)

Melinda Telli

Dr. Telli has disclosed that she is a consultant for AstraZeneca and has contracts with Abbie, Calithera, Biomarin, Medivation, Genterch, Novartis, OncoSec and Vertex.

Efficacy and tolerability of veliparib (V, ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: A randomized, phase 2 study

Melinda Telli

Dr. Telli has disclosed that she is a consultant for AstraZeneca and receives research funding (institution) from AbbVie, BioMarin, Medivation, Phamaris.

Committee Member
Melinda Telli

Dr. Telli has disclosed that she receives consulting fees from AstraZeneca. She also disclosed that she does contracted research for Novartis, AbbVie, Biomarin, Medivation, Genterch, Phamaris, OncoSec and Vertex. These relationships do not impact her ability to review presentations.

Inhibiting ADP-ribosylation factor 3 activation to suppress breast cancer metastasis

Yong Tang

Dr. Tang has no relevant financial relationships to disclose.

Efficacy and tolerability of veliparib (V, ABT-888) in combination with carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer: A randomized, phase 2 study

Kamani Tennekoon

Dr. Tennekoon has no relevant financial relationships to disclose.

Prognostic value of molecular tumor infiltrating lymphocyte (mTL) signatures in HER2-positive breast cancer patients in M851 and FinHer/FinXX trials

Kathleen Tener

Ms. Tener has no relevant financial relationships to disclose.

Vitamin D-dependent calcium signalling in breast cancer

Martin Tennewood

Dr. Tennewood has no relevant financial relationships to disclose.

Prognostic value of molecular tumor infiltrating lymphocyte (mTL) signatures in HER2-positive breast cancer patients in M851 and FinHer/FinXX trials

Elena Tennvall-Nittby

Dr. Tennvall-Nittby has no relevant financial relationships to disclose.

The combination of preoperative computed tomography lymphography and intraoperative fluorescence imaging navigation for sentinel lymph node biopsy of early breast cancer patients

Keiko Teramoto

Dr. Teramoto has no relevant financial relationships to disclose.

Difference of immune microenvironment between primary and recurrent tumours in breast cancer patients

Mayako Terao

Dr. Terao has no relevant financial relationships to disclose.

Utility of LigaSure™ vessel-sealing device in axillary dissection for breast cancer surgery: A randomized single center study

Meiyako Terao

Dr. Terao has no relevant financial relationships to disclose.

The importance of hormone receptor status in biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HR2 positive recurrent and advanced breast cancer

Megumi Teraoka

Dr. Teraoka has no relevant financial relationships to disclose.

Impact of MAP gene amplification on disease recurrence and effects of adjuvant irinotecan in early breast cancer

Suetaro Terasawa

Dr. Terasawa has no relevant financial relationships to disclose.

Phase II neoadjuvant trial of nanoparticle albumin-bound paclitaxel and trastuzumab in patients with node-negative, HER-2 positive breast cancer (GMC-B054)

Risu Terasawa

Dr. Terasawa has no relevant financial relationships to disclose.

Committee Member

Dr. Tercero has disclosed that he is a full time employee of and owns stock options of Inbiomotion SL. He also disclosed that he is one of the authors of an Inbiomotion patent, but does not have intellectual property rights.
P6-09-24 Vitamin D level impacts odds of pathologic complete response following neoadjuvant therapy in operable breast cancer
Simon Thézenas
Mr. Thézenas has no relevant financial relationships to disclose.

P6-09-28 Prognostic impact of the inclusion of uPA/PAI-1 in ER/HER2- and/or early breast cancer adjuvant treatments decision-making
Simon Thézenas
Mr. Thézenas has no relevant financial relationships to disclose.

P6-12-14 Proteasome inhibitors prevent bi-directional HER2/estrogen receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2/ER breast cancer cells
Gitta Thiede
Gitta Thiede has no relevant financial relationships to disclose.

P3-08-01 The REQUITE-AB study: Validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality of life in breast cancer patients
Hubert Thierens
Mr. Thierens has no relevant financial relationships to disclose.

P5-15-12 Real-life activity of oral vinorelbine in metastatic breast cancer patients in the Unicancer SEIME database
Petit Thierry
Dr. Thierry has no relevant financial relationships to disclose.

P6-09-30 22-gene recurrence score® in patients with primary metastatic ER/HER2- breast cancer
Marc Thill
Dr. Thill has no relevant financial relationships to disclose.

P6-09-10 Results of multigene assay (MammaPrint®) and molecular subtyping (BluePrint®) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIME decision impact study
Marc Thill
Dr. Thill has no relevant financial relationships to disclose.

P2-01-13 Can axillary lymph node clearance be avoided in women with node positive breast cancer receiving primary chemotherapy?
Kirthikah Thillai
Kirthikah Thillai has no relevant financial relationships to disclose.

P3-17-09 Resolution of DCIS in patients with early breast cancer receiving primary chemotherapy for invasive breast cancer
Kirthikah Thillai
Kirthikah Thillai has no relevant financial relationships to disclose.

P3-14-07 Neoadjuvant radiotherapy in mediastinal and immediate palliagous free flap reconstruction: Findings from the primary radiotherapy and DIEP flap (PRADA) pilot study
Paul Thiruchelvam
Dr. Thiruchelvam has no relevant financial relationships to disclose.

P5-08-21 The effect of family history on screening procedures and prognosis in breast cancer patients - Results of a large population-based case-control study on breast cancer
Kathrin Thome
Ms. Thome has no relevant financial relationships to disclose.

P3-07-11 Inhibition of PI3K or CDK-mediated Smad3 phosphorylation reduces triple negative breast cancer cell EMT, migration and invasion
Auran Thomas
Mr. Thomas has no relevant financial relationships to disclose.

P5-07-11 Nuclear-activated oligonucleotide probes for detection of breast cancer circulating tumor cells (CTCs): Early clinical results
Alexandra Thomas
Dr. Thomas has no relevant financial relationships to disclose.

P3-07-11 Inhibition of PI3K or CDK-mediated Smad3 phosphorylation reduces triple negative breast cancer cell EMT, migration and invasion
Alexandra Thomas
Mr. Thomas has no relevant financial relationships to disclose.

P3-10-04 Disparities in human epidermal growth factor receptor 2 testing: A testing completion: A population-based retrospective cohort study, 2010-2013
Alexandra Thomas
Dr. Thomas has no relevant financial relationships to disclose.

P3-17-10 The impact of the presence of ductal carcinoma in situ in patients with invasive ductal carcinoma
Alexandra Thomas
Dr. Thomas has no relevant financial relationships to disclose.

P5-07-02 African Americans have more aggressive invasive lobular carcinoma subtypes and inferior early outcomes: SEER 2010-2013
Alexandra Thomas
Dr. Thomas has no relevant financial relationships to disclose.

P6-09-24 Vitamin D level impacts odds of pathologic complete response following neoadjuvant therapy in operable breast cancer
Alexandra Thomas
Dr. Thomas has no relevant financial relationships to disclose.

P2-03-12 A simulation study depicting the inconsistency of adjuvant online compared to genomic testing when determining the benefit of chemotherapy
Daniel Thomas
Mr. Thomas has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Author</th>
<th>Acknowledgment</th>
</tr>
</thead>
<tbody>
<tr>
<td>P4-02-07</td>
<td>Preoperative assessment of breast cancer survival using ultrasound diameter and shear wave elastography</td>
<td>Alastair Thompson</td>
<td>Alastair Thompson has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-04</td>
<td>Which measure of the interim changes in breast tumoral volume at breast MRI in response to neoadjuvant chemotherapy best predicts final pathological response?</td>
<td>Alastair Thompson</td>
<td>Dr. Thompson has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-03-03</td>
<td>Recurrent functionally diverse in-frame ESR1 gene fusions drive endocrine resistance in breast cancer</td>
<td>Aubrey Thompson</td>
<td>Dr. Thompson has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-03</td>
<td>Intratumor heterogeneity of the estrogen receptor predicts less benefit from tamoxifen therapy and poor long-term breast cancer patient survival - Retrospective analyses of the STO-3 randomized trial</td>
<td>Carie Thompson</td>
<td>Dr. Thompson has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P07-02</td>
<td>Identification of breast cancers with an indolent disease course: 10 gene indolent threshold validation in a Swedish randomized trial of tamoxifen vs. no, with 20-year outcomes</td>
<td>Carie Thompson</td>
<td>Dr. Thompson has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P05-06</td>
<td>Prognostic value of molecular tumor infiltrating lymphocyte (mTIL) signatures in HER2-positive breast cancer patients in N9831 and FinHer/FxxX trials</td>
<td>E Thompson</td>
<td>Dr. Thompson has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Committee Member</td>
<td>Engineering mesenchymal stem cells(MSCs) to secrete tumour-suppressing exosomes for breast cancer therapy</td>
<td>Ian Thompson</td>
<td>Dr. Thompson has disclosed that he receives consulting fees from Exosome Diagnostics. This relationship does not impact his ability to present an unbiased presentation.</td>
</tr>
<tr>
<td>ID</td>
<td>Title</td>
<td>Author(s)</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>P08-01</td>
<td>Race and age differences in PAM50 biomarker status in the Carolina breast cancer study</td>
<td>Leigh Thorne</td>
<td></td>
</tr>
<tr>
<td>P04-06</td>
<td>Clinical implications of somatic mutations in post-menopausal early-stage estrogen receptor (ER)+/positive HER2-negative breast cancer (BC): Results from the BIG 1-98 study</td>
<td>Thuerlimann</td>
<td></td>
</tr>
<tr>
<td>S1-10</td>
<td>Serum-triglyceride among triple negative breast cancer patients as a biomarker of poor outcome</td>
<td>Inger Thune</td>
<td></td>
</tr>
<tr>
<td>P4-12-02</td>
<td>Investigation of the recurrence dynamics of breast cancer (BC) according to the body mass index (BMI)</td>
<td>Three-arms Investigators</td>
<td></td>
</tr>
<tr>
<td>P2-09-05</td>
<td>12 years median follow up (MFI) of BIG 1-98: Adjuvant letrozole, tamoxifen and their sequence for postmenopausal women with endocrine responsive early breast cancer</td>
<td>Thuerlimann</td>
<td></td>
</tr>
<tr>
<td>P4-12-01</td>
<td>Independent validation of ESR1 Y537S signature in BIG 1-98: A randomized, double-blind, phase II trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer</td>
<td>Thuerlimann</td>
<td></td>
</tr>
<tr>
<td>P1-01-20</td>
<td>Inertial focusing circulating breast cancer cells based on the novel 3D printed serpentine microfluidic chip</td>
<td>Jie Tian</td>
<td></td>
</tr>
<tr>
<td>P2-05-38</td>
<td>Spectral CT based radiomics signature: A potential biomarker for preoperative prediction of lymph node metastasis in breast cancer</td>
<td>Jie Tian</td>
<td></td>
</tr>
<tr>
<td>S4-02</td>
<td>The Y537S ESR1 mutation is a dominant driver of distant ER+ positive breast cancer metastasis</td>
<td>Lin Tian</td>
<td></td>
</tr>
<tr>
<td>P2-08-09</td>
<td>Aurora kinase A protein stability is negatively regulated by AT15a2 and PTEN in breast cancer: Prognostic and therapeutic implications</td>
<td>Weihua Tian</td>
<td></td>
</tr>
<tr>
<td>P2-02-07</td>
<td>Predicting germline mutations in BRCA1/2 and beyond: A comparison of women with single and multiple breast primaries</td>
<td>Yuan Tian</td>
<td></td>
</tr>
<tr>
<td>P6-07-16</td>
<td>Quantitative proteomic analysis of FGFR by mass spectrometry may improve identification of FGFR amplified tumors sensitive to inhibitor therapy</td>
<td>Yuan Tian</td>
<td></td>
</tr>
<tr>
<td>P3-04-04</td>
<td>S100B as a predictive biomarker and monitoring tool in endocrine resistant breast cancer</td>
<td>Tiberio</td>
<td></td>
</tr>
<tr>
<td>S3-02</td>
<td>Plasma microRNA levels for predicting therapeutic response to neoadjuvant treatment in HER2-positive breast cancer: Results from Neo-ALTTO</td>
<td>Paul Tiberio</td>
<td></td>
</tr>
<tr>
<td>P2-06-05</td>
<td>Development and validation of a new non-parametric breast cancer risk assessment model on US and European screening populations</td>
<td>Jeffrey Tice</td>
<td></td>
</tr>
<tr>
<td>P5-09-05</td>
<td>A model with pleomorphic risk score and mammographic density predicts interval cancers</td>
<td>Jeffrey Tice</td>
<td></td>
</tr>
<tr>
<td>OT1-01-10</td>
<td>Multi-center phase IB trial of ACY-1215 (Bicalutamide) combined with nab-paclitaxel in unresectable or metastatic breast cancer</td>
<td>Amy Tersten</td>
<td></td>
</tr>
<tr>
<td>OT2-01-19</td>
<td>An endomicroscopic phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer</td>
<td>Amy Tersten</td>
<td></td>
</tr>
<tr>
<td>P6-01-08</td>
<td>Identifying metastatic drivers in patient derived xenograft models of triple negative breast cancer</td>
<td>Trang Tieu</td>
<td></td>
</tr>
</tbody>
</table>
P5-16-12 Pertuzumab and trastuzumab in combination with weekly paclitaxel delivers high pCR rates with favourable toxicity profile in neo-adjuvant treatment of Her-2 positive breast cancer
Thomas Tigges Dr. Tigges has no relevant financial relationships to disclose.

P6-09-07 Mutation characteristics and tumor infiltrating lymphocytes in early and metastatic HER2-positive breast cancer
Serena Tikas Ismests Tikas has no relevant financial relationships to disclose.

P1-04-03 Cross talk between RNA methyltransferase and demethylase regulates breast cancer growth and progression
Santosh Timilsina Santosh Timilsina has no relevant financial relationships to disclose.

P1-09-02 Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative breast cancer
Kirsten Timms Ms. Timms has disclosed that she is an employee of Myriad Genetics - receives salary and stock options, IP (HRD patent).

P6-09-09 Evaluation of tumor infiltrating lymphocytes (TILs) and their association with homologous recombination deficiency and BRCA1/2 mutation status in triple-negative breast cancer (TNBC): A pooled analysis
Kirsten Timms Ms. Timms has disclosed that she has a patient with, receives salary from and has ownership in Myriad Genetics, Inc.

S6-01 BRCA1 methyltransfer status, clonning and treatment effect in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRL3)2012)
Kirsten Timms Ms. Timms has disclosed that she has a patent with, receives salary from and has ownership in Myriad Genetics.

P4-22-20 Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomized, neoadjuvant phase II study (ABCSG-34)
Christoph Tinchon Dr. Tinchon has no relevant financial relationships to disclose.

P6-10-01 Efficacy and safety of the therapeutic cancer vaccine bevacizumab (L-Bulp25) in early breast cancer: Results from a prospective, randomized, neoadjuvant phase II study (ABCSG-34)
Christoph Tinchon Dr. Tinchon has no relevant financial relationships to disclose.

P1-09-05 The role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+/HR+ phase II trial evaluating 12-weeks of neoadjuvant TAM and endocrine therapy (TT) versus T+T in HER2-positive hormone-receptor-positive early breast cancer (DBC)
Julie To Dr. To has no relevant financial relationships to disclose.

P6-07-24 HER2 160-3p and HER2 688-7p as novel circulating mRNA as potential prognostic biomarkers in breast cancer
Nesip Tiryakioglu Nesip Tiryakioglu has no relevant financial relationships to disclose.

OT2-01-15 PARTNER - Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients
Marc Tuskeowitz Dr. Tuskeowitz has no relevant financial relationships to disclose.

P2-03-01 The mutational landscape of breast cancers from PALB2 germline mutation carriers
Marc Tuskeowitz Mr. Tuskeowitz has no relevant financial relationships to disclose.

P2-05-02 The predictive value of sentinel node biopsy (SNB) in early breast cancer after neo-adjuvant chemotherapy (NACT): A prospective study
Wadim Tajima Dr. Tajima has no relevant financial relationships to disclose.

P4-21-15 Tissue-based IHC versus SL: A time, motion and cost assessment in a lean operating day care oncology unit
Wadim Tajima Prof. Tajima has no relevant financial relationships to disclose.

S6-02 What to do with non-visualized sentinel nodes; to dissect or not to dissect the axilla?
Vivianne Tjan-Heijnen Dr. Tjan-Heijnen has no relevant financial relationships to disclose.

P2-01-04 Use of axillary ultrasound impacts outcome of node positive breast cancer patients
Vivianne Tjan-Heijnen Dr. Tjan-Heijnen has no relevant financial relationships to disclose.

P6-03 Preserving fertility in young women undergoing chemotherapy for early breast cancer: The Maastricht experience
Vivianne Tjan-Heijnen Ms. Tjan-Heijnen has no relevant financial relationships to disclose.
First results from the multicenter phase III DATA study comparing 3 versus 6 years of anastrozole after 2-3 years of tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer

Vivianne Tjan-Heijnen
Ms. Tjan-Heijnen has no relevant financial relationships to disclose.

BELLE-3: A phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2-, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment

Vivianne CG Tjan-Heijnen
Ms. Tjan-Heijnen has disclosed receives contract research with University Hospital.

Determination of a serum progranulin (GPR88/PGRN) level associated with overall survival in metastatic breast cancer patients

Katherine Tkaczuk
Dr. Tkaczuk has no relevant financial relationships to disclose.

Improvement in risk predictive value of Nottingham prognostic index by determining GPR88 tumor tissue expression for estrogen receptor positive breast cancer patients

Katherine Tkaczuk
Dr. Tkaczuk has no relevant financial relationships to disclose.

PD4-02
The importance of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HR2 positive recurrent and advanced breast cancer

Hidekazu Todoroki
Dr. Todoroki has no relevant financial relationships to disclose.

Development of photoacoustic vascular imaging system for breast cancer

Kohei Togashi
Kohei Togashi has no relevant financial relationships to disclose.

The importance of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HR2 positive recurrent and advanced breast cancer

SNI Teh
Dr. Teh has no relevant financial relationships to disclose.
EndoPredict multigene test in the prediction of response and outcome after neoadjuvant hormonal treatment with letrozole and palbociclib (OOTR-N007)  
Masakazu Toi  
Dr. Toi has no relevant financial relationships to disclose.

Duration of fasting before taking lapatinib is associated with skin toxicity in neoadjuvant treatment of HER2 positive breast cancer: A cohort study from JBCRG-16/Neo-LaTH  
Masakazu Toi  
Masakazu Toi has disclosed that he has a contract with Novartis.

Development of photoacoustic vascular imaging system for breast cancer  
Masakazu Toi  
Dr. Toi has no relevant financial relationships to disclose.

Development of mathematical prediction models to identify disease-free survival events for HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy and trastuzumab  
Masakazu Toi  
Masakazu Toi has no relevant financial relationships to disclose.

Utility of Ligasure™ vessel-sealing device in axillary dissection for breast cancer surgery: A randomized single center study  
Takashi Tokiwa  
Mariko Tokiwa has no relevant financial relationships to disclose.

A randomized phase II neoadjuvant study comparing docetaxel and cyclophosphamide (TC) with 5-fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel (FEC-D) for hormone receptor-negative breast cancer: The Kanagawa breast oncology group (KBOG) 1101 study  
Takashi Tokiwa  
Takashi Tokiwa has no relevant financial relationships to disclose.

The clinical importance of nuclear wild-type p53-induced phosphatase 1(Wip1) expression in breast cancer patients  
Eriko Tokunaga  
Dr. Tokunaga has no relevant financial relationships to disclose.

Epithelial paradox; clinical significance of co-expression of E-cadherin and vimentin in the invasion and the metastasis of breast cancer  
Eriko Tokunaga  
Dr. Tokunaga has no relevant financial relationships to disclose.

Phase 3 study of olaparib versus physician's choice in patients with metastatic breast cancer who have stable brain metastases previously treated with an anthracycline, a taxane, and capecitabine  
Takashi Tokiwa  
Takashi Tokiwa has no relevant financial relationships to disclose.

A phase 2 study of daclizumab plus pembrolizumab for patients with hormone receptor positive (HR+), HER2-negative (HER2-) metastatic breast cancer (MBC)  
Sara Tolaney  
Dr. Tolaney has disclosed that she is a consultant for Nektar Therapeutics. She has also disclosed that she receives research funding from Exelixis, Novartis, Pfizer, AstraZeneca, Genentech/Roche, Lilly and Merck.

Phase I dose-escalation trial of ONT-380 in combination with trastuzumab in patients (pts) with HER2+ breast cancer brain metastases  
Eli Lilly  
Ms. Tolaney has disclosed that she receives research funding from Exelixis, Genentech/Roche, Lilly, Novartis and Pfizer.

Phase 3b/2 study to evaluate endoxan-meyeloid in combination with pembrolizumab in patients with metastatic triple-negative breast cancer  
Eli Lilly  
Ms. Tolaney has disclosed that she has contracts with Lilly, Genentech, Pfizer, Merck, Novartis, Exelixis, Eisai and AZ.
Phase I study of the JAK 1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2 negative metastatic breast cancer (MBC)  Sara Tolaney  Dr. Tolaney has no relevant financial relationships to disclose.

Analysis of renal function in MONARCH 1: A phase 2 study of abemaciclib, a CDK4 & 6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for metastatic breast cancer (MBC)  Sara Tolaney  Ms. Tolaney has disclosed that she has contracts with Merck, Novartis, Lilly, AstraZeneca, Pfizer, Exelixis and Genentech/Roche.

Multivariate analysis of subtype and gene expression signatures predictive of pathological complete response (pCR) in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance)  Sara Tolaney  Dr. Tolaney has disclosed that she receives research funding from Genentech.

Integrated analyses of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2 positive breast cancer  Sara Tolaney  Dr. Tolaney has disclosed that she has a contract with Genentech.

"Optimizing Her2-Directed Treatment in Early Stage Disease"  Sara Tolaney  Dr. Tolaney has disclosed that she does contracted research for Genentech, Exelixis, Lilly, Novartis, Merck and Pfizer. These relationships do not impact her ability to present an unbiased presentation.

Three-monthly dynamic evaluation of CEA and CAT-3 (followed by 18-FDG PET) vs usual practice in the follow-up of early breast cancer (EC) patients (pts): A prospective randomised trial (KRONOS-patient-oriented new surveillance study, Italy)  Sara Tomasini  Ms. Tomasini has no relevant financial relationships to disclose.

Epigenome-wide association study for breast cancer risk using whole genome and target captured bisulphite sequencing: A pooled case-control study nested in the breakthrough generations study  Katarzyna Tomczyk  Ms. Tomczyk has no relevant financial relationships to disclose.

Results of multigene assay (MammaPrint™) and molecular subtyping (BluePrint™) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIME decision impact study  Oliver Tome  Dr. Tome has no relevant financial relationships to disclose.

The impact of intrinsic subtypes and molecular features on aromatase inhibitor induced reduction of proliferation marker of Ki67 in primary ER+ breast cancer: A POETIC study  Monique Tomiczek  Ms. Tomiczek has no relevant financial relationships to disclose.

Clinical significance of sequential measurements of ESR1 mutations in plasma cell-free DNA in estrogen receptor positive recurrent metastatic breast cancer patients  Mai Tomiguchi  Dr. Tomiguchi has no relevant financial relationships to disclose.

Differential expression of exosomal mRNA between breast cancer patients with recurrence and no recurrence  Mai Tomiguchi  Dr. Tomiguchi has no relevant financial relationships to disclose.

Development of a prediction model by gene expression profiles for pathological CR after neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer  Mai Tomiguchi  Dr. Tomiguchi has no relevant financial relationships to disclose.

Cyclin d1 binding to chromatin and the induction of chromosomal instability requires the fuzzy domain  Peter Tompa  Dr. Tompa has no relevant financial relationships to disclose.

Determining the optimal vaccination strategy using a combination of the folate binding protein (FBP) peptide vaccine (E39+GM-CSF) and an attenuated version (E39) to maximize the immunologic response in breast cancer patients  Annie Toms  Ms. Toms has no relevant financial relationships to disclose.
OT2-03-05  NRG oncology/NSABP B-51/RTOG 1304: A phase III superiority clinical trial designed to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) will reduce invasive cancer events in patients (pts) with positive axillary (Ax) nodes and convert to ypN0 after neoadjuvant chemotherapy (NC)

Mylin Torres  Mylin Torres has no relevant financial relationships to disclose.

P1-10-07  PAINTER: Evaluation of eribulin tolerability and correlation between a set of polymorphisms and neuropathy in patients with metastatic breast cancer

Valter Torti  Valter Torti has no relevant financial relationships to disclose.

P1-17-04  Presentation of a Bayesian decision model for the treatment of ductal carcinoma in situ (DCIS) of the breast

Salvador Tortajada  Mr. Tortajada has no relevant financial relationships to disclose.

P4-21-22  HER2-associated frequent phenotypic as a potential therapeutic target in breast cancer patients

Tharcisch Tortelli  Dr. Tortelli has no relevant financial relationships to disclose.

P5-02-06  Metabolomics profiling of breast cancer and adjacent tissue

Tharcisch Tortelli  Mr. Tortelli has no relevant financial relationships to disclose.

P6-12-10  Bone seeking matrix metalloproteinase-2 inhibitors prevent bone metastatic breast cancer growth

Ecole Toshinari  Dr. Toshinari has no relevant financial relationships to disclose.

P4-22-24  A retrospective study about re-biopsy at disease progression on T-DM1

Yagi Toshinari  Dr. Toshinari has no relevant financial relationships to disclose.

P6-09-13  The association between pT status after neoadjuvant chemotherapy and sites of first distant relapse after surgery: A substudy of the EORTC 10094/BIG-08 trial

Nathan Touati  Mr. Touati has no relevant financial relationships to disclose.

P5-13-01  Socioeconomic and economic factors are essential determinants of weight gain between before and after cancer diagnosis: Results from the prospective population-based NutriNet-Santé cohort

Mathilde Touvier  Dr. Touvier has no relevant financial relationships to disclose.

P6-06-01  High-grade human cytomegalovirus IEA is associated with expression of COX-2 and 5-LO in human breast cancer samples

Joel Touma  Mr. Touma has no relevant financial relationships to disclose.

P6-06-02  Low expression levels of hormone receptors (ER-α and PGR) in human breast cancer samples is significantly associated with high-grade human cytomegalovirus IEA

Joel Touma  Mr. Touma has no relevant financial relationships to disclose.

P4-13-01  Prospective association between breast cancer risk and an individual dietary index based on the British Food Standards Agency nutrient profiling system

Mathilde Touvier  Dr. Touvier has no relevant financial relationships to disclose.

P5-13-01  Socioeconomic and economic factors are essential determinants of weight gain between before and after cancer diagnosis: Results from the prospective population-based NutriNet-Santé cohort

Mathilde Touvier  Dr. Touvier has no relevant financial relationships to disclose.

P4-17-05  Global Cancer Institute online tumor boards to improve global patterns of clinical practice for breast cancer

Diego Touya  Dr. Touya has no relevant financial relationships to disclose.

P5-13-01  Socioeconomic and economic factors are essential determinants of weight gain between before and after cancer diagnosis: Results from the prospective population-based NutriNet-Santé cohort

Mathilde Touvier  Dr. Touvier has no relevant financial relationships to disclose.

P6-01  Association between BMI and residual intraductal levels in post-menopausal women using adjacent lesional: Results of a prospective study

Holly Tovey  Ms. Tovey has no relevant financial relationships to disclose.

P2-08-14  Association between BMI and residual intraductal levels in post-menopausal women using adjacent lesional: Results of a prospective study

Carol Townsley  Ms. Townsley has no relevant financial relationships to disclose.

P2-03-07  Stomatitis in patients treated with first-line everolimus (EVE) plus letrozole (LET): Results from BOLERO-4 trial

Tatsuya Toyama  Tatsuya Toyama has no relevant financial relationships to disclose.

P2-11-08  The prognostic impact of neutrophil-to-lymphocyte ratio (NLR) in breast cancer tissue

Tatsuya Toyama  Tatsuya Toyama has no relevant financial relationships to disclose.

P6-07-34  The prognostic impact of neutrophil-lymphocyte ratio (NLR) in breast cancer tissue

Tatsuya Toyama  Tatsuya Toyama has no relevant financial relationships to disclose.
The importance of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive recurrent and advanced breast cancer

Satoshi Toyoshima

Dr. Toyoshima has no relevant financial relationships to disclose.

Tumor RNA disruption index as a tool to predict response to neoadjuvant chemotherapy in breast cancer: Optimizing timing of biopsy

Nora Trubuli

Dr. Trubuli has no relevant financial relationships to disclose.

Phase II/III study of oral olaparib (TV-864), a dual CYP17A1 inhibitor and androgen receptor (AR) antagonist, in patients with advanced AR positive triple negative (TNBC) or estrogen receptor (ER) positive breast cancer (BC)

Tiffany Traina

Dr. Traina has no relevant financial relationships to disclose.

Phase IV study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy

Tiffany Traina

Dr. Traina has disclosed that she receives from InnoCem: salary support for a clinical trial (to the institution). Medivation: salary support for a clinical trial (to the institution).

Phase I/II trial of palbociclib in combination with bicalutamide for the treatment of androgen receptor (AR)+ metastatic breast cancer

Tiffany Traina

Dr. Traina has disclosed that she receives from Innocrin: salary support for a clinical trial (to the institution). Medivation: salary support for a clinical trial (to the institution).

Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy

Tiffany Traina

Dr. Traina has disclosed that she receives from InnoCem: salary support for a clinical trial (to the institution).

Phase I/II trial of palbociclib in combination with bicalutamide for the treatment of androgen receptor (AR)+ metastatic breast cancer

Tiffany Traina

Dr. Traina has disclosed that she receives from Innocrin: salary support for a clinical trial (to the institution). Medivation: salary support for a clinical trial (to the institution).

The DETECT V-study - Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemotherapy or endocrine therapy in patients with HER2-positive and hormone-receptor positive metastatic breast cancer

Elisabeth Trapp

Dr. Trapp has no relevant financial relationships to disclose.

DETECT III and IV - Individualized CTC-based therapy of metastatic breast cancer

Elisabeth Trapp

Dr. Trapp has no relevant financial relationships to disclose.

The DETECT V-study - Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemotherapy or endocrine therapy in patients with HER2-positive and hormone-receptor positive metastatic breast cancer

Elisabeth Trapp

Dr. Trapp has no relevant financial relationships to disclose.

Dynamics of circulating tumor cells during the course of chemotherapy and prognostic relevance across molecular subtypes in high-risk early breast cancer patients - Results from the adjuvant SUCCESS A trial

Elisabeth Trapp

Dr. Trapp has no relevant financial relationships to disclose.

Active surveillance with a combination of tumor marker CA27.29 and detection of circulating tumor cells two year after primary diagnosis strongly predicts subsequent progression

Elisabeth Trapp

Ms. Trapp has no relevant financial relationships to disclose.

Profiling miRNA in high risk post-operative early breast cancer patients to detect possible association to correlation with immune system antitumor response

Elisabeth Trapp

Dr. Trapp has no relevant financial relationships to disclose.
Determining the optimal vaccination strategy using a combination of the folate binding protein (FBP) peptide vaccine (E39+GM-CSF) and an attenuated version (E39) to maximize the immunologic response in breast cancer patients

P6-10-04
Alfred Trappey
Dr. Trappey has no relevant financial relationships to disclose.

Broken promise of liquid biopsy: Plasma DNA does not accurately reflect tumor DNA in metastatic breast cancer

P6-07-03
Heidi Trask
Ms. Trask has no relevant financial relationships to disclose.

Circulating tumor cells (CTC) and endothelial cells (EC): prognostic value in HER2 negative metastatic breast cancer patients treated with first line weekly paclitaxel and bevacizumab: First results of a prospective cohort from the French Breast Cancer InterGroup Unicancer (UCBG): COMET study

P3-01-02
Eliezer Tredent
Mr. Tredent has no relevant financial relationships to disclose.

Multi-center phase IB trial of ACY-1215 (Ricolinostat) combined with nab-paclitaxel in unresectable or metastatic breast cancer

P5-16-05
Nileshca Treede
Dr. Treede has disclosed that as an employee he receives salary from Acetylon.

MINT trial yields MammaPrint High1/High2 risk classes associated with significant differences in pCR and receptor subtype

P5-16-08
Tina Treece
Ms. Treece has disclosed that she is an Agendia employee.

Aurora kinase-A protein stability is negatively regulated by eEF1α2 and PTEN in breast cancer: Prognostic and therapeutic implications

P3-13-08
Sudhakar Treillex
Ms. Treillex has no relevant financial relationships to disclose.

Failure associated with genetic testing in a cohort of breast cancer survivors

P3-08-03
Amy Trenham-Dietz
Ms. Trenham-Dietz has no relevant financial relationships to disclose.

Survivorship care planning is associated with breast cancer survivors’ reported quality and coordination of care

P4-05-05
Amy Trenham-Dietz
Ms. Trenham-Dietz has no relevant financial relationships to disclose.

Adjuvant and neoadjuvant chemotherapy for elderly patients (>70 years) with early high-risk breast cancer. A retrospective analysis of 166 patients

P5-14-08
Emmanuelle Tresch
Emmanuelle Tresch has no relevant financial relationships to disclose.

Differential expression of microRNAs (miRNAs) in HER2 negative breast cancer (BC)

P5-07-09
Lucie Treilla
Lucie Treilla has no relevant financial relationships to disclose.

The predictive value of sentinel node biopsy (SNB) in early breast cancer after neo-adjuvant chemotherapy (NACT): A prospective study

P2-01-02
Bich Trinh
Dr. Trinh has no relevant financial relationships to disclose.

Trastuzumab IV versus SC: A time, motion and cost assessment in a lean operating day care oncology unit

P4-21-15
Bich Trinh
Prof. Trinh has no relevant financial relationships to disclose.

Immediate breast reconstruction is highly accepted by breast cancer patients undergoing mastectomy when routinely offered—Recent experience of an Australian tertiary oncoplastic breast unit

P3-14-08
Bich Trinh
Dr. Trinh has no relevant financial relationships to disclose.

Triple-negative first line study: Randomization trial of nab-paclitaxel and atezolizumab, a PD-L1 inhibitor, in patients with triple negative breast cancer (TNBC) (NCT03250146)

P02-01-14
Debashish Tripathy
Dr. Tripathy has no relevant financial relationships to disclose.

Impact of estrogen receptor-positive metastatic breast cancer exposed to contemporary hormonal therapy

P3-05-04
Debashish Tripathy
Dr. Tripathy has disclosed that she receives consulting fees from Novartis, Nektar Pharmaceuticals and Puma Biotechnology. She also disclosed that she does contracted research for Novartis. These relationships do not impact her ability to review presentations.

Phase 3 study of etirinotecan pegol versus treatment of physician’s choice in patients with metastatic breast cancer who have stable brain metastases previously treated with an anthracycline, a taxane, and capecitabine

P03-04-08
Debu Tripathy
Debu Tripathy has disclosed that he is a consultant for Nektar Therapeutics, Puma Pharmaceuticals and Novartis. He has also disclosed that he is a Principal investigator for Novartis.
OT2-01-22
NCT02456857: A phase II trial of liposomal doxorubicin, bevacizumab and everolimus (DAE) in patients (pts) with localized triple-negative breast cancer (TNBC) with tumors predicted insensitive to standard neoadjuvant chemotherapy (NACT)
Debu Tripathy
Debu Tripathy has no relevant financial relationships to disclose.

OT3-02-05
NCI-2016-00367: A phase IIB study of neoadjuvant ZT regimen (enzalutamide therapy in combination with weekly paclitaxel) for androgen receptor (AR)-positive triple-negative breast cancer (TNBC)
Debu Tripathy
Debu Tripathy has no relevant financial relationships to disclose.

P2-11-09
Selenux, a selective inhibitor of nuclear export, demonstrates efficacy in preclinical models of triple negative breast cancer
Debu Tripathy
Dr. Tripathy has disclosed that he is on Advisory Board for Puma Biotechnology.

P3-07-01
The role of CBP/FOXM1 in triple negative breast cancer
Debu Tripathy
Dr. Tripathy has disclosed that he is on the advisory Board/consultant for NEKTAR Therapeutics, Puma Pharmaceuticals and Novartis.

P4-06-04
Lapatinib after pertuzumab and ado-trastuzumab emtansine in metastatic HER2-positive breast cancer
Debu Tripathy
Dr. Tripathy has disclosed that he is a consultant for Puma Biotechnology, NEKTAR Pharmaceuticals and Novartis.

P4-21-20
Incidence and severity of diarrhea with neratinib + intensive loperamide prophylaxis in patients (pts) with HER2+ early-stage breast cancer (EBC): Interim analysis from the multicenter, open label, phase II control trial
Debu Tripathy
Dr. Tripathy has disclosed that he is a consultant for NEKTAR Pharmaceuticals and Novartis.

P5-08-08
Baseline (BL) characteristics, treatment (tx) patterns, and outcomes in patients with hormone receptor (HR)+ vs HR- HER2+ disease from the SystHERs registry
Debu Tripathy
Dr. Tripathy has disclosed that he receives consulting fees from Nektar Pharmaceuticals, Merck, and Novartis. He has also disclosed that he receives grant support to his institution from Novartis, Genentech/Roche, Pfizer, and Puma Pharmaceuticals.

P5-08-27
Trajectory of patient (Pt) reported physical function (PF) during and after neoadjuvant chemotherapy in the I-SPY 2 trial
Debu Tripathy
Dr. Tripathy has disclosed that he receives consulting fees from Nektar Pharmaceuticals, Merck, and Novartis. He has also disclosed that he receives grant support to his institution from Novartis, Genentech/Roche, Pfizer, and Puma Pharmaceuticals.

P6-09-35
Proposal for a new breast cancer staging classification: Incorporating clinical and biologic factors
Debu Tripathy
Dr. Tripathy has disclosed that he receives consulting fees from Nektar Pharmaceuticals, Merck, and Novartis. He has also disclosed that he has a contract with Novartis (paid to institution).

P7-07
Discovery of molecular predictors of late breast cancer specific events (BCSE) in ER+, node+ breast cancer - new transcriptome expression whole gene analysis of the phase II adjuvant trial SWOG S0914
Debu Tripathy
Dr. Tripathy has no relevant financial relationships to disclose.

P4-20-07
Research biopsies in oncology-patient willingness, perceptions, understanding, and experience: An integrative review
Elizabeth Tripp
Ms. Tripp has no relevant financial relationships to disclose.

P4-21-13
HER2 activity regulates the pro-trastuzumab immune tumor microenvironment
Piyanka Tripathy
Piyanka Tripathy has no relevant financial relationships to disclose.

P3-07-04
The new oral SGDD AZD0946 is efficacious in antagonizing ER and circumventing resistance to endocrine therapy
Meghana Trivedi
Meghana Trivedi has no relevant financial relationships to disclose.

P5-10-01
Adherence to healthy lifestyle behaviors in a predominantly Hispanic population of women undergoing screening mammography
Meghna Trivedi
Dr. Trivedi has no relevant financial relationships to disclose.
P5-16-12 Pertuzumab and trastuzumab in combination with weekly paclitaxel delivers high pCR rates with favourable toxicity profile in neo-adjuvant treatment of Her-2 positive breast cancer

Rohit Trivedi
Dr. Trivedi has no relevant financial relationships to disclose.

P5-16-14 NOSTRA PRELIM: A non randomised pilot study designed to assess the ability of image guided core biopsies to detect residual disease in patients with early breast cancer who have received neoadjuvant chemotherapy to inform the design of a planned trial

Sachin Trivedi
Dr. Trivedi has no relevant financial relationships to disclose.

P1-05-11 Comprehensive comparison of breast cancer molecular portraits by African and European ancestry in the cancer genome atlas

Melissa Troester
Ms. Troester has no relevant financial relationships to disclose.

P08-01 Race and age differences in PAM50 biomarker status in the Carolina breast cancer study

Melissa Troester
Ms. Troester has no relevant financial relationships to disclose.

P4-21-14 Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy

Tiffany Troso-Sandoval
Dr. Troso-Sandoval has no relevant financial relationships to disclose.

P2-08-03 Targeting inflammatory pathways: A phase 2 trial of the JAK-inhibitor ruxolitinib in combination with exemestane for aromatase inhibitor-resistant, estrogen receptor-positive breast cancer

Andrea Troxel
Dr. Troxel has no relevant financial relationships to disclose.

P4-22-14 Single agent palbociclib with or without trastuzumab for the treatment of ER+ advanced breast cancer

Andrea Troxel
Andrea Troxel has no relevant financial relationships to disclose.

P1-11-02 The role of quantitative estrogen receptor status in predicting breast tumor response to neoadjuvant chemotherapy

Suzan Troyan
Ms. Troyan has no relevant financial relationships to disclose.

P4-22-08 A single-arm phase 2 study to assess clinical activity, efficacy and safety of eszalcitamid with trastuzumab in HER2+ AR- metastatic or locally advanced breast cancer

Maureen Trudeau
Ms. Trudeau has no relevant financial relationships to disclose.

P6-09-39 The effect of the use of tamoxifen orally administered in combination with exemestane on p53 expression status in patients with breast cancer treated with endocrine therapy

Maureen Trudeau
Dr. Trudeau has no relevant financial relationships to disclose.

P6-12-17 Effect of a multimodal treatment program (estrogen receptor antagonist, cediranib, and ivermectin) on p53 expression in patients with breast cancer treated with neoadjuvant chemotherapy

Marla Truffi
Dr. Truffi has no relevant financial relationships to disclose.

P6-07-06 The role of quantitative double-blind, placebo-controlled, phase II study of enzalutamide with or without trastuzumab in patients with metastatic breast cancer (ERIBBEN)

Cristina Truica
Dr. Truica has no relevant financial relationships to disclose.

P1-10-06 Hypofractionated nodal radiotherapy (RT) did not increase arm morbidity compared to conventional fractionated nodal RT

Pauline Truong
Ms. Truong has no relevant financial relationships to disclose.

P6-08-11 The association between pCR status after neoadjuvant chemotherapy and sites of first distant recurrence after surgery: A substudy of the EORTC 10994/BCIS-1-00 trial

Pauline Tryfonidis
Dr. Tryfonidis has no relevant financial relationships to disclose.

P5-16-12 Phyllodes tumours of the breast: The British Columbia cancer agency experience

Pauline Tryfonidis
Ms. Tryfonidis has no relevant financial relationships to disclose.

P5-16-12 The association between pCR status after neoadjuvant chemotherapy and sites of first distant recurrence after surgery: A substudy of the EORTC 10994/BCIS-1-00 trial

Konstantinos Tryfonidis
Dr. Tryfonidis has no relevant financial relationships to disclose.
A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unselectable locally advanced or metastatic breast carcinoma (NCT07223180) 

Michaela Tsai  
Ms. Tsai has no relevant financial relationships to disclose.

Predictive value of breast MRI in detecting mammographically occult contralateral breast cancer: Can we target women more likely to have contralateral breast cancer based on primary tumor clinicopathologic factors? 

Michaela Tsai  
Dr. Tsai has no relevant financial relationships to disclose.

Increased glycolysis directly activates transcriptional coactivator SRC-3 to promote aggressive metastatic breast cancer 

Ming-Jer Tsai  
Dr. Tsai has no relevant financial relationships to disclose.

Risk stratification with EndoPredict signature for luminal subtype breast cancers: Re-analyzing microarray experiments with Han-Chinese origin 

Ming-Lin Tsai  
Dr. Tsai has no relevant financial relationships to disclose.

Increased glycolysis directly activates transcriptional coactivator SRC-3 to promote aggressive metastatic breast cancer 

Sophia Tsai  
Dr. Tsai has no relevant financial relationships to disclose.

Risk stratification with EndoPredict signature for luminal subtype breast cancers: Re-analyzing microarray experiments with Han-Chinese origin 

Ming-Lin Tsai  
Dr. Tsai has no relevant financial relationships to disclose.

Randomized phase II study of induction bevacizumab, etoposide and cisplatin followed by whole brain radiotherapy (WBRT) versus WBRT alone in breast cancer with untreated brain metastases (A-PLUS) 

Ling-Ming Tseng  
Ling-Ming Tseng has no relevant financial relationships to disclose.

Proliferation and p21 refine risk of relapse in residual disease after HER2-directed therapies 

Ling-Ming Tseng  
Ling-Ming Tseng has no relevant financial relationships to disclose.

Targeting SET to disrupt oncogenic CIP2A feedforward loop shows therapeutic potential in triple negative breast cancer cells 

Ling-Ming Tseng  
Dr. Tseng has no relevant financial relationships to disclose.

Trends in age shifting and decreasing mortality of female breast cancer in Taiwan with emerging molecular subset of unmet medical need: A 30-year cohort observation from Taipei Veterans General Hospital 

Ling-Ming Tseng  
Dr. Tseng has no relevant financial relationships to disclose.

FOXA1 induces a pro-metastatic secretome through ER-dependent and independent transcriptional reprogramming in endocrine-resistant breast cancer 

Anna Tsimelzon  
Dr. Tsimelzon has no relevant financial relationships to disclose.

The Y537S ESR1 mutation is a dominant driver of distant ER-positive breast cancer metastasis 

Anna Tsimelzon  
Ms. Tsimelzon has no relevant financial relationships to disclose.

Genome-wide identification of transcripts regulated by estrogen in MCF-7 cells using BrU-seq 

Nick Tsinoremas  
Mr. Tsinoremas has no relevant financial relationships to disclose.

Mutation characteristics and tumor infiltrating lymphocytes in early and metastatic HER2-positive breast cancer 

Eleftheria Tsolaki  
Eleftheria Tsolaki has no relevant financial relationships to disclose.

Global Cancer Institute online tumor boards to improve global patterns of clinical practice for breast cancer 

Taras Tsolko  
Dr. Tsolko has no relevant financial relationships to disclose.

Prognostic factors in breast cancer (BC) associated with the development of brain metastases (BM): A retrospective study of 726 pts 

Maiya Tsoutsou  
Dr. Tsoutsou has no relevant financial relationships to disclose.

Prognostic factors in breast cancer (BC) associated with the development of brain metastases (BM): A retrospective study of 726 pts 

Maiya Tsoutsou  
Dr. Tsoutsou has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Author</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3-10-14</td>
<td>Breast cancer provider delay after the 2011 triple disaster in Fukushima, Japan</td>
<td>Manaharu Tsubokura</td>
<td>Dr. Tsubokura has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-36</td>
<td>Clinicopathological predictors for low risk recurrence distinguished by 21-gene recurrence score in estrogen receptor-positive invasive breast cancer patients</td>
<td>Yause Tsuchida</td>
<td>Yause Tsuchida has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-04-13</td>
<td>Difference of immune microenvironment between primary and recurrent tumors in breast cancer patients</td>
<td>Bami Tsuda</td>
<td>Bami Tsuda has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-13-11</td>
<td>Utility of LigaSure™ vessel-sealing device in axillary dissection for breast cancer surgery: A randomized single center study</td>
<td>Hitoshi Tsuda</td>
<td>Dr. Tsuda has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-11-07</td>
<td>Duration of fasting before taking lapatinib is associated with skin toxicity in neoadjuvant treatment of HER2 positive breast cancer: A cohort study from BCRG16Neo-LaTH</td>
<td>Moe Tsuda</td>
<td>Moe Tsuda has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-11-08</td>
<td>Stomatisit in patients treated with first-line everolimus (EVE) plus letrozole (LET): Results from BOLERO-4 trial</td>
<td>Koshide Togawa</td>
<td>Koshide Togawa has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-11-03</td>
<td>Difference between 1st and 2nd generation serotonin receptor antagonists in triplet antiemetic therapy for highly emetogenic chemotherapy in breast cancer patients - according to recent multi-institutional double-blind randomized clinical research on the AC regimen</td>
<td>Michiko Tsuneizumi</td>
<td>Dr. Tsuneizumi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-11-02</td>
<td>Photodynamic therapy for the treatment of primary breast cancer: Preliminary results of a phase III clinical trial</td>
<td>Dylan Tsukagoshi</td>
<td>Dr. Tsukagoshi has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-07-15</td>
<td>Alcoholic consumption increases mammographic density in women aged ≥65 years</td>
<td>Kenji Tsunoda</td>
<td>Kenji Tsunoda has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-07-09</td>
<td>Impact of germline and/or somatic alterations in Lynch syndrome in breast cancer patients</td>
<td>Nobuyuki Tsunoda</td>
<td>Nobuyuki Tsunoda has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-21-14</td>
<td>A randomized phase II trial of trastuzumab + capecitabine versus lapatinib + capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes; WJOG6110B/ELTOP</td>
<td>Kenji Tsunoda</td>
<td>Kenji Tsunoda has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-07-16</td>
<td>The ectopic FOXA1 expression correlates to the luminal breast cancer stem cell</td>
<td>Yukiko Tsushima</td>
<td>Dr. Tsushima has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-06-04</td>
<td>Efficacy of compression therapy using surgical gloves for nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: A phase II multicenter study by the Kamigata breast cancer study group</td>
<td>Shigeru Tsuyuki</td>
<td>Dr. Tsuyuki has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-34</td>
<td>Risk stratification with EndoPredict signature for luminal subtype breast cancers: Re-analyzing microarray experiments with Han Chinese origin</td>
<td>Wih-Hyun Tu</td>
<td>Dr. Tu has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-06-05</td>
<td>An annotated collection of pre- and post-therapy breast cancer patient-derived xenograft models built from fine needle aspiration samples aligned with ongoing clinical trials documenting response to treatment</td>
<td>Yiheng Tu</td>
<td>Yiheng Tu has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-06-06</td>
<td>Comprehensive analysis of the DNA damage repair and maintenance pathways that regulate TNBC sensitivity to replication stress</td>
<td>Yiheng Tu</td>
<td>Yiheng Tu has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
P4-05-02
Conditional inactivation of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) in the mouse mammary epithelium alters mammary gland development
Andrew Turner

- Dr. Turner has no relevant financial relationships to disclose.

P4-05-01
Diet, development and predisposition to breast cancer: The impact of sugar derived metabolites (AGEs) on pubertal mammary gland development
David Turner

- Dr. Turner has no relevant financial relationships to disclose.

P6-07-12
A physical activity and dietary counseling intervention in breast cancer survivors and changes in known and novel prognostic biomarkers
David Turner

- Dr. Turner has no relevant financial relationships to disclose.

P1-02-01
Circulating tumor DNA analysis to predict relapse and overall survival in early breast cancer - Longer follow-up of a proof-of-principle study
Nicholas Turner

- Dr. Turner has no relevant financial relationships to disclose.

P4-22-05
Palbociclib in combination with endocrine therapy in treatment-naive and previously treated elderly women with HR+, HER2- advanced breast cancer: A pooled analysis from randomized phase 2 and 3 studies
Nicholas Turner

- Dr. Turner has disclosed that he receives Advisory Board honoraria from Pfizer. He has also disclosed that he has a contract with Pfizer.

P4-22-06
Treatment postprogression in women with endocrine-resistant HR+/HER2- advanced breast cancer who received palbociclib plus fulvestrant in PALOMA-3
Nicholas Turner

- Dr. Turner has disclosed that he receives Advisory Board honoraria from Pfizer and has contracts with Pfizer.

P4-22-07
Long-term safety of palbociclib in combination with endocrine therapy in treatment-naive and previously treated women with HR+, HER2- advanced breast cancer: A pooled analysis from randomized phase 2 and 3 studies
Nicholas Turner

- Dr. Turner has disclosed that he receives consulting fees from Novartis Oncology, AstraZeneca, Pfizer, Roche Pharmaceuticals, Clovis Oncology, Bionarx Pharmaceuticals, Tesaro Biotech and Astellas. He also disclosed that he does contracted research for CRUK's Clinician Scientist Fellowship Breakthrough Breast Cancer Programme and Centre grant. He has also disclosed that he has contracts with Pfizer.

Speaker, Educational Session
"Mechanisms of resistant to therapy in ER positive cancer"
Nicholas Turner

- Dr. Turner has disclosed that she is employed by and has a contract with Eli Lilly and Company.

P6-11-11
Abemaciclib exposure-response relationship in patients with metastatic breast cancer in MONARCH 1
P. Turner

- P. Turner has disclosed that she is employed by and has a contract with Eli Lilly and Company.

PD8-05
Comparative analysis of the genomic landscape of breast cancers from women of African and European ancestry
Jigyasa Tuteja

- Jigyasa Tuteja has no relevant financial relationships to disclose.

P2-04-07
Immune profiling of post neoadjuvant high metastatic risk (RCB-II/III) residual disease in patients with early triple negative breast cancers
Andrew Tutt

- Dr. Tutt has no relevant financial relationships to disclose.

P1-05-14
Copy number aberration-induced gene breakage analysis identifies recurrent EDF11 in breast cancer
Andrew Tutt

- Dr. Tutt has no relevant financial relationships to disclose.

P2-04-07
Immune profiling of post neoadjuvant high metastatic risk (RCB-II/III) residual disease in patients with early triple negative breast cancers
Andrew Tutt

- Dr. Tutt has no relevant financial relationships to disclose.

P2-04-07
BRCA2 methylation status, silencing and treatment effect in the TEF trial: A randomised phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/17/142)
Andrew Tutt

- Dr. Tutt has no relevant financial relationships to disclose.

S6-01
BRCA1 methylation status, silencing and treatment effect in the TEF trial: A randomised phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/17/142)
Andrew Tutt

- Dr. Tutt has no relevant financial relationships to disclose.
**Speaker, Mini-Symposia 2**

**Clinical implications of DNA repair and genome instability research**
Andrew Tutt

Dr. Tutt has disclosed that he receives salary from The Institute of Cancer Research. He also disclosed that he receives royalty from The Institute of Cancer Research. He disclosed that he receives consulting fees from AstraZeneca, Myriad Genentics, Roche, Vertex, Eisai and Merck. These relationships do not impact his ability to present an unbiased presentation.

**DBCG 07-READ: A randomized phase II trial comparing six cycles of docetaxel and cyclophosphamide (DC) to three cycles of epirubicin and cyclophosphamide followed by three cycles of docetaxel (EC-D) in patients with early breast cancer**
Malgorzata Twena

Dr. Twena has disclosed that she is a consultant for Pfizer and Eisai Europe. She also disclosed that she has contracts with Novartis and Roche and receives travel support from Roche and Novartis.

**Radioactive seed localization versus wire guided localization of nonpalpable invasive and in situ breast cancer: A Danish multicenter randomized controlled trial**
Tove Tvedskov

Mr. Tvedskov has disclosed that he is a speaker for Eisai and has contracts with Nektar and Eisai.

**DBCG 09-READ: A randomized phase III trial comparing six cycles of docetaxel and cyclophosphamide (DC) to three cycles of epirubicin and cyclophosphamide followed by three cycles of docetaxel (EC-D) in patients with early breast cancer**
Malgorzata Twena

Dr. Twena has disclosed that she is a consultant for Pfizer and Eisai Europe. She also disclosed that she has contracts with Novartis and Roche and receives travel support from Roche and Novartis.

**Radioactive seed localization versus wire guided localization of nonpalpable invasive and in situ breast cancer: A Danish multicenter randomized controlled trial**
Tove Tvedskov

Mr. Tvedskov has no relevant financial relationships to disclose.

**Phase II neoadjuvant trial of nanoparticle albumin-bound paclitaxel and trastuzumab in patients with node-negative, Her2 positive breast cancer (OMC-BC04)**
Kazuhisa Uchiyama

Dr. Uchiyama has no relevant financial relationships to disclose.

**Profiling miRNA in high risk post-operative early breast cancer patients to detect possible association with immune system antitumor response**
Marie Tzschaschel

Dr. Tzschaschel has no relevant financial relationships to disclose.

**The DETECT V-study - Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo- or endocrine therapy in patients with HER2-positive and hormone-receptor positive metastatic breast cancer**
Marie Tzschaschel

Dr. Tzschaschel has no relevant financial relationships to disclose.

**A simulation study depicting the inconsistency of adjuvant online compared to genomic testing when determining the benefit of chemotherapy**
Sujatha Udayasankar

Sujatha Udayasankar has no relevant financial relationships to disclose.

**A comparison of oncotype dx recurrence scores in a screen detected vs a symptomatic cohort of patients with breast cancer: A UK experience**
Sujatha Udayasankar

Sujatha Udayasankar has no relevant financial relationships to disclose.

**The long term outcomes of Metastatin RTqPCR intra-operative sentinel node analysis in early breast cancer**
Sujatha Udayasankar

Sujatha Udayasankar has no relevant financial relationships to disclose.

**Eribulin induces vascular remodeling and reoxygenation in advanced breast cancer patients: A comparative study with bevacizumab**
Kyle Udd

Dr. Udd has no relevant financial relationships to disclose.

**Reduced serum B-cell maturation antigen levels predict poor outcome in metastatic breast cancer patients in a phase 3 randomised 2nd-line hormone therapy trial**
Miguel Ueda

Dr. Ueda has no relevant financial relationships to disclose.

**The feasibility of nurse intervention to improve and maintain the BMI of breast cancer survivors over 25 to appropriate levels**
Kanou Uehara

Kanou Uehara has no relevant financial relationships to disclose.
### Real World data and patterns of care of metastatic breast cancer (MBC) in Brazil: First results of LACOG 0312 retrospective study

**Deise Uema**

Deise Uema has no relevant financial relationships to disclose.

### A randomized phase II study of Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer

**Yukari Uemura**

Dr. Uemura has no relevant financial relationships to disclose.

### Adherence to healthy lifestyle behaviors in a predominantly Hispanic population of women undergoing screening mammography

**William Ueng**

Mr. Ueng has no relevant financial relationships to disclose.

### Phase III study of neoadjuvant pembrolizumab combined with chemotherapy and paclitaxel (PaCt) for anthracycline-resistant triple-negative breast cancer (TNBC)

**Nianto Ueno**

Nianto Ueno has no relevant financial relationships to disclose.

### Adherence to healthy lifestyle behaviors in a predominantly Hispanic population of women undergoing screening mammography

**William Ueng**

Mr. Ueng has no relevant financial relationships to disclose.

### Circulating tumor cells in triple-negative breast cancer patients express prostate related genes and show different genetic profiles in US and German patient cohorts

**Nianto Ueno**

Nianto Ueno has no relevant financial relationships to disclose.

### Circulating tumor cells in triple-negative breast cancer patients express prostate related genes and show different genetic profiles in US and German patient cohorts

**Nianto Ueno**

Nianto Ueno has no relevant financial relationships to disclose.

### Landscape of somatic mutations in inflammatory breast cancer whole-genome sequences

**Naoto Ueno**

Dr. Ueno has no relevant financial relationships to disclose.

### Rates of immune infiltration in patients with triple-negative breast cancer by molecular subtype and in patients with inflammatory and non-inflammatory breast cancers

**Naoto Ueno**

Dr. Ueno has no relevant financial relationships to disclose.

### Impact of androgen receptor expression in fluoxymesterone-treated, estrogen receptor-positive metastatic breast cancer exposed to contemporary hormonal therapy

**Naoto Ueno**

Dr. Ueno has no relevant financial relationships to disclose.

### Circulating breast cancer based on circulating protein biomarker profile using the OLINK proteomics multiplexed proximity extension assay

**Naoto Ueno**

Dr. Ueno has no relevant financial relationships to disclose.

### Landscape of somatic mutations in inflammatory breast cancer whole-genome sequences

**Naoto Ueno**

Dr. Ueno has no relevant financial relationships to disclose.

### Impact of enrollment in clinical trials on survival of metastatic breast cancer patients

**Naoto Ueno**

Dr. Ueno has no relevant financial relationships to disclose.

### Immune characterization of inflammatory breast cancer and correlation to pathological complete response

**Naoto Ueno**

Dr. Ueno has no relevant financial relationships to disclose.

### The importance of immune receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive breast cancer

**Hiroaki Ueo**

Dr. Ueo has no relevant financial relationships to disclose.

### The importance of loco-regional tumor burden and surgery on survival in patients with de novo stage IV breast cancer; post-hoc analyses of protocol MF07-01

**Umit Ugurlu**

Dr. Ugurlu has no relevant financial relationships to disclose.

### Sentinel lymph node biopsy by contrast-enhanced ultrasonography with sonoazix in patients with breast cancer - Prospective multicenter study

**Kumiko Uji**

Dr. Uji has no relevant financial relationships to disclose.
Patterns of translational dysregulation in models of estrogen receptor (+) and (-) breast cancer

Determination of the prognostic role of early and end-of-neoadjuvant chemotherapy 18F-FDG PET/CT in patients with locally advanced breast cancer

Neo-adjuvant treatment with trastuzumab and pertuzumab associated with palbociclib and fulvestrant in HER2-positive and ER-positive breast cancer: Effect on Ki67 during and after treatment. A phase II Mikelangelo study

The REQUITE-AB study: Validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality of life in breast cancer patients

Patient derived DCLS mouse intraductal (SMIC) models recapitulate the full spectrum of human patient pathology and histologic features including progression to invasion in a subset of cases.

Prediction of underestimation associated with flat epithelial atypia, atypical ductal hyperplasia and atypical lobular hyperplasia by needle biopsy: Experience in an Argentine breast unit

Geographic variation in the female breast cancer mortality rates across counties in United States

Patient derived DCLS mouse intraductal (SMIC) models recapitulate the full spectrum of human patient pathology and histologic features including progression to invasion in a subset of cases.

The REQUITE-AB study: Validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality of life in breast cancer patients

Proliferation and p21 refine risk of relapse in residual disease after HER2-directed therapies

Neo-adjuvant treatment with trastuzumab and pertuzumab associated with palbociclib and fulvestrant in HER2-positive and ER-positive breast cancer: Effect on Ki67 during and after treatment. A phase II Mikelangelo study

Determining the prognostic role of early and end-of-neoadjuvant chemotherapy 18F-FDG PET/CT in patients with locally advanced breast cancer

Delineation of breast cancer based on circulating protein biomarker profile using the OLINK proteomics multiplexed proximity extension assay

Neo-adjuvant treatment with trastuzumab and pertuzumab associated with palbociclib and fulvestrant in HER2-positive and ER-positive breast cancer: Effect on Ki67 during and after treatment. A phase II Mikelangelo study

Proliferation and p21 refine risk of relapse in residual disease after HER2-directed therapies

Neo-adjuvant treatment with trastuzumab and pertuzumab associated with palbociclib and fulvestrant in HER2-positive and ER-positive breast cancer: Effect on Ki67 during and after treatment. A phase II Mikelangelo study

Geographic variation in the female breast cancer mortality rates across counties in United States
**P1-07-17**
The SCAN-B study: 5-year summary of a large-scale population-based prospective breast cancer translational genomics platform covering a wide geography of Sweden (NCT02306096)

Johan Vallon-Christersson

Dr. Vallon-Christersson has no relevant financial relationships to disclose.

**P4-01-04**
Assessing response in locally advanced breast cancer treated with neoadjuvant chemotherapy: Predictive and prognostic potential of volume-based metabolic variables with 18F-FDG PET/CT

Elies Val-Pérez

Dr. Val-Pérez has no relevant financial relationships to disclose.

**P3-13-26**
Deep-Infrared imaging to identify venous impairment after breast cancer surgery

Jean-Baptiste Valsamis

Jean-Baptiste Valsamis has no relevant financial relationships to disclose.

**P3-13-27**
Early detection of secondary lymphedema after cancer treatments

Jean-Baptiste Valsamis

Jean-Baptiste Valsamis has no relevant financial relationships to disclose.

**P3-13-28**
Lipofilling of the axilla to reduce secondary lymphedema after axillary lymph node dissection

Jean-Baptiste Valsamis

Jean-Baptiste Valsamis has no relevant financial relationships to disclose.

**P2-02-02**
ESR1 mutations in circulating tumor cell versus circulating cell-free DNA of metastatic breast cancer patients before first-line endocrine therapy and at progression

Mai Van

Mai Van has no relevant financial relationships to disclose.

**P2-04-09**
The prognostic and predictive effect of tumor infiltrating lymphocytes is not determined by B-cells or PD-L1 expression in inflammatory breast cancer

Christophe Van Berckelaer

Mr. Van Berckelaer has no relevant financial relationships to disclose.

**S6-02**
The efficacy and safety of the addition of ibandronate to adjuvant hormonal therapy in postmenopausal women with hormone-receptor positive early breast cancer: First results of the TEAM IIB trial (BOOG 2006-04)

A van Bochove

Dr. van Bochove has no relevant financial relationships to disclose.

**P5-14-03**
Adjuvant dose dense doxorubicin-cyclophosphamide (ddAC) or docetaxel-AC (TAC) for high-risk breast cancer: First results of the randomized MATADOR trial (BOOG-2004-04)

Aart van Bochove

Dr. van Bochove has no relevant financial relationships to disclose.

**P1-03-14**
The concept of breast contour preserving surgery as parameter in breast cancer surgery

Mieke van Bommel

Mieke Van Backstal has no relevant financial relationships to disclose.

**P3-13-12**
The concept of breast contour preserving surgery as parameter in breast cancer surgery

Anne-Elisabeth van Bommel

Dr. van Bommel has no relevant financial relationships to disclose.

**P5-14-06**
The effect of adjuvant chemotherapy in a large consecutive series of ER-pos HER-2 negative early breast cancers

Ben van Calster

Ben van Calster has no relevant financial relationships to disclose.

**P6-10-07**
Concordance of local immunohistochemistry with TargetPrint microarray based assessment of ESR, PR and Her2 and BluePrint molecular subtyping in the Symphony Triple A study

Jesper van Crijns

Jesper van Crijns has no relevant financial relationships to disclose.

**P1-03-04**
Concordance of local immunohistochemistry with TargetPrint microarray based assessment of ESR, PR and Her2 and BluePrint molecular subtyping in the Symphony Triple A study

Thuy van Dalen

Dr. van Dalen has no relevant financial relationships to disclose.

**P3-13-12**
The concept of breast contour preserving surgery as parameter in breast cancer surgery

Thuy van Dalen

Dr. van Dalen has no relevant financial relationships to disclose.

**P6-09-03**
Impact of 70-gene signature use on adjuvant chemotherapy decisions in early breast cancer patients: Results of the prospective symphony triple A study

Thuy van Dalen

Dr. van Dalen has no relevant financial relationships to disclose.

**P2-01-26**
Long survival of patients with locally advanced breast cancer on combined neoadjuvant chemotherapy and immune adjuvant: Modern lessons from an old study

Ben van Calster

Ben van Calster has no relevant financial relationships to disclose.

**P3-13-12**
The concept of breast contour preserving surgery as parameter in breast cancer surgery

Wester van Crijns

Wester van Crijns has no relevant financial relationships to disclose.

**P1-03-04**
The concept of breast contour preserving surgery as parameter in breast cancer surgery

Thuy van Dalen

Thuy van Dalen has no relevant financial relationships to disclose.

**P6-09-03**
The concept of breast contour preserving surgery as parameter in breast cancer surgery

Thuy van Dalen

Thuy van Dalen has no relevant financial relationships to disclose.

**P2-01-26**
Validation of a Chinese nomogram with a Dutch breast cancer population: Excellent prediction of the probability of axillary lymph node metastasis

Hester van Crijns

Hester van Crijns has no relevant financial relationships to disclose.

**P4-01-01**
Validation of a Chinese nomogram with a Dutch breast cancer population: Excellent prediction of the probability of axillary lymph node metastasis

Prof. Dr. van Dam has disclosed that he has received consulting fees as member of the scientific advisory board of SurgiVision. Prof. Dr. van Dam and W B Nagengast have received an unrestricted research grant of SurgiVision for the development of molecular fluorescence imaging. He has also disclosed that SurgiVision has supported this study by delivering free-of-charge the intraoperative imaging system and BlackBox imaging system.

**P2-01-02**
Validation of a Chinese nomogram with a Dutch breast cancer population: Excellent prediction of the probability of axillary lymph node metastasis

Thuy van Dalen

Thuy van Dalen has no relevant financial relationships to disclose.

**P2-01-02**
The predictive value of sentinel node biopsy (SNB) in early breast cancer after neo-adjuvant chemotherapy (NACT): A prospective study

Peter van Dalen

Peter van Dalen has no relevant financial relationships to disclose.
BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer

Gert Van den Eynden
Dr. Van den Eynden has no relevant financial relationships to disclose.

Detection of ESR1 mutations in matched primary and metastatic samples from endocrine-resistant lobular breast cancer patients

Gert Van den Eynden
Gert van den Eynden has no relevant financial relationships to disclose.

Risk of primary and contralateral breast cancer in BRCA1/2 mutation carriers previously affected with ovarian cancer

The predictive value of sentinel node biopsy (SNB) in early breast cancer after neo-adjuvant chemotherapy (NACT): A prospective study

Dr. Van den Mooter has no relevant financial relationships to disclose.

Trastuzumab IV versus SC: A time, motion and cost assessment in a lean operating day care oncology unit

Tom Van den Mooter
Dr. Van den Mooter has no relevant financial relationships to disclose.

Estrogen receptor-positive breast cancer in BRCA1 mutation carriers shows a BRCAness profile, suggesting sensitivity to drugs targeting homologous recombination deficiency

Nicole van der Kolk Dr. van der Kolk has no relevant financial relationships to disclose.

Selective elimination of axillary surgery after primary systemic treatment in clinically node-positive breast cancer patients by combining PET/CT and the MARI procedure (marking the axilla with radioactive iodine seeds)

Mariele van der Noordaa
Dr. Van der Noordaa has no relevant financial relationships to disclose.

Preserving fertility in young women undergoing chemotherapy for early breast cancer; the Maastricht experience

Marlene van der Poel
Dr. van der Poel has no relevant financial relationships to disclose.

An optimized workflow to analyze ESR1 mutations in both circulating cell-free and circulating tumor cell DNA by digital PCR

Belinda van der Vlugt - Daane
Ms. Van der Vlugt-Daane has no relevant financial relationships to disclose.

How population-based data complement trial data in the adjuvant endocrine treatment of ER+/HER2+ breast cancers

Elsken van der Wall
Dr. van der Wall has no relevant financial relationships to disclose.

The effects of treatment-induced symptoms, depression and age on sexuality in premenopausal women with early breast cancer receiving adjuvant endocrine therapy

Andre van der Westhuizen
Andre van der Westhuizen has no relevant financial relationships to disclose.

The efficacy and safety of the addition of ibandronate to adjuvant hormonal therapy in postmenopausal women with hormone-receptor positive early breast cancer. First results of the TEAM IIb trial (BOOG 2006-04)

A van der Velden
Dr. van der Velden has no relevant financial relationships to disclose.

Long survival of patients with locally advanced breast cancer on combined neoadjuvant chemotherapy and immune potentiation: Modern lessons from an old study

Elsken van der Wall
Dr. van der Wall has no relevant financial relationships to disclose.
Gene expression differences between ductal carcinoma in situ with and without progression to invasive breast cancer
Carolien van Deurzen
Dr. van Deurzen has no relevant financial relationships to disclose.

Intratumoral heterogeneity of Ki67 expression in early breast cancers exceeds variability between individual tumours
Paul Van Diest
Dr. Van Diest has no relevant financial relationships to disclose.

How population-based data complement trial data in the adjuvant endocrine treatment of ER+/HER2+ breast cancers
Helena van Doorn
Dr. van Doorn has no relevant financial relationships to disclose.

Risk of primary and contralateral breast cancer in BRCA1/2 mutation carriers previously affected with ovarian cancer
Frederike van Dulmhoorn
Dr. Van Dulmhoorn has no relevant financial relationships to disclose.

Breast cancer after Hodgkin lymphoma: Influence of endogenous and exogenous gonadal hormones on the radiation dose-response relationship
Anna van Eggermond
Ms. Van Eggermond has no relevant financial relationships to disclose.

Selective elimination of axillary surgery after primary systemic treatment in clinically node-positive breast cancer patients by combining PET/CT and the MARI procedure (marking the axilla with radioactive iodine seeds)
Paul Van Diest
Dr. Van Diest has no relevant financial relationships to disclose.

Intratumoral heterogeneity of Ki67 expression in early breast cancers exceeds variability between individual tumours
Paul Van Diest
Dr. Van Diest has no relevant financial relationships to disclose.

The predictive value of sentinel node biopsy (SNB) in early breast cancer after neo-adjuvant chemotherapy (NACT): A prospective study
Mireille van Goethem
Dr. Van Goethem has no relevant financial relationships to disclose.

Breast cancer after Hodgkin lymphoma: Influence of endogenous and exogenous gonadal hormones on the radiation dose-response relationship
Helena van Doorn
Dr. van Doorn has no relevant financial relationships to disclose.

First results from the multicenter phase III DATA study comparing 3 versus 6 years of anastrozole after 2-3 years of tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer
Irene Van Hellemond
Ms. Van Hellemond has no relevant financial relationships to disclose.

SYD985, a novel anti-HER2 ADC, shows promising activity in patients with HER2-positive and HER2-negative metastatic breast cancer
Carla van Herpen
Ms. van Herpen has disclosed that he is a principal investigator in the trial.

Evaluation of subclonality in the CTC and DTC compartment of patients with metastatic breast cancer using low pass whole genome and AmpliSeq panel sequencing
Steven Van Laere
Dr. Van Laere has no relevant financial relationships to disclose.

The prognostic and predictive effect of human infiltrating lymphocytes is not determined by B-cells or PD-L1 expression in inflammatory breast cancer
Steven Van Laere
Ms. Colpaert has no relevant financial relationships to disclose.

Stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer
Steven Van Laere
Dr. Van Laere has no relevant financial relationships to disclose.

CDK4 phosphorylation status and corresponding gene expression profile predict sensitivity to Palbociclib
Steven Van Laere
Dr. Van Laere has no relevant financial relationships to disclose.

The efficacy and safety of the addition of Bandonet to adjuvant hormonal therapy in postmenopausal women with hormone-receptor positive early breast cancer. First results of the TEAM IB trial (BOOG 2006-04)
A van Leeuwen-Stok
Dr. van Leeuwen-Stok has no relevant financial relationships to disclose.
Safety assessment of extended adjuvant endocrine therapy with letrozole; results of the randomized phase III IDEAL trial (BOOG 2006-05)
A Elise van Leeuwen-Stok
Dr. van Leeuwen-Stok has no relevant financial relationships to disclose.

Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006-05)
A Elise van Leeuwen-Stok
Dr. van Leeuwen-Stok has no relevant financial relationships to disclose.

Adjuvant dose dense doxorubicin-cyclophosphamide (DDAC) or docetaxel-AC (TAC) for high-risk breast cancer: First results of the randomized MATADOR trial (BOOG 2004-04)
Elise van Leeuwen-Stok
Dr. van Leeuwen-Stok has no relevant financial relationships to disclose.

The association of breast cancer subtype and breast cancer survival with parity and time since last birth
Erik Van Limbergene
Mr. Van Limbergen has no relevant financial relationships to disclose.

Adjuvant dose dense doxorubicin-cyclophosphamide (DDAC) or docetaxel-AC (TAC) for high-risk breast cancer: First results of the randomized MATADOR trial (BOOG 2004-04)
Marissa van Maaren
Ms. Van Maaren has no relevant financial relationships to disclose.

A consecutive series of early breast cancers with a low estrogen receptor expression
Erik Van Limbergene
Mr. Van Limbergen has no relevant financial relationships to disclose.

The association of breast cancer subtype and breast cancer survival with parity and time since last birth
Erik Van Limbergene
Mr. Van Limbergen has no relevant financial relationships to disclose.

Validation of a Dutch breast cancer population: Excellent prediction of the probability of axillary lymph node metastasis
Marissa van Maaren
Ms. Van Maaren has no relevant financial relationships to disclose.

Breast cancer subtype and breast cancer survival with parity and time since last birth
Marissa van Maaren
Ms. Van Maaren has no relevant financial relationships to disclose.

Influence of timing of radiation therapy following breast-conserving surgery on 10-year disease-free survival
Marissa van Maaren
Ms. Van Maaren has no relevant financial relationships to disclose.

Preserving fertility in young women undergoing chemotherapy for early breast cancer: The Maastricht experience
Anne-Marie van Riel
Dr. van Riel has no relevant financial relationships to disclose.

The efficacy and safety of the addition of bortezomib to adjuvant hormonal therapy in postmenopausal women with hormone-receptor positive early breast cancer: First results of the TEAM-IIB trial (BOOG 2006-04)
A van Rossum
Dr. van Rossum has no relevant financial relationships to disclose.

The effect of adjuvant chemotherapy in a large consecutive series of ER- and HER-2 negative early breast cancers
Els Van Nieuwenhuysen
Dr. Van Nieuwenhuysen has no relevant financial relationships to disclose.

Long-term survival in HER2-positive metastatic breast cancer: The first blow is half the battle
Mette van Ramshorst
Dr. van Ramshorst has no relevant financial relationships to disclose.

Can surrogate pathological subtyping replace molecular subtyping? Outcome results from the MINDACT trial
Laura van ’t Veer
Dr. van ’t Veer has disclosed that she receives salary from Agendia. She has also disclosed that she has stock ownership.
DNA repair deficiency biomarkers and MammaPrint high1/(ultra)high2 risk as predictors of veliparib/carboplatin response: Results from the neoadjuvant I-SPY 2 trial for high risk breast cancer
Laura van’t Veer

Dr. van’t Veer has disclosed that she has stock ownership in and receives compensation from Agendia, Inc.

Phase II of POSSEIDON: A phase II / randomized phase II trial of tamoxifen plus taxelob or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment
Harm van Tinteren

Harm van Tinteren has no relevant financial relationships to disclose.

Adjuvant dose dense doxorubicin-cyclophosphamide (DDAC) or docetaxel-AC (TAC) for high risk breast cancer: First results of the randomized MATADOR trial (BOOG-2004-04)
Erik van Werkhoven

Mr. van Werkhoven has no relevant financial relationships to disclose.

Systematic review of clinical trials for monoclonal antibody biosimilars in HER2-positive breast cancer
Alicia Vana

Ms. Vana has disclosed that she receives salary from and has ownership in Pfizer Inc.

Adjuvant dose dense doxorubicin-cyclophosphamide (DDAC) or docetaxel-AC (TAC) for high risk breast cancer: First results of the randomized MATADOR trial (BOOG-2004-04)
Erik van Werkhoven

Mr. van Werkhoven has no relevant financial relationships to disclose.

Lymphatic microsurgical preventive healing approach (LYMPHA) for the primary prevention of lymphedema
John Vanderberge

Mr. Vanderberge has no relevant financial relationships to disclose.

Deep Infrared Imaging to identify venous impairment after breast cancer surgery
Lasbeth Vandenberghen

Lasbeth Vandenberghen has no relevant financial relationships to disclose.

Early detection of secondary lymphedema after cancer treatments
Lasbeth Vandenberghen

Lasbeth Vandenberghen has no relevant financial relationships to disclose.

Lipofilling of the axilla to reduce secondary lymphedema after axillary lymph node dissection
Lasbeth Vandenberghen

Lasbeth Vandenberghen has no relevant financial relationships to disclose.

Weight gain after breast cancer diagnosis and patients' opinion on weight loss strategies
Joel VanderVelde

Ms. VanderVelde has no relevant financial relationships to disclose.

Combined targeted therapies for advanced triple negative breast cancer: A phase II trial of nab-paclitaxel and bevacizumab followed by maintenance targeted therapy with bevacizumab and erlotinib
Carol vanHaelst

Dr. vanHaelst has no relevant financial relationships to disclose.

Value of cancer care for metastatic breast cancer patients and providers
Diana Vania

Ms. Vania has no relevant financial relationships to disclose.

Deep Infrared Imaging to identify venous impairment after breast cancer surgery
Sophie Vankerkhove

Ms. Vankerkhove has no relevant financial relationships to disclose.

Early detection of secondary lymphedema after cancer treatments
Sophie Vankerkhove

Ms. Vankerkhove has no relevant financial relationships to disclose.

Lipofilling of the axilla to reduce secondary lymphedema after axillary lymph node dissection
Sophie Vankerkhove

Ms. Vankerkhove has no relevant financial relationships to disclose.

A multi-institutional, prospective study of incorporating the genomic platform breast cancer index as a tool for decision-making regarding extension of adjuvant endocrine therapy
G J vanLonden

GJ vanLonden has no relevant financial relationships to disclose.

Intra-tumor heterogeneity of the estrogen receptor predicts less benefit from tamoxifen therapy and poor long-term breast cancer patient survival: Retrospective analyses of the STO-3 randomized trial
Laura van’t Veer

Dr. van’t Veer has no relevant financial relationships to disclose.
Quantitative Elisa measurements in TNBC from the I-SPY 2 Trial correlate with HER2-EGFR co-activation and heterodimerization
Laura van't Veer
Dr. van't Veer has no relevant financial relationships to disclose.

P6-11-02
Efficacy of lapatinib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial
Laura van't Veer
Dr. van't Veer has no relevant financial relationships to disclose.

P6-11-04
Identification of breast cancers with an indolent disease course: 70 gene indolent threshold validation in a Swedish randomized trial of tamoxifen vs. no, with 20-year outcomes
Laura van't Veer
Dr. van't Veer has no relevant financial relationships to disclose.

P7-02
Comprehensive genomic characterization of circulating tumor cells (CTCs) in metastatic breast cancer (MBC) sheds light on the biology of blood-borne metastasis
Laura VantVeer
Dr. VantVeer has no relevant financial relationships to disclose.

P1-11-04
Assessing response in locally advanced breast cancer treated with neoadjuvant chemotherapy: Predictive and prognostic potential of volume-based metabolic variables with 18F-FDG PET/CT
Elena Vaquero
Ms. Vaquero has no relevant financial relationships to disclose.

P6-07-03
Pilot study of carboplatin, nab-paclitaxel and pembrolizumab for metastatic triple-negative breast cancer (ongoing clinical trial)
Vinay Varadan
Dr. Varadan has no relevant financial relationships to disclose.

P3-04-16
Association of co-amplicons with immune infiltration in subtypes of HER2-Positive breast cancer
Vinay Varadan
Dr. Varadan has no relevant financial relationships to disclose.

P3-04-17
Breast cancer brain metastases show limited intrinsic subtype switching, yet exhibit acquired ERBB2 amplifications and activating mutations
Vinay Varadan
Dr. Varadan has no relevant financial relationships to disclose.

P4-04-17
Global transcriptional repression by the coactivator SRC-1 mediates disease progression in treatment-resistant breast cancer
Vinay Varadan
Dr. Varadan has no relevant financial relationships to disclose.

P1-10-11
Pheno vs. supine positioning for optimizing radiation heart exposure during left breast radiotherapy: A simple clinical tool for prediction
Zoltán Varga
Dr. Varga has no relevant financial relationships to disclose.

P1-07-08
Mixed ductal-lobular carcinomas of the breast: Abrogated cell adhesion in the clonal evolution from ductal to lobular morphology
Ana Cristina Vargas
Dr. Vargas has no relevant financial relationships to disclose.

P6-07-06
Effect of serum biomarkers (activin A, CAIX, HER2, TIMP-1, and uPA) on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with Xeava: CCTG MA.31
Monali Vasekar
Dr. Vasekar has no relevant financial relationships to disclose.

P1-01-04
Comprehensive genomic characterization of circulating tumor cells (CTCs) in metastatic breast cancer (MBC) sheds light on the biology of blood-borne metastasis
Charles Vakal
Mr. Vakal has disclosed that he is the Executive Vice President of Genomic Research at NanoOncics.
Identifying patient-specific neoepitopes for cell-based and vaccine immunotherapy across breast cancer classifications reveals rarely shared recurrent neoepitopes

Charles Vaske

Dr. Vaske has disclosed that he is an employee of NantOmics.

Feasibility and safety of avoiding granulocyte colony-stimulating factor prophylaxis during the paclitaxel portion of dose dense doxorubicin-cyclophosphamide and paclitaxel regimen

Ines Vaz-Luis

Dr. Vaz-Luis has no relevant financial relationships to disclose.

Treatment of early HER2-positive breast cancer in trastuzumab era: are everyday clinical practice: An overview after 10 years of its approval

Silvia Vazquez

Ms. Vazquez has no relevant financial relationships to disclose.

Influence of timing of radiation therapy following breast-conserving surgery on 10-year disease-free survival

Renske Veenstra

Renske Veenstra has no relevant financial relationships to disclose.

Radioactive seed localization versus wire guided localization of nonpalpable invasive and in situ breast cancer: A Danish multicenter randomized controlled trial

Renee Veenstra

Renske Veenstra has no relevant financial relationships to disclose.

Opto-acoustic imaging of the breast: Diversification and reclassification of suspicious breast masses

Michael Velazquez

Dr. Velazquez has no relevant financial relationships to disclose.

Colcemid (C) combined with paclitaxel (P) as a first-line treatment in patients (pts) with advanced triple-negative breast cancer (CLEI7 study): Updated clinical and biomarker results

Thierry Vela

Thierry Vela has no relevant financial relationships to disclose.

A phase I study of RAD1901, an oral selective estrogen receptor degrader, to determine changes in the 18F-FES uptake and tumor responses in ER-positive, HER2-negative, advanced breast cancer patients

Clasina Venema

Clasina Venema has no relevant financial relationships to disclose.
Risk of metastases after ipsilateral breast tumour recurrence changes overtime according to patient and tumour characteristics: Implications for treatment
Silvia Veneroni Ms. Veneroni has no relevant financial relationships to disclose.

Paolo Verderio Dr. Venet has no relevant financial relationships to disclose.

Elizabeth Ver Hoeve Dr. Verma has no relevant financial relationships to disclose.

Jo-Anne Vergilio Ms. Verheuvel has no relevant financial relationships to disclose.

Cees Verhoef Dr. Verheuvel has no relevant financial relationships to disclose.

Sunil Verma Dr. Verma has disclosed that he is a consultant for Amgen, AstraZeneca, Eli Lilly, Merck, Pfizer, Novartis and Roche. He has also disclosed that he is Medical Director, OncologyEducation.com (not compensated).

Manuela Ventura Ms. Ventrua has disclosed that her Post-doc salary is partially subsidized by Merrimack Pharmaceuticals as an industry-academic scholarship program (MITACS).

Fleur Verhoest Dr. Verheuvel has no relevant financial relationships to disclose.

Jean-Luc Verhaeghe Dr. Verhaeghe has no relevant financial relationships to disclose.

Kaitlyn Vennard Dr. Verma has disclosed that he is a consultant for Amgen, AstraZeneca, Eli Lilly, Merck, Pfizer, Novartis and Roche. He also disclosed he is Medical Director, OncologyEducation.com (not compensated).

Nicole Verheuvel Ms. Verheuvel has no relevant financial relationships to disclose.

Emmanuelle Ventura Dr. Verma has disclosed that he is a consultant for Amgen, AstraZeneca, Eli Lilly, Merck, Pfizer, Novartis and Roche. He also disclosed he is Medical Director, OncologyEducation.com (not compensated).

Sandra Verma Dr. Verma has disclosed that he is a consultant for Amgen, AstraZeneca, Eli Lilly, Merck, Pfizer, Novartis and Roche. He also disclosed he is Medical Director, OncologyEducation.com (not compensated).

Ignaise Vergote Dr. Vergilio has disclosed that he receives salary from and has ownership in Foundation Medicine, Inc.

Sunil Verma Dr. Verma has disclosed that he is a consultant for Amgen, AstraZeneca, Eli Lilly, Merck, Pfizer, Novartis and Roche. He has also disclosed that he is Medical Director, OncologyEducation.com (uncompensated).

Jo-Anne Vergilio Ms. Verheuvel has no relevant financial relationships to disclose.

Manuela Ventura Ms. Ventrua has disclosed that her Post-doc salary is partially subsidized by Merrimack Pharmaceuticals as an industry-academic scholarship program (MITACS).

Jo-Anne Vergilio Ms. Verheuvel has no relevant financial relationships to disclose.

Sunil Verma Dr. Verma has disclosed that he is a consultant for Amgen, AstraZeneca, Eli Lilly, Merck, Pfizer, Novartis and Roche. He has also disclosed that he is the Medical Director of OncologyEducation.com (uncompensated).

Sunil Verma Dr. Verma has disclosed that he is a consultant for Amgen, AstraZeneca, Novartis, Roche, Eli Lilly, Pfizer, Merck and Roche. He has also disclosed that he is the Medical Director of OncologyEducation.com (uncompensated).

Sunil Verma Dr. Verma has disclosed that he is a consultant for Amgen, AstraZeneca, Novartis, Roche, Eli Lilly, Pfizer, Merck and Roche. He has also disclosed that he is the Medical Director of OncologyEducation.com (uncompensated).

Sunil Verma Dr. Verma has disclosed that he is a consultant for Amgen, AstraZeneca, Novartis, Roche, Eli Lilly, Pfizer, Merck and Roche. He has also disclosed that he is the Medical Director of OncologyEducation.com (uncompensated).

Sunil Verma Dr. Verma has disclosed that he is a consultant for Amgen, AstraZeneca, Novartis, Roche, Eli Lilly, Pfizer, Merck and Roche. He has also disclosed that he is the Medical Director of OncologyEducation.com (uncompensated).

Sunil Verma Dr. Verma has disclosed that he is a consultant for Amgen, AstraZeneca, Novartis, Roche, Eli Lilly, Pfizer, Merck and Roche. He has also disclosed that he is the Medical Director of OncologyEducation.com (uncompensated).

Sunil Verma Dr. Verma has disclosed that he is a consultant for Amgen, AstraZeneca, Novartis, Roche, Eli Lilly, Pfizer, Merck and Roche. He has also disclosed that he is the Medical Director of OncologyEducation.com (uncompensated).

Sunil Verma Dr. Verma has disclosed that he is a consultant for Amgen, AstraZeneca, Novartis, Roche, Eli Lilly, Pfizer, Merck and Roche. He has also disclosed that he is the Medical Director of OncologyEducation.com (uncompensated).
First-line ribociclib plus letrozole in patients with de novo HR+, HER2- advanced breast cancer (ABC): A subgroup analysis of the MONALEESA-2 trial

Sunil Verma

Verma has disclosed that he is a consultant for Amgen, AstraZeneca, Novartis, Roche, Eli Lilly, Pfizer and Merck. He also disclosed that he is the medical director of OncologyEducation.com (uncompensated).

Evaluation of HER2 expression and amplification on CTCs using DEPArray analysis and sorting followed by FISH

Peter Vermeulen

Dr. Vermeulen has no relevant financial relationships to disclose.

Primary analysis of BERENICE: A phase II cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with locally advanced, inflammatory, or early-stage, unilateral, and invasive HER2-positive breast cancer

Mark Verrill

Mr. Verrill has disclosed that he is on Advisory boards and consultancy for Roche Products; receives speaker fees and institutional funding from Roche Products and has stock holding of Roche Products.

The predictive value of sentinel node biopsy (SNB) in early breast cancer after neo-adjuvant chemotherapy (NACT): A prospective study

Ingé Verslegers

Dr. Verslegers has no relevant financial relationships to disclose.

TruRisk® based next-generation sequencing in BRCA1/2-negative breast and ovarian cancer families reveal high mutation prevalence in additional risk genes

Beatrix Versmold

Ms. Versmold has no relevant financial relationships to disclose.

Effectiveness of myofascial techniques in addition to a standard physical therapy program as postoperative intervention for upper limb pain in breast cancer patients: A randomized controlled trial

Nele Vervloesem

Nele Vervloesem has no relevant financial relationships to disclose.

Next generation sequencing (NGS) reveals high mutation rates in all established breast cancer subtypes with subtype-specific patterns

P1-05-12

Dr. Vessela has no relevant financial relationships to disclose.

Next generation sequencing (NGS) reveals high mutation rates in all established breast cancer subtypes with subtype-specific patterns

P1-05-12

Dr. Vessela has no relevant financial relationships to disclose.

Prevalence of insulin-like growth factor-1 receptor (IGF1R) expression in circulating tumor cells (CTCs) of patients with early breast cancer and its association with E-cadherin expression and patient survival

Eleni-Kyriaki Vetsika

Eleni-Kyriaki Vetsika has no relevant financial relationships to disclose.

DBCG 07-READ: A randomized phase III trial comparing six cycles of docetaxel and cyclophosphamide (DC) to three cycles of epirubicin and cyclophosphamide followed by three cycles of docetaxel (EC-D) in patients with early breast cancer

Peter Michael Vestlev

Dr. Vestlev has disclosed that he is a consultant at Oncology Venture. He also disclosed that he has contracts with Pierre Fabre, Novartis, Puma, Pfizer and Roche. He disclosed that he has ownership in Novo-Nordisk.

Low expression levels of hormone receptors (ER-α and PGR) in human breast cancer samples is significantly associated with high-grade human cytomegalovirus-IEA

Katja Vetvik

Katja Vetvik has no relevant financial relationships to disclose.

High-grade human cytomegalovirus IEA is associated with expression of COX-2 and 5-LO in human breast cancer samples

Katja Vetvik

Katja Vetvik has no relevant financial relationships to disclose.

Vitamin D level impacts odds of pathologic complete response following neoadjuvant therapy in operable breast cancer

Maria Viala

Dr. Viala has no relevant financial relationships to disclose.

Prognostic impact of the inclusion of uPA/PAI-1 in ER+/Her2- pN0 early breast cancer adjuvant treatments decision-making

Marie Viala

Dr. Viala has no relevant financial relationships to disclose.

Primary analysis of BERENICE: A phase II cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with locally advanced, inflammatory, or early-stage, unilateral, and invasive HER2-positive breast cancer

Giuseppe Viale

Dr. Viale has disclosed that he is on the Advisory Board for Roche.

Neo-adjuvant treatment with trastuzumab and pertuzumab associated with palbociclib and fulvestrant in HER2-positive and ER-positive breast cancer: Effect on Ki67 during and after treatment: A phase I Michelangelo study

Giuseppe Viale

Dr. Viale has disclosed that he is a consultant and speaker for Roche.

Can surrogate pathological subtyping replace molecular subtyping? Outcome results from the MINDACT trial

Giuseppe Viale

Dr. Viale has no relevant financial relationships to disclose.
Clinical implications of somatic mutations in post-menopausal early-stage estrogen receptor (ER)-positive HER2-negative breast cancer (BC): Results from the BIG 1-98 study

Giuseppe Viale
Dr. Viale has no relevant financial relationships to disclose.

Evaluation of growth modulation index as a marker of benefit for consecutive lines of treatment for metastatic breast cancer

Vicente Vicente
Dr. Vicente has no relevant financial relationships to disclose.

PAINTER: Evaluation of eribulin tolerability and correlation between a set of polymorphisms and neuropathy in patients with metastatic breast cancer

Patricia Vici
Ms. Vici has no relevant financial relationships to disclose.

MRI oncoplot/NAAB B-8.5/RTGO I 1304: A phase III superiority clinical trial designed to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (MA) or the addition of INRT to breast RT post breast-conserving surgery (BCS) will reduce invasive cancer events in patients (pts) with positive axillary (Ax) nodes and convert to ypT0 after neoadjuvant chemotherapy (NG)

Frank Vicini
Dr. Vicini has no relevant financial relationships to disclose.

A randomized trial evaluating biopsychology spectroscopy vs. tongue measurement in the prevention of lymphedema following breast cancer treatment

Frank Vicini
Dr. Vicini has disclosed that he is on the Advisory Board/CMO for Impedimed.

9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian short-HER trial

Roberto Vicini
Mr. Vicini has no relevant financial relationships to disclose.

Comparison of the Sport breast cancer-stratifier mRNA assay with central ER, PR, HER2, and Ki67 immunohistochemistry (IHC) for rapid biomarker analysis in developing countries

Chu Victor
Mr. Chu has disclosed that he is an employee and a stockholder of Cepheid.

A randomized trial evaluating bioimpedance spectroscopy vs. tape measurement in the prevention of lymphedema following breast cancer treatment

Gregory Vidal
Dr. Vidal has disclosed that he is a consultant and speaker for Lilly.

Use of an optometry library based next generation omics platform for the development of a novel trastuzumab predictive assay

Gregory Vidal
Dr. Vidal has no relevant financial relationships to disclose.

VENTANA (SOLT-I-1002): Oral metronomic vinorelbine combined with endocrine therapy in luminal/HER2-negative early breast cancer: A window of opportunity trial

Maria Vidal
Dr. Vidal has no relevant financial relationships to disclose.

Randomized phase II study evaluating different schedules of naxoloxilax in metastatic breast cancer (MBC): Results of the SNAP study

Maria Vidal
Ms. Vidal has no relevant financial relationships to disclose.

PAM50 intrinsic subtype as a predictor of pathological complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2-positive breast cancer: First results of the PAMCLA clinical trial

José Vidal-Martínez
Mr. Vidal-Martínez has no relevant financial relationships to disclose.

IMENEO: International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEOadjuvant chemotherapy

José Vidal-Martínez
Mr. Vidal-Martínez has no relevant financial relationships to disclose.

"Can breast cancer outcomes be improved in countries that lack national healthcare insurance?"

Tatiana Vidaurre Rojas
Dr. Vidaurre Rojas has no relevant financial relationships with commercial interests to disclose.

Primary analysis of BERENICE: A phase II cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with locally advanced, inflammatory, or early-stage, unilateral, and invasive HER2-positive breast cancer.

Claudia Viatri
Ms. Viatri has disclosed she receives fee for speakers' bureaus from Roche and contracted research from Roche.

Molecular evaluation of Peruvian patients with hereditary breast cancer reveals a novel germline mutation in BRCA1

Carla Vigil
Ms. Vigil has no relevant financial relationships to disclose.

Molecular evaluation of Peruvian patients with hereditary breast cancer reveals a novel germline mutation in BRCA1

Patrice Vickers
Ms. Vickers has no relevant financial relationships to disclose.

P5-09-08
Immunomodulation effects of metronomic oral Vinorelbine (mVRL), with or without capecitabine (CAPE), on Treg levels in advanced breast cancer (ABC) patients (pts). Preliminary results of the VICTOR-5 study

Luigi Vigorè

Dr. Vigorè has no relevant financial relationships to disclose.

Serum thymidine kinase 1 activity as a pharmacodynamics marker of cyclin-dependent kinase 4/6 inhibition in patients with early stage breast cancer receiving neoadjuvant palbociclib

Gian Vik

Gian Vik has no relevant financial relationships to disclose.

Evaluation of a mRCA score based on biological factors to enhance prognostic stratification by the American Joint Committee on Cancer (AJCC) Staging System

Jose Vik

Dr. Vik has no relevant financial relationships to disclose.

Preliminary results of a Bayesian decision model for the treatment of ductal carcinoma in situ (DCIS) of the breast

Jose Vik

Mr. Vik has no relevant financial relationships to disclose.

Efficacy and gene expression results from SOLTI1007 NEOERIBULIN phase II clinical trial in HER2-negative early breast cancer

Patricia Villagrasa

Dr. Villagrasa has no relevant financial relationships to disclose.

Experience in the ABC Medical Center of Mexico City 2010-2015 using scalp-cooling system (DigniCap) for prevention of alopecia induced by chemotherapy

Alberto Villalobos

Dr. Villalobos has no relevant financial relationships to disclose.

CCND1 amplification in early breast cancer patients: Correlation with subtypes and prognosis

Jose Villalobos

Ms. Villalobos has no relevant financial relationships to disclose.

VICTORIANE: A randomized phase 3 study assessing the addition of oral vinorelbine to aromatase inhibitors for the treatment of patients with metastatic breast cancer

Cristian Villanueva

Dr. Villanueva has disclosed that he is a consultant.

Stomatitis in patients treated with first-line everolimus (EVE) plus letrozole (LET): Results from BOLERO-4 trial

Cristian Villanueva

Cristian Villanueva has no relevant financial relationships to disclose.

First-line ribociclib plus letrozole in patients with de novo HR+, HER2- advanced breast cancer (ABC): A subgroup analysis of the MONALEESA-2 trial

Cristian Villanueva

Cristian Villanueva has no relevant financial relationships to disclose.

Treatment of early HER2-positive breast cancer in tradusumadexa in everyday clinical practice: An overview after 10 years of its approval

Rafael Villanueva

Mr. Villanueva has no relevant financial relationships to disclose.

Young women with breast cancer in Mexico: A report of the pilot phase of the "Mujer Joven y Fuerte" prospective cohort study

Sylvia Villareal-Garza

Ms. Villareal-Garza has no relevant financial relationships to disclose.

Predictive factors of pathologic complete response to neoadjuvant chemotherapy in patients with luminal HER2-1 local advanced breast cancer using the OMSI microarray

Antonio Villa-Romero

Dr. Villa-Romero has no relevant financial relationships to disclose.

Evaluation of tumor infiltrating lymphocytes (TILs) and their association with homologous recombination deficiency and BRCA1/2 mutation status in triple-negative breast cancer (TNBC): A pooled analysis

Shaveta Vinayak

Dr. Vinayak has disclosed that she receives travel and accommodation expenses from Incyte.

Identification of SARBR1905, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong antitumor activity in wild-type and mutant ER+ breast cancer models

Sylvia Vincent

Ms. Vincent has no relevant financial relationships to disclose.
A comprehensive molecular analysis of medullary breast carcinoma: A model of immunomodulatory triple-negative breast cancer subtype
Anne Vincent-Salomon
Dr. Vincent-Salomon has no relevant financial relationships to disclose.

Comparative mutational landscapes of primary breast cancer and first metastatic relapse: Results from the ESOPE study
Anne Vincent-Salomon
Dr. Vincent-Salomon has no relevant financial relationships to disclose.

Preoperative assessment of breast cancer survival using ultrasound diameter and shear wave elastography
Sarah Vinnicombe
Ms. Vinnicombe has no relevant financial relationships to disclose.

Which measure of the interim changes in breast tumoral volume at breast MRI in response to neoadjuvant chemotherapy best predicts final pathological response?
Sarah Vinnicombe
Dr. Vinnicombe has no relevant financial relationships to disclose.

Inhibition of cancer-associated fibroblast function by farnesoid X receptor activation: Experimental basis for a novel therapeutic strategy in breast cancer
Valentina Vircillo
Ms. Vircillo has no relevant financial relationships to disclose.

VENTANA (SOLTI-1501): Oral metronomic vinorelbine combined with endocrine therapy in luminal/HER2-negative early breast cancer: A window of opportunity trial
Juan Virizuela
Dr. Virizuela has no relevant financial relationships to disclose.

Neoadjuvant non-pegylated liposomal docetaxel, trastuzumab and pertuzumab in patients with HER2+ breast cancer - Final results of the SOLTI OPTI-HER HEART study
Juan Antonio Virizuela
Dr. Virizuela has no relevant financial relationships to disclose.

An international multicenter study to evaluate reproducibility of automated scoring methods for assessment of Ki67 in breast cancer
Shakeel Virk
Shakeel Virk has no relevant financial relationships to disclose.

Predictive effect of cytotoxic tumor infiltrating lymphocytes in HER2-positive metastatic breast cancer: A novel study with CTCG MA.31
Shakeel Virk
Shakeel Virk has no relevant financial relationships to disclose.

Effect of serum biomarkers (actin A, CAI, HER2, TIMP-1, and uPA) on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with docetaxel: CTCG MA.31
Shakeel Virk
Shakeel Virk has no relevant financial relationships to disclose.

Maintenance of genomic integrity in dormant circulating tumor cells
Monika Vishnoi
Dr. Vishnoi has no relevant financial relationships to disclose.

The evolution of breast cancer circulating tumor cells mediating brain metastasis
Monika Vishnoi
Dr. Vishnoi has no relevant financial relationships to disclose.

RANK ligand as a target for breast cancer prevention in BRCA1 mutation carriers
Jane Viswanadhapalli
Ms. Viswanadhapalli has disclosed that she is a recipient of a Amgen Preclinical Research Program Grant.

Cross-talk between RNA methyltransferase and demethylase regulates breast cancer growth and progression
Suryavathi Viswanadhapalli
Dr. Viswanadhapalli has no relevant financial relationships to disclose.

An optimized workflow to analyze ESR1 mutations in both circulating cell-free and circulating tumor cell DNA by digital PCR
Silvia Vitale
Ms. Vitale has no relevant financial relationships to disclose.

Two-year follow-up results of a multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer
Courtney Vito
Dr. Vito has no relevant financial relationships to disclose.
Phase II trial of pertuzumab, trastuzumab, and nab-paclitaxel in patients (pts) with HER2 overexpressing (HER2+) locally advanced or inflammatory breast cancer (LABC) or untreated stage IV metastatic breast cancer (MBC)

Courtney Vito

Dr. Vito has no relevant financial relationships to disclose.

A novel BRD4 inhibitor enhances endocrine therapy efficacy and circumvents endocrine-resistance in estrogen receptor-positive breast cancer models

Phil Vitorino

Mr. Vitorino has disclosed that he receives salary from Gilead Sciences.

Multi-omics and immune-omics profiling reveal distinct molecular signatures of young Asian breast cancers

Pamela Viscarza

Ms. Viscarza has no relevant financial relationships to disclose.

The efficacy and safety of the addition of B mandolate to adjuvant hormonal therapy in postmenopausal women with hormone-receptor positive early breast cancer. First results of the TEAM IIB trial (BOOG 2006-04)

S Vliek

Dr. Vliek has no relevant financial relationships to disclose.

A multi-OMIC analysis to explore the impact of “actionable” genomic alterations on protein pathway activation: Clinical implication for precision medicine in metastatic breast cancer

Linda Vocica

Ms. Vocica has no relevant financial relationships to disclose.

Breast cancer and its metastases

Anika von Heesen

Dr. von Heesen has no relevant financial relationships to disclose.

Comparison of axillary sentinel lymph node biopsy versus no axillary surgery in patients with early-stage invasive breast cancer and breast-conserving surgery: A randomized prospective surgical trial. The Intergroup-Sentinel-Mamma (INSEMA) trial

Gunter von Minckwitz

Dr. von Minckwitz has no relevant financial relationships to disclose.

Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSinto in triple-negative early breast cancer

Gunter von Minckwitz

Dr. von Minckwitz has no relevant financial relationships to disclose.
Outcome after neoadjuvant chemotherapy in progesterone receptor negative breast cancer patients - A pooled analysis of individual patient data from ten prospectively randomised controlled neoadjuvant trials

Gunter von Minckwitz

Mr. Von Minckwitz has no relevant financial relationships to disclose.

Efficacy and safety of darbepoetin alfa or epoetin beta in 2994 high risk early breast cancer patients participating in the German adjuvant intergroup node-positive study (GAIN)

Gunter von Minckwitz

Mr. von Minckwitz has disclosed that he receives research funding from Amgen and Roche.

Development and validation of a nomogram predicting pathological axillary status (ypN0 vs. ypN+) in a subgroup of patients converting from cN+ to ycN0 through neoadjuvant therapy (NAT) - A transSENTINA substudy

Gunter von Minckwitz

Mr. von Minckwitz has no relevant financial relationships to disclose.

Dual HER2 blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: A subanalysis of data from the randomised phase III GeparSepto trial

Gunter von Minckwitz

Mr. von Minckwitz has disclosed that he receives research funding from Celgene and Roche.

Peripheral sensory neuropathy occurrence and resolution: Results from the neoadjuvant randomised GeparSepto study (GBG 69)

Gunter von Minckwitz

Mr. von Minckwitz has disclosed that he receives research funding from Celgene.

Evaluation of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarker in different subtypes of breast cancer treated with neoadjuvant therapy - A metaanalysis of 1771 patients

Gunter von Minckwitz

Mr. von Minckwitz has no relevant financial relationships to disclose.

Randomised phase II study evaluating different schedules of nab-paclitaxel in metastatic breast cancer (MBC): Results of the SNAP study

Roger von Moos

Mr. von Moos has no relevant financial relationships to disclose.

Expression of EP3-receptor expression is a prognostic marker for overall survival and progression-free survival in sporadic breast cancer

Viktoria von Schönfeldt

Ms. Von Schönfeldt has no relevant financial relationships to disclose.

What to do with non-visualized sentinel nodes; to dissect or not to dissect the axilla?

Adri Voogd

Ms. Voogd has no relevant financial relationships to disclose.

Use of axillary ultrasound impacts outcome of node positive breast cancer patients

Adri Voogd

Dr. Voogd has no relevant financial relationships to disclose.

Association of pre-chemotherapy peripheral blood pro-inflammatory (IL-6, CRP) and coagulation (D-dimer) markers with chemotherapy toxicity in women with breast cancer

Nilesh Vora

Dr. Vora has no relevant financial relationships to disclose.

EVIDOS trial: Phase II trial of the nelipepimut-S peptide vaccine in women with DCIS of the breast

Lana Vormik

Ms. Vormik has no relevant financial relationships to disclose.

Evaluating cosmetic outcome following breast conserving surgery in trials: panel versus objective evaluation and the role of patient reported outcome measures (PROMs)

Elke Voss

Ms. Voss has no relevant financial relationships to disclose.

Capable in combination with luminal andbasal subtype patients with HER2-negative metastatic breast cancer: Final PFS results of a phase II trial (AGMAT MBC-6)

Zaneta Voskova

Ms. Voskova has no relevant financial relationships to disclose.

Immunotherapy alkylation chemotherapy in patients with oligometastatic breast cancer harboring homologous recombination deficiency: The DUGO study

Marie-Jeanne Vranken Peeters

Dr. Vranken Peeters has no relevant financial relationships to disclose.

Selective elimination of axillary surgery after primary systemic treatment in clinically node positive breast cancer patients by combining PET/CT and the NARI procedure (marking the axilla with radioactive iodine seeds)

Marie-Jeanne Vranken Peeters

Dr. Vranken Peeters has no relevant financial relationships to disclose.

The concept of breast contour preserving surgery as parameter in breast cancer surgery

Marie-Jeanne Vranken Peeters

Dr. Vranken Peeters has no relevant financial relationships to disclose.

Variation in the use of neoadjuvant chemotherapy for breast cancer in the Netherlands: A lack of consensus

Marie-Jeanne Vranken Peeters

Ms. Vranken Peeters has no relevant financial relationships to disclose.

Characterisation of metastatic breast carcinomas for biomarkers of therapeutic options

Semir Vrancic

Dr. Vrancic has no relevant financial relationships to disclose.

Long-term follow-up of early stage breast cancer patients with results of MammaPrint®, Oncotype DX® and MammoStrat® risk classification assay

Vesna Vrcelj

Dr. Vrcelj has no relevant financial relationships to disclose.
Specific detection of anti-Her2 PEGylated PrecisionMRX® nanoparticles measured using superparamagnetic relaxometry
Erika Vreeland
Ms. Vreeland has no relevant financial relationships to disclose.

Determining the optimal vaccination strategy using a combination of the folate binding protein (FBP) peptide vaccine (E39+GM-CSF) and an attenuated version (E39) to maximize the immunologic response in breast cancer patients
Timothy Vreeland
Dr. Vreeland has no relevant financial relationships to disclose.

Preserving fertility in young women undergoing chemotherapy for early breast cancer; the Maastricht experience
Birgit Vriens
Dr. Vriens has no relevant financial relationships to disclose.

Preserving fertility in young women undergoing chemotherapy for early breast cancer; the Maastricht experience
Ingeborg Vriens
Dr. Vriens has no relevant financial relationships to disclose.

Looking beyond the margins: Economic costs and complications associated with repeated breast-conserving surgeries
Lan Vu
Lan Vu has disclosed that he receives salary from Health Care Services Corporation.

Adjuvant and neoadjuvant chemotherapy for elderly patients (≥70 years) with early high-risk breast cancer: A retrospective analysis of 316 patients
Perrine Vuagnat
Dr. Vuagnat has no relevant financial relationships to disclose.

Neoadjuvant weekly carboplatin and paclitaxel followed by dose dense epirubicin and cyclophosphamide in triple negative breast cancer patients: A single arm phase II study from the Belgian Society of Medical Oncology
Peter Vuylsteke
Dr. Vuylsteke has no relevant financial relationships to disclose.

CCND1 amplification in early breast cancer patients: Correlation with subtypes and prognosis
David Wachter
Mr. Wachter has no relevant financial relationships to disclose.

Mixed ductal-lobular carcinomas of the breast: Abrogated cell adhesion in the clonal evolution from ductal to lobular morphology
Nic Wadell
Dr. Wadell has no relevant financial relationships to disclose.

Incidence and severity of diarrhea with nanoparticles in patients (pts) with HER2+ early-stage breast cancer (EBC): Interim analysis from the multicenter, open-label, phase II clinical trial
Mark Wade
Dr. Wade has no relevant financial relationships to disclose.

Randomized, placebo-controlled trial of duloxetine for aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS) in early stage breast cancer (SWOG 1202)
James Wade
Mr. Wade has no relevant financial relationships to disclose.

PowerPIN trial: Changes in tumor proliferation index and quality of life with 7 days of preoperative tamoxifen
Mark Wade
Dr. Wade has no relevant financial relationships to disclose.

A randomized, double-blind, placebo-controlled clinical trial to evaluate extended adjuvant endocrine therapy (5 years of letrozole) in postmenopausal women with hormone-receptor positive breast cancer who have completed previous adjuvant endocrine therapy: Initial results of NRG oncology/NSABP B-42
James Wade, III
Mr. Wade has no relevant financial relationships to disclose.

DCIS and the risk of breast cancer death - A case control study
Charlotta Wadsten
Dr. Wadsten has no relevant financial relationships to disclose.

A large-scale functional screen to identify resistance mechanisms to selective estrogen receptor degraders fulvestrant and GDC-810 in ER+ breast cancer
Nikhil Wagle
Dr. Wagle has disclosed that he has a consulting or advisory role in Novartis and receives research funding from Novartis. He also disclosed that he has stock and other ownership interests in Foundation Medicine.

The role of HER2 mutations in resistance to endocrine therapy in ER+ breast cancer
Nikhil Wagle
Dr. Wagle has disclosed that he has a consulting or advisory role in Novartis and receives research funding from Novartis. He also disclosed that he has stock and other ownership interests in Foundation Medicine.

Whole exome and transcriptome sequencing of resistant ER+ metastatic breast cancer
Nikhil Wagle
Dr. Wagle has disclosed that he is a consultant for Novartis, research funding from Novartis and has ownership in Foundation Medicine.
"The genomics of metastatic breast cancer: what are we learning?"

Speaker: Nikhil Wagle

Dr. Wagle has disclosed that he receives consulting fees from Novartis. He also disclosed that he does contracted research for Novartis. He has ownership interest in Foundation Medicine. These relationships do not impact his ability to present an unbiased presentation.

Male breast cancer— infusing a little blue into the sea of pink

Speaker: Herbert Wagner

Mr. Wagner has no relevant financial relationships to disclose.

Femara plus ribociclib or placebo as neo-adjuvant endocrine therapy for women with ER+, HER2-negative early breast cancer (The Fellows trial)

Speaker: Jamie Wagner

Dr. Wagner has no relevant financial relationships to disclose.

Prognostic and predictive relevance of cell cycle progression (CCCP) score in ductal carcinoma in situ: Results from the UK/AUS DCIS trial

Speaker: Susanne Wagner

Ms. Wagner has disclosed that she receives salary and has ownership in Myriad.

OT3-02-06

Identification of a cancer stem cell specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer

Speaker: Claes Wahlestedt

Dr. Wahlestedt has no relevant financial relationships to disclose.

Phase II clinical trial of neratinib in patients 60 and older with HER2 over-expressed or mutated breast cancer: Trial design considerations for older adults

Speaker: James Waisman

Dr. Waisman has no relevant financial relationships to disclose.

Identification of a cancer stem cell specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer

Speaker: Anke Waha

Anke Waha has no relevant financial relationships to disclose.

Phase II trial of pertuzumab, trastuzumab, and nab-paclitaxel in patients (pts) with HER2 overexpressing (HER2+) locally advanced or inflammatory breast cancer (LABC) or untreated stage IV metastatic breast cancer (MBC)

Speaker: James Waisman

Dr. Waisman has no relevant financial relationships to disclose.

Association of pre-chemotherapy peripheral blood pro-inflammatory (IL-6, CRP) and coagulation (D-dimer) markers with chemotherapy toxicity in women with breast cancer

Speaker: James Waisman

Dr. Waisman has no relevant financial relationships to disclose.

The share thoughts on breast cancer study: A Greater Plains collaborative cohort characterization project

Speaker: Lemuel Waitman

Lemuel Waitman has no relevant financial relationships to disclose.

Metabolomic profiling of breast cancer and adjacent tissue

Speaker: Angela Waitzberg

Ms. Waitzberg has no relevant financial relationships to disclose.

Metabolomic profiling of breast cancer and adjacent tissue

Speaker: James Waisman

Dr. Waisman has no relevant financial relationships to disclose.

Whole exome and transcriptome sequencing of resistant ER+ metastatic breast cancer

Speaker: Aida Waks

Ms. Waks has no relevant financial relationships to disclose.

Primary analysis of BERENICE: A phase II cardiac safety study of pertuzumab, trastuzumab, and nedoxabtindifiurine-based chemotherapy in patients with locally advanced, inflammatory, or early-stage, unilateral, and invasive HER2-positive breast cancer

Speaker: Maeve Waldron-Lynch

Maeve Waldron-Lynch has disclosed that she is an employee of F Hoffmann-La-Roche.

Primary analysis of BERENICE: A phase II cardiac safety study of pertuzumab, trastuzumab, and nedoxabtindifiurine-based chemotherapy in patients with locally advanced, inflammatory, or early-stage, unilateral, and invasive HER2-positive breast cancer

Speaker: Maeve Waldron-Lynch

Maeve Waldron-Lynch has disclosed that she is a salaried Roche employee and a Roche shareholder.

Whole exome and transcriptome sequencing of resistant ER+ metastatic breast cancer

Speaker: Maeve Waldron-Lynch

Maeve Waldron-Lynch has disclosed that she is an employee of F Hoffmann-La-Roche.

Pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: Efficacy analysis of a phase II cardiac safety study (TRYPHAENA)

Speaker: Maeve Waldron-Lynch

Maeve Waldron-Lynch has disclosed that she is an employee of F Hoffmann-La-Roche.
Phase I dose-escalation trial of ONT-380 in combination with
trastuzumab in patients (pts) with HER2+ breast cancer brain
metastases  Luke Walker  Mr. Walker has disclosed that he receives salary for clinical research at
Oncothyreon Inc.

Efficacy results of a phase 1b study of ONT-380, an oral HER2-
specific inhibitor, in combination with capcitabine (C) and
trastuzumab (T) in HER2+ metastatic breast cancer (MBC),
including patients (pts) with brain metastases (mets)  Luke Walker  Mr. Walker has disclosed that he receives salary from Cascadian
Therapeutics, Inc.

Tropomysin-related kinase A is overexpressed in HER2-positive
breast cancer.  Marjorie Walker  Ms. Walker has no relevant financial relationships to disclose.

A multiplexed immunofluorescence identifies phenotypic
heterogeneity of circulating tumor cells in breast cancer
that masquerade breast reconstruction in elderly women:
Complications and the impact of individual surgeons  Anne Wallace  Dr. Wallace has no relevant financial relationships to disclose.

Trajectory of patient (Pt) reported physical function (PF) during
and after neoadjuvant chemotherapy in the I-SPY 2 trial  Anne Wallace  Dr. Wallace has no relevant financial relationships to disclose.

Efficacy of hip60 inhibitor ganetespib plus standard
neoadjuvant therapy in high-risk breast cancer: Results from the
-I-SPY 2 trial  Anne Wallace  Dr. Wallace has no relevant financial relationships to disclose.

The evaluation of ganetespib/temsirolimus plus standard
neoadjuvant therapy in high-risk breast cancer: Results from the
-I-SPY 2 trial  Anne Wallace  Dr. Wallace has no relevant financial relationships to disclose.

Intraoperative tumor detection using a ratiometric activatable
fluorescent peptide: A first-in-human phase I study allows
tumors to be visualized in the operating room  Anne Wallace  Dr. Wallace has no relevant financial relationships to disclose.

Oncotype DX® recurrence score in bilateral synchronous
primary/invasive breast cancer  Jonathan Wallach  Dr. Wallach has no relevant financial relationships to disclose.

BRE12-158: A phase II randomized controlled trial of
genomically directed therapy after preoperative chemotherapy
in patients with triple negative breast cancer (TNBC)  Radhika Walling  Dr. Walling has no relevant financial relationships to disclose.

The UK COSI trial: Randomizing patients with low or low
intermediate grade ductal carcinoma in situ (DCIS) to surgery or
active monitoring  Matthew Wallis  Mr. Wallis has no relevant financial relationships to disclose.

Prognostic and predictive marker in the tumor
microenvironment of breast cancers  U Margaretha Walton  Dr. Walton has no relevant financial relationships to disclose.

Reliability and acceptance of e-based survey instruments for
measuring patient reported outcomes (PRO) in breast cancer
patients: First results of the ePROCOM study  Diethelm Wallwiener  Prof. Wallwiener has no relevant financial relationships to disclose.

Reliability and acceptance of e-based survey instruments for
measuring patient reported outcomes (PRO) in breast cancer
patients: First results of the ePROCOM study  Markus Wallwiener  Prof. Wallwiener has no relevant financial relationships to disclose.

Tumor and serum DNA methylation in women receiving
neoadjuvant chemotherapy (PST) with or without vorinostat in
primary operable HER2-negative breast cancer in TBCRC008  Bridget Walsh  Ms. Walsh has no relevant financial relationships to disclose.

The impact of the 21 gene recurrence score (RS) on
chemotherapy prescribing in estrogen receptor (ER) positive,
lymph node positive early stage breast cancer in Ireland  Janeice Walsh  Ms. Walsh has no relevant financial relationships to disclose.
Bromodomain inhibitors represent a rational therapeutic option for the treatment of invasive lobular carcinoma

The impact of the introduction of breast cancer screening on a symptomatic breast cancer unit

Randomized phase II study evaluating different schedules of nab-paclitaxel in metastatic breast cancer (MBC): Results of the SNAP study

Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multi-center trial

Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer

Precision medicine: delay of treatment among a racially diverse, urban breast cancer population

Cyclin D1 binding to chromatin and the induction of chromosomal instability requires the fuzzy domain

Long-term effects of weight loss on breast cancer biomarkers in postmenopausal women

Prognostic values of circulating tumor cells (CTC) and cancer associated macrophage-like cells (CAML) enumerations in metastatic breast cancer: The role for innate immunity in the metastatic process

Cyclin D1 binding to chromatin and the induction of chromosomal instability requires the fuzzy domain

Comparison of survival and clinicopathological features between patients with breast cancer and HIV infection versus breast cancer without HIV infection

The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer

Evaluation of the effects of palbociclib plus letrozole on QTc interval

Accurate and reliable automated breast density measurements with no ionizing radiation using fat-water decomposition MRI

Association of hedgehog signaling pathway with luminal B subtype of breast cancer affected patients of Pakistan

An orally bioavailable selective estrogen receptor downregulator

Metabolic obesity, adipose inflammation and aromatase: Potential drivers of breast cancer risk in women with normal body mass index

Non-invasive endoscopic axillary lymph node dissection in breast conservative surgery

Proliferative effects in T-cells after TRAIL-induced apoptosis in TRAIL-resistant triple negative breast cancer cells

Reduced serum R-cell maturation antigen levels predict poor outcome in metastatic breast cancer patients in a phase 1 randomized 2nd-line hormone therapy trial

MIR-146a functions as suppressive non-coding gene via indirect regulation of Let-7 to promote asymmetric division and inhibit the self-renewal ability of breast cancer stem-like cells
Use of an aptamer library based next generation omics platform for the development of a novel trastuzumab predictive assay
Jie Wang
Dr. Wang has disclosed that he receives salary from and has ownership from Chris Life Sciences.

Determining the breast tumor margin through genomics of the cancer-stromal interaction
Jinhua Wang
Dr. Wang has no relevant financial relationships to disclose.

Determining the breast tumor margin through genomics of the cancer-stromal interaction
Jinhua Wang
Dr. Wang has no relevant financial relationships to disclose.

Genomic analysis of molecular discordance of paired primary and recurrent triple negative breast cancer
Jinhui Wang
Dr. Wang has no relevant financial relationships to disclose.

The 3'UTR signature defines a highly metastatic subgroup of triple-negative breast cancer
Lei Wang
Dr. Wang has no relevant financial relationships to disclose.

Determining the breast tumor margin through genomics of the cancer-stromal interaction
Jinhua Wang
Dr. Wang has no relevant financial relationships to disclose.

Impact of TP53 functional mutation type on clinical outcomes of advanced breast cancer patients
Lei Wang
Dr. Wang has no relevant financial relationships to disclose.

The 3'UTR signature defines a highly metastatic subgroup of triple-negative breast cancer
Lei Wang
Dr. Wang has no relevant financial relationships to disclose.

Impact of TP53 functional mutation type on clinical outcomes of advanced breast cancer patients
Lei Wang
Dr. Wang has no relevant financial relationships to disclose.

Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer
Peng Wang
Dr. Wang has no relevant financial relationships to disclose.

The 3'UTR signature defines a highly metastatic subgroup of triple-negative breast cancer
Peng Wang
Dr. Wang has no relevant financial relationships to disclose.

Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer
Peng Wang
Dr. Wang has no relevant financial relationships to disclose.

Predictive and prognostic value of 61-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin
Ruo-Xi Wang
Dr. Wang has no relevant financial relationships to disclose.

Breast cancer risk prediction using a polygenic risk score in women of African ancestry: Findings from GWAS in breast cancer in the African diaspora
Ruo-Xi Wang
Dr. Wang has no relevant financial relationships to disclose.

Predictive and prognostic value of 61-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin
Ruo-Xi Wang
Dr. Wang has no relevant financial relationships to disclose.

Breast cancer risk prediction using a polygenic risk score in women of African ancestry: Findings from GWAS in breast cancer in the African diaspora
Ruo-Xi Wang
Dr. Wang has no relevant financial relationships to disclose.

Scalp cooling alopecia prevention trial (SCALP) for patients with early stage breast cancer
Tao Wang
Tao Wang has no relevant financial relationships to disclose.

Cardiac safety of dual anti-HER2 therapy in the neoadjuvant setting for treatment of HER2-positive breast cancer
Tao Wang
Dr. Wang has no relevant financial relationships to disclose.

Cardiac safety of dual anti-HER2 therapy in the neoadjuvant setting for treatment of HER2-positive breast cancer
Tao Wang
Dr. Wang has no relevant financial relationships to disclose.

CTEA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer
Tao Wang
Dr. Wang has no relevant financial relationships to disclose.

CTEA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer
Tao Wang
Dr. Wang has no relevant financial relationships to disclose.

A role of extracellular miRNA in breast cancer metastasis
Shihen Emily Wang
Dr. Wang has no relevant financial relationships with commercial interests to disclose.

“A role of extracellular miRNA in breast cancer metastasis”
Shihen Emily Wang
Dr. Wang has no relevant financial relationships with commercial interests to disclose.

Risk factors of bioclinical recurrence, locoregional failure pattern and role of postmastectomy radiotherapy for T1-2 breast cancers with 1-3 positive axillary lymph nodes
Shulian Wang
Shulian Wang has no relevant financial relationships to disclose.

Risk factors of bioclinical recurrence, locoregional failure pattern and role of postmastectomy radiotherapy for T1-2 breast cancers with 1-3 positive axillary lymph nodes
Shulian Wang
Shulian Wang has no relevant financial relationships to disclose.

CTEA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer
Tao Wang
Dr. Wang has no relevant financial relationships to disclose.

CTEA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer
Tao Wang
Dr. Wang has no relevant financial relationships to disclose.

CTEA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer
Tao Wang
Dr. Wang has no relevant financial relationships to disclose.

CTEA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer
Tao Wang
Dr. Wang has no relevant financial relationships to disclose.

CTEA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer
Tao Wang
Dr. Wang has no relevant financial relationships to disclose.

CTEA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer
Tao Wang
Dr. Wang has no relevant financial relationships to disclose.

CTEA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer
Tao Wang
Dr. Wang has no relevant financial relationships to disclose.

CTEA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer
Tao Wang
Dr. Wang has no relevant financial relationships to disclose.

CTEA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer
Tao Wang
Dr. Wang has no relevant financial relationships to disclose.

CTEA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer
Tao Wang
Dr. Wang has no relevant financial relationships to disclose.

CTEA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer
Tao Wang
Dr. Wang has no relevant financial relationships to disclose.

CTEA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer
Tao Wang
Dr. Wang has no relevant financial relationships to disclose.

CTEA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer
Tao Wang
Dr. Wang has no relevant financial relationships to disclose.

CTEA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer
Tao Wang
Dr. Wang has no relevant financial relationships to disclose.

CTEA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer
Tao Wang
Dr. Wang has no relevant financial relationships to disclose.

CTEA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer
Tao Wang
Dr. Wang has no relevant financial relationships to disclose.

CTEA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer
Tao Wang
Dr. Wang has no relevant financial relationships to disclose.

CTEA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer
Tao Wang
Dr. Wang has no relevant financial relationships to disclose.

CTEA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer
Tao Wang
Dr. Wang has no relevant financial relationships to disclose.

CTEA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer
Tao Wang
Dr. Wang has no relevant financial relationships to disclose.

CTEA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer
Tao Wang
Dr. Wang has no relevant financial relationships to disclose.

CTEA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer
Tao Wang
Dr. Wang has no relevant financial relationships to disclose.

CTEA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer
Tao Wang
Dr. Wang has no relevant financial relationships to disclose.

CTEA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer
Tao Wang
Dr. Wang has no relevant financial relationships to disclose.

CTEA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer
Tao Wang
Dr. Wang has no relevant financial relationships to disclose.

CTEA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer
Tao Wang
Dr. Wang has no relevant financial relationships to disclose.
P3-07-12 Targeting SET to disrupt oncogenic CIP2A feedforward loop shows therapeutic potential in triple negative breast cancer cells
Wan-Lun Wang
Wan-Lun Wang has no relevant financial relationships to disclose.

P1-10-10 Risk factors of locoregional recurrence, locoregional failure pattern and role of postmastectomy radiotherapy for T1-2 breast cancers with 1-3 positive axillary lymph nodes
Weihu Wang
Weihu Wang has no relevant financial relationships to disclose.

P4-02-10 Adjunct diagnosing with breast specific gamma imaging or ultrasound in symptomatic women with mammographic dense breasts. A single center retrospective and comparative analysis
Kaiachen Wang
Kaiachen Wang has no relevant financial relationships to disclose.

P3-05-35 BCL008805 polymorphism in CYP19A1 gene is related to the prognosis of early breast cancer
Xiaojia Wang
Xiaojia Wang has no relevant financial relationships to disclose.

P4-07-07 Reduced expression of miR-200c-3p contributes to cell migration and invasion in paclitaxel-resistant breast cancer cell
Xiaojia Wang
Dr. Wang has no relevant financial relationships to disclose.

P4-21-26 Population pharmacokinetics (PK) and exposure-response (E-R) analysis of trastuzumab emtansine (T-DM1) in patients with HER2+ metastatic breast cancer (MBC) who have received at least two prior regimens of HER2-directed therapy
Xin Wang
Xin Wang has disclosed that he receives salary from and has ownership in Roche.

P4-22-14 Single agent palbociclib with or without trastuzumab for the treatment of HR+ advanced breast cancer
Xingmei Wang
Xingmei Wang has no relevant financial relationships to disclose.

P5-02-05 Biology and long-term prognosis of screening detected non-palpable breast cancer by ultrasound in hospital-based Chinese population (2001-2014)
Xuqing Wang
Dr. Wang has no relevant financial relationships to disclose.

P3-04-12 Pacificisol induced meme- and TMEM-mediated pro-metastatic changes in the breast cancer microenvironment
Yang Wang
Yang Wang has no relevant financial relationships to disclose.

P3-07-11 A randomized trial of accelerated breast radiotherapy utilizing either 3-dimensional radiotherapy versus intensity modulated radiotherapy
Ying Wang
Dr. Wang has no relevant financial relationships to disclose.

P4-22-18 Phase II safety, efficacy, and molecular analysis of ribociclib (LY2835219) plus letrozole for the treatment of ER+, HER2- advanced breast cancer
Yingbo Wang
Yingbo Wang has disclosed that he is a Novartis employee and has ownership in Novartis.

P1-06-11 A targetable EGFR-driven tumor-initiating program in breast cancer
Yu-Chang Wang
Yu-Chang Wang has no relevant financial relationships to disclose.

P6-11-14 Src homology 2 domain containing transforming protein 1 and steroid receptor coactivator-3 as novel targets for triple-negative breast cancer
Yuhan Wang
Yuhan Wang has no relevant financial relationships to disclose.

P1-10-03 A randomized trial of accelerated breast radiotherapy utilizing either 3-dimensional radiotherapy versus intensity modulated radiotherapy
Yunfei Wang
Dr. Wang has no relevant financial relationships to disclose.

P4-16-01 Evaluation of miracle mouthwash (MMW) plus hydrocortisone or prednisolone mouth rinses as prophylaxis for everolimus-associated stomatitis: Results of a randomized phase II study
Yunfei Wang
Dr. Wang has no relevant financial relationships to disclose.

P5-06-05 Preclinical characterization of VZV-64, a selective DNA-dependent protein kinase (DNA-PK) inhibitor in combination with doxorubicin in breast and ovarian cancers
Yuan Wang
Yuan Wang has disclosed that he is an employee of may own stock or stock options in Vertex Pharmaceuticals Incorporated.

P6-01-09 PIK3CA 2046 suppress triple negative breast cancer metastasis by targeting ARHGA18 and causing sustained Rho A activation
Zhishan Wang
Zhishan Wang has no relevant financial relationships to disclose.

P6-07-34 The prognostic impact of inositol polyphosphate 5-phosphatase PIPP (INPP5J) expression in breast cancer tissue
Yumi Wanifuchi
Yumi Wanifuchi has no relevant financial relationships to disclose.

P3-08-01 Truffl* based next-generation sequencing in BRCA1/2-negative breast and ovarian cancer families reveal high mutation prevalence in additional risk genes
Barbara Wappenschmidt
Barbara Wappenschmidt has no relevant financial relationships to disclose.
Feasibility of assessing radiation response with MRI/CT directed preoperative accelerated partial breast irradiation in the prone position for hormone sensitive early stage breast cancer

Lai Wei
Dr. Wei has no relevant financial relationships to disclose.

Comparison of the mutational landscape of breast cancer during pregnancy and non-pregnant controls

Wilko Weichert
Dr. Weichert has no relevant financial relationships to disclose.

High concordance of ER, PR, HER2 and Ki67 by Gemalpurt® breast cancer stratifier assay

Jodi Weidler
Dr. Westler has disclosed that she receives salary from and has ownership in Cepheid.

High concordance of a closed system, near point of care, RT-qPCR breast cancer assay for HER2 (ERBB2) mRNA compared to both IHC/FISH and quantitative immunofluorescence

Jodi Weidler
Ms. Weidler has disclosed that she receives salary from and has ownership in Cepheid.

Mutational landscape of breast cancers from PALB2 germline mutation carriers

Britta Weigelt
Ms. Weigelt has no relevant financial relationships to disclose.

Intra-tumor genetic heterogeneity and histological heterogeneity within metastatic breast cancers: Genotypic-phenotypic correlations

Britta Weigelt
Ms. Weigelt has no relevant financial relationships to disclose.

Analytical validation for the RT-qPCR based multiplex mRNA measurements of ER, PgR, HER2, and Ki67 from FFPE tumor tissue using the GeneXpert breast cancer stratifier assay

Jodi Weidler
Ms. Weidler has disclosed that she receives salary from and has ownership in Cepheid.

Highly reproducible decentralized gene expression analysis of ER, PG, HER2 and MK67 on an automated, standardized molecular diagnostics platform, Gemalpurt

Jodi Weidler
Ms. Weidler has disclosed that she receives salary from and has ownership in Cepheid.

The genomic landscape of breast metaplastic carcinoma

Britta Weigelt
Dr. Weigelt has no relevant financial relationships to disclose.

Intra-tumor genetic heterogeneity and histological heterogeneity within metastatic breast cancers: Genotypic-phenotypic correlations

Britta Weigelt
Ms. Weigelt has no relevant financial relationships to disclose.

Mutational landscape of breast cancers from PALB2 germline mutation carriers

Britta Weigelt
Ms. Weigelt has no relevant financial relationships to disclose.

The landscape of somatic genetic alterations in BRCA1 and BRCA2 breast cancers

Britta Weigelt
Ms. Weigelt has no relevant financial relationships to disclose.

The ASCO-recommended prognostic factors uPA/PAI-1 in a multicenter cohort study (PiA)

Edith Weigert
Dr. Weigert has no relevant financial relationships to disclose.

The genomic landscape of breast metaplastic carcinoma

Britta Weigelt
Dr. Weigelt has no relevant financial relationships to disclose.

DNA methylation signature predicting bevacizumab efficacy in metastatic breast cancer

Andreas Weinhäusel
Dr. Weinhäusel has no relevant financial relationships to disclose.

Elucidating the tumor immune microenvironment phenotype in early stage untreated BRCA mutated breast cancer patients

Andreas Weinhäusel
Dr. Weinhäusel has no relevant financial relationships to disclose.

Identification of SARA41805, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong antitumor activity in wild-type and mutant ER+ breast cancer models

Michael Weinstein
Mr. Weinstein has no relevant financial relationships to disclose.

A new oral SERD AIZD4196 for treatment of hormone dependent postmenopausal breast cancer

Hazel Weir
Dr. Weir has disclosed that she is an employee of Astrazeneca Oncology iMED.
The new oral SERD AZD9496 is efficacious in antagonizing ER and circumventing resistance to endocrine therapy.

Utility of the orally bioavailable selective estrogen receptor degrader AZD9496 in ER+ HER2- breast cancer.

A phase 1 study of AZD9496, a novel oral, selective estrogen receptor degrader (SERD) in women with estrogen receptor positive, HER-2 negative advanced breast cancer (ABC).

Hypofractionated nodal radiotherapy (RT) did not increase arm morbidity compared to conventional fractionated nodal RT.

Utility of the orally bioavailable selective estrogen receptor degrader AZD9496 in ESR1 mutant preclinical models of estrogen receptor positive breast cancer.

Phase 1 study of the antibody-drug conjugate (ADC) SGN-LIV1A in patients with heavily pretreated metastatic breast cancer.

Phase 1 study evaluating the safety and clinical activity of lumetuzumab combined with pertuzumab and paclitaxel in HER2-low metastatic breast cancer.

Breast carcinoma with 21-gene recurrence score lower than 18: Rate of distant metastases in a large series with clinical follow-up.

The genomic landscape of breast metaplastic carcinoma.

Intra-tumor genetic heterogeneity and histologic heterogeneity within metaplastic breast cancers: Genotypic-phenotypic correlations.

Mutational landscape of breast cancers from PALB2 germline mutation carriers.

Dual inhibition of the MEK5 and PI3K pathways synergistically reduces proliferation and viability in triple negative breast cancer cells.

Diagnosing cognitive impairment ("chemo brain") in breast cancer survivors.
Two-year follow-up results of a multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer

A multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer: Early results of unplanned boost participants

Evaluation of tumor infiltrating lymphocytes (TILs) and their association with homologous recombination deficiency and BRCA1/2 mutation status in triple-negative breast cancer (TNBC): A pooled analysis

The REQUITE-AB study: Validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality of life in breast cancer patients

A multi-center trial of intra-operative electronic brachytherapy during breast conservation surgery for early stage breast cancer: Early results of unplanned boost participants

Primary analysis of BERNICE: A phase II cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with locally advanced, inflammatory, or early-stage, unilateral, and invasive HER2-positive breast cancer

Relative neoadjuvance in triple negative tumors in the SweBCG91-RT randomized clinical trial

Prediction of underestimation associated with flat epithelial atypia, atypical ductal hyperplasia and atypical lobular hyperplasia by needle biopsy: Experience in an Argentine breast unit

Comparative performance of surveillance mammography and breast MRI in women with a history of breast cancer

Accurate and reliable automated breast density measurements with no missing radiation using flat-water decomposition MRI

Breast density change at 6 months is associated with change at 12 months as measured by fat-water decomposition MRI in women on tamoxifen

Real World data and patterns of care of metastatic breast cancer (MBC) in Brazil: First results of IACOG 0512 retrospective study

Intensified alkylating chemotherapy in patients with oligometastatic breast cancer harboring homologous recombination deficiency: The OLIGO study

Concordance of local immunohistochemistry with TargetPrint microarray based assessment of ER, PR and Her2 and BluePrint molecular subtyping in the Symphony Triple A study

Adjuvant dose dense doxorubicin-cyclophosphamide (ddAC) or docetaxel-AC (TAC) for high-risk breast cancer: First results of the randomized MATADOR trial (BOOG-2004-04)

Impact of 70-gene signature use on adjuvant chemotherapy decisions in early breast cancer patients: Results of the prospective symphony triple A study

Comprehensive characterization of matched pre-treatment biopsies and residual disease of doxorubicin treated breast cancer

Comprehensive characterization of matched pre-treatment biopsies and residual disease of doxorubicin treated breast cancer

Estrogen receptor positive breast cancer in BRCA2 mutation carriers shows a BRCAlike profile, suggesting sensitivity to drugs targeting homologous recombination deficiency
Influence of race and age on mastectomy rates in women with stage I, hormone-sensitive breast cancers: A SEER-based study
Julia White
Dr. White has no relevant financial relationships to disclose.

Updated safety results from the first multicenter, open-label, phase IIb study investigating the combination of pertuzumab with subcutaneous trastuzumab and a taxane in patients with HER2-positive metastatic breast cancer (GAPPHIRE)
Michelle White
Ms. White has no relevant financial relationships to disclose.

Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multi-center trial
Richard White, Jr.
Dr. White has no relevant financial relationships to disclose.

Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multi-center trial
Richard White, Jr.
Dr. White has no relevant financial relationships to disclose.

Cambridge brain mets trial 1 (CamBMT1): A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy
Eilish Whitfield
Ms. Whitfield has no relevant financial relationships to disclose.

Characterization of an estrogen-dependent murine model of human estrogen receptor-positive breast cancer bone metastasis
Susan Whitman
Ms. Whitman has no relevant financial relationships to disclose.

DCIS biological risk profile predicts risk of recurrence after breast conserving surgery in a Kaiser Permanente NW population
Pat Whitworth
Dr. Whitworth has no relevant financial relationships to disclose.

“Targeting breast cancer stem cells: Challenges and Opportunities”
Max Wicha
Dr. Wicha has disclosed that he receives consulting fees from MedImmune, Verastem, Paganini, Roche and Comorant and Van Andel Res. Inst. He also disclosed that he does contracted research for MedImmune, Dompe, Paganini and Verastem. He has ownership interest in OncoMed. These relationships do not impact his ability to present an unbiased presentation.

A randomized, double-blinded, placebo-controlled clinical trial (15 years of aromatase) in postmenopausal women with hormone-receptor positive breast cancer who have completed previous adjuvant endocrine therapy: Initial results of NRG oncology/NSABP B-42
D Lawrence Wickerham
Dr. Wickerham has no relevant financial relationships to disclose.

A randomized trial of accelerated breast radiotherapy utilizing either 3-dimensional radiotherapy versus intensity modulated radiotherapy
Kodi Widner
Dr. Widner has no relevant financial relationships to disclose.

The missing link: Chemicals, epigenetics and breast cancer
Marin Widschwendter
Ms. Widschwendter has no relevant financial relationships to disclose.

Investigating the effects of low-dose mixtures of environmental contaminants on breast cancer initiation
Martin Widschwendter
Mr. Widschwendter has no relevant financial relationships to disclose.

Dual HER2-Blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: A subanalysis of data from the randomized phase III GeparSepto trial
Hermann Wiedinghaus
Mr. Wiedinghaus has no relevant financial relationships to disclose.
Peripheral sensory neuropathy occurrence and resolution: Results from the neoadjuvant randomized GeparSepto study (GBG 69)

Hermann Wiebringhaus
Mr. Wiebringhaus has no relevant financial relationships to disclose.

Estrogen receptor quantitative measures and differences in breast cancer survival

Charles Wiggins
Dr. Wiggins has no relevant financial relationships to disclose.

Predictive value of serum anti-Mullerian hormone (AMH) in the outcome of emergency fertility preservation treatments indicated by breast cancer

Mia Wikander
Ms. Wikander has no relevant financial relationships to disclose.

The UK LORES trial randomising patients with low or low intermediate grade ductal carcinoma in situ (DCIS) to surgery or active monitoring

Margaret Wilcox
Ms. Wilcox has no relevant financial relationships to disclose.

Identification, clinical characteristics and treatment outcomes of somatic human epidermal growth factor receptor 2 (HER2) metastatic breast cancer (MBC) mutations in metastatic breast cancer patients

Rams Wildiers
Dr. Wildiers has disclosed that he receives institutional funding.

Age-related microRNA and their biomarker potential in chemotherapy-treated older breast cancer patients

Rams Wildiers
Dr. Wildiers has no relevant financial relationships to disclose.

The effect of adjuvant chemotherapy in a large consecutive series of ER-positive HER2-negative early breast cancers

Rams Wildiers
Dr. Wildiers has no relevant financial relationships to disclose.

Neoadjuvant weekly carboplatin and paclitaxel followed by dose dense epirubicin plus trastuzumab plus chemotherapy in the treatment of patients with HER2-positive metastatic breast cancer

Jon Wiggins
Dr. Wiggins has disclosed that he receives salary from and has ownership in Macromics.

The PI3K-inhibitor, copanlisib, has selective activity in luminal breast cancer cell lines and shows robust combined activity with hormonal blockade and CDK-4/6 inhibition in ER-positive breast cancer cell line xenografts

Scott Wilhelm
Dr. Wilhelm has disclosed that he is an employee of Bayer.

The PARP inhibitor, olaparib, has selective activity in luminal breast cancer cell lines and shows robust combined activity with hormonal blockade and CDK-4/6 inhibition in ER-positive breast cancer cell line xenografts

Edwin Wilkins
Dr. Wilkins has disclosed that he receives consulting fees from Pfizer, Amgen and Roche. He also disclosed that he does contracted research for Roche and Teva. He also disclosed other interests with Leo Pharma, Pfizer and Roche. These relationships do not impact his ability to present an unbiased presentation.

Impact of radiotherapy on complications and patient-reported satisfaction with breast reconstruction: Findings from the prospective multicenter MROC study

Celine Wilke
Ms. Wilke has disclosed that she receives salary from Novartis.

The association of breast cancer subtype and breast cancer survival with parity and time since last birth

Rams Wildiers
Dr. Wildiers has no relevant financial relationships to disclose.

The P13K inhibitor, copanlisib, has selective activity in luminal breast cancer cell lines and shows robust combined activity with hormonal blockade and CDK-4/6 inhibition in ER-positive breast cancer cell line xenografts

Scott Wilhelm
Dr. Wilhelm has disclosed that he is an employee of Bayer.

Evaluation of patients with breast cancer and germline BRCA1 mutation who are treated with olaparib

Rams Wildiers
Dr. Wildiers has disclosed that he receives institutional funding.

The dose dense chemotherapy regimen FAMTX followed by dose dense epirubicin plus paclitaxel with or without trastuzumab in the treatment of patients with HER2 positive metastatic breast cancer

Jon Wiggins
Dr. Wiggins has disclosed that he receives salary from and has ownership in Macromics.

The effect of adjuvant chemotherapy in a large consecutive series of ER-positive HER2-negative early breast cancers

Rams Wildiers
Dr. Wildiers has no relevant financial relationships to disclose.

A consecutive series of early breast cancers with a low estrogen receptor expression

Rams Wildiers
Dr. Wildiers has no relevant financial relationships to disclose.
P2-11-03 Incidence and severity of diarrhea with neratinib + intensive loperamide prophylaxis in patients (pts) with HER2+ early-stage breast cancer (EBC): Interim analysis from the multicenter, open-label, phase II control trial
Mary Wilkinson
Ms. Wilkinson has no relevant financial relationships to disclose.

P4-16-02 Evaluation of miracle mouthwash (MMW) plus hydrocortisone or prednisolone mouth rinses as prophylaxis for everolimus-associated stomatitis: Results of a randomized phase II study
Sharon Wilks
Dr. Wilks has no relevant financial relationships to disclose.

P5-15-03 nab-paclitaxel + carboplatin or gemcitabine vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the tricity trial
Sharon Wilks
Dr. Wilks has no relevant financial relationships to disclose.

P6-12-15 Efficacy results of a phase 1/2 study of glucocorticoid receptor (GR) antagonist mifepristone (MIFE) in combination with erulin in GR-positive triple-negative breast cancer (TNBC)
Sharon Wilks
Dr. Wilks has no relevant financial relationships to disclose.

S4-03 Targeted and selective degradation of estrogen receptor (ER) alpha by PROTACs
Ryan Willard
Mr. Willard has disclosed that he receives salary and has ownership.

P2-04-04 BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple-negative breast cancer
Karen Willard-Gallo
Ms. Willard-Gallo has no relevant financial relationships to disclose.

OT3-02-05 NCI-2016-00367: A phase IIB study of neoadjuvant ZT regimen (enzalutamide therapy in combination with weekly paclitaxel) for androgen receptor (AR)-positive triple-negative breast cancer (TNBC)
Jie Willey
Dr. Willey has no relevant financial relationships to disclose.

P5-15-12 Real-life activity of oral vinorelbine in metastatic breast cancer patients in the Unicancer ESMO database
Jacot William
Dr. William has no relevant financial relationships to disclose.

P2-03-02 Differential mutation pattern between neoadjuvant and metastatic settings in breast cancer patients
Casey Williams
Casey Williams has no relevant financial relationships to disclose.

P6-08-03 Dynamics of cancer stem cell surface marker, CD44 and CD44v6 in the antitumor efficacy of PARP inhibitor in combination with PI3K pathway inhibitor in TNBC xenograft model
Casey Williams
Dr. Willey has no relevant financial relationships to disclose.

P6-08-04 Preclinical efficacy of dasatinib in combination with PARP inhibitor plus standard cytotoxic agent in triple-negative breast cancer xenograft model
Casey Williams
Dr. Williams has no relevant financial relationships to disclose.

P6-08-09 Cancer stem cells define 3D etcoplastic growth response to rational combinations of PI3K isoform specific inhibitors in TNBC
Casey Williams
Casey Williams has no relevant financial relationships to disclose.

P3-07-02 Any see-missing actionable targets in breast cancer? Novel insights into recurrent Net alterations
Casey Williams
Casey Williams has no relevant financial relationships to disclose.

P2-07-02 Concordance with National comprehensive cancer network (NCCN) metastatic breast cancer guidelines and impact on overall survival
Courtney Williams
Ms. Williams has no relevant financial relationships to disclose.

P5-07-08 The role of inducible nitric oxide synthase in the stemness of triple negative breast cancer
Kaye Williams
Dr. Williams has no relevant financial relationships to disclose.

P2-03-02 Differential mutation pattern between neoadjuvant and metastatic settings in breast cancer patients
Kristin Williams
Ms. Williams has no relevant financial relationships to disclose.

OT1-04-01 Cambridge brain mets trial 1 (CamBMT1): A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy
Michael Williams
Dr. Williams has no relevant financial relationships to disclose.
Photodynamic therapy for the treatment of primary breast cancer: Preliminary results of a phase I/IIa clinical trial
Norman Williams
Dr. Williams has no relevant financial relationships to disclose.

Safety and efficacy results from phase I study of BNil 710 plus nab-paclitaxel in HER 2 negative metastatic breast cancer
Stephen Williamson
Dr. Williamson has no relevant financial relationships to disclose.

Independent validation of ErA/ll gene signature in B1G 1/98: A randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer
Scooter Willis
Mr. Willis has disclosed that he has stock in SYSGenomics, LLC.

Gain and amplification of RAC1 GTP-ase in BC: Explaining alterations in patients by experiments using TNBC model
Scooter Willis
Dr. Willis has no relevant financial relationships to disclose.

Adapt of MR imaging contrast kinetic thresholds for prediction of neoadjuvant chemotherapy response in breast cancer subtypes: Results from ACRIN 6657 / I-SPY 1 trial
Lisa Wilmes
Dr. Wilmes has no relevant financial relationships to disclose.

Serum-High-density among triple negative breast cancer patients as a biomarker of poor outcome
Tom Wilsgaard
Dr. Wilsgaard has no relevant financial relationships to disclose.

Does MRI influence surgical planning more than clinical outcome? A cohort study of breast cancer patients receiving neoadjuvant therapy
Christine Wilson
Dr. Wilson has no relevant financial relationships to disclose.

Does radiographic features influence the decision to order a breast MRI? A prospective cohort study
Christine Wilson
Dr. Wilson has no relevant financial relationships to disclose.

Clinical outcome of patients with advanced triple negative breast cancer with germline and somatic variants in homologous recombination gene
Gregory Wilson
Mr. Wilson has no relevant financial relationships to disclose.

Long term risk of explantation with Strattice™ assisted breast reconstruction, is it any different to submuscular reconstruction?
Michelle Wilson
Ms. Wilson has no relevant financial relationships to disclose.

The DETECT V-study - Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo- or endocrine therapy in patients with HER2-positive and hormone-receptor positive metastatic breast cancer
Pauline Wimberger
Dr. Wimberger has no relevant financial relationships to disclose.
DETECT III and IV: Individualized CTC-based therapy of metastatic breast cancer

Pauline Wimberger
Dr. Wimberger has no relevant financial relationships to disclose.

Serum levels of RANKL are increased in primary breast cancer patients in the presence of disseminated tumor cells in the bone marrow

Pauline Wimberger
Ms. Wimberger has no relevant financial relationships to disclose.

Patient derived DClS mouse-intracranial (MInC) models recapitulate the full spectrum of human patient pathology and histologic features including progression to invasion in a subset of cases

Onalisa Winblad
Dr. Winblad has no relevant financial relationships to disclose.

Comparative analysis of the genomic landscape of breast cancers from women of African and European ancestry

Wendy Winckler
Ms. Winckler has no relevant financial relationships to disclose.

A phase 2 study of eribulin followed by doxorubicin and cyclophosphamide as preoperative therapy for HER2-negative inflammatory breast cancer

Eric Winer
Dr. Winer has disclosed that he is a consultant for Genentech/Roche, Novartis and Verastem. He has also disclosed that he receives research funding from Genentech/Roche (Inst) and Novartis and Travel from Genentech/Roche.

Feasibility and safety of avoiding granulocyte colony-stimulating factor prophylaxis during the paclitaxel portion of dose dense doxorubicin-cyclophosphamide and paclitaxel regimen

Eric Winer
Dr. Winer has no relevant financial relationships to disclose.

A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capetakin (C) and trastuzumab (T) in patients with pretreated HER2- unresctable locally advanced or metastatic breast carcinoma (MBC) (HER2/CLINB)

Eric Winer
Dr. Winer has no relevant financial relationships to disclose.

The metastatic breast cancer project: Translational genomics through direct patient engagement

Eric Winer
Dr. Winer has disclosed that he is a consultant for Genentech/Roche, Novartis and Verastem. He has also disclosed that he receives research funding from Genentech/Roche (Inst) and Novartis and Travel from Genentech/Roche.

Phase I dose-escalation trial of ONT-380 in combination with trastuzumab in patients (pts) with HER2+ breast cancer brain metastases

Eric Winer
Dr. Winer has no relevant financial relationships to disclose.

First-line ribociclib plus letrozole in patients with de novo HR+, HER2- advanced breast cancer (ABC): A subgroup analysis of the MONALEESA-2 trial

Eric Winer
Dr. Winer has no relevant financial relationships to disclose.

Impact of pre-operative exercise and mind-body interventions on patient-reported outcomes in women with newly diagnosed breast cancer

Eric Winer
Dr. Winer has no relevant financial relationships to disclose.

Phase I study of the JAK 1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2 negative metastatic breast cancer (MBC)

Eric Winer
Dr. Winer has no relevant financial relationships to disclose.

Whole exome and transcriptome sequencing of resistant ER+ metastatic breast cancer

Eric Winer
Dr. Winer has disclosed that he is a consultant for Genentech/Roche, Novartis and Verastem. He has also disclosed that he receives research funding from Genentech/Roche (Inst); Novartis (Inst) and travel, accommodations and expenses from Genentech/Roche.

Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer

Eric Winer
Dr. Winer has disclosed that he is a consultant for Verastem and has contracts with Genentech/Roche (Inst), Novartis (Inst) and Merck (Inst). He has also disclosed that he receives travel, accommodations and expenses from Genentech/Roche.

Impact of pre-operative exercise on breast cancer gene expression

Eric Winer
Dr. Winer has no relevant financial relationships to disclose.

The Long and Winding Road: Glancing Back, But Moving Forward

Dr. Winer has no relevant financial relationships with commercial interests to disclose.
Efficacy and safety of everolimus plus exemestane in HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy, in routine clinical practice: 2nd interim analysis from STEPAUT

Ivo Winiger-Candolfi

Mr. Winiger-Candolfi has disclosed that he receives salary from Novartis Pharma GmBH and Novartis Pharma AG.

Targeted and selective degradation of estrogen receptor (ER) alpha by PROTACs

James Winkler

Mr. Winkler has disclosed that he receives salary and has ownership.

Negative progesterone receptor is associate early breast cancer relapse, even among good prognosis tumors

Megan Winner

Dr. Winner has no relevant financial relationships to disclose.

The importance of the ultimate ratio of Omega-6 to Omega-3 fatty acids in the efficacy of fish oil supplements in suppressing inflammation in obese postmenopausal women

Laura Winokur

Ms. Winokur has no relevant financial relationships to disclose.

Predictive value of quantitative HER2 and HER3 levels combined with downstream signaling markers in HER2-positive advanced breast cancer patients treated with lapatinib

John Winslow

Mr. Winslow has disclosed that he receives salary from LabCorp.

Identification of SARE49503, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong antitumor activity in wild-type and mutant ER+ breast cancer models

Chris Winter

Mr. Winter has no relevant financial relationships to disclose.

Negative progesterone receptor is associate early breast cancer relapse, even among good prognosis tumors

Megan Winner

Dr. Winner has no relevant financial relationships to disclose.

Predictive value of ultra-high ESR1 mRNA expression in early breast cancer

Ralph Wirtz

Dr. Wirtz has disclosed that he receives salary and royalties from and has ownership in STRATIFYER Molecular Pathology GmbH. He has also disclosed that he has a patent with STRATIFYER Molecular Pathology GmbH. He disclosed that he is a consultant for and has a contract with BioNTech Diagnostics GmbH.

Weight gain after breast cancer diagnosis and patients’ spread on weight loss strategies

Lisa Winton

Dr. Winton has no relevant financial relationships to disclose.

A one-day protocol with activities lower than 20 MBq for the detection of sentinel lymph nodes - Experience after 150 cases

Ute Winzer

Ute Winzer has no relevant financial relationships to disclose.

A phase I/IIa study of the whole-cell vaccine BriaVax™ in metastatic or locally recurrent breast cancer patients (NCT00095862)

Charles Wiseman

Dr. Wiseman has disclosed that he is a Director of Briacell Therapeutics and owns stock and is the principal for Wiseman Research Initiatives and Wiseman Cancer Research Foundation, a 501c3 public charity.

Rates of ipsilateral breast tumor recurrence (IBTR) following breast conserving surgery (BCS) and hypofractionated radiotherapy for ductal carcinoma in situ (DCIS)

Gordon Wishart

Prof. Wishart has no relevant financial relationships to disclose.

A phase I trial of the safety and immunogenicity of a DNA plasmid-based vaccine (WOKVAC) encoding epitopes derived from three breast cancer antigens (IGFBP2, HER2, and IGF1R) in patients with breast cancer

Kari Wisinski

Dr. Wisinski has disclosed that she has a contract with Novartis.

Femara plus ribociclib or placebo as neo-adjuvant endocrine therapy for women with ER+, HER2-negative early breast cancer - The Feline trial

Kari Wisinski

Dr. Wisinski has disclosed that she has a contract with Novartis.

A phase I/IIa study of the whole-cell vaccine BriaVax™ in metastatic or locally recurrent breast cancer patients (NCT00095862)

Charles Wiseman

Dr. Wiseman has disclosed that he is a Director of Briacell Therapeutics and owns stock and is the principal for Wiseman Research Initiatives and Wiseman Cancer Research Foundation, a 501c3 public charity.

A phase I trial of the safety and immunogenicity of a DNA plasmid-based vaccine (WOKVAC) encoding epitopes derived from three breast cancer antigens (IGFBP2, HER2, and IGF1R) in patients with breast cancer

Kari Wisinski

Dr. Wisinski has disclosed that she has a contract with Novartis.

A phase I trial of the safety and immunogenicity of a DNA plasmid-based vaccine (WOKVAC) encoding epitopes derived from three breast cancer antigens (IGFBP2, HER2, and IGF1R) in patients with breast cancer

Kari Wisinski

Dr. Wisinski has disclosed that she has a contract with Novartis.

Weight gain after breast cancer diagnosis and patients’ spread on weight loss strategies

Lisa Winton

Dr. Winton has no relevant financial relationships to disclose.

A one-day protocol with activities lower than 20 MBq for the detection of sentinel lymph nodes - Experience after 150 cases

Ute Winzer

Ute Winzer has no relevant financial relationships to disclose.

Predictive value of ultra-high ESR1 mRNA expression in early breast cancer

Ralph Wirtz

Dr. Wirtz has disclosed that he receives salary and royalties from and has ownership in STRATIFYER Molecular Pathology GmbH. He has also disclosed that he has a patent with STRATIFYER Molecular Pathology GmbH. He disclosed that he is a consultant for and has a contract with BioNTech Diagnostics GmbH.

Weight gain after breast cancer diagnosis and patients’ spread on weight loss strategies

Lisa Winton

Dr. Winton has no relevant financial relationships to disclose.

A one-day protocol with activities lower than 20 MBq for the detection of sentinel lymph nodes - Experience after 150 cases

Ute Winzer

Ute Winzer has no relevant financial relationships to disclose.

Predictive value of ultra-high ESR1 mRNA expression in early breast cancer

Ralph Wirtz

Dr. Wirtz has disclosed that he receives salary and royalties from and has ownership in STRATIFYER Molecular Pathology GmbH. He has also disclosed that he has a patent with STRATIFYER Molecular Pathology GmbH. He disclosed that he is a consultant for and has a contract with BioNTech Diagnostics GmbH.

A phase I/IIa study of the whole-cell vaccine BriaVax™ in metastatic or locally recurrent breast cancer patients (NCT00095862)

Charles Wiseman

Dr. Wiseman has disclosed that he is a Director of Briacell Therapeutics and owns stock and is the principal for Wiseman Research Initiatives and Wiseman Cancer Research Foundation, a 501c3 public charity.

Rates of ipsilateral breast tumor recurrence (IBTR) following breast conserving surgery (BCS) and hypofractionated radiotherapy for ductal carcinoma in situ (DCIS)

Gordon Wishart

Prof. Wishart has no relevant financial relationships to disclose.

A phase I trial of the safety and immunogenicity of a DNA plasmid-based vaccine (WOKVAC) encoding epitopes derived from three breast cancer antigens (IGFBP2, HER2, and IGF1R) in patients with breast cancer

Kari Wisinski

Dr. Wisinski has disclosed that she has a contract with Novartis.
Clonal heterogeneity in breast cancer and its impact on clinical biomarkers
Melissa Wilson Sayres

Establishment of molecular profiling for individual treatment decisions in early breast cancer - Clinical impact of PAM50 and PAM50 risk of recurrence score after more than 16 years follow up
Erik Wist

Proteomic response in breast cancer treated with neoadjuvant chemotherapy with and without bevacizumab: Reverse phase protein array (RPMA) results from NeoAva - A randomized phase II study
Erik Wist

Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer
Erik Wist

Long-term recurrence risk and risk-based follow-up after breast cancer treatment
Agnes Whitkiewicz

PI3K/PDK1 mediates resistance to CDK4/6 inhibitors through dysregulation of S-phase cyclins/cyclin dependent kinases (CDKs)
Agnes Whitkiewicz

Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer
Agnes Whitkiewicz

Clinical outcomes of estrogen-receptor negative breast carcinoma are associated with protein hormone-cognate receptor gene expression
James Witteveen

The effect of family history on screening procedures and prognosis in breast cancer patients - Results of a large population-based case-control study on breast cancer
Isabell Witzel

An integrated molecular analysis of invasive lobular carcinoma
Leesa Wockner

A phase I trial of the safety and immunogenicity of a DNA plasmid based vaccine (WOKVAC) encoding epitopes derived from three breast cancer antigens (IGFBP2, HER2, and IGF1R) in patients with breast cancer
Malgorzata Wojtowicz

OT3-01-03
A phase I trial of the safety and immunogenicity of a DNA plasmid-based vaccine (WOKVAC) encoding epitopes derived from three breast cancer antigens (IGFBP2, HER2, and IGF1R) in patients with breast cancer
Malgorzata Wojtowicz

OT3-01-04
A phase I trial of the safety and immunogenicity of a DNA plasmid-based vaccine (WOKVAC) encoding epitopes derived from three breast cancer antigens (IGFBP2, HER2, and IGF1R) in patients with breast cancer
Malgorzata Wojtowicz

Influence of winter season, driving distance, and time on receipt of breast conserving therapy among Iowa urban and rural patients
Cydney Wolf

Comprehensive genomic characterization of circulating tumor cells (CTCs) in metastatic breast cancer (MBC) sheds light on the biology of blood-borne metastasis
Denise Wolf

Quantitative Erb measurements in TNBC from the I-SPY 2 TRIAL correlate with HER2-EGFR co-activation and heterodimerization
Denise Wolf

DNA repair deficiency biomarkers and MammaPrint high1/(ultra)high2 risk as predictors of veliparib/carboplatin response: Results from the randomised I-SPY 2 trial for high risk breast cancer
Denise Wolf

IMENEO: International Meta-analysis of circulating tumor cell detection in early breast cancer patients treated by Neoadjuvant chemotherapy
Denise Wolf

Prostate-Ca:2020: A prospective, multicenter study to determine the effectiveness of a biomarker assay to distinguish benign from invasive breast cancer in women with BI-RADS 3, 4 and 5 imaging reports
Judith Wolff

Prostate-specific antigen expression is a prognostic marker for overall survival and progression-free survival in sporadic breast cancer
Verena Wolf
Negative progesterone receptor is associated with early breast cancer relapse, even among good prognosis tumors.

Antonio Wolff
Dr. Wolff has no relevant financial relationships to disclose.

Use of a 3-D bioabsorbable tissue marker in 61 patients over two years.

Greg Wolgamot
Dr. Wolgamot has no relevant financial relationships to disclose.

MRI oncology/NAACP B-52/RTG 1304: A phase III superiority clinical trial designed to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNR1 to breast RT post breast-conserving surgery (BCS) will reduce invasive cancer events in patients (pts) with positive axillary (Ax) nodes and convert to pN0 after neoadjuvant chemotherapy (NC).

Norman Wolmark
Dr. Wolmark has no relevant financial relationships to disclose.

A randomized, double-blinded, placebo-controlled clinical trial to evaluate extended adjuvant endocrine therapy (5 years of letrozole) in postmenopausal women with hormone-receptor positive breast cancer who have completed previous adjuvant endocrine therapy.

Catherine Womack
Dr. Womack has no relevant financial relationships to disclose.

Breast cancer subtype, age and lymph node status as predictors of local recurrence following breast-conserving therapy.

Julia Wong
Dr. Wong has no relevant financial relationships to disclose.

Mitochondria-nuclear communication regulates epithelial-mesenchymal transition and metastasis in triple negative breast cancer.

Lee-Jun Wong
Dr. Wong has no relevant financial relationships to disclose.

Use of natural language processing on mammography and pathology findings to supplement BI-RADS to improve clinical decision making in breast cancer care.

Stephen Wong
Dr. Wong has no relevant financial relationships to disclose.
High concordance of ER, PR, HER2 and Ki67 by central IHC and FISH with mRNA measurements by GeneXpert® breast cancer stratifier assay

High concordance of a closed system, near point of care, RT-qPCR breast cancer assay for HER2 (ERBB2) mRNA compared to both IHC/FISH and quantitative immunofluorescence

Analytical validation for the RT-qPCR based multiplex mRNA measurements of ER, PgR, HER2, and Ki67 from FFPE tumor tissue using the GeneXpert breast cancer stratifier assay

Cost-effectiveness of pre-implantation genetic diagnosis for BRCA mutation carriers

COLET: A multistage, phase 2 study evaluating the safety and efficacy of a doublet regimen of cobimetinib (C) in combination with paclitaxel (P) or triplet regimens of C in combination with atezolizumab (atezo) plus either P or nab-paclitaxel (nab-P) in metastatic triple-negative breast cancer (TNBC)

Circulating cell-free DNA (cfDNA) measured by a simple fluorescent assay to predict relapse in triple negative breast cancer patients receiving neoadjuvant chemotherapy: A biomarker substudy of prospective observational study (NCT02001519, NCT02001506)

Adherence to healthy lifestyle behaviors in a predominantly Hispanic population of women undergoing screening mammography

Evaluation of the relationship between psychological distress and risk for breast cancer

A paradigm shift for insulin-like growth factor-1 receptor function in triple negative breast cancers

A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA)

Updated safety results from the first multicenter, open-label, phase Ib study investigating the combination of pertuzumab with subcutaneous trastuzumab and a taxane in patients with HER2-positive metastatic breast cancer (SAPPHIRE)

Circulating tumor cells in triple-negative breast cancer patients express prostate related genes and show different genetic profiles in US and German patient cohorts

Delineation of breast cancer based on circulating protein biomarker profile using the OLINK proteomics multiplexed proximity extension assay
Landscape of somatic mutations in inflammatory breast cancer whole-genome sequences

Wendy Woodward
Dr. Woodward has no relevant financial relationships to disclose.

Rates of immune infiltration in patients with triple-negative breast cancer by molecular subtype and in patients with inflammatory and non-inflammatory breast cancers

Wendy Woodward
Dr. Woodward has no relevant financial relationships to disclose.

Flutamide reduced tumor progression and altered steroid hormone secretion in human and canine inflammatory breast cancer cell lines

Wendy Woodward
Dr. Woodward has no relevant financial relationships to disclose.

Immune characterization of inflammatory breast cancer and correlation to pathological complete response

Wendy Woodward
Dr. Woodward has no relevant financial relationships to disclose.

Network integration of epigenomic data: Leveraging the concept of master regulators in ER-negative breast cancer

Maria Worsham
Dr. Worsham has no relevant financial relationships to disclose.

A phase II open-label study of lucitanib in patients (pts) with FGFR aberrant metastatic breast cancer (MBC)

Kenton Wride
Dr. Wride has disclosed that he receives salary from Clovis Oncology.

Flutamide reduced tumor progression and altered steroid hormone secretion in human and canine inflammatory breast cancer cell lines

Chang-Wu Wu
Dr. Wu has no relevant financial relationships to disclose.

Targeting SET to disrupt oncogenic CIP2A feedforward loop shows therapeutic potential in triple negative breast cancer cells

Chia-Yun Wu
Dr. Wu has no relevant financial relationships to disclose.

Dual inhibition of the MEK5 and PI3K pathways synergistically reduces proliferation and viability in triple negative breast cancer cells

Thomas Wright
Dr. Wright has no relevant financial relationships to disclose.

Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: A meta-analysis

Jiong Wu
Dr. Wu has no relevant financial relationships to disclose.

Comparison of axillary nodal status between different defined clinically node positive breast cancers: Is ACOSOG Z0011 criteria applicable to preoperative cytologically negative axilla?

Jiayi Wu
Dr. Wu has no relevant financial relationships to disclose.

Development and application of whole processing management for patients with breast carcinoma: A novel management strategy for breast health

Jiong Wu
Dr. Wu has no relevant financial relationships to disclose.
A single-center report of 125 cases of incidental internal mammary lymph node biopsy in free abdominal flap breast reconstruction
Jiong Wu
Jiong Wu has no relevant financial relationships to disclose.

High concordance of ER, PR, HER2 and Ki67 by central IHC and FISH with mRNA measurements by Genexpert® breast cancer stratifier assay
Natalie Wu
Dr. Wu has disclosed that she receives salary from and has ownership in Cepheid.

High-concordance of a closed system, near point of care, RT-qPCR breast cancer assay for HER2 (ERBB2) mRNA compared to both IHC/FISH and quantitative immunofluorescence
Natalie Wu
Ms. Wu has disclosed that she receives salary from and has ownership in Cepheid.

Highly reproducible decentralized gene expression analysis of ESR1, PGR, ERBB2 and MAE67 on an automated, standardized molecular diagnostics platform, Genexpert
Natalie Wu
Ms. Wu has disclosed that she receives salary from and has ownership in Genexpert.

Analytical validation for the RT-qPCR based multiplex mRNA measurements of ER, PGR, HER2, and Ki67 from FFPE tumor tissue using the Genexpert breast cancer stratifier assay
Natalie Wu
Ms. Wu has disclosed that she receives salary from and has ownership in Genexpert.

Weekly doxorubicin and daily oral cyclophosphamide followed by nab-paclitaxel for adjuvant therapy of high-risk localized breast cancer
Qian Wu
Dr. Wu has no relevant financial relationships to disclose.

Environmental influence on epigenetic markers in the development of breast cancer
Wenting Wu
Wenting Wu has no relevant financial relationships to disclose.

Utilization of oncotype DX for breast cancer in different facility types in Louisiana
Xiao-Cheng Wu
Dr. Wu has no relevant financial relationships to disclose.

Genomic analysis of molecular discordance of paired primary and recurrent triple negative breast cancer
Xiwei Wu
Dr. Wu has no relevant financial relationships to disclose.

Pterostilbene enhances TRAIL-induced apoptosis in TRAIL-resistant triple negative breast cancer cells
Yao-Chung Wu
Dr. Wu has no relevant financial relationships to disclose.

An international multicenter study to evaluate reproducibility of automated scoring methods for assessment of Ki67 in breast cancer
Ying Wu
Ying Wu has no relevant financial relationships to disclose.

Molecular mechanisms of alcohol-associated breast cancer
Zhongdao Wu
Dr. Wu has no relevant financial relationships to disclose.

The role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+/HR- phase II trial evaluating 12-weeks of nesadjuvant TDM1 + endocrine therapy (ITT) versus T + ET in HER2-positive hormone-receptor-positive early breast cancer (EBC)
Rachel Wuerstlein
Ms. Wuerstlein has disclosed that she is a consultant.

Safety and efficacy of trastuzumab emtansine (T-DM1) in 399 patients with central nervous system metastases: Exploratory subgroup analysis from the EAMILLSA study
Rachel Wuerstlein
Ms. Wuerstlein has disclosed that she is a consultant for Roche, Celgene, Pfizer, Nanostring, Agenda, Novartis and Eisai.

Results of multigene assay (MammaPrint®) and molecular subtyping (BluePrint®) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIME decision impact study
Rachel Wuerstlein
Dr. Wuerstlein has disclosed that she is on an Advisory Board.

Technology as a change agent for improving breast cancer quality care
Debra Wujcik
Ms. Wujcik has disclosed that she is a consultant for Carevive.

A multiOMIC analysis to explore the impact of “actionable” genomic alterations on protein pathway activation: Clinical implication for precision medicine in metastatic breast cancer
Julia Wulfkuhle
Dr. Wulfkuhle has disclosed that she is a co-inventor on technologies licensed in from Theranostics and is a shareholder at Theranostics Health.

Quantitative EoT measurements in TNBC from the I-SPY 2 TRIAL correlate with HER2-EGFR co-activation and heterodimerization
Julia Wulfkuhle
Ms. Wulfkuhle has disclosed that she is a Theranostics Health, LLC shareholder.
<table>
<thead>
<tr>
<th>S2-06</th>
<th>DNA repair deficiency biomarkers and MammaPrint high/ultra high risk as predictors of veliparib/carboplatin response</th>
<th>Julia Wulfkuhle</th>
<th>Dr. Wulfkuhle has no relevant financial relationships to disclose.</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2-04-02</td>
<td>Recognition of autologous neoantigens by tumor infiltrating lymphocytes derived from breast cancer metastases</td>
<td>John Wunderlich</td>
<td>Dr. Wunderlich has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT3-03-03</td>
<td>Challenges faced across borders to open European academic multicentre projects: The ET-IE5 program part of the ERA-Net TRANSCAN-IFC 2011</td>
<td>Rachel Würstlein</td>
<td>Dr. Würstlein has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-05-05</td>
<td>PTPN11 affects breast cancer initiation and progression through Stat5 signaling pathway</td>
<td>John Wysolmerski</td>
<td>Dr. Wysolmerski has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>PD5-07</td>
<td>From monocyte to angiogenic to the expansion of tumor infiltrating lymphocytes for adoptive T cell therapy</td>
<td>Xianen Xie</td>
<td>Dr. Xie has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-10-04</td>
<td>Disparities in human epidermal growth factor receptor 2 testing completion: A population-based retrospective cohort study, 2010-2013</td>
<td>Xiaojun Xia</td>
<td>Dr. Xia has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-04-22</td>
<td>Porous silicon microparticle potentiates anti-tumor immunity</td>
<td>Xiang Xiao</td>
<td>Dr. Xiao has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-01-39</td>
<td>Axillary reverse mapping using fluorescence imaging in the surgical treatment for breast cancer patients</td>
<td>Jingjing Xiang</td>
<td>Dr. Xiang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-07-11</td>
<td>MicroRNA-367a promotes tumor growth and stemness potential by targeting FBXW7 in breast cancer</td>
<td>Guodong Xiao</td>
<td>Dr. Xiao has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-07-10</td>
<td>Identification of preclinical mechanisms driving acquired resistance to selective ErbB degraders (TEHDs), CDK4/6 inhibitors, or to combinations of both agents</td>
<td>Yang Xiao</td>
<td>Dr. Xiao has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-07-29</td>
<td>Time on treatment of everolimus versus endocrine monotherapy or chemotherapy for early-line treatment of HR+/HER2- metastatic breast cancer: A retrospective chart review study in the US</td>
<td>Jipan Xie</td>
<td>Dr. Xie has disclosed that he is a consultant for Novartis Pharmaceuticals Corporation.</td>
</tr>
<tr>
<td>P5-15-02</td>
<td>Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer</td>
<td>Xiaoyang Xie</td>
<td>Dr. Xie has disclosed that he is an employee of Eisai.</td>
</tr>
<tr>
<td>P3-03-15</td>
<td>Synergistic suppression of triple negative breast cancer with the combination of PI3K inhibitor (alpelisib, BYL719) and CDK inhibitor (ribociclib, LEE011)</td>
<td>Quanhua Xing</td>
<td>Dr. Xing has disclosed that he is an employee of Eisai Ltd, UK.</td>
</tr>
<tr>
<td>P3-04-23</td>
<td>Combination therapy of targeted anticancer pathways and estrogen receptor ligands and their responses in de novo and tamoxifen-resistant cell models</td>
<td>Rui Xiong</td>
<td>Dr. Xiong has disclosed that he is an employee of Eisai.</td>
</tr>
<tr>
<td>P3-04-24</td>
<td>A randomized, open-label, multicenter, phase 1c/2 study of eribulin mesylate in combination with PEGylated recombinant human hyaluronidase in patients with human epidermal growth factor receptor 2-negative, high-hyaluronan metastatic breast cancer</td>
<td>Dongpu Xing</td>
<td>Dongpu Xing has disclosed that he is an employee of Eisai.</td>
</tr>
<tr>
<td>P3-04-25</td>
<td>Phase Ia study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple negative breast cancer</td>
<td>Dongpu Xing</td>
<td>Dongpu Xing has disclosed that he is an employee of Eisai.</td>
</tr>
<tr>
<td>P4-04-22</td>
<td>Time on treatment of everolimus versus endocrine monotherapy or chemotherapy for early-line treatment of HR+/HER2- metastatic breast cancer: A retrospective chart review study in the US</td>
<td>Yaping Xie</td>
<td>Dr. Xie has disclosed that he is a consultant for Novartis Pharmaceuticals Corporation.</td>
</tr>
<tr>
<td>P2-01-39</td>
<td>Axillary reverse mapping using fluorescence imaging in the surgical treatment for breast cancer patients</td>
<td>Jingjing Xiang</td>
<td>Dr. Xiang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-04-23</td>
<td>Combination therapy of targeted anticancer pathways and estrogen receptor ligands and their responses in de novo and tamoxifen-resistant cell models</td>
<td>Rui Xiong</td>
<td>Dr. Xiong has disclosed that he is an employee of Eisai.</td>
</tr>
<tr>
<td>P3-04-24</td>
<td>Identification of preclinical mechanisms driving acquired resistance to selective ErbB degraders (TEHDs), CDK4/6 inhibitors, or to combinations of both agents</td>
<td>Yang Xiao</td>
<td>Dr. Xiao has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-07-29</td>
<td>Time on treatment of everolimus versus endocrine monotherapy or chemotherapy for early-line treatment of HR+/HER2- metastatic breast cancer: A retrospective chart review study in the US</td>
<td>Jipan Xie</td>
<td>Dr. Xie has disclosed that he is a consultant for Novartis Pharmaceuticals Corporation.</td>
</tr>
<tr>
<td>P5-07-10</td>
<td>Identification of preclinical mechanisms driving acquired resistance to selective ErbB degraders (TEHDs), CDK4/6 inhibitors, or to combinations of both agents</td>
<td>Yang Xiao</td>
<td>Dr. Xiao has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-04-22</td>
<td>Porous silicon microparticle potentiates anti-tumor immunity</td>
<td>Xiang Xiao</td>
<td>Dr. Xiao has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-01-39</td>
<td>Axillary reverse mapping using fluorescence imaging in the surgical treatment for breast cancer patients</td>
<td>Jingjing Xiang</td>
<td>Dr. Xiang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-07-11</td>
<td>MicroRNA-367a promotes tumor growth and stemness potential by targeting FBXW7 in breast cancer</td>
<td>Guodong Xiao</td>
<td>Dr. Xiao has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-07-10</td>
<td>Identification of preclinical mechanisms driving acquired resistance to selective ErbB degraders (TEHDs), CDK4/6 inhibitors, or to combinations of both agents</td>
<td>Yang Xiao</td>
<td>Dr. Xiao has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-04-24</td>
<td>A randomized, open-label, multicenter, phase 1c/2 study of eribulin mesylate in combination with PEGylated recombinant human hyaluronidase in patients with human epidermal growth factor receptor 2-negative, high-hyaluronan metastatic breast cancer</td>
<td>Dongpu Xing</td>
<td>Dongpu Xing has disclosed that he is an employee of Eisai.</td>
</tr>
<tr>
<td>P3-04-23</td>
<td>Combination therapy of targeted anticancer pathways and estrogen receptor ligands and their responses in de novo and tamoxifen-resistant cell models</td>
<td>Rui Xiong</td>
<td>Dr. Xiong has disclosed that he is an employee of Eisai.</td>
</tr>
<tr>
<td>P3-04-24</td>
<td>Identification of preclinical mechanisms driving acquired resistance to selective ErbB degraders (TEHDs), CDK4/6 inhibitors, or to combinations of both agents</td>
<td>Yang Xiao</td>
<td>Dr. Xiao has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
Tumor microenvironment of metastasis (TMEM) score is associated with early distant recurrence in hormone receptor (HR) positive, HER2-negative early stage breast cancer (ESBC) - Xiaoxian Xue

Obesity and breast cancer: The adipocyte-macrophage interaction as a mediator of metastasis - Nalini Yadav

Synchronous bilateral breast cancer compared to unilateral breast cancer: A population based study - Siddhartha Yadav

Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with Trastuzumab - Martin Yaffe

Development of photacoustic vascular imaging system for breast cancer - Takayuki Yagi

Role of tumor microenvironment, as assessed by breast MRI background parenchymal enhancement (BPE), in modulating response to neoadjuvant chemotherapy in young women with localized breast cancer - Adam Yala

PD-L1 expression and decreased tumor-infiltrating lymphocytes are associated with poor prognosis in patients with triple negative breast cancer - Mai Yamada

Development of photacoustic vascular imaging system for breast cancer - Iku Yamaga

Zoledronic acid combined with neoadjuvant chemotherapy for HER2-negative early breast cancer (JONIE 1 trial): Survival outcomes of a randomized multicenter phase 2 trial - Kazuhiko Yamagami

Efficacy of compression therapy using surgical gloves for nanoparticle albumin-bound-paclitaxel-induced peripheral neuropathy: A phase II multicenter study by the Kamigata breast cancer study group - Ayano Yamaguchi

DYRK2 contributes to the generation of breast cancer stem cells through AKT4 - Noriko Yamaguchi

A randomized phase II study of Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer - Takaaki Yamaguchi

PD-L1 expression and decreased tumor-infiltrating lymphocytes are associated with poor prognosis in patients with triple negative breast cancer - Rin Yamaguti

Duration of fasting before taking lapatinib is associated with skin toxicity in neoadjuvant treatment of HER2 positive breast cancer: A cohort study from JBCRG-16/Neo-LaTH - Naohito Yamamoto

A multi-center prospective study of radiofrequency ablation therapy for small breast carcinomas - Naohito Yamamoto

Influence of exercise or educational programs on long-term physical activity by patients after surgery for primary breast cancer: A randomized trial - Seiichito Yamamoto

Clinical significance of sequential measurements of ESR1 mutations in plasma cell-free DNA in estrogen receptor positive recurrent metastatic breast cancer patients - Yutaka Yamamoto

Differential expression of exosomal miRNAs between breast cancer patients with recurrence and no recurrence - Yutaka Yamamoto

A comprehensive analysis of GNAS DNA copy number, levels of mRNA and protein expression in primary breast cancer - Yutaka Yamamoto

Development of a predictive model by gene expression profiles for pathological CR after neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer - Yutaka Yamamoto
P1-02-09  Clinical significance of sequential measurements of ESR1 mutations in plasma cell-free DNA in estrogen receptor positive recurrent metastatic breast cancer patients
Mutsuko Yamamoto-Ibusuki  Dr. Yamamoto-Ibusuki has no relevant financial relationships to disclose.

P6-09-46  A comprehensive analysis of GNAS DNA copy number, levels of m6A RNA and protein expression in primary breast cancer
Mutsuko Yamamoto-Ibusuki  Mutsuko Yamamoto-Ibusuki has no relevant financial relationships to disclose.

P6-09-48  Development of a predictive model by gene expression profiles for pathological CR after neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer
Mutsuko Yamamoto-Ibusuki  Mutsuko Yamamoto-Ibusuki has no relevant financial relationships to disclose.

P4-21-14  A randomized phase II trial of trastuzumab + capecitabine versus lapatinib + capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110/B01T0P
Takaharu Yamazaki  Takaharu Yamazaki has no relevant financial relationships to disclose.

P4-02-01  Endothelial vascular remodeling and neovascularization in advanced breast cancer patients: A comparative study with bevacizumab
Tomohiko Yamanaka  Dr. Yamane has no relevant financial relationships to disclose.

P2-01-17  The combination of preoperative computed tomography lymphography and intraoperative fluorescence imaging navigation for sentinel lymph node biopsy of early breast cancer patients
Kazuki Yamashita  Dr. Yamashita has no relevant financial relationships to disclose.

P4-21-24  Development of mathematical prediction models to identify disease-free survival events for HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy and trastuzumab
Hiroyasu Yamashiro  Hiroyasu Yamashiro has no relevant financial relationships to disclose.

P5-12-01  Randomized trial of exercise intervention vs. usual care for breast cancer patients with aromatase inhibitor to prevent and improve the aromatase inhibitor induced arthralgia
Keiko Yamashiro  Keiko Yamashiro has no relevant financial relationships to disclose.

P6-01-17  Breast epithelial paradox: clinical significance of co-expression of E-cadherin and vimentin in the invasion and the metastasis of breast cancer
Nama Yamashita  Ms. Yamashita has no relevant financial relationships to disclose.

P5-07-11  The clinical importance of nuclear wild-type p53-induced phosphatase (Wip1) expression in breast cancer patients
Nami Yamashita  Nami Yamashita has no relevant financial relationships to disclose.

P6-01-17  Clinicopathological predictors for low risk recurrence distinguished by 21-gene recurrence score in estrogen receptor-positive invasive breast cancer patients
Hideto Yamashita  Hideto Yamashita has no relevant financial relationships to disclose.

P2-05-36  Clinicopathological predictors for low risk recurrence distinguished by 21-gene recurrence score in estrogen receptor-positive invasive breast cancer patients
Takako Yanagisawa  Ms. Yanagisawa has no relevant financial relationships to disclose.

P1-10-09  Evaluation of the Oncotype Dx and comprehensive assays for therapeutic stratification in early hormone receptor positive breast cancer
Elizabeth Yan  Dr. Yan has no relevant financial relationships to disclose.

P1-05-27  Synergistic suppression of triple negative breast cancer with the combination of PI3K inhibitor (alpelisib, BYL719) and CDK inhibitor (ribociclib, LEE011)
Tu Yan  Tu Yan has no relevant financial relationships to disclose.

P1-03-15  Synergistic suppression of triple negative breast cancer with the combination of PI3K inhibitor (alpelisib, BYL719) and CDK inhibitor (ribociclib, LEE011)
Jin Yan  Dr. Yan has no relevant financial relationships to disclose.

P1-08-07  Assessing the impact of loss of PI3K protein on endocrine therapy resistance
Pengbo Yan  Pengbo Yan has no relevant financial relationships to disclose.

P1-02-04  Adipocyte fatty acid binding protein levels predict risk of obesity associated breast cancer
Siyang Yan  Siyang Yan has no relevant financial relationships to disclose.

P6-07-26  ST8SIA1 is over-expressed in triple negative breast cancer and associated with p53 mutations
Yanming Yan  Yanming Yan has no relevant financial relationships to disclose.

P2-01-37  Technical feasibility and validity of sentinel lymph node biopsy in patients with palmaris breast tumor recurrence
Takako Yamagawa  Ms. Yamagawa has no relevant financial relationships to disclose.

P1-08-13  The clinical importance of nuclear wild-type p53-induced phosphatase (Wip1) expression in breast cancer patients
Nama Yamashita  Nami Yamashita has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Author</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2-05-27</td>
<td>Baseline serum CA15-3 levels are associated with prognosis for breast cancer patients with non-complete pathological response to neoadjuvant chemotherapy</td>
<td>Ayako Yanai</td>
<td>Ms. Murase has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-05-17</td>
<td>Establishment and preliminary clinical application of breast cancer CTC detection kit based on immune magnetic lipid microsphere/human breast mammaglobin.</td>
<td>Benlong Yang</td>
<td>Dr. Yang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-02-01</td>
<td>Pre-operative breast MRI would not benefit breast cancer patients’ survival, even in young patients treated with breast-conservative surgery</td>
<td>Benlong Yang</td>
<td>Benlong Yang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-14-06</td>
<td>A single-center report of 125 cases of incidental internal mammary lymph node biopsy in free abdominal flap breast reconstruction</td>
<td>Benlong Yang</td>
<td>Benlong Yang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-01-09</td>
<td>MIRNA-200b suppresses triple negative breast cancer metastasis by targeting ARHGAP18 and causing sustained Rho A activation</td>
<td>Chengfeng Yang</td>
<td>Chengfeng Yang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-12-06</td>
<td>Progesterone receptor subtype-specific androgen receptor modulator (E2AR), endosperm-derived growth inhibition of androgen receptor-positive breast cancer in patient-derived preclinical models</td>
<td>Chuan He Yang</td>
<td>Dr. Yang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-01-02</td>
<td>Integration of whole-genome sequencing and functional screening to identify breast cancer lung metastatic drivers</td>
<td>Hai-Yuan Yang</td>
<td>Hai-Yuan Yang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-03-01</td>
<td>An international multicenter study to evaluate reproducibility of automated scoring methods for assessment of Ki67 in breast cancer</td>
<td>Hau Yang</td>
<td>Hau Yang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-05-05</td>
<td>Prognostic values of circulating tumor cells (CTC) and cancer associated macrophage-like cells (CAML) enumerations in metastatic breast cancer: The role for innate immunity in the metastatic process</td>
<td>Huiyang Yang</td>
<td>Huiyang Yang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-07-13</td>
<td>The mutation detection and a high-throughput screening of driver mutations in PI3K/AKT pathway based on next-generation sequencing</td>
<td>Jiao Yang</td>
<td>Jiao Yang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-07-06</td>
<td>Inhibition of HIDAC as targeted therapy for breast cancers</td>
<td>Jin Yang</td>
<td>Dr. Yang has disclosed that he is an employee of AstraZeneca.</td>
</tr>
<tr>
<td>P3-03-14</td>
<td>Etilo derived drug resistance-inhibiting global DNA hypermethylation by promoting the DNMT3 gene expression</td>
<td>Nan Yang</td>
<td>Nan Yang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-02-08</td>
<td>Promoter-002: A prospective, multi-center study to determine the effectiveness of a biomarker assay to distinguish benign from invasive breast cancer in women with BI-RADS 3, 4 and 5 imaging reports</td>
<td>Rebecca Yang</td>
<td>Dr. Yang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT2-01-20</td>
<td>Phase II study of neoadjuvant pentaximustine combined with capecitabine and paclitaxel (CTPC) for anthracycline-resistant triple-negative breast cancer (TNBC)</td>
<td>Wei Yang</td>
<td>Wei Yang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>OT2-03-05</td>
<td>NCI-2016-003337: A phase IIb study of neoadjuvant 21 regimen alendotomide therapy in combination with weekly paclitaxel for androgen receptor (AR)-positive triple-negative breast cancer (TNBC)</td>
<td>Wei Yang</td>
<td>Wei Yang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-04-11</td>
<td>ER is required for mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer cells and patients’ tumors</td>
<td>Wei Yang</td>
<td>Wei Yang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-16-30</td>
<td>Feasibility trial for identification of patients for eliminating breast cancer surgery following neoadjuvant systemic therapy</td>
<td>Wei Yang</td>
<td>Dr. Yang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-13-24</td>
<td>Non-liposuction endoscopic axillary lymph node dissection in breast conservant surgery</td>
<td>Weige Yang</td>
<td>Weige Yang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-01-02</td>
<td>Diagnostic value of breast specific gamma imaging for breast cancer</td>
<td>Weige Yang</td>
<td>Weige Yang has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
A phase 2 open label study of everolimus in combination with endocrine therapy in resistant hormone receptor-positive HER2-negative advanced breast cancer

Denise Yardley
Dr. Yardley has no relevant financial relationships to disclose.

Everolimus plus trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: Overall survival results from BOLERO-2

Denise Yardley
Ms. Yardley has no relevant financial relationships to disclose.

Baseline (BL) characteristics, treatment (tx) patterns, and outcomes in patients with hormone receptor (HR)+ vs HR- HER2+ disease from the SyStHERs registry

Denise Yardley
Ms. Yardley has disclosed that she is a speaker for Novartis and Genentech and has a contract with Genentech (paid to institution).

nab-paclitaxel + carboplatin or gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the toxicity trial

Denise Yardley
Ms. Yardley has no relevant financial relationships to disclose.

Everolimus plus trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: Overall survival results from BOLERO-2

Denise Yardley
Ms. Yardley has no relevant financial relationships to disclose.

Baseline (BL) characteristics, treatment (tx) patterns, and outcomes in patients with hormone receptor (HR)+ vs HR- HER2+ disease from the SyStHERs registry

Denise Yardley
Ms. Yardley has disclosed that she is a speaker for Novartis and Genentech and has a contract with Genentech (paid to institution).

Quantitative ERα measurements in TNBC from the I-SPY 2 TRIAL correlate with HER2-EGFR co-activation and heterodimerization

Christina Yau
Ms. Yau has no relevant financial relationships to disclose.

Intra-tumor heterogeneity of the estrogen receptor predicts less benefit from tamoxifen therapy and poor long-term breast cancer patients survival - Retrospective analyses of the STD-3 randomized trial

Christina Yau
Dr. Yau has no relevant financial relationships to disclose.

Non-anthracycline-containing docetaxel plus cyclophosphamide was inferior to docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative or HER2 positive breast cancer: Long term follow-up result from NATT study

Guodan Ye
Dr. Ye has no relevant financial relationships to disclose.

A phase 1 safety study of topical cetuximab [BPM35143] for the prevention of chemotherapy-induced alopecia (CIA)

Ran Ye
Ran Ye has no relevant financial relationships to disclose.

Reduced expression of miR-200c-3p contributes to cell migration and invasion in paclitaxel-resistant breast cancer cell

Zikun Ye
Dr. Ye has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Author</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3-12-03</td>
<td>Evaluation of women with BRCA mutations and breast cancer tested at an NCI designated comprehensive cancer center: A cost of illness estimation</td>
<td>Xiangyang Ye</td>
<td>Has disclosed that AstraZeneca funding this research.</td>
</tr>
<tr>
<td>P4-21-10</td>
<td>Characterization of menorrhagia-related diarrhea in patients with early-stage HER2+ breast cancer: Analyses from the phase III CaSTRi trial</td>
<td>Yining Ye</td>
<td></td>
</tr>
<tr>
<td>P1-01-05</td>
<td>Prognostic values of circulating tumor cells (CTC) and cancer associated macrophage-like cells (CAML) enumerations in metastatic breast cancer: The role for innate immunity in the metastatic process</td>
<td>Zhong Ye</td>
<td>Has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P05-03</td>
<td>Effect of PD-1 and PD-L1 in the tumor microenvironment on overall survival of triple-negative breast cancer patients</td>
<td>Jennifer Yearley</td>
<td>Dr. Yearley has disclosed that she is an employee of Merck &amp; Co, Inc.</td>
</tr>
<tr>
<td>S2-06</td>
<td>DNA repair deficiency biomarkers and MammaPrint high/ultra-high risk as predictors of veliparib/carboplatin response: Results from the neoadjuvant I-SPY 2 trial for high risk breast cancer</td>
<td>Douglas Yee</td>
<td>Mr. Yee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-11-02</td>
<td>A longitudinal look at toxicity management within a platform trial: Lessons from the I-SPY 2 TRIAL</td>
<td>Douglas Yee</td>
<td>Dr. Yee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-05-02</td>
<td>Quantitative Erβ measurements in TNBC from the I-SPY 2 TRIAL correlate with HER2-EGFR co-activation and heterodimerization</td>
<td>Douglas Yee</td>
<td>Dr. Yee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-11-18</td>
<td>Trajectory of patient (Pt) reported physical function (PF) during and after neoadjuvant chemotherapy in the I-SPY 2 trial</td>
<td>Douglas Yee</td>
<td>Dr. Yee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-11-02</td>
<td>Efficiency of HP80 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial</td>
<td>Douglas Yee</td>
<td>Dr. Yee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-11-04</td>
<td>The evaluation of paslumab/mercenomab plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial</td>
<td>Douglas Yee</td>
<td>Dr. Yee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>S5-07</td>
<td>Aromatase inhibitors and endothelial function: Is there an association with early cardiovascular disease?</td>
<td>Douglas Yee</td>
<td>Dr. Yee has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Committee Member</td>
<td></td>
<td>Douglas Yee</td>
<td>Dr. Yee has disclosed that he receives consulting fees from AstraZeneca and AbbVie. He also has ownership interest in Agapem Biotechnologies, Inc. These relationships do not impact his ability to review presentations.</td>
</tr>
<tr>
<td>P3-07-08</td>
<td>Molecular subtype-specific expression of long noncoding RNA regulates proliferation of basal-like breast cancer cells</td>
<td>Albert Yeh</td>
<td>Mr. Yeh has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-07-30</td>
<td>Identifying novel glycosylation markers in HER2+ breast cancer using MALDI mass spectrometry</td>
<td>Elizabeth Yeh</td>
<td>Dr. Yeh has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>QT3-01-07</td>
<td>A phase II study of abalosib followed by dasatinib and cyclophosphamide as preoperative therapy for HER2-negative inflammatory breast cancer</td>
<td>Eren Yen</td>
<td>Dr. Yen has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>QT2-02-03</td>
<td>Pilot study of carbon-189 bevacizumab positron emission tomography for imaging angiogenesis in patients with inflammatory breast carcinoma receiving preoperative chemotherapy</td>
<td>Eren Yen</td>
<td>Dr. Yen has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-16-09</td>
<td>Overall survival of patients with non-metastatic triple negative breast cancer who received neoadjuvant vs adjuvant chemotherapy: Cohort analysis of National cancer data base [NCDB) 2010 - 2012</td>
<td>Fina Yen</td>
<td>Dr. Yen has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-21-35</td>
<td>Phase II trial of pertuzumab, trastuzumab, and nab-paclitaxel in patients (pts) with HER2 overexpressing (HER2+) locally advanced or inflammatory breast cancer (LABC) or untreated stage IV metastatic breast cancer (MBC)</td>
<td>Christina Yew</td>
<td>Dr. Yen has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
A phase 3, open-label, randomized, 2-arm international study of the oral dual PARP inhibitor talazoparib in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA)

Rinat Yerushalmi
Dr. Yerushalmi has no relevant financial relationships to disclose.

The association between angiotensin receptor blockers usage and breast cancer characteristics

Rinat Yerushalmi
Prof. Yerushalmi has no relevant financial relationships to disclose.

The association between smoking and breast cancer characteristics and outcome

Haeseung Yi
Haeseung Yi has no relevant financial relationships to disclose.

Adherence to healthy lifestyle behaviors in a predominantly Hispanic population of women undergoing screening mammography

Shin YI
Dr. Yi has no relevant financial relationships to disclose.

Evaluation of a risk score based on biologic factors to enhance prognostic stratification by the American Joint Committee on Cancer (AJCC) Staging System

Sali YI
Sali Yi has disclosed that he receives salary from Gilead Sciences.

The importance of loco-regional tumor burden and surgery on survival in patients with de novo stage IV breast cancer; post hoc analyses of protocol MF07-01

Emin Yildirim
Dr. Yildirim has no relevant financial relationships to disclose.

Are we missing actionable targets in breast cancer? Novel insights into recurrent Notch alterations

Bahar Yilmazel
Bahar Yilmazel has disclosed that he receives salary from and has ownership in Foundation Medicine.

Synergistic suppression of triple negative breast cancer with the combination of PI3K inhibitor (alpelisib, BYL719) and CDK inhibitor (ribociclib, LEE011)

John Yin
Dr. Yin has no relevant financial relationships to disclose.

Phase II trial of pertuzumab, trastuzumab, and nab-paclitaxel in patients (pts) with HR+ HER2+ locally advanced or inflammatory breast cancer (LABC) or untreated stage IV metastatic breast cancer (MBC)

John Yin
Dr. Yin has no relevant financial relationships to disclose.

Initial focusing circulating breast cancer cells based on the novel 3D-printed serpentine microfluidic chips

Pengju Yin
Pengju Yin has no relevant financial relationships to disclose.

Race associated disparities in an urban population of adolescent and young adult (AYA) women with breast cancer

Ruijie Yin
Ruijie Yin has no relevant financial relationships to disclose.

Maintenance of genomic integrity in dormant circulating tumor cells

Wei Yin
Dr. Yin has no relevant financial relationships to disclose.

The evolution of breast cancer circulating tumor cells mediating brain metastasis

Wei Yin
Dr. Yin has no relevant financial relationships to disclose.

"Overcoming obstacles to breast conservation surgery in Malaysia"

Cheng-Har Yip
Dr. Yip has disclosed that she receives consulting fees from AstraZeneca, Genomic Health and Pfizer. These relationships do not impact her ability to present an unbiased presentation.

MIRI trial yields MammaPrint High1/High2 risk classes associated with significant differences in pCR and receptor subgroups

Erin Yoder
Ms. Yoder has disclosed that she is an Agendia employee.

Utility of Ligasure™ vessel-sealing device in adjuvant dissection for breast cancer surgery: A randomized single center study

Kozue Yokoyama
Dr. Yokoyama has no relevant financial relationships to disclose.

The combination of preoperative computed tomography lymphography and intraoperative fluorescence imaging navigation for sentinel lymph node biopsy of early breast cancer patients

Kazuhito Yoneda
Dr. Yoneda has no relevant financial relationships to disclose.

Difference between 1st and 2nd generation serotonin receptor antagonists in triplet antiemetic therapy for highly emetogenic chemotherapy in breast cancer patients - according to recent multi-institutional double-blind randomized clinical research on the AC regimen

Naohiro Yonemoto
Dr. Yonemoto has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td>P6-07-13</td>
<td>Association of pre-chemotherapy peripheral blood pro-inflammatory (IL-6, CRP) and coagulation (D-dimer) markers with chemotherapy toxicity in women with breast cancer</td>
<td>Susan Yost</td>
<td></td>
</tr>
<tr>
<td>P6-01-07</td>
<td>Mitochondria-matrix communication regulates epithelial-mesenchymal transition and metastasis in triple negative breast cancer</td>
<td>Patricia Yotnda</td>
<td></td>
</tr>
<tr>
<td>P5-02-05</td>
<td>Biology and long-term prognosis of screening detected non-palpable breast cancer by ultrasound in hospital based Chinese population (2001-2014)</td>
<td>Shamshah You</td>
<td></td>
</tr>
<tr>
<td>P3-14-13</td>
<td>Total mastectomy and immediate breast reconstruction for breast cancer: A ten-year Canadian single institution experience</td>
<td>Sami Younan</td>
<td></td>
</tr>
<tr>
<td>P4-06-05</td>
<td>Treatment of ESR1 mutant and PIK3CA mutant patient derived breast cancer xenograft models reveals differential anti-tumor responses to estrogen receptor degraders and PI3K inhibitors in vivo</td>
<td>Amy Young</td>
<td></td>
</tr>
<tr>
<td>P6-07-08</td>
<td>The complete spectrum of ESR1 mutations from 7590 breast cancer tumor samples</td>
<td>Geneva Young</td>
<td></td>
</tr>
<tr>
<td>P5-07-08</td>
<td>The impact of circulating androgens on the androgen receptor in aromatase inhibitor resistant breast cancer</td>
<td>Leonie Young</td>
<td></td>
</tr>
<tr>
<td>P3-04-03</td>
<td>SSTR2b as a predictive biomarker and monitoring tool in estrogen resistant breast cancer</td>
<td>Leonie Young</td>
<td></td>
</tr>
<tr>
<td>P3-04-15</td>
<td>Steroid receptor co-activator 1 modulation of cancer cell reprogramming in endocrine resistant breast cancer</td>
<td>Leonie Young</td>
<td></td>
</tr>
<tr>
<td>P3-04-17</td>
<td>Global transcriptional repression by the coactivator SRC-1 mediates disease progression in treatment-resistant breast cancer</td>
<td>Leonie Young</td>
<td></td>
</tr>
<tr>
<td>P3-04-18</td>
<td>The impact of circulating androgens on the androgen receptor in aromatase inhibitor resistant breast cancer</td>
<td>Leonie Young</td>
<td></td>
</tr>
<tr>
<td>P6-07-13</td>
<td>Identification of a cancer stem cell specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer</td>
<td>Richard Young</td>
<td></td>
</tr>
<tr>
<td>Page</td>
<td>Title</td>
<td>Authors</td>
<td>Financial Relationships</td>
</tr>
<tr>
<td>------</td>
<td>--------------------------------------------------------------------------------------------------</td>
<td>-----------------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>P5-15-03</td>
<td>nab-paclitaxel + carboplatin vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the tNACity trial</td>
<td>Robyn Young</td>
<td>Mr. Young has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-12-04</td>
<td>Phase I dose-escalation trial of ONT-380 in combination with trastuzumab in patients [pts] with HER2+ breast cancer brain metastases</td>
<td>Jerry Younger</td>
<td>Mr. Younger has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-17-01</td>
<td>Long-term rates of breast preservation after breast-conserving therapy for ductal carcinoma in situ</td>
<td>Bruce Youngson</td>
<td>Dr. Youngson has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-03-02</td>
<td>Breast implant associated anaplastic large cell lymphoma (BIA-ALCL): The UK experience and first reported case of neoadjuvant brentuximab</td>
<td>Magdi Youssef</td>
<td>Magdi Youssef has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-13-25</td>
<td>Oncoplastic breast surgery is oncologically safe in locally advanced breast cancer after neoadjuvant chemotherapy, an Egyptian experience</td>
<td>Mina Youssef</td>
<td>Dr. Youssef has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-13-25</td>
<td>Oncoplastic breast surgery is oncologically safe in locally advanced breast cancer after neoadjuvant chemotherapy, an Egyptian experience</td>
<td>Omar Youssef</td>
<td>Dr. Youssef has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-21-18</td>
<td>Cardiac safety of dual anti-HER2 therapy in the neoadjuvant setting for treatment of HER2-positive breast cancer</td>
<td>Anthony Yu</td>
<td>Mr. Yu has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-01-10</td>
<td>Cumulative analysis of breast cancer sentinel lymph node identification rate by radioisotope: A 15-year experience</td>
<td>Ben-Long Yu</td>
<td>Ben-Long Yu has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Speaker, Basic Science Forum 1</td>
<td>A comparison of the micro-impulse radio SAVI SCLATI to the radioactive 125I seed in localization of non-palpable breast cancer for breast conserving therapy</td>
<td>Eddy Yu</td>
<td>Mr. Yu has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-16-05</td>
<td>Clinical utility of serial monitoring of circulating tumor DNA (ctDNA) in patients with breast cancer</td>
<td>Hsing-Ting Yu</td>
<td>Hsing-Ting Yu has disclosed that he is an employee of Cardinal Health.</td>
</tr>
<tr>
<td>P6-08-17</td>
<td>Clinical utility of serial monitoring of circulating tumor DNA (ctDNA) in patients with breast cancer</td>
<td>Pui Yu</td>
<td>Dr. Yu has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-10-05</td>
<td>Stochastic heterogeneity in the matched control study</td>
<td>James Yu</td>
<td>Dr. Yu has disclosed that he is an employee of 21st Century Oncology.</td>
</tr>
<tr>
<td>P6-11-07</td>
<td>Methylation of BRCA1 and response to the PARP inhibitors veliparib</td>
<td>Jie Hui</td>
<td>Dr. Hui has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-02-11</td>
<td>Clinical utility of serial monitoring of circulating tumor DNA (ctDNA) in patients with breast cancer</td>
<td>Jieh-Cheng Yu</td>
<td>Dr. Hui has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-36</td>
<td>Tamoxifen resistance: EVF expression in hormone receptor-positive and HER2-negative breast cancer</td>
<td>Jieh-Cheng Yu</td>
<td>Dr. Hui has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-50</td>
<td>Impact of young age on recurrence and mortality after surgery in breast cancer: 15 years active surveillance</td>
<td>Jieh-Cheng Yu</td>
<td>Dr. Hui has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-14-12</td>
<td>Oncologic outcomes of immediate breast reconstruction after neoadjuvant chemotherapy in breast cancer patients: A matched case control study</td>
<td>Jieh-Cheng Yu</td>
<td>Dr. Hui has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-13-07</td>
<td>Ovarian disease-free survival among patients with breast cancer</td>
<td>Jieh-Cheng Yu</td>
<td>Jieh-Cheng Yu has disclosed that he is an employee of 21st Century Oncology.</td>
</tr>
<tr>
<td>OIT-01-05</td>
<td>Randomized phase II study of induction bevacizumab, etoposide and cisplatin followed by whole brain radiotherapy (WBRT) versus WBRT alone in breast cancer with untreated brain metastases (A-LIUSD)</td>
<td>Jieh-Cheng Yu</td>
<td>Jieh-Cheng has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-11-06</td>
<td>Development and application of whole processing management for patients with breast carcinoma: A novel management strategy for breast health</td>
<td>Ke-Da Yu</td>
<td>Dr. Ke-Da Yu has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-06-07</td>
<td>Clinical and molecular relevance of intra-tumor genetic heterogeneity in breast cancer: Integrative analysis of data from The Cancer Genome Atlas</td>
<td>Ke-Da Yu</td>
<td>Ke-Da Yu has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
A new oral SERD AZD9496 for treatment of hormone dependent postmenopausal breast cancer

Adjunct diagnosing with breast specific gamma imaging or ultrasound in symptomatic women with mammographic dense breasts: A single center retrospective and comparative analysis

Early detection of development of a pre-metastatic niche in lungs in response to primary breast tumor using human spectrometry

Decoding the genetic basis of mammary neovascularization and their putative role in promotion of distant metastases

Risk factors of loco-regional recurrence, loco-regional failure pattern and role of postmastectomy radiotherapy for T1-2 breast cancers with 1-3 positive axillary lymph nodes

Cyclin d1 binding to chromatin and the induction of chromosomal instability requires the fuzzy domain

Role of stromal discoid domain receptor-1 in breast cancer

Phase 2 trial of everolimus and/or trastuzumab in hormone refractory, hormone receptor (HR)-positive, HER2-normal metastatic breast cancer (MBC)

Phase 2 trial of pertuzumab, trastuzumab, and nab-paclitaxel in patients (pts) with HER2 overexpressing (HER2+) locally advanced or inflammatory breast cancer (LABC) or untreated stage IV metastatic breast cancer (MBC)

Association of pre-chemotherapy peripheral blood pro-inflammatory (IL-6, CRP) and coagulation (D-dimer) markers with chemotherapy toxicity in women with breast cancer

The impact of genomic mutation on metastatic breast cancer treatment: A retrospective clinical trial

The impact of genomic mutation on metastatic breast cancer treatment: A retrospective clinical trial

Genomic analysis of molecular discordance of paired primary and recurrent triple negative breast cancer

Genomic and microenvironmental intra-tumor heterogeneity in DCIS

Synergistic suppression of triple negative breast cancer with the combination of P38 inhibitor (apilimod, BI17203) and CDK inhibitor (ribociclib, LEE011)

Selinexor, a selective inhibitor of nuclear export, demonstrates efficacy in preclinical models of triple negative breast cancer

Phase 2 trial of pertuzumab, trastuzumab, and nab-paclitaxel in patients (pts) with HER2 overexpressing (HER2+) locally advanced or inflammatory breast cancer (LABC) or untreated stage IV metastatic breast cancer (MBC)

The impact of genomic mutation on metastatic breast cancer treatment: A retrospective clinical trial

Selinexor, a selective inhibitor of nuclear export, demonstrates efficacy in preclinical models of triple negative breast cancer

Phase II clinical trial of neratinib in patients 60 and older with HER2 over-expressed or mutated breast cancer: Trial design considerations for older adults

Phase II trial of everolimus and/or trastuzumab in hormone refractory, hormone receptor (HR)-positive, HER2-normal metastatic breast cancer (MBC)

Phase II trial of erlotinib in patients 60 and older with HER2 over-expressed or mutated breast cancer: Trial design considerations for older adults

Phase II trial of the addition of pembrolizumab to letrozole and palbociclib in patients with metastatic estrogen receptor positive breast cancer who have stable disease on letrozole and palbociclib

Femara plus ribociclib or placebo as neo-adjuvant endocrine therapy for women with ER+, HER2-negative early breast cancer - The Feline trial

Genomic analysis of molecular discordance of paired primary and recurrent triple negative breast cancer

Genomic and microenvironmental intra-tumor heterogeneity in DCIS

Synergistic suppression of triple negative breast cancer with the combination of P38 inhibitor (apilimod, BI17203) and CDK inhibitor (ribociclib, LEE011)
Circulating tumor DNA (ctDNA): A real-time application of precision medicine to the management of metastatic breast cancer (MBC)
Vittorina Zagonel
Dr. Zagonel has no relevant financial relationships to disclose.

Mutation characteristics and tumor infiltrating lymphocytes in early and metastatic HER2-positive breast cancer
Flora Zegouri
Ms. Zegouri has no relevant financial relationships to disclose.

200 experiences of oncoplastic surgery with the omental flap reconstruction
Zahra Zeha
Dr. Zeha has no relevant financial relationships to disclose.

Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases
Claudia Zaharia
Dr. Zaharia has no relevant financial relationships to disclose.

Metabolic obesity, adipose inflammation and aromatase: Potential drivers of breast cancer risk in women with normal body mass index
Heba Zahid
Heba Zahid has no relevant financial relationships to disclose.

Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial SepaSixto in triple-negative early breast cancer
Erik-Michael Zahn
Mr. Zahn has no relevant financial relationships to disclose.

Synchronous bilateral breast cancer compared to unilateral breast cancer: A population based study
Dana Zakalik
Dr. Zakalik has no relevant financial relationships to disclose.

Application of digital-PCR technology to determine c-MET copy number variation in paired primary breast cancer and brain metastases
Rasheed Zakaria
Rasheed Zakaria has no relevant financial relationships to disclose.

Three-monthly dynamic evaluation of CEA and CA15-3 (followed by 18-FDG PET) vs usual practice in the follow-up of early breast cancer (BC) patients (pts): A prospective randomized trial (RONOS15-patient-oriented new surveillance study, Italy)
Claudio Zamagni
Dr. Zamagni has no relevant financial relationships to disclose.

Neo-adjuvant treatment with trastuzumab and pertuzumab associated with palbociclib and fulvestrant in HER2-positive and ER-positive breast cancer: Effect on Ki67 during and after treatment: A phase II Michelangelo study
Claudio Zamagni
Dr. Zamagni has no relevant financial relationships to disclose.

miR363-3p mediates maintenance and resistance of breast cancer stem cells (BCSC)
Khalil Zaman
Khalil Zaman has no relevant financial relationships to disclose.

T-DM1 in HER2 positive advanced breast cancer patients: Real world practice from a multicenter observational study
Alberto Zambelli
Mr. Zambelli has no relevant financial relationships to disclose.

Cytotoxic potential of the RG7388 MDM2-p53 binding antagonist and the GSK2830371 WIP1 inhibitor on MX-1 and MCF-7 human breast cancer cells
Maryam Zanjirband
Ms. Zanjirband has no relevant financial relationships to disclose.

Early utilization pattern of palbociclib 1 year post-approval in the United States
Katrin Zaragoza
Dr. Zaragoza has no relevant financial relationships to disclose.

Cytosponge potential of the HER2+/HER2- breast cancer patient’s saliva, with a potential role in early breast cancer detection
Antonella Zanetti
Dr. Zanetti has no relevant financial relationships to disclose.
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2 positive early breast cancer (BIG 1-06)
Dimitrios Zardavas
Mr. Zardavas has no relevant financial relationships to disclose.

PYTHIA: A phase II study of palbociclib plus fulvestrant versus placebo plus fulvestrant for pretreated patients with ER+/HER2- metastatic breast cancer
Dimitrios Zardavas
Dimitrios Zardavas has no relevant financial relationships to disclose.

Low-level gonosomal mosaicism of a de novo BRCA1 gene mutation - The origin of a constitutional mutation in a breast cancer family
Verena Zarghooni
Dr. Zarghooni has no relevant financial relationships to disclose.

Association of pre-chemotherapy peripheral blood pro-inflammatory (IL-6, CRP) and coagulation (D-dimer) markers with chemotherapy toxicity in women with breast cancer
Laura Zavala
Ms. Zavala has no relevant financial relationships to disclose.

Predictive value of quantitative HER2 and HER2 levels combined with downstream signaling markers in HER2 positive advanced breast cancer patients treated with lapatinib
Anton Zavroschi
Anton Zavroschi has no relevant financial relationships to disclose.

Novel CD146-downstream signaling pathway involved in breast tumor suppression
Hatem Zayed
Dr. Zayed has no relevant financial relationships to disclose.

Women’s experiences with a decision aid for neoadjuvant systemic therapy for operable breast cancer
Nicholas Zdenkowski
Mr. Zdenkowski has no relevant financial relationships to disclose.

A fit-for-purpose NGS system that reports ERBB2 (HER2) mutations and copy number variants for clinical trials research and drug development
Robert Zeigler
Dr. Zeigler has disclosed that he receives salary from and has ownership in Asuragen, Inc.

Prospective association between breast cancer risk and an individual dietary index based on the British Food Standards Agency nutrient profiling system
Laurent Zelak
Dr. Zelak has no relevant financial relationships to disclose.

The measurement of gait speed: An easy way to select older patients with breast cancer for an adapted therapeutic decision making
Laurent Zelak
Dr. Zelak has no relevant financial relationships to disclose.

Sociodemographic and economic factors are essential determinants of weight gain between before and after cancer diagnosis: Results from the prospective population-based NuHear-Santé cohort
Laurent Zelak
Dr. Zelak has no relevant financial relationships to disclose.

Enhancing compliance with national nutrition recommendations in breast cancer survivors. Experience in an underprivileged community
Laurent Zelak
Dr. Zelak has no relevant financial relationships to disclose.

Committee Member
Richard Zejnullah
Dr. Zejnullah has no relevant financial relationships with commercial interests to disclose.

TRINITI-1: Ribociclib + everolimus (EVE) + exemestane (EXE) triplet combination in men or postmenopausal women with HR+, HER2- advanced breast cancer (ABC) following progression on a cyclin-dependent kinase (CDK) 4/6 inhibitor
Amelia Zelnak
Ms. Zelnak has disclosed that she is a consultant for Pfizer and Novartis.

MADELINE: A prospective observational study of mobile app-based patient reported outcomes in advanced breast cancer
Amelia Zelnak
Dr. Zelnak has disclosed that he is a consultant for Pfizer Inc and Novartis Inc.

Phase 2 trial of everolimus and/or trastuzumab in hormone refractory, hormone receptor (HR) positive, HER2-normal metastatic breast cancer (MBC)
Amelia Zelnak
Dr. Zelnak has disclosed that he is a consultant for Pfizer Inc and Novartis Inc.

Phase 2 trial of everolimus and/or trastuzumab in hormone refractory, hormone receptor (HR) positive, HER2-normal metastatic breast cancer (MBC)
Amelia Zelnak
Dr. Zelnak has no relevant financial relationships to disclose.

Tumor-infiltrating lymphocytes (TILs) is associated with improved overall survival in triple-negative breast cancer (TNBC) patients treated with neoadjuvant chemotherapy (FAC)
Gustavo Zenun
Dr. Zenun has no relevant financial relationships to disclose.

A monoclonal antibody against hypo-glycosylated bone sialoprotein (I) has application for diagnostic purposes in samples of breast cancer patients and for treatment of skeletal metastases caused by MDA-MB-231 breast cancer cells in rats
Michael Zepp
Dr. Zepp has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>Symposium</th>
<th>Title</th>
<th>Author</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1-03-10</td>
<td>HER2 expression in clinical breast cancer samples: A novel detection methodology for HER2 protein quantitation using fluorescent nanoparticles</td>
<td>Haiyan Zhai</td>
<td>Dr. Zhai has disclosed that he is an employee of BioGenex.</td>
</tr>
<tr>
<td>OT1-04-05</td>
<td>A phase I randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2-negative, hormone receptor-positive breast cancer and bone metastases</td>
<td>Emily Chang</td>
<td>Ms. Zhang has disclosed that she receives salary from Bayer HealthCare.</td>
</tr>
<tr>
<td>P4-07-11</td>
<td>MicroRNA-367a promotes tumor growth and stemness potential by targeting FBXW7 in breast cancer</td>
<td>Nonliang Zhang</td>
<td>Dr. Zhang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-16-07</td>
<td>Non-anticholinergic-containing docetaxel plus cyclophosphamide was inferior to docetaxel, anticholinergic and cyclophosphamide in neoadjuvant treatment of triple negative or HER2 positive breast cancer: Long-term follow-up result from NATT study</td>
<td>Chunfang Zhang</td>
<td>Dr. Zhang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-06-06</td>
<td>Development of HER2-pB for metastatic breast cancer treatment</td>
<td>Guoqiang Zhang</td>
<td>Dr. Zhang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-15-02</td>
<td>Phenotypically distinct HRG positive cancer cells impact standard of care therapies in metastatic breast cancer models</td>
<td>Hong Zhang</td>
<td>Hong Zhang has disclosed that he is an employee of Merck Pharmaceuticals and holder of stock options.</td>
</tr>
<tr>
<td>P3-13-24</td>
<td>Non-invasive endoscopic axillary lymph node dissection in breast conservative surgery</td>
<td>Hongwei Zhang</td>
<td>Hongwei Zhang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-01-02</td>
<td>Diagnostic value of breast specific gamma imaging for breast cancer</td>
<td>Hongwei Zhang</td>
<td>Hongwei Zhang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-07-10</td>
<td>MiR-146a functions as suppressive non-coding gene via indirect upregulation of Let-7 to promote asymmetric division and inhibit the self-renewal ability of breast cancer stem-like cells</td>
<td>Jie Zhang</td>
<td>Dr. Zhang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-02-06</td>
<td>Biology and long-term prognosis of screening detected non-palpable breast cancer by ultrasound in hospital-based Chinese population (2001-2014)</td>
<td>Jie Zhang</td>
<td>Dr. Zhang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-07-11</td>
<td>MicroRNA-367a promotes tumor growth and stemness potential by targeting FBXW7 in breast cancer</td>
<td>Jie Zhang</td>
<td>Dr. Zhang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-07-10</td>
<td>MiR-146a functions as suppressive non-coding gene via indirect upregulation of Let-7 to promote asymmetric division and inhibit the self-renewal ability of breast cancer stem-like cells</td>
<td>Jie Zhang</td>
<td>Dr. Zhang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-22-03</td>
<td>Palbociclib in combination with endocrine therapy in treatment-naive and previously treated elderly women with HR+, HER2- advanced breast cancer: A pooled analysis from randomized phase 2 and 3 studies</td>
<td>Ke Zhang</td>
<td>Ke Zhang has disclosed that he receives salary from and has ownership in Pfizer.</td>
</tr>
<tr>
<td>P4-22-06</td>
<td>Treatment progression in women with endocrine-resistant HR+/HER2- advanced breast cancer who received palbociclib plus fulvestrant in PALOMA-3</td>
<td>Ke Zhang</td>
<td>Ke Zhang has disclosed that he receives salary from and has ownership in Pfizer.</td>
</tr>
<tr>
<td>P3-02-06</td>
<td>Magnetic resonance imaging (MRI) surveillance for patients with dense breasts and a previous breast cancer (BC) and/or High risk lesion</td>
<td>Liying Zhang</td>
<td>Liying Zhang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-22-03</td>
<td>Immunohistochemistry profiling and comprehensive analyses for therapeutic stratification in early hormone receptor positive breast cancers</td>
<td>Nick Xiao Zhang</td>
<td>Mr. Zhang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-22-14</td>
<td>Single agent palbociclib with or without trastuzumab for the treatment of Rb+ advanced breast cancer</td>
<td>Paul Zhang</td>
<td>Dr. Zhang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-05-27</td>
<td>Evaluation of the Oncotype DX and comprehensive assays for therapeutic stratification in early hormone receptor positive breast cancers</td>
<td>Roy Zhang</td>
<td>Dr. Zhang has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-01-18</td>
<td>A multiplexed immunofluorescence identifies phenotypic heterogeneity of circulating tumor cells in breast cancer</td>
<td>Roy Zhang</td>
<td>Dr. Zhang has no relevant financial relationships to disclose.</td>
</tr>
</tbody>
</table>
Protein tyrosine kinase 6 (PTK6) promotes survival of endocrine therapy-resistant ER+ breast cancer cells

Weijia Zhang

Dr. Zhang has no relevant financial relationships to disclose.

Spectral CT based radiomics signature: A potential biomarker for preoperative prediction of lymph node metastasis in breast cancer

Xiang Zhang

Xiang Zhang has no relevant financial relationships to disclose.

The Y537S ESR1 mutation is a dominant driver of distant ER-positive breast cancer metastasis

Xiang Zhang

Xiang Zhang has no relevant financial relationships to disclose.

Committee Member/Moderator, Mini-Symposia 1 “Harnessing the Immune System in Breast Cancer Therapies”

Xiang Zhang

Dr. Zhang has no relevant financial relationships with commercial interests to disclose.

Biology and long-term prognosis of screening detected non-palpable breast cancer by ultrasound in hospital-based Chinese population (2001-2014)

Xiaohui Zhang

Dr. Zhang has no relevant financial relationships to disclose.

ERα propelled drug-resistance-facilitating global DNA hypermethylation by promoting the DNMT1 gene expression

Xin Zhang

Dr. Zhang has no relevant financial relationships to disclose.

Transmembrane protein 33 (TMEM33) induces apoptosis via UPR signaling and autophagy in breast cancer cells

Xiyuan Zhang

Dr. Zhang has no relevant financial relationships to disclose.

Molecular mechanism of alcohol-associated breast cancer

Yanmei Zhang

Dr. Zhang has no relevant financial relationships to disclose.

Biology and long-term prognosis of screening detected non-palpable breast cancer by ultrasound in hospital-based Chinese population (2001-2014)

Yanna Zhang

Dr. Zhang has disclosed that he receives salary from, has a patent with and has ownership in Biotheranostics, Inc.

Impact of treatment history on prognostic ability of breast cancer index (BCI): Subset analysis from a validation study of patients with hormone receptor-positive (HR+) breast cancer with 1-3 positive nodes

Yi Zhang

Dr. Zhang has disclosed that he receives salary from, has a patent with and has ownership in Biotheranostics, Inc.

Prognostic impact of genomic risk stratification with breast cancer index in patients with clinically low risk, hormone receptor-positive, node-negative, TN breast cancer

Yi Zhang

Dr. Zhang has disclosed that he receives salary from and has ownership in Biotheranostics, Inc.

Correlation of breast cancer index (BCI) risk classification with tumor grade and Ki-67 in a large series of patients with early-stage, ER+ breast cancer

Yi Zhang

Dr. Zhang has disclosed that he receives salary from and has ownership in Biotheranostics, Inc.

An optimized 80-gene assay for the molecular diagnosis of triple negative breast cancer

Yi Zhang

Dr. Zhang has disclosed that he receives salary from and has ownership in Biotheranostics, Inc.

A single-center report of 125 cases of incidental internal mammary lymph node biopsy in free abdominal flap breast reconstructions

Yingying Zhang

Yingying Zhang has no relevant financial relationships to disclose.

SOX9 is a critical regulator of triple-negative breast cancer cell growth and invasion

Yun Zhang

Yun Zhang has no relevant financial relationships to disclose.

Inhibition of death-associated protein kinase 1 enhances chemotherapy action against triple-negative breast cancer

Yun Zhang

Yun Zhang has no relevant financial relationships to disclose.

Tumor and serum DNA methylation in women receiving preoperative chemotherapy (PST) with or without vorinostat in primary operable HER2-negative breast cancer in TBCRC008

Zhe Zhang

Zhe Zhang has no relevant financial relationships to disclose.

FOXA1 induces a pro-metastatic secretome through ER-dependent and independent transcriptional reprogramming in endocrine-resistant breast cancer

Dongyu Zhao

Dongyu Zhao has no relevant financial relationships to disclose.

Inhibition of death-associated protein kinase 1 enhances chemotherapy action against triple-negative breast cancer

Jing Zhao

Jing Zhao has no relevant financial relationships to disclose.

SOX9 is a critical regulator of triple-negative breast cancer cell growth and invasion

Dekuang Zhao

Dekuang Zhao has no relevant financial relationships to disclose.

Inhibition of death-associated protein kinase 1 enhances chemotherapy action against triple-negative breast cancer

Dekuang Zhao

Dekuang Zhao has no relevant financial relationships to disclose.

SOX9 induces a pro-metastatic secretome through ER-dependent and independent transcriptional reprogramming in endocrine-resistant breast cancer

Dongyu Zhao

Dongyu Zhao has no relevant financial relationships to disclose.

Inhibition of death-associated protein kinase 1 enhances chemotherapy action against triple-negative breast cancer

Jing Zhao

Jing Zhao has no relevant financial relationships to disclose.
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Author</th>
<th>Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3-07-01</td>
<td>Selinexor, a selective inhibitor of nuclear export, demonstrates efficacy in preclinical models of triple negative breast cancer</td>
<td>Ming Zhao</td>
<td>Dr. Zhao has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-10-02</td>
<td>A signature predictor of early vs. late recurrence after radiation treatment (RT) for breast cancer that may inform the biology of early, aggressive recurrences</td>
<td>Shuang Zhao</td>
<td>Dr. Zhao has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-07-01</td>
<td>A pan-cancer perspective of functional proteomics provides novel information content for uncommon breast cancer subtypes</td>
<td>Wei Zhao</td>
<td>Dr. Zhao has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-13-01</td>
<td>Proteomic response in breast cancer treated with neoadjuvant chemotherapy and with безносовым: Reverse phase protein array (RPPA) results from Nofosv-A randomized phase II study</td>
<td>Wei Zhao</td>
<td>Dr. Zhao has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-01-18</td>
<td>Early detection of development of a pre-metastatic niche in lungs in response to primary breast tumor using Raman spectroscopy</td>
<td>Chao Zheng</td>
<td>Dr. Zheng has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-01-19</td>
<td>Decoding the genetic basis of mammary involution and their putative role in promotion of distant metastases</td>
<td>Chao Zheng</td>
<td>Dr. Zheng has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-12-16</td>
<td>Delivery and anti-tumor activity of nanoparticle formulations (Nanocarrier)-based xenografts models of triple negative breast cancer</td>
<td>Jinli Zheng</td>
<td>Dr. Zheng has disclosed that he is conducting research under Sponsored Research Agreement with Merck KgaA, Darmstadt, Germany.</td>
</tr>
<tr>
<td>P2-08-11</td>
<td>An orally bioavailable selective estrogen receptor downregulator</td>
<td>Shiiling Zheng</td>
<td>Dr. Zheng has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-09-02</td>
<td>Breast cancer risk prediction using a polygenic risk score in women of African ancestry: Findings from GWAS in breast cancer in the African diaspora</td>
<td>Wei Zheng</td>
<td>Wei Zheng has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-06-04</td>
<td>Triple negative breast cancer patient-derived xenografts: Molecular characteristics and sensitivity to emerging therapies</td>
<td>Xianfeng Zheng</td>
<td>Xianfeng Zheng has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-35</td>
<td>BCL2BOS2 polymorphism in LFP3A1 gene is related to the prognosis of early breast cancer</td>
<td>Yubing Zheng</td>
<td>Yubing Zheng has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-09-29</td>
<td>Clinicopathological characteristics and survival outcomes in invasive papillary carcinoma of the breast: A population-based study</td>
<td>Yuli Zhang</td>
<td>Dr. Zheng has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-11-08</td>
<td>Molecular subtype-specific expression of long noncoding RNA regulates proliferation of basal-like breast cancer cells</td>
<td>Yonglan Zheng</td>
<td>Yonglan Zheng has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-09-02</td>
<td>Breast cancer risk prediction using a polygenic risk score in women of African ancestry: Findings from GWAS in breast cancer in the African diaspora</td>
<td>Yonglan Zheng</td>
<td>Yonglan Zheng has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P8-05</td>
<td>Comparative analysis of the genomic landscape of breast cancers from women of African and European ancestry</td>
<td>Yonglan Zheng</td>
<td>Yonglan Zheng has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-08-07</td>
<td>Assessing the impact of loss of NF1 on endocrine therapy resistance</td>
<td>Zeyi Zheng</td>
<td>Zeyi Zheng has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-08-01</td>
<td>Regulation of estrogen receptor β by NF1</td>
<td>Ze-Yi Zheng</td>
<td>Ze-Yi Zheng has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-15-16</td>
<td>Utilization and outcomes of embolization in triple negative metastatic breast cancer: Real-world findings</td>
<td>Zhe Zheng</td>
<td>Zhe Zheng has disclosed that he receives a salary from Sanoquin, Inc.</td>
</tr>
<tr>
<td>P1-05-29</td>
<td>Genomic variants in 5 male breast cancers using whole exome sequencing</td>
<td>Zhe Zhang</td>
<td>Zhe Zhang has disclosed that he receives a salary from Sanoquin, Inc.</td>
</tr>
<tr>
<td>P5-05-32</td>
<td>Molecular mechanism of alcohol-associated breast cancer</td>
<td>Zhong Zhao</td>
<td>Zhong Zhao has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-01-06</td>
<td>Diffuse optical tomography can predict pathologic complete response in patients with HER2 or triple negative breast cancer undergoing neoadjuvant chemotherapy</td>
<td>Zhihao Zhao</td>
<td>Zhihao Zhao has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-02-05</td>
<td>Biology and long-term prognosis of screening detected non-palpable breast cancer by ultrasound in hospital-based Chinese population (2001-2014)</td>
<td>Ying Zhao</td>
<td>Dr. Zhao has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Page</td>
<td>Title</td>
<td>Author</td>
<td>Financial Relationships</td>
</tr>
<tr>
<td>------</td>
<td>----------------------------------------------------------------------</td>
<td>---------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>P1-01-17</td>
<td>Establishment and preliminary clinical application of breast cancer CTC detection kit based on immune magnetic lipid microsphere/human breast mammaglobin</td>
<td>Bingqing Zhou</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-08-11</td>
<td>Histone acetyltransferase 1 interacts with estrogen receptor alpha (ERα) and affects the transcriptional activity of ERα in breast cancer cells</td>
<td>Jianhong Zhou</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-01-19</td>
<td>Axillary reverse mapping using fluorescence imaging in the surgical treatment for breast cancer patients</td>
<td>Jun Zhou</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-04-10</td>
<td>High-affinity activated natural killer (haNK) cells augment trastuzumab efficacy in a mouse model of HER2-positive human metastatic breast cancer</td>
<td>Longen Zhou</td>
<td>Has disclosed that he receives salary from Nanobioscience.</td>
</tr>
<tr>
<td>P6-07-29</td>
<td>Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer: Potential drivers of breast cancer risk in women with normal body mass index</td>
<td>Shulin Zhou</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-05-05</td>
<td>Metabolic obesity, adipose inflammation and aromatase: Tumor and serum DNA methylation in women receiving preoperative chemotherapy (PST) with or without vorinostat in primary operable HER2-negative breast cancer in TBCRC008</td>
<td>Yidong Zhou</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-09-15</td>
<td>Biology and long-term prognosis of screened detected non-palpable breast cancer by ultrasound in hospital-based Chinese population (2001-2014)</td>
<td>Yidong Zhou</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-02-05</td>
<td>Histone acetyltransferase 1 interacts with estrogen receptor alpha (ERα) and affects the transcriptional activity of ERα in breast cancer cells</td>
<td>Zhenqi Zhou</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-05-01</td>
<td>Increased glycolysis directly activates transcriptional coactivator SRC-3 to promote aggressive metastatic breast cancer</td>
<td>Bokai Zhu</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-08-08</td>
<td>Identification of tumor-promoting and tumor-inhibiting genes with age dependent expression in breast cancer patients</td>
<td>Haiyan Zhu</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-03-10</td>
<td>A fit-for-purpose NGS system that reports HER2 (v0.03) mutations and copy number variants for clinical trials research and drug development</td>
<td>Huiping Zhu</td>
<td>Receives salary from and has ownership in Asuragen, Inc.</td>
</tr>
<tr>
<td>P6-06-01</td>
<td>Analysis of breast cancer in young women in the department of defense (DOD) database</td>
<td>Kangmin Zhu</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-01-16</td>
<td>Comparison of axillary nodal status between different defined clinically node negative breast cancer: Is ACOSOG Z0011 criteria applicable to preoperative cytologically negative axilla?</td>
<td>Li Zhu</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P2-01-08</td>
<td>A nomogram to predict the survival benefit of surgical axillary staging in T1 breast cancer patients</td>
<td>Liling Zhu</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-01-09</td>
<td>The development of nomograms to predict axillary lymph node status in breast cancer patients</td>
<td>Liling Zhu</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-06-07</td>
<td>Establishment and characterization of ST941/C; an ESR1-mutant ER+ breast cancer cell line and xenograft from a patient with acquired resistance to endocrine therapy</td>
<td>Qingli Zhu</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-04-26</td>
<td>Establishment and characterization of ST941/C; an ESR1-mutant ER+ breast cancer cell line and xenograft from a patient with acquired resistance to endocrine therapy</td>
<td>Qingli Zhu</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-03-05</td>
<td>Biology and long-term prognosis of screened detected non-palpable breast cancer by ultrasound in hospital-based Chinese population (2001-2014)</td>
<td>Qingli Zhu</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-01-20</td>
<td>Inertial focusing circulating breast cancer cells based on the novel 3D-printed serpentine microfluidic chips</td>
<td>Shuping Zhu</td>
<td>No relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>Session</td>
<td>Title</td>
<td>Authors</td>
<td>Financial Relationships</td>
</tr>
<tr>
<td>---------</td>
<td>-----------------------------------------------------------------------</td>
<td>-----------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>P3-07-17</td>
<td>Squalene epoxidase is a potential metabolic oncogene by amplification with clinical implications in breast carcinoma: An in silico pan-cancer study with in vitro evidence</td>
<td>Gabriele Zoppoli</td>
<td>Dr. Zoppoli has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-08-21</td>
<td>The effect of family history on screening procedures and prognosis in breast cancer patients - Results of a large population-based case-control study on breast cancer</td>
<td>Christine zu Eulenburg</td>
<td>Ms. zu Eulenburg has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-07-32</td>
<td>Vitamin D as a potential biomarker of aggressiveness in non-metastatic breast cancer</td>
<td>Leyre Zubiri</td>
<td>Leyre Zubiri has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-05-28</td>
<td>Melatonin treatment: A transcriptomic networks in a xenograft model of breast cancer</td>
<td>Debora Zuccari</td>
<td>Dr. Zuccari has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-04-12</td>
<td>Both spliced and unspliced XBP1 regulates breast cancer cell fate response to antiestrogens via NFkappaB signaling</td>
<td>Alan Zwart</td>
<td>Dr. Zwart has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-06-11</td>
<td>A targetable EGFR-driven tumor-initiating program in breast cancer</td>
<td>Dongmei Zuo</td>
<td>Dongmei Zuo has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-03-06</td>
<td>Mechanisms of CUBN T cell immunosuppression in triple negative breast cancer</td>
<td>Dongmei Zuo</td>
<td>Dr. Zuo has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-01-02</td>
<td>Integration of whole-genome sequencing and functional screening to identify breast cancer lung metastatic drivers</td>
<td>Wen-Jia Zuo</td>
<td>Wen-Jia Zuo has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-09-21</td>
<td>Clinical evaluation of mtrR-100 as a predictor of estrogen responsiveness in hormone-receptor positive breast cancer</td>
<td>Giorgia Zucchini</td>
<td>Dr. Zucchini has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-12-02</td>
<td>Prognostic factors and survival according to tumor subtype in women presenting with breast cancer brain metastases at initial diagnosis</td>
<td>Ariel Zwenger</td>
<td>Dr. Zwenger has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-11-04</td>
<td>Looking beyond the margins: Economic costs and complications associated with repeated breast-conserving surgeries</td>
<td>Adam Zysk</td>
<td>Mr. Zysk has disclosed that he receives salary from and has ownership in Diagnostic Photonics, Inc and is a consultant for InnoVative Designs, Inc. He has also disclosed that he has a patent with University of Illinois at Urbana-Champaign; Diagnostic Photonics, Inc.</td>
</tr>
<tr>
<td>P1-09-21</td>
<td>The effect of family history on screening procedures and prognosis in breast cancer patients - Results of a large population-based case-control study on breast cancer</td>
<td>Christine zu Eulenburg</td>
<td>Ms. zu Eulenburg has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-10-21</td>
<td>Both spliced and unspliced XBP1 regulates breast cancer cell fate response to antiestrogens via NFkappaB signaling</td>
<td>Alan Zwart</td>
<td>Dr. Zwart has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-07-17</td>
<td>Squalene epoxidase is a potential metabolic oncogene by amplification with clinical implications in breast carcinoma: An in silico pan-cancer study with in vitro evidence</td>
<td>Gabriele Zoppoli</td>
<td>Dr. Zoppoli has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P5-08-21</td>
<td>The effect of family history on screening procedures and prognosis in breast cancer patients - Results of a large population-based case-control study on breast cancer</td>
<td>Christine zu Eulenburg</td>
<td>Ms. zu Eulenburg has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-07-32</td>
<td>Vitamin D as a potential biomarker of aggressiveness in non-metastatic breast cancer</td>
<td>Leyre Zubiri</td>
<td>Leyre Zubiri has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-05-28</td>
<td>Melatonin treatment: A transcriptomic networks in a xenograft model of breast cancer</td>
<td>Debora Zuccari</td>
<td>Dr. Zuccari has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-04-12</td>
<td>Both spliced and unspliced XBP1 regulates breast cancer cell fate response to antiestrogens via NFkappaB signaling</td>
<td>Alan Zwart</td>
<td>Dr. Zwart has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-06-11</td>
<td>A targetable EGFR-driven tumor-initiating program in breast cancer</td>
<td>Dongmei Zuo</td>
<td>Dongmei Zuo has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P4-03-06</td>
<td>Mechanisms of CUBN T cell immunosuppression in triple negative breast cancer</td>
<td>Dongmei Zuo</td>
<td>Dr. Zuo has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P6-01-02</td>
<td>Integration of whole-genome sequencing and functional screening to identify breast cancer lung metastatic drivers</td>
<td>Wen-Jia Zuo</td>
<td>Wen-Jia Zuo has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P3-09-21</td>
<td>Clinical evaluation of mtrR-100 as a predictor of estrogen responsiveness in hormone-receptor positive breast cancer</td>
<td>Giorgia Zucchini</td>
<td>Dr. Zucchini has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-12-02</td>
<td>Prognostic factors and survival according to tumor subtype in women presenting with breast cancer brain metastases at initial diagnosis</td>
<td>Ariel Zwenger</td>
<td>Dr. Zwenger has no relevant financial relationships to disclose.</td>
</tr>
<tr>
<td>P1-11-04</td>
<td>Looking beyond the margins: Economic costs and complications associated with repeated breast-conserving surgeries</td>
<td>Adam Zysk</td>
<td>Mr. Zysk has disclosed that he receives salary from and has ownership in Diagnostic Photonics, Inc and is a consultant for InnoVative Designs, Inc. He has also disclosed that he has a patent with University of Illinois at Urbana-Champaign; Diagnostic Photonics, Inc.</td>
</tr>
</tbody>
</table>